,nct_id,primaryOutcomes,startDate,status,study_type,phases,secondaryOutcomes,otherOutcomes
0,NCT01976351,The relationship between the mucosal morphology by imaging enhanced endoscopy and the presence of high-grade intraepithelial neoplasia from non-dysplastic specialized intestinal metaplasia.,2009-09,TERMINATED,OBSERVATIONAL,['NA'],,
1,NCT04806243,os（overall survival）,2021-05-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],DoR,
2,NCT00877136,Evaluate patient experience with Therasphere.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],Tumor response to treatment with TheraSphere®,
3,NCT01217450,"Tumor response, as evaluated by the RECIST",2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Toxicities graded using the NCI Common Toxicity Criteria,
4,NCT01674309,Tumor control rate of the primary tumor and metastasis,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],metastasis response rate,
5,NCT03979131,Pathological complete response (pCR) rate,2019-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Surgical complete resection rate (R0),
6,NCT00890188,Overall response(CR+PR) and Clinical benefit (CR+PR+SD),2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"To determine the progression free survival, overall survival (OS)and assess the safety profile",
7,NCT04209491,Proportion of the following missions of the coordinator Nurse,2019-09-09,UNKNOWN,OBSERVATIONAL,['NA'],Number of early unscheduled readmissions during the first month following interventional radiology treatment for patients included in the study.,
8,NCT04745390,Treated lesion progression,2021-08-01,RECRUITING,INTERVENTIONAL,['NA'],"Comparison of Quality of Life (QOL) Using a Standardly-Used Validated Instrument. Specifically, measures of physical, social/family, and functional well being. Overall symptoms, function, global health status will also be compared.",
9,NCT00003046,Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12,1997-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10,NCT01749865,Time to recurrence,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease Free Survival,Adverse Events
11,NCT05523271,Adenoma detection rate,2023-01-16,RECRUITING,INTERVENTIONAL,['NA'],Non-neoplastic detection rate,
12,NCT03476434,polyp miss rate,2015-02,COMPLETED,INTERVENTIONAL,['NA'],adenoma miss rate,
13,NCT05201885,The positive rate of oncological contamination of peritoneal washings,2022-01-15,RECRUITING,OBSERVATIONAL,['NA'],Disease free survival,
14,NCT02527824,overall response rate,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],toxicity profiles - the number of participants and grade of intensity of treatment related adverse events,
15,NCT05134532,Progression-free survival (PFS) by RECIST v 1.1,2021-12-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety profiles by NCI-CTCAE version 5,
16,NCT03982641,Cost relate to HCRU,2019-04-16,UNKNOWN,OBSERVATIONAL,['NA'],Rate of preoperative chemo-radiation therapy in patients with rectal cancer,
17,NCT00689702,Complete pathological remission rate,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Rate of sphincter sparing surgical procedure Toxicity/safety,
18,NCT04556344,Change in patient emotional skills from baseline to 15 days after the end of intervention,2020-10-26,RECRUITING,INTERVENTIONAL,['NA'],Patient satisfaction,
19,NCT03418584,radical rate,2017-12-05,UNKNOWN,INTERVENTIONAL,['NA'],operation time,
20,NCT01979549,Adverse events,2013-12,UNKNOWN,OBSERVATIONAL,['NA'],,
21,NCT00811447,Time to progression,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Laboratory toxicities/symptomatology,
22,NCT04213794,Incidence of adverse events of cytoreductive surgery (CRS) with heated intra-peritoneal chemotherapy (HIPEC) in this patient population,2019-11-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Progression free survival (PFS),
23,NCT01830907,Infectious complication,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Length of hospital stay,
24,NCT00982449,To evaluate the potential for enzymatic targeting as evidenced by the ability to image 124I-FIAU tracer uptake in tumor at baseline and following chemotherapy or biologic therapy with agents that may induce viral TK activation.,2010-12,COMPLETED,INTERVENTIONAL,['NA'],To describe changes in viral DNA in plasma as a function of chemotherapy and the association with imaging by FIAU-PET,
25,NCT00427804,Fractional Absorption of Calcium,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,
26,NCT03714555,CA19-9 Plasma Level,2019-10-17,TERMINATED,INTERVENTIONAL,['PHASE2'],Incidence of Toxicities,Disulfiram/Copper Gluconate Serum Levels - Area Under the Curve (AUC)
27,NCT03904927,Progression-free survival,2019-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Local control,
28,NCT03730558,Evaluate the efficacy of aflibercept in terms of progression-free survival (PFS) in association with FOLFIRI in patients treated in common practice for metastatic colorectal cancer (CCRM) after failure of oxaliplatin + anti-EGFR-based treatment,2017-11-08,UNKNOWN,OBSERVATIONAL,['NA'],,
29,NCT00002896,,1993-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
30,NCT03714958,Part1: Dose Maximum Tolerated,2018-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression-Free Survival (PFS),
31,NCT04964297,Hydrogen (H2) gas,2021-08-09,RECRUITING,INTERVENTIONAL,['NA'],Response time of the Perf-AlertTM device.,
32,NCT05945823,ORR by investigator assessment,2023-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],6-month PFS rate,
33,NCT03204201,Number of urethras identified under white light and fluorescence,2017-07-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of adverse events related to trial intervention,
34,NCT02324023,T-stage in left sided colonic cancer determined by endoscopic ultrasound compared to histological stage,2014-11,COMPLETED,INTERVENTIONAL,['NA'],Perfusion in left sided colonic cancer determined by contrast enhanced endoscopic ultrasound compared to histological vascular immunostaining,
35,NCT05999162,Onset time,2023-08-04,COMPLETED,OBSERVATIONAL,['NA'],Re-admission,
36,NCT02643173,Recurrence of HCC,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,
37,NCT03170115,Tumor downstaging after induction chemotherapy followed by chemoradiotherapy with or without aspirin,2017-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall survival,
38,NCT05519930,Evaluation of endoscopic ultrasound for early detection of pancreatic cancer in the high-risk group as defined by inclusion criteria to determine their level of risk and perform surveillance accordingly,2016-10-18,SUSPENDED,OBSERVATIONAL,['NA'],,
39,NCT04083365,Pathological complete response (pCR) rate after durvalumab treatment,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease-free survival (DSF),
40,NCT06285097,Objective response rate (ORR) in Part 2 Expansion,2024-02-08,RECRUITING,INTERVENTIONAL,['PHASE1'],AUC of PF-07820435 and its active metabolite under fasted and fed conditions (Part 2 subset) subset of participants in Part 2,
41,NCT00553683,Overall tolerability,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Overall survival at 6, 12, and 24 months",
42,NCT04695782,1-year local control,2020-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Patient reported outcomes,
43,NCT04846842,Objective response rate (ORR),2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
44,NCT02934464,Progression-Free Survival (PFS),2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life EuroQol EQ-5D,
45,NCT02901600,Determination of the histological localisation of DMBT1,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,
46,NCT01394939,Determine Radiographic Response Rate of Patients Enrolled in the Phase 2a Portion of the Study,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
47,NCT02504983,Complete remission,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],Safety and tolerability of TACE plus sorafenib therapy recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.,
48,NCT04609410,Total intra-operative blood loss,2020-10-30,RECRUITING,INTERVENTIONAL,['NA'],Surgery and hepatic resection time,90-day quality of life
49,NCT00576498,Proportion of patients with biopsy confirmed intestinal metaplasia,2005-10,COMPLETED,INTERVENTIONAL,['NA'],Inter observer variability in reading of mucosal and vascular patterns,
50,NCT05609370,Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C,2023-01-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Number of Participants with anti-drug antibodies (ADAs) to Tislelizumab, and Bevacizumab in Arm A, Arm B and Arm D",
51,NCT04721223,Objective response rate (ORR),2021-04-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants with Treatment-related Adverse Events(TRAE),
52,NCT04666688,Part 2: PFS or ORR [Preliminary Efficacy],2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Part 1: Pharmacodynamics (PD) of LYT- 200,
53,NCT05438797,incidence of adverse events( AE )and Serious adverse events(SAE),2021-04-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Progression-free survival (PFS),
54,NCT05000554,pCR rate,2021-07-02,RECRUITING,INTERVENTIONAL,['PHASE2'],operative mortality,
55,NCT05445973,Local tumor progression rate,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],Technical success rate of radiofrequency ablation using contrast-enhanced US-CT/MRI fusion image,
56,NCT05273931,Changes in adherence to the lifestyle recommendations between baseline and the 4 week follow-up,2022-03-16,COMPLETED,INTERVENTIONAL,['NA'],,
57,NCT00527891,,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,
58,NCT03115398,Number of Missed Scheduled Radiotherapy Treatments,2017-02-16,COMPLETED,INTERVENTIONAL,['NA'],Survival Status,
59,NCT01791322,Correct identification of tumor mutant genes,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
60,NCT00493402,Overall survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Time to progression,
61,NCT04991948,The objective response rate (ORR) at the tumor assessment on Day 94 [Visit 15]),2021-11-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,
62,NCT01445327,"Number of Participants With Specific Tumor Markers in Stool, Urine, or Serum Detected Prior to Treatment and After Treatment",2007-02-20,TERMINATED,OBSERVATIONAL,['NA'],Number of Participants With Chronic Gastrointestinal Injury After Radiotherapy,Here is the Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC) v3.0.
63,NCT05570279,Complete clinical response,2016-04-01,RECRUITING,OBSERVATIONAL,['NA'],Incidence of pelvis fractures,
64,NCT03515850,classifications vascular branches of IMA,2018-01-05,UNKNOWN,OBSERVATIONAL,['NA'],,
65,NCT00464893,rate of all specific postoperative complications newly observed during a period of 30 days after surgery in those study patients who received at least the first 3 doses of catumaxomab,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"disease-free survival at 3, 6, 9, 12 18 and 24 months after EOT, defined as the time from study enrolment to the point of diagnosis of recurrent disease or death, whichever occurred first",
66,NCT06255912,Treatment Emergent Adverse Events,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],overall response rate,
67,NCT04542837,ORR,2020-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],OS,
68,NCT05566834,To determine any increase of treatment emergent adverse events when Minnelide capsules are given in combination with paclitaxel.,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE1'],Plasma levels of Minnelide when given with paclitaxel,
69,NCT03961867,disease-free survival,2020-09-15,RECRUITING,INTERVENTIONAL,['PHASE3'],Treatment related Adverse Events,
70,NCT00932308,The degree of inflammation in the rectosigmoid epithelium as judged by the density and composition of the cellular infiltration.,2006-09,COMPLETED,INTERVENTIONAL,['NA'],Changes in bulk fecal and epithelial associated microbiota that may determine changes in colorectal epithelial cell biologic pathways.,
71,NCT05386056,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Change from baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Score,
72,NCT03621852,tissue yield,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
73,NCT00001428,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
74,NCT01871363,Pathological complete remission rate (pCR),2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Acute and late toxicity,Disease-free survival
75,NCT00467922,"Determine the relative effects of a standard, colloid or crystalloid based strategy for hand-assisted laparoscopic colectomy surgery on decreasing length of stay",2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],1. Determine the effects of the three fluid management strategies on post-operative fluid requirements in colorectal surgery. on the incidence and severity of post-operative complications. on return of gastrointestinal function.,
76,NCT02311361,Number of Adverse Events in Each Cohort With Grade 1 Through 5 Related to Study Drug,2015-03-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),
77,NCT00531180,Correlation between 4-dimensional computed tomography (4D CT) derived ventilation and single photon emission tomography (SPECT) aerosol Tc-99m determined ventilation,2007-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,
78,NCT05868317,Pathologic complete response,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],objective response rate to induction chemotherapy,
79,NCT03312374,Disease Free Survival,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,
80,NCT06056336,2-year disease-free survival in non-pCR patients,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival,
81,NCT03493880,Pathological response,2015-09-01,RECRUITING,OBSERVATIONAL,['NA'],yp TNM Stage,
82,NCT05443230,Long-term results,2022-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
83,NCT05374252,cCR rate,2022-05-07,RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence rate of Grade ≥3 PD-1monoclonal antibody-related adverse events,
84,NCT05473156,Dose-Expansion: Overall response rate(ORR) (assessed by the Investigator according to RECIST version 1.1),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
85,NCT05244174,Level of Fecal elastase-1,2022-01-25,RECRUITING,INTERVENTIONAL,['NA'],Prevalence of PEI,
86,NCT01759238,Progression free survival rate,2013-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicity,
87,NCT05342636,Objective Response Rate (ORR),2022-07-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase,
88,NCT02577393,Superiority of EGCG in reducing Grade II esophagitis as assessed by RTOG scores in patients with lung cancer receiving radiation,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Improved quality of life with usage of EGCG for treatment of radiation-esophagitis in patient with lung cancer.,
89,NCT05617755,Maximal tolerated dose of AB-1015,2022-11-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Co-expression of ALPG and MSLN targets on tumor cells,
90,NCT00201747,Most efficacious of two combination regimens of sequential CPT-11 and MMC in patients with advanced and previously untreated esophageal and GE junction adenocarcinomas,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Evaluate if pre- and/or post-treatment Topo I-, CE and NQ01-gene expression in fresh tumor specimens and adjacent tissue, are associated with antitumor efficacy or toxicity.",
91,NCT00747292,Length of hospital stay,2007-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Pain, time till flatus, time till bowels open, incidence of nausea and vomiting, quality of life",
92,NCT04099901,Reduction of the incidence of fever during neutropenia,2019-11-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor response evaluation,
93,NCT01265979,WB-DWI as early predictor for regorafenib treatment response,2011-01,COMPLETED,OBSERVATIONAL,['NA'],Evaluation WB-DWI parameters in correlation with progression free survival (PFS),
94,NCT01016639,,2003-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
95,NCT02550769,Evaluate the effectiveness of the T-TME versus L-LAR with the LARS score in patients with rectal cancer.,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,
96,NCT00478634,Dose Limiting Toxicities,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Objective Response Rate,
97,NCT02607072,3-year disease free survival,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
98,NCT00003125,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
99,NCT05045573,Pathological tumor response,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],Rate of Healthy liver hypertrophia,
100,NCT04821284,Progression-free survival,2021-12-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumor stiffness,
101,NCT01397305,Feasibility of Pemetrexed Prior to Surgery,2011-04-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Pharmacokinetic parameters of [6R] 5,10-mTHF, 5-formyl-THF, 5-methyl-THF and THF calculated from plasma",
102,NCT00377936,Overall survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of clinically significant abnormal laboratory values,
103,NCT05484908,Mortality rate,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Model for end-stage liver disease (MELD) score variation,
104,NCT04550663,The occurrence of AEs and SAEs during the study treatment,2020-09-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
105,NCT01970748,Bleeding,2009-08,RECRUITING,INTERVENTIONAL,['PHASE4'],Complication survival,
106,NCT05692895,Diagnosis and prognosis of colorectal carcinoma,2023-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
107,NCT03256994,Description of the clinical context in which SIR-Spheres are applied,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],Diagnosis- and treatment-related considerations,
108,NCT00473980,Immune reactivity,1998-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
109,NCT02588781,overall response rate,2015-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of subjects with Adverse Events as a measure of safety and Tolerability,
110,NCT05035914,Objective response rate,2021-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Score of quality of Life,
111,NCT06017661,IL-8 level,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],Patients' quality of life,
112,NCT06259292,Prospective Longitudinal Clinical Outcomes Assessment using HHT Clinical Outcomes Scale,2023-11-13,RECRUITING,OBSERVATIONAL,['NA'],Treatment Outcomes Assessment with HHT Treatment Outcomes Scale,
113,NCT04857684,Proportion of patients with grade 3-4 treatment-related adverse events as assessed by CTCAE v5.0,2021-06-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Recurrence-free survival (RFS) after resection,
114,NCT05541146,Rate of complete peritoneal response after 04 cycles of intraperitoneal (IP) chemotherapy (CMT) associated with systemic CMT with XP.,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
115,NCT02327819,time until a new liver tumor is found,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,
116,NCT05131698,Objective response rate,2021-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
117,NCT01859728,Overall Response Rate,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety,Biomarker evaluation
118,NCT02112656,Overall Survival (OS),2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression-free survival (PFS),
119,NCT03843853,Progression-free Survival(PFS),2019-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
120,NCT02050503,Pain Intensity Difference,2012-12,COMPLETED,OBSERVATIONAL,['NA'],number of episodes of breakthrough pain requiring additional (rescue) analgesic treatment after administration of the study medication,safety of intranasal transmucosal fentanyl
121,NCT00403624,Tumour response,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease free and Overall survival ; Adverse events,
122,NCT04830618,Metachronous recurrence,2012-09-11,COMPLETED,OBSERVATIONAL,['NA'],,
123,NCT00700258,"Efficacy: best response, progression-free survival, overall survival",2008-02-13,COMPLETED,OBSERVATIONAL,['NA'],Safety: absolute and relative incidence of therapy interruption,
124,NCT01211379,Change in Colorectal Cancer Screening Rate,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,
125,NCT03167112,Time to Progression (TTP).,2017-07-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
126,NCT00991614,Patency of the stent,2009-12,COMPLETED,OBSERVATIONAL,['NA'],"Procedural success, implant duration, symptom resolution",
127,NCT02003339,Modifications of functional MRI parameters,2013-11,COMPLETED,INTERVENTIONAL,['NA'],Change of VEGF (vascular endothelial growth factor) release,
128,NCT06015022,Change in Prognostic Liver Secretome signature (PLSec) score,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in quality of life measured by the chronic liver disease questionnaire,HCC incidence
129,NCT03175146,Response rate within the treated liver lesion,2017-09,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,
130,NCT01692873,Biomarkers,2012-02,COMPLETED,INTERVENTIONAL,['NA'],Histology,
131,NCT01100814,,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
132,NCT00497224,Objective Response Rate,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Tolerability of Erlotinib Dose Escalation,
133,NCT03381651,Progression free survival,2018-02-22,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,
134,NCT05705219,Diagnostic yield of the 3D-MPUS data acquisition,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Relationship between baseline and one-month 3D-MPUS measurements and treatment response after three-months,
135,NCT00072033,Feasibility of successful study therapy completion and survival after surgery,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Feasibility in Switzerland after surgery,
136,NCT00564694,Reliability and clinical and psychometric validity of the European Organization of Research for the Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-CR29),2007-05,COMPLETED,OBSERVATIONAL,['NA'],,
137,NCT00922896,"To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer",2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
138,NCT03790111,Project Overall Survival Rate at Month 6,2019-03-13,TERMINATED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Serum Albumin,
139,NCT02112240,Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.,2013-05,WITHDRAWN,INTERVENTIONAL,['NA'],Feasibility,
140,NCT05911789,Response rate after surgery,2023-08-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Margins for clinical target volume(CTV) and gross tumor volume (GTV),
141,NCT04208724,Intention to get screened for cancer (type of cancer will be determined by the community-based organization) pre- and post-intervention,2020-11-18,COMPLETED,INTERVENTIONAL,['NA'],,
142,NCT04304001,Rate of Colorectal Cancer Screening,2021-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Colorectal Cancer Screening Self-Efficacy Scale,
143,NCT03577665,2-year local control ratio of the treated liver area,2018-05-21,RECRUITING,INTERVENTIONAL,['NA'],5-year disease-free survival rate of treated patients,
144,NCT03026881,"DLT and safety: Adverse Events (AEs), physical examination, vital signs including blood pressure (BP), pulse, electrocardiogram (ECG) and laboratory findings including clinical chemistry, hematology, urinalysis.",2017-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Plasma Clearance (CL/F),
145,NCT00869739,"Relationship functioning in survivors and partners as assessed by the Dyadic Adjustment Scale (129) and the Miller Social Intimacy Scale (130) at baseline, 2 months, and 5 months",2008-08,COMPLETED,INTERVENTIONAL,['NA'],"Coping skills in survivors and partners as assessed by the Coping Strategies, Social Problem Solving Scale-Revised, and La Trobe Communication Questionnaires at baseline, 2 months, and 5 months",
146,NCT04024917,Cardiac Coherence Program Adherence Rate,2021-09-21,RECRUITING,INTERVENTIONAL,['NA'],Duration of cardiac coherence sessions in minutes,
147,NCT05169437,Overall Response Rate (ORR) - Independent Central Review (ICR),2022-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
148,NCT03347292,Dose Limiting Toxicities(DLTs),2018-06-18,COMPLETED,INTERVENTIONAL,['PHASE1'],Duration of stable disease,
149,NCT00017212,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
150,NCT01937715,Progression-Free Survival (PFS),2014-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change From Baseline in Functional Assessment of Cancer Therapy-Colorectal (FACT-C) (Phase 2),
151,NCT04418401,Recurrence-free rate in one year,2020-06-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Adverse effects,
152,NCT04387071,Objective response rate (CR + PR),2021-04-29,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,Immune cell populations
153,NCT06102759,Progression Free Survival,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
154,NCT00073736,Safety and tolerability,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determine effect of MB07133 on tumor size,
155,NCT00039403,Recommended phase II doses,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1'],"Frequency, extent, and duration of any tumor responses",
156,NCT01732393,lower grade of mucositis,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",duration of mucositis,
157,NCT01836991,the overall survival time,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
158,NCT04269083,"R0, number of patients achieving R0 resection.",2020-05-24,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],safety profile,
159,NCT05084859,Part 2 - Objective response rate,2021-11-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Part 2 - Blood samples for measurement of the plasma levels of SM08502 and its metabolite,
160,NCT03746353,perioperative complications,2018-09-05,TERMINATED,INTERVENTIONAL,['NA'],Measure quality of life,
161,NCT00622674,Maximum tolerated dose (MTD) of bortezomib,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Disease response as measured by RECIST criteria,
162,NCT04014101,Objective response rate(ORR),2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
163,NCT01403402,Congenital Muscle Disease Patient and Proxy Reported Outcomes,2009-09,RECRUITING,OBSERVATIONAL,['NA'],,
164,NCT03291561,Gastrointestinal function score,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Physical fitness index,
165,NCT01110668,To evaluate time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],To determine progression-free survival and the response rate of nilotinib in patients with advanced GIST previously treated with imatinib ≥600 mg.,
166,NCT02331641,"Number of postoperative complications after MH or MMH, graded based on the Dindo's classification (Dindo et al. Ann Surg 2004;240:205-13)",2005-01,COMPLETED,OBSERVATIONAL,['NA'],Long-term outcome (overall and disease-free survival),
167,NCT05253053,Dose limiting toxicity (DLT),2022-04-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Volume of Distribution,changes of main circulating metabolites of TT-00420 in plasma
168,NCT00003780,,1998-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
169,NCT06182865,Measurement of liver reserve obtained from the Ga-68 Dolacga PET performed in HCC patients after proton therapy.,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs),
170,NCT04864054,To determine the Recommended Phase II Dose (RP2D) of ECT204,2022-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],"To characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204, in our study subject population",
171,NCT04422249,Survival rate,2019-12-23,RECRUITING,INTERVENTIONAL,['NA'],intraoperative parameters,Incidence of postoperative complications
172,NCT02762721,Estimate the frequency of FGFR2 fusions in archived iCCA or mixed HCC-CCA tumor tissue samples,2016-06-06,COMPLETED,OBSERVATIONAL,['NA'],Formulate genetic screening recommendations for newly diagnosed patients with iCCA or mixed HCC-CCA,
173,NCT02752360,Anastomotic Stenosis Rate,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],The time of reconstruction in the surgery of Intestinal Anastomosis,
174,NCT02050737,Disease free survival or progression free survival,2013-10,TERMINATED,OBSERVATIONAL,['NA'],To investigate the correlation between biomarkers identified in plasma samples with the expression of the same biomarkers at tissue level.,
175,NCT01212887,Dose of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes that gives the highest frequency in the circulation as measured by the primary assays (recommended phase II dose),2007-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Long-term follow up for insertional mutagenesis,
176,NCT02680990,Feasibility of Large-Scale Trial: Adherence & Contamination,2015-12,COMPLETED,INTERVENTIONAL,['NA'],Assessing the interaction between frailty and the Band Together program,
177,NCT03904537,Disease-free survival (DFS）,2019-02-19,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","The quality of life by EQ-5D-5L (EuroQol Group, Chinese versions )",
178,NCT02869269,Circulating helper T cell activity,2015-10,COMPLETED,OBSERVATIONAL,['NA'],Cytotoxic T cell and natural killer cell activity,CD4 and Treg cell activity and change of percentage of CD39 and CD73
179,NCT02324127,Hsp90α Concentration of plasma,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],,
180,NCT02663427,detection rate of gastric cancer among all group,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,
181,NCT02041481,DLT defined as an adverse event or abnormal laboratory value assessed as at least possibly related to the combination of MEK inhibitor MEK162 and FOLFOX graded according to NCI CTCAE v4.03,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Survival,
182,NCT04602299,focal lesion detection rate,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],rate of procedures reaching the minimal time,
183,NCT02139488,To quantify motion of the esophageal tumor over the course of chemoradiation,2014-04-18,COMPLETED,OBSERVATIONAL,['NA'],,
184,NCT03569488,validation of the French version of the LARS score,2020-01-24,RECRUITING,OBSERVATIONAL,['NA'],,
185,NCT04491955,Objective Response Rate (ORR) for Quadruple Therapy,2020-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants Hospitalized Due to Serious Adverse Events Attributed to Progressive Disease (PD),Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
186,NCT03777943,Immunohistochemistry (IHC) analysis,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],Laser capture microdisssection (LCM) followed by gene expression analysis,
187,NCT03867409,Interpersonal Distance,2018-11-05,COMPLETED,INTERVENTIONAL,['NA'],,
188,NCT00733889,• Complete clinical response rate and objective clinical response rate after the administration of 3 cycles of chemotherapy plus cetuximab and after induction chemotherapy followed by concomitant chemoradiotherapy plus cetuximab,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],• To determine EGFR expression in the tumour and attempt to correlate it with efficacy,
189,NCT05566899,Acceptability and feasibility of EGD-SC measured by Linear Scale,2023-02-08,RECRUITING,INTERVENTIONAL,['NA'],Number of participants with AE's will be measured by the Cancer Therapy Evaluation Program Common Toxicity Criteria (CTC) Version 5.0,Acceptability and feasibility of EGD-SC measured by Linear Scale
190,NCT00055848,,2001-12,COMPLETED,OBSERVATIONAL,['NA'],,
191,NCT05693649,CRC screening completion at 3 years,2023-06-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Choice of test,
192,NCT01126840,Compare Predictors of Health-Related Quality of Life (QOL) among Colorectal Cancer (CRC) Survivors who have Lynch Syndrome (LS) with patients who have Sporadic CRC,2010-06-20,COMPLETED,OBSERVATIONAL,['NA'],,
193,NCT01674374,Proportion of patients with severe mucositis (WHO score 3 or 4),2013-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Quality of Life as assessed by EORTC QLQ Head and Neck Cancer-Specific Module function and symptom sub-scores between groups (with 1 being not at all and 4 being very much),
194,NCT02305758,Progression-Free Survival (PFS): Time to Event,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate (ORR),
195,NCT04834505,To construct a diagnosis model for distinguishing FAIP from PC and further validate its efficacy,2021-05-11,RECRUITING,OBSERVATIONAL,['NA'],Compare the efficacy of EUS based on the model with that of CT/MRI/PET-CT in differentiating between FAIP and PC,
196,NCT00956930,Time to Progression (TTP) in Patients Treated With TACE and Y90,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
197,NCT00666991,Determine maximum tolerated dose and to assess qualitative and quantitative toxicities,2008-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Determine pharmacokinetics of intraperitoneal administration,
198,NCT03672422,Length of time from progression from Acute Recurrent Pancreatitis to Chronic Pancreatitis,2017-06-30,COMPLETED,OBSERVATIONAL,['NA'],Number of subjects with abnormal oral glucose tolerance test (OGTT),
199,NCT03518502,Overall survival,2012-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Median survival time (MST),
200,NCT00001431,,1995-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
201,NCT00063401,"To determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer.",2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],To access EGFR expression by immunohistochemical assay.,
202,NCT02326727,Plasma concentration of cytokines,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],,
203,NCT00394433,10-month Progression-Free Survival Rate,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-Free Survival,
204,NCT05930860,Recurrence rate,2021-12-12,RECRUITING,OBSERVATIONAL,['NA'],,
205,NCT01102088,Maximum Tolerated Dose (MTD) of Simultaneous Integrated Boost (SIB),2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Pathologic Response,
206,NCT05489289,Recurrence free survival (RFS) by BICR,2022-09-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Types and proportions of adverse events (AEs),
207,NCT05045976,Change of Functional Assessment of Cancer Therapy- Colorectal,2021-09-19,RECRUITING,INTERVENTIONAL,['NA'],M.D. Anderson Symptom Inventory,
208,NCT02185768,Rate of patients in objective response (complete or partial response),2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Treatment tolerance,
209,NCT04150705,Technical Feasibility of PET/MRI as Measured by the Completion of the Study With Acceptable Image Quality in ≥70% of Scans,2020-06-01,TERMINATED,INTERVENTIONAL,['NA'],Percentage of Scans With Changes in Perceived Disease Status as Measured by PET/MRI Tumor Regression Grade Relative to the Conventional MRI Only Tumor Regression Grade,
210,NCT00865709,Progression-Free Survival (PFS),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response,
211,NCT05280210,pathological complete response rate(pCR),2022-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],prediction accuracy of PTC,
212,NCT02004262,"2nd-line Cohort: OS (All Data, FAS)",2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events in Each Treatment Arm Treatment Regimen,
213,NCT01404156,treatment response,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",EORTC QOL,
214,NCT03059147,Rate of dose limiting toxicities,2017-03-27,TERMINATED,INTERVENTIONAL,['PHASE1'],Progression-free survival,
215,NCT05246839,Impact of Brief Videos,2022-04-28,RECRUITING,OBSERVATIONAL,['NA'],,
216,NCT05286086,Comprehension Complication Index (CCI),2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Hospital Anxiety and Depression Scale (HADS) test : anxious and depresion scale,
217,NCT04487704,Assess Safety as defined by the NCI CTCAE v5.0,2020-04-07,RECRUITING,INTERVENTIONAL,['NA'],overall survival,
218,NCT03073226,Sensitivity,2016-02-06,COMPLETED,INTERVENTIONAL,['NA'],Endoscopists confidence,
219,NCT00782457,"Lymph nodes isolated, circumferential margin involved, rate of complications and length of stay",2002-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
220,NCT00500188,Disease-free survival (DFS) time,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
221,NCT04380480,Percentage of Recent Weight Loss,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],"Changes of participants' intestinal flora assessed by blood, urine and stool test",
222,NCT04563416,the diagnosis efficiency of the computer-assist diagnosis tool,2020-07-10,UNKNOWN,OBSERVATIONAL,['NA'],,
223,NCT03010085,"Checklist of functional recovery (Questionnaire, liver function test of aspartate aminotransferase and alanine aminotransferase)",2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life,
224,NCT00414843,Establish Repository of Human Bile,2006-12,TERMINATED,OBSERVATIONAL,['NA'],,
225,NCT05381792,Serial gut microbiome changes after endoscopic resection of colorectal advanced neoplasia.,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],"The differences in the bacterial gene markers (Fn, m3, Bc and Ch) between advanced adenoma and CRC",
226,NCT04427527,CRC screening - clinic level,2020-08-19,RECRUITING,INTERVENTIONAL,['NA'],CRC screening - community level,
227,NCT00871169,Overall Response Rate (ORR),2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,
228,NCT05381636,Progression free survival (PFS),2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
229,NCT05994001,Incidence of Treatment-Emergent Adverse Events(Phase I),2023-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",OS,
230,NCT00003810,,1999-08-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
231,NCT05312216,Objective response rate (ORR),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (AEs),
232,NCT02534961,Infection after radiofrequency ablation,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
233,NCT02143115,"Compare the test characteristics (sensitivity, specificity, positive and negative predictive value) of Computed Tomography colonography (CT-C) in the post Colorectal cancer resection using optical colonoscopy as the reference standard",2011-08,COMPLETED,OBSERVATIONAL,['NA'],Compare the costs and outcomes of Computed Tomography Colonography versus independent Optical Colonoscopy plus Computed Tomography for post Colorectal Cancer resection surveillance.,
234,NCT01754896,FIT Kit uptake,2012-04,COMPLETED,INTERVENTIONAL,['NA'],Rejection rates,
235,NCT04592393,Detection of pancreas cancer,2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Detection of pancreas cancer,Identification of super-high risk group of developing pancreas cancer
236,NCT01336049,Objective response rate,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
237,NCT03158610,Progression Free Survival 2 (PFS2),2018-01-29,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Number of participants with quality of life (QoL) as assessed by CTCAE v4.0,
238,NCT01927146,Overall survival,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],,
239,NCT02014025,survival rate,2013-03,COMPLETED,INTERVENTIONAL,['NA'],intraoperative parameters,postoperative complications
240,NCT01901042,Changes in quality of life,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
241,NCT04221893,Overall response rate (ORR),2020-08-07,RECRUITING,INTERVENTIONAL,['NA'],Time to new systemic therapy,
242,NCT04501913,Staff ability to act on identified threshold healthcare parameters,2019-12-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Changes in PGHD/PROs,
243,NCT06226857,progression-free survival,2024-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],progression-free survival based (per protocol),
244,NCT04130854,Pathological Complete Response Rate,2020-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease free survival,Exploratory Immunological Response
245,NCT01071941,Characterize rRp450 pharmacokinetics and viral shedding.,2010-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Correlate radiographic and pathologic assessments of tumor response.,
246,NCT04576572,Tumor recurrence,2020-06-15,COMPLETED,OBSERVATIONAL,['NA'],The Best Criteria,
247,NCT01929902,Placement of Aquamantys Device,2013-07,COMPLETED,OBSERVATIONAL,['NA'],Device Complications,
248,NCT05451160,30-day complete ablation rate,2022-03-16,RECRUITING,INTERVENTIONAL,['NA'],Equipment failure rate,
249,NCT04852250,Secondary intervention rate,2021-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],"Type, incidence, relatedness, and severity of adverse events with severity ≥ Grad 3 (severity according to NCI CTCAE version 5.0)",
250,NCT03250273,Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1),2017-11-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS) at 24 Months,
251,NCT06144853,The number of patients with metabolic response according to FDG-PET/CT evaluated by PERCIST 1.0 one lesion after PIPAC 3,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The number of patients where FDG-PET/CT evaluated by PERCIST one lesion agrees with histological response according to PRGS after PIPAC 1 and 3,
252,NCT00380055,"Proportion of individuals receiving recommended screening for prostate, breast, colorectal, and cervical cancer.",2006-10,COMPLETED,INTERVENTIONAL,['NA'],Cost-effectiveness of using community navigators to improve cancer care among rural Native Americans.,
253,NCT00376909,"Screening rates as measured by mammography, Pap test, hfoBT, sigmoidoscopy, barium enema and colonoscopy",2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
254,NCT04401709,Two-year disease free survival (DFS),2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),
255,NCT00057382,,2003-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
256,NCT06259149,VTE events within 28 days after surgery,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],Any bleeding event within 28 days after surgery,
257,NCT04638036,Feasibility of molecular fluorescence-guided surgery using Cetuximab-800CW,2020-11-13,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluation of the distribution of Cetuximab-IRDye800CW,
258,NCT05540483,AEs,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],Overal Survival,
259,NCT03403101,progression free survival (PFS),2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity evaluated according to the Common Terminology Criteria Adverse Events,
260,NCT00795301,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
261,NCT01349309,Functional Oral Intake Scale (FOIS),2007-06,COMPLETED,INTERVENTIONAL,['NA'],,
262,NCT04898504,Overall survival at 2 years,2021-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life using EQ-5D-5L,
263,NCT02813967,Overall survival,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,the oesophagus-specific quality-of-life
264,NCT05087459,Comparison of total amount of postoperative drainage fluid between treatment group and control group,2021-06-30,UNKNOWN,OBSERVATIONAL,['NA'],The change of platelet count from baseline at different time points,
265,NCT00003332,,1997-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
266,NCT05675904,disease-free survival,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
267,NCT02119676,Overall Survival (OS),2014-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Treatment-emergent Adverse Events (TEAEs),
268,NCT02147145,Determine the natural history of small (< 30 mm) SELs discovered evaluated by EUS.,2008-08,COMPLETED,OBSERVATIONAL,['NA'],"Compare SEL size estimation based on EUS, EGD and computer tomography (CT).",
269,NCT01558583,Participant-reported most important attribute from survey,2011-07,COMPLETED,INTERVENTIONAL,['NA'],Unlabeled screening test options,
270,NCT01271504,Phase 2: Number of Participants With Markedly Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters,2011-07-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Percentage of Participants With Overall Response,
271,NCT02066701,to determine if assay of aberrantly methylated gene markers can discriminate Barrett's Esophagus tissue (and presence of dysplasia) from esophageal squamous and gastric cardia tissue.,2012-05,COMPLETED,OBSERVATIONAL,['NA'],Assess the accuracy of candidate markers in stool for detection of Barrett's Esophagus,
272,NCT05519410,1-year DFS%,2022-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],2-year DFS%,
273,NCT04821765,Locoregional control rate,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Radiomics analysis,
274,NCT01904942,Proteomic investigations,2008-10,COMPLETED,OBSERVATIONAL,['NA'],Infrared spectroscopic investigations,
275,NCT00923897,To determine the change in index symptom(s) using an 11 point numerical rating scale for patients with locally advanced hepatocellular cancer or hepatic metastases treated with 8Gy,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],To determine serum marker and radiographic response with 8Gy,
276,NCT04476082,Prevalence of Malnutrition According to the Global Leadership Initiative on Malnutrition criteria (GLIM criteria),2020-06-25,COMPLETED,OBSERVATIONAL,['NA'],Intestinal Microbiome,
277,NCT04127864,Cytokines in R848 stimulated blood,2019-10-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Cytokines in unstimulated blood,
278,NCT00003596,,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
279,NCT00279292,injection for pain in pancreatic cancer patients at 1 month and 3 months.,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3'],To estimate the effect of treatment on quality of life at 1 month and 3 month,
280,NCT04980287,metastasis rate,2021-01-12,RECRUITING,OBSERVATIONAL,['NA'],3-year DFS,
281,NCT01506336,overall progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival,
282,NCT05134961,3-year survival,1999-01-01,COMPLETED,OBSERVATIONAL,['NA'],Duodenal cancer recurrence,
283,NCT00914615,"Determine one year local progression free rate, defined as lack of progression within the irradiated volume, using RECIST criteria.",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Cytokine response to radiation and association with complications,
284,NCT05023928,Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0,2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Disease-free Survival,
285,NCT04961918,PFS,2021-07-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],OS,
286,NCT01034189,"To determine the clinical response rate in patients with loco-regional esophageal squamous cell carcinoma treated with cetuximab combined with twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (C-TP-CCRT, 40 Gy).",2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Safety and toxicity of cetuximab combined with twice weekly TP-CCRT, followed by surgery.",
287,NCT02150447,Time-to-bleeding event,2009-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Overall survival,
288,NCT01476631,"Exercise will decrease serum markers (insulin, C-peptide, IL-6 and PGE-2) in a dose response manner.",2008-11,TERMINATED,INTERVENTIONAL,['NA'],Participants in the 60 minute intervention will have significantly higher physical activity levels (measured by pedometer and accelerometer) than those in the 30 minute intervention at three months.,
289,NCT01580631,Determine the inter-observer agreement of a consensus driven NBI classification system in Barrett's esophagus.,2012-10,SUSPENDED,OBSERVATIONAL,['NA'],Negative predictive value of the newer NBI classification in identifying dysplasia in Barrett's esophagus.,
290,NCT04246710,Reliability of PDAC molecular subtyping on biopsy samples,2018-01-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
291,NCT03492164,Number of Adverse Events,2018-03-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
292,NCT04207944,Percent of patients with IPMN progression as measured by a composite of several indicators,2020-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Percent of patients with cyst progression as measured by radiographic images,Percent of patients with Inflammatory Marker Progression
293,NCT00409994,Phase II: Tumour blood flow assessed CT-PET + CTp,2006-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Phase II:Incidence of acute side effects of rapamycin, assessed according to CTCv 4.0",
294,NCT06278064,Plasma proteins in patients with esophagus cancer,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
295,NCT00041665,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
296,NCT00526617,Pharmacokinetic Profile,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
297,NCT04501887,Progression-free survival,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Positive rate,
298,NCT04796818,Absolute change in the true diffusion coefficient (D),2020-08-12,RECRUITING,INTERVENTIONAL,['NA'],Diffusion related parameters in intravoxel incoherent motion diffusion weighted imaging,
299,NCT04007640,fibroinflammatory lesions at histology in obese patients,2019-06-18,RECRUITING,INTERVENTIONAL,['NA'],Biomarkers of pathways activation measured by immunohistochemistry on resected pancreatic parenchyma,
300,NCT02785263,The fraction of enrolled patients choosing the lower radiation dose,2016-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Response evaluation assessed by diffusion weighted imaging,
301,NCT03977220,Recommended dose for Phase II study,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
302,NCT02418052,Incidence of post-operative cervical esophagogastric anastomotic leakage,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,
303,NCT00091312,Disease-free survival at 5 years,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Correlation of clinical, histological, and biological prognostic factors with outcome",
304,NCT03670134,Determine association between thickness of neosquamous epithelium measured with volumetric laser endomicroscopy and recurrence of Barrett's esophagus following endoscopic therapy,2018-08-06,WITHDRAWN,INTERVENTIONAL,['NA'],Develop a volumetric laser endomicrosopy feature scoring index to stratify the risk of disease recurrence in patients with Barrett's esophagus following treatment,
305,NCT02744729,Semiquantitative Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan,2015-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Contrast-enhanced CT,
306,NCT00002897,,1992-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
307,NCT03186326,Progression-free survival (PFS) according to the investigator,2018-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
308,NCT00898781,"Correlation of the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers",2007-11,TERMINATED,OBSERVATIONAL,['NA'],,
309,NCT03999658,Objective Response Rate,2023-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of STI-3031,
310,NCT05339581,PVTT RR/NR,2022-05-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Duration of response (DOR),
311,NCT03152565,Progression Free Survival,2018-03-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immunophenotype signature in tumor biopsies before and during treatment.,
312,NCT05247346,Incidence of intervention-emergent adverse events and serious adverse events,2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],Scattering parameters,
313,NCT00728078,morbility,2008-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",recurrence rate,
314,NCT01775267,Liver free of tumors [ Time Frame: At 3 months ] [ Designated as safety issue: No ],2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Postoperative liver and renal function,
315,NCT03884179,Accuracy of EUS-FNA vs Radiology,2007-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Accuracy of EUS FNA vs CEA,
316,NCT05741255,Montreal Cognitive Assessment,2022-01-05,COMPLETED,INTERVENTIONAL,['NA'],,
317,NCT05048524,The percentage of subjects with R0 resection after surgery,2021-09-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers of treatment response by single cell RNA sequencing and whole exome sequencing,
318,NCT02971956,Overall Response Rate (ORR),2017-01-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients Experiencing Grade 3-4 Treatment-Related Toxicity,
319,NCT04778345,Maximum standardized uptake value [SUVmax (for PET/CT only)] for peritoneal carcinomatosis,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],1-year progression patterns,
320,NCT05770882,Progression-free survival (PFS),2023-04-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to progression (TTP),
321,NCT01384708,to determine whether or not tissue is neoplastic or non-neoplastic,2010-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
322,NCT04540081,Overall Adherence to CLOVER Metrics,2020-10-05,COMPLETED,INTERVENTIONAL,['NA'],Hepatitis C screening,
323,NCT04538404,New surgical score using preoperative parameters to predict 30-day mortality after colon cancer surgery in the elderly population,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
324,NCT00593060,To determine the pharmacokinetics of combined treatment with cetuximab and temsirolimus.,2007-11-01,COMPLETED,INTERVENTIONAL,['PHASE1'],To document objective response rate and progression-free survival in patients treated with the combination.,
325,NCT01482299,4-month progression-free survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarker assessment,
326,NCT01075048,Progression-Free Survival (PFS) Using Computed Best Response Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Received Front-Line Systemic Therapy,2010-01-26,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Treatment-Emergent Infection and Infestation Adverse Events Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Received Front-Line Systemic Therapy,
327,NCT01829035,The overall survival (OS) of oral sorafenib given as monotherapy daily compared to sorafenib with combination cTACE in subjects,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3'],Evaluation of adverse events,
328,NCT03619759,Length of stay,2018-03-22,COMPLETED,OBSERVATIONAL,['NA'],Time to first successful oral intake,
329,NCT01512407,1-year recurrence rate,2011-11,COMPLETED,INTERVENTIONAL,['NA'],Health-related quality of life assessment,
330,NCT04609176,Objective Response Rate (ORR) According to RECIST 1.1 based on investigator assessment,2020-11-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants Experiencing an Adverse Event (AE),
331,NCT03638141,Objective response rate (ORR) using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.,2019-10-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants experiencing study drug-related toxicities,
332,NCT03613389,Clinical assessment of Oral Mucositis,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
333,NCT00624182,Safety (toxicities as assessed by NCI CTCAE version 3),2008-02,SUSPENDED,INTERVENTIONAL,['PHASE1'],Survival rate,
334,NCT04813913,Difference in carotid stiffness between baseline and at 4 months of bevacizumab treatment.,2019-05-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],Progression-free survival at 12 months.,
335,NCT03958435,Percentage of Participants with treatment-related Adverse Events as Assessed by CTCAE v4.0 for adjuvant therapy for stage II and stage III colon cancer,2018-11-09,UNKNOWN,OBSERVATIONAL,['NA'],,
336,NCT01464151,low- or high grade dysplasia or colorectal cancer during follow-up,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,
337,NCT04136236,The diagnosis efficiency of Artificial Intelligence,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA'],Contrast the diagnosis efficiency of Artificial Intelligence with endoscopists,
338,NCT02391038,Phase 2- Overall Response Rate,2014-12,TERMINATED,INTERVENTIONAL,['PHASE1'],Phase 2- Number of Participants With ATA in Serum,
339,NCT00554892,Overall morbidity including infectious and non infectious complications,2007-09,COMPLETED,INTERVENTIONAL,['NA'],Evaluate the postoperative complications classified according to the DINDO classification.,
340,NCT06222619,Overall survival,2020-01-30,COMPLETED,OBSERVATIONAL,['NA'],Recurrence free survival,
341,NCT02289053,Prevalence of advanced adenomas among 40-49 year old individuals with and without a family history of colorectal cancer,2006-04-01,COMPLETED,OBSERVATIONAL,['NA'],Absolute prevalence of advanced adenomas in 40-49 year old individuals with a family history of colorectal polyps,Risk factors associated with the presence of advanced adenomas
342,NCT00075738,Objective response rate,2003-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
343,NCT01531777,ORR (Objective Response Rate),2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],QoL (Quality of Life),
344,NCT03439085,Objective response rate (ORR),2018-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
345,NCT02968069,Accuracy of the diagnostic model in histological prediction of gastric cancerous lesions,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],,
346,NCT01253837,Phase II: Investigation of the anti-cancer activity of L19TNFα as measured by Objective Response Rate (ORR),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Investigation of early signs of anti-tumor activity of L19TNFα,
347,NCT05934643,Average daily energy expenditure in MET.h,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],30-day complication rate,
348,NCT05339984,Estimation of the intraoperative portocaval post-procedural gradient.,2023-01-03,RECRUITING,INTERVENTIONAL,['NA'],Prediction of the evolution of hepatic artery and portal vein flows after surgery,
349,NCT02301338,acute healthcare utilization (AHCU) rates,2014-11,TERMINATED,OBSERVATIONAL,['NA'],,
350,NCT01256034,Postoperative Infectious Complication,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],"Plasma IL-6, CRP, Th1/Th2 Balance",
351,NCT05012397,"Overall Response Rate (ORR) of treatment with milademetan, as defined as the percentage of patients who have achieved confirmed complete response (CR) or Partial Response (PR) according to RECIST v1.1 criteria",2021-11-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
352,NCT05585580,Objective response rate （ORR),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE,
353,NCT02266849,Output weight,2014-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Gastrointestinal transit time,Patient evaluation
354,NCT02479217,Number of Participants with Adverse Events,2006-07,COMPLETED,OBSERVATIONAL,['NA'],Disease free survival (DFS),
355,NCT05587556,The survial rate of the patients,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
356,NCT02464618,Compliance with scheduled upper endoscopy and colonoscopy,2014-06-26,COMPLETED,INTERVENTIONAL,['NA'],Bowel preparation quality,Social contact's activity
357,NCT02535117,Overall survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0,
358,NCT02926716,Accuracy for identifying the status of resection margin,2015-12-14,COMPLETED,OBSERVATIONAL,['NA'],Microvessel density,
359,NCT04322539,Overall Survival (OS),2020-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed,
360,NCT05210049,Sensitivity and Specificity of Esocheck/Esoguard in a Veteran population,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],Cost of two screening strategies,
361,NCT00242086,,2004-10,COMPLETED,INTERVENTIONAL,['NA'],,
362,NCT06090994,3-year disease-free survival rate (DFS),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],"The incidence and severity of adverse reactions (ADR), severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR)",Changes in carcinoembryonic antigen (CEA) compared to baseline period (difference)
363,NCT00033241,,2001-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,
364,NCT06018077,Dİetary Total Antioxidant Capacity (DTAC),2022-10-15,RECRUITING,OBSERVATIONAL,['NA'],,
365,NCT00004256,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
366,NCT04701060,objective response rate,2021-01-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],Feasibility as measured by rate of enrollment,To investigate the clinical efficacy of PD-L1 expression in predicting the combination of Camrelizumab and apatinib
367,NCT03008499,Relief degree of tumors,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival（OS）,
368,NCT01015118,"PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).",2009-11-17,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.,
369,NCT02657044,Recurrence rate at follow-up colonoscopy after 6 months,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],R0-resection rate,
370,NCT04612712,Phase II part - Objective response rate(ORR),2021-01-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-Free Survival (PFS),
371,NCT04931420,Progression Free Survival,2025-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The Effect of Interventions on Circulating Tumor DNA (ctDNA),
372,NCT05359406,Early Tumor Shrinkage,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Acute toxicity associated with immunotherapy,
373,NCT05465590,Volume of distribution (VZ),2022-12,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,
374,NCT00719199,• The primary objective of this study is to determine the recommended phase 2 dose of IMO 2055 when combined with FOLFIRI and cetuximab in patients with histologically proven advanced or metastatic colorectal cancer (CRC).,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],• To investigate potential markers of IMO 2055 immune activation and effect on cellular immunity.,
375,NCT05656326,Successful implementation,2021-08-23,RECRUITING,OBSERVATIONAL,['NA'],Satisfaction of the patient-led home-based follow-up,
376,NCT04588025,Measure change in blood flow within the pancreatic cancer as measured by the P4.,2020-10-14,RECRUITING,INTERVENTIONAL,['NA'],,
377,NCT05168527,ORR,2021-09-03,RECRUITING,INTERVENTIONAL,['PHASE2'],DOR,
378,NCT02751086,Rate of patients alive,2016-04,RECRUITING,OBSERVATIONAL,['NA'],Rate of complications after discharge,
379,NCT02439086,Accuracy of Texture analysis PET-CT,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],Accuracy of Texture analysis MRI,
380,NCT03344614,PFS,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],DCR,
381,NCT06111872,To evaluate the efficacy of Ketamine- Midazolam as a sedative agent in ERCP in terms of sedation failure rate.,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2'],To compare the depth of sedation,
382,NCT03744962,Frequency of microsatellite instability,2018-11-10,UNKNOWN,OBSERVATIONAL,['NA'],,
383,NCT00901173,Esophageal squamous cell carcinoma,2014-02-10,COMPLETED,OBSERVATIONAL,['NA'],,
384,NCT04074447,The proportion of ctDNA content decreased in patients with good therapeutic effect,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
385,NCT01718808,Progression free survival in week 12,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],"Overall treatment utility (OTU) (predefined composite endpoint including clinical benefit, tolerability and acceptability of the treatment)",
386,NCT05385692,Phase Ib: Recommended Phase II Dose (RP2D),2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-free Survival (PFS),
387,NCT04233840,"Phase II portion - Recurrence-free survival (defined as the time from randomization to HCC recurrence or death from any cause, whichever occured first)",2019-02-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",HBsAg level,
388,NCT05434520,30-day Readmission,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],Histological Specimen,
389,NCT06189560,Video fluoroscopic swallowing study,2022-06-21,TERMINATED,INTERVENTIONAL,['NA'],Rosenbek penetration-aspiration scale,
390,NCT04868149,Amount of future liver remnant volume increment by percentage after stage I ALPPS,2020-09-02,RECRUITING,INTERVENTIONAL,['NA'],Inflammatory markers associated with inflammation and regeneration after stage 1 ALPPS,
391,NCT03377842,Progression-free survival (PFS),2018-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
392,NCT05641922,Safety,2023-07,WITHDRAWN,INTERVENTIONAL,['NA'],Assessment Module (1),Assessment Module (2)
393,NCT02987907,proportions of participants with severe adverse events according to CTCAE v4.03,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],time to progression (TTP),
394,NCT00197405,,1999-08,UNKNOWN,OBSERVATIONAL,['NA'],,
395,NCT00696345,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
396,NCT04764240,OS,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
397,NCT03881501,PFS,2019-03-05,UNKNOWN,OBSERVATIONAL,['NA'],Safety as measured by number and grade of adverse events,
398,NCT05988372,R0 Surgical Resection Rate,2023-10-23,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of Life (QOL),
399,NCT02269332,Adenomatous Polyps,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,
400,NCT05895942,Degree of tumor regression,2021-09-10,RECRUITING,OBSERVATIONAL,['NA'],,
401,NCT04351880,Anxiety and Depression measured through the Hospital Anxiety and Depression Scale,2020-04-16,COMPLETED,INTERVENTIONAL,['NA'],Re-hospitalization and Emergency Department Visits,
402,NCT03130166,Postoperative recovery,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],Whole blood gene expression profiling,
403,NCT02959359,The primary objective of the study is annual recurrence-free survival after curative resection of HCV-HCC for up to 5 years.,2016-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],Overall survival,
404,NCT03172416,Tolerability of PIPAC with oxaliplatin in combination with IV nivolumab by monitoring dose limiting toxicities,2017-04-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Area under the curve (AUC) of oxaliplatin and in combination with IV nivolumab administered via PIPAC using blood drawn from patient.,
405,NCT01386346,Evaluation of dose limiting toxicity (DLT),2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
406,NCT05114213,Mean cumulative pain index,2021-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Death from any cause,
407,NCT00842244,Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs),2009-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression-Free Survival (PFS),Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Cisplatin and Capecitabine
408,NCT02646514,Patency of metal stent,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],Complication rate,
409,NCT05400681,Relative frequency of ctDNA in peritoneal lavage and peripheral blood,2020-08-01,RECRUITING,OBSERVATIONAL,['NA'],Prognostic value of ctDNA in peritoneal lavage and peripheral blood,
410,NCT04780789,Interobserver variability of the methods used for assessing tumor response to the treatment,2015-02-01,COMPLETED,OBSERVATIONAL,['NA'],"Response to the treatment, as assessed by volumetric analysis",
411,NCT00667641,Maximum tolerated dose of paclitaxel in combination with bortezomib,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
412,NCT03407495,The Sensitivity and specificity of IOP-enhanced MRI,2018-11-22,COMPLETED,INTERVENTIONAL,['PHASE2'],The size of lesions detected in liver,
413,NCT05162248,Disease-Free Survival,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
414,NCT05052801,Overall Survival,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of Participants with an Anti-bemarituzumab Antibody Formation,
415,NCT00851968,overall survival,2008-12,COMPLETED,INTERVENTIONAL,['NA'],"serum alanine aminotransferase (ALT), bilirubin, prothrombin time, serum albumin and pre-albumin on postoperative 1, 3, 7 day, resection rate, procedure-related complications and hospital mortality,expression of HIF and P-, E-, and L-selectin",
416,NCT03613142,Rate of reflux esophagitis after operation,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],postoperative quality of life,
417,NCT03113214,Maximum Tolerated Dose,2017-02-02,COMPLETED,INTERVENTIONAL,['NA'],Time to Local Failure,
418,NCT01932918,lung injury score,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
419,NCT00134069,Pharmacodynamics of the combination of irinotecan when given in combination with sorafenib and cetuximab in tumor tissues,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
420,NCT01545544,"presentation of NHL and HCV infection, and treatments of NHL and HCV infection",2006-11,UNKNOWN,OBSERVATIONAL,['NA'],haematological response,
421,NCT02438839,Proportion of patients with locoregional tumor control with chemoradiation alone two years after end of treatment,2015-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],"Response and tumor control on MRI scans compared to clinical observations, including rectoscopic examination",
422,NCT02480114,"Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))",2015-07,COMPLETED,INTERVENTIONAL,['PHASE3'],"Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)",
423,NCT05667298,Safety (proportion of patients developing Grade 3 or above adverse events),2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-free survival,
424,NCT06143722,Progression-Free Survival (PFS),2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
425,NCT06006286,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-08-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
426,NCT02836925,SVR12,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity - Incidence of Adverse Events,
427,NCT04576208,Number of Participants with Treatment Emergent Adverse Events (TEAEs) of ≥Grade 3 Diarrhea Occurring During the First 4 Cycles of TAK-788 Dosing,2020-11-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Health-Related Quality of Life (HRQoL) as Assessed by Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Score,
428,NCT00153881,To determine the maximum tolerated dose of oral capecitabine in combination with fixed doses of weekly docetaxel and concurrent radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1'],"To investigate the feasibility of assaying thymidine phosphorylase, cyclin B, MPM-2, and perturbations in cell cycle as potential markers of efficacy.",
429,NCT01733628,Progression Free Survival (PFS),2012-10-23,COMPLETED,OBSERVATIONAL,['NA'],"Number of Participants With ""White Coat"" AHT With 24 Hours Ambulatory BP Measure",
430,NCT00829595,"Response, defined by postvaccination antibody titers",2005-05,COMPLETED,INTERVENTIONAL,['NA'],,
431,NCT06261125,Progression-free survival (PFS),2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Correlation between serum cytokines and overall survival and immune-related adverse events
432,NCT00005616,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
433,NCT05214820,Tumor uptake of 68Ga-PSMA,2022-01-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Radiation dose (mGy),
434,NCT05407584,Confirmed ORR,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE2'],second objective disease progression,
435,NCT05495217,Operative time,2021-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Tumor size,
436,NCT04126733,Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator,2019-10-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Different Severity Types of TEAEs Per Common Terminology Criteria for Adverse Events (CTCAE) v5,
437,NCT02907385,Incidence of overall anastomotic leak,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Incidence of post operative anastomotic leaks,
438,NCT05443087,Trough concentration (Ctrough),2022-08-29,RECRUITING,INTERVENTIONAL,['NA'],Safety: drug toxicity,
439,NCT03753659,Objective response rate (ORR) according to RECIST 1.1,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Identification of molecular biomarkers in tumor tissue and blood samples by immunohistochemical and molecular analyses in a central lab,
440,NCT05431244,Objective Response Rate (ORR),2022-07-01,WITHDRAWN,INTERVENTIONAL,['NA'],Best Overall Response Rate (BOR),
441,NCT04365751,Overall survival,2019-12-26,RECRUITING,INTERVENTIONAL,['NA'],Local rate of progression,
442,NCT04510935,mean percentage change from post- to pre-operative values of invasion of HepG2 cells cultured in patients' serum,2020-08-20,COMPLETED,INTERVENTIONAL,['NA'],serum IL-2 level,
443,NCT02893982,maximum tolerated dose,2017-11-09,TERMINATED,INTERVENTIONAL,['PHASE1'],local control,
444,NCT03233555,Use of preventive services,2013-09-03,COMPLETED,INTERVENTIONAL,['NA'],,
445,NCT01324284,Quality of bowel preparation in Same day Low volume PEG with placebo versus same day low volume PEG with Lubiprostone,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
446,NCT05304481,Relapse-free survival rate,2022-05-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in respiratory rate,
447,NCT05585437,patient complication rate,2021-11-11,COMPLETED,OBSERVATIONAL,['NA'],,
448,NCT01189877,Measure pO2 in rectal cancers,2010-08,COMPLETED,INTERVENTIONAL,['NA'],Correlate immunohistochemical analysis of endogenous markers of hypoxia,
449,NCT00584597,The specific aim will be to determine the safety of TRAUMEEL S for mucositis in head and neck cancer patients undergoing radiation therapy,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
450,NCT03589443,Validate the binding of the peptides using the SFE,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Use of the SFE to detect QRH and KSP via contrast,
451,NCT05282433,Progression-free survival,2022-04-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,
452,NCT02376452,progression free survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of life questionnaire,
453,NCT02873598,The Maximum Tolerated Dose (MTD) of Stereotactic Body Radiotherapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients Who Have Not Developed Distant Progression After Induction Chemotherapies.,2016-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],Quality of Life (QOL),
454,NCT02495311,The corrleation coefficient between the size of myoma and Overactive Bladder Symptoms Scores,2014-11-15,RECRUITING,OBSERVATIONAL,['NA'],Comparisons of the constipation/diarrhea rates between the adenomyosis group and the control group,
455,NCT00639522,Dose limiting toxicity,2008-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],Pharmacokinetics,
456,NCT04303403,Maximum Tolerated Dose,2018-07-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival,
457,NCT02976142,Overall 2-year survival,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life,
458,NCT05032027,grade 3 entiritis,2021-08-27,RECRUITING,INTERVENTIONAL,['NA'],Changes in intestinal flora,
459,NCT04133155,Progression-free survival,2019-09-16,COMPLETED,OBSERVATIONAL,['NA'],Toxicity profile,
460,NCT00827684,Objective response rates,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Translational Research,
461,NCT01429038,"Incidence of infections (bacterial, viral, fungal, parasitic) and cancers",2012-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Anti-MSC donor HLA antibodies.,
462,NCT02421536,"Change from baseline in ""out of clinic"" pain at 2 months",2016-01-14,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline mucositis pain at 2 months,
463,NCT04317248,"Progression-Free-Survival (PFS), month",2020-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events,
464,NCT00352638,Colorectal cancer screening compliance,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Cost,
465,NCT01577758,AUC0-21 Days: Area Under the Curve Day 0 to Day 21 for MMAE,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With Antitherapeutic Antibodies (ATA),
466,NCT01762293,Progression Free Survival(PFS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events as a Measure of Safety,"body vitals, laboratory parameters"
467,NCT04418739,Overall Complications,2020-01-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Ease of surgery,
468,NCT02375958,Incidence rate of dose limiting toxicities,2015-04-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetic paramater Tmax,
469,NCT00026273,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
470,NCT00737646,Changes in colorectal cancer screening rates (4 modalities),2009-07,COMPLETED,INTERVENTIONAL,['NA'],"Changes in measures of attitudes, beliefs, opinions, and social influence surrounding CRC screening among patients, clinicians, and clinical staff.",
471,NCT04493632,Resection Rates,2022-04-12,RECRUITING,OBSERVATIONAL,['NA'],,
472,NCT01831245,Pathological Anatomic diagnosis (PAD) on a tumor biopsy,2011-01,COMPLETED,OBSERVATIONAL,['NA'],C - reactive protein,Leakage of anastomosis
473,NCT00605150,Progression,2008-01,COMPLETED,OBSERVATIONAL,['NA'],Number of Participants With Unacceptable Side Effects After Treatment,
474,NCT05999396,Safety 3-Hematology-White Blood Cells,2024-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,
475,NCT04151355,incidence of mucositis,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],serum levels of tumor necrosis factor α (TNF-α),
476,NCT05810792,Incidence and severity of Treatment-Emergent Adverse Events as assessed by NCI-CTCAE,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Carbohydrate antigen 19-9,
477,NCT05971069,The safety and efficacy of the decision algorithm for the aberrant left hepatic artery preservation/ligation with real time near-infrared fluorescence imaging,2021-12-17,COMPLETED,INTERVENTIONAL,['NA'],Number of participants with liver-related postoperative complications as assessed by serum aspartate transaminase(AST) and alanine transferase(ALT),
478,NCT05213312,Pathological Complete Response (pCR) rate,2022-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of Treatment-Emergent Adverse Events,
479,NCT06298916,Primary Part 2 - Correlation of 64Cu-LNTH-1363S biodistribution with Immunohistochemistry FAP expression,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Secondary Part 2 Validate optimal radioactivity in patients with sarcoma or GIT cancer,Exploratory Part 1 and Part 2
480,NCT04377048,response rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
481,NCT05612347,"Incidence of advanced neoplasia in each study group, annual FIT and colonoscopy, assessed by comparing the detection of advanced neoplasia between the two study groups.",2023-06-14,RECRUITING,INTERVENTIONAL,['NA'],"Major and minor harms within 30 days of colonoscopy, as measured through chart review and telephone interview.",
482,NCT04581876,progression free survival,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
483,NCT04481828,Tumor stage (American Joint Committee on Cancer 8th Edition),2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
484,NCT00815113,"Characterization of the high-rik individual for gastric cancer - ""Gastric Cancer Phenotype""",2009-10,COMPLETED,OBSERVATIONAL,['NA'],Establish a screen plan for high-risk population for gastric cancer,
485,NCT03187028,Feasibility - Participant satisfaction,2017-08-03,COMPLETED,INTERVENTIONAL,['NA'],Wearable activity monitor (weekly minutes of physical activity),
486,NCT00151671,Factor V at day 3 after surgery,2003-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Infections,
487,NCT01341210,The influencing factors of behavior intentions towards participating in clinical trials,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],The subjective norm and behavior intentions towards clinical trials in cancer patients,
488,NCT01227772,Optimal dosing schedule,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Induction of specific cytotoxic T-lymphocyte (CTL) response,
489,NCT02908204,Overall survival,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],Long-term complications incidence rate,
490,NCT04612569,Impact of a multimodal package of prehabilitation and rehabilitation in patients with low anterior resection syndrome,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],Assessment of the improvement of pelvic floor contractility,
491,NCT05851534,Time to functional recovery,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Evaluation of quality of life for cancer patients,
492,NCT03476421,Rates of local recurrence,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
493,NCT01278537,Quality of life,2011-02,COMPLETED,INTERVENTIONAL,['NA'],Stress,
494,NCT05117723,Risk stratification for patients with IPMN into those that require more intensive screening and possibly intervention versus those that are unlikely to progress to malignancy.,2021-08-26,RECRUITING,OBSERVATIONAL,['NA'],,
495,NCT00288444,Determine the molecular interaction,2006-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Determine safety and efficacy,
496,NCT04794465,Time to treatment,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],Time to symptoms,
497,NCT00060502,"Change in Lean Body Mass (LBM) from baseline to the end of first cycle, as measured by bioelectrical impedance analysis (BIA).",2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"Change in 6-minute walk test distance from baseline to the end of the first cycle; Safety, Karnofsky performance status; Survival.",
498,NCT00066846,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
499,NCT02557724,post operative liver injury,2015-09,COMPLETED,OBSERVATIONAL,['NA'],(AST) Aspartate Aminotransferase,
500,NCT00408772,Conversion rate of nonresectable disease to resectable disease,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Duration of response,
501,NCT00729677,Number of Participants by History of Nausea Who Reported Nausea During the First Week of Chemotherapy,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,
502,NCT04108494,3 years relapse-free survival,2019-01-01,RECRUITING,INTERVENTIONAL,['NA'],5 years overall survival,Postoperative morbidity
503,NCT04624217,ORR,2020-11-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",OS,
504,NCT02154737,Rate of dose limiting toxicities of each subject,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Adverse events related to pulse dose erlotinib and gemcitabine,
505,NCT03833700,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),2019-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
506,NCT01380262,number of patients with a severe skin toxicity,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],quality of life assessed with DLQI,
507,NCT03433703,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),2018-04-26,TERMINATED,INTERVENTIONAL,['PHASE2'],Time to Progression (TTP),
508,NCT04135690,Progression free survival rate at 6 months,2019-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
509,NCT04111380,Objective Response Rate [ORR],2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
510,NCT04569799,No Viable Disease on CT/MRI Imaging.,2020-10-14,COMPLETED,INTERVENTIONAL,['PHASE4'],Lesions Missed or Miscategorized on CT/MRI Imaging.,
511,NCT00826501,Compare median time to pseudocyst recurrence between patients undergoing EUS or Surgical Cysto-gastrostomy,2009-01,COMPLETED,INTERVENTIONAL,['NA'],Median time to pseudocyst recurrence at 24 month follow-up.,Compare pain medication usage
512,NCT03377361,Objective response rate (ORR) by investigator (Part 1B and Part 2),2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests,
513,NCT05327517,Overall Survival,2022-04-10,RECRUITING,INTERVENTIONAL,['NA'],Laryngo-esophageal dysfunction free survival,
514,NCT02600949,Incidence of adverse events (AEs),2016-05-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Levels of intracellular cytokine staining of T cells,
515,NCT01756183,radical resection rate,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival time,
516,NCT01127425,primary: Length of stay,2006-07,TERMINATED,INTERVENTIONAL,['NA'],"secondary: Nursing hours, pain and recovery",
517,NCT05015296,1-year recurrence-free survival after surgery,2021-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
518,NCT03579836,DCR(Disease Control Rate) in combination therapy of BEY1107 and Gemcitabine (Phase II),2018-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of subjects with Adverse events in BEY1107 and Gemcitabine combination (Phase II),
519,NCT00444041,The primary objective of this study is the Resectability (R0) rate after neoadjuvant Bevacizumab in potentially resectable mCRC.,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
520,NCT05227378,Objective Response Rate (ORR),2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Lymphocyte,
521,NCT04263948,Rates and grades toxicity and early tumor responses,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
522,NCT02658019,Number of Participants With Treatment-Related Adverse Events,2016-05-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response (DoR),
523,NCT02319018,"Maximum tolerated dose and the recommended phase II doses of mFOLFOX given in combination with alisertib, defined as the dose level at which the probability of dose limiting toxicities is 30%",2015-08-27,COMPLETED,INTERVENTIONAL,['PHASE1'],"Anti-tumor activity associated with this treatment, evaluated using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors version 1.1",Tumor expression by immunohistochemistry
524,NCT03063918,Quality of life assessed by City of Hope-Quality of Life-Colorectal Cancer,2017-04-28,COMPLETED,INTERVENTIONAL,['NA'],,Scores from the Decisional Conflict Scale
525,NCT02423785,Changes in retinal surface before and after therapy as measured by optical coherence tomography,2014-05,TERMINATED,OBSERVATIONAL,['NA'],,
526,NCT05330429,Randomized Cohort: Progression-free Survival (PFS) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2022-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety Run-in and Randomized Cohorts: Antidrug Antibodies (ADA) to Magrolimab,
527,NCT02605044,Overall survival,2014-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Progression Free Survival (PFS),
528,NCT04505696,Pre-post Questionnaire,2020-08-05,COMPLETED,INTERVENTIONAL,['NA'],,
529,NCT05588388,6- month Progression Free Survival (PFS) rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,Tissue and blood based biomarkers
530,NCT04425564,Peak and trough levels of capecitabine and relation to dosing,2016-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
531,NCT02092519,diagnostic accuracy,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
532,NCT01808417,Feasibility of real-time intraoperative NIR lymphatic mapping,2013-06-21,COMPLETED,INTERVENTIONAL,['PHASE1'],Identification of sentinel lymph nodes,
533,NCT02333188,"DLT rate in course 1 for each of the three genotype groups, graded according to NCI CTCAE v 4.0",2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Cumulative doses of the drugs will be calculated as the sum of all doses received on protocol therapy for each patient,
534,NCT02949258,2-year survival rate,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],in-hospital mortality rate,
535,NCT01362582,Questionnaire EORTC - Quality of Life,2010-03,TERMINATED,INTERVENTIONAL,['PHASE3'],Assessment of nutritional status,
536,NCT04567069,Health-related quality of life (QoL): 36-Item Short Form (SF-36),2020-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Health-related quality of life (QoL): 36-Item Short Form (SF-36),
537,NCT00416351,Response Rate for Participants With Non-Hodgkin's Lymphoma,2006-06-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Participants Evaluated for Toxicity,
538,NCT03983174,fecal incontinence,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
539,NCT05985109,Overall response rate,2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],treatment-related adverse event,
540,NCT02235246,pain score,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,
541,NCT05903703,Evaluation the clinical disease progression (PD) at 6 weeks intervals,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
542,NCT04741308,Change from baseline immune function at follow-up.,2021-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Change from baseline chemotherapy response at follow-up.,
543,NCT05694949,All-cause mortality at 30 days after operation,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Major Adverse Cardiovascular Events (MACE),
544,NCT03172403,Correlation between skeletal muscle and degree myostatin,2018-08-02,TERMINATED,INTERVENTIONAL,['NA'],Analysis level of myostatin muscular expression and blood samples results,
545,NCT00669370,To determine the quality of life (EORTC QLQ-C30 and QLQ-STO22),2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],"To evaluate time to progression (TTP), overall response rate (ORR) and overall survival (OS).",
546,NCT03803254,Overall Survival (OS),2019-01-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse Events,
547,NCT04380337,Clinical complete response (cCR),2020-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
548,NCT01411176,The proportion of patients had no or mild peristalsis during the therapeutic procedures,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Adverse events and adverse drug reactions,
549,NCT03253536,Quality of life,2017-07-10,RECRUITING,OBSERVATIONAL,['NA'],correlation Qol with late toxicity,
550,NCT01769248,Diagnostic Yield of EUS-FNB and EUS-FNA,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Percentage of Patients in Whom a Diagnosis is Achieved After Crossover (%),
551,NCT04540146,cytokine levels,2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
552,NCT05730595,Overall survival,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Function score,
553,NCT00814086,Number of patients who have at least 1 dose-limiting toxicity or delay in therapy for more than 2 weeks,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Objective tumor response (partial or complete) assessed by Response Evaluation Criteria for Solid Tumors (RECIST),
554,NCT00954174,Overall Survival,2009-08-17,UNKNOWN,INTERVENTIONAL,['PHASE3'],Patient-reported Peripheral Neuropathy Symptoms - Post Baseline,
555,NCT00689364,The recurrence and metastasis rates for 1、2、3、4 and 5-year.,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],Survival index: the survival rate for1、2、3、4 and 5-year.,
556,NCT00002470,,1990-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
557,NCT04281784,Proportion of Patients With EHR Documentation of Goals of Care Discussions,2020-04-23,COMPLETED,INTERVENTIONAL,['NA'],All-cause Mortality at 1 Year (Safety Outcome),
558,NCT01288625,Incidence and duration of oral mucositis,na,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,
559,NCT03682289,Objective response rate (ORR) for endometrial cohort,2019-01-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall percent change in tumor size,
560,NCT01564810,the rate of patients converted to resection for liver metastases,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],tumor response,
561,NCT03755440,Response rate,2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),
562,NCT00031863,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
563,NCT03843749,Objective Response Rate(ORR),2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,
564,NCT00262210,We expect to enter 25 patients per year and finish accrual of patients within 4 years.,1995-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
565,NCT02789826,The number of lymph nodes in the postoperative spicement.,2016-06,COMPLETED,INTERVENTIONAL,['NA'],Duration of Surgery,
566,NCT02470533,Time to progression,2015-04-30,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of life,
567,NCT00074009,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
568,NCT04440930,Incidence of oral mucositis grade 2 or higher as measured by the Revised Oral Assessment Guide.,2020-09-02,COMPLETED,INTERVENTIONAL,['NA'],Date of onset of oral mucositis grade 2 or higher as measured by Revised Oral Assessment Guide.,
569,NCT02560974,Disease-free survival rate,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Incidence of adverse events,
570,NCT04052152,Adverse reaction rate,2019-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
571,NCT01860144,Objective response rate,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],resection rate,
572,NCT04391933,Is MRI usefull in colon cancer patients,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],,
573,NCT05545124,1-year recurrence-free survival,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],adverse events,
574,NCT05661357,ORR,2023-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
575,NCT04303429,Disease Free Survival (DFS),2020-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),Cost Utility Analysis
576,NCT01830647,Safety: Incidence of adverse events,2013-04,COMPLETED,OBSERVATIONAL,['NA'],Efficacy: Time to disease progression,
577,NCT06205706,"identification of dose/dose range fulfilling favorable PK and pharmacodynamic profile, with acceptable safety",2023-12-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of response (DoR).,
578,NCT05233553,Incidence of SSC-COVID in hospitalized COVID-patients of the first wave,2020-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
579,NCT02699047,Serum albumin,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,
580,NCT02046278,Assessment of the overall Subject safety by incidence of pre specified procedure related Adverse Events.,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Performance Rate of anastomotic leak (both radiological and clinical leaks),
581,NCT05734105,Progression-free Survival (PFS),2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),
582,NCT05883176,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Median overall survival time (mOS),Treatment-related adverse events
583,NCT05587738,Prevalence of type-specific HPV types,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
584,NCT00636883,"Response rate (partial and complete response, stable disease, and progressive disease)",2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall survival,
585,NCT01239095,Number of patients with adverse events or complications,2011-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,
586,NCT04606914,Radiographic tumor assessment per RECIST v1.1 criteria,2021-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety profile of treatment with carboplatin-mirvetuximab soravtansine according to CTCAE v4.03,
587,NCT00275951,Confirmed objective response rates,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],"Progression-free survival (PFS), overall survival (OS), treatment-related toxicity",
588,NCT04045236,Distant recurrence,2021-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],Quality of life Scale (QOLS),
589,NCT04532515,Proportion of surgeries with full sealant coverage - successful application,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],Hospital length of stay,
590,NCT05821582,Primary Objective- Intestinal side effects of chemotherapy,2023-03-27,WITHDRAWN,OBSERVATIONAL,['NA'],,
591,NCT05747482,disease free interval,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],postoperatory mortality,
592,NCT00078897,Median Selenium Blood Levels at One Year.,2005-01-20,TERMINATED,INTERVENTIONAL,['PHASE3'],,
593,NCT03958890,OS,2019-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Duration of response,
594,NCT00525915,Pathologic Complete Response Rate,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
595,NCT04804696,Pathologic complete response rate,2021-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
596,NCT01245816,Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment.,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Presence of high grade dysplasia or villous adenoma in any polyp resected.,
597,NCT00582400,Number of Patients With Response to Treatment (RECIST Criteria),2004-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression Free Survival,
598,NCT03306693,Change in patient emotional skills from baseline to 15 days after intervention,2017-10-26,TERMINATED,INTERVENTIONAL,['NA'],Patient satisfaction,
599,NCT00915863,the incidence of pancreatic fistula,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],"the incidence of other postoperative complications, mortality, delayed gastric emptying, intra-abdominal hemorrhage, and intra-abdominal abscess",
600,NCT00938080,"Safety (Adverse Events, laboratory assessments and the presence of sAGX0085 bacteria in blood)",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],"Pharmacokinetics of serum samples, buccal smears and saliva samples",
601,NCT04840056,Gastric cancer and gastric dysplasia,2021-04-15,RECRUITING,OBSERVATIONAL,['NA'],Area under the receiver operating characteristic curve of machine learning model,
602,NCT04251403,Correlation of pathologic diagnosis from gastric aspirate compared with diagnosis from standard endoscopic inspection and biopsies.,2020-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
603,NCT04357158,Diagnostic accuracy in distinguishing colorectal carcinoma from healthy controls,2020-05-25,COMPLETED,INTERVENTIONAL,['NA'],Acceptance rate,
604,NCT05298020,PFS,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],AEs,
605,NCT00478946,maximum tolerated dose,2006-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",safety and efficacy,
606,NCT05156463,Use of Actigraph to measure changes in activity and sedentary behavior,2022-04-12,WITHDRAWN,INTERVENTIONAL,['NA'],Exercise Self-Efficacy Scale This scale assesses an individual's beliefs in their ability to continue exercising on a 3 time/week basis at moderate intensities for 40+ min. per session in the future.,
607,NCT04896684,Biological collection associated with clinical data,2021-04-29,RECRUITING,OBSERVATIONAL,['NA'],Optimize treatment success rates for IBD,
608,NCT03869034,Progression Free Survival (PFS) assessed by RECIST 1.1,2019-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Recurrence-free survival (RFS),Biomarkers of treatment response by single-cell RNA sequencing
609,NCT01068327,Maximally tolerated dose (MTD) of stereotactic radiotherapy and concurrent nelfinavir mesylate,2007-11-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacogenomic status of CYP2C19*2 (G681A) (correlative),
610,NCT01437007,"To evaluate feasibility of administering TKM-080301 via HAI, and establish MTD and DLT.",2011-08-26,COMPLETED,INTERVENTIONAL,['PHASE1'],To evaluate the potential conversion rate from unresectable to resectable disease.,
611,NCT03829462,Overall survival,2019-03-28,RECRUITING,INTERVENTIONAL,['PHASE3'],Time to Deterioration,
612,NCT05911243,Acceptability (feasibility),2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Change in body weight (kg),
613,NCT02534233,Number of patients with treatment-related adverse events (pain and dysphagia),2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Histological evaluation of treatment zone for intestinal metaplasia (BE patients),
614,NCT03774680,Measurement of pharmacokinetics parameters of Cetuximab for targeted colon cancer,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
615,NCT02436902,Overall survivals,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Recurrence rates,
616,NCT05426135,"Treatment response of anti-cancer therapy at first evaluation in patients with lung/stomach/colorectal cancer (CR, PR, PD, SD).",2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
617,NCT03750786,Overall Response Rate,2018-12-18,COMPLETED,INTERVENTIONAL,['PHASE3'],Duration of Response,
618,NCT05959395,"Safety of the VectRx treatment evaluated by incidence of Adverse events (AEs) such as first and second-degree burns, edema and abdominal pain, will be assessed [safety and tolerability].",2023-08-15,RECRUITING,INTERVENTIONAL,['NA'],,
619,NCT03297996,Prevalence and relative abundance of selected fecal microbial taxa,2011-11-23,COMPLETED,OBSERVATIONAL,['NA'],,
620,NCT00247260,"This is a multicentre, open label study to evaluate the safety and efficacy of three escalating radioactivity levels (MBq) of 32P BioSiliconTM in patients with unresectable hepatocellular carcinoma",2005-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],To evaluate the association between tumour marker serum alpha-fetoprotein (AFP) and target tumour response with the three radioactivity levels (MBq),
621,NCT05391477,Comparison of the AIOD and HOD negative predictive value (NPV) for adenoma in rectosigmoid polyps ≤ 5 mm with respect to histology,2023-02-27,RECRUITING,INTERVENTIONAL,['NA'],Proportion of patients accepting to have their polyps diagnosed by the AI system or human optical diagnosis (designed questionnaire),
622,NCT04687163,Overall survival,2020-12-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse Events,
623,NCT02728921,Change in plasma volume,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Incidence of postoperative complications,"Change in heart rate, change in central venous oxygen saturation, change in haemoglobin concentration in blood, change in blood pressure, change in central venous pressure, change in plasma lactate and diuresis."
624,NCT00904839,Progression-free Survival Rate at 9 Months (PFS-9),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory Biomarker and Pharmacogenetic Analysis for VEGF,
625,NCT06325891,Microbiome analysis using gastric mucosal brushing,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],Microbiome analysis using gastric mucosal biopsy,
626,NCT00780494,Progression-Free Survival (PFS),2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Vascular Endothelial Growth Factor Tumor Response Biomarker,
627,NCT01730586,Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA),2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-Free Survival (PFS),
628,NCT04827485,Left colon distension score,2022-01-13,TERMINATED,INTERVENTIONAL,['NA'],Left colon sessile serrated lesion detection rate,
629,NCT05338866,3-year progression free survival rate,2022-01-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Patients' quality of life scale,
630,NCT03784417,Tumor necrosis induction by EUS-guided laser ablation (LA) - Number of patients with necrosis of the tumor,2019-10-15,TERMINATED,INTERVENTIONAL,['NA'],Overall survival,
631,NCT05443321,Total clinician-reported medical errors,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],Time between transferred patient arrival and entry of admission orders,
632,NCT03788447,total dose of remifentanil,2019-06-04,COMPLETED,INTERVENTIONAL,['NA'],,
633,NCT00543777,Overall Image Quality of Magnetic Resonance Elastography (MRE),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Hepatic Steatosis,
634,NCT00296062,Phase II: Determine the toxicity of bevacizumab in combination with this regimen in patients with metastatic colorectal cancer.,2006-03,TERMINATED,INTERVENTIONAL,['PHASE1'],Phase I: Maximum tolerated dose in patients ≥ 65 years of age measured by CTC version 3.0 at end of Safety in the Elderly component of study,
635,NCT03095703,Number of participants with treatment-related adverse events,2017-10-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Immunohistochemistry of mTOR targets,
636,NCT05458986,Intent to complete a colonoscopy,2023-05-15,RECRUITING,INTERVENTIONAL,['NA'],Incidence of completed colonoscopies,
637,NCT02670746,Adverse Event (AE),2015-10-01,TERMINATED,OBSERVATIONAL,['NA'],Evaluate the resources utilized for treatment of pancreatic adenocarcinoma with the combination nab-paclitaxel/gemcitabine in routine clinical practice,
638,NCT00252564,Progression-free Survival (PFS) Rate at 1 Year.,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Objective Response Rate,
639,NCT05651594,Overall response rate (ORR),2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE2'],ORR,
640,NCT06317896,2-year recurrence-free survival rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Correlation between metastasis，primary tumor and CTCs in blood through NGS and CTC-DNA,
641,NCT02042430,Number of participants with an increase in CD8+ T cells,2014-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Changes in IDO1 expression by IHC,
642,NCT00142038,Response Rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life,
643,NCT05141721,Phase 3: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by blinded independent review committee (IRC),2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Phase 2 and 3: The feasibility of manufacturing a patient-specific vaccine defined by the proportion of patients for whom vaccine was successfully manufactured from those randomized to the vaccine arm.,
644,NCT03993626,Immune Disease Control Rate (iDCR),2018-05-22,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment,
645,NCT05735912,Rate of adverse events,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],Pancreatic insufficiency,
646,NCT03167775,DCR and/or 6-months survival rate,2016-11-28,UNKNOWN,INTERVENTIONAL,['NA'],the rate of incidence of adverse events,
647,NCT00577538,,2006-04,COMPLETED,OBSERVATIONAL,['NA'],,
648,NCT04548765,Colonoscopy Ordered at 6 months,2020-07-24,COMPLETED,INTERVENTIONAL,['NA'],Colonoscopy Result,
649,NCT00079365,,2001-05,UNKNOWN,INTERVENTIONAL,['NA'],,
650,NCT04269369,The frequency of severe ﬂuoropyrimidine-related toxicity,2020-02-18,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
651,NCT03750175,Feasibility of ctDNA analysis for RAS mutation analysis,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],Lead time,
652,NCT04466631,Utilization of specific competences by participants,2020-06-15,UNKNOWN,OBSERVATIONAL,['NA'],Number of participants maintaining their social activities,
653,NCT05639972,Feasibility of administering E7 TCR-T cell therapy as induction treatment for LAHPVC,2024-06-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",2-year and 5-year disease free survival (DFS),
654,NCT00003714,Patient Response,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
655,NCT04902352,SMA margin status,2021-04-06,RECRUITING,INTERVENTIONAL,['NA'],Disease free survival,
656,NCT04013347,number of patient with surgical complications,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],number of patient with anastomotic dehiscence,
657,NCT05061082,Genetic and epigenetic changes of the tumor,2021-10-26,UNKNOWN,OBSERVATIONAL,['NA'],,
658,NCT04593407,Percentage of surgical referral after treatment,2020-11-03,RECRUITING,INTERVENTIONAL,['NA'],Cumulative complications rate after treatment,
659,NCT05194878,Disease-free survival,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],CT assessment of response to neoadjuvant treatment,
660,NCT03176485,Modulatory effect of systemic Raf inhibition in the MEK/Erk and PI3 /AKT/mTOR pathways in patients undergoing targeted therapy for metastatic disease,2014-10-17,COMPLETED,INTERVENTIONAL,['NA'],Modulatory effect of Ras inhibition in Epidermal Growth Factor Receptor (EGFR) and Activating Protein-1 (AP1) signaling pathways (IHC and RPPA).,
661,NCT04578444,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
662,NCT01801085,"Composite preparation, dispensing and administration time",2011-10,TERMINATED,OBSERVATIONAL,['NA'],Capital item utilization (hospital bed and infusion pump),
663,NCT05252390,Phase 1b Food Effect Substudy: Effect of Food on the Pharmacokinetics (PK) of NUV-868,2022-03-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
664,NCT03069508,Cmax Pharmacokinetic (PK) assessment of clemizole hydrochloride (200 mg vs. 300 mg vs. 400 mg vs. 500 mg by mouth),2017-02-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival associated with clemizole hydrochloride,
665,NCT02125396,Overall survivals,2019-05-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Recurrence rates,
666,NCT04722120,Quantitative image quality analysis,2016-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
667,NCT00549276,,2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
668,NCT03253939,3-years overall survival,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
669,NCT00973869,Concentration of curcumin in colorectal tissue after treatment,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],Presence of curcumin and its metabolites in peripheral blood and urine,
670,NCT00008047,,1999-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
671,NCT01882660,"Wnt target gene expression (APCDD1, AXIN2, DKK1, LGR5 and ASCL2)",2013-07,TERMINATED,INTERVENTIONAL,['NA'],Tumor differentiation,
672,NCT04404673,Urinary and sexual outcomes after rectal resection,2020-02-21,UNKNOWN,OBSERVATIONAL,['NA'],,
673,NCT02729948,Incidence of adverse events associated with TCE use,2016-07-28,COMPLETED,INTERVENTIONAL,['NA'],,
674,NCT04592913,Event-free survival (EFS),2020-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],To compare Arm A relative to Arm B on pathological complete response (pCR) rate,
675,NCT01056913,Anastomotic Leakage,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Clinical Relevant Stenosis,
676,NCT00131911,Confirmed Response Rate,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response,
677,NCT01497964,Objective Response Rate,2011-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacokinetic parameter Vss,
678,NCT04298489,ex vivo Maximal Inhibition Index (MI),2017-05-01,UNKNOWN,INTERVENTIONAL,['NA'],Progression free survival (PFS) after chemotherapy,
679,NCT00047112,overal survival,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],recurrence free survival,
680,NCT00470782,,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
681,NCT05951231,Lactate level in microdialysate from hilar plate after normothermic machine perfusion - 4 hours,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Pyruvate level in microdialysate from hilar plate after of Dual-end-ischemic Hypothermic Oxygenated Perfusion machine perfusion in extended criteria donors livers - 2 hours,Donor associated variables - Donor risk index
682,NCT02527967,Hospital length of stay (days),2013-01,COMPLETED,OBSERVATIONAL,['NA'],Readmission rate (%),
683,NCT03233360,Time to treatment recurrence,2017-04-17,COMPLETED,OBSERVATIONAL,['NA'],,
684,NCT01762514,Effect on improving mucositis,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence and severity of Hypocalcemia,
685,NCT02503150,"Progression Free Survival, PFS",2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse Events,
686,NCT02330536,Respiratory change,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
687,NCT03776370,The five-year survival rates of rectal cancer between the two groups were compared.,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
688,NCT03387774,Incidence of Severe Acute Oral Mucositis (Grade of CTC-AE ≥ 3),2018-01-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],The Adverse events Related to Ulinastatin,
689,NCT00293462,Comparison of the Mean Number of Days for Mucositis to Heal Across by Group,2005-06-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Comparison of Combined Mean Score on the Pain Questionnaire by Group,
690,NCT03192644,recurrence-free survival (RFS),2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall survival (OS),
691,NCT04652492,TTP assessed by independent review committee(IRC),2020-10-27,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety,
692,NCT01269970,early metabolic response to predict pathological response and outcome,2004-01,COMPLETED,OBSERVATIONAL,['NA'],"to study correlations between early metabolic response, late metabolic response, histopathological response and outcome.",
693,NCT01726309,Correlation between the type and degree of reported skin and/or eye reaction and the SNP profile of the EGFR domain III region.,2011-05,TERMINATED,OBSERVATIONAL,['NA'],Correlation between the SNP profile(s) and disease response,
694,NCT01896869,Overall Survival (OS),2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor Marker Kinetics as Assessed by Median Carbohydrate Antigen 19-9 (CA19-9) Levels,
695,NCT01854255,Clinical Benefit Rate,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Observed Survival,median time ot progression
696,NCT04004650,Perineal wound healing rate 30 days,2019-06-28,UNKNOWN,INTERVENTIONAL,['NA'],Female sexual distress,
697,NCT03731754,Complication rate of perineal wound,2018-11-20,UNKNOWN,INTERVENTIONAL,['NA'],The operation time,
698,NCT03431311,"Incidence, nature, and severity of adverse events graded according to NCI CTCAE v4.0",2018-03-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
699,NCT03474822,Number of participants with treatment-related adverse events as assessed by NCI CTCAE 4.0,2018-08-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immunological index,
700,NCT03322969,disease free survival,2017-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
701,NCT04172402,Overall response rate (ORR),2019-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
702,NCT02524119,Progression Free Survival,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Objective Response Rate (ORR) Based on mRECIST and RECIST 1.1,
703,NCT00836303,Completion of Colorectal cancer screening,2005-12,COMPLETED,INTERVENTIONAL,['NA'],Patient adherence to physician recommended colorectal cancer screening test,
704,NCT00813163,Survival Rate,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],pharmacogenetics,
705,NCT02408406,Functional Assessment of Cancer Therapy-General (FACT-G) scores,2015-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in health resource utilization,Individual patient changes in Functional Assessment of Cancer Therapy-General (FACT-G) total scores
706,NCT06090656,progression free survival，PFS,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],"Patient-reported outcomes, PRO",
707,NCT04533490,DFS（disease-free survival）,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],OS（overall survival rate）,Exploratory analysis of biomarkers for predicting efficacy
708,NCT04718402,adverse events (AEs),2021-03-30,TERMINATED,INTERVENTIONAL,['PHASE1'],overall survival (OS),
709,NCT02786524,Change in Patient-Reported Symptom Burden as Determined by the National Comprehensive Cancer Network Distress Screening Tool,2016-02-15,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival Rate,
710,NCT01514110,to determine the Maximum tolerated dose and dose limiting toxicity of RAD001 in combination with paclitaxel and carboplatin,2008-01-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Toxicity of combination Paclitaxel/carboplatin/RAD001 in advanced adenocarcinoma of the stomach and gastroesophageal junction,
711,NCT03822130,Successful conversion rate of operation,2019-02-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],PFS,
712,NCT05221957,Complications,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Mortality,
713,NCT05800106,Relative bioavailability (F),2018-12-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Proportion of subjects with abnormal 12-lead electrocardiogram (ECG),
714,NCT06184841,Adverse Events,2020-06-18,COMPLETED,INTERVENTIONAL,['PHASE1'],The overall survival (OS),
715,NCT05905887,Disease control rate,2023-09-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,
716,NCT00355355,Overall survival,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
717,NCT05959356,Progression free survival,2023-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality-adjusted time without symptoms or toxicity,"Treatment-emergent genetic mutations (e.g., KRAS, NRAS, BRAF, SMAD4, HER2, Etc.)"
718,NCT03404661,Methylated DNA markers as measured by mean percentage of total human DNA per pancreatic juice volume,2018-01-11,COMPLETED,OBSERVATIONAL,['NA'],,
719,NCT00337545,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
720,NCT02738359,"Prevalence of advanced colorectal neoplasia or cancer identified by each screening strategy (OC, CC and FIT)",2017-11-03,RECRUITING,OBSERVATIONAL,['NA'],Rate of colorectal cancer identified by each screening strategy,Quality assessment of colonoscopy and capsule endoscopy
721,NCT04548752,Progression-free survival (PFS),2021-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of response (DoR),
722,NCT01836653,Progression-free survival,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Response rate,Progression-free survival among the RAS wild type subpopulation
723,NCT02108782,Progression-free survival,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of adverse events graded according to National Cancer Institute (NCI) CTCAE version 4.0,Plasma levels of circulating angiogenic factors and soluble receptors
724,NCT02202317,Number of Subjects Whose Y-90 Based PET/CT (Positron Emission Tomography/Computed Tomography)Scans Detected Extrahepatic Non-target Embolization.,2013-04,COMPLETED,INTERVENTIONAL,['NA'],Comparison of Y-90 PET/CT to Y90 SPECT,
725,NCT03712943,Maximum Tolerated Dose,2018-10-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Frequency and Severity of Adverse Events,
726,NCT06084299,Maximum tolerated dose [Safety and Tolerability],2020-05-27,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
727,NCT02814461,The maximal tolerated dose (MTD),2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
728,NCT03200249,Complete histological response rate,2016-12-22,COMPLETED,INTERVENTIONAL,['NA'],Tolerance,
729,NCT00860860,Toxicity defined by NCI Common Terminology Criteria for Adverse Events version 3.0,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],"pharmacokinetics and biodistribution of TF2 and Lu-177-labeled IMP-288, sensitivity of pretargeted imaging with In-111-labeled IMP-288, and tumor response using RECIST criteria",
730,NCT04458740,Assess how the patients and their family members face the disease,2018-10-29,COMPLETED,OBSERVATIONAL,['NA'],,
731,NCT01739894,Overall survival (OS) rate,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events,
732,NCT06015659,6-month Progression-Free Survival (PFS) Rate,2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Grade 3-5 Treatment-related Toxicity Rate,
733,NCT04739696,Caregiver: Change in Center for Epidemiological Studies Depression Scale (CESD),2021-02-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Caregiver: Job Satisfaction,
734,NCT04858334,Improvement in relapse-free survival (RFS),2021-06-22,RECRUITING,INTERVENTIONAL,['PHASE2'],OS in those who received any platinum-based perioperative chemotherapy versus no platinum-based perioperative chemotherapy,RFS and OS differences with those who had resectable disease at diagnosis
735,NCT05578677,"Size of biopsy specimen, as assessed by a blinded study investigator",2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"The percentage biopsies with the presence of dysplasia, as assessed by a blinded upper GI pathologist",
736,NCT01386502,To determine the safety and tolerability of escalating doses of anti PD1 antibody (CT-011) in combination with subcutaneous p53 vaccine.,2011-06-15,WITHDRAWN,INTERVENTIONAL,['PHASE1'],To determine the clinical efficacy of this combination.,
737,NCT04605731,Overall response,2021-08-03,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,Gene expression signatures
738,NCT04634526,Rate of R1 cases assessed by surgeon,2018-04-18,RECRUITING,OBSERVATIONAL,['NA'],Disease free survival,
739,NCT05512260,Feasibility regarding iDA format,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],Self-reported lifestyle behaviors,Satisfaction with the iDA and the decision
740,NCT02355353,Tumor regression grade (TRG),2015-02,UNKNOWN,INTERVENTIONAL,['NA'],"Histopathological measurements of tumor tissue cellularity /density, Necrosis, Proliferation (ki-67)",
741,NCT06280105,objective response rate (ORR) per RECIST1.1,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Occurence of AE and SAE,
742,NCT01374451,Progression-free Survival (PFS) Per Local Radiological Review,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Summary of Pasireotide Concentrations Following Intramuscular Injection of Pasireotide LAR 60mg,
743,NCT00842491,Progression free survival,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],The alteration of relative regional blood volume of the tumor,
744,NCT00747097,Progression-free survival,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"overall survival, objective response, safety",
745,NCT04930315,1-year tumor recurrence-free rate,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
746,NCT05775900,Pharmacokinetic (PK) characteristics 2,2023-02-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of Life (QOL),Treatment-emergent genetic mutations
747,NCT02907099,Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors 1.1,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
748,NCT01044732,Detection Rates for Adenomas and for Total Polyps,2009-03,COMPLETED,INTERVENTIONAL,['NA'],Times for Withdrawal Phase and for Complete Procedure,
749,NCT00217711,"Efficacy of Oxaliplatin, Irinotecan, and Capecitabine",2005-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
750,NCT05449873,Local tumor progression rate,2021-10-18,RECRUITING,INTERVENTIONAL,['NA'],Complication rate,
751,NCT01984580,Changes in zinc-regulated cellular proteins within Barrett's tissue,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],Changes in cellular microRNA profile; changes in protein cancer biomarkers,
752,NCT05163665,Cost of each closure,2022-08-23,COMPLETED,INTERVENTIONAL,['NA'],Successful Tissue approximation,
753,NCT02311439,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of FOLFIRINOX plus Concurrent Radiotherapy with Capecitabine,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Tumor response,Number of Cases will have radical surgery
754,NCT01608646,Objective tumor response,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse event incidence,
755,NCT05231382,Two-years progression-free survival rate,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE3'],"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30.",
756,NCT02169908,Thermal thresholds,2014-05,COMPLETED,INTERVENTIONAL,['NA'],Tactile sensitivity,Characterization of pain neuropathy
757,NCT02537158,recurrence-free survival,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],overall survival,
758,NCT03715517,Cumulative 72-hour opioid consumption (OC_0-72h),2018-10-04,RECRUITING,INTERVENTIONAL,['NA'],Comprehensive Complication Index (CCI) score Comprehensive Complication Index (CCI) score Comprehensive Complication Index (CCI) score,Cumulative incidence (proportion) of postoperative vasopressor and/or inotrope dependency (%)
759,NCT06020885,Tolerated fraction dose,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],The rate of grade 3 or 4 toxicities according to CTCAE5.0,
760,NCT06267378,"The sensitivity & specificity of blood based biomarkers for the prediction of baseline clinical frailty levels & post-operative measures of frailty, mortality and adverse events",2023-08-30,RECRUITING,OBSERVATIONAL,['NA'],Overall survival at 3 months and 5 years (the latter via cancer registry returns),
761,NCT04599920,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification.,2020-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Changes in the concentrations of N-nitroso compounds in feces.,
762,NCT04942626,Identification of the maximum tolerated dose for capecitabine administered concomitantly with standard radiotherapy in combination with Anakinra at a fixed dose of 100 mg s.c,2021-08-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Quality of life based on treatment arm and surgical procedures/organ preservation,
763,NCT00675194,response rate,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Analysis of the dose and efficacy of Epoetin beta weekly in anaemic patients,
764,NCT01408407,Maximum skin toxicity,2011-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,
765,NCT02869802,Number of days between biopsy and return of comprehensive genomic results.,2016-10-06,RECRUITING,OBSERVATIONAL,['NA'],Overall Survival,Targetable mutations
766,NCT01238965,To assess the safety of this regimen,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall survival,
767,NCT04466696,Postoperative length of stay,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
768,NCT03983993,Clinical benefit rate (CBR),2019-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
769,NCT01850368,Tumor stabilization rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Treatment related toxicity,
770,NCT00307866,"To assess the proportion of correct final, therapy deciding diagnosis based on unenhanced plus SH U 555 A enhanced MR imaging compared to contrast-enhanced dual-phase spiral CT.",2001-04,COMPLETED,INTERVENTIONAL,['PHASE3'],To assess safety and tolerability of SH U 555 A administration.,
771,NCT01274962,Compliance to chemotherapy - patients receiving at least 85% of planned full-dose of chemotherapy prescribed at each cycle for the 12 cycles,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival rate,
772,NCT05176964,pathological complete response(pCR),2021-12-31,RECRUITING,OBSERVATIONAL,['NA'],predictive biomarkers andquality of life(QoL),
773,NCT04260139,Lymph Node Yield in Colon Cancer Resection Specimens,2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
774,NCT01287130,"To assess for evidence of anti-tumor activity with this combination, per tumor measurements",2011-01-07,COMPLETED,INTERVENTIONAL,['PHASE1'],To evaluate the safety and tolerability of the combination of AZD6244 and cetuximab in patients with K-RAS mutated metastatic colorectal cancer,
775,NCT01143922,,2009-08,UNKNOWN,OBSERVATIONAL,['NA'],,
776,NCT02569242,Overall Survival,2015-12-14,COMPLETED,INTERVENTIONAL,['PHASE3'],Duration of Response,
777,NCT05775419,5-years overall survival (OS),2021-06-30,RECRUITING,INTERVENTIONAL,['NA'],5-year progression-free survival (PFS),
778,NCT01431599,downstaging effect of tumor,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],bladder and small bowel toxicity after chemoradiation,
779,NCT04777604,Overall survival rate,2021-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
780,NCT01585727,Urogenital function,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Fecal incontinence,
781,NCT00332865,Objective swallowing using videofluoroscopy and endoscopic evaluation of swallowing,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Swallowing scale of EORTC HN 35,
782,NCT06253650,ctDNA clearance (negative ctDNA status) at 1 year,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Translational analyses
783,NCT00234416,Incidence of DLT,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Nature, incidence and severity of adverse events (AEs) and serious adverse events (SAEs)",
784,NCT02032485,fluorescence intensity of tumoral and healthy tissues after IV injection of ICG to patients with peritoneal carcinomatosis from colorectal origin.,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
785,NCT02979795,Tumor regression rate,2016-11,UNKNOWN,OBSERVATIONAL,['NA'],Distant metastasis,
786,NCT05351983,Feasibility of the process,2022-09-22,RECRUITING,INTERVENTIONAL,['NA'],Chemosensitivity testing,
787,NCT02244632,Frequency and severity of dose limiting toxicity (DLT) or other Adverse Events (AE),2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
788,NCT02628093,Versatility Score,2016-02-17,COMPLETED,INTERVENTIONAL,['NA'],Operative Procedure Time,
789,NCT02402036,Serum microRNA Quantification,2015-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
790,NCT06157814,Number of participants retained for entirety of the study,2023-06-16,RECRUITING,INTERVENTIONAL,['NA'],Symptom Measures,
791,NCT06209970,Numerical Rating Scale,2024-01-20,RECRUITING,INTERVENTIONAL,['NA'],,
792,NCT03730441,"correlation between ADR of screening and all colonoscopies (screening, surveillance, diagnostic)",2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
793,NCT06216405,"Comparing the percentage of patients with at least one right colon polyp detected according to the randomization group, and adjusted for Boston Bowel preparation scale, for the operator, for the endoscope and for stratification factors.",2022-01-20,COMPLETED,INTERVENTIONAL,['NA'],,
794,NCT03165591,Effect of V3-P on tumor burden,2017-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Effect of V3-P on sugar and bilirubin levels,
795,NCT03812562,Recurrence rate,2019-02-07,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Overall increase in future liver remnant (FLR),
796,NCT04125849,Postoperative respiratory complications,2020-04,UNKNOWN,INTERVENTIONAL,['NA'],30-day mortality after surgery,
797,NCT05367687,"Recurrence-Free Survival (RFS), as Determined by the investigator",2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0,
798,NCT03053167,Progression Free Survival [PFS],2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease Control Rate [DCR],Quality of Life [WHO-QOL]
799,NCT01442974,"Effect of nab-paclitaxel on pancreatic cancer stroma, new vessel formation and tumor cell metabolism.",2011-01,COMPLETED,INTERVENTIONAL,['NA'],Activity of nab-paclitaxel in combination with gemcitabine against PDA in relation with changes in tumor stroma and tumor metabolic activity.,
800,NCT03542136,"To evaluate the efficacy of evaluating the vibrotactile sense using a multi frequency tactilometry, in patients hand and foot. This is by assessing the changes in the measurements of a multi frequency tactilometry device in between each two time points.",2018-06-04,COMPLETED,INTERVENTIONAL,['NA'],To evaluate if Oxaliplatin induced polyneuropathy can be earlier detected by using a multi frequency tactilometry compared with Common Terminology Criteria for Adverse Events scale (CTCAE).,
801,NCT01489410,Number of Patients with Post-Embolization Syndrome,2012-10,WITHDRAWN,INTERVENTIONAL,['NA'],Overall Survival,
802,NCT04287400,K-RAS Mutation,2019-03-05,RECRUITING,OBSERVATIONAL,['NA'],Radiomics - MR image findings,
803,NCT00425425,Response rate (histological remission) (Phase II),2006-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Metabolic response rate,
804,NCT01721785,Diagnostic performance of the techniques under investigation,2012-10,COMPLETED,OBSERVATIONAL,['NA'],To determine the inter-observer agreement for the imaging techniques under investigation,
805,NCT01817205,dose limiting toxicity,2013-03,TERMINATED,INTERVENTIONAL,['NA'],treatment response by alphafetoprotein,
806,NCT03186014,Recurrent dysphagia,2017-06,UNKNOWN,INTERVENTIONAL,['NA'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
807,NCT01374750,To evaluate recurrence-free survival,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate the safety with sirolimus,
808,NCT01289288,Receipt of CRC screening,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
809,NCT02335151,Peak of CTC in the postoperative phase after curative tumor removal,2016-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of surviving patients,
810,NCT01320683,Progression-free Survival,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
811,NCT02917798,baseline to post-results change in distress levels,2016-07-12,RECRUITING,OBSERVATIONAL,['NA'],,
812,NCT02272738,Number of patients with Adverse Events,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival time,
813,NCT04621370,Complete response,2020-12-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Euro Qol-5 dimensions 3 levels (EQ5D-3L),
814,NCT06052332,Grade ≥3 toxicities during treatment,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
815,NCT04447352,Comparison of progression-/disease-free survival (PFS/DFS) between arms,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE3'],Rate of post-operative morbidity/mortality at day 30 after surgery acc. to Clavien-Dindo classification,
816,NCT01083875,Evaluation of mucositis using the Oral Mucositis Assessment Score,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],"Frequency of treatment-emergent, drug-related Serious Adverse Events",
817,NCT01470586,Comparison of Oxidative stress markers in patients with colorectal cancer and controls,2009-05,COMPLETED,INTERVENTIONAL,['NA'],Validation of oxidative stress markers in patients with colorectal cancer undergo surgical resection,
818,NCT02229136,Incidence of Grade ≥ 2 stomatitis,2014-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Reduction in pain score on questionnaires,Time to Disease Progression of next anti-cancer therapy
819,NCT00557557,Primary endpoint is to determine the maximum tolerated dose and dose limiting toxicity of 5-FU delivered with 40mg/m² of Oxaliplatin via IHP.,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Secondary endpoints will be to determine the response rate and survival after IHP with 5-FU and Oxaliplatin.,
820,NCT01488552,Complete Response Rate,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Observing toxicity outcomes,
821,NCT05418543,CH-EUS FNA has higher diagnostic accuracy for bile tuct tumors,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
822,NCT00005590,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,
823,NCT05603065,Pathological complete response rate (pCR),2022-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Quality of life measurement and evaluation 2,
824,NCT01018381,Patient survival,2006-06,COMPLETED,INTERVENTIONAL,['NA'],Disease recurrence,
825,NCT01172860,treatment safety,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
826,NCT00037089,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
827,NCT03329534,Ratio of non-acidic to acidic reflux events,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],Gastroesophageal reflux disease-health related quality of life instrument,
828,NCT04107324,Liver Function,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Resection rate,
829,NCT00996333,To Determine Response Rate to the GTX Regimen in Patients With Pancreatic Cancer,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity Assessment,
830,NCT01297998,Maximum tolerated dose,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants with dose limiting toxicity,
831,NCT01532804,Disease-free survival,2011-07-28,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of life by using the quality of life questionnaire score,
832,NCT02713529,Objective Response Rate (ORR) Per Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST),2016-04-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",AMG 820 Pharmacokinetic Parameter by Dose Group: Accumulation Ratio (AR),
833,NCT01434550,Number of Participants With Overall Survival (OS),2012-03,WITHDRAWN,INTERVENTIONAL,['NA'],Number of Participants With Adverse Events (AEs),
834,NCT01283217,3-year disease free survival(DFS),2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
835,NCT00003424,,1997-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
836,NCT00955591,Comparison of anal cytology screening outcome derived from specimens collected by a flocked nylon swab vs a Dacron swab,2009-03-12,COMPLETED,INTERVENTIONAL,['NA'],,
837,NCT03803241,Liver volume,2019-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],Liver volume,
838,NCT01379521,Time to Progression (TTP) Based on the Modified RECIST Criteria,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With a Decrease in the Sum of the of Longest Diameters (SLD) of Target Lesions From Baseline to 30 Months,
839,NCT03775395,Overall survival,2018-12-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Progression Free Survival (PFS),
840,NCT05230771,2-year overall survival rate,2022-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
841,NCT01516216,Median Progression-free Survival (PFS),2012-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Hazard Ratio Between Baseline Plasma 25(OH)D Levels and OS,
842,NCT00634751,Overall Response Rate,2008-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
843,NCT00712751,"To investigate the feasibility, tolerability, acceptability (including adherence) and efficacy of CSI-SH, a psycho-educational intervention, on the primary outcome of sexual functioning among RC survivors.",2008-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],"To explore baseline variables that may influence the effectiveness of CSI-SH (i.e., moderators such as socio-demographic and medical variables).",
844,NCT01171482,Progression free survival (PFS),2015-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall survival,
845,NCT00591123,"Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the Combination of 5-fluorouracil, Leucovorin, Oxaliplatin, and Erlotinib.",2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],"Toxicity of the Combination of FOLFOX, 5-FU, and Erlotinib",
846,NCT02239900,Maximum Tolerated Dose (MTD) of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT),2014-08-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Response Rate of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT),
847,NCT05714644,CRC Screening Completion Rates,2023-05-31,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Diagnostic Colonoscopy Completion Rates,
848,NCT02005965,To compare global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.,2007-08-13,UNKNOWN,OBSERVATIONAL,['NA'],Investigation of potential association between length of operation with number of complications and length of post-operative ITU/HDU stay.,
849,NCT02961140,Incidence of postoperative complication,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],Length of stay,
850,NCT03000816,Progression-free survival,2015-04,COMPLETED,INTERVENTIONAL,['NA'],overall survival,
851,NCT06092944,Heart rate (HR),2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],Analgesia satisfaction,
852,NCT04245865,The rate of progression free patients at six months,2020-06-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
853,NCT06124378,pCR,2023-11-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Gene mutation signatures of colon cancer,
854,NCT03802097,Incidence of surgical site infections within 30 days,2018-12-27,COMPLETED,INTERVENTIONAL,['NA'],Incidence of remote non-surgical site infections,
855,NCT03045484,Total Dose of Oxycodone,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],Quality-of-Life Index,
856,NCT02741856,Primary endpoint in adenocarcinoma when switching chemotherapy,2016-11-04,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Health economics,
857,NCT06304545,Pathological Complete Response rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],3-years Overall Survival rate,
858,NCT05862051,Progression free survival (PFS),2021-12-14,RECRUITING,INTERVENTIONAL,['NA'],Quality of life measure,
859,NCT06069960,Overall survival（OS）,2023-10-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Disease-free survival，DFS,
860,NCT03882866,Objective Response Rate (ORR),2019-03-28,UNKNOWN,INTERVENTIONAL,['NA'],Quality of life of two treatment regimens in patients,
861,NCT03428321,Thermal ablations,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
862,NCT00459108,Four Month Progression-free Survival (PFS),2007-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Safety and Tolerability,
863,NCT02795429,Phase II: Overall Response Rate (ORR) Per RECIST v1.1,2016-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase Ib and Phase II: PD-L1 Percent Positive Tumor,
864,NCT00282672,5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Years,2006-02,COMPLETED,INTERVENTIONAL,['NA'],5 Year Extension: All Cause Mortality of the Group From 2 to 5 Years.,
865,NCT00302094,Program to fuse 3D ultrasound and PET/CT data,2006-06,COMPLETED,OBSERVATIONAL,['NA'],,
866,NCT00407654,Progression-free Survival (Bevacizumab-treated Group),2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Response (Bevacizumab-treated Group),
867,NCT05360420,Time benefits based on US and immediate CEUS with current routine,2022-10-26,RECRUITING,INTERVENTIONAL,['NA'],The economic benefit based on US and immediate CEUS with current routine,
868,NCT04714190,Overall survival (OS),2021-03-24,RECRUITING,INTERVENTIONAL,['PHASE3'],Tumor progression time (TTP),
869,NCT02638909,"Clinical Benefit Rate (CBR) of ceritinib, as defined as the percentage of patients who have achieved complete response, partial response, and stable disease at 2 months per RECIST 1.1) to ceritinib by investigator assessment",2015-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Objective tumor response based on computed tomography scans (or magnetic resonance imaging if patients are allergic to iodinated contrast) per RECIST 1.1 criteria,
870,NCT03368963,Overall response rate based on modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,2018-01-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Response rate,
871,NCT00199654,Time to colorectal cancer relapse,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Comparison of the medical cost in the two detection strategies,
872,NCT00142467,"Time to disease progression of gemcitabine, oxaliplatin and bevacizumab regimen in patients with hepatocellular carcinoma.",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
873,NCT00733850,Progression-free survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival,
874,NCT03630354,Perceived physical function incongruence,2019-01-18,COMPLETED,INTERVENTIONAL,['NA'],Fear of recurrence,
875,NCT00677443,To compare the combination of S-1 and oxaliplatin to the combination of capecitabine and oxaliplatin in terms of progression free survival in patients previously untreated by systemic therapy for advanced or metastatic colorectal carcinoma.,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],To evaluate and compare the quality of life of the patients and safety profiles of the two treatment groups.,
876,NCT05631041,The change between groups in response rate (RECIST),2022-12-31,RECRUITING,INTERVENTIONAL,['PHASE3'],Changes in serum levels of the measured biological marker serum permeability glycoprotein in ng/ml,
877,NCT00656123,Number of Patients Experiencing a Grade 3 or Above Treatment-related Toxicity,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Percent Fold change in amount of interferon gamma-producing Ep-CAM-specific CD8 T cells after vaccination,
878,NCT06202131,mOS,2023-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
879,NCT05827471,Detection of protein for early rapid diagnosis of colon cancer.,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
880,NCT03956641,evolution of exercise tolerance,2019-09-17,UNKNOWN,INTERVENTIONAL,['NA'],measurement of parameters reflecting the physical condition,
881,NCT04906733,Correlation of ex vivo sensitivity test on patient-derived organoid models with clinical outcomes,2021-04-15,UNKNOWN,OBSERVATIONAL,['NA'],,
882,NCT01970254,"Rate of a positive result (hepatitis B surface antigen [HBsAg], hepatitis B core antibody [anti-HBc], and hepatitis B surface antibody [anti-HBs]) before first chemotherapy",2013-06-24,COMPLETED,OBSERVATIONAL,['NA'],,
883,NCT02738697,Overall survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
884,NCT05696002,Quality of life (survey),2023-01-14,RECRUITING,OBSERVATIONAL,['NA'],,
885,NCT03891472,Improvement of the overall survival.,2017-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
886,NCT05185245,Overall Survival,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],Disease-Free Survival,
887,NCT02029326,To explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform,2010-02-01,COMPLETED,OBSERVATIONAL,['NA'],3. To analyze correlation between the quantity of circulating tumor cells and treatment response to cetuximab,
888,NCT05365256,Level of psychological well-being,2022-04-15,RECRUITING,INTERVENTIONAL,['NA'],,
889,NCT00388700,"Primary Outcomes: Assess the efficacy and safety of GM-CT-01 administered with 5-FU, LV, and Avastin® in the first-line treatment of unresectable, locally advanced, and/or metastatic CRC.",2006-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Explore progression-free survival (PFS) and survival,
890,NCT04042831,Progression-free survival (PFS) at first scan,2020-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,The number of patients that had biomarkers related to tumor evaluation and resistance
891,NCT00513539,Overall survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],"Quality of life as assessed by EORTC QLQ 30 and PAN 26 at baseline and 1, 3, and 6 months after completion of study treatment",
892,NCT04098796,Objective response rate (ORR),2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Exploration of biomarkers (PD-L1 expression, TMB at the baseline, changes of AFP and T lymphocyte in peripheral blood)",
893,NCT05700188,Overall survival (OS),2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],Progression-free survival (PFS),
894,NCT02967848,Change in global and local liver function,2016-10-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Radiotherapy dose sparing of functional liver,
895,NCT05926726,RP2D of JWATM214 in HCC patients,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],overall survival (OS),
896,NCT05208762,Number of participants with DLTs by dose level,2022-10-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of anti-drug antibodies (ADAs),
897,NCT02190656,Number of participants with no LARS; minor LARS and major LARS,2014-05,COMPLETED,OBSERVATIONAL,['NA'],Correlation between LARS score and EORTC QLQ-C30 questionnaire score,LARS score in participants who have had laparoscopic surgery and participants who have had open surgery
898,NCT02951390,Adenoma detection rate,2016-07,COMPLETED,INTERVENTIONAL,['NA'],Total procedure time,
899,NCT01438385,Establishing a database that contains all Interventional Endoscopies,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],,
900,NCT04811703,Dose-limiting toxicities,2021-07-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Rates of adverse events and operative complications,
901,NCT01949870,The Number of Dose-limiting Toxicities,2013-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
902,NCT02459457,overall survival,2015-07-01,COMPLETED,INTERVENTIONAL,['PHASE3'],adverse event,
903,NCT00755534,Time To Progression,2008-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Correlation of the molecular characteristics of the tumor with the clinical outcome,
904,NCT00003923,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
905,NCT02953782,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),2016-11-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
906,NCT00227734,Objective response (complete response [CR] and partial response [PR]) measured after completion of study treatment,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse drug reactions measured after completion of study treatment,
907,NCT05826743,Study Success Case(Avoidance of ostomy),2023-12-04,RECRUITING,INTERVENTIONAL,['NA'],,
908,NCT04457297,Disease-free survival 1 (DFS1),2020-07-08,RECRUITING,INTERVENTIONAL,['PHASE3'],Treatment Completion Rate,
909,NCT06084689,Disease control rate (DCR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerability of the combination,
910,NCT06252649,PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1),2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Maximum Plasma Concentration (Cmax) of Sotorasib,
911,NCT04947371,Adverse events rate,2018-12-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival,
912,NCT01273662,disease stabilization,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],time-to-tumor progression,
913,NCT00844727,,2003-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
914,NCT04094675,Change in colon polyp burden by staging,2019-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in well-being assessment,
915,NCT05334836,Prevalence of pancreatic steatosis determined by fat quantitation on MRI,2022-04-06,RECRUITING,INTERVENTIONAL,['NA'],Risk factors for pancreatic steatosis in patients with presumed IPMN or MCN,
916,NCT02695966,T lymphocyte changes,2015-05,COMPLETED,OBSERVATIONAL,['NA'],T lymphocyte localisation,
917,NCT03980704,Infectious complications,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Length of stay,
918,NCT04977596,CT value of lesion portal phase,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
919,NCT01296984,3-year local recurrence,2011-02,COMPLETED,OBSERVATIONAL,['NA'],Stoma function,
920,NCT00506844,Pathologic stage Tumor regression grade,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease-free survival,
921,NCT04706910,Minimum lesion detectability (SUV),2021-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],Gallbladder disease questionnaire,
922,NCT00003799,MTD of oxaliplatin when combined with radiation therapy and fluorouracil based on the incidence of DLT as assessed by CTC version 2.0,1999-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
923,NCT02941562,Pathological Response,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],3-year Overall Survival,
924,NCT05824559,Progression Free Survival (PFS) rate at 16 weeks,2023-08-07,RECRUITING,INTERVENTIONAL,['PHASE1'],Safety and tolerability of ME-344 administered in combination with bevacizumab,
925,NCT05185947,"Evaluate efficacy of bidirectional chemotherapy using intraperitoneal and intravenous paclitaxel and oral nilotinib by calculating the rate of downstaging of peritoneal disease burden to become resectable, based on Peritoneal Carcinomatosis Inde...",2022-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Assess clinicopathologic response to therapy,
926,NCT04089150,Locoregional control (Locoregional Response Rate LRR),2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),ePRO Acceptability
927,NCT01957241,BIOMARKER PANEL SELECTION AND MODELING,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],SURVIVAL AND RT-RELATED TOXICITY ANALYSIS AND MODELING,
928,NCT05830292,Diagnostic accuracy of DRS probe to differentiate normal versus tumour tissue in vivo,2022-05-20,RECRUITING,INTERVENTIONAL,['NA'],Feasibility of DRS probe to differentiate normal versus tumour tissue in vivo,
929,NCT03001505,Overall survival,2017-05-04,WITHDRAWN,OBSERVATIONAL,['NA'],Local recurrence,
930,NCT02000739,Time to Disease Progression,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,
931,NCT06173466,Cumulative opioid consumption of 72 hours after surgery,2023-12-15,RECRUITING,INTERVENTIONAL,['NA'],Sleep quality,
932,NCT03822936,Progression free survival,2018-02-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],intra and perioperatory complications,
933,NCT05731947,Phase 2: Progression Free Survival (PFS),2023-04-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: DOR as Assessed by the Investigator,
934,NCT01545141,Change in the Number of Tumor-infiltrating CD8+ Cells.,2012-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Treatment Related Adverse Events,
935,NCT03206125,Esophageal squamous cell carcinoma,2017-08-01,TERMINATED,OBSERVATIONAL,['NA'],,
936,NCT05669807,Objective Response Rate,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life assessment,
937,NCT02045680,Improved tissue oxygen delivery,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],Time taken for patient to first mobilise following surgery,
938,NCT03624725,Effects of quality of life,2018-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
939,NCT06023121,Detection of levels of an exosome-based liquid biopsy signature,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
940,NCT01405638,Colorectal Cancer Screening,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,
941,NCT00216788,Urine sucrose level falls below 90 mg after 8 weeks of therapy,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Reduction of patient symptoms consistent with GERD,
942,NCT05043688,pCR,2021-09-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],AE,PD-L1 expression
943,NCT00152087,- Adverse experience,2002-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
944,NCT04534543,Change in PME/PDE (ΔPME/PDE): predictive,2021-12-15,RECRUITING,INTERVENTIONAL,['NA'],Response to treatment,
945,NCT01088581,2-year recurrence rate and adverse events,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],overall survival,
946,NCT01881932,Proportion of Colorectal and Breast Cancer Patients in Each Arm Who Require Dose Reduction or Discontinuation Due to Chemotherapy-induced Peripheral Neuropathy.,2013-02,TERMINATED,INTERVENTIONAL,['NA'],,
947,NCT05286320,objective response rate,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival and overall survival,Immune biomarkers
948,NCT05017922,Number of bleeding episodes,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
949,NCT00997958,Identification of maximum tolerated dose of CellCept in patients with advanced pancreatic cancer,2004-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
950,NCT03044613,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2017-07-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Recurrence-Free Survival,
951,NCT04957511,"Microbiome change through analysis of biological samples (fecal specimen, blood, vaginal swab, oral mucosal swab).",2021-06-29,RECRUITING,OBSERVATIONAL,['NA'],,
952,NCT02587884,Overall Survival,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],Time to recurrence,
953,NCT01360892,Cumulative incidence of carcinogenesis of hepatocellular carcinoma,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],The cumulative incidence and severity of decompensated cirrhosis,
954,NCT00681499,Quality of Life,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
955,NCT02580253,Desease free Survival,2017-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall Survival,
956,NCT00004193,"Determine the response rate, duration of response, and time to progression in patients with metastatic and/or locally recurrent adenocarcinoma of the colon or rectum treated with ISIS 2503, an antisense inhibitor of H-ras",1999-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Determine the safety profile of this regimen in these patients.,
957,NCT06111105,Collection of clinical plasma samples at relevant time points,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],Prognostic value of ctDNA analysis at relevant time points,
958,NCT01674959,feasibility of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],efficacy of concurrent IMRT combined with capecitabine for the treatment of gastric cancer patients,
959,NCT00100945,1-year overall survival rate,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
960,NCT06161818,Disease-free survival,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Future ctDNA analysis,
961,NCT04087889,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
962,NCT03642561,overall survival,2019-09-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",objective response rate,
963,NCT03829098,90 day mortality,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],Hospital based costs,
964,NCT04557969,Assess disease-free intervals (DFIs) between surgical resection of disease for at least 5 years,2020-12-18,RECRUITING,OBSERVATIONAL,['NA'],Characterize genomic and clinicopathologic features of GISTs,
965,NCT01885702,Safety and feasibility of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients,2010-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Clinical responses, e.g. disease-free survival, determined according to the standard protocol.",
966,NCT02842047,Repeated Measures ANCOVA Model (F-Statistic),2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],Change in FAMCARE Scale,
967,NCT04073615,(Phase 2) Progression Free Survival (PFS) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator Assessment,2019-11-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",(Phase 1b and 2) Number of Participants with Adverse Events (AEs) that Worsen in Severity as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0,
968,NCT03306901,3-year overall survival,2017-10-20,RECRUITING,INTERVENTIONAL,['NA'],Treatment-related complications or adverse events,
969,NCT00128622,Safety as measured by rate of adverse events during study drug treatment,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Rate of immune response as measured by ELISPot at week 10,
970,NCT00532909,"Maximum tolerated dose of vandetanib in combination with capecitabine, oxaliplatin and bevacizumab",2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Dose limiting toxicities associated with the combination,
971,NCT01706809,"The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival.",2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
972,NCT04426669,Safety of tumor reactive autologous lymphocytes with knockout of the CISH gene - Incidence of Adverse Events,2020-05-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Toxicity profiles resulting from treatment using these engineered tumor-infiltrating lymphocytes,
973,NCT01859182,"Proportion of patients who have a response (PR or CR), assessed by the RECIST v1.1",2013-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Changes in QOL evaluated using the Functional Assessment of Cancer Therapy - General (FACT-G),
974,NCT00005878,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
975,NCT06055010,Subproject dependent,2014-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
976,NCT05539417,The variation in treatment and awareness of lateral lymph nodes in patients with rectal cancer.,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],Presence of presacral abscess,
977,NCT03546660,Feasibility of imaging of the Esophagus using a SECM Capsule,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
978,NCT01770132,Evaluate the number of subjects with adverse events which occur when up to 3 sites within the pancreas are treated with PDT using a total dose of 50 or 100 J per site,2013-04-19,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival,
979,NCT01903018,Number of severe Radiation Induced Mucositis (WHO grade >=3),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
980,NCT04781413,3-year relapse-free survival (RFS),2021-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Peritoneal metastasis rate,
981,NCT01042782,maximum tolerated-dose (MTD) of RAD001 in combination with Mitomycin C,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],"safety and tolerability of the combination of RAD001 and Mitomycin C as assessed by frequency, severity, and duration of treatment-related adverse effects",
982,NCT02653521,Toxicity of treatment,2015-12-30,UNKNOWN,INTERVENTIONAL,['NA'],Overall Survival（OS）,Dosimetric Parameters
983,NCT02866045,Proportion of patients receiving a definitive histologic diagnosis for gastrointestinal SELs by single incision needle-knife biopsy (SINK biopsy) vs. EUS-guided fine needle biopsy (EUS-FNB).,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],Proportion of patients for whom a mitotic rate may be calculated for gastrointestinal stromal tumors (GISTs) using SINK biopsy vs. EUS-FNB,
984,NCT02178358,Overall Survival (OS): Number of Events,2014-08-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in EORTC QLQ Hepatocellular Carcinoma (HCC-18) Questionnaire Score,
985,NCT04539769,Diabetes remission rate,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
986,NCT01033578,Overall Survival,1999-10,UNKNOWN,INTERVENTIONAL,['NA'],Time to Recurrence,
987,NCT01108107,The frequency of patients requiring adjuvant chemotherapy based on the histological evaluation of the preparation from the operation.,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
988,NCT02216487,Safety,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
989,NCT02935764,progression free survival,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],quality of life questionnaire,
990,NCT05896787,pCR,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],AE,
991,NCT05359393,NED rate,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Acute toxicity associated with immunotherapy,
992,NCT05987709,Assess colorectal cancer screening completion,2022-03-17,COMPLETED,INTERVENTIONAL,['NA'],Assess the proportion who completed follow-up testing.,
993,NCT06223022,Patients' reported Quality of life,2024-01-20,RECRUITING,INTERVENTIONAL,['NA'],Patients' experiences of prostata cancer related to symptoms and side effects of treatment and diagnosis.,Sick-leave
994,NCT03579732,Number of subjects with gastric cancer,2018-06-29,COMPLETED,OBSERVATIONAL,['NA'],Number of fatal cases due to colorectal cancer,
995,NCT01926769,Disease Control Rate,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression Free Survival,
996,NCT02812186,Peak Airway Pressures,2016-12-27,COMPLETED,INTERVENTIONAL,['PHASE4'],Surgical Rating Scale,
997,NCT02115373,Phase 2: Number of Participants Who Were Progression-free at 12 Weeks (PFS Status) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2014-05-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1b: Accumulation Ratio of AUC (Racc (AUC),
998,NCT03800953,overall radiographic response,2019-03-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],New metastasis-free survival,
999,NCT04940546,Adverse events,2021-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
1000,NCT03887702,"Time until adverse liver outcome, assessed by incidence of adverse liver outcome",2020-01-17,TERMINATED,INTERVENTIONAL,['PHASE3'],Death due to any cause,
1001,NCT03366012,Patient Tolerability determined by Score on Likert Scale,2018-08-01,SUSPENDED,INTERVENTIONAL,['NA'],Number of Serious Adverse Events (SAEs),
1002,NCT02092389,Percentage of Patients With Fecal Calprotectin (fC) Level ≤ 150 µg/g After 12 Months of Treatment With Adalimumab,2014-07,TERMINATED,OBSERVATIONAL,['NA'],Correlation Between fC and Workability Determined by WPAI:UC Questionnaire,
1003,NCT02702089,morbidity,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],Reintervention rate,
1004,NCT03604237,pathologic diagnosis,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,
1005,NCT02804737,Effectiveness of Web-based instructions,2014-07,COMPLETED,OBSERVATIONAL,['NA'],Benefit of web-based instructions,
1006,NCT04037241,Assess efficacy by overall survival,2021-11-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Evaluation of Quality-of-Life using the 5-level EQ-5D version (EQ-5D-5L) questionnaire,Assess the persistence of CAR-T cells in liver tumor biopsies over time.
1007,NCT05056051,To assess the additive diagnostic yield as assessed by proportion of patients with recurrence be use of WATS-3D,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],To assess if the order by which tissue is sampled affects the diagnostic yield of WATS-3D by comparing the proportion of patients with recurrence between groups.,
1008,NCT05081687,cCR + PathCR,2020-02-20,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall toxicity,
1009,NCT00019747,Time to Progression,1999-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1010,NCT01108705,Compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to sorafenib and receive brivanib plus best supportive care (BSC) to those receiving placebo plus BSC,2010-05,TERMINATED,INTERVENTIONAL,['PHASE3'],"Assess serious and nonserious adverse events, laboratory evaluations, significant physical examination findings and ECG results",
1011,NCT00354224,Response Rate as Determined by RECIST.,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression-free Survival,
1012,NCT03577067,renal resistive index (RRI),2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
1013,NCT00997633,Detected volume measured by SPECT compared to the number of subsequent sequential postoperative intraperitoneal chemotherapy courses,1991-05,COMPLETED,OBSERVATIONAL,['NA'],"The relationship between SPECT, feasibility of SPIC (intraperitoneal chemotherapy), and clinical variables",
1014,NCT00622999,Complication rate,2003-01,COMPLETED,OBSERVATIONAL,['NA'],Mortality,
1015,NCT04013152,Collection of clinical data following surgery with robotic assistance in colorectal pathologies,2018-06-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Quality of the mesorectum by using Quirke classification,
1016,NCT03783936,Best Objective Response Rate (bORR),2019-01-24,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Grade 3-4 Treatment Related Adverse Events,
1017,NCT05909995,"Incidence of TEAEs leading to dose interruption, dose reduction, or discontinuation of either of the study drugs",2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Duration of Response,
1018,NCT00077987,Anti-tumor efficacy,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor control survival safety,
1019,NCT03804203,Efficacy of palliation using the short course scheme compared with the standard scheme: Likert scale,2017-11-08,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life (QoL): EORTC questionnaire C15-PAL,
1020,NCT04832763,Change in health-related quality of life (HRQoL),2019-09-27,TERMINATED,INTERVENTIONAL,['NA'],Biomarker analysis - C-Reactive Protein,
1021,NCT00086567,Create a multi-institutional repository from which investigations of serum proteomic signature profiles of epithelial ovarian cancer and relapse will be developed and validated,2005-12-12,COMPLETED,OBSERVATIONAL,['NA'],,
1022,NCT01028495,Survival,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],"Karnofsky Performance Scale, Clinical Laboratory Assessment, and Molecular Markers",
1023,NCT00341484,Genetic determinants,1998-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
1024,NCT05980221,Metabolome,2020-08-24,RECRUITING,INTERVENTIONAL,['NA'],Response of the fed and fasted metabolome to PERT,
1025,NCT03346980,Inter-observer agreement of the Spigelman Score evaluated by expert endoscopists.,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],Inter- and intra-observer agreement of the Spigelman Score and the endoscopic sub-scores evaluated by novices.,
1026,NCT05353127,Influence of different CPET data averaging intervals on the numerical values of CPET-,2022-04-12,COMPLETED,OBSERVATIONAL,['NA'],High- or Low-risk for postoperative complications,
1027,NCT00358566,Overall survival time,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Progression Free Survival,
1028,NCT01558648,short -term quality of life (QOL),2012-03-14,COMPLETED,OBSERVATIONAL,['NA'],Complications,predict EUS T3/T4/stricture or earlier EUS disease
1029,NCT00016029,,2000-08,TERMINATED,INTERVENTIONAL,['NA'],,
1030,NCT03811379,Objective Response Rates (ORR),2018-11-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events (AEs),
1031,NCT04819516,Number of Participants With Abnormal Laboratory Values,2020-12-07,RECRUITING,INTERVENTIONAL,['PHASE1'],Numeric rating scale,
1032,NCT00268333,Response rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
1033,NCT02390947,Overall Survival(OS),2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],The severity of Adverse Events,
1034,NCT03493009,rate of adequate cleansing level,2018-05-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
1035,NCT04044859,To evaluate safety of ADP-A2M4CD8 as monotherapy or in combination with either nivolumab or pembrolizumab,2019-08-20,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
1036,NCT01526590,Lesion Margin,2012-07,WITHDRAWN,INTERVENTIONAL,['NA'],Degree of venous washout,
1037,NCT06100003,Specificity,2023-10-18,RECRUITING,OBSERVATIONAL,['NA'],,
1038,NCT01603004,Progression free survival,2012-05-14,COMPLETED,OBSERVATIONAL,['NA'],best response,
1039,NCT03167970,The overall diagnostic accuracy of capsule endoscopy in predicting the presence and extent of Barrett's esophagus in comparison to standard esophagogastroduodenoscopy,2017-05-03,COMPLETED,OBSERVATIONAL,['NA'],Incidence of Treatment related adverse events of capsule endoscopy in comparison to standard esophagogastroduodenoscopy,
1040,NCT05893810,High-grade radiation-induced oral mucositis,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life according QLQ-H&N43,
1041,NCT04705194,Correlation coefficient between preoperative FLR-GC and post-operative ICG R15,2019-07-08,UNKNOWN,OBSERVATIONAL,['NA'],Correlation coefficient between growth in FLR volume and growth in FLR-GC after the first stage,
1042,NCT00049712,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1043,NCT03910699,Anastomotic leakage rate,2019-04-10,UNKNOWN,INTERVENTIONAL,['NA'],Serious adverse events rate,
1044,NCT00277303,Safety and tolerability,2005-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters,
1045,NCT05468892,PFS,2019-10-29,COMPLETED,INTERVENTIONAL,['PHASE2'],"Safety and tolerability analysis: defined as the evaluation of incidence and severity of AEs, graded according to NCI- CTCAE, version 5.0 (v. 5.0).",
1046,NCT04194034,Disease Control Rate (Phase II part),2020-01-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1047,NCT04715321,Predictive performance of CT perfusion,2013-02-15,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival (DFS),
1048,NCT04594772,Measuring the proportion of patients undergoing surgical resection using historical data compared to 32 patients in current study.,2021-03-17,RECRUITING,INTERVENTIONAL,['PHASE2'],"Measuring the safety of neoadjuvant therapy will be determined using CTCAE v5, reported as proportions of patients experiencing toxicities, graded using CTCAE v. 5.0.",
1049,NCT04147078,Disease-free Survival (DFS),2019-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of Treatment-Related Adverse Events [Safety and Tolerability],
1050,NCT00069108,Progression Free Survival,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Marked Post-baseline Laboratory Abnormalities by Trial Treatment,
1051,NCT03825887,Total opioid consumptions,2018-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Assess serious adverse events,
1052,NCT01043835,Disease free survival,2010-02,UNKNOWN,INTERVENTIONAL,['NA'],"Complications, recurrence, quality of life measured by EORTC QLQ-C30 V 3.0 and EORTC QLQ-STO22",
1053,NCT05699278,Rate of patients who remain in a gastric cancer clinical trial to trial completion,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1054,NCT05697107,PFS,2021-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],OS,
1055,NCT00004252,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1056,NCT01032850,Number of Participants Experiencing Adverse Events,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),
1057,NCT06152783,Histopathology was used as the diagnostic gold standard to evaluate the diagnostic performance of CellTouch in the diagnosis of early gastric cancer.,2023-11-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],"Using histopathology as the diagnostic gold standard, the diagnostic performance of CellTouch and ME-NBI in the differential diagnosis of low-grade intraepithelial neoplasia and high-grade intraepithelial neoplasia was evaluated.",
1058,NCT02394795,Overall Survival (OS) in All Participants,2015-05-29,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Treatment-emergent Adverse Events (TEAE),
1059,NCT05253716,3-year disease free survival after discharge,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],"toxicity of chemotherapy graded according to the CTCAE, version 5.0",
1060,NCT05494060,Disease Free Survival (DFS),2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Free Survival (DFS) rate at 3 years,Toxicity by CTCAE v5.0 criteria
1061,NCT05245786,Number of patients with impactful finding using 64Cu-M5A positron emission tomography (PET) imaging.,2022-08-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Count of Adverse Events.,
1062,NCT06144385,Rate and severity of clinically-significant abnormalities in laboratory testings,2022-03-24,RECRUITING,INTERVENTIONAL,['PHASE1'],Overal survival (OS),
1063,NCT02581709,Feasibility of intervention implementation,2016-05,TERMINATED,INTERVENTIONAL,['NA'],Cognitive Reserve Scale,
1064,NCT06333665,Disease-free survival,2024-02-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],perioperative 90-day mortality,
1065,NCT06187103,Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning.,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Patient experience of HyperSight imaging,
1066,NCT00830778,Reduction of clinical postoperative pancreatic fistula (POPF) rate,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Reduction of the severity of postoperative complications,
1067,NCT00928928,Oxidative stress markers in patients with colorectal cancer operated with open or laparoscopic approach,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
1068,NCT01008358,Tumor response by Response Evaluation Criteria In Solid Tumors (RECIST),2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in Hepatitis C Virus (HCV) viral load,
1069,NCT05054959,complete remission rate,2021-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],local control,
1070,NCT03410030,Phase II: Disease control rate (CR+PR+SD x18 weeks),2017-12-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Changes in patient's self-reported pain levels,Changes in circulating tumor stem cells
1071,NCT01136031,response rate (phase II part),2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",toxicities,
1072,NCT04745988,Major pathological response (MPR) rate,2021-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],The incidence of adverse events,
1073,NCT03944421,Genotoxic potential of Faecal extracts from volunteers consuming intervention diets rich in red and processed meat versus diets containing Quorn,2019-07-03,COMPLETED,INTERVENTIONAL,['NA'],Changes in MicroRNA Expression,Blood Glucose
1074,NCT02409472,Health Related Quality of Life,1998-04,COMPLETED,INTERVENTIONAL,['NA'],Disease free survival (DFS),
1075,NCT05687474,Feasibility - reliability,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants.,
1076,NCT03403634,Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions,2018-04-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1,Overall Survival
1077,NCT01252628,"The evaluation of antitumor effects of PX-866 in combination with cetuximab versus cetuximab in patients with incurable metastatic colorectal cancer and/or patients with incurable progressive, recurrent or metastatic SCC of the head and neck.",2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1078,NCT03168139,"Combination Therapy: Safety - adverse events, vital signs, ECG, hematology & safety laboratory",2017-04-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Combination Therapy: Efficacy - time to event analyses,
1079,NCT03563170,"Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1",2018-05-25,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",ORR for Phase 2 Single Arm Component,
1080,NCT01442155,Disease-Free Survival (Time to Event),2011-10,COMPLETED,OBSERVATIONAL,['NA'],Safety: Percentage of Participants With Adverse Events,
1081,NCT06040541,Dose Limiting Toxicities,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-Free Survival (PFS),
1082,NCT01962649,Measurement of fluorescence intensity within focal hepatic lesions,2013-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
1083,NCT05908786,Major Pathologic Response (MPR) Rate,2023-12-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Post-Operative Mortality,
1084,NCT01142388,Progression-free Survival,2010-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Objective Response Rate,
1085,NCT04420026,"Evaluation of the primary success rate of percutaneous ablation treatment with IRE of hepatic tumors, as a function of the ultrasound visibility of the tumor, when using automatic CT cone-beam fusion and ultrasound",2020-07-06,COMPLETED,INTERVENTIONAL,['NA'],Evaluate the global survival at 12 months,
1086,NCT00051480,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1087,NCT06313047,CYP2B6,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1088,NCT01456156,overall survival,2008-01,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants with Adverse Events,
1089,NCT00831493,Maximum Tolerated Dose (MTD) of Vorinostat + Chemoradiation,2009-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1090,NCT00467129,Progressive disease-free survival,2002-07,UNKNOWN,OBSERVATIONAL,['NA'],,
1091,NCT03158571,Overall survival,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1092,NCT03305913,Maximum Tolerated Dose (MTD),2017-07-31,COMPLETED,INTERVENTIONAL,['PHASE1'],Incidence of Treatment-Emergent Adverse Events,
1093,NCT05453851,Proportion of patients that are free of metastatic disease to the liver from a pancreatic primary,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to overall survival (OS),Incidence of adverse events (AEs)
1094,NCT03626350,Adverse Events,2018-06-12,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Submucosal endoscopy technique and device used,
1095,NCT04791176,MST,2021-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of III-IV grade adverse events,
1096,NCT00386516,Stable disease (SD) rate and progression-free survival (PFS) times,2006-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"Safety, tolerability and Quality of Life (QoL)",
1097,NCT01609361,Post operative morbidity at 30 days according to DINDO CLAVIEN classification,2012-11,COMPLETED,INTERVENTIONAL,['NA'],Duration of laxation (gas and stool),
1098,NCT05606081,Rates of colorectal neoplasia per number of colonoscopies performed,2022-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
1099,NCT02884154,diagnostic sufficiency,2016-08,COMPLETED,INTERVENTIONAL,['NA'],complications,
1100,NCT05493683,Objective response rate(ORR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of Response (DOR),
1101,NCT04573621,Number of participants with pelvic sepsis,2020-10,UNKNOWN,INTERVENTIONAL,['NA'],Any complications associated with drain removal after surgery,
1102,NCT06326346,16 week disease control rate,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse event assessed by NCI-CTCAE Version 5.0,
1103,NCT04406714,"Proportion of subjects, ages 50-75, who complete CRC screening within 6 months (Trial - Age Group 50-75)",2020-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Proportion of subjects who complete a follow-up diagnostic colonoscopy at 60 days (Sub-study - Age Group 45-49),Number of days from abnormal FIT result date to diagnostic colonoscopy (Trial - Age Group 50-75)
1104,NCT04460937,Incidence of adverse events,2021-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Biomarkers,
1105,NCT02718430,Safety and tolerability taking into account treatment-limiting toxicities (TLTs),2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Biodistribution and shedding of VXM01,
1106,NCT00767234,Identify Biomarkers,2008-08,TERMINATED,OBSERVATIONAL,['NA'],,
1107,NCT03516890,Overall survival of all patients,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],Recurrence-free of staged partial hepatectomy patients,
1108,NCT04510064,margin-free-(R0) resection rate,2020-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival (OS),
1109,NCT05897749,PFS,2023-06-16,RECRUITING,INTERVENTIONAL,['PHASE4'],quality of life,
1110,NCT01806675,Change From Baseline in Maximum Standard Uptake Values (SUVmax),2013-03-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free Survival (PFS),
1111,NCT03290937,Objective response rate (Dose expansion),2017-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Duration of response,
1112,NCT05164848,Incidence of Treatment-related Adverse Events，afety and Tolerability,2021-12-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],The incidence of neutralizing antibody (Nab),The correlation of biomarkers with efficacy
1113,NCT00021398,tolerated dose of preoperative hyperfractionated radiation and concurrent chemotherapy,1996-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1114,NCT00345761,Safety (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0),2006-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",concentrations of anti-bevacizumab antibody,
1115,NCT01030042,Overall Survival,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression free survival,
1116,NCT03662204,Biomarker Evaluation,2018-08-23,COMPLETED,OBSERVATIONAL,['NA'],,
1117,NCT00725712,Number of Participants Who Required Concomitant Medications,2007-03-31,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Duration of Overall Survival (OS)of GSK1363089,
1118,NCT00436501,Median Progression-Free Survival (PFS) (Phase II),2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With PFS (Phase II),
1119,NCT00844454,Local treatment responses,2008-05,COMPLETED,INTERVENTIONAL,['NA'],Disease-free survivals and overall survivals,
1120,NCT04246684,organ preservation,2020-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Translational / biomarker studies,
1121,NCT01774019,"Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last",2013-02-20,COMPLETED,INTERVENTIONAL,['NA'],All-cause Mortality,
1122,NCT01943253,Procedure time,2011-05,COMPLETED,INTERVENTIONAL,['NA'],complication rate,
1123,NCT00440934,Response rate,2007-02,TERMINATED,INTERVENTIONAL,['PHASE2'],To determine the influence of the treatment on the hepatic function of patients with a diagnosis of cirrhosis. To determine the impact of the treatment by means of electromagnetic waves on the overall survival of patients.,
1124,NCT05213195,Maximal Tolerable Dose#MTD#,2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Antitumor efficacy-Overall survival (OS),
1125,NCT00346281,Safety profile of the patients defined by the Adverse Events profile.,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Will assess ease of use, tumour response, duration of response, progression free survival and overall survival. Target tumour response summaries for the study will be performed.",
1126,NCT00374985,maximum tolerable dose and safety,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1127,NCT00002551,Survival and Relapse-free survival,1994-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1128,NCT00365508,24-hour Point Prevalence Abstinence at the 6-month Follow up,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Rate of Compliance During the First 2 Weeks,
1129,NCT04878692,Measurement of the percentage of Onco-Rash failure by counting the number of patients with a rash grade ≥ 2 (NCI-CTCAE scale).,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA'],Percentage of patients for whom treatment for acne (anti-inflammatory or antibiotic) has been introduced,
1130,NCT04683965,Objective response rate(ORR),2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
1131,NCT01500993,Overall survival,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Local recurrence rate,
1132,NCT06017284,Rate of nausea/vomiting,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall survival (OS),
1133,NCT01234324,Frequency of pT3/T4 categories after surgery,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequencies of pN2/N3 categories after surgery,
1134,NCT02017704,Number of Patients With Pathologic Complete Response,2014-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Local Disease Recurrence,
1135,NCT03723447,Cumulative 48-hour Post Surgical Opiate Use (Oral Morphine Equivalent),2018-10-23,COMPLETED,INTERVENTIONAL,['PHASE4'],Postoperative Complications,
1136,NCT01944930,Rate of Detectable Peritoneal Metastases,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1137,NCT01928290,Number of Participants With an Objective Response,2013-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events,
1138,NCT02387138,Dose limiting toxicities,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1139,NCT04005521,Swallowing ability,2019-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Maximal Interincisal opening (MIO),Incremental Cost Effectiveness Ratio (ICER)
1140,NCT05671809,ARP,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],MASCP and Wexner,
1141,NCT04591028,Number of lymph nodes removed for each lymphatic station of gastrectomy,2022-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,
1142,NCT00912743,Tumour Response,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
1143,NCT05502276,R0 resection rate,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
1144,NCT05903885,Fecal Immunochemical Test (FIT) kite return rate,2023-10-02,RECRUITING,INTERVENTIONAL,['NA'],Fecal Immunochemical Test (FIT) kit positive rate,
1145,NCT06045715,disease-free survival,2022-08-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],distant metastasis-free survival,
1146,NCT00839332,Phase 2: Overall Survival (OS),2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Electrocardiogram QTc Prolongation,Number of Deaths During the Phase 1 Post-study Period
1147,NCT05706974,Rate of bile duct cancer patients who remain in a clinical study to completion,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1148,NCT01208194,Evaluation of median progression-free survival (PFS) in both treatment groups,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Assessment of the safety profile of MGN1703,
1149,NCT05440357,Progression-free survival rate,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],Safety-TEAEs,To explore the association of cilinical outcomes with treatment pattern
1150,NCT00544700,Time to progression (TTP),2007-11-26,TERMINATED,INTERVENTIONAL,['PHASE3'],Long-term bevacizumab treatment costs,
1151,NCT06225609,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Total hospitalization costs,The number of patients with complications after total mesorectal excision for rectal cancer
1152,NCT01662739,"Collection of life-style, familiar, clinical, histological and biomolecular data",2010-01,UNKNOWN,OBSERVATIONAL,['NA'],Collection of biological samples (blood and cancer tissue samples),"Analysis of epidemiology, risk factors, family history and unidentified susceptibility genes and proteins"
1153,NCT01063517,Progression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients],2010-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Deterioration in QoL Anxiety Domain Score in the Overall Study Population,
1154,NCT01234701,Inter-observer agreement among expert radiologists in diagnosing primary liver tumors by Magnetic Resonance Imaging (MRI).,2010-10,COMPLETED,OBSERVATIONAL,['NA'],Investigate the diagnostic efficacy of radiologists' certainty of diagnosis (CoD) in accurately predicting primary liver tumors assessed by Magnetic Resonant Imaging (MRI),
1155,NCT03443492,progression free survival (PFS),2018-03-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1156,NCT00734513,Patient's psychological adjustment,2003-01,COMPLETED,INTERVENTIONAL,['NA'],Gender and marital satisfaction as moderators of the effects of partner-assisted ED.,
1157,NCT01693432,Objective response rate,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease control rate,
1158,NCT03972527,IThe primary effectiveness endpoint is the severity of oral mucositis at week 6 of radiation treatment according to the Oral Mucositis Index (OMI) score.,2022-08-05,RECRUITING,INTERVENTIONAL,['NA'],Changes in overall quality of life over the 6-week treatment period,
1159,NCT04145297,"Recommended phase 2 dose of ulixertinib in combination with a fixed dose of hydroxychloroquine in subjects with advanced, RAS, non-V600 BRAF, ERK or MEK mutated gastrointestinal malignancies",2020-03-17,COMPLETED,INTERVENTIONAL,['PHASE1'],Efficacy of ulixertinib and hydroxychloroquine in the study population: Objective response rate (PR and CR),
1160,NCT04963283,Disease Control Rate (DCR),2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory Biomarker analysis - Tumor tissue,
1161,NCT02368886,Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3,2015-03-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in QOL (According to the Linear Analogue Self-Assessment [LASA] Questionnaire),Pharmacokinetics (PK) Parameters of Regorafenib Using Liquid Chromatography Mass Spectrometry
1162,NCT03046862,Response rate,2017-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerability as measured by number and grade of toxicity events,
1163,NCT03855800,High grade dysplasia (HGD) or cancer diagnosis in Immediate Surgery group,2018-05-11,RECRUITING,INTERVENTIONAL,['NA'],High grade dysplasia (HGD) or cancer diagnosis in clinical follow up group,
1164,NCT05820906,Overall response rate ( ORR) per RECIST 1.1,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease control rate (DCR) per RECIST 1.1,
1165,NCT01402180,Local control,2010-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse Events,
1166,NCT03225937,Objective Response Rate according to RECIST 1.1 criteria,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression Free Survival,
1167,NCT03178383,Integration of health-relation practices assessed via church survey,2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],Implementation: Extent to which intervention is implemented as intended as assessed by a fidelity checklist completed by staff,
1168,NCT02905968,anastomotic leak rate,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Time Frame: Reoperation rate after anastomotic leak,
1169,NCT03665506,Overall survival,2018-06-25,COMPLETED,OBSERVATIONAL,['NA'],Patient-reported outcomes (PROs) on quality of life (QoL),Assessment of health economic parameters
1170,NCT00041249,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1171,NCT02763748,Tumor recurrence rate,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],"the all number of postoperative complications（ frequency,reflux esophagitis and bile reflux gastritis）",
1172,NCT04738214,Pathologic response rate,2021-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Disease free survival,
1173,NCT05807646,The changes of the level of circulating tumor cells in the peripheral blood,2025-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Postoperative recovery course,
1174,NCT05285358,Incidence of adverse events,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Functional status,
1175,NCT05184400,Overall survival (OS),2015-01-01,RECRUITING,OBSERVATIONAL,['NA'],Incidence of adverse events,
1176,NCT01147991,"Demonstration by ELIspot assays of the frequency of T-lymphocytes recognizing major histocompatibility complex (MHC) class I and II-restricted epitopes within EBNA1 and LMP2 in peripheral blood at sequential time-points before, during, and up to 9 mo ...",2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Measurement of EBV-genome levels in plasma,
1177,NCT04333927,Overall Survival,2020-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
1178,NCT03631537,nutritional status,2018-08-20,UNKNOWN,INTERVENTIONAL,['NA'],adverse events,
1179,NCT00604409,"To determine the safety, toxicity, and recommended phase II dose (RPTD) of capecitabine when administered concurrently with SIR-Spheres in patients with advanced cancer.",2006-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Efficacy,
1180,NCT02143869,body composition,2013-12,COMPLETED,OBSERVATIONAL,['NA'],perioperative complications,comparison of the body composition obtained by BIA and anthropometric measurements.
1181,NCT03586973,24-Week Progression-Free Survival Rate (PFSR),2018-08-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
1182,NCT02851004,ORR,2016-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacokinetic,safety according to immune status
1183,NCT02132858,Tumor response measured using the tumor regression grading system,2014-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Tumor heterogeneity in patients with partial response to radiation,PET-computed tomography parameters
1184,NCT02943603,number of adverse events related to toxicity,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],PD-L1 expression in tumor cells,
1185,NCT03714490,R0(microscopically margin-negative) resection rate,2018-10-23,RECRUITING,INTERVENTIONAL,['PHASE2'],QoL by QLO-CR29,"circulating tumor DNA, and other potential biomarkers such as T-cell receptor"
1186,NCT03199274,Tumor perfusion measured by contrast-enhanced ultrasound between ultrasound-triggered microbubble destruction pulses,2017-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
1187,NCT02626728,morbidity,2015-09,COMPLETED,OBSERVATIONAL,['NA'],short-term oncological result,
1188,NCT01634126,FIT Kit adherence,2012-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
1189,NCT03628248,Colonic perfusion in the marginal artery after inferior mesenteric artery ligation between groups,2020-03-10,COMPLETED,INTERVENTIONAL,['NA'],Presence of post-surgery complications,
1190,NCT02575313,Measurement of Tolerability,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Treatment Break Measurement,
1191,NCT05223816,PFS,2024-01-24,RECRUITING,INTERVENTIONAL,['PHASE2'],anti-HSV-1 antibody,
1192,NCT00846482,Number of Patients With Excision Repair Cross-complementing Group-1 (ERCC1) Protein Change When Treated With Oxaliplatin,2008-02,COMPLETED,INTERVENTIONAL,['NA'],Determine Extent of ERCC Polymorphism and Its Relationship to Change in Its Level,
1193,NCT01048463,Serum level of proalbumin,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Records of food intake,
1194,NCT05573776,Comparison of muscle variation between exercise therapy alone and high protein supplement combination groups,2020-08-01,RECRUITING,INTERVENTIONAL,['NA'],Overall Survival (OS),
1195,NCT04834986,Feasibility as measured by rate of enrollment,2021-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],adverse reactions,To investigate the clinical efficacy of PD-L1 expression in predicting the combination of Tislelizumab and Lenvatinib.
1196,NCT01270893,Percent of Apoptotic Tumor Cells Pre- and 7 Days Post Nilotinib Treatment,2011-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
1197,NCT00482365,Etiologic factors associated with hepatocellular carcinoma in different ethnic groups across the US,2002-04,COMPLETED,OBSERVATIONAL,['NA'],Serum repository for registry patients,
1198,NCT03039062,Relationship of serum miR-122 level and DILI or hepatic failure,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],Normal physiological range of miR-122 in healthy population,
1199,NCT01357486,Time to radiologic progression,2011-11-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
1200,NCT01459965,Documented change in Quality Of Life,1993-07,COMPLETED,INTERVENTIONAL,['NA'],Documented change in symptoms and concerns specific for patients with MBDO,
1201,NCT03768375,Progression Free Survival,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1202,NCT04889820,3-year overall survival,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],circulating tumor DNA,
1203,NCT03672305,The efficacy of c-Met/PD-L1 CAR-T cells in the treatment of HCC,2018-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],The amplification and persistence of c-Met/PD-L1 CAR-T cell in the subjects varied with time,
1204,NCT04389502,Correct Answers (60% group),2020-05-15,UNKNOWN,INTERVENTIONAL,['NA'],Correct Answers (80% group),
1205,NCT00289445,activity,1999-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1206,NCT00976508,Number of Participants With Dose Limiting Toxicities (DLT),2009-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants With Objective Response,
1207,NCT02182687,Freedom From Progression Over Time,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life - Questionnaires Include PIQ-6 and SF-36v2 Health Survey,
1208,NCT00857545,Progression-free Survival (PFS),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
1209,NCT00027833,,2001-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1210,NCT00536523,Alterations in serotonin levels associated with increased constipation,2007-04,TERMINATED,OBSERVATIONAL,['NA'],,
1211,NCT05988918,Progression Free Survival,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Median Progression- Free Survival (PFS) within each cancer subtype,
1212,NCT01713244,Recurrence-free Survival,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],Overall Survival,Number of participants with adverse events
1213,NCT03766945,Fatigue,2017-07-27,UNKNOWN,OBSERVATIONAL,['NA'],Quality of Life,
1214,NCT04316975,Correlation of Mean Mutational Load (ML) and Treatment Resistance,2020-04-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Correlation of Mutational Load and Stricture Formation,
1215,NCT03037437,Time to tumor progression evaluated via tumor imaging,2017-02-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,
1216,NCT04321577,Gallbladder cancer risk score,2020-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],Disease-free survival,
1217,NCT02149784,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of Participants with Adverse Events both in surgery group and chemotherapy group,
1218,NCT04023448,anterior resection syndrome incidence,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],Long-term postoperative complication incidence,
1219,NCT02614703,Total Number of Subjects With Neoplasia When Using Acetic Acid Chromoendoscopy Versus Standardized Random Biopsies.,2017-03-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
1220,NCT00788281,operation mortality,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],fee,
1221,NCT05461664,Duration Of Response,2022-07-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],serious adverse events,
1222,NCT00994526,"Urinary biomarker (DHN-MA:dihydroxynonene mercapturic acid), will be measured before and after every interventional period",2009-10,COMPLETED,INTERVENTIONAL,['NA'],Fecal biomarkers,
1223,NCT04674267,Association of geriatric consultation with number of unplanned ED visits/hospitalizations among older adult participants,2022-01-18,RECRUITING,INTERVENTIONAL,['NA'],,
1224,NCT02248038,5 years overall survival rate,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1225,NCT00220181,,2003-04,COMPLETED,OBSERVATIONAL,['NA'],,
1226,NCT02496273,ELISPOT assays,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],overall survival (OS),
1227,NCT05520801,Objective response rates (ORR),2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],Quality of Life (QoL) after treatment,
1228,NCT00903396,Complete Response (no Episodes of Nausea or Vomiting),2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Average Level of Nausea Reported and the Proportion of Patients Experiencing a Complete Response Independent of Treatment Arm,
1229,NCT00666107,"Determine if vaccinations will activate the subject's immune systems sufficiently that the HIV-1 viral load either increases from the baseline value, or becomes detectable and stays detectable after being undetectable at the baseline visit",2008-06,UNKNOWN,INTERVENTIONAL,['NA'],,
1230,NCT00049335,Feasibility of enrolling patients aged 70 years or older to a Phase II trial including pharmacokinetic sampling,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],"Explore, at a preliminary level, the feasibility of studying genetic polymorphisms and gene expression levels of enzymes involved in drug metabolism and resistance to capecitabine",
1231,NCT00555295,,2007-12,UNKNOWN,OBSERVATIONAL,['NA'],,
1232,NCT03902678,Percentage of patients with portal vein thrombosis who underwent EUS guided FNA and had complications as a result of the invasive maneuver,2017-05-11,UNKNOWN,INTERVENTIONAL,['NA'],,
1233,NCT01166490,Incidence of adverse events and laboratory abnormalities,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Incidence of antitherapeutic antibodies in blood,
1234,NCT05766605,The one-year DFS rate,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse events,
1235,NCT02015923,Assess the impact of overall survival in patients with unresectable metastatic colorectal cancer treated with chemotherapy alone vs surgery followed by chemotherapy.,2013-12,TERMINATED,INTERVENTIONAL,['PHASE4'],Study of possible survival factors,
1236,NCT03607656,3-year Disease Free Survival rate,2018-06-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",EORTC QLQ-C30 scale,
1237,NCT06104267,Adherence rates,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],self-rating depression scale（SDS）,
1238,NCT02271646,pain score at recovery room both at rest and movement (cough),2014-08,COMPLETED,INTERVENTIONAL,['NA'],"Distribution of local anesthetic drugs after performing ultrasound guided TPVB at T5-6, T7-8 and T9-10.",
1239,NCT03957733,3-year disease free survival (DFS) rate.,2017-11-23,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Surgical complications.,
1240,NCT02111941,"Incidence of dose-limiting toxicities (DLT), graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2014-04-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Time to disease recurrence (TDR),Induction of antibodies specific for FRalpha
1241,NCT00637637,Progression-free survival at 6 months,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Duration of use of anticonvulsive drugs,
1242,NCT03570684,ratio of patients with 2 or more reloads,2018-01-05,UNKNOWN,INTERVENTIONAL,['NA'],complication rate,
1243,NCT04510285,Rate of ctDNA Clearance at 6 Months,2020-08-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1244,NCT05103501,Disease-free Survival (DFS),2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival Rate,
1245,NCT03569137,difference in microbiome biomarkers between patients developing colitis after exposure to targeted therapy and those not developing colitis,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA'],"Creation of a predictive score of the occurrence of diarrhea in patients treated with Ibrutinib for malignant hemopathy B, including the biomarkers of the intestinal microbiome and the clinical characteristics of the patient",
1246,NCT04511559,Analysis ctDNA methylation status and its Correlation to early diagnosis and prognostic evaluation of gastric cancer.,2020-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1247,NCT04956107,Development of ´fear of cancer recurrence' after PE or CRS+HIPEC for colorectal cancer,2021-01-25,RECRUITING,OBSERVATIONAL,['NA'],Risk factors associated with developing psychological distress,
1248,NCT00003296,,1998-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1249,NCT03735589,Persistence of nCTLs after their adoptive transfer,2023-12-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",T cell populations and higher anti-tumor responses,Overall survival assessed by irRECIST
1250,NCT02569723,Feasibility of 14C Oxaliplatin Microdose as a Clinical Assay to Predict Oxaliplatin Exposure,2015-10-16,COMPLETED,INTERVENTIONAL,['NA'],Response Rate Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,
1251,NCT01917552,recurrence-free survival,2013-08-19,RECRUITING,INTERVENTIONAL,['PHASE3'],Safety profiles,
1252,NCT06084013,Perfusion status,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Best practice usage of ICG for pancreatic surgery,
1253,NCT02127359,Describe Impact of Information Derived from Exome Sequencing,2012-09,COMPLETED,OBSERVATIONAL,['NA'],,
1254,NCT00002523,,1993-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1255,NCT02213692,Blood loss,2014-05,TERMINATED,OBSERVATIONAL,['NA'],Postoperative complications,
1256,NCT04802876,Overall Response rate (ORR) (Cohort 3),2021-04-12,RECRUITING,INTERVENTIONAL,['PHASE2'],"Incidence, seriousness, treatment-related and intensity of Treatment Emergent Adverse Events",
1257,NCT01116635,Histopathological correlation with surgically resected tumor,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",maximum tolerated dose,
1258,NCT01845805,Progression-free Survival,2014-01-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
1259,NCT00026104,Overall survival,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival,
1260,NCT04745130,Overall Survival (OS),2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Objective Response Rate,
1261,NCT03906565,Tumor response to utidelone treatment,2019-04-12,SUSPENDED,INTERVENTIONAL,['PHASE2'],Safety profile associated with utidelone injection,
1262,NCT03796702,Postoperative morbidity,2011-11-01,TERMINATED,INTERVENTIONAL,['NA'],Quality of life of patients after ileostomy closure,
1263,NCT02273206,"Changes From Baseline in Number of Participants With Colorectal, Breast, and/or Cervical Cancer Screening",2014-01,COMPLETED,INTERVENTIONAL,['NA'],Self-efficacy and Behavior Towards Cancer Screening/Mental Health Utilization,
1264,NCT02327065,Diagnostic Yield on malignancy,2014-12,UNKNOWN,INTERVENTIONAL,['NA'],Blood contamination and cellularity in specimens obtained by EUS-FNA and EUS-FNB with Slow-pull or suction,
1265,NCT06306755,Detection rate of upper gastrointestinal (esophageal/gastric) malignant lesions,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Quality of life Scale Score,
1266,NCT03418558,Objective Response Rate according to RECIST 1.1 criteria,2015-07-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression Free Survival,
1267,NCT04110977,Rate of radiation dermatitis grade ≥2,2020-10-10,UNKNOWN,INTERVENTIONAL,['NA'],Rate of radiation-induced oral mucositis grade ≥3,
1268,NCT04701853,Parastomal hernia verified by computer tomography,2021-05-01,RECRUITING,INTERVENTIONAL,['NA'],Back pain,
1269,NCT04541173,Progression free survival (PFS) by RECIST 1.1,2020-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],Subject function,
1270,NCT06031584,Phase II: Objective response rate (ORR),2024-01-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase Ib/II: Anti-drug antibody (ADA),
1271,NCT05973227,"image quality (sharpness, brightness, etc) and surgeon's feedback regarding the ergonomics and safety of Trident System v1.0 during surgery.",2023-07-06,RECRUITING,INTERVENTIONAL,['NA'],- level of oxygenation (StO2) of the exteriorized colon before resection with the Trident System v1.0 - the level of oxygenation (StO2) provided by the system at the site chosen by the surgeon based on the clinical evaluation.,
1272,NCT00003025,,1997-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1273,NCT03572582,Objective Response Rate (ORR),2018-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V4.03 (Safety and Tolerability),
1274,NCT06177288,converted resection rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adverse events,
1275,NCT05007145,Pathologic complete response (pCR) rate,2021-08-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease Free Survival (DFS),
1276,NCT01167725,Overall survival (OS),2010-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Comparison of OS and PFS according to patients' peritoneal surface tumor genotype for the NAD(P)H,
1277,NCT03803436,Overall Survival,2019-01-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Complications rate,
1278,NCT03812874,Safety as measured by number of participants with a dose limiting toxicity (DLT),2020-10-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To evaluate change in AFP levels.,
1279,NCT02319200,rate of HCC occurrence and liver related-death or transplantation.,2015-06,TERMINATED,INTERVENTIONAL,['PHASE3'],"occurrence of liver-related complications (Ascites , gastrointestinal bleeding, encephalopathy)",
1280,NCT02022553,tumor reduction,2006-02,UNKNOWN,INTERVENTIONAL,['NA'],,
1281,NCT05842317,Overall response rate (ORR),2022-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Conversion surgery rate,
1282,NCT01345773,The incidence of symptomatic or asymptomatic VTE,2010-05,COMPLETED,OBSERVATIONAL,['NA'],Risk factors for the development of VTE,
1283,NCT04530981,AUC from time 0 and extrapolated to infinity (AUC0-∞),2021-09-22,RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of Adverse Events,
1284,NCT03264404,Progression-Free Survival (PFS),2017-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),
1285,NCT05997524,Loco-regional and Distant Tumor Control After Completion of Treatment,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
1286,NCT00004257,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1287,NCT02495532,Lymph nodes harvested,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],Adjuvant therapy,
1288,NCT04424043,"Progression-free survival, PFS",2020-07-08,RECRUITING,INTERVENTIONAL,['NA'],"Overall survival, OS",
1289,NCT01915472,Safety,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Assess PK,
1290,NCT02098291,Pharmacodynamic,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Serious and Non-Serious Adverse Events,
1291,NCT06277453,3-year overall survival,2023-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1292,NCT01653171,Visibility at upper endoscopy,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,
1293,NCT04837885,Standardized uptake value (SUVmax) on liver metastases,2021-09-24,RECRUITING,INTERVENTIONAL,['PHASE2'],177Lu-DOTA-peptide dosimetry,
1294,NCT06271980,Recurrence Free Survival,2023-04-15,COMPLETED,OBSERVATIONAL,['NA'],Overall Survival,
1295,NCT00401570,"The proportion of patients, in each dose cohort, with a confirmed tumor response",2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate the immunogenicity of M200,
1296,NCT06010901,Objective response rate (ORR),2024-01-13,RECRUITING,INTERVENTIONAL,['PHASE1'],Neutralizing antibodies (NaB),
1297,NCT03333486,Relapse Rate,2017-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Transplant Related Mortality,Myeloid Chimerism Expressed as a Percentage of Donor Cells
1298,NCT03401957,Percentage of detected circulating DNA RAS mutations during 1st line cetuximab exposure.,2018-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival from the start of 1st line treatment with cetuximab.,
1299,NCT05835960,Establish the feasibility of immune analysis and NGS in informing patient treatment decisions.,2019-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
1300,NCT06169202,Progression-free Survival (PFS),2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],Disease Control Rate (DCR),
1301,NCT01300143,Time of tumor progression radiologically (CTScan) measured by mRECIST (Modified Response Evaluation Criteria In Solid Tumor).,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival,
1302,NCT00193141,"To compare the efficacy of full dose radiation therapy versus preoperative radiation therapy plus surgical resection, when used in combination with neo-adjuvant chemotherapy, in the treatment of localized esophageal cancer",1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate the toxicity of additional chemotherapy and radiation therapy following completion of neo-adjuvant treatment.,
1303,NCT03211416,Overall response rate defined as partial or complete response per immune-related Response Evaluation Criteria in Solid Tumors,2017-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to tumor progression,Change in levels of immunosuppressive cells
1304,NCT02921256,Neoadjuvant Rectal Cancer (NAR) Score,2017-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Rate of Sphincter Preservation,Relationship Between Radiographic Findings and Pathologic Outcomes
1305,NCT03117920,Disease Control rate (DCR),2017-04-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacodynamic effect of Minnelide on tumour using PET Scans,Biomarkers predictive of response to Minnelide
1306,NCT00462852,Incidence of venous thromboembolism reduction,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect of drug combination on serological markers of thromboangiogenesis,
1307,NCT01549418,Clinically significant bleeding after colorectal polypectomy,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],Proportion of clinically significant delayed bleeding in both groups,
1308,NCT05913570,Pathological complete response (pCR) rates,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with any treatment-related delays in the planned surgery of no more than 28 days after the last preoperative Cadonilimab dose,
1309,NCT00757965,Exploration of mutations at other loci that may predispose to endometrial cancer,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],,
1310,NCT01256203,Skin erythema responses of control (unprotected) and Solar Protection Formula® SPF 60-protected sites to light exposure,2013-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Proportion of subjects with adverse events as a measure of safety,
1311,NCT00080873,Area under the curve (AUC) of the modified Walsh mucositis scale,2004-04,COMPLETED,INTERVENTIONAL,['NA'],Two sample t test and the Wilcoxon sum test.,
1312,NCT06332274,Efficacy of tislelizumab compared to placebo as measured by DFS (Disease-free survival),2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Cost effectiveness analysis: ICER,
1313,NCT00020930,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1314,NCT04512729,Colonic Adenoma,2020-08-04,UNKNOWN,OBSERVATIONAL,['NA'],Risk factors for Colonic adenoma,
1315,NCT00465842,Number of participants with presence of serum protein markers,2006-06-20,TERMINATED,OBSERVATIONAL,['NA'],Number of participants with presence of serum protein markers with resectable and unrsectable HCC.,
1316,NCT05734430,Prevalence and spectrum of pathogenic and likely pathogenic germline variants in appendix cancer patients and their biological parents,2022-11-11,RECRUITING,OBSERVATIONAL,['NA'],"Association of germline genetic variants with clinical, pathologic and molecular features of appendix tumors",
1317,NCT01567631,Number of participants with operation complication,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of participants with abnormal liver function or discomfort symptoms induced by the operation,
1318,NCT03635619,MRI TN staging in Esophageal Cancer,2018-09-02,UNKNOWN,OBSERVATIONAL,['NA'],MRI prediction of prognosis in esophageal cancer,
1319,NCT06128798,Physiology Return of Bowel Function,2023-09-26,RECRUITING,INTERVENTIONAL,['NA'],Length of Hospital Stay,
1320,NCT03469479,Overall survival,2018-03-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse Events,
1321,NCT00189345,Selection of better dose level based on the confirmed tumor response.,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Effects of removab(TM),
1322,NCT00455559,To determine the efficacy and safety of perifosine plus imatinib mesylate in patients with advanced GIST who develop progressive disease or recurrence while receiving imatinib mesylate.,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],"To determine whether inhibition of Akt phosphorylation correlates with survival, time to disease progression, or response rate in patients with advanced GIST treated with imatinib mesylate plus perifosine.",
1323,NCT00951496,Median Progression-free Survival,2009-08-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Patient Reported Nausea,
1324,NCT03958669,To prospectively evaluate molecular fingerprint analysis of HCC tumor tissue to predict therapy responses,2019-11-01,TERMINATED,OBSERVATIONAL,['NA'],Changes of ultrasound elastography under treatment with Sorafenib,
1325,NCT01675908,Complications related to stent dysfunction,2012-08-22,COMPLETED,INTERVENTIONAL,['NA'],Procedural complications,
1326,NCT01121562,Clinical Benefit Response Rate (CBR),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],"Dose-corrected Trough Plasma Concentrations of Sunitinib, SU012662 and Total Drug (Sunitinib + SU012662).",
1327,NCT00003524,,1996-10-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1328,NCT01504256,Rate of macroscopic complete remissions of peritoneal carcinomatosis,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Detection of disseminated tumor cells via PCR,
1329,NCT01751516,"Negative post-chemoradiation PET/MRI scan, as correlated with surgical pathology",2012-10,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
1330,NCT05360732,To assess the toxicity profile of a regimen of alternating FOLFOX and FOLFIRI patients assessed as per NCI's CTCAE v5.0 criteria.,2022-04-22,RECRUITING,INTERVENTIONAL,['PHASE2'],To assess the Delayed Toxicity Rate,
1331,NCT02315625,Median Amount of Time Subject Survives Without Disease Progression After Treatment,2015-04-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-Serious Adverse Events,
1332,NCT04803019,Time to progression,2019-12-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1333,NCT04670588,Mean serum ctDNA concentration,2021-03-31,WITHDRAWN,OBSERVATIONAL,['NA'],Response based on standard clinical assessments,
1334,NCT00938470,Percentage of Participants With Pathologic Complete Response (PCR),2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Overall Clinical Tumor Response (CR or PR),
1335,NCT00058487,Toxic effects,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1336,NCT02595957,Health impacts of SF receipt,2014-09-16,RECRUITING,OBSERVATIONAL,['NA'],,
1337,NCT00455091,Primary endpoint: Primary endpoint: the 3-years recurrence rate (excluding those recur within first year).,2007-05,TERMINATED,OBSERVATIONAL,['NA'],"Secondary endpoints: the first 2 year tumor recurrence rates,the recurrence-free survival,the overall survival.anti-viral efficacy.",
1338,NCT05756725,Number of open orders for mammography screening,2023-07-25,COMPLETED,INTERVENTIONAL,['NA'],Appropriateness of Implementation Strategies,
1339,NCT03642652,Follow-up colonoscopy 120 days after a positive fecal occult blood test,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
1340,NCT06010303,Overall Response Rate (ORR),2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events (AEs),
1341,NCT05838768,Frequency of dose reductions as a measure of tolerability,2023-06-27,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of participants with anti tislelizumab antibodies,
1342,NCT05927844,severity of TEAE and SAE,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
1343,NCT01888978,Timing of biopsy and treatment,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival,
1344,NCT04345783,OS,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1345,NCT01759706,Adherence to the pathway,2010-10,COMPLETED,INTERVENTIONAL,['NA'],Postoperative outcome,
1346,NCT01502410,Objective Response by RECIST Criteria v 1.1,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Presence of BRAF Mutation or RET/PTC Rearrangement,
1347,NCT02710838,the lesion of early gastric cancer by infrared endoscopy,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],the invasive depth of early gastric cancer by infrared endoscopy,
1348,NCT00836407,Percent of Patients Experiencing an Unacceptable Toxicity,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression Free Survival (PFS),
1349,NCT00208260,Response,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Secondary resection,
1350,NCT05645679,Efficacy of the Hybrid Argon Plasma Coagulation Technique,2021-04-02,RECRUITING,OBSERVATIONAL,['NA'],,
1351,NCT02427269,Collaboration with other investigators,2015-04-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
1352,NCT01032746,"Receipt of colorectal cancer screening exam (fecal occult blood test, flexible sigmoidoscopy, or colonoscopy) within 4 months following delivery of an electronic message within the personal health record",2005-03,UNKNOWN,INTERVENTIONAL,['NA'],Distribution of risk-status among participants who complete the web-based risk-assessment tool,
1353,NCT04693377,Pain response,2021-03-16,RECRUITING,INTERVENTIONAL,['NA'],Technical success for cryoablation,
1354,NCT01546519,The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-24hours]) Following Multiple Doses of Vismodegib,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Apparent Non-renal Clearance (CLNR/F) of Vismodegib,
1355,NCT02794805,13CO2/12CO2 ratio,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1356,NCT00784290,Step 2(Phase II) Response rate(RR),2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Step 2(Phase II) Safety,
1357,NCT05493878,Expression levels of ITGA2b and SELP on Tumor Educated PLatelets for diagnosis of pancreatic and biliary cancer,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Correlation between expression levels of ITGA2b and SELP on TEPs and the commonly used tumour marker CEA and CA 19-9 in the diagnosis of pancreatic and biliary cancer.,
1358,NCT02762474,Progress free survival,2014-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",CTCAE 4.0 toxicity,
1359,NCT05871892,Metabolic function of the liver evaluated by the PET tracer 18F-FDGal,2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],,
1360,NCT04961125,germline variant detection rate in the polyposis population,2021-08-02,RECRUITING,OBSERVATIONAL,['NA'],,
1361,NCT01126112,Progression-free survival rate at 6 months,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluation of molecular predictive markers for response.,
1362,NCT02267707,Pharmacokinetics - CL,2015-05-27,TERMINATED,INTERVENTIONAL,['PHASE1'],Gemcitabine PK profile,
1363,NCT01821248,Curative resection rate,2013-07-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],Response rate and toxicity,
1364,NCT05595811,overall survival,1999-01-01,COMPLETED,OBSERVATIONAL,['NA'],adjuvant oncologic treatment,
1365,NCT04268888,Time to TACE Progression (TTTP) - phase II primary outcome,2019-05-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",QOL: EORTC QLQ-C30,
1366,NCT02873520,Quality of life,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1367,NCT05321134,Assess safety & quality event rate for SP platform transabdominal and transanal colorectal operations,2022-04-28,RECRUITING,INTERVENTIONAL,['NA'],,
1368,NCT05570942,Changes of irritable bowel symptoms,2021-12-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],The presence of bacteremia,
1369,NCT04541381,Grade 3 or Higher Toxicity (Co-Primary Endpoint),2022-02-07,RECRUITING,INTERVENTIONAL,['NA'],Overall Survival,
1370,NCT03110939,local recurrent rate,2017-03-21,WITHDRAWN,INTERVENTIONAL,['NA'],mortality rate after treatment,
1371,NCT04460456,"Duration of response, defined as the time from date of first response (CR or PR)",2020-07-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Progression free survival,
1372,NCT04049357,CCE detection rate of polyps compared to OC,2020-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
1373,NCT01439724,Incidence and / or Severity of Oral Mucositis,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],"Oral Mucositis Survival Free, Pain, Opioid Treatment, Hospitalization, Treatment Interruption, Treatment Delay, Patient Weight Loss, Nasogastric Tube or of a Gastrostomy.",
1374,NCT05302011,pathological response,2020-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
1375,NCT00003049,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1376,NCT02876224,Percentage of Participants with Adverse Events,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE1'],Percentage of Participants with Anti-therapeutic Antibodies (ATAs) Response to Atezolizumab,
1377,NCT04563338,Progression-free survival,2021-06-04,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-free survival rate,
1378,NCT03828227,"Health-related quality of life (HRQoL) at 6 months in the ""candidate group"".",2019-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Performance status geriatric (PSG) score.,
1379,NCT02168426,ileus rate,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3'],adverse effect rate,
1380,NCT04743102,pathological complete remission,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],Overall Survival,
1381,NCT05300945,OS,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse Events,
1382,NCT01526486,Nodal yield,2009-06,COMPLETED,INTERVENTIONAL,['NA'],Oncologic outcomes--survival,
1383,NCT01298011,Grade III/IV histological response in tumor specimen rate after induction therapy.,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
1384,NCT04843943,Events Free Survival (EFS) Assessed by RECIST1.1,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
1385,NCT03209336,The basic information and medical history achieved (questionnaire),2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],The short-term complications,
1386,NCT00767468,Correlation between hepatic retention and clearance of technetium Tc 99m mebrofenin (MEB) and technetium Tc 99m sestamibi (MIBI) and clearance (and other pharmacokinetic parameters) of sorafenib tosylate,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Median overall survival,
1387,NCT01100372,Remission rates (complete response and partial response),2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicity,
1388,NCT02709213,Determination of the aetiologies of colitis using microbiological examination of the stools +/- colonoscopy,2016-11,COMPLETED,OBSERVATIONAL,['NA'],"Identification of anamnestic, clinical and biological predicting factors for patients requiring diagnostic colonoscopy",
1389,NCT02645981,Overall Survival,2016-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Percentage of adverse events,
1390,NCT00294203,"Post-operative hemoglobin, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte fraction measured on post-operative days 1, 4, 8, and between days 20 and 30",2006-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Post-operative quality of life related to anemia measured by Functional Assessment of Cancer Therapy - Anemia (FACT-An) between post-operative day 20 and 30 and post-operative transfusion requirement,
1391,NCT04954339,Distinct immunophenotypes and dynamic changes of tumor-infiltrating immune cells in Hepatocelluar carcinoma treated with treated with atezolizumab-bevacizumab assessed by flow cytometry (and/or CyTOF),2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Dynamic changes in T-cell receptor (TCR) repertoire of peripheral mononuclear cells,
1392,NCT01417611,polyp/adenoma detection rate (per-polyp/adenoma analysis and per-patient analysis),2010-09,COMPLETED,INTERVENTIONAL,['NA'],characterization of polyp,
1393,NCT02102893,"To establish the database for GEP-NET by register the clinical presentation, diagnosis, stages, treatment and clinical outcome of GEP-NET patients.",2014-02-13,COMPLETED,OBSERVATIONAL,['NA'],,
1394,NCT01129310,Overall Response Rate and dose limiting toxicity,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],"Progression Free Survival, overall survival, death, alterations in quality of life outcomes",
1395,NCT00673504,Time to Progression,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety,
1396,NCT02873442,Progress-free survival,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life,
1397,NCT00870961,Rate of accrual,2009-02,TERMINATED,INTERVENTIONAL,['NA'],"Correlation of vitamin D levels with vitamin D modifiers (e.g., levels of skin pigmentation, dietary vitamin D intake, and sun exposure)",
1398,NCT02386618,Efficacy of endoscopic treatment od local residual neoplasia (absence of neoplastic tissue in post-EMR scar proven by endoscopic and histologic examination),2013-10,COMPLETED,INTERVENTIONAL,['NA'],,
1399,NCT00572143,Quality of life; EORTC-QLQ-C30 and EQ 5D,2007-06,COMPLETED,INTERVENTIONAL,['NA'],Cost-effectiveness Serious clinical events,
1400,NCT00897754,VEGF165b protein expression as measured by ELISA,2007-07-24,COMPLETED,OBSERVATIONAL,['NA'],,
1401,NCT00861783,maximum tolerated dose,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],tumor measurement,
1402,NCT03515538,Duration of Severe Oral Mucositis (SOM),2018-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Patient-reported pain,
1403,NCT04571489,Progression free survival (PFS),2020-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Patient-reported outcome (PRO),
1404,NCT05166239,6-month progression-free survival rate,2022-01-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of patients with treatment-related adverse events,
1405,NCT01976494,"Efficacy: Analgesic effect, Accuracy of bolus 2 mL administration",2013-10,COMPLETED,INTERVENTIONAL,['NA'],Safety: Frequency of complications occurring after bolus,
1406,NCT00068003,"Bank of autologous blood, stem cells, and/or tumor tissue from patients currently with cancer",2003-09-08,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Long-term storage of data and biospecimens,
1407,NCT02489838,Lung dose measured with actual lung mass vs Lung dose measured with conventional method.,2012-02-03,COMPLETED,OBSERVATIONAL,['NA'],,
1408,NCT01236443,Toxicity of HPPH at different doses,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],"Determine optimal PDT parameters using HPPH in HGD, CIS and Barrett's esophagus",
1409,NCT01458353,Peritoneal contamination after finishing the ileocolonic anastomosis,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1410,NCT01118897,To assess the feasibility of concurrent chemo-radiation with dose escalated IMRT in locally advanced inoperable gallbladder and pancreatic cancers,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
1411,NCT05767697,Number of subjects who still survive at 1 year,2020-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
1412,NCT06324825,Recovery rate of Low-grade Intraepithelial Neoplasia,2022-10-24,RECRUITING,INTERVENTIONAL,['NA'],Adverse event rate,
1413,NCT02641691,Complete Response Rate,2016-05-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Anorectal Function as Measured by the FACT-C Questionnaire,
1414,NCT05763277,progression free survival,2022-07-22,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
1415,NCT05733000,Overall response rate (ORR),2023-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
1416,NCT02145416,Changes on DW MRI during CRT in anal cancer.,2015-01-27,COMPLETED,OBSERVATIONAL,['NA'],Correlation of the change in functional images over CRT with outcome of CRT,To use PET SUV data in a radiotherapy in silico modelling exercise to determine if dose sparing of active pelvic bone marrow (PBM) is possible without compromising target coverage by radiation.
1417,NCT03662035,Progression Free Survival,2018-09-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease Control Rate,
1418,NCT01103479,Colorectal Cancer (CRC) Screening Completion,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Provider Recommendation of CRC Screening,
1419,NCT05453292,Disease-free survival,2024-01-15,RECRUITING,INTERVENTIONAL,['NA'],Re-treatment rate,
1420,NCT03838913,Determination of involved signal pathways,2019-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,
1421,NCT02545725,Questionnaire on Quality of Life,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
1422,NCT05032014,(objective remission rate)ORR,2021-11-19,UNKNOWN,INTERVENTIONAL,['NA'],OS,
1423,NCT01191411,"Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem.",2010-10,COMPLETED,INTERVENTIONAL,['NA'],,
1424,NCT05776875,Grade 3 or higher Treatment Related Adverse Events,2023-06-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to untaceable progression,
1425,NCT05985954,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2024-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,
1426,NCT00575562,The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],"The secondary objectives are to determine the degree of immunogenicity, gain information on the pharmacokinetic profile, assess the anti-tumor effects of KRN330 and determine the maximum tolerated dose (MTD).",
1427,NCT05167448,Phase 2: The anti-tumor activity of ES104,2022-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: The immunogenicity of ES104,
1428,NCT02661945,Accuracy (accurate if the distance (between margin dots and tumor margin measured by histopathology) was less than 1 mm),2015-07,COMPLETED,INTERVENTIONAL,['NA'],,
1429,NCT01477177,"Reduction in Barrett's Histology Grade, Using the Modified Vienna Classification",2011-08,TERMINATED,INTERVENTIONAL,['NA'],"Reduction in Barrett's Histology Grade, Using the Modified Vienna Classification",
1430,NCT03291899,Response rate,2017-01-03,TERMINATED,INTERVENTIONAL,['PHASE2'],overall survival,
1431,NCT00551759,Proportion of Patients With Pathologic Complete Response,2008-10-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1432,NCT05597384,Autogenous blood marker localization was not inferior to intraoperative colonoscopy localization,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],Adverse events related to endoscopic tattooing,
1433,NCT00006387,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1434,NCT05327582,Object response rate (ORR),2022-04-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of participants with laboratory test abnormalities,
1435,NCT00817934,"TOTAL COLON CLEANSING, TO BE ABLE TO PERFORM COLONOSCOPY",2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1436,NCT00089362,"MTD, defined as the dose level where the observed DLT incidence in no more than one out of six patients treated at a particular dose level",2004-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1437,NCT01012362,Number of Participants Who Experienced a Dose Limiting Toxicity (DLT),2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants With Treatment-Related Adverse Events,
1438,NCT05480891,community education,2023-04-05,RECRUITING,OBSERVATIONAL,['NA'],,
1439,NCT04834661,overall postoperative complication rate,2021-10-20,COMPLETED,OBSERVATIONAL,['NA'],,
1440,NCT01649271,Dose Limiting Toxicities During cycle1,2012-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],Clinical Benefit,
1441,NCT00860665,Correlation of adenoma detection rate with case volume of endoscopists,2006-10,COMPLETED,OBSERVATIONAL,['NA'],Patient acceptance in relation to procedural factors (e.g. sedation),
1442,NCT03504618,Prognostic factor of progression free survival,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],Overall survival after 24 months,
1443,NCT00003118,Overall survival,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1444,NCT03799731,Progression Free Survival (PFS) at 6 months,2018-07-11,COMPLETED,INTERVENTIONAL,['PHASE2'],AMHRII (Anti-Mullerian Hormone type II receptor) expression,
1445,NCT00038701,Patient Survival Rate,1999-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1446,NCT00003029,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1447,NCT05040815,Disease free survival (DFS),2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Exercise Behavior and Physical Fitness,Relationship between radiotherapy treatment planning variables and acute toxicity.
1448,NCT05653934,Anxiety assessment,2023-05,RECRUITING,INTERVENTIONAL,['NA'],Morbidity,
1449,NCT00667082,To determine the Maximum tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the combination NPI-0052 and Vorinostat,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],To evaluate the anti-tumor activity of NPI-0052 and vorinostat,
1450,NCT04615806,Sensitivity and specificity of lymph node dissection,2020-09-22,UNKNOWN,INTERVENTIONAL,['NA'],The mapping of sentinel lymph nodes in esophageal cancer,
1451,NCT03271073,Progression-free survival (PFS),2016-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life(QoL),
1452,NCT00660582,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1453,NCT03697564,Progression Free Survival (PFS),2019-10-31,SUSPENDED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
1454,NCT01418222,"Progression-free survival: time from randomization to tumor progression or death, tumor assessments according to RECIST criteria",2011-09-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety: Incidence of adverse events,
1455,NCT02381249,Progressive ratio task breakpoint for a sweet-fat reward,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Subjective symptom score,Sigstad score
1456,NCT04905147,Postoperative time to the first passage of flatus.,2021-07-01,UNKNOWN,INTERVENTIONAL,['NA'],Length of postoperative hospital stay,
1457,NCT02379039,Loco regional control,2015-05,COMPLETED,OBSERVATIONAL,['NA'],Site specific toxicity,
1458,NCT06005493,Objective Response Rate (ORR),2023-07-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Preliminary antitumor activity with target expression pre- and post-delivery of AZD5863,
1459,NCT00152607,"The primary outcome for recipients will be the assessment of patient and graft survival. Comparison to results of contemporaneous, non-randomized cadaver donor transplants will be made.",2000-04,TERMINATED,INTERVENTIONAL,['PHASE4'],,
1460,NCT01197612,Olfaction,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Sinonasal Health,
1461,NCT01250158,To demonstrate the feasibility of the liver PILP intervention.,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,
1462,NCT02229071,Adverse events,2014-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to progression(TTP),Time to symptomatic progression(TTSP)
1463,NCT01336881,Biomarkers associated with hepatoblastoma subtypes and cancer stages,2011-04,COMPLETED,OBSERVATIONAL,['NA'],Exome sequencing,
1464,NCT00075452,Overall survival,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Progression-free survival,
1465,NCT00049608,,2002-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1466,NCT02065765,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1467,NCT00533533,To define the dose-limiting toxicity and maximum tolerated dose in phase I study To evaluate the overall response rate in phase II study,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",1) To evaluate the safety and tolerability of the treatment combination. 2) To estimate overall survival. 3) To estimate the time to progression and the duration of overall response.,
1468,NCT05833594,Disease Control Rate,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],"1-, 2-, 3-year Progression-free survival rate (PFS).",
1469,NCT00273585,Colorectal cancer screening self-efficacy,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Colorectal cancer screening decisional conflict,
1470,NCT03426397,2-year non-regrowth disease-free survival,2017-05-10,RECRUITING,OBSERVATIONAL,['NA'],Quality of life,
1471,NCT05204173,1-year survival rate,2021-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],3-year progressive free survival (PFS),
1472,NCT01129167,Frequency of local invasion modalities in surgical population,2009-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
1473,NCT04370925,Peritoneal recurrence free survival,2020-06-04,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of participants with adverse events,
1474,NCT06003218,Area under curve of Numerical Rating Scale of pain during and within 24 hours after surgery.,2023-10-16,RECRUITING,INTERVENTIONAL,['NA'],Numeric Rating Scale of subjective sleep quality on the first and second nights after surgery.,Incidence of postoperative complications during hospital stay.
1475,NCT02734823,Changes in markers of ovarian reserve in premenopausal women undergoing tyrosine kinase inhibitor therapy for cancer,2016-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],Ovarian response to controlled ovarian hyperstimulation in patients who elect to undergo IVF for fertility preservation,
1476,NCT02013830,Percentage of Participants With Objective Response (OR),2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival - Percentage of Participants Event Free at 12 Months,
1477,NCT04080843,Objective response rate(ORR),2019-11-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety: NCI CTC AE Version 4.0.3,
1478,NCT00782366,"Assess accessibility and feasibility, including positive and negative aspects of integrating predictive genomics at the clinic focusing on patients' and physicians' attitudes",2008-03,COMPLETED,OBSERVATIONAL,['NA'],Assess effects of predictive genomics on self-reported health behavior and on physician-patient interaction,
1479,NCT01758341,Number of RFA-procedures with technical failures,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of patients with interventional complications,Mortality
1480,NCT03316222,Dose-Limiting Toxicity,2018-04-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1481,NCT05923450,Disease-free Survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1482,NCT02574013,Length of hospital stay,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative complications,
1483,NCT04200131,"Obtaining histological diagnosis by using ""The Moray"" micro forceps.",2020-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Quality of the sample,
1484,NCT03673501,Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population,2019-02-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population,
1485,NCT06323291,Feasibility of Utilizing the Digital Health Coaching Program,2024-03-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
1486,NCT02420678,"Reliability of FACT-Hep, EORTC QLQ-HCC18 and NFHSI-18",2015-04,UNKNOWN,OBSERVATIONAL,['NA'],Death rates,
1487,NCT00584402,Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography,2007-04,COMPLETED,INTERVENTIONAL,['NA'],"Number of Participants With an Increase in Echogenicity (Brightness) of Small Intrahepatic Tumors Following Contrast-enhanced Sonography Based on Tumor Type, Size, Location and Depth",
1488,NCT04088955,Compare the duration of actual vs. intended treatment for cancer patients on capecitabine who are prescribed capecitabine with sensor.,2019-09-06,UNKNOWN,OBSERVATIONAL,['NA'],,
1489,NCT00829413,Specificity: Percentage of True Negative Lesions Among All Benign Lesions Per Truth Standard',2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Inter-reader Agreement,
1490,NCT03853278,Functional Assessment of Cancer Therapy- Colorectal,2018-01-15,COMPLETED,INTERVENTIONAL,['NA'],The Functional Assessment of Chronic Illness Therapy-Fatigue,
1491,NCT03923309,3-year overall survival,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
1492,NCT04927780,Overall survival,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE3'],Patient reported Quality of Life as assessed using Exocrine Pancreatic Insufficiency (EPI) questionnaire,
1493,NCT03095781,Recommended phase II dose of the combination of XL888 and pembrolizumab as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2017-07-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Response duration as assessed by RECIST 1.1,Immune profile effects of pembrolizumab and Hsp90 inhibitor XL888 assessed in serum and tumor biopsies
1494,NCT03718624,Conversion to negative rate,2018-10-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events,
1495,NCT05765357,Area under drug concentration - time curve (AUC0-t),2017-07-16,COMPLETED,INTERVENTIONAL,['PHASE1'],Apparent volume of distribution (Vd/F),
1496,NCT04781192,Progressin Free Survival (PFS),2022-03-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
1497,NCT00202774,Determine time to disease progression,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],"Determine safety of combination, objetive response rate, time to onset of response , duration of response, time to treatment failure, one year survival time, overall survival time",
1498,NCT05024539,Regorafenib in combination with other drugs,2021-06-20,UNKNOWN,OBSERVATIONAL,['NA'],Survival differences among the patients with different clinical phenotypes and genotypes,
1499,NCT04141449,Incidence of curative-intent treatment,2020-11-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Patients treated for cancer,
1500,NCT02571725,Phase 2: Objective response rate (ORR),2016-02-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Progression free survival (PFS),
1501,NCT06114251,Postoperative recurrence of liver cancer,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1502,NCT01694238,Stoma hernia frequency at 12 months,2013-06,COMPLETED,INTERVENTIONAL,['NA'],30 day mortality,
1503,NCT04814043,conversion rate to resection,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1504,NCT02233205,Number of Participants with Serious and Non-Serious Adverse Events,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to Disease Progression,
1505,NCT00634894,Median Progression-free survival (PFS): Time to progression or death from complete response (CR),2008-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
1506,NCT03314935,Phase 2: Objective Response Rate (ORR),2017-11-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tlast of INCB001158 in Participants Treated With INCB001158 in Combination With Chemotherapy Following the First Dose on Cycle 1 Day 1 and on Cycle 2 Day 1 Following Repeated Dose Administration,
1507,NCT01684098,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1508,NCT04220827,Incidence of adverse events,2019-12-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
1509,NCT06304350,Pathological complete remission (pCR),2024-02-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety (incidence of adverse drug reactions),
1510,NCT01084460,,1997-01,COMPLETED,OBSERVATIONAL,['NA'],,
1511,NCT02353052,Number of participants with tumor metastasis,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],,
1512,NCT05060770,IBD associated CRC oncogenesis,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1513,NCT01094626,Difference in lesion conspicuity between S-MRI and N-MRI,2010-04,WITHDRAWN,INTERVENTIONAL,['NA'],Concordance of tumor measurements between S-MRI images and tumor specimens post-resection vs. concordance of tumor measurements between N-MRI and tumor specimens post-resection,
1514,NCT06082648,Quality of life Scale (EORTC QLQ-CR38),2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],Proctoanal manometry,
1515,NCT01048320,The primary outcome measure for the study is to establish the Maximum Tolerated Dose of the drug regimen based on the endpoint of dose-limiting toxicity,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Characterise safety profile of Gemcitabine Plus Oxaliplatin in Combination with imatinib mesylate (Glivec) in Patients with Gemcitabine-Refractory Advanced Adenocarcinoma of the Pancreas,
1516,NCT04498689,Progression Free Survival,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
1517,NCT00369460,"Collection of information on weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count",2006-01,COMPLETED,OBSERVATIONAL,['NA'],,
1518,NCT01068132,Progression free survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
1519,NCT04886193,TRG grade,2021-04-16,UNKNOWN,INTERVENTIONAL,['NA'],the incidence and severity of adverse events,
1520,NCT05725200,"Main Study: To evaluate the anti-tumor activity, measured as objective response rate (ORR) of MTB-nominated therapies with drugs not approved or implemented in standard of care (SOC) for treatment of mCRC.",2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Main study: Patient-reported outcome measures.,
1521,NCT05450835,Early operative morbidity,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],The number of attempts to insert anvil fork into oesophagus,
1522,NCT03237507,PFS: Progression Free Survival,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],Safety,
1523,NCT00853931,Response rate,2009-10,COMPLETED,INTERVENTIONAL,['NA'],Overall survival,
1524,NCT00967655,2-year survival rate,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1525,NCT04496765,Local recurrence,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1526,NCT06190639,Disease-free survival (DFS),2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
1527,NCT05113134,Patient and Observer Scar Assessment Scale (POSAS),2015-03-02,COMPLETED,INTERVENTIONAL,['NA'],Female Sexual Function Index (FSFI) questionnaire,
1528,NCT02345460,Number of Patients Undergoing Surgical Resection After Receiving at Least 4 of the 6 Courses of Preoperative Chemotherapy,2015-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants Experiencing Perioperative (30-day) Mortality,
1529,NCT00300521,overall recurrence-free survival rate at three year,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],hazard rate of vascular invasion on survival rate and recurrence-free survival rate,
1530,NCT02138981,overall survival time,2014-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Number of Adverse Events,
1531,NCT02283372,Maximum tolerated dose (MTD),2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE1'],Frequency of RT adaptation based on MR guidance,
1532,NCT03937895,Phase 2a - Objective Response Rate (ORR),2019-12-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2a - Toxicity (according to CTCAE 5.0),
1533,NCT00437424,The primary objective of this study is to determine the effect of BMS-582664 on subjects with varying levels of hepatic impairment and guide prescribers with regards to dosing in specialized populations,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],To assess efficacy of BMS-582664 in subjects with advanced solid tumor malignancies and subjects with HCC by CT or MRI,
1534,NCT03599778,Disease-free survival (DFS),2018-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1535,NCT04593134,Quality of Life (EORTC QLQ-STO22),2020-11-10,RECRUITING,INTERVENTIONAL,['NA'],Circadian rhythms(using Actigraph),
1536,NCT05019534,Evaluate tolerability and safety and identify the recommended Phase 2 dose(RP2D),2021-08-15,RECRUITING,INTERVENTIONAL,['PHASE1'],Preliminary efficacy,
1537,NCT06216561,Drug concentration in tumor,2023-11-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Adverse Events (AEs),
1538,NCT02114164,Intraoperative Pneumoperitoneal Pressure (mmHg),2016-08,COMPLETED,INTERVENTIONAL,['NA'],Smoke Evacuation Quality,
1539,NCT03469596,presence of nodal status,2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
1540,NCT04795661,Rate of complete pathological response (pCR) after surgery,2021-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],The prognostic value of lung immune prognostic index (LIPI),
1541,NCT04522336,Clinical complete response (cCR),2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],PFS at 24 months,Tumor T cell infiltrate
1542,NCT02267213,Disease Control Rate (DCR),2014-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],"PK parameters, including AUC, Cmax and Tmax of S,S-TLC388, S,R-TLC388, metabolites TLC-U1, TLC-U2, and topotecan",
1543,NCT02036008,Reader diagnostic accuracy using Gdfos vs. EcGd compared to gold standard,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],Reader diagnostic accuracy of EcGd-enhanced imaging vs. Gdfos-enhanced imaging compared to gold standard (subgroup analysis for small lesions less than or equal to 1cm),
1544,NCT04512937,Rate of patients with R0 resection,2020-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Progression-free survivial (PFS),
1545,NCT00652054,Overall tumor response rate (ORR - the proportion of patients with objective evidence of PR or CR),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],To investigate the relationship of S-1 plasma levels (components and metabolites) with safety and efficacy parameters,
1546,NCT05224596,Sensitivity and specificity of the cfDNA methylation-based model in detecting gastric cancer.,2021-01-18,UNKNOWN,OBSERVATIONAL,['NA'],"Sensitivity and specificity of a ctDNA mutation-based model and a serum protein-based model in detecting gastric cancer, respectively.",Sensitivity and specificity of a blood miRNA-based model in detecting gastric cancer.
1547,NCT00425360,Survival at 1 year,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Survival and response as assessed by delayed-type hypersensitivity,
1548,NCT04539808,Proportion of participants with R0 resection,2021-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of grade >= 3 toxicities,Proportion of LAPC participants who die within 30 days of surgery
1549,NCT05111444,Objective Response Rate (ORR),2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
1550,NCT01694966,To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the Proportion of Subjects With at Least One Histologically Proven Adenoma or Carcinoma.,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1551,NCT04084496,Disease free survival,2019-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
1552,NCT03609151,Progression free survival,2018-06-30,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,
1553,NCT06260111,Level of Pain,2024-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Triceps skinfold,
1554,NCT01040559,Dose-limiting toxicity assessed according NCI CTC AE v3.0,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics parameters of idarubicin and idarubicinol,
1555,NCT04182724,ORR(phase II),2019-11-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PFS(phase I/II),
1556,NCT06322147,R0 resection rate,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],Early Tumor Shrinkage,
1557,NCT04697394,Continuous retention of patients completing electronic data.,2022-03-15,RECRUITING,OBSERVATIONAL,['NA'],Symptom cluster identification,
1558,NCT02210559,Number of Participants Who Had Surgical Complications Post-Resection,2014-07-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median Progression-Free Survival,
1559,NCT04481100,Objective response rate (ORR),2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
1560,NCT04215861,Raman spectra,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA'],objective response rate,
1561,NCT04440332,Postoperative pulmonary infection rate and its relationship between peripheral blood of lymphocyte and immunocyte.,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1562,NCT03124498,Phase II: Disease Control Rate,2017-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1563,NCT02219854,3-year disease free survival rate,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative recovery situation,
1564,NCT03166436,Survival,2017-06-08,UNKNOWN,INTERVENTIONAL,['NA'],Augmentation of antitumor immunity,
1565,NCT03652428,Maximum Tolerated Dose of Gemcitabine and nab-Paclitaxel in LAPC patients receiving proton therapy,2019-04-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life through and after treatment,
1566,NCT00259532,,2005-02,UNKNOWN,INTERVENTIONAL,['NA'],,
1567,NCT02891083,Disease free survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],side effect of adjuvant therapy,
1568,NCT06320080,Progression-free survival (PFS),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Immunogenicity,
1569,NCT01214720,Duration of Overall Survival - Time to Event,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Bevacizumab Concentration in the Presence of Gemcitabine and Erlotinib,
1570,NCT06251115,Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT),2024-01-26,RECRUITING,INTERVENTIONAL,['NA'],Efficacy: antitumor activity of QY-1-T in subjects with HBV-related HCC,Efficacy: antiviral activity of QY-1-T
1571,NCT04104334,Clinical examination and laboratory tests show no evidence of complications or untreated medical problems,2019-05-08,TERMINATED,INTERVENTIONAL,['NA'],Rate of hospital readmission and mortality postoperative,
1572,NCT00309179,"Objective tumor response (CR or PR) and disease control (CR, PR or SD) rates will be evaluated in this study based on RECIST criteria and modified WHO criteria.",2007-09-24,COMPLETED,INTERVENTIONAL,['PHASE2'],"Pharmacokinetics: Blood samples will be taken on Days 1, 2, and 15 during Cycle 1 and Day 1. Pharmacodynamics: Blood will be taken prior to dosing on Day 1, Days 1, 2, and 15 during Cycle 1 and Day 1.",
1573,NCT00841191,Percentage of Participants With Clinical Benefit Response (CBR),2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Percent Change From Baseline in Hepcidin Level,
1574,NCT00003147,,1998-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1575,NCT03017690,The total time for product preparation and administration,2017-04-12,COMPLETED,OBSERVATIONAL,['NA'],Patient satisfaction,
1576,NCT02578459,Visual Analog Scale Pain Scores,2016-04,WITHDRAWN,INTERVENTIONAL,['NA'],Adverse Events,
1577,NCT06234007,pathology complete response(pCR),2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (AEs),
1578,NCT02667925,Quantification by visual analysis the intensity of fixation of the solvent characterized in the intraperitoneal cavity,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],Correlate site of relapse to localisation of labeled intraperitoneal solvent by nanocis in peritoneal cavity,
1579,NCT00907543,Quality of life as assessed by FACT-E,2009-04,COMPLETED,INTERVENTIONAL,['NA'],Safety and morbidity,
1580,NCT00580359,To evaluate each response rate of S-1 and capecitabine in the elderly and/or poor performance status patients with recurrent or metastatic gastric cancer,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],"the duration of response, time to progression, progression-free survival,overall survival,the safety profiles,the quality of life,the CYP2A6 genetic polymorphism and its association with clinical outcomes in patients treated with S-1",
1581,NCT00442507,Time to Progression (TTP),2007-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Incidence and Severity of Toxicities,
1582,NCT00094978,,2004-10-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1583,NCT01726452,Overall survival,2013-01-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1584,NCT01200316,Efficacy of Rocking Chair Motion on Surgical-Induced Stress,2012-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1585,NCT05880992,Adherence rate,2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],Major complications,
1586,NCT04580667,To determine the cut-off values from the RadTox test results during early radiation treatment from all evaluable subjects to differentiate high toxicity score from average or low toxicity score.,2020-10-01,RECRUITING,OBSERVATIONAL,['NA'],To determine the cut-off values from the RadTox test performed during early radiation treatment with patients categorized according to demographics and treatment options to differentiate high toxicity score from average or low toxicity score.,
1587,NCT01543607,Safety: Number of Bile Leak After RFA Procedure,2012-02,TERMINATED,INTERVENTIONAL,['NA'],Effectiveness: Change From Baseline in Bile Duct Diameter.,
1588,NCT01995942,The primary endpoint will be time to relapse pertaining to the primary objective of relapse rate at 1 year and 3 years.,2013-06-07,UNKNOWN,OBSERVATIONAL,['NA'],"Measurement of the change in mrEMVI from pre to post pre-operative therapy, will be based on a new proposed EMVI-TRG classification (EMVI TRG 1-5).",
1589,NCT02490735,progression-free survival(PFS),2015-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival(OS),Stage at diagnosis
1590,NCT04278287,Local control rate,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",ctDNA analysis,
1591,NCT05508737,Objective response rate (ORR),2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of participants with Adverse Events that are related to treatment,
1592,NCT01198535,MTD of RO4929097,2010-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1593,NCT04476537,Number of participants assigned therapy with OncoTreat,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
1594,NCT02302794,3-year disease free survival rate,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1595,NCT05783622,Incidence of Clinically Significant Laboratory Abnormalities,2023-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Correlation of EGFR expression level with anti-tumor activity and safety,
1596,NCT05983133,Number of participants with DLTs by dose level,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
1597,NCT04385147,procedure related complications,2020-05-18,COMPLETED,OBSERVATIONAL,['NA'],Effect of COVID-19 precautions on staff number,
1598,NCT00710697,ECG interval change,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],Safety/Efficacy,
1599,NCT04098471,5-years disease free survival rate,2019-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire,
1600,NCT06316908,Pain Score using the Visual Analog Scale,2020-02-25,COMPLETED,INTERVENTIONAL,['PHASE4'],Incidence of Vomiting,
1601,NCT03735407,Number of Incidence of Device and Procedure Related Serious Adverse Events (SAE),2019-02-01,COMPLETED,INTERVENTIONAL,['NA'],To Evaluate Subject's Satisfaction,
1602,NCT03000374,Pathologic complete response (pCR),2017-05-30,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
1603,NCT00897039,Correlation of a statistically significant discriminator of sensitivity with complete response rate,2006-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1604,NCT02572141,Disease-free survival,2015-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Postoperative complications,
1605,NCT01506687,Completion of verified CRC screening event (FOBT;colonoscopy) event in experimental vs. control groups within 48 weeks,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Screening preferences; predictors of CRC screening and screening preference.,
1606,NCT02248519,Post-operative hospital stay,2014-12,UNKNOWN,INTERVENTIONAL,['NA'],Oncologic outcomes (R0-resection rate and lymph node yield),Time to return to daily activity
1607,NCT01135056,Overall Survival,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Disease control rate,
1608,NCT03076502,Pathological diagnosis,2017-04,UNKNOWN,OBSERVATIONAL,['NA'],Tumor status（worse/ maintain/ better）,
1609,NCT06261138,Progression Free Survival (PFS) per mRECIST,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],Adverse events (AEs),
1610,NCT02343835,Characterization of the intra-tumoral and systemic immune response to IRE in unresectable pancreatic cancers,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Comparison immune response between non-ablated and ablated pancreatic cancer and pre-ablated and post ablated serum,Overall survival and (local and distant) progression-free survival.
1611,NCT03405909,Diagnostic value of standardised CEUS-based algorithms for the non-invasive diagnosis of HCC in high-risk patients,2018-04-21,COMPLETED,OBSERVATIONAL,['NA'],Influence of histological grading on contrast enhancement behaviour,
1612,NCT02637596,Quality of life after RFA of pancreatic cancer,2013-02,COMPLETED,INTERVENTIONAL,['NA'],3- months perioperative morbidity and mortality,Overall Survival
1613,NCT01080521,Cognitive function as measured by the HeadMinder Customized Research Tool (CRT),2010-04,COMPLETED,OBSERVATIONAL,['NA'],Patient-reported cognitive function as measured by Patient Assessment Own Functioning scale and web CRT,
1614,NCT03165344,Esophageal stenosis rate,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],Side effect of drugs,
1615,NCT05191940,Locoregional tumor control,2022-05-16,RECRUITING,INTERVENTIONAL,['NA'],"Incidence of CTCAE v5.0 Grade 2 - Grade 5 acute, subacute and late toxicities",
1616,NCT03677960,Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL,2018-12-17,TERMINATED,INTERVENTIONAL,['PHASE1'],Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.,Histopathology of areas with biopsy-proven disease following multiple doses of ABI-1968 Topical Cream.
1617,NCT02944539,Relative copy number of mitochondrial DNA,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,
1618,NCT00785122,Safety assessment,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Non-Cellular immunomonitoring,
1619,NCT05967143,Change scores from baseline to follow-up timepoints of the European Organization for Research and Treatment of Cancer Quality of Life Hepatocellular Carcinoma module (EORTC QLQ-HCC18),2023-06-19,RECRUITING,OBSERVATIONAL,['NA'],Healthcare Resource Utilization summarized at follow-up timepoints,
1620,NCT02282111,Diagnostic Accuracy,2014-07,TERMINATED,INTERVENTIONAL,['NA'],Percent Sample Contribution to Immunohistochemistry Diagnosis,
1621,NCT03273647,Disease-free survival time,2017-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],overall survival time,
1622,NCT02795156,Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations,2016-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations,
1623,NCT02890979,Detection of gene mutations using next generation sequencing (NGS),2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],Sensitivity and specificity of the NGS probes to detect underlying esophageal dysplasia or cancer,
1624,NCT00843375,Biospecimen Retention: Samples with DNA,2019-08-07,RECRUITING,OBSERVATIONAL,['NA'],,
1625,NCT03758209,Change in preoperative functional status - FVC by the end of rehabilitation,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],"Delay in beginning of adjuvant oncotherapy (chemotherapy, radiotherapy).",
1626,NCT03253302,Positive rate of circumferential resection margin (CRM) of the specimens,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],the rate of postoperative complications,
1627,NCT02715492,Number of patients with portal vein thrombosis,2018-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1628,NCT02602249,Reduced size of the tumor.,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],"Safety, as measured by the rate of adverse events and serious adverse events",
1629,NCT05985239,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],Total hospitalization costs,Adjuvant chemotherapy in patients after low anterior resection for rectal cancer.
1630,NCT00005809,,2000-07,COMPLETED,INTERVENTIONAL,['NA'],,
1631,NCT02805829,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants with tumor recurrence metastasis as a Measure of effectiveness,T cell subsets figures
1632,NCT03470350,Phase II: Response rate (RR) of galunisertib in combination with capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.,2018-08-24,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Baseline molecular status of potential predictive markers of tumor response,
1633,NCT02539342,"Measure the Development of Oral Mucositis (Grade >/= 2) in Children, Adolescents and Young Adults.",2016-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Tolerability of Four Times Daily Caphosol Therapy
1634,NCT05241210,Adenoma Detection Rate,2021-12-13,RECRUITING,INTERVENTIONAL,['NA'],,
1635,NCT00313794,"To assess the best overall response rate per RECIST (BRR) in patients with metastatic adenocarcinoma of the colon or rectum treated with CP-675,206 .",2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],"To obtain pharmacokinetic (PK) data to be evaluated in a future meta analysis of CP-675,206 pharmacokinetics.",
1636,NCT06313801,Complications from polychemotherapy.,2023-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Аssessment of the quality of life,
1637,NCT00174616,MRI staging and TME surgery,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Measure safety - NCI-CTC version 2,
1638,NCT02719782,Safety of the TCR-T treatment,2015-07-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],Systemic release of inflammatory cytokines after administration of transduced T cells compared to baseline,"1-year PFS (progression free survival) which is measured by the number of patients with stable disease after 1 year, using mRECIST"
1639,NCT00469339,"Examine whether a family-centered feedback approach, as compared to an individual-focused approach, encourages communications regarding family risk and the development of strategies to adopt health promoting behaviors within the household.",2007-04-27,COMPLETED,OBSERVATIONAL,['NA'],,
1640,NCT05445245,Self-report Questionnaire,2022-04-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1641,NCT04442581,Number of Participants With Objective Response (Complete or Partial Response),2021-04-20,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events,
1642,NCT00033657,Pathologic Complete Response Rate,2002-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Recurrence-free Survival Time,
1643,NCT00164879,The stoma rate in the two groups of patients,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Hospital stay,
1644,NCT00055419,"The objective of this study will be to monitor the safety of administering cetuximab,via an access program, to subjects with metastatic colorectal carcinoma who have exhausted all standard therapies or treatment options.",2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1645,NCT03706742,Hepatitis C Screening,2018-09-10,COMPLETED,INTERVENTIONAL,['NA'],Cost: Cost per-HCV diagnosis,
1646,NCT01303029,Progression free survival,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of rash in patients treated with erlotinib and progression free survival and overall survival and treatment relationship,
1647,NCT05915351,Overall Response Rate (ORR),2023-06-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
1648,NCT05867901,Drug retreatment response rate,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],MRD versus imaging examination,
1649,NCT06061328,Maintenance as assessed by maintenance of other measures,2024-02-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Feasibility of Intervention Measure (FIM),
1650,NCT06173310,To measure the reproducibility of qDCE-MRI measurement of BRPC.,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
1651,NCT02115022,Staging capability of each study procedure,2014-07,COMPLETED,OBSERVATIONAL,['NA'],"Patient survival time, and tumor recurrence-free survival",
1652,NCT04409340,Detection of focal HCC lesions,2020-10-05,RECRUITING,OBSERVATIONAL,['NA'],,
1653,NCT03082833,Objective response rate (ORR) by RECIST 1.1,2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1654,NCT02033213,Changes in Lactate Levels During Esophageal Carcinoma Surgery Using Restrictive or Liberal Fluid Management.,2011-06,COMPLETED,INTERVENTIONAL,['NA'],Total Volume of Administered Intraoperative Fluid,
1655,NCT00677079,Objective response rate,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Cancer antigen 125 response (participants with elevated CA125),
1656,NCT02395016,overall survival（OS）,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],To determine the safety of the treatment with Nimotuzumab and Gemcitabine (NCI Common Terminology Criteria for Adverse Events v4.03),
1657,NCT01871571,Rate of CPR in the pathology specimen,2013-08-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence and nature of AEs of special interest for bevacizumab (grades) according to NCI CTCAE v4.0,
1658,NCT00450424,Impact of Standard Informed Consent vs CD-ROM Educational Intervention on Knowledge About Microsatellite Instability (MSI) Testing,2007-06,COMPLETED,INTERVENTIONAL,['NA'],Patient Satisfaction With the Preparation to Make a Decision,
1659,NCT02313688,3-year disease free survival,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],The positive rate of proximal resection margin,
1660,NCT04298320,Incidence of Treatment-Emergent Adverse Events,2020-03-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PFS,
1661,NCT01896310,The diagnostic accuracy of the new classification system,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,
1662,NCT00789893,To examine the effect of dilator use in minimizing vaginal stenosis so that patients are able to use the pre-radiation baseline dilator size 6 months after starting dilator use.,2008-11,COMPLETED,OBSERVATIONAL,['NA'],To explore patient-reported self-efficacy as it relates to the use of the vaginal dilator.,
1663,NCT00953511,histopathologic response to chemoradiation,2009-08,COMPLETED,INTERVENTIONAL,['NA'],prognosis,
1664,NCT03448302,Blood flow of tumor,2018-03-10,UNKNOWN,OBSERVATIONAL,['NA'],Permeability surface of the tumor,
1665,NCT06161207,3-year disease free survival rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Postoperative quality of life (measured by EQ-5D),
1666,NCT04128332,The feasibility of delivering pre-operative SABR followed by immediate surgery as determined by rate of post-operative complications at 30 days.,2020-10-26,UNKNOWN,INTERVENTIONAL,['NA'],Acute and late toxicity of pre-operative SABR: Number of adverse events,
1667,NCT05600608,"To determine the diagnostic accuracy of the augmented exhaled breath test, in the prediction of oesophago-gastric cancer (OGC).",2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],To identify the mechanistic pathways and origins of the production of breath Volatile compounds by investigating the tumour lipidome.,
1668,NCT04819971,Percentage of Participants With Pathological Complete Response (pCR),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of All Participants That Discontinued Study Treatment Due to AE,
1669,NCT01002443,Histological grading improvement rate,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1670,NCT01583361,disease free survival,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],safety,
1671,NCT03942900,Peripheral CD4 anti-telomerase immunity and MDSC (Myeloid-Derived Suppressor Cells) analysis,2020-04-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
1672,NCT03985046,Local Control Rate,2019-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
1673,NCT02162641,The proportion of nodes detected will be expressed per inguinal nodal basin and per number of patients,2014-09,WITHDRAWN,OBSERVATIONAL,['NA'],Delays in receiving radiotherapy treatment,
1674,NCT05839197,Objective remission rate (ORR),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events and toxicities of Apatinib in combination with Camrelizumab,
1675,NCT04529668,histopathology,2015-10-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
1676,NCT00328770,Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Sirolimus Toxicity/Intolerance,
1677,NCT01835041,Maximum Tolerated Dose,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants with a Clinical Response
1678,NCT04809025,Diagnostic accuracy,2021-05-24,UNKNOWN,OBSERVATIONAL,['NA'],Procedure duration,
1679,NCT01256047,postoperative infectious complication,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],"plasma IL-6, CRP, Th1/Th2 balance",
1680,NCT03630640,Local recurrence-free survival during a 1-year follow-up after Nivolumab neoadjuvant/adjuvant therapy and EP procedure,2018-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Frequency of discontinuations treatment due to AEs,
1681,NCT04850027,Disease free survival,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],Postoperative complications,
1682,NCT01613053,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1683,NCT02423278,Relapse-free Survival,2010-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Length of Hospital stay,
1684,NCT04224779,Area under the Receiver Operating Characteristic (ROC) curve of total cfDNA (defined as circulating cell-free DNA in plasma) percent change between the baseline sample (T1) and the sample at the end of the neo-adjuvant treatment (T3),2021-02-18,RECRUITING,INTERVENTIONAL,['NA'],Tumoral response assessed by Magnetic resonance Imaging (MRI),
1685,NCT05666271,Adjacent organ thermal injury rate,2022-08-29,RECRUITING,OBSERVATIONAL,['NA'],,
1686,NCT01109615,Response rate,2010-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall survival,
1687,NCT06320990,"Feasibility, by retention rate",2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Objective response rate (ORR) of pancreatic MCN,
1688,NCT05296369,Progression-free survival(PFS),2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,
1689,NCT01975064,Over all survival,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4'],Over all survival,
1690,NCT01816659,Comparison of Ki-67 in Tumor Samples,2013-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1691,NCT05482529,disease free survival rate,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],R0 resection rate,
1692,NCT05550025,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2021-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],The median overall survival time (mOS),
1693,NCT03587532,An ICGA based cutoff point to predict anastomotic leakage and graft necrosis after esophageal reconstructive surgery.,2021-12-13,RECRUITING,INTERVENTIONAL,['NA'],pulse pressure,
1694,NCT05965999,"Agreement between positive EsoGuard test results and upper endoscopy diagnosis (i.e., subjects with BE/EAC newly diagnosed by upper endoscopy)",2023-04-11,RECRUITING,OBSERVATIONAL,['NA'],"Agreement between negative EsoGuard test results and upper endoscopy diagnosis (i.e., subjects determined not to have BE/EAC on upper endoscopy)",
1695,NCT00503685,"Percentage of Participants With Complete Response (CR) or Partial Response [PR, Objective Response Rate (ORR)]",2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],"Expression of IGF Binding Proteins (IGFBP2, IGFBP3)",
1696,NCT01804998,3 year disease free survival rate,2013-03-27,COMPLETED,INTERVENTIONAL,['NA'],5 year disease specific death rate,
1697,NCT05210283,To validate the association of circulating tumor DNA (ctDNA) with recurrence-free interval (RFI).,2021-12-15,RECRUITING,OBSERVATIONAL,['NA'],To assess time from positive ctDNA to clinical recurrence,
1698,NCT00056030,Surgical resectability rate as assessed by surgical resection of liver metastases,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life as assessed by UNISCALE and Symptom Distress Scale every 6 weeks,
1699,NCT03122509,Overall Response Rate,2017-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1700,NCT05912075,Dose-limiting toxicities (DLTs),2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Distant metastasis-free survival,
1701,NCT03718897,Overall survival rate,2018-09-14,UNKNOWN,OBSERVATIONAL,['NA'],,
1702,NCT06115499,Overall Survival (OS) (Phase III),2023-12-06,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of adverse events,
1703,NCT04913077,Rate of GIST tumors,2020-03-10,SUSPENDED,INTERVENTIONAL,['NA'],data for cost-benefit calculation,
1704,NCT04227353,Data completion rates,2021-01-30,COMPLETED,INTERVENTIONAL,['NA'],Change in Quality of life,
1705,NCT03396029,A questionnaire-based lifestyle score,2014-11-01,COMPLETED,INTERVENTIONAL,['NA'],Body weight,
1706,NCT02494791,Cost-effectiveness of universal enhanced screening strategy to identify women with Lynch Syndrome and their family members via cascade testing,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Discovery of novel genetic mutations and molecular events in unexplained MMR loss (Lynch-like Syndrome),
1707,NCT03109886,Overall Safety Profile,2017-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of overall Response (DoR),
1708,NCT00934882,"Effect of BAY73-4506 on the pharmacokinetics of mFOLFOX6 and FOLFIRI (Cmax, AUC, through concentration of BAY73-4506 and Cmax, AUC of Platinum, Irinotecan and its metabolite SN-38, 5-Flourouracil)",2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor response,
1709,NCT06177496,overall survival,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Progression-free survival,
1710,NCT00251862,Patient Adherence (Test Completion),2005-01,COMPLETED,INTERVENTIONAL,['NA'],Screening Intentions,
1711,NCT04888806,12-month progression-free survival (PFS),2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival(OS),
1712,NCT01569672,"Amount of time from abnormal evaluation of the breast, cervix, and colon or rectum to needed tests and treatment",2006-11,COMPLETED,INTERVENTIONAL,['NA'],Number of barriers and effect of barriers on receiving needed tests and treatment,
1713,NCT04612530,Safety of the combination treatment IRE + immunotherapy based on adverse events,2020-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Pain based on the Visual Analog Score (VAS),
1714,NCT04751370,Pathological complete response,2022-02-08,SUSPENDED,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
1715,NCT00816634,Response rates of both regimens,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],a) progression-free survival b) quality of life c) toxicity d) overall survival e) predictive markers,
1716,NCT05721885,Degree of radiation-induced oral mucositis (RTOG criteria),2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
1717,NCT00507143,SLCO1B1 and PXR genotypes and pharmacokinetics of SN-38,2006-08,UNKNOWN,INTERVENTIONAL,['NA'],"SLCO1B1 and PXR genotypes and response duration, time to progression and overall survival",
1718,NCT00897923,"Cellular uptake of PBMCs and PMNLs as measured by reader/visual interpretation, semiquantitative grading system, and tumor-to-background uptake ratios",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
1719,NCT04809935,Pain score,2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE4'],Cost-effectiveness of two types approach,
1720,NCT04617821,overall survival,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],postoperative complications,
1721,NCT03804372,Percentage of patients presenting hepatitis B virus reactivation,2020-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of patients experiencing adverse events.,
1722,NCT00045526,Major response rate (complete and partial response),2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
1723,NCT01318239,MR perfusion parameter,2010-07,COMPLETED,INTERVENTIONAL,['NA'],diffusion parameter,
1724,NCT03825328,OS,2019-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1725,NCT05990959,Disease free survival,2022-04-22,RECRUITING,OBSERVATIONAL,['NA'],,
1726,NCT04677504,Progression Free Survival (PFS),2021-02-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of ADAs to Atezolizumab,
1727,NCT05099848,Surgical conversion rate,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,
1728,NCT05554367,ORR (Cohort 4),2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events (AE) (All Cohorts),Plasma RAS allelic burden in in relation to response (Cohorts 3 and 4)
1729,NCT01111838,To Determine Overall Objective Response.,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1730,NCT00021138,,2001-04,COMPLETED,INTERVENTIONAL,['NA'],,
1731,NCT01147380,Side Effect of Cadaveric Donor Liver NK Cell Infusion,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Anti-HCV Effect of This Treatment (If Applicable),
1732,NCT00191646,Progression Free Survival (PFS),2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival,
1733,NCT02887235,Quality of life measurement,2016-03,COMPLETED,INTERVENTIONAL,['NA'],Food security assessment plus HDMTM from baseline to 12 weeks,
1734,NCT01556399,Significant differences in molecular abnormalities.,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
1735,NCT02448056,Patient survival,2015-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1736,NCT05301699,postoperative complications during hospitalization,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
1737,NCT03657641,Overall survival (OS),2019-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1738,NCT01523639,Reduction in the chemotherapy-associated steatosis,2012-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Reduction in chemo-therapy associated steatohepatitis (CASH),
1739,NCT00209742,3-years disease-free survival rate (DFS),2005-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Dose intensity (compliance), 5-year disease-free survival rate, 3- and 5-year survival rate, incidence of other adverse drug reactions, QOL",
1740,NCT01107639,Progression-free survival (PFS),2010-05-27,COMPLETED,INTERVENTIONAL,['PHASE3'],Time to progression (TTP),
1741,NCT04967495,Overall survival (OS),2021-07-09,RECRUITING,INTERVENTIONAL,['NA'],Duration of portal patency,
1742,NCT06160323,The mean change in VAS pain score at 3 months,2023-11-10,RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
1743,NCT05349045,PFS,2022-05-05,RECRUITING,OBSERVATIONAL,['NA'],OS,
1744,NCT00016978,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1745,NCT00191568,"To evaluate recurrence free one year survival, time to disease progression and local recurrence rate, analyzed at the end of the study",2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess overall survival at the end of the 24 months follow up period;To assess acute and late toxicity (every month for the first 3 months and then every three months for 24 months after treatment discontinuation),
1746,NCT01872377,Toxicity defined as grade 3 or 4 gastro-intestinal or other non-haematological toxicity,2013-07,TERMINATED,INTERVENTIONAL,['NA'],CyberKnife radiation dose measured in Gy delivered to the tumour and surrounding organs vs. the frequency of grade 3-4 toxicity defined by CTCAE v4.0,
1747,NCT03232814,Adherence rates,2017-10-05,WITHDRAWN,INTERVENTIONAL,['NA'],Participants' Overall Experiences: Qualitative Interviews,
1748,NCT01938027,Total Mesorectal Excision(TME) quality,2013-09,COMPLETED,INTERVENTIONAL,['NA'],"30-day postoperative complications, No. of harvested LN","Oncologic outcome(2-year local recurrence free survival, 5-year survival)"
1749,NCT04253249,Treatment pancreatic cyst without surgery,2018-05-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
1750,NCT06073483,The rate of postoperative complications,2023-10-15,RECRUITING,INTERVENTIONAL,['NA'],Intraoperative instrument operation error rate,
1751,NCT03021668,Rate of Surgical Site Infection,2017-01,COMPLETED,INTERVENTIONAL,['NA'],30-d Readmission,
1752,NCT03099486,Progression Free Survival (PFS) at 2 Months,2017-10-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Toxicities Due to Regorafenib and 5-FU/LV Combination Therapy,
1753,NCT01350206,overall survival,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],Time to progression,
1754,NCT04663035,1-year recurrence-free survival (RFS) rate,2020-12-21,RECRUITING,INTERVENTIONAL,['PHASE2'],"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30 and the EORTC QLQ-HCC18.",
1755,NCT02009631,To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF),2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor Assessment,
1756,NCT02396745,Safety: Long-term (Study Related Adverse Events),2016-01-25,TERMINATED,INTERVENTIONAL,['NA'],Additional Interventions (Number of Subsequent Follow up Treatment Interventions),
1757,NCT04550260,Progression free survival (PFS) per RECIST 1.1 as assessed by BICR,2020-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Progression free survival (PFS) per RECIST 1.1 as assessed by BICR,Adverse events (AEs)
1758,NCT06242418,change in value of ctDNA concentration,2024-03-25,RECRUITING,INTERVENTIONAL,['PHASE2'],quality of life as assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).,
1759,NCT03880721,Specificity,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1760,NCT05659290,Progression-free Survival (PFS),2023-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
1761,NCT00188565,- To determine the efficacy of celecoxib in combination with preop RT and continuous infusional 5-FU. Pathologic complete response rate (pCR) will be used as the endpoint.,2004-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Quality of life (FACT, EORTC)",
1762,NCT02363218,Overall survival rate,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression-free survival,
1763,NCT01940237,Change in Hamilton Depression Scale (HAMD-17),2012-04,TERMINATED,INTERVENTIONAL,['NA'],,
1764,NCT01675934,Percentage of cases in which right-sided retroflexion is successful with the adult and pediatric colonoscopes.,2012-02,WITHDRAWN,INTERVENTIONAL,['NA'],Reasons for failure of retroflexion.,
1765,NCT00354887,Number of Participants With Overall Response,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1766,NCT04698915,Median Overall Survival after SBRT completion,2021-05-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Median Progression Free Survival after SBRT Completion per RESIST 1.1,
1767,NCT00891930,Part 2: Objective Response Rate (ORR),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Subjects With Worst Post-baseline Grade 3 or Higher Laboratory Toxicities,
1768,NCT05284864,Determine and compare morbidity and mortality rates in patients with early and late stoma closure,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Determine and analyze quality of life assisted by the SF36 scale in early vs late ileostomy closure,"Determine the patient's percentage with anterior resection syndrome, after early and late ileostomy closure assisted by the LARS scale."
1769,NCT00682786,Rate of Tumor Downstaging Compared With Historical Controls.,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine Patient Fears and Expectations of Pharmacogenetics.,
1770,NCT01740648,Identify the maximally tolerated dose of Trametinib to be used in combination with 5FU and radiation in patients with rectal cancers.,2012-11-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Frequency of patients undergoing sphincter preserving surgery,
1771,NCT00120939,"Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.",na,COMPLETED,INTERVENTIONAL,['PHASE1'],"Tumor response rate 8, 16 and 24 weeks, and common PK parameters at 24 weeks",
1772,NCT03407417,Completion of initial FIT screening,2018-11-08,RECRUITING,INTERVENTIONAL,['NA'],Completion of repeat Annual FIT screening,
1773,NCT00020501,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1774,NCT00098579,MTD of alvocidib when given every three weeks in conjunction with doxorubicin hydrochloride,2004-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Therapeutic activity of alvocidib in combination with doxorubicin hydrochloride in patients with advanced solid tumors,
1775,NCT00844168,Dose-limiting toxicity (DLT) as defined by the Common Terminology for Adverse Events (CTAE) version 3,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1776,NCT03627559,Pyruvate concentration postoperatively,2013-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
1777,NCT03125980,3-year disease free survival,2017-05,RECRUITING,INTERVENTIONAL,['PHASE3'],Relapse-free survival (RFS),
1778,NCT05698992,General Quality of life,2023-02-27,RECRUITING,OBSERVATIONAL,['NA'],Rehabilitation process,Discharge destination
1779,NCT02780284,Percentage of participants retained at the end of study,2015-03,COMPLETED,INTERVENTIONAL,['NA'],"Percentage of participants with collected, processed, and analyzed stool samples",
1780,NCT06256185,Sub-analysis (ML Model vs. Logistic Model vs. NCCN Guideline),2010-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
1781,NCT02204306,disease control rate,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],median overall survival,drug toxicities
1782,NCT00346099,Percentage of patients with clinical complete response rate in tumor in the pelvis at 4 to 6 weeks after completion of radiation therapy,2006-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],The toxicity of panitumumab in combination with chemotherapy and in combination with chemoradiotherapy,
1783,NCT05795374,Postoperative morbidity.,2022-03-01,COMPLETED,OBSERVATIONAL,['NA'],Recurrence,
1784,NCT06156748,Overall survival,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
1785,NCT01549756,,2012-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1786,NCT06199973,Progressive free survive assessed by Independent Review Committee,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Effectiveness: overall survive assessed by the researchers,
1787,NCT04046133,Safety and tolerability- 12 months post CRT,2020-10-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],Patient reported outcome - 12 months follow up,
1788,NCT05356585,Detectable ctDNA at the Completion of TNT,2023-12-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Correlation of Complete Response TNT,The correlation of ctDNA at end of TNT with relapse-free survival
1789,NCT03821948,Blood-based biomarkers associated with genetic and epigenetic alterations.,2019-01-03,COMPLETED,OBSERVATIONAL,['NA'],,
1790,NCT01847794,HER2 positive CTC,2013-06,UNKNOWN,INTERVENTIONAL,['NA'],clinical significance of HER 2 positive CTC,
1791,NCT03493152,,na,TEMPORARILY_NOT_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1792,NCT01785537,Change from baseline in the number of traditional cigarette smoked,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],Traditional and electronic smoking (overall smoking) cessation,
1793,NCT02426762,freedom from surgical site infection,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Pain Scores on the Visual Analog Scale,
1794,NCT05620732,AE/SAE,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],ORR,
1795,NCT02845973,differences in abundance of gut microbiota,2012-01,COMPLETED,OBSERVATIONAL,['NA'],evidence of colorectal neoplasia,diet difference in patients with different clinical outcomes
1796,NCT03111368,Diagnostic yield,2015-04-27,COMPLETED,INTERVENTIONAL,['NA'],,
1797,NCT02042859,"Improvement in size(patency of bile duct) measured by cholangiography or cholangioscopy, immediately post ablation",2013-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
1798,NCT00063427,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1799,NCT00980603,response rate,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],time to progression,
1800,NCT00176787,"e. The relationship of intratumoral levels of thymidylate synthase, dipyrimidine dehydrogenase and thymidine phosphorylase determined immunohistochemically to response",2000-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1801,NCT06090825,Descriptions and scores of real status of hospice care in different hospitals,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
1802,NCT04592029,Progression free survival (PFS) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST).,2020-09-27,UNKNOWN,INTERVENTIONAL,['PHASE1'],DOR assessed by investigators according to mRECIST.,
1803,NCT05582018,Safety,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Assessment Module (1),Precision
1804,NCT05669521,Mucositis,2022-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Secondary efficacy/outcome mucositis,
1805,NCT05453630,Number of participants who complete colonoscopy within 1 year of the colonoscopy referral,2022-06-16,RECRUITING,INTERVENTIONAL,['NA'],Number of participants who have colonoscopies with cecal intubation,
1806,NCT01073046,Influence of Naso-Gastric/Jejunal Tube on Postoperative complications,2010-01,COMPLETED,OBSERVATIONAL,['NA'],Influence of Naso-Gastric/Jejunal Tube on Postoperative Patient's Comfort,
1807,NCT01563133,Descriptive criteria in nCLE sequences for the characterization of pancreatic masses and lymph nodes,2012-06,UNKNOWN,INTERVENTIONAL,['NA'],Feasibility and safety data on nCLE during EUS-FNA procedure,
1808,NCT03261947,Disease Control Rate (DCR) in Tumor-Specific Cohorts,2017-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],"Percentage of Participants With Clinically Significant Changes in Vital Sign Measurements, Reported as Adverse Events in Tumor-Specific Cohorts",
1809,NCT03382600,Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR),2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Discontinuing From Study Treatment Due to AE(s),
1810,NCT06018857,Overall Survival,2017-05-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1811,NCT04885283,Time to Start Postoperative Chemotherapy,2021-01-20,COMPLETED,OBSERVATIONAL,['NA'],,
1812,NCT01876901,Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA,2010-08-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among CAA,
1813,NCT02216149,Frequency of coronary artery dysfunction,2015-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Survival status,
1814,NCT03286738,percentage of use FOLFIRI regimen and target agents,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,
1815,NCT03631173,Total hospital stay,2019-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Risk factors of postoperative pancreatic fistula at 90 days after surgery,Number of patients expired at an average of 10 days
1816,NCT05445401,DMSM score,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Postoperative complication rate of grade IIIa or above.,
1817,NCT03908788,Proportion of patients with mCRC (metastatic colorectal cancer) who develop a RAS (rat sarcoma viral oncogene homolog) mutation under anti-EGFR (epidermal growth factor receptor) therapy,2018-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Evaluation of the following criterion: frequency of mutated alleles,
1818,NCT05563766,Rate of pathological complete response with itraconazole,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Determine the utility of ctDNA and exosome characterization as a prognostic marker,
1819,NCT05215379,The rate of cCR,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",quality of life,
1820,NCT00423293,Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for Adverse Events),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Five-Year Rate of Colostomy-free Survival,
1821,NCT02461043,3 year relapse free survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],3 year overall survival,5 year overall survival
1822,NCT00002933,Effectiveness of irinotecan in treating patients who have metastatic or recurrent colorectal cancer.,1996-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1823,NCT00262990,To show superiority of patupilone in overall survival compared to doxorubicin in taxane/platinum resistant patients with ovarian cancer,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],To explore relationships between Cmin (pre-dose patupilone blood concentration) and efficacy/adverse events,
1824,NCT06184152,Early HCC Detection,2023-11-28,RECRUITING,OBSERVATIONAL,['NA'],Early HCC Detection,
1825,NCT03150706,"Serum CEA, TSH, T3, free T4, EKG,CT (or MRI) scans of evaluable/measurable lesions by RECIST 1.1.",2017-05-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1826,NCT04974047,pCR Rate,2021-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number Of Participants Experiencing Treatment-Emergent Adverse Events,
1827,NCT00056992,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1828,NCT03832985,Initiation of risk reduction behavior,2020-11-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Health Education Impact Questionnaire (heiQ),
1829,NCT03489707,Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening,2020-01-09,COMPLETED,INTERVENTIONAL,['NA'],Number of participants who attend high resolution anoscopy,Host/viral methylation and its association with high-grade squamous intraepithelial lesions.
1830,NCT01470404,germline polymorphisms in xenobiotic metabolism genes in toxicity profile,2008-07-10,COMPLETED,OBSERVATIONAL,['NA'],,
1831,NCT04138381,Clinical benefit rate (CBR) for the use of selinexor in monotherapy,2019-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinical benefit rate (CBR),
1832,NCT05303818,Deep venous thrombosis and embolic pulmonary disease,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Safety of rivaroxaban,
1833,NCT02817126,Locoregional recurrence rate,2016-07-10,UNKNOWN,INTERVENTIONAL,['NA'],Self reported sexual function for female patients,
1834,NCT02228785,Antibody Levels,1994-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Intra-gastric pH,
1835,NCT05604573,detection sensitivity of genetic mutation by mmADPS,2022-02-09,RECRUITING,OBSERVATIONAL,['NA'],correlation of genetic mutation and prognosis,
1836,NCT01104129,Positive mutation rate in tumors/IPMN lesions vs. control,2009-07-09,COMPLETED,OBSERVATIONAL,['NA'],Percentage of patients with genetic abnormalities correctly detected in stool samples,
1837,NCT00005926,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1838,NCT01104077,Percentage of IPMN patients with relatives with pancreatic cancer or IPMN,2008-11-17,COMPLETED,OBSERVATIONAL,['NA'],Percentage of IPMN patients exhibiting higher malignant potential or recurrence following surgical resection,
1839,NCT05533541,Primary End point,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],Secondary End point 4,
1840,NCT04806464,Part2:ORR,2021-03-16,UNKNOWN,INTERVENTIONAL,['PHASE1'],"Part 2:PD-L1, PD-1",
1841,NCT03647839,Objective response per iRECIST,2018-09-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
1842,NCT04720521,Detection rate of gastric neoplastic lesion,2019-05-10,UNKNOWN,INTERVENTIONAL,['NA'],Sensitivity of detecting gastric neoplastic lesion,
1843,NCT05214339,Objective response rate (ORR) by RECIST 1.1,2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
1844,NCT00637364,"Safety of the FEP-BY02 HIFU system determined by the frequency and severity of adverse events (AEs) categorized and graded for severity according to the Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE)",2008-03,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1845,NCT00005077,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1846,NCT02576964,Objective response rate,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
1847,NCT03396614,The cardiopulmonary (dys)function in EC survivors treated with neo-CRT followed by surgical resection will be compared to cardiopulmonary (dys)function in EC survivors treated with surgical resection alone.,2017-10-21,COMPLETED,OBSERVATIONAL,['NA'],,
1848,NCT04627142,Objective Response (OR) according to RECIST version 1.1,2020-11-23,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of patients experiencing grade ≥3 treatment-related AEs during the entire treatment period,
1849,NCT03301454,Estimate the overall survival for patients suffering from Esophageal cancer,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Estimate the consequences of pursuing chemotherapy,
1850,NCT00005640,Number of Procedures Resulting in Improved Detection,1999-06,COMPLETED,INTERVENTIONAL,['NA'],,
1851,NCT03073694,Comprehensive Complication Index (CCI) score.,2017-07-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,
1852,NCT06060990,Serum copper (Cu) as a predictive biomarker of the response to systemic treatment of biliary tract cancer patients,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
1853,NCT01194206,Rate of downstaging of stage B and C Hepatocellular Carcinoma using Stereotactic Body Radiotherapy,2010-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Survival rate,
1854,NCT01606241,"Proportion of patients who experience severe toxicities (grades 3-5 of the National Cancer Institute's Cancer Therapy Evaluation Program [CTEP] Common Terminology Criteria for Adverse Events, version 4.0)",2012-07-24,COMPLETED,INTERVENTIONAL,['PHASE1'],Percentage change in plasma concentration of cytokines and chemokines,Percent change in antigen-specific cytokine profiles
1855,NCT03744247,Overall Survival (OS),2019-04-21,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Time to Progression (TTP),
1856,NCT00199173,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1857,NCT04953585,overall survival time,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1858,NCT05664178,Participant Treatment Outcome,2023-02-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1859,NCT02358395,Pharmacokinetic profile of BBI608 when administered in combination with Sorafenib.,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival,
1860,NCT01310699,Number of Participants With Nonpolypoid (Flat and Depressed) Colorectal Neoplasm,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Percentage of Nonpolypoid (Flat) Missed Lesions,
1861,NCT05378867,AUCtau，Area under the curve over the dosing interval,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],DOR，Duration of response,
1862,NCT01250015,Comparison of the two groups' overall wish to be screened,2007-09,COMPLETED,OBSERVATIONAL,['NA'],Impact of different summary points on subject's desire to be screened,
1863,NCT03245346,Overall survival (OS),2017-12-19,UNKNOWN,INTERVENTIONAL,['NA'],Plasma levels of ropivacaine and sufentanil,
1864,NCT03828318,Global quality of life (QoL),2019-09-01,RECRUITING,INTERVENTIONAL,['NA'],,
1865,NCT04724070,Construction of a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues.,2019-10-16,RECRUITING,OBSERVATIONAL,['NA'],Describe the prevalence of actionable genomic aberrations in patients with advanced cancers in Hong Kong,
1866,NCT05328960,Yearly incidence of rectal cancer,2022-02-15,RECRUITING,OBSERVATIONAL,['NA'],Treatment changes,
1867,NCT05040347,Concentration of NETs markers and anti-β2 glycoprotein I,2020-08-18,COMPLETED,OBSERVATIONAL,['NA'],,
1868,NCT02689284,Duration of Response,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Terminal Half-life,
1869,NCT04390243,Objective Response Rate (ORR) at 24 Weeks,2020-11-16,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Patients With Grade 3+ Adverse Events,
1870,NCT01416168,Feasibility of the Intervention,2008-12,COMPLETED,INTERVENTIONAL,['NA'],Effect Size Estimates for Within-group Changes Between Baseline and 1-month,
1871,NCT03026452,Tumor size assessed by MRI,2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Alpha Fetoprotein (AFP) level assessed by ELISA,
1872,NCT04362449,Nausea according to the Common Terminology Criteria for Adverse Events (CTCAE) V4.03,2019-01-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Health economics in the context of duration of hospital attendance,
1873,NCT04289792,Kaplan-Meier Estimate of Progression-Free Survival (PFS),2020-05-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Participants With Treatment Emergent Adverse Events (TEAEs),
1874,NCT02781337,Disease-free survival,2012-05,RECRUITING,OBSERVATIONAL,['NA'],Molecular characteristics of colorectal adenocarcinoma.,
1875,NCT01143285,Toxicities frequently associated with chemotherapy,2010-04,COMPLETED,INTERVENTIONAL,['NA'],Overall survival,
1876,NCT03198546,Number of Patients with Dose Limiting Toxicity,2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Median CAR-T cell persistence,
1877,NCT05190575,ORR,2022-01-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety & tolerability,
1878,NCT05293496,Number of participants with AEs leading to study treatment discontinuation,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Duration of PSA response for mCRPC,
1879,NCT01729221,Incidence of hepatocellular carcinoma post stem cell therapy in hepatitis C virus infected patients,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],Compare the incidence of hepatocellular carcinoma in patients who had received stem cell therapy to those who had received the standared line of care,asses liver functions in both groups
1880,NCT03679910,Diagnostic value of cell migration inducing protein (CEMIP) in serum of pancreatic cancer as non invasive marker.,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1881,NCT04623749,"Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by Trans abdominal US-FNAC. diagnostic accuracy",2021-12,UNKNOWN,INTERVENTIONAL,['NA'],"Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by EUS-FNAC. diagnostic accuracy",
1882,NCT00447122,Overall Survival for Patients With Metastatic Pancreatic Cancer.,2007-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1883,NCT01966133,Disease-free survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Complications of transarterial chemoembolisation,Health-related quality of life assessment
1884,NCT01425996,Adverse Event/Serious Adverse Event,2011-10-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change from baseline in tumor marker/biomarkers,
1885,NCT05610163,Clincal Complete Response (cCR) Rates,2022-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events (AEs),
1886,NCT03869294,Overall survival,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],adverse events,
1887,NCT02654288,The dynamic change patterns of sera IgG4 and IL-10 of pancreatic cancer after gemcitabine-based chemotherapy will be recorded.,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],The correlation of the changes of IgG4 and IL-10 with the overall survival after chemotherapy will be analyzed.,
1888,NCT04157140,Time To Progression(TTP),2019-11-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events,
1889,NCT01184482,Maximum tolerated dose,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Genetic variations and activation status for EGFR and ErbB2 pathways,
1890,NCT05720676,To use PDX and PDO to evaluate the efficacy of various treatments.,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1891,NCT00155103,,2004-08,UNKNOWN,OBSERVATIONAL,['NA'],,
1892,NCT05221775,adverse effect,2021-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],OS,
1893,NCT03768414,Overall survival (OS),2019-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Changes in carbohydrate antigen 19-9 (CA 19-9) levels,
1894,NCT05650216,pCR,2022-12-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
1895,NCT06257030,LPFS,2024-02-05,RECRUITING,OBSERVATIONAL,['NA'],Post-treatment dosimetry analysis,
1896,NCT01216345,best overall response (according to RECIST 1.0),2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety of the treatment combination,
1897,NCT02989870,Occurrence of Treatment Related Adverse Events,2017-03-27,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
1898,NCT00367861,Progression free survival,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Toxicity,
1899,NCT06325826,Hepatocellular Carcinoma,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1900,NCT03889795,Maximum Tolerated Dose and/or Recommended Dose within the tested C3 dose range,2019-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],Assess molecular changes induced by C3 administration in the blood for biomarker sensitivity/resistance assessment,
1901,NCT04042805,Objective Response Rate (ORR),2019-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor mutation burden in association with ORR and survival.,
1902,NCT03752086,pancreatic fistula,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],major complications (Clavien-Dindo ≥III),
1903,NCT03185988,Response Rate(RR) for each cohort in intent to treat (ITT) population,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,
1904,NCT02885753,progression-free survival,2016-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,
1905,NCT00372944,Median time to death (TTD),2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess the safety and tolerability of AZD6244 in the treatment of advanced or metastatic pancreatic cancer by review of adverse events (AEs) and laboratory parameters.,
1906,NCT01735955,Number of Participants With Adverse Events and Serious Adverse Events,2013-03-29,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Participants With Clinical Benefit From Nilotinib,
1907,NCT00937248,Comparing the use of a prone pillow and simple ankle fixation device vs. the use of a CVID for immobilization rectal patients during the course of preoperative radiation therapy using KV CBCT for IGRT.,2009-04,COMPLETED,INTERVENTIONAL,['NA'],quantify interfractional set-up displacements using either of the two devices;determine a standard planning target volume margin; evaluate the role of soft-tissue image matching for IGRT using CBCT.,
1908,NCT00303914,"Prevalence, severity, and interference due to physical and psychological symptoms experienced by cancer patients as assessed by MD Anderson Symptom Inventory at baseline and days 28-35 following initial assessment",2006-03-14,COMPLETED,OBSERVATIONAL,['NA'],Focus and scope of interventions chosen to improve symptom control,
1909,NCT00020787,To determine whether a concomitant G17DT-chemotherapy regimen affects tumor response in subjects with gastric or gastroesophageal cancer.,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],"Time to disease progression, best overall response, and survival will be evaluated in the intent-to-treat population and the evaluable population.",
1910,NCT05688020,Postprocedural bleeding,2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE4'],Side effects,
1911,NCT03778879,Percentage of patients who are ineligible for surgical resection due to toxicity from SBRT + CCX872-B or SBRT alone,2019-08-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Mean time to death,
1912,NCT03518489,Change from Baseline Numeric Rating Scale for Pain(NRS scale) at 7 weeks,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],The Adverse events Related to lappaconitine,
1913,NCT03381053,Number of participants with tumor metastasis,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1914,NCT02944188,incidence of postoperative complications,2014-12-01,COMPLETED,INTERVENTIONAL,['NA'],operative mortality,postoperative hospital stay
1915,NCT06128551,Dose Limiting Toxicities,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-Free Survival (PFS),
1916,NCT05712356,Incidence of adverse events,2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,
1917,NCT02610218,Correlation of HER2 status on CTCs and cfDNA with clinical outcomes,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],Gene variations associated with resistance in HER2-targeted therapy,
1918,NCT02309177,Grade 3 or 4 TEAE,2015-01-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Duration of Response,
1919,NCT02435953,Overall survival rate,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],Adverse event rate,
1920,NCT02659852,Median patency duration,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],complication rate,
1921,NCT00004195,Primary Goal to demonstrate that eniluracil at current clinical doses,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate DPD recovery and uracil levels,Specific Aims
1922,NCT04106856,Grade 3 or higher gastrointestinal toxicity rate,2019-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Number patients that require a medical intervention or hospitalization due to hypotension,Patient reported quality of life assessment- review of symptoms and how they interfere in life
1923,NCT05379595,Cohorts D and E: Number of Participants with Vital Signs Abnormalities,2022-07-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Cohorts D and E: Progression Free Survival (PFS),
1924,NCT00220246,,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1925,NCT04395469,Tumor Hypoxia,2021-05-18,RECRUITING,INTERVENTIONAL,['NA'],,
1926,NCT05619172,Objective response rate (ORR) according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),2022-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Time course of ADAs against nanrilkefusp alfa,
1927,NCT03894917,Characterize the Change in disease and treatment patterns of advanced hepatocellular carcinoma (HCC) in older patients in the US.,2019-09-13,RECRUITING,OBSERVATIONAL,['NA'],,
1928,NCT05661292,Asian Pacific Colorectal Screening (APCS) score validation in Mexican population.,2019-08-01,RECRUITING,OBSERVATIONAL,['NA'],Optimal Fecal Immunochemical Test (FIT) valued for Advanced Colorectal Neoplasia (ACN) detection.,
1929,NCT01736410,Overall Response Rate (ORR),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Treatment Failure (TTF),
1930,NCT05599932,Pharmacokinetics (PK): AUCinf,2022-12-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1931,NCT04776148,Overall Survival (OS),2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score,
1932,NCT02094625,Target Serum Level NAC,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Glutathione serum level,
1933,NCT00001254,To determine an approach to the localization and management of tumor in patients with ZES.,1991-10-29,COMPLETED,OBSERVATIONAL,['NA'],,
1934,NCT04933669,Progression free survival（PFS）,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE2'],R0 resection rate,
1935,NCT04638868,Number of circulating tumor cells,2020-11-17,UNKNOWN,INTERVENTIONAL,['NA'],,
1936,NCT03285906,progression-free survival,2017-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",median Overall Survival,
1937,NCT05925413,Objective response rate (ORR),2023-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (safety),
1938,NCT03400592,Objective response rate,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Potential predictive biomarkers of nimotuzumab,
1939,NCT03825705,Overall Response Rate(ORR),2019-04-23,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1940,NCT00622440,Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL),2008-05-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Response With >75% Adherence,
1941,NCT00068692,3-year Overall Survival Rate,2003-10-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Failure Pattern,
1942,NCT05361954,Incidence of immune-related adverse events (IrAEs),2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Assess immunoglobulin levels,
1943,NCT00004187,,1999-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1944,NCT01048216,To evaluate feasibility of conformal radiation therapy in patients with metastatic colorectal liver cancer and determine its safety,2006-11,UNKNOWN,INTERVENTIONAL,['NA'],Set up verification with cone-beam CT (OBI on Boar Imager),
1945,NCT00154102,Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety - Number of Patients Experiencing Any Adverse Event,
1946,NCT00005060,Event-free survival,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Rate of complete resection (RO) and postoperative mortality as measured after surgery,
1947,NCT02376985,Incidence of oral mucositis (Over Grade 1) after everolimus treatment,2015-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],Health-related quality of life (HRQOL),
1948,NCT04469426,Assessing 'Change' via European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - C30 questionnaire after 6 months,2020-08-15,RECRUITING,INTERVENTIONAL,['NA'],Bowel function Low Anterior Resection Syndrome score,
1949,NCT00006472,,2000-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1950,NCT03783442,Overall Survival (OS),2018-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Number of Participants Experiencing Adverse Events (AEs),
1951,NCT00629265,Change in Penetration-Aspiration Scale (PAS) Score,2008-03,COMPLETED,INTERVENTIONAL,['NA'],Performance Status Scale for Head and Neck Cancer Patients (PSS); The Head and Neck Cancer Inventory (HNCI),
1952,NCT04229355,Progression-free survival,2021-02-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],Overall survival,
1953,NCT03888859,Frequency of ARTEMIS T cell treatment-related adverse events,2017-12-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],"Time to baseline for serum IL-2, IL-4, IL-6, IL-10, TNF-α and INFγ",
1954,NCT03050333,Proportion of complete resections without recurrence,2013-04-25,UNKNOWN,OBSERVATIONAL,['NA'],,
1955,NCT03888092,Number of patients with adverse events (AEs) as a measure of safety and tolerability,2017-08-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
1956,NCT00069940,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1957,NCT03517852,"Tumor blood flow (velocity, mm/sec)",2018-08-15,COMPLETED,INTERVENTIONAL,['NA'],Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.,
1958,NCT03566797,Incidence of SC-CIP in patients at risk,2018-07-20,RECRUITING,OBSERVATIONAL,['NA'],NOD2 polymorphisms,
1959,NCT00349817,skill in discussing these issues with patients,2005-10,UNKNOWN,INTERVENTIONAL,['NA'],,
1960,NCT03364114,Rate of device- and procedure-related serious adverse events (SAEs),2018-02-09,RECRUITING,INTERVENTIONAL,['NA'],Post Procedure Pain,
1961,NCT03178812,Prediction of malignant potential of pancreatic cyst by measuring TNF levels,2017-06,UNKNOWN,INTERVENTIONAL,['NA'],,
1962,NCT03661671,Detection rate of gastric neoplastic lesion,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Sensitivity of detecting gastric neoplastic lesion,
1963,NCT00081237,Maximum tolerated dose and recommended dose for future trials as measured by CTC v3.0,2004-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to progression as measured by Kaplan Meier and RECIST every 6 weeks during treatment and then every 8 weeks,
1964,NCT02400398,Weight,2015-04-27,COMPLETED,OBSERVATIONAL,['NA'],Changes in microbiome analysis,
1965,NCT05984589,To compare the difference in WCRF/AICR score between the intervention (RISE-PSMT) and control (SSMT) groups.,2024-01-29,RECRUITING,INTERVENTIONAL,['PHASE2'],To assess percent change across the various component scores on the WCRF/AICR (e.g. grams of fiber) to better understand what might be driving any changes in the overall WCRF/AICR composite score.,
1966,NCT02705105,Number of Subjects Experiencing Dose-limiting Toxicity,2016-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Objective Tumor Response Rate According to RECIST,
1967,NCT00825955,To compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to Sorafenib and receive Brivanib plus best supportive care (BSC) to those receiving placebo plus BSC,2009-02-17,COMPLETED,INTERVENTIONAL,['PHASE3'],"To assess safety profile of brivanib. Safety will be assessed by the number of adverse events (AEs), serious adverse events (SAEs), periodic data monitoring committee (DMC) review",
1968,NCT01388790,Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments,
1969,NCT00448760,Pathologic Complete Response,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
1970,NCT02073500,Overall survival (OS),2009-09,RECRUITING,OBSERVATIONAL,['NA'],Disease-free survival (DFS),
1971,NCT03002051,Clinical success for obstructive jaundice,2016-10,COMPLETED,INTERVENTIONAL,['NA'],Adverse events,
1972,NCT01704690,Response rate,2012-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Number of Participants with Adverse Events and the degree of each adverse event,
1973,NCT00062374,Histological Response Determined by FDG Uptake Correlates,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Free Survival (DFS)
1974,NCT00313599,Maximum tolerated dose (MTD) of lapatinib in course 1,2006-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics during the first 2 weeks of treatment,
1975,NCT02639026,Number of Adverse Events,2016-01-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1976,NCT04256226,Overall survival,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],Recurrence-free survival,
1977,NCT01316263,"Percentage of Participants With Tumor Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Clinical Benefit Rate) at 12 Weeks",2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Human Anti-Olaratumab (IMC-3G3) Antibody Results,
1978,NCT05334849,Levels of circulating exosomal lncRNA-GC1,2018-11-01,COMPLETED,OBSERVATIONAL,['NA'],Survival outcomes of circulating exosomal lncRNA-GC1,
1979,NCT02597712,Change in Ki67 Biomarker Expression,2013-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Abundance of Biomarkers of ECL Cell Hyperplasia,
1980,NCT04759638,Overall Survival (OS),2017-03-21,COMPLETED,OBSERVATIONAL,['NA'],Pathological Complete Response (CR),
1981,NCT01373125,To characterize reflux symptomatology before and after radiofrequency ablation in subjects with dysplastic Barrett's Esophagus (BE).,2011-06,COMPLETED,OBSERVATIONAL,['NA'],Correlate the physiologic and morphologic changes in the neosquamous epithelium (NSE) after ablation with the frequency and type of refluxate seen on pH-Impedance.,
1982,NCT01220999,Mean 111^In-CS-1008 Serum Maximum Concentration by Gamma Counting Following the Day 36 Infusion of 111^In-CS-1008,2010-10-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Subjects With Best Overall Metabolic Response,
1983,NCT05816837,Displacement distance,2022-04-20,RECRUITING,OBSERVATIONAL,['NA'],,
1984,NCT01716949,Number of hyperthermia applications by patient,2012-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Rate of acute and late toxicity,
1985,NCT02936856,Detection of numbers of confirmatory diagnosis of malignant lesions before and after hepatic arteriography,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],Detection of distribution of confirmatory diagnosis of malignant lesions before and after hepatic arteriography,
1986,NCT03104283,Progression-free survival (PFS),2017-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
1987,NCT02715882,"Safety and tolerability evaluation as measured by adverse events and assessed as changes in vital signs and clinical laboratory measurements, physical examination findings and ECG readings",2015-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Blood leukocytes by FACS,
1988,NCT05650151,Infection rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
1989,NCT04906434,vital signs changes from baseline,2020-02-26,RECRUITING,INTERVENTIONAL,['PHASE1'],PFS,
1990,NCT05099237,Cohort 3 - Primary outcome measure: feasibility of monitoring for the daily weights:,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],"Cohorts 1,2 and 3 Device acceptability",
1991,NCT02704156,The Median Survival Time Will be Determined.,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],The Quality of Life Will be Analyzed.,
1992,NCT04575922,Overall response rate for unirradiated lesions (ORR),2020-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
1993,NCT00083785,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1994,NCT00625651,Progression-free survival,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The incidence of anti-AMG 655 antibody formation,
1995,NCT03727633,Percentage of participants presenting a disease control at 4 months,2018-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life questionnaire (QLQ) QLQ-C30,
1996,NCT00808145,Safety of the combination of gemcitabine/cisplatin/sorafenib,2009-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Effectiveness of gemcitabine/cisplatin/sorafenib in shrinking tumors extending time to progression of disease,
1997,NCT01298570,Progression Free Survival (PFS),2011-04-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Patients With Severe Adverse Events,
1998,NCT04083651,Overall Survival,2020-01-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
1999,NCT02564614,Change From Baseline to Week 6 in HIF1A mRNA Level in Tumor Tissue,2016-05-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Plasma Decay Half-Life (t1/2),
2000,NCT05659251,Pathological Complete Response (PCR),2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],The changes in the peripheral blood immunoprofile and tumor tissue sample among non-PCR (NPCR) and PCR patients,
2001,NCT03216135,Microbial community profiling,2017-07-20,UNKNOWN,OBSERVATIONAL,['NA'],Generate a tissue microarray,
2002,NCT04490733,Neuropsychological battery test,2020-08-17,RECRUITING,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
2003,NCT03200691,Pathologic Complete Response Rate,2017-08-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.,
2004,NCT02184195,Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1),2014-12-16,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Adverse Events (AEs),
2005,NCT02226666,Survey,2013-08,COMPLETED,OBSERVATIONAL,['NA'],Respiratory Rate,
2006,NCT00512304,feasibility of treatment,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2007,NCT05897268,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,
2008,NCT01923155,Adenoma detection rate,2012-03,COMPLETED,INTERVENTIONAL,['NA'],Cecal intubation TIME,
2009,NCT02871804,the incidence of pancreatic fsitula grade B/C,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],the incidence of conversion from laparoscopic surgery to open surgery,
2010,NCT03096717,incidence of dysplasia in relation to therapy performed,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2011,NCT05475613,For patients with liver transplantation: The 2-year event-free survival rate,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],For all patients with HCC downstaging: Rate of successful tumor downstaging,
2012,NCT03781154,Physical Activity,2019-10-17,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of Life Assessment,
2013,NCT03306966,Number of patients with adverse events related to the index-procedure.,2018-05-01,WITHDRAWN,OBSERVATIONAL,['NA'],Number of patients with colectomy related re-interventions.,
2014,NCT04151524,Overall Survival,2019-10-23,UNKNOWN,OBSERVATIONAL,['NA'],,
2015,NCT04716257,Ovarian specific overall survival,2021-01-14,UNKNOWN,OBSERVATIONAL,['NA'],Quality of life questionnaire,
2016,NCT02034968,Progression free survival(PFS),2014-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Objective Response Rate,Adverse events
2017,NCT05458115,Adverse effect,2022-09-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2018,NCT01173250,,na,COMPLETED,INTERVENTIONAL,['NA'],,
2019,NCT01268384,R0 resection rate,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
2020,NCT04000802,MODE-MDT scores,2019-05-23,COMPLETED,OBSERVATIONAL,['NA'],Decision factors,
2021,NCT02828124,Incidence of Laboratory Test Toxicity Grade Shifting From Baseline,2016-08-23,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of Positive Anti-drug Antibody (ADA),
2022,NCT02531620,Number of participants recruiting,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],Bowel Function Assessment,
2023,NCT00576680,Response Rate,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To Determine the Safety and Tolerability of This Drug Combination.,
2024,NCT00560560,Estimate of the 6 Month Survival Probability,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Counts of Circulating Tumor Cells (CTCs),
2025,NCT04993846,Quantitative analysis of the dental plaque microbiome in patients with pancreatic cancer vs. healthy controls and IPMN patients,2021-07-26,UNKNOWN,OBSERVATIONAL,['NA'],Qualitative analysis of OM and periodontal status between the various stages of PC,
2026,NCT04065984,Mean muscle attenuation pre and postoperatively,2019-04-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Sequential CT changes in body composition,
2027,NCT01924624,disease-free survival,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,
2028,NCT05213637,Recurrence-free survival (RFS),2018-04-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events (AE),
2029,NCT05745909,Ileus,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],Quality of life in patients with ostomy,
2030,NCT02888743,Overall response rate,2017-08-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Prognostic effect of T-cell infiltration,Patient reported symptomatic adverse events(AEs)
2031,NCT02011594,PFS (Progression free survival),2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Disease control rate (DCR),
2032,NCT01832467,overall response of re-treatment with cetuximab-based chemotherapy,2013-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],progression-free survival,
2033,NCT00361309,Progression free survival of hepatocellular carcinoma (HCC) patients treated with SU011248.,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
2034,NCT02062632,Change in Mouth Pain as Measured by Average Area Under the Curve Per Assessment,2014-04-14,TERMINATED,INTERVENTIONAL,['PHASE2'],Patient Preference for Continued Therapy at Initial Dose and Crossover,Quality of Life Using European Organization for Research and Treatment of Cancer Quality of Life-Lung Cancer 13 and Functional Assessment of Cancer Therapy-Lung
2035,NCT06304987,AE rate,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],immune-related adverse event rate,
2036,NCT03146637,OS,2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],SRR,
2037,NCT02781285,The influences of traditional Chinese medicine standardized treatment on the overall survival (OS) of patients with advanced gastric cancer by the method of Propensity Score.,2014-12,RECRUITING,OBSERVATIONAL,['NA'],The influences of Western Medicine treatment mainly by chemotherapy on the overall survival (OS) of patients with advanced gastric cancer by the method of Propensity Score.,
2038,NCT06232434,increased survival,2024-02-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",blood chemistry,
2039,NCT02392377,Biological Pathway Perturbation Upon Exposure to Chemotherapy,2015-02,TERMINATED,INTERVENTIONAL,['PHASE2'],Occurrence of Grade 3 or 4 Toxicity Per the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0,
2040,NCT02555501,Lesion size,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2041,NCT02422147,This study will evaluate the clinical outcomes (effectiveness) of all patients with pancreatic cyst lesions undergoing EUS-guided ethanol ablation. This will include complete resolution of the pancreatic cyst lesion at the end of the treatment period.,2016-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
2042,NCT02723578,Progression-free survival,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
2043,NCT02008656,disease-free survival (DFS),2013-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],major adverse events,
2044,NCT04862793,Feedback from CoPS results in change in patient discomfort.,2021-06,UNKNOWN,INTERVENTIONAL,['NA'],Make an immediate measure to assess the quality of individual colonoscopy performance.,
2045,NCT04649671,Improvement of insulin resistance,2021-03-02,TERMINATED,INTERVENTIONAL,['NA'],Adverse events,
2046,NCT01751763,"Treatment pattern of Sorafenib: duration and doses of Sorafenib, dose modification/discontinuation of Sorafenib, concomitant anti-cancer therapy, treatment after observed radiological recurrence.",2013-07-09,COMPLETED,OBSERVATIONAL,['NA'],Time to recurrence (TTR),
2047,NCT00094965,Adverse events.,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor evaluations for response or progressive disease.,
2048,NCT01726296,Percentage of eligible CRC and NSCLC survivors with medical record documentation of compliance with NCCN guidelines,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Change in percentage of eligible survivors with documentation of compliance with NCCN survivorship guidelines after conducting the targeted educational initiative at participating sites,
2049,NCT01889303,Disease free survival,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],feasibility (including adverse events ),
2050,NCT02969473,Overall survival (OS),2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Acute treatment-related toxicities,
2051,NCT02662465,Oral mucositis WHO classification,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],Visual analog scale,
2052,NCT04354246,Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).,2020-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],To characterize the immunogenicity of the Triplet combination (COM902 + COM701 + Pembrolizumab).,Preliminary antitumor activity of the triplet combination (COM902 + COM701 + Pembrolizumab).
2053,NCT00658593,Overall survival,2008-10-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Toxicity,
2054,NCT02437136,Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 2 (Melanoma pre-treated),2015-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to Response (TTR),
2055,NCT05114148,Rate of unacceptable toxicity.,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],Assessment of regional liver function,
2056,NCT05222854,proportion of patients with genomic alterations,2017-10-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],The proportion of patients with actionable genomic alterations in all patients,
2057,NCT05927298,Precision-Matched Treatment Utilization Rate,2023-03-06,RECRUITING,OBSERVATIONAL,['NA'],Correlation of Immune Phenotypes and Molecular Profiles,Genetic and Environmental Factors in Pancreatic Cancer
2058,NCT00400569,Number of Participants With Overall Response (OR),2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious Adverse Events (SAEs),
2059,NCT01896856,Progression Free Survival (PFS),2013-10-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Objective Response Rate,
2060,NCT01575990,Appropriate colorectal cancer screening,2012-03,COMPLETED,INTERVENTIONAL,['NA'],Appropriate screening for stool cards,
2061,NCT01952210,General nutritional status,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Treatment tolerance,
2062,NCT04136769,Feasibility of visceral debranching,2020-02-07,RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
2063,NCT00923052,To study and characterize both quantitatively and qualitatively SOCSC from various primary and metastatic solid organ cancers from time of surgery or other cancer directed therapy to time of recurrence or progression using an exhaustive list of ...,2009-02-09,TERMINATED,OBSERVATIONAL,['NA'],"To determine whether SOCSC are present in the blood and/or bone marrow, and study their quantitative and/or qualitative changes over the course of the disease, from time of initial presentation to time of recurrence and/or metastasis.To sp...",
2064,NCT03213054,Incidence rate of adverse event,2017-07-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],Tumor response,
2065,NCT00508001,Tumour Stabilisation Rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
2066,NCT02833246,objective pill count,2016-06-28,COMPLETED,INTERVENTIONAL,['NA'],,
2067,NCT04979611,Standard uptake value (SUV),2020-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2068,NCT01707121,Length of hospital stay,2012-12,COMPLETED,OBSERVATIONAL,['NA'],Health economic analysis,
2069,NCT01602406,Incidence rate of Dose Limiting Toxicities,2012-09-21,COMPLETED,INTERVENTIONAL,['PHASE1'],Frequency of stable disease according to RECIST,
2070,NCT03407716,Change in general subscale of the Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF),2019-03-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Perceived treatment efficacy as measured by the Subject Global Impression of Change,"Change in inflammation biomarkers (adiponectin, cortisol, IL-6)"
2071,NCT02926040,Change from baseline in HRQol measured by health questionnaire,2016-10,TERMINATED,OBSERVATIONAL,['NA'],,
2072,NCT05582278,Cancer embolism withdraws,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2073,NCT03203837,"Percentage change in angiogenic, inflammatory and immune biomarkers",2017-07-05,TERMINATED,OBSERVATIONAL,['NA'],Treatment Response- Overall Survival,
2074,NCT03233776,"Establish the maximum tolerated dose of anakinra (MTD, 100, 200 or 300 mg).",2017-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Short term overall survival,
2075,NCT03513705,1-year overall survival,2018-05-22,COMPLETED,INTERVENTIONAL,['NA'],Use of smartphone application,Quality of life with Area Under the Curve (AUC) up to 1 year after diagnosis
2076,NCT00405561,Progression free survival;at 18 weeks after registration,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Safety and Tolerability,
2077,NCT00639314,delayed gastric empty after pancreaticoduodenectomy,2005-10,COMPLETED,INTERVENTIONAL,['NA'],"evaluation of quality of life, early and late complications after pancreaticoduodenectomy",
2078,NCT00198081,"Concentration of PGEM in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months",2005-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Clinical Changes in IPMN Progression.,
2079,NCT04307901,Complete mucosal visualization combining incomplete investigations,2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],Patient preference,
2080,NCT03486379,response rate (confirmed complete and partial response).,2016-03,COMPLETED,OBSERVATIONAL,['NA'],Toxicity,
2081,NCT05009069,Percentage of Participants With Pathological Complete Response (pCR),2022-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Adverse Events,
2082,NCT03696472,5-years overall survival rate,2018-12,UNKNOWN,INTERVENTIONAL,['NA'],Recovery time after surgery,
2083,NCT01346410,Local Control Rate,2008-09,COMPLETED,INTERVENTIONAL,['NA'],Late Toxicity Rate,
2084,NCT00546065,recurrence-free survival,2006-08,TERMINATED,INTERVENTIONAL,['NA'],,
2085,NCT01439633,Number of Subjects in Which the Targeted Locations Identified Through OFDI Imaging Correlates With the Biopsies.,2010-10,COMPLETED,INTERVENTIONAL,['NA'],,
2086,NCT02465983,Safety of IV administration of CART-meso-19 with cyclophosphamide as lymphodepleting chemotherapy in patients with pancreatic cancer using the NCI CTCAE v4.03 criteria,2015-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
2087,NCT05017207,Risk factors relate to pancreatic fistula,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],Short-term result in treatment of post-operative pancreatic fistula,
2088,NCT03356535,Hepatocellular Carcinoma,2015-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
2089,NCT02178956,Overall Survival,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Adverse Events,
2090,NCT00263029,Response rate (both clinical and pathological) of the primary rectal cancer observed after the chemoradiotherapy. Histologically confirmed complete resection rate (R0 rate).,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse events collection,
2091,NCT01630239,MR Images,2012-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
2092,NCT04204382,Clinical grade of radioactive oral mucositis,2019-12-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],Recovery time of oral mucositis,
2093,NCT02991196,Dose Escalation Part: Number of Participants with Immune-related Response (per Criteria Modified from RECIST Version 1.1 [irRECIST]),2016-12-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants with Primary Pharmacodynamic (PDy) Effects of the Combination Regimen on Myeloid-Derived Suppressor Cells (MDSCs) and their Subsets in Peripheral Blood,
2094,NCT01493713,Correlation of overall objective responses evaluated by conventional imaging techniques with the morphologic response evaluated by MDCT and the histopathologic response after the resection of hepatic metastases.,2011-11-16,COMPLETED,INTERVENTIONAL,['PHASE4'],Examine the influence of a potential predictive and prognostic tumour biomarker -mutations in K-RAS- after start of therapy on progression free survival,
2095,NCT03048266,Relationship of Serum Global Metabolic Profiles with Subsequent Development of Aggressive PNET,2015-11-05,RECRUITING,OBSERVATIONAL,['NA'],Prospectively Identify Potential miRNA Biomarkers of Serum with miRNA Sequencing in MEN1 Patients Who Have Developed Aggressive PNETs (Cases) and MEN1 Patients Who Have Developed Non-Aggressive PNETs (Controls),
2096,NCT03448835,Incidence of adverse events following treatment (safety),2018-03-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],pathological tumor regression grade,
2097,NCT00255827,"To assess the side effects, dose-limiting toxicity and maximum tolerated dose.",2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To assess the rate of recurrence after treatment.,
2098,NCT04126655,TS inhibition in plasma,2020-02-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2099,NCT01586611,The difference Progression Free Survival (PFS) between Gemcitabine and FOLFOX treated patients in hENT1 high and hENT1 low pancreatic adenocarcinoma.,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],Health-related quality of life (HRQL) parameters in patients with metastatic pancreas adenocarcinoma treated in both treatment arms.,
2100,NCT00679913,Survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Morbidity,
2101,NCT01826396,R0 resection rate,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],disease free survival,adverse reactions
2102,NCT01322152,Rate of Diarrhea,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events as a Measure of Safety and Tolerability,
2103,NCT03594929,"serum AST (unit/L) following liver resection, measured at 24 hours",2016-08-15,UNKNOWN,INTERVENTIONAL,['NA'],Mortality,
2104,NCT01422993,Number of Screened Patients Who Participate and Complete the Study,2011-07,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants With Measured Improvement,
2105,NCT00824161,Percentage of Progression Free Survival,2009-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
2106,NCT04109924,Median progression free survival (PFS),2019-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Aggregate rates of adverse events,
2107,NCT03099382,Overall Survival (OS),2017-05-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2108,NCT00593008,To determine the dosing regimen appropriate for Phase 2 studies of the combination,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],To document objective response rate and progression-free survival in patients treated with this combination,
2109,NCT00629486,cytokine polymorphisms increase risk for hepatocellular carcinoma,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,
2110,NCT03614910,Tumor response,2018-05-15,COMPLETED,OBSERVATIONAL,['NA'],Cancer related pain,
2111,NCT04571710,Objective response rate,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Cmax,
2112,NCT04270500,"Sleep quality by an Actigraphy: ""change"" is being assessed",2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],"Hospital Anxiety and Depression Scale (HADS): ""change"" is being assessed","Weight: ""change"" is being assessed"
2113,NCT01860222,overall survival,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],local tumor progression,
2114,NCT03413904,Conversion to open,2018-03-27,UNKNOWN,INTERVENTIONAL,['NA'],Long-term postoperative complications,
2115,NCT02634645,Overall improvement of patient outcomes in patients treated with endoscopic eradication therapy (EET).,2015-01,RECRUITING,OBSERVATIONAL,['NA'],Median time to recurrence of neoplasia,
2116,NCT03510871,the percentage of subjects with tumor shrinkage after study drug treatment,2019-02-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2117,NCT06098898,Maximal Tolerable Dose,2023-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1'],Overall response rate (ORR),
2118,NCT05358704,Positron emission tomography (PET),2022-05-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Magnetic resonance imaging (MRI),Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
2119,NCT03790059,Tumor-free survival,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,
2120,NCT03861702,Disease Control Rate (DCR),2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of Life Assessment,
2121,NCT01131689,MTD,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2122,NCT01228734,Progression Free Survival (PFS) Time,2010-09-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Subjects With Curative Surgery of Liver Metastases,
2123,NCT05183776,Safety of a fractional administration device for holmium radioembolization,2022-07-12,COMPLETED,INTERVENTIONAL,['NA'],Accurate dosimetry based on MRI and SPECT imaging of holmium-166.,
2124,NCT02428101,"Correlation of single nucleotide polymorphisms of ABCG2 gene (G34A - rs2231137 and A/A -rs3114018 genotypes) with peripheral neuropathy grades, using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE)",2014-11,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
2125,NCT03941873,Phase 2: Objective response rate (ORR),2019-02-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2126,NCT02824484,Change in post-traumatic growth from baseline to post-intervention assessment and at 6 months follow-up. Post-Traumatic Growth Inventory (PTGI) will be used to assess this outcome,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],Change in anxiety and depression from baseline to post-intervention assessment and at 6 months follow-up. Hospital Anxiety and Depression Scale (HADS) will be used to assess this outcome,"Expectancy about change in personal growth as a result of the intervention (Treatment Expectancy, TE)"
2127,NCT01775254,Change in Quality of Life,2013-01,COMPLETED,OBSERVATIONAL,['NA'],Change in Demands of Illness,Psychometric analysis of a modified version of the Neurotoxicity Sub-scale.
2128,NCT00869843,Efficacy of the technique on surface liver tumors using saline lined RF Surface ablation.,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Determine a safe (non-popping upper limit) of power per area that will permit a 1 cm depth of tissue destruction without inflow occlusion and a 2 cm depth with inflow occlusion.,
2129,NCT00503737,"Increase the knowledge of providers as it pertains to current guidelines and strategies about CRCS; assist offices design a CRCS policy, assist offices adopt a CRC reminder system and increase the screening rates of CRC.",2007-09,COMPLETED,INTERVENTIONAL,['NA'],"synthesize information about the strengths and weaknesses of the toolbox from the primary care physician's (PCP) point of view to aid in future development of an interactive, web-based version of the Toolbox.",
2130,NCT04949646,"Change in the quality of life of the patient at 3 months postoperatively, based on the SF-36 questionnaire",2021-09-19,RECRUITING,INTERVENTIONAL,['NA'],"Difference in the low anterior syndrome symptoms of the patient, based on the LARS questionnaire",
2131,NCT06009029,Overall survival (OS),2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
2132,NCT04340986,Overall survival,2020-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Progression time under chemotherapy,
2133,NCT03071198,Disease Free Survival (DFS),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Predictor efficacy of neoadjuvant chemotherapy for DFS,
2134,NCT06203600,Overall survival (OS) (Phase III),2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of adverse events,
2135,NCT00683358,PhaseⅠ; safety (NCI CTCAE v.3) PhaseⅡ；time to progression (RECIST),2008-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Tumor regression(Imaging study, tumor marker, etc.)",
2136,NCT00006221,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2137,NCT01668381,"variation of serum IL-10,TGF-β1,IFN-γ concentration of HCC patients before and 1,4 weeks after radiofrequency ablation therapy",2012-08,UNKNOWN,OBSERVATIONAL,['NA'],"variation of suppression ability of CD4+CD25+ T cells of HCC patients on cytokine secretion before and 1,4 weeks after radiofrequency ablation therapy",
2138,NCT04196465,Major pathologic response rate,2019-09-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Patterns of cancer progression/relapse,Discovery of predictive and/or prognostic biomarkers
2139,NCT03128281,Incidence of Shoulder Pain After Laparoscopic/Robotic Surgery,2018-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
2140,NCT03641118,Skeletal muscle radiation attenuation at L3,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],oxygen uptake at lactate threshold,
2141,NCT03383367,participation rate at future colonoscopy,2017-08-24,UNKNOWN,INTERVENTIONAL,['NA'],Cost-utility analysis of the reminder letter for surveillance colonoscopy,
2142,NCT06135558,DFS,2016-01-30,COMPLETED,OBSERVATIONAL,['NA'],,
2143,NCT00624260,Percentage of patients with a non removable recurrence,2008-06,COMPLETED,INTERVENTIONAL,['NA'],Cost of the strategy,
2144,NCT04920955,Specificity for relapse detection,2021-02-10,COMPLETED,OBSERVATIONAL,['NA'],Sensitivity for CRC detection,
2145,NCT04066491,Double-blind Part: Overall Survival,2019-09-20,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Double-blind Part: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), Treatment Related TEAEs and Adverse Events of Special Interest (AESIs) According to NCI-CTCAE Version 5.0",
2146,NCT06221423,Overall Survival (OS),2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
2147,NCT04275986,Adverse events (AE),2020-01-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of Life (QOL): questionnaires,
2148,NCT00126256,"Progression-free survival after two lines of chemotherapy, defined as the time duration from randomization until progression after two lines of chemotherapy or death whatever the cause in the absence of progression or last-follow-up",2002-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Costs,
2149,NCT01398449,Overall survival,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],Failure pattern,
2150,NCT02153450,Dose-limiting toxicity (DLT) rate scored according to the National Cancer Institute Common Toxicity Criteria version 4,2015-05-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Overall survival,
2151,NCT03694522,Progression-Free Survival (PFS),2018-09-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment-emergent Adverse Events (TEAEs),
2152,NCT05786482,Hospital Anxiety and Depression Scale (HADS),2023-02-12,RECRUITING,INTERVENTIONAL,['NA'],Satisfaction and Adherence,Sleep (Exploratory)
2153,NCT04780802,The change in the perfusion pattern of HCC tumors,2022-05-01,COMPLETED,INTERVENTIONAL,['NA'],Tumor response,
2154,NCT02871115,Rates of study enrollment,2017-01,COMPLETED,INTERVENTIONAL,['NA'],Rates Of Appropriate Influenza Vaccinations,
2155,NCT05412589,ORR,2022-06-10,RECRUITING,INTERVENTIONAL,['PHASE2'],TRAE,
2156,NCT02363374,"Number of patients with pathological complete response (pCR), i.e. ypT0N0.",2015-03-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
2157,NCT00052507,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2158,NCT01486745,,2008-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
2159,NCT02024217,R0 resection rate,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],safety and tolerability of the treatment regimen,over-all survival
2160,NCT05234177,Recurrence-Free Survival,2022-06-21,RECRUITING,OBSERVATIONAL,['NA'],Positive Predictive Value,Lead Time
2161,NCT00336609,,2005-11,UNKNOWN,OBSERVATIONAL,['NA'],,
2162,NCT03820921,Feasibility of MMR status analysis on EUS-FNB pancreatic specimens,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Progression-free survival,
2163,NCT04831827,Primary Endpoint (intention-to-treat),2021-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],Secondary Outcome (per protocol analysis),
2164,NCT02159898,Mellow and Pinkas Dysphagia Score at Baseline and 2 Weeks Following the Treatment,2015-01,COMPLETED,INTERVENTIONAL,['NA'],GERD-HRQL,
2165,NCT03988556,Rate of discontinuation due to AEs,2019-07-04,COMPLETED,INTERVENTIONAL,['NA'],Oral mucosa lesions assessment - Time until resolution,Use of the device - Cumulative dose
2166,NCT00068380,"Baseline Gene Expression Levels of the Target Genes (PDGF-R and PDGF), Genes Associated With Induction of Apoptosis (Bcl-2, Bax), and Cell Cycle Regulatory Genes (p53, p21, p27",2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2167,NCT01943786,To estimate the proportion of patients with advanced colorectal cancer in whom KRAS mutation can be detected in circulating extracellular DNA,2013-04,UNKNOWN,OBSERVATIONAL,['NA'],Number of each adverse event per cycle,
2168,NCT06158919,PFS,2023-11-20,RECRUITING,INTERVENTIONAL,['NA'],OS,
2169,NCT03348150,overall survival,2017-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],costs and health benefits,
2170,NCT02981524,Objective Response Rate (ORR),2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response (DOR),
2171,NCT00589030,,2007-04,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
2172,NCT00215956,Side Effect Profile of Topotecan,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Response Rate,
2173,NCT02449135,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
2174,NCT05451849,Phase 2 - Disease Control Rate (DCR),2022-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2175,NCT02498353,pathological complete remission rate,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],toxicity of radiotherapy based on the CTCAE v3.0 (common terminology criteria for adverse events，CTCAE v3.0),
2176,NCT00154531,,2004-08,UNKNOWN,OBSERVATIONAL,['NA'],,
2177,NCT04121273,Number of patient with dose limiting toxicity,2019-10-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],Number of Peripheral CAR-T cell,
2178,NCT02328664,Sensitivity of biopsies for residual cancer,2015-08,TERMINATED,INTERVENTIONAL,['NA'],The proportion of patients with residual cancer in the resected specimen if malignancy was unsuspected during the endoscopic polypectomy,
2179,NCT05352165,Pathologic Complete Response,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],anus-saving rate,
2180,NCT01955837,Overall Survival（OS）,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression-free Survival (PFS) (Mutant Type KRAS),
2181,NCT00025168,,2001-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2182,NCT00971841,Number of Adverse Events (AEs) Per Participant,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Complete Response to Tumor,
2183,NCT02774447,Number of patients who were able to return home after day-case closure of loop-ileostomy,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,
2184,NCT04262609,faecal incontinence after prostate radiation therapy,2019-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Quality of life after prostate radiation therapy,
2185,NCT05672524,Clinical complete response of study participants,2022-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2186,NCT00602602,Progression-free survival,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of potentially resectable patients who are able to proceed to successful resection,
2187,NCT04104074,Incidence of treatment-emergent adverse events,2019-11-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
2188,NCT02356471,Number of Patients Who Self-report Wearing the Consumer-based Activity Monitor at Least 16 Days of the 21 Day Period,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Change in Fatigue Assessment- Fatigue Visual Analog Scale (FVAS).,
2189,NCT00508404,Objective Response Rate,2007-05-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Resection Rate,
2190,NCT02060669,Progression free survival,2010-06-20,TERMINATED,INTERVENTIONAL,['PHASE3'],,
2191,NCT00538850,Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30),2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing,
2192,NCT03061435,Prevalence of abnormal anal cytology and hrHPV DNA in women with VIN 2/3 or vulvar cancer,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA'],"Assess t he correlation between abnormal anal cytology, hrHPV DNA, and AIN",
2193,NCT01160419,Collection of the R0-Resection rate,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2194,NCT03156777,Number of circulating tumor cell (CTC),2016-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,
2195,NCT02852525,Sensitivity and Specificity of probe based endomicroscopy as compared to histopathology in diagnosing Barrett's metaplasia,2014-02,COMPLETED,INTERVENTIONAL,['NA'],Tissue and blood Biomarker evaluation in targeted biopsies obtained at endomicroscopy in patients diagnosed to have Barrett's metaplasia and dysplasia,
2196,NCT05394246,Tumor lesions,2022-05-20,RECRUITING,INTERVENTIONAL,['NA'],,
2197,NCT01003808,"To evaluate the maximum tolerated dose, dose-limiting toxicities, type/frequency/degree of adverse events and NY-ESO-1 antigen-specific immune response of IMF-001 alone in patients with esophageal cancer.",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],To evaluate clinical activity (tumor response and time to progression).,
2198,NCT03413436,overall survival,2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE4'],toxicities of adjuvant chemotherapy,
2199,NCT05727852,Indicators of arterial stiffness,2023-01-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Composite of clinical records,
2200,NCT05092373,"To assess the safety and tolerability of TTF, including the maximum tolerated dose (MTD).",2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE1'],"To assess the objective response rate, progression-free survival and overall survival",
2201,NCT01790633,Accessibility of Testing Results,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Access to Care,Proportion of Rapid Test Failures
2202,NCT03147768,PRIMARY EFFICACY AS A SEALANT: Intra-operative blood loss,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE1'],SECONDARY SAFETY: Surgical space abscess,SECONDARY EFFICACY: Total hospital stay (Duration and cost Metric )
2203,NCT01434147,occurence of toxicity,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],post-surgery morbidity,
2204,NCT04780256,recurrence rate,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA'],costs,
2205,NCT03444051,pancreatic mass anatomopathological characterization,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
2206,NCT03255343,size of tumor,2017-03-13,UNKNOWN,INTERVENTIONAL,['NA'],HPFS,
2207,NCT02563054,Time to disease progression,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Incidence of adverse events,
2208,NCT01374425,PFS According to RECIST Version 1.1 in Participants With High Vascular Endothelial Growth Factor (VEGF)-A Levels Versus Participants With Low VEGF-A Levels,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Complete Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels,
2209,NCT05215574,Incidence of Adverse Events,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of Patients with Objective Responses,
2210,NCT03415919,confirmation of diagnosis by pathologist,2018-07-13,UNKNOWN,OBSERVATIONAL,['NA'],,
2211,NCT02317731,Bowel preparation quality,2014-12,TERMINATED,INTERVENTIONAL,['NA'],Tolerability will be measured by subjective survey including a 5-point scale and a visual analog scale filled by the subjects the day of the colonoscopy,
2212,NCT05379985,Number of Participants with Dose-Limiting Toxicity (DLT),2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-Free Survival (PFS),
2213,NCT02106884,QOL Global Health Status Deterioration-free Median Survival,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Laboratory Safety Assessment,
2214,NCT00040599,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2215,NCT01516489,FOBT completion and return,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",FOBT completion rate among previously non-adherent patients and FOBT kit return time by arm,
2216,NCT06034964,OS,2020-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Safety and Tolerability,
2217,NCT04992143,1-year survival rate,2021-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease control rate,
2218,NCT00749450,3-year disease-free survival,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],"Quality of life as assessed by EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and GOG Ntx4",
2219,NCT06308328,The AUC of the predictive model,2024-04-01,RECRUITING,OBSERVATIONAL,['NA'],The important predictors of severe oropharyngeal mucositis in the predictive model,
2220,NCT01444495,local and systemic recurrence rate,1999-01,COMPLETED,INTERVENTIONAL,['NA'],downstaging of rectal cancer,
2221,NCT00004931,DFS rate,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Survival rate,
2222,NCT04319757,Phase Ib/II starting dose for ACE1702,2020-05-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluate immune function after administering ACE1702,"Shift in serum tumor marker values (CA-125, CA 19-9, and CEA levels, in applicable tumor types)"
2223,NCT03928652,Tumor regression grade,2019-04-24,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,
2224,NCT06201065,Overall Survival (OS),2023-12-26,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse Events,
2225,NCT03190941,Frequency and severity of treatment-related adverse events,2017-09-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2226,NCT02139475,Boston bowel preparation scale (BBPS),2013-12,TERMINATED,OBSERVATIONAL,['NA'],,
2227,NCT02213497,Number of Adverse Events,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
2228,NCT03192618,Disease-free survival (DFS),2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall survival (OS),
2229,NCT04175912,Objective response rate,2020-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,Specimen banking
2230,NCT01739465,stent patency,2012-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",overall survival rate,
2231,NCT01217060,Pathologic Complete Response (PCR) Rate,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease-free Survival (DFS) Time,
2232,NCT00832689,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2233,NCT05154474,Rate of patients with sarcopenia diagnosed with metastatic cancer.,2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Rate of patients with sarcopenia at diagnosis across the inclusive population,
2234,NCT02962063,pathologic complete response rate,2016-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",overall survival (OS),
2235,NCT01192971,TTP (Time to Progression),2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],QoL (quality of life): EORTC QLQ-C30,
2236,NCT05704192,Overall Survival(OS),2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],Progression free survival(PFS) per mRECIST,
2237,NCT01418729,Overall survival,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],time to symptomatic progression (TTSP).,
2238,NCT02840331,Peritoneal metastases in terms of location,2017-07-31,UNKNOWN,INTERVENTIONAL,['PHASE3'],Histological evidence of apoptosis,
2239,NCT00510692,Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum.,2006-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Number of Subjects With Adverse Events.,
2240,NCT02640586,Predictive value of preoperative MRI(7-9 weeks after the completion of preoperative chemo-radiotherapy) for assessing pCR,2016-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Predictive value of preoperative MRI(7-9 weeks after the completion of preoperative chemo-radiotherapy) for assessing pathological response according to Tumour Regression Grade (TRG),
2241,NCT06100692,oral mucositis scale,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2242,NCT03724591,Anastomosis leakage rate,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire,
2243,NCT03329183,Objective Response Rate(ORR),2019-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),
2244,NCT03577535,Oral mucositis grade in patients during chemotherapy and radiotherapy treatments,2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Nutritional status of the patients during Chemotherapy and radiotherapy treatments,
2245,NCT02412579,Using next-generation sequencing methods to detect isomiRs across different HCC cohorts at all stages undergoing liver transplantation.,2015-03,COMPLETED,OBSERVATIONAL,['NA'],,
2246,NCT00158886,To determine the MTD of oral topotecan in combination with pelvic radiation,2001-11-08,TERMINATED,INTERVENTIONAL,['PHASE1'],To evaluate the toxicity and potential efficacy of oral topotecan and concurrent pelvic radiation for the treatment of rectal cancer. To determine pathologic response to treatment and assessment of sphincter preservation.,
2247,NCT02971345,Overall Survival,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Time To Progression,
2248,NCT02033070,Endoscopic clearance rate for Barrett's Esophagus,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],Histological clearance rate for intestinal metaplasia,Histological clearance rate for dysplasia
2249,NCT01141478,Overall Survival Rate Between Time of Consent and Time of Death,2010-09-08,TERMINATED,INTERVENTIONAL,['NA'],,
2250,NCT02406118,TME quality & circumferential resection margin (CRM),2015-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of harvested Lymph Nodes,5-year overall survival
2251,NCT00284258,Progression free survival,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Over all survival, Response rate, Adverse event, Medical economy",
2252,NCT02524925,"Analyzing Neuropeptide Y, Cortisol and Adrenocorticotropic hormones levels in blood samples",2012-04,COMPLETED,INTERVENTIONAL,['NA'],Evaluating postoperative pain between the two protocols with scale,
2253,NCT02426034,"Safety, which was assessed by recording the incidence and severity of adverse events",2015-05-15,COMPLETED,INTERVENTIONAL,['PHASE4'],"Quality of life, measured by the questionnaire of EORTC QLQ-C30",
2254,NCT04280640,Correlation between treatment response in CTCs and in vivo,2021-06,WITHDRAWN,OBSERVATIONAL,['NA'],"Sensitivity, specificity, and predictive values of CTC cultures' treatment response",
2255,NCT03107650,Evaluation of the circumferential margin status in the rectal specimen according international consensus (positive margin if tumor ≤ 1mm from circumferential margin),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],Survival,
2256,NCT04729855,HOTTIP gene expression,2022-04-15,UNKNOWN,OBSERVATIONAL,['NA'],EIF4EBP,
2257,NCT03753789,Percentage of Lesions Where Re-ablation is Suggested,2019-11-05,TERMINATED,INTERVENTIONAL,['NA'],Hospital Resource Utilization,
2258,NCT04755452,Surgical rating scale,2020-12-23,COMPLETED,INTERVENTIONAL,['NA'],"Other Kidney injury markers, include; TFF,VEGF, Osteoactivin, Clusterin, and Calbindin",
2259,NCT05039060,The change of gut microbiota diversity,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA'],The change of gut microbiota metabolite,
2260,NCT00538291,Response Rate,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2261,NCT01868139,Response Rate to Therapy,2013-06,TERMINATED,INTERVENTIONAL,['NA'],Safety of Spray Cryotherapy in This Setting;,
2262,NCT02018757,time to progression,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Proportion of Participants with Adverse Events,
2263,NCT00025246,Determination whether patients with completely resected high-risk primary GIST who undergo adjuvant treatment with imatinib mesylate have prolonged survival compared to historical controls,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Toxicities, graded according to the National Cancer Institute Common Toxicity Criteria",
2264,NCT00470184,Complete Response,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life Improved Rate,
2265,NCT04717947,Quality of the specimen,2020-02-25,UNKNOWN,OBSERVATIONAL,['NA'],,
2266,NCT02538341,GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Enzyme-linked Immune Absorbent Spot (ELISpot) Interferon Gamma (IFNg) Levels From Baseline at 6 Weeks,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate Rheumatoid Arthritis Disease Activity Using the Clinical Disease Activity Index (CDAI),
2267,NCT03637686,Patients with high risk of recurrence can be identified with ctDNA profiling performed immediately after treatment for CRC.,2018-06-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Can ctDNA detect recurrence earlier than standard-of-care?,
2268,NCT01289821,Objective Response (OR),2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Stable Disease (DOSD),
2269,NCT00004087,maximum tolerated dose,1997-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2270,NCT05109130,Change of circulating tumor cells during laparoscopic or transanal endoscopic surgery,2021-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Disease free survival,
2271,NCT06335654,high confidence diagnosis rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2272,NCT02698462,Diagnostic yield,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Positive predictive value,Comparison of diagnostic yield in detecting advanced neoplasia of FIT with the national CRC screening yield
2273,NCT01046487,For safety: NCI-CTCAE scale version 3.0,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],For anti tumoral efficiency : RECIST criteria,
2274,NCT00003307,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2275,NCT01313416,"Toxicity Evaluation: From Time of First Treatment With CT-011 (Pidilizumab, MDV9300)",2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Disease Response: Evaluated Using the Revised Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines (v1.1),
2276,NCT01333709,Ro resection rate,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of metastases,
2277,NCT00741481,compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by time to disease progression,2006-06,COMPLETED,OBSERVATIONAL,['NA'],compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by tumour response rate following RECIST criteria.,
2278,NCT00453323,To evaluate the response rate,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],To estimate the overall survival,
2279,NCT05984576,Local control,2023-06-21,RECRUITING,OBSERVATIONAL,['NA'],,
2280,NCT05646355,Number of Participants who Completed Colonoscopy at 6 Months,2023-03-15,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants with Positive FIT Test who Complete Colonoscopy at 6 Months,
2281,NCT06282809,Evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
2282,NCT03978078,Number of biological risk factors for metastatic digestive cancer,2016-09-12,RECRUITING,INTERVENTIONAL,['NA'],,
2283,NCT05964543,Objective response rate (ORR),2023-06-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival (PFS),
2284,NCT04694521,intestinal function,2016-09,COMPLETED,INTERVENTIONAL,['NA'],the overall postoperative morbidities,
2285,NCT02802124,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2015-06,TERMINATED,INTERVENTIONAL,['NA'],Number of participants with tumor response as assessed by RECIST 1.1,
2286,NCT02514525,percentage of all treated patients who have complete eradication of all dysplasia (CE-D),2016-03,UNKNOWN,INTERVENTIONAL,['NA'],Number of CryoBalloon ablation treatments required to achieve CE-D or CE-IM,
2287,NCT04924075,Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR),2021-08-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to Surgery (TTS),
2288,NCT03640208,Difference in paired pre-/post-test score,2019-02-27,RECRUITING,INTERVENTIONAL,['NA'],Barriers faced to scheduling colorectal cancer screening,
2289,NCT02325232,Identification of celiac patients at higher risk of developing small bowel neoplasia and evaluation of the the usefulness of VCE and DBE,2012-02,UNKNOWN,INTERVENTIONAL,['NA'],The diagnostic yeld of DBE and VCE in this setting of patients,A flowchart for early diagnosis of small bowel tumors in CD patients
2290,NCT00003076,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2291,NCT00515931,Target tumor response rate,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse effects of radiation therapy,
2292,NCT05040464,Variation of the endoscopic response between AZA and MTX groups,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,
2293,NCT04360577,Total AUC of FACT-Gastric TOI,2020-05-27,RECRUITING,INTERVENTIONAL,['NA'],Average trajectory of Modified Edmonton Symptom Assessment Scale,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
2294,NCT03174405,Progression Free Survival Rate (PFS) @ 12 months,2017-07-17,COMPLETED,INTERVENTIONAL,['PHASE2'],Translational research,
2295,NCT01763125,Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.,2003-11,RECRUITING,OBSERVATIONAL,['NA'],,
2296,NCT05568316,Biochemical Measurements,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],Lenght of Hospital Stay of Participants,
2297,NCT03116152,Overall Survival,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response,
2298,NCT04585919,Conditional Odds Ratio of Patients Screened for Social Needs During Intervention Compared to Patients Screened During Usual Care,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],Number of Reminders Per FIT Return,
2299,NCT05092880,progression-free survival,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Cost-effectiveness: Productivity Cost Questionnaire (PCQ),
2300,NCT00083720,Number of Participants With Serious Adverse Events,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
2301,NCT04053231,Overall Survival,2019-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Number of redo-surgery,
2302,NCT04711434,The percentage of patients from randomization to the first appearance of one of the following: adenomatous polyps or second primary tumors,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall Survival,
2303,NCT02316028,toxicity of escalating doses of decitabine administered by HAI,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",measuring Global DNA methylation of cell free DNA,
2304,NCT01939223,Disease Free Survival (DFS) as Assessed by the Investigator,2013-12-02,TERMINATED,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),
2305,NCT05035381,Objective response rate,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events,
2306,NCT05174845,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2021-10-01,COMPLETED,OBSERVATIONAL,['NA'],Sub-analyzes of the primary and secondary outcomes,
2307,NCT00179751,"Phase II-To explore the anti-tumor activity of the combination of lenalidomide on days 1 - 21 and gemcitabine days 1, 8, and 15 every 28 days in subjects with advanced pancreatic carcinoma.",2005-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II-To evaluate the safety profile of the combination of lenalidomide and gemcitabine as combination therapy in subjects with advanced pancreatic carcinoma.,
2308,NCT02804802,Colorectal cancer diagnosed by colonoscopy after a positive fecal occult blood test (Hemoccult II),2013-02,UNKNOWN,OBSERVATIONAL,['NA'],,
2309,NCT05662813,Objective response rate,2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
2310,NCT00411450,Time to Response,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Who Developed Antibodies to Panitumumab,
2311,NCT06190652,PFS,2018-10-13,COMPLETED,OBSERVATIONAL,['NA'],RP,
2312,NCT03977272,Overall survival,2019-03-27,COMPLETED,INTERVENTIONAL,['PHASE2'],EORTC QLQ - PAN26 score,
2313,NCT04178759,Volume of regenerated liver after liver resection,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],Evaluation of short term surgical outcomes,
2314,NCT03813953,Overall survival in months,2019-02-20,UNKNOWN,INTERVENTIONAL,['NA'],Disease free survival,
2315,NCT00843830,"The Percentage of Participants That Patients Complete Radiation Therapy, All Three Vaccinations, and Evaluation for Tumor Response Four Weeks After the Third Vaccination.",2006-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Patients That Respond to Treatment,
2316,NCT05634525,Overall survival (OS),2023-05-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2317,NCT02916511,Local control rate,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival,
2318,NCT03275974,Change in tumor size,2021-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,
2319,NCT00540943,The safety and tolerability of the maximum tolerated dose defined as a dose regimen where no more than 1 of 6 subjects experiences a dose limiting toxicity.,2007-07-13,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to progression,
2320,NCT05713903,Mesocolic Resection Plane,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],Overall Survival,
2321,NCT01189227,Recurrence-free Survival (RFS),2010-08,TERMINATED,INTERVENTIONAL,['PHASE3'],Frequencies of Adverse Events as Assessed by the NCI CTCAE v4.0,
2322,NCT01054274,Overall survival and Median Survival,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Successful rate of stent placement,
2323,NCT06289803,diagnostic efficacy,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],Rate of R0 resection,
2324,NCT01590147,"Feasibility of implementing a YST among patients undergoing chemotherapy (participating rate, adherence, and retention)",2011-06,COMPLETED,INTERVENTIONAL,['NA'],"Mediating variables (self efficacy, response expectancies, inflammatory biomarkers) intervention effect on fatigue, treatment-related symptoms, and QOL",
2325,NCT02535988,The proportion of patients with an abscopal response assessed at 7-8 weeks after the initiation of treatment.,2015-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"The proportion of patients alive with abscopal responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study.",
2326,NCT01804179,Rate of Test Kit Completion,2011-02-11,COMPLETED,INTERVENTIONAL,['NA'],Time to Kit Return,
2327,NCT00168987,improvement of quality of life at two months,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],"improvement of nutritional state (body weight, muscle mass, body cell mass, phase angle, serum albumin)",
2328,NCT06328738,Incidence of electrocardiogram abnormalities,2024-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Brain metastases response (Phase 1b only),
2329,NCT03500874,3 Year Relapse Free Survival Rate,2018-05-28,TERMINATED,INTERVENTIONAL,['PHASE3'],Liver-specific RFS,Serum ctDNA methylation levels
2330,NCT04523493,Overall survival (OS),2020-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Immunogenicity,Tumor mutation burden (TMB)
2331,NCT03459339,Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy,2017-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
2332,NCT03093870,Progression-free Survival (PFS) - Part 1,2017-07-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",ECOG Performance Status - Part 1,
2333,NCT01839773,Progression Free Survival (PFS),2013-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety,
2334,NCT02948985,Correlation of RAS status on CTCs with clinical outcomes,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],Correlation of mutant gene in ctDNA with cetuximab resistance.,
2335,NCT03197155,Hepatocellular recurrence event,2016-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
2336,NCT04430179,Change in Lund-Mackay sinus computed tomography (LMK-CT) score,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in biomarkers concentrations in nasal secretion measured by enzyme-linked immunosorbent assay (ELISA),
2337,NCT04517448,Change in the response scores to the standardized questionnaire Quality of life questionnaire in cancer patient,2020-10-16,UNKNOWN,OBSERVATIONAL,['NA'],Change in the Activity of daily living score,
2338,NCT06016829,EORTC-QLQ-CR29,2021-07-25,COMPLETED,OBSERVATIONAL,['NA'],,
2339,NCT02515344,Patient participation rate to colorectal cancer screening,2015-08,COMPLETED,INTERVENTIONAL,['NA'],Number of cancers screened in (versus diagnosed outside) the screening procedure.,
2340,NCT05771584,Immunologic efficacy of AST-301 immunization,2023-07-04,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in central memory T-cell populations between Arm 1 and Arm 2,
2341,NCT05116917,Objective response rate (ORR),2021-11-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events as assessed by CTCAE v5.0,
2342,NCT00087074,"Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart",2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to treatment failure,
2343,NCT03750461,Number of Participants With Wound Occurrences in Current Study Compared to Historical Controls,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],Quality of Life After Mesh Implantation,
2344,NCT00183885,Tumor Response,2004-10-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of participants with grade 3 or higher toxicity,
2345,NCT01086618,Overall survival for ≥ 2 years (phase III),2010-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Economic evaluation (phase III),
2346,NCT05262855,"Performance [sensitivity, specificity, accuracy] of [68Ga]FAPI-46 PET imaging to detect FAP-expressing cells, using histopathology as truth standard.",2022-05-02,RECRUITING,INTERVENTIONAL,['PHASE2'],[68Ga]FAPI-46 accumulation observed by (PET)/ (CT) pre and post in patients undergoing Neoadjuvant treatment.,
2347,NCT04140435,The increment in diagnostic yield,2019-10-22,RECRUITING,OBSERVATIONAL,['NA'],The inter-observer agreement,
2348,NCT05220722,Phase 2: To Assess Overall Response Rate (ORR),2022-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: To Assess Overall Survival (OS),
2349,NCT05861505,Overall survival (OS) per patient,2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE3'],Cost-effectiveness ratio (ICER),
2350,NCT00598546,"Instrument: EORTC QLQ-C30, QLQ-STO22, and MSK-10. The intent of this study is to assess QOL in long-term survivors of all surgical procedures performed for the treatment of gastric cancer.",2004-09,COMPLETED,OBSERVATIONAL,['NA'],,
2351,NCT03015675,Progression Free Survival,2017-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Response Rate,
2352,NCT03045770,Adverse Event（AE）,2017-02-10,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life (QoL),
2353,NCT00795977,To establish the maximally tolerated dose (MTD) and dose limiting toxicities (DLT) of intratumoral autologous dendritic cell vaccination in combination with OK-432,2003-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To evaluate the immune response of patients treated with this regimen based on the presence and characterization of tumor-infiltrating white blood cells,
2354,NCT00132704,apoptotic response,2004-08,COMPLETED,OBSERVATIONAL,['NA'],,
2355,NCT02850783,Identification rate of SLNM with preoperative PET/CT imaging and intraoperative NIR fluorescence imaging in patients with colon carcinoma.,2015-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
2356,NCT06193356,Performance of detecting a recurrence at an endoscopic resection scar.,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Performance of a learning tool in improving detection of recurrence at an endoscopic resection scar compared between endoscopists with different experience level,
2357,NCT04649372,Incidence of Treatment-Emergent Adverse Events (CTCAE),2021-01-13,COMPLETED,INTERVENTIONAL,['NA'],Evaluation of Pain pre and post-treatment,
2358,NCT03362177,Incidence of a Thrombocytopenia-induced chemotherapy dose modification during the second or third on study chemotherapy cycles.,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],AEs/SAEs overall safety of romiplostim,
2359,NCT06202716,Progression-free Survival (PFS),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety,
2360,NCT03804255,"Factors influencing heterogeneity of capacity for biomarker testing, from among modifiable testing practice-related factors, e.g. cost, complexity, technologic complexity, lack of familiarity, physician and patient demand",2019-01-08,WITHDRAWN,OBSERVATIONAL,['NA'],Proportion of pathology practices testing for novel biomarkers using a standard reflexive testing protocol,
2361,NCT01416038,Number of reported adverse events,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Levels of cell mediated immunity targeting the survivin epitopes,
2362,NCT01048892,Recommended phase II dose of Seneca Valley virus-001 (NTX-010),2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Development of antibodies to NTX-010,
2363,NCT04965259,Changes in the profile of metabolome in urine and plasma as high-risk patients develop HCC.,2021-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
2364,NCT04387903,Tumor recurrence,2000-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Risk factors for surgical reoperation,
2365,NCT05103631,Number of Patients with Dose Limiting Toxicity,2021-06-17,RECRUITING,INTERVENTIONAL,['PHASE1'],Median T cell persistence,
2366,NCT00873600,"Chemotherapy tolerability as measured by dose reduction, treatment delay, and incidence of grade 3-5 toxicities",2007-10,WITHDRAWN,OBSERVATIONAL,['NA'],3-year disease-free survival,
2367,NCT04288999,Locally recurrent free survival,2019-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],QOL,
2368,NCT00054249,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2369,NCT03461354,AUC for the Oral Mucositis Daily Questionnaire mouth and throat soreness question #2,2018-04-09,RECRUITING,INTERVENTIONAL,['NA'],Oral mucositis grade,Drug-related adverse events
2370,NCT00343408,,2005-11-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2371,NCT03110510,Overall Overall Response Rate,2019-09-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival,
2372,NCT05400408,identification of Volatile Organic Compounds that can be related to Colorectal malignancy.,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Test Sensitivity and specificity for pancreatic cancer.,
2373,NCT06295094,Peritoneal disease-free survival,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of patients not receiving adjuvant chemotherapy,
2374,NCT01379872,"Synthesise the data obtained for objectives 1-3 together with information from previous studies and expert opinion to estimate the safety, clinical efficacy and cost-effectiveness of new technologies compared to conventional standards",2011-06,COMPLETED,OBSERVATIONAL,['NA'],,
2375,NCT01774643,"Engraftment rate compared to clinical data (response to treatment, disease-free survival, overall survival)",2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
2376,NCT00002575,Overall survival,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Compare the differences in quality of life of patients treated with these regimens,
2377,NCT04546802,Viral eradication,2019-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Adverse events,Overall survival
2378,NCT04907643,Patient-Reported Outcomes Measurement Information System Gastrointestinal Belly Pain over 30 days from the baseline,2021-10-05,RECRUITING,INTERVENTIONAL,['NA'],Opioid prescriptions of Morphine Milligram Equivalents (MME),Dosage of VR (minutes per week)
2379,NCT03193216,Percentage of Patients With Successful Eradication,2017-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Treatments (Mean),
2380,NCT00550836,Overall Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency and Severity of Observed Adverse Effects,
2381,NCT00138060,tumor response rate,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4'],pharmacokinetics,
2382,NCT01661972,Median Progression Free Survival (PFS),2012-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median Survival,
2383,NCT05848154,Objective response rate (ORR) of neoadjuvant therapy in patients with non-metastatic pancreatic cancer,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The mechanisms of drug resistance to neoadjuvant chemotherapy,
2384,NCT00220129,2 year overall survival,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to improvement of dysphagia,
2385,NCT05066139,Impact of EPODIG-G program on treatment.,2021-09-17,RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
2386,NCT03740165,PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants,2018-12-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Pathological Complete Response (pCR) Rate,
2387,NCT03306394,Abnormalities in vital signs,2016-10-18,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of life using the questionnaire EORTC QLQ-C30,
2388,NCT05410535,The survival rate of gastric cancer,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE4'],,
2389,NCT04316182,Rate of AEs leading to treatment discontinuation,2020-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],Rate of patients who develop new extra-hepatic spread,
2390,NCT05248750,Overall survival,2021-07-22,RECRUITING,OBSERVATIONAL,['NA'],,
2391,NCT01980407,Response rate,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease control rate,
2392,NCT00767936,identify mutations in the hepatitis B virus genome that predisposes these high risk individuals to the development of liver cancer,2008-03,TERMINATED,OBSERVATIONAL,['NA'],,
2393,NCT03011255,Local control,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
2394,NCT02729493,Disease control rates,2015-11-14,UNKNOWN,INTERVENTIONAL,['NA'],,
2395,NCT00362739,Establish a set of normal ranges for various parameters in healthy individual specimens and compare to specimens from individuals with lung disease to determine parameters resulting in disease susceptibility and severity.,2005-09,COMPLETED,OBSERVATIONAL,['NA'],,
2396,NCT02298959,Recommended combination dose of ziv-aflibercept and pembrolizumab,2015-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Time-to-progression,Effects on tumor vasculature and vascular active molecules
2397,NCT06060769,HCC incidence rate,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
2398,NCT05380414,"Number of patients with at least one actionable alteration defined as an alteration shown to predict for sensitivity to a drug FDA/EMA approved for use in another cancer type, or a relevant alteration for inclusion in a clinical trial.",2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],Duration of response (DoR),
2399,NCT01675258,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
2400,NCT03896646,Tumor objective response rate (ORR),2019-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Development of a model correlating normal liver radiation dose to liver function using single-photon emission computed tomography computed tomography hepatobiliary iminodiacetic acid (SPECT CT HIDA) imaging,
2401,NCT05962723,"sensitivity, specificity and accuracy",2023-08-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2402,NCT02293811,Analysis of expression of P2RX7,2015-02-09,TERMINATED,INTERVENTIONAL,['NA'],Five isoforms of the P2RX7 protein,
2403,NCT01197118,overall survival,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2404,NCT03929094,Progression Free Survival,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
2405,NCT04410601,Evaluation of Dysphagia- Esophago-gastro-duodenoscopy (EGD),2020-05-14,UNKNOWN,INTERVENTIONAL,['NA'],Evaluation of Standard Dysphagia Rehabilitation,
2406,NCT00815087,The Change From Baseline and Cut Point VFSS in Velocity of Displacement of Hyoid Bone at 1 to 3 Months,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Questionnaire of Life Quality,
2407,NCT05493995,Disease Control Rate (DCR),2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-free survival (PFS),
2408,NCT03960021,Immune response triggered by RFA: Quantification of interaction of PD-1 and PD-L1 in lung metastases using immune Förster Resonance Energy Transfer (iFRET).,2019-03-04,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline metastatic disease at 12 months,
2409,NCT01483040,The primary endpoint is reaching the cecum of the colon with PeerScope B S,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
2410,NCT06189482,Body Mass Index,2022-06-01,TERMINATED,INTERVENTIONAL,['NA'],Penetration-Aspiration Scale,
2411,NCT02150733,Composite of plasma pharmacokinetic parameters of Tivantinib,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Composite of plasma pharmacokinetic parameters of Tivantinib metabolites,
2412,NCT06155383,Pathological complete response (pCR) rate,2023-11-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
2413,NCT02368236,"Participation in risk-appropriate colorectal cancer testing (i.e., participation in any CRIS-recommended test based on patients' risk factors).",2008-12,COMPLETED,INTERVENTIONAL,['NA'],Testing difference in receipt of any type of colorectal cancer testing.,
2414,NCT05751850,Overall survival (OS),2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE3'],Progression free survival (PFS),
2415,NCT01715363,Clinical tolerance of immediate preoperative chemotherapy,2012-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2416,NCT05074589,Overall Survival(OS),2018-01-25,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of life（QoL）,
2417,NCT01923948,Postoperative Opioid Consumption,2013-05,COMPLETED,INTERVENTIONAL,['NA'],Postoperative Pain Scores on the Visual Analog Scale,
2418,NCT00147134,Overall survival,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],The proportion of completion of LAP,
2419,NCT02908451,Adverse events (AEs) graded according to CTCAE v4.03.,2017-04-24,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall Response Rate Evaluated by Response Evaluation Criteria in Solid Tumor (RECIST),
2420,NCT03393416,Incidence of Treatment-Emergent Adverse Events（Safety）,2018-04-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
2421,NCT00005050,,1999-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2422,NCT02503111,Anal dysplasia treatment on a per-patient basis,2015-11,TERMINATED,INTERVENTIONAL,['NA'],Acceptability of treatment,
2423,NCT05723718,Tumor Regression Grade,2022-12-20,RECRUITING,OBSERVATIONAL,['NA'],Quality of Life score,
2424,NCT00897403,Collection of blood and tissue,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,
2425,NCT03400072,M6 Health-Related quality of life (HRQoL),2018-08-03,RECRUITING,INTERVENTIONAL,['NA'],,
2426,NCT02024438,The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],quality of life,
2427,NCT01468688,Frequency and characteristics of dose limiting toxicities (DLTs) at each dose level during the first cycle of therapy,2012-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],"Clinical benefit rate (CBR) defined as the rate of confirmed complete response (CR) or partial response (PR), or stable disease (SD) which lasts for at least 16 weeks.",
2428,NCT01830270,curative resection rate,2011-05,TERMINATED,INTERVENTIONAL,['PHASE2'],global survival,
2429,NCT04067960,"Changes in symptoms, quality of life (QOL), and perceptions about pharmacogenomics (PGx) testing",2019-06-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Provider opinions surrounding the clinical utility/relevancy of PGx testing in cancer patients,
2430,NCT03286244,Percentage of patients who suffer at least one adverse event,2018-03-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],Progression-free survival,
2431,NCT05564338,Recurrence-free survival (RFS) as assessed by the investigator between Arm B and Arm D,2023-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Participants Reported Outcome as measured at Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and its hepatocellular carcinoma cancer module QLQ-HCC18,
2432,NCT01524094,Overall survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Side effects of treatment,
2433,NCT06045975,local recurrence-free survival,2023-12-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety of Durvalumab/Tremelimumab infusions,"Consittution of a sequential biobank comprising peripheral samples (serum, plasma)"
2434,NCT00001603,,1996-12,COMPLETED,OBSERVATIONAL,['NA'],,
2435,NCT06116136,Objective Response Rate (ORR),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Objective Response Rate (ORR),
2436,NCT03722121,"distance ""home of patients - treatment center""",2017-03-23,UNKNOWN,OBSERVATIONAL,['NA'],,
2437,NCT05128032,Radiotracer distribution,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],Technical success of radiotracer delivery as measured by ability to deliver radiotracer,
2438,NCT01961778,Percentage of Barrett's esophagus ablated during the initial treatment session.,2013-11,COMPLETED,INTERVENTIONAL,['NA'],Patient discomfort,
2439,NCT00041808,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2440,NCT02348229,Compartition of postoperative hospital stay,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline in C-Reactive Protein( CRP) and visceral proteins level,
2441,NCT01373164,Phase 2: Overall Survival (OS),2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up,
2442,NCT01274624,Pharmacokinetic parameters for irinotecan and 5-FU when combined with REOLYSIN®,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],"In vitro studies in human-derived colorectal cancer cells including the isogenic cell lines, to study the mechanism and scientific basis of synergy between irinotecan and reovirus",
2443,NCT05681234,Evaluation of tissue distribution of 18F-RD2,2022-08-24,COMPLETED,INTERVENTIONAL,['NA'],,
2444,NCT03981510,Children with NF1 and gastrointestinal symptoms has a longer transit time through the colon and fewer fast bowel movements than healthy children.,2019-06-13,UNKNOWN,INTERVENTIONAL,['NA'],,
2445,NCT02911974,The total area of procured tissue between the FNA and FNB needles,2016-08,COMPLETED,INTERVENTIONAL,['NA'],Diagnostic adequacy between the FNA and FNB needles,
2446,NCT01266564,Progression-free survival in a real life setting assessed by computer tomography,2010-09-03,COMPLETED,OBSERVATIONAL,['NA'],Safety: incidence of adverse events,
2447,NCT06196788,Overall survival，OS,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],disease control rate (DCR),
2448,NCT01610895,Quality of Bowel Cleanliness,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],Patient satisfaction with preparation,
2449,NCT05379790,Maximum-tolerated dose,2022-05-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Area Under the Curve (AUC) ratio intraperitoneal/systemic irinotecan,
2450,NCT00364078,,2006-06,COMPLETED,OBSERVATIONAL,['NA'],,
2451,NCT04343950,Intervention 3: Participation in breast cancer screening program,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],Incremental cost ratio,
2452,NCT05668910,The performance of each single feature and the ensemble model with integrated features for early GC detection in each clinical stage,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],"The performance of the ensemble model in combination of possible GC related biomarkers such as PG, G17, and/or Hp levels for early GC detection",
2453,NCT00262847,Progression-free Survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Impact on Quality of Life Measured by the Functional Assessment of Cancer Therapy-Ovary Trial Outcome Index (FACT-O TOI),
2454,NCT01630174,,2009-10,UNKNOWN,OBSERVATIONAL,['NA'],,
2455,NCT00424827,"Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity Associated With This Regimen.,
2456,NCT03950908,Identification of signet ring cell carcinoma (SRCC) foci.,2017-10-12,COMPLETED,INTERVENTIONAL,['NA'],Dose of sedation.,
2457,NCT01433016,PDR Peak,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2458,NCT04988945,Downstaging for hepatectomy,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Pathological response,
2459,NCT04550897,Adverse Events related to BM7PE,2020-08-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Radiological response to BM7PE,
2460,NCT06281145,Primary endpoint - Working memory,2024-03-15,RECRUITING,INTERVENTIONAL,['NA'],Secondary endpoint - Serious Adverse Events (SAE),
2461,NCT00695201,Determine the MTD of hepatic arterial floxuridine (FUDR) & dexamethasone (Dex) given via implanted pump in combination w biweekly intravenous Oxaliplatin + systemic irinotecan (CPT-11) in patients w unresectable hepatic metastases from colorectal cancer.,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],"To procure normal and disease liver tissue for evaluation of TS, p53, p21, TOPO 1, DPD, and ERCC levels.",
2462,NCT06010212,ORR（Objective response rate）,2023-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PFS（Progression-free survival）,
2463,NCT06087263,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
2464,NCT05817370,Change in HSIL treatment,2023-05-02,RECRUITING,INTERVENTIONAL,['NA'],Change in Maintenance of HSIL screening and treatment,
2465,NCT03582306,Feasibility - adherence,2018-07-23,COMPLETED,INTERVENTIONAL,['NA'],Acceptability,
2466,NCT03338647,"Progression (total of local, intra- and extrahepatic)",2017-10-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],Cost-benefit,
2467,NCT06323421,Acceptability,2024-04-22,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Systemic inflammation
2468,NCT05818982,Progression-free survival,2023-02-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
2469,NCT05948826,Recommended Phase 2 Dose (RP2D),2023-09-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Accumulation ratio (Rac) of TORL-3-600,
2470,NCT00971399,complete response of RINV (no vomiting and no rescue medication),2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2471,NCT04117958,Number of subjects with changes in electrocardiogram (ECG),2020-01-20,TERMINATED,INTERVENTIONAL,['PHASE1'],"Overall survival (OS), 2-year OS",
2472,NCT05208047,Part 2 - Progression Free Survival (PFS),2022-04-14,RECRUITING,INTERVENTIONAL,['PHASE3'],Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30),
2473,NCT03904667,Operative outcomes,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Postoperative survival,Disease-free survival
2474,NCT03998566,Safety Endpoint,2019-04-24,COMPLETED,INTERVENTIONAL,['NA'],"Changes From Baseline at the Final RT Appointment, 3 Month, 6 Month, 12 Month and 18 Month in EORTC QoL (QLQ-C30)","Changes From Baseline Final RT Appointment, 3 Months, 6 Months, 12 Months, and 18 Months in QLQ-PAN26"
2475,NCT02082886,Overall survival rate,2014-02,COMPLETED,OBSERVATIONAL,['NA'],Rates of complications,
2476,NCT03427684,Maximum tolerated dose AND Dose limited toxicity,2016-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",2-year disease-free survival,
2477,NCT01950572,sample aquisition,2013-09-09,RECRUITING,OBSERVATIONAL,['NA'],,
2478,NCT05398380,Five years overall survival,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Changes in quality of life assessed by EORTC QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30),Percentage of patients with circulating tumor DNA (ctDNA)
2479,NCT00888797,Rate of recurrent and metastatic cancer,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Early postoperative morbidity and mortality,
2480,NCT03690323,Overall survival,2015-04-07,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life questionnaire,
2481,NCT02102022,Objective response rate (ORR),2014-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",AFP (alpha feto-protein) changes,
2482,NCT01324141,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE),2011-03-18,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants With Human Immunodeficiency Virus (HIV) in Biopsy Tissue From Rectal Mucosa,
2483,NCT03671252,3-year disease free survival rate,2018-11-16,RECRUITING,INTERVENTIONAL,['PHASE3'],Long term quality of life,
2484,NCT06266871,pCR rate,2024-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",2-year OS rate,
2485,NCT04258072,Progression-Free Survival (PFS),2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2486,NCT03663062,Risk model of colorectal adenomas and CRC,2017-12-27,COMPLETED,OBSERVATIONAL,['NA'],The incidence of colorectal adenomas or CRC in patients who are smokers or who have high alcohol intake,
2487,NCT01529827,Transplant Related Mortality (TRM),2012-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Time to Neutrophil Engraftment,
2488,NCT02598687,Dose Limiting Toxicity (DLT ),2015-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],metabolic response,
2489,NCT01347333,Local Tumor Recurrence Rate,2008-09,COMPLETED,INTERVENTIONAL,['NA'],Late Complication Rates,
2490,NCT01310478,Dose limiting toxicity and maximum tolerance dose of continous intravenous Endostar in combination with mFOLFOX6,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],Parameters of human pharmacokinetics of continous intravenous Endostar in combination with mFOLFOX6,
2491,NCT03730675,Overall survival,2018-11-10,UNKNOWN,INTERVENTIONAL,['NA'],"Treatment Safety in terms of type, incidence, severity timing, seriousness, and relatedness of adverse events and laboratory abnormalities",
2492,NCT02135822,Overall response rate,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety and tolerability,
2493,NCT06284746,Objective Response Rate（ORR）,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],The incidence of adverse events during treatment,
2494,NCT04744831,Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review Following IV Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2-overexpressing Metastatic Colorectal Cancer,2021-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of Participants Positive for Treatment-emergent Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (NAb) in Participants Who Were Administered T-DXd,
2495,NCT04294784,objective response rate(ORR),2020-04-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],patient-reported outcomes (PROs),
2496,NCT02864849,Major adverse events,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29),
2497,NCT03931304,Evaluation of 3-years disease free survival,2018-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
2498,NCT00967616,"Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer",2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer",
2499,NCT06178198,Duration of response according to localized mRECIST,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in regional liver function,Post-treatment dosimetry based on Y90 PET-CT
2500,NCT04724239,The progression-free survival (PFS) rates at 18 weeks,2021-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of response (DoR),
2501,NCT03723915,Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1,2018-11-14,TERMINATED,INTERVENTIONAL,['PHASE2'],Immune Response Determined by Analysis of pre-and Post- Treatment Biopsies and Blood-based Immune Markers,
2502,NCT05630937,Objective Response Rate (ORR) (Phase II),2020-11-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
2503,NCT03597204,"Number of subjects diagnosed colonic adenoma, advanced adenoma or cancer",2015-10-07,COMPLETED,INTERVENTIONAL,['NA'],,
2504,NCT03026140,Disease free survival,2017-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Relapse free survival,
2505,NCT05578820,Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients' urine),2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2506,NCT04487717,Prognostic group's 5-yr Overall Survival(OS) rate,2020-07-29,RECRUITING,OBSERVATIONAL,['NA'],Subgroup analysis,
2507,NCT05391321,"Preference ranking of 4 validated sexual QOL questionnaires in French, FSFI, PISQ-IR, PISQ-12, BISF assessed on the collection of questionnaire returns by patients",2023-05-12,RECRUITING,INTERVENTIONAL,['NA'],,
2508,NCT03207724,"Maximum Tolerated Dose (MTD) of onivyde, 5-fluorouracil/folinic acid in combination with Xilonix",2017-10-16,COMPLETED,INTERVENTIONAL,['PHASE1'],Mean change in global score of patient-reported response to therapy (FAACT questionnaire- Functional Assessment of Anorexia/Cachexia Therapy),
2509,NCT04425876,R0 resection rate,2020-12-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],Minimum concentration (Cmin),
2510,NCT00921661,Dose-limiting toxicity (DLT) combination with FOLFIRI,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Immunogenicity,
2511,NCT04822103,Feasibility of immunochemotherapy defined as at least 80% of the patients completed all planned courses,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],Major pathological response,
2512,NCT05157451,Feasibility of enrollment (enrollment rate),2023-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Time to next treatment,
2513,NCT04844385,progression-free survival rate,2021-02-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life assessed by QLQ-C30,
2514,NCT03841110,The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.,2019-02-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Duration of FT500 persistence,
2515,NCT00280007,"to assess collateral tumor vessel growth on MRT / CT after 3, 6, and 12 months",2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],cost,
2516,NCT03283956,Safety of the DC bead TACE,2017-09-13,UNKNOWN,OBSERVATIONAL,['NA'],Tumor response,
2517,NCT03607370,Complete pathologic response assessed by pathologist Dworak scale,2017-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Urinary catheter removal timing,
2518,NCT03974542,rescreening of CRC,2019-10,UNKNOWN,INTERVENTIONAL,['NA'],,
2519,NCT04443322,Recurrence-Free Survival (RFS),2020-09-19,RECRUITING,INTERVENTIONAL,['NA'],Percentage of Participants who Experience an Adverse Event (AE),
2520,NCT00949312,Disease-free survival (time to local or distant recurrence after resection),2009-05,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival (time to death from colorectal cancer),
2521,NCT05643859,Change in microbiome colonic mucosa: microbiome diversity,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
2522,NCT04134897,2-year local recurrence rate,2019-10-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],Preoperative tumor-associated complications rate,
2523,NCT02041507,Adenoma Detection Rate.,2014-02,COMPLETED,INTERVENTIONAL,['NA'],Need for sedation/analgesia and its dosage,Patients willingness to repeat the examination.
2524,NCT03517488,Determine the safety and tolerability profile of XmAb20717,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2525,NCT03744624,Operative time,2017-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Mortality,
2526,NCT05411783,Anastomotic leak,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],Post-operative complications,
2527,NCT04394585,Eating restriction score (XEatR) at 3 months postoperatively,2020-04-20,RECRUITING,INTERVENTIONAL,['NA'],seum hemoglobin,
2528,NCT03492151,Accuracy of risk-stratification of IPMNs,2018-10-01,RECRUITING,OBSERVATIONAL,['NA'],Imaging quality,
2529,NCT02613260,Completion of FIT- one year,2016-01-01,COMPLETED,INTERVENTIONAL,['NA'],Cost,
2530,NCT01897454,Percentage of Participants Achieving R0 Resection (R0 Resection Rate),2012-01-27,TERMINATED,INTERVENTIONAL,['PHASE2'],Vascular Reconstruction,
2531,NCT03493763,Time of hepatocellular carcinoma recurrence,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],Adverse effect of 5hmC blood test,
2532,NCT00648635,Quality of Life (QOL) Survey Responses,2008-03-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
2533,NCT02461966,Serum Aflatoxin Level in Liver Cancer Patients,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,
2534,NCT06239155,Progress free survival (PFS),2019-09-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2535,NCT02392143,Colorectal Cancer Screening,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,
2536,NCT04031625,Patient survival,2012-11-26,UNKNOWN,OBSERVATIONAL,['NA'],Collection of patient and treatment characteristics,
2537,NCT02465112,relapse-free survival (RFS),2015-09,TERMINATED,INTERVENTIONAL,['PHASE3'],Impact of the therapy on 5-year RFS in treatment and control group,
2538,NCT00931229,enroll 150 patients,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],,
2539,NCT00897429,Cancer-specific mortality (B6),2007-07,COMPLETED,OBSERVATIONAL,['NA'],Evaluation of up to 768 new genes for their relationship with colon cancer recurrence (B4,
2540,NCT00534131,Oncological safety assessment - where appropriate,2004-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
2541,NCT03416699,The grade score of the specimens integrity,2017-11-15,UNKNOWN,OBSERVATIONAL,['NA'],the grade of anastomotic leakage,
2542,NCT02028845,The cannulation success rate,2014-01,COMPLETED,INTERVENTIONAL,['NA'],"The duration of the cannulation, immediate and late complications.",
2543,NCT02402699,Identify and describe observed adverse events (AEs) based on liver function abnormalities and changes in hepatitis viral load,2015-12-15,COMPLETED,OBSERVATIONAL,['NA'],,
2544,NCT03439462,"Progression-free Survival at 6 Months (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)",2018-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Overall Response Rate (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)",
2545,NCT02035072,Proportion of resectable patients,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression free survival (PFS/local PFS),
2546,NCT05604560,Pathologic Response Rate as assessed by number of patients with a grade 0-2 pathologic response,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Free Survival (DFS),
2547,NCT05897138,Objective response rate (ORR),2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival(OS),
2548,NCT01351194,overall survival,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],disease-free survival,
2549,NCT00632333,Safety(toxicities as assessed by NCI CTCAE version3),2008-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],survival,
2550,NCT05178524,Species composition and differential analysis of gut microbiota,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
2551,NCT04296058,Disease free survival (DFS),2007-01-08,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
2552,NCT02400996,Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
2553,NCT04713332,Matrix metalloproteinases(MMPs),2019-07-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
2554,NCT00474097,"to assess if follow-up telephone calls after surgery affects patient satisfaction, surgical outcomes and quality of life in the early post-operative phase after colorectal surgery",2006-02,COMPLETED,OBSERVATIONAL,['NA'],"to track readmissions, complications and emergency room visits via telephone calls to ensure communication between the patients and the surgical office is optimal.",
2555,NCT05281783,The efficacy,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],Incidence of Treatment-Emergent Adverse Events [Safety],
2556,NCT00096967,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2557,NCT01064622,Progression-free Survival,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Activity (Overall Response Rate) in Crossover Patients,
2558,NCT05744219,Recovery after iv Iron,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Performance status,
2559,NCT00005870,,1999-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
2560,NCT01005225,Solid tumor biological insights,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
2561,NCT05497947,SOAL- VF,2021-07-03,COMPLETED,OBSERVATIONAL,['NA'],,
2562,NCT06157216,3-year Disease-Free Survival (DFS) rate,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],3-year Overall Survival (OS) Rate,Association between prognosis with multi-omic sequences
2563,NCT01236989,the prognostic impact of anatomical resection by means of intraoperative ultrasound (IOUS) guided vessel compression versus nonanatomical resection in terms of disease free and overall survival,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],the impact of anatomical resection versus non-anatomical resection in terms of postoperative mortality and morbility,
2564,NCT06184698,Objective Response Rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
2565,NCT01401699,Number of Subjects in Which the Entire Distal Esophagus Can be Visualized Using the Balloon Based Optical Coherence Tomography Screening,2006-09,COMPLETED,INTERVENTIONAL,['NA'],,
2566,NCT02538562,Incidence of HER2 positivity among gastric and gastroesophageal junction tumor samples,2011-10-11,COMPLETED,OBSERVATIONAL,['NA'],Correlation between HER2 status and gender,
2567,NCT04780529,Number of participants with CAR-T treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 24 months ],2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Efficacy will be assessed according to RECIST1.1 or EORTC or PERCIST criteria,
2568,NCT05447923,Colorectal cancer disparities seen in people of color and minority populations,2022-05-22,RECRUITING,INTERVENTIONAL,['NA'],,
2569,NCT02448693,Number of residual neoplastic tissue detected with both techniques (NBI versus WLE),2015-05,COMPLETED,INTERVENTIONAL,['NA'],Number of missed lesions on basal colonoscopy,
2570,NCT01231399,Overall Survival,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2571,NCT04548531,Shared Decision Making (SDM) Process Scale Score,2020-09-10,COMPLETED,INTERVENTIONAL,['NA'],Colon Cancer Screening Rate,
2572,NCT02280811,Duration of Response,2014-10-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Expression of Programmed Cell Death 1 (PD-1) by Circulating E6 T-Cell Receptor (TCR) T-Cells,
2573,NCT00200200,To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer,2004-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"To compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitors",
2574,NCT00145314,"To compare efficacy, as measured by time to disease progression, of treatment with cetuximab in combination with the FLOX regimen compared to FLOX alone, in first- line treatment of patients with metastatic cororectal cancer",2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],"To measure response rates, response duration, secondary surgical curative resection frequency, safety profile, overall survival and quality of life in the treatment groups.",
2575,NCT05622357,Sphincter saving surgery,2018-03-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease free survival,
2576,NCT00563316,Number of Participants With Clinically Significant Adverse Events (AEs),2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2577,NCT06104215,Dose-limiting toxicity（DLT）,2023-10-22,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],PFS,
2578,NCT05642962,Change in body mass index/BMI from baseline to 4 months,2022-11-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2579,NCT00341705,,2001-04-27,COMPLETED,OBSERVATIONAL,['NA'],,
2580,NCT00262951,Number of Patients in Whom Tumor Was Resectable,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
2581,NCT06168786,Progression-free survival (PFS),2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],AEs,
2582,NCT02337465,Percent of Patients Whose Plan Quality Was Not Not Affected in the Presence of the Ultrasound Probe,2015-09-22,COMPLETED,INTERVENTIONAL,['NA'],,
2583,NCT03717519,Overall survival,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],Clinic-pathological variables,
2584,NCT04050345,TRACC Part C (Randomised ctDNA guided adjuvant chemotherapy versus SoC study):,2016-12-05,RECRUITING,OBSERVATIONAL,['NA'],"Relationship between ctDNA detection before, during and after treatment",
2585,NCT00056459,Progression free survival,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Tolerability and safety profile,
2586,NCT05452382,Overall survival,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],Positive resection margins,
2587,NCT05364788,Characterise the genes of appendiceal cancer.,2024-02-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Descriptive analysis in proportions,
2588,NCT02538913,Anal incontinence,2015-09,TERMINATED,INTERVENTIONAL,['NA'],In-hospital time,
2589,NCT02526134,Patients rate in which a significant variation in the area to be irradiated will be observed between before evaluation and evaluation after laying the trustees.,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of trustees (2 up 6 maximum) and set up their positions estimated success rate of implementation and the evaluation of the safety and toxicity (complications) associated with the establishment trustees (composite measure),
2590,NCT06087289,"Evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as measured by lab safety tests",2023-04-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determine the plasma exposure of KAND567,
2591,NCT01085331,Part 2 or Phase 2 Randomised Part: Progression Free Survival (PFS),2010-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Part 2 or Phase 2 Randomized Part: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death",
2592,NCT03544736,Incidence of Treatment-Emergent Adverse Events,2018-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Health Related Quality of Life (EORTC QLQ-OG25),
2593,NCT00987935,Time to Progression (TTP) in Phase II,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib",
2594,NCT01726010,diagnostic yield,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],,
2595,NCT04465214,"Outcomes from: PRO-CTCAE, Neuro-QOL, Numeric Rating Scale for Pain, 6-Minute Walking Test, Stroop Test, and Normalized Reaction Time Tests",2020-11-23,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Evaluation of iPhone based tests of cognitive functioning and reaction time for reliability and validity,
2596,NCT00411229,Clinical laboratory tests,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2597,NCT01462903,• the safety and tolerability of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],• immune efficacy and anti-tumor effects of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).,
2598,NCT02109146,DFS(Disease free survival),2014-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
2599,NCT00017537,Determine the optimum biologic dose of MVF-HER-2 (628-647)-CRL 1005 vaccine that will induce snit-HER-2 antibody in patients with metastatic or recurrent cancer,2000-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Document any clinical responses to this drug in these patients.,
2600,NCT03254836,Actigraphy,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],"Follow-up cancer treatment (Adjuvant chemotherapy, timing and duration)",
2601,NCT02871336,Optimization of the surgical care of the patients,2014-11,RECRUITING,OBSERVATIONAL,['NA'],,
2602,NCT04221347,Detection of spectroscopic markers differences among specified groups,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],Measure of sensitivity and specificity of identified biomarkers for surveillance of HCC,
2603,NCT02009774,Accuracy optical biopsy,2014-01,COMPLETED,OBSERVATIONAL,['NA'],Adenoma detection rate,
2604,NCT05165264,Overall Survival (OS),2022-02-16,RECRUITING,OBSERVATIONAL,['NA'],OS measured by Programmed Death-Ligand 1 (PD-L1) combined positive score (CPS),
2605,NCT04936750,overall survival,2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],,
2606,NCT06282484,corelation between the gastric xanthoma and gastric mucosa diseases,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
2607,NCT03416582,Percentage of patients using Intervention materials,2018-11-29,COMPLETED,INTERVENTIONAL,['NA'],Influence of Nurse-Delivered Telephone Intervention on Symptom Self-Management,
2608,NCT00876148,,na,COMPLETED,OBSERVATIONAL,['NA'],,
2609,NCT04994236,Objective response of intrahepatic lesions,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],The rate of adverse events,
2610,NCT01311232,Hepatitis B virus reactivation,2010-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
2611,NCT04081168,One-year local tumor progression-free survival,2020-12-15,RECRUITING,INTERVENTIONAL,['NA'],Mortality,
2612,NCT01552434,"MTD of temsirolimus, defined as the dose level below the dose at which 2 of 6 patients experience DLT",2012-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Levels of surrogate anti-angiogenesis markers,The properties of the tissue microvasculature.
2613,NCT01567488,Percentage of patients with progression-free survival (PFS),2011-06-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of patients with Adverse Events,
2614,NCT01095432,Study samples of rectal mucosa (the moist lining of the rectum) using PWS.,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,
2615,NCT01251536,PFS Probability Rate at 9 Months in the Dose Escalation Arm,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Deaths Till 30 Days From Last Cetuximab Administration,
2616,NCT02642978,Surgical Complication,2015-09-01,UNKNOWN,INTERVENTIONAL,['NA'],locoregional recurrence rate,liver function
2617,NCT01661829,Incidence of anterior resection syndrome after stoma closure,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
2618,NCT03693248,Progression free survival,2018-12-19,UNKNOWN,INTERVENTIONAL,['PHASE3'],days of management in intensive care unit,
2619,NCT02702414,Objective Response Rate (ORR),2016-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE),
2620,NCT01978249,Comparison of the overall survival between patients who underwent primary tumor resection and patients who received chemotherapy without primary tumor resection,2013-09,TERMINATED,INTERVENTIONAL,['NA'],Analysis of primary tumor related complications in the chemotherapy group and postoperative complications in the primary tumor resection followed by the chemotherapy group.,To compare the quality of life between the two groups using the Korean version of EORTC QLQ (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire)-C30.
2621,NCT05673512,Progression-Free-Survival（PFS）,2023-05-12,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
2622,NCT01394497,Graft survival,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Primary graft dysfunction,
2623,NCT04148092,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2624,NCT05021263,Quality of Recovery 40 Questionnaire,2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,
2625,NCT01617876,Diagnostic accuracy of enhanced ME (combining ME-NBI and ME-AIM),2010-03,COMPLETED,OBSERVATIONAL,['NA'],The relationships between the microsurface patterns and the histopathological findings,
2626,NCT05643833,Overall survival,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2627,NCT01413451,Background ratio of maximum counts,2011-07-12,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Antibody uptake vs. IHC mesothelin expression,
2628,NCT01505842,Prevalence of dysplastic lesions,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],Number and rate of targeted and non-targeted biopsies detecting dysplasia and non-dysplasia,
2629,NCT05462236,Objective response rate based on Response Evaluation Criteria in Solid tumors (RECIST) Version 1.1,2023-04-14,RECRUITING,INTERVENTIONAL,['PHASE2'],PK evaluation,
2630,NCT04110769,The rate of genetic mutation,2019-07-17,RECRUITING,INTERVENTIONAL,['NA'],oncologic outcome,
2631,NCT05401045,Fatigue state using the Revised Piper Fatigue Scale (RPFS),2023-01-20,COMPLETED,INTERVENTIONAL,['NA'],Quality of life using the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC-C30),
2632,NCT00844233,Tumour resectability at surgery,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0),
2633,NCT03055130,The different incidence of cervical neoplasm between controls and patients by performing Thinprep Cytology Test,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],Find drugs relating to HPV infection of IBD patients,
2634,NCT02508883,mortality,2015-04,COMPLETED,OBSERVATIONAL,['NA'],"Finding the cut-off value of highest sensitivity and specificity of Rockall, Glasgow-Blatchford and AIMS65 scores employing the receiver operating curve (ROC).",
2635,NCT00965861,To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases,2010-05,TERMINATED,OBSERVATIONAL,['NA'],,
2636,NCT02760199,"The quantitative uptake op 89Zr-AMG211 in tumor tissue, organs and blood circulation expressed in SUV (Standardized Uptake Value)",2016-08,COMPLETED,INTERVENTIONAL,['PHASE1'],"Number of patients with adverse events after 89Zr-AMG211 injection as a measure of safety and tolerability. Incidence, nature and severity of adverse events (according to CTCAE version 4.03) will be measured.",Evaluate 89Zr-AMG211 as a complementary tool for improved patient selection for targeted therapy with AMG 211.
2637,NCT02839109,Tumor response,2015-02,COMPLETED,OBSERVATIONAL,['NA'],Disease free survival (DFS),
2638,NCT04001569,Progression-free survival rate,2019-05-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse event,
2639,NCT05096715,Dose Limiting Toxicity Rate,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Out of field response rate,
2640,NCT03317483,Treatment response,2015-11-12,COMPLETED,OBSERVATIONAL,['NA'],Adverse events (AEs),
2641,NCT02648841,Disease-free survival,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse Event,
2642,NCT03180437,OS,2017-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",CA 19-9,
2643,NCT01064999,toxicity,2010-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",overall survival,
2644,NCT03904732,Number of deaths due to any other cause,2019-04-15,COMPLETED,OBSERVATIONAL,['NA'],,
2645,NCT05659576,Reduce opioid use,2022-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2646,NCT05730686,To describe the natural history and clinical outcomes of patients with Fibrolamellar carcinoma of the liver,2023-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2647,NCT03277209,Causality of adverse events (AEs) and serious adverse events (SAEs) and grading according to NCI CTCAE v.4.03.,2017-07-25,TERMINATED,INTERVENTIONAL,['PHASE1'],Assessment of metabolic changes in tumour using non-invasive imaging (18FDG-PET),Correlation between changes in T cell distribution and diurnal cortisol variation.
2648,NCT05551052,Specificity for CRC of the Next-Gen CRC Screening Test,2022-09-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Specificity for no colorectal neoplastic findings of the Next-Gen CRC Screening Test,
2649,NCT00113763,Progression-free Survival Time,2004-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Duration of Stable Disease,
2650,NCT00597610,To measure the response of primary rectal cancer to neoadjuvant chemotherapy and/or radiation therapy using 3-D TRUS,2003-11,COMPLETED,INTERVENTIONAL,['NA'],To correlate these findings with post-operative pathologic examination,
2651,NCT00582296,"To assess adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations in patients with Lynch Syndrome.",2004-12,RECRUITING,OBSERVATIONAL,['NA'],"To evaluate predictive factors for adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations.",
2652,NCT05053555,To prospectively evaluate the clinical effectiveness of the use of high dose rate brachytherapy (HDRBT) for the treatment of both primary liver malignancies.,2022-04-24,RECRUITING,INTERVENTIONAL,['NA'],,
2653,NCT02534337,Progression-Free-Survival,2015-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Time-to-Progression,
2654,NCT00397384,MTD defined as the dose level at which fewer than 2 out of 6 patients experience DLT graded using CTCAE-v3,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Antitumor effect observed,
2655,NCT05620498,Objective response rate (ORR),2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE2'],AE,
2656,NCT05619614,Mean gaze time per area of influence,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
2657,NCT00844064,To determine the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT) of two cycles of AP 12009 administered intravenously at weekly intervals and for four days every other week.,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1'],"To determine the potential antitumor activity of AP 12009 administered intravenously at weekly intervals and for four days every other week, as assessed by the effect on tumor size and tumor markers.",
2658,NCT00642746,Response Rates of Radiographically Measurable Disease,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Time to Second Progression (From Start of First-Line Regimen),
2659,NCT03086369,Phase 2: Overall Survival (OS),2017-06-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Health Status on the EuroQol 5-Dimension 5 Level (EQ-5D-5L),
2660,NCT00600522,"The primary outcome measure was the rate of failure of conservative resection, i.e. the rate of patients who received TSs or MHs despite they fitted in the eligibility criteria.",2004-01,COMPLETED,OBSERVATIONAL,['NA'],"The secondary outcome measure was the safety of the procedure. For that, we studied morbidity, mortality, amount of blood loss, rate of blood transfusions, and postoperative trend of liver function tests.",
2661,NCT01369329,Number of Participants With Clinical Response at Week 6,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With CDAI 70-point Response at Week 3,
2662,NCT02568787,Change from baseline in immunological markers,2016-05,COMPLETED,INTERVENTIONAL,['NA'],Change from Baseline in Quality of Life,
2663,NCT05331040,Model,2020-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
2664,NCT00004891,Determine if fludeoxyglucose F 18 positron emission tomography (FDG-PET) is superior to CT scan,1999-09,COMPLETED,INTERVENTIONAL,['NA'],Determine the accuracy of FDG-PET,
2665,NCT03455608,Duration of feeding tube dependence,2018-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Hospitalization/Emergency Department (ED) Presentation,
2666,NCT05441254,Progression Free Survival(PFS),2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Peritoneal Cancer Index (PCI) assessed on preoperative CT (CT-PCI),"Adverse event (AE) rate, serious adverse event (SAE) rate, etc"
2667,NCT02851381,FG-3019 treatment regimen to increase OS (overall survival),2016-08,WITHDRAWN,INTERVENTIONAL,['NA'],,
2668,NCT00652366,OS Assessed From Point of Randomization,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],PFS Assessed From the Start of 4-Week Run-In,
2669,NCT00343239,"To determine the R0 resection rate for the treatment of locally advanced gastric carcinoma with Docetaxel, Cisplatin, Fluorouracil combination.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2670,NCT00305643,Incidence of Hand/Foot Syndrome (HFS) > Grade 1 at 16 Weeks Based on the CTC 3.0 Criteria.,2006-02,TERMINATED,INTERVENTIONAL,['PHASE3'],Incidence of Hand/Foot Syndrome (HFS) > Grade 1 at 16 Weeks Based on WHO Criteria.,
2671,NCT06136026,The detection rate of Colorectal Adenomatous Polyp.,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The canceration rate of Colorectal Adenomatous Polyp.,
2672,NCT02219529,Number of gastric focal lesions founded by MCE Versus Standard Gastroscopy,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Adverse events of both procedures,
2673,NCT02586987,"Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (slit lamp fundoscopy)",2015-12-28,COMPLETED,INTERVENTIONAL,['PHASE1'],MEDI4736 and/or tremelimumab anti-drug antibody (ADA) level in Plasma,
2674,NCT00934791,Liver Volume at 2 Years After Kidney Transplantation,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,
2675,NCT01941173,"Feasibility of a shorter infusion time, determined by rate of greater or equal to grade 2 hypersensitivity reactions as graded according to CTCAE version 4.0",2014-01,WITHDRAWN,INTERVENTIONAL,['NA'],"Incidence of grade 3 and above toxicities, graded according to CTCAE version 4.0",Time on protocol therapy
2676,NCT00313560,Recurrence Free Survival,2006-03-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Death as Assessed by Median Overall Survival (Months),
2677,NCT02644863,Overall survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Phenotypic analysis of T cells,
2678,NCT03276091,Participation to the colonoscopy,2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],cancer and adenoma detected,
2679,NCT03277235,Self-report Questionnaire,2017-09,UNKNOWN,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
2680,NCT01023412,Rate of post-operative complications,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Rate of post-operative infectious complications,
2681,NCT04313868,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2014-06-13,RECRUITING,INTERVENTIONAL,['PHASE1'],"Clinical research testing for antibodies to retrovector gp70 env, replication-competent retrovirus in peripheral blood lymphocytes (PBLs); vector integration into genomic DNA of PBLs, and circulating hGM-CSF protein",
2682,NCT02670265,Weight loss,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Length of hospital stay,
2683,NCT01157052,The primary objective of this study is to determine potential pharmacokinetic interactions between oxaliplatin and calcium and magnesium.,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
2684,NCT02650986,Number of Participants With Feasibility Concerns in Manufacturing of NY-ESO-1/ dnTGFbetaRII Engineered Cells,2017-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumor Response (Complete and Partial Response),
2685,NCT03396354,Number of retrieved LN,2018-01-02,UNKNOWN,INTERVENTIONAL,['NA'],,
2686,NCT00017043,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2687,NCT02036112,The perioperative morbidity,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],Three years survival postoperatively,Three years local recurrence postoperatively
2688,NCT04006769,Adverse Events (AE) And Serious Adverse Events(SAE),2020-10-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Quality of Life(QOL),
2689,NCT00197444,Response rate,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival rate,
2690,NCT01163305,Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy,2010-06-30,COMPLETED,OBSERVATIONAL,['NA'],RECIST-based tumor response at 10 weeks after chemotherapy,
2691,NCT00408681,Functional Recovery,2006-06,COMPLETED,INTERVENTIONAL,['NA'],Causes of Death,Agents Added to Treat GVHD More Than 3 Days After Enrollment
2692,NCT03940417,"Docking time,min",2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],cost,
2693,NCT02649790,Part H: 2- Year Progression-free Survival (PFS),2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Part H: Overall Survival (OS),
2694,NCT02510001,Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetic Plasma t1/2 Etc for PF-02341066 and Binimetinib,
2695,NCT03117348,Morbidity of infection,2017-04-15,COMPLETED,INTERVENTIONAL,['NA'],Mortality,
2696,NCT00075218,Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in EQ-5D Health State Profile Index,
2697,NCT01426646,Relapse-free survival,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
2698,NCT05636085,Specificity,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Positive predictive value and negative predictive value,
2699,NCT01503372,progression-free survival rate at 6 months,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],evaluation of the predictive and prognostic relevance of biomarkers,
2700,NCT03611504,Rebleeding rate,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],Mortality,
2701,NCT06022770,Nutritional risk screening（NRS） 2002 scale,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],quality of life of patients with esophageal and gastric cancer before and after chemotherapy,
2702,NCT03415763,Disease free survival,2018-11-05,RECRUITING,INTERVENTIONAL,['PHASE3'],The quality of life postoperatively,
2703,NCT03961776,Predictive value of Apparent Diffusion Coefficient measured using MRgRT system,2020-06-08,RECRUITING,OBSERVATIONAL,['NA'],,
2704,NCT00515411,6 Month Progression Free Survival (PFS),2006-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
2705,NCT04773769,Blood Counts,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA'],,
2706,NCT05524155,Overall response rate ( ORR),2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
2707,NCT00320294,Safety,2005-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life,
2708,NCT00012922,,na,COMPLETED,INTERVENTIONAL,['NA'],,
2709,NCT00366509,"procure and analyze gastrointestinal, oropharyngeal, lung and/or blood specimens from healthy research volunteers and subjects with lung disease",2006-09-18,COMPLETED,OBSERVATIONAL,['NA'],,
2710,NCT00524706,"Evaluate the response rate of S-1, Leucovorin, and Oxaliplatin with recommended dose in phase II",2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II - Safety - Time to treatment failure (TTF) - Progression free survival (PFS) - Overall survival (OS),
2711,NCT05586516,Incidence of treatment-emergent adverse events [Safety and Tolerability],2022-10-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival [OS],
2712,NCT01155440,Restoration of bowel function,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Pain intensity,
2713,NCT00747448,"Primary objectives of the study are to enable analysis of patient outcomes 2 years after final treatment and report on the effectiveness of the device in eradicating, decreasing or downgrading of the lesions.",2009-05,COMPLETED,OBSERVATIONAL,['NA'],,
2714,NCT02748161,Objective tumor response,2015-08,TERMINATED,INTERVENTIONAL,['NA'],Number of repeat DEB-TACE procedures per lesion,
2715,NCT06194786,Dietary target-red meat,2023-05-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Disease free survival,
2716,NCT05493956,Overall survival,2019-04-01,RECRUITING,INTERVENTIONAL,['NA'],Hepatobiliary symptom index,
2717,NCT03208621,Change in treatment strategy,2017-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Mortality,
2718,NCT01396148,Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours Post Dose AUC(0-8) for Sunitinib and Its Metabolite,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],"Estimated Sunitinib Plasma Concentration at Which 50% of the Maximum Effect (EC50) for Each Selected Safety Endpoint (e.g., Absolute Neutrophil Count) Was Observed",
2719,NCT05528367,the rate of resectable patients with negative incisal margin R0 resection rate,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2720,NCT02037646,Time to diagnosis of advanced colorectal neoplasms,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Patient anxiety levels,
2721,NCT02647099,Time To Recurrence (TTR),2016-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Frequency and severity of adverse events (AE),
2722,NCT03292289,"Quality of life 1 year after the second intervention, using LARS score",2018-01-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"Quality of life of patients with a second stoma placement, using LARS score",
2723,NCT02813278,Length of hospital stay,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2724,NCT01880658,Disease-free Survival rate(DFS),2013-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Over all survival,genetic patterns, quality of life, toxic effects, convenience",
2725,NCT06024356,pathologic complete response,2023-09-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],overall survival (OS),The expression of PD-1
2726,NCT05435313,objective response rate (ORR),2022-07-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events as assessed by NCI CTCAE v5.0,
2727,NCT02062749,Maximum Tolerate Dose (MTD) of Oxaliplatin in Hyperthermic Intraperitoneal Chemotherapy,2014-05-19,COMPLETED,INTERVENTIONAL,['PHASE1'],Differences in Genetic Aberrations in Pediatric Colon Cancer Patients and Adult Patients,"Time to Recurrence After HIPEC in Pediatric, Adolescent and Young Adult Age Colon Cancer Patients"
2728,NCT05644379,Adverse Events (AEs),2022-11-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2729,NCT03321396,Number of Patients With Postpolypectomy Electrocoagulation Syndrome,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],Number of Patients With Late Tissue Injury,
2730,NCT04233866,Overall survival (OS),2020-08-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Instrumental Activities of Daily Living (IADL),Geriatric assessment scores and biomarkers of aging (CRP and IL-6)
2731,NCT02395224,survival,2014-09,UNKNOWN,OBSERVATIONAL,['NA'],Health related quality of life,
2732,NCT05109468,Change in Sexual quality of life score,2021-06-06,RECRUITING,OBSERVATIONAL,['NA'],,
2733,NCT03901651,Adenoma detection rate with standard colonoscope and retroview colonoscope.,2019-01-02,COMPLETED,INTERVENTIONAL,['NA'],Size of lesions (adenomas and polyps) detected with the standard colonoscope and Retroview colonoscope.,
2734,NCT03146377,Objective response rate,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
2735,NCT00020579,Pharmacology and pharmacokinetics,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor response by CT scan every 12 weeks,
2736,NCT05590117,variation in grades of mucositis,2022-10-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1'],Change in the biological marker Citrulline,
2737,NCT00002951,Locoregional control rate,1996-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2738,NCT03898921,3-year overall survival rate,2019-03-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Safety profile: incidence of complications,Radiation-induced liver injury
2739,NCT04321850,Pain intensity: Visual analog scale,2019-06-10,TERMINATED,INTERVENTIONAL,['NA'],Neutropenia,
2740,NCT01585805,Response rate of single-agent veliparib (Part II),2012-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (Parts I and II),Differentially expressed genes found
2741,NCT00561990,Time to tumor progression (TTP) and overall survival (OS) in chemotherapy-naive patients. To assess the efficacy of Nimotuzumab as add on therapy to Gemcitabine in comparison with Gemcitabine and placebo,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",To evaluate the objective tumor response (overall response rate [ORR]) and duration of response (DR) To evaluate the safety profile of Nimotuzumab in combination with Gemcitabine To evaluate quality of life (QoL) according to EORTC,
2742,NCT05298722,Prediciton of surgical resectability,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],Measurement of quality of life in patients with pancreatic cancer,
2743,NCT02673177,Incidence of sexual and urinary dysfunction,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],Anus preservation rate,
2744,NCT01544790,Postoperative complications modified Clavien-Dindo classification (MCDC) grade 2 and higher,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Costs (euro),
2745,NCT04400357,Percentage of patients with pancreatic adenocarcinoma who achieve administration of adjuvant chemotherapy at 8 weeks postoperatively,2020-06-15,UNKNOWN,INTERVENTIONAL,['NA'],Comparison of perioperative inflammatory response (Interleukin-6),
2746,NCT05903456,Objective Response Rate,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],adverse event,
2747,NCT00827047,Overall survival and disease free survival,2009-01,COMPLETED,INTERVENTIONAL,['NA'],"Bleeding and blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications",
2748,NCT04284943,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,
2749,NCT01788995,Treatment discontinuations/modifications,2012-10-15,COMPLETED,OBSERVATIONAL,['NA'],Progression-free survival,
2750,NCT00954876,Primary objective is to assess PFS in patients with WT KRAS CRC treated with the combination regimen of capecitabine and cetuximab,2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],To perform exploratory analyses of serum and tumor biomarkers (EGFR mutations and genotyping) on toxicity and efficacy.,
2751,NCT01215838,Accuracy of a new MR protocol in diagnosing HCC and other liver lesions.,2010-08,TERMINATED,OBSERVATIONAL,['NA'],,
2752,NCT01919541,Protein Synthesis,2016-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
2753,NCT04090645,Evaluate SAE's associated with TheraSphere® treatment,2014-05-22,COMPLETED,INTERVENTIONAL,['NA'],,
2754,NCT05928819,Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists and correlation with final histology reading.,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
2755,NCT02102984,Relief of malignant biliary obstruction,2014-04,COMPLETED,INTERVENTIONAL,['NA'],cost/effecacy,gallbladder in situ
2756,NCT05568667,Assessment of the programme feasability,2022-10-17,COMPLETED,INTERVENTIONAL,['NA'],Assessment of the evolution on CRC risk factors knowledge,
2757,NCT01048281,NER activity by routine pathologic analysis,2002-08,RECRUITING,OBSERVATIONAL,['NA'],,
2758,NCT02052050,Abdominal isometric endurance,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Lower back muscle strength,Muscle structure
2759,NCT02419677,Recurrence-free survival,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse events,
2760,NCT00433927,Objective response rate,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Safety and toxicity (according to NCI-CTCAE),
2761,NCT04145726,The portion of frail patients undergoing esophageal resection and 6 -month all-cause of mortality,2019-09-25,UNKNOWN,OBSERVATIONAL,['NA'],One-year all-cause mortality in frail vs. non-frail patients One-year all-cause mortality in frail vs. non-frail patients One-year all-cause mortality in frail vs. non-frail patients,postoperatively complications in frail vs. non-frail
2762,NCT05917431,PFS,2023-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Recurrence pattern,
2763,NCT05993234,Real-World Time to Next Treatment (rwTTNT1) in Participants With HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma,2023-12-05,RECRUITING,OBSERVATIONAL,['NA'],European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Stomach (EORTC QLQ-STO22) Score in Participants With HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma,
2764,NCT02229045,PFS(Progression-free survival ),2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],OS (Overall survival ),ORR (Overall tumor response)
2765,NCT00005634,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2766,NCT01825824,Local control rate,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Treatment related toxicity,
2767,NCT03472365,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2018-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Subjects With Treatment-related Adverse Events (AEs),
2768,NCT01942083,To investigate the maximum tolerated dose (MTD) of OPB-111077,2013-05-29,TERMINATED,INTERVENTIONAL,['PHASE1'],Biomarker of OPB-111077,
2769,NCT05111314,Intraindividual intralesional difference in maximum standardized uptake value (SUVmax),2022-02-11,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Incidence of adverse events,
2770,NCT00713427,Number of Participants With Absence of Recurrent Biliary Obstruction,2007-07,COMPLETED,INTERVENTIONAL,['NA'],Change in Bilirubin,
2771,NCT05523245,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of models in prediction tumor response,2022-06-24,RECRUITING,OBSERVATIONAL,['NA'],The negative predictive value of models in prediction tumor response,
2772,NCT05701488,Number of Participants with Adverse Events,2023-04-21,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of Participants with Surgical Complications,
2773,NCT01292681,Correlation early changes in imaging and treatment outcome,2009-08,UNKNOWN,INTERVENTIONAL,['NA'],Correlation pretreatment imaging values and treatment outcome,
2774,NCT04727996,Disease control rate,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival,
2775,NCT01714622,the changes of metabolic syndrome,2012-10,WITHDRAWN,OBSERVATIONAL,['NA'],the changes of insulin resistance after gastrectomy,
2776,NCT05517343,Proportion of definite depression cases,2022-08-20,RECRUITING,INTERVENTIONAL,['NA'],Depression score,
2777,NCT00977613,Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater,2007-04,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival,
2778,NCT04348916,Recommended Phase 2 Dose (RP2D) of ONCR-177,2020-05-20,TERMINATED,INTERVENTIONAL,['PHASE1'],Changes in the level of HSV-1 antibodies compared to baseline,
2779,NCT02199912,biological and radiological markers,2013-10-07,COMPLETED,INTERVENTIONAL,['NA'],loss of fat body mass and/or lean body mass,
2780,NCT02323464,Prevalence of sleep apnea,2015-01-07,COMPLETED,OBSERVATIONAL,['NA'],Sex differences,
2781,NCT02080702,Frequency of anastomosis leakage rate,2014-08,TERMINATED,OBSERVATIONAL,['NA'],Handling of the device,
2782,NCT05371223,Disease Control Rate (DCR),2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],The Overall Survival (OS),Identification of pancreatic cancer disease evolution trough pathway analysis a in primary tumor and peritoneal sites during treatments
2783,NCT02100696,"Maintenance Phase: Percentage of Participants With Remission at Week 66 Among Participants Who Had Achieved a Clinical Response at Week 14, as Determined by the MCS",2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE3'],Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ),
2784,NCT03609892,Helicobacter pylori eradication,2018-08-01,COMPLETED,INTERVENTIONAL,['PHASE4'],adverse events,
2785,NCT01360853,Survival,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Full Pharmacokinetics,
2786,NCT03595722,Complications,2019-07-11,UNKNOWN,INTERVENTIONAL,['NA'],Radiological changes,
2787,NCT00040092,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2788,NCT05946226,Incidence and severity of dose-limiting toxicity (DLTs) within 28 days after IMC002 infusion,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE1'],CAR-positive cell counts in peripheral blood,long-term safety
2789,NCT00030732,Gemcitabine + Capecitabine vs. Gemcitabine alone,2001-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2790,NCT06050317,AE,2023-08-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of response,
2791,NCT05873829,Chemotherapy Induced Peripheral Neuropathy Symptoms Assessment,2022-04-25,COMPLETED,INTERVENTIONAL,['NA'],,
2792,NCT03421912,Overall patient satisfaction after 30 days treatment,2018-02-16,COMPLETED,INTERVENTIONAL,['NA'],Use rate of dermocorticoids,
2793,NCT06186089,Composition and diversity of gut microbiota,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Inflammatory factor,
2794,NCT06248580,The frequency of HDV in certain regions of Southern Anatolia,2024-01-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The rate of HIV and HCV co-infection in HDV positive patients,
2795,NCT03777540,Post-operative mortality In-hospital mortality was defined that occurred during hospitalization up to 90 days excluded post-operative mortality. Postoperative mortality,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
2796,NCT02847767,Changes in tumour vasculature as assessed by changes PL derived model parameters,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],Association (correlation) between aggregate QOL scores and PK derived model parameters,
2797,NCT01882868,Percentage of Participants With Overall Response,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Volume of Distribution at the Steady State (Vss) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis,
2798,NCT04884581,Negative Predictive Value (NPV),2021-05-12,COMPLETED,INTERVENTIONAL,['NA'],,Performance metrics of the endoscopist with the aid of GI Genius CADx
2799,NCT05771181,objective response rate (ORR),2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],advert events,
2800,NCT05064059,Overall Survival (OS),2021-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score,
2801,NCT04768660,Length of hospital stay,2021-02-14,UNKNOWN,INTERVENTIONAL,['NA'],,
2802,NCT03943043,maximum tolerated dose,2017-07-21,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Number of responder (in term of CR, PR, SD) to GEMOX plus nab-paclitaxel as assessed by RECIST 1.1",
2803,NCT00786643,Best Response (BR),2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Progression,
2804,NCT02079623,Tumor response,2013-11,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,Pain registration
2805,NCT05198609,Overall survival,2022-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],Disease control rate,
2806,NCT02591667,Percentage of viable cells within the resected peritoneal deposits after completion of neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab.,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
2807,NCT00587600,The primary assessment for our first specific aim will be to determine the effect of photodynamic therapy on biomarkers after photodynamic therapy.,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The primary assessment for our second specific aim will be to assess if specific biomarkers can be correlated with the confirmed histological elimination of their Barrett's esophagus.,
2808,NCT01396681,recurrence/metastasis free survival,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety and tolerability,
2809,NCT05245331,LARS score,2022-08-04,RECRUITING,INTERVENTIONAL,['NA'],Adverse effects related to both treatments.,
2810,NCT00727376,Clinical benefit of the Polyflex Esophageal Stent as a means to maintain oral nutrition during chemotherapy and/or radiation,2008-03,COMPLETED,OBSERVATIONAL,['NA'],,
2811,NCT06136949,Frequency of overexpression of STARD3 in both early and advanced CRC patients,2023-05-22,RECRUITING,OBSERVATIONAL,['NA'],Concordance between the presence of selected molecular alterations on primary tumour tissues and organoids,
2812,NCT04504565,the sensitivity of SPECT/CT with 99mTc-3PRGD2 in the diagnosis of lymph node metastasis,2020-08-01,UNKNOWN,INTERVENTIONAL,['NA'],The Incidence of Adverse Events,
2813,NCT05797883,Objective response rate (ORR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease control rate (DCR),
2814,NCT01366183,"Percent of women, who are 70 years or older, able to complete at least 4 cycles of treatment regardless of dose reduction and delays",2011-08-15,UNKNOWN,OBSERVATIONAL,['NA'],Percent of patients reporting adverse events as assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events,"Pharmacokinetic parameters including paclitaxel AUC, carboplatin AUC, paclitaxel total body clearance, and time that plasma paclitaxel concentration remains above threshold 0.05 uM/L"
2815,NCT00900016,Independence of tumor fibroblast activation protein (FAP) activity and Met-α2-antiplasmin expression,2007-08,COMPLETED,OBSERVATIONAL,['NA'],Potential plasma surrogates of plasma dipeptidyl peptidase activity and plasma antiplasmin converting enzyme,
2816,NCT04521153,The rate of subjects of major pathological response (MPR),2021-03-25,RECRUITING,INTERVENTIONAL,['NA'],Safety and toleraty,
2817,NCT00233623,Time to progression (6 months after Last patient in),2004-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"Objective Response Rate, Duration of Response, Disease control rate, Overall Survival, (6 months after Last patient in)",
2818,NCT00952016,"Objective response rate, to include complete response and partial response, as defined radiologically using RECIST (Response, Evaluation Criteria in Solid Tumours) on imaging CT scans performed during treatment.",2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],Disease stabilisation rate; progression free survival; 1 year survival and median overall survival; Quality of Life assessment; toxicity assessment.,
2819,NCT01765231,the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],"the incidence of hepatitis B virus maintained response, the incidence of hepatitis B virus sustained response, the incidence of hepatitis B virus relapse and hepatitis B virus relapse related hepatitis",
2820,NCT03546985,Area under the curve (AUC) of pain score of oral mucositis,2017-12-26,COMPLETED,INTERVENTIONAL,['NA'],Incidence of adverse events,
2821,NCT05513716,Proportion of genetic mutations,2024-02-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Association with molecular subtypes and categorical variables,
2822,NCT00510354,Tumor assessments should be performed by a CT or MRI scan after 4 months. Response to treatment with RAD001 plus Imatinib mesylate at 4 months (defined as progression-free survival (PFS) at 4 months).,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Tolerability and safety assessed by AEs and SAEs. Objective tumor response rate (complete response [CR] and partial response [PR]) assessed by CT or MRI PFS at month 12 for patients with data available from follow up observation (optional),
2823,NCT02863783,Relative Ease of Detection of the Tumor with Fiducial,2016-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"Pancreatitis, abdominal pain, infection, bleeding following placement.",
2824,NCT04735900,Optimize cutoff value,2020-09-14,UNKNOWN,INTERVENTIONAL,['NA'],Determine progression free and 9-month survival,Exploratory objective 3
2825,NCT04850040,Major Pathological Response(MPR) 10%,2021-05-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Intraoperative and postoperative complications,
2826,NCT06310590,Localized Objective response rates (ORR),2023-08-08,RECRUITING,INTERVENTIONAL,['PHASE1'],"Radioactivity of Yttrium-90 for 9 participants, assessed by liquid scintillation counter",
2827,NCT01249443,"Incidence of adverse events during paclitaxel and carboplatin treatment according to dose-limiting toxicities (DLTs), graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)",2013-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Effects of therapy on HIV viral load and CD4 cell count,
2828,NCT00466505,Progression-free Survival (PFS),2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Serum TGF-alpha: Treatment Cycle 2,
2829,NCT00006379,Evaluation of Donor Engraftment,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Event free and overall survival,
2830,NCT02086461,Symptoms suggestive of delayed gastric emptying,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],Delayed gastric emptying,
2831,NCT03417921,Emergent Adverse Events,2021-04-26,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2832,NCT00541021,Progression-free survival,2006-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Biomarkers of response,
2833,NCT05675462,Serious adverse event (SAE).,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Detection of systemic and local immune activation in tumors and peripheral blood mononuclear cell will be assessed by single cell RNA seq and/or bulk RNA seq.,
2834,NCT05510908,Number of cancers in people with HIV (PWH) who present for care at domestic AMC sites,2023-07-25,RECRUITING,OBSERVATIONAL,['NA'],Proportion of participants eligible for AMC trials who are successfully enrolled,3. State of planned cancer therapy for cancer patients with HIV initiating therapy or currently under treatment
2835,NCT03427411,Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response,2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response (Complete Response or Partial Response),Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
2836,NCT04404491,PFS,2020-06-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],OS Qol,
2837,NCT05596760,EHR documentation of Goals of Care discussions,2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],Anxiety and depression (HADS),
2838,NCT00145665,correlation FLT-uptake in colorectal liver metastases and the histologically determined proliferation,2005-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",correlation FLT and recurrence rate,
2839,NCT00008099,Disease Recurrence,1998-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival,
2840,NCT03096899,Overall Survival,2016-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
2841,NCT02578264,Determining sensitivity of assay in known cancer patients,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
2842,NCT00538954,Recovery of gastrointestinal function: Time to pass flatus/stool (hours following the end of surgery),2006-08,COMPLETED,INTERVENTIONAL,['NA'],Patient activity level: measured by activPAL® activity meter,
2843,NCT01387295,Response Rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],PFS,
2844,NCT05420870,Anorectal manometry,2022-05-23,RECRUITING,INTERVENTIONAL,['NA'],,
2845,NCT03045952,overall survival,2013-01,COMPLETED,INTERVENTIONAL,['NA'],disease free survival,
2846,NCT01472601,disease-free survival,2011-05-24,UNKNOWN,OBSERVATIONAL,['NA'],,
2847,NCT03974074,Serum albumin level,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Rate of postoperative complications,
2848,NCT03221608,Incidence of endoperitoneal recurrence at 36 months,2017-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],HIPEC toxicity rate,
2849,NCT03254394,Area Under the Curve (AUC) of Intensity of Oxaliplatin-induced Cold Pain/Unpleasantness vs Time,2017-09-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The Cumulative Dose of Oxaliplatin,
2850,NCT00690300,tumor response,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],toxicity / safety,
2851,NCT03481296,Colorectal cancer screening test-specific adherence at 12 months (Colonoscopy),2018-08-20,COMPLETED,INTERVENTIONAL,['NA'],Change in knowledge about colorectal cancer and colorectal cancer screening between baseline and 6 months,
2852,NCT06206278,Overall survival (OS),2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2853,NCT01932125,Safety: Incidence of adverse events,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Clinical benefit rate (complete response + partial response + stable disease),
2854,NCT02096354,Overall Survival,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life (QOL) by QOL questionnaire,
2855,NCT00448136,PFS - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],EORTC QLQ-C30 Functional and Symptom Scale Scores,
2856,NCT01623258,Define the rate of upstaging of colon carcinoma lymph node metastasis with define the rate of upstaging of colon carcinoma lymph node metastasis with sentinel lymph node (SLN) mapping,2002-12,COMPLETED,OBSERVATIONAL,['NA'],,
2857,NCT02132325,Change in level of distress as measured by distress scores on the Distress Thermometer,2014-04,COMPLETED,INTERVENTIONAL,['NA'],,
2858,NCT02132403,Maximum Tolerated Dose (MTD),2014-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Disease Response based on RECIST Criteria,
2859,NCT00052897,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2860,NCT05843877,"Duration between surgery and time ""fit for adjuvant treatment"" (postoperative day X)",2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Comparison of long-term oncological course (24 months) in both arms: occurence of metastases,
2861,NCT00079872,The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],to characterize the quantitative and qualitative toxicities of both treatment arms in this patient population,
2862,NCT03812705,Response rate,2018-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of response,
2863,NCT05488522,Primary Objective,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression Free survival,
2864,NCT01621048,"toxicity: EORTC QLQ H&N35 questionnaire, the university of Michigan Xerostomia questionnaire (XQ) and the MD Anderson Dysphagia Inventory.",2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],,
2865,NCT01196247,Determine the percent of patients who are alive at one year,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2866,NCT03273920,3-year relapse-free survival,2017-09-25,UNKNOWN,INTERVENTIONAL,['NA'],Immune response,
2867,NCT03287453,Self-reported intentions to engage in behavior change to reduce risk of colorectal cancer,2017-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
2868,NCT06078930,Overall Survival (OS),2021-04-06,RECRUITING,OBSERVATIONAL,['NA'],Disease Free Survival (DFS),
2869,NCT03190616,Progression-free Survival(PFS),2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
2870,NCT01283893,Evaluation of operative procedure according to predetermined criteria,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],,
2871,NCT01606124,"Percent Change in Rectal ACF, Pre- and Post Intervention at 6 Months",2012-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Tolerability as Estimated Using the Percent Dose of Treatment Received at 6 Months,
2872,NCT00851084,Progression Free Survival (PFS) Rate at 12 Months,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Immunogenicity of Intravenous (IV) Aflibercept,
2873,NCT02581423,Incidence of treatment discontinuation due to AEs,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4'],Incidence of toxocity-related dose reductions,
2874,NCT00925015,Number of Participants With an Adverse Event (AE),2009-06-17,COMPLETED,INTERVENTIONAL,['PHASE1'],"AUC0-24 of Irinotecan Following Administration of Cetuximab / Irinotecan Alone, or in Combination With 10 mg/kg Dalotuzumab",
2875,NCT03412799,Recommended dose of SBP-101,2018-06-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Peak plasma concentration (Cmax) for all three drugs,
2876,NCT00005842,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2877,NCT03862885,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2878,NCT04492033,P2: Objective response rate (ORR) of CTX-009 (ABL001) in combination with paclitaxel in patients with BTC,2020-06-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",P2: Overall survival (OS),
2879,NCT05617378,Risk factor,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
2880,NCT02349594,Change of TNF-α production in pg/ml,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4'],(anti-) Oxidant status and oxidative damage,
2881,NCT03430778,difference between SpHb value and SaHb value (SpHb - SaHb),2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
2882,NCT03140332,Scannographic evaluation of tumor response with mRECIST criteria,2017-02-27,COMPLETED,INTERVENTIONAL,['NA'],,
2883,NCT06189664,Detection of adenocarcinoma,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2884,NCT00684229,cancer recurrence,2007-12,WITHDRAWN,INTERVENTIONAL,['NA'],length of post operative hospitalization,
2885,NCT02457390,Detection of synchronous liver metastases with CE-LUS,2015-01,COMPLETED,INTERVENTIONAL,['NA'],CE-LUS feasibility,
2886,NCT03891953,Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR001.,2019-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Time to Progression (TTP),
2887,NCT05807542,Pathological complete response,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Objective Response Rate (ORR),
2888,NCT00003797,,1999-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2889,NCT04292990,Pain Intensity Measure,2020-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],Quality-of-Life composite Index,
2890,NCT03429530,the role of circulating miRNAs in diagnosis of HCV related hepatocellular carcinoma.,2018-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,
2891,NCT01281761,response rate,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2892,NCT04490668,Comparison of the rate of anastomotic leakage,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2893,NCT03949231,Overall survival,2019-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse event rate,
2894,NCT04310176,progression-free survival (PFS),2019-05-24,RECRUITING,INTERVENTIONAL,['PHASE2'],metastases resection rate (R0/R1/R2),
2895,NCT05541783,Scores on the physical function and pain symptom scales of EORTC QLQ-C30 questionnaire,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],Scores on ST22 questionnaire,
2896,NCT02123381,changes of serum vascular endothelial growth factor（VEGF）level before and after radiotherapy,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],grade 3-5 adverse events,
2897,NCT01333124,Complete resection rate,2011-09-28,TERMINATED,INTERVENTIONAL,['PHASE2'],The feasibility and compliance,
2898,NCT02456051,Pancreatic cancer diagnosis,2015-04,TERMINATED,OBSERVATIONAL,['NA'],Mortality,
2899,NCT00002801,,1996-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2900,NCT04167293,24-week progression-free survival (PFS) rate,2019-11-16,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse Events,
2901,NCT04790227,Secondary outcome after chemo-radiotherapy,2022-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2902,NCT03515941,Number of Participants Who Complete the Recommended Therapy From Each Arm,2018-06-22,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Median Time to Recurrence,
2903,NCT02937389,"The classification of gastric conduit ischemia by endoscopic findings predicts the major complications of gastric conduit (strictures, leakage, necrosis)",2015-05,COMPLETED,OBSERVATIONAL,['NA'],Biological examination of gastric conduit as assessed by the Mitochondrial DNA copy number,
2904,NCT01446458,Maximum tolerated total dose of stereotactic body radiation to patients with resectable or borderline resectable pancreas cancer following FOLFIRINOX chemotherapy,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Clinical and pathologic objective response rate as measured by MRI (clinical response) and histopathology and rate of complete resection (R0) (pathologic response),
2905,NCT02676349,To assess the efficacy of two neoadjuvant therapies in patients with borderline resectable pancreatic carcinoma evaluated on histological R0 resection margin rate,2016-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Evaluate the progression-free survival,
2906,NCT01487785,Incidence rate and category of dose limiting toxicities (DLTs),2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Serum tumor marker Ca 19-9,
2907,NCT02448979,Long term survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Postoperative complications,
2908,NCT03469726,Diagnostic accuracy of CE-DW-MRI,2017-12-22,UNKNOWN,INTERVENTIONAL,['NA'],Assess local resectability,Progression free survival
2909,NCT03597126,Change in Female Sexual Function Index [FSFI],2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
2910,NCT03203304,Number of participants with adverse events,2017-08-25,TERMINATED,INTERVENTIONAL,['PHASE1'],Rate of local control of the SBRT treated lesion,
2911,NCT02110498,To develop and prospectively validate a panel of molecular markers to differentiate benign pancreatic cysts from those with malignant potential using surgical pathology as the gold standard,2014-03,RECRUITING,OBSERVATIONAL,['NA'],"To determine the sensitivity, specificity, and overall accuracy of imaging (CT, MRI and EUS) in patients with pancreatic cysts",To determine the proportion of patients with malignancy in operable pancreatic cysts
2912,NCT05853692,Oral Mucositis,2022-10-10,RECRUITING,INTERVENTIONAL,['NA'],Severity of Oral Mucositis,
2913,NCT01797224,Major malformations,2012-03,RECRUITING,OBSERVATIONAL,['NA'],Infant follow-up,
2914,NCT01807156,Number of Patients With Advanced Hepatocellular Cancer (HCC) Receiving Tivozanib Who Are Free From Progression,2013-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria,
2915,NCT04266548,surgical benefit rate of fluorescent image,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],Post operative Mortality,
2916,NCT04118114,Treatment related adverse events rate,2019-09-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2917,NCT03326375,Local tumor control (efficacy fo SBRT),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Radiation induced liver disease (RILD),
2918,NCT00415454,Toxicity,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Gene expression in pancreas,
2919,NCT02934529,Overall Survival,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Safety and tolerance as measured by the NCI-CTCAE version 4.03 criteria,
2920,NCT03745326,Frequency and severity of treatment-related adverse events,2019-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2921,NCT03331406,Number of participants that adhered to physical activity program,2017-12-01,COMPLETED,INTERVENTIONAL,['NA'],Number of participants with adverse events,
2922,NCT01276405,Disease-free survival,2010-03,TERMINATED,OBSERVATIONAL,['NA'],Safety (Incidence of adverse events),
2923,NCT06037954,Attrition rates,2023-09-07,RECRUITING,INTERVENTIONAL,['NA'],Treatment satisfaction,
2924,NCT03445936,Incisional hernia,2018-02-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Cost analysis,
2925,NCT03271255,Progression-free Survival (PFS) Time,2018-05-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate),
2926,NCT03325361,Anastomotic leakage,2017-10,UNKNOWN,INTERVENTIONAL,['NA'],,
2927,NCT01912586,Changes in sexual function based on the (IIEF)-5 score and NPT,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Compliance and overall patient satisfaction based on the self reported compliance diary and IIEF-5 score and NPT,
2928,NCT00579891,establish a serum and tissue bank,1989-03-28,COMPLETED,OBSERVATIONAL,['NA'],,
2929,NCT06185374,National Annie Colonoscopy Survey Score,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Percentage of Participants who Had Adequate Bowel Preparation at Colonoscopy Appointment,
2930,NCT01456585,Number of participants with adverse events,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival,
2931,NCT04712292,Rate of radical surgery,2020-09-08,UNKNOWN,OBSERVATIONAL,['NA'],Mortality,
2932,NCT02436044,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2933,NCT00833508,Change of Anaerobic threshold of 1.5ml/min/kg or more,2009-01,COMPLETED,INTERVENTIONAL,['NA'],Operative outcome,
2934,NCT05710406,Disease free survival (DFS) (Phase III),2023-05-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Alternative disease free survival,"• Patient Reported Outcomes Version of Common Terminology Criteria for Adverse Events for symptoms of rash, diarrhea, and fatigue"
2935,NCT00003833,overall survival,1999-02,COMPLETED,OBSERVATIONAL,['NA'],,
2936,NCT03838406,Objective response rate,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],Overall survival,
2937,NCT03231176,Objective Response Rate (ORR),2017-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety and tolerability of varlitinib when combined with capecitabine,
2938,NCT01853644,Overall Response Rate (ORR),2013-06-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS) in Platinum-resistant Ovarian Cancer to Treatment With Single Agent Tivozanib,
2939,NCT02375581,all cause mortality,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],incidence rates of radiation-related pneumonitis and esophagitis,
2940,NCT01782690,Overall Survival Stratified by Rash,2012-03-31,COMPLETED,OBSERVATIONAL,['NA'],Score in Participant Questionnaire: Quality of Life,
2941,NCT02507882,"Specific miRNA levels and their association with degree of fibrosis, cirrhosis and HCC",2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,
2942,NCT02323776,Postoperative complications,2014-12,TERMINATED,OBSERVATIONAL,['NA'],,
2943,NCT01037790,Response Rates,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2944,NCT00137683,colorectal cancer screening,2001-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",knowledge,
2945,NCT00036400,Number of red blood cell transfusions,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],"Hemoglobin levels during preoperative chemoradiation; effect on quality of life measured by patient self-reported Linear Analog Scale Assessment, Functional Assessment of Cancer Therapy-Anemia, and Brief Fatigue Inventory; tumor response; safety",
2946,NCT03217773,Short-term morbidity,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],Local recurrence,
2947,NCT04597151,Categorical responses to program evaluation survey,2020-10-12,COMPLETED,INTERVENTIONAL,['NA'],Frequency of responses to the baseline socio-demographics survey,Change in Lifestyle Score on the National Institute of Health (NIH)/ National Cancer Institute (NCI) Automated Self- Administered 24-hour Dietary Assessment Tool (ASA24)
2948,NCT00597129,safety MTD,2004-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",efficacy,
2949,NCT04642690,Serum and Tissue Biomarkers,2020-09-24,TERMINATED,OBSERVATIONAL,['NA'],Biomarkers and disease progression,
2950,NCT03962179,Technique - % of patients with successful implantation of VACStent,2019-09-22,UNKNOWN,INTERVENTIONAL,['NA'],Sealing of leak - % of patients with successful implantation of VACStent,
2951,NCT06051851,Progression-free survival（PFS）,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
2952,NCT06085677,"Serologic concentrations of ghrelin, gastrin, pepsinogens and vitamin B12",2023-11-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2953,NCT01852890,"Number of grade 3, 4, & 5 adverse events during radiation",2014-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Number of grade 3, 4, & 5 adverse events post-treatment",
2954,NCT03775798,Incidence of hepatocellular carcinoma after direct-acting antivirals for HCV,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],Adverse events after direct-acting antivirals for HCV,
2955,NCT02159248,Evaluate safety and toxicity,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Assess the anti-tumor response.,
2956,NCT03564405,Objective Response Rate,2016-12-05,COMPLETED,INTERVENTIONAL,['NA'],,
2957,NCT04074135,Characterization of the natural and clinical histories of VHL pancreatic neuroendocrine tumors and cystic lesions,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],distribution of time from initial presentation with pancreatic tumors to the time that surgery is recommended,
2958,NCT03356236,Progression-free survival (PFS),2018-04-17,RECRUITING,OBSERVATIONAL,['NA'],severity of Adverse events (AE),
2959,NCT01641276,Identification of different group of specific frequencies of modulation in hepatitis B carriers with and without hepatocellular carcinoma associated with biofeedback response,2012-04,COMPLETED,INTERVENTIONAL,['NA'],Characterization of differences biofeedback response in hepatitis B carriers with and without hepatocellular carcinoma,
2960,NCT00336700,2-year Recurrence Free Survival (RFS),2006-06,TERMINATED,INTERVENTIONAL,['PHASE2'],KRAS Mutational Status,
2961,NCT00641615,Safety (toxicities as assessed by NCI CTCAE version 3),2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],"Specific CTL induction in vitro, Objective rate as assessed by RECST criteria",
2962,NCT02195232,Percent Change in D-dimer Value,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Cumulative Incidence of VTE at 56 Days,
2963,NCT01155609,Decrease in mucositis severity and time to complete response,2010-09,COMPLETED,INTERVENTIONAL,['NA'],Improvement in quality of life,
2964,NCT00004895,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2965,NCT01904630,Data on association between sequence variants in exons and CRC risk,2012-12,COMPLETED,OBSERVATIONAL,['NA'],,
2966,NCT01760356,Change in the Percentage of expression of IL-2 in CD4 and CD8 subsets of T lymphocytes.,2011-05-01,TERMINATED,OBSERVATIONAL,['NA'],Post transplant surgical complications,
2967,NCT00027274,Risk of Cancer with Specific Mutations,2001-11-28,RECRUITING,OBSERVATIONAL,['NA'],,
2968,NCT05962450,Progression-Free Survival (PFS),2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to Quality of Life (QoL) Deterioration,
2969,NCT02545309,bile acid transporter genes,2015-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],upper gastrointestinal bleeding episodes,
2970,NCT00035100,Tumor response rate,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],pharmacogenetic analyses with blood and tumor samples from these patients,
2971,NCT03510923,Costs,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],Other aberrant findings requiring additional therapy,
2972,NCT04003792,conversion rate to complete resection in patients with initially inoperable liver-only metastases due to colorectal cancer after treatment with HAI of oxaliplatin with FOLFIRI and bevacuzimab systemic treatment.,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2973,NCT03516994,Proportion of Whites who complete advance care planning,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Patient Quality of Life,
2974,NCT03899428,Time to decline to ≥ 2 log10 IU/mL of serum HBsAg,2019-05-02,RECRUITING,INTERVENTIONAL,['PHASE2'],"Adverse events assessed in terms of seriousness, severity, and relationship to the study material according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",
2975,NCT01030757,Tumor Response Rate (Complete Response + Partial Response).,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],"Toxicity, Progression Free Survival, Clinical Benefit Rate (Complete Response + Partial Response + Stable Disease), Median Duration of Clinical Benefit, and Median Overall Survival of Subjects.",
2976,NCT01111591,Short term outcome,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],Long term outcome,
2977,NCT01167712,Progression-Free Survival,2010-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life Score as Measured by Functional Assessment of Cancer Therapy-Ovary-Total Outcome Index (Fact-O TOI),Changes in the Tumor Perfusion Parameters as Quantified by Vascularity or Blood Volume; Perfusion or Blood Flow; Mean Transit Time; and Microvascular Permeability or Permeability Surface Area Product
2978,NCT01131078,Time to Progression (TTP),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Overall Complete Response,
2979,NCT04926324,Determination of the clinical complete response rate,2022-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determination of the organ preservation rate,
2980,NCT00651742,Overall Tumor Response Rate (ORR),2006-01-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE),
2981,NCT01283802,the technical feasibility,2004-06,COMPLETED,OBSERVATIONAL,['NA'],Efficacy,
2982,NCT02335970,Degree of physical disability estimated by the Disability Rating Index (DRI),2005-09-05,COMPLETED,INTERVENTIONAL,['NA'],PEF (Peak Expiratory Flow),
2983,NCT01465308,Change from baseline in oral mucositis grades,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in baseline weight in one month,
2984,NCT04011033,Disease Control Rate (DCR),2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Alpha-fetoprotein (AFP),
2985,NCT00548236,"To evaluate the ability of a multi-center, telephone-based physical activity intervention to increase weekly physical activity levels in sedentary patients treated with adjuvant chemotherapy for Stage I-III breast or colorectal cancer.",2007-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"To evaluate the impact of a physical activity intervention upon fitness, exercise self-efficacy, anthropometric measures, and quality of life in a group of patients with stage I-III breast or colorectal cancer.",
2986,NCT01015833,Overall Survival,2010-02-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Best Overall Response Rate,
2987,NCT01095523,To compare the overall survival of patients at high risk for developing peritoneal carcinomatosis from colorectal cancer who undergo mandatory second look surgery + HIPEC and CRS (if applicable) vs. similar patients who receive standard of care.,2010-01-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],To determine recurrence-free survival in both arms. To investigate selection criteria for patients who might benefit from a strategy of MSLS with CRS + HIPEC.,
2988,NCT01779583,"• Correlation of plasma level and kinetics of gastric cancer derived exosomes (at baseline and monthly during therapy until tumor progression or death) and time-to-event end-points: Overall survival, Progression-free survival and Overall response rate.",2013-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2989,NCT04666090,Pathological Complete Response (PCR),2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],The changes in the peripheral blood immunoprofile among non-PCR (NPCR) and PCR patients,
2990,NCT03305146,Comparison between gene mutations found into the pancreatic cystic tumor fluid to gene mutations found into tissue specimen,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Evaluate the feasibility of the molecular biology analysis of the pancreatic cystic tumor fluid to distinguish the pancreatic cysts.,
2991,NCT03300921,Number of Adverse Events,2017-09-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,
2992,NCT00103324,Confirmed response probability (complete and partial),2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
2993,NCT00444795,"Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), Unexpected AEs/ADRs, and Unexpected SAEs/SADRs",2007-05,COMPLETED,OBSERVATIONAL,['NA'],"Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) According to Response Evaluation Criteria in Solid Tumors (RECIST)",
2994,NCT03302637,Presence or absence of bacterial taxa will be compared in oral and pancreatic samples.,1992-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
2995,NCT03179540,Rate of macroscopically positive resection margin,2018-03-16,RECRUITING,INTERVENTIONAL,['NA'],Bowel Function,
2996,NCT02730702,Whether rectal LEBS readings can predict the presence of advanced adenomas in the colon.,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,
2997,NCT03397654,Incidence of treatment-emergent adverse events (safety and tolerability),2018-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Improvement of progression-free survival rate (PFSR; efficacy),
2998,NCT05070104,Recommended Phase 2 Dose,2023-03-30,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Overall Survival,
2999,NCT03015168,overall survival,2012-01,COMPLETED,OBSERVATIONAL,['NA'],grade 3 or higher treatment related small bowel toxicity,
3000,NCT02318784,Overall Response Rate (ORR),2015-07-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability,
3001,NCT01043523,Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure,2009-12,COMPLETED,OBSERVATIONAL,['NA'],"Sensitivity, Specificity and Accuracy of Blinded Read of Precontrast and Combined Precontrast/Postcontrast Images Based on Final Diagnosis.",Change in Information About Lesion Characterization Obtained From the Combined Precontrast and Postcontrast Images as Compared With the Precontrast Images
3002,NCT00801294,PFS,2006-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Effectiveness of dose reduction guidelines in managing adverse events,
3003,NCT00416494,Response Rate (Percentage of Participants With Partial or Complete Response),2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety and Tolerability,Effect on Wound Angiogenesis
3004,NCT02809534,12-week Progression-free survival rate(PFR 12w),2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),
3005,NCT02485119,"tmax (time to reach maximum drug concentration in plasma) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me",2015-08-14,COMPLETED,INTERVENTIONAL,['PHASE1'],Immunogenicity evaluation based on anti-BAY94-9343 antibody count,
3006,NCT05201430,3-year disease free survival,2021-08-27,RECRUITING,INTERVENTIONAL,['PHASE3'],adverse event,
3007,NCT00663819,Proportion of Subjects Who Experience a Clinical and/or Radiologic Anastomotic Leak,2008-04,TERMINATED,INTERVENTIONAL,['NA'],"Determine the Efficacy and Further Substantiate Safety of CBSG Used in Conjunction With Circular Staplers When Performing High-risk Colorectal, Coloanal, and Ileoanal Anastomoses.",
3008,NCT02284529,To evaluate the incidence of grade 0-3 neurosensory symptoms (paresthesia) in the end of study,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3009,NCT01699399,Proportions of patients requiring sedation,2012-08,COMPLETED,INTERVENTIONAL,['NA'],patient pain during insertion,post-procedure discomforts and 30 days complication rate
3010,NCT02991638,Adverse events and severe adverse events,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
3011,NCT06102785,Progression Free Survival,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
3012,NCT00427349,Four-month Progression-free Survival Rate,2008-11-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate,
3013,NCT01972490,the rate of patients converted to resection for liver metastases,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],tumor response,
3014,NCT02842203,ctDNA assessment and relation to clinical outcome,2016-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],ctDNA versus CEA,
3015,NCT06076265,Positive detection rate of CEA,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
3016,NCT00074867,"At the completion of Stage 1 of the study, it did not meet the objective response criteria to proceed to Stage 2 of the trial.",2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"Given the outcome of the primary objective, analysis of secondary objectives were not formalized.",
3017,NCT04184960,Operative links on gastric intestinal metaplasia (OLGIM),2019-12-05,RECRUITING,OBSERVATIONAL,['NA'],,
3018,NCT03060642,Oral and esophageal 16S rRNA gene sequencing,2018-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Gastric aspirate mass spectrometry,
3019,NCT02041897,Rate of change of diagnosis,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of Participants with Adverse Events,
3020,NCT04109105,Effectiveness and security analysis in the prevention of anastomosis leakage through the protection of ileocolic anastomosis with NHS-PEG coated collagen patch.,2019-01-15,UNKNOWN,OBSERVATIONAL,['NA'],Number of hospital readmissions.,
3021,NCT02668380,Adverse Events,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],Objective response rate,
3022,NCT04970316,Development of stoma-related issues after PE or CRS+HIPEC for colorectal cancer,2021-01-25,RECRUITING,OBSERVATIONAL,['NA'],Risk factors associated with developing organ specific late adverse effects,
3023,NCT05996276,Overall survival (OS),2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],Progression-free survival (PFS).,
3024,NCT04209933,helicobacter pylori eradication,2020-05-25,COMPLETED,INTERVENTIONAL,['PHASE4'],symptoms effective rates,adverse events
3025,NCT00388037,Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3026,NCT00578071,Number of Participants With Dose-limiting Toxicities (DLTs),2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pathological Complete Response Rates Associated With This Regimen.,
3027,NCT02817425,Overall Survial (OS),2013-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Dose intensity,
3028,NCT05944237,Number AEs Related to Atezolizumab (Dose Escalation and Expansion Phase),2023-07-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Assess change in tumour T cell infiltration in baseline and on-treatment biopsies,
3029,NCT04127734,1-year stomafree survival,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA'],1 year mortality,Hospital related costs
3030,NCT03699332,Fluorescent signal at time of surgery,2018-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Optimal dose of the dual-labeled antibody preparation,
3031,NCT02673710,Sarcopenia quantified via CT-scan defined as a skeletal muscle index at the 3rd lumbar vertebra below 41 for women and below 43 or 53 for men with a Body Mass Index below or above 25 respectively,2016-03-14,COMPLETED,OBSERVATIONAL,['NA'],First Progression Free Survival (PFS1) is defined as the time between initial diagnosis and first progressive disease,
3032,NCT05128708,detection of post operative wound infection in both groups,2020-08-07,COMPLETED,INTERVENTIONAL,['NA'],,
3033,NCT05704530,To observe the ctDNA MRD dynamics during adjuvant immunotherapy .,2023-03-29,RECRUITING,INTERVENTIONAL,['NA'],,
3034,NCT04777942,"Progression-free survival, PFS",2021-02-20,RECRUITING,INTERVENTIONAL,['NA'],"Overall survival, OS",
3035,NCT05982184,Patient reported anxiety measured by the 6-item Spielberger State-trait Anxiety (STAI-6) inventory at admission.,2023-10-03,RECRUITING,INTERVENTIONAL,['NA'],Quality of recovery is a comprehensive 40-item questionnaire (QoR-40) used to assess the rate of recovery after surgery.,Rate and type of complications during surgery as recorded in the EHR
3036,NCT05304936,Determine the maximum tolerated dose (MTD),2022-10-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of Response,
3037,NCT05445570,Specificity of the InterVenn test,2022-05-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3038,NCT04519138,Proportion of patients with pre-specified adverse events,2020-09-30,COMPLETED,INTERVENTIONAL,['NA'],Amount of visible biopsy material over or under 5 mm at endoscopy examination,
3039,NCT05669339,Maximally tolerated dose,2024-04,RECRUITING,INTERVENTIONAL,['PHASE1'],Change in the biomarker TGF-B,
3040,NCT04624555,Participant acceptance of mt-sDNA as a follow up strategy compared to colonoscopy as measured by the Stool Test Satisfaction Survey.,2024-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3041,NCT03792854,Qol (EORTC QLQCR29) absolute values and change over time,2018-12-01,RECRUITING,OBSERVATIONAL,['NA'],late toxicity,
3042,NCT05506943,Best Overall Response,2023-01-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Exposure Response by Pharmacokinetic (PK) Sampling,
3043,NCT05407519,RFS rate,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],AEs,
3044,NCT00504361,"Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes will be obtained.",2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
3045,NCT05967429,Assess the quality of life,2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3046,NCT00185081,"Pharmacokinetics, biodistribution and dosimetry of In-IMP-205",2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3047,NCT03755739,Complete response (CR) rate before or at Month 6,2018-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Cause of death (COD) when appropriate,
3048,NCT04154748,Complete ablation rate 6 weeks after APC treatment.,2002-06-04,COMPLETED,INTERVENTIONAL,['NA'],Complete ablation rate at the end of follow-up,
3049,NCT03909724,Progression Free Survival,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Liquid biopsies,
3050,NCT00812864,"Mean value and dispersion of the main plasmatics pharmacokinetics parameters of capécitabine, 5'DFUR, 5-FU and FBAL.",2009-01,COMPLETED,INTERVENTIONAL,['PHASE4'],"Objective response comparing lesions' targets according to RECIST criteria, at course n°3 and n°6.",
3051,NCT03957902,Assessment of changes in acetylation levels of COX enzymes in platelets and non-neoplastic and neoplastic colonic tissues,2019-05-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Assessment of changes in major urinary metabolite of PGE2 (PEG-M) levels depending on drug dosis,
3052,NCT04729322,Objective response rate,2021-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3053,NCT06137170,Overall Survival (OS),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],"Proportion of patients in the sequential treatment groups who received myelopoiesis supporting therapy, differentiating between prophylactic and for therapeutic purpose",
3054,NCT00454519,overall survival time,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],perioperative morbidity and mortality,
3055,NCT05038397,Recurrence free survival (RFS) after resection,2018-01-30,COMPLETED,INTERVENTIONAL,['NA'],Rate of post operative hepatic decompensation,
3056,NCT01205711,Progression-free survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
3057,NCT03702309,Collection and annotation of biospecimens,2017-08-03,RECRUITING,OBSERVATIONAL,['NA'],Correlative Studies Questionnaire,
3058,NCT02548910,Trial Feasibility,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Change in Physiologic Parameters (Cardiac Index),
3059,NCT05254327,Efficacy of BMX-001 as measured by Grade 3 and above associated with hematologic Toxicities,2022-08-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3060,NCT02547064,Time to Intubation,2015-10,COMPLETED,INTERVENTIONAL,['NA'],Airway Injury,
3061,NCT03679338,Rate of success of the use of a treatment based on radiofrequency for all the target stenosis.,2018-03-22,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
3062,NCT02528110,overall survival,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2'],complication rate,
3063,NCT01563991,Morbidity,2007-02,COMPLETED,INTERVENTIONAL,['NA'],,
3064,NCT00416858,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3065,NCT01915693,patient-reported dysphagia,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],cost,
3066,NCT05601388,evaluate the immunohistochemical (IHC) expression of IMP3 in CRC and to correlate its expression with some known clinicopathological parameters.,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
3067,NCT04771715,Overall Survival,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],Incidence of treatment-related adverse events (TRAE),
3068,NCT00020345,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3069,NCT00588575,,2004-10,COMPLETED,OBSERVATIONAL,['NA'],,
3070,NCT02825550,Tumor Response (Efficacy),2016-04,COMPLETED,INTERVENTIONAL,['NA'],Serum Level of AFP,
3071,NCT01583686,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),2012-05-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3072,NCT02575378,Progression-free survival,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
3073,NCT03222895,Distribution of lymph node metastases,2019-03-01,RECRUITING,OBSERVATIONAL,['NA'],3- and 5-year overall and disease free survival,
3074,NCT03550625,Assessment of the computer- made optical diagnosis of each colorectal polyp,2018-07-15,UNKNOWN,OBSERVATIONAL,['NA'],,
3075,NCT01969591,solid diet time,2011-01,COMPLETED,INTERVENTIONAL,['NA'],"Complications:anastomotic leakage,intestinal obstruction,wound infection",
3076,NCT00256269,To assess the overall response rate,2005-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Evaluation of Time to Death,
3077,NCT03950141,progression-free survival,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,Safety and tolerability as measured by number and grade of toxicity events
3078,NCT04831814,Rate of accurate diagnosis of sessile serrated polyps/adenoma by the Endoscopists in the two groups.,2019-04-04,COMPLETED,INTERVENTIONAL,['NA'],Diagnostic Characteristics,
3079,NCT01151852,Progression-free Survival,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety and Tolerability of Imatinib,
3080,NCT04190498,The study will compare OSA prevalence in a group of patient curatively resected for NASH-related HCC with a group of HCV-related HCC.,2020-01-21,WITHDRAWN,OBSERVATIONAL,['NA'],The study will compare non-recurrence-free survival rate between groups.,
3081,NCT03811431,Number of patients in whom contrast enhanced ultrasound guided liver biopsy leads to the final diagnosis as compared to conventional ultrasound guided liver biopsy. The final diagnosis will be assessed based on histological examination.,2011-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3082,NCT02164149,CT scan after colon cancer surgery. The length of the tumour feeding artery will be measured on the images.,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,
3083,NCT04451512,Complete resection rate,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],related costs of treatment,
3084,NCT05343013,To determine the 6-month ctDNA clearance rate in colorectal cancer patients with minimal residual disease following 6 months of TAS-102 therapy.,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3085,NCT06287723,3-year disease free survival,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Time to molecular recurrence,
3086,NCT01930318,Insulin resistance in perioperative period of gastrointestinal laparoscopic surgery,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],Self-rating anxiety scale and self-rating questionnaire for depression before surgery,
3087,NCT01845753,Rate of Lynch Syndrome in a population of primary colorectal cancer,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,
3088,NCT05435014,Phase II part: target lesion response at 6 weeks after TAE/TACE treatment.,2022-09-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II part: Safety variables evaluation - ECG test,
3089,NCT02085460,Incidence of Grade ≥3 Oral Mucositis Determined by Clinical Examination and Assessed by Central Review According to the Common Terminology Criteria of Adverse Events (CTCAE) Version 3.0.,2014-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Subjects Who Did Not Developed Grade ≥3 Mucositis,
3090,NCT03645187,number of patients with improved radiology,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,
3091,NCT04989855,ORR,2021-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety and Tolerability,
3092,NCT01375569,Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC).,2011-06-22,COMPLETED,INTERVENTIONAL,['PHASE2'],Count of Participants With Adverse Events,
3093,NCT01569282,Morbidity,2011-10,WITHDRAWN,INTERVENTIONAL,['NA'],"The numbers of Surgical, Radiological or Endoscopical therapeutic re-interventions",
3094,NCT03516695,Effectiveness of TheraSphere® treatment in participants with liver cancers in a real-life setting,2018-02-23,TERMINATED,OBSERVATIONAL,['NA'],TheraSphere® Dosimetry in the subgroup of HCC participants,
3095,NCT02145013,Mortality,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],Survival outcomes,Impact of PET CT on overall survival following liver resection
3096,NCT05474794,Sensitivity and Specificity of DFI-EUS in the diagnosis of SELS,2022-07-20,RECRUITING,INTERVENTIONAL,['NA'],,
3097,NCT05983419,Safety for full resection in BE,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
3098,NCT05608200,Overall survival (OS),2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse Events (AEs),
3099,NCT05420415,5-year DFS,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],5-year OS,
3100,NCT01010360,,2009-08,COMPLETED,OBSERVATIONAL,['NA'],,
3101,NCT04258644,R0 resection rate,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],3-year OS,
3102,NCT04359732,Imaging parameters as potential predictors of tumor response,2020-05-08,RECRUITING,INTERVENTIONAL,['NA'],Early regression model (ERI),
3103,NCT02447679,tumor recurrence,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3104,NCT05257694,Recurrence-free survival (RFS),2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],Recurrence,
3105,NCT05970627,Rate of pathological complete responses (pCR),2023-07-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The incidences and types of adverse events (AE) and severe adverse events (SAE),
3106,NCT03269903,Through-the-scope stent placement (feasibility): incidence of device related adverse device events at moment of stent placement,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],"Retrosternal pain related to esophageal stent, measured with the Visual Analog Scale (functional outcome)",
3107,NCT00502671,"Percentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE",2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Percentage of Participants With Early Withdrawal or Discontinuation Due to an AE,
3108,NCT03121729,occurrence rate of severe complications,2017-06-21,UNKNOWN,INTERVENTIONAL,['NA'],Procalcitonin,
3109,NCT05956990,Fear of Progression Questionaire-Short Form (FoP-Q-SF),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Platelet count,
3110,NCT04659382,Progression-free survival at 9 months,2020-10-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3111,NCT04573088,Postoperative pain as measured by VAS score,2020-06-22,UNKNOWN,INTERVENTIONAL,['NA'],Anxiety and depression measured by State-Trait Anxiety (STAI) questionnaire,
3112,NCT02856815,Recurrence Free Survival (RFS),2018-05-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Hematological examination,
3113,NCT06246344,surgical difficulty,2023-12-01,RECRUITING,OBSERVATIONAL,['NA'],QLQ-CR29,
3114,NCT03475004,Objective Response,2018-09-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
3115,NCT05732623,Diet and the risk of eoCRC,2022-12-05,RECRUITING,OBSERVATIONAL,['NA'],,
3116,NCT00457743,Number of Subjects With Clinical Benefit Response (CBR) Based on the Extramural Review Committee Assessment in Recommended Dose Group,2005-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival Time,
3117,NCT01034358,Twelve Month Antibody Response to the Human Papillomavirus (HPV) Vaccine (Geometric Mean Titers [GMT]),2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3118,NCT00287859,Maximum tolerated dose,2004-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3119,NCT04229537,Rate of adverse events,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
3120,NCT01491217,Overall response rate(ORR) evaluation,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3121,NCT02057471,Hemoglobin levels,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4'],C Reactive Protein levels,Number of adverse events associated with intravenous iron infusion
3122,NCT05239741,Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) For RAS Wild-type Participants,2022-04-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE),
3123,NCT01549275,Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study.,2010-04,COMPLETED,OBSERVATIONAL,['NA'],Correlation Between the Growth Speeds of Cultured Cells and Worsening of AJCC TNM Stages or HCC Related Death 6 Months After Plating of Cells,
3124,NCT03382327,Comparison of the intra-operative modifications rates,2017-10-16,COMPLETED,INTERVENTIONAL,['NA'],Preoperative images independent analysis,
3125,NCT04013841,Intestinal microbiome composition,2021-04-08,COMPLETED,INTERVENTIONAL,['NA'],Intestinal microbiome composition,
3126,NCT01325649,Locoregional recurrence rate,2009-02,COMPLETED,OBSERVATIONAL,['NA'],Rate of involvement of circumferential resection margin (pCRM positive of resected specimens,
3127,NCT01552200,NaviAid™ G-Eye procedure adenoma detection rate compared to the standard colonoscopy procedure adenoma detection rate,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,
3128,NCT04444167,Objective response rate (ORR),2020-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of subjects who develop detectable anti-drug antibodies (ADAs),
3129,NCT00838656,Percentage of patients completing 12 courses of chemotherapy,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Rates of optimal and suboptimal interval debulking,
3130,NCT02437656,The efficacy will be assessed on the operative specimen by the complete histological response rate (absence of tumor cells : pCR).,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Sphincter preservation rate and downstaging rate,
3131,NCT06068452,Cardiopulmonary Exercise Testing (CPET)/ Portsmouth - Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (P-POSSUM) predicted mortality versus actual 30 day mortality,2021-03-24,COMPLETED,OBSERVATIONAL,['NA'],Cardiopulmonary Exercise Testing (CPET) / Portsmouth - Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (P-POSSUM) predicted morbidity versus actual post-operative morbidity,
3132,NCT00991003,The primary endpoint was the number of cancerous lesions and polyps detected on CCE compared to conventional colonoscopy,2007-11,COMPLETED,INTERVENTIONAL,['NA'],"Secondary endpoints were completeness of the exam completeness, patient acceptance and adherence to preparation regimen",
3133,NCT00215514,"To assess patient tolerance and toxicity of postoperative adjuvant regimen using epirubicin, cisplatin, and infusional 5-FU before and after a course of radiotherapy among patients with curatively resected gastric or gastroesophageal adenocarcinoma.",2000-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
3134,NCT00826410,number of surgical site infections according to CDC guidelines after laparotomy in general surgery,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],risk factors for surgical site infections,
3135,NCT03430700,Progression-Free Survival (PFS) measured from start of study treatment to the date of objective progression (investigator assessed using RECIST 1.1) or date of death from any cause (in the absence of progression).,2019-05-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease response,
3136,NCT01572987,Complete histological eradication of Barrett's esophagus,2011-09,TERMINATED,INTERVENTIONAL,['NA'],Complication rates,
3137,NCT01905384,Rate of Long-term Stent Failure,2017-11-08,COMPLETED,INTERVENTIONAL,['NA'],Rates of Adverse Stent-related or Intervention-related Outcomes,
3138,NCT02270450,Number of Days Alive and Outside of the Hospital,2015-03-09,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival,
3139,NCT00309530,Overall survival,1990-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3140,NCT04838496,The main study parameter is the proportion of patients with a pathological complete response (pCR) and those patients who started a wait and see strategy and have sustained clinical complete response (cCR) at 1 year.,2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Costs,
3141,NCT04771637,ASA status,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],internal environment,heart rate
3142,NCT02599324,Phase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 6,2015-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1b: Apparent Total Clearance at Steady-State (CLss/F) for Ibrutinib in Cohorts 1 to 4,
3143,NCT04850430,Mortality rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
3144,NCT06258525,To evaluate the efficacy of SAMe in preventing oxaliplatin associated liver injury as determined by lack of injury on histopathologic analysis in patients with liver only stage IV colorectal cancer.,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To evaluate safety and tolerability of SAMe in combination with SOC oxaliplatin based systemic therapy.,
3145,NCT00140036,Correlation of genotype with safety and efficacy measures.,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3146,NCT05307198,pCR rate,2022-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Concentration of DAMP,
3147,NCT01478594,Investigator-assessed Progression-Free Survival (PFS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-Free Survival Events by Tumor Placental Growth Factor (PIGF) RNA Level,
3148,NCT05148494,Quality of bowel preparation,2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE4'],Post-operative complications,
3149,NCT02890355,Overall Survival (OS),2016-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of Response (DoR),Genomic Alterations Identified by the BROCA-homologous Recombinant (HR) Assay
3150,NCT01571024,Maximum Tolerated Dose (MTD),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Biomarkers of Clinical Benefit,
3151,NCT03602885,Number of Participants With Accurate Understanding of Chemotherapy Benefits at 8-12 Weeks,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],Discussions About End-of-life Care Preferences With Healthcare Proxy and Care Team,
3152,NCT06215651,Conversion success rate,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
3153,NCT04218253,Incidence of complications at 30 days after surgery,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative hospital stay,
3154,NCT05963490,ORR,2023-04-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
3155,NCT00049400,dose defining,2003-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Symptomatic deterioration,
3156,NCT04440605,Diagnostic Accuracy of cIII,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],Diagnostic Accuracy of cTN,
3157,NCT05900583,pathological complete response (pCR),2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Overall survival (OS),
3158,NCT03097276,proportion of patients with total hospitalization of less than 15 days during the first postoperative month,2017-04-17,COMPLETED,INTERVENTIONAL,['NA'],,
3159,NCT04071184,Maximum tolerated dose (MTD) or Recommended phase 2 dose (RP2D),2019-05-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],Objective response rate (ORR),
3160,NCT04812808,Change in IL-6/GP-130/STAT3 pathway expression (%),2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],Number of patients with adverse events,
3161,NCT02150317,the overall survival rate of each group,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3162,NCT00637091,Response rate,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"Progression free survival, overall survival",
3163,NCT04066153,Unmet physical functioning needs,2019-08-20,COMPLETED,OBSERVATIONAL,['NA'],Physical activity level,
3164,NCT00024258,Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3165,NCT05366816,Number of Participants Achieving Overall Response,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Related Toxicity and Adverse Events,
3166,NCT03349827,radical resection rate,2018-01-05,TERMINATED,INTERVENTIONAL,['NA'],complication rate,
3167,NCT05018208,Quantification of false alerts and downstream clinical actions (Arm 2),2021-12-15,RECRUITING,OBSERVATIONAL,['NA'],Point-in-time assessment of physiological signals from standard of care devices (Arm 1),
3168,NCT02308319,Recurrence free survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Reactivation of hepatitis B,
3169,NCT05610826,Progression-free Survival,2023-03-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Difference in imaging characteristics,
3170,NCT01774162,Sampling Adequacy,2011-09,COMPLETED,INTERVENTIONAL,['NA'],Adverse events,
3171,NCT00212589,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3172,NCT04808687,Objective response rate,2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
3173,NCT02721576,Objective response rate,2016-07-05,TERMINATED,INTERVENTIONAL,['PHASE4'],Progression free survival,
3174,NCT06149481,Phase II: Overall response rate (ORR) defined as the CR+PR of the IO regimen in mCRC,2024-03-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
3175,NCT05531331,The change in the adaptation of the experimental group according to the Ostomy Adjustment Inventory-23 scores at the end of the second month,2021-11-01,COMPLETED,INTERVENTIONAL,['NA'],The change in the ability of individuals with stoma to care for their stoma at the end of the 2nd month,
3176,NCT02589860,Melphalan exposure,2015-10-30,WITHDRAWN,OBSERVATIONAL,['NA'],,
3177,NCT00635323,Overall response rate,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Laboratory tests,
3178,NCT01887041,Outcome of Quality of Life.,2010-01,TERMINATED,INTERVENTIONAL,['PHASE4'],"The incidence of surgical complications and complications, with regard to the endo-scopic stent insertion, are further aspects that shall be examined in this study.",
3179,NCT05643105,Anastomotic leak,2022-12-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Local recurrence,Intraoperative complications
3180,NCT05602935,Pathologic complete response (pCR) rate,2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival(OS),
3181,NCT02882503,To evaluate pancreatic tumor ablation effect,2016-06,WITHDRAWN,INTERVENTIONAL,['NA'],Biochemical profile,
3182,NCT01279330,Completion of Fecal Occult Blod Test,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],Proportion of uninterpretable test.,
3183,NCT04341909,any procedure related adverse outcome,2020-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
3184,NCT04637048,Evaluate the overall survival rate of all patients with hepatobiliary tumor,2017-02-16,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Evaluate the Progression Free Survival rate of patients with hepatobiliary tumor,
3185,NCT04786600,Overall survival,2021-11-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Best overall response,
3186,NCT00005979,,1998-07-22,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3187,NCT05629065,Proportion of patients with an SIC at 60 days for arm 1 (patient +clinician nudge) vs arm 2 (no nudge).,2022-11-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Patient preferences,
3188,NCT01801930,Dose Limiting Toxicity (DLT),2013-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor Response Rate in Cycle 1,
3189,NCT04892342,Objective Response Rate (ORR) by Independent Central Review (ICR),2021-09-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",ADA,
3190,NCT00003522,,1997-08-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3191,NCT06213519,Overall survival,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and Tolerability,
3192,NCT05265663,Overall survival,2020-10-13,RECRUITING,INTERVENTIONAL,['NA'],Progression of disease (local and distant),
3193,NCT01861873,volumetric uptake values of 18-FDGal will be measured and the 18-FDGal PET/CT one month after stereotactic body radioation therapy will be compared to the baseline status in sub-volumes receiving more than 15 Gy,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],evaluate toxicity to SBRT by toxicity scoring system that includes biochemical measures as well as symptomatic scores.,
3194,NCT04955119,Positive predictive value,2021-07-30,UNKNOWN,INTERVENTIONAL,['NA'],The sensitivity and specificity of CEUS LR-5,
3195,NCT00244348,overall survival of patients resected for cure versus (vs.) resected for palliation vs. not resected.,2005-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",cost,
3196,NCT05766748,Recommended Phase 2 Dose,2023-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Body Weight,
3197,NCT01985763,Percent Change in Tumor Size,2013-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
3198,NCT01342653,disease free survival,2011-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],Quality of life after phase I and Phase II,
3199,NCT05223036,Percentage change in duodenal polyp burden,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Future candidate biomarkers measured by genomic and transcriptomic platforms in residual tissue biopsies of adenomas and normal mucosa,
3200,NCT03668418,Correspondence with chemo-sensitivity data collected in zebrafish model,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA'],Time to tumour progression,
3201,NCT02898415,Cancer specific survival,2015-06,COMPLETED,OBSERVATIONAL,['NA'],Recurrence Free Survival,
3202,NCT02465502,Percentage of participants without disease progression or death at the end of 8 weeks,2015-07-21,COMPLETED,INTERVENTIONAL,['PHASE2'],"Percentage of participants with grade 1 or higher adverse events, using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03",
3203,NCT04776655,Progression free survival (PFS) in patients with RASmut at liquid biopsy and RASwt on tissue.,2021-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],Compliance,
3204,NCT02644148,Quality of life,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Complications,
3205,NCT05879328,Recurrence-free survival (RFS),2022-12-23,RECRUITING,OBSERVATIONAL,['NA'],Comparison with historical series,
3206,NCT01691625,the quality of life,2012-09,COMPLETED,INTERVENTIONAL,['NA'],progression-free survival,Immunological assessment
3207,NCT04672980,Dose limiting toxicities (DLTs) of RTX-321:,2021-04-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Anti-tumor activity of RTX-321,
3208,NCT06178939,incidence of postoperative delirium,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],total score of QOR-40,
3209,NCT01636674,time to recurrence,2009-07,UNKNOWN,INTERVENTIONAL,['NA'],,
3210,NCT05579444,Identification of microbial determinants of gastrointestinal diseases.,2022-11-11,TERMINATED,OBSERVATIONAL,['NA'],Quantify change in microbial species over time post colonoscopy,
3211,NCT01384240,to determine whether tissue in nepoplastic or non-neoplastic,2010-04,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,
3212,NCT05740995,Major pathological regression (MPR) rate,2020-12-01,RECRUITING,OBSERVATIONAL,['NA'],"The correlation between detection of genomic, immune, microbial and metabolite features and the rate of therapeutic responses.",
3213,NCT02323360,Local control (efficacy of SBRT in selected HCC patients with an incomplete response after TACE/TAE),2014-11,TERMINATED,INTERVENTIONAL,['NA'],toxicity (incidence of acute and late complications),
3214,NCT03076216,Safety / Tolerability of Device as determined by the number of treatment emergent adverse events (TEAEs) evaluated according to CTCAE V4.0,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],Pain Scores,Tumor Response
3215,NCT06267417,To measure grade of oral mucositis in patients receiving laser arm placebo arm.,2023-04-10,RECRUITING,INTERVENTIONAL,['NA'],,
3216,NCT01375738,Blood sugar stabilization after gastrectomy,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],,
3217,NCT03242369,Quality of bowel cleansing according to Boston Bowel Preparation Scale (BBPS),2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],Detection of colorectal neoplasia,
3218,NCT02128958,Number of Subjects With Overall Survival,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Pharmacokinetics (PK) Parameters of CF102 - AUC_0-12, Steady State (ng*h/mL)",
3219,NCT05415475,Obtain the maximum tolerated dose of CEA-CAR-T cells[Safety and Tolerability],2021-09-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacodynamics of CEA-CAR-T cells[Cell dynamics],Changes in the number of tumor-infiltrating immune cells of CEA- CAR-T treatment in patients with CEA-positive
3220,NCT00000611,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3221,NCT01639326,Overall objective response rate (RR) by RECIST criteria v1.1,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall response duration,
3222,NCT04386772,Hypertrophy degree of standardized FLR,2020-05-27,UNKNOWN,INTERVENTIONAL,['NA'],Immunohistochemical stainings of liver parenchyma,
3223,NCT06202781,Single-cell profiling,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
3224,NCT00724503,Progression-Free Survival (PFS) at Any Site,2006-08,COMPLETED,INTERVENTIONAL,['NA'],Percentage of Participants With Overall Response,
3225,NCT02615665,Overall survival,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
3226,NCT01941641,Objective tumour response rate,2013-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of response to neoadjuvant therapy,
3227,NCT01865071,Mortality,2011-09,UNKNOWN,INTERVENTIONAL,['NA'],,
3228,NCT05815303,pCR,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
3229,NCT03447691,score of QoR40 (Quality of Recovery 40),2017-08-27,UNKNOWN,INTERVENTIONAL,['NA'],score of QoR40 (Quality of Recovery 40),
3230,NCT01464593,Determine the Local Tumor Control at 1 Year Post Randomization,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
3231,NCT05311319,Disease Free Survival (DFS),2022-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety: adverse events,
3232,NCT00991094,Dose-response relationships for normal tissue toxicity after proton therapy,2005-05-27,RECRUITING,OBSERVATIONAL,['NA'],Symptom burden,
3233,NCT01078311,To demonstrate the correlation of trough sorafenib level with overall survival in advanced hepatocellular carcinoma,2010-02,UNKNOWN,OBSERVATIONAL,['NA'],To correlate trough sorafenib level with side effects (rash and hypertension),
3234,NCT00973440,To determine the feasibility and added clinical utility of a self-administered computer-based version of an abbreviated comprehensive geriatric assessment tool.,2009-03,COMPLETED,OBSERVATIONAL,['NA'],,
3235,NCT05584540,Enrollment Rate,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],CSQ-I Score,The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Ratings
3236,NCT04833387,Pathological complete response,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Clinical complete response (CCR),
3237,NCT02527577,consumption of morphine over the first 48 hours postoperative.,2010-04,TERMINATED,INTERVENTIONAL,['NA'],pharmacokinetic of ropivacaine (plasma concentrations),
3238,NCT04929015,Correlation of ctDNA clearance with activity of chemotherapy,2021-04-29,RECRUITING,INTERVENTIONAL,['NA'],Associations between CA125 levels and ctDNA levels,
3239,NCT05939401,ctDNA,2023-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3240,NCT03512756,Overall Survival,2018-03-27,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Progression Free Survival,
3241,NCT00103168,Overall survival,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Adverse events,
3242,NCT05620771,Progression Free Survival (PFS),2022-11-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
3243,NCT01688557,Diagnostic accuracy of innovative colonoscopy,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Pain intensity (VAS scale),Area under the ROC curve (AUC)
3244,NCT04479527,PFS,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of AE and SAE,
3245,NCT02983578,Physical Examinations,2017-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,Radiomic measurements
3246,NCT03613194,Identification and characterization of the tumoral intermediaries on the hepatic metastasis and/or peritoneal),2018-06-25,UNKNOWN,INTERVENTIONAL,['NA'],,
3247,NCT02273362,Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining),2014-11-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse Event Profile,Erlotinib Hydrochloride Plasma Level
3248,NCT01180166,progression-free survival,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival time,
3249,NCT01955096,food intake time,2010-09,COMPLETED,INTERVENTIONAL,['NA'],readmission,
3250,NCT00846131,To Evaluate sorafenib as an adjunct to Y-90 for control of HCC as a bridge/downstage to transplant,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],To identify predictive and prognostic markers of how the liver cancer will respond to treatment.,
3251,NCT04522011,The incidence of postoperative complications,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3252,NCT02141295,"Progression-free Survival (PFS), Time to Event",2014-06-30,TERMINATED,INTERVENTIONAL,['PHASE2'],Cmax Accumulation Ratio (AR) of Vanucizumab,
3253,NCT05833815,Progression free survival,2022-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Chemotherapy Toxicity,
3254,NCT04515615,The incidences and types of adverse events,2020-09-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment completion rate,
3255,NCT05517811,Post-operative thrombotic and hemorrhagic complications,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],pre-operative distant metastasis,
3256,NCT03435107,Objective response rates (RECIST 1.1),2018-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3257,NCT05797805,Evaluate efficacy of tegavivint as a single agent,2023-09-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluate efficacy of combination of tegavivint plus pembrolizumab
3258,NCT03068052,Colonoscopy participation,2017-05-08,COMPLETED,INTERVENTIONAL,['NA'],Risk assessment completion,
3259,NCT06065059,Measure anti-tumor activity using RECIST 1.1 (Phase 2 only),2023-12-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Assess changes in levels of ubPCNA in response to TNG348 as single agent or in combination,
3260,NCT04891900,Objective Response Rate (ORR),2021-05,UNKNOWN,INTERVENTIONAL,['NA'],Duration of Overall Survival (OS),
3261,NCT00084604,"Time to progression, evaluated using RECIST",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"Incidence of toxicity, evaluated using CTCAE version 3.0",
3262,NCT00077519,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3263,NCT02850172,severity of symptom (QLQ-OES18 questionnaire),2016-05,UNKNOWN,INTERVENTIONAL,['NA'],length of mechanical ventilation,
3264,NCT00727831,Incidence and severity of CNS toxicity and neurocognitive changes taken from patients' medical records and measured using the Mini-Mental State questionnaire and MRI data,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of antibodies to glucarpidase measured serologically at the start of each methotrexate course and at follow-up visits if present during therapy,
3265,NCT01126346,"Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population",2010-05,COMPLETED,INTERVENTIONAL,['NA'],"Improve overall post-operative QOL ratings at 3 months, relative to discharge",
3266,NCT00565708,Disease-free survival,2008-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Overall survival,
3267,NCT04536922,Treatment,2021-01-27,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
3268,NCT03716531,2 Year Overall Survival,2019-03-19,RECRUITING,INTERVENTIONAL,['NA'],Adverse events associated with IORT,
3269,NCT06335147,pathologic complete response（pCR）,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Incidence of Treatment-Emergent Adverse Events,
3270,NCT05620628,PFS (progression free survival),2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE2'],ORR (objective response rate),
3271,NCT05291988,Demographic information,2022-10-08,TERMINATED,INTERVENTIONAL,['NA'],COVID-19 impact assessment,
3272,NCT04404777,3 year survival,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],MDT effect on treatment of local recurrence,
3273,NCT00707681,To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Overall survival, Overall survival rate, Change from baseline of the highest weight observed, Change from baseline of body weight",
3274,NCT06013774,Device Feasibility,2021-05-25,COMPLETED,INTERVENTIONAL,['NA'],Radioactivity distribution in 3D,
3275,NCT03563248,Proportion of participants with R0 resection,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment related serious adverse events,
3276,NCT04677244,Procedure impact,2021-11-11,RECRUITING,INTERVENTIONAL,['NA'],,
3277,NCT04334421,Comprehensive Complication index,2020-04-03,COMPLETED,OBSERVATIONAL,['NA'],Perineal hernia,
3278,NCT05994638,Side effects after radiotherapy,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],Impact of dysphagia on quality of life,
3279,NCT01694342,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
3280,NCT00526578,Identification of susceptibility genes in high risk familial pancreatic cancer (FPC) pedigrees using cutting-edge genetic analysis methods,2002-06-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3281,NCT04738240,Clinical anastomotic leak,2019-03-11,COMPLETED,INTERVENTIONAL,['NA'],,
3282,NCT02630420,Safety and tolerability based on regular clinical assessment and NCI Common Terminology Criteria for Adverse Events,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Progression free survival,"Changes in genetic aberrations over the course of the disease by comparing archival, baseline and progression samples."
3283,NCT00503776,Number of Patients With Each Degree of Swallowing Dysfunction,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Changes in the Frequency and Types of Dietary Intakes,
3284,NCT04290364,Use of healthcare services,2019-09-21,COMPLETED,OBSERVATIONAL,['NA'],Carer satisfaction with palliative care,
3285,NCT04947826,Objective response rate,2021-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival rate at 12-month time point,Discontinuation rate due to any adverse events
3286,NCT04802954,Stratification of the risk of hepatocarcinogenesis in high-risk patients by a deep learning-based cross-analysis.,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],Characterization of the interface of the nodules with the adjacent hepatic parenchyma by a deep learning-based cross-analysis,
3287,NCT02112747,Successfully following screening guidelines appropriate to the participant's risk profile,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Cost effectiveness of the interventions,
3288,NCT04682158,Progression Free Survival,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
3289,NCT05327738,Proportion of progression-free participants,2022-12-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of grade >= 3 adverse events,Descriptive summary of tumor and tumor immune cell populations
3290,NCT02486497,Recurrence free survival,2015-06,COMPLETED,INTERVENTIONAL,['NA'],Toxicity,
3291,NCT05531864,visual analogue scale,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],Intraoperative heart rate changes,
3292,NCT02157454,Self-efficacy for coping with cancer (measured by the German short form of the Cancer Behavior Inventory),2014-06,COMPLETED,INTERVENTIONAL,['NA'],Patient competence (assessed by a self-rating measure of patient competence in oncology in validation process),
3293,NCT00579579,"To prospectively evaluate bowel, sexual and bladder function in patients who undergo resection for stage I-III rectal cancer.",2006-11-28,COMPLETED,OBSERVATIONAL,['NA'],"To evaluate the expectations, informational needs and satisfaction with the surgical consent process in patients undergoing resection for stage I-III rectal cancer.",
3294,NCT00326911,Progression-free Survival (PFS),2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],"Change From Baseline in Assessment of Pain Using BPI Short Form, Interference, at Cycle 2 Week 4",
3295,NCT02219893,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease free survival,
3296,NCT06061146,PFS,2023-10-05,RECRUITING,INTERVENTIONAL,['PHASE2'],AE,
3297,NCT03724071,Phase II part - Overall response rate,2018-10-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3298,NCT01980810,response rate,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2'],number of adverse event,
3299,NCT06017323,Proglumide Recommended Phase II dose and schedule (RP2D),2023-10,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Change in tumor marker (CA19-9),
3300,NCT04512833,Local control time,2020-08-12,RECRUITING,OBSERVATIONAL,['NA'],Adverse reaction,
3301,NCT03061162,Side effects of pulsed low dose rate radiation therapy,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Time to progression,
3302,NCT02760537,self-reported status of the series of HBV vaccinations by follow-up calls in seven months after mailing the results verified by the medical records,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,
3303,NCT06063928,Changes in genomic knowledge,2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],,
3304,NCT05727787,Maximum tolerated dose (MTD) of Single Fraction GRID SBRT,2023-02-23,RECRUITING,INTERVENTIONAL,['NA'],Molecular correlatives: TCR repertoire analysis.,
3305,NCT06141109,PFS,2022-01-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Area Under the Plasma Concentration Versus Time Curve (AUC) of MB07133,
3306,NCT00321100,Objective Response Rate (ORR),2006-04-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
3307,NCT01065818,"Optimal Timepoint During the Course of Neoadjuvant Therapy [CRT, CT (Chemotherapy) or RT Radiotherapy)] That FLT-PET Imaging Can Predict Response",2009-08,TERMINATED,INTERVENTIONAL,['NA'],,
3308,NCT05646537,stoma compliance scores of the participants,2023-01-01,COMPLETED,INTERVENTIONAL,['NA'],comfort level of the participants,
3309,NCT02515734,Best deepness of response,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of adverse events,
3310,NCT00030498,Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3311,NCT05990569,Patient satisfaction assessed using the Likert scale after receiving Bupivacaine pudendal nerve block with or without Methylene Blue.,2023-08-12,RECRUITING,INTERVENTIONAL,['NA'],Complications,
3312,NCT02575339,Phase II: Time to Progression (TTP),2016-07-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II: Radiographic Response Rate (RRR),
3313,NCT05544929,Dose intensity,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE1'],Elimination half-life (T1/2) of KFA115 or pembrolizumab,
3314,NCT04764409,Identification of all the kinds of complications according to the Common Terminology Criteria for Adverse Events (CTCAE v4.0) and their systematization.,2021-01-12,UNKNOWN,OBSERVATIONAL,['NA'],,
3315,NCT03896958,Assessment of benefit of return of research results by SpeciCare Outcome Monitor Board,2019-03-21,UNKNOWN,OBSERVATIONAL,['NA'],,
3316,NCT05510895,Tumor regression grade (TRG),2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Translational research 3,
3317,NCT00309543,Overall survival,1993-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3318,NCT03595904,Number of Participants Who Completed a Screening Colonoscopy,2017-11-20,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants Who Were No-show Appointments,
3319,NCT04132505,Maximum tolerated dose (MTD),2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,Effect of this binimetinib/hydroxychloroquine treatment on changes in muscle and fat mass
3320,NCT04779151,Overall Response Rate (ORR),2021-04-07,SUSPENDED,INTERVENTIONAL,['PHASE2'],,
3321,NCT04241276,To assess the efficacy of ATRA when given in combination with gemcitabine and nab-paclitaxel based on progression free survival (PFS).,2020-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To assess quality of life (QOL) of patients receiving ATRA in combination with Gemcitabine and Nab-Paclitaxel: EQ-5D-5L,
3322,NCT04247256,Objective Response Rate,2020-05-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Biomarkers ABCG2, ABCB1, SRPK1",
3323,NCT00610636,Both groups of patients were analyzed with intention-to-treat principle. The primary end-point was time-to-progression. The secondary points were overall survival and surgical morbidity.,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Surgical morbidity, Chemotherapeutic complications",
3324,NCT03535259,MST,2018-05-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Rate of III-IV grade adverse events,
3325,NCT01843049,Dose limiting toxicity(DLT),2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Late toxicity,Local recurrent rate within the >50% SUVmax region of the primary tumor
3326,NCT01438476,Postoperative Pain Experience,2012-01-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3327,NCT03532204,Progression Free Survival,2019-04-15,WITHDRAWN,INTERVENTIONAL,['NA'],Quality of life EORTC QLQ CR29,
3328,NCT02792842,The discontinuation rate of oxaliplatin due to OIPN,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3329,NCT02744651,Number of correct histopathological diagnoses from submucosal tumors in the upper GI tract.,2017-02-17,TERMINATED,INTERVENTIONAL,['NA'],,
3330,NCT03400657,overall survival,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],Differences in overall survival after performing MDT at center,
3331,NCT03506321,Compare chromoendoscopy predictions and HD-WL/NBI predictions of submucosal invasive cancer (SMIC) and residual or recurrent adenoma (RRA) to compare correlation with histological findings,2018-02-07,COMPLETED,INTERVENTIONAL,['NA'],Compare the difference between live endoscopic assessment and use of carefully selected endoscopic images to predict SMIC,
3332,NCT02665741,Adenoma Detection Rate,2016-01,COMPLETED,INTERVENTIONAL,['NA'],Withdrawal Time,
3333,NCT04893876,Global Quality of Life (QoL),2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Frailty,
3334,NCT01126645,Primovist®-enhanced MRI is non-inferior or superior compared with contrast-enhanced multislice CT,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],safety of SIR Spheres,
3335,NCT06001372,The rate of study completion by enrolled participants. Study completion is defined as participating in at least 2 of the 3 Ketamine-Assisted Psychotherapy (KAP) sessions.,2023-10-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],The proportion of screened patients that meet criteria on the Existential Distress Scale (EDS: Single domain ≥ 3 or total score ≥ 6).,
3336,NCT01658878,ORR for Nivolumab plus Ipilimumab plus Cabozantinib Combination Cohort,2012-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Effective T-Half of nivolumab,
3337,NCT04861987,Maximum Plasma Concentration (Cmax) of capecitabine,2021-06-18,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of participants with Adverse Events of Special Interest (AESI),
3338,NCT04873895,Serious adverse event (SAE) rate,2022-01-24,RECRUITING,INTERVENTIONAL,['PHASE1'],axitinib treatment intensity,
3339,NCT05158374,"Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel",2022-08,UNKNOWN,INTERVENTIONAL,['NA'],Change in the proportions of bacterium the colorectal microbiome after aspirin and/or metformin medication,
3340,NCT04267549,R0-surgery conversion rate,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],surgery-related complications,pathological response
3341,NCT05515796,ORR (objective response rate) per RECIST 1.1,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],R0 resection rate,EORTC QLQ-CR29
3342,NCT05914077,Proportion of patients with IPMN with GNAS and KRAS mutations in intracystic fluid obtained by EUS-FNA versus pancreatic juice obtained by ADPJ-secr after both techniques.,2023-09-13,RECRUITING,INTERVENTIONAL,['PHASE3'],Proportion of patients with Serious Adverse Events,
3343,NCT05278728,The rate of grade 3/4 toxicity,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The disease control rate,
3344,NCT03084133,Participation rate in screening colonoscopy for first-degree relatives of patients with RCC or advanced adenoma.,2017-04-10,COMPLETED,INTERVENTIONAL,['NA'],"Quality criteria for screening colonoscopy using the following parameters: visualization rate of the bottom of the colon, the withdrawal time of the colonoscope (Withdrawal time), quality of the colic preparation using the Boston scale.",
3345,NCT02674815,Compliance,2016-02,COMPLETED,INTERVENTIONAL,['NA'],Clavien-Dindo Classification Sore,
3346,NCT02912949,Duration of response per RECIST v1.1 as per local Investigator's assessment.,2015-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Evaluation of overall survival (OS),
3347,NCT04889404,Incidence of adverse events related to the safety specifications,2021-05-22,RECRUITING,OBSERVATIONAL,['NA'],,
3348,NCT05518903,Relationship between 68Ga-FAPI-46 PET metrics and staging examinations in PDA,2022-11-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3349,NCT00112918,Disease-free Survival in Stage III Cancer Patients - Number of Events,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis,
3350,NCT00199797,"Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and Serious TEAEs in Patients With Metastatic Colorectal Cancer.",2005-04-18,COMPLETED,INTERVENTIONAL,['PHASE1'],"Tumor Response in Patients With Metastatic Colorectal Cancer Receiving huA33, Oxaliplatin and 5-FU Plus Leucovorin.",
3351,NCT03916809,Feeding-tube-free food intake (days),2017-07-12,RECRUITING,INTERVENTIONAL,['NA'],Upper esophageal sphincter (UES) opening width (mm),M.D. Anderson Dysphagia Inventory (MDADI) (number)
3352,NCT04640103,Adverse event rate,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Incidence of second tumor in patients with Lynch syndrome,
3353,NCT02062515,Number of Participants with Adverse Events,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3354,NCT02143401,Incidence of adverse events,2014-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Time to treatment failure,Change in cleaved and total CK18 levels in serum
3355,NCT05173246,Objective response rate (ORR),2020-11-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Severe toxicity,
3356,NCT01041612,Obstruction of 1st C-SEMS or presence of jaundice at death without stent exchange,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Death of patients,
3357,NCT04800549,Nurse Observation Chart of Child Mucositis Evaluation,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,
3358,NCT05512793,Adenoma miss rate (AMR),2023-05-24,COMPLETED,INTERVENTIONAL,['NA'],Withdrawal time. (First/second colonoscopy),
3359,NCT00936832,Response rate at 3 months as assessed by RECIST criteria,2009-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Translational research including pharmacodynamic studies of plasma and rectal tumor biopsies and histological and molecular studies,
3360,NCT02195011,The Number of Participants With Treatment-Related Adverse Events and Serious Adverse Events as a Measure of Safety,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival,
3361,NCT05745558,Percentage of patients willing to participate in prehabilitation program,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],Work status,
3362,NCT00443040,Time to Return of Upper and Lower GI Function,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Laboratory Values,
3363,NCT00683085,Number of Participants Without Grade 4 Hematological or Grade 3 to 4 Non-hematological Adverse Events,2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Tumor Regression,
3364,NCT00122291,response,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3365,NCT04509492,The number of patients with occult hepatic metastasis missed by CT or MRI during staging of pancreatic and GI malignancy.,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
3366,NCT05443217,Long-term outcomes after treatment,2022-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Objective response rate,
3367,NCT05162118,RP2D (phase 1),2022-03-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",CEA,
3368,NCT03908333,Disease Control Rate,2019-05-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Changes in patient's self-reported pain levels: Brief Pain Inventory (BPI),
3369,NCT05173909,"Serum LEVELS of IL-2, IL-4, IL-6, IL-10, TNF-ɑ, IFN-γ",2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
3370,NCT05682794,disease-free survival ratev,2014-01,COMPLETED,OBSERVATIONAL,['NA'],DRM status,
3371,NCT01373021,total amount of administered fentanyl,2011-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3372,NCT00006081,Number of Patients with Response after 2 Cycles of Treatment,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3373,NCT01878422,Progression Free Survival (PFS) of first and second line treatment strategy,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of partecipants with adverse events as a measure of safety and tolerability,
3374,NCT00756548,Efficacy - Preparation Quality Using a 4 Point Scale,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Serum Chemistry Results (Osmolality),
3375,NCT01350167,Efficacy of screening measure to detect very early/early stage HCC (Barcelona Clinic Liver Cancer Staging System),2001-11,UNKNOWN,INTERVENTIONAL,['NA'],Cost - Effectiveness of screening measure,
3376,NCT00341276,Linkage of genetic markers,1995-07-06,COMPLETED,OBSERVATIONAL,['NA'],Gene environment interactions (case control),
3377,NCT00056355,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3378,NCT00030108,Nerve growth factor levels before and after drug administration,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],"Tubulin polymerization in PBMCs prior to the start of the infusion, just before the end of the infusion, 5 hours after the end of the infusion and before the start of the infusion on day 2 of the ixabepilone on course 1",
3379,NCT04854434,Arm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2021-06-29,TERMINATED,INTERVENTIONAL,['PHASE2'],"Arm A, B and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs",
3380,NCT01772407,Cost during the 2 postoperative years,2009-09,COMPLETED,OBSERVATIONAL,['NA'],"Mortality, morbidity and quality of life during the 2 postoperative years",
3381,NCT04010071,Progression-free Survival (PFS),2020-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of 6-months and 1-year overall survival,Tumor mutation burden
3382,NCT00778102,Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Complications Related to Second Resective Surgery,
3383,NCT06238193,MSI status,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],Copy-number variations (CNVs),PD-L1 level
3384,NCT02597075,Change in Patient-reported symptoms as measured by ESAS-r,2016-03-17,TERMINATED,INTERVENTIONAL,['NA'],Initiation or increase of anti-hypertensive drugs,
3385,NCT01341132,,2011-05,UNKNOWN,OBSERVATIONAL,['NA'],,
3386,NCT01676714,Overall Response Rate,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients Who Experienced Treatment Related Toxicities,
3387,NCT00023946,Overall survival,2001-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3388,NCT04615013,Maximum tolerated dose and recommended phase 2 dose (RP2D),2020-11-23,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,Concordance of cell free deoxyribonucleic acid (DNA)
3389,NCT00414570,correlate 18F-FLT uptake with hENT1 expression with biopsy samples where available,2007-11,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],to demonstrate the safety of 18F-FLT manufactured at the Edmonton PET Centre,
3390,NCT05890742,"Event Free Survival, EFS(EFS), defined as the time from randomization to the first determination using RECIST v1.1 of inoperable disease progression, local recurrence or distant metastasis after surgery, or death from any cause, whichever occurs first.",2023-05-25,RECRUITING,INTERVENTIONAL,['PHASE3'],"Overall-survival(OS), defined as the time from randomization to death from any cause",
3391,NCT03993743,Incidence and type of adverse events induced by CD147-CART hepatic artery infusions,2019-05-27,UNKNOWN,INTERVENTIONAL,['PHASE1'],CD147-CART detection in extrahepatic sites,
3392,NCT06246630,Objective Response Rate,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Concordance between drug sensitivity test results and patients' treatment response,
3393,NCT02965976,Delayed Gastric Emptying Assessed Radiographically by Nuclear Medicine Emptying Study,2016-12-30,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life Score as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 OES18,
3394,NCT02207959,Gastric neoplasia presence,2015-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Specificity for the detection of neoplasia,
3395,NCT00569699,Progression free survival,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"Safety, Response rate, Time to progression, Time to treatment failure, Overall survival, Treatment situation",
3396,NCT04070313,Relapse-free survival (RFS),2019-07-11,TERMINATED,INTERVENTIONAL,['PHASE2'],safety profile,
3397,NCT05395780,Objective response rate (ORR),2022-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Correlation between expression level and mutation of FGFR1OP2-related proteins and efficacy,
3398,NCT02890511,Number of participants with dose limiting toxicity(DLT) to determine maximum tolerated dose(MTD),2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PK parameters for DHP107 derived from determining their plasma concentrations using validated assays.,
3399,NCT02511522,Proportion of patients achieving improvement of liver cancer pain/discomfort,2015-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Proportion of patients reporting clinically significant improvement in QoL from baseline to day 30 and day 90,
3400,NCT00769730,HBV viral load,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
3401,NCT03993873,Define the Recommended Phase 2 Dose,2019-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
3402,NCT00673322,Determine the safety of using modified T cells by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).,2008-05,TERMINATED,INTERVENTIONAL,['PHASE1'],Pharmacodynamics,
3403,NCT03702491,PFS,2018-08-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3404,NCT00120172,"To evaluate the efficacy (measured by time to progression) of oxaliplatin, capecitabine, and bevacizumab as first-line therapy in elderly patients with metastatic colorectal cancer.",2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Vulnerable Elders Survey (VES-13) and Geriatric Depression Scale (GDS) scores,
3405,NCT03423056,Peak oxygen comsumption,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA'],Peak oxygen comsumption - 3 weeks,
3406,NCT02980029,Malonyl carnitine and tripalmitin levels will be measured in the preand post-treatment blood samples using mass spectrometry blood samples using mass spectrometry.,2017-10-06,RECRUITING,INTERVENTIONAL,['PHASE1'],"Toxicities will be graded as per NCI-CTCAE v4.03, based on recorded adverse events, physical examinations, and clinical laboratory assessments.",
3407,NCT05709197,Delayed gastric emptying (DGE),2023-04-17,RECRUITING,INTERVENTIONAL,['NA'],Functional outcome at 12 months,
3408,NCT01325883,The relative decrease in exercise capacity (LT) associated with NAC prior to upper gastrointestinal cancer resection will predict outcome (1 year mortality) following surgery.,2011-04,COMPLETED,OBSERVATIONAL,['NA'],Patients whose LT changes following NAC so that they move into a higher risk category will have a worse outcome (1 year mortality) when compared with those who do not increase risk category.,
3409,NCT03082079,progression-free survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],patient satisfaction scores,
3410,NCT05687747,Sensitivity of FAPI-PET/MRI to detect intrahepatic HCC using contrasted multiphasic MRI liver as standard comparison,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Sensitivity estimation of 68Gallium-FAPI-46 PET/MRI in per-lesion analysis for all lesions with available surgical resection samples for histopathology assessment,
3411,NCT02510118,Quality of life,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Progression-free Survival (PFS),
3412,NCT06236464,Primary Endpoint,2023-09-25,RECRUITING,OBSERVATIONAL,['NA'],Secondary Endpoint,
3413,NCT02022033,Feasibility of Adjuvant FOLFOX-A,2014-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease-free Survival,
3414,NCT05502198,MELD-score,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],Quality of life (Questionnaire),
3415,NCT06115837,Cancer specific survival,2023-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
3416,NCT00980382,"*phase I study:the maximum tolerated doses (MTD)of S-1 and docetaxel,recommended dose for subsequent phase II study *phase II study: evaluation of efficacy and toxicities of this new combination regimen in metastatic",2004-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To investigate the time to progression and overall survival,
3417,NCT01879904,curative resection rate (3 month),2010-02,COMPLETED,INTERVENTIONAL,['NA'],Curative resection rate (1 year),
3418,NCT06032767,RTOG/EROTC Acute Radiation Reaction Scoring Standard,2023-08-14,RECRUITING,OBSERVATIONAL,['NA'],,
3419,NCT00025415,Toxicity evaluation graded according to the NCI common toxicity criteria and relationship to the study drug,2001-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Child-Pugh Classification,
3420,NCT00832637,Tumor Control Rate,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicity,
3421,NCT04136600,Objective Response Rate,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Effect,
3422,NCT00799474,Willingness to Receive the Human Papillomavirus (HPV) Vaccine,2008-12,COMPLETED,OBSERVATIONAL,['NA'],Knowledge of HPV,
3423,NCT05170256,Progression free survival (PFS) .,2022-02-04,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,Frequency of PD-L1 status by CPS score
3424,NCT00390195,Disease control rate in Phase II,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumor marker,
3425,NCT02627729,Short Form 36 Quality of life Questionnaire,2009-06,COMPLETED,INTERVENTIONAL,['NA'],Functional outcome measured with Overactive Bladder validated 8 scale,
3426,NCT02352688,Length of postoperative hospital stay,2015-05,COMPLETED,INTERVENTIONAL,['NA'],30-day mortality,
3427,NCT01393340,Effect of Omalizumab on nasal polyp size and evolution of nasal polyps,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],"Evaluation of adverse events, directly or by general physical examination, blood sampling , review of concomitant medication or symptom scores.",
3428,NCT00690677,To evaluate the effect of LBH589 on overall survival (OS) in patients with colorectal cancer,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to tumor progression and response rates,
3429,NCT06035471,cfDNA methylation markers,2023-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3430,NCT01176604,Overall survival,2010-08-04,COMPLETED,INTERVENTIONAL,['NA'],,
3431,NCT02837874,Dumping syndrome,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],Gastritis,
3432,NCT00001452,"Genotype and clinical phenotype correlation in patients with PPNAD, Carney Complex, Peutz-Jeghers Syndrome and related conditions.",1995-12-14,COMPLETED,OBSERVATIONAL,['NA'],,
3433,NCT05178576,Recurrence-free survival (RFS) at one year,2022-06-24,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Immunogenicity,
3434,NCT04867590,"The rate of full eradication of Barrett esophagus (metaplasia), which is defined by the absence of residual Barrett esophagus in the check-up endocopy after 3 months",2022-03-25,RECRUITING,INTERVENTIONAL,['NA'],Build a model to predict incomplete response for eradication of Barrett's eosophagus on the basis of each independent predictor coefficient in the multivariate regression logistic model,
3435,NCT04004234,Progression-free survival (PFS) at 6 months,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of participants with laboratory test abnormalities,
3436,NCT03487523,Number of participants taking part in the Scottish national bowel cancer screening programme,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,
3437,NCT03542214,Safety of the calcium electroporation procedure in colorectal cancer (registration of adverse events; CTCAE v4 will be used),2018-04-24,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumorregression,
3438,NCT00419159,The Number of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers Predictive of Clinical Benefit (Median PFS and OS by PTEN ) on Everolimus (RAD001) 10mg/Day,
3439,NCT04464967,Phase 2a - To assess objective response rate (ORR) of SNK01 in combination with cetuximab in subjects with advanced EGFR cancers.,2021-03,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2a - Impact of SNK01 in combination with cetuximab on quality of life in subjects with advanced EGFR cancers evaluated using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13).,
3440,NCT04327050,success rate,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA'],complications,
3441,NCT02724358,Time to progression,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
3442,NCT03399071,Pathological complete response rate of combination FLOT-A,2017-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Median overall survival by Kaplan Meir method,
3443,NCT06054685,PFS,2023-04-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3444,NCT05127759,ORR,2022-03-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
3445,NCT00004235,objective tumor response rate,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],treatment response,
3446,NCT03507998,Number of participants with adverse events and/or abnormal laboratory values that are related to treatment,2017-06-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],CGX1321 half life,
3447,NCT01862718,Safety of Ablation plus radiation,2013-11-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3448,NCT05873621,Number of harvested extra-mesorectal lymph nodes,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],Time of surgery,
3449,NCT02205307,Anastomotic Leak Rate,2015-01,TERMINATED,INTERVENTIONAL,['NA'],Incidence of Post-Operative Abscess Requiring Surgical Management,
3450,NCT02619266,Appetite Visual Analog Scale,2015-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Nutritional status,The Questionnaire of Acupuncture-related Events(QAE)
3451,NCT00075686,Overall survival comparison between treatment groups,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3'],"Pain and quality of life comparison between treatment groups as measured by patient questionnaire at baseline, before each course, and then completion of study treatment",
3452,NCT03611712,Fatigue by the Brief Fatigue Inventory-Taiwanese Form,2019-02-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"The change of of biomarkers (inhibitory immune factors, dendritic cells makers, tumor-associated macrophages, immune-regulatory markers and oncogenic-mediated immune markers) will be combined to report the immune profile.",
3453,NCT00220051,Acute toxicity has been evaluated in previous phase I studies and should occur to a similar extent.,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Bowel function and quality of life,
3454,NCT04767906,time on treatment (TT),2021-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],occurence of clinical symptoms of liver dysfunction (safety endpoint),
3455,NCT01192763,Frequency and severity of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE),2010-08,TERMINATED,INTERVENTIONAL,['PHASE1'],"Proportion of cancer stem cells (CD44+, CD24+, ESA+ population of cells) self-renewal and tumorigenesis as measured by FACS",
3456,NCT02032914,The prevalence of colonic neoplasm,2014-01,COMPLETED,OBSERVATIONAL,['NA'],Prevalence of intestinal tuberculosis,
3457,NCT04615143,Disease-free survival,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Major pathological response rate,
3458,NCT03938324,Change in Patient activation as measured by the Patient Activation Measure (PAM-13),2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in Emotional Health as measured by the Brief Symptom Inventory (BSI 18),
3459,NCT02558868,Overall Survival,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival,
3460,NCT05138159,Overall Survival,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
3461,NCT01993472,Progression free survival (PFS),2013-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of Life,
3462,NCT02948426,Overall Maximum Tolerated Dose of Actimmune (Interferon Gamma-1b),2017-02-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Time to Disease Progression,Number of Participants With a Grade 3 or Higher Dose-Limiting Toxicity (DLT)
3463,NCT02817178,Progression-free survival,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,
3464,NCT06225921,Feasibility of combination adebrelimab and dalpiciclib as assessed by number of participants who experience adverse events,2023-12-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
3465,NCT01334710,Comparison of MRI/CT Scans to Pre-treatment Scan,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicity Assessment,
3466,NCT01346839,Differences in Time to Documented Follow-up of a Red Flag Suggestive of Cancer,2011-02,COMPLETED,INTERVENTIONAL,['NA'],Trigger Positive Predictive Value,
3467,NCT05113459,"pathologic Complete Response, PCR",2021-12-18,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Overall survival , OS",
3468,NCT05092750,To assess the feasibility how the Sentinel Lymph Node (SLN) mapping by using novel magnetic tracers (FerroTrace) and using the indocyanine green (ICG) for colorectal cancer.,2021-09-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3469,NCT01324856,abdominal complications,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
3470,NCT06270017,Tumour growth,2022-01-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",response evaluation,
3471,NCT06269978,Half-life,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall response rate,
3472,NCT05101148,Proportion of patients who take each gastrointestinal medication,2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Time to last measurable concentration (tlast) of selumetinib and N-desmethyl selumetinib,
3473,NCT06123455,Overall survival (OS),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety profile,Changes in CD8+ T cell infiltration in tumor tissue
3474,NCT00004005,Disease-free survival,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3475,NCT01038544,The primary outcome measure will be the accuracy of the combination of EUS and EBUS to correctly diagnose the presence or absence of mediastinal lymph node metastases compared to EUS alone.,2009-12,COMPLETED,INTERVENTIONAL,['NA'],Change in treatment plan based on EBUS,
3476,NCT05679583,R0 rate,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor recurrence,
3477,NCT01134601,Maximum Tolerable Dose of Selumetinib (AZD6244) Hyd-Sulfate in Combination With Radiation Therapy (RT) and Capecitabine in Participants With Locally Advanced Adenocarcinoma of the Rectum.,2010-05-24,TERMINATED,INTERVENTIONAL,['PHASE1'],"Changes in Phosphorylated ERK (pERK) in Peripheral Blood Mononuclear Cells and Tumor, and Transforming Growth Factor Alpha (TGFa) Levels",Dose-Limiting Toxicity (DLT)
3478,NCT02089737,Number of Participants With Adverse Drug Reactions,2010-06,COMPLETED,OBSERVATIONAL,['NA'],Overall Survival,
3479,NCT02550847,The tumor recurrence rate after operation at 6 months,2014-08,UNKNOWN,OBSERVATIONAL,['NA'],The overall survival after operation at 6 months,
3480,NCT05653960,Adverse event rate of EMR or ESD for colorectal neoplasms,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3481,NCT06118060,Heart rate variability,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Abdominal pain,
3482,NCT03484195,The ratio of tumor downstaging to stage 0 and stage I,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life (QLQ C30),
3483,NCT02372162,Availability of comprehensive imaging and molecular fingerprint data of individual tumors,2015-07,COMPLETED,OBSERVATIONAL,['NA'],Biomarker analysis,
3484,NCT01265576,failure free survival,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],clinical benefit response,
3485,NCT03889093,Change in concentrations of PBMC,2018-08-09,RECRUITING,INTERVENTIONAL,['NA'],Change in concentrations of PBMC,
3486,NCT00681330,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To evaluate immunological responses,
3487,NCT06217094,Maximum tolerated dose,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,
3488,NCT06181318,Predicting the posthepatectomy hemorrhage after major liver resection,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Correlation between remnant liver function after major liver resection and postoperative mortality,
3489,NCT04750772,finial clinical staging（TNM）,2019-10-16,RECRUITING,INTERVENTIONAL,['NA'],SUVmax,
3490,NCT02784652,Pain relief rate,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
3491,NCT04503694,"Evaluation of the efficacy of the combination of nivolumab and regorafenib when administered before and after standard, pre-operative short-course radiation therapy.",2021-03-25,RECRUITING,INTERVENTIONAL,['PHASE2'],"Evaluation of the efficacy of the combination of nivolumab and regorafenib when administered before and after standard, pre-operative short-course radiation therapy.",
3492,NCT04727723,Progression Free Survival (PFS),2021-03-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Information about the patient's diagnosis-related group (DRG),
3493,NCT01929460,Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Median Cyst Fluid Amylase,
3494,NCT00703365,To evaluate the efficacy (progression free survival (PFS)) of sorafenib in patients with advanced/unresectable HCC.,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],"To evaluate overall, survival, overall response rate (RECIST), time to progression (TTP), disease control rate (DCR) and side-effect profile of sorafenib in combination with gemcitabine in patients suffering from HCC.",
3495,NCT01807325,Gene classifier that will classify lesions as benign or malignant with 95% certainty,2012-12,COMPLETED,OBSERVATIONAL,['NA'],,
3496,NCT03694431,Caregiver preparedness for caregiving using the Preparedness for Caregiving Scale,2019-01-07,TERMINATED,INTERVENTIONAL,['NA'],HBPC clinician perception of facilitators and barriers to implementation of HBPC services,
3497,NCT04986566,Intervention Acceptability as reported by participants,2021-10-19,RECRUITING,INTERVENTIONAL,['NA'],"Healthcare resource use (e.g., hospital readmission)",
3498,NCT00342186,Collection of 3400 samples,2002-09-27,COMPLETED,OBSERVATIONAL,['NA'],,
3499,NCT00895388,Quality of LIfe (EQ 5D),2009-05,WITHDRAWN,INTERVENTIONAL,['NA'],ICIQ Urinary function Short form,
3500,NCT00107679,Time to high-grade anal dysplasia or anal cancer,2005-02,COMPLETED,OBSERVATIONAL,['NA'],time from low-grade anal dysplasia to normal,
3501,NCT03254121,"Characterisation of genomic mutations of HCC, developed in HCV patients with SVR",2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
3502,NCT00251186,To measure the response (CR/PR) for a novel chemotherapy/biologic combination-capecitabine/cetuximab for patients with metastatic colorectal cancer who are too fragile for more intensive chemotherapy doublet regimens.,2006-04,TERMINATED,INTERVENTIONAL,['PHASE2'],To describe the baseline quality of life and functional characteristics of elderly patients or those with multiple comorbidities enrolled in this study and assess the impact of disease and its treatment on such functional characteristics.,
3503,NCT04111029,Serial Quantification of ctDNA in plasma samples by means of real-time PCR post treatment,2020-01-16,RECRUITING,OBSERVATIONAL,['NA'],Mortality,
3504,NCT01528878,Tolerability of Stereotactic Body Radiotherapy (SBRT) Based on Number of Cumulative Acute Toxicities Occurring Within 90 Days of Treatment and Related to SBRT.,2009-04,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival of Patients With Liver Cancer or Metastases to the Liver,
3505,NCT02038114,Impact of Patient Pamphlets on knowledge,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Impact of patient education pamphlets on health-related quality of life (HRQoL),Impact of patient education pamphlets on patient satisfaction with care
3506,NCT00003411,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3507,NCT04214119,Difference in methylation of gene markers to discriminate gastric cancer from non-pathological esophageal squamous and gastric cardia tissue.,2016-01-12,RECRUITING,OBSERVATIONAL,['NA'],Specificity of candidate biomarker HPP1,
3508,NCT04155671,Overall Survival(OS),2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Objective Overall Response Rate (ORR),
3509,NCT04118933,objective response rate,2019-07-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3510,NCT03478488,Overall Survival (OS),2018-04-16,RECRUITING,INTERVENTIONAL,['PHASE3'],Time to progression (TTP),
3511,NCT05471596,Prospective Power/Time Analysis of In Vivo Laparoscopic Microwave Ablation Thermodynamics in Hepato-Pancreato-Biliary Sold Tumors Utilizing a Single Generator at a Single Surgical Center,2022-02-14,COMPLETED,OBSERVATIONAL,['NA'],90 day complication rate,
3512,NCT00515853,Cleveland Clinic Incontinence (CCI) Score,2006-11-27,COMPLETED,INTERVENTIONAL,['NA'],,
3513,NCT00867321,Time to Progression (TTP) (Phase II),2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumor Response at 6 Months,
3514,NCT05359939,Hepatocellular carcinoma - sensitivity and specificity of two PET tracers,2023-01-16,RECRUITING,INTERVENTIONAL,['NA'],Hepatocellular carcinoma - sensitivity and specificity of MRI and CT,
3515,NCT00238394,Time to disease progression,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Laboratory measures,
3516,NCT04757311,Progression Free Survival (PFS),2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],Advers events,Percentage of use biologics in right side tumors.
3517,NCT04410887,Pathological response rate,2020-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease free survival (DFS),
3518,NCT03402477,Rate of regrowth,2018-01-10,RECRUITING,OBSERVATIONAL,['NA'],Diagnostic accuracy of MRI to detect regrowth during follow-up after complete response,
3519,NCT02526095,DIsease free survival,2014-06,RECRUITING,OBSERVATIONAL,['NA'],Death,
3520,NCT01761266,Overall Survival (OS),2013-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib,Percent Change From Baseline in Serum Biomarker
3521,NCT03050814,"Progression Free Survival Between the Standard of Care (SOC) Arm A, and Standard of Care (SOC) Arm B + lead-in",2017-04-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants That Are Hospitalized Because of Adverse Events Attributed to Disease Progression,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
3522,NCT03378128,Percentage of patients experiencing grade 3 or 4 post-operative complications,2018-01-12,COMPLETED,INTERVENTIONAL,['NA'],Score of Suidan preoperative predictive index parameters,
3523,NCT05270642,local tumor progression,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3524,NCT00899002,Identification of proteomic profiles and molecular pathways involved in tumor progression,2007-07,WITHDRAWN,OBSERVATIONAL,['NA'],Association between fibrolamellar carcinoma and hepatocellular carcinoma in terms of molecular aberrations and clinicopathologic features,
3525,NCT01175291,Progression Free Survival,2010-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events,
3526,NCT02342600,Disease Control Rate (DCR),2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Number and type of adverse events,
3527,NCT01077817,"Number of Cases of Esophageal Cancer Per 100,000 Woman-Years (Intent-to-Treat Analysis)",2010-02-26,COMPLETED,OBSERVATIONAL,['NA'],,
3528,NCT01954732,"Pancreatic tumor cell proliferation and apoptosis as measured by the percentage of cells Ki-67+, percentage of cells TUNEL+, and mitotic counts in tissue samples",2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Percentage of pancreatic cancer stem cells in tissue samples,
3529,NCT04660812,Number of Participants With Treatment-emergent Adverse Events,2021-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Anti-Drug Antibodies to the Biologic Component(s) of Combination Therapy,
3530,NCT00028834,Objective response rate (complete or partial responses),2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
3531,NCT05982197,Change in severity of radiation induced mucositis,2023-01-03,COMPLETED,INTERVENTIONAL,['NA'],,
3532,NCT00089635,Duration of Response,2004-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
3533,NCT01215578,Predictive molecular markers of response to sunitinib,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Residual concentration,
3534,NCT01916148,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
3535,NCT02500199,Part 2 Overall Response Rate (ORR),2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],Progression Free Survival (PFS),
3536,NCT02994693,Longitudinal assessment of the Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy,2016-12,RECRUITING,OBSERVATIONAL,['NA'],,
3537,NCT01664494,Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment,2010-04,COMPLETED,OBSERVATIONAL,['NA'],Median Dose of Capecitabine,
3538,NCT05438420,Tumor response using RECIST version 1.1 throughout study,2023-01-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in the area under curve (AUC) of Q702 and its primary metabolites,
3539,NCT04394598,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of the concurrent chemotherapy cycles that patients can receive during radiotherapy,
3540,NCT05980481,Safety(adverse event),2023-08-04,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Duration of relief (DOR),
3541,NCT01927497,30-day Uncomplicated Perineal Wound Healing,2013-03-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3542,NCT00006037,,1999-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3543,NCT01975688,"Area under the concentration-time curve extrapolated to infinity (AUC(0-∞)) of THC, 11-hydroxy-THC, CBD, 7-hydroxy-CBD and 6-hydroxy-CBD after a single dose of Sativex",2014-02,TERMINATED,INTERVENTIONAL,['PHASE1'],The incidence of adverse events as a measure of subject safety,
3544,NCT02892305,Overall Survival,2018-05-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Intraoperative estimated blood loss,
3545,NCT05720338,Composite endpoint comparison,2023-04-13,RECRUITING,INTERVENTIONAL,['PHASE3'],Cost analysis for overall healthcare costs,
3546,NCT04385641,Non hematologic toxicity,2019-10-08,UNKNOWN,INTERVENTIONAL,['NA'],Tumor assessment,
3547,NCT02460835,Median Time to Local Progression,2016-01-26,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival,Incidence of Radiation Induced Liver Disease (RILD)
3548,NCT00506571,Maximal overall response rate,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Progression-free survival, Overall survival, Toxicity assessment, & Pharmacokinetic characteristics and association with genetic polymorphism",
3549,NCT03804593,"Rate of SEPT9 gene promoter methylation positivity in patients with cirrhosis, based on the HCCBloodTest.",2018-12-17,COMPLETED,OBSERVATIONAL,['NA'],,
3550,NCT00853203,To collect information about factors affecting colon and rectal cancer patients' quality of life (QOL) in order to develop a QOL program.,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],"To look at acceptability of an Expressive Disclosure Group Program for colon and rectal cancer patients, and examine its effect on quality of life.",
3551,NCT00331422,Number of Patients Who Underwent Optimal Cytoreduction After Chemotherapy,2005-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of Life Score of Patients Receiving Neoadjuvant Chemotherapy,
3552,NCT05178030,The negative predictive value of the ddPCR assay with regard to KIT exon 11 circulating tumour mutation,2021-05-11,RECRUITING,OBSERVATIONAL,['NA'],Determination of time between first detection of secondary mutations and progression,
3553,NCT04853017,Evaluate the safety of ELI-002,2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Determine the biomarker reduction and clearance rate,
3554,NCT01731821,the postoperative pancreatic fistula(POPF) rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3'],morbidity and mortality,
3555,NCT00319683,,na,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3556,NCT02959151,Number of patients with adverse event,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Detection of transferred T cells in the circulation using quantitative -PCR,
3557,NCT01946646,maximum-tolerated dose,2013-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3558,NCT04130763,The number of adverse events,2019-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],The number of adverse events,
3559,NCT06253598,Objective response rate using RECIST v1.1,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],AE,
3560,NCT01764789,Quality of life(QoL),2010-10,COMPLETED,INTERVENTIONAL,['NA'],Inflammation,
3561,NCT01621919,,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],,
3562,NCT01798173,Dosage of the vitamin B12 and the folates,2008-06-20,COMPLETED,INTERVENTIONAL,['NA'],,
3563,NCT00005944,,1999-07-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3564,NCT01035385,progression free survival (PFS),2009-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],"response rate, incidence of postoperative complications,pathological response rate,R0 resection rate, 5-year overall survival,duration of disease control",
3565,NCT02929186,FIT Completion Rate,2017-01,COMPLETED,INTERVENTIONAL,['NA'],Mail/Electronic Message Engagement,
3566,NCT05998122,Complete response rate (CR),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Wexner score,
3567,NCT05796245,Incidence rate of Serious infections,2023-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Incidence rate of malignancy,
3568,NCT04601272,Shared Decision Making Process Measure,2020-09-29,COMPLETED,OBSERVATIONAL,['NA'],Knowledge,
3569,NCT01494077,Accuracy of diluted CEA level,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,
3570,NCT06078709,Pathologic complete response,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity of chemoradiation between groups receiving proton based versus photon-based radiotherapy,
3571,NCT06277921,the type of complications and the incidence of it,2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3572,NCT03149978,TRG,2014-07-01,UNKNOWN,OBSERVATIONAL,['NA'],Number of participants with chemoradiation-related adverse events as assessed by CTCAE v4.0,
3573,NCT01576380,disease control rate (DCR),2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],progression free survival (PFS) per independent central review,
3574,NCT05759923,Occurence of DLTs,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE1'],PK parameter: AUCO-24,
3575,NCT04166318,Change in FIQoL in the de-intensified CRT arm,2020-01-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of and predictors for cardiovascular toxicity in patients receiving fluorouracil or capecitabine,Overall survival
3576,NCT05891028,Standardized uptake value,2023-05-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Adverse events collection,
3577,NCT05449483,R0 Surgical Resection Rate .,2022-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
3578,NCT03433092,Gastrointestinal Tract Cancer Incident Measure,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
3579,NCT03342417,Clinical Response,2018-02-14,TERMINATED,INTERVENTIONAL,['PHASE2'],Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Recurrence rate,Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - QLQ-OV28
3580,NCT05824403,Diagnostic tools,2023-11-28,RECRUITING,OBSERVATIONAL,['NA'],Clinical data access,
3581,NCT05716620,HCC detection rate of US vs AMRI in cirrhotic patients,2022-02-08,RECRUITING,OBSERVATIONAL,['NA'],Survival of patients,
3582,NCT02958566,Hospital stay cost,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Patient satisfaction,
3583,NCT01744340,"If Eribulin Mesylate, up to a Maximum Dose of 1.4 mg/m2 Day 1 and 8 of a 21 Day Cycle, Can be Safely Combined With Full Dose Cetuximab for Patients With Advanced Head and Neck Cancer and Colon Cancer.",2012-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Response Rate (Whether Patient's Disease is Progressing or Being Controlled) of Patients With Head and Neck Cancer Treated With Eribulin Mesylate and Cetuximab.,
3584,NCT04044651,Overall survival (OS),2019-10-30,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",OS stratified according to degree of PVTT (Vp0-3 vs Vp4),AFP level change
3585,NCT01806740,Correlation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to Sorafenib,2013-05-09,TERMINATED,INTERVENTIONAL,['PHASE4'],Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Time to Progression,
3586,NCT05916443,Identification of EO-CRC specific signatures and pathways,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3587,NCT01204749,Progression-Free Survival,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall health status using EuroQOL(EQ-5D),
3588,NCT02618447,Ability of the 4D PC MRA to measure flow direction of flow as compared to reference standards of the Doppler Flow Analysis,2014-08-05,TERMINATED,INTERVENTIONAL,['NA'],,
3589,NCT02736448,Progression free survival,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],toxicity,
3590,NCT00821990,Survival,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3591,NCT04960072,Overall Survival (OS),2021-06-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Change in Quality of Life,
3592,NCT05804799,Measurement of standard deviation of CT attenuation values at the liver,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],Sensitivity to detect malignant liver tumor,
3593,NCT02494388,Accuracy of EUS-guided nCLE in a cohort of cystic pancreatic tumors,2015-06,TERMINATED,OBSERVATIONAL,['NA'],Number of participants with adverse events as a measure of safety,
3594,NCT02514278,Rate of organ preservation and absence of stoma,2016-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Disease-free survival,
3595,NCT01785212,transection speed,2013-03,COMPLETED,INTERVENTIONAL,['NA'],Perioperative T-cell subsets,Costs and health economics
3596,NCT05508503,Accuracy,2022-10-21,COMPLETED,OBSERVATIONAL,['NA'],Combined specificity,
3597,NCT05802056,Incidence of adverse events,2023-11-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,
3598,NCT05160168,"Expansion (Phase 2): Expansion Cohorts 1, 2, 3 and 4: confirmed Objective Response Rate (ORR)",2022-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
3599,NCT01839604,Number of Participants With Dose Limiting Toxicities During Cycle 1,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1'],"Evaluation of Pharmacokinetics (PK) of AZD9150 (Following Single Administrations in Patients With HCC) by Determining Tmax, Using the Plasma Concentration Data.",
3600,NCT02530983,Completion of the Mayo Clinic Upper Digestive Disease Survey by patients at varying time points following surgery,2015-08,RECRUITING,OBSERVATIONAL,['NA'],"Establishment of ""normal"" or expected scores from the Mayo Clinic Upper Digestive Disease Survey",
3601,NCT04212286,"The sensitivity, specificity and accuracy of CEUS and EOB-MRI",2019-10-23,COMPLETED,INTERVENTIONAL,['NA'],"The sensitivity, specificity and accuracy of combined CEUS and EOB-MRI",
3602,NCT02324374,"Unblinded Analysis of Endocytoscopic Images of Colorectal Lesions (Technical quality of the images will be compared to histology and rated on a scale of 1-5 (1-worst, 3- acceptable, 5-being equal to histology)",2011-06,COMPLETED,INTERVENTIONAL,['NA'],,
3603,NCT00688766,Compare the progression free survival (PFS) in both study arms,2008-08,TERMINATED,INTERVENTIONAL,['PHASE3'],Evaluate the safety and tolerability of IPI-504 in this patient population,
3604,NCT03621319,Rate of stricture-free eradication of dysplastic BE,2019-07-24,TERMINATED,INTERVENTIONAL,['NA'],Cost-effectiveness of HAPC vs. RFA in the treatment of dysplastic BE,
3605,NCT04340193,Number of treated participants with laboratory abnormalities,2020-09-15,TERMINATED,INTERVENTIONAL,['PHASE3'],,
3606,NCT04593446,The rate of surgical site infection,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],The patient's tolerability for bowel preparation,
3607,NCT01286428,Phase II: The number of surgical oblation procedures that present data showing equivalent location of the ablation probe when compared to the US and Pathfinder Guidance System 3D image data.,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
3608,NCT04309747,Effectiveness analysis,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA'],Secondary validity analysis,
3609,NCT03402607,Change in Quality of Life (QOL) Using EORTC C-30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30),2018-08-08,TERMINATED,INTERVENTIONAL,['NA'],The Total Healthcare System Costs Associated With PLA vs HIGRT,
3610,NCT04083053,High Resolution Anoscopy (HRA) discomfort scale,2019-09-17,COMPLETED,INTERVENTIONAL,['NA'],,
3611,NCT04145388,Number of patients identified at high risk of cancer,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
3612,NCT04656249,Progression free survival (PFS),2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],The Rate of Treatment Related Adverse Events,Clinical benefit rate (CBR)
3613,NCT05099549,Phase 2a/Expansion,2021-11-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2a/Expansion,
3614,NCT00258180,"Number of Participants Experiencing Intervention-related Adverse Events, as Defined by CTCAE at 1 Month",2005-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3615,NCT02328365,Postoperative mortality at one year,2014-03,COMPLETED,INTERVENTIONAL,['NA'],Medical complications,Findings and interventions at medical visits
3616,NCT03847636,Complete eradication rate of DAs,2019-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Median number of CryoBalloon treatments to complete eradication.,
3617,NCT02859155,Survival,2009-01,COMPLETED,INTERVENTIONAL,['NA'],Recurrence,
3618,NCT05846971,The impact of methylation assay on physician confidence in clinical care decision-making.,2021-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
3619,NCT02885727,Improvement in median Progression Free Survival using the combination of RT and durvalumab.,2017-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
3620,NCT03587818,The Longitudinal Preparedness for Colorectal Cancer Surgery Questionnaire (PCSQ),2012-11-01,COMPLETED,INTERVENTIONAL,['NA'],Behaviour pertaining when and how to seek health care for recovery support: Visits at outpatients clinics,
3621,NCT02579330,Grade of macroscopic contamination according to adjusted Boston Bowel Preparation Score (0-3).,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative pain (VAS-score),
3622,NCT05051046,Rate of complete colonoscopies,2022-01-31,RECRUITING,INTERVENTIONAL,['NA'],Medico economic criteria,
3623,NCT01210911,Survival after 6 months,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],toxicity profile,
3624,NCT03829410,Phase 2: Number of Participants with an Objective Response Rate (ORR),2019-05-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Onvansertib,
3625,NCT01627119,To measure the expression level of CTGF in patient blood and tissue,2009-07,UNKNOWN,OBSERVATIONAL,['NA'],To determine the survival probability of gastric cancer patients after surgery,
3626,NCT02420509,Progression-Free Survival,2015-08-27,TERMINATED,OBSERVATIONAL,['NA'],Quality of Life,
3627,NCT05802394,Resection rate,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],Major pathological response,The prognostic role of targeted therapy selected based on MRD
3628,NCT05676190,objective response rate (ORR),2023-01-09,RECRUITING,INTERVENTIONAL,['NA'],,
3629,NCT02133079,electrocardiogram,2012-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",changes in antigen specific T cells,Change from baseline in subpopulation of CD8+ T cells at the end of vaccination
3630,NCT03030404,Characterization of the natural and clinical histories of hereditary gastric cancer syndromes,2017-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
3631,NCT03065855,Post-operative urinary retention requiring re-catheterisation,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],Urethrorrhagia,
3632,NCT02849015,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival（OS）,
3633,NCT03542799,Safety: Occurrence of study related adverse events,2018-05-22,UNKNOWN,INTERVENTIONAL,['PHASE1'],Effectiveness: duration of in vivo survival of EGFR CART,
3634,NCT05600335,incidence of various postoperative complications,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],radicality of surgery,
3635,NCT02578888,"FAMCARE Survey will be administered, a 20 item scale measuring the degree to which family members are satisfied with the healthcare providers' behaviors. Comparison of family member scores between 2 arms, as well as at face value will be evaluated.",2015-04,COMPLETED,INTERVENTIONAL,['NA'],,
3636,NCT04801459,Late postoperative recovery results,2021-04-02,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
3637,NCT02970526,Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).,2016-07,COMPLETED,OBSERVATIONAL,['NA'],pain assessed by visual analog scale (VAS).,
3638,NCT00096031,Overall Survival at 6 Months,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Progression,
3639,NCT03883919,Tolerability between two different dose levels of paricalcitol added to the combo regimen of liposomal irinotecan plus 5-FU / LV as measured by the occurrence of grade 3 and 4 toxicities,2019-07-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Duration of stable disease,
3640,NCT05246982,PFS,2022-03-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],DOR,
3641,NCT02100254,Change in likelihood of CRC screening in previously unscreened subjects,2009-10-01,COMPLETED,INTERVENTIONAL,['NA'],"Influential factors in behavior changes, assessed using qualitative analyses of text from participant interviews, including affective associations with the program, participants' cognitive-affective influences, and predisposing influences",
3642,NCT04146298,Objective response rate,2021-10-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
3643,NCT00950144,"Relationship among characteristics (i.e., sociodemographic, disease, health status) associated with illness perceptions, overall symptom distress, and QOL)",2008-12,COMPLETED,OBSERVATIONAL,['NA'],,
3644,NCT00004873,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3645,NCT00253812,The primary outcome measure will be the mean number of adenomas detected on the blinded video review for each endoscopy,2005-11,UNKNOWN,INTERVENTIONAL,['NA'],Primary endoscopist adenoma count for each modality.,
3646,NCT02399995,changes in the quality of life (QoL),2015-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3647,NCT06311032,Number of Decisions to Continue Surveillance Imaging,2023-03-29,COMPLETED,OBSERVATIONAL,['NA'],,
3648,NCT03344289,polyp detection rates,2018-01-21,COMPLETED,INTERVENTIONAL,['NA'],"sensitivity, specificity, and accuracy of optical diagnosis on a per polyp basis",
3649,NCT00394615,To learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy.,2003-10,TERMINATED,INTERVENTIONAL,['NA'],,
3650,NCT03094351,Overall Survival Rate,2017-07-29,RECRUITING,INTERVENTIONAL,['PHASE3'],Disease Free Survival Rate,
3651,NCT04221854,"The Detection Rate of Colorectal Polyps, Advanced Adenomatous Polyps and Cancer by Two Screening Methods",2020-01-06,UNKNOWN,INTERVENTIONAL,['NA'],,
3652,NCT01231022,Protective effection of peripheral hematopoietic stem cell infusion for DILI,2010-08,COMPLETED,OBSERVATIONAL,['NA'],Change of cytokines,
3653,NCT00109941,Survival,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Opioid growth factor markers,
3654,NCT00336960,Pathologic complete response rate,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,
3655,NCT01991678,Pharmacokinetics (PK) of NKTR-102 and its metabolites,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety and tolerability of NKTR-102,
3656,NCT04025437,Overall survival,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Recurrence-free survival,
3657,NCT03637569,Overall survival,2018-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
3658,NCT03930043,Metagenomic Linkage Groups (MLGs),2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3659,NCT01479803,Diagnostic accuracy of fine needle aspiration Echo Tip® HD ProCore™ versus EchoTip® in the etiological cyto histological in pancreatic solid tumors explored under endoscopy ultrasonography.,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],ease of puncture between the 2 types of equipment.,
3660,NCT05199285,Confirmed objective response rate (ORR),2023-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
3661,NCT04522544,Objective response rate (ORR) [according to RECIST 1.1] at 6 months.,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of Life (QoL),Translational research
3662,NCT06208748,To estimate the median progression free survival (mPFS),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To describe patient-reported quality of life outcome measures.,
3663,NCT02580929,mortality,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],,
3664,NCT02413437,diagnostic accuracy,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],,
3665,NCT02484833,Incidence of grade 3-4 AEs,2015-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of life assessed by EORT QLQ-C30 and DLQI questionnaires,
3666,NCT00176761,To assess the antitumor response of this immunotherapy regimen.,2000-03,TERMINATED,INTERVENTIONAL,['PHASE2'],To evaluate the toxicity of this treatment regimen.,
3667,NCT01858649,the major pathological response rate,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Post operative complication,
3668,NCT00988897,"Primary endpoint for the first thirteen patients according to the Simons Design: Clinical DCR (Disease Control Rate) at the end of stage I, based on Response Evaluation Criteria on Solid Tumors (RECIST) criteria.",2009-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall response rate of stage I and II,
3669,NCT02831179,Maximum tolerated dose determined by dose limiting toxicities defined as any toxicity in the first course evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2017-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Poly-adenosine diphosphate (ADP)-ribosylated (PAR) level,
3670,NCT04144907,13C Phenylalanine Oxidation,2021-04-26,RECRUITING,INTERVENTIONAL,['NA'],,
3671,NCT03414125,One-time Screening Completion,2018-09-07,COMPLETED,INTERVENTIONAL,['NA'],Choice of FIT versus Colonoscopy,
3672,NCT03634683,Safety based on Incidence of Treatment-Emergent Adverse Events (AEs) and Serious AEs,2018-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life of patients,
3673,NCT02767986,causal attributions of breast cancer,2016-05-10,COMPLETED,OBSERVATIONAL,['NA'],,
3674,NCT03736720,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Grade 3+ Treatment Related Adverse Events (TRAE),
3675,NCT01177631,Recurrence,2009-02,COMPLETED,INTERVENTIONAL,['NA'],,
3676,NCT00956475,Most common areas of concern,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,
3677,NCT02695628,Post-treatment Maximum Standardized Uptake Value (SUVmax) in Tumor and Normal Tissue,2016-09-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events Related to 18F-fluoromisonidazole (18F-FMISO),
3678,NCT00539617,Progression Free Survival (PFS),2007-10-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Time to Progression (TTP),
3679,NCT05031975,"To assess the activity in terms of seroreversion of TEMIRI consolidation regimen administered to patients with high-risk stage II (pT4) or III MSS, MGMT silenced CRC and positive post-adjuvant ctDNA after standard oxaliplatin-based adjuvant chemotherapy.",2022-05-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life as assessed using the Euro Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L),To assess the accuracy of ctDNA as disease recurrence biomarker
3680,NCT01009593,Overall Survival,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Overall Response Rate (ORR),
3681,NCT02305186,Safety: Incidence of Dose-Limiting Toxicities (DLTs),2015-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Response Rate (RR),
3682,NCT04741152,No hidden insulinomas,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
3683,NCT04889768,R0 resection,2021-07-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adverse Events,
3684,NCT01146769,Maximum Squeeze Pressure,2010-04,UNKNOWN,INTERVENTIONAL,['NA'],Functional Outcomes,
3685,NCT00514930,To estimate the local and remote intra-hepatic and extra-hepatic recurrence rates and their impact on survival.,2007-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Complications and unexpected adverse events (early and late) related to RFA aspirator treatment to be assessed. Data points to be collected as per proforma for trial.,
3686,NCT06192862,CRC screening uptake rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],qualitative factors checklist associated with CRC screening,
3687,NCT04417764,Incidence of Adverse Events,2019-06-20,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival,
3688,NCT03780946,Pancreatic fistula,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Discharge of the magnets,
3689,NCT00243841,6 Month Local In-field Control,2004-05,COMPLETED,INTERVENTIONAL,['NA'],Phase II: Number of Patients With Treatment Related Grade 3 or 4 Adverse Events,
3690,NCT01927978,"The effectiveness of 18F-FDG PET in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients.",2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
3691,NCT06196294,Number of Patients with Dose Limiting Toxicity,2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Median γδT cell persistence,
3692,NCT04735133,surgical wound complications (SWC),2018-11-18,COMPLETED,INTERVENTIONAL,['NA'],length of stay in the hospital,
3693,NCT02829788,Peritoneal carcinomatosis staging,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,
3694,NCT05185531,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,
3695,NCT02388256,Recovery of physical function,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Adverse events related to acupuncture,Adherence to enhanced recovery program after surgery
3696,NCT02575014,Number of participants with hyperbaric oxygen treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],Change in Carcinoembryonic antigen,
3697,NCT00761345,To Determine the Dose Limiting Toxicities,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],To Measure Progression Free Survival and Overall Survival,
3698,NCT05652361,Incidence of discrepancies between the surgeon's preparation and the prediction of the CoBot system,2021-05-19,RECRUITING,INTERVENTIONAL,['NA'],Assessment of oncological outcomes: Frequency of Loco-Regional Tumor Free Survival (LRFS),
3699,NCT04285008,rate of adequate cleansing level after using the Pure-Vu System as compare to sandard of care colonoscopy procedure,2020-03-03,WITHDRAWN,INTERVENTIONAL,['NA'],,
3700,NCT02333409,pain scores in numeric rating scale (NRS),2015-03,TERMINATED,INTERVENTIONAL,['NA'],Quality of Life scores,
3701,NCT05954871,Number of Participants with Dose-Limiting Toxicities (DLTs),2024-01-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-Free Survival (PFS) After Enrollment as Determined by Investigator According to RECIST v1.1,
3702,NCT01441492,60-day ≥ Grade II Complication Rate,2011-09,COMPLETED,INTERVENTIONAL,['NA'],Composite Quality of Life Scores,
3703,NCT00064181,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3704,NCT05662488,Response of total lesion activation to anti-PD1-based combination therapy shown in [68Ga]FAPI and [18F] FDG PET Scans,2020-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Progression-free survival after treatment,
3705,NCT04140526,Rate of treatment related adverse events (TRAE) according to CTCAE v5.0,2020-09-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
3706,NCT02827786,"EMA (colour scale) images will be compared to baseline US grey-scale images for a specific target lesion, as determined by standard of care imaging (US, CT, MRI or PET) and/or histologically proven lesion in a given subject.",2016-09,UNKNOWN,INTERVENTIONAL,['NA'],US grey-scale and EMA colour maps will be obtained from both target liver lesions and background liver tissue from the same subject and compared.,
3707,NCT05136326,To evaluate the rate of complete pathologic response (pCR),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],"To assess the incidence, nature, and severity of adverse events",
3708,NCT01589146,"symptomatic objectively confirmed VTE, asymptomatic ultrasonography-confirmed DVT or VTE-related death",2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
3709,NCT02353936,response rate,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression free survival,
3710,NCT01450696,Overall Survival - FAS,2011-12,TERMINATED,INTERVENTIONAL,['PHASE3'],Trastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS,
3711,NCT01415063,overall survival,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],disease-free survival,
3712,NCT02279719,Assessment of Disease Control Rate in the Intent to Treat Population- Phase II,2014-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Assessment of the Pharmacodynamic Studies as Well as the Concentration of Study Drug (Either Napabucasin or Amcasertib) in Tumors,
3713,NCT02409199,Progression-free survival (PFS),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Safety (incidence of adverse events),
3714,NCT06268015,Proportion of subjects with a best overall response of complete response or partial response according to iRECIST,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Months of progression-free survival,
3715,NCT05775939,Change in mean standardized uptake value (SUV) changes in the heart,2023-01-20,RECRUITING,INTERVENTIONAL,['NA'],Cardiac related death,
3716,NCT01092689,"Quantify and characterize HCA-DNA adducts in resected human pancreatic tissue after a dietary relevant dose of PhIP, the most mass abundant HCA in charred meat.",2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Quantify [14C]PhIP and [14C]PhIP metabolites in urine and plasma.,
3717,NCT03745794,Number of Participants Discharged Opioid-Free,2019-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Patients and Family Free of Opioid Use,
3718,NCT03716063,Metastasis recurrence rate in 1 year,2018-10-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],Metastasis recurrence rate in 3 years,
3719,NCT03440515,treatment success rate,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3720,NCT03924466,Feasibility and added value of 68GaNOTA-Anti-HER2 in neoadjuvant setting of breast carcinoma,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Influence image-guide biopsy on patient management,
3721,NCT05609656,The incidence rate of adverse events according to CTCAE v. 4.0,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,immune infiltration by PD-1 and PD-L1 staining
3722,NCT05615129,Overall survival,2021-10-01,COMPLETED,OBSERVATIONAL,['NA'],Pathologic complete response rate (pCR),
3723,NCT04854213,To assess the efficacy of SBRT in inducing a regressive genetic trajectory of KRAS gene (evaluated by NGS technique) after SBRT treatment.,2021-10-06,RECRUITING,INTERVENTIONAL,['NA'],Metabolic response (exploratory studies),
3724,NCT03693846,Number of Participants With Progression-Free Survival at 6 Months,2019-02-15,TERMINATED,INTERVENTIONAL,['PHASE2'],Duration of Response,
3725,NCT04981119,Percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02 identified by next generation sequencing,2021-10-29,RECRUITING,OBSERVATIONAL,['NA'],Percentage of enrolled participants who experience an adverse event (AE) related to apheresis,
3726,NCT05945797,Shortening of CBD cannulation time,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
3727,NCT00878163,Maximum tolerated dose of erlotinib hydrochloride defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients,2009-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Time to treatment failure,
3728,NCT00587314,Response to treatment,2004-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
3729,NCT00051545,"Time to relapse, relapse being defined as the first recurrence of HCC (intra- or extrahepatic).",1999-11,TERMINATED,INTERVENTIONAL,['PHASE3'],Dose of Seocalcitol,
3730,NCT05026268,Post-operative complications rate,2021-09,UNKNOWN,INTERVENTIONAL,['NA'],The time to discharge from hospital,
3731,NCT03093129,recurrence free survival 2 years after surgery,2018-01-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Predictive value of tumour biomarkers in terms of predicting response to artesunate therapy,
3732,NCT02561273,Overall Response Rate,2015-09-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free Survival,
3733,NCT02038621,Progression Free Survival (PFS),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],health-related quality of life (HRQOL,
3734,NCT03828799,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2019-05-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determination of circulating free DNA concentration,
3735,NCT02831556,Experimental ultrasound diagnosis agreement with final reference standard diagnosis,2016-07,RECRUITING,OBSERVATIONAL,['NA'],Experimental ultrasound image quality.,
3736,NCT05518110,Patients free of disease progression,2023-05-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerability,Comparison of new methods of multi-omics data integration vs existing models using AUROC
3737,NCT02423720,"Adherence to the intervention, as assessed by frequency and duration of practicing the exercises (recorded in a log and responses to text messages)",2015-04-28,COMPLETED,INTERVENTIONAL,['NA'],"Adherence to the intervention, as assessed by frequency and duration of practicing the exercises (recorded in a log and responses to text messages)","Sleep quality, as assessed by NCCN Distress Thermometer and NIH PROMIS instruments at the beginning, midpoint and end of the study"
3738,NCT03597672,The number of new cases of gastric carcinoma,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Time of finding nee cases,
3739,NCT04802486,Number of patients that adhered to the exercise conditions of the study,2016-06-29,COMPLETED,INTERVENTIONAL,['NA'],Porportion of subjects with improved cachexia-related symptoms 3 months,
3740,NCT04918459,Death adjusted cumulative incidence of rebleeding at 30-day,2021-08-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Mortality rate at 6 months,
3741,NCT06103435,Survival,1996-01,COMPLETED,OBSERVATIONAL,['NA'],Rate of readmissions,
3742,NCT00360971,Duration of Oral Mucositis as Measured in Terms of Days,2006-07,TERMINATED,INTERVENTIONAL,['PHASE3'],Time to Second Primary Tumor,
3743,NCT00305760,Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux. Safety is Defined as the Number of Treatment-related Grade 3 or 4 Adverse Events Observed in Greater Than 5% of the Patient Population,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3744,NCT02785068,To correlate disease response according to RECIST with levels of irinotecan and SN-38 in tumor tissue,2016-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Presence of anti-drug antibodies will be assessed,
3745,NCT03140670,Progression-Free Survival (PFS) at 6 Months (PFS6),2017-09-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicity at Least Possibly Related to Rucaparib,
3746,NCT03399331,severity of OM,2017-07-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],pain,
3747,NCT00889343,To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Safety,
3748,NCT04668781,Fluid volume intraoperatively and postoperatively,2020-12-21,RECRUITING,INTERVENTIONAL,['NA'],Mortality,
3749,NCT04550494,Percent of patients who demonstrate simultaneous Rad51 activation,2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall response rate,Tumor genomic alterations potentially associated with sensitivity or acquired resistance to talazoparib
3750,NCT04264260,survival,2019-12-24,RECRUITING,INTERVENTIONAL,['PHASE2'],serious adverse effect,
3751,NCT04027348,Proportion of Patients With Obstruction Clearance,2019-06-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3752,NCT00730158,Proportion of Participants With Grade 2-4 Toxicities,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Circulating Tumor DNA - Percentage of Patients With DNA Mutations,
3753,NCT03708783,the incidence of postoperative complications within 30 days,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],3-year disease free survival,
3754,NCT03310892,Colonoscopy completion rate,2017-10-09,COMPLETED,INTERVENTIONAL,['NA'],Colonoscopy scheduling rate,
3755,NCT04837508,Objective Response Rate (ORR) by Independent Review Committee (IRC),2021-06-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of anti-drug antibody (ADA),
3756,NCT01759056,Safety and tolerability of AVX-470 over 28 days of treatment,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Measure the induction of or change in a human anti-bovine immunoglobulin antibody (HABA) response to AVX 470,Evaluate the effects of AVX 470 on biomarkers of ulcerative colitis activity over 28 days of treatment compared to Baseline
3757,NCT03215355,Improved image quality after injection as determined by contrast-to-background calculation and expert observation.,2017-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],"Toxicity with ""off label"" dosing",
3758,NCT01229943,Progression Free Survival,2010-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
3759,NCT01795274,Acute toxicity of carbon ion radiotherapy observed within 3 months of study treatment,na,WITHDRAWN,INTERVENTIONAL,['NA'],overall survival,
3760,NCT05600933,"To collect biologic samples from participants undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors and hematologic malignancies",2023-05-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],"To collect detailed history, demographic, treatment data, and perioperative findings.",
3761,NCT00507351,Pain and symptom data across multiple institutions,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,
3762,NCT00914537,High resolution anoscopy,2009-06-02,COMPLETED,OBSERVATIONAL,['NA'],,
3763,NCT06327386,Evaluation efficacy of tumor regression level,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],SUV,
3764,NCT04742959,Dose limiting toxicity (DLT),2021-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Volume of Distribution (Vd),Genetic Alteration Status
3765,NCT02892643,Vitamin B12 cumulative supplement quantity,2016-10-27,COMPLETED,INTERVENTIONAL,['NA'],Overall survival,
3766,NCT00192712,time to treatment failure,2002-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","response rate, survival, toxicity",
3767,NCT01181609,Percentage of Participants Achieving Overall Disease Control (ODC),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],OS - Time to Event,
3768,NCT04883970,Standardized uptake value（SUV）,2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
3769,NCT05890339,The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Proportion of participants need to rehospitalized after surgery,
3770,NCT05122091,Pathological remission rate (PRR),2021-11-05,RECRUITING,INTERVENTIONAL,['PHASE2'],R0 resection rate,
3771,NCT04193904,To assess the safety of MRx0518 in combination with hypofractionated preoperative radiation through the collection of adverse events,2019-12-20,TERMINATED,INTERVENTIONAL,['PHASE1'],Margin status,Genomic changes
3772,NCT03070574,Reduction in the occurrence of any colorectal neoplasia in LS patients,2017-11-24,TERMINATED,INTERVENTIONAL,['PHASE2'],Significant findings & illnesses - adverse events,
3773,NCT06324032,Evaluation of EUS-E accuracy quantitative,2020-12-17,RECRUITING,OBSERVATIONAL,['NA'],"Complication rate (perforations, bleeding) of the procedure",
3774,NCT03210129,Change in physical activity behavior,2017-07-06,COMPLETED,INTERVENTIONAL,['NA'],Cost-effectiveness of the intervention,
3775,NCT01152437,Percentage of Participants With Disease Control (DC),2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],"Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 8 (Cpre,ss,8)",
3776,NCT05052671,Progression free survival (PFS),2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],Overall survival (OS) in ctDNA positive versus ctDNA negative.,
3777,NCT03689712,Cumulative Incidence of Severe Oral Mucositis,2018-10-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3778,NCT02179463,Pathological Response,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],downstage proportion,
3779,NCT02166190,Clinical Success- composite,2014-06,TERMINATED,INTERVENTIONAL,['NA'],Mutational Profile of DNA post interventional procedure,Safety Profile and Quality of Life
3780,NCT01675128,Number of Participants With a Change in elF4e Protein Levels in Matched Pre and Post Tumor Biopsies,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With a Decrease in elF4E mRNA Expression in Peripheral Blood,
3781,NCT00003546,overall survival,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3782,NCT03023436,2-year Median survival time,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Morbidity and mortality,Molecular biomarker alteration
3783,NCT04483284,Progression Free Survival,2020-06-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],The incidence of AEs and SAEs by NCI-CTCAE v5.0,
3784,NCT00515216,Overall Response Rate (ORR),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease),
3785,NCT00003531,Number of Participants With Objective Response and Stable Disease,1996-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3786,NCT01552291,Morbidity,2012-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Perioperative immunocompetence,
3787,NCT05041335,Aggregate specimen length (ASL),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adequacy of diagnosis,
3788,NCT05821361,Overall response rate ( ORR) per RECIST 1.1,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR) per RECIST 1.1,
3789,NCT02565017,Acceptability of IBM Watson Oncology,2015-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
3790,NCT02314052,Phase 2: Preliminary Antitumor Activity,2015-01-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",AUClast (hr*ng/mL) - DCR-MYC Levels in Blood (Phase 1b Only): Dosing Day 1 and Day 8,
3791,NCT00589563,Severity of Chronic GVHD,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Disease Relapse/Progression at 2 Years Post HSCT,
3792,NCT01320319,Nutritional supplementation with 960mg EPA three times a day positively affects muscle function and mass,2011-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The secondary aim is to look at the aerobic performance.,
3793,NCT02326779,Overall survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Adverse events,
3794,NCT02567396,Tolerability of talazoparib in patients with varying degrees of hepatic and renal dysfunction,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Response rate,The pharmacodynamic effects of talazoparib
3795,NCT02233712,Diptheria Toxoid Antibody Levels,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events,
3796,NCT02173353,Evaluate the use of ultrasound to detect motion of pancrease and surrounding structures,2014-02,COMPLETED,OBSERVATIONAL,['NA'],Quality of ultrasound imaging for Pancreas,Assess organ motion and compare in conjunction with magnetic resonance imaging or CT
3797,NCT04863768,association between gene mutational status and disease-free survival,2006-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Descriptives,
3798,NCT00048126,Tumor measurements (RECIST criteria),2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],"Time to progression, time to response, duration of response, time to treatment failure, survival.\n",
3799,NCT03666442,tumor area in endoscopy,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],tumor thickness in TRUS,
3800,NCT04948125,Objective response rate(ORR),2021-04-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],Duration of response(DOR),
3801,NCT01987726,Proportion of patients who have multiple options recommended,2013-09-03,COMPLETED,OBSERVATIONAL,['NA'],Presence of any oncogene or tumor suppressor gene mutations or amplifications identified by NGS on tumor tissue in each cohort,
3802,NCT01225523,Progression-free survival,1997-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Rate of local recurrences and metastasis,
3803,NCT02238613,Tumor Response rate,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],Adverse events,
3804,NCT04237441,survival following pancreatic surgery,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
3805,NCT00063986,Peri-operative Mortality at 30 Days,2004-06-24,COMPLETED,INTERVENTIONAL,['PHASE2'],Rate of Conversion to Open Operation After Neoadjuvant Therapy,
3806,NCT00242788,Objective tumour response (CR and PR) at study closure based on the RECIST,2004-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Incidence of controlled disease (CR, PR and SD) at study closure",
3807,NCT06024252,Overall survival,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Treatment pattern,
3808,NCT01354795,"Compare the degree of cytologic quality in specimen obtained by EUS-FNA with or without suction, pushing the stylet or injecting air.",2010-09,COMPLETED,INTERVENTIONAL,['NA'],"Compare the diagnostic yield in specimen obtained by EUS-FNA with or without suction, pushing the stylet or injecting air.",
3809,NCT02456285,Adherence to an evidence-informed common pathway assessed using guidelines suggested by the European Society of Medical Oncology (ESMO),2015-05-20,COMPLETED,OBSERVATIONAL,['NA'],,
3810,NCT02238821,Scoring the expression of COX-2 in colorectal cancer tissue sections by Immunohistochemical analysis,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
3811,NCT01790230,Assessment of subject's safety by incidence of related Adverse Events,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Assessment of the device's application technique,
3812,NCT01113736,If there is a decrease on adhesion formation of AlloMEM™ used in formation of a temporary loop ileostomy.,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Decrease in operative time and a promotion of peritoneal remodeling,
3813,NCT05001347,Objective Response Rate (ORR) in each Tumor Type,2021-11-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Assessment of PK parameter: tmax,
3814,NCT03700541,Change in number of circulating tumor cells prior to surgery to 2 - 4 weeks after surgery,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Pain assessment,
3815,NCT00772083,self-reported seeking of medical care for diagnosis of anemia found at time of blood donation,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
3816,NCT04443816,Loss of health related quality of life (HRQL),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],Disability,
3817,NCT04281511,progressive-free survival,2019-04-03,COMPLETED,OBSERVATIONAL,['NA'],,
3818,NCT03267173,Number of patients with tumor response,2017-06-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Number of patients with adverse event,
3819,NCT01384227,To determine whether tissue is neoplastic or non-neoplastic,2009-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
3820,NCT06148298,Level of c-ERBB1 in blood using Chromatin immunoprecipitation and Reverse transcription-quantitative polymerase chain reaction,2023-05-24,RECRUITING,OBSERVATIONAL,['NA'],,
3821,NCT00735917,Six Month Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-Free Survival,
3822,NCT06208371,Five-year survival rate,2024-01-15,RECRUITING,INTERVENTIONAL,['PHASE3'],Treatment-related Adverse Events,
3823,NCT06172634,treatment related adeverse event,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",overall response rate,
3824,NCT01905969,Relapse free survival,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
3825,NCT00810771,Colorectal Cancer (CRC) Screening Rate.,2009-02,COMPLETED,INTERVENTIONAL,['NA'],If Colorectal Cancer Screening Screening (CRCS) Discussed With Provider.,
3826,NCT01421680,Postoperative complication rate,2011-08,COMPLETED,INTERVENTIONAL,['NA'],Patient compliance of oral nutritional supplements,
3827,NCT00260585,,1999-06,RECRUITING,OBSERVATIONAL,['NA'],,
3828,NCT05631574,"To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.",2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],"To evaluate the efficacy of BMF-219 monotherapy in subjects with unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.",
3829,NCT03566056,"Hypotension, defined as mean arterial bloodpressure <65 mmHg, measured by invasive arterial blood-pressure, the first morning after surgery at 06.00 (AM)",2018-01-18,COMPLETED,OBSERVATIONAL,['NA'],,
3830,NCT03629691,PFS (progression-free survival),2015-02-01,COMPLETED,OBSERVATIONAL,['NA'],LRC (duration of locoregional control ),
3831,NCT04625543,Major Pathological Response (MPR) rate,2020-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],The incidence of adverse events,
3832,NCT04928625,Recommended Phase II Dose (RP2D),2021-08-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],Objective response rate (ORR),
3833,NCT05740956,Efficacy of HS-10502: Objective response rate (ORR)（Stage 2）,2023-06-09,RECRUITING,INTERVENTIONAL,['PHASE1'],[Stage 1 and Stage 2] Efficacy of HS-10502: Time to PSA progression (for prostate cancer only),
3834,NCT01077739,Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression,
3835,NCT01648894,Percentage of pathological complete response after pathological examination of surgical specimen defined by the absence of persistent tumor cell invasion and lymph node (ypT0N0) in group 7 weeks versus 11 weeks in the group,2012-10-25,COMPLETED,INTERVENTIONAL,['PHASE3'],Functional results (LARS score),
3836,NCT05803382,Recommended phase 2 dose (RP2D),2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Molecular subpopulations particularly sensitized to BETi and capecitabine,
3837,NCT03886571,"Measuring cell-free and exosomal-miRNA biomarkers using small RNA-Seq in matched tissue and plasma from patients with PDAC, PNs, pancreatitis and normal pancreas for early detection.",2018-09-15,RECRUITING,OBSERVATIONAL,['NA'],,
3838,NCT01902823,Satisfaction with Care,2011-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The Inventory of Recent Life Experiences for Cancer Patients,
3839,NCT03857815,PFS,2019-03-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],ORR,
3840,NCT00949182,Safety and tolerability as assessed by NCI CTCAE v3.0,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],"AFP and VEGF serum levels as assessed at baseline, prior to each HACE treatment, and then every 3 months thereafter",
3841,NCT03117023,sleep time,2017-04-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],side effects,
3842,NCT00075647,Overall survival (OS),2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Expression and phosphorylation status of p70s6k,
3843,NCT04374877,[Part D] Objective response rate (ORR),2020-04-22,RECRUITING,INTERVENTIONAL,['PHASE1'],[Part D] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs),
3844,NCT02454790,Late toxicity,2014-09,RECRUITING,OBSERVATIONAL,['NA'],Loco-regional tumor control,Patient-rated symptoms and Quality-of-Life
3845,NCT01407107,The Number of Participants Experiencing Dose Limiting Toxicities (DLT),2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With a Pathological Complete Response (pCR),
3846,NCT00719641,Number of Participants Without Re-looping Among Those With Looping,2008-08-05,COMPLETED,OBSERVATIONAL,['NA'],,
3847,NCT05310565,Patient Retention,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],Patient-reported outcomes,
3848,NCT03610100,"Number of participants that have survived throughout treatment and also into follow-up, as measured by the primary cause of death and date of death CRFs.",2015-12,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Number of patients with treatment-related adverse events as assessed by CTCAE v4.03. Toxicity is assessed by CTCAE v4.03 alongside Quality of Life Questionnaires, QLQ-C30 and QLQ-PAN26.","Discovery of possible biomarkers which may predict any additional benefit of Acelarin over gemcitabine. These will be assessed from plasma, cell pellet and serum samples collected from participants throughout the trial."
3849,NCT02854839,Time To progression,2016-11-28,COMPLETED,INTERVENTIONAL,['PHASE2'],"Safety of MG4101 as evaluated by Incidence of adverse events (AEs), serious adverse events (SAEs)",
3850,NCT05377034,Best Overall Response Rate (BORR) at 12-months post-randomization.,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality-adjusted life years at 18 months.,Occurrence of adverse events leading to death.
3851,NCT01004003,Time to Progression (TTP) in Phase II,2009-10-22,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
3852,NCT01287637,Postsurgical morbidity.,2011-02,COMPLETED,INTERVENTIONAL,['NA'],Socio-economic effect of early reversal of temporary ileostomy,
3853,NCT00644254,Overall cancer-specific survival,2007-10,COMPLETED,OBSERVATIONAL,['NA'],Disease-free survival (DFS)& Correlation of ECLNI with other pathological variables,
3854,NCT03435536,Kinetic of circulating tumor DNA evaluation in resected pancreatic cancer.,2018-02-26,COMPLETED,INTERVENTIONAL,['NA'],Correlation between circulating tumor DNA rate and Ca19.9 dosage,
3855,NCT02628951,objective response rate,2016-05-26,COMPLETED,INTERVENTIONAL,['PHASE2'],response rate according to molecular subtypes,
3856,NCT04316078,Feasibility of PEP (percent of patients using videos/complete questionnaires),2020-03-15,COMPLETED,INTERVENTIONAL,['NA'],Secondary clinical outcomes 4 (treatment intensity and continuity),
3857,NCT03796884,Pharmacodynamics effect on cGMP levels,2019-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Guanylin levels,PCNA expression
3858,NCT01978808,the overall diagnostic accuracy rate of both needles,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,
3859,NCT03090139,Time-to-first Indicator of Sub-optimal Therapy,2017-03-28,COMPLETED,OBSERVATIONAL,['NA'],Physician Survey Questionnaire,
3860,NCT06048367,Safety and Tolerability Assessment of CNSI-Fe(II),2022-10-14,RECRUITING,INTERVENTIONAL,['PHASE1'],PK Parameters Assessment: t1/2 (h) Profile Assessment of CNSI-Fe(II),
3861,NCT04103372,Demonstrate a change in rectal preservation rates,2019-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Assess patient willingness to be randomised,
3862,NCT01019382,Objective response rate (complete and partial response) on CT according to RECIST criteria,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacokinetic analysis of blood samples,
3863,NCT04687410,Total tissue area,2020-06-15,UNKNOWN,INTERVENTIONAL,['NA'],Suitability for molecular analyses,
3864,NCT04694391,genomic characteristics of relapsed esophageal cancer,2012-09-14,UNKNOWN,OBSERVATIONAL,['NA'],,
3865,NCT00548626,Evaluate if the early change of needle during EUS-FNA for suspected pancreatic cancer can reduce the number of passes needed to obtain a preliminary cytological diagnosis of neoplasia.,2007-10,COMPLETED,INTERVENTIONAL,['NA'],Influence of different factors in obtaining a positive cytological result,
3866,NCT01276795,Protein balance,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,
3867,NCT00801320,To gain experience in appropriate clinical processing of tumor samples and determining cell yield.,2008-09,COMPLETED,INTERVENTIONAL,['NA'],"Based on feasibility of collection of blood samples of subjects, quantification of T cell subsets, regulatory T cells, activated memory effector cells, and DC phenotype at pre-surgery and post-surgery time points.",
3868,NCT02742935,The severity of adverse events (AEs) determined as per NCI CTCAE V4.03.,2016-04-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3869,NCT03545711,ORR,2018-05-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PFS,
3870,NCT03137706,Young's modulus (stiffness) on fresh tissue,2016-11-14,TERMINATED,OBSERVATIONAL,['NA'],,
3871,NCT03599947,Sensitivity and specificity of the model in the diagnosis of colorectal cancer,2018-07-16,UNKNOWN,OBSERVATIONAL,['NA'],,
3872,NCT04687969,Diagnostic value of multimodal imaging in primary prostate cancer patients,2022-10-23,RECRUITING,OBSERVATIONAL,['NA'],Scan-rescan repeatability,
3873,NCT05010863,Getting serum,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
3874,NCT02319187,progression free survival,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],quality of life,
3875,NCT00582335,Evidence of mutations in selected candidate genes,1998-02-10,COMPLETED,OBSERVATIONAL,['NA'],,
3876,NCT06165380,Objective Response Rate,2023-10-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety,
3877,NCT06120127,Progression free survival,2023-09-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Grade 3-4 adverse effect rate,
3878,NCT00034034,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3879,NCT03971747,Incidence of treatment related adverse events as assessed by CTCAE v4.0[Safety of C-TCR055],2019-08-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],OS,DCR
3880,NCT01555489,Safety of Ascorbic Acid in Combination With Gemcitabine and Erlotinib for Stage IV Pancreatic Cancer,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Evaluate Quality of Life Using Functional Assessment of Cancer Therapy-General (FACT-G) Quality Assessment Instrument,
3881,NCT05989724,MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II),2023-09-19,RECRUITING,INTERVENTIONAL,['PHASE1'],CL,SON-DP concentration in tumor biopsy tissue
3882,NCT04659148,Oncological outcome,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3883,NCT05245968,Progression-free survival (PFS),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Metabolite ratio,
3884,NCT01096745,Time to progression,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Response rate Overall survival Safety profile,
3885,NCT00585221,Time to Progression (TTP).,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3886,NCT05888675,Overall survival,2016-07-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Immune function,
3887,NCT02913066,Complete Remission Rate (CR),2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression-Free-Survival (PFS),
3888,NCT02117479,Overall Survival (OS),2014-03,TERMINATED,INTERVENTIONAL,['PHASE3'],Participants With Treatment-Emergent Adverse Events (TEAEs),
3889,NCT02604615,"overall survival, OS",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],"disease control rate,DCR",
3890,NCT03308773,Time to development of type 2 diabetes,2009-01-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
3891,NCT02246049,Progression-free survival (PFS) at 10 months,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Treatment duration,
3892,NCT00602745,Overall Survival,2008-02,TERMINATED,INTERVENTIONAL,['PHASE3'],Clinical Benefit assessed by Time to Symptoms Worsening (TTSW),
3893,NCT04835142,ORR,2021-02-24,UNKNOWN,INTERVENTIONAL,['PHASE3'],Overall survival (OS),
3894,NCT03796429,overall survival (OS) of GS regimen plus PD-1 antibody (Toripalimab),2018-12-17,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of adverse Events of GS regimen plus PD-1 antibody (Toripalimab),
3895,NCT04087421,"Bowel function, change in symptom 1 score assessed using the Measure Yourself Medical Outcome Profile (MYMOP2) Score.",2019-09-17,RECRUITING,INTERVENTIONAL,['PHASE3'],Health economics assessed using the ICEpop CAPability measure for Adults (ICECAP-A).,
3896,NCT01624285,"Recurrence-free survival, evaluated using the new international criteria proposed by the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Committee",2012-07-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to first HCV viral recurrence,
3897,NCT05253313,One-year survival after randomization,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
3898,NCT00047710,"Safety of combination Radiation, Bevacizumab, and Capecitabine.",2002-09,COMPLETED,INTERVENTIONAL,['PHASE1'],To evaluate quality of life in patients receiving this therapy.,
3899,NCT00660205,,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
3900,NCT05997459,PFS,2023-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3901,NCT03385577,Program Acceptability - Plan to continue intervention exercises after completion of the study,2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],Depressive Symptoms,
3902,NCT03387904,Disease Control Rate (DCR),2019-01-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],NGS(Next Generation Sequencing) detecting,
3903,NCT00003704,overall survival,1999-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3904,NCT03829969,OS,2019-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Patient-Reported Outcomes collected via the EORTC QLQ-OES18,
3905,NCT04985357,Best overall response (BOR),2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3906,NCT02385630,Post-prandial satiety gut hormone area under the curve,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Fasting ghrelin concentration,
3907,NCT03274011,Progression Free Survival,2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Response Rate,
3908,NCT03221127,Death,1984-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Infectious disease,
3909,NCT05394740,ORR in Phase II part,2022-06-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of adverse events,Biomarkers in the PhIb and PhII cohort
3910,NCT00077142,Maximum Tolerated Dose (MTD) of TAC-101,2001-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3911,NCT01927341,Overall Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Based on Local Radiology Assessment: Phase 2,2013-11-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
3912,NCT02722395,Planning target volume (PTV),2016-08,COMPLETED,OBSERVATIONAL,['NA'],,
3913,NCT05998447,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the Investigator.,2023-09-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
3914,NCT03606928,Objective response rate,2018-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Safety: adverse events as assessed by CTCAE v4.0,
3915,NCT02780648,Acute toxicity rates of grade 3 gastrointestinal and hematologic toxicities (as raw percentage),2016-05-01,COMPLETED,INTERVENTIONAL,['NA'],Patient self-report of quality of life,
3916,NCT00789958,Stratum-specific (R0 and R1) 2-year Overall Survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],2-year Overall Local Relapse Rate,
3917,NCT00630084,"Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.",2006-08,COMPLETED,INTERVENTIONAL,['PHASE4'],Safety - adverse event rate and profile,
3918,NCT04362839,Recommended dose level of the combination,2020-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Objective response rate (ORR),Immune response
3919,NCT05699655,Pathological complete response,2023-05-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Objective Response Rate (ORR),
3920,NCT04443036,PFS,2020-06-11,UNKNOWN,INTERVENTIONAL,['NA'],Adverse events,
3921,NCT04842916,Peripheral blood mononuclear cells (PBMCs) and host immunity parameters in responders and non-responders,2020-09-22,UNKNOWN,OBSERVATIONAL,['NA'],Psychological status of patients in relation to therapy response,
3922,NCT01591733,Rate of R0 Resection,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Utilization of Health Services (Emergency Room, Hospital and Intensive Care Unit)",
3923,NCT03416322,Adenoma detection rate,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],Boston Intestinal Preparation Scale,
3924,NCT00516347,"Gene-environment interactions, such as smoking, alcohol, and Helicobacter pylori status, on familial susceptibility to heartburn and Barrett's esophagus",2002-06,UNKNOWN,OBSERVATIONAL,['NA'],Comparison of the mortality from esophageal adenocarcinoma in family members with heartburn and Barrett's esophagus with deaths from other causes,
3925,NCT06335576,C-index,2024-03-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Sensitivity and specificity of model,
3926,NCT05595122,Stentdysfunction after technical successful EUS-CDS,2022-12-02,RECRUITING,INTERVENTIONAL,['NA'],Costs,
3927,NCT01783951,Progression free survival（PFS）,2013-02-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life,
3928,NCT05472948,Progression-free survival (PFS),2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety variables (Incidence of Adverse Events [Safety and Tolerability]),
3929,NCT05447715,Sequential treatment of PFS with furoquitinib in second-line (F-C group) versus third-line (C-F group),2022-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3930,NCT01525771,Maximum tolerated dose,2011-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",efficacy,
3931,NCT04601961,HIF-1 gene expression,2020-03-04,RECRUITING,INTERVENTIONAL,['NA'],Number of Circulating tumour cells,
3932,NCT00718354,Event Free Survival (EFS) - Composite endpoint of overall survival plus free of symptomatic VTE .,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],"Incidence of SVTE Overall survival Major and minor haemorrhages during chemotherapy and / or up to 30 days after last dose is provided. Serious adverse events, All reported adverse events HIT",
3933,NCT00080951,tumor response rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],quality of life,
3934,NCT02549456,Major postoperative complications,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],Functional outcome,
3935,NCT00909103,Value of endoscopic ultrasound elastography for the differential diagnoses of pancreatic masses.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
3936,NCT03477019,difference in measured response between treated and untreated lesions,2018-11-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Occurrence of adverse effects,
3937,NCT01172028,Maximum-tolerated dose (MTD) of combination ALIMTA and Taxotere,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Antitumor activity,
3938,NCT00052689,Proportion of patients alive at 6 months (Arm II),2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to treatment failure,
3939,NCT01248637,correlation of intratumoral hypoxia with patient survival rate,2010-10,COMPLETED,OBSERVATIONAL,['NA'],to assess utility of circulating osteopontin and miR-210 for identifying hypoxia,
3940,NCT00814242,tumor recurrence rate in one or two years; Disease-free survival;Overall survival.,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Overall survival rate in one, two，three or five years; Disease-free survival in one, two，three or five years; hepatic function of patients after surgery, the incidence rate of complications and the decline level of serum AFP concentration.",
3941,NCT05142033,Percent of patients referred for molecularly targeted clinical trials,2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],Percent of patient participating in microbiome collection and analysis,
3942,NCT02586285,Time to tumor recurrence,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],Overall survival,
3943,NCT00715325,To determine the success rate in reaching within working distance of the Cecum with no complications.,2008-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","To assess the ability to perform routine therapeutic interventions such as biopsies, polypectomies, APC etc. as compared to therapeutic interventions with standard colonoscopes found in the literature.",
3944,NCT04982276,Objective response rate (ORR),2021-07-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of subjects who develop detectable anti-drug antibodies (ADAs),
3945,NCT00551421,"Objective Tumor Response Rate Defined as the Proportion of Patients With a Best Overall Response of CR or PR, Per RECIST Criteria (Phase II)",2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
3946,NCT00308516,"Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment",2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death",
3947,NCT03142282,Progression free survival,2019-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
3948,NCT03946917,Objective response rate (ORR),2019-03-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Intestinal microorganism,
3949,NCT00089960,Objective response rate as defined using modified RECIST criteria.,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"Pharmacokinetic Endpoints: 1. The AMG 706 PK parameters (Cmax, t1/2, AUC0-24, C24); 2. To explore the PK/PD relationships",
3950,NCT00118261,Number of patients that develop study drug related toxicity,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of patients that can increase the erlotinib dose to 200mg,
3951,NCT00030511,,2001-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3952,NCT01481805,Biomarkers predictive,2010-01-14,COMPLETED,OBSERVATIONAL,['NA'],The RTK activation status.,
3953,NCT02415023,safety and tolerance,2014-11-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacokinetic profiles of Fruquintinib combined with Paclitaxel,
3954,NCT04971525,Cumulative Occurrence of Malignancies in CD Participants With PAF,2023-04-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Number of Participants With Comorbidities,
3955,NCT01038154,all cause mortality,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],free time of disease recurrence,
3956,NCT03170869,Local Recurrence Rate (LRR),2017-04-12,TERMINATED,INTERVENTIONAL,['NA'],Survival Time,
3957,NCT05107219,Cyclic guanosine monophosphate (cGMP) levels,2022-10-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Vasodilator-stimulated phosphoprotein (VASP) phosphorylation in normal appearing duodenal mucosa,Cellular response
3958,NCT03073785,Local control,2016-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor and organ motion,Pharmacokinetics parameters of zoledronic acid
3959,NCT04749108,3-year Disease free survival (DFS) for Phase III,2021-11-26,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Evaluation of sexual function in women by Female Sexual Function Index (FSFI) questionnaire score,
3960,NCT06285019,objective response rate (ORR),2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],adverse event (AE),
3961,NCT01774851,Progression Free Survival (PFS),2013-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3962,NCT05575986,Days required for platelet recovery to ≥75×10^9/ L,2022-10,RECRUITING,INTERVENTIONAL,['PHASE4'],Safety of treatment,
3963,NCT05138302,OS,2021-04-19,UNKNOWN,OBSERVATIONAL,['NA'],,
3964,NCT02345746,Determine response rate,2012-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
3965,NCT01643499,DLT rate in course 1 for each of the two most common genotype groups (*1*1 and *1*28),2012-03-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Cumulative dose intensity of irinotecan hydrochloride,
3966,NCT05103020,curative-intent resection rate,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall response rate (ORR),
3967,NCT00988936,To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response to Avastin® (the anti-angiogenesis drug) plus chemotherapy treatment before the full course of treatment is completed.,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],To gain experience with [F-18]RGD-K5 PET/CT in order to improve the study design and conduct of future studies.,
3968,NCT04317352,Mortality,2019-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
3969,NCT02417753,Changes in Immune Parameters in the Malignant Ascites of Patients With Advanced Cancer Following Therapy With AZD9150,2015-04-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival (PFS) in Patients With Malignant Ascites Treated With AZD9150,
3970,NCT02880306,the risk of developing hepatocellular carcinoma,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,
3971,NCT04329494,Incidence of adverse events,2020-08-21,RECRUITING,INTERVENTIONAL,['PHASE1'],Cytoreductive surgery rate (Arm 3),
3972,NCT06009705,Assessment of the incidence of treatment-related adverse events Incidence of Treatment-Emergent Adverse Events.,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],Assessment of progression-free survival (PFS) in elderly esophageal cancer patients treated with toripalimab in combination with S-1 and radiotherapy.,
3973,NCT05443841,number of patients who had positive pleural lavage cytology,2022-07-18,RECRUITING,OBSERVATIONAL,['NA'],Time period from date of surgery to the date of death,
3974,NCT02461979,number of HCC patients with abnormal (APAL) VDR polymorphism,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],,
3975,NCT04443543,clinical complete response rate,2020-06-22,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival,
3976,NCT05916261,Disease control rate (DCR),2023-04-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],overall survival (OS),
3977,NCT04029909,Dose limiting toxicity(DLT),2019-07-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],Maximal tolerable dose(MTD),T1/2
3978,NCT05144698,Safety of RAPA-201 Cell Therapy,2021-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of Life (QOL),T Cell Immune Reconstitution
3979,NCT03088163,Response rate,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,
3980,NCT04816045,Tumor stage,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",VAR2,
3981,NCT04599777,Overall survival (OS),2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],DOR assessed by investigators according to mRECIST.,
3982,NCT06152263,"Microvascular density differences between the atrophic and non-atrophic mucosa, as well as cancerous and non-cancerous mucosa",2023-09-30,RECRUITING,OBSERVATIONAL,['NA'],,
3983,NCT05621824,Number of Participants with no clear pancreas lesions,2022-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Number of Participants with other pancreas diseases,
3984,NCT04744649,Major pathologic response (MPR),2021-03-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse event incidence rate,
3985,NCT05746195,Feasibility of Intervention Measure (FIM),2023-11-03,RECRUITING,INTERVENTIONAL,['NA'],Change in mean total daily fiber intake (g/d) reported on the Food Frequency Questionnaire (FFQ),
3986,NCT06072287,Illness-related distress,2023-06-28,RECRUITING,OBSERVATIONAL,['NA'],Cognitive and Behavioural Responses to Symptoms,
3987,NCT02845999,number of patients with clinical or biological grade 3 or 4 treatment-related adverse events as assessed by CTCAE v4.0,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3988,NCT03360695,Disruptions in Cancer Care,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],PHQ-9,
3989,NCT05174117,3 month objective response rate,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],3 month Quality of Life score,
3990,NCT04007744,Response rate of sonidegib in combination with pembrolizumab (Part B),2020-02-13,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-free survival (PFS),Level of serum soluble PDL-1
3991,NCT00842257,Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Control Rate as Defined by RECIST Criteria,
3992,NCT02834013,Overall response rate (ORR),2017-01-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Progression free survival (PFS),
3993,NCT03200821,Survival,2000-08-14,COMPLETED,INTERVENTIONAL,['PHASE3'],Gastrin-17 Antibodies,
3994,NCT00556803,Overall survivals,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],Recurrence rates,
3995,NCT03988998,the 2-years recurrence rate,2022-01-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],the 2-years overall survival.,
3996,NCT01642446,Overall survival,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Quality of life(Qol),
3997,NCT04920019,Amount of postoperative opioid consumption,2020-10-22,COMPLETED,INTERVENTIONAL,['NA'],Mortality,
3998,NCT03633539,Postoperative complications,2020-08,WITHDRAWN,INTERVENTIONAL,['NA'],5-year overall survival rate,
3999,NCT02704988,Increased lymph node sample,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Indication for adjuvant treatment,
4000,NCT00001191,,1983-02-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4001,NCT03082378,survival,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],complication,
4002,NCT04908813,Objective Response Rate (ORR) per RECIST 1.1 assessed by IRRC,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events (AE),
4003,NCT06079242,Liver-specific overall response rate (ORR) according to RECIST 1.1,2023-10-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Duration of liver-specific DOR assessed by the investigator,
4004,NCT00789841,Gastrointestinal transit time in NET patients,2008-09,COMPLETED,OBSERVATIONAL,['NA'],Changes in carcinoid symptoms and biomarkers,
4005,NCT05628610,objective response rate,2022-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],progression free survival,
4006,NCT02529579,6-month SR,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",QOL,Serum tumor biomarker
4007,NCT03469375,Progression free survival,2014-04-01,COMPLETED,OBSERVATIONAL,['NA'],Histopathologic staging,
4008,NCT00262769,Overall Survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Toxicity,
4009,NCT03813381,Body weight change,2015-11,COMPLETED,INTERVENTIONAL,['NA'],Waist circumference reduction,
4010,NCT01257360,Rate of pathological complete remissions,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Correlative biomarker analyses,
4011,NCT02426450,Safety and Tolerability,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
4012,NCT05427383,Overall Survival (OS) according to RECIST 1.1 by IRC,2022-04-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of neutralizing Antibody，Nab,Change from baseline in CA72-4 (carbohydrate antigen 724)
4013,NCT05350007,Tanatophobia,2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],lack of social support,
4014,NCT04247165,"Incidence of treatment-related AEs, SAEs, AEs leading to discontinuation, death, and laboratory abnormalities",2020-06-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Rate of downstaging to surgical resection,
4015,NCT01924260,"Dose-limiting toxicity (DLT) defined as any related (possibly, probably, or definitely) grade 3 non-hematological toxicity or any attributable grade 4 toxicity graded according to the National Cancer Institute (NCI) CTCAE version 4.0",2013-08-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Maximum-tolerated dose (MTD) defined as the maximum dose level at which less than 2 patients experience DLT graded according to NCI CTCAE version 4.0,
4016,NCT00539877,"The objectives of this study are to assess the feasibility, to determine the maximum tolerated dose, and to assess the toxicities of intraperitoneally administered CPT-11 in gastric cancer patients with peritoneal seeding.",2004-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4017,NCT02503969,Individual attended colorectal cancer screening,2015-09,COMPLETED,OBSERVATIONAL,['NA'],Individual accepted colorectal cancer screening after refusing the initial invitation for colorectal cancer screening,
4018,NCT02784639,Area under ROC curve,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,
4019,NCT00047346,"Pharmacokinetic (PK) and pharmacodynamic profile, as measured by Cmax, Tmax, AUC0-24, AUC0-infinity, Cl/F, T1/2, accumulation ratio, and Cssmin",2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],"Objective response rates (partial, complete, stable disease), as measured by CT scans using RECIST criteria",
4020,NCT04495621,Best overall response rate (ORR) according to RECIST v.1.1,2020-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of treatment emergent adverse events (TEAEs),
4021,NCT02112214,The incidence of gastric cancer between the intervention and placebo groups,2014-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Modification of atrophy score,
4022,NCT03013712,Toxicity profile of the EpCAM targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Anti-tumor efficacy of CAR-T therapy by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1,
4023,NCT00477880,Response,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4024,NCT03728348,"Specificity of the Multi-target Stool DNA Test in Average Risk Population, Ages 45-49",2018-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
4025,NCT00735241,Toxicity and safety,2008-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4026,NCT00452751,overall survival,2006-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],cost-effectiveness,
4027,NCT02449967,Number of participants with Adverse events,2015-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
4028,NCT05888623,Adenoma Detection Rate,2022-10-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Adenocarcinoma detection rate,Bowel preparation quality
4029,NCT05052099,Overall response rate (ORR),2021-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence and severity of adverse events (AEs) (with severity determined according to NCI CTCAE v5.0),
4030,NCT04009876,cCR (clinical complete response) rate in LARC ( locally advanced rectal cancer ) patients treated with chemo - chemoradiation.,2019-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall toxicity,
4031,NCT03258450,The acceptability of the intervention will be assessed through the Client Satisfaction Questionnaire.,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],Psychological distress will be accessed through The Hospital Anxiety and Depression Scale (HADS),
4032,NCT05152147,Overall survival,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence of anti-drug antibodies (ADAs),
4033,NCT06203587,Establishment and optimization of imaging method for [68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347 PET/CT.,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
4034,NCT03918499,Progression-free Survival,2019-04-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Response,
4035,NCT03136406,Objective response rate by irRC,2017-08-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 4.03.",
4036,NCT01658917,"To collect biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors.",2012-07-24,COMPLETED,OBSERVATIONAL,['NA'],"To collect detailed history, demographic, treatment data, and perioperative findings.",
4037,NCT04589247,Proportion of participants with change in their physician-assessed burden score,2020-11-16,RECRUITING,OBSERVATIONAL,['NA'],,Management changes as assessed by a Clinician Feedback Form
4038,NCT02182778,Overall survival rate,2014-07-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants with Adverse Events as a Measure of Safety,
4039,NCT00872014,Progression free survival (PFS) rate at 4 months,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],"Baseline values of and changes from baseline in pharmacodynamic, immunologic, biochemical, transcriptional, pharmacogenetic and angiogenic markers",
4040,NCT03098758,specific markers in peritoneal cells,2017-05-08,UNKNOWN,OBSERVATIONAL,['NA'],,
4041,NCT01325961,Medico-economic study : medical cost differential between 3 ways of Radiotherapy by IMRT (helical tomotherapy and dynamic arc therapy : RapidArc and VMAT).,2011-03,COMPLETED,INTERVENTIONAL,['NA'],clinical response and safety of the treatment by radiotherapy,
4042,NCT04352894,Best modality of ICG injection,2020-09,UNKNOWN,INTERVENTIONAL,['NA'],Sensitivity of ICG fluorescence,
4043,NCT02466724,Patients with Excelent Colonoscopy preparation,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Use of web-based educational platform,
4044,NCT04189809,Rate of therapeutic proposals correctly predicted by the BCLC international classification,2019-11-30,UNKNOWN,OBSERVATIONAL,['NA'],Rates and causes of discrepancies,
4045,NCT00964080,To determine the dose of MBP-426 for use in the Phase II portion of this study of MBP-426 administered every 21 days in combination with leucovorin (folinic acid or FA) and fluorouracil (5-FU),2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To characterize the safety profile of the combination therapy,
4046,NCT06047379,Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain.,2023-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4047,NCT03151213,visual analogue pain scale (VAS Pain) post operatively,2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
4048,NCT04109573,Manometric indices,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Patient reported outcomes,
4049,NCT03998033,The recommended phase 2 dose (RP2D) regimen of ET140202 T-cell therapy,2019-05-30,TERMINATED,INTERVENTIONAL,['PHASE1'],Assess the persistence of ET140202 T cells circulating in blood over time.,
4050,NCT02078700,percentage of cancer patients that accept and attend the early palliative care programme,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],percentage of cancer patients that receive the proposal of early palliative by the oncologists-pneumologists,
4051,NCT01552226,Post-operative pain control day 5,2010-01,UNKNOWN,INTERVENTIONAL,['NA'],Patient use of supplemental narcotic analgesia day 5,
4052,NCT04165018,Diagnostic yield between FNB samples placed in formalin for pathology evaluation from two different types of needle,2021-04-09,COMPLETED,OBSERVATIONAL,['NA'],"Rate of adverse events of utilizing the FNB technique, including pancreatitis, bleeding, or perforation",
4053,NCT06232759,Progression-free survival,2022-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
4054,NCT00984048,Changes in biomarkers in patients that have acquired clinical resistance.,2009-08,COMPLETED,OBSERVATIONAL,['NA'],Number of participants with adverse events relating to the liver biopsy procedure,
4055,NCT06276153,overall survival,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],progression-free survival,
4056,NCT04564313,Objective Response Rate (ORR),2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE1'],Graft Rejection (GR),
4057,NCT03139487,Rate of clinical relevant bleeding,2017-08-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Time to recurrent or aggravated venous thromboembolism,
4058,NCT00052910,Overall Survival,2002-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease Free Survival,
4059,NCT01926444,"Measurements of Visceral Pain, Using a 100-mm Visual Analog Scale (VAS)",2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Subject Satisfaction and Acceptability of the Colonic Analgesia - Patient's Global Impression of Abdominal Pain,
4060,NCT02551991,Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT),2015-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Duration of Response (DoR),
4061,NCT02575859,Positive predictive value of preoperative/intraoperative assessment of primary tumor-related risk factors for the development of metachronous peritoneal metastases in patients undergoing curative surgery for colorectal cancer.,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Peritoneal progression-free survival,Progression-free survival
4062,NCT04038736,Evaluation of the performance of the C-scan System in detecting polyps≥10 mm compared to FIT results,2019-12-26,COMPLETED,INTERVENTIONAL,['NA'],,
4063,NCT05640791,Incidence of adverse events,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
4064,NCT01579812,Recurrence-Free Survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
4065,NCT02728427,Catherization time,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],Catheter obstruction,
4066,NCT04958044,Safety,2021-05-25,COMPLETED,INTERVENTIONAL,['PHASE1'],90 days survival,
4067,NCT03228667,Objective Response Rate,2018-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Progression Free Survival,
4068,NCT06076811,The prognostic value of ctDNA status,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],Molecular characterization,
4069,NCT04721301,Number of participants and severity of treatment-related adverse Events as assessed by CTCAE v4.0,2017-01-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Tissue Response,
4070,NCT01794676,Modified genetic factors that exist and may influence the phenotypic presentation of disease in unrelated MEN 1 families.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,
4071,NCT01565811,complication rate,2010-08,COMPLETED,OBSERVATIONAL,['NA'],To evaluate prognostic significance of perihepatic LN involvement with overall survival and disease free survival,
4072,NCT01835223,"PFS, Assessed Using Standard RECIST Criteria",2013-07-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival Rate,"Drug Exposure, as Assessed by Steady State PK"
4073,NCT03907527,Maximal tolerated dose of PRGN-3005,2019-04-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of PRGN-3005 T Cells,
4074,NCT01411826,Feasibility,2011-07,COMPLETED,INTERVENTIONAL,['NA'],Colon cancer screening attitudes,
4075,NCT01658436,Stage 1 - Progression Free Survival (PFS) Rate Analysis at 16 Weeks as Per Local Radiology Review,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Stage 1 - Disease Control Rate,
4076,NCT05014360,Percentage Change from Baseline in Colorectal Polyp Burden for Polyps >=2 mm at Week 24,2021-11-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Levels of JAK/STAT Pathway Signaling Effector Proteins including pSTAT-3 Relative to Baseline Levels in Colorectal Polyps,
4077,NCT05841706,Rate of Protocol adherence,2023-08-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Number of blood products received,
4078,NCT02430701,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Overall survival (OS),
4079,NCT06041945,Non-inferiority in Adenoma Detection Rate,2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],Change in the cost of polypectomy and histology in screening programs,
4080,NCT03137628,metabolomics,2017-03-20,UNKNOWN,OBSERVATIONAL,['NA'],,
4081,NCT02856568,"MTD of ricolinostat or a dose up to 240 mg/day whichever is lower, of ACY-1215",2017-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Time to treatment failure,Laboratory correlates measured from tissue by immunofluorescence
4082,NCT06133023,Clinical success within 180 days of randomisation,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Incidence of new pancreatic cancer,
4083,NCT00586989,1. The number of patients and the number of lesions with HGD or early ACA detected with WLE and ETMI 2. The number of patients with HGD and early ACA detected with targeted biopsies only with ETMI and WLE,2007-12,COMPLETED,OBSERVATIONAL,['NA'],1. The positive predictive value (PPV) of HRE and AFI 2. The reduction of false-positive findings after NBI (both the initial in vivo NBI assessment as well as later assessment based on still images),
4084,NCT05240950,Efficacy (recurrence-free survival),2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (PK) indicator (AUC),
4085,NCT05812430,Objective Response Rate(ORR),2023-04-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate(DCR),
4086,NCT01193452,response rate,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events as a Measure of Safety and Tolerability,
4087,NCT01910610,Duration of Disease Control (DDC),2013-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Safety profile of each treatment sequence,
4088,NCT03601351,Disease free survival.,2018-05-04,COMPLETED,OBSERVATIONAL,['NA'],Perioperative complications.,
4089,NCT00966667,Normative influences of family and friends,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,
4090,NCT02681601,Anthropometric measurement: Body Composition,2016-07-19,TERMINATED,INTERVENTIONAL,['NA'],Quality of life: Appetite,
4091,NCT02785523,"Assessing the quality of life(QOL) in 5 grades and recording: appetite, mental state, sleep, fatigue, pain, attitude towards treatment, daily life ability, treatment of severity of side effects.",2016-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],Vanillylmandelic acid (VMA) in urine.,
4092,NCT06023147,Objective response rate (ORR),2023-09-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Disease control rate (DCR),
4093,NCT02669914,Overall Response Rate of Intracranial Disease,2016-09-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
4094,NCT05585554,Overall Survival (OS),2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Treatment-related toxicity,
4095,NCT00165568,To compare the percent change in tumor radioactivity uptake and retention after radiolabeled fluorouracil administration in subjects who receive bevacizumab versus those who do not receive bevacizumab.,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],to evaluate the relationship between initial change in tumor radioactivity uptake and retention.,
4096,NCT05781581,All-cause mortality at 30 days after operation,2023-03-19,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Major Adverse Cardiovascular Events (MACE),
4097,NCT03311776,Predictive biomarkers,2008-07-03,RECRUITING,OBSERVATIONAL,['NA'],,
4098,NCT01955122,Adenoma and Polyp Miss Rate,2013-07,COMPLETED,INTERVENTIONAL,['NA'],Patient Satisfaction,
4099,NCT01722903,Quantity of CTCs isolated during liver and/or lung metastasectomy,2012-08,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
4100,NCT02202928,Progress-free survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Phenotypic analysis of T cells,
4101,NCT01766986,Overall Survival,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
4102,NCT03850912,'Emergency Department - Treat and Release' (EDTR) Rate at 30-days,2019-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Sustainability of ePRO symptom management within a health system,
4103,NCT01167049,Tumor response will be evaluated using RECIST criteria. Survival data will be analyzed by Kaplan Meier method. 95% CI will be provided,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4104,NCT02487992,Overall Survival(OS),2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease-free survival,Adverse events
4105,NCT01248663,Delayed gastric emptying,2007-04,COMPLETED,INTERVENTIONAL,['NA'],Measurement of plasma intestinal peptides,
4106,NCT05856864,Adverse Events（AEs）,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
4107,NCT01248273,To determine the maximum tolerated dose over three dose levels.,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],To record the progression free interval,
4108,NCT05233098,Effective dose (Gy) for the whole body,2023-02-04,COMPLETED,OBSERVATIONAL,['NA'],,
4109,NCT00499850,"Safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin",2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4110,NCT01114035,gene identification,2010-04,COMPLETED,INTERVENTIONAL,['NA'],mutation identification,
4111,NCT00040833,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4112,NCT01401309,Detecting,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
4113,NCT00375999,Overall Survival,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4114,NCT04195828,major pathological response,2020-06-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],R0 resection rate,
4115,NCT05740111,Number of resectable cancers detected in patients diagnosed through the surveillance programme compared to the unscreened individuals as reported to the Cancer Registry of Norway.,2022-09-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],The psychological well-being of participants undergoing surveillance as assessed by the Psychological Well-being Questionnaire,
4116,NCT05770739,postoperative length of stay,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],30-day readmission rate,
4117,NCT03902379,Examine feasibility of an online CCI as defined by participant's evaluation of the online intervention,2016-07-27,WITHDRAWN,INTERVENTIONAL,['NA'],Examine acceptability of an online CCI,
4118,NCT00215722,Determine the Efficacy of the combination treatment (cetuximab plus capecitabine and oxaliplatin) as first-line therapy based on the overall response rate (ORR) according to the RECIST criteria.,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Evaluate the Quality of Life,
4119,NCT06123156,the patient's response,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse and suspected adverse events,
4120,NCT01693848,Effect of resection of metastasis on urinary excretion of modified nucleosides,2012-09,COMPLETED,OBSERVATIONAL,['NA'],Identification of modified nucleosides as biomarkers for colorectal cancer,
4121,NCT04014478,Visual Analog Scale Changes over the time,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life Score Changes over the time,
4122,NCT05392413,Imaging examination,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
4123,NCT00716976,Incidence of Hearing Loss,2008-06-23,COMPLETED,INTERVENTIONAL,['PHASE3'],Hearing Loss Among Patients Carrying/Not-carrying Two Key Gene Mutations (TPMT and COMT),
4124,NCT03110484,Overall response rate,2021-07-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4125,NCT05821452,MPR rate,2023-05-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],PFS,
4126,NCT02873741,Presence of Anal hr-HPV,2016-07,COMPLETED,OBSERVATIONAL,['NA'],,
4127,NCT00332163,Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Overall Dermatologic Quality of Life Index (DLQI) Score,
4128,NCT00865527,Proportion of enrolled patients who attend for their assigned screening test,2010-03,TERMINATED,INTERVENTIONAL,['NA'],Proportion of patients found to have invasive colorectal carcinoma,
4129,NCT02698137,procedure-related adverse events,2016-03,COMPLETED,OBSERVATIONAL,['NA'],technical failure of the procedure,
4130,NCT04271813,Objecitve response rate,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease control rate,
4131,NCT04840264,60-day Obstruction Clearance Rate,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of Life assessed by EORTC QLQ-OG25,
4132,NCT05255588,"Sensitivity and specificity of the EarlyTect® CRC test for detecting CRC compared to the colonoscopy, both in terms of detecting CRC.",2022-02-10,RECRUITING,OBSERVATIONAL,['NA'],Clinical sensitivity of the EarlyTect® CRC for detecting Tis,
4133,NCT04695262,EUS-E accuracy in terms of qualitative and quantitative elastography,2021-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
4134,NCT05129215,Area under the curve (AUC),2020-03-06,COMPLETED,OBSERVATIONAL,['NA'],Negative prediction value (NPV),Net reclassification index (NRI)
4135,NCT05387876,Microbiome alterations,2022-02-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
4136,NCT01519609,Degree of bowel cleansing,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
4137,NCT02773524,Overall Survival,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Rates of Adverse Events,Evaluation of regorafenib Maximum Plasma Concentration [Cmax] between Asia and Rest of World cohorts.
4138,NCT01916239,Gene expression profiling in colon tissues,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",microRNA expression profiling in colon tissues,
4139,NCT00398398,Overall Response Rate,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity Profile,
4140,NCT03524820,response to treatment,2017-10-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4141,NCT05348187,therascreen® KRAS RGQ PCR Kit,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,
4142,NCT03588533,Adverse event,2018-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survivals (OS),
4143,NCT06208046,5-year overall survival,2023-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
4144,NCT00264446,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4145,NCT01406249,Progression-free survival rate,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety,
4146,NCT00427375,"Compare the proportion of patients presenting at least 1 component of the composite outcome (4 components: death, recurrence, major morbidity and severe after effects) at 2 years after",2007-03-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of life (QLQ C30 - CR38),
4147,NCT01129570,The maximum tolerated dose of siliphos in patients with advanced hepatocellular carcinoma,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor response as measured by RECIST criteria and AFP concentrations,
4148,NCT01340508,Pathological complete response rates,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Sphincter Preservation rates,
4149,NCT01182116,Improved function and capacity of the neorectum.,2009-03,COMPLETED,INTERVENTIONAL,['NA'],,
4150,NCT00096733,Survival of the potential liver transplant recipient,2004-10,COMPLETED,OBSERVATIONAL,['NA'],Recipient survival from time of transplant (either living or deceased donor),Recipient complications
4151,NCT00022334,Dose limiting toxicity and maximum tolerable dose.,2001-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",clinical response in patients with measurable disease.,
4152,NCT04499833,hepatocellular carcinoma recurrence,2021-03-25,RECRUITING,INTERVENTIONAL,['NA'],hepatocellular carcinoma recurrence through liquid biopsy,
4153,NCT00513357,Change in Appetite as Measured by ESAS,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4154,NCT05922930,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-10-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4155,NCT06275204,Healthcare workers' assessment of feasibility and acceptability of the proposed practical implementation of a screening program,2024-03-04,RECRUITING,OBSERVATIONAL,['NA'],Participation rate of subjects selected for the program,
4156,NCT00719303,Progression-free survival,2012-06-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],Change in self-reported quality of life measured using RAND-36,Vitality measured using RAND-36 and GSRS-IBS
4157,NCT03911167,Postoperative complication rate，%,2017-09-01,COMPLETED,OBSERVATIONAL,['NA'],"hospitalization expenses,yuan",
4158,NCT02284802,accuracy of confocal endomicroscopy,2014-09-10,COMPLETED,INTERVENTIONAL,['NA'],,
4159,NCT01971775,Amount of drain at postoperative period,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3'],4. Postoperative hospital stay Complications,
4160,NCT00034333,,2002-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4161,NCT04245644,Overall survival,2019-03-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4162,NCT01832948,Objective Response Rate (ORR),2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
4163,NCT02227914,Time To Progression (TTP) - Phase 2,2014-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS) - Phase 2,
4164,NCT01039506,Progression free survival,2009-10-15,COMPLETED,OBSERVATIONAL,['NA'],Safety events,
4165,NCT00236249,"Readiness for discharge, checked twice a day",2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Clinical side effects twice a day,
4166,NCT01648465,15 month PFS (Progression-Free Survival) rate,2012-08-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Association of biologic markers with disease progression,
4167,NCT02139215,The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting,2014-04,COMPLETED,OBSERVATIONAL,['NA'],,
4168,NCT06060704,ORR（Objective response rate）,2023-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life: EORTC QLQ-C30,
4169,NCT04789200,Marking and distension of the bowel lumen at CT of the abdomen,2020-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Delineation of bowel wall enhancement related to concurrent intravenous contrast at CT of the abdomen and pelvis,
4170,NCT03104569,Number of participants with Acute cholangitis,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Number of participants with Post-ERCP pancreatitis,
4171,NCT06130826,Recommended phase 2 dose,2024-06-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacokinetics of M5A-IL2 (M5A-ICK blood clearance ),
4172,NCT02370849,Objective response rate as measured by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Treatment safety and toxicity as measured by Common Toxicity Criteria for Adverse Effects(CTCAE 3.0),
4173,NCT04646187,cumulative incidence of out-of-range fecal calprotectin results at 48 weeks follow-up,2021-03-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4'],Identification of predictors of successful de-escalation.,Patients' attitudes towards deprescribing anti-TNF agents
4174,NCT02928224,"(Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm",2016-10-13,COMPLETED,INTERVENTIONAL,['PHASE3'],Phase 3: Number of Participants With Shifts in Left Ventricular Ejection Fraction (LVEF) From Baseline to Maximum Grade On-treatment,(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Final Analysis
4175,NCT01929915,Perioperative immunoprofile,2013-07,COMPLETED,INTERVENTIONAL,['NA'],survival rate,
4176,NCT03251417,Disease control rate,2017-09-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Median overall survival time,
4177,NCT00210249,Number of Participant Deaths,2002-09,COMPLETED,OBSERVATIONAL,['NA'],,
4178,NCT03812770,Progression Free Survival (PFS),2018-08-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events,
4179,NCT05192018,Feasibility of early reversal of adefunctioning ileostomy,2021-12-25,UNKNOWN,INTERVENTIONAL,['NA'],,
4180,NCT04730544,Progression-free survival (PFS) at week 24 for two combination schemes.,2021-04-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to Health-related quality of life (HRQoL) score definitive deterioration (TUDD),
4181,NCT00529412,incidence of small bowel obstruction,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3'],intraoperative and postoperative morbidity and mortality.,
4182,NCT01994681,Obtaining a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population.,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,
4183,NCT05730192,Positive percent agreement (PPA),2023-05-10,RECRUITING,INTERVENTIONAL,['NA'],,
4184,NCT00845884,response rate,2009-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Safety, PFS, overall survival",
4185,NCT03264716,Hepatic Progression free survival,2017-08-31,COMPLETED,INTERVENTIONAL,['NA'],An overall tumor response classification,
4186,NCT02869477,Survival of patients,2002-01,RECRUITING,OBSERVATIONAL,['NA'],Collection of patients characteristics,
4187,NCT03410641,"Incidence of the group of cancers related to smoking, diet or body mass index",1972-01-15,COMPLETED,OBSERVATIONAL,['NA'],Incidence of prostate cancer,
4188,NCT04699539,1-year Local Control Rate (1y-LCR),2021-03-31,RECRUITING,INTERVENTIONAL,['NA'],Overall Survival(OS),
4189,NCT04512209,Biophysical properties of the tumor tissue - measurement of hydraulic conductivity,2019-10-11,RECRUITING,INTERVENTIONAL,['NA'],Measurement of Pt penetration,
4190,NCT04686942,sensitive of detection tumor,2020-12-17,UNKNOWN,OBSERVATIONAL,['NA'],,
4191,NCT02130752,Surgical duration,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative Mortality and Morbidity,
4192,NCT03152487,Subject assessment of abdominal pain,2017-04-24,COMPLETED,INTERVENTIONAL,['NA'],Pain per the VAS tool.,
4193,NCT00903136,Comparison of participants' satisfaction with the TCE vs esophagogastroduodenoscopy (Phase II),2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Results of the histologic analysis of any biopsy specimens (Phase II),
4194,NCT01715233,Response,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
4195,NCT01795027,overall survival,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of Participants with Adverse Events,
4196,NCT05809869,Rate of abscopal effect,2023-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Distant control rate,
4197,NCT01077986,phase II part: response rate,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacodynamics: biomarkers in blood and tumor tissue,
4198,NCT00405873,Best overall tumour response according to RECIST; within 20 weeks after registration; confirmation 6 +/- weeks later,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Safety and Tolerability,
4199,NCT04187937,R0 resection rate,2020-06-17,TERMINATED,INTERVENTIONAL,['NA'],Time for resection,
4200,NCT06148402,Objective Response Rate,2024-01,RECRUITING,INTERVENTIONAL,['PHASE2'],ctDNA and efficacy,
4201,NCT05956847,Changes in ecDNA content in different gastric precancerous lesions,2023-08-10,RECRUITING,OBSERVATIONAL,['NA'],,
4202,NCT03915171,Sensitivity and specificity of blood MSI detected by NGS,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Correlation between MMR gene and other gene mutations,
4203,NCT03806218,Minimum diameter of ablation zone per unit time,2015-05-16,COMPLETED,INTERVENTIONAL,['NA'],Local tumor progression (LTP),Ablation time
4204,NCT03202992,Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL,2017-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Histopathology of areas with biopsy-proven disease following single and multiple doses of ABI-1968 Topical Cream.,
4205,NCT00257426,Median survival,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],number of subjects with toxicities,
4206,NCT00352404,Histological proof of neoplastic tissue (Intraepithelial neoplasia or cancer),2003-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Prediction of extent and severity of inflamed mucosa,
4207,NCT00564265,Number of Patients Who Survived,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
4208,NCT00790218,Maximum Plasma Concentration of CF102 (Cmax),2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102,
4209,NCT03531632,Number of Participants With Adverse Events,2018-06-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The Number of Participants With Response Based on the Change in Tumor Volume,
4210,NCT05963724,Adenoma Detection Rate,2022-09-01,COMPLETED,INTERVENTIONAL,['NA'],Withdrawal Time,
4211,NCT04607668,Myelopreservation,2020-10-16,TERMINATED,INTERVENTIONAL,['PHASE3'],Anti-tumor Efficacy,
4212,NCT02897778,Change from Baseline in T-Cell Morphology,2016-08-24,COMPLETED,INTERVENTIONAL,['PHASE1'],λz (Terminal Elimination Rate Constant) of Entinostat when given as a Single Supratherapeutic Dose,"Variability and Changes in Protein Lysine Acetylation in Peripheral Blood Cells after a Single Dose of Entinostat, when given at a Supratherapeutic Dose and Examine the Underlying Biological Variation"
4213,NCT04172714,Tumor to Normal Liver Activity Ratio (TNR),2019-12-16,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants With Tumor Response Using Imaging Modified Response Criteria in Solid Tumors (m-RECIST) Post Y90 Embolization,
4214,NCT04684355,Quality of life degree,2020-12-22,UNKNOWN,INTERVENTIONAL,['NA'],Anxiety and depression degree,
4215,NCT00765869,Involvement in screening decision,2008-07,UNKNOWN,INTERVENTIONAL,['NA'],Influence of doctor on screening decision,
4216,NCT01013805,Tolerability Rate of patients treated with integrated pre-operative radiotherapy with FOLFOX chemotherapy regimen,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Dose Intensity of the treatment drug,
4217,NCT03337087,Best response rate (Phase II),2018-11-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of adverse events (Phase II),
4218,NCT01919151,Survival,2008-06,UNKNOWN,OBSERVATIONAL,['NA'],,
4219,NCT06154785,To assess the impact of the stable low-pressure approach (using Airseal Insufflator) and its associated parameters into the the early rehabilitation program after colorectal surgery on length of stay.,2023-12-15,RECRUITING,OBSERVATIONAL,['NA'],The Surgical and Medical morbidity at 30 days,
4220,NCT03941184,Incidence Rate of SCAD,1995-01-01,COMPLETED,OBSERVATIONAL,['NA'],SCAD recurrence,Odds of validated rheumatoid arthritis in SCAD cases compared to controls
4221,NCT03085992,Disease-free survival rate at 2 years,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Pathological complete response rate,
4222,NCT01551589,radiation pneumonitis and radiation esophagitis,2012-03,COMPLETED,INTERVENTIONAL,['NA'],Local control rate/ Inside irrational field recurrence rate,
4223,NCT00423254,To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],to describe any objective tumor responses to the treatment with MKC1106-PP,
4224,NCT00004066,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4225,NCT03187184,PGx Test Interpretation,2017-05-20,COMPLETED,INTERVENTIONAL,['NA'],Chemotherapy Toxicity,
4226,NCT03283761,Objective Response Rate,2017-09-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety and Toxicity Profile of the Combination of Nab-paclitaxel and FOLFOX,
4227,NCT02108444,the incidence of hepatitis B virus delayed reactivation,2007-01,COMPLETED,OBSERVATIONAL,['NA'],overall survival rate,
4228,NCT05039944,Optimal combination dose (only IIa),2021-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],ADA,
4229,NCT01177007,Progression-free Survival (PFS) of the Treated Lesion(s) According to RECIST and EASL Criteria,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Mean Radiation Dose Delivered to Total Liver,
4230,NCT01520259,gallbladder cancer/pre-cancer,2012-01-10,COMPLETED,OBSERVATIONAL,['NA'],,
4231,NCT05980689,Complete response (CR) rate,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Long-term anal function,
4232,NCT06218420,To evaluate the efficacy of stereotactic body radiotherapy (SBRT) as bridging therapy for patients with hepatocellular carcinoma (HCC) enlisted for liver transplantation (LT).,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To assess the occurrence of adverse events related to SBRT during waiting time period and after LT,
4233,NCT01695772,Percentage of Participants Achieving Complete Resection (R0 Resection),2012-10-16,COMPLETED,INTERVENTIONAL,['PHASE4'],"Percent Probability Of Being Alive and Disease Free at Months 3, 6, 9, and 12",
4234,NCT00068575,Median Overall Survival (OS),2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4235,NCT00544011,Objective response (complete and partial) rate,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Biomarkers predictive of efficacy,
4236,NCT05138887,acute radiation-induced proctitis (ARP) incidence,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],cancer remission rate assessed by imaging,adverse events
4237,NCT01982487,PFS (Phase IIb),2013-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Toxicity rate, graded according to NCI CTCAE version 4.0",
4238,NCT03047603,PIVKA-II,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],"ALT, AST，γ-GT， AFU",
4239,NCT02205008,relapsed free survival,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],overall survival,surgery and intraperitoneal chemotherapy-related morbidity and mortality
4240,NCT05225207,Number of Participants With Non-serious ADRs,2019-05-28,COMPLETED,OBSERVATIONAL,['NA'],Percentage of Participants With Overall Response,
4241,NCT02436018,Low pulse oximetry incidence,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],Other adverse events,
4242,NCT03883802,ctDNA as surrogate marker for disease free period,2019-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],ctDNA in Wnt-5a high patients,Thymidine Kinase activity
4243,NCT00979329,,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,
4244,NCT04969835,Percentage of patients with Adverse Events (AEs) at RP2D AVA6000 dose level in tumour-specific expansion arms.,2021-07-16,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
4245,NCT00068744,"Event-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter (Phase III)",2003-07,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Quality of life as measured by EORTC Quality of Life Questionnaire-C30 and ASCT at 12 and 26 weeks, then every 6 months for 2 years after entry",
4246,NCT01426490,Antioxidant and DNA methylation,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4247,NCT00879333,Overall Survival (OS),2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Everolimus Steady State Concentraions at Predose (Cmin) and Cmax by Region Asia vs. Rest of the World (ROW) at Week 5,
4248,NCT01104181,HC2 can accurately test for oncogenic HPV in anal specimens,2010-03,COMPLETED,INTERVENTIONAL,['NA'],Sensitivity and specificity of cytology with HC2,
4249,NCT04111978,Progression-free survival (PFS) for each study group,2020-11-05,RECRUITING,INTERVENTIONAL,['PHASE3'],Health related quality of life (QoL) assessed by Functional Assessment of Cancer Therapy - Ovarian (FACT-O) questionnaire for each study group,
4250,NCT01504997,The Incidence of Post-operative Intra-abdominal Infectious Complications,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
4251,NCT00937482,MTD defined as the dose at which no patients develop treatment-related grade 5 toxicity and less than 30% of patients develop acute dose limiting toxicities (DLT) assessed using NCI CTCAE version 4.0,2009-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Vascular MRI studies,
4252,NCT03851939,ORR,2019-02-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],DCR,
4253,NCT05408169,Number of screening tests returned to the central laboratory and successfully processed providing an adequate result.,2022-06-20,COMPLETED,INTERVENTIONAL,['NA'],Acceptability of interventions (qualitative),
4254,NCT00063960,overall survival,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],time to hepatic recurrence or progression,
4255,NCT04605913,Determine safety of (m)-GCN+TTF,2022-04-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
4256,NCT06296706,OS,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Plasma concentration of docetaxel (free and total),
4257,NCT00511446,Progression-free survival rate,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Median overall survival,
4258,NCT01033240,Time to Progression (TTP) Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer,2010-07-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Treatment-Emergent Adverse Events Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer,
4259,NCT04099134,Quality of life in pancreatic cancer patients,2018-10-10,RECRUITING,OBSERVATIONAL,['NA'],Evaluation of predictive and prognostic markers,
4260,NCT04305145,Proportion of patients with Steroid-Free Colitis,2020-08-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Response Rate,
4261,NCT02889276,"Change in Global Health Status/QoL (subscale of EORTC QLQ-C30, Version 3) scores in cancer survivors",2017-02-20,TERMINATED,INTERVENTIONAL,['NA'],Change in Self-efficacy to regulate exercise scale score,
4262,NCT05374122,Cholangiocarcinoma diagnosis confirmation after biopsy and six-month follow-up,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Insufficient biopsy sample rate,
4263,NCT05706025,Testing difference in Biomarkers between Control and BE/EAC patients,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Testing difference in Multiple Biomarkers between Control and BE/EAC patients,
4264,NCT03867084,Overall Survival (OS),2019-05-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],"Change from Baseline in European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Health Utility Score",
4265,NCT00483782,Progression-free survival,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Health economics,
4266,NCT04408599,Define a maximum tolerated dose (MTD) or pharmacologically active dose (PAD),2020-06-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Half-life (t1/2) of NC410,
4267,NCT00122876,Safety,2005-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Survival,
4268,NCT01027221,Principal purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumoral activity,2009-11,COMPLETED,INTERVENTIONAL,['NA'],"quality of life according to the EORTC QoL questionnaire after 6, 12, 18 and 24 months",
4269,NCT03407001,Accuracy of contrast enhanced ultrasound (CEUS) with contrast agent sulfur hexafluoride lipid-type A microspheres and B-mode non-contrast enhanced ultrasound,2018-01-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Assessment of CEUS and contrast enhanced magnetic resonance imaging (CE-MRI) Liver Imaging Reporting and Data Systems (Li-Rads),
4270,NCT01754272,Primary colorectal cancer tumor blocks,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],Metastatic tumor blocks,Residual blood samples
4271,NCT01640860,Response rate,2007-12,COMPLETED,OBSERVATIONAL,['NA'],"progression free survival, overall survival and adverse events",
4272,NCT05517681,The number of positive lymph nodes,2020-09-07,COMPLETED,INTERVENTIONAL,['NA'],The incidence of postoperative complications,
4273,NCT03549494,Quality of Life,2018-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Results of laboratory tests,
4274,NCT03308552,Overall survival（OS）,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse events,
4275,NCT02647476,Postoperative complication rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall survival,
4276,NCT04164017,Accuracy,2019-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,
4277,NCT03770689,Number of Participants Who Experienced Dose Limiting Toxicity (DLT) Confirmed by Safety Monitoring Committee (SMC),2019-03-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Apparent Terminal Half-life (t1/2) of Peposertib,
4278,NCT00025025,,2001-10,COMPLETED,OBSERVATIONAL,['NA'],,
4279,NCT01738633,"items DY (dyspnoea), AP (appetite loss) and QL2 of the QLQ C30",2013-01,TERMINATED,INTERVENTIONAL,['NA'],item EA (eating) of OES18,
4280,NCT00001805,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4281,NCT01167738,Progression-free survival at 6 months,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicity,
4282,NCT03615599,Incident cases of breast cancer among subjects with documented dietary habits.,2002-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Incident cases of prostate cancer among subjects with documented dietary intakes.,Incident cases of colorectal cancer among subjects with documented dietary habits.
4283,NCT05462496,Achievement of overall immune response,2023-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival rate (OS),
4284,NCT04194879,Sensitivity & specificity of colorectal cancer detection,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4285,NCT00321958,HGD or inoperable intramucosal or submucosal carcinoma and severe squamous dysplasia: measure of reduction in size of HGD or carcinoma,2006-04,TERMINATED,OBSERVATIONAL,['NA'],Number of treatment sessions needed to ablate dysplasia,
4286,NCT01758965,Delayed bleeding rate after ESD,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
4287,NCT02367001,Evaluate the effect on the participation (of the population) in cancer screening of an intervention involving the general practitioner (integration of signature) in the invitation letters,2014-02,COMPLETED,INTERVENTIONAL,['NA'],"Cost-effectiveness of different strategies for each cancer screening (breast, colorectal and cervical) as measured by cost effectiveness ratio (total costs in Euros divided by total screened people)",
4288,NCT02252250,Adequacy of the total mesorectal excision(TME) based on standard guidelines on pathologic evaluation of TME specimens.,2014-10,COMPLETED,INTERVENTIONAL,['NA'],Oncologic outcomes in subjects receiving transanal hybrid-laparoscopic total mesentery excision.,Quality of life outcomes evaluation
4289,NCT03657914,Number of lymph nodes dissected,2017-07-12,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative drainage tube indwelling time,Local recurrence rate of tumor within 3 years
4290,NCT04046575,Maximum tolerated dose (MTD) of hypofractionated IMRT with chemotherapy,2019-11-07,RECRUITING,INTERVENTIONAL,['PHASE1'],Number and type of adverse events experienced by patient,
4291,NCT03975465,Timing of Aspiration (category),2018-09-10,RECRUITING,INTERVENTIONAL,['NA'],,M.D. Anderson Dysphagia Inventory (MDADI) (number)
4292,NCT05068752,Disease Control Rate of Vemurafenib in Combination with Sorafenib,2021-10-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Measure phospho ERK and phospho AKT in plasma,Clinical Activity of Vemurafenib in Combination with Sorafenib
4293,NCT01775280,Primary endpoint ist the percentage of patients that can be downstaged to resectability,2012-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Immunological response to radioembolization,
4294,NCT05163236,sensitivity of the fecal immunochemical test for the detection of colorectal cancers,2021-04-20,COMPLETED,OBSERVATIONAL,['NA'],Treatment,
4295,NCT05063019,"Predicting intraoperative PCI scores for patients with peritoneal carcinomatosis, using MR Enterography and CT",2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,
4296,NCT01167374,Maximum Tolerated Dose (MTD),2011-08,TERMINATED,INTERVENTIONAL,['NA'],Progression-free Survival,
4297,NCT03160924,Post-operative hospital stay,2016-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Direct hospital costs,
4298,NCT00387348,Change in Hamilton Depression Rating Scale (HAM-D) Scores,2006-03,TERMINATED,INTERVENTIONAL,['PHASE3'],Side Effect Burden,
4299,NCT03515369,3-year disease free survival,2018-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],EORTC QLQ-C30,safety and tolerability
4300,NCT02618356,Median disease progression free survival (mPFS) of Raltitrexed combined with S-1,2015-12-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4301,NCT01859858,Pharmacokinetics of SN-38,2013-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4302,NCT03991104,Response rate,2019-05-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival time,"Health-related Quality of life (HR-QoL, Phase II)"
4303,NCT04644250,Pathologic complete response rate,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],R0 resection rate,
4304,NCT03355391,colorectal cancer rate,2018-01-30,UNKNOWN,OBSERVATIONAL,['NA'],,
4305,NCT01190462,Percentage of patients free from progression and alive after 12.5 weeks following the first dose of treatment,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Correlation between overall response rate, progression-free survival, overall survival, and safety with skin toxicity and efficacy",
4306,NCT03071094,Overall Response Rate (ORR) According to RECIST 1.1.,2017-07-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4307,NCT00299299,,2006-06,UNKNOWN,OBSERVATIONAL,['NA'],,
4308,NCT00792363,Response Rate,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression free survival,
4309,NCT06041477,OS,2023-09,RECRUITING,INTERVENTIONAL,['PHASE3'],Safety profiles of all participants,
4310,NCT05319730,Objective Response Rate (ORR),2023-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase,
4311,NCT02706301,Change in Pain Severity assessed using the Brief Pain Inventory (BPI),2016-07,COMPLETED,INTERVENTIONAL,['NA'],Change in Self-Efficacy for Pain Control assessed using the subscale of the Chronic Pain Self-Efficacy Scale,Patient Satisfaction assessed using the Client Satisfaction Questionnaire 10-item version
4312,NCT00010062,,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4313,NCT00450788,cancer incidence,2007-03-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Mortality,
4314,NCT03820544,Intraoperative Estimated Blood Loss,2017-09-01,TERMINATED,INTERVENTIONAL,['NA'],,
4315,NCT05583890,Health inequalities,2022-08-25,RECRUITING,OBSERVATIONAL,['NA'],,
4316,NCT03144661,Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs),2017-05-25,TERMINATED,INTERVENTIONAL,['PHASE1'],Analysis of biomarkers,
4317,NCT04834011,"Preoperative radiologic assessment of patients with diagnosis of right-sided colon cancer. The investigators evaluated: fascia of Fredet; vascular structures (ileocolic vessels; right colic artery, middle colic artery, trunk of Henle); lymph nodes.",2013-01-01,UNKNOWN,OBSERVATIONAL,['NA'],perioperative outcomes: rate of conversion,
4318,NCT04950166,Clinically Significant Events (CSE),2021-11-30,COMPLETED,INTERVENTIONAL,['PHASE2'],Pegsitacianine fluorescence and imaging performance,
4319,NCT02433639,progression-free survival at 4-months (PFS4mo),2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],safety and tolerability as measured by number and grade of toxicity events,"protein/genomic biomarkers of efficacy from serum, plasma or tumor"
4320,NCT05848739,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],ST316 Assessment Objective Response Rate (ORR),
4321,NCT04498520,Incidence of treatment-related adverse events (AE),2021-03-31,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Median progression-free survival (PFS),
4322,NCT02151032,Gist and Verbatim Knowledge for a Colorectal Cancer Screening Program,2012-11,COMPLETED,OBSERVATIONAL,['NA'],,
4323,NCT03686709,Therapy Monitoring Using Whole-Body Post-therapy PET/CT Imaging,2018-06-19,RECRUITING,INTERVENTIONAL,['NA'],,
4324,NCT01995084,Optimal time frame between administration of 18F-HX4 and PET scan,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
4325,NCT06006260,Self-report Questionnaire,2023-11-20,RECRUITING,OBSERVATIONAL,['NA'],,
4326,NCT01863355,Pain score(VAS) within 48hrs after surgery,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],,
4327,NCT00700102,Overall Survival: Time From Randomization to Death From Any Cause,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Response Rate: Participants With Response Status Based on RECIST Criteria,
4328,NCT04970914,Progression-free survival (PFS),2021-11-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),Number of TB cells count and interleukin-6/8/10
4329,NCT06092242,Progression Free Survival,2023-10-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life score,
4330,NCT05742438,MMP,2023-04-12,COMPLETED,INTERVENTIONAL,['NA'],Mortality,
4331,NCT03313700,3-year disease free survival rate,2017-09-25,COMPLETED,INTERVENTIONAL,['NA'],operation time,
4332,NCT01317069,duration of survival after operation,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],disease free survival,
4333,NCT02005913,tumor recurrence,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4334,NCT04306458,Total number of dissected lymph nodes,2021-01-18,RECRUITING,INTERVENTIONAL,['NA'],Quality of life after esophagectomy,
4335,NCT03082911,Participation,2017-03-13,COMPLETED,INTERVENTIONAL,['NA'],Help to decide about participation,
4336,NCT04658589,Number of harvested lymph nodes in D2 lymph node dissection,2021-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Conversion to open surgery,
4337,NCT04702230,DWI/IVIM values,2017-09-11,TERMINATED,OBSERVATIONAL,['NA'],early responders,
4338,NCT04371224,Progression-free survival,2020-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],QOL: eortc qlq-c30,
4339,NCT00091195,Survival,2004-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4340,NCT01895530,Difference in gene expression of citokynes,2010-07,COMPLETED,INTERVENTIONAL,['NA'],Postoperative complications,
4341,NCT00188266,Phase II: Comparison of acute toxicity rates with those observed in their previous study of 20 patients treated similarly to the SWOG INT 0116 protocol.,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Survival and disease-specific survival,
4342,NCT05999812,"Objective Response Rate of of ATRA, bevacizumab and atezolizumab combination",2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Frequency of adverse events,
4343,NCT05029102,Progression Free Survival,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
4344,NCT01505530,Overall Survival (OS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Anti-LY2495655 Antibodies,
4345,NCT04926532,Objective response rate (ORR),2019-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
4346,NCT02291133,Number of Participants With Toxicity Related to Electrochemotherapy,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinical Response Evaluation According to RECIST v1.1,
4347,NCT03303352,"Cytological diagnostic accuracy of EUS FNA, for ""fast"" and ""slow"" passages",2017-07-24,COMPLETED,INTERVENTIONAL,['NA'],"The linear relationship between needle acceleration and outcomes 1,2,3 and 4",Subgroup analysis for trans-gastric and trans-duodenal route
4348,NCT02079389,"A change in the stage of Tumor, lymph Node and metastases (TNM-stage)",2013-05,COMPLETED,INTERVENTIONAL,['NA'],A change in the postoperative treatment strategy,Does the use of contrast enhanced ultrasound examination during surgery for colon and rectum cancer provides more findings of liver metastases?
4349,NCT05477576,Phase 3: PFS as determined by BICR,2022-03-24,RECRUITING,INTERVENTIONAL,['PHASE3'],Phase 3: DoR,Phase 3: QTc
4350,NCT00087334,Response rate,2004-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival in (phase II),
4351,NCT06327269,Recurrence-free survival with adjuvant therapy,2021-04-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
4352,NCT01092091,Tumor response,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Plasma arginine levels,
4353,NCT03076567,Relation of DNA methylation marakers to gastric cancer status,2017-03-09,COMPLETED,OBSERVATIONAL,['NA'],,
4354,NCT04390724,Patient Group 2: HCC Resection,2020-07-17,RECRUITING,OBSERVATIONAL,['NA'],,
4355,NCT04761783,Examine the impact of SIGNATERA on treatment decisions on tumor assessment timepoints after initiation of immunotherapy,2021-05-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Determine the impact of SIGNATERA on patient reported outcomes,
4356,NCT04048278,Upregulation or Downregulation of Gene Expression.,2018-11-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Specimen outcome measure,
4357,NCT01326845,Difference in the Frequency of Overall Newly Occurring GI Adverse Events (AEs) in the Two Treatment Arms,2011-12,TERMINATED,INTERVENTIONAL,['PHASE4'],Difference in Reducing Serum Ferritin After Each Month of Study Drug Administration Between the Two Groups,
4358,NCT01287585,Overall survival,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety and tolerability - number of participants with adverse events.,
4359,NCT03609710,Anastomotic leak rate,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Reoperation rate after anastomotic leak,
4360,NCT00061958,"Objective response (OR) defined as a complete or partial remission, evaluated using RECIST criteria",2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicity graded according to the Common Toxicity Criteria version 2,
4361,NCT02603757,Increase in serum Vitamin D3 level during chemotherapy in the active supplementation group compared to the control group.,2016-03,COMPLETED,INTERVENTIONAL,['NA'],Overall survival (OS),
4362,NCT06074432,Mortality,2023-07-25,COMPLETED,OBSERVATIONAL,['NA'],,
4363,NCT04552405,Evaluate changes in calprotectin levels,2017-09-12,COMPLETED,INTERVENTIONAL,['NA'],Evaluate changes in stool inflammatory markers,
4364,NCT04642664,Objective Response Rate (ORR),2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Event,Clinical benefit rate (CBR)
4365,NCT06214533,Postoperative opioid use,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Post-operative hospital time,
4366,NCT00746590,Overall Best Tumor Response Rate (Proportion of Subjects With Complete or Partial Response) as Defined by Modified RECIST,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Changes in Laboratory Measurements,
4367,NCT04440865,Adenoma Detection Rate (ADR),2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],Morbidity: bleeding rate (%),
4368,NCT03121807,Overall survival,2014-09-01,COMPLETED,INTERVENTIONAL,['NA'],Cycles of salvage chemotherapy completed,
4369,NCT01002287,"The Incidence of Adhesions, Defined as the Proportion of Subjects Presenting at the Follow-up Surgery (10-12 Weeks) With One or More Adhesions to the Midline Incision, Regardless of Extent and/or Severity.",2009-10,TERMINATED,INTERVENTIONAL,['NA'],Mobilization Time,
4370,NCT04386057,Dose Limiting Toxicity-Lead In,2020-05-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
4371,NCT01697449,Percentage of Participants With At Least One Adverse Event (AE),2009-03,COMPLETED,OBSERVATIONAL,['NA'],Progression Free Survival (PFS),
4372,NCT04123379,Significant Tumor Necrosis (STN),2020-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
4373,NCT00270166,Proportion of patients without transfusion after first month.,1995-02,COMPLETED,INTERVENTIONAL,['PHASE3'],"Proportion of responders, change of hemoglobin (not by transfusion), cumulative transfusion rate, proportion of patients transfused during the double-blind phase, excluding the first month; mean change score of baseline quality of life parameters; safety",
4374,NCT06003998,Overall survival,2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Peritoneum/plasma ratio of intraperitoneal irinotecan,
4375,NCT05845450,major pathological response rate,2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],microbiota,Overall survival
4376,NCT01126463,Maximal tolerated dose,2010-05-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Bio-availability,
4377,NCT05068739,Success rate of cannulation,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],Procedure time,
4378,NCT04045496,Find Recommended Phase 2 Dose (RP2D) of JAB-3312,2019-09-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],Duration of response ( DOR ),
4379,NCT03446157,Disease Control Rate,2018-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity of Treatment,
4380,NCT06119425,Opted to be screened by either SOC or study diagnostic test,2023-10-12,RECRUITING,INTERVENTIONAL,['NA'],Opted to be screened by the study diagnostic test instead of SOC,
4381,NCT01849588,Decline in HCV-RNA Level,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4'],Overall Survival,Decrease Alpha-fetoprotein(AFP) Level > 20% From the Baseline
4382,NCT04429542,Incidence of Dose Limiting Toxicities (DLTs),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Immunogenicity of BCA101 and pembrolizumab,
4383,NCT04466891,Confirmed objective response rate (ORR) by independent central review (ICR),2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of anti-drug antibodies (ADAs),
4384,NCT05603572,To determine the Recommended Phase 2 Dose (RP2D) for oral + IT administration,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To assess area under the curve (AUC) of KAT (oral and oral + IT),
4385,NCT03806075,Mutation of gene associated with Peutz-Jeghers syndrome,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Intestinal microbiota of patients with PJS,The association of STK11 with intestinal microbiota of patients with PJS
4386,NCT02331914,Secondary GIST mutations in circulating tumor DNA of patients with progressive disease on TKI treatment,2014-12-08,RECRUITING,OBSERVATIONAL,['NA'],Secondary mutations in circulating tumor DNA related to pharmacokinetics of TKI,
4387,NCT05402592,Shorter Length Of Hospitalization,2022-07-13,COMPLETED,INTERVENTIONAL,['NA'],Higher quality of life on the 30th day after surgery in patients given a carbohydrate-rich beverage before surgery,
4388,NCT06281379,Postoperative outcome,2023-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
4389,NCT04287218,Change of total score on Fear of Cancer Recurrence Inventory (FCRI) from baseline to 2nd follow-up,2023-05-10,RECRUITING,INTERVENTIONAL,['NA'],Comparison of changes in health care usage between intervention arm and aTAU,Perceived risk of recurrence measured by the visual analogue scale from 1-100
4390,NCT04253106,Number of subjects in whom somatic mutations or methylation profiles are detected.,2020-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Replicability of observations over successive endoscopies. Correlation between blood and gastric fluid.,
4391,NCT05043857,Local Recurrence Rate,2021-07-06,RECRUITING,INTERVENTIONAL,['NA'],Overall Survival,
4392,NCT03351647,Measurement of serum ustekinumab trough concentrations (expressed in microg/mL) at week 8.,2018-02-14,COMPLETED,OBSERVATIONAL,['NA'],Clinical evaluation at week 24,
4393,NCT00064051,Objective response rate (partial and complete response) as assessed by RECIST criteria,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety and feasibility,
4394,NCT00681421,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To evaluate immunological responses,
4395,NCT03465722,"Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST), Version 1.1",2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30). Change in Individual Scores in Patients With Advanced GIST Treated With Avapritinib Compared to Patients Treated With Regorafenib,
4396,NCT06221748,Overall Survival (OS)(Phase III),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of echocardiograms abnormalities,
4397,NCT02696759,Number of Subjects Who Complete Fecal Collection,2016-07,TERMINATED,INTERVENTIONAL,['NA'],,
4398,NCT02536183,Feasibility of treatment,2016-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Determine the Changes in Pharmacodynamic Immune Markers in Participants,
4399,NCT05047510,HCC lesions,2021-09-10,RECRUITING,INTERVENTIONAL,['NA'],,
4400,NCT05542680,Reflux symptoms,2022-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Skin pressure injury,
4401,NCT05969847,Organ preservation,2023-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Anorectal function,
4402,NCT01983371,Prospectively evaluate the diagnostic accuracy of ferumoxytol-enhanced MRI in the setting of colorectal cancer with histopathologic analysis as the gold standard.,2013-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
4403,NCT04656782,Standardized imaging protocol consensus among panelists,2021-01-26,UNKNOWN,OBSERVATIONAL,['NA'],Description of heterogeneity of mCRC imaging protocols,
4404,NCT03555149,Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2018-09-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Percentage of Participants With at Least One Adverse Event (AE),
4405,NCT02930902,Incidence of toxicities as defined by Common Terminology Criteria for Adverse Events version 4.0,2017-02-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Resection rate,Overall survival (OS)
4406,NCT04858009,Progression-free survival,2024-01-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Morbidity,
4407,NCT05279612,Investigate patients ORR,2021-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],R0 resection,
4408,NCT01465802,Median Time of Occurrence of Cmax (Tmax) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort III,2011-12-26,COMPLETED,INTERVENTIONAL,['PHASE2'],"Mean Plasma Ctrough for PF-05199265 by Visit for Cohorts I, II and III",
4409,NCT05247164,Proportion of patients with procedure-related Adverse Events,2022-05-17,RECRUITING,INTERVENTIONAL,['NA'],Baseline portal CTC concentration in patients with progressive versus non-progressive diseases,
4410,NCT01345175,To compare the efficacy of rifaximin and placebo in the treatment of bowel dysfunction as measured by MSKCC Bowel Function Instrument (BFI score) in patients following Anterior Resection (AR) or Sphincter Preserving Surgery (SPS) for rectal cancer.,2011-04-26,COMPLETED,INTERVENTIONAL,['PHASE3'],efficacy of metronidazole,
4411,NCT00961571,Progression-free Survival,2009-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4412,NCT05453760,Area under the curve (AUC) of the Lung ultrasound score,2022-08-21,RECRUITING,OBSERVATIONAL,['NA'],Complications according to the Dindo-Clavien classification,
4413,NCT03700593,Rate of postoperative complications and mortality of the SP robot,2018-10-15,UNKNOWN,OBSERVATIONAL,['NA'],Assessment of patients' postoperative body image satisfaction,
4414,NCT02507414,"Relative changes in plasma-hormone concentrations (pro-ANP, PGF2, GLP-1, ACTH, cortisone, adrenaline, IL-1, IL-6, TNF-alfa and CRP (stress hormones)) from baseline.",2014-08,COMPLETED,INTERVENTIONAL,['NA'],Relative changes in systemic vascular resistance from baseline measured in dyn.s/cm5,
4415,NCT02682485,Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18),2017-03-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18),
4416,NCT01899976,Maintenance of a total serum bilirubin level ≤ 3.0 mg/dL or a reduction of >30% if baseline value was greater than 3.0 mg/dL,2013-08,COMPLETED,INTERVENTIONAL,['NA'],total number of adverse events,
4417,NCT00144378,median survival,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],"quality of life, response rates, time to tumor progression, toxicity",
4418,NCT04258150,Objective response rate (ORR),2020-04-16,TERMINATED,INTERVENTIONAL,['PHASE2'],"Incidence of treatment-related AEs, SAEs, AEs leading to discontinuation, death, and laboratory abnormalities",
4419,NCT02550613,The recurrence rate at 3 months after treatment,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],The overall survival after treatment,
4420,NCT05667350,The sensitivity and specificity of the combined model in detection of biliary tract cancers.,2022-02-28,RECRUITING,OBSERVATIONAL,['NA'],The sensitivity and specificity of the combined model in detection of different stages of biliary tract cancers.,
4421,NCT02631499,Early recurrence rates,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],Overall Survival,
4422,NCT01705340,MTD of Akt inhibitor MK-2206 and lapatinib ditosylate in combination with trastuzumab determined by dose limiting toxicities as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1'],"Overall response rate (ORR), evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
4423,NCT04826003,Percentage of Participants with Adverse Events,2021-07-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change on 4-1BB tumor expression levels,
4424,NCT02784470,Gastric Outlet Obstruction Scoring System (GOOSS) score,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
4425,NCT03028584,EHR-based SCPs and care planning,2017-09-11,COMPLETED,OBSERVATIONAL,['NA'],Impact of providing EHR-based care planning,
4426,NCT01494506,Overall Survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Pharmacokinetic Measurements of Total Irinotecan,
4427,NCT00536874,Overall Survival at 18 Months,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Specific Tumor Marker Response (Ca 19-9) to Neoadjuvant Therapy,
4428,NCT02599662,Maximum Tolerated Dose,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],QOL surveys,
4429,NCT00822562,Overall survival rate,2009-01,COMPLETED,INTERVENTIONAL,['NA'],"non-tumor life span, intra-liver recurrence rate, metastasis rate",
4430,NCT00303771,Progression Free Survival (survie sans progression),2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival (survie globale),
4431,NCT02557490,Progression-free survival (PFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],overall survival (OS),
4432,NCT06067438,"Development of atrial fibrillation (AF), or completion of seven-day course of amiodarone",2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Serum amiodarone level, classified as therapeutic or subtherapeutic",
4433,NCT04589234,Progression Free Survival,2020-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Radiologic response,
4434,NCT04069468,QoL Measurements Using FACT-HEP Questionnaire Before and After Treatment,2019-03-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],"Determination of a correlation between Dose volume histogram (DVH) for total perfused tumour, Index lesion and whole normal liver tissue, using 99mTc-MAA (SPECT or SPECT/CT) and Y-90 (PET/CT or PET/MRI).",
4435,NCT05673148,Overall Survival (OS),2023-01-10,RECRUITING,INTERVENTIONAL,['PHASE3'],Time to local recurrence (TLR),
4436,NCT05185869,Adverse Events (AEs),2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),
4437,NCT01518829,Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
4438,NCT01330823,TNF-alpha,2006-06,SUSPENDED,INTERVENTIONAL,['PHASE3'],hospital stay,
4439,NCT01389583,disaese control rate,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],response rate,
4440,NCT05411679,Overall Response Rate (ORR) as measured using RECIST v1.1,2023-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of treatment-emergent AEs leading to dose reduction of trial treatment,Magnitude of response to first-line chemotherapy
4441,NCT02909062,EAM Max Step-count On-Chemotherapy - EAM Max Step-count Pre-Chemotherapy,2016-05,COMPLETED,OBSERVATIONAL,['NA'],,
4442,NCT03718650,Radiosensitivity Index and Degree of Pimonidazole Staining,2021-04-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Correlative Biomarkers,
4443,NCT06205173,The effectiveness of Cold and Hot Compress Nursing Interventions on the Quality of Life,2020-08-19,COMPLETED,INTERVENTIONAL,['NA'],The Effectiveness of Cold and Hot Compress Nursing Interventions on the Neurological Changes in the Hands and Feet.,
4444,NCT04481256,Feasibility difined as the percentage of patients completing at least two cycles of bintrafusp alfa,2020-11-11,RECRUITING,INTERVENTIONAL,['NA'],adverse events,Biomarker
4445,NCT05768282,The proportion of patients with esophageal stenosis after RFA,2016-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],The adverse events rate,
4446,NCT01786980,Overall survival,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,
4447,NCT03219918,Adenoma detection rate,2017-06-19,TERMINATED,INTERVENTIONAL,['NA'],Malignancy detection,
4448,NCT02358070,Lifestyle factors,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
4449,NCT05898828,Phase II Component: To assess the frequency of immunologic responses to purified cancer-testis (CT) antigens in EsC participants receiving adjuvant vaccinations with H1299 cell lysate/Montanide(R) ISA-51 VG in combination with entinostat and niv...,2024-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II Component: To determine progression free survival (PFS) in EsC participants receiving the investigational adjuvant vaccine regimen,
4450,NCT04752358,Efficacy: Overall Response Rate (ORR),2021-09-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs,
4451,NCT05627427,Progression-free Survival (PFS) (RECIST1.1),2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],TEAE rates,
4452,NCT01572974,Health State Utility as measured by the Time Trade-off (TTO) method/Standard Gamble (SG) method,2010-01,TERMINATED,OBSERVATIONAL,['NA'],SF-36 general health (GH) subscale,
4453,NCT06212817,Dietary fiber intake,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Length of hospital stay,
4454,NCT00161460,Colorectal cancer screening test utilization,2005-06,COMPLETED,INTERVENTIONAL,['NA'],Cancer worry score,
4455,NCT03399253,Overall survival,2017-12-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",progression free survival,
4456,NCT00845689,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4457,NCT00003753,,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4458,NCT00617981,Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant Intrahepatic HCC Tumor o Any New Extrahepatic HCC Tumor o Death From Any Cause,2008-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety,
4459,NCT02296658,Distant metastasis free survival,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Chemoradiotherapy-induced toxicities assessed by CTCAE 4.0,Comparison of dosimetric differences between radiation techniques
4460,NCT05572801,Disease free survival,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Health related quality of life,
4461,NCT00857805,Overall survival,2009-01-07,COMPLETED,INTERVENTIONAL,['NA'],Downstaging,
4462,NCT01717014,Distal Margins,2013-05,TERMINATED,INTERVENTIONAL,['NA'],Usability: Manueverability,
4463,NCT06151262,Incidence of CIM,2024-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and Tolerability,
4464,NCT01016860,Maximum tolerated dose (MTD) and the recommend phase II dose (RP2D) for the combination of irinotecan and OSI-906 in patients with advanced cancer.,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,
4465,NCT04048317,Evaluate the effectiveness of drug-eluting bead trans-arterial chemo-embolization in patients of hepatocellular carcinoma,2019-09-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
4466,NCT00445965,response rate,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],cumulative toxicities,
4467,NCT01977066,"Physical functioning score, as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) EORTC QLQ-C30",2013-11,COMPLETED,INTERVENTIONAL,['NA'],Overall quality of life from EORTC QLQ-C30 and the specific module for pancreatic cancer(QLQ-PAN26),Fatigue (Multidimensional Fatigue Inventory (MFI))
4468,NCT02255669,duration of stent patency,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],stent related complication,
4469,NCT01875380,Progression-free survival rate at 6 months,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in ECOG performance status over time from baseline,Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters.
4470,NCT00313755,with at least one adenoma after white light NBI in the right colon.,2006-04,COMPLETED,INTERVENTIONAL,['NA'],Number of hyperplastic polyps detected by white light vs NBI.,
4471,NCT02089633,Time To Progression (TTP),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety events,To evaluate the association between the biomarkers of ornithine transcarbamoylase (OTC) and argininosuccinate synthetase (ASS) in liver tissue and clinical response treated with PACOX regimen
4472,NCT03562234,Change in liver function,2018-10-22,UNKNOWN,OBSERVATIONAL,['NA'],Post-operative 30 day complications using the International Study Group for Liver Surgery (ISGLS) complications score,
4473,NCT02965794,Length of stay,2014-10,COMPLETED,OBSERVATIONAL,['NA'],Time to return to normal diet,
4474,NCT00002955,,1995-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4475,NCT02389751,"MTD and recommended phase II dose of ganetespib, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2015-04-10,COMPLETED,INTERVENTIONAL,['PHASE1'],pCR for patients who undergo surgical resection after neoadjuvant therapy,
4476,NCT01834469,Feasibility study of the (intravenously injected) ICG imaging of tumoral implants in patients with peritoneal carcinomatosis from ovarian carcinoma,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4477,NCT02278458,The number of patients who suffer adverse events,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],Progression-free survival,
4478,NCT02595021,Postoperative complications,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Hospitalization days,
4479,NCT00354978,Median Progression-free Survival (PFS),2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4480,NCT05159479,Relationship of baseline cardiovascular risk with FIC,2021-10-13,RECRUITING,OBSERVATIONAL,['NA'],Cardiovascular symptom assessment,
4481,NCT05524012,Tumor regression grading (TRG),2022-11-30,RECRUITING,OBSERVATIONAL,['NA'],Surrogate marker: Carcinoembryonic Antigen (CEA),
4482,NCT03465982,pathologic complete response (pCR),2018-06-05,RECRUITING,INTERVENTIONAL,['NA'],OS,
4483,NCT04776421,comprehensive complication index,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall Survival,
4484,NCT03228147,A tea product with the highest total average nutrition supplement scores as assessed by questionnaires,2017-07-25,COMPLETED,INTERVENTIONAL,['NA'],,
4485,NCT02842580,The primary objective is the percentage of patients without failure of the strategy 16 months after the randomization.,2016-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression free survival (PFS) at 2 years and at 3 years,
4486,NCT05332821,Overall Survival(OS),2022-12-28,RECRUITING,OBSERVATIONAL,['NA'],Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0,
4487,NCT01538498,Devleopment for the peritoneal carcinomatosis index (PCI),2008-04,COMPLETED,OBSERVATIONAL,['NA'],,
4488,NCT00813072,objective tumor response,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"progression-free survival, duration of tumor response, time to progression, time to treatment failure, disease control rate, 1-year survival rate,and overall survival; pharmacokinetics and pharmacogenetics of PEP02 and irinotecan",
4489,NCT04140500,"Part B: Progression-free Survival (PFS), Defined as the Time from the First Study Treatment to the First Occurrence of Progression per Investigator Assessment or Death from any Cause, Whichever Occurs First",2019-11-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Part B: Percentage of Participants with Adverse Events,
4490,NCT04017650,Incidence of treatment-related grade 3 adverse events,2019-06-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of response,
4491,NCT01963429,local progression-free survival(LPES),2013-09-30,COMPLETED,INTERVENTIONAL,['NA'],disease-free survival (DFS),overall survival (OS)
4492,NCT04389177,Major pathologic response,2020-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],R0 resection rate,
4493,NCT02513784,Difference in Esophageal F. Nucleatum Between Experimental Group and no Intervention Group,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,
4494,NCT00964457,response rate,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4495,NCT06031129,Visceral Pain,2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],Visceral Pain,
4496,NCT06115655,Specificity,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
4497,NCT05044312,Correlating the sleep disturbance and its types among patients with gastrointestinal cancers.,2024-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
4498,NCT04791254,Differences in patterns of plasma gut hormone and cytokine levels as measured by ELISA between study participants.,2021-07-15,RECRUITING,OBSERVATIONAL,['NA'],"Correlation between nutritional status, body composition and physical fitness",
4499,NCT05689138,microbial features by 16s rRNA sequencing,2020-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4500,NCT02233595,tumor volume,2014-10-15,TERMINATED,OBSERVATIONAL,['NA'],,
4501,NCT00851955,All cause mortality,2007-05,COMPLETED,OBSERVATIONAL,['NA'],"For pancreatic patients from whom tissue samples will be available, we will examine the association between presence/absence of each marker in the tissue versus the marker level in blood and in pancreatic juice.",
4502,NCT00980889,confirmed stent failure,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Survival,
4503,NCT04745403,Analysis of modifications of tumour microenvironment caused by mRNA HBV/TCR T-cell treatment,2022-05-20,RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluation of anti-tumor efficacy of mRNA HBV/TCR T-cell treatment,
4504,NCT04422730,comparaison of quality of life score between 4 groups,2020-06-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4505,NCT04508387,respiratory parameters: tidal volume,2019-04-22,COMPLETED,INTERVENTIONAL,['NA'],morphine consumption,
4506,NCT03223818,Length of post-operative hospital Stay,2018-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
4507,NCT00981110,The rate of patients with a Surgical site infection,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4508,NCT02395523,local progression - free survival,2015-03-05,COMPLETED,INTERVENTIONAL,['NA'],overall survival,
4509,NCT05136092,The abundance of fructose in tumor extracts,2022-02-16,RECRUITING,INTERVENTIONAL,['NA'],The abundance of Xylose and [13C]-Xylose in the in the tumor,
4510,NCT05935579,Objective response rate,2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival rate,
4511,NCT05772923,Rate of successful organ preservation,2021-04-16,RECRUITING,INTERVENTIONAL,['NA'],Number of patients with complications after completion or salvage TME-surgery,
4512,NCT00254137,Objective response rate (CR+PR),2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Grade 3/4- toxicities.,
4513,NCT04131946,Characterize individual -level facilitators and barriers to engaging in CRC screening and related diagnostic tests and treatment when applicable,2019-11-12,COMPLETED,INTERVENTIONAL,['NA'],,
4514,NCT01341366,Duration of hospital stay,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Lymphocyte subsets,
4515,NCT01885351,CRCS adherence provided by the electronic medical record,2013-03-01,COMPLETED,INTERVENTIONAL,['NA'],Feasibility of MyCRCS+ in target setting - patient survey,Development of MyCRCS+ intervention content
4516,NCT02734004,Second Stage Cohorts: DCR at Week 24,2016-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Initial and Second Stage Cohorts: Number of Participants With Anti-Drug Antibody (ADA) Response to MEDI4736,
4517,NCT02021500,Overall Survival,2014-01-02,COMPLETED,OBSERVATIONAL,['NA'],Disease progression,
4518,NCT00305838,Number of patients required to detect a significant difference in CA 125 doubling time before and after starting tamoxifen,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4519,NCT02841657,Postoperative complications,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],Oncological radicality,
4520,NCT03238885,Pathological complete response(pCR),2013-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
4521,NCT00669734,"MTD of falimarev, defined as the dose level that 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) and that at least 2/3 or 2/6 patients treated with the next higher dose have had DLT",2010-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Cytokine production,
4522,NCT02645864,Maximum tolerance dose,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival,
4523,NCT04656041,Pathologic Complete Response Rate,2021-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
4524,NCT06054984,Characterize the Peak of Peripheral Blood Concentration and Area under the Peripheral Blood concentration versus time curve of TCRT cells and observe their proliferation and persistence in body,2021-09-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],"Evaluate tumor size (mm) , tumor biomarker CA19-9 (U/ml), ORR/DCR/PFS and OS of patients with advanced pancreatic cancer",To explore the correlation between the proliferation and persistence of TCRT cells in body and the efficacy
4525,NCT03209349,Full colon exam,2017-06-14,COMPLETED,INTERVENTIONAL,['NA'],Adenoma detection rates,
4526,NCT04631692,Colorectal cancer screening uptake,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
4527,NCT01180452,Frequency of dysplasia and adenocarcinoma,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Success of endoscopic detection,
4528,NCT02861885,patients with sessile serrated lesions,2016-02-24,UNKNOWN,OBSERVATIONAL,['NA'],Detection techniques diagnosis performance,
4529,NCT01642186,Efficacy Endpoints for Part 1 of the Study is Progression-free Survival at 6 Months (PFS6),2012-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Tissue Biomarkers Collected,
4530,NCT05559775,ORR,2022-08-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4531,NCT00127036,"Number of Participants Per Treatment Arm, Per Tumor Tissue Response Classifier",2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious Adverse Events (SAEs),
4532,NCT04215471,Objective Response,2020-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between genetic profile and tumor response,
4533,NCT03379844,"Safety, expressed as the rate of unacceptable toxicity.",2017-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in hepatic function as determined by hepatobiliary scintigraphy,
4534,NCT05739981,Minimal Residual Disease,2023-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",OS,
4535,NCT00310362,Appointment Nonadherence-colonoscopy,2007-07,COMPLETED,INTERVENTIONAL,['NA'],Preparation Non-adherence-flexible Sigmoidoscopy,
4536,NCT00943280,The primary outcome variable for this aim will be the number of subjects in each group that need to be contacted until 20 in each group agree to participate in this study.,2009-01,COMPLETED,OBSERVATIONAL,['NA'],"To access variables for prediction of non-participation: age, gender, education level, employment, marital status, esophageal symptoms",
4537,NCT04899492,Testing the feasibility of smoking cessation interventions evaluated in French cancer patients undergoing surgery,2021-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Evaluate the efficacy of interventions on patient quality of life,
4538,NCT03718351,En-block resesction rate,2018-09-24,UNKNOWN,INTERVENTIONAL,['NA'],Morbidity defined by the Clavien-Dindo classification,
4539,NCT05200325,CPV-measured cost savings,2021-06-06,COMPLETED,INTERVENTIONAL,['NA'],CPV-measured use case analysis,
4540,NCT00116454,"to determine if the Lipiocis treatment decreases the % of tumoral recurrence after 24 months, judged on the rise of alpha-fetoprotein and the reappearance of one or more tumours on the hepatic CT scan",2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Deterioration of the hepatocellular function,
4541,NCT03509428,Post-operative length of hospital stay,2018-03-26,UNKNOWN,INTERVENTIONAL,['NA'],Nutrition -4,
4542,NCT00227773,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
4543,NCT05570487,The number of lymph nodes,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
4544,NCT03177382,disease free survival,2017-06-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],assessment of nutritional status,
4545,NCT04657042,DVF errors in healthy volunteers and cancer patients,2020-11-05,RECRUITING,OBSERVATIONAL,['NA'],,
4546,NCT04852211,2-year recurrence-free survival,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],5 - year Overall survival,
4547,NCT00062426,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4548,NCT01312389,Number of Participants With Adverse Events,2011-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinical Response,
4549,NCT01218841,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4550,NCT00126633,Micrometastases for predicting time to progression and overall survival,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4551,NCT03124212,Establishing the CASCADE Cohort,2017-04-01,RECRUITING,OBSERVATIONAL,['NA'],Cancer Surveillance,
4552,NCT03958812,Discrimination between Malignant and Benign Gastric/Breast Lesions and normal group with each diagnostic method (Na-nose/GC-MS/CTC),2019-06-15,UNKNOWN,OBSERVATIONAL,['NA'],Comprehensive diagnostic model of VOCs and CTCs,
4553,NCT03468335,Time to Treatment Failure of second-line treatment (TTF2),2018-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Growth modulation index (GMI),
4554,NCT05858385,Incidence of severe RTOM,2022-09-22,RECRUITING,OBSERVATIONAL,['NA'],Risk factors of severe RTOM,Changes from the pain in xerostomia combined with RTOM patients
4555,NCT02231385,Additional serrated lesions diagnosed after acetic acid spraying,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],Complication rate,
4556,NCT03450889,Incidence of colorectal cancer during protocolled endoscopic surveillance,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],Incidence of post-colonoscopy complications,
4557,NCT05718284,POST-OPERATIVE PULMONARY COMPLICATIONS,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],CARDIO-VASCULAR COMPLICATIONS,
4558,NCT00636948,Symptomatic anastomotic leakage following low anterior resection of the rectum for cancer with and without a defunctioning stoma. Anorectal function after one and five years without defunctioning stoma.,1999-12,COMPLETED,OBSERVATIONAL,['NA'],Reoperation within 30 days of initial surgery.,
4559,NCT02578368,Overall survival (OS),2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Toxicity - Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
4560,NCT05405530,The incidence of hypoxia,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],The incidence of other adverse events,
4561,NCT01520779,Recurrence of hepatocellular carcinoma,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
4562,NCT03503071,Brief pain inventory (BPI),2018-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Brief pain inventory (BPI),
4563,NCT00208936,,1996-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4564,NCT01607788,Post-transplant survival,2009-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4565,NCT03812289,Proportion of participants who are transplanted or with localized disease control per Milan criteria,2019-02-07,TERMINATED,INTERVENTIONAL,['NA'],Incidence of liver toxicity assessed per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0,Proportion of histopathologic changes in irradiated tumor sites relative to uninvolved liver tissue
4566,NCT02452424,Treatment-emergent Adverse Events (TEAEs) in Participants Regardless of Causality While Taking PLX3397 in Combination With Pembrolizumab,2015-07-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Summary of the Percentage of Participants With Objective Response Rate Assessed by RECIST v1.1 During Pembrolizumab and PLX3397,
4567,NCT00558233,Receipt of colorectal cancer screening,2007-11,COMPLETED,INTERVENTIONAL,['NA'],Number of polyps and cancers found by screening tests performed,
4568,NCT04117087,Fold change in interferon-producing mutant-KRAS-specific cytotoxic (CD8) and helper (CD4) T cells at 16 weeks,2020-05-28,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
4569,NCT06018896,Quality of life (QOL),2023-08-25,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall survival (OS),
4570,NCT06212128,operative time required for primary resection of rectal tumour,2016-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],duration of hospitalisation,
4571,NCT04973046,The tissue oxygen saturation score of gastric tube during esophagectomy,2020-11-01,COMPLETED,OBSERVATIONAL,['NA'],The rate of anastomotic leakage,
4572,NCT05544474,Degree of consensus,2023-11-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
4573,NCT02606396,Change in dysphagia severity according to validated symptom score,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],"Incidence of procedure related adverse events, classified according to the American Society of Gastrointestinal Endoscopy lexicon",
4574,NCT03415815,Numbers of lymph nodes and percentages of patients with surgeries,2017-12-12,UNKNOWN,OBSERVATIONAL,['NA'],Impact factors of lymph metastases,Effects of surgeries on the extents of the patients with esophageal cancer who received surgeries
4575,NCT00653107,Dysphagia measured with the dysphagia grading scale at week +2 after start of treatment. Pain at rest measured with ESAS at week +2 after start of treatment.,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Health related quality of life,
4576,NCT04893408,long time survival in patients operated for pancreatic cancer,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4577,NCT00040859,Objective tumor response rate,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
4578,NCT01738620,items SL (sleep disorder) and QL2 of the QLQ C30,2013-01,TERMINATED,INTERVENTIONAL,['NA'],PSQI score,
4579,NCT02758951,Phase III (n=358): histological response of colorectal PM to neoadjuvant systemic therapy,2017-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4580,NCT03391232,Number of Participants With Treatment Related Adverse Events,2018-05-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Predicted Antigen Specific T Cell Responses Per Patient,Number of Participants Having Induced Recruitment of TILs
4581,NCT05932836,Accuracy of Organoid drug sensitivity test in predicting the response to mFOLFOX6 infusion in HCC patients with successful Organoid culture,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],The predictive effect of Organoid drug sensitivity test on the survival of patients with HCC.,
4582,NCT05752357,Percentage of disease recurrence,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],Progression-free survival,
4583,NCT03061591,Size of polyps,2017-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Curcumin and curcuminoid levels in urine.,
4584,NCT04605042,diagnostic specificity of WS technique and SNP technique by EUS-FNB,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Cell density of WS technique and SNP technique by EUS-FNB,
4585,NCT00436267,Hepatic and systemic toxicity,2006-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Survival,
4586,NCT00550563,"Relationship between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity",2007-08,COMPLETED,INTERVENTIONAL,['NA'],,
4587,NCT04908176,area under the plasma concentration-time curve (AUC) of midazolam,2022-08-24,RECRUITING,INTERVENTIONAL,['PHASE1'],"area under the plasma concentration-time curve at steady state (AUC,ss) of metabolite",
4588,NCT01469598,Response rate,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Adverse Events,
4589,NCT03350126,Disease Control Rate (DCR),2017-12-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Toxicity according to NCI-CTCAE version 4.0 (National Cancer Institute Common Terminology Criteria for Adverse Events),",
4590,NCT01525550,Progression-Free Survival (PFS): Investigator Assessment,2012-06-06,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Participants With Eastern Co-operative Oncology Group Performance Status (ECOG-PS),
4591,NCT03159585,treatment-related adverse events as assessed by CTCAE v4.03,2017-04-14,COMPLETED,INTERVENTIONAL,['PHASE1'],assess the expression of tumor markers,
4592,NCT06099821,Progression free survival,2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],treatment-related adverse event,
4593,NCT01344538,"Evaluate Whether 2.0g of Ginger Taken Daily, Standardized to 5%-Gingerols for Four Weeks Will Result in Bioactive Levels in Colonic Tissue Sufficient to Reduce Mucosal Prostaglandin E2 (PGE2), a Marker of Cyclooxygenase Function Versus Placebo.",2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4594,NCT02106806,oxidative stress markers,2011-05,COMPLETED,INTERVENTIONAL,['NA'],FACIT-F,CTCAE
4595,NCT00583479,Compare the clinical effectiveness of EUS-guided CB performed with a single injection versus two injections of medication into the celiac ganglion region,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4'],complications related to CB,
4596,NCT00582647,"To obtain & store tissues, blood, peritoneal, pleural, cyst & other gastrointestinal fluid from patients with benign or malignant tumors in order to carry out future laboratory studies on the causes, prevention, diagnosis & treatment of certain cancers.",2000-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4597,NCT05212025,Overall Response Rate (ORR),2022-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of Grade 3 or Higher Treatment-Related Toxicity,
4598,NCT03223376,Progression free survival (PFS),2017-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],The European Organization for Reasearch and Treatment of Cancer（EORTC ） Quality of Life Questionnaire-Core 30 V3.0 (QLQ-C30 v3.0),
4599,NCT05451043,Investigating and establishing the efficacy of propranolol in boosting the effects of immunotherapy in biliary tract tumors,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
4600,NCT02961296,The rate of exceeding the resistance criteria in Helicobacter pylori(H. pylori) antibiotic susceptibility test(Agar dilution method),2016-10,UNKNOWN,OBSERVATIONAL,['NA'],The success rate of H. pylori strain separation,
4601,NCT04594863,SIRT-6 expression,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4602,NCT05462717,Dose Limiting Toxicities,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-Free Survival (PFS),
4603,NCT03115008,Number of polypectomies for gastroenterology trainees to achieve competency,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
4604,NCT01717729,recurrence rate,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Complete Ablation,
4605,NCT01092078,Colon Cancer Screening Behavior,2010-05,COMPLETED,INTERVENTIONAL,['NA'],Social Influence relating to colon cancer screening,
4606,NCT00253383,Correlate preferences for care and care received as measured by After Death Bereaved Family Member Interview with a family member of the deceased,2003-01,COMPLETED,INTERVENTIONAL,['NA'],"Caregiver burden as measured by Montgomery-Borgatta Caregiver Burden Scale at baseline, one month, and every three months thereafter (given to caregivers of patients)",
4607,NCT00019110,,1995-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4608,NCT02995850,II: Safety,2017-02-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",RR (response rate),
4609,NCT03316599,The Maximum Tolerated Dose of ficlatuzumab when administered in combination with gemcitabine and nab-paclitaxel,2018-01-17,COMPLETED,INTERVENTIONAL,['PHASE1'],The progression free survival in this population of patients.,
4610,NCT00968175,The efficacy of EUS-CPN and analgesic therapy in pain relief of patients with unresectable pancreatic cancer when compared with analgesic therapy,2009-06,COMPLETED,INTERVENTIONAL,['NA'],To evaluate the efficacy of EUS-CPN and analgesic therapy in improvement of quality of life (QOL),
4611,NCT03519074,Efficacy Evaluation: Timing,2016-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4612,NCT01575340,change in inflammatory markers,2011-07,COMPLETED,INTERVENTIONAL,['NA'],assessing the risk of inflammatory and nutritional complications,
4613,NCT01786850,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
4614,NCT04194268,survival,2019-12-03,RECRUITING,INTERVENTIONAL,['NA'],Quality of life EORTC QLQ Pan26,
4615,NCT03811652,Percentage of patients with changes in laboratory parameters from baseline,2018-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
4616,NCT00825669,overall survival,2008-12,COMPLETED,INTERVENTIONAL,['NA'],the changes of the PVTT,
4617,NCT00001693,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4618,NCT03168594,Overall response rate (ORR),2017-04-29,TERMINATED,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events （Safety and Tolerability）,
4619,NCT04444921,Progression-free survival,2020-11-17,RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence of adverse events,
4620,NCT02526836,Lymph nodes harvest,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Survival outcome,
4621,NCT02869581,Survival of patients with pancreatic neoplasms,2000-01,RECRUITING,OBSERVATIONAL,['NA'],Collection of patients characteristics,
4622,NCT03120104,Change of The Wexner Score,2017-06,UNKNOWN,INTERVENTIONAL,['NA'],Change of Functional assessment of Cancer Therapy - Colorectal (FACT-C),
4623,NCT03064308,Feasibility of a home based exercise programme following surgery in the older patient.,2017-06-26,COMPLETED,INTERVENTIONAL,['NA'],Hand Strength Test,Intervention Compliance Questionnaire
4624,NCT05551416,New strategies for gastric cancer (GC) early diagnosis,2021-09-09,RECRUITING,OBSERVATIONAL,['NA'],Characterization of the microbiome: 16S rRNA studies,
4625,NCT04444232,Alters' intent to become screened for CRC in the next six months,2014-09-09,COMPLETED,INTERVENTIONAL,['NA'],,
4626,NCT01079767,3-month disease-control rate according to RECIST criteria,2010-01,TERMINATED,INTERVENTIONAL,['PHASE2'],3-month objective response rate according to RECIST criteria,
4627,NCT00622622,Safety(toxicities as assessed by NCI CTCAE version 3),2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],survival,
4628,NCT03529669,Completion Rate,2018-04-18,COMPLETED,INTERVENTIONAL,['NA'],Number of Patients Who Would be Prepared to Repeat the Procedure,
4629,NCT03035279,Number of participants with dose-limiting toxicities (DLT),2017-03-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Maximum observed serum concentration (Cmax) of SC-006,
4630,NCT04798612,T-cell infiltration in tumor,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Immunological and inflammatory cytokines and interleukins,
4631,NCT01669356,postoperative body composition change compared to preoperation measurement,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,complicatons incidence after surgery
4632,NCT00885066,Clinical or laboratory toxicities as assessed by CTC,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4633,NCT01882933,Overall survival,2013-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Score QLQ-STO 22,
4634,NCT02871999,"Pain degree change after surgery, Graded according to Numerical Rating Scale(NRS)",2016-08,COMPLETED,INTERVENTIONAL,['NA'],Testosterone(Male) in blood,
4635,NCT03469284,Change in Pain Scores Assessed Within the Numeric Rating Scale (NRS) Component of the Modified Harris Mucositis-related Pain Assessment Tool,2019-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Pain Duration,
4636,NCT02215070,Percentage of GI Toxicity From the Preparatory Regimen and the GVHD Prophylaxis in Stem Cell Transplantation (SCT) Patients Who Are Treated With Pasireotide,2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Free Survival Compared to Historical Controls,Evaluate GI Toxicity Assessment by Video Capsule Endoscopy.
4637,NCT02632864,two-year overall survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Hepatobiliary phase signal change after proton beam therapy,
4638,NCT05982834,objective response rate,2023-05-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4639,NCT04713891,Clinically significant abnormality in physical examinations,2021-03-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],Progression free survival (PFS),
4640,NCT00378066,time to progression,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],"overall survival, safety, response",
4641,NCT04526314,Overall survival,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4642,NCT04103697,3-year disease-free survival,2019-08-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],Preoperative tumor-associated complications rate,
4643,NCT04081779,Response rate among primary care providers (PCPs) to the PCP survey,2020-02-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Local oncology clinics' attitudes towards survivorship care implementation,
4644,NCT05914389,TRG0/1,2023-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Minimal Residual Disease (MRD),
4645,NCT00477841,"Relief of dysphagia measured by dysphagia scores, survival time from the interventional procedure to the last follow-up.",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"Successful rate of stent placement, Stent-related complications and morbidity, Overall rate of mortality",
4646,NCT05024097,Number of treated patients who achieve complete pathologic response,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
4647,NCT03030508,Disease-free survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],Three year disease free survival rate,
4648,NCT01008566,Toxicities and tolerability of this regimen as assessed by NCI CTCAE version 4.0,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression-free rate according to the Response Evaluation Criteria in Solid Tumors (RECIST),
4649,NCT02323906,Dose-Limiting Toxicity (DLT),2015-01-16,TERMINATED,INTERVENTIONAL,['PHASE1'],Time to progression (TTP),
4650,NCT03407040,Availability of stored specimens and/or data,2018-01-30,TERMINATED,OBSERVATIONAL,['NA'],,
4651,NCT01047111,Disease free survival,2010-05,COMPLETED,INTERVENTIONAL,['NA'],Locoreginal recurrence and recurrence pattern,
4652,NCT06088459,All adverse events (AE),2023-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Immunogenicity,
4653,NCT04083378,Impact of software use on the minimal margins of ablated lesions properly covered by ablation on a three-dimensional analysis,2020-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Liver function,
4654,NCT05876338,Change from Baseline in Quality of Life Level on the EORTC QLQ-CR29 Quality of Life,2023-07-11,RECRUITING,INTERVENTIONAL,['NA'],,
4655,NCT03425058,"The concordance and accuracy of response evaluation results determined by ctDNA, CTCs compared with imaging and serum tumor biomarkers(CEA, CA19-9,CA72-4 et al)",2017-11-22,COMPLETED,OBSERVATIONAL,['NA'],The concordance of mutations in tumor tissue and ctDNA,
4656,NCT01862003,Best overall response,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Occurrence and Severity of Adverse Events,
4657,NCT00023868,,2001-11-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,
4658,NCT02288195,Local-regional failure-free survival,2014-08-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Rate of receiving pre-operative or post-operative chemoradiation,
4659,NCT01819766,Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],Determine Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC and HGD.,
4660,NCT01053182,morbidity of postoperative pulmonary complications,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],"diaphragm movement, pulmonary function, stomach emptying",
4661,NCT00296114,,2004-02,COMPLETED,OBSERVATIONAL,['NA'],,
4662,NCT00630045,disease free survival rate,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],response rate and safety of XELOX as a neoadjuvant regimen,
4663,NCT00107861,- Evaluate the safety of a single IV administration of Ad.hIFN-β.,2005-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Explore preliminary clinical activity.,
4664,NCT02633098,Recurrence free survival at 2 years,2017-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins),
4665,NCT05333809,Objective response rate (ORR),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
4666,NCT06178848,frontal spectral power,2023-06-26,COMPLETED,INTERVENTIONAL,['NA'],Riker sedation-agitation score,
4667,NCT01003015,Adverse Event Collection,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Full Pharmacokinetics profile of BAY73-4506 and metabolites (for Korea only),
4668,NCT02407392,"Feasibility as assessed by the ratio of patients approached to recruited, percentage of patients who complete both endoscopies",2015-07,UNKNOWN,INTERVENTIONAL,['NA'],Number of adverse events,
4669,NCT01263353,Evaluate safety and tolerability profile of pasireotide LAR in combination with everolimus in patients with advanced metastatic NET,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],"To assess the biochemical response (chromograninA, CgA) to pasireotide LAR in combination with everolimus",
4670,NCT05577143,Area under the ROC curve (AUC) of the TFPI-1 biomarker,2022-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Extension of c-index to the 3-group case proposed by Van Calster B et al.,
4671,NCT05993923,Change in functional status after colorectal cancer surgery between groups,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The rate of early unscheduled re-hospitalizations or admissions to the emergency department between groups,
4672,NCT04930991,Safety and Tolerability,2021-09-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Correlation,
4673,NCT00622557,,2007-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
4674,NCT01281943,Progression free survival (PFS),2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Polymoprhism assessment,
4675,NCT00894725,short-term morbidity rate,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3'],long-term outcome,
4676,NCT05687552,comparison of pet -ct finding with ct finding,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4677,NCT04518852,overall survival (OS),2020-09-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],duration of response,conversion rate of hepatectomy
4678,NCT05394714,Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D),2022-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in Biomarkers (CEA and CA19-9),
4679,NCT06061744,recurrence,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
4680,NCT00093379,2 Year Failure Free Survival,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Progression-Free Survival at 2-Year,
4681,NCT05110378,Oxford NOTECHS II,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,
4682,NCT02727153,Mortality,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Readmission rate,
4683,NCT00899626,Development of new screening strategies based on substances found in tissue and biofluid samples,2002-06,RECRUITING,OBSERVATIONAL,['NA'],,
4684,NCT00489515,Ability of surgically defined sentinel lymph nodes to predict whether other lymph nodes are involved with the tumor,1999-02,COMPLETED,OBSERVATIONAL,['NA'],,
4685,NCT01617278,Mean number of adenomas per colonoscopy,2012-01,COMPLETED,INTERVENTIONAL,['NA'],To estimate the recruitment rate,
4686,NCT05639153,"Part 2: Number, severity and duration of treatment-emergent adverse events (TEAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0",2022-05-13,RECRUITING,INTERVENTIONAL,['PHASE1'],Immunogenicity by measurement of Incidence of anti-drug antibodies (ADA),
4687,NCT00884767,"Correlation of genetic profiles and peptide, protein, and neurotrophic factors with neurological toxicity",2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4688,NCT00121914,time to tumour progression,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],causes of death,
4689,NCT02613156,Perioperative complications,2014-06,COMPLETED,OBSERVATIONAL,['NA'],relapse-free survival,
4690,NCT00539253,Nodule Enhancement,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
4691,NCT02706184,Common toxicity criteria for diarrhea Version 4.0,2015-07,COMPLETED,INTERVENTIONAL,['PHASE3'],ECM/BCM-Index,stool microbiome analyses
4692,NCT05523778,Rate of POPF within 3 months after EN.,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],Total cost of hospitalization,
4693,NCT05464875,Duration Of Response,2022-07-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Vd（volume of distribution）,Assessment of dose effect of antineoplastic agents
4694,NCT03317119,"Maximum tolerated dose defined for the combination of trametinib, and Trifluridine and Tipiracil Hydrochloride (TAS?102) as the highest dose level at which 0-1 out of 6 patients experience dose limiting toxicities",2018-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,
4695,NCT05751265,Objective Response Rate (ORR),2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-free survival,
4696,NCT05609396,Uptake,2022-05-03,COMPLETED,INTERVENTIONAL,['NA'],"Uptake by deprivation, sex and age",
4697,NCT04811898,The recommended phase II dose of LNA-i-miR-221 (RP2D),2019-01-14,COMPLETED,INTERVENTIONAL,['PHASE1'],To assess the efficacy of LNA-i-miR-221,
4698,NCT00786058,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
4699,NCT02328716,disease-free survival period,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],Study of Ex vivo correlation.,
4700,NCT02818530,Changes in anterior chamber depth measured by ultrasound.,2017-06-21,TERMINATED,INTERVENTIONAL,['NA'],Time dependent changes in anterior chamber depth during prolonged trendelenberg position.,
4701,NCT01681446,disease free survival,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of Participants with Adverse Events,
4702,NCT00224692,Pain score,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,
4703,NCT02425683,Number of Patients Completing Full 6 Cycles,2015-03-26,TERMINATED,INTERVENTIONAL,['PHASE2'],Disease-free survival (DFS),
4704,NCT00152217,Overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3'],"Relapse-free survival, adverse events",
4705,NCT05994456,Pathological complete remission (pCR) rates,2023-03-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Related Adverse Events,
4706,NCT02587793,survival,2014-10,COMPLETED,OBSERVATIONAL,['NA'],cancer progression,
4707,NCT01262417,abdominal and peri-hepatic adhesion during the second operation,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],tumour evolution in patients,
4708,NCT02931929,"Preliminary targeting properties of 68Ga-NeoBOMB1 in advanced, GRP positive GIST tumours as assessed by SUV",2016-11-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To extrapolate absorbed tumour doses for potential application of 177Lu NeoBOMB1 (in first 6 patients),
4709,NCT03085004,Incidence of serious and minor adverse events occurring within 30 days post ablation,2019-04-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,
4710,NCT00411762,Median Progression Free Survival,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median Overall Survival,
4711,NCT02816879,Accuracy of cytology specimens for Dacron swab compared to flocked nylon (NF) swab in predicting histology outcome,2013-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"Cost effectiveness analysis evaluating differences in survival, the cost of out-patient procedures & in-patient hospitalizations for invasive anal cancer.",
4712,NCT06135571,Metastatic rate of No.253 lymph node,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],5-year overall survival rate,
4713,NCT03130621,Pedigree analysis,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],somatic mutation landscape of hereditary upper gastrointestinal cancer,
4714,NCT03848182,Change in CD4 T cell responses after TT booster vaccine,2017-07-21,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in CD8 T cell responses after TT booster vaccine,Change in myeloid-derived suppressor cells
4715,NCT00630240,"The blood levels of anticancer drugs (epirubicin, mitomycin C and cisplatin) will be determined within one hour and at the third day after TACE.",2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
4716,NCT02717923,Progression-Free Survival of maintaining treatment（mPFS）,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4717,NCT04030637,Accuracy of COLOSAFE,2019-02-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4718,NCT00973193,Pathological Complete Response (pCR),2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],"Safety, pathologic R0 resection, negative Circumferential Resection Margin, pathologic downstaging, tumor regression grade, quality of mesorectal excision, rate of sphincter-preservation, Disease-Free Survival, local control rate, translational research",
4719,NCT01251458,• To establish the maximum tolerated dose (MTD) and a suitable dose for Phase II evaluation of Torisel® given as a weekly dose in patients with advanced hepatocellular carcinoma (HCC),2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",• To determine overall survival (OS),
4720,NCT02210039,Number of Participants With Tolerability of the Procedure,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,
4721,NCT02607787,Feasibility,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],Capillary blood sample,
4722,NCT02404753,3-year progression-free survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Postoperative quality of life,
4723,NCT03231462,Pulmonary complications,2015-03-06,RECRUITING,OBSERVATIONAL,['NA'],The change of symptom,
4724,NCT02859415,Number of Participants Whose Best Response is a Complete Response (CR) or Partial Response (PR),2019-08-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","To Develop Methodologies for Assessing Effects of Mithramycin on Cancer Stem Cells, Hematopoietic Stem Cells, Mesenchymal Stem Cells, and Circulating Tumor Cells (CTC)",Number of Participants With a Dose-limiting Toxicity (DLT)
4725,NCT00594113,CRC screening completion,2007-08,COMPLETED,INTERVENTIONAL,['NA'],"PAPM stage and perceived barriers among participants preferring various screening methods (iFOBT, Colonoscopy)",
4726,NCT01128387,MTD of Panitumumab in Combination With Cisplatin/Fluorouracil and Radiation for Locally Advanced Esophageal Cancer Determined by Number of Participants Experiencing DLT,2010-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pathologic Response,
4727,NCT03039608,the time when stricture occurs,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],the frequency of complications,
4728,NCT00598247,RECIST Response,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Toxicity,
4729,NCT01023529,Effect on patient's target symptom.,2009-11,COMPLETED,OBSERVATIONAL,['NA'],Time to improvement in patient's symptoms and QoL.,
4730,NCT05728606,Total incidence of postoperative complications,2023-01-20,RECRUITING,INTERVENTIONAL,['NA'],Robotic surgical completion rate,
4731,NCT01937104,ONSD and PaCO2,2013-09,COMPLETED,INTERVENTIONAL,['NA'],ONSD and PaCO2,ONSD and PaCO2
4732,NCT01624025,disease control rate according to the RECIST v1.1,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4733,NCT01962376,progression-free survival(PFS),2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],Objective response rate (ORR),Adverse events
4734,NCT00201318,"We expect to enter 33 patients per year. Taking into account 10﹪dropout rate, we may finish accrual of patients within 3 years.",2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4735,NCT01740375,2-year disease-free survival (DFS) rate,2012-11,TERMINATED,INTERVENTIONAL,['PHASE3'],treatment-related mortality,
4736,NCT04653181,postoperative complications,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],Need for red blood cell transfusion,
4737,NCT02175914,CT and MRI imaging for desmoids,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
4738,NCT04885439,Patient and Caregiver Anxiety,2015-07-01,COMPLETED,INTERVENTIONAL,['NA'],Patient Symptom Burden,
4739,NCT05555888,complete response (CR) rate,2022-12-12,RECRUITING,INTERVENTIONAL,['PHASE2'],10 year Quality of Life,
4740,NCT04969107,disease-specific survival,2012-01-01,RECRUITING,INTERVENTIONAL,['NA'],recurrence-free survival,
4741,NCT05616039,Clinical outcomes- Microscopic positive resection margin rate,2022-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Complications,
4742,NCT05854394,6-minute-walking-distance (6MWD),2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],Quality of Life Scale,
4743,NCT05904886,Overall Survival (OS),2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab,
4744,NCT01730937,Overall Survival,2013-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality Adjusted Life Years,
4745,NCT01996969,Predictive biomarker in terms of disease control rate,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Assessment of adequate response evaluation modality after regorafenib treatment,
4746,NCT01669720,Number of Patients Who Progressed,2012-12,TERMINATED,INTERVENTIONAL,['PHASE2'],"Number of Participants Who Experienced a Toxicity Profile of Adjuvant Ziv-aflibercept, up to 2-years of Duration, for Patients Who Previously Received Systemic Perioperative Therapy (Regimen) and Surgical Resection/Ablation.",
4747,NCT02576184,radiological incisional hernia rate,2015-12,COMPLETED,INTERVENTIONAL,['NA'],Clinical incisional hernia rate,
4748,NCT01418742,"Time until unblinding of skin therapy allocation (basic skin treatment with or without doxycycline) due to insufficient efficacy (i.e. unbearable skin toxicity, measured by patient's allocating point 6 through 10 on a visual analogue scale)",2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Severity of panitumumab related adverse events,
4749,NCT00075595,Time to death from progression,2002-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of grade 3 or 4 toxicity,
4750,NCT06196658,Objective Response Rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],5) Volume of ascites measured by ultrasonography and/or frequency and volume of ascites aspiration,
4751,NCT03253107,Discovery of predicting bio-markers for gastric cancer chemotherapy response,2015-11-30,RECRUITING,OBSERVATIONAL,['NA'],Combination prediction model for palliative chemotherapy response in gastric cancer,
4752,NCT05655494,Proportion of patients who self-refer to cancer clinical trials,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Mediators of intervention effectiveness,
4753,NCT05113290,Objective response rate (ORR) according to mRECIST criteria,2021-12-28,UNKNOWN,INTERVENTIONAL,['PHASE4'],Number of participants with adverse events,
4754,NCT04141566,Specific Quality of life of patients with PCPC and PLIC,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],90 day morbidity and mortality rate,
4755,NCT01671891,circulating tumor cells level changes after radiotherapy,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],RECIST-based tumor response at 10 week after radiotherapy,
4756,NCT01457287,Cognitive Function,2003-10,COMPLETED,OBSERVATIONAL,['NA'],Potential mechanisms leading to fatigue and/or cognitive decline,
4757,NCT02065037,Polyp Detection Rate,2014-06,TERMINATED,INTERVENTIONAL,['NA'],advanced lesion per patient detection rate,patient comfort by a validated nurse administered comfort score
4758,NCT00009893,survival at 6 months,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],tumor response rate,
4759,NCT05914987,Number of Subjects Receiving Targeted Therapy,2023-12-04,RECRUITING,OBSERVATIONAL,['NA'],,
4760,NCT04677088,Safety evaluation of the TCR-T treatment,2018-03-29,UNKNOWN,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
4761,NCT04980157,Colorectal Cancer Screening Status,2021-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
4762,NCT01544452,Synchronous colon cancers and liver metastasis,2010-08,TERMINATED,INTERVENTIONAL,['NA'],sensitivity/specificity of CT versus MR versus Peroperative ultrasonography of the liver,
4763,NCT03748485,disease free survival,2019-04-30,RECRUITING,INTERVENTIONAL,['NA'],complication in 30 days post surgery,
4764,NCT02808780,"Long-term Safety: Participants with Adverse Events of Interest (AEIs) and Serious Adverse Events (AEs) Including Malignancies, Pregnancies, and Non-serious Malignancies",2016-12-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Health Care Utilization: Evaluate the Reasons for Hospitalization in Participants in Each Cohort,
4765,NCT03006926,DLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIR,2017-02-13,COMPLETED,INTERVENTIONAL,['PHASE1'],DLT+Expansion Part: Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status,
4766,NCT02191969,To measure the change in fatigue after three months between the intervention and control arm,2014-06,COMPLETED,INTERVENTIONAL,['NA'],To measure changes in Self-Efficacy at baseline between the intervention and control groups.,
4767,NCT00651677,operative time,2011-04,WITHDRAWN,INTERVENTIONAL,['NA'],urinary and sexual function,
4768,NCT03544255,Number of organoids successfully generated from pancreatic cancer biopsies,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],Response of the pancreatic cancer organoids to the selected anti-cancer drugs,
4769,NCT02298907,Oxygen uptake at lactate threshold,2010-06,COMPLETED,OBSERVATIONAL,['NA'],Number of patients with adverse post-operative outcome measures,
4770,NCT06307314,Different grades radiotherapy-induced oral mucositis,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],Tumor response,
4771,NCT05419011,"Cumulative incidence rate of the composite endpoint of adenomas (tubular, tubulovillous and serrated), advanced adenomas and colon cancer",2023-03-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of extracolonic neoplasms,Immune cell gene enrichment analysis
4772,NCT03221335,Severe adverse events,2016-05,RECRUITING,INTERVENTIONAL,['NA'],Survival,
4773,NCT03276156,Incidence of adverse events,2016-02-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],Quality of life(QoL),
4774,NCT04336241,Recommended Phase 2 dose (RP2D) of RP2,2019-10-17,RECRUITING,INTERVENTIONAL,['PHASE1'],Percentage of stable disease (SD),
4775,NCT02512263,Muscular strength measured by Microfet,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],Depression measured by questionnaire,
4776,NCT01883336,Progress of pancreatic cyst,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
4777,NCT05752890,To distinguish the clonality of recurrent HCC as the original or a de novo one for post-radiotherapy patterns of failure,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4778,NCT06046846,To investigate the usability in terms of user satisfaction of the asensei app to deliver a mHealth prehabilitation programme.,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],To collect preliminary data and assess for change on a participants quality of life by using the EORTC QLQ-OG25 questionnaire in order to inform the sample size for a fully powered RCT as part of the feasibility study.,Semi structured interviews
4779,NCT04160897,The 5-year cumulative incidence of hepatocellular carcinoma,2019-10-22,UNKNOWN,OBSERVATIONAL,['NA'],The 5-year cumulative liver disease-related mortality,
4780,NCT01618474,disease free survival,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],CTC negative conversion rate,
4781,NCT03126071,PFS,2017-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],AEs,
4782,NCT00734890,Toxicity,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4783,NCT02549755,To Compare Changes in 11C-acetate Uptake at One and Three Months Following Radiotherapy With Pre-treatment Uptake of 11C-acetate,2015-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4784,NCT00161213,Progression-free Survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
4785,NCT05205187,Response of target organ,2022-02-28,RECRUITING,OBSERVATIONAL,['NA'],,
4786,NCT03319459,Incidence of dose-limiting toxicity (DLT),2018-01-18,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (PK) of FATE-NK100,
4787,NCT03496441,Evaluate the feasibility of fecal samples' analysis,2018-01-30,COMPLETED,OBSERVATIONAL,['NA'],Evaluation the presence of a correlation between fecal microbiota composition and the risk of anastomotic leak.,
4788,NCT04192071,Information seeking behavior,2020-01-06,RECRUITING,INTERVENTIONAL,['NA'],,
4789,NCT03554434,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
4790,NCT06250075,The use of probiotics can modify the incidence of postoperative complications,2020-12-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Modulation of nutritional parameters using probiotics-phase angle,
4791,NCT04506983,Percentage of adverse events,2022-06-10,SUSPENDED,INTERVENTIONAL,['PHASE1'],Proliferation ratio of CAR-T cells,
4792,NCT01082224,Sensitivity of contrast-enhanced CT scan vs contrast-enhanced MRI for diagnosing hepatocellular carcinoma (HCC),2010-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Diagnostic value of sensitivity and PPV when patients are stratified by AFP level (elevated vs normal),
4793,NCT05358249,PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1,2022-10-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II: Dose intensity by treatment,
4794,NCT01234246,,2010-03,UNKNOWN,OBSERVATIONAL,['NA'],,
4795,NCT01962246,Disease-free survival(DFS),2012-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Death related to operation,
4796,NCT00385203,"Tumour Metabolic Activity as Assessed by Change in Central Review of Standardised Uptake Value (SUVMax) at Day 29, in Patients With GIST Tumours. SUVmax at Day 29 Minus SUVmax at Baseline.",2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Anti-tumour Activity as Measured by Total Lesion Volume at Week 16 in GIST Patients by Central Review of CT Images.,
4797,NCT00511576,To determine the overall tumor response of orally administered MGCD0103 in combination with IV docetaxel according to Response Evaluation Criteria in Solid Tumors (RECIST) methodology.,2007-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,
4798,NCT03500757,Standard System Usability Score on a Likert Scale,2018-04-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
4799,NCT03472833,25(OH) vitamin D,2018-04-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Quality of Life questionnaire,
4800,NCT00006009,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4801,NCT03429816,Aim 2: Correlation of molecular subtypes with histological response after neoadjuvant therapy in patients,2018-04-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Aim 2: Correlation of molecular subtypes with relapse-free survival,Aim 2: Correlation of molecular subtypes with overall survival
4802,NCT00988195,"Plasma arginase and arginine levels,as well as tumour response, i.e. an effect on growth in the milieu of arginine depletion.",2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],"Overall Survival, Time to Progression",
4803,NCT00164892,Recurrence free survival and the quality of life score within the two years of study period,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Overall survival in long term,
4804,NCT03963726,PFS,2019-06-03,UNKNOWN,INTERVENTIONAL,['NA'],Quality of life score of tumor patients(0-60),
4805,NCT02592603,Number of serrated lesions >=5mm,2015-10,COMPLETED,INTERVENTIONAL,['NA'],Proportion of minor adverse events,
4806,NCT01460589,3-year disease free survival rate,2011-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],side effects of chemotherapy,
4807,NCT01972373,Sensitivity of the marker bevacizumab-IRDye800CW,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Collection of safety regarding administration of Bevacizumab-IRDye800CW,
4808,NCT02336724,Disease Control Rate,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
4809,NCT00507273,Current patterns of medical practice in management of patients with GIS,2005-08,COMPLETED,OBSERVATIONAL,['NA'],,
4810,NCT01071824,Pouch function 4 month after closure of protective ileostomy.,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],Pouch function 2 and 12 month respectively after closure of protective ileostomy.,
4811,NCT05739110,Overall survival,2022-07-15,COMPLETED,OBSERVATIONAL,['NA'],Disease-free survival,
4812,NCT01211561,Reduction in ACF biomarkers,2010-12,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
4813,NCT04172532,Progression-free survival rate (Phase II),2021-01-11,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Gene signature of tumor,Gene signature of cell-free DNA from peripheral blood
4814,NCT01938326,Maximum pain score using VAS at postoperative day#1,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],EORTC-C30 and STO22,
4815,NCT03115957,Morbidity of infection,2017-04-14,COMPLETED,INTERVENTIONAL,['NA'],Laboratory examination,
4816,NCT04058236,Changes in serum heparan sulfate concentrations,2019-08-15,UNKNOWN,INTERVENTIONAL,['PHASE4'],Changes in levels of Inflammatory markers Interleukin-1 and CRP,
4817,NCT03043313,Confirmed Objective Response Rate (cORR) Per RECIST 1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B,2017-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry),
4818,NCT01834014,To evaluate the values of angiogenesis-related growth factors in plasma with Progression-free survival (PFS),2013-05,COMPLETED,INTERVENTIONAL,['NA'],Exploratory analysis of the relevance of tumor size and expression level of angiogenesis-related growth factors in plasma,
4819,NCT06164769,blood loss,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,
4820,NCT00867724,Ability to screen the entire length of the colon to the cecum.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],"Safety endpoints to include incidence of bowel perforation, Colonic bleeding, Damage to colon, rectum and anus mucosa or any other Adverse events",
4821,NCT04372992,Percentage of participants with good compliance to adjuvant therapy,2020-09-01,TERMINATED,INTERVENTIONAL,['NA'],Costs analysis,
4822,NCT02138929,"Maximum Tolerated Dose (MTD) of LDE225 in Combination with Everolimus in Participants with Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction (GEJ) or Stomach in the Second or Third Line Setting",2014-11-10,COMPLETED,INTERVENTIONAL,['PHASE1'],"Safety of LDE225 in Combination with Everolimus in a Cohort of Participants with Metastatic Nuclear Gli-1 Expressing Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach per CTCAE.",
4823,NCT04246203,DFS,2021-12-12,RECRUITING,OBSERVATIONAL,['NA'],,
4824,NCT00094809,Grade 4 Neutropenia,2003-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Antibiotic Use Due to Febrile Neutropenia,
4825,NCT00451022,To facilitate the continuous usage of stored research specimens collected from subjects under completed and ongoing protocols.,2004-09-13,RECRUITING,OBSERVATIONAL,['NA'],,
4826,NCT02800330,"As primary endpoint, AUC of regorafenib alone and AUC of regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake, respectively) will be related.",2016-05,COMPLETED,INTERVENTIONAL,['PHASE4'],The clearance of regorafenib alone and regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake respectively) will be related,
4827,NCT05817201,Overall survival,2022-07-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Progression-Free survival,
4828,NCT00613743,difference of pain alleviation in the two branches one hour after mouthwash and as well as the duration of pain relief.,2007-12,COMPLETED,INTERVENTIONAL,['NA'],the requirement of supplementary systemic analgesics,
4829,NCT00131599,,2002-08,UNKNOWN,OBSERVATIONAL,['NA'],,
4830,NCT05280379,Levels of pro-inflammatory cytokines en chemokines,2022-09-19,RECRUITING,OBSERVATIONAL,['NA'],,Carcino-embryonal antigen
4831,NCT00010270,,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
4832,NCT00982059,The proportion of screened patients with any polyp or any high risk polyp will be calculated.,2008-05,COMPLETED,OBSERVATIONAL,['NA'],Proportion calculation/identification of: demographic/treatment influences on polyp prevalence; subgroups w/polyp prevalence >20%; pts with polyps beyond 30cm flexible sigmoidoscope; pts with adenomatous polyp(s) on colonoscopy in/outside prior RT fields,
4833,NCT01640665,Maximum Tolerated Dose / Safety,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Response,
4834,NCT02915965,overall survival rate,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of adverse event based on CTCAE 4.0,
4835,NCT05638048,Incidence of Peripheral central venous catheter-associated thrombosis in patients with PICC tube,2022-07-10,COMPLETED,INTERVENTIONAL,['NA'],Patients' satisfaction with health education after PICC catheterization,
4836,NCT00525785,Complete Pathologic Response Rate,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4837,NCT04622098,Estimating the prevalence and types of sub-epithelial lesions among patients undergoing EGDs in Egypt.,2020-11-18,UNKNOWN,OBSERVATIONAL,['NA'],characterization of SEL in Egypt,
4838,NCT02399943,"Percentage of patients who experience complete response, partial response, or stable disease",2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Date of first confirmed response to the first date in which progression is observed,
4839,NCT06089369,Recurrence-Free Survival (RFS) at 24 Months,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score,
4840,NCT01129206,Overall Response,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Correlation of FDG PET Response With Response Rate,
4841,NCT05987514,predicting HCC response to treatment,2021-10-07,RECRUITING,INTERVENTIONAL,['NA'],predicting disease-free survival,
4842,NCT03412994,Progression-free survival (PFS),2018-02-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life(QoL),
4843,NCT05686499,ratio of low-fidelity simulator trained endoscopists with improved colonoscopy performance on real patients to high-fidelity simulator trained endoscopists with improved performance on real patients,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
4844,NCT04555265,Early tumor recurrence,2020-09-01,COMPLETED,INTERVENTIONAL,['NA'],Other tutor recurrence,
4845,NCT05880472,Number of adverse event per patient per grade by CTCAE v5.0,2023-05,RECRUITING,INTERVENTIONAL,['NA'],Operator hand and total body dose (mSv),Implantation experience by questionnaire to the operator
4846,NCT01838317,Glucose to Insulin Ratio,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in Serum and MRI End Points,
4847,NCT04358354,Overall Survival (OS),2020-10-22,RECRUITING,INTERVENTIONAL,['PHASE3'],Treatment associated toxicities,
4848,NCT00994864,"Examine the predictive value of PET-assessed tumour FDG uptake response after one course of preoperative chemotherapy on the outcome of adjuvant therapy, measured by 3-year DFS.",2009-11,COMPLETED,INTERVENTIONAL,['NA'],Create a frozen tumour bank for future studies,
4849,NCT04595838,The incidence of severe oral mucositis symptomatic events observed during the second cycle of chemotherapy.,2020-08-31,COMPLETED,INTERVENTIONAL,['NA'],Analgesic use to control mouth pain,
4850,NCT04736121,Duration of Response (DoR),2021-05-28,RECRUITING,INTERVENTIONAL,['NA'],Quality of life metrics - EQ-5D-5L Questionnaire,
4851,NCT02988635,Functional Assessment of Cancer Therapy-General (FACT-G) (Quality of life measure),2014-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Resource utilization at the end of life (EOL): emergency room admissions,
4852,NCT00449163,Overall Survival up to 2 Years,2006-03-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Rate of Toxicity in Study Participants,
4853,NCT00882869,To evaluate the efficacy of AEG35156 in combination with sorafenib based on PFS(PII) using sorafenib alone for comparison,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To determine the response rate of AEG35156 in combination with sorafenib in advanced HCC,
4854,NCT01560949,Number of Participants With Resectability Rate,2012-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Correlative Studies Including DPC4 (SMAD4) Staining and Circulating Tumor Cells (CTC) Post-Surgery,
4855,NCT00758381,Progression Free Survival,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],- overall Response Rate (RECIST Criteria) - duration of response - overall survival time,
4856,NCT03499626,Definition of MTD (maximum tolerable dose),2017-05-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression Free Survival,
4857,NCT02074202,The pathological diagnosis of the liver tumor will be compared with the test result of the PET/CT scan findings.,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
4858,NCT02845986,overall postoperative morbidity rates,2016-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],The variation of prealbumin,
4859,NCT02415699,Disease free survival,2015-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Side Effect,
4860,NCT02526043,Overall survival,2015-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Incidence of postoperative complications,
4861,NCT01697072,Overall Survival,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Immunogenicity,
4862,NCT00983801,Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST),2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serum Chemistry Abnormalities,Number of Participants With Best Response as Assessed With Modified RECIST
4863,NCT06084234,Proportion of HCC detected at late stage,2023-12-26,RECRUITING,INTERVENTIONAL,['PHASE4'],Number of participants who encountered screening related Psychological harm,
4864,NCT04514497,Occurrence of grade 4 hematologic AEs (Dose Expansion Phase),2021-10-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in tumor expression patterns of pS343-NBS1,Tumor deoxyribonucleic acid damage response (DDR) gene mutations present
4865,NCT02961998,Incidence of participants with clinically definite Sorafenib-related Hand Foot Syndrome,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Overall survival,
4866,NCT02499939,Functional Assessment of Cancer Therapy Gynecological Oncology Group Neurotoxicity-12 item scale,2016-02-10,COMPLETED,INTERVENTIONAL,['NA'],Balance Assessment,
4867,NCT00062283,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4868,NCT01442324,Effectiveness of IRE for the treatment of metastatic liver cancer or cholangiocarcinoma.,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],Time to in situ recurrence,
4869,NCT05621707,Overall Survival Rate,2022-11-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment related complications,
4870,NCT00593073,Baseline assessment while waiting to see primary care physician and 90-day follow-up telephone survey.,2005-07,COMPLETED,INTERVENTIONAL,['NA'],Follow-up survey to assess participant discussion of colorectal cancer with their healthcare provider and compliance with CRC screening,
4871,NCT05277675,1-year overall survival,2021-11-01,UNKNOWN,INTERVENTIONAL,['NA'],immune-related adverse events,
4872,NCT01601808,Overall survival,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Patient pain assessment,
4873,NCT03665714,Change of Serum Prealbumin level,2018-10-23,COMPLETED,INTERVENTIONAL,['NA'],Incidence of postoperative Infections,
4874,NCT03274427,Progression-free Survival,2017-07-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],quality of life,
4875,NCT01984658,Safety and tolerability,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Efficacy; Tumor change,Safety & efficacy; Quality of life
4876,NCT02451384,the changes of CTCs countings between the pre and post-operation among the arms,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],,
4877,NCT02999217,Changes in haemoglobin level,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],Duration of hospital stay,
4878,NCT06149546,Effectiveness of a multi-modal nutrition-led intervention in preventing loss of muscle strength (hand-grip strength) during chemotherapy,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Effectiveness of the intervention compared to the control on Overall Survival,
4879,NCT00398333,"To assess the efficacy of a nutritional intervention with supplementation enriched in EPA to improve the tolerance to the antineoplastic treatment, using the variation in quality of life changes as the tolerability index.",2005-06,TERMINATED,INTERVENTIONAL,['PHASE4'],To assess the effect of a nutritional supplement over the nutritional status of the patient with disseminated neoplastic illness.,
4880,NCT05708924,Determine Maximum Tolerated Dose (MTD) of FT538,2023-04-28,SUSPENDED,INTERVENTIONAL,['PHASE1'],Adverse Events,Tumor biopsies (if feasible) at the time of catheter placement and catheter removal for study related analysis
4881,NCT02448966,Long term survival,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],Postoperative complications,
4882,NCT02157974,Hepatic glucose release,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Hepatic de novo lipogenesis,Bile Acid Metabolomics: sphingosine-1-phospate
4883,NCT00436514,,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,
4884,NCT05368051,pathologic complete response（pCR）,2021-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
4885,NCT03925883,Rate of follow-up colonoscopy,2019-07-29,COMPLETED,INTERVENTIONAL,['NA'],,
4886,NCT01624090,Number of Participants With an Objective Response (Complete Response + Partial Response),2012-09-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-Serious Adverse Events,
4887,NCT04692545,Length of hospital stay,2016-12-01,COMPLETED,OBSERVATIONAL,['NA'],Prolonged length of stay,
4888,NCT05022030,Progression free survival (PFS) rate at 9 months,2021-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse event rate,
4889,NCT06181201,histological response according to Ryan classification,2024-01-19,RECRUITING,OBSERVATIONAL,['NA'],,
4890,NCT01583699,Qualitative MALT-features on Endomicroscopy,2012-04,COMPLETED,INTERVENTIONAL,['NA'],Sensitivity and Specificity of Endomicroscopy to diagnose GI-MALT-Lymphoma,
4891,NCT05334069,Provision of blinded reference set of cancer versus non-cancer blood samples,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],Test performance at the time of initial cancer diagnosis by clinical stage,
4892,NCT04292496,Anastomotic leakage,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],Postoperative surgical complications,
4893,NCT04206254,2-year recurrence-free survival rate,2019-12-19,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall survival,
4894,NCT04667403,Satisfaction of patients with advanced or metastatic pancreatic cancer of the impact of telemedicine in the management of their pain.,2022-02-07,UNKNOWN,INTERVENTIONAL,['NA'],Number of unscheduled hospitalizations recorded of each patient.,
4895,NCT00002655,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4896,NCT05327452,Change in Physical Activity Participation,2022-10-31,RECRUITING,INTERVENTIONAL,['NA'],Biomarkers for Cardiovascular and Metabolic Health - c-reactive protein,
4897,NCT05118724,Disease-free Survival (DFS),2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
4898,NCT05617430,Progression free survival (PFS) per RECIST v1.1,2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
4899,NCT00124163,,2005-07,UNKNOWN,OBSERVATIONAL,['NA'],,
4900,NCT02230553,overall response rate,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
4901,NCT01347697,Performance in Timed-Stands Test,2011-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Local recurrence,
4902,NCT01196494,,na,TERMINATED,INTERVENTIONAL,['NA'],,
4903,NCT03422601,disease-free survival (DFS),2017-07-13,UNKNOWN,OBSERVATIONAL,['NA'],,
4904,NCT01464918,Total time taken to complete the ESD procedure,2011-11,UNKNOWN,INTERVENTIONAL,['NA'],Safety,
4905,NCT00077298,Time to tumor progression,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
4906,NCT02647671,Colonic-mucosal Associated Metabolomic Profile.,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Biomarkers of liver function,
4907,NCT03890354,Post operative compliction,2019-02-21,COMPLETED,OBSERVATIONAL,['NA'],Surgical outcome,
4908,NCT00524121,Overall Survival,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Response by EGFR Mutation Status,
4909,NCT02460822,Patient Satisfaction and Usability of the MyChemoCare Application,2014-10,COMPLETED,INTERVENTIONAL,['NA'],Improved Quality of Life,
4910,NCT05969899,Objective Response Rate（ORR）,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate（DCR）,
4911,NCT05175092,Overall Survival (OS),2023-11,WITHDRAWN,INTERVENTIONAL,['NA'],Quality of Life Survey Score: EORTC QLQ-LMC21,
4912,NCT06009484,Postoperative venous thromboembolic event,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4913,NCT05453435,12-month HBV reactivation rate,2022-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of HBV-related chemotherapy disruption,
4914,NCT06252545,The clinical trial education and communication needs,2024-02-02,RECRUITING,INTERVENTIONAL,['NA'],,
4915,NCT04461561,"The NoMAD Instrument, to describe respondents' experiences of using the intervention in the workplace.",2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],"The interview, using framework analysis, informed by normalization process theory toolkit",
4916,NCT04847063,To determine the correlation between ex vivo simulated HIPEC in the SMART system and in vivo HIPEC with respect to two measures of response to treatment: percent necrosis and Ki-67,2021-10-19,RECRUITING,INTERVENTIONAL,['PHASE1'],To measure Quality of Life by FACT-C and EQ-5D-5L,
4917,NCT00049296,"Determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-Hodgkin's lymphoma.",2002-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4918,NCT00621036,Safety and tolerability,2007-10-19,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Kinetics of humoral immune response development,
4919,NCT02699606,Objective Response Rate (ORR),2016-07-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma Concentration of Erdafitinib,
4920,NCT02380443,To evaluate the anti-tumor effect of AlloStim combined with cryoablation at the new proposed dose and frequency schedule (Part 2),2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess change from baseline in Health-Related Quality of Life (HRQoL),"Immunological response 9whether immune response correlates with Overall Survival (OS), RECIST and histopathology)"
4921,NCT05524844,Correlation between Enterobacteriaceae (from 16S) and NOTCH3 expression in BE tissue.,2021-02-09,RECRUITING,OBSERVATIONAL,['NA'],,
4922,NCT04687631,Conversion resection rate of liver metastases,2021-01-14,RECRUITING,INTERVENTIONAL,['PHASE3'],time interval from chemotherapy to hepatectomy,
4923,NCT02239328,Patient Reported Outcomes Measurement Information System (PROMIS) Scores.,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,
4924,NCT00940316,Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD),2010-01-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect on Downstream Targets of Epidermal Growth Factor Receptor (EGFR) in Skin Rash Associated With Pharmacologic EGFR Inhibition,
4925,NCT01669668,"Local recurrence, defined as the recurrence at the size of original tumor",2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Ability of patients who develop recurrence to undergo salvage transplantation,
4926,NCT03089268,Risk of developing metachronous advanced lesions or cancers,2017-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Prevalence of serrated lesions in FOBT screening population,
4927,NCT03628079,Tumour response: CT/MRI assessed according to RECIST 1.1,2018-05-25,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in tumour load and TTP according to irRECIST,Association between S-mebendazole and efficacy and safety
4928,NCT01392027,Validation of glycoprotein panel as a pancreatic cancer biomarker,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,
4929,NCT01422928,Changes in immune biomarker levels,2010-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Changes in Symptom Scores,
4930,NCT00242502,Progression-free Survival (PFS) Rate,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4931,NCT05469061,pCR,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease-free Survival，DFS,
4932,NCT04787354,disease-free survival,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Toxicity profiles,
4933,NCT02276300,Safety and tolerability of HER2-derived peptide vaccination measured by clinical and chemical parameters.,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4934,NCT04033107,Progression-free survival,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v3.0,
4935,NCT03990532,Overall survival (phase II),2019-04-30,RECRUITING,INTERVENTIONAL,['NA'],1-year local progression-free survival,
4936,NCT01693861,Effect of chemotherapy on urinary excretion of modified nucleosides,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Identification of modified nucleosides as biomarkers for colorectal cancer
4937,NCT00003652,,1999-01-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4938,NCT05587387,Overall survival (OS 2),2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],Adverse event,
4939,NCT03828266,Abdominal Infection rate after colorectal surgery.,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Outcome of Abdominal Infection Treatment,
4940,NCT04512417,Progression-free Survival (PFS) per RECIST 1.1,2020-08-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],Failure mode,
4941,NCT03995017,Overall Response Rate (ORR),2020-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
4942,NCT04494945,Cascade screening rate among Lynch or HBOC positive carriers,2020-03-09,RECRUITING,INTERVENTIONAL,['NA'],,
4943,NCT02044224,Patient Satisfaction With Anaesthesia Technique,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Description of patient characteristics,
4944,NCT02693847,Proportion of patients who developed a first liver decompensation of cirrhosis during follow-up,2006-02,COMPLETED,OBSERVATIONAL,['NA'],All cause mortality,
4945,NCT05412576,The incidence of moderate to severe pain (NRS score≥4）during movement (i.e.deep breathing) 24 hours after surgery,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],Length of hospital stay,
4946,NCT04201730,The time to first flatus,2019-12-25,COMPLETED,INTERVENTIONAL,['NA'],Incidence of postoperative complications,
4947,NCT00193817,Overall survival,2005-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of Life,
4948,NCT01077869,Feasibility of FDG-PET in the evaluation of radiation-induced mucositis.,2010-01,TERMINATED,OBSERVATIONAL,['NA'],,
4949,NCT04915599,Change in Feasability Questionnaire (regarding Patient reported tolerance of cryotherapy with Cooral ®),2021-06-22,COMPLETED,INTERVENTIONAL,['NA'],Change in degree of acute OM up to 6 weeks after EOT,
4950,NCT05801666,Arts' Dumping Questionnaire,2023-02-10,RECRUITING,INTERVENTIONAL,['NA'],Medical charts and drug use.,
4951,NCT06286956,Assess that the use of the device meet the established functional requiremnt of allowing the removal of polyps,2021-04-19,RECRUITING,INTERVENTIONAL,['NA'],Assessment of anorectal continence,
4952,NCT03655223,Incidence Rates: Number of newborns who screen positive comparative to the whole sample,2018-10-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Impact of Screening: Semi-structured parent interviews.,
4953,NCT04181970,Percentage of patients with advanced GIST with available molecular status of KIT/PDGFR before initiating systemic therapy for advanced disease,2019-06-30,RECRUITING,OBSERVATIONAL,['NA'],Percentage of amputation,
4954,NCT01060423,Progression free survival rate,2010-02,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall survival,
4955,NCT03516448,OS （Overall Survival）,2016-03-24,UNKNOWN,INTERVENTIONAL,['PHASE3'],RFS(Recurrence Free Survival),
4956,NCT02205398,Incidence of Dose Limiting Toxicities (DLTs),2014-07-28,TERMINATED,INTERVENTIONAL,['PHASE1'],Progression Free Survival,
4957,NCT05822752,Best Overall Response (BOR) per Investigator,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
4958,NCT03196791,Number of Retrieved Lymph Nodes Per Participant,2017-10-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Intraoperative Blood Loss Amount,
4959,NCT04718038,Progression-free survival(PFS),2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],Safety,
4960,NCT00633334,"The first goal of this proposal is to collect cells from the peripheral blood, tumor draining lymph nodes and tumor infiltrating lymphocytes in patients with early or late stage gastrointestinal cancers.",2003-09,COMPLETED,OBSERVATIONAL,['NA'],"The second goal is to evaluate using novel proteomic, CellomicTM, and genomic techniques the serum and peripheral blood lymphocytes of these patients for protein, cellular changes and genetic markers that correlate with the presence of cancer.",
4961,NCT02570893,The overall survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],Scores of Quality of life,
4962,NCT00225745,To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls,2004-04,COMPLETED,OBSERVATIONAL,['NA'],To generate hypotheses for future studies and treatment based on the findings,
4963,NCT03895359,Time to Intrahepatic Progression,2019-05-27,RECRUITING,INTERVENTIONAL,['PHASE3'],Cost-benefit,
4964,NCT00034502,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4965,NCT06325267,Clinical characteristics of overall cohort by liver disease etiology,2010-01-01,RECRUITING,OBSERVATIONAL,['NA'],Risk factors of prognosis in overall cohort and different etiologies,
4966,NCT00711412,Determine Pathologic Complete Response,2006-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],Correlate Proteomic and Pharmacologic Characteristics With Prognosis and Response to Therapy.,
4967,NCT05174286,CRC Screening Uptake,2023-03-19,RECRUITING,INTERVENTIONAL,['NA'],Change in Life's Simple 7 Score (CVD Risk Screening Measure),
4968,NCT02164448,gas passing,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],sips of water time,soft diet time
4969,NCT04804956,Identification of mesorectal microbial biomarkers as prognostic factor for rectal cancer,2021-04-01,RECRUITING,OBSERVATIONAL,['NA'],Evaluation of mesorectal dysfunctionality and dysbiosis on tumor progression,
4970,NCT05247905,Progression free survival (PFS),2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in Overall Quality of Life Question (Q30) from the EORTC QLQ-C30 questionnaire,
4971,NCT01514045,Collect detailed clinical and epidemiological information on patients with gastric cancer; with a family history of gastric cancer in a first or second degree relative; or persons with a known germline mutation in their CDH1 (E-Cadherin) gene,2011-04,RECRUITING,OBSERVATIONAL,['NA'],,
4972,NCT04554771,Efficacy defined as pathological response to chemoradiotherapy according to the Mandard criteria,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Feasibility delay,Predictive biomarkers using oa RNA sequencing
4973,NCT01595217,"EHCC performance on DWI, ADC map and MRCP",2012-03,COMPLETED,INTERVENTIONAL,['NA'],"ADC, SNR, CNR and SIR for EHCC lesion under different b values",
4974,NCT02055313,Qualitative Data Collection: Patients' Experience of Exceptional Disease Course,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
4975,NCT02868242,Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event,2016-08-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Virologic Failure,
4976,NCT05496270,3-year diseases free survival,2014-01,COMPLETED,OBSERVATIONAL,['NA'],Local recurrence rate,
4977,NCT02335411,Objective Response Rate For PD-L1 Positive Participants in Cohorts 1 and 3,2015-02-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Control Rate For PD-L1 Positive Participants,
4978,NCT01867918,Overall survival from time of randomization,2013-05,TERMINATED,INTERVENTIONAL,['NA'],,
4979,NCT01492907,Pharmacokinetic Metabolite Profile of Radiolabeled MeIQx in Urine,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Quantify ambient adducts in the human pancreas,
4980,NCT06163365,Primary hypothesis,2022-07-26,RECRUITING,OBSERVATIONAL,['NA'],Secondary hypothesis,
4981,NCT05604950,Selection of treatment modalities for elderly patients with oesophageal cancer,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4982,NCT04981665,2-year Recurrence Free Survival Rate (2-year RFS rate),2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events (AEs),
4983,NCT05190445,Overall response rate (ORR) as defined by RECIST v1.1,2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,Compare levels of HER2 protein expression and/or gene amplification and HER2 gene amplification in ctDNA isolated before treatment initiation with clinical benefit derived from study treatment
4984,NCT02157363,operating time,2014-06-16,TERMINATED,INTERVENTIONAL,['NA'],,
4985,NCT03132792,"Number of subjects with dose-limiting toxicity (DLT) and adverse events (AEs) and determination of optimally tolerated dose range, including serious adverse events (SAE).",2017-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Interval between the date of first T cell infusion and date of disease progression or death due to any cause,
4986,NCT02072486,Overall survival (OS),2013-11-18,COMPLETED,INTERVENTIONAL,['NA'],"Granzyme B level variations by presence of grade 3 or higher AE, characterized using National Cancer Institute Common Terminology Criteria for Adverse Events severity grade",Proportion of cluster of differentiation (CD)8+ T cells expressing granzyme B
4987,NCT05788874,SUVmax,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4988,NCT01383707,Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS),2011-08-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
4989,NCT00719797,Progression free survival,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Surrogate markers predictive of bevacizumab activity,
4990,NCT04829383,Frequency and severity of toxicities,2021-03-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Median overall survival (OS),
4991,NCT02382263,"PHASE II: Evaluate the effectiveness of two selected schemes of gemcitabine and nab-paclitaxel, vs. gemcitabine alone. (Six months overall survival)",2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II: change in FAP and Cav-1 tumor markers as an inidicatior of treatment efficacy,
4992,NCT02063230,"Dose Normalized Cmax, Unbound Selumetinib",2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4993,NCT04102098,"Recurrence-Free Survival (RFS), as Determined by IRF",2019-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab,
4994,NCT01688908,Cost for saving 1 quality-adjusted life year (QALY),2012-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change of life quality due to early diagnosis and treatment,
4995,NCT03922152,"Assessment of symptoms [odynophagia, chest-back pain, dysphagia, regurgitation]",2009-01-01,COMPLETED,INTERVENTIONAL,['NA'],Assessment of the Overall Survival,
4996,NCT00868569,overall survival,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],resection rate of liver metastasis progression-free survival,
4997,NCT00682227,Safety (toxicities as assessed by NCI CTCAE version 3),2006-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],Immunological and clinical response,
4998,NCT02613650,Incidence of dose limiting toxicities (DLTs) of combination MEK162 and mFOLFIRI,2016-08-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4999,NCT05051475,Level of late post-procedural pain (at day 30 after treatment),2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],The rate of complications,
5000,NCT05180864,Overall survival,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],Cost-effectiveness,
5001,NCT00681876,Time To Progression,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],"Quality of life, Symptoms improvement",
5002,NCT03802747,Dose-Limiting Toxicity of Y-90+SBRT in Combination with Dual Immune Checkpoint Blockade,2019-08,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Time to Tumor Progression (TTP),
5003,NCT03482791,Physician-reported toxicity of PBT for esophageal cancer,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Overall survival (OS)of PBT for patients with resectable versus unresectable esophageal,
5004,NCT00094029,,2004-09,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
5005,NCT03449264,Proportion of patients who consent to participate in the study,2017-07-27,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life assessment at baseline for all participants in the study
5006,NCT04751591,Early operative mortality rate,2021-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],En bloc resection rate,
5007,NCT05030363,Change of FACIT-F score,2021-10-25,UNKNOWN,INTERVENTIONAL,['NA'],"Exploratory biomarker studies - Urine malondialdehyde - ALDH2 polymorphism (ALDH2 *1/*2, rs671 A/G) - Change of inflammatory cytokines",
5008,NCT05423886,Detection rate of colorectal cancer and advanced adenomas,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Acceptability,
5009,NCT05788224,mortality and morbidity correlated with the management of older (=>75 years old) patients admitted to emergency department with a complicated colorectal cancer,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5010,NCT05461430,BOR,2022-07-15,RECRUITING,OBSERVATIONAL,['NA'],PFS,
5011,NCT04679597,pathological complete response,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],Neoadjuvant rectal cancer score,number of participants with acute side effects
5012,NCT01415089,Quality of life,2009-05,COMPLETED,INTERVENTIONAL,['NA'],Satisfaction with intervention,
5013,NCT00965965,Comprehension of randomly assigned educational document,2009-08,COMPLETED,INTERVENTIONAL,['NA'],Readiness to undergo colorectal cancer screening,
5014,NCT03389126,response rate,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5015,NCT06245356,Treatment specific safety,2024-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life questionnaire - Colorectal (QLQ-CR29),
5016,NCT01789658,Mucositis grade - WHO Oral Toxicity Scale,2012-10,COMPLETED,INTERVENTIONAL,['NA'],Emotional and Psychological status,S-Albumin
5017,NCT02797405,Validation of the correlation between the clinical tumor response and the results of A/MS bioassays using tumor samples,2016-10,TERMINATED,INTERVENTIONAL,['NA'],Validation of the correlation between the healthy tissue response (i.e. AE reported as per CTCAE v4) and the results of MS/A bioassays using skin biopsies,
5018,NCT03454620,Dose Limited Toxicity (DLT),2018-04-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immunogenicity of GC1118,
5019,NCT06066931,The assessment of the frequency of early postoperative complications,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The assessment of the frequency of late postoperative complications and quality of life,
5020,NCT00256334,Test the hypothesis that resveratrol modulates Wnt signaling in vivo in colon cancer and normal colonic mucosa,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5021,NCT02356276,5-year overall survival,2015-05-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],side effects,CEA mRNA expression of peritoneal lavage fluid
5022,NCT05181488,3-year local recurrence rate,2020-04-02,RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
5023,NCT04172571,Objective response rate (ORR),2018-11-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of subjects who develop detectable anti-drug antibodies (ADAs),
5024,NCT06315101,Survival analysis,2023-09-01,COMPLETED,OBSERVATIONAL,['NA'],Adverse Events assessment,
5025,NCT04869618,Diagnostic performance of SPECTRA IMDx for assessment of lower risk lesion (GIM/LGD/Gastritis/Normal) and higher risk lesions (HGD/EGC) against the gold standard of histopathology from gastric resection specimen,2021-05,UNKNOWN,INTERVENTIONAL,['NA'],Evaluation of performance of HD-WLE combined with NBI in detection of HGD/EGD prior to ER.,
5026,NCT05939687,hernia rate,2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life indicators by HerQLes scale,
5027,NCT00101348,MTD of bevacizumab combined with cetuximab and erlotinib hydrochloride determined by DLT graded according to the CTCAE version 3 (Part II),2005-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival,
5028,NCT06166589,ORR,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
5029,NCT01798134,Freedom From Tumor Progression at 6 Months,2012-12,COMPLETED,INTERVENTIONAL,['NA'],12 Month Survival,
5030,NCT02009449,Pharmacokinetic (PK) parameters,2013-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Anti-Pegilodecakin antibody formation,
5031,NCT01438450,Survival,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Change from baseline in Child status at 1 year,
5032,NCT04232384,Yield of malignant cells,2020-06-15,TERMINATED,INTERVENTIONAL,['NA'],Cellularity of the smear of the smear,
5033,NCT02087475,Progress Free Survival,2011-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Life Quality,
5034,NCT01765673,Change in Swallowing Frequency 70 & 110 Hz,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],Change in Swallow Initiation Time,
5035,NCT00062257,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5036,NCT03259035,Measurement of organ preservation rate,2018-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Cost effectiveness using the EQ-5D-5L questionnaire,
5037,NCT00477711,Tumor response rate,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"Time to progression Disease control rate Overall survival K-ras, b-raf, p53 gene mutation and EGFR gene copy number vs. tumor response safety",
5038,NCT05385549,PFS,2022-09-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5039,NCT03033927,Progression Free Survival,2017-01-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5040,NCT01381822,To determine the MTD and DLT(s) of TH-302 when used in combination with sunitinib.,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],To make a preliminary assessment of the efficacy of TH-302 in combination with sunitinib as determined by the response rate and the progression-free survival in subjects with advanced RCC treated at the RP2D.,
5041,NCT01004159,12-week Progression Free Survival Rate Upon Escalation of Cetuximab Dose to 500mg/m2 in Combination With Irinotecan After Progression on Standard Dose Therapy in Patients With KRS Wild Type Colorectal Cancer,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Response Rate of Cetuximab 500mg/m2/Week in Combination With Irinotecan in the Enrolled Patient Population,
5042,NCT02748772,PFS,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],RR,
5043,NCT01736904,Progression free survival which is calculated from the start of treatment to disease progression or death,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Objective response rate which includes complete response(CR) and partial response(PR) participants,Overall survival which is calculated from the start to treatment to the death
5044,NCT00974610,Detection of peptide and protein markers in serum,2008-08,COMPLETED,OBSERVATIONAL,['NA'],Identification of the protein/peptide involved,
5045,NCT03250637,Colorectal cancer,1993-12,COMPLETED,OBSERVATIONAL,['NA'],,
5046,NCT01845675,overall response rate,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],toxicities,
5047,NCT01465113,Arm 2 (high grade dysplasia): 15-Prostaglandin dehydrogenase expression,2010-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],effects on insulin resistance,
5048,NCT05297955,Data analysis of relationship between CTC and pathological indicators of hepatocellular carcinoma,2013-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
5049,NCT06205836,Complete Response Rate,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants experiencing grade 3 or above drug-related toxicities requiring treatment discontinuation,
5050,NCT01493336,Relative bioavailability: Area under the concentration-time curve (AUC),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety: Incidence of adverse events,
5051,NCT05171166,Progression-free survival,2021-12-24,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Number of paitents with treatment-related adverse events,
5052,NCT03708042,Overall survival,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Comparison of pathological diagnosis between specimens of endoscopic biopsy and surgically resected in esophageal cancer,
5053,NCT01267305,TEG values,2011-01,COMPLETED,INTERVENTIONAL,['NA'],inhospital mortality,
5054,NCT02788526,Overall survival,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
5055,NCT04549064,Diagnosis of Pancreatic Cancer,2020-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5056,NCT06214988,textbook outcome; stoma-free survival at two years without major LARS,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Quality of life by European Organization for Research and Treatment of Cancer- Cancer30 (EORTC-C30),
5057,NCT03230318,Substudy 2: Progression Free Survival at 3 Months (PFS 3),2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Grade 3-5 Treatment-emergent Adverse Events (TEAEs),
5058,NCT04846309,"frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment",2021-10-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Pathological complete response (pCR) rate,
5059,NCT05985252,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Total hospitalization costs,Adjuvant chemotherapy in patients after low anterior resection for rectal cancer.
5060,NCT06089382,Recurrence-Free Survival (RFS),2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score,
5061,NCT05301842,Progression Free Survival (PFS) for Arm A vs Arm C,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall Survival (OS) for Arm B vs Arm C,
5062,NCT02512172,Number of Patients Experiencing a DLT (dose-limiting toxicity) as defined by NCI CTCAE v4.0,2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
5063,NCT01393197,Time to progression,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],remission rate,
5064,NCT04294953,morphine consumption,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Postoperative patient satisfaction,
5065,NCT00845039,Progression-Free Survival (PFS) Rate at 18 Weeks,2009-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Serum Anti-IMC-A12 Antibody Assessment,The Number of Participants Who Died During 30-Day Follow-Up
5066,NCT03792932,Recurrence Free Survival,2019-02-02,RECRUITING,INTERVENTIONAL,['NA'],Detected lymph node number,
5067,NCT01943500,The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter.,2013-09-30,COMPLETED,OBSERVATIONAL,['NA'],,
5068,NCT06220058,Incidence of incisional hernia.,2024-01-15,RECRUITING,INTERVENTIONAL,['NA'],Morbidity and mortality rates,
5069,NCT01391611,Non-progression Rate Based on RECIST 1.0 Criteria (CR+PR+SD),2011-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Response Per Choi Criteria,
5070,NCT01075893,Number of stem cells in the colonic crypt,2010-02,COMPLETED,OBSERVATIONAL,['NA'],Stem cell position in colonic crypt,
5071,NCT02354898,Pharmacokinetic profile of BBI503,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival,
5072,NCT03818997,Objective response rate,2019-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Duration of stable disease using RECIST 1.1 and iRECIST,
5073,NCT01532427,Safety,2012-06,COMPLETED,OBSERVATIONAL,['NA'],usability,
5074,NCT01054911,Number of Participants With Adverse Events,2009-10,TERMINATED,INTERVENTIONAL,['NA'],Alteration in Diffusion and Vascularity Kinetics,
5075,NCT01489566,RFS(Recurrence Free Survival),2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],QOL score,
5076,NCT05264896,3 year disease free survival,2022-03-21,RECRUITING,INTERVENTIONAL,['PHASE3'],Pathology - tumor regression grade,
5077,NCT02683655,Progression free survival,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5078,NCT04715074,Impact of #iBeatCRC Mass Media Campaign on EOCRC early detection benefit.,2023-05-27,COMPLETED,INTERVENTIONAL,['NA'],,
5079,NCT02119663,Overall Survival (OS),2014-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Participants With Treatment-Emergent Adverse Events (TEAEs),
5080,NCT05435053,Incidence of treatment related adverse events [Safety and Tolerability],2022-09-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of life using EORTC QLQ-C30,
5081,NCT01242605,"To investigate the safety and tolerability of the combination of cisplatin, gemcitabine and selumetinib, and to establish the recommended phase II dose of selumetinib when given in this combination.",2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Response rate,
5082,NCT03746249,Progression Free Survival (PFS),2018-12-17,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse Events,
5083,NCT02646462,Ratio of malignant/total number of lymph nodes,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],Number of N1 patients,
5084,NCT01766661,post-operative morbidity,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],local and/or distant recurrence of neoplasm,
5085,NCT03246516,Time limit of first doctor consultation,2017-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Survival,
5086,NCT00049101,,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5087,NCT00601198,"Test Drug in 28 Patients and Assess PSN. If 5 or More Have Grade 3 & 4 PSN, Trial Will be Terminated.",2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],"Assess PSN in 69 Patients. If Total Number of Cumulative PSN is > or Equal to 14, Drug Will be Rejected.",
5088,NCT02395640,progression free survival,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],quality of life questionnaire,
5089,NCT00674973,Progression-Free Survival,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events (AEs),
5090,NCT02889679,Incomplete resection rate (histologic),2016-09,COMPLETED,INTERVENTIONAL,['NA'],,
5091,NCT05432934,Total postoperative opioid consumption in the first 48 hours after surgery (hydromorphone equivalents.,2022-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Length of stay in hospital (days).,
5092,NCT04888403,Pathologic Complete Response(pCR),2021-12-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],postoperative complications rate,
5093,NCT05811546,Difference in DNMT1 and EZH2 expression.,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5094,NCT01286883,Primary endpoint: correlation of stem cell markers on CTCs with response to therapy,2011-02,TERMINATED,OBSERVATIONAL,['NA'],Secondary Outcome: Correlation of stem cell markers in primary tumors with stem cell markers in CTCs,
5095,NCT02537340,Detection rate,2016-09,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
5096,NCT02351219,Radical resection rate,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
5097,NCT03760822,Quality of life at 4 months as assessed by the following dimension of the EORTC QLQ-ELD14 questionnaire: illness burden,2018-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-free survival,
5098,NCT02550119,"Proportion of patients with complete response, defined as no emesis and no use of rescue medication",2006-04-19,TERMINATED,INTERVENTIONAL,['NA'],Proportion of patients who agreed to be randomized out of all patients who qualify for randomization,
5099,NCT01360086,Non-toxicity rate,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life as assessed by QLC-C30 and STO-22 questionnaires,
5100,NCT01217034,Overall Survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Time to Extrahepatic spread,
5101,NCT02585908,Reduced size of the tumor.,2019-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Safety, as measured by the rate of adverse events and serious adverse events",
5102,NCT04731220,Number and percentage of cases and controls who complete each part of the study,2020-07-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
5103,NCT03286348,Local Control rate,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall Survival,
5104,NCT06300489,MTD（maximum tolerable dose）,2024-03-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,
5105,NCT03100708,Overall Survival (years),2016-04,UNKNOWN,OBSERVATIONAL,['NA'],Quality of lfe questionnaire (EORTC QLQ-C15-PAL),
5106,NCT04037007,Cannulation success rate within 5 minutes,2019-07-03,RECRUITING,INTERVENTIONAL,['NA'],Technical success,
5107,NCT02827682,Duration time in PACU,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],length of hospital stay (LOS),
5108,NCT05038254,Rate of acute care visits,2021-05-12,RECRUITING,INTERVENTIONAL,['NA'],Change in symptom management,
5109,NCT03692429,Occurence of Dose Limiting Toxicities,2018-11-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,
5110,NCT05472753,Change in the alpha diversity index (Shannon),2022-11-16,UNKNOWN,INTERVENTIONAL,['NA'],Change in stool calprotectin,
5111,NCT02295774,Gamma H2AX Histone Levels in Colonic Biopsy During Standard White Light Colonoscopy and Colonoscopy for Which Methylene Blue MMX Was Taken Prior to Initiating the Colonoscopy,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],To Evaluate the Staining Quality Obtained With Oral Methylene Blue MMX® Tablets.,
5112,NCT03166553,Objective response rate and/or 1-year survival rate,2016-11-28,UNKNOWN,INTERVENTIONAL,['NA'],the rate of incidence of adverse events,
5113,NCT04166435,Overall Response Rate,2020-06-17,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
5114,NCT01882478,Response,2013-06,COMPLETED,OBSERVATIONAL,['NA'],Predictors of response,
5115,NCT02614157,3-year local recurrence,2016-05,TERMINATED,INTERVENTIONAL,['NA'],postoperative complications,
5116,NCT05746962,proportion of colonoscope loop formation,2023-03-06,RECRUITING,INTERVENTIONAL,['NA'],evaluation of risk factors about loop formation,
5117,NCT00534001,Prequit Change in Cigarettes Per Day,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Abstinence,
5118,NCT04781270,conversion resection rate,2021-04-15,RECRUITING,INTERVENTIONAL,['PHASE3'],Early tumor shrinkage,
5119,NCT05147168,Quality of Life(SF-36),2021-11-22,RECRUITING,OBSERVATIONAL,['NA'],,
5120,NCT05934981,Number of patients with pain at 24 hours after the end of the intervention by VAS ≤ 3 without taking opioids (without step 2 and step 3 analgesics).,2023-08-30,RECRUITING,INTERVENTIONAL,['NA'],Evaluation of predictive factors of opioid intake,
5121,NCT02565641,Overall objective response rate,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
5122,NCT04880148,Change from baseline in Xerostomia Grade (CTCAE) at weekly assessments,2021-11-03,RECRUITING,INTERVENTIONAL,['NA'],Change from baseline in health-related QoL (EORTC QLQ-H&N43) questionnaire,
5123,NCT05571098,Psychosocial Adjustment to Illness Scale (PAIS-SR) scores should be lower in the NNP applied group than in the non-applied group.,2021-07-08,COMPLETED,INTERVENTIONAL,['NA'],,
5124,NCT02216799,Achievement of target blood glucose (140 mg/dL to 200 mg/dL),2013-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Developement of hypoglycemia ( blood glucose < 70 mg/dL),
5125,NCT02396498,DFS: Disease-Free Survival,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],Safety as measured by Adverse Events and Serious Adverse events In the process of the total treatment according CTCAE4.0,
5126,NCT03294343,Occult cancer or precancerous lesion in histological specimen,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],Incidence of primary uterine cancer,
5127,NCT01834235,Overall Survival,2013-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immunologic Correlates,
5128,NCT00007826,,2000-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5129,NCT03579758,Overall survival,2019-04-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Incidence of residual disease after or at the time of re-resection,
5130,NCT03203525,Incidence of adverse events,2020-06-23,RECRUITING,INTERVENTIONAL,['PHASE1'],Biomarker analysis,
5131,NCT02861209,Change in self-management skills,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],Cost of care,Change in perceptions on self-management in HCPs using the Clinician Support for Patient activation measure
5132,NCT00004879,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5133,NCT03601923,Progression Free Survival,2018-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Evaluation of the safety and tolerability of niraparib as assessed by the Common Terminology Criteria for Adverse Events (CTCAE),
5134,NCT01902953,Efficacy of Lymphoseek for Detection of Sentinel Nodes,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Localization Rates,
5135,NCT05943444,Low Anterior Resection Syndrome (LARS) score 1 year after surgery,2023-08-08,RECRUITING,INTERVENTIONAL,['NA'],The incidence of postoperative anastomotic complications,
5136,NCT05919095,Radical resection rate,2023-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The incidence of treatment-related adverse event,
5137,NCT01911988,Disease Free Survival,2013-06,UNKNOWN,OBSERVATIONAL,['NA'],5 years overall survival,
5138,NCT01749956,Pathologic Complete Response Rate,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],The Number of Participants Who Experienced Serious or Non-Serious Adverse Events as a Measure of Safety.,
5139,NCT04517643,Number of Patients That Met the Criterion That the Dose Estimated With Tc-99m MAA SPECT Was Within 15% of the Dose Estimated From Y-90 SPECT,2020-11-12,COMPLETED,INTERVENTIONAL,['NA'],,
5140,NCT00354705,Occurence of Recurrent Colon Cancer,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5141,NCT00066716,Pathological response rate at time of surgical resection,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicities and safety,
5142,NCT01923987,R0 resection rate,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicity,
5143,NCT01907607,Number of Participants With Non Progression at 4 Months,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Efficacy Assessment of PD-0332991 in Terms of Overall Survival Time,
5144,NCT06209099,Organ-preservation rate,2023-12-05,RECRUITING,INTERVENTIONAL,['NA'],Major adverse events,
5145,NCT04010006,operating time,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],3-year overall survival rate,
5146,NCT01619475,Pain control in living donors following partial hepatectomy,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,
5147,NCT01695447,pancreatic fistula,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],Hospital stay,
5148,NCT00383760,Objective Response (Complete and Partial) Evaluated Using RECIST Criteria,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Stable Disease Rate,
5149,NCT02287025,Proportion of Patients Who Discontinue Prior to Documented Progression of Disease (PD) or Death,2014-11-11,TERMINATED,INTERVENTIONAL,['PHASE4'],Satisfaction of Investigator/Nurse With Enhanced Drug-specific Information Via SMART Questionnaire,
5150,NCT02140723,Interaction between the status of the biomarker TP53 and response to treatment,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],overall survival,
5151,NCT04919824,Procedure time,2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Delayed post-procedural adverse event,
5152,NCT03096054,Determination of the maximal dose,2017-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Determine the median progression,
5153,NCT00677781,Postoperative morbidity,2008-02,COMPLETED,OBSERVATIONAL,['NA'],Mortality,
5154,NCT00568750,Response as assessed by fusion PET/CT scan according to EORTC PET Study Group criteria,2008-01-22,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse drug reactions according to NCI CTCAE v3.0,
5155,NCT05143151,Objective response rate (ORR),2021-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival rate (OS),
5156,NCT02588443,Number of Adverse Events,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5157,NCT04797923,Rate of R0 resection,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5158,NCT03891784,Objective response rate (ORR),2019-10-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
5159,NCT01882205,The difference in total number of neoplastic lesions detected by chromoendoscopy and virtual chromoendoscopy,2008-05,UNKNOWN,INTERVENTIONAL,['NA'],The difference in the ratio number of neoplastic lesions/ total number of lesions between chromoendoscopy and virtual chromoendoscopy,Number of biopsies per colonoscopy taken in the different groups.
5160,NCT01789983,"To measure the feasibility of implementing the WWE program among cancer patients, age ≥60, as they undergo cytotoxic chemotherapy treatment.",2012-10,COMPLETED,OBSERVATIONAL,['NA'],To measure relationships between physical activity levels and p16 levels.,
5161,NCT03392571,To evaluate 2 year survival from date of entry into study,2018-08-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Time to Recurrence,
5162,NCT02649361,Progress free survival (PFS),2016-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),
5163,NCT01863745,Number of participants with adverse events,2013-06-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5164,NCT05617352,The number of lymph nodes,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
5165,NCT06303583,Complete pathological response rate,2022-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Safety will be analyzed through the incidence of adverse events, serious adverse events",
5166,NCT01819961,infective complications,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],plasma immunological markers,
5167,NCT05741372,"Maximum measured concentration of the analyte in plasma) for each component of the transporter cocktail: digoxin, furosemide, metformin, and rosuvastatin (Cmax)",2023-04-25,RECRUITING,INTERVENTIONAL,['NA'],,
5168,NCT02574637,Percentage of Participants With Crohn's Disease Activity Index (CDAI) Remission at Week 8,2016-01-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Abdominal Pain Remission,
5169,NCT02425605,Overall survival,2014-12-03,COMPLETED,INTERVENTIONAL,['PHASE2'],toxicity defined as NCI-CTC(version 4.02),
5170,NCT05718349,Microbial composition,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
5171,NCT05632939,The recommended dose,2023-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival（OS）,
5172,NCT04973098,Adverse Event of Special Interest,2021-08-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
5173,NCT00089024,Number of Participants Experiencing Grade 3-4 Toxicity While Receiving the Study Treatment,2004-02-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5174,NCT02508389,Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) Criteria,2015-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],"Number of Participants With Tumor Outcomes Defined as Locoregional Failure, Distant Metastases, Disease Progression and Deaths",
5175,NCT04605796,ORR,2020-04-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),ADA
5176,NCT02720601,Progression-free survival (PFS),2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Toxicity,
5177,NCT01750619,Technical success.,2011-07,RECRUITING,OBSERVATIONAL,['NA'],Endoscopic en bloc resection rate,
5178,NCT01175460,Maximum tolerated dose (MTD) of s-1 in combination with nedaplatin and thoracic radiotherapy,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Objective response rate,
5179,NCT01447927,Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Adverse Event Rates,
5180,NCT02765620,Evaluate treatment response by PERCIST to RECIST 1.1 criteria after the whole treatment process,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],PFS,
5181,NCT02425137,Disease control rate (DCR),2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"safety profile (percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v4.03 grade)",
5182,NCT01688232,relapse in relation with the immunoscore determined on a tumor section.,2012-09-27,UNKNOWN,OBSERVATIONAL,['NA'],relapse in relation with the immunological events and psychological status of the patient during the monitoring,
5183,NCT01092975,Safety: the presence or absence of mucosal or systemic toxicity related the the topical application of phenylephrine.,2010-03,TERMINATED,INTERVENTIONAL,['PHASE1'],"Efficacy: the the mucositis severity area-under-the-curve (AUC) where the severity of oral mucositis on each treatment day will be scored, summed, and plotted graphically.",
5184,NCT03840928,RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health),2015-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
5185,NCT04752670,Technical Success rate,2021-05-27,COMPLETED,OBSERVATIONAL,['NA'],Adverse Events,
5186,NCT05785234,Total consumption of fentanyl in 24 hours after surgery,2023-04,RECRUITING,INTERVENTIONAL,['NA'],,
5187,NCT06267703,Chronic atrophic gastritis,2024-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5188,NCT03217253,Recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction,2018-03-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Best response,
5189,NCT03989180,"Performance of the C-Scan system in terms of communication between the C-Scan Capsule and the System Track in different locations, positions and configurations.",2016-01-06,COMPLETED,OBSERVATIONAL,['NA'],,
5190,NCT03338543,pain score,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],times of breakthrough pain (BTP),complications
5191,NCT00025142,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5192,NCT02169765,Overall survivals,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Recurrence rates,morbidity
5193,NCT00868998,Response Rate,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicity,
5194,NCT01178151,To determine the response rate of Everolimus in patients with advanced cancer and PJS.,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],To assess markers for activated mTOR pathway (including phospho-S6 and phospho-4E BP1) in all pre-treatment tissue specimens and collected specimens during treatment and correlate with response to treatment.,
5195,NCT05183295,Tolerability of the NEAAR medical food,2022-04-27,WITHDRAWN,INTERVENTIONAL,['NA'],Progression-free Survival,
5196,NCT05689775,Perineal wound healing,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],Abdominal wall strength,
5197,NCT00190515,Disease-free survival,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Rate of adverse event,
5198,NCT03223740,Progression Free Survival,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],R0 Resection Rate,
5199,NCT02860429,neural electrophysiological test,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],"stress hormone,in blood.",
5200,NCT02672488,Overall Survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Objective Response Rate,
5201,NCT04134832,The survival will be evaluated by Kaplan Meier Method. The prognostic factors will be evaluated with univariate and multivariate analysis by Cox regression model.,2019-06-27,UNKNOWN,OBSERVATIONAL,['NA'],,
5202,NCT04685395,Incidence of oral mucositis,2019-12-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],The pain score,
5203,NCT00339183,Overall Survival,2006-06-30,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Adverse Events (AEs),
5204,NCT00423696,Progression-free survival at 6 months,2006-03-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
5205,NCT01271166,Tumour response as assessed by CT scan and RESIST,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
5206,NCT05335460,TRG0/1,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],ORR,PCR rate
5207,NCT05984485,3-year Disease Free Survival,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of participants with treatment-related adverse events,
5208,NCT02581462,Phase III: Median Progression Free Survival,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Phase III: Median OS,
5209,NCT03722056,rates of intraoperative tumour rupture,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
5210,NCT05164406,Transfusion,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
5211,NCT05129774,5-year OS,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Postoperative complications,
5212,NCT01401075,Quality of Life,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Safety and tolerability,
5213,NCT00470353,Change in proliferative labeling index of normal rectal mucosa as measured by Ki67 IHC staining,2006-09,TERMINATED,INTERVENTIONAL,['NA'],"Effects of cholecalciferol on biological markers of proliferation (i.e., cyclin D1, protein kinase C, vitamin D receptor, p21, and p27) as measured by IHC at baseline and after 6 months of study treatment",
5214,NCT06229080,Mean absorbed dose ratio between the protected perfused liver and unprotected perfused liver,2023-03-15,RECRUITING,INTERVENTIONAL,['NA'],Serious adverse event,
5215,NCT04808791,Safety/Tolerability,2021-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
5216,NCT00568646,Objective tumor response rate based on tumor measurements according to the RECIST,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5217,NCT05029882,Objective Response Rate (ORR),2021-10-13,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
5218,NCT04813523,Major pathologic response (MPR),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Pathologic complete response (pCR),
5219,NCT05737953,Types and concentrations of cfDNA and proteins contained in the vesicular fluid,2022-07-13,RECRUITING,OBSERVATIONAL,['NA'],Development of a progressive benign malignancy prediction model,
5220,NCT01170104,Time to progression,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],To evaluate the toxicity profiles,
5221,NCT05876026,Difference in T1 relaxation time (ms) in the rectal cancer tumor measured in IntelliSpace-software before and after neoadjuvant radiochemotherapy.,2023-05-08,RECRUITING,OBSERVATIONAL,['NA'],,
5222,NCT01589328,Reduction in depression score,2012-03-15,COMPLETED,INTERVENTIONAL,['NA'],Overall survival,
5223,NCT01324076,Progression-free survival,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life,
5224,NCT03925870,Duration of response (DOR),2019-06-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS) rates,
5225,NCT00985192,Overall Disease-control Rate in Patients With Previously Treated Unresectable or Metastatic Adenocarcinoma of the Upper Gastrointestinal Tract Treated With Everolimus.,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarker Correlations: Time to Progression,
5226,NCT02584985,R1 resection rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Disease-free survival at 3 years,
5227,NCT01187901,Change in Duodenal Polyp Burden From Baseline to 6 Months,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants,
5228,NCT04493905,30-day postoperative morbidity assessed by Clavein-Dindo classification,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],"Cancer recurrence or cancer-related death at 90 days, 1, 3- and 5-years",
5229,NCT02205047,Near Complete Pathological Response Rate,2015-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity,
5230,NCT04498117,Investigator Assessed Progression Free Survival,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Change in Quality of Life,Potential Biomarkers
5231,NCT01439698,Number of Participants with Adverse Events,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],Number of overall stent occlusion-free days post intervention,
5232,NCT02501603,compare progression free survival as measured by RECIST 1.1,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],safety as measured by CTCAE,
5233,NCT03215264,Maximum Tolerated Dose (MTD) of Hydroxychloroquine and Entinostat in Combination With Regorafenib,2017-10-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5234,NCT05527301,Change in Low Anterior Resection Syndrome score from Baseline to 8 weeks,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Change of fecal metabolites assessed by fecal analysis,
5235,NCT03563274,Safety,2018-06-21,TERMINATED,OBSERVATIONAL,['NA'],"Percentage of patients downstaged to surgery, transplantation or any local ablative therapy (RFA/MWA…)",
5236,NCT00659867,The primary objective is to investigate whether chromoscopy-guided endomicroscopy has a higher sensitivity than standard endoscopy with respect to detection of IN and to compare the proportion of patients with at least one IN,2008-12,TERMINATED,INTERVENTIONAL,['NA'],Efficacy of chromoscopy-guided endomicroscopy in the detection of lesions and in the reduction of the number of biopsies. Time needed for the examination will be measured and compared between the two groups.,
5237,NCT01558921,Disease related Treatment Failure (DrTF),2011-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life LARS,
5238,NCT00498407,• Objective response rate (RR),2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],• Characterize the quantitative and the qualitative toxicities of the CP-4055 treatment in this patient population,
5239,NCT04572542,Objective response rate,2020-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease Control Rate（DCR）,
5240,NCT03014284,Expression of B7-H1,2017-01-20,WITHDRAWN,OBSERVATIONAL,['NA'],,
5241,NCT04928807,pathological complete response (pCR) rate,2021-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],dverse events (AEs) were graded according to the NCI CTCAE version 5·0,
5242,NCT01116271,"Objective Response Rate will be assessed by the RECIST guideline documented in the European Journal of Cancer, 2009.",2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS) for patients with K-ras or B-raf mutations treated with combination of irinotecan and Selumetinib (AZD6244),
5243,NCT00896753,"Development of cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
5244,NCT04511455,Time-on-treatment,2020-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Translational research,
5245,NCT04056260,sensitivity and specificity,2020-03-20,UNKNOWN,INTERVENTIONAL,['NA'],,
5246,NCT03038217,5y OS,2017-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],Changes of ctDNA level when disease recurs,
5247,NCT06197438,Objective response rate(ORR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease control rate(DCR),
5248,NCT05154812,Tumor progression rate,2020-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],quality of life (QOL) questionnaire,
5249,NCT00176800,Median Recurrence Free Survival Time,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Patients That Require Dose Modification Due to Toxicity,
5250,NCT05194293,Objective response rate (ORR) (unconfirmed),2023-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Pathologic complete response,Immune biomarkers
5251,NCT01514786,Number of Participants Reporting Preferred Screening Type as Reported by Chart Audits,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
5252,NCT02400788,Phase 2 : Time To Progression (TTP),2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5253,NCT00828620,PET response on day 7,2009-01,TERMINATED,OBSERVATIONAL,['NA'],To asses the correlations between biomarkers and PET changes after Cetuximab,
5254,NCT01282502,To determine Maximum Tolerated Dose (MTD) of midostaurin in combination with standard 5-FU chemoradiation,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],To evaluate proteomic markers of response and resistance to midostaurin-based chemoradiation,
5255,NCT01657383,Surgical Outcome,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
5256,NCT03118349,Occurrence of graded adverse events (AEs) in each subject,2017-06-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Cl,Evaluate the relationship between circulating CA19-9 levels and MVT-1075 pharmacokinetics
5257,NCT04596384,Maximum CCI,2021-02-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in Sleep,
5258,NCT02730104,Time to disease progression,2015-11-23,COMPLETED,OBSERVATIONAL,['NA'],Patient satisfaction with treatment,
5259,NCT05957744,Length of stay,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
5260,NCT01320852,Overall Survival,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,
5261,NCT03044587,Progression-free survival [PFS],2018-01-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Retrospective central radiological review,Tumor Evolution under systemic therapy
5262,NCT04432597,Level increase in CD3+ tumor infiltrating T cells post-treatment compared to pre-treatment,2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",overall response rate (ORR),
5263,NCT01963182,severe toxicity (according to NCI-CTC cotation) and response with adapted dose of irinotecan,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"evaluation of treatment efficacy (progression-free survival, duration of response)",
5264,NCT06251297,number of sessions performed,2023-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],concordance of peripheral neuropathy evaluation,
5265,NCT04635527,Number of participants experiencing clinical and laboratory adverse events (AEs),2020-12-24,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall survival (OS) in two arms,
5266,NCT01906021,To measure accuracy of temperature monitoring using non-invasive thermomap (temperature imaging profile) method compared to the currently accepted invasive thermocouples method,2013-09-23,COMPLETED,INTERVENTIONAL,['NA'],,
5267,NCT05173298,collected blood samples,2021-08-02,RECRUITING,OBSERVATIONAL,['NA'],Biomarkers on the efficacy of Atezolizumab+Bevacizumab for advanced HCC,
5268,NCT05555316,Down stage rate,2019-11-10,RECRUITING,INTERVENTIONAL,['PHASE2'],TACE frequency and ablation frequency,
5269,NCT01411436,Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar,2009-05,COMPLETED,OBSERVATIONAL,['NA'],"The status of therapy with Nexavar [duration of treatment, daily dose] in a various settings according to baseline data [such as demographic data, Child-Pugh status, ECOG-PS]",
5270,NCT00386828,The primary endpoint is pathologic complete response (pCR) rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Post-Surgical Complication Rates:,
5271,NCT00209612,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2004-04,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.,
5272,NCT05064670,Health-related quality of life,2022-01-11,RECRUITING,INTERVENTIONAL,['NA'],Health-related quality of life,
5273,NCT05846867,recommended phaseII dose,2023-05-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Correlation between biomarkers and efficacy,
5274,NCT02635347,Percentage of Participants Completing Entire Intervention Protocol,2015-11,COMPLETED,INTERVENTIONAL,['NA'],Number of Subjects Not Completing Intervention Protocol,
5275,NCT05867303,Incidence of Adverse Events [Safety and tolerability],2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression Free Survival (PFS),
5276,NCT03520257,overall survival,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5277,NCT00119899,Economic evaluation (9 months),2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Economic evaluation,
5278,NCT02830633,The postoperative voiding function assessed by IPSS questionnaire.,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],C-reactive protein,
5279,NCT00928161,Frequency of acid reflux episode (during each 24 hour pH probe),2012-11,WITHDRAWN,INTERVENTIONAL,['NA'],,
5280,NCT05193292,Objective Response Rate,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of Response,
5281,NCT03152435,Occurrence of study related adverse events as assessed by CTCAE v4.0,2017-06-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determine duration of in vivo survival of EGFR CART .,
5282,NCT01265810,"Assess the severity of patient-reported oral adverse events as determined by the change in the Modified-VHNSS2.0 score 3 times a week, from onset of oral adverse events during the active oral rinse period with Caphosol versus NaCl 0.9%",2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Side Study: Explorative analysis of polymorphism in genes encoding for pharmacokinetic and pharmacodynamic variables related to the pharmacodynamics of the TKIs,
5283,NCT06310993,Primary Outcome Measure,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Secondary Outcome 7,
5284,NCT00025337,Overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression free survival,
5285,NCT00457327,Morbidity and mortality until day 30 postoperative,2006-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Ranking of factors influencing quality of life,
5286,NCT00017199,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5287,NCT03401229,Change From Baseline in NBS at Week 40,2018-01-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in SF-36v2 Mental Health at Week 56,
5288,NCT03299660,Pathological Response rate,2018-04-30,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine rate of downstaging,
5289,NCT02555813,Number of participants with adverse events,2015-05-08,COMPLETED,OBSERVATIONAL,['NA'],Best Overall Response,
5290,NCT03295006,Alternative two-compartment TheraSphere dosimetry methodology,2016-10-31,COMPLETED,OBSERVATIONAL,['NA'],Dose reproducibility,Normal tissue dose and tumor dose using post-procedural PET/CT Imaging
5291,NCT04594811,Phase 2: Objective response rate (ORR),2021-01-21,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of participants with anti-drug antibodies (ADA) to NT-I7,
5292,NCT00601692,Maximum tolerated dose of docetaxel when administered together with irinotecan hydrochloride and radiotherapy,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Clinical and pathological complete response rate,
5293,NCT06001476,Incidence of complications in the application of cold snare polypectomy for 5-9mm small bowel polypectomy in patients with PJS,2023-08-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Incidence of complications within 28 days after enteroscopy,
5294,NCT04215731,Disease-free survival,2020-03-27,RECRUITING,INTERVENTIONAL,['PHASE3'],local recurrence rate,
5295,NCT05351931,"Incidence of diarrhoea, fecal urgency, anal skin toxicity/mucositis and anal pain CTCAEv5.0 ≥ grade 2 during and up to 6 months after RCT. Anal skin toxicity/mucositis is to be verified by photos.",2022-06,UNKNOWN,INTERVENTIONAL,['NA'],Disease free and overall survival at 3 and 6 months after stop of RCT.,Incidence of AEs CTCAEv5.0 grade ≥ 2 considered probably related to investigational products/placebo.
5296,NCT01560377,PINPOINT System Utility in Left Colectomy Surgery,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety of the PINPOINT System,
5297,NCT05587452,Specificity,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5298,NCT03895255,Anastomotic Leakage Rate,2016-10-02,UNKNOWN,INTERVENTIONAL,['NA'],The postoperative hospital stay,
5299,NCT04380012,Objective Response Rate,2019-12-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],The Incidence of Adverse Events,
5300,NCT00011960,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5301,NCT05356117,Protein Supplementation (PS) Rate,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],Psychosocial function - Physical Function,
5302,NCT00877071,The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],The Local Effects of the LC BeadTM in the Explanted Liver of Those Patients Who go on to Receive Liver Transplantation,
5303,NCT00524069,Margin status after pancreatic resection,2007-01,WITHDRAWN,INTERVENTIONAL,['NA'],Toxicity,
5304,NCT02402062,Objective Response Rate,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers in Serum and Tumor Tissue,
5305,NCT03616574,Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0,2019-04-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Serum concentration of CA102N,Analysis of urinary COX-2 metabolites by LC-MS/MS
5306,NCT05875870,Sleep-wake rhythm,2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],Survival rate,
5307,NCT05195281,Evaluation of molecular subtype modification,2021-07-14,RECRUITING,INTERVENTIONAL,['NA'],,
5308,NCT02870920,Overall Survival,2016-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate,
5309,NCT04323917,Assessments of diagnosis of PC by EMT-TF mRNA levels in blood,2017-11-02,UNKNOWN,OBSERVATIONAL,['NA'],Prediction of prognosis of PC by EMT-TF mRNA levels in blood,
5310,NCT02177552,The proportion of participants alive one year after randomisation,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Registration of further lines of therapy,Analysis of cmet by immunohistochemistry
5311,NCT00867477,Comparison Patient's PMRR + Mean Exhaled NO Measurement,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5312,NCT04891874,Participants Without Recurrence (Disease-free).,2015-08-01,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival (OS) Rate.,Number of Participants Occured Adverse Events(AE)
5313,NCT00681798,Define Recommended Dose (RD),2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],"Determine antitumour activity as determined by overall response rate (RR), progression free survival (PFS), disease control rate and duration of response",
5314,NCT00119912,1. Evaluate the effect on CRC mortality and morbidity by screen detection of CRC and removal of precursor lesions (polypectomy of adenomatous polyps).First evaluation after 5 years.,1999-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],2. Clarify possible psychosocial effects of endoscopic screening and how it may influence lifestyle and lifestyle related morbidity and overall mortality. Evaluation in 2005.,
5315,NCT04584008,Objective response rate (ORR) of patients receiving targeted agent,2020-09-23,RECRUITING,INTERVENTIONAL,['NA'],Differences of OS between 2 groups,
5316,NCT05493800,The incidence of Severe Oral Mucositis(SOM).,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Total cumulative dose of opioid analgesics,Auto hematopoietic stem cell engraftment
5317,NCT04159974,Evaluation of Safety and efficacy (measured by an increase of pathological complete response rate),2019-09-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Assessment of the subject's esophageal-cancer-related quality of life using the Functional Assessment of Cancer Therapy-Esophageal (FACT-E) questionnaire,
5318,NCT01121848,Progression-Free Survival (PFS),2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Median Overall Survival (OS),
5319,NCT05037461,Change in tumor size,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],overall survival,
5320,NCT00498134,"Changes in cell proliferation, apoptosis and oncogene expressions",2004-03,UNKNOWN,INTERVENTIONAL,['NA'],The incidence of gastric cancer in a high risk area,
5321,NCT04660695,Clinical Success,2019-08-15,COMPLETED,OBSERVATIONAL,['NA'],Type of fluid employed,
5322,NCT00460681,disease-free survival,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],overall survival,
5323,NCT03535207,overall survival rate,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],toxicities,
5324,NCT00043004,Survival rate as measured by Kaplan Meier method at 30 months,2002-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Response to treatment (arm II) as measured by RECIST criteria from start of treatment until disease progression,
5325,NCT05111353,Safety of neoantigen SLP vaccine as measured by number of subjects experiencing each type of adverse event,2022-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Immunogenicity of neoantigen peptide vaccine as measured by the phenotype of neoantigen-specific T cells (only Arm 1 and Arm 2),
5326,NCT01271322,Correlation between change in tumor metabolism (detected by PET) and histopathological response,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],association between change in tumor metabolism between PET Baseline and PET1 and overall survival as well as disease-free survival,
5327,NCT01416714,create a database for the collected tissue,2008-07-02,SUSPENDED,OBSERVATIONAL,['NA'],To create tissue microarrays for each gastrointestinal cancer subtype,
5328,NCT00977717,neuropathy,2008-09,COMPLETED,OBSERVATIONAL,['NA'],,
5329,NCT02466906,Disease-free survival（DFS）,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse effects (AE),
5330,NCT06296056,potential efficacy,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
5331,NCT04513418,Rate of postoperative nutrition and immune-related complications,2020-11-10,RECRUITING,INTERVENTIONAL,['PHASE3'],Long-term survival,
5332,NCT04389086,Proportion of patients with a clear resection margin,2020-11-13,RECRUITING,INTERVENTIONAL,['PHASE3'],Colorectal cancer specific quality of life,
5333,NCT00196885,"muscle cross-sectional area, peak forces",2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],muscle 31Phospho-magnetic-resonance spectroscopy,
5334,NCT05082948,Composite of stent migration or total stent dislodgement,2021-07-20,RECRUITING,INTERVENTIONAL,['NA'],Length of procedure,Dysphagia
5335,NCT06302751,Unplanned hospital readmissions,2024-02-26,RECRUITING,INTERVENTIONAL,['NA'],Healthcare costs,
5336,NCT02338778,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",immunology index,
5337,NCT01736072,End of Conversion to Open Surgery,2011-12,COMPLETED,INTERVENTIONAL,['NA'],Oncological Efficacy,Sexual Disfunction Assessment
5338,NCT06277518,admitted to ICU after surgery,2023-09-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5339,NCT04940442,Number of patients with screening completion,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,
5340,NCT02965417,Best overall response (OR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2016-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
5341,NCT06255262,Progress Free Survival 1 (PFS1),2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival(OS),
5342,NCT00540982,Number of Participants With Grade 3 and 4 Toxicities,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5343,NCT06225622,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE1'],R0 resection,Gene polymorphism
5344,NCT03747068,"to determine whether preoperative exposure to anti-TNF therapy affects histological measures of fibrosis in the rectum, as increased rectal fibrosis may be a potential factor in adverse anastomosis complications following IPAA surgery",2009-10-09,COMPLETED,OBSERVATIONAL,['NA'],,
5345,NCT05041608,Safety of procedure,2021-02-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Quality of Life after procedure,
5346,NCT02998268,Disease free survival rate,2017-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Reduction of local immune infiltration.,Association of anti-PD1 therapy with increased intra-tumoral immune cell infiltration.
5347,NCT06294808,Agreement between TBI calculated from pre-operative imaging versus those obtained from post-surgical pathological assessment.,2017-07-17,COMPLETED,OBSERVATIONAL,['NA'],,
5348,NCT02154646,Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT),2014-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Percentage of Participants with a Tumor Response,
5349,NCT05919030,Progression-Free Survival (PFS),2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of participants experiencing Adverse Events (AEs),
5350,NCT06022887,Acceptability of the study,2023-10-18,RECRUITING,INTERVENTIONAL,['NA'],Microbial Deoxyribonucleic acid (DNA) isolation: 16S on V4 region,
5351,NCT04409002,Disease Control Rate With RECIST 1.1 Criteria,2020-07-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Treatment-Related Adverse Events Per CTCAE v5.0,
5352,NCT00005877,,1999-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5353,NCT04728139,Evaluation of Glypican 3 role as a predictive and diagnostic marker of colorectal marker .,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Addition of Glypican 3 to the routine markers of colorectal cancer . - Correlatin of this marker with the disease pathology and management procedures .,
5354,NCT01833637,"Trend perceived symptom burden and quality of life in our female patients with advanced gynecologic, breast, thoracic, or gastrointestinal malignancies.",2012-10,COMPLETED,INTERVENTIONAL,['NA'],Assess level of understanding about advance care planning in both the control and intervention group.,
5355,NCT00291785,"Phase I: determine the Maximum Tolerated Dose, dose limiting toxicities, safety profile and antitumor activity",2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5356,NCT01455831,Disease Free Survival,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Other post-operative (day 0 - day 28) complications,
5357,NCT02772575,response,2016-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
5358,NCT04489368,"Perform a clinical audit of patient outcomes (OS, RFS, pCR rate) after new-adjuvant chemoradiation and esophagectomy",2020-01-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5359,NCT02321969,Recurrence/Number/Size of metachronous colorectal adenoma(s),2010-08,COMPLETED,INTERVENTIONAL,['NA'],Adverse effect(s) of GTE supplementation,
5360,NCT06123338,Pathological Complete Response Rate (pCR),2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5361,NCT00058474,Loco-regional disease control as assessed by evidence of tumor at 3 years,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Convenience of care as assessed by NSABP C-06 convenience of care scale adapted from ECOG after definitive analysis,
5362,NCT06259058,R0 resection rate,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of adverse events,
5363,NCT04673448,Best objective response,2021-10-18,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,
5364,NCT04268654,Anastomotic leakage,2017-06-13,COMPLETED,INTERVENTIONAL,['NA'],Hospital Stay,
5365,NCT06122493,1-year progression-free survival,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
5366,NCT03706326,Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v4.0,2018-09-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median CAR-T cell persistence,
5367,NCT04379596,"Part 2, Part 3 and Part 4: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)",2020-06-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Comparison of OS,
5368,NCT02965248,peritoneal metastasis rate,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Toxicity by NCI CTCAE v.4.0,
5369,NCT00559013,"Number of Participants With Major Colorectal Related Adverse Events: Leak, Stricture and Hemorrhage.",2007-03,COMPLETED,INTERVENTIONAL,['NA'],,
5370,NCT00557713,Pathologic Complete Response Rate,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Surgical Morbility,
5371,NCT00087503,To assess the antitumor activity of edotecarin by repeating radiographic assessments at 6-week intervals for all patients.,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Blood samples for PK evaluation will be collected during Cycles 1 and 2 and limited to the patients included in the first stage of the study.,
5372,NCT04171986,Incidence of 3 and 4 degrees neutropenia within 6 weeks from the start of hyperfractionated radiotherapy,2019-11-10,UNKNOWN,INTERVENTIONAL,['NA'],,
5373,NCT00032344,"Phase I: Risk factors include: family history; dietary; fat, fiber, calcium; alcohol history; tobacco use; physical activity; obesity; NSAID use; and, biomarkers: BRDU, PCNA",1993-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Phase III: Medical outcomes including mortality. Colonoscopy outcomes in subgroup of polyp free patient at baseline to determine long term risk.,
5374,NCT03956056,Safety of Neoantigen Peptide Vaccine as Measured by the Number of Serious Adverse Events,2020-02-13,TERMINATED,INTERVENTIONAL,['PHASE1'],Immunogenicity of the Neoantigen Peptide Vaccine as Measured by Multiparametric Flow Cytometry,
5375,NCT00789763,TO DETERMINE MTD,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],RESPONSE (ACCORDING TO RECIST),
5376,NCT04821778,Overall survival,2002-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Distant metastasis free survival,Radiomics analysis
5377,NCT04125914,Percent weight loss,2017-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Physical activity,
5378,NCT00516165,Progression-free Survival Rate at 24 Weeks,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
5379,NCT03677050,Boston Bowel Preparation Score,2018-09-14,COMPLETED,INTERVENTIONAL,['NA'],Adenoma detection rate,
5380,NCT03254511,R staging (residual of tumor),2016-07-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],heparin induced thrombocytopenia,
5381,NCT03785210,Best Overall Response (BOR),2019-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS) of Nivolumab Combined With Oral Vancomycin and Tadalafil in Participants With Refractory Hepatocellular Carcinoma (HCC) or Liver Dominant Metastatic Cancer From Colorectal Cancer or Pancreatic Ductal Adenocarcinoma (PDAC),Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
5382,NCT05276791,Primary endpoint is the proportion of patients with no evidence of residual or local recurrent neoplasia during 12 months follow-up after baseline.,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Additional histopathologic evaluation may be performed to evaluate potential differences between the two techniques.,
5383,NCT04729283,LARS score,2021-04-12,UNKNOWN,OBSERVATIONAL,['NA'],IIEF5,
5384,NCT04425122,Microbiological culture from biopsy specimens,2020-07-01,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
5385,NCT03336775,The change of Videofluoroscopic Dysphagia Scale (VDS) from baseline to week 4.,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],The change of Quality of Life (QOL) scores from baseline to week 4 and week 16.,
5386,NCT05798884,Score Changes on the FACT/GOG-Ntx questionnaire,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Short Form 12 item(version 2) Health Survey (SF-12V2),
5387,NCT00116935,Recurrence-free survival,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],GIST-specific survival,
5388,NCT02672774,Real-time imaging of angiogenesis in gastric and colorectal tumors by using M-NBI and pCLE examinations,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],Validation of endoscopic imaging findings from immunohistochemical analysis with MVD calculations,
5389,NCT05622071,Objective Response Rate,2023-10-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life questionnaire - Hepatocellular Carcinoma (QLQ-HCC-18),
5390,NCT04985604,Phase 2: Evaluate the efficacy of tovorafenib monotherapy or in combination with other therapies,2021-07-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Phase 2: Assess the safety and tolerability of tovorafenib as monotherapy, or in combination with other therapies",
5391,NCT04531228,progression-free survival,2020-10-11,UNKNOWN,INTERVENTIONAL,['NA'],adverse effects,
5392,NCT05375708,Progression-free survival,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Depth of response,
5393,NCT05509478,ORR,2022-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS) Rate at 12 months,
5394,NCT02192333,"Mean of the two z scores of the two highest scores for the symptoms that determined the participant's eligibility as ""high need"" assessed using patient-reported outcomes (PRO) survey",2015-08-03,COMPLETED,INTERVENTIONAL,['NA'],Social support assessed using the patient-reported outcomes (PRO) survey,
5395,NCT03468244,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall Survival of Personalized mRNA Tumor Vaccine,
5396,NCT04249622,"Reduction rate of >= grade 2 abdominal toxicities including abdominal distension, abdominal pain, diarrhea, dyspepsia, stomach pain, and typhlitis",2020-09-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Other pertuzumab induced gastrointestinal toxicities (PIGT) such as abdominal pain, bloating and flatulence","Difference in the fecal microbiome, hydrogen breath test, and permeability test"
5397,NCT03109938,Diagnostic Accuracies,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,
5398,NCT03125343,3-year disease free survival.,2017-01,RECRUITING,INTERVENTIONAL,['NA'],Health economic evaluation,
5399,NCT04848753,To compare IRC-assessed events-free survival (EFS) in 2 arms,2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],5- year OS rate,
5400,NCT06001658,Average minimum Euclidean distance from CD8+ T cells to immunosuppressive tumor-associated macrophages (TAMs) at the per-cell level in patients with a major pathologic response versus pathologic non-responders.,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],R0 resection rate,
5401,NCT04323722,Evaluate using imaging techniques and dosimetric analysis the performance of empty versus filled bladder radiotherapy treatment,2020-09-08,RECRUITING,INTERVENTIONAL,['NA'],IMRT (Intensity-Modulated Radiotherapy) dosimetric study in patients with filled or empty bladder,
5402,NCT02393703,successful isolation of exosomes,2015-03,RECRUITING,OBSERVATIONAL,['NA'],evaluation of the liver microenvironment,
5403,NCT01311050,,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5404,NCT00628784,"Confirm the feasibility and safety of endoscopic cryotherapy in patients with Barrett's esophagus with LGD, HGD, intramucosal cancer and in patients with severe squamous dysplasia.",2007-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],"Assess the incidence of side effects, complications, adverse events and number of treatment sessions needed to reach primary endpoints.",
5405,NCT05398822,Local recurrence of rectal cancer,2019-07-18,COMPLETED,OBSERVATIONAL,['NA'],,
5406,NCT00005076,Determine the complete and partial response rates and time to progression in patients with refractory advanced colorectal carcinoma treated with cetuximab and irinotecan.,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine the tumor epidermal growth factor receptor levels in patients treated with this regimen,
5407,NCT06326892,Surgical Site Infections (SSI),2023-07-31,RECRUITING,OBSERVATIONAL,['NA'],Overall postoperative complications,
5408,NCT00242723,"permit evaluation of patients referred to the Thoracic Surgery Branch, NCI in order to identify individuals who will be suitable candidates for treatment/intervention protocols",2005-11-09,RECRUITING,OBSERVATIONAL,['NA'],,
5409,NCT04739202,Objective response rate,2021-03-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Safety, treatment-related adverse events",
5410,NCT00969410,To evaluate safety and tolerability of AV-299 (formerly SCH 900105) administered IV in subjects with advanced solid tumors who have liver metastases,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],To investigate the effect of AV-299 (formerly SCH 900105) on gene expression patterns in peripheral blood mononuclear cells and liver biopsies in subjects with advanced solid tumors who have liver metastases,
5411,NCT03939975,Response,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
5412,NCT02561494,Change of the administered fentanyl dose from postoperative 6 h to postoperative 5 day,2015-06,COMPLETED,INTERVENTIONAL,['NA'],Change of the pain score from postoperative 6 h to postoperative 5 day,
5413,NCT06087718,Clinical feasibility of the Maastro boosting technique.,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Complications within the first 30 days after completion of salvage total mesorectal excision (TME) surgery up to 3 years after treatment.,Collecting 3D ultrasound measurements of the gross tumor volume (GTV) and intestinal wall layers at every fraction of Maastro applicator brachytherapy.
5414,NCT03570502,Postoperative pancreatic fistula according the 2016 update of the International Study Group (ISGPS),2016-11,UNKNOWN,OBSERVATIONAL,['NA'],Diabetes,
5415,NCT00660699,Incidence of Severe Toxicities,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
5416,NCT01813253,Overall Survival,2013-05-13,TERMINATED,INTERVENTIONAL,['PHASE3'],Incidence of adverse events,
5417,NCT02896803,Response rate,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicities according CTCAE v4.03,
5418,NCT04188990,Mortality rate,2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],Patient's functional status,
5419,NCT03782428,"Level of circulating inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10, IL-12, IL-17A, IL17C &IL-22) pre and post intervention.",2016-08-26,COMPLETED,INTERVENTIONAL,['NA'],Number of patients with chemotherapy induced diarrhoea assessed by CTCAE v3.0,
5420,NCT04214990,The incidence of gastric cancer between the intervention and placebo groups,2020-02-15,RECRUITING,INTERVENTIONAL,['PHASE3'],Improvement of atrophy and intestinal metaplasia,
5421,NCT01164202,Percentage of Patients With Occurrence of Severe Bleeding and/or Liver Failure,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Disease-free Survival,
5422,NCT05485077,Negative predictive value and positive predictive value of polygene methylation in colorectal cancer,2022-07-09,RECRUITING,OBSERVATIONAL,['NA'],,
5423,NCT01477866,All cause mortality,na,SUSPENDED,INTERVENTIONAL,['NA'],,
5424,NCT02089763,Time to progression (TTP),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety profile of PEG-BCT-100 treatment,"Biomarker study - to explore the predictive and prognostic functions of tissue biomarkers, ornithine transcarbamylase (OTC) and arginine succinate synthetase (ASS)"
5425,NCT04868877,To evaluate the ORR of MCLA-129 alone or in combination with Osimertinib in molecularly defined populations of advanced/metastatic solid tumors.,2021-04-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Proportion of patient with treatment discontinuations,
5426,NCT04556253,The rate of pathologic complete response(pCR%),2020-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5427,NCT02373020,"virulence genes: eaeA, bfpA and stx. PCR",2011-01,COMPLETED,OBSERVATIONAL,['NA'],Strains: OF E COLI,
5428,NCT05068076,Comparison of treatment response two hours post procedure with Perfluorobutane with routine CECT/CEMRI done at 1 month post procedure using modified RECIST criteria for HCC.,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],Targeting of lesions (fulfilling CEUS LIRADS 4/5 criteria) in the Kupffer phase for ablation,
5429,NCT01175317,Peak Value of I-FABP,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Average Intraoperative CO2 Gap,
5430,NCT02648282,Distant Metastasis Free Survival (DMFS),2016-07-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Experiencing a Grade 3 or Above Treatment Related Toxicities,
5431,NCT03418948,Adenoma miss rate (%),2017-12-08,UNKNOWN,INTERVENTIONAL,['NA'],To compare patient reported outcomes e.g. pain,
5432,NCT01294202,Rate of reduction/stabilisation of tumour size at 4 months according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"Treatment emergent adverse events, classified by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.",
5433,NCT05313906,ORR,2022-05-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],DCR,
5434,NCT02370498,Overall Survival (OS) in PD-L1 Positive Participants,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of All Participants That Discontinued Study Treatment Due to AE,
5435,NCT02057146,Accuracy of single operator endoscopy plus pCLE in the biliary and pancreatic ductal system diagnosing premalignant and malignant lesions.,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,
5436,NCT04695184,anastomotic leak,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],Length of post-operative hospital stay,
5437,NCT00737802,Pressure at the gastric sling and clasp fibers,2013-04-12,TERMINATED,OBSERVATIONAL,['NA'],,
5438,NCT06322563,SAE-Safety and Tolerability,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
5439,NCT02597348,5 years overall survival (OS),2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"Quality of life (QOL) of patients of Group LT followed by chemotherapy, using the NIDDK questionnaire of Liver Transplantation Database",
5440,NCT00391118,Part 2: Progression-Free Survival (PFS),2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"PK: AUC During the Dosing Interval at Steady State (AUCτ,ss) for Part 2 of Study",
5441,NCT01717066,time to recurrence,2012-04,COMPLETED,INTERVENTIONAL,['NA'],overall survival,side effect
5442,NCT04514835,Progression-free survival（PFS）,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Objective Response Rate，ORR,Exploratory analysis of biomarkers for predicting efficacy
5443,NCT03289533,Number of Participants With Abnormal Laboratory Parameter Values (Chemistry) as Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Version (v) 4.03,2017-09-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With Positive Anti-Drug Antibodies (ADAs) and Positive Neutralizing Antibodies (nAbs),
5444,NCT03030937,Adverse Event（AE）,2017-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of Life (QoL),
5445,NCT04915833,Polyp detection rate of computer-aided following standard colonoscopy.,2021-04-26,UNKNOWN,INTERVENTIONAL,['NA'],Adenoma miss rate of standard high-definition colonoscopy.,
5446,NCT00093782,Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria),2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Progression,
5447,NCT01985958,Number of Participants With Adverse Events,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,
5448,NCT01131234,Incidence of adverse events as graded by the NCI CTCAE version 4.0,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Preliminary antitumor efficacy,
5449,NCT01105650,Response Rate,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
5450,NCT00006366,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5451,NCT04392479,Overall response rate (ORR).,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Exploratory biomarkers,
5452,NCT03767517,Patient symptom burden (Edmonton Symptom Assessment Scale [ESAS]),2020-08-24,COMPLETED,INTERVENTIONAL,['NA'],Patient satisfaction with care (Feeling Heard and Understood),Exploratory Aim 1f. Caregiver bereavement (Caregiver Bereavement Items ([CBI])
5453,NCT05513261,Adenoma Detection Rate (ADR),2023-11-17,RECRUITING,INTERVENTIONAL,['NA'],Characterization of the detected lesions.,
5454,NCT00020917,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5455,NCT03309917,Change in internal carotid artery blood flow when mean arterial pressure (MAP) is set to 80-85 and 60-65 mmHg,2017-12-27,COMPLETED,INTERVENTIONAL,['NA'],Comparison of the slope of linear regression of MAP and internal carotid artery blood flow for the evaluations when MAP is set to 80-85 and 70-75 mmHg and that of the evaluations when MAP is set to 70-75 and 60-65 mmHg,
5456,NCT06212635,Correlation between systemic inflammation and hemostasis measured by novel assays,2022-12-02,RECRUITING,OBSERVATIONAL,['NA'],Number of participant going to transplant,
5457,NCT01679054,Expected and Unexpected Provider Costs,2011-10,COMPLETED,OBSERVATIONAL,['NA'],Expected and Unexpected Societal Costs,
5458,NCT03823079,the duration after returning to normal,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],the rate of pathological complete response.,
5459,NCT02558205,Correlation of CT perfusion metrics to radiation dose deposition of Y-90 as measured by PET/CT,2015-07,WITHDRAWN,OBSERVATIONAL,['NA'],Correlation between CT perfusion metrics and post treatment response as measured by RECIST 1.0 criteria,
5460,NCT04150874,Number of Participants with Early Tumor Response,2020-02-19,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Number of Participants with Early Signs of Radiation Induced Liver Disease (RILD),
5461,NCT05566249,Cost,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],Oncologic outcomes,
5462,NCT03543514,Crompehension Complexity Index (CCI),2022-02-02,RECRUITING,OBSERVATIONAL,['NA'],Hospital Anxiety and Depression Scale (HADS),
5463,NCT06287814,3-year disease-free survival (DFS),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Time to molecular recurrence,
5464,NCT05512377,Objective response (OR),2022-11-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Change from baseline in EORTC QLQ-BIL21 tiredness domain score,
5465,NCT05765214,CRC-KPSS change and screening uptake,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
5466,NCT01061515,Overall survival,2011-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
5467,NCT00021047,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5468,NCT00012324,Overall survival,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Response to treatment in patients with and without prior therapy,
5469,NCT02616926,overall survival,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],disease free survival,
5470,NCT03616431,Determine prevalence of pancreatic enzyme insufficiency in patients with pancreatic neoplasms.,2018-07-03,COMPLETED,OBSERVATIONAL,['NA'],"To identify, through semi structured interviews and thematic analysis, diet-related themes of interest in a subset of patients involved in this study",
5471,NCT05281211,Number of participants experiencing 90 day morbidity,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],Number of participants being disease free (Disease free survival),
5472,NCT05047991,Progression-Free Survival (PFS),2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],UGT1A1,
5473,NCT04821258,Rate of complications.,2021-04,UNKNOWN,INTERVENTIONAL,['NA'],Quality of life assessment.,
5474,NCT00962312,6-month survival rate,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumour biomarker analysis,
5475,NCT01642797,number of participant with gastric IM/IN/CA,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],number of biopsies needed per patient,
5476,NCT04975932,Progression free survival(PFS),2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],Adverse event(AE),
5477,NCT05942560,Change in anxiety symptoms at 12 months,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
5478,NCT05692024,Change in hepatic fat fraction.,2024-03-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in liver fibrosis assessment and plasma levels of liver enzymes,Change in stool metabolomics
5479,NCT01152710,complete pathological remission rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],long-term rectal and urogenital morbidity,
5480,NCT05336058,Screening of genetic targets for kit development,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5481,NCT00086996,Pathological Complete Response,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free Survival,
5482,NCT05155124,Incidence of DLT（Dose-limited toxicity）,2022-09,RECRUITING,INTERVENTIONAL,['PHASE1'],Adverse Eevents,
5483,NCT00261378,Objective response rate measured according to RECIST and EASL,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Time To Progression,
5484,NCT05536102,Pathological complete remission rate,2022-09-05,RECRUITING,INTERVENTIONAL,['PHASE2'],3-year PFS rate,Adverse events (AEs)
5485,NCT02950025,"Number of Grade 3 or Greater Toxicity Occurring in Patients Receiving Online, Adaptive, MRI-guided SBRT to the Abdomen and in Patients Receiving Non-adaptive SBRT",2017-01-19,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Local Failure,
5486,NCT05520788,Progression-free survival (PFS),2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],Quality of Life (QoL) after treatment,
5487,NCT03148093,Reasons for dose adjustments and/or discontinuation of treatments,2017-06-30,TERMINATED,OBSERVATIONAL,['NA'],Burden for caregivers providing support to patients enrolled in the registry per Modified Caregiver Strain Index (MCSI),Progression free survival
5488,NCT05465993,recurrence rate,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],Incremental cost-effectiveness ratios (ICERs),
5489,NCT05825664,Curative rate,2023-04-07,RECRUITING,INTERVENTIONAL,['NA'],Procedure time,
5490,NCT04021277,Number of patients with adverse device effects,2019-09-17,RECRUITING,INTERVENTIONAL,['PHASE1'],Best overall response (Part 1b only),
5491,NCT02226289,Response rate,2020-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression free survival,
5492,NCT03732768,Maximum Tolerated Dose (MTD),2020-06-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,
5493,NCT04478175,Program faisability,2021-04-29,COMPLETED,INTERVENTIONAL,['NA'],Patient's satisfaction measured by VAS,
5494,NCT02976909,R0 resection rate,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse envents,
5495,NCT02466009,Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability.,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Subject's Quality of Life as Assessed by the Comprehensive Geriatric Assessment Form While Receiving Study Treatment.,
5496,NCT03762837,Gallbladder cancer,2019-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
5497,NCT04923646,Return proportion,2021-06-30,COMPLETED,INTERVENTIONAL,['NA'],Return proportion,
5498,NCT00217581,Time to Progression,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
5499,NCT06012734,The RP2D of LB-100 when given in combination with standard doses of atezolizumab,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],The incidence of dose-limiting toxicity,Concentration of LB-100 and endothall in tumor tissue
5500,NCT03585673,Overall response rate,2018-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse event,
5501,NCT05828875,Quality of Life Assessment survey,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
5502,NCT06233253,Satisfaction with the intervention (Acceptability),2023-09-29,RECRUITING,INTERVENTIONAL,['NA'],Intent for future CRC screening,
5503,NCT00003216,,1998-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5504,NCT04801511,PCR rate,2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],2-year disease-free survival rate,
5505,NCT05907642,Low Anterior Resection Syndrome Questionnaire Score,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],The European Organization for Research and Treatment of Cancer quality of life questionnaire c-30,
5506,NCT01290783,Progression Free Survival (PFS),2011-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Safety,
5507,NCT03843957,Percent of Patients Who Complete the mPATH-CRC Program,2019-10-31,COMPLETED,INTERVENTIONAL,['NA'],mPATH-CheckIn Feasibility,
5508,NCT00207831,Compare the rate of pathologic complete response of the primary tumor in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],Compare overall survival,
5509,NCT00006115,,1999-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5510,NCT04955730,Surgical Site Infection - Organ/Space Incisional,2021-08-05,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Time to Initiation of Planned Oncologic Therapy,
5511,NCT01063192,The primary end point is to evaluate the time to progression after gemcitabine alone versus Gemcitabine-based combination induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer.,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],"The secondary end points are to evaluate the disease control rate, overall survival time, toxicity profile and compliance after induction chemotherapy and concurrent chemoradiotherapy .",
5512,NCT00030797,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5513,NCT04477343,Maximum tolerable dose [Safety and Tolerability],2020-11-23,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival,
5514,NCT00005586,All-cause mortality,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease recurrence,
5515,NCT01797770,anastomotic leak,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],Readmission,
5516,NCT05710809,Dynamic Gait Index (DGI),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Body composition,Recurrence of cancer
5517,NCT00855218,Time to Progression (TTP) - Independent Radiological Review (Primary Analysis),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor Response - Investigator Assessment,
5518,NCT01129778,Percentage of Time Esophageal pH< 4,2009-11,TERMINATED,INTERVENTIONAL,['NA'],Reflux Disease Questionnaire Score on Day 1 After Therapy Completion,
5519,NCT06281405,Complete response (CR) rate,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of surgical complications,
5520,NCT06218433,Sensitivity and specificity of positive utDNA for urothelial cancer within one year of follow-up,2023-04-10,RECRUITING,INTERVENTIONAL,['NA'],Urothelial cancer grade,Cost of utDNA screening
5521,NCT01555801,Diagnostic accuracy,2012-02,UNKNOWN,INTERVENTIONAL,['NA'],,
5522,NCT01339273,Morphine Consumption in the First 48hours After the Operation,2011-09,COMPLETED,INTERVENTIONAL,['NA'],Time to Hospital Discharge,
5523,NCT00001240,,1989-01,COMPLETED,OBSERVATIONAL,['NA'],,
5524,NCT02611024,Response Rate,2016-05-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
5525,NCT02122523,Number of fluorescent lymph nodes,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Number of Lymph nodes with metastasis,
5526,NCT04728321,Objective response rate (ORR),2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events (AEs),
5527,NCT03386825,"BRAF mutation (yes, no, unknown)",2018-01-31,COMPLETED,OBSERVATIONAL,['NA'],Duration of treatment (months),
5528,NCT03606590,Overall response rate,2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],Severity and frequency of adverse events,
5529,NCT00010166,,2000-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5530,NCT00861107,evaluation of any drug-related toxicity associated with AlloStim administration as well as the reversibility of such toxicity.,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",evaluation of the immunological response to AlloStim administration,
5531,NCT00129870,Time to treatment failure (TTF) for the conventional oxaliplatin (CO) schedule in comparison with the intermittent oxaliplatin (IO) schedule,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4'],Reasons for treatment discontinuation,
5532,NCT00884520,Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.,2009-04,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
5533,NCT05182255,Number of participants with clinically relevant device migration,2022-04-28,RECRUITING,OBSERVATIONAL,['NA'],,
5534,NCT02945878,gradings of oral mucositis,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,
5535,NCT00003439,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5536,NCT00290316,To compare the accuracy of the EUS and CT scan for detection of the primary and metastatic carcinoma of the liver.,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],2.2.5 To study characteristic echoendoscopic findings of the primary and secondary liver tumor.,
5537,NCT02567942,natural killer cell activity,2016-02,COMPLETED,INTERVENTIONAL,['NA'],helper T cell activity,change of percentage of CD39 and CD73
5538,NCT05051670,major complication,2021-12-16,COMPLETED,INTERVENTIONAL,['NA'],Hospital stay,
5539,NCT00059891,Determine the risk of complications and feasibility of total anorectal reconstruction using the Acticon Neosphincter prosthesis after abdominoperineal resection in patients with anal or rectal cancer.,2003-01,COMPLETED,INTERVENTIONAL,['NA'],"Determine continence, bowel function, and quality of life of patients treated with this surgery.",
5540,NCT03719716,Health related quality of life: EuroQol EQ-5D-5L,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],Trial feasibility assessment: conversion rate,
5541,NCT05917990,Changes in constructive communication,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5542,NCT00557024,Overall survivals,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],Recurrence rates,
5543,NCT00503867,Number of Participants With Adverse Events Grade 3 or Higher,2007-07-18,TERMINATED,INTERVENTIONAL,['NA'],Overall Survival,
5544,NCT05257863,Development of a preoperative score for morbidity/mortality in colorectal surgery,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5545,NCT01233713,Overall post-operative complication rate defined according to the Clavien-Dindo Classification,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",In-hospital costs,
5546,NCT02723942,Radiological assessment,2015-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",CAR-T cell testing,
5547,NCT00752063,Progression-free survival,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Tumor response rate, overall survival and safety of the regimen in HCC patients",
5548,NCT05274204,,na,TEMPORARILY_NOT_AVAILABLE,EXPANDED_ACCESS,['NA'],,
5549,NCT01683357,feasibility on an intention-to-treat basis,2001-09,COMPLETED,OBSERVATIONAL,['NA'],safety of the procedure,reliability of the procedure from an oncological standpoint
5550,NCT04824053,"Change from baseline levels in pro-inflammatory circulating markers C-reactive protein (CRP), interleukin (IL)-6, macrophage inhibitory cytokine 1 (MIC-1) and tumour necrosis factor alpha (TNFα), as well as in fecal calprotectin.",2022-02-28,RECRUITING,INTERVENTIONAL,['NA'],To assess the effect of treatment on colorectal adenoma recurrence,
5551,NCT02632006,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life,
5552,NCT05871164,Carcinological efficacy of pancreatic radiofrequency,2023-06-12,RECRUITING,OBSERVATIONAL,['NA'],,
5553,NCT02740985,The incidence of adverse events,2016-06-17,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression free survival,
5554,NCT00940030,"Anastomotic leakage, wound infection (including deep abscess)",2007-10,COMPLETED,INTERVENTIONAL,['NA'],patient's symptoms (through questionaire),
5555,NCT03963544,Overall survival (OS),1990-01,RECRUITING,OBSERVATIONAL,['NA'],,
5556,NCT03364907,change in tissue platinum exposure before and after flushing,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],total and unbound platinum concentration in instillate,
5557,NCT01209013,Incidence of esophageal stenosis,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Measure oligomer concentrations,
5558,NCT00372450,Change in health-related quality of life from baseline to 30 days and 3 months after self-expanding plastic stent or self-expanding metal stent placement,2006-12,WITHDRAWN,INTERVENTIONAL,['NA'],Overall rate of mortality,
5559,NCT01821612,Completion rate of all preoperative and operative therapy,2013-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Overall survival,
5560,NCT00666926,Percentage of Participants With Tumor Metabolic Response (Reduction of ≥15%) in Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET),2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Caspase-3,
5561,NCT04148378,Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing,2020-03-02,UNKNOWN,OBSERVATIONAL,['NA'],Validation of Sequencing Methods,
5562,NCT06313970,Objective response rate (ORR),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
5563,NCT00687596,Overall Survival (OS),2008-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],"Relationship Between Tumor Gene Expression of Messenger Ribonucleic Acid (mRNA) Ratio of Co-activators, Co-repressors and Efficacy Parameters",
5564,NCT04329299,Gastric cancer,2012-12-03,COMPLETED,OBSERVATIONAL,['NA'],,
5565,NCT05715255,Change in reported PRO-CTCAE Symptoms,2023-05-08,RECRUITING,INTERVENTIONAL,['NA'],Change in unscheduled health care visits,
5566,NCT01807117,Negative Predictive Values for PET-CT and PET-MRI,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,
5567,NCT00566644,Rate of atypical endometrial hyperplasia or endometrial cancer during the active follow-up period of the study,2007-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
5568,NCT03717402,Frequency of Symptom Survey Completion,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],Usability,
5569,NCT03035006,Best objective response evaluation of portal vein tumor thrombosis,2017-04-14,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival of overall disease,
5570,NCT00468416,Functioning anastomosis and no occurrence of adverse events related to device use,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5571,NCT04098237,Feasibility of completing pancreatic enzyme replacement therapy during the first 8 weeks of the study: daily compliance diary,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Mean change in daily active minutes from baseline,
5572,NCT02141945,Performance of Metabiomics Colon Polyp and Colorectal Cancer Assay,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
5573,NCT05902533,Assess patient reported GI toxicity using PRO-CTCAE Diarrhea,2023-08-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Proportion of patients requiring a treatment break due to toxicity; measured by more than 3 consecutive fractions missed.,
5574,NCT02928120,Diagnostic potential of hypermethylated DNA as a biomarker for colorectal cancer,2015-02,UNKNOWN,OBSERVATIONAL,['NA'],Hypermethylated DNA as a follow-up biomarker for disease recurrence,
5575,NCT04857203,The Role of Vitamin D in response to neoadjuvant therapy for the patients with locally advanced rectal cancer,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
5576,NCT02403050,Intra- and inter-observer variability of tumor target volume (cubic centimetres) estimation,2015-03,UNKNOWN,OBSERVATIONAL,['NA'],local recurrence of tumor,
5577,NCT06055166,PFS rate,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],AEs,
5578,NCT05235932,3-year disease free survival rate,2022-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],inflammatory immune response,
5579,NCT03658837,Quantitative Assessment using EORTC QLQ-OES-24,2019-01-03,COMPLETED,OBSERVATIONAL,['NA'],Qualitative analysis,
5580,NCT05237310,Additional Adenoma Detection,2022-02-02,UNKNOWN,INTERVENTIONAL,['NA'],,
5581,NCT00681577,safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To evaluate immunological responses,
5582,NCT02174549,Overall Response rate (ORR) by RECIST,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of Response,Progressive Free Survival
5583,NCT03311789,The percentage of patients alive and without progression at 6 months,2017-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",List of adverse event frequency and grade,
5584,NCT00026234,Survival rate,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse events as assessed by NCI CTC version 2.0,
5585,NCT05902624,Effectiveness of Hepatitis B virus vaccine(HBV) in treatment of cutaneous warts .,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5586,NCT05673434,Safety assessed by Incidence of Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs),2023-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],CAR-T cell testing,
5587,NCT03535727,Progression-free Survival (PFS) Using RECIST 1.1 Criteria,2018-06-21,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Safety of the Combination of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Patients With Untreated Metastatic PDA.",
5588,NCT00251355,To assess the maximum tolerated dose of weekly gemcitabine when administered with continuous infusion 5-fluorouracil and external beam radiation.,1998-01,COMPLETED,INTERVENTIONAL,['PHASE1'],to obtain a preliminary assessment of the efficacy of this regimen in this patient population.,
5589,NCT06027515,Completion Rate (Feasibility),2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],Actigraphy Compliance Rate (Feasibility),Patient-Reported Measures on Physical Function Score
5590,NCT02076594,Progression Free Survival (PFS),2013-01,TERMINATED,INTERVENTIONAL,['PHASE3'],"Tolerability of the treatments evaluated in term of occurrence of: side effects graded according to the NCI-CTCAE scale (version 4.0); serious adverse reactions, expected and unexpected",
5591,NCT00445497,Incidence of serious adverse events (randomized and registered patients),2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Health service costs (randomized patients),
5592,NCT00852228,Incidence of complete macroscopic resections (R0+R1) of unresectable liver metastases following chemotherapy.,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],The per-operative and post-operative complications associated to liver surgery,
5593,NCT01910974,SAFETY THAT IS TO SAY PERFORATION RATE AND delayed BLEEDING ONE,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,
5594,NCT00955344,Colorectal Cancer Screening Rates,2009-09,COMPLETED,INTERVENTIONAL,['NA'],Content of practice improvement plan,
5595,NCT05429866,Modification(s) in the immune blood markers of treated subjects on treatment at the occurence of any grade 3 or 4 irAE.,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5596,NCT05280665,30-day mortality,2022-02-14,COMPLETED,OBSERVATIONAL,['NA'],Hospital stay,Neoadjuvant treatment usage
5597,NCT04828486,Progression-free survival (PFS),2021-05-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in quality of life (QOL),
5598,NCT01698710,Frequency of Pancreatitis,2012-11,TERMINATED,INTERVENTIONAL,['NA'],Size of Cystic Lesion,
5599,NCT00012363,6-month survival rate,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicities,
5600,NCT00009880,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5601,NCT01391208,Safety of peptide application,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5602,NCT01258608,Time to Progression-Blinded Independent Central Review (BICR) Assessment,2011-02-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Serum Concentration of Mapatumumab,
5603,NCT06117891,Overall survival (OS),2023-11-27,RECRUITING,OBSERVATIONAL,['NA'],Treatment sequences post first-line AB or other IO combinations,
5604,NCT01547845,PRO symptom measurement,2012-02-10,COMPLETED,OBSERVATIONAL,['NA'],,
5605,NCT03660449,Progression-Free Survival,2017-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],rate of grade 3-4 radiation pneumonitis,
5606,NCT05575622,"CTC-PD-L1, exosomal PD-L1, and exosomal LAG-3",2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
5607,NCT05254171,Overall Survival (OS),2022-08-08,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Progression Free Survival (PFS),Exploratory
5608,NCT00416767,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5609,NCT05970666,Occurence of AE and SAE,2023-11-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival（OS）,
5610,NCT03766659,Diagnostic yield,2019-06-19,RECRUITING,INTERVENTIONAL,['NA'],morbidity rate,
5611,NCT01519817,Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine,2012-01-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Changes in Soluble Cluster of Differentiation 40L (sCD40L),
5612,NCT04191421,Maximal tolerated dose (MTD) of siltuximab that can be combined with spartalizumab,2020-01-17,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival time,
5613,NCT06057831,Correlation between PET/MRI reported pCR and complete(pCR) or incomplete response(non-pCR) to total neoadjuvant therapy determined by final pathology will be defined.,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],A feasibility study done to evaluate the benefit of using PET/MRI with respect to improved identification of the target and hence target delineation,
5614,NCT00364013,Progression-free Survival,2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Adverse Events (AEs),
5615,NCT02843802,Relief degree,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival（OS）,
5616,NCT05233436,Objective response rate (ORR) in Dose Expansion (Part 2),2022-02-24,TERMINATED,INTERVENTIONAL,['PHASE1'],Time to event endpoints (OS) in Dose Expansion (Part 2),
5617,NCT00797485,Time to failure of strategy,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Quality of life as assessed by EORTC QLQ-C30 questionnaire (v 3.0) at baseline, every 3 months during induction chemotherapy, and at discontinuation of treatment",
5618,NCT05500157,PLD-Q 4 weeks,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],Cost-effectiveness iMCQ,
5619,NCT03113604,"Rate of expression of SLAM3 and MDR transcripts, correlation with the responder status or not with Sorafenib",2015-11-20,WITHDRAWN,OBSERVATIONAL,['NA'],,
5620,NCT04930016,specific need for QoL therapy of colorectal cancers survivors in specific QoL dimensions,2021-04-14,COMPLETED,OBSERVATIONAL,['NA'],colorectal cancer survivors' recollections of their illness an therapy,
5621,NCT01087658,"Occurence of peripheral sensory neuropathy (PSN) grade 2, 3 and 4 assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE)",2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression Free Survival / PFS (for metastatic patients),
5622,NCT02150746,Percentage of patients with successful in vivo animal engraftment of isolated circulating tumor cells,2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
5623,NCT05201612,Objective response rate (ORR),2022-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of response (DOR),Biomarker molecular substudy
5624,NCT03743428,Identify biomarkers specific to apatinib or bevacizumab by proteomic analysis,2020-10-22,SUSPENDED,INTERVENTIONAL,['NA'],Overall Survival (OS),
5625,NCT00870558,Tumor recurrence at 2 years,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5626,NCT02355249,The incidence of respiratory complications,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],Health-related quality of life scores（HRQoL）,blood biomarker analysis
5627,NCT02956772,Progression free survival,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,Quality of life using EuroQol five dimensions five levels questionnaire
5628,NCT05850884,evaluate the intestinal parasitic infections in patients with intestinal cancer in comparison to non-cancer individuals,2023-11-30,RECRUITING,OBSERVATIONAL,['NA'],,
5629,NCT00997802,sensitivity in the detection of colorectal polyps and cancers in CTC,2009-10,COMPLETED,INTERVENTIONAL,['NA'],specificity and predictive values in the detection of colorectal polyps and cancers in CTC.,
5630,NCT01875549,Stent patency,2013-05,WITHDRAWN,INTERVENTIONAL,['NA'],survival period,complication
5631,NCT05999227,18F-FDG PET analysis,2023-06-20,RECRUITING,INTERVENTIONAL,['NA'],,
5632,NCT05859581,Coincidence rate with pathological result,2023-04-02,RECRUITING,INTERVENTIONAL,['NA'],,
5633,NCT03210064,ORR,2017-05-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],QoL,
5634,NCT06143579,Overall response rate (ORR),2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
5635,NCT00109850,Overall Survival at 2 Years,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression Free Survival,
5636,NCT02016274,progression free survival,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,quality of life
5637,NCT02701088,Tolerance profile: Proportion of patients with no significant toxicities responsible for irradiation breaks,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],The acute and late toxicities assessed according the SOMA/LENT scale,
5638,NCT03088423,tumor response assessments,2011-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
5639,NCT05424432,Pathologic complete response,2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Health related quality of Life related to esophageal carcinoma,
5640,NCT02191761,Determine the MTD,2014-06-19,COMPLETED,INTERVENTIONAL,['PHASE1'],Total Clearance of SM04755 after oral administration,
5641,NCT05929820,Rate of completion of a CRC screening test,2023-09-15,RECRUITING,INTERVENTIONAL,['NA'],Qualitative feedback on details of CRC screening test,
5642,NCT04744792,Disability of patients and spouses,2006-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
5643,NCT01627808,Stroke volume variation,2011-09,COMPLETED,OBSERVATIONAL,['NA'],Stroke volume variation,
5644,NCT06232538,UCAD can be used as a diagnostic technology for gallbladder cancer with the sensitivity more than 90%,2024-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5645,NCT06253520,Safety,2024-04-07,RECRUITING,INTERVENTIONAL,['PHASE1'],Safety,
5646,NCT03017807,Number of patients with dose limiting toxicity.,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of anti-EGFR antibody after single dose and under the stable blood concentration.,
5647,NCT04119830,Objective response rate,2022-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Objective response rate,
5648,NCT04147481,Incidence of postoperative chronic pain,2019-10-21,UNKNOWN,INTERVENTIONAL,['NA'],Gastrointestinal decompression,The numeric rating scale of postoperative pain
5649,NCT03260179,AE,2017-08-31,UNKNOWN,INTERVENTIONAL,['PHASE1'],PFS,Exosomes
5650,NCT03427814,Progression Free Survival (PFS) by Investigator Assessment,2018-07-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),
5651,NCT00003260,,1998-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
5652,NCT05692596,Database creation,2022-10-06,RECRUITING,OBSERVATIONAL,['NA'],,
5653,NCT02475499,Incident pancreatic cancer,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
5654,NCT03783871,Primary Technical Efficacy,2019-02-17,COMPLETED,INTERVENTIONAL,['NA'],Local tumor progression (LTP),EORTC QLQ-HCC18 Questionnaire
5655,NCT04859582,Overall Survival (OS),2018-11-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Percentage of Participants Discontinuing Study Drug Due to AEs,
5656,NCT05584592,Changes in patient's comprehensive quality of life composite,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],"Skeletal muscle mass index (Skeletal muscle mass index, SMI) changes",
5657,NCT00921869,Determination of the MTD of E7050 given orally twice daily. MTD is the highest dose at which no more than 1 out of 6 patients experiences dose-limiting toxicity (DLT),2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],"Best overall tumor response, duration of response and stable disease, assessed by Response Evaluation Criteria in Solid Tumors.",
5658,NCT02650661,Change in percentage of patients meeting the posttraumatic growth inventory (PTGI) goal,2015-11-23,COMPLETED,INTERVENTIONAL,['NA'],Cost effectiveness analysis,
5659,NCT06247956,ORR based on RECIST v1.1 assessment.,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],DCR based on RECIST v1.1 assessment,
5660,NCT05418387,Acceptability of the intervention,2022-09-30,WITHDRAWN,INTERVENTIONAL,['NA'],Proportion of patients who attend a scheduled appointment after their surgery with hepatologists or urologists in control vs. intervention group,
5661,NCT03077685,Incidence of Treatment Emergent Adverse Events (safety and tolerability),2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in tumor markers,
5662,NCT00104065,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5663,NCT04798560,Development of Postoperative pancreatic fistula after pancreaticoduodenectomy,2018-10-10,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,
5664,NCT00876551,Closure of postsurgical leak,2008-01,UNKNOWN,INTERVENTIONAL,['NA'],C reactive protein,
5665,NCT00851136,Incidence and nature of dose-limiting toxicities,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Incidence of anti-PRO95780 antibodies,
5666,NCT05012007,Percentage of returned FIT Kits,2021-08-01,COMPLETED,INTERVENTIONAL,['NA'],Percentage of returned FIT Kits,Interim analysis
5667,NCT00391183,Improvement in the physical functioning scale (containing five items) of EORTC QLQ-30 one month after after biliary stenting.,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Performance status change,
5668,NCT01364376,overall survival,2011-06,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants with grade 3/4 adverse Events,
5669,NCT02756455,% of patients without leaks after gastric surgery correctly identified by PCT and CRP,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],PCT cut-off that gives good negative predictive value for leak after gastric surgery in 5th POD,
5670,NCT05916001,Surgical site infection (SSI),2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adipocytes cross sectional area (CSA) in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT),
5671,NCT02000999,"• Sensitivity accuracy of cytology, FISH and mutation profiling using histologic diagnosis in conjunction with clinical and/or imaging follow-up as the gold standard.",2013-11,COMPLETED,OBSERVATIONAL,['NA'],• Technical success and ease of procedure,
5672,NCT01126450,"Safety / Tolerability (type, frequency, severity, and relationship of adverse events to study drug)",2009-10,TERMINATED,INTERVENTIONAL,['PHASE1'],"Lab correlatives (FCGRIIa and FCGRIIIa polymorphisms, K-Ras and B-Raf mutations)",
5673,NCT05304234,Feasibility of screening protocol,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5674,NCT02052921,Disease-free survival (DFS),2011-11,TERMINATED,INTERVENTIONAL,['NA'],Operative complication rate,Overall survival (OS)
5675,NCT03275987,screening mammography or colonoscopy,2014-04-23,COMPLETED,INTERVENTIONAL,['NA'],,
5676,NCT05549960,Feasibility of pre-planned laser setting in lesion ablation,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],Rate of resectability,
5677,NCT02236884,Composite mesure of prioperative feasibility and safety,2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Composite mesure of oncological outcome,
5678,NCT01668680,"Length of progression free survival (PFS), measured in months.",2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],"Quality of life, as expressed by FACT-C.",
5679,NCT00278876,2-year Relapse Free Survival Rate,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity Profile,
5680,NCT01613950,Incidence rate of Dose Limiting Toxicities.,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Severity of adverse events (AEs),
5681,NCT04991090,the responsive rate of dose escalation of LLN,2021-08-13,RECRUITING,INTERVENTIONAL,['NA'],prognosis outcome-3-year Lateral Local Recurrence,
5682,NCT01640782,"Progression Free Survival will be defined as the time from date of randomisation to date of first appearance of local, regional or distant relapse, or death from any cause; patients alive without relapse will be censored at date last known to be alive.",2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Adverse events,
5683,NCT04984018,OS,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],DCR,PD-L1 CPS
5684,NCT03724851,Maximum Tolerated Dose,2018-11-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacodynamics of TEW-7197,
5685,NCT05504265,Postoperative pain score,2022-08-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Rate of pulmonary infection,
5686,NCT04663763,pCR rate,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of Life Scale,
5687,NCT05709249,Two-year disease-free survival (DFS),2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Changes in total score on the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM),
5688,NCT01689792,Polyp detection rate,2011-11,COMPLETED,INTERVENTIONAL,['PHASE4'],Acceptability and tolerability of medication using patient questionnaires,
5689,NCT00855985,pancreatic fistula rate,2004-07,UNKNOWN,INTERVENTIONAL,['NA'],major complication,
5690,NCT00718562,Disease Control Rate (DCR) in all patients with either sunitinib-resistant GIST or in patients with GIST who are intolerant of sunitinib,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],PK profile,
5691,NCT05384444,Disease-free Survival,2022-06-08,RECRUITING,INTERVENTIONAL,['NA'],insulin,
5692,NCT03760614,Dose limiting toxicity (DLT),2021-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Overall response rate (ORR),
5693,NCT01165346,non-progression part,2009-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],Medical costs,
5694,NCT00096278,Disease-free Survival,2004-09-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Survival,Proteinuria After Completion of Bevacizumab
5695,NCT05627297,Good/Poor overall survival,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
5696,NCT04599140,Incidence of adverse events (AEs),2020-10-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),Biomarker analysis
5697,NCT00568529,Response Rate,2007-10,SUSPENDED,INTERVENTIONAL,['PHASE2'],time to progression and overall survival,
5698,NCT04319354,Ryan tumor regression grade system (number of patients with complete/partial/no response),2019-11-18,COMPLETED,INTERVENTIONAL,['NA'],Number of participants with 1 and 2-year disease free recurrence,
5699,NCT02464215,Postoperative complication rate,2014-03-01,UNKNOWN,INTERVENTIONAL,['NA'],3-year disease free survival rate,
5700,NCT03822572,Primary Endpoint - disease free survival (DFS),2019-02-14,RECRUITING,INTERVENTIONAL,['NA'],Exploratory Endpoint - molecular and biochemical markers (will be defined during the course of the study),
5701,NCT04999332,Curative resection rate,2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-emergent adverse event rate,
5702,NCT00084929,Number of Participants With Advanced Adenomas (>=5mm) Detected by CT Colonoscopy (Per Patient),2005-02,COMPLETED,INTERVENTIONAL,['NA'],Interobserver Sensitivity Variability,
5703,NCT06033482,The lymph node metastasis rates in No.12aa and No.12av groups.,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
5704,NCT02515513,Identify gene networks within the skeletal muscle between the groups,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],Survival data,
5705,NCT01293448,Treatment effect,2010-12,COMPLETED,INTERVENTIONAL,['NA'],Post procedure pain,
5706,NCT05920980,Pain scores of movement-evoked pain at postoperative 24 hours,2023-06-05,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],plasma lidocaine concentration,
5707,NCT05161624,"Receiver operating characteristic curve, ROC",2021-12-15,UNKNOWN,OBSERVATIONAL,['NA'],"Area under curve, AUC",
5708,NCT03066557,PFS,2017-03-15,UNKNOWN,INTERVENTIONAL,['NA'],QoL,
5709,NCT04513951,Progression-free Survival,2020-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
5710,NCT03523312,The proportion of patients who undergo definitive surgery,2018-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5711,NCT03375060,Composite histologic score of neosquamous epithelium following endoscopic eradication therapy (EET),2017-08-02,COMPLETED,OBSERVATIONAL,['NA'],Recurrence rate of intestinal metaplasia (Barrett's esophagus),
5712,NCT01585662,recurrence rate of pancreatic pseudocyst,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],The complication rate,
5713,NCT03309722,distant recurrence,2008-10-10,RECRUITING,OBSERVATIONAL,['NA'],,
5714,NCT03655002,Incidence of adverse events,2019-02-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,Circulating immune cell profiles circulating tumor deoxyribonucleic acid (DNA)
5715,NCT00480584,Maximum Tolerated Dose (MTD),2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Recommended Phase II Dose (RPTD),
5716,NCT00517920,Objective Response Rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5717,NCT05626569,1-year progression-free survival,2022-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,
5718,NCT01738217,"Third step: assess the rate of patients in whom, among the 7 liver segments, the surgeon will be able to selectively target a predefined area.",2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Third step: assess the ability of the medical device to detect tumor lesions which were previously known.,
5719,NCT02633020,Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial Lymphocytes,2016-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Total Celiac Disease GSRS (CeD-GSRS) Score at Week 12,
5720,NCT00209690,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.,
5721,NCT00004103,,1998-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5722,NCT06161909,disease-free survival (DFS),2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],recurrent metastasis pattern,
5723,NCT00166881,Overall survival (OS),2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],"Objective response rates (CR, PR)",
5724,NCT05625737,Objective Response Rate (ORR),2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Event (AEs),Exploratory endpoint
5725,NCT03895723,disease-free survival (DFS),2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Sugical complications,
5726,NCT01444014,Visual assessment of the distribution of gastric carcinoids.,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Plasma or serum concentrations of biomarkers such as gastrin and chromogranin A (CgA),
5727,NCT02737228,Overall Response Rate (ORR),2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinical laboratory tests,
5728,NCT00216034,Time of recurrence (calculation of 3-year disease-free survival and overall survival rates),2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],"Relations of survival rate with compliance, postoperative complication, QOL, adverse events, recurrence status, and expression of immune or tumor markers",
5729,NCT02598414,Anastomotic leak rate,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Mortality,
5730,NCT04097444,Progression-free survival (PFS),2019-10-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Functional Assessment of Cancer Therapy (FACT) / Gynaecologic Oncology Group (GOG) Neurotoxicity 4,
5731,NCT02454075,A Reduction of 25% in the Gastric ECL Cell Density.,2011-04-11,TERMINATED,INTERVENTIONAL,['PHASE2'],"Acid Control Study 3, Control of Gastric Acid Secretion Assess by Changes in Drug-controlled Gastric Acid Analysis: Acid Output",
5732,NCT01828918,postoperative early recurrence,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
5733,NCT02230410,Eradication of Barrett's Esophagus,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,
5734,NCT01893801,Complete Response Rate,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-Free Survival,
5735,NCT00642733,Overall survival; time to progression,2007-08,TERMINATED,INTERVENTIONAL,['PHASE4'],"AEs, lab parameters",
5736,NCT04143191,Recurrence-free survival,2019-09-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life,
5737,NCT05636618,Area under the concentration-time curve (AUC) [Time Frame: 42 days following last dose of [212Pb]VMT-α-NET; up to 3 years,2023-09-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Biodistribution of [212Pb]VMT-α-NET using a microdose of the therapeutic surrogate, [203Pb]VMT-α-NET",
5738,NCT01302613,The primary study endpoint for the phase I portion of this study is to assess surgical complications through the Clavien grading system.,2011-03,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The primary endpoint of the phase II portion of the study is complete pathologic response.,
5739,NCT01309256,Acute-inflammatory response after undergoing robotic and laparoscopic gastrectomy,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
5740,NCT04869956,Surgical site infection,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],Recurrences of CRC after surgery,
5741,NCT03521037,Area under the plasma rucaparib concentration-time curve from time zero up to the last time point with quantifiable concentration (AUC0-last),2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],Incidence of dose modifications [Safety and Tolerability],Cumulative amount of rucaparib metabolite(s) excreted in urine during urine collection period post rucaparib dose
5742,NCT03252808,Dose Limiting Toxicity (DLT),2017-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-free survival (PFS) by irRECIST,1 year survival rate
5743,NCT04304209,complete response rate,2019-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor response,
5744,NCT00611858,Pathological Complete Response Rate,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],1-Year Overall Survival Rate,1-Year Disease-Free Survival Rate
5745,NCT04732494,Objective Response Rate (ORR) Assessed By The Investigator's Review Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1,2021-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events And Serious Adverse Events,
5746,NCT00165633,Relapse-free survival period.,2004-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
5747,NCT05297903,Objective Response Rate (ORR),2022-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Objective Response Rate (ORR) in patients who did not received prior immunotherapy,
5748,NCT05951842,Postoperative immune function (NK cell count),2018-04-16,WITHDRAWN,INTERVENTIONAL,['NA'],,
5749,NCT04792892,Toxicity related to treatment,2021-08-01,RECRUITING,OBSERVATIONAL,['NA'],Sexual function,
5750,NCT01402687,Develop and validate a clinically applicable SNP-based screening platform for mucositis risk,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,
5751,NCT03886753,Change in symptoms,2019-05-15,TERMINATED,OBSERVATIONAL,['NA'],Assess therapeutic range,
5752,NCT00281788,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5753,NCT04535401,"Maximum tolerated dose (MTD) of elimusertib (BAY 1895344) in combination with irinotecan, fluorouracil, and leucovorin (FOLFIRI)",2021-08-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],ATM status,Status of deoxyribonucleic acid damage repair (DDR) genes
5754,NCT01425879,Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free Survival,
5755,NCT05930496,Acceptability,2024-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Effects of an 8 week supervised exercise intervention on fecal concentrations of other short chain fatty acids,
5756,NCT00911092,Initial complete clinical response,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Prolonged clinical response at one year,
5757,NCT01472250,chemotherapy regimen,2011-11,COMPLETED,OBSERVATIONAL,['NA'],treatment expense,
5758,NCT01891552,time to progression,2013-05,COMPLETED,OBSERVATIONAL,['NA'],number of adverse events,quality of life
5759,NCT00427102,Determine pharmacokinetic parameters of oral MRX-1024.,2007-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Possibly show a trend in activity of MRX-1024 in preventing or reducing oral mucositis.,
5760,NCT06190301,The cumulative occurrence rate of complications of grade ≥2 within 2 years after treatment commencement,2024-01-11,RECRUITING,INTERVENTIONAL,['NA'],overall survival,
5761,NCT01050426,"One year overall survival, measured from the date of registration.",2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],"Evaluation of the role of FDG-PET in predicting overall survival, progression free survival and objective response rate in locally advanced pancreatic cancer.",
5762,NCT04632199,Incidence of Treatment-emergent adverse events,2021-03-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Optimal injected radioactivity range,
5763,NCT00230451,To determine the rate of complete histologic response induced by this neoadjuvant chemotherapy and radiation therapy regimen.,1997-11,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess the qualitative and quantitative toxicities of this regimen.,
5764,NCT01330186,Tumor response,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,
5765,NCT00071994,Progression-free survival rate in patients treated with ZD 1839,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],EGFR expression,
5766,NCT04571294,Overall Survival (OS),2020-05-26,RECRUITING,INTERVENTIONAL,['NA'],post-operative outcomes,
5767,NCT05842187,PFS (Progressive free survival),2023-03-03,RECRUITING,INTERVENTIONAL,['NA'],DCR (Disease control rate),
5768,NCT00447967,Objective Response Rates,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Symptoms improvement,
5769,NCT02799251,Presence of post operative infection,2016-06,COMPLETED,OBSERVATIONAL,['NA'],Anesthetic and surgical parameters,
5770,NCT02761408,Number of participants with treatment-related adverse events assessed by CTCAEv5.0,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],,
5771,NCT00152243,Overall survival and relapse-free survival,1997-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Adverse events,
5772,NCT00637988,Measure PGE production in Barrett's metastatic tissue & determine the reduction from baseline of PGE production would be equivalent on Day 10 in esomeprazole 40mg bid + aspirin treatment compared to esomeprazole 40 mg bid + rofecoxib 25 mg qd treatment,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4'],"To determine in which of the four treatment groups the reduction in the baseline in PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue is the greatest.",
5773,NCT03009253,translational resection rate,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],Local control rate,
5774,NCT02532803,Measurement of the accuracy of a novel MRI assessment tool to accurately stage Early Rectal Cancers and Polyps,2015-08-13,UNKNOWN,INTERVENTIONAL,['NA'],Measurement of the Sensitivity and specificity of MRI for lymph node metastasis,
5775,NCT02175992,Health-related quality of life,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
5776,NCT02975141,MTD of afatinib in combination with gemcitabine/nab-paclitaxel,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],Incidence of Treatment-Emergent Adverse Events,
5777,NCT03463876,Objective Response Rate (ORR),2018-02-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival(PFS),
5778,NCT01239355,Progression-free Survival,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
5779,NCT00207051,determination of maximum tolerated dose (MTD),2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Efficacy based on duration of response and time to progression based on assessment,
5780,NCT00759226,Primary endpoint rate of freedom of progression (PR+CR+SD).,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],"Secondary endpoint median survival, progression free survival and toxicity.",
5781,NCT01724775,Prognosis assessment of postoperative patients,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],Safety assessment of the patients in perioperation period,
5782,NCT00381706,Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma,2006-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Treatment Failure in Patients With Adenocarcinoma,
5783,NCT05290480,'Patient Mobility and Observer Mobility Scale,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
5784,NCT04852367,To quantify the enhancement in intratumoural doxorubicin concentration when delivered with ThermoDox® and mild hyperthermia generated non-invasively by focused ultrasound (FUS) compared to free drug alone,2021-06-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Change in patient symptom scores in patients with pancreatic cancer treated with of ThermoDox® and FUS compared to those treated with doxorubicin,To assess effects of ThermoDox® and FUS treatment compared to free drug alone on pancreatic tumour biomarkers
5785,NCT04534309,Weight change at 6 months in Coach-Directed Program,2020-09-22,COMPLETED,INTERVENTIONAL,['NA'],Weight change at 6 months in Self-Directed and App-Directed Weight Loss Programs,Weight change at 12 months by program
5786,NCT05204433,effectiveness of methylation markers from stool samples,2019-01-05,UNKNOWN,OBSERVATIONAL,['NA'],assess the capacities of RF model in screening potential clinical biomarkers.,
5787,NCT05511051,Overall Survival,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],"Safety and tolerance evaluated by incidence, severity and outcomes of AEs",
5788,NCT01523808,Number of Patients With Dose-limiting Toxicities up to Week 4 After Treatment,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Summary of CA 19.9 Over Time,
5789,NCT02636738,Technique success,2016-06-06,TERMINATED,INTERVENTIONAL,['NA'],,
5790,NCT04715308,To assess the impact of urinary diversion/reconstruction subtypes on quality-of-life,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],To measure the rate of reintervention for complications associated with urinary diversion/reconstruction,
5791,NCT00210106,Complete Hepatic Response Rate at 3 Months,2003-06,COMPLETED,INTERVENTIONAL,['NA'],Event-free Survival,
5792,NCT02818907,"disease-free survival according to the consensus DATECAN (Bonnetain F et al, European Journal of Cancer 2014)",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,
5793,NCT00601705,Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate,2008-01-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Postoperative Adjuvant Chemoradiotherapy Feasibility,
5794,NCT01221324,postoperative inflammatory complications,2010-11,COMPLETED,OBSERVATIONAL,['NA'],Anastomotic leakage,
5795,NCT01625351,Feasibility of haploidentical HSCT,2012-08-20,COMPLETED,INTERVENTIONAL,['PHASE1'],event-free survival,
5796,NCT01787864,Presence of dysplasia before and after ablation,2013-02,COMPLETED,OBSERVATIONAL,['NA'],,
5797,NCT02359565,Change in the percentage of CD8+ T cells that are PD-1+ due to treatment with pembrolizumab (Stratum C),2015-05-22,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in quantitative imaging parameters,
5798,NCT05409417,Drug Safety,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",DCR,
5799,NCT02975661,Disease free survival (DFS),2017-02-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Concomitant medication,
5800,NCT01939665,Safety (number of adverse events),2013-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumor response,
5801,NCT03716596,overall survival,2018-10-22,UNKNOWN,INTERVENTIONAL,['PHASE1'],Related tumor markers,
5802,NCT03006705,Relapse-free survival (RFS),2017-01-31,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety will be analyzed through the incidence of laboratory abnormalities,
5803,NCT01053104,"Toxicities (frequency at each of grades 2, 3 and 4, over all cycles)",2009-11,COMPLETED,OBSERVATIONAL,['NA'],Dose intensity in mg/m2/week and toxicities as for stage 1,
5804,NCT04791644,This study will compare fecal microbiota richness and composition differences between LS patients with no previous adenoma at inclusion in AAS-Lynch study and LS patients with history of adenoma or adenoma at inclusion in AAS-Lynch study.,2021-04-20,RECRUITING,OBSERVATIONAL,['NA'],Gut microbiota composition description,
5805,NCT03748927,"Characterize the natural history of Fibrolamellar hepatocellular carcinoma (FL- HCC), including clinical presentation, family history, patterns of disease progression, response or lack of response to therapeutic interventions, disease recurre...",2019-04-08,WITHDRAWN,OBSERVATIONAL,['NA'],,
5806,NCT01471249,improvement of dysphagia post stenting,2011-06,TERMINATED,OBSERVATIONAL,['NA'],Quality of life post stenting,
5807,NCT06309485,Efficacy of WGI-0301 in combination with Sorafenib based on ORR per RECIST 1.1.,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Anti-tumor activity if WGI-0301 in combination with Sorafenib based on OS.,
5808,NCT05600309,Overall Survival (OS),2022-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score,
5809,NCT00438906,To determine the diagnostic yield of screening high risk patients,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,
5810,NCT00503321,progression-free survival,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Anticancer effect, time to treatment failure (TTF), QOL (FACT-BRM), compliance, adverse drug reactions and immunological factors",
5811,NCT03972956,Confirmation of diagnosis by pathologist,2020-12-23,RECRUITING,OBSERVATIONAL,['NA'],,
5812,NCT05019794,Objective Response Rate (ORR),2020-05-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Accumulation ratio (Racc),
5813,NCT03410914,Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF),2018-08-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Average Length of Stay in Hospital,
5814,NCT01790139,Colonic bubble-related image quality,2013-02,COMPLETED,INTERVENTIONAL,['NA'],diagnostic performance,
5815,NCT04820712,Overall survival,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],Cancer-specific survival,
5816,NCT04766502,Peritoneal Regression Grading Score (PRGS),2022-01-11,RECRUITING,INTERVENTIONAL,['NA'],Quality of life mesure,
5817,NCT03837301,complete resection rate (%) of tumor,2018-09-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5818,NCT06216743,Sensitivity and specificity of different MRI sequences to diagnose T4 colon carcinoma.,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Establishing an MRI Protocol that is optimized for the clinical staging of colon tumors,
5819,NCT02495896,Progression-free survival,2015-09-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
5820,NCT05674773,Metachronous (advanced) neoplasia,2019-05-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Associations with treatment choice,
5821,NCT00290615,Response Rate (Percentage of Participants With Partial or Complete Response),2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,Effect on Wound Angiogenesis
5822,NCT02981498,progression-free survival rate,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],AE event,
5823,NCT03631641,Incidence rate of non-colonic cancers,2018-08-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5824,NCT02776683,Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs) in the Specified Categories Selected for Primary Endpoint Assessment,2016-06-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression-Free Survival (PFS) Time as Assessed by Central Imaging Review,
5825,NCT06251050,The incidence of Severe Oral mucositis (WHO grade ≥3),2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Taste function,
5826,NCT04574245,5-year overall survival,2010-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],The prognostic predictive value for patients with different C-GCLM classification,
5827,NCT02077777,Molecular analysis of gene expression levels of μ-protocadherin and other related proteins,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"Evaluation of protein expression level of μ-protocadherin, Ki-67, Caspase-3 and Histone H2AXγ, evaluation of DNA oxidative damage and intra-mucosal concentration of 5-Acetylsalicylic acid",
5828,NCT00402025,Number of Participants Positive for Anti-herpes Simplex Virus-1 (HSV-1) Antibodies,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Change From Baseline in Pain Intensity,
5829,NCT06314737,Overall Survival,2010-10-02,COMPLETED,OBSERVATIONAL,['NA'],,
5830,NCT02792023,The number of patients with colorectal cancer among those with a positive immunochemical fecal test (Positive predictive value),2016-06-30,UNKNOWN,INTERVENTIONAL,['NA'],The number of patients without a significant lesion among those with a negative immunochemical fecal test (negative predictive value) after the colonoscopy and after the upper endoscopy,
5831,NCT01505205,,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,
5832,NCT03528863,Acceptability as assessed by adherence to practice instructions,2018-05-07,COMPLETED,INTERVENTIONAL,['NA'],"Efficacy as assessed by a ""Are You at Peace?"" one-item spiritual probe",
5833,NCT00002689,Survival,1995-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Patterns of failure,
5834,NCT03547999,Overall Survival (OS),2018-06-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),
5835,NCT00660894,Disease-free survival,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Identification of predictive markers,
5836,NCT01874938,Progression Free Survival (PFS) Rate,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2'],PFS,
5837,NCT06223061,"Compliance to pre-, intra-, and post-operative audit standards",2023-07-31,RECRUITING,OBSERVATIONAL,['NA'],Rates of unsuspected gallbladder cancer.,
5838,NCT01133340,To define the usefulness of Endoscopic clip placement and 3T-MRI imaging for accurate target volume definition in rectal cancer patients undergoing pre-operative chemoradiation.,2010-06,COMPLETED,INTERVENTIONAL,['NA'],To assess the differences in pelvic lymph node (CTV) volume definition between Ct and MRI images.,
5839,NCT00047762,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5840,NCT00349076,"Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.",2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],"Resection rate, rate of sphincter preservation, tumor regression, cumulative incidence of local and distant recurrences, overall survival, toxicity, quality of life",
5841,NCT05523960,the rate of major complications,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5842,NCT02632188,Progress-free survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life,
5843,NCT03975049,Disease-free survival,2019-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Treatment related quality of life,Tumor regression grade after neoadjuvant therapy
5844,NCT00489697,evaluation of the response to bevacizumab based chemotherapy by RECIST criteria,2007-01,COMPLETED,INTERVENTIONAL,['NA'],survival time,
5845,NCT03434834,Percentage of Imaged Sites Correctly Categorized as Barrett's Mucosa,2018-09-25,COMPLETED,INTERVENTIONAL,['NA'],Percentage of Imaged Sites With Adequate Tissue Contact to Acquire a High Quality Image,
5846,NCT04258137,Assessment of cancer outcome in terms of overall survival (2 distincts population),2020-09-04,RECRUITING,INTERVENTIONAL,['NA'],Proportion of patients treated with a targeted therapy (in 2 distincts populations),
5847,NCT00084591,Acute toxicity by CTCAE at 6 weeks following study completion,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Quality of life as assessed by Quality of Life Questionnaire Core 30 Items (QLQ-C30) before and after radiotherapy and then every 6 months after surgery,
5848,NCT00362102,Response according to the RECIST criteria accessed every 6 weeks,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"Time to progression, duration of achieved response, and the disease control rate will be accessed in all patients who received Cetuximab. The worst toxicity grades per patients will be tabulated for adverse events and laboratory measurements.",
5849,NCT03479645,Colorectal screening rate,2018-03-23,COMPLETED,INTERVENTIONAL,['NA'],FIT kit return rate by insurance status,
5850,NCT02942329,Overall survival rate,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Safety as measured by the rate of AEs, deaths and laboratory abnormalities (e.g. Grade 3 or higher per CTCAE v4 )",
5851,NCT01978444,3-year disease free survival,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],3-year overall survival,Postoperative intraperitoneal free cancer cell (IFCC)
5852,NCT04711473,Colorectal Cancer Screening Completion,2021-10-27,COMPLETED,INTERVENTIONAL,['NA'],Choice of Colorectal Cancer Screening Test,
5853,NCT00587145,To evaluate the clinical responses to preoperative S-1 plus docetaxel,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],"the clinical downstaging,the pathologic responses, toxicity profile,the disease-free survival,overall survival,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics and the difference in pharmacokinetics between before and after gastrectomy",
5854,NCT03649321,Overall Response Rate (ORR),2019-01-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With an Adverse Event of Grade 3 or Higher,
5855,NCT05522894,Objective response rate (ORR),2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence and severity of adverse events(AEs),The level of ctDNA in blood
5856,NCT00858871,To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatment,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],To compare health-related quality of life,
5857,NCT06134765,The incidence of reduced absolute neutrophil count(ANC) of grade ≥3 in the first cycle of chemotherapy,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5858,NCT03124394,Overall Survival,2015-06-01,UNKNOWN,OBSERVATIONAL,['NA'],Cost-effectiveness,
5859,NCT03008343,Relief degree of tumors,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival（OS）,
5860,NCT05137899,Hepatectomy,2022-10-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity to Atezolizumab/Bevacizumab,
5861,NCT02019199,Tumor Motion,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
5862,NCT03448731,Efficacy in the prevention of skin toxicity,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events,
5863,NCT04843956,Quality of the sample in relation to the technique,2020-01-08,UNKNOWN,INTERVENTIONAL,['NA'],Sample contamination relative to technique,
5864,NCT05239507,"To describe the OS rate in patients with unresectable HCC including estimates of survival rates at 6, 12, and 18 months and at 2 years",2022-02-01,COMPLETED,OBSERVATIONAL,['NA'],To describe the demographic and clinical characteristics of patients with unresectable HCC,"To investigate the correlation between survival outcomes and clinical characteristics, liver function, and underlying disease in unresectable HCC"
5865,NCT03137004,six-month overall survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Event（AE）,
5866,NCT02498613,Objective response rate,2016-08-31,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression-free survival,Changes in levels of angiogenesis/ inflammatory markers (angiome panel) (all cohorts)
5867,NCT00784667,To determine the response rate (RECIST criteria). Responses will be evaluated for the whole patient group and separately for k-ras wild-type and k-ras mutant tumours,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
5868,NCT02793479,Elimination Rate of Barrett's Esophagus in the study population,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5869,NCT00874224,Time to functional Recovery,2010-01,COMPLETED,INTERVENTIONAL,['NA'],Reasons for delay of discharge after functional recovery,
5870,NCT03386500,"Count of Adverse events, serious adverse events and dose limiting toxicities",2017-11-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Effect of study treatment on locoreginal progression free survival survival (PFS).,Single-dose and repeated-dose pharmacokinetic profiles of BMX-001
5871,NCT04800497,Association between circulating tumor cells and disease-free-survival,2019-02-07,RECRUITING,OBSERVATIONAL,['NA'],Association between circulating tumor cells and overall survival,
5872,NCT00321594,Tumor Response in Patients With Inoperable HCC Using Belinostat (Phase II),2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5873,NCT05720598,The primary endpoint of this study is the identification rate of ICG-guided SN in advanced GC patients.,2022-11-04,RECRUITING,INTERVENTIONAL,['NA'],Pathological status and regression grade of the retrieved sentinel node after neoadjuvant chemotherapy,
5874,NCT05022927,Safety of ERY974 (Dose limiting toxicities) [Mono dose escalation part],2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Biomarkers of ERY974 [Mono dose escalation part],
5875,NCT00597311,recurrence rate,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Impact on quality of surgical resection,
5876,NCT03731819,Table time of Abbreviated PB MRI,2018-11-05,COMPLETED,INTERVENTIONAL,['NA'],Requirement for re-examination,
5877,NCT01860846,Total Activity Impairment (TAI),2013-05,COMPLETED,OBSERVATIONAL,['NA'],Number of Participants With Serious Adverse Events,
5878,NCT03516916,"Impact of demographic, socioeconomic and religious factors on HRQoL in rectal cancer survivors with a colostomy",2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5879,NCT02513849,"A change in Ki67 expression following tamoxifen therapy, by comparing the pre- and post- tamoxifen biopsies",2015-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],A change in ER-β expression,
5880,NCT04947696,Changes in DNA-methylation patterns from the pre to postoperative setting,2021-07-30,UNKNOWN,OBSERVATIONAL,['NA'],Relapse of pancreatic cancer,
5881,NCT00711191,Number of Participants With Dose Limiting Toxicities (DLTs),2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Carbohydrate Antigen 19-9 (CA 19-9),Recommended Phase 2 Dose (RP2D) of CP-870893 in Participants With Advanced Pancreas Cancer
5882,NCT05566743,PFS,2022-09-11,RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
5883,NCT02253602,Ferumoxytol dose response,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,
5884,NCT03671369,Number of Participants With Serious Adverse Events (SAEs) and Fatal SAEs,2018-10-02,COMPLETED,OBSERVATIONAL,['NA'],,
5885,NCT05197933,3-year disease-free survival rate (DFS),2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],Postoperative recovery course（Highest Body Temperature）,
5886,NCT02210182,pharmacokinetics,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Biomarker,
5887,NCT00004248,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5888,NCT05364489,Progression Free Survival (PFS),2022-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Drug-Related Safety Indicators,
5889,NCT01539018,time to progression (TTP):recist criteria,2012-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of Life Using EQ-5D questionnaire.,
5890,NCT02309619,Mortality and complications.,2008-01,UNKNOWN,INTERVENTIONAL,['NA'],Quality of life.,
5891,NCT00386984,Overall survival time,1999-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Prognostic relevance of the Somatostatin receptors,
5892,NCT00044967,overall survival,2002-05,COMPLETED,OBSERVATIONAL,['NA'],,
5893,NCT06236568,Survival,2024-02-06,RECRUITING,INTERVENTIONAL,['NA'],Graft survival,
5894,NCT05320692,PFS assessed by BIRC,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE3'],The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0,
5895,NCT00539643,Response to Treatment by RECIST Criteria,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
5896,NCT05292443,PFS: Progression-free survival,2021-12-20,WITHDRAWN,OBSERVATIONAL,['NA'],TTD: Time to Treatment Discontinuation,
5897,NCT02745639,Pathological response rate,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Acute Toxicity,
5898,NCT05034185,To evaluate the diagnostic performance of the CADx support tool compared to optical prediction of polyp histology by the Clinician in real-time colonoscopy in a clinical setting,2021-03-03,COMPLETED,OBSERVATIONAL,['NA'],To determine the diagnostic performance of CADx versus optical prediction of polyp histology by endoscopist in the subgroup analysis,
5899,NCT03703063,Treatment safety as assessed by CTCAE v4.03,2018-09-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],Response rate,
5900,NCT05002127,Phase 3,2022-01-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
5901,NCT01057355,Decrease in volume of the pancreatic cyst by cross-sectional imaging studies (CT or MR) performed before and after treatment,2010-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
5902,NCT05178745,Assessment of resection rate (R0/R1),2016-09-07,COMPLETED,OBSERVATIONAL,['NA'],Safety (serious and non-serious adverse events occurring during treatment,
5903,NCT02034110,Overall Response Rate (ORR) in the Multiple Myeloma (MM) Cohort,2014-03-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events (AEs),
5904,NCT02873845,Objective burden score in the dimensions of the COBQoL questionnaire with good psychometric properties,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,
5905,NCT00345696,Progression Free Survival,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Resection rate of hepatic or pulmonary metastases,
5906,NCT00004904,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5907,NCT05991947,Differences in ctDNA gene and tumor-specific proteins expression,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
5908,NCT00720993,- To select a threshold for Mahalanobis distance to determine the best operating characteristics (sensitivity and specificity) in subjects with cancer and subjects without cancer. - To explore other empirical metrics based on previous exploratory data,2008-08,UNKNOWN,OBSERVATIONAL,['NA'],"- To obtain data to estimate sensitivity, specificity, and the ROC curve for a test based on M-distance. - To determine the variability of sensitivity and specificity estimates",
5909,NCT00428285,High grade dysplasia (AIN 2/3),2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Tolerability and safety of the treatment,
5910,NCT02151019,Reduction in incidence of grade 2 or higher GI toxicity,2014-10-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Differences in the toxicity profile between the two types of neoadjuvant concomitant chemotherapy, graded by the NCI-CTCAE Version 4",
5911,NCT02612077,Progression-free Survival,2008-05,COMPLETED,OBSERVATIONAL,['NA'],Quality of Life - Global Health Status,
5912,NCT01415479,Intention to undergo CRC screening in the next six months,2011-08,COMPLETED,INTERVENTIONAL,['NA'],Completion of CRC screening,
5913,NCT03832621,"Evaluate the efficacy, measured as 8-month PFS rate, of the combination of temozolomide, nivolumab and ipilimumab in patients achieving disease control following 2-month lead-in treatment with single agent TMZ",2019-03-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Assess quality of life,Evaluate the tumor mutational load
5914,NCT04720131,Objective response rate,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety,
5915,NCT00423306,Response Rate,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],toxicities,
5916,NCT04687384,Changes in levels of systemic inflammatory response expressed by CRP and IL-6 in serum between the two groups,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Time to first bowel movement,Time to local cancer recurrence or metastatic spread
5917,NCT04383210,Objective Response Rate,2020-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5918,NCT05231850,Primary End point: Disease Free survival [ Time Frame: 3 years ],2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
5919,NCT02891538,Change in methylation from baseline when compared to the control arm,2017-01-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5920,NCT01544413,Completement of performance of laparoscopic sentinel lymph node biopsy,2012-02,COMPLETED,INTERVENTIONAL,['NA'],"Detection rate of laparoscopic sentinel lymph node, learning curve",
5921,NCT01666145,Successful Insertion of Ablation Antenna Into Target Lesion,2012-02,COMPLETED,INTERVENTIONAL,['NA'],Percentage of Participants With Significant Ease of Lesion Targeting Using Advanced Image Guidance (AIM),
5922,NCT03034850,Blood loss,2015-04,COMPLETED,OBSERVATIONAL,['NA'],Maximum Lysis (ML) HEPTEM Rotational thromboelastometry (ROTEM),
5923,NCT03219593,Progression-free survival (PFS),2017-09-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events(AEs),Tumor biomarkers
5924,NCT01501240,"Diagnostic sensitivity of gadoxetic acid-enhanced MR imaging to detect HCC in the cirrhotic liver, using thin-section whole-explant as the standard of reference",2012-01,WITHDRAWN,OBSERVATIONAL,['NA'],To characterize borderline hepatocelluar nodules,
5925,NCT01657773,Statistical analysis,2012-04,COMPLETED,OBSERVATIONAL,['NA'],Laboratory Assay and Measurement,
5926,NCT02000089,Evaluate pancreatic juice for early cancer markers.,2014-01-06,RECRUITING,INTERVENTIONAL,['PHASE3'],Compare pancreas juice with pancreas cyst fluid,Diagnostic performance of a tumor marker gene test for CA19-9 interpretation
5927,NCT00677586,Severe complication rate after resection of primary and metastatic lesions,2010-07,COMPLETED,INTERVENTIONAL,['NA'],Postoperative hospital stay,
5928,NCT02780921,percentage of patients reaching the complete oncological treatment fixed in a multidisciplinary tumour board,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],quality of life,
5929,NCT04803318,Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Assessing overall survival,
5930,NCT02893930,Overall Response Rate,2017-04-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response,
5931,NCT03839550,Recurrence-free survival(RFS),2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5932,NCT01673607,,2012-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5933,NCT03960775,CRP level in blood,2019-04-30,COMPLETED,INTERVENTIONAL,['NA'],HOD (hospital days),
5934,NCT01466504,p63 expression levels,2011-05,TERMINATED,OBSERVATIONAL,['NA'],Tumor response,
5935,NCT05242991,Hyposalivation,2021-03-01,RECRUITING,INTERVENTIONAL,['NA'],,
5936,NCT06056726,Peri-operative complications,2021-02-18,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
5937,NCT00889187,Grade 3-5 Toxicity Rate [Phase II],2009-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Surgical Mortality Rate [Phase II],
5938,NCT01321450,Total operation time,2009-03,COMPLETED,OBSERVATIONAL,['NA'],postoperative intervention,
5939,NCT02133612,3 year overall survival,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],3 year disease-free survival,Number of Participants with Adverse Events
5940,NCT05714878,Duke Activity Status Index before surgery,2023-03-22,RECRUITING,INTERVENTIONAL,['NA'],30-day readmission rate,
5941,NCT05021250,ORR,2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Frequency of AE,
5942,NCT05853094,Microbiome functional gene capacity in postoperative stoma pouch and distal intestine by metagenomic sequencing,2023-06-23,RECRUITING,INTERVENTIONAL,['NA'],Overall Survival,
5943,NCT03778593,Response rate of treated participants,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events of participants,EORTC -QoL-C30
5944,NCT00554125,Disease-free survival,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],overall survival,
5945,NCT04177875,Objective Response Rate (ORR),2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],The incidence of adverse events and the incidence of severe adverse events（ grade 3-4),
5946,NCT01395563,muscle mass and strength,2009-01,WITHDRAWN,INTERVENTIONAL,['NA'],quality of life,
5947,NCT06119867,Comparision of the incidence of stage III colon cancer between European and Japanese pathological investigation methods.,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE3'],"Comparison of the extramural invasion (venous, lymphatic, perineural) between the European and Japanese pathological approaches",
5948,NCT04752267,Different pattern in radiomics mpMRI and FMAU PET kinetic analysis parameters,2021-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5949,NCT02837029,Phase IB: Objective Response Rate (ORR),2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Disease Control Rate (DCR),Circulating Free DNA (cfDNA) Mutation Analyses
5950,NCT05745857,Evaluate if the combination of tracers improves lesion detection by the number of invisible lesions detected,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Eventually further specify and objectify the improvement of qFME by standardisation,
5951,NCT03187314,Objective response rate (ORR),2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Health-related quality of life (HRQoL),
5952,NCT05781568,Biomarker dosage,2023-02-24,RECRUITING,OBSERVATIONAL,['NA'],,
5953,NCT03432806,successful isolation of exosomes,2017-11-28,RECRUITING,OBSERVATIONAL,['NA'],,
5954,NCT00235898,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5955,NCT01946139,Incidence of HSIL Among Women Who Were HRA Negative for HSIL at Study Entry,2013-12-04,COMPLETED,INTERVENTIONAL,['NA'],Acceptability of Anal Cancer Screening,
5956,NCT02909530,Correct histological diagnosis of the mass assessed by each needle,2016-09,COMPLETED,INTERVENTIONAL,['NA'],Adverse events,
5957,NCT00869258,Conversion Rate of Inoperable to Operable,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5958,NCT05693519,Overall survival,2022-12-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Standardized incidence of second primary malignancies,
5959,NCT01261962,Gene expression,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],Humoral immunity and neutrophil function,
5960,NCT02703714,Overall Response Rate (ORR),2016-05-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival (OS) Stratified by Sub-type of Biliary Cancer,
5961,NCT05525286,Parts C and D: The assessment of the efficacy of SOT102 in monotherapy and in combination with first-line SoC treatment,2022-03-31,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Parts C and D (monotherapy and combination with SoC): Number of participants with antibodies against SOT102,Parts C and D (monotherapy and combination with SoC): Relationship between the intensity of CLDN18.2 expression and clinical outcome
5962,NCT02564146,Overall survival (OS),2016-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Neurotoxicity Assessment FACT taxane score,
5963,NCT03897543,Incidence of adverse events (AEs),2019-08-30,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Alpha Fetoprotein Serum concentrations,
5964,NCT05083780,Number of participants with treatment-related adverse events assessed by CTCAE v5.0,2021-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Objective Response Rate,
5965,NCT02523053,Time to tumor recurrence,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,
5966,NCT06230328,Epidemiological profile and pathological staging,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Description of clinical condition,
5967,NCT01956812,overall survival,2013-12,TERMINATED,INTERVENTIONAL,['PHASE3'],Clinical benefit,
5968,NCT00899132,Characterization of TAB3 and its signaling networks that are involved in tumorigenesis,2007-02,TERMINATED,OBSERVATIONAL,['NA'],,
5969,NCT05954429,objective response rate (ORR),2023-07-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],adverse events,
5970,NCT05133102,Intra-class correlation coefficients (ICC) by BE status,2021-03-19,RECRUITING,OBSERVATIONAL,['NA'],,
5971,NCT05672316,Overall response rate (ORR) (Phase II),2023-05-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of toxicity (Phase II),
5972,NCT00300547,Feasibility of MR colonography to diagnose possible synchronous carcinomas and polyps,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Altered operative strategy due to findings on MR colonography,
5973,NCT04406857,Incidence of Dose-limiting Toxicities (Part IB),2021-03-17,TERMINATED,INTERVENTIONAL,['PHASE1'],Neoadjuvant Rectal Score at the Maximum-tolerated Dose,"Interactions of Capecitabine, IPdR and Their Metabolites"
5974,NCT02550743,Maximum Tolerated Dose of BYL719,2016-06-03,TERMINATED,INTERVENTIONAL,['PHASE1'],Pathologic Complete Response for Patients With Rectal Cancer,
5975,NCT06032338,Performance of colonoscopy in FIT positive patients,2023-09-14,RECRUITING,INTERVENTIONAL,['NA'],Cost-effectiveness analysis,
5976,NCT04415853,Overall survival,2021-01-21,RECRUITING,INTERVENTIONAL,['PHASE3'],Apparent Volume of Distribution (Vd/F) of Lerotinib,
5977,NCT03938623,number of patients screened positive using the patient-centered approach after training of face to face training or e-learning,2018-01-24,UNKNOWN,OBSERVATIONAL,['NA'],,
5978,NCT01904968,"Mutational status evaluation of BRAF, KRAS and PI3KCA :",2011-12,WITHDRAWN,OBSERVATIONAL,['NA'],,
5979,NCT01558947,the relapse-free survival time/rate,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5980,NCT02444897,VAS score,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Bowel motility,
5981,NCT04611035,Efficacy of second-line therapy,2020-01-20,UNKNOWN,OBSERVATIONAL,['NA'],Haematologic and non-haematologic toxicities,
5982,NCT04204850,Disease control rate,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Side Effects Reported,
5983,NCT02578732,Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.,2016-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A,
5984,NCT02850874,Peritoneal disease-free survival,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Postoperative mortality,
5985,NCT05794048,Theranostic metabolic signatures of TNEP.,2022-06-08,RECRUITING,INTERVENTIONAL,['NA'],Comparison of metabolic profiles on surgical specimen,
5986,NCT05945082,Presence of F.nucleatum in a colon cancer biopsy,2017-11-29,RECRUITING,INTERVENTIONAL,['NA'],,
5987,NCT02291614,Number of Participants With Treatment Emergent Adverse Events (TEAEs),2014-11-27,TERMINATED,INTERVENTIONAL,['PHASE1'],Progression Free Survival (PFS) at 6 Months in Participants Treated at the MTD,
5988,NCT00595985,time to progression,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],toxicity,
5989,NCT05245877,"Venous thromboembolism, number of patients",2022-08-17,RECRUITING,INTERVENTIONAL,['PHASE4'],Post-operative hemoglobin below 70 g/l,
5990,NCT01014039,Colorectal cancer mortality,1983-03,COMPLETED,INTERVENTIONAL,['NA'],colorectal cancer incidence,
5991,NCT05914766,Self-Efficacy (CASE-Cancer),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],Quality of Life (FACT-C),
5992,NCT01789502,Adverse events related to the stent insertion,2012-01,COMPLETED,INTERVENTIONAL,['NA'],Surgical outcomes,
5993,NCT04911647,Re-intervention rate,2021-06,UNKNOWN,INTERVENTIONAL,['NA'],"Procedure related complication, Postoperative complication",
5994,NCT04713241,Feasibility as measured by acceptance rate of participation in study,2022-01,WITHDRAWN,INTERVENTIONAL,['NA'],Nasogastric tube (NG TB) output,
5995,NCT04119622,Major pathological response rate,2019-10-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
5996,NCT05535569,(Phase II) PFS,2017-07-17,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PFS,
5997,NCT03808272,Clinical success rate,2019-04-17,COMPLETED,INTERVENTIONAL,['NA'],,
5998,NCT00969033,Determine the difference in progression-free survival (PFS) for CS-1008 administered in combination with irinotecan and irinotecan alone.,2009-07,TERMINATED,INTERVENTIONAL,['PHASE2'],To determine the Incidence of anti- CS-1008 antibody formation.,
5999,NCT04985136,Stage II：Overall survival （OS）,2021-09-26,TERMINATED,INTERVENTIONAL,['PHASE3'],Proportion of neutralizing antibody (Nab),
6000,NCT03250078,Early Stage Pancreatic Cancer or Precursor Lesions,2016-11,RECRUITING,OBSERVATIONAL,['NA'],Serum Bio-bank,
6001,NCT05791747,social representations,2023-03-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Intention to turn to hypnosis,
6002,NCT01832246,diagnostic accuracy between endoscopic ultrasonographic staging and conventional endoscopic staging,2014-12,UNKNOWN,OBSERVATIONAL,['NA'],,
6003,NCT01579591,The impact of the probiotic preparation on increasing the TRG1-2 rate.,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],Determine whether VSL#3® can have an impact on reduction of late toxicity at 12 and 36 months.,
6004,NCT01395017,Overall Survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),
6005,NCT00954525,"Safety, assessed by toxicity (graded by NCI CTC), urinalysis, ECG, basic metabolic panel, CBC, and osmolality.",2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression-free survival,
6006,NCT05828446,To compare the diagnostic performance of US+/- CEUS and AMRI for HCC detection in an at-risk population,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],To perform a cost-effectiveness analysis comparing US to different alternative screening strategies for HCC in Switzerland.,
6007,NCT03574493,"Efficacy of surgical method (success determined by composite of Oncologic, morbidity and functional outcomes)",2018-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6008,NCT00810953,"Any severe events, tumor marker CA19-9, and tumor size (CT scan)",2009-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",TDP,
6009,NCT03280407,Disease free survival,2017-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life (QoL),
6010,NCT00644020,DFS(disease free survival),2007-12,UNKNOWN,OBSERVATIONAL,['NA'],1.OS （Overall Survival） 2.QOL (quality of life),
6011,NCT00669812,Survival at 1 year,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicity,
6012,NCT03140189,rate of major postoperative complications,2017-06-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],disease-free survival,
6013,NCT04483076,pCR rate,2021-01-13,RECRUITING,INTERVENTIONAL,['PHASE3'],Five-year overall survival,
6014,NCT03993353,Overall Survival (OS),2020-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse event rates,
6015,NCT04625894,Dose-limiting toxicities (DLT),2020-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],Quality of life assessment,
6016,NCT02489201,Number of participants with Adverse Events,2015-07-21,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival,
6017,NCT03524508,Progression Free Survival by independent central reviewer,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Response rates determined by the independent central reviewer,
6018,NCT05346757,Sensitivity for advanced colorectal neoplasm,2022-03-23,RECRUITING,INTERVENTIONAL,['NA'],Cost-effectiveness for advanced colorectal neoplasm detection,
6019,NCT01453452,"Increase in fruit and vegetable consumption by 1 full serving per day (not including iceberg lettuce, potatoes, or fruit juices) OR reduce caloric intake by 100 kcal/day",2012-03,COMPLETED,INTERVENTIONAL,['NA'],DNA methylation patterns,
6020,NCT05530785,Objective Response rate,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],number of participants with treatment-related adverse events,
6021,NCT00648102,"To establish safety and tolerability profile of CDX1307 alone and with adjuvant in patients with breast, colorectal, pancreatic, bladder and ovarian cancer",2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Investigate clinical activity,
6022,NCT00603863,"safety will be evaluated based upon physical examinations, hematology and chemistry laboratory testing as well as toxicity",2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Efficacy and Clinical benefit measures such as quality of life, pain assessments, etc.",
6023,NCT00002997,,1998-02-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6024,NCT04607291,Model Development for Prediction of Intent and Colorectal Cancer (CRC) Screening Behaviors,2019-09-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Prediction of Which CRC Screening Test is Most Acceptable,
6025,NCT03272984,Postoperative length of stay,2015-04-01,COMPLETED,INTERVENTIONAL,['NA'],Time to semi-liquid diet,
6026,NCT04329429,Objective Response Rate (ORR),2020-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
6027,NCT02602327,Maximum tolerated dose (MTD),2017-01-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Biomarker response,
6028,NCT05933122,Number and proportion of women with sexual dysfunction defined as a total FSFI,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],"Differences (Month 6 - Month -1 and Month 12 - Month 6) in the score of the ""satisfaction"" dimension of the FSFI scale (Q14-Q16) between the groups with and without treatment by a sexologist (cohort here vs. elsewhere)",
6029,NCT05391867,Overall survivability,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
6030,NCT05181826,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,2019-05-21,RECRUITING,OBSERVATIONAL,['NA'],Ascertain Sample Stability,
6031,NCT06017141,Neutrophil extracellular traps (NET) formation,2023-05-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in gene expression,
6032,NCT01266720,Toxicities as assessed by NCI-CACAE ver3,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],Survival,
6033,NCT03809247,16sRNA and metagenomics,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
6034,NCT05349331,Progression-free survival,2022-05-05,RECRUITING,INTERVENTIONAL,['NA'],pCR rate in surgery group,Correlation of serum tumor molecular marker with survival
6035,NCT02422095,Natural history and disease progression in pancreatic cysts,2015-02,WITHDRAWN,OBSERVATIONAL,['NA'],Evaluate the role of plastic stents in patients undergoing EUS-guided drainage of pancreatic fluid collections.,
6036,NCT06040632,ctDNA analysis,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],Postoperative morbidities,
6037,NCT00607282,"Improvement of erectile function using IIEF-5 (International Index of Erectile Function-5), SEP Q2, Q3 (Sexual Encounter Profile Q2,Q3), and GEQ (Global efficacy Question)",2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"Improvement of erectile function using IIEF-5, SEP Q2,Q3, and GEQ",
6038,NCT04169399,Progression free survival (PFS),2019-11-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events,
6039,NCT05679050,Disease-free Survival(DFS),2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-Emergent Adverse Event Rate,
6040,NCT06085755,ORR (Objective response rate),2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression free survival (PFS),
6041,NCT02748551,"""Major"" Surgical Morbidity",2016-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],Extent of lymph node dissection,
6042,NCT01444521,Overall response rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to event efficacy,
6043,NCT04607057,Body weight change for 2 months after surgery,2020-12-22,UNKNOWN,INTERVENTIONAL,['PHASE4'],Mortality rate,
6044,NCT03665571,NK cell activity,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],Survival of participants,
6045,NCT05250648,Peritoneal Recurrence Free Survival,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE4'],Quality of Life with EORTC validated questionnaire Colorectal Cancer Module (QLQ-CR29).,
6046,NCT04595929,Comparison of Overall survival (OS) in both arms,2020-02-10,RECRUITING,INTERVENTIONAL,['NA'],Rate of post-operative morbidity/mortality at day 30 after surgery acc. to Clavien-Dindo classification,
6047,NCT00002506,,1992-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6048,NCT04701645,Number of implanted microdevices successfully retrieved,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Correlate extent of tumor response with genetic features of the tumor tissue
6049,NCT01286987,Part 1: Recommended Part 2 Dose of Talazoparib,2011-01-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Part 1: Apparent Volume of Distribution (Vz/F) of Talazoparib
6050,NCT04745091,Complete pathologic response,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6051,NCT02641925,HOMA-IR change,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],HOMA-IR change according to anastomosis type,
6052,NCT05396560,Fecal Immunochemical Test Sensitivity and Specificity,2022-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
6053,NCT05645094,cCR and pCR rates,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Acute toxicity associated with Envafolimab,
6054,NCT00819559,Disease-free survival,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival Local recurrence Early or late complication associated with preoperative radiotherapy Quality of life Accuracy of clinical staging Difference of surgical outcome between laparoscopic and open surgery,
6055,NCT00629421,development of hepatocellular carcinoma,2001-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6056,NCT01742169,Completion of fecal occult blood test (FOBT),2013-01,COMPLETED,INTERVENTIONAL,['NA'],,
6057,NCT00730483,Safety - Number of CTCAE v3.0 Events 1 Month Post DEB-TACE,2009-02,TERMINATED,INTERVENTIONAL,['NA'],Symptomatic Response by Assessing Symptom Severity in Patients,
6058,NCT00613080,"The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0, Occurring Preoperatively",2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients Who Underwent Abdominoperineal Resection,
6059,NCT03579004,Disease free survival,2017-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Pathological complete response rate following chemoradiotherapy,
6060,NCT03475966,Change in functional walking capacity as measured by the six-minute walk test (6MWT),2017-02-22,UNKNOWN,INTERVENTIONAL,['NA'],Heart rate - assessment of change over time,Lower extremity strength - assessment of change over time
6061,NCT02983045,Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D),2016-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6062,NCT04605419,Registration of treatment related pain through a Visual Analogue Score (VAS),2020-10-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],The rate of patient's that have gained from the treatment,
6063,NCT02064803,Change from baseline Gastric Outlet Obstruction Score System - GOOSS,2013-06,COMPLETED,INTERVENTIONAL,['NA'],Overall survival,
6064,NCT03281447,Self evaluated Self Efficacy for Cancer,2016-02-26,COMPLETED,INTERVENTIONAL,['NA'],Health-related Quality of Life,
6065,NCT02954302,"Delayed gastric emptying,rate",2016-09,UNKNOWN,INTERVENTIONAL,['NA'],"wound infection,rate","nonsurgical complications,rate"
6066,NCT02070419,Difference in tumor grade,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Survival rate,
6067,NCT02363049,overall survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Rate of secondary curative resection (R0),
6068,NCT00310050,Quantitative Toxicity of Pemetrexed When Administered With Concomitant Radiation Therapy,2005-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants That Survived,
6069,NCT03733197,Scale development,2024-01,WITHDRAWN,INTERVENTIONAL,['NA'],Pilot intervention,
6070,NCT03688555,Change From Baseline to Week 12 in Nasal Polyp Score as Measured by Nasal Endoscopy (Assessed Centrally),2018-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Patient Global Impression of Change in Disease Severity,
6071,NCT00126867,,2005-05,TERMINATED,OBSERVATIONAL,['NA'],,
6072,NCT01104116,Positive and Negative Predictive Value of PET Imaging for Identifying Malignant IPMN,2009-09,TERMINATED,INTERVENTIONAL,['NA'],Change in Lesion Characteristics to Assess Benefit of PET Scans,
6073,NCT00188331,,2003-11,COMPLETED,OBSERVATIONAL,['NA'],,
6074,NCT04310709,Response rate,2020-06-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
6075,NCT02050178,Safety and tolerability of OMP-54F28 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (PK) of OMP-54F28 when administered in combination with nabpaclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer,
6076,NCT04205071,Measure the improvement in balance for patients with chronic CIPN,2020-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Improvement in patient-reported chemotherapy-induced peripheral neuropathy symptoms,Nerve conduction test (NCT) result analysis
6077,NCT00791544,Dose-limiting toxicities (DLT) based on grade = or > 3 hematological or non-hematological toxicity and on fasting hyperglycemia,2008-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Anti tumoral activity,
6078,NCT00400179,Median Survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Time to Treatment Failure (TTF),
6079,NCT01066624,Incidence of Oral Mucositis,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,
6080,NCT00911820,7-month Progression-Free Survival,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-Free Survival,
6081,NCT04705818,Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort D,2021-07-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Blood kynurenin level,
6082,NCT01786122,Changes in Health Related Quality of Life (EORTC QLQ-C30),2013-04,UNKNOWN,INTERVENTIONAL,['NA'],progression-free survival,
6083,NCT00966706,Progression-free survival at 6-months,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,
6084,NCT01102335,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],Overall survival,
6085,NCT01522677,Safety,2012-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Sustained immunity,
6086,NCT02605265,Pathologic Complete Response,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Surgical complications,
6087,NCT02189226,Complete resection rate,2013-11,COMPLETED,INTERVENTIONAL,['NA'],adverse event,
6088,NCT04591379,Safety - Adverse reactions are classified according to CTCAE version 4.0,2021-02-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Efficacy - local immunological changes,Quality of recovery
6089,NCT03546569,ctDNA/cfDNA levels in relation to colorectal stent placement,2018-05-01,COMPLETED,OBSERVATIONAL,['NA'],Metastatic ability of the cancer cells,
6090,NCT06331403,Acceptability of Intervention,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6091,NCT04494919,The technical success rate,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],The adverse events rate,
6092,NCT02048943,Incidence of adverse events graded by NCI CTCAE version 4.0,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Biomarker expression levels in tumor specimens,
6093,NCT00230191,The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis.,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],The secondary objectives of the study are to assess the safety and tolerability of RK-0202 in these subjects and to explore whether the ProGelz™ vehicle alone is active in these subjects.,
6094,NCT01936233,recurrence free survival,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],adverse events,
6095,NCT02784353,The incidence and severity of general complication,2016-10-04,COMPLETED,INTERVENTIONAL,['NA'],"Grasping power(dynamometer, kg)(Changes in the parameters of rehabilitation)",
6096,NCT02500147,Difference in percentage liver fat between Metformin arm and Placebo arm in adolescents and young adults with PCOS and with elevated percentage liver fat (>/=4.8%),2011-09-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],"The association of percentage liver fat with M30, a hepatic apoptosis marker",
6097,NCT02227667,Best Response Rate,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Evaluated for Toxicities to Determine Safety,
6098,NCT05975645,Overall response rate (ORR),2023-08-15,RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of Serious adverse events (SAEs),
6099,NCT01130805,Response rate,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicities,
6100,NCT04937322,Adverse Events,2016-01-25,COMPLETED,OBSERVATIONAL,['NA'],stent occlusion-free duration,
6101,NCT06245798,overall survival rate,2023-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6102,NCT03139058,"Determine the prevalence, by registry data analysis, of cirrhosis in patients with VADS cancer",2018-08-20,UNKNOWN,INTERVENTIONAL,['NA'],,
6103,NCT03233724,Maximum Tolerated Dose (MTD) of Tetrahydrouridine,2018-04-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Changes in Gene, Endogenous Retroviral (ERV), Micro Ribonucleic Acid (RNA) Expressions, Deoxyribonucleic Acid (DNA) Methylation Signatures and Tumor Microenvironment",Number of Participants With a Dose Limiting Hematologic Toxicity (DLT)
6104,NCT04072679,Incicende of Adverse Events (AEs),2018-10-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Anti-drug antibody (ADA),
6105,NCT00003087,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6106,NCT00160836,Sensitivity and specificity for the diagnosis of malignancy with both devices,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],unusual findings at histopathological examination of surgical specimens.,
6107,NCT00689715,recurrence during follow up,2006-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",predictive factors for complete resolution,
6108,NCT00586053,To optimize diagnostic performance of CTC in the unprepared colon for colorectal polyp detection using electronic stool subtraction and computer-aided diagnostic techniques.,2000-08,COMPLETED,OBSERVATIONAL,['NA'],The cost-effectiveness ratio of CTC in the unprepared colon will compare favorably with other colorectal screening tests,
6109,NCT04297423,Adenoma detection rate,2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE4'],Tolerability and satisfaction with preparation,
6110,NCT02910843,Pathological near complete or complete tumor response (npCR or pCR),2017-02-22,TERMINATED,INTERVENTIONAL,['PHASE1'],Postoperative complications,
6111,NCT04338191,3-year Disease-free survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life assessed by SF-36,
6112,NCT04062721,Incidence of treatment-emergent adverse events,2021-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Potential predictive biomarkers,
6113,NCT04046250,Mucositis,2019-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence Adverse Events That Are Related to Treatment,
6114,NCT04520295,Change from baseline in molecular biomarkers at time on best overall response,2020-05-19,RECRUITING,OBSERVATIONAL,['NA'],Change from baseline in molecular biomarkers at time on disease progression,
6115,NCT01630798,validate binding of the fluorescent-labeled peptide to esophageal neopla,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6116,NCT00683787,Overall Response Rate,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicity,
6117,NCT05442138,Tumor Regression Grading,2022-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6118,NCT05001763,"Time to defaecation, measured in hours, from the time the surgery ends till the first observed",2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of adverse events related to drug usage,
6119,NCT02131441,abdominal adhesion,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],time to disease recurrence,
6120,NCT05500391,2-year compliance to the customized surveillance plan,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Support care needs identified,Evaluation of the causes of recruitment failures
6121,NCT02488161,Mortality,2010-06,COMPLETED,OBSERVATIONAL,['NA'],Number of participants with Cancer recurrence,
6122,NCT06280248,Complete resolution or a decrease in the sizes of pancreatic fluid collections (PFCs),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6123,NCT02167087,Number of procedures with successful identification of sentinel nodes,2015-03,COMPLETED,INTERVENTIONAL,['NA'],"Localization of the identified sentinel nodes, and whether or not they are included within the normal resection lines",
6124,NCT00062023,"Percentage Change in Colorectal ACF Patients Treated with Sulindac, Aspirin or Ursodiol",2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6125,NCT05408221,ORR,2022-11-11,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",OS,
6126,NCT01928524,Median Overall Survival,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6127,NCT05761717,Overall survival (OS) after initial administration.,2023-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6128,NCT04762914,Complication rate,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],Anaerobic threshold,
6129,NCT00813540,Safety (Monitoring for Adverse Events),2009-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Feasibility (Adherence to the exercise training program),
6130,NCT02988934,Incremental yield for dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings.,2016-04,TERMINATED,OBSERVATIONAL,['NA'],Outcomes of patients undergoing WATS sampling.,
6131,NCT04066543,PFS,2019-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6132,NCT05078515,Specificity of PREDICT score,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6133,NCT04837118,Aerobic fitness,2021-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Feasibility of Automated Self Assisted 24-hour recall (ASA24) (24-hour dietary recall),
6134,NCT02505750,"Rate of rectum preservation either with local excision or watch and wait strategy after neoadjuvant treatment without non salvageable locally progressive disease at 3 years post treatment, or permanent stoma.",2015-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Tumour regression score on the operative specimen,Quality of Life
6135,NCT03697044,Time to Hepatic Progression (TtHP),2019-01,UNKNOWN,OBSERVATIONAL,['NA'],Quality of Life post DEBIRI delivery,
6136,NCT01270438,Progression-free survival of patients treated with FOLFOX6 plus bevacizumab with or without gamma-secretase inhibitor RO4929097,2010-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Pharmacokinetics and pharmacodynamics of gamma-secretase inhibitor RO4929097,
6137,NCT01905150,12-month survival rate,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,Adverse Events
6138,NCT01298401,Dose-limiting toxicity of ganitumab and capecitabine given concurrently with radiotherapy,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival (for patients treated at maximum-tolerated dose of ganitumab),
6139,NCT00669292,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2006-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",survival(Phase II),
6140,NCT01225757,Fluid administration decrease,2010-11,WITHDRAWN,INTERVENTIONAL,['NA'],Cardiac complications,
6141,NCT05076279,number of retrieved lymph nodes,2021-11-15,RECRUITING,INTERVENTIONAL,['NA'],3 year relapse-free survival,
6142,NCT04267575,Number of Participants With Complications Due To Cold Plasma Application,2019-07-30,UNKNOWN,INTERVENTIONAL,['NA'],,
6143,NCT03563144,Progression-Free Survival,2018-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Evaluation of safety as determined by incidence or treatment-emergent adverse events,
6144,NCT06159478,Overall response rate (centrally assessed),2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse event rate,
6145,NCT00045747,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6146,NCT04040374,Per patient diagnosis of gastric cancer,2019-07-01,COMPLETED,INTERVENTIONAL,['NA'],Agreement on image and IOU based diagnosis of gastric cancer between AI and expert endoscopists,
6147,NCT02256800,Progression-free survival,2014-08-13,COMPLETED,INTERVENTIONAL,['NA'],overall survival,
6148,NCT00051532,"Overall survival, defined as the time from start of treatment to death",1999-09,TERMINATED,INTERVENTIONAL,['NA'],Dose of seocalcitol (seocalcitol treated patients),
6149,NCT01022541,Overall response rates,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Other parameters of efficacy (response and survival) in patients with unresectable liver-only metastases treated with this neoadjuvant combination,
6150,NCT02733809,Overall and disease-free survival genes.,2014-01,RECRUITING,INTERVENTIONAL,['PHASE4'],Potential genetic targets for resistance.,
6151,NCT01911832,quality of life,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],short-term complication of the surgery,
6152,NCT02404935,Progression Free Survival at 6 months,2013-11-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6153,NCT01591421,Recommended phase II dose of BKM120 (Phase I Component),2012-09-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Translational Research,
6154,NCT00215995,Number of Participants With Desired Response,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Overall Survival,
6155,NCT06334458,Validation of igenetic biomarker testing in liquid biopsy followed by radiological exam as early cancer diagnostic tool,2023-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
6156,NCT02093104,Liver Tumour Perfusion using CT & C-arm systems in 40 patients at VGH over a 3 month period,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,
6157,NCT01246960,Progression-Free Survival (PFS),2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies,Number of Participants With Adverse Events (AEs)
6158,NCT05962502,Objective response rate (ORR),2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Drug-related adverse reactions,
6159,NCT03109457,Hep C cAg by Immunohistochemistry,2017-09-06,COMPLETED,OBSERVATIONAL,['NA'],,
6160,NCT01903395,utilization of preventive colonoscopy,2012-03,COMPLETED,INTERVENTIONAL,['NA'],time delay between signed informed consent and utilization of colonoscopy,
6161,NCT00007813,,1997-05-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6162,NCT00626158,To establish the maximum tolerated dose of fixed-dose rate gemcitabine plus capecitabine given by biweekly administration in patients with advanced pancreatic and biliary tract malignancies.,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],"Frequency, type, and grade of adverse events using this combination in this patient population",
6163,NCT03910387,Weight stability,2019-04-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of response,
6164,NCT01551641,Treatment efficacy,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety,
6165,NCT04400292,The number of lymph nodes visualized to be fluorescent and nonfluorescent.,2020-05-20,RECRUITING,INTERVENTIONAL,['NA'],,
6166,NCT06070636,Objective response rate (ORR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival (OS),
6167,NCT05123209,Incidence of adverse events (AEs) and abnormal laboratory test results as assessed by CTCAE V5.0,2021-08-24,UNKNOWN,INTERVENTIONAL,['PHASE1'],Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood),
6168,NCT02324335,Incidence of Severe OM During Radiation Therapy in Subjects Receiving a Cumulative IMRT Dose of at Least 55 Gy,2014-08-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Onset of Severe Oral Mucositis (WHO Grade ≥3),
6169,NCT04701476,Overall Response Rate (ORR) for the NSCLC cohort,2021-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],TTP,
6170,NCT04665362,Treatment related adverse events,2021-01-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],Progression free survival,
6171,NCT05428358,Change in treatment strategy,2022-08-30,RECRUITING,INTERVENTIONAL,['NA'],Healthcare costs,
6172,NCT05293158,HBsAg change from baseline to week 6,2024-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Change of Cellular response (IFN gamma),
6173,NCT03716518,Completion Rate of 8-cycle Adjuvant Chemotherapy,2018-12-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Incidence of SAEs,
6174,NCT01411072,Overall Survival,2011-09,UNKNOWN,INTERVENTIONAL,['NA'],,
6175,NCT02855944,Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population),2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival (ITT Population),
6176,NCT03785665,Measure the variability of the motility (Whole gut transit time from ingestion to excretion {hours}) of the MD1 (Motility dummy 1) capsules in the Gastrointestinal tract of human subjects with and w/out polyps in previous Colonoscopy.,2019-06-15,COMPLETED,INTERVENTIONAL,['NA'],,
6177,NCT01507103,Change From Baseline in IFN-gamma Secretion of Mononuclear Cells in Response to Carcinoembryonic Antigen (CEA) by ELISpot at Post-baseline,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Immunological Response in Peripheral Blood at Week 18 (Follow-up / end-of Trial),
6178,NCT01179724,bleeding incidence after ESD,2009-07,UNKNOWN,INTERVENTIONAL,['NA'],the size of healing ulcer after ESD,
6179,NCT02125448,"Distinct and combined sensitivity, specificity, predictive values, and accuracy of MRI and PET-CT for identifying histopathological complete response.",2013-10,COMPLETED,OBSERVATIONAL,['NA'],Experienced patient burden (UMC Utrecht only).,
6180,NCT04668872,Correlation of tissue necrosis and radiation-induced cell injury levels with delivered dose at 14-21 days,2020-12-07,RECRUITING,OBSERVATIONAL,['NA'],,
6181,NCT03322280,Overall survival (OS),2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],Duration of portal patency,
6182,NCT05750030,"Safety of atezolizumab/bevacizumab in combination with FMT, measured by incidence and severity of treatment-related adverse events, determined according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0.",2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life (QoL) as assessed by the patient-reported outcome EQ-5D-5L (European Quality of Life 5 Dimensions 3 Level Version) questionnaire.,Differences in serum and stool metabolomic and lipidomic signatures in patients before and after FMT.
6183,NCT00836992,"Overall quality of life (QOL) scores at baseline, weeks 1, 3, 5, and end of treatment as assessed by LASA",2009-01,COMPLETED,OBSERVATIONAL,['NA'],Percentage of patients for which physician reports indicate that availability,
6184,NCT03487016,Progression-free survival,2019-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life as assessed by EORTC-QLQ-C30,Kinetics of circulating tumor DNA during first-line chemotherapy
6185,NCT02181140,Diagnostic Accuracy,2011-08,COMPLETED,INTERVENTIONAL,['NA'],Complication Rates,
6186,NCT01145456,"Recommended phase II dose of RO4929097 in combination with gemcitabine hydrochloride, defined as the dose level in which no more than 1 of 6 patients or 0/3 experience DLT, graded according to NCI CTCAE version 4.0",2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Objective response according to RECIST criteria 1.1,
6187,NCT03007212,changes in Radiological Response in the (CT/ MRI) after the intervention,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6188,NCT05450393,Prospective collection of PillCamTM SB3 capsule endoscopy and DAE procedures data,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6189,NCT02038738,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","We want to determine if the 68Ga-DOTATATE PET Scan changes care plans compared to conventional imaging/diagnostic techniques (Octreoscan, MRI, CT)",
6190,NCT02369757,Participation rates,2012-10,COMPLETED,INTERVENTIONAL,['NA'],Qualitative analysis,
6191,NCT02242409,4 month progression free survival,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
6192,NCT01641939,Overall Survival (OS) - Phase 2 (Dose Selection Portion of the Study),2012-09-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Systemic Clearance (CL) - Stage 1,
6193,NCT00777192,Association between inflammatory cytokines and development of treatment-related symptom burden in colorectal cancer patients,2008-08,TERMINATED,OBSERVATIONAL,['NA'],Neurocognitive and neuropsychiatric symptoms in colorectal cancer patients,
6194,NCT00326495,Overall Rate of Response,2006-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Count of Participants With Adverse Events,
6195,NCT05464030,Part 2A: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators,2022-08-04,RECRUITING,INTERVENTIONAL,['PHASE1'],Part 2A: Number of Participants with Symptomatic Adverse Events (AEs),
6196,NCT02674373,Progression free survival (PFS),2015-09,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival (OS),
6197,NCT00049348,Percentage of margin-free resections produced by each program,2003-10-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect of therapy and recurrence on CA19-9 values,
6198,NCT03900910,The reinfection rate,2018-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
6199,NCT01011010,Safety and toxicity as assessed by NCI CTCAE v3.0 criteria,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE1'],Correlative studies,
6200,NCT03485196,Disease Free Survival,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],Overall survival(OS),
6201,NCT02575898,Feasibility of a creative writing intervention in an advanced cancer population,2016-01-14,COMPLETED,INTERVENTIONAL,['NA'],,
6202,NCT01813942,The number of patients correctly identified by recurrence predictive model,2013-03,UNKNOWN,OBSERVATIONAL,['NA'],,
6203,NCT05736705,Speed of Endoscopic Submucosal Dissection,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Rate of esophageal stricturing post-procedure,
6204,NCT00986661,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of hepatic administration of PV-10,2009-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,Exploratory Correlative Endpoints
6205,NCT01164722,Complete Response Through 1 Year,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Incidence of Metachronous Lesions,
6206,NCT05652348,Next generation sequencing of organoid cultures,2022-12-08,RECRUITING,OBSERVATIONAL,['NA'],,
6207,NCT06050200,Successful resection,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall morbidity,
6208,NCT02966483,Overall survival,2016-04,RECRUITING,INTERVENTIONAL,['NA'],The patient's Quality of life: EORTC QLQ-30 questionnaire,
6209,NCT04203160,Phase 2: Overall Response Rate (ORR),2020-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of Toxicities,
6210,NCT00549952,incidence and severity of oral mucositis,2007-10,UNKNOWN,OBSERVATIONAL,['NA'],,
6211,NCT04136002,Specificity of advanced neoplasia detection,2019-10-08,RECRUITING,OBSERVATIONAL,['NA'],Sensitivity and specificity of advanced adenoma detection,
6212,NCT03589339,[Dose Expansion Part]: Safety Evaluation at RP2D,2019-01-16,RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluation of the body kinetic profile of intratumorally injected NBTXR3,
6213,NCT03032874,To determine colonoscopy polyp and cancer detection rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],To detect colorectal cancer early using symptoms based assessment,
6214,NCT01098422,PFS,2010-01,TERMINATED,INTERVENTIONAL,['NA'],60 Day All-cause Mortality Rate,
6215,NCT02312817,Repeat Screening (Every 6 Months),2014-12,COMPLETED,INTERVENTIONAL,['NA'],Suspicious Lesion,
6216,NCT02067754,Circulating tumor cell,2013-09-11,COMPLETED,OBSERVATIONAL,['NA'],mutation profiling of circulating free DNA,"Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer"
6217,NCT03062358,Overall Survival (OS),2017-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Number of Participants Who Discontinued Study Treatment Due to an AE,
6218,NCT00601549,Oncologic Results,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Functional recovery of patients,
6219,NCT05411133,Incidence and severity of adverse events,2022-05-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Effect of Cabotamig (ARB202) on tumour as determined by changes in RECIST evaluation from baseline,
6220,NCT01554059,Pathological complete response rate,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety data of this regimen,
6221,NCT04230018,Mutation Consistency of metastatic and primary sites of colorectal cancer patients with postoperative metastasis,2018-12-28,UNKNOWN,OBSERVATIONAL,['NA'],Mutation Consistency of tissue and blood sample,prediction accuracy of survival rate
6222,NCT05869474,Overall survival (OS),2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],Visual analog scale (VAS),
6223,NCT03933449,Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus,2016-12-29,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE),
6224,NCT01098760,For subjects randomized into HFSR study subgroup: overall HFSR incidence in the first 3 weeks of Sorafenib treatment,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],For HFSR study subgroup: a mean HFSR grade determined at the end of the first 3 weeks of sorafenib treatment.,
6225,NCT05165602,the relationship between 68Ga SUVmax before treatment and the therapeutic effect will be assessed by SPSS26.0,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],the relationship between the dynamic change of 68Ga SUVmax and the therapeutic effect will be assessed by SPSS26.0,
6226,NCT06091748,Specificity of 68Ga-DOTATOC PET-CT Imaging for Detection of Somatostatin Receptor Positive GEP-NET,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence and severity of AE and SAE,
6227,NCT02443883,Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab,2015-07-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment,
6228,NCT05528783,The diagnostic sensitivity and specificity of FIT-DNA detection for local recurrence and advanced colorectal neoplasm of CRC.,2022-04-25,RECRUITING,OBSERVATIONAL,['NA'],3.The time interval between CRC recurrence and advanced colorectal neogenesis after the first positive appearance was detected by FIT-DNA detection.,
6229,NCT03464305,5 year overall survival,2018-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Time to Treatment Failure,
6230,NCT03722498,Progression-free survival,2018-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Objective response rate,
6231,NCT03417765,Incidence of treatment-emergent adverse events,2018-09-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Assessment of quality of life,
6232,NCT04495387,change of taste chemotherapy-related alterations,2021-07,UNKNOWN,OBSERVATIONAL,['NA'],Emotions elicited by foods,
6233,NCT05336266,Feasibility determined by the number of patients that take the prescribed dose of ketorolac (4 times daily) for 5 consecutive days.,2022-07-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Mean change in calories consumed from baseline through the End-of-Treatment visit,
6234,NCT03457896,Progression free survival (PFS) with neratinib plus cetuximab therapy,2018-05-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],Frequency of adverse events assessed using CTCAE 4.0,
6235,NCT06035133,"tumor regression grading, TRG",2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6236,NCT03941938,Anastomotic leak,2019-05-02,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative complications,
6237,NCT02842294,"time to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning)",2013-05,UNKNOWN,OBSERVATIONAL,['NA'],treatment preference,
6238,NCT03888313,The patient's experience of participating in a pretreatment group consultation,2019-04-26,COMPLETED,OBSERVATIONAL,['NA'],,
6239,NCT05222971,6-month progression-free survival rate,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-free survival,
6240,NCT02475889,PD-L1 expression in primary tumor,2007-11,COMPLETED,OBSERVATIONAL,['NA'],,
6241,NCT05755672,"Follow-up examination of tumour remission, progression or recurrence",2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],Quality of life changes,
6242,NCT03263429,Recommended phase 2 dose of CB-839 in combination with panitumumab and irinotecan hydrochloride (Phase I),2017-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
6243,NCT01828762,Vital signs，physical examinations and adverse events,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
6244,NCT05337137,Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2022-05-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of participants with adverse events (AEs),
6245,NCT05495152,Disease-free Survival (DFS),2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,
6246,NCT01100801,Response Rate (RR),2010-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6247,NCT00143533,Dose limiting toxicities,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6248,NCT04068610,Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in Part 2,2019-09-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Positive ADA to Bevacizumab in Part 1 (S1),
6249,NCT02581501,Identification of Maximum Tolerated Dose and Dose Intensity in Patients with Pancreatic Cancer,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Progression Free Survival,Assess Safety and Toxicity based upon NCI Common toxicity criteria version 4.1.
6250,NCT02693236,objective rate response (CR+PR) as measured by RECIST criteria,2014-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",number of participants with adverse events,
6251,NCT04030260,The progression-free survival (PFS) rates at 6 months,2019-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety variables will be summarized using descriptive statistics based on adverse events collection,
6252,NCT06143644,2-year recurrence free survival rate of the cohort evaluated by ctDNA,2022-01-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Time point of ctDNA MRD test for recurrence monitoring,
6253,NCT02387307,Recommended dose (RD) of rSIFN-co,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],FDG-PET response (lesion volume) before and after administration of rSIFN-co,"Evaluation of levels (counts) of 2'5'-oligoadenylate synthetase, before and after administration of rSIFN-co"
6254,NCT05000294,Objective response rate (ORR),2021-12-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease control rate (DCR),
6255,NCT06201585,The rate of postoperative complications,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Intraoperative instrument operation error rate
6256,NCT06246448,Time to functional recovery,2024-01-23,RECRUITING,INTERVENTIONAL,['NA'],Abdominal wall complaints,
6257,NCT00164918,Bowel function and related symptoms early post-op,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6258,NCT03855904,To evaluate the efficacy of TC-325 in preventing 30-day rebleeding following the index malignant hemorrhage: Rebleeding rate,2019-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"1. To evaluate the efficacy of TC-325 in immediate hemostasis and rebleeding at 24 hours, 72 hours, 90 days and 180 days following presentation at initial bleeding episode as well as 6-month survival rate",
6259,NCT03578445,Clinical impact of EUS-guided microbiopsies in patients with pancreatic cystic lesions,2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],Diagnostic values of gene mutations (NGS analyses) in microbiopsy material in the surgical subcohort,
6260,NCT00063141,Overall Survival,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Health Economics,
6261,NCT00172627,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6262,NCT04660123,helicobacter pylori eradication,2020-12-20,COMPLETED,INTERVENTIONAL,['PHASE4'],symptoms improvement rates,adverse events
6263,NCT03608046,Tumor response rate,2018-10-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events,
6264,NCT04456283,5 years Survival,2019-05-20,UNKNOWN,OBSERVATIONAL,['NA'],,
6265,NCT04786704,Detection of advanced colorectal neoplasia,2021-03-22,COMPLETED,OBSERVATIONAL,['NA'],Efficacy of sDNA in the detection of advanced colorectal neoplasia in low-risk asymptomatic subgroup.,
6266,NCT02649868,To determine the imaging characteristic of radiopaque beads including qualitatively comparing virtual and actual bead perfusion in evaluating tumor vascularity in the treatment of hepatic tumors using bead embolization.,2016-01-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,
6267,NCT04642547,Progression free survival,2020-12-02,COMPLETED,INTERVENTIONAL,['NA'],Safety endpoint,
6268,NCT01899261,Severe Treatment-related Toxicity,2010-10-07,COMPLETED,INTERVENTIONAL,['NA'],Time to Local Progression (TTLP) of Treated Lesions,
6269,NCT05546879,Percentage Proportion of patients experiencing adverse events,2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE1'],Best overall objective response rate (ORR),PK-PD evaluation
6270,NCT02973750,Association of Age With Changes,2016-10-20,COMPLETED,OBSERVATIONAL,['NA'],Impact of Inflammation on Toxicity and Relative Dose-Intensity (RDI),Overall Survival (OS)
6271,NCT04917263,pathological complete response on the operative specimen,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
6272,NCT02754661,Number of Participants With an Actionable Lesion on CCE vs. CTC Confirmed by Optical Colonoscopy,2016-09,COMPLETED,INTERVENTIONAL,['NA'],Predictive Value of a Negative (NPV) of CCE Versus CTC in the Detection of Polyps ≥6 mm,
6273,NCT03057171,"Expression of THRIL, PACER",2015-05,UNKNOWN,OBSERVATIONAL,['NA'],,
6274,NCT01278381,Major Complication rate,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,
6275,NCT04520932,Treatment response,2021-03-30,RECRUITING,INTERVENTIONAL,['NA'],,
6276,NCT00070434,"Response (confirmed and unconfirmed response, complete response, partial response)",2004-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
6277,NCT00219557,Overall Survival (OS),2005-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in 26-item Pancreatic Cancer-specific Quality of Life Questionnaire (QLQ-PAN26) Score at Day 1 of Every Cycle and End of Study,
6278,NCT00005862,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6279,NCT05396781,Procedure time,2022-01-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Clinical impact,Performance Characteristics
6280,NCT05769725,DFS,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6281,NCT00201331,To compare the DFS and OS of HDFL vs. weekly bolus 5-FU plus high dose LV as adjuvant chemotherapy for N2 colon cancer,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],"3. To assess the disease-free survival of patients with high or low TS level of N2 colon cancer, when adjuvant chemotherapy of 5-FU was administered by bolus or continuous infusion .",
6282,NCT00003044,,1996-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6283,NCT05296005,Incidence of adverse events,2022-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],18F-FDG dPET/CT to evaluate and characterize residual primary tumor following neoadjuvant chemotherapy and initial chemoradiation therapy for subsequent adaptive boost radiation delivery.,Standard uptake value SUVmax Tumor-to-liver metrics
6284,NCT04559451,Postoperative liver function failure,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],Postoperative morbidities and mortalities,
6285,NCT03417843,Incidence of adverse and serious adverse events,2018-02,UNKNOWN,INTERVENTIONAL,['NA'],Technical efficiency of the method,
6286,NCT00112632,"Overall tumor response (complete response, partial response, stable disease, and progression of disease)",2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
6287,NCT05084833,Proportion of patients who report completing a colonoscopy or Cologuard test (Cologuard test plus colonoscopy if Cologuard is positive) within 12 months of randomization,2022-02-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Cost and Cost-Effectiveness Analysis,
6288,NCT03421327,Qualitative analysis of how parents and children with either Huntington's Disease or hereditary cancer communicate about genetic risk information,2017-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
6289,NCT05690048,Adverse event documentation of FMT in advanced HCC,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Change of Hepatic function,
6290,NCT01805622,Effectiveness (RE-AIM Framework),2012-08,UNKNOWN,INTERVENTIONAL,['NA'],Implementation (RE-AIM Framework),Cost-effectiveness analysis
6291,NCT00017082,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6292,NCT04929652,Objective response rate (ORR),2021-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Assess the anti-tumor activity:DCR,
6293,NCT01144195,Objective Response Rate,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
6294,NCT00041652,,2000-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6295,NCT00208546,toxicity,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],translational research,
6296,NCT05961111,Systemic Immune Response,2023-06-24,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Quality of Life Assessment,
6297,NCT03654534,"body weight loss ratio at 1, 3, 6 months",2019-04-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],severe side effects on digestive tract,
6298,NCT00327093,"Elaboration of a predictive model, based on biological and functional imaging parameters, for the response to monoclonal antibodies as assessed through RECIST criteria 2 months after the beginning of treatment",2006-05,TERMINATED,INTERVENTIONAL,['PHASE4'],Correlation between the response at 2 months and that at 6 months of treatment (taking into account the therapeutic adjustments during the 6-month follow-up),
6299,NCT01010334,Number of courses delivered (relative dose intensity for adjuvant studies),2009-03,TERMINATED,INTERVENTIONAL,['NA'],"Measure quality of life using a FACT G tool, before and at best response and at the end of the treatment",
6300,NCT00300027,Echocardiogram every 2 cycles (q 2 cycles),2006-04,TERMINATED,INTERVENTIONAL,['PHASE1'],Fluorodeoxyglucose positron emission tomography (FDG-PET) (3 scans prior to C3),
6301,NCT04357873,"Objective Response Rate (ORR), investigator assessment",2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
6302,NCT04683744,"Identify patient knowledge, attitudes, and beliefs that influence decisions to engage in cancer screening and prevention during the COVID-19 pandemic, and barriers to uptake",2021-01-11,UNKNOWN,OBSERVATIONAL,['NA'],,
6303,NCT04634448,The Prevalence of Appendiceal Tumours in Periappendicular Abscess,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Surgery after follow-up MRI,
6304,NCT05700110,To develop a Radiomics model based on pre-operative CT porto-venous phase imaging that accurately predicts Resection Margin status in pancreatic head malignancy,2022-05-05,RECRUITING,OBSERVATIONAL,['NA'],,
6305,NCT03112668,Feasibility defined as survey follow ups,2017-12-06,COMPLETED,INTERVENTIONAL,['NA'],,
6306,NCT00006016,Survival,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6307,NCT02318888,Surgery for small bowel obstruction,2009-12,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative complications,
6308,NCT00003427,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6309,NCT05360745,Change in quality of life,2022-06-29,WITHDRAWN,INTERVENTIONAL,['NA'],Adverse events due to chemotherapy,
6310,NCT05845502,Overall survival (OS),2023-05-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6311,NCT04593615,3-year disease free survival rate,2020-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Inflammatory and immune response,
6312,NCT00426153,Percent Change in Liver Volume,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Change in Subject Reported Outcomes Using Mean Health Related Quality of Life (HRQoL) Scores,
6313,NCT05918224,The incidence of Severe Oral mucositis (WHO grade ≥3),2022-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Oral activities scores,
6314,NCT01768741,Total survival time and disease free survival time,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],Regulatory T cells and associated cytokines in liver cancer、para-carcinoma and healthy liver tissue,Hospital costs
6315,NCT03850769,R0 resection rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6316,NCT02937506,Patient Satisfaction,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6317,NCT01612546,CRLX101 (CPT) Uptake in Tumor and Nearby Normal Tissue,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
6318,NCT00172159,Response rate and resectability after neoadjuvant therapy.,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Survival of the patients.,
6319,NCT05442632,The proportion of patients who require blood product infusion or intervention with platelet raising drugs due to bleeding during the perioperative period,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of liver failure,
6320,NCT05558436,Diagnostic sensitivity,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],"Diagnostic specificity, accuracy, positive predictive value and negative predictive value",
6321,NCT00471328,Progression-free Survival (PFS) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set,
6322,NCT03807999,3-months deterioration-free rate,2015-02-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
6323,NCT04455282,Difference in CTC detection rate between peripheral and tumor draining veins.,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],Dynamic Biobank,
6324,NCT04188535,Ability to measure disease control (for imaging registry expansion cohort),2020-01-15,RECRUITING,INTERVENTIONAL,['NA'],Dosimetric change,
6325,NCT04892810,To compare induced immunomodulation by RFA and MWA in HCC patients,2021-05-31,UNKNOWN,OBSERVATIONAL,['NA'],To evaluate early induced immunomodulation after MWA in HCC patients,
6326,NCT02314871,Change from baseline number of circulating cancer cells at 3 weeks after surgery,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Pain intensity assessment,
6327,NCT03040986,Proportion of Participants With an Objective Response (Partial Response + Complete Response),2017-07-21,COMPLETED,INTERVENTIONAL,['PHASE2'],"Overall Percent Change in Variant Allele Fraction (VAF, %) of KRAS in Participants With Detectable KRAS Mutant Circulating Tumor Deoxyribonucleic Acid (ctDNA) at Baseline and After Treatment",
6328,NCT05810402,Percentage of patients with CTCs-PD-L1+ by CellSearch® technique,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Progression Free Survival,
6329,NCT04796025,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2021-09-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Median overall survival time (mOS),Treatment-related adverse events
6330,NCT03505320,Objective Response Rate (ORR) of zolbetuximab as a single agent by central review (Cohort 1),2018-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Minimal Residual Disease (Cohort 5),
6331,NCT06028724,Real world prevalence of clinically useful mutations in solid tumors,2023-05-26,RECRUITING,OBSERVATIONAL,['NA'],To evaluate the association between somatic genetic alterations and the clinical characteristic of the enrolled patients,
6332,NCT01651013,Percentage of patients with K-Ras mutation,2010-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,predictive factors for response to treatment
6333,NCT00103298,Response and duration of response,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Correlation of health-related quality of life with length of survival,
6334,NCT01482520,Genotypes,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,
6335,NCT02568748,Number of patients with ablated hcc,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6336,NCT02843191,Pathologic complete response,2016-12,RECRUITING,INTERVENTIONAL,['PHASE3'],Peripheral neuropathy,
6337,NCT05924997,Adverse events (AEs) and serious adverse events (SAEs),2023-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
6338,NCT00958841,Percentage of Responders at Month 6 - Pooled Pancreatic NETs (PNETs),2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Nelson's Syndrome: Number of Patients Attaining Normalization or a More Than 50% Reduction in Primary Biochemical Tumor Marker,
6339,NCT05674526,Maximum Tolerated Dose,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Response Rate,
6340,NCT02453490,Objective response rate,2015-10-11,TERMINATED,INTERVENTIONAL,['PHASE3'],R0 resection rate of liver,The early tumor shrinkage （ETS）and depth of response(DPR)
6341,NCT02486198,The relief of neurotoxicity in patients with grade 2 or higher neurotoxicity by means of CTC 4.03 and EORTC QLQ-CIPN20,2015-05-05,COMPLETED,INTERVENTIONAL,['PHASE3'],quality of life,
6342,NCT00633607,"Establish a Hereditary Colorectal Tumor Registry to facilitate development and implementation of epidemiological, clinical and cancer control research.",2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
6343,NCT03360461,To investigate the ability of EMI-137 to produce visible fluorescence in regional lymph nodes draining the colon cancer.,2018-02-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],Study of in vivo imaging compared against ex vivo fluorescent detection,
6344,NCT02811497,Overall response rate (ORR),2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of treatment-emergent adverse events (AEs),
6345,NCT01905202,Number of patients with adverse events,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],Number of participants who develop C. difficile induced diarrhea,48 hour gastroesophageal pH measurement
6346,NCT01345526,"PFS rate, toxicity, compliance",2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6347,NCT02774512,ZAK expression level by immunohistochemistry on frozen material (surgical specimen) by Western blot and on paraffinembedded tissues section using an immunohistochemistry approach,2016-05,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Half-life of nilotinib,
6348,NCT04256707,Combination Therapy Period: Arm C: Number of Patients With Adverse Events (AEs),2020-01-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Combination Therapy Period: Arm C: Overall Response Rate (ORR) as Assessed by RECIST 1.1,
6349,NCT05703750,Overall Survival(OS),2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],Progression free survival(PFS) per mRECIST,
6350,NCT04513119,The incidence of local tumor progression (LTP),2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Tumor-free survival,
6351,NCT04066660,Disease Control Rate,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of Life (QoL),
6352,NCT05187481,Overall survival,2021-11-15,RECRUITING,INTERVENTIONAL,['PHASE3'],the United States Eastern Oncology Collaboration Group (ECOG) score scale,
6353,NCT00559351,"mean, median, 1-year, 3-year, 5-year overall survival",2001-12,TERMINATED,INTERVENTIONAL,['PHASE3'],curative resection rate,
6354,NCT02399306,Body Weight Change from baseline to the end of treatment,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival,
6355,NCT02789800,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes,2016-04-22,COMPLETED,INTERVENTIONAL,['NA'],Evaluation of Intervention Effectiveness - Change in Patient-Centredness,
6356,NCT00706576,Number of participants with opioid growth factor toxicity,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in plasma opioid growth factor levels,
6357,NCT05877573,pCR rate,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],SAE,
6358,NCT03635489,Progression-Free Survival (PFS),2018-08-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Adverse Events (AEs),
6359,NCT03388190,Primary - progression-free survival (PFS),2018-05-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Secondary 8 - Quality-of-life (QoL),Exploratory 5 - Histologic and molecular tumor biomarkers
6360,NCT03350945,Tumor localization time,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Blood loss,
6361,NCT02162758,Percentage of Participants With Recurrence of Intestinal Metaplasia (IM),2014-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Change From Baseline in the Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) Total Score,
6362,NCT05236972,Disease Free survival [ Time Frame: 3 years ],2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall Survival [ Time Frame: 5 years ],
6363,NCT00803647,Reported Adverse Events.,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.,
6364,NCT03213314,Correlation between the pre-operative liver health assessment score and the post-operative liver function composite integer-based risk score.,2017-09-07,COMPLETED,INTERVENTIONAL,['NA'],• To evaluate LiverMultiScan image interpretations correlated with post-operative length of stay.,
6365,NCT00072332,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6366,NCT00051467,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6367,NCT00488332,Optical assessment of oral mucositis in patients undergoing radiation or chemoradiation for head and neck cancer treatment,2006-03,TERMINATED,OBSERVATIONAL,['NA'],,
6368,NCT04821895,genetic profiles in gastrointestinal stromal tumor (GIST) patients,2021-08-28,RECRUITING,OBSERVATIONAL,['NA'],To help for search the potential targeted agents for the treatment of these wild type GIST patients,
6369,NCT02983500,Rate of patients with loss of > 5 % body weight,2016-08-28,COMPLETED,OBSERVATIONAL,['NA'],Cachexia assessment,
6370,NCT02231203,Change in ex vivo production of pro-inflammatory cytokine IL-6 in LPS stimulated whole blood,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Change in in vivo systemic inflammatory response parameters,Cognitive function
6371,NCT02435186,progress-free survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],"safety as measured by adverse events, vital signs, clinical lab tests, ECG and physical examination",
6372,NCT01659632,,2010-04,UNKNOWN,OBSERVATIONAL,['NA'],,
6373,NCT05715632,pCR rate,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],Adverse reactions and perioperative complications (Security),
6374,NCT00075504,Response Rate According to RECIST Criteria,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
6375,NCT03914443,Rate of participants with dose limiting toxicities (DLTs),2019-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
6376,NCT00137592,colorectal cancer screening,2005-10,COMPLETED,INTERVENTIONAL,['NA'],colorectal cancer screening knowledge,
6377,NCT03214939,Сytotoxicity,2016-09-27,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Relapse-free period,
6378,NCT04517019,Evaluation of the impact of an Activity tracker based Fitness programme on the Qualitiy of Life after oncological Therapy,2020-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
6379,NCT03654131,Freedom from local lesion progression (analyzed on patient-level),2018-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life as descriptive statistics: EORTC QLQ-C30,
6380,NCT05593393,"The termination of the follow-up of IPMN patients, including death termination and recommended surgery termination.",2022-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The new development of worrisome features or high-risk stigmata,
6381,NCT06017583,Complete response rate,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Disease free survival,
6382,NCT02051283,Predictive value of MRI determined contrast-enhanced and diffusion-weighted sequence pattern towards outcome (tumour recurrence < 1 year versus > 1 year),2014-02,UNKNOWN,OBSERVATIONAL,['NA'],"Correlation of predictive MRI parameters with histology obtained from biopsy during radio-frequency ablation (tumor grade, microvascular invasion, Keratin 19 status)",
6383,NCT04909866,PFS,2021-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",OS,
6384,NCT05497531,Comparison of the amount of ctDNA in draining vein plasma sample to peripheral vein sample through ratio of mean allele frequency,2022-09-07,RECRUITING,INTERVENTIONAL,['NA'],Number of unique alterations found in ctDNA compared to number of alterations derived next generation sequencing (NGS),
6385,NCT06109961,Phase 1 recruitment rate,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2 numbers of closure all external openings of fistula tracts,
6386,NCT02523170,Diagnostic accuracy,2014-07,COMPLETED,INTERVENTIONAL,['NA'],Assess margins,
6387,NCT01338948,rate of conversion (to laparotomy or laparoscopy assisted),2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6388,NCT05322486,Overall survival,2020-10-29,UNKNOWN,OBSERVATIONAL,['NA'],Progression free survival (PFS),
6389,NCT01070355,Histological Ki67 cancer cell proliferation index,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Urinary markers of prostaglandin metabolism,
6390,NCT00826384,Overall survival,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6391,NCT03735511,Overall Survival,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA'],Progression-Free Survival,
6392,NCT02289183,3-year disease free survival rate,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],3-year recurrence pattern,
6393,NCT02521129,Number of participants with complications,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6394,NCT00393068,Pathologic Complete Response (pCR) Rate,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-Free Survival,
6395,NCT03528785,"Number of patients achieving R0 resection after preoperative nanoliposomal irinotecan (nal-IRI), Oxaliplatin, Leucovorin (LV), 5-FluoroUracil (5-FU)",2018-03-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],assess surgical morbidity,
6396,NCT04083573,Consistency between the result from medical monitor and that from medical augmented reality glass,2019-09,UNKNOWN,OBSERVATIONAL,['NA'],,
6397,NCT00995358,Overall survival after the 1st vaccination,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Time to progression after the 1st vaccination,
6398,NCT02425930,Disease-Free Survival,2013-08,COMPLETED,OBSERVATIONAL,['NA'],Expenditure of hospitalization,
6399,NCT01951521,Complete response rate,2014-09-01,UNKNOWN,INTERVENTIONAL,['NA'],(disease-free) survival,
6400,NCT01471353,Sorafenib Activity,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Correlative Tissue Analysis,
6401,NCT03914170,Median Progression free survival (PFS),2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],Liver metastases resection rate,
6402,NCT00165490,"To determine the response to the combination of cetuximab, cisplatin, irinotecan, and radiation therapy in resectable esophageal carcinoma.",2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],To determine the progression-free survival of patients treated with combination chemotherapy and radiation therapy.,
6403,NCT02922049,Detection of persistent or recurrent intestinal metaplasia/dysplasia and esophageal and gastric lesions by confocal laser endomicroscopy and classic histopathology,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Sensitivity and specificity of the procedure,
6404,NCT02172651,VDR Binding Sites,2014-07-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Number of Participants with Serious and Non-Serious Adverse Events,
6405,NCT05033392,Pathological complete response rate,2021-09-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
6406,NCT03614013,Survival,2018-07-04,UNKNOWN,OBSERVATIONAL,['NA'],,
6407,NCT01139138,Dose limiting toxicities,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
6408,NCT01198704,Predictive factors of HCC recurrence,2009-01,COMPLETED,OBSERVATIONAL,['NA'],Correlation of HCC differentiation between liver biopsy and explant liver,
6409,NCT00421824,Response rate,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
6410,NCT01459614,Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
6411,NCT04357483,Incidence of POPF,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Postoperative complication,
6412,NCT05632328,Objective Response Rate,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Grade 3-5 Treatment-related Toxicity Rate,
6413,NCT02358161,Dose limiting Toxicity (DLT) and MTD of LDE225 co-administered with gemcitabine and nab-paclitaxel,2015-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression free survival,
6414,NCT06091423,Progression free survival (PFS),2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse event (AEs),
6415,NCT05004831,PFS,2022-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerance,
6416,NCT00892424,Determine the MTD of sorafenib and RT in patients with liver metastases using an iso-toxicity radiation dose allocation scheme. Determine the acute toxicity (< 3 months) of sorafenib when combined with RT in patients with liver metastases.,2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Document any observed late toxicities of treatment. Determine 1) the in-field local control based on CT response at 3 months;2)the time to progression and overall survival of this cohort, 3)changes in quality of life in these patients",
6417,NCT04269746,Evaluate the diagnostic value of long noncoding RNA (CCAT1) expression,2020-12,UNKNOWN,OBSERVATIONAL,['NA'],,
6418,NCT06308445,Evaluation of the safety profile of two doses of rapamycin in adolescents with Familial Adenomatous Polyposis.,2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Evaluation of the effect of rapamycin on the size of the largest polyp in each segment (rectum, left colon, transverse colon and right colon) in adolescents with Familial Adenomatous Polyposis",
6419,NCT01077999,Percentage of pathologic complete responses,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity profile,
6420,NCT04610086,Satisfaction,2020-11-19,UNKNOWN,OBSERVATIONAL,['NA'],Participation in cancer decision making,
6421,NCT03097666,Efficacy: Percent Eradication by therapeutic dose,2017-03-20,COMPLETED,INTERVENTIONAL,['NA'],Efficacy: Treatment,
6422,NCT04491942,Recommended phase 2 dose (RP2D) of BAY 1895344,2021-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-free survival (PFS),
6423,NCT03359850,Apparent Total Body Clearance (CL/F) of Niraparib and M1 During PK Phase,2018-02-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Change From Baseline in Temperature During Extension Phase,Clearance of Unbound Niraparib and M1 (CLfu/F) During PK Phase
6424,NCT04952688,retinal vascular density retinal vascular density,2020-12-14,RECRUITING,INTERVENTIONAL,['NA'],,
6425,NCT01342705,Cumulative incidence of HepatoCellular Carcinoma during follow-up,2011-05,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of Participants with Adverse Events as a Measure of Safety and Tolerability,
6426,NCT03367247,Feasibility of the BOLSTER Intervention,2018-04-24,COMPLETED,INTERVENTIONAL,['NA'],Acceptability of the BOLSTER Intervention,
6427,NCT02751892,Change in minutes spent in moderate and vigorous intensity physical activity measure with the International Physical Activity Questionnaire long version,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Change in minutes spent in moderate and vigorous intensity physical activity with accelerometry,
6428,NCT01224392,reduction in metabolic tumor activity,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],cost evaluation,
6429,NCT03488537,sensitivity/specificity for CRC,2018-02-28,COMPLETED,INTERVENTIONAL,['NA'],Sensitivity/specificity for detection of CRC and/or polyps before and after bowel preparation,
6430,NCT04660058,corelation between the bile acid profile and gastric microbiota in different groups,2020-12-20,COMPLETED,OBSERVATIONAL,['NA'],,
6431,NCT02812628,3-year local recurrence,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],3-year disease-free survival,Perforation rate
6432,NCT05608967,Usability,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],Complications,
6433,NCT03426904,Relapse free survival after randomization,2018-10-24,RECRUITING,INTERVENTIONAL,['PHASE3'],Pathological tumor stage,
6434,NCT02407561,Gene expression profiling will be undertaken to determine if RNA is a superior biomarker to protein,2015-02,TERMINATED,OBSERVATIONAL,['NA'],,
6435,NCT00379743,Difference between the two intervention groups in the proportion of participants who complete at least one of the recommended screenings.,2006-10,COMPLETED,INTERVENTIONAL,['NA'],Stage at diagnosis.,
6436,NCT05415345,evaluate the concentration of IgG antibodies to HEV,2021-10-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Serious adverse events occurred throughout the study,
6437,NCT03619668,Changes in position and shape of the tumour during RT.,2018-06-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Change in functional imaging parameter: Ktrans.,
6438,NCT03727763,Objective Response Rate(ORR),2018-10-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
6439,NCT04670445,"Change in participant knowledge, using the Immunotherapy Knowledge Assessment",2021-01-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Patient questions asked in visit with oncologist,
6440,NCT03667911,Boston bowel preparation score,2018-09-15,UNKNOWN,INTERVENTIONAL,['NA'],cecal intubation rate,
6441,NCT00504257,Six Month Progression Free Survival (PFS),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
6442,NCT00003864,,1999-09-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6443,NCT03069664,Change in experienced quality of life,2017-11-17,RECRUITING,INTERVENTIONAL,['NA'],Change in need for pancreatic enzyme supplements,
6444,NCT05317325,The number of treatment-related adverse events,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Disease-free Survival,
6445,NCT00001568,,1997-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6446,NCT01477814,colorectal cancer screening,2008-07,COMPLETED,INTERVENTIONAL,['NA'],cost-effectiveness of various strategies for screening,
6447,NCT04406831,Analysis of miRNA profile,2015-04,RECRUITING,OBSERVATIONAL,['NA'],miRNA PCR expression,
6448,NCT02375880,"Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.",2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Efficacy - Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1),
6449,NCT06294548,Phase II,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease Control Rate (DCR),
6450,NCT06152419,Patient questionnaire on radiotherapy-related anxiety,2023-10-17,RECRUITING,INTERVENTIONAL,['NA'],,
6451,NCT01012011,Adverse events collection,2009-09,COMPLETED,OBSERVATIONAL,['NA'],Performance status,
6452,NCT05252078,DFS,2022-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],3-year OS rate,
6453,NCT03323996,Semi-Structured interviews,2017-07-26,UNKNOWN,OBSERVATIONAL,['NA'],,
6454,NCT02863770,"The yield of EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.",2016-07,RECRUITING,INTERVENTIONAL,['NA'],Quantitative Parameters of Pancreas Lesions,
6455,NCT01351103,Maximum Tolerated Dose or Recommended Dose for Expansion of LGK974 as a single agent or in combination with PDR001 in patients treated,2011-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Absorportion and plasma concentrations of PDR001,
6456,NCT02958683,Change in volume of each thoracoabdominal compartment during breathing,2011-07,COMPLETED,OBSERVATIONAL,['NA'],Synchrony of chest wall movement,
6457,NCT00949273,postoperative complications,2009-07,UNKNOWN,OBSERVATIONAL,['NA'],3-years overall survival,
6458,NCT00586404,"To determine the prevalence and incidence of low grade dysplasia, high grade dysplasia and adenocarcinoma in a large cohort of patients with Barrett's esophagus",2007-11,TERMINATED,OBSERVATIONAL,['NA'],"To determine the magnitude of the contribution of selected factors (e.g. age, gender, ethnicity, obesity, tobacco use, alcohol use, ASA/NSAID/PPI use, duration of GERD symptoms, length of BE, HH) to the risk of HGD and CA",
6459,NCT01935778,disease-free survival,2013-10-02,RECRUITING,INTERVENTIONAL,['PHASE3'],safety profile,
6460,NCT01666184,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
6461,NCT02614339,Disease free survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],recurrence rate of polyps after polypectomy,
6462,NCT00389935,Blood Transfusion requirements,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Hemoglobin overall complication rate Constipation Neuropathy,
6463,NCT03132922,Measurement of RCL in genetically modified T cells.,2017-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Number and % of subjects having any Long Term Follow Up Adverse Events (AEs),MAGE-A4c1032T cell trafficking in tumor lesion(s).
6464,NCT05484687,the concentration of tumor micrometastasis markers were determined by ELISA,2020-03-24,COMPLETED,INTERVENTIONAL,['NA'],the concentration of immune indexes were determined by ELISA,
6465,NCT03217643,Evaluate the 2-year progression-free survival,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
6466,NCT02017015,Overall Response Rate (ORR) Based on Independent Radiological Review (IRR),2013-12-24,COMPLETED,INTERVENTIONAL,['PHASE2'],Kaplan-Meier Estimate of Overall Survival (OS),
6467,NCT05605197,Incidence of Adverse events after U87 CAR-T cells infusion [Safety and Tolerability],2022-10-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacodynamics of U87 CAR-T cells,
6468,NCT05030246,Overall Survival (OS),2021-07-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
6469,NCT04666558,Lower Extremity Functional Scale (LEFS),2020-11-30,COMPLETED,INTERVENTIONAL,['NA'],General health-related quality of life (5-Level EQ-5D [EQ-5D-5L]),Program acceptability (Unified Theory of Acceptance and Use of Technology - UTAUT)
6470,NCT03144765,Quality of Mesorectal Excision,2018-01-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],3-year oncologic outcomes,
6471,NCT03800602,Overall response rate (ORR),2019-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Biological response: carcinoembryonic antigen (CEA),
6472,NCT00702884,Progression-free Survival Rate,2008-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],Quantitative Assessment of Proliferating Tumor Cells and Apoptosis,
6473,NCT03448341,To assess the changes of deglutition function by means of Videofluoroscopy (VFS) from before to after radiochemotherapy,2016-07-16,COMPLETED,OBSERVATIONAL,['NA'],"To correlate radiation dose features received by the different swallowing related structures (SWOARs) to the changes of MDADI, FEES and VFS scores from before to after treatment by using a Machine Learning Methodology",
6474,NCT04229524,The incidence of anastomotic fistula,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6475,NCT02422680,Patient Satisfaction,2015-03-23,WITHDRAWN,OBSERVATIONAL,['NA'],Patient Pain (own Perception),
6476,NCT06326437,the Kessler psychological distress scale-10,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Locke-Wallace Marital Adjustment Scale,
6477,NCT02012231,Phase 1 dose escalation: Identification of Recommended Phase 2 Dose Safety of PLX8394,2014-02,TERMINATED,INTERVENTIONAL,['PHASE1'],Identification of Recommended Phase 2 dose (RP2D),
6478,NCT02460198,Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor,2015-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response (DOR) Per RECIST 1.1 as Assessed by the Central Imaging Vendor,
6479,NCT05732181,Pain severity,2017-05-09,COMPLETED,INTERVENTIONAL,['NA'],,
6480,NCT03581890,Postoperative 1-year mortality rate (study 2),2007-12-01,UNKNOWN,OBSERVATIONAL,['NA'],Postoperative 90-day mortality (study 2),
6481,NCT02010567,Pathological Complete Response (pCR) Rate,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS) Based on Pathological Complete Response (pCR).,
6482,NCT04227808,1-year RFS rate,2019-12-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Health-related quality of life,
6483,NCT06233994,Progression Free Survival (PFS),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6484,NCT00898768,"The main outcome measure will be the number of neoplastic small bowel lesions, with determination of size, location and histological characteristics at baseline and at follow-up after 2 years.",2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],The secondary endpoint will be the number of complications following endoscopic procedures: rates of capsule retention and postpolypectomy bleeding and perforation.,
6485,NCT00686569,Early detection of postoperative complications,2007-04,COMPLETED,OBSERVATIONAL,['NA'],,
6486,NCT02870010,Tolerance: toxicities will be defined according to the scale: National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTC AE v3.0) to determine the limiting dose,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6487,NCT01679756,Overall surgical morbidity,2013-03,UNKNOWN,INTERVENTIONAL,['NA'],Readmission,
6488,NCT01938313,Recovering Rate,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
6489,NCT03310632,tumor assessment in millimeters,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Eastern Cooperative Oncology Group (ECOG) status,
6490,NCT03038100,Overall Survival - PD-L1-Positive Subpopulation,2017-03-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab,
6491,NCT02839954,Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR-pNK cells,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II: Objective Response Rate,
6492,NCT06037343,Hypervascular capsule,2023-02-23,RECRUITING,OBSERVATIONAL,['NA'],Infiltrative nature Classification of the hepatic lesion by LI-RADS in MRI,
6493,NCT00696696,4-month Progression Free Survival (PFS) Rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival (mOS),
6494,NCT06206707,Clinical remission of immune-mediated diarrhea,2024-01-23,RECRUITING,INTERVENTIONAL,['NA'],Endoscopic remission,
6495,NCT01130142,Overall survival comparison,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Comparison of PFS, TTP and ORR",
6496,NCT03065868,Compare regression rate of gastric polyps between H. pylori eradication and non-eradication groups. Regression of gastric polyp: one of below 1) Disappearance of gastric polyp 2) Reduction of polyp size over 50%,2015-12-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6497,NCT04139135,EFS,2019-12-12,RECRUITING,INTERVENTIONAL,['PHASE3'],5-year OS rate,
6498,NCT05278078,"Expression analysis of slimming myokines, cachectic factors, cytokines genes by Real-Time PCR",2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6499,NCT00228189,Toxicity,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6500,NCT04559087,Postoperative complications,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],survival,
6501,NCT00582699,"The levels of specific cytokines (IL-1, Il-6, TNF-alpha, as well as IL-10, Il-15 and IFN-gamma), the diagnosis of Depression, depressive symptom severity, and the pattern of depressive symptoms.",2005-11,COMPLETED,OBSERVATIONAL,['NA'],,
6502,NCT05655780,Molecular profile of the tumor,2023-01-09,RECRUITING,OBSERVATIONAL,['NA'],,
6503,NCT04547725,6-month disease control rate,2020-09-16,RECRUITING,INTERVENTIONAL,['NA'],Safety evaluation,
6504,NCT05053191,Frequency of nurses' use of family centered care practices,2021-09-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
6505,NCT00028405,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6506,NCT02704130,Intrahepatic Disease-free Survival,2016-03,TERMINATED,INTERVENTIONAL,['NA'],Postoperative Morbidity,
6507,NCT01531712,Resectability rate after neoadjuvant treatment with chemotherapy plus chemoradiotherapy.,2011-02-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Adverse events,
6508,NCT02110082,"The primary safety endpoint is the incidence, potential significance, and clinical importance of adverse events",2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Trough observed concentration (Cmin) of BMS-663513 in combination with Cetuximab,
6509,NCT02609451,Quality Of Life (GQLI - Questionnaire),2007-11,TERMINATED,INTERVENTIONAL,['NA'],Quality Of Life (GQLI - Questionnaire),
6510,NCT02691052,Global Health Status/Quality of Life Score at 3 months,2014-12,COMPLETED,OBSERVATIONAL,['NA'],Correlations of tumor response and survival with genetic alterations,
6511,NCT06106750,Clinical success,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Adverse events,
6512,NCT00813696,overall survival,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],time to progression,
6513,NCT03448549,3 year disease free survival,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],The accuracy of assessment of preoperative CT images on the stage,
6514,NCT02422433,Feasibility of the marking OFDI capsule for diagnosing BE by comparing OFDI images and biopsy diagnosis,2014-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Sensitivity of the marking OFDI Capsule to correctly detect and mark the region of interest in BE,
6515,NCT04674228,Number of participants who required endoscopic resection of advanced upper gastrointestinal (GI) neoplasms,2021-05-07,COMPLETED,OBSERVATIONAL,['NA'],Number of participants with evidence of progression of upper GI disease,
6516,NCT01094561,S-MRCP and S-EUS Concordance,2006-07,COMPLETED,INTERVENTIONAL,['NA'],The Positive Predictive Value of S-MRCP,
6517,NCT04224480,Number of CD8+ Ki67+ T cells found in resected tumour from subjects,2019-12-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
6518,NCT02301091,Overall survival rates,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of participants with adverse events,
6519,NCT04599660,To evaluate the onset of other neoplasms in very-low and low risk GIST patients,2020-11-25,COMPLETED,OBSERVATIONAL,['NA'],Overall survival (OS).,
6520,NCT03188432,Quality of life (QOL) assessed using Functional Assessment of Cancer Therapy-Ovarian questionnaire,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Response rates evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,
6521,NCT03143140,completed tumor necrosis,2014-05-22,UNKNOWN,INTERVENTIONAL,['NA'],tumor recurrence,
6522,NCT02171286,Number of days between receipt of archival tumour tissue and generation of the OncoPanel Report,2014-10,COMPLETED,OBSERVATIONAL,['NA'],Percent of cases in which a Oncopanel report is generated on a tumour specimen that has been received,Concordance between Oncopanel results and ctDNA sequencing
6523,NCT02347904,The percentage of patients completing the preplanned number of 6 cycles of SOX.,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival,AUC of S-1
6524,NCT02423226,Progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Treatment related adverse events,
6525,NCT04042298,Brachial artery flow mediated dilation (FMD),2019-06-25,UNKNOWN,OBSERVATIONAL,['NA'],Arterial blood pressure,
6526,NCT05375643,Genomic testing uptake,2023-04-03,RECRUITING,INTERVENTIONAL,['NA'],Acceptability of questionnaire modality,
6527,NCT03502317,Global Health Score,2018-08-14,UNKNOWN,INTERVENTIONAL,['NA'],Health care utilization,
6528,NCT00473941,Depressive symptoms,2005-09,COMPLETED,INTERVENTIONAL,['NA'],,
6529,NCT01309126,Overall Survival (OS),2011-04,TERMINATED,INTERVENTIONAL,['PHASE3'],Change in Quality of Life,
6530,NCT01880918,The rate of anastomotic leakage.,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],Rate of other device related complications and measures during hospitalization and post procedure.,
6531,NCT05721846,Adverse events,2023-05-03,RECRUITING,INTERVENTIONAL,['PHASE1'],Disease control rate,
6532,NCT03889626,Progression Free Survival (PFS),2019-03-22,UNKNOWN,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),Adverse Events
6533,NCT00686114,overall survival,2008-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],Health-related quality of life,
6534,NCT00692211,Colorectal Cancer Screening,2008-06,COMPLETED,INTERVENTIONAL,['NA'],,
6535,NCT04668976,Percent frequency liver toxicity,2020-11-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression free survival,
6536,NCT00061308,response rate,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],response duration time to response time to progression survival safety,
6537,NCT05180565,To measure the incidence of serious adverse events related to using the device,2019-12-18,COMPLETED,INTERVENTIONAL,['NA'],To measure the patient tolerability of the device using a patient questionnaire,
6538,NCT03653377,HPV vaccination,2018-12-17,COMPLETED,OBSERVATIONAL,['NA'],,
6539,NCT03951324,Frequency and type of criteria visually identified on malignant VLE clips,2019-05-10,UNKNOWN,OBSERVATIONAL,['NA'],Number of procedures needed to view and conduct to use VLE for diagnostic confirmation,
6540,NCT00966277,Number of Participants With Venous Thromboembolic Events (VTE),2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6541,NCT04696757,DFS,2018-02-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
6542,NCT06168084,Helicobacter pylori eradication,2023-06-06,RECRUITING,INTERVENTIONAL,['PHASE4'],adverse events,
6543,NCT00788957,Part 2: Percentage of Participants With an Objective Response,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Part 2: Minimum Observed Drug Concentration During the Dosing Interval (Cmin) for Ganitumab,
6544,NCT03959150,One year disease-free survival,2020-01-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Exploratory biomarkers,
6545,NCT03299946,Number of patients who complete pre-op treatment and proceed to surgery.,2018-05-14,COMPLETED,INTERVENTIONAL,['PHASE1'],Disease free survival (DFS),
6546,NCT04331184,Local tumor progression,2020-01-28,UNKNOWN,INTERVENTIONAL,['NA'],technical success rate,
6547,NCT05667259,Overall Survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6548,NCT01249638,TFS,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],"ORR, OS, Quality of Life, PFS-1",
6549,NCT04080154,Progress free survival (PFS),2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],
6550,NCT05322499,Objective response rate (ORR),2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
6551,NCT02848638,Degree and distribution of Y90 particle uptake,2012-07,COMPLETED,OBSERVATIONAL,['NA'],,
6552,NCT04212026,The objective response rate (ORR) after the 5th dose of nivolumab of the reference liver metastasis that was not biopsied.,2020-06-28,TERMINATED,INTERVENTIONAL,['PHASE2'],Adverse events,
6553,NCT05153304,Treatment-related Adverse Events,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of response,
6554,NCT01335074,Maximum Tolerated Dose,2011-04,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall response rate,
6555,NCT05742568,Changes in the diversity and structure of fecal microbiota,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE4'],Eradication rate of Helicobacter pylori,
6556,NCT00002883,,1996-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6557,NCT00166465,Proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated using the exact binomial distribution.,2003-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6558,NCT05580445,Recommended phase 2 dose (RP2D) of CT-707 in combination with toripalimab and gemcitabine,2022-08-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease control rate (DCR) according to RECIST v1.1,"Predictive biomarkers for response to the combination of CT-707, toripalimab and gemcitabine"
6559,NCT03316053,Cell Markers,2017-11-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6560,NCT02997956,Median Progression Free Survival,2017-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of patients alive at two years post treatment,
6561,NCT02704299,Progression-Free-Survival(PFS),2016-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Incidences of adverse events or serious adverse events,
6562,NCT04112940,Amount of Residue in the Pharynx,2016-12-19,COMPLETED,OBSERVATIONAL,['NA'],Number of Participants Reporting Dislike of Thickened Liquid Stimuli,
6563,NCT02688712,Evaluation of pathologic response,2016-03-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Immunologic monitoring parameters,
6564,NCT00209703,Incidence and severity of adverse event,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2'],"Determine the clinical response rate, disease-free survival(DFS), overall survival(OS)",
6565,NCT01747642,Number of patients who have prolonged survival,2012-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Reduction in serum alpha-fetoprotein level and decrease in tumor size,
6566,NCT01964534,Progression-free survival (PFS),2013-12-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of Adverse Events,
6567,NCT02385578,The rates of EGC detection,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,
6568,NCT00769652,Change in Patient Generated Subjective Global Assessment (PG-SGA) Score at Time of Initial Presentation and Throughout Study,2006-10,TERMINATED,INTERVENTIONAL,['NA'],,
6569,NCT00084461,Objective response rate,2004-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Incidence of toxicity,
6570,NCT00594984,Safety and tolerability of interventions will be collected,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Efficacy on tumor progression and progression free survival will be collected on all enrolled subjects,
6571,NCT01982994,Percentage of patients with diagnosed gastrointestinal cancer who showed daily compliance using activity monitors and tablet computers to measure physical activity.,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Percentage of patients with a diagnosis of gastrointestinal cancer that benefit from an intervention of physical activity daily planning and education.,
6572,NCT00700570,Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants by Best Overall Tumor Response According to RECIST Version 1.1,
6573,NCT05663515,Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6574,NCT00687843,Relapse-free survival,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Overall survival, quality of life, drug compliance, adverse events, serial changes of tumor markers",
6575,NCT02018107,"Number and Percentage of Tumors With Complete, Circumferential Ablation Margin Visibility During FDG PET/CT-guided Liver Ablations (AP-PET-1 v. Contrast-enhanced MRI)",2014-01,COMPLETED,INTERVENTIONAL,['NA'],Does an Inadequate Ablation Margin on PET Predict Local Progression? Compare to MRI?,
6576,NCT01032057,Progression-free survival at 39 weeks (from registration) according to RECIST criteria,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Radiotherapy quality assurance (adherence to protocol),
6577,NCT06310473,Pathologic complete remission rate (pCR),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
6578,NCT04675138,Concordance Rate,2020-08-20,UNKNOWN,OBSERVATIONAL,['NA'],Reason for Discordance,
6579,NCT01251237,Overall Acceptance on VAS (100mm) rating,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Efficacy on five-grade scale for pre-defined colon areas,
6580,NCT04230187,Progression-free survival (PFS),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],"Toxicity assessed using the NCI common toxicity criteria, version 5.0.",
6581,NCT05438771,Oral Care Control Chart,2021-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Number of participants with abnormal laboratory test results,patient education
6582,NCT04152265,Completion of the assigned screening strategy,2019-11-01,UNKNOWN,INTERVENTIONAL,['NA'],Determination of anthropometric data,
6583,NCT02517268,Percentage of Patients Discharged by Post-operative Day 5,2015-06-24,COMPLETED,INTERVENTIONAL,['NA'],"Incidence of Post-operative Complications (DGE, Anastomotic Leaks, Intra-abdominal Abscesses, Wound Infection, UTI, Respiratory Compromise, Renal Failure, Etc.)",
6584,NCT05205330,Disease Control rate (DCR),2021-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Safety and Tolerability of CR6086 combined with AGEN2034,
6585,NCT03500471,Overall postoperative morbidity and mortality,2018-04-16,COMPLETED,OBSERVATIONAL,['NA'],cost,3-year Overall survival rate
6586,NCT05352204,overall survival,2020-04-30,COMPLETED,OBSERVATIONAL,['NA'],disease-free survival,
6587,NCT00875615,Number of Subjects Experiencing Adverse Events,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients Achieving Clinical Benefit,
6588,NCT00004102,,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6589,NCT02200315,Postoperative surgical site infection,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Hospital stay,
6590,NCT03646591,Completion rate of preoperative FLOT regimen,2017-11-15,COMPLETED,OBSERVATIONAL,['NA'],Postoperative mortality,
6591,NCT00554372,Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival,
6592,NCT03463616,Percentage of patients who needed additional radiology examination/s before treatment planning after routine MRI of abdominal organs compared with routine CT of abdominal organs.,2018-03-15,COMPLETED,OBSERVATIONAL,['NA'],Disease free survival after 3 years,
6593,NCT06061432,Rate of complications during endoscopic gastrointestinal anastomoses using transmural self-expandable prostheses to restore the gastrointestinal continuity in patients after Hartmann procedure (Endo-HARP),2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Rate of clinical success of endoscopic gastrointestinal anastomoses using transmural self-expandable prostheses to restore the gastrointestinal continuity in patients after Hartmann procedure (Endo-HARP),
6594,NCT04697303,Overall survival,2020-10-26,COMPLETED,OBSERVATIONAL,['NA'],FSFI-6,
6595,NCT04569331,Quality of life related to health (European Organization for the Research and treatment of Cancer Quality of Life Questionnaire (QLQ-CR29).,2020-05-15,COMPLETED,INTERVENTIONAL,['NA'],Low anterior resection syndrome (LARS),Percentatge of patients with postoperative paralytic ileus
6596,NCT00562640,Best Response,2007-10-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6597,NCT04892927,Improved information sharing,2021-05-03,UNKNOWN,OBSERVATIONAL,['NA'],,
6598,NCT02857608,Concordance (the proportion of the number of subjects with lymph nodes identified by Lymphoseek and standard of care methods compared to the number of subjects with lymph nodes identified by standard of care methods),2016-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
6599,NCT00155558,To determine the maximum tolerated dose and dose limiting toxicity,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],response,
6600,NCT02531607,Sensitivity and specificity of biomarkers in the diagnosis of cancer,2014-11-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Medical Record Review,
6601,NCT05638438,the objective response rate (ORR),2022-12-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Adverse events,
6602,NCT00080236,Peak absolute change in aspartate transaminase (AST) values measured from baseline to up to 3 days post-transplantation,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6603,NCT05088811,Diagnostic value of long non coding RNA UCA-1 and WRAP53 in Hepatolcellular carcinoma,2021-08-21,UNKNOWN,OBSERVATIONAL,['NA'],,
6604,NCT04434989,Disease-free survival,2020-06-01,RECRUITING,INTERVENTIONAL,['NA'],Adverse events,
6605,NCT01385748,Cumulative Radiation Dose at Which Severe Oral Mucositis (World Health Organization [WHO] Score ≥ 3) Was First Observed,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,Overall Treatment Compliance According to the Patient Diary
6606,NCT00897494,Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis,2005-02,COMPLETED,OBSERVATIONAL,['NA'],,
6607,NCT02502760,Post operative complications,2015-08,COMPLETED,INTERVENTIONAL,['NA'],Health Related Quality of Life,Cost Effectiveness of treatment
6608,NCT06332716,Progression-free survival（PFS）,2022-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall survival（OS）,
6609,NCT04024345,Multidimensional Scale of Perceived Social Support,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6610,NCT00357474,overall survival rate,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease free survival rate and recurrence rate,
6611,NCT03599362,Number of Participants Who Proceeded to Surgical Resection,2018-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6612,NCT00732745,Progression-free survival (Phase II) at 5 months,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Correlation of tumor characteristics and tumoral expression with response and outcome (Phase II),
6613,NCT01264952,"Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms)",2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Treatment Evaluation of Tumor Response - Measurements of Tumor Lesions by Contrast Enhanced Ultrasonography (US-Doppler), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Histology",
6614,NCT05715905,Rate of patients who remain in a colon cancer clinical trial to trial completion,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6615,NCT03428126,Immune-related Best Overall Response Rate.,2018-03-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Control Rate,
6616,NCT05314101,progression free survival,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Objective Response Rate (ORR),Overall survival (OS)
6617,NCT04493060,Disease control rate at 12 weeks (DCR12),2020-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events (AEs),Changes in the cytokine profile pre- and post-treatment
6618,NCT06065371,Primary Endpoint,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),Exploratory Endpoint
6619,NCT04489238,Establish a prospective database of patients with Young Onset Colorectal Cancer,2020-07-22,RECRUITING,OBSERVATIONAL,['NA'],,
6620,NCT00311272,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6621,NCT00107250,Dose limiting toxicity,2005-01-21,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumour Response,
6622,NCT06091137,Appendectomy is associated with risk of subsequent CRC incidence,2022-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6623,NCT04857528,Rate of Participants With Detectable Circulating HPV DNA in Blood/Tumor Samples,2020-10-06,RECRUITING,OBSERVATIONAL,['NA'],Accuracy of HPV DNA Levels in Predicting Cancer Recurrence at 24 Months,
6624,NCT00710632,"Clinical condition, defined as diagnosis and stage of disease, treatment, and performance status at baseline",2007-09,UNKNOWN,INTERVENTIONAL,['NA'],,
6625,NCT01203969,rate of 30 day morbidity and mortality,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Duration of postoperative hospital stay,
6626,NCT05991544,Oral Mucositis Grading Index:,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
6627,NCT01034865,,2001-05,COMPLETED,OBSERVATIONAL,['NA'],,
6628,NCT04609137,"Number of patients (n, %) developing a clinically-relevant pancreatic fistula (CR-POPF)",2020-10-13,COMPLETED,INTERVENTIONAL,['NA'],"Number of patients (n, %) requiring an unplanned hospital readmission after discharge",
6629,NCT04090450,MR radiomics extracted features.,2019-09-23,UNKNOWN,OBSERVATIONAL,['NA'],,
6630,NCT04672005,Time to treatment failure (TTF),2021-01-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between variation in variant allele fraction (% cfDNA) or amplifications and tumor objective response during chemotherapy,Correlation between variation of ctDNA and progression free survival
6631,NCT01734967,"Describe confocal imaging criteria for pancreatic masses, lymph nodes or liver metastases",2012-11,COMPLETED,INTERVENTIONAL,['NA'],Feasibility,
6632,NCT06138028,PFS,2023-09-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",toxicities,
6633,NCT04603339,Feasibility - acceptability of the intervention (2),2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],Bio-sample Collection,
6634,NCT06121089,Disease-free survival.,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],Number of days of inpatient treatment.,Quality of life in patients after ICR and RHC using questionnaire.
6635,NCT06231524,Overall survival,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],Progression-free survival,
6636,NCT01049620,To assess the maximum tolerated dose (MTD),2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Response rate,
6637,NCT03848962,Collection of Biospecimens for Novel Research Uses,2016-06-30,RECRUITING,OBSERVATIONAL,['NA'],,
6638,NCT04006301,Part 2: Overall Response Rate (ORR),2019-07-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Change From Baseline in QTc Interval Based on the Fridericia Correction (QTcF) Method,
6639,NCT03416803,2-year overall survival,2018-02,UNKNOWN,INTERVENTIONAL,['NA'],,
6640,NCT03132025,Progression-free Survival of Patients with Apatinib and Capecitabine Combination That is prolonged,2017-04-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6641,NCT01704664,Phagocytic activity of blood platelets in gastric cancer patients.,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],,
6642,NCT03673072,Primary efficacy endpoint is overall survival (OS),2019-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of patients with any serious perioperative morbidity or mortality,
6643,NCT04749862,Participant Recruitment,2021-03-22,RECRUITING,OBSERVATIONAL,['NA'],Intervention implementation process measures: frequency of reported problems,Information systems
6644,NCT04822506,time to first flatus (TFF),2021-07-31,RECRUITING,INTERVENTIONAL,['NA'],Adverse Event Assessment,
6645,NCT00445861,"Determine the safety of neoadjuvant radiotherapy in combination with cetuximab, docetaxel, and cisplatin",2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determine the duration of response and patterns of failure,
6646,NCT03926039,Decisional Conflict Scale,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],Liver Cancer Treatment Options Related Knowledge Scale,Decision Regret Scale
6647,NCT02322593,Overall Survival,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease Control Rate,
6648,NCT03109639,Tissue adequacy rate will be measured by assessing for the presence of histological core tissue representative of the lesion in the samples obtained using the two needles,2017-04-13,COMPLETED,INTERVENTIONAL,['NA'],Qualification of the sample obtained using the two needles will be performed by spectroscopic analysis.The ratio of absorbance at 260 nm and 280nm; the ratio of absorbance at 260nm and 230nm will be measured,
6649,NCT03685591,"Number of Participants With Tumor Reponse per PCWG2 and RECIST v1.1 (Parts 2A, 2B)",2018-10-04,TERMINATED,INTERVENTIONAL,['PHASE1'],"Median Intra-Tumor T cells (Parts 2A, 2B)",
6650,NCT04371042,Registry creation,2019-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
6651,NCT04002778,Procedure duration,2015-08,COMPLETED,INTERVENTIONAL,['NA'],Diagnostic yield,
6652,NCT02908165,EASL criteria for tumor response,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
6653,NCT00113360,Progression Free Survival (PFS),2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6654,NCT02013154,Number of subjects with treatment emergent adverse events related to study treatment (DKN-01 as monotherapy or in combination with paclitaxel or pembrolizumab),2014-05-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression Free Survival (PFS),
6655,NCT02101918,Objective Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2014-06-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Baseline Permeability Surface (PS),Tumor Perfusion Parameters at Time of Progression
6656,NCT04254107,Number of participants with a dose-limiting toxicity (DLT) at each dose level,2020-05-29,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of participants with antidrug antibodies (ADA),
6657,NCT01708824,Whether the PA and dietary intake targets are met at the end of intervention;,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Possible side effects arising from the intervention,
6658,NCT05648006,Progression-free survival,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity by CTCAE v5.0,
6659,NCT01042028,Phase II: Progression-free survival as measured from inclusion to either documentation of disease progression or death,2010-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Survival All events grade 1-5 according to NCI-CTCAE in fase I All Adverse events grade 1-5 according to NCI-CTCAEW in Fase II Correlation between effect of treatment and tumourmarkers Quality of life - EORTC QLQ Time to failure of Strategy,
6660,NCT01130363,Number of patients with fundic gland polyps and PPI use that have a higher gastric pH,2006-10,TERMINATED,OBSERVATIONAL,['NA'],,
6661,NCT06075836,Reader speed with vs without AI assistance.,2023-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6662,NCT00286130,the percentage of patients surviving without disease progression in each arm at 9 months,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety,
6663,NCT02268006,Pathological complete remission rate (pCR),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life,
6664,NCT01628640,Tumor necrosis,2012-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
6665,NCT00898495,Comparison of pretreatment clinical tumor staging vs post-treatment pathologic staging (at resection),2007-05-11,COMPLETED,OBSERVATIONAL,['NA'],,
6666,NCT04110093,Progress Free Survival,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse Effect,
6667,NCT04938986,Number of cases where the recommendations for patient care according to the Immunoscore® are considered beneficial compared to the standard care decision,2022-04-04,RECRUITING,INTERVENTIONAL,['NA'],"Actual survival (patient alive without recurrence, alive with recurrence, dead)",
6668,NCT00022698,Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0),2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],"Number of Participants With Any Adverse Events, Serious Adverse Events and Deaths",
6669,NCT04030624,The Feasibility of Remote Electronic Patient Monitoring Intervention,2020-09,WITHDRAWN,INTERVENTIONAL,['NA'],Health Care Utilization,
6670,NCT01339169,Visual assessment of the distribution of gastric carcinoids.,2011-01-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma or serum concentrations of biomarkers such as gastrin or chromogranin A (CgA).,
6671,NCT02809846,Change in Daily Opioid Use Assessed as Recorded by the Subject in Their Analgesia Diary.,2016-07,TERMINATED,INTERVENTIONAL,['NA'],,
6672,NCT06242457,Complete resection of adenocarcinomas located in the jejunum or ileum is associated with 5-year survival rates of 20% to 30%.,2023-07-15,COMPLETED,OBSERVATIONAL,['NA'],,
6673,NCT04146441,Volume change of primary tumor,2020-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Rate of reported toxicity,
6674,NCT03005756,"Total radiation exposure (DLP, mGy*cm)",2017-01-25,UNKNOWN,INTERVENTIONAL,['NA'],Procedure time,
6675,NCT04471194,Difference in Percentage of Participants Who Completed Any Cervical PLUS Colorectal Cancer Screening Tests,2021-02-18,COMPLETED,INTERVENTIONAL,['NA'],Difference in Percentage of Participants Who Completed At-home Cervical PLUS Colorectal Cancer Screening Tests,
6676,NCT00039793,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6677,NCT00101998,"Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.",2003-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],"Additional measures of Bowel movement (BM) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use.",
6678,NCT01031784,Toxicity of Ho-166 poly lactic microspheres using CTC vs 3 criteria,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],tumor response according to RECIST criteria,
6679,NCT04348084,impact of clinically relevant (CR-) POPF,2009-01-30,COMPLETED,OBSERVATIONAL,['NA'],identifying positive and negative prognostic factors,
6680,NCT05943951,"the analysis of lymphadenectomy in the course of right hemciolectomy, in relation to the radicality of surgical resection that is performed",2022-04-01,COMPLETED,OBSERVATIONAL,['NA'],Vascular anatomical variability,
6681,NCT04490694,Objective remission rate（ORR）,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
6682,NCT01460641,Tumor stage change from Computed Tomography (CT) perfusion measurement,2011-11,COMPLETED,OBSERVATIONAL,['NA'],Tumor perfusion as measured by perfusion CT.,
6683,NCT06069297,Cancer cachexia related factors,2023-07-14,RECRUITING,INTERVENTIONAL,['NA'],Disease-specific health-related quality of life,
6684,NCT05628038,Local objective response rate,2022-08-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerability of the treatment,
6685,NCT03831698,Retention rate of participants,2019-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of participants with treatment-related adverse events in each arm.,
6686,NCT01541683,measurement of Palatability of the PEG-electrolyte solution,2012-01,COMPLETED,INTERVENTIONAL,['NA'],Side effects,
6687,NCT04683497,Number of new liver metastases identified using CE-IOUS,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of new liver metastases using CE-IOUS in the subgroup of patients with missing metastases.,
6688,NCT05375604,To characterize the safety and tolerability of CDK-004.,2022-06-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,
6689,NCT00209651,objective tumor response,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Response duration, time to progression, overall survival, and safety will also be assessed.",
6690,NCT05299411,Serum Hb level,2023-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Serum hepcidin level,Quality of life associated anemia
6691,NCT06172478,Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Pharmacokinetic Parameter Area Under the Concentration Curve for HER3-DXd,
6692,NCT01598077,Dose-limiting toxicities (DLTs),2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],"Serum concentration of LJM716,",
6693,NCT01346917,Prevalence of postoperative nausea and vomiting.,2011-04,COMPLETED,INTERVENTIONAL,['NA'],Duration of postoperative hospital stay.,
6694,NCT06124729,cCR,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Disease-free survival (DFS) and overall survival (OS),
6695,NCT01099631,Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Peripheral Blood T Cells Count,
6696,NCT00177242,Ascertain the median survival of advanced pancreatic cancer patients treated with Gefitinib and docetaxel.,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine the time course of serial CA19-9 measurements during treatment.,
6697,NCT04295473,3-year survival rate,2020-03-02,RECRUITING,INTERVENTIONAL,['NA'],Quality of life in PGSAS-45 scale,
6698,NCT05708872,Effect of methods of self-regulation of mental state on postoperative pain perception changes,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],Effect of methods of self-regulation of mental state on anxiety changes,
6699,NCT01363739,Progression-Free Survival,2009-04,UNKNOWN,OBSERVATIONAL,['NA'],Overal survival,
6700,NCT02525965,Overall survival rates of each group,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],Occurrence rate of recurrence of each group,
6701,NCT01504711,Percentage of Participants With Control of Vomiting and Rescue Medication Control,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival,
6702,NCT05920863,Major pathological response,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Recurrence-free survival (RFS),
6703,NCT03944447,Treatment of Symptoms,2018-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Monitoring Adverse Events,
6704,NCT05350501,Response to treatment at 6 months,2023-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Immunogenicity and cross-reactivity,
6705,NCT01360801,Accuracy of Agreement Between Imaging and Histology,2011-02,TERMINATED,OBSERVATIONAL,['NA'],Presence of Residual Disease,
6706,NCT04851132,Progression-free survival (PFS),2021-03-11,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life (QOL): questionnaire EORTC QLQ-C30 (version 3),Quality of Life (QOL): questionnaire EORTC QLQ-OES18
6707,NCT02195141,• Pathological complete remission rate (pCR),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events (according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events v3.0 (CTCAE),• Disease-free survival
6708,NCT00716157,Assess incidence and patterns of nausea and vomiting in patients undergoing concurrent chemotherapy and radiation,2004-10,COMPLETED,OBSERVATIONAL,['NA'],Study the incidence of mucositis and esophagitis,
6709,NCT01125020,tumor recurrence and metastasis,2008-12,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative survival,
6710,NCT00848783,Number of Patients With One-year Recurrence-free Survival,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival Rate; Toxicity; Evaluation of Sites of Relapse of Failing Patients,
6711,NCT00356889,Number of Confirmed Tumor Responses.,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response,
6712,NCT02421354,"Objective Response Rate, Defined as Complete Remission + Partial Remission + Clinical Improvement",2015-05-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6713,NCT03699319,MTD of CPI-613 when given in combination with mFOLFIRINOX,2018-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Surgical resection rates,
6714,NCT02841800,survival benefit,2016-06,COMPLETED,INTERVENTIONAL,['NA'],repeated biliary interventions,
6715,NCT00003225,To assess the toxicity profile of Irinotecan and Ethyol when administered together on this schedule.,1997-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","To determine the clinical benefit of intravenous Irinotecan and Ethyol in patients with colorectal cancer, as measured by performance status, analgesic consumption, quality of life and survival.",
6716,NCT01090505,overall survival,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],response rate,
6717,NCT02943837,"Diagnostic accuracy (proportion of correctly classified subjects (ture positive + true negative) among all subjects ) , compared to the gold standard diagnosis",2016-10-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
6718,NCT00960427,Correlation of disease-free survival with post-treatment value and change in expression of colorectal cancer stem cell markers after neoadjuvant chemoradiotherapy,2009-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
6719,NCT03844620,"Treatment-related adverse events (TRAEs) of interest (grade 3/4 toxicity, intolerable grade 2 toxicity, or any toxicity requiring dose reduction) between arms",2019-01-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of patients referred to clinical trial,
6720,NCT03298945,Population level adenoma detection rate (ADR),2018-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Adequate bowel prep quality,renal failure
6721,NCT04965597,Graft-Versus Host-Disease (GVHD)-Free Event-Free Survival (EFS),2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of cytomegalovirus (CMV) reactivation requiring therapy by day 180 post-HCT,
6722,NCT03116984,3-year overall survival(OS),2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6723,NCT04672603,Incidence of urinary dysfunction,2021-04-08,RECRUITING,INTERVENTIONAL,['NA'],Positive Circumferential Resection Margin Rate,
6724,NCT04842812,Safety of TILs/CAR-TILs treatment in advanced solid cancers,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Primary clinical efficacy of the TILs/CAR-TILs treatment in advanced solid cancers,
6725,NCT03023722,Response Rate as Measured Per RECIST 1.1 Criteria,2017-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Drug Toxicity,
6726,NCT02013492,Effect of beta-adrenergic blockade on the host immune system,2014-01-21,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Overall survival,
6727,NCT04005170,clinical complete response rate,2019-06-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of treatment-related adverse events as assessed by CTCAE v4.0,The impact of IDO1 expression on clinical response
6728,NCT05188573,Clinical performance of test: Specificity,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Stage Shift,
6729,NCT00285701,,2006-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6730,NCT02806076,12 month local tumor progression (LTP) rate,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA'],Technical success rate,Technical efficacy 2
6731,NCT01313026,changes in LARS score,2011-01,TERMINATED,INTERVENTIONAL,['NA'],Patient Satisfaction,
6732,NCT00416507,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6733,NCT04500392,The incidence of hypoxia,2021-05-06,RECRUITING,INTERVENTIONAL,['NA'],Other adverse events include other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force and HFNC supportive oxygen therapy-related adverse events.,
6734,NCT03294252,Recommanded dose for the extension phase,2017-05-24,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-Free Survival,
6735,NCT00026364,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6736,NCT04947995,The sensitivity and specificity of blood-based multi-omics assay for early detection of gastric cancer with comparison to EGD and/or histological diagnosis.,2021-06-15,UNKNOWN,OBSERVATIONAL,['NA'],,
6737,NCT00902902,,2008-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6738,NCT05833672,ORR (objective response rate),2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],R0 resection rate,
6739,NCT01584830,Overall Survival (OS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety variables will be summarized using descriptive statistics based on adverse events collection,
6740,NCT02781155,Adherence to moxa regimen assessed by Daily Moxa Diary,2016-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidents of additional interventions administered as prophylaxis or therapy to maintain or improve blood counts,
6741,NCT06278493,Maximum tolerated dose (MTD),2018-08-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6742,NCT02547142,Quality Of Life,2016-01-18,TERMINATED,INTERVENTIONAL,['NA'],Total duration of time from date of metastatic diagnosis to date of death,
6743,NCT03029611,Rate of Pathologic Complete Response (CR),2017-04-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Tumor Burden,Predictive Signature of CR Induction When Vaccinated With an IGFBP-2 Vaccine in Combination With Neoadjuvant Chemotherapy Assessed by Whole Exome Sequencing on Vaccinated Patients' Tumors
6744,NCT05250791,Clinicians' reasons for not recruiting patients.,2023-02-02,RECRUITING,INTERVENTIONAL,['NA'],Total hospital stays including readmission,Pro-inflammatory cytokine levels
6745,NCT04488159,Disease-free survival (DFS),2024-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Cost analysis,
6746,NCT00493428,"Document and Compare the effects of the GABAb receptor agonist Baclofen on the time to develop tumor metastasis in patients with non-metastatic HCC at diagnosis who subsequently undergo surgical resection, ablation or chemoembolization.",2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Document and compare the effects of the GABAb receptor agonist Baclofen on changes in serum tumor markers ( alpha-fetoprotein andd CA19-9 levels) in patients with no-metastatic HCC at diagnosis.,
6747,NCT03824899,pathological response rate,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,
6748,NCT00057980,Overall survival,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Cyclooxygenase-2 expression in tumor tissue and nonmalignant liver tissue in correlation to response,
6749,NCT00815308,Number of Participants With Overall Response Rate (RR),2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With K-ras Gene Mutation,
6750,NCT04525989,Incidence of acute grade 2-5 gastrointestinal toxicity,2021-04-20,RECRUITING,INTERVENTIONAL,['NA'],Cost effectiveness analysis measured by QALY,Exploratory: Difference in concentrations of CEA (carcinoembryonic antigen) between treatment arms
6751,NCT02726243,Composition of fecal microbiota by 16S sequencing,2014-11,COMPLETED,OBSERVATIONAL,['NA'],Profile of fecal bile acids,
6752,NCT00507585,"To study the highest tolerable dose of oxaliplatin used in combination with 5-fluorouracil, leucovorin, and Avastin® (bevacizumab) for patients with advanced cancer that has spread to the liver.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6753,NCT00492752,Overall Survival,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Time of Maximum Concentration (Tmax) After 21 Days of Sorafenib Treatment,
6754,NCT02129218,"Individual patient compliance, defined by following assigned target glycemic load index >= 75% of the time between weeks 4 and 12",2015-02-16,COMPLETED,INTERVENTIONAL,['NA'],Hours of nutritionist time per week,Change in serum levels of proteins affected by carbohydrate metabolism
6755,NCT03817567,Objective response rate (ORR),2018-07-17,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
6756,NCT04937738,Histopathological regression rate (Becker regression criteria),2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Median overall survival,
6757,NCT01222208,Whole body protein balance,2011-03,COMPLETED,INTERVENTIONAL,['NA'],Synthesis rates of hepatic secretory proteins,
6758,NCT02299843,mortality during perioperation,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],,
6759,NCT02984501,Incidence of Treatment-Emergent Adverse Events,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Local-regional Tumor Control,
6760,NCT00908752,"To compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy",2009-07-20,COMPLETED,INTERVENTIONAL,['PHASE3'],To evaluate the safety of brivanib in combination with TACE,
6761,NCT03164382,Overall survival,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Time to Intrahepatic tumor Progression,
6762,NCT02557061,Number of alive patients,2009-04,COMPLETED,INTERVENTIONAL,['NA'],Rate of preoperative blood T-lymphocytes,
6763,NCT01768195,the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],the incidence of hepatitis B virus relapse and relapse related hepatitis,
6764,NCT05199584,Objective Response Rate (ORR),2022-05-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in steady-state exposure to study medication,
6765,NCT06040099,Progression Free Survival (PFS),2024-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of Response (DoR),
6766,NCT04966195,overall survival,2015-12-01,COMPLETED,INTERVENTIONAL,['NA'],objective response rate,
6767,NCT01598597,Percentage of subjects who complete the survey and who provide evaluable genetic information (DNA),2012-03,COMPLETED,OBSERVATIONAL,['NA'],"Demographic distribution (age, sex) of subjects participating in this study",
6768,NCT04906174,Incidence of complications after liver resection,2021-04-10,RECRUITING,OBSERVATIONAL,['NA'],,
6769,NCT00646100,survival rates,2007-07,COMPLETED,INTERVENTIONAL,['PHASE4'],quality of life,
6770,NCT01744054,Evaluate y90-PET/MRI and PET/CT for potential on reporting technical success of radioembolization,2012-10-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,
6771,NCT01525082,Radiographic Response (RR),2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],O6-methylguanine DNA Methyltransferase (MGMT) by Promoter Methylation,
6772,NCT03126435,Overall Survival,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE3'],Serum Carcinoma Antigen 19-9 (CA 19-9) Response Rate,"Change From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score"
6773,NCT02564263,Overall Survival (OS) in All Participants,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE),
6774,NCT02290574,Adverse Event of Laparoscopic TME and Hyperthermia With CCRT,2014-11,TERMINATED,INTERVENTIONAL,['NA'],Pathologic Complete Response of Hyperthermia With CCRT,
6775,NCT05400031,Oral mucositis grading,2022-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
6776,NCT03365986,The incidence of hereditary colorectal cancer,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],cost-effect for hereditary colorectal cancer screening,
6777,NCT02368977,Device usability factors,2013-11-12,UNKNOWN,INTERVENTIONAL,['NA'],Patient safety assessed by number of subjects with adverse events as a measure of safety and tolerability,
6778,NCT00288925,"Safety, Pharmacokinetics",2005-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Tumour shrinkage, Tumour objective response rate",
6779,NCT04328948,Major progression-free survival,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Long term toxicity,
6780,NCT02982486,Response to therapy as evaluated by RECIST 1.1,2017-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,
6781,NCT05540951,objective response rate,2018-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
6782,NCT01043016,Maximum tolerated dose,2009-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],Treatment efficacy as measured by computed tomography (CT) or magnetic resonance imaging (MRI) and endoscopy exam 3 weeks after the start of study treatment according to the Response Evaluation Criteria In Solid Tumors (RECIST) standard,
6783,NCT04290806,Course of treatment (treatment reality),2019-12-04,RECRUITING,OBSERVATIONAL,['NA'],,
6784,NCT03141034,Progression-free survival (PFS),2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity and tolerability of regimen as measured by the count of the worst grade of adverse event experienced by each participant,
6785,NCT00004911,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6786,NCT05663450,Rate of R1-resection during oncologic surgery,1996-05-01,COMPLETED,OBSERVATIONAL,['NA'],Post-surgical survival,
6787,NCT01436721,the size of any subphrenic collection or pleural effusion,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",incidence of postoperative morbidity,
6788,NCT04970498,Changes of ADC map of MRI,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6789,NCT02013050,Duration of Severe Oral Mucositis (SOM),2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],"Percent of Patients With RECIST 1.1 Classification of ""Complete Response""",
6790,NCT06205485,Quality of Life defined using the LARS score,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Validate the magnetic resonance tumour regression grade (MR-TRG) in patients with T1 and T2 rectal cancer,
6791,NCT03738111,Maximum Tolerated Dose,2018-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Overall Survival,Molecular Marker
6792,NCT01456598,3 year relapse free survival,2011-11-21,COMPLETED,INTERVENTIONAL,['NA'],3 years overall survival,
6793,NCT05749900,"Phase II: Objective response rate, ORR",2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of Life (QoL),
6794,NCT03732235,time to progression,2018-10-01,UNKNOWN,OBSERVATIONAL,['NA'],Number of adverse events,
6795,NCT00495625,Number of Participants With Progressive Disease (PD) at Interim Analysis,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious Adverse Events (SAEs),
6796,NCT05397444,Hospital readmissions,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],prolonged length of stay,
6797,NCT03352349,Change of Portal vein pressure,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse effect of Terlipressurinum,
6798,NCT05141656,OS,2019-08-31,UNKNOWN,OBSERVATIONAL,['NA'],PFS,
6799,NCT05451901,Time to clinical success from randomization,2022-07-29,RECRUITING,INTERVENTIONAL,['NA'],Morphological change of pancreas,
6800,NCT02841865,Response to treatment,2015-07-24,COMPLETED,OBSERVATIONAL,['NA'],Impact of Choi criteria and Progression of Disease,
6801,NCT03856255,Mean Score Indicating Ease of Use in Taking a Picture That Included the Measuring Device and Polyp in Order to Photo-document the Measurement Reading,2019-06-24,TERMINATED,INTERVENTIONAL,['NA'],Mean Difference in Size of Polyp,
6802,NCT00588900,The Percentage of Patients Who Are Progression-free at 12 Weeks From the Start of Second-line Therapy,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
6803,NCT04090554,Distribution of acceptability scores,2019-09-24,COMPLETED,INTERVENTIONAL,['NA'],Prevalence of other benign esophageal pathologies,
6804,NCT01676194,Survival,2012-08,TERMINATED,INTERVENTIONAL,['PHASE3'],Efficacy of TACE,
6805,NCT05152472,Progression-Free Survival (PFS),2022-01-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Tolerability profile,
6806,NCT00306137,Percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period,2005-12,TERMINATED,INTERVENTIONAL,['PHASE3'],Health related quality of life measurements,
6807,NCT03838796,Disease free survival,2019-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
6808,NCT00023933,Maximum tolerated dose of 131I-HuCC49^CH2 based on dose-limiting toxicities,2001-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Immune response,
6809,NCT00316420,MTD and DLT for the combination therapy of gemcitabine and capecitabine,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor Response,
6810,NCT03419663,the relationship between overall cereal consumption and gastric cancer occurance,2017-09-12,COMPLETED,OBSERVATIONAL,['NA'],the relationship between other grain and gastric cancer occurance,
6811,NCT00123825,To determine the response rate of the combination gemcitabine and cisplatin in patients with advanced biliary tract and gallbladder cancers,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess the biomarker CA 19-9 response to the regimen and to correlate the CA 19-9 response with radiologic response and survival,
6812,NCT04490551,Yield of Advanced Neoplasia,2019-12-05,COMPLETED,INTERVENTIONAL,['NA'],Yield of Proximally Located Advanced Neoplasia,
6813,NCT02466113,Disease free survival,2016-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
6814,NCT03082495,Change in Cardiorespiratory fitness,2017-06-26,COMPLETED,INTERVENTIONAL,['NA'],Safety: Adverse event rate,Number of positive lymph nodes
6815,NCT02394834,Overall survival (OS),2015-05-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],"Evaluation of the Relationship between a Change in Each Biomarker in Tumor Tissue at Baseline and the Discontinuation of the Protocol Treatment of the Main Study, and Efficacy Endpoints",
6816,NCT05334719,Incidence of treatment-related adverse events (TRAE) that have led to treatment discontinuation,2022-02-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Incidence of Adverse Events (AEs),
6817,NCT00910676,To reduce by 30 % the frequency of folliculitis by a local corticotherapy beginning at the same time that the treatment by EGF-R inhibitors began,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess the patient quality of life with the DLQI questionnaire,
6818,NCT06278454,Adverse events (AE) and severe adverse events (SAE),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Resection rate (R0 and R1),Distribution of NRT6008 injection in human body and radioactivity of biological samples
6819,NCT03393182,Postoperative 30-day morbidity rate,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],QOL measurement : EORTC QLQ-C30/STO22,
6820,NCT06198400,Evaluation of the blood flow in pancreatic remnant with use of ICG,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Correlation between ICG perfusion and development of pancreatic fistula,
6821,NCT05243966,Proportion of participants with treatment emergent adverse events during the study,2022-01-10,RECRUITING,OBSERVATIONAL,['NA'],Percentage of split thickness skin graft take at 1 week post Matrix™ application,
6822,NCT04197310,Objective Response Rate (ORR),2019-12-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Treatment Related Adverse Events,
6823,NCT05653453,Overall survival (OS),2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Progression Free Survival rate at 6 months,
6824,NCT04640792,Comparison of the Adenoma Per Extraction (APE) between the two arms,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],Comparison of the Adenoma Detection Rate (ADR) between the two arms,
6825,NCT01641887,Participant Satisfaction,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],Patient decisions,
6826,NCT06242613,Compare robotic gastrectomy with the conventional laparoscopic approach in terms of oncologic safety.,2023-05-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Compare robotic gastrectomy with the conventional laparoscopic approach in terms of cost-utility outcomes.,
6827,NCT06070623,Role of elastography and color Doppler to follow up after TACE.,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6828,NCT02759601,Determine Maximum Tolerated Dose,2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase I & II: To determine pharmacokinetic parameters for tefinostat and CHR-2847 when administered orally at different dose levels and dose schedules.,Phase I & II: To determine the impact of HDACi on anti-tumour immune responses.
6829,NCT01772706,To evaluate the efficacy of preventive and curative low energy laser induced mucositis in patients receiving concomitant chemotherapy and radiotherapy for squamous cell carcinoma of the head and neck with stage III-IV,2008-10-30,UNKNOWN,INTERVENTIONAL,['NA'],To assess the quality of life using the QLQ-HN35 questionnaire.,To document the Overall survival calculated from the date of randomization to death from any cause or up to 5 years.
6830,NCT02468726,Success of bowel cleansing,2011-11,COMPLETED,INTERVENTIONAL,['NA'],Stool weight,
6831,NCT05970705,PFS,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],DOR,AE
6832,NCT01831310,neutrophil functions,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Length of stay,
6833,NCT00095992,Response,2005-03-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Molecular correlates on archival tumor specimens and peripheral blood mononuclear cells (PBMCs),
6834,NCT01102556,Creation of a registry and blood/tissue bank,2004-07,RECRUITING,OBSERVATIONAL,['NA'],"Improvement in the diagnosis, prevention, detection, and treatment of pancreatic cancer.",
6835,NCT01799044,Safety,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Efficacy,Feasibility
6836,NCT04637698,The objective response rate of patients with pancreatic cancer receiving OH2 injection.,2021-02-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To evaluate the impact of OH2 in patients with pancreatic cancer on the quality of life,
6837,NCT01568151,Number of participants who undergo colorectal screening because of interventions,2009-04,COMPLETED,INTERVENTIONAL,['NA'],Number of problems associated with intervention program,
6838,NCT03511703,overall survival,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6839,NCT02685631,Response to treatment with Y90 microspheres either as mono therapy or as part of multidisciplinary management of their specific disease,2015-07,COMPLETED,OBSERVATIONAL,['NA'],Time to Progression,
6840,NCT05652894,Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Independent Review Committee(IRC),2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse events,
6841,NCT06036745,Disease-free survival,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
6842,NCT05441475,To evaluate the objective response rate of ABSK-011 combined with atezolizumab in subjects with advanced FGF19 overexpression or unresectable HCC,2021-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6843,NCT05901376,The different of MiR-223 level between gastric cancer and control group,2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],,
6844,NCT04966143,Overall Response rate（ORR）,2021-08-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],
6845,NCT02929797,Disease-free survival,2016-08,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Quality of life,
6846,NCT05211323,Progression free survival (PFS),2022-12-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall response rate,
6847,NCT03144804,Overall Response Rate,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Disease Control Rate,
6848,NCT00165464,"To assess the response rate of patients with esophageal or gastric carcinoma to weekly Taxotere, Cisplatin, and Irinotecan (CPT-11).",2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess the toxicity of this combination in esophageal or gastric carcinoma.,
6849,NCT04753359,Exfoliated intestinal epithelial cell transcriptomics,2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],Fasting insulin,Bowel habits
6850,NCT06229340,Objective response rate,2023-10-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
6851,NCT05211388,Conformity with planned ablation zone,2022-07-11,RECRUITING,INTERVENTIONAL,['NA'],,
6852,NCT00444093,Treatment Efficacy,2007-03-05,TERMINATED,INTERVENTIONAL,['PHASE3'],Diarrhea Assessment,
6853,NCT04180033,Diagnostic yield advanced colorectal neoplasia,2020-02-18,COMPLETED,INTERVENTIONAL,['NA'],Burden of colonoscopy,
6854,NCT06206096,ORR,2021-05-26,RECRUITING,INTERVENTIONAL,['PHASE2'],"Safety and tolerability by incidence, severity and outcome of adverse events",
6855,NCT00019006,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6856,NCT05062889,ct-DNA clearance rate after the end of target-driven adjuvant treatment (ERASE-CRC part 1 target-driven),2023-05-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival TD1 (OS-TD1),
6857,NCT02900664,Frequency of dose reductions,2016-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],Presence and/or concentration of anti-CJM112 antibodies.,
6858,NCT02150135,ECOG score change,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression free survival rate,
6859,NCT03995459,Evolution from baseline of liver volume and liver function values,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],Evolution from baseline of liver volume and liver function values,
6860,NCT00202111,Five-year survival,1998-01,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life outcomes,
6861,NCT00506207,Blood level of irinotecan and S-1 and their metabolites,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],"Maximal response rate, progression-free survival, survival",
6862,NCT03246438,CRC screening completion,2017-11-14,COMPLETED,INTERVENTIONAL,['NA'],Choice of screening test,
6863,NCT02649569,Number of patients who successfully use the activity monitor (i.e. wearing the activity monitor throughout the treatment course),2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
6864,NCT00004897,,1999-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6865,NCT00571740,Progression-free survival (PFS) rate at 6 months,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Quality of life,
6866,NCT00960167,Maximally tolerated dose of RT,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],"Tumor control, patterns of failure and survival",
6867,NCT05406167,Health Related Quality of Life (HRQOL) scores,2022-04-12,RECRUITING,OBSERVATIONAL,['NA'],Long-term toxicities related to Radiotherapy,
6868,NCT05522738,RP2D,2022-08-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Safety and tolerance evaluated by incidence of SAE,
6869,NCT04796454,Progression-free survival (PFS),2022-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Jaundice scale,
6870,NCT02665312,Assessment of the incidence of cardiovascular events during the first three cycles of therapy with capecitabine or 5-FU,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6871,NCT04023136,"Estimation of the intraoperative portocaval post-hepatectomy gradient This pressure differential is performed before the parietal closure, after resection. We consider that the simulation is accurate if the difference with the measurement is ≤ 4 mmHg.",2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],Prediction of changes in portal vein flow,
6872,NCT02624154,The survival rate,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,
6873,NCT01384253,Safety and tolerability: To measure the number of participants who experience adverse events after intraperitoneal (IP) administration of ²¹²Pb-TCMC-Trastuzumab.,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics: To determine the plasma pharmacokinetics and assess the extent of exit of radioactivity from the peritoneal cavity by γ-camera imaging.,
6874,NCT00303758,Overall survival,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Duration of hospitalization,
6875,NCT00602147,Association between SNPs in genes that influence melphalan metabolism and development and/or severity of mucositis,2007-07,TERMINATED,OBSERVATIONAL,['NA'],,
6876,NCT03428477,Progression Free Survival (PFS),2018-05-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],New Primary Cancers,Change in lean body mass (exploratory endpoint)
6877,NCT02129322,Time to Recurrence (TTR),2015-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),Circulative tumor cell (CTC) level change
6878,NCT05737563,Overall survival (OS),2023-02-17,RECRUITING,INTERVENTIONAL,['PHASE3'],Disease Control Rate (DCR),
6879,NCT01893294,"MTD of gemcitabine hydrochloride defined as the dose at which no more than 3 of 6 patients experience grade 3 or greater adverse events, as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0",2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],"Incidence of delayed adverse events associated with this treatment, graded according to the NCI CTCAE v3.0",
6880,NCT02395705,Overall survival rate,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3'],predictive factors,
6881,NCT05225428,Video Education Acceptability (Qualitative Interview Study),2022-08-04,RECRUITING,INTERVENTIONAL,['NA'],,
6882,NCT01333917,Apoptosis,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants with Adverse Events,
6883,NCT02720926,Determine the recommended phase 2 dose of TKI258 in combination with XELOX (Capecitabine and Oxaliplatin),2011-09,TERMINATED,INTERVENTIONAL,['PHASE1'],Measure the Area under the plasma concentration versus time curve (AUC) of TKI258 at specific timepoints,
6884,NCT05481476,objective response rate (ORR),2023-09,RECRUITING,INTERVENTIONAL,['PHASE2'],adverse events (AE),
6885,NCT00462553,Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival,
6886,NCT01272791,Overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety,
6887,NCT02969148,the 3-year disease-free survival rate,2016-11,RECRUITING,INTERVENTIONAL,['NA'],the number of bowel obstruction,the time of hospital stay
6888,NCT03781193,Correlation between psychological predictors questionnaires outcome and quality of life,2018-03-06,UNKNOWN,OBSERVATIONAL,['NA'],,
6889,NCT04838964,Objective Response Rate (ORR) by Independent Review Committee (IRC),2021-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of anti-drug antibody (ADA),
6890,NCT05202236,objective response rate (ORR),2021-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6891,NCT06109207,Feasibility of combination camrelizumab and dalpiciclib as assessed by number of participants who experience adverse events,2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
6892,NCT02047305,Complete Response,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,
6893,NCT02081469,To compare the HBV relapse rate during the follow-up period in HBV carriers with malignant tumor receiving tenofovir for 24 and 48 weeks after the end of chemotherapy.,2014-03-17,COMPLETED,INTERVENTIONAL,['PHASE4'],"To estimate the efficacy of TDF during chemotherapy with after chemotherapy and post-chemotherapy,as measure by the HBV reactivation, clinical relapse and adverse events in all patients.",
6894,NCT03645980,Phase II: Time to progression (TTP2),2018-10-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II: Adverse Events,
6895,NCT01995240,"Reproducibility of DCE, T2* and DWI MRI in pancreatic cancer.",2013-04,COMPLETED,INTERVENTIONAL,['NA'],"To explore the relation between in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI and treatment outcome.",
6896,NCT03779009,Tumor status of the sentinel lymph node (SLN) and other lymph nodes (LN's),2018-03-01,RECRUITING,INTERVENTIONAL,['NA'],Immunological markers,
6897,NCT03140007,Diagnostic accuracy of cholangioscopy or cholangiography,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA'],Correlation between impression of malignancy and cytopathology in the ERCP arm compared to the cholangioscopy arm,
6898,NCT01065441,The primary endpoint is the evaluation of any drug-related toxicity associated with AlloStimTM administration as well as the reversibility of such toxicity.,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The tertiary end-point is the evaluation of the immunological response to AlloStim-TM administration.,
6899,NCT00342004,All cancer incidence,1997-05-01,COMPLETED,OBSERVATIONAL,['NA'],All deaths,
6900,NCT03028155,Assessment of 3-month overall morbidity and mortality,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Assessment of health related quality of life (HRQOL): SF-36,
6901,NCT06081647,The incidence of hypoxia,2023-10-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The incidence of severe hypoxia,The incidence of other adverse events
6902,NCT04046445,valuate anti-tumor effect of study treatment by measure of Progression-free survival (PFS),2019-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluate anti-tumor effect of study treatment by measure of Relapse Free Survival (RFS),Assess shedding and viremia of VSV-GP128
6903,NCT04058964,Progression free survival (PFS),2020-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,Overall survival
6904,NCT00982592,Median Progression-free Survival (PFS),2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Toxicities (grades1 and 2),
6905,NCT06030895,Safety Outcomes,2022-12-12,COMPLETED,INTERVENTIONAL,['NA'],,
6906,NCT00411112,Survival without recurrence after 3 years,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],,
6907,NCT03482362,Doubling of progression free survival,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Gene alterations/expression profiles (i.e. baseline, relapse) in tumor tissue upon progression","Overall response rate of vinorelbine in patients with KRAS mutant, BRAF wildtype, BRAF-like colon cancer vs. KRAS wildtype, BRAF mutant, BRAF-like colon cancer."
6908,NCT05158907,Improvement in detection rate of adverse effects of patient reported adverse effect (AE) scale versus the standard CTCAE grading by a physician.,2021-11-23,SUSPENDED,INTERVENTIONAL,['NA'],Reduction in cost of cancer care using patient reported AE scale.,
6909,NCT01238666,Phase II: The number of surgical oblation procedures that present data showing equivalent location of the ablation probe when compared to the US and Pathfinder Guidance System 3D image data.,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
6910,NCT00229567,passage of stool.,2005-09,TERMINATED,INTERVENTIONAL,['NA'],time to readiness for discharge from hospital,
6911,NCT06281925,Proportion of Participants with Peripheral Neuropathy at Visit 5,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6912,NCT00323011,,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6913,NCT02881554,Sulfur colloid (SC) uptake on single photon emission computed tomography/computed tomography (SPECT/CT) imaging,2016-12-21,RECRUITING,INTERVENTIONAL,['NA'],Changes in sulfur colloid uptake in single photon emission computed tomography/computed tomography imaging,
6914,NCT01677559,Dose-limiting toxicities (DLTs),2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Antitumor activity of MLN8237 and nab-paclitaxel combination therapy,
6915,NCT01668498,Percentage of patients developing no skin toxicity ≥ grade 2,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Skin-toxicity related dose reductions of panitumumab,
6916,NCT03452501,Incidence of adverse events (AEs) to Remsima®,2018-08-26,COMPLETED,OBSERVATIONAL,['NA'],Proportion of switched patients with UC achieving disease control.,
6917,NCT00112697,Progression-free survival rate at 6 months,2003-10-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
6918,NCT06100016,Specificity,2023-10-18,RECRUITING,OBSERVATIONAL,['NA'],,
6919,NCT03189719,PFS Per RECIST 1.1 As Assessed By Investigator in All Participants,2017-07-25,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10),
6920,NCT01941953,Disease Control Rate according to RECIST 1.1,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events,
6921,NCT04633382,Reduction of bed-days,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6922,NCT02351089,Change in incidence of loose/watery stools,2015-02,TERMINATED,INTERVENTIONAL,['NA'],,
6923,NCT03146234,Safety and tolerance,2017-03-17,COMPLETED,INTERVENTIONAL,['NA'],Engraftment,Anti-tumor responses to CAR-GPC3 T cell infusions
6924,NCT01441453,Cut-off value of liver stiffness measured in kilopascal (kPa) able to predict the occurrence of postoperative liver failure.,na,UNKNOWN,INTERVENTIONAL,['NA'],,
6925,NCT04097028,Number of Patients With a Pathologic Complete Response,2019-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Patients With Grade 3 or Higher Treatment Related Adverse Events,
6926,NCT02129829,Incidence of HCC or decompensated cirrhosis,2011-10,COMPLETED,OBSERVATIONAL,['NA'],Treatment rate,Accuracy of non-invasive fibrosis assessment
6927,NCT05596370,correlation of genetic mutation burden and prognosis,2022-01-06,RECRUITING,OBSERVATIONAL,['NA'],correlation of microbiome in stool and prognosis,
6928,NCT03807947,Pain and discomfort during and after procedures,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],Access-related adverse events,
6929,NCT02228200,Change in quality of life,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Health care utilization,Intervention nurses' experience
6930,NCT04659590,Stability of buffer transfer medium,2020-11-06,COMPLETED,OBSERVATIONAL,['NA'],Comparison between tumour surface imprint and rectal mucous imprint,
6931,NCT04449874,Percentage of Participants With Dose-Limiting Toxicities (DLTs),2020-07-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Relationship Between Tumor Pharmacodynamic Effects of GDC-6036,
6932,NCT05647941,Detection of levels of circulating exosomal lncRNA-GC1,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
6933,NCT05179486,Significant factors that may contribute to the etiology of biliary tree cancer,2017-09-25,RECRUITING,OBSERVATIONAL,['NA'],,
6934,NCT03515252,Incidence of Treatment-Emergent Adverse Events [Safety],2005-04-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Quality of Life (QOL),
6935,NCT06282120,Progression Free Survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],EORTC-QLQ (European Organization for Research and Treatment of Cancer - Quality of life Questionnaire) C30 (version 3.0),
6936,NCT04957407,pepsinogen value for precanceous lesion and Gastric cancer,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6937,NCT04272268,Rate of respiratory complications within 30 days after surgery,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],Recruitment rate,
6938,NCT03990675,Growth rate,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6939,NCT04104672,Number of participants with clinically significant changes in vital signs and clinical laboratory parameters,2019-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall response rate,AB680 gene expression
6940,NCT05156307,Colorectal cancer,2021-05-20,RECRUITING,OBSERVATIONAL,['NA'],,
6941,NCT04000906,Determine the maximal tolerated dose (MTD) of Nab paclitaxel (Abraxane®) administered IP by PIPAC in concomitance with cisplatin.,2020-11-11,RECRUITING,INTERVENTIONAL,['PHASE1'],The QoL,
6942,NCT05301556,Serum Pre-Albumin,2022-06-24,COMPLETED,INTERVENTIONAL,['NA'],Nutritional Risk Screening (NRS) 2002,Adverse Events
6943,NCT00497107,Disease-free survival,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Overall survival, compliance, adverse events, QOL, tumor markers",
6944,NCT00048139,Tumor measurement (RECIST criteria),2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"Efficacy: Time to progression, time to response, duration of response, time to treatment failure, survival.",
6945,NCT06066138,Feasibility of reducing drug exposure while maintaining plasma drug concentration,2024-04-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],"Minimal frequency (median, range) of atezolizumab dosing to keep the trough concentration at or above 6 microgram/mL",
6946,NCT03924804,1. The change of bladder volume,2019-06-19,COMPLETED,INTERVENTIONAL,['NA'],,
6947,NCT05986890,Gastric emptying as per gastric emptying scintigraphy at 7 days post-operatively.,2023-08-17,RECRUITING,INTERVENTIONAL,['NA'],Improvement of quality of life as measured GIQLI,
6948,NCT02618811,Complications,2014-01,COMPLETED,OBSERVATIONAL,['NA'],Need for opioid analgesia postoperatively,
6949,NCT01533090,Evaluation of the overall quality of bowel preparation,2010-04,COMPLETED,INTERVENTIONAL,['NA'],compliance,
6950,NCT01127698,"Fractures, hip fractures",1987-03,COMPLETED,OBSERVATIONAL,['NA'],,
6951,NCT06008119,Progression-free Survival (PFS),2023-11-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Disease control rate (DCR),
6952,NCT04510129,PD-L1/PD-1 inhibitor response,2020-02-05,RECRUITING,OBSERVATIONAL,['NA'],,
6953,NCT04114591,Life,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
6954,NCT01690715,Prognosis (disease graduation),2012-07,TERMINATED,OBSERVATIONAL,['NA'],Relation established between survival and degree of underlying liver dysfunction,
6955,NCT05799820,Objective Response Rate (ORR),2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
6956,NCT06031285,"RFS, recurrence-free survival",2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6957,NCT04158908,Potential Improvements to the Oncolo-GIST Manual According to Structured Qualitative Surveys,2020-01-17,COMPLETED,OBSERVATIONAL,['NA'],,
6958,NCT03862768,Progression-free Survival,2019-07,UNKNOWN,INTERVENTIONAL,['NA'],Overall Survival,
6959,NCT00637728,Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale,
6960,NCT00461929,~ presence or absence of genetic abnormality as seen in CML patients on imatinib,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4'],,
6961,NCT05789485,proportion of patients achieving (ratio of delivered to planned treatment) RDI ≥ 90%,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6962,NCT01371942,,2010-05,UNKNOWN,OBSERVATIONAL,['NA'],,
6963,NCT01114087,Average difference of the concentration of spermatozoa in the ejaculate measured before treatment and after 6 months of treatment.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],Plasmatic concentration of the inhibitors of tyrosine kinase,
6964,NCT05339321,Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT),2021-04-14,UNKNOWN,INTERVENTIONAL,['PHASE1'],Efficacy: antiviral activity of SCG101,
6965,NCT00664482,Treatment-emergent changes in localized injection site reactions following each dose,2007-05,COMPLETED,INTERVENTIONAL,['NA'],Feasibility,
6966,NCT05200299,2-year Disease-free survival,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of Life assessed by SF-36,
6967,NCT00924690,Elaboration using the Elaboration Likelihood Scale,2009-06,COMPLETED,INTERVENTIONAL,['NA'],Behavioral Intention to Engage in Colorectal Cancer Screening or Physical Activity,
6968,NCT04663789,Clinically relevant postoperative pancreatic fistula (CR-POPF),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Length of postoperative hospital stay,
6969,NCT05186116,Disease free survival,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Donor quality of life,
6970,NCT03473587,Change in colorectal cancer screening rate,2014-11-07,UNKNOWN,INTERVENTIONAL,['NA'],,
6971,NCT01676259,ORR at 6 months,2018-03-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6972,NCT01325909,Maintain or improve physical fitness (anaerobic threshold measured by CPET)after treatment with neoadjuvant chemoradiotherapy in colorectal cancer patients.,2011-03,COMPLETED,INTERVENTIONAL,['NA'],Activity levels before during and after neoadjuvant chemoradiotherapy,
6973,NCT03222076,"Safety and Tolerability of Presurgical Nivolumab With or Without Ipilimumab, Defined as the Number of Participants With of Adverse Events.",2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),
6974,NCT01922492,Changes of insulin secretory function,2008-05,UNKNOWN,INTERVENTIONAL,['NA'],Adverse effects,
6975,NCT05197322,Pathological complete response rate (pCR),2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Health-related Quality of Life (QoL) and functional outcome,
6976,NCT05170802,CT scan finding new lymph nodes,2017-12-20,RECRUITING,OBSERVATIONAL,['NA'],Data on adverse events and complications related to Irreversible Electroporations.,
6977,NCT02454673,Disease Free Survival,2013-09,COMPLETED,OBSERVATIONAL,['NA'],Estimate of TN Change From Baseline to Surgery,
6978,NCT04341337,qualitative analysis of the interviews,2019-03-02,COMPLETED,OBSERVATIONAL,['NA'],,
6979,NCT02483832,CRC screening follow-up rate,2015-02,COMPLETED,INTERVENTIONAL,['NA'],Changes in attitudes towards CRC and CRC screening as measured by survey,
6980,NCT05954702,Mortality,2023-07-21,RECRUITING,INTERVENTIONAL,['NA'],Drain use time,
6981,NCT03986502,Caregiver burden,2021-01-22,COMPLETED,INTERVENTIONAL,['NA'],,
6982,NCT00003326,,1997-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6983,NCT04138212,overall survival,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE3'],postoperative complications,
6984,NCT06221657,Proportion of subjects maintained at HBV DNA <29 IU/mL,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],blood Phosphorus levels,
6985,NCT06319404,The immune function of tumor draining lymph nodes of colorectal cancer patients was previously identified based on radiomics,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6986,NCT01591109,,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
6987,NCT05113264,Patient Engagement with the Penny chatbot,2021-08-02,RECRUITING,INTERVENTIONAL,['NA'],Patient Satisfaction with the Penny chatbot interactions will be measured by the Promoter Score,
6988,NCT03770988,Objective Response Rate,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety assessed by incidence of treatment-emergent adverse events,
6989,NCT05550701,cancer specific survival,2021-05-05,COMPLETED,OBSERVATIONAL,['NA'],,
6990,NCT03879811,response rate of TMZ followed by nivolumab in participants with MMR-proficient Colorectal Cancer,2019-03-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
6991,NCT02614534,Locoregional Control (LC),2015-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life questionnaires QLQ-CR29,
6992,NCT05148767,Toxicity effect,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,
6993,NCT02215889,Percent of transplanted patients receiving second stage hepatectomy within 4 weeks of segment 2/3 transplantation.,2014-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
6994,NCT04826432,postoperative digestive leakage,2020-09-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6995,NCT00478309,Factors that moderate the impact of GERA feedback on CRC screening utilization,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,
6996,NCT06114420,Cancer-specific survival,2023-01-30,RECRUITING,OBSERVATIONAL,['NA'],Find a differentially expressed gene,
6997,NCT06236282,Operation time,2012-05-01,COMPLETED,OBSERVATIONAL,['NA'],TME quality (Operative outcome),
6998,NCT05891301,gastrointestinal dysfunction,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],Patient Mobility in the hospital,
6999,NCT02813824,Number of patients with at least one adenoma seen on chromo-endoscopy 48 months after complete withdrawal of polyps and initiation of treatment (aspirin or placebo),2017-11-14,RECRUITING,INTERVENTIONAL,['PHASE3'],Load serrated polyps after 24 and 48 months of treatment,
7000,NCT02745847,The toxicities following SBRT will be determined.,2016-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],The quality of life will be analyzed.,
7001,NCT03614650,percentage of adverse effects after EIE cell injection,2018-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The anti-cancer effects,
7002,NCT03706157,Histological analysis of biopsy samples for the evaluation of the kinetics of distribution of doxorubicine in tumor compartments depending on the solvent used for drug reconstitution,2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE4'],"In vivo evaluation of the kinetics of distribution of doxorubicine in tumoral tissue with confocal laser endomicroscopy, depending on the solvent used for drug reconstitution",
7003,NCT06184867,Number of Participants with Genetic Testing Uptake,2023-10-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Acceptance and Usability of the Relational Agent,
7004,NCT02330497,Safety of the pancreatic radiofrequency ablation under EUS guidance,2015-02,COMPLETED,INTERVENTIONAL,['NA'],Safety of the pancreatic radiofrequency ablation under EUS guidance,
7005,NCT04618809,"Percentage of treatment plan changes. (Count # of treatment changes 2-3 months after comprehensive geriatric assessment. Site coordinators will complete follow-up chart review of each patient to see what, if any, changes were made)",2020-09-22,RECRUITING,INTERVENTIONAL,['NA'],Fitbit assessed functional status. Fitbit data: heart rate,
7006,NCT00602082,Objective response rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
7007,NCT04982653,Radiographic incidence rate of incisional hernia,2022-01-04,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events (AEs),
7008,NCT03288987,Progression Free Survival (PFS),2016-10-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Positive Anti-drug Antibody (ADA) Samples Among Patients (Immunogenicity),
7009,NCT05348668,Progression-free Survival,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7010,NCT04737213,Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7011,NCT06311279,Anastomotic leak amount,2024-03-05,RECRUITING,INTERVENTIONAL,['NA'],,
7012,NCT04560894,Progression-free survival(PFS)evaluated by the Blinded Independent Central Review Committee (BICR) based on RECIST V1.1,2020-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Anti-drug antibody (ADA),
7013,NCT02716207,The maximum tolerated dose will be determined,2016-03,COMPLETED,INTERVENTIONAL,['NA'],Pain intensity will be determined.,
7014,NCT04169347,Efficacy/objective response rate,2019-12-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Evaluating for the velocity of tumor response to this regimen,
7015,NCT05226572,Diagnostic yield (%) of repeated EUS-fine needle biopsy of pancreatic masses after previous non-diagnostic or inconclusive results,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],"Sensitivity (%), specificity(%), positive predictive value(%), negative predictive value(%), specimen adequacy(%), Bethesda classification, adverse events incidence (%) and factors that influenced repeated EUS-fine needle biopsy performance.",
7016,NCT01496521,occurrence of high grade dysplasia and invasive ESCC,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],occurrence of high grade dysplasia and invasive ESCC,
7017,NCT06275958,Progression-Free Survival,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Cost-effectiveness,
7018,NCT05244798,"Pathology complete response rate, pCR",2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],"Circulating tumor DNA, ctDNA",
7019,NCT02628067,Objective Response Rate (ORR),2015-12-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of Participants who Discontinue Study Intervention due to AEs,
7020,NCT03681951,Percentage of Participants Achieving Complete Response or Partial Response Based on RECIST 1.1 Criteria-Part 4,2018-11-16,TERMINATED,INTERVENTIONAL,['PHASE2'],Time Invariance Following Repeat Dose of Pembrolizumab-Part 3,
7021,NCT01547260,Immunomodulatory effect (phase II).,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinical efficacy,
7022,NCT03531125,Comparison of whole transcriptome RNA sequencing of EUS derived pre-operative sample and whole transcriptome RNA sequencing of biopsies either taken from the pancreatic cancer during resection or repeat biopsy using EUS,2018-07-02,TERMINATED,OBSERVATIONAL,['NA'],"Percentage and number of patients that undergo EUS and follow up EUS or surgery that have a) histopathological evidence of adenocarcinoma in their biopsy and surgical samples, and b) of suitable RNA quality for analysis",
7023,NCT00963612,To assess the ability of BOLD MRI to predict microvascular invasion in hepatocellular carcinoma via assessment of intratumoral oxygenation.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],To identify a quantitative threshold tumor R2* value using BOLD MRI technique reasonably sensitive of predicting microvascular invasion in HCC pre-operatively.,
7024,NCT03300609,Progression free survival 1,2018-02-27,TERMINATED,INTERVENTIONAL,['PHASE3'],Treatment Response,
7025,NCT01167816,Toxicity,2010-07,TERMINATED,INTERVENTIONAL,['PHASE1'],Determine the effect of azacitidine therapy on DNA methylation in peripheral blood cells,
7026,NCT02981641,Overal survival,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],Local control rate,
7027,NCT01998009,The proportion of participants with a positive colonoscopy finding indicating an advanced colorectal neoplasia who also have a positive fecal occult blood test result,2011-05,COMPLETED,INTERVENTIONAL,['NA'],The proportion of participants with a negative colonoscopy finding who also have a negative fecal occult blood test result,
7028,NCT04880044,Proportion of participants negative via EC/EG who subsequently are proven negative via EGD,2022-01-05,RECRUITING,INTERVENTIONAL,['NA'],,
7029,NCT03349762,Distant Metastasis-Free Survival rate,2018-11-02,RECRUITING,OBSERVATIONAL,['NA'],Immunity function,
7030,NCT03430843,Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set,2018-01-26,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants Experiencing Adverse Events (AEs),
7031,NCT03207594,Number of patient who self-report smoking cessation,2016-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Compliance with smoking cessation,
7032,NCT01315795,Reduction of total liver volume after 18 months of treatment by means of CT-scan,2011-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Assessment of quality of life after 18 months of treatment,
7033,NCT01861691,Early complication rate,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Health-related QOL score,
7034,NCT02976896,Disease control rate,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life using esophageal special scale QLQ - OES18,
7035,NCT02669992,Number of participants with postoperative stoma site hernia,2015-06,RECRUITING,INTERVENTIONAL,['NA'],Postoperative Hospital stay,
7036,NCT00280618,Time to Tumor Progression (TTP) and Response Rate: evaluated by RECIST,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events collections and evaluation,
7037,NCT04437212,Major Pathological Response Rate (MPR),2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Perioperative complication rate,
7038,NCT03927898,1 year Progression-Free-Survival (PFS),2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Expression of PD-L1 on circulation tumor cell,
7039,NCT05883683,Identification of effective drugs or drug combinations,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Correlation between organoid and PDX drug sensitivities,
7040,NCT00234182,Occurrence of recurrent disease,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Death of the patient,
7041,NCT03695952,Objective response rate,2018-07-01,RECRUITING,OBSERVATIONAL,['NA'],Adverse events,
7042,NCT04738188,Downstaging success rate,2020-03-18,RECRUITING,INTERVENTIONAL,['NA'],Recurrence rate of Hepatocellular carcinoma,
7043,NCT01262560,Change in Radiation Esophagitis-related Pain at 4 Weeks as Measured by the Numerical Rating Pain Scale for Pain on Swallowing (NRPS),2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Patient Reported Difficulty in Swallowing Associated With Manuka Honey Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE),
7044,NCT01163812,Compliance of lymph node dissection,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],distance to resection margin and number of harvested lymph nodes,
7045,NCT05068635,Number of patients who developped morbidity after subgastrectmy for gastric cancer,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7046,NCT01239056,Technical Success of Endoscopic Ultrasound-guided Single-access Pseudocyst Drainage With a Fully Covered Self-expanding Metal Stent ; Anchored With a Double Pigtail Plastic Stent Inserted Through the Metal Stent Lumen,2009-08,COMPLETED,OBSERVATIONAL,['NA'],Adverse Events,
7047,NCT05623150,Primary outcome measure CHALNA2,2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],7th outcome measure CHALNA2,
7048,NCT02155088,Maximum Tolerated Dose (MTD),2014-10-30,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression-Free Survival (PFS),
7049,NCT00008281,,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7050,NCT03145558,Progression Free Survival,2017-12-05,SUSPENDED,INTERVENTIONAL,['PHASE2'],Duration of CR,Time to local recurrence
7051,NCT01072981,The primary objective is to assess overall survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],The secondary objective is to assess disease free survival and to conduct correlative scientific studies of subject samples to determine the mechanism of any observed anti-tumor effect.,
7052,NCT02128100,Grade 3 or Higher Adverse Event(s) as a Measure of Safety and Tolerability,2014-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Response Rate for Participants as Assessed by Contrast-enhanced CT Scan of the Abdomen at 12 Months.,Quality of Life Assessment at 12 Months Post-treatment
7053,NCT04258111,ORR,2020-08-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events (AE),
7054,NCT03152370,Number of participants with any non-serious adverse event (AE),2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE1'],Mean peak-trough fluctuation (PTF) of E7046 and its metabolite ER-888188 in plasma,
7055,NCT05742750,Objective Response Rate (ORR),2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
7056,NCT00923520,Determine the Maximum Tolerated Dose,2009-03-25,COMPLETED,INTERVENTIONAL,['PHASE1'],Anti-tumor Effects,
7057,NCT01666730,Median Overall Survival (OS),2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Grade 3 and 4 Toxicities According to NCI CTCAE Version 4.0,
7058,NCT05027711,Treatment related Toxicity,2021-08-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Evaluation of potential prognostic biomarkers,
7059,NCT02689401,Assess the safety of intravenous ferumoxytol for the use in esophageal cancer patients,2016-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Determine the accuracy of MRI-ferumoxytol for the identification of positive metastatic nodes in patients with esophageal cancer,
7060,NCT05007912,Anastomosis complication,2021-06-21,UNKNOWN,OBSERVATIONAL,['NA'],,
7061,NCT05756699,HCC detection rate,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Positive predictive value,
7062,NCT06014372,Rate of pCR,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],DFS,OS
7063,NCT02582034,"The primary endpoint is to compare the response rate of the treated lesion at the first radioembolization, evaluated using European Association for the Study of the Liver (EASL) criteria of yttrium-90 marked glass microspheres SIRT",2015-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Post-therapeutic dosimetry measured by Positron emission tomography-computed tomography PET / CT,
7064,NCT05201404,Overall Survival (OS),2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE3'],Pharmacokinetics (PK) of namodenoson in this population,"Quality of Life (QOL), using the hepatocellular carcinoma- (HCC-) specific module of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Hepatocellular Carcinoma 18-question Module (EORTC QLQ-HCC18)"
7065,NCT06326502,Dose-limiting Toxicity (DLT),2024-02-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,
7066,NCT02941861,Recurrence rate of Liver Carcinoma after surgery,2016-08,COMPLETED,OBSERVATIONAL,['NA'],,
7067,NCT03683446,Postoperative Complications,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7068,NCT04156087,Progression-free survival (PFS),2020-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7069,NCT03694977,Identification of potential biomarkers of MCS110 in combination with PDR001,2019-01-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety as measured by number and grade of toxicity events,
7070,NCT00006015,Overall toxicity,2000-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7071,NCT02822352,To compare the rates of neoplasia detection using virtual chromoendoscopy compared to high definition white light (HDWL) endoscopy,2016-08,COMPLETED,INTERVENTIONAL,['NA'],To compare the duration of time taken using each technique,
7072,NCT02745509,Overall survival,2016-03,COMPLETED,INTERVENTIONAL,['NA'],Post-operative quality of life,
7073,NCT04159363,Caregivers' quality of life,2020-02-01,UNKNOWN,INTERVENTIONAL,['NA'],Caregivers' anxiety and depression,
7074,NCT02347956,morbidity,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",mortality,
7075,NCT04968145,30-day re-admission,2017-07-19,COMPLETED,INTERVENTIONAL,['NA'],Patient reported outcomes,
7076,NCT03890731,Severity (by Worst Grade) of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs),2019-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Dose Modifications,
7077,NCT04317599,First-line Systemic anticancer therapy (SACT) treatment patterns in BRAFV600E mutant mCRC patients,2020-04-12,COMPLETED,OBSERVATIONAL,['NA'],Time to treatment cessation,
7078,NCT04680598,HBV Reactivation rate,2020-12-25,RECRUITING,OBSERVATIONAL,['NA'],adverse event,
7079,NCT00559455,"Tumor Response Rate evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) by physical examination, chest X-ray, abdomen-pelvis CT (Computed tomography) scan",2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Time to Progression (TTP), 6 month survival, overall survival, AFP",
7080,NCT02608229,Maximum Tolerated Dose (MTD) of BVD-523,2016-06-06,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
7081,NCT00237172,To study the antineoplastic effect of the investigational drug.,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],To study the safety and pharmacokinetics of the investigational drug.,
7082,NCT02632448,Maximum Tolerated Dose(s),2016-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
7083,NCT02728167,Normalized blood loss (ml/cm2),2016-04,TERMINATED,INTERVENTIONAL,['NA'],Number of patients with postoperative complications assessed using Dindo-Clavien classification,
7084,NCT05679960,Accuracy of Urine PolypDx device in detecting colorectal cancer,2022-08-15,RECRUITING,INTERVENTIONAL,['NA'],Negative Predictive Value Urine PolypDx device in detecting colorectal cancer (CRC),
7085,NCT01308190,Local recurrence,2010-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7086,NCT01045200,Patient satisfaction,2002-01,COMPLETED,OBSERVATIONAL,['NA'],Resource utilisation,
7087,NCT03330561,Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03,2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE1'],"Biomarkers (CD137, soluable HER2, cell surface antigens for immunotyping) in tumor tissues and blood samples",
7088,NCT01791361,The prevalence of KRAS testing and impact of the KRAS test results on patterns of Vectibix use in patients with metastatic colorectal cancer (mCRC) treated with Vectibix,2012-09-19,COMPLETED,OBSERVATIONAL,['NA'],"To characterize the results of KRAS testing in the three rounds of chart abstraction that will be carried out at 0, 12 and 24 months to indicate if there are any differences in results from each of the three rounds",
7089,NCT03937362,Accuracy of clinical response evaluations for detecting substantial residual locoregional disease,2019-08-08,UNKNOWN,OBSERVATIONAL,['NA'],Accuracy of clinical response evaluations for detecting any residual locoregional disease,
7090,NCT06205472,The 3-year Overall Survival,2024-01-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Local Control Rate,
7091,NCT04853043,Progression free survival (PFS),2021-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS).,
7092,NCT05192044,Feasibility of enhanced recovery after pancreatico-dudenectomy,2021-12-25,UNKNOWN,INTERVENTIONAL,['NA'],,
7093,NCT01042041,"Dose adjustment, number and percentage of subjects with adverse events, laboratory changes, number and percentage of subjects with laboratory values that are outside the pre-determined ranges, cumulative toxicity, and TLT.",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to Disease Progression,
7094,NCT02785887,Relative dose intensity,2014-08-01,COMPLETED,INTERVENTIONAL,['NA'],Early mortality,Optional Translational Substudy: Blood metabolites
7095,NCT03298204,Overall survival,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],Distant metastasis free survival,
7096,NCT03688906,"Diagnosis of colorectal cancer or advanced adenomas in patients undergoing routine screening colonoscopy, or post-colonoscopy",2018-01-12,COMPLETED,OBSERVATIONAL,['NA'],,
7097,NCT02821533,Tumor response,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],overall survival,
7098,NCT03732781,Explore efficacy (expansion cohort),2020-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7099,NCT01218880,Maximum tolerant dose,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],objective response rate,
7100,NCT01492049,Colorectal cancer screening (CRCS) Rate of Participants,2012-08-07,COMPLETED,INTERVENTIONAL,['NA'],,
7101,NCT04948398,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
7102,NCT00447330,Median Progression-Free Survival (PFS),2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Survival,
7103,NCT03847428,Recurrence-free survival (RFS) for Arm A vs Arm C,2019-04-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Time from randomization to recurrence/progression on next therapy (RFS2/PFS2) for Arm A vs Arm C and Arm B vs Arm C,
7104,NCT02252913,safety and tolerability,2014-09,COMPLETED,INTERVENTIONAL,['PHASE1'],PK parameters,
7105,NCT01086267,Toxicity will be evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacokinetics (PK) for BMS-908662 as determined by accumulation index [AI].,
7106,NCT02088775,Local control,2014-02,COMPLETED,INTERVENTIONAL,['NA'],Change in dose measured by PET-CT scan,
7107,NCT05116696,All-cause mortality,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],Hospital adverse event,
7108,NCT06099314,Overall survival 2(OS2),2023-10,RECRUITING,OBSERVATIONAL,['NA'],"Disease control rate 2 (DCR2, investigators based on RECIST1.1)",
7109,NCT01310062,,2010-08,UNKNOWN,OBSERVATIONAL,['NA'],,
7110,NCT01660971,"Maximum tolerated dose of gemcitabine hydrochloride and dasatinib given together with erlotinib hydrochloride, determined by incidence of dose-limiting toxicity graded according to NCI CTCAE v 4.0",2012-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Serious and other significant adverse events (AEs), graded according to NCI CTCAE v 4.0",
7111,NCT06197425,The time to recurrence (TTR),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
7112,NCT01693445,maximum tolerated dose,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],disease control rate,
7113,NCT00189657,,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7114,NCT03413514,The cycle of neoadjuvant chemotherapy,2018-01-03,UNKNOWN,INTERVENTIONAL,['NA'],The involvement of patients during the shared decision making,
7115,NCT04534075,Intensity of the urgency syndrome,2020-09-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Acute side-effects,Composition of microbiota
7116,NCT05632744,Safety of the CG-100 Intraluminal Bypass Device,2023-03-15,RECRUITING,INTERVENTIONAL,['NA'],Safety of the CG-100 Intraluminal Bypass Device,
7117,NCT05592626,Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR),2023-01-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1 and 2 (Dose Escalation and Expansion): Anti-drug Antibody (ADA) formation,
7118,NCT05043987,Number of participants with dose-limiting toxicities (DLTs) during the DLT evaluation period.,2022-11-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],CPO102 immunogenicity: Number of participants with anti-drug-antibody (ADA),
7119,NCT05219539,Change of general surgical skills score,2021-11-11,COMPLETED,OBSERVATIONAL,['NA'],Changes of clinical research possibilities score,
7120,NCT04090060,Number of persons who practice the companion examination,2020-01-17,COMPLETED,INTERVENTIONAL,['NA'],Concordance between self-examination and clinician examination stratified by waist circumference.,
7121,NCT05370001,Carbon dioxide level from an arterial line (PaCO2) after 15 minutes of HFJV.,2022-06-13,COMPLETED,INTERVENTIONAL,['NA'],Injury of the airway following endotracheal intubation.,
7122,NCT05131919,"To assess the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancers by objective response rate (ORR)",2022-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],To assess the date of relapse,
7123,NCT05773144,Chemotherapy Relative Dose Intensity,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
7124,NCT06293898,To determine the maximum tolerated dose (MTD) if reached or maximum administered dose (MAD) and two or more recommended doses for dose expansion (RDEs) of BL-M07D1,2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,
7125,NCT05778851,The impact of EsoCheck/EsoGuard on health care provider's decision for upper endoscopy referral,2023-04-12,RECRUITING,INTERVENTIONAL,['NA'],The impact of EsoCheck/EsoGuard on health care provider's patient risk assessment for BE,
7126,NCT02617134,Adverse events attributed to the administration of the anti-MUC1 CAR-T cells,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Objective Response Rate,
7127,NCT00002625,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7128,NCT02053805,"Prevalence, stage and pathology of screen-detected prostate cancer in BRCA1/BRCA2 founder mutation carriers and Lynch mutation carriers",2014-02,UNKNOWN,INTERVENTIONAL,['NA'],"Accuracy of different screening tests (PSA, free to total PSA, prostate MRI) in detecting prostate cancer among men with genetic predispositions.",Genomic and biological profiles in samples from BRCA and Lynch mutation carriers and characterize changes related to prostate cancer.
7129,NCT04511039,Maximum tolerated dose/ recommended phase II dose,2021-06-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of subjects with DNA damage response,
7130,NCT02893540,PFS1,2016-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",QOL,
7131,NCT00471484,Objective tumor response rate as measured by RECIST criteria,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Tissue VEGF expression,
7132,NCT04473794,Clinical utility of Compcyst in pancreatic cysts as assessed by patient chart review,2022-07-20,RECRUITING,OBSERVATIONAL,['NA'],,
7133,NCT01743300,The feasibility of midazolam as a phenotyping probe for sunitinib exposure (area under concentration time curve)in cancer patients,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],The influence of sunitinib on CYP3A4 activity,
7134,NCT04851054,VEGF in serum on postop day 4,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7135,NCT03688230,Progression Free Survival (PFS),2019-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events summarized by CTCAE severity grade (v5.0).,
7136,NCT03336658,correlation of ITB based calculated N stage with real N stage in CRC - patients,2015-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],correlation of ITB based calculated DFS with real DFS in CRC - patients,
7137,NCT04958720,Diagnostic and therapeutic approach,2020-04-27,RECRUITING,OBSERVATIONAL,['NA'],Create and validate a predictive model,
7138,NCT02596113,Genes' mutations rate in patients who are submitted screening colonoscopy and they presented with cancerous lesion,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,
7139,NCT04297280,Objective Response Rate (ORR),2020-04-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
7140,NCT01390194,image quality outcome,2011-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
7141,NCT01516944,Disease-free survival(DFS),2012-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",R0-resection rate,
7142,NCT01370928,Patients´ evaluation of pain and discomfort,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Caecum intubation rate,
7143,NCT04259762,Completion of a Pap Smear test to screen for cervical cancer,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in Self-Efficacy measured using the Health Behavior Survey,
7144,NCT01450046,Number of Participants With Treatment Related Adverse Events,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacodynamic (PD) Markers of Vitamin E δ-Tocotrienol Activity in Peripheral Blood,
7145,NCT05224882,The assessment of the prevalence of oral adverse events induced by chemotherapy in pediatric cancer patients .,2023-08-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Assessment of dental awareness among parents of pediatric cancer patients .,
7146,NCT05267275,incidence of complications related to rectal anastomosis,2021-11-30,RECRUITING,INTERVENTIONAL,['NA'],,
7147,NCT00728650,Survival,2003-10,COMPLETED,OBSERVATIONAL,['NA'],Efficacy,
7148,NCT01051167,Response rate (RECIST-Criteria),2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],"Secondary objectives: Safety, Quality of life",
7149,NCT01921751,Overall Survival,2013-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Correlation Between SMAD4 Status Determined by Immunohistochemistry (IHC) and Genetic SMAD4 Status,
7150,NCT01516710,Perioperative morbidity,2012-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Incidence of incisional hernia,
7151,NCT00265876,Response (complete [CR] and partial response [PR] or stable disease [SD]) at 8 weeks,2006-04-26,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Toxicity,
7152,NCT02318095,Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen,2015-02-17,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants Who Received an R0 Resection,
7153,NCT00005858,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7154,NCT02623621,Progression Free Survival,2015-11,COMPLETED,OBSERVATIONAL,['NA'],,
7155,NCT02786329,Incidence of recurrences:,2016-06,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Rate of postoperative complications after TIVA versus inhalation anaesthesia,Rate of local anaesthetics systemic toxicity incidence
7156,NCT00629863,Overall survival at 12 months of patients last randomized and at 48 months of patients first randomized,2004-09,COMPLETED,INTERVENTIONAL,['NA'],"Health resource utilization, including the selection of treatments and subsequent use of health service resources",
7157,NCT02032953,Net protein balance,2013-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
7158,NCT03917173,Disease free survival,2020-06-01,RECRUITING,INTERVENTIONAL,['NA'],patients performing the adjuvant chemotherapy.,
7159,NCT00116389,6 month survival,na,TERMINATED,INTERVENTIONAL,['PHASE2'],performance status,
7160,NCT00002722,,1996-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7161,NCT04917276,Specificity,2021-06-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7162,NCT05911152,3-year overall survival,2016-01-01,RECRUITING,OBSERVATIONAL,['NA'],Postoperative pain score,
7163,NCT06037980,median PFS,2023-11-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Perioperative morbidity and mortality,
7164,NCT00290966,to detect a significant increase in time to progression in favor of docetaxel plus cisplatin and 5-FU compared to cisplatin plus 5-FU. Tumor assessments (assessed with WHO criteria) had to be performed every 8 weeks until progression,1998-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Patients were to be followed until death (overall survival). Clinical and laboratory were assessed with NCIC-CTG scale, before each cycle. Quality of life and clinical benefit were assessed every 2 weeks until progression and then every 3 months.",
7165,NCT00162526,To evaluate the tolerability and the safety of a Tocopherol formulation in the prevention or suppression of the serverity of oral mucositis induced by myeloablative agonist.,2005-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],To evaluate the toxicity and the safety of a Tocopherol formulation in the prevention or suppression of the serverity of oral mucositis induced by myeloablative agonist.,
7166,NCT06321081,progression free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overal survival,
7167,NCT01245582,Overall Survival (OS),2011-07,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Response Rate (RR),
7168,NCT04548440,R0 resection rate of patients who underwent surgery following preoperative treatment,2020-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of patients with adverse events and severity according to NCI CTCAE v5.0,
7169,NCT04028479,Progression-free survival (PFS) - 5th line of therapy,2021-05-05,RECRUITING,OBSERVATIONAL,['NA'],Overall survival (OS),
7170,NCT00084942,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7171,NCT00303888,Safety,2006-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7172,NCT06256315,30-day overall complication rate,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],The rehospitalization rate within 30 days after surgery,
7173,NCT01524783,Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment,2012-03-30,COMPLETED,INTERVENTIONAL,['PHASE3'],Pharmacokinetics (PK): Predose Concentration (Cmin) of Everolimus at Day 29,
7174,NCT01403103,Comparison of the expression of 15-PGDH mRNA and protein levels in normal colorectal mucosa,2012-04,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],"Number of patients with grade 3 related toxicities of a single 100,000 IU dose of 25-OH-vitamin D3",
7175,NCT00263354,To evaluate the progression-free survival in the ITT population,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],To investigate safety using NCI-CTC criteria version 2,
7176,NCT02754856,Incidence of adverse events,2016-07-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7177,NCT00003085,,1996-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7178,NCT05304741,Overall Survival,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],Diagnostic Indicators,
7179,NCT01405183,Prevalence of hepatitis C in renal cell carcinoma patients,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
7180,NCT03681600,3-year disease free survival,2018-01-01,TERMINATED,OBSERVATIONAL,['NA'],"Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging",
7181,NCT02940496,Incidence of dose limiting toxicity (DLT),2016-12-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
7182,NCT04774679,Correlation of a macroscopically visible fragments in the 22g EUS-FNA needle specimens with final histologic diagnosis,2021-02-06,UNKNOWN,INTERVENTIONAL,['NA'],Area Under the size of the macroscopically visible core size versus histologic core size,
7183,NCT02314819,overall survival,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],"Safety and tolerance evaluated by incidence, severity and outcomes of AEs",
7184,NCT01015820,Mean Blood Vessel Radius (BVR),2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
7185,NCT00854854,Determine response rate,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Determine safety of combination,time to treatment failure, overall survival time",
7186,NCT02465593,anti-tumor activity,2015-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7187,NCT05419479,Switch Maintenance-Progression Free Survival,2022-11-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Treatment-Related Adverse Events,
7188,NCT02201797,repeatability coefficient (RC),2014-10,COMPLETED,INTERVENTIONAL,['NA'],,
7189,NCT05201872,The positive rate of bacterial contamination of peritoneal washings,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA'],Postoperative complications,
7190,NCT01812876,Number of participants with adverse events; incidence of Shenqifuzheng'ADRs and identify factors that contributed to the occurrence of the adverse reaction,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],,
7191,NCT00611507,Response rate - RECIST criteria (unidimensional),2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free Survival (PFS),
7192,NCT04795180,Length of hospital stay (number of days),2013-12-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Anorectal functional outcome assessed by Colorectal Functional Outcome Questionnaire (COREFO) questionnaire,
7193,NCT01156831,Locoregional control,2007-11,COMPLETED,OBSERVATIONAL,['NA'],Tumor regression grade,
7194,NCT01964027,PFS and OS,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7195,NCT04783831,POPF,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],Position and degradation of biodegradable stents,
7196,NCT03427268,Progression-free Survival Rate at Three Months,2018-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Response Rate (ORR),
7197,NCT03734068,Tumor response,2018-06-13,UNKNOWN,OBSERVATIONAL,['NA'],number of treatment required to achieve objective response in HCC patients,
7198,NCT02984566,Difference in accumulated patient dose distribution with and without KIM,2020-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Patient-reported quality of life as measured by the European Organization for Research and Treatment of Cancer Quality-of-Life-Questionnaire-Hepatocellular Carcinoma 18 Module (EORTC QLQ-HCC18),
7199,NCT02879721,"Change in expression of proteins associated with inflammation, proliferation and cancer development",2009-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Change in regulation of potential new biomarkers associated with esophageal cancer,
7200,NCT06265844,Serum prealbumin,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],Feeding amount,
7201,NCT04601610,ORR,2021-06-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",OS,
7202,NCT00004127,Clinical response rate,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7203,NCT01498757,Biomarkers predictive,2012-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
7204,NCT00350753,Time to progression,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers,
7205,NCT00250835,Pathologic Complete Response (PCR),2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Pelvic Local Control Rate,
7206,NCT01538550,colorectal cancer mortality,2012-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Psychological effects of screening,Pain reduction during Colonoscopy
7207,NCT04677192,OS,2021-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Complete ablation rate,
7208,NCT00387530,Evidence of Epstein-Barr virus (EBV) lytic phase activation (expression of EBV antigens BZLF1 and LMP2) as assessed by biopsy on day 3 of course 1,2006-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Tumor response in patients with measurable disease as assessed by RECIST criteria,
7209,NCT05128890,Hospital charges,2016-04-16,RECRUITING,OBSERVATIONAL,['NA'],,
7210,NCT02246725,"Quality of Life, such as pain, anxiety.",2014-10,UNKNOWN,OBSERVATIONAL,['NA'],Survival,Numbers of chemotherapy cycles
7211,NCT04784520,progression-free survival,2021-06-22,TERMINATED,INTERVENTIONAL,['PHASE2'],duration of response,HA121-28 plasma concentration
7212,NCT06086457,Overall survival (OS),2024-02-04,RECRUITING,INTERVENTIONAL,['PHASE3'],QUALITY OF LIFE: Change From Baseline in the EORTC QLQ-OES18 Subscale Score in Participants,Biomarkers for the predicting of efficacy
7213,NCT01913223,Safety outcome,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Effectiveness of the procedure in terms of complete neoplasia resections,
7214,NCT03042442,Rate of patients with loss of > 5% body weight,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],"Assessing the survival rate by phone-calls follow-up every 6 months, up to 2 years",
7215,NCT00900432,Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1),2004-07,COMPLETED,OBSERVATIONAL,['NA'],,
7216,NCT00293436,Disease-free survival (phase II),2005-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (phase II),
7217,NCT02575807,Phase 2: Progression Free Survival (PFS),2016-03-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
7218,NCT00604721,Number of Participants With Radiographic Objective Response (OR),2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival (OS),
7219,NCT02338518,3 year progression free survival,2015-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse events of preoperative chemotherapy,Sensitivity analysis of primary outcome adjusted for stratification factors
7220,NCT05763927,pCR following neoadjuvant chemotherapy,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],1 year OS(overall survival) rate,
7221,NCT02069145,Safety and tolerability of OMP-54F28 in combination with sorafenib in patients with hepatocellular cancer,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (PK) of OMP-54F28 and sorafenib when administered in combination to patients with hepatocellular cancer,
7222,NCT00680901,Overall Survival in All Randomized Participants,2008-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Number of Participants With a Worst-case on Therapy Grade 3 or Grade 4 for the Indicated Hematology Parameters,
7223,NCT05727163,Objective Remission Rate (ORR),2022-07-29,RECRUITING,INTERVENTIONAL,['PHASE2'],"Safety (including chemotherapy-related adverse events, catheterization-related adverse events, surgical complications, etc.)",
7224,NCT03982121,Recommanded phase 2 dose (RP2D),2019-06-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
7225,NCT01745874,Evaluate the diagnostic accuracy of whole-body MRI for the staging of rectal cancer before and after neoadjuvant treatment,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],Tumoral regression after neoadjuvant treatment,
7226,NCT04230772,Incidence of surgical complications,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of retrieved lymph nodes,
7227,NCT00103311,Objective Response (CR or PR) as Determined by the RECIST Criteria,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
7228,NCT04973631,histologic type,2003-05,COMPLETED,OBSERVATIONAL,['NA'],,
7229,NCT02853474,Overall survival (as intent-to treat analysis),2016-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of patients treated with chemotherapy,
7230,NCT05509751,Acceptability of the intervention and the study,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],Effect of the intervention on unplanned healthcare utilization,
7231,NCT00533884,Delirium and delirium symptoms by the NEECHAM Confusion Scale and Confusion Assessment Method (CAM),2007-10,COMPLETED,OBSERVATIONAL,['NA'],"Falls, injuries, and other complications",
7232,NCT02005809,Post-ESD bleeding rate according to second look endoscopy,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],Post ESD bleeding rate according to bleeding degree during endoscopic submucosal dissection,
7233,NCT00478140,Objective Response (Complete and Partial Response),2007-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
7234,NCT02261844,Improved metabolic profile of liver cells,2015-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Decreased hepatic inflammation,
7235,NCT00322712,Time to Death,2006-09,TERMINATED,OBSERVATIONAL,['NA'],,
7236,NCT04224415,Objective Response Rate,2020-01-31,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse events(AE) and severe adverse events(SAE),
7237,NCT04299880,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2020-02-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7238,NCT05229783,Rate of both high grade dysplasia and esophageal adenocarcinoma lesions detected by electronic chromoendoscopy versus rate of such lesions detected by white light endoscopy plus systemic biopsies according to Seattle protocol.,2022-05-11,RECRUITING,INTERVENTIONAL,['NA'],Cost effectiveness of the detection of both early esophageal adenocarcinoma and high grade dysplasia with electronic chromoendoscopy versus cost effectiveness of Seattle protocol.,
7239,NCT06308510,Sensitivity mFast-SeqS,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Concordance detection rates peritoneal dissemination,
7240,NCT06298123,Recurrence-Free Survival (RFS),2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],Overall Survival (OS),"Imaging data (enhanced CT and MRI） and histopathology data, if available."
7241,NCT01963949,Biopsy of Liver Masses,2013-10,WITHDRAWN,OBSERVATIONAL,['NA'],,
7242,NCT00511264,,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,
7243,NCT05016245,Safety assessed within 60 days post treatment using NCI-CTCAE v5.0,2021-09-13,RECRUITING,INTERVENTIONAL,['PHASE3'],Procedure technical success,
7244,NCT01949194,A biomarker (in blood or tissue) that may be predictive of level of response to regorafenib,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Objective Response Rate (RR),
7245,NCT00915382,progression-free survival,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],overall survival,
7246,NCT00623805,Progression-free Survival,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With a R0 Resection,
7247,NCT04404595,Phase 2: Objective Response Rate (ORR) per independent central read,2020-10-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1b/2: Cytokine expression level in blood after CT041 infusion,
7248,NCT03099031,Venous thromboembolism recurrence,2015-05,COMPLETED,OBSERVATIONAL,['NA'],Heparin induced thrombocytopenia,Premature treatment discontinuation
7249,NCT02401971,time to progression(TTP),2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],overall survival (OS),
7250,NCT01595321,Number of participants with adverse events as a measure of toxicity,2012-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Time to disease progression using immune correlates,
7251,NCT04005365,ORR,2019-11-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7252,NCT02604979,Evaluate the heart-rate corrected QT (QTc) interval (msec) during robotic-assisted laparoscopic gastrectomy,2015-09-23,COMPLETED,OBSERVATIONAL,['NA'],,
7253,NCT01697891,Change in Subjective Dysphagia Assessment Score: EAT-10 from baseline,2012-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in M. D. Anderson dysphagia inventory from baseline,
7254,NCT05055635,Local control,2021-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],To investigate 6-month surgical site morbidity,
7255,NCT01569984,Tumor perfusion,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Blood flow,
7256,NCT05822557,Health and feeding related quality of life,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],Adverse Events,
7257,NCT05839002,Five-year survival of patients,2010-05-21,COMPLETED,OBSERVATIONAL,['NA'],,
7258,NCT01158274,Incidence of adverse events graded according to NCI CTCAE version 4.0 (Parts 2a and 2b),2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall response rate (Parts 2a and 2b),
7259,NCT01715441,Non-progression rate,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Response rate,Cmax and Tmax of sorafenib and irinotecan
7260,NCT02624726,Overall Response Rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicity profile (CTCAE v4.0),
7261,NCT05313854,Patient overall survival,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Pathology diagnosis,Progression-free Survival
7262,NCT00426829,Toxicity (during and within 1 month after completion of radiotherapy),2007-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7263,NCT01954745,Median Progression Free Survival (PFS),2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival (OS),
7264,NCT05462873,Dose intensity,2023-04-04,RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of anti-drug antibody (ADA),
7265,NCT04007770,Cognitive difficulties as measured by the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog),2019-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7266,NCT05068531,Time to tumor recurrence as assessed by detection or change in level of circulating tumor DNA after tumor resection with curative intent,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],Disease-specific survival after complete tumor resection,
7267,NCT00642577,Progression-free survival.,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],"AEs, laboratory tests",
7268,NCT00220649,"To determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine",2004-03,COMPLETED,INTERVENTIONAL,['PHASE1'],"To document any antitumor activity with biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine administered on this schedule",
7269,NCT00193167,overall response rate,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],toxicity,
7270,NCT05870748,Objective Response Rate (ORR),2023-07-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerabilty,
7271,NCT02959385,Overall survival,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Determination of internal target volume (ITV) of thoracic esophageal cancer by evaluating movement of ultrasonic endoscopically placed titanium clips, with or without swallowing, during radiotherapy simulation",
7272,NCT03966209,Acute Graft Rejection Rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Over all survival Rate,
7273,NCT00560365,Overall survival by intention-to-treat analysis,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],NHS cost per life-year saved,
7274,NCT06011473,feasibility of CGM system,2023-08-27,RECRUITING,INTERVENTIONAL,['NA'],SSI rate,
7275,NCT04737187,Survival Probability at 18 Months,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs),
7276,NCT03594422,Safety and tolerance,2018-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Anti-tumor activities of HQP1351,
7277,NCT00002525,5-year Overall Survival Rate in Patients With Dukes' B3/C Disease,1993-10-01,TERMINATED,INTERVENTIONAL,['PHASE3'],5-year Disease-free Survival Rate in Patients With Dukes' B2 Disease,
7278,NCT04718701,Progression-free survival (PFS),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],The incidence and severity of adverse events (AEs) and severe adverse events (SAEs),
7279,NCT00112658,Survival (Phase III),2004-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall response rate (Phase III),
7280,NCT03200340,Duration of Severe Oral Mucositis (SOM) during the active treatment and short-term follow-up periods,2018-07-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Reduction in patient-reported mucositis-related mouth pain and analgesic use,"Healthcare resource use including reliance on gastrostomy feeding, unplanned office visits, emergency room visits, and hospitalizations"
7281,NCT02603159,"overall survival, OS",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],pathologic complete response rate,
7282,NCT03222635,"Overall survival (descriptive statistics in SPSS, percentages, survival analysis)",2017-07-25,RECRUITING,INTERVENTIONAL,['NA'],Quality of life during follow-up endoscopies (questionnaires),
7283,NCT04246125,Maximum absorbed skin dose and dose distribution,2020-10-13,COMPLETED,OBSERVATIONAL,['NA'],,
7284,NCT03346005,The ability of AeonoseTM to distinguish between patients with and without colorectal cancer in a FIT-positive population in terms of sensitivity and specificity.,2017-11-09,COMPLETED,INTERVENTIONAL,['NA'],Acceptance rate of AeonoseTM.,
7285,NCT01169558,Safety: Number of Participants With Serious and Specific Adverse Events,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Efficacy: Progression-free Survival,
7286,NCT05182112,determine the maximum tolerated dose of focal simultaneously integrated boost (SIB),2021-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
7287,NCT01894828,Improvement of nutritional status,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],Reducing number of complications,
7288,NCT03138044,Overall survival rate,2017-05-20,UNKNOWN,INTERVENTIONAL,['NA'],Tumor response rate,
7289,NCT03902600,Acute grade 3 or higher GI AEs,2018-05-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],overall survival,
7290,NCT00145860,,2002-04,TERMINATED,OBSERVATIONAL,['NA'],,
7291,NCT00014456,Define dose limiting adverse events associated with the combination,2000-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Objective antitumor response,
7292,NCT04948762,Resection status,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],Return of bowel function,
7293,NCT04506398,molecular-subtype heterogeneity between primary HCC and post-transplant HCC recurrence,2020-09-10,UNKNOWN,OBSERVATIONAL,['NA'],Recurrence-Free Survival (RFS),
7294,NCT05101616,major pathologic response rate,2022-07-01,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",perioperative complications,
7295,NCT05201105,Recurrence-free survival after abdominal-perineal amputation in case of failure of radiochemotherapy,2021-10-15,COMPLETED,OBSERVATIONAL,['NA'],Overall survival after abdominal-perineal amputation,
7296,NCT03365765,disease-free survival,2018-02-12,COMPLETED,INTERVENTIONAL,['PHASE3'],incidence of adverse reactions after chemotherapy,
7297,NCT05240404,Disease-free survival,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Predictive Biomarkers,
7298,NCT05507632,Objective response rate (ORR),2022-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival rate,
7299,NCT05518032,Objective response rate,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Objective response rate,
7300,NCT00494299,Time to Progression (TTP),2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),
7301,NCT02061956,Efficacy,2011-01,COMPLETED,OBSERVATIONAL,['NA'],Safety,
7302,NCT00363051,Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 1) Based on Response Evaluation Criteria in Solid Tumors (RECIST),2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect of Octreotide Depot on the Trough Concentrations of Everolimus,
7303,NCT05352802,The incidence and severity of postoperative complications,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],Oncological outcomes,
7304,NCT04141995,Number of patients able to undergo resection surgery,2021-02-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of subjects with grade 4 thrombocytopenia and grade 3-4 diarrhea,
7305,NCT02334332,"Patient/informal caregiver satisfaction with timing, content, and delivery of the intervention",2015-01,WITHDRAWN,INTERVENTIONAL,['NA'],Change in mean survey scores,
7306,NCT06119906,Contrast of neoplastic vs non-neoplastic Barrett's,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Image quality of Hyper-Spectral Endoscopy after post-hoc analysis,
7307,NCT00091117,MTD,2004-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7308,NCT04972149,complication,2021-05-18,UNKNOWN,OBSERVATIONAL,['NA'],number of use for each surgical instruments,
7309,NCT04351321,The incidence of postoperative morbidity,2020-07,UNKNOWN,INTERVENTIONAL,['NA'],Overall incidence of postoperative morbidity,
7310,NCT02872779,Difference from baseline in the number of free mutant DNA in blood,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],Evaluation of response based on the RECIST 1.1 guideline,
7311,NCT03088150,Overall survival (OS),2017-07-13,RECRUITING,INTERVENTIONAL,['NA'],Time to progression,
7312,NCT05740852,Pneumonia,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7313,NCT02687230,Half-life (T1/2) of MVT-2163 alone and in combination with MVT-5873,2016-07-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Presence of anti-drug antibodies (ADA) using an MVT-5873 ADA assay,
7314,NCT04172779,Modulation of gene expression signatures associated with hepatocellular carcinoma (HCC) risk,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in quality of life (QOL),Changes in GSTp levels in the liver
7315,NCT05424068,Measuring safety/practicality as assessed during one-on-one with the health coach (analyzed as qualitative data),2022-12-02,RECRUITING,INTERVENTIONAL,['NA'],Physiological measures of Performance,Measure of performance status
7316,NCT05100446,Helicobacter pylori eradication,2021-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
7317,NCT05344820,level of fatigue,2022-05-19,RECRUITING,INTERVENTIONAL,['NA'],level of rumination,
7318,NCT05411757,Adverse Events (AEs),2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Best of response (BOR),Lymphocyte subtype
7319,NCT01694511,Incidence of detected dysplasia by each endoscopic technique.,2009-11,COMPLETED,INTERVENTIONAL,['NA'],The number of biopsies taken and the duration of the different endoscopic techniques.,The endoscopic prediction capability of present dysplasia compared to histopathology for HRME.
7320,NCT02036216,"To collect the DNA samples from the plasma, blood cells and solid tumor tissues in the patients with HCC.",2014-01,UNKNOWN,OBSERVATIONAL,['NA'],"Early diagnosis, treatment monitoring and prognosis evaluation.",
7321,NCT02677129,Short Physical Performance Battery,2014-08,COMPLETED,INTERVENTIONAL,['NA'],Activities of daily living,
7322,NCT05514301,Sensitivity of polydeep vs high experienced endoscopist blinded to polydeep,2023-01-30,COMPLETED,INTERVENTIONAL,['NA'],To compare the diagnostic yield of the optical diagnosis,
7323,NCT00459030,Comparison of traditional print versus simple electronic communication versus usual care in terms of increasing colorectal cancer (CRC) screening rates,2005-10,COMPLETED,INTERVENTIONAL,['NA'],Mediating effect of potential cognitive-affective factors related to CRC screening,
7324,NCT02089919,The number of participants with adverse events,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements,The dose of CSC vaccine
7325,NCT00652132,Rate of Brock grade ≥ 1 hearing loss,2007-12-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Feasibility of central audiology review,
7326,NCT05216120,Overall response rate of pemigatinib,2022-06-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE V4.0,
7327,NCT00732082,To determine the dose limiting toxicities of IMP321 in patients being treated with gemcitabine for advanced pancreas cancer.,2009-02,TERMINATED,INTERVENTIONAL,['PHASE1'],To evaluate the clinical response and time to disease progression with computed tomography examinations at two month intervals (current standard of care in gemcitabine-treated patients).,
7328,NCT03087071,Response rate,2017-12-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
7329,NCT01288612,Percentage of Subjects Who Agreed to Participated in the Esophageal Assessment,2011-02,COMPLETED,INTERVENTIONAL,['NA'],Acceptability,
7330,NCT04009954,The time ranging from operation day to the day of first defecation,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA'],Concentration of fecal calprotectin,
7331,NCT04978350,Reach of Genetic Testing Among Family Members,2021-10-01,RECRUITING,INTERVENTIONAL,['NA'],Integration of Workbook into Genetic Counselor Work Environment,
7332,NCT05938322,Adherence to the ketogenic diet,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Investigate indices of quality of life,
7333,NCT05181865,Phase 2a (Expansion): ORR (CR + PR) assessed centrally by RECIST v1.1,2022-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1: PK parameters - Half-life (t1/2),Phase 1 (Exploratory): Explore the predictive potential of biomarkers measured in blood and/or tumor tissue in response to FL-301
7334,NCT02857218,Technical feasibility of ultrasmall superparamagnetic iron oxide (USPIO) - magnetic resonance imaging (MRI) of the chest,2018-04-27,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Sensitivity and specificity of PET/CT imaging,
7335,NCT05690451,Accuracy per patient,2021-12-28,RECRUITING,OBSERVATIONAL,['NA'],Sensitivity per patient,
7336,NCT02280070,3-years Disease Free Survival rate,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Pattern of first recurrence,
7337,NCT02393248,Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2,2015-02-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Part 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State),
7338,NCT05742620,3y-DFSR,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],3y-OSR,
7339,NCT00060567,"To determine the Maximum tolerated dose of E7070 in combination with irinotecan in patients with GI tract, pancreatic or lung tumors.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],"Safety, E7070 activity and Pharmacokinetics",
7340,NCT05186402,Overall survival,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7341,NCT02552121,Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events,2015-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Part 2: Duration of Response,
7342,NCT00531245,"In a phase I study, to determine the maximum tolerated dose(MTD) In a phase II study, to evaluate the efficacy(response rates) and toxicities",2006-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","To investigate the time to progression(TTP), overall survival and toxicity",
7343,NCT01539993,Assess efficacy of percutaneous and transarterial treatments for liver cancer.,2008-11,COMPLETED,OBSERVATIONAL,['NA'],long term follow up,
7344,NCT00017056,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7345,NCT06155318,Diagnostic Accuracy,2019-09-05,RECRUITING,OBSERVATIONAL,['NA'],,
7346,NCT00438737,Safety (rate of perioperative safety findings),2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
7347,NCT06187961,Number of Patients Amendable to Curative Surgical Interventions,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of Life (QoL) after treatment,
7348,NCT02278653,Functional outcome,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],Early detection of local failure (standard surgery still possible),
7349,NCT02995096,Overall survival,2016-01,COMPLETED,OBSERVATIONAL,['NA'],Hepatocellular carcinoma specific survival,
7350,NCT05859477,1-year progression-free survival (PFS),2022-06-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity Summary,
7351,NCT04994093,Optimization of pHLA:TCR binding affinity and toxicity,2021-10-06,UNKNOWN,OBSERVATIONAL,['NA'],,
7352,NCT04047173,2-year local progression-free survival rate,2019-08-12,UNKNOWN,INTERVENTIONAL,['NA'],incidence of complications,Radiation-induced liver injury
7353,NCT05833126,Objective Response Rate,2023-12-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Graft Rejection,
7354,NCT02539537,Progression-Free-Survival (PFS),2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of life questionnaire - Core 30 (QLQ-C30),
7355,NCT03859128,BICR-RFS,2019-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of AEs,
7356,NCT02478996,peak oxygen uptake (VO2peak),2015-08,UNKNOWN,INTERVENTIONAL,['NA'],quality of life,feasibility of the online-based sports program
7357,NCT01786694,functional success of microdialysis,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],the quality of life after the surgery,
7358,NCT05790590,lesion conspicuity on portal venous phase,2023-05-30,RECRUITING,INTERVENTIONAL,['NA'],Contrast media (CM) dose,
7359,NCT06030180,Clinical Utility,2023-02-23,RECRUITING,INTERVENTIONAL,['NA'],Patient Compliance,
7360,NCT00335829,Time to Tumor Progression (TTP) of Targeted Lesions,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety and Treatment Toxicity - Cycles 2 and 3,
7361,NCT03235167,metastasis free survival time,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
7362,NCT02940067,Peak power - measured using cardiopulmonary exercise testing,2017-03-28,COMPLETED,INTERVENTIONAL,['NA'],Well-being,
7363,NCT02209441,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
7364,NCT05067374,Adherence to the hepatitis C screening,2022-03-23,RECRUITING,OBSERVATIONAL,['NA'],Care access and prospective care cascade : percentage of cured women,
7365,NCT00760721,Obtaining HBV Screening Test,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Knowledge and Attitudes Regarding HBV Screening,
7366,NCT00249301,The safety of MLN8054 will be based on the continuous monitoring and observation of patients and the collection and evaluation of adverse events and serious adverse events and the assessment of their potential relationship to the study medication.,2005-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7367,NCT03182270,Diagnostic performance of the Cellvizio nCLE system in the characterization of pancreatic cysts,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],Feasibility data on nCLE during EUS-FNA procedure (rate of successful nCLE procedure),
7368,NCT00726037,T-reg Suppression From a Fractionated Dose of Ontak in Patients With Metastatic Pancreatic Cancer,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Optimal Time for Future Dendritic Cell Vaccine Administration,
7369,NCT05426811,Progression-free Survival (PFS),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence and severity of adverse events (AE) and serious adverse events (SAE),
7370,NCT02886104,Overall survival,2016-08,RECRUITING,INTERVENTIONAL,['NA'],Complete ablation rate in CRLM,
7371,NCT02883790,Quality of sleep assessed using the PSQI scale,2015-10,TERMINATED,INTERVENTIONAL,['NA'],Quality of Life evaluated according to SF-12 scale,Number and typology of adverse events
7372,NCT01555762,Progression-Free Survival,2012-03-05,COMPLETED,OBSERVATIONAL,['NA'],Percentage of Participants With Balducci Score,
7373,NCT01181245,To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Maximal tumor response as determined by RECIST criteria,
7374,NCT00513851,Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of OSI-930,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1'],"Safety, Pharmacokinetic profile, Pharmacodynamic relationships, Preliminary antitumor activity",
7375,NCT03186898,Overall Survival (OS),2017-06-22,RECRUITING,INTERVENTIONAL,['PHASE3'],Exploratory - Overall Quality of Life (QOL),
7376,NCT00075465,Time to tumor progression,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Tolerability,
7377,NCT01993784,Objective response rate,2013-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",adverse events,
7378,NCT00253370,The Proportion of Patients With Objective Response (Complete Response or Partial Response),2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
7379,NCT05844371,The 1-year DFS rate,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7380,NCT01362127,Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia.,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],HRQOL and Swallowing Function,
7381,NCT01013649,Overall survival (Phase III),2010-04-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Changes in fatigue,
7382,NCT01423734,reproducibility of diffusion weighted imaging for neuroendocrine liver metastases.,2011-08-23,COMPLETED,OBSERVATIONAL,['NA'],evaluate the reproducibility perfusion insensitive diffusion coefficients (ADC high) of liver metastases,
7383,NCT04924179,Progression-free survival (PFS),2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],AEs,
7384,NCT04189393,"Compositional changes of the oral and gut microbiome, assessed by alpha-diversity using 16S rRNA (ribosomal ribonucleic acid) sequencing, described in a surgical patient journey from moment of diagnosis until full recovery",2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],"Compositional changes of the oral and gut microbiome, assessed by beta-diversity using 16S rRNA sequencing, correlated to the development of infectious complications (30-day)",
7385,NCT02829918,Overall Response Rate (ORR) After 4 Cycles of Treatment,2016-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),
7386,NCT00025441,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7387,NCT03734952,overall survival,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],Side effects,
7388,NCT04051450,Generation of candidate biomarkers PD-L1/PD1/GEP by laboratory assay qPCR for prognostication.,2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
7389,NCT00955097,identification of liver tumors,2008-05,TERMINATED,INTERVENTIONAL,['PHASE1'],improved ablation of liver tumors,
7390,NCT01429961,Time to progression (TTP),2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],toxicity,
7391,NCT05178303,The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis (Arm 1),2015-11-30,COMPLETED,INTERVENTIONAL,['NA'],The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis/Hcc (Arm 2),
7392,NCT02189421,Technical success of the direct peroral cholangioscopy,2014-04,UNKNOWN,INTERVENTIONAL,['NA'],Adverse events associated with direct POC,
7393,NCT04208958,Objective Response Rate (ORR),2020-01-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of VE800 Bacterial Strain Colonization in Stool,
7394,NCT02928627,presence of miR-221 and mR-222 in the blood,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA'],correlation of expression of miR-221 and miR-222 in tissue and blood samples,
7395,NCT02213419,Rate of Subjects with Complete or Partial response of treatment,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],Incidence rate of adverse events after treatment,
7396,NCT01462994,"Percentage of patients with histologically proven GIST, measurable lesion in imaging and activating CKIT and PDGFRA mutation, where detection of tumor specific DNA encoding for mutated CKIT or PDGFA is possible in the plasma at least at one timepoint",2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7397,NCT01364493,Objective response rate,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],adverse events,
7398,NCT05800561,predictive accuracy of HVPG and ICG-r15 on PHLF,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
7399,NCT06029829,Compare Progression Free Survival (PFS) Regimen using RECIST 1.1.,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7400,NCT02494037,Survival,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],Qualitative Experience of Care (QEC),
7401,NCT03846726,PFS,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],OS,
7402,NCT03775525,Dose-limiting toxicity,2019-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Apparent Volume of Distribution (Vd/F),
7403,NCT05608044,Objective Response Rate,2022-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants Positive for Balstilimab Anti-drug Antibodies Following Treatment with Balstilimab,
7404,NCT03151564,Metastasis Detection Accuracy,2017-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7405,NCT04941287,Progression free survival (PFS),2021-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Immunogenicity,Tumor microenvironment modulation and immunologic response
7406,NCT00415168,Percentage of Participants With Objective Response (Objective Response Rate),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Who Died During the Study,
7407,NCT02664974,Maintenance of body weight,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Improvement of tolerance to chemotherapy,
7408,NCT02963207,Accuracy measures in comparison to the final histopathology in regards to polyps' subtype (SSA/P versus non-SSA/P),2013-06,COMPLETED,INTERVENTIONAL,['NA'],Agreement in predicting post-colonoscopy surveillance interval with final histopathology,
7409,NCT02208804,Posttreatment tumor to non-tumor activity concentration ratio on SPECT/CT,2014-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Clinical and laboratory toxicity,
7410,NCT04384575,Specificity,2020-02-22,COMPLETED,OBSERVATIONAL,['NA'],,
7411,NCT02726334,Maximum Tolerated Dose,2016-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7412,NCT00660140,To determine the response rate and time to failure for patients treated with this regimen,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival times,
7413,NCT00215982,response rate,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],toxicity and tolerability,
7414,NCT04106024,PFS,2018-10-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7415,NCT05421702,Type of anastomosis,2022-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Preoperative colonoscopic examination result,
7416,NCT05199168,Incidence of the recurrent laryngeal nerve injury,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],Operation time (thoracic phase),
7417,NCT04721132,Incidence of adverse events (AEs),2021-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
7418,NCT05561699,safety（AE or SAE）,2022-09-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Disease free survival（DFS）,
7419,NCT04091165,Acceptability of Smart Phone Application,2019-09-23,COMPLETED,OBSERVATIONAL,['NA'],Adherence to Recommended Nutritional Plan,
7420,NCT05704985,"Incidence of Adverse Events (AE) of DK210 (EGFR) in combination with radiation, chemotherapy, or checkpoint blockers in Parts B, C, D",2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE1'],"Serum concentrations of proinflammatory cytokines such as IL-6, IL-10, TNFa, IL-1b, and interferon (IFN)-g will be assessed at various time points",
7421,NCT00123851,"To determine the response rate of OSI-774 when given in combination with oxaliplatin and capecitabine in patients with previously-treated locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma",2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"To evaluate the toxicities of the combination of OSI-774, oxaliplatin and capecitabine in this population of patients with colorectal cancer",
7422,NCT02486601,Complete pathological response rate,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Assessment of genetic polymorphism involved in tumor-response when appropriate,
7423,NCT00051688,,2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7424,NCT01917617,Completion rate during the 12 weeks in the short hydration group,2013-05-22,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
7425,NCT03914950,Participants With Increased Tracer Uptake Over the Pancreatic Lesion With and Without TOF,2014-02-07,COMPLETED,INTERVENTIONAL,['NA'],Lesion Size,
7426,NCT05044728,Immune Related Adverse Events (irAEs),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],2-year survival rate,
7427,NCT01828047,Postoperative ileus symptoms; microvascular flow index (MFI),2013-11,COMPLETED,OBSERVATIONAL,['NA'],,
7428,NCT06178445,ORR,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"The incidence, nature, causality, seriousness, and severity of adverse events using NCI CTCAE 5.0",
7429,NCT00508573,Number of Women Participating in Registry,2007-05,RECRUITING,OBSERVATIONAL,['NA'],,
7430,NCT04037787,Length of stay,2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],Healthcare costs,
7431,NCT05980403,Lymphatic metastases,2023-07-18,RECRUITING,OBSERVATIONAL,['NA'],,
7432,NCT01629524,Association between immune related cytokine and number of lymph nodes retrieved.,2012-06,COMPLETED,OBSERVATIONAL,['NA'],,
7433,NCT00835679,Patients With a Biologic Response,2009-12,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Number of Patients With the Given Severity of Post-operative Complications Within the Specified Duration,
7434,NCT01929499,DFS (Disease free survival),2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],QoL (quality of life),
7435,NCT05470452,AFROC-AUC,2021-07-28,RECRUITING,INTERVENTIONAL,['NA'],Cancer Identification Diagnosis Compliance Rate,
7436,NCT05678218,Lymph nodes identified compared to surgery,2022-09-05,RECRUITING,OBSERVATIONAL,['NA'],Short term and long term complications of the EUS (+/- tissue acquisition) procedure for patients with pCCA and iCCA,
7437,NCT00830557,Collection of information regarding food preparation and intake by survey,2000-10,RECRUITING,OBSERVATIONAL,['NA'],,
7438,NCT04799431,Number of participants experiencing study drug-related toxicities,2023-05-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
7439,NCT05576571,Evaluate efficacy (methylation profiling results),2020-10-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7440,NCT04644068,"The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.",2020-11-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Module 6: To evaluate the effect of AZD5305 on the PK of Camizestrant.,
7441,NCT00566800,Histologic regression of Barrett esophagus with high-grade dysplasia by chemoprevention with erlotinib hydrochloride,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],Toxicity,
7442,NCT04473677,The accuracy of the new qFIT to diagnose colorectal advanced adenoma.,2020-08-17,COMPLETED,OBSERVATIONAL,['NA'],Develop a predictive model of advanced colorectal neoplasms which includes the value of qFIT.,
7443,NCT03328065,Type of determinants which are privileged by the patients to choose a treatment,2017-12-19,TERMINATED,OBSERVATIONAL,['NA'],,
7444,NCT02140034,Overall Survival,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],Peritoneal Recurrence Rate,
7445,NCT02269683,R1 resection rate,na,WITHDRAWN,INTERVENTIONAL,['NA'],,
7446,NCT06123637,Remifentanil requirement,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7447,NCT00534664,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7448,NCT05487443,Progression free survival (PFS),2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall survival (OS),
7449,NCT04722133,Objective response rate (ORR),2020-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of treatment related adverse events (TRAE),
7450,NCT03069599,Immunological outcome,2017-02-15,TERMINATED,OBSERVATIONAL,['NA'],Cancer specific survival,
7451,NCT01289028,Percent of Patients Achieving Complete Response (CR),2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression Free Survival (PFS) of the Patients Who Were Included Due to an Intolerability of a Prior Treatment.,
7452,NCT03977090,"Extended period recommended dose,RDE",2019-04-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],"Antidrug antibody, ADA",
7453,NCT05744362,Overall survival,2022-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
7454,NCT05833971,pathologic complete response (pCR),2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease-free survival(DFS),
7455,NCT03010813,Perioperative complications,2016-12,COMPLETED,INTERVENTIONAL,['NA'],Voice function after TORS,
7456,NCT01458509,feasibility of electronic PRO assessment,2011-10-11,COMPLETED,OBSERVATIONAL,['NA'],problems people experience,
7457,NCT04270929,Safety of oxaliplatin PEDD-PRVI: maximum tolerable dose (MTD),2019-12-23,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Serologic response rates (CA 19-9),
7458,NCT04334395,Complication rate,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],The survival time,
7459,NCT00006112,,1996-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7460,NCT00116506,Evaluate 1 year progression-free survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],"Determination of the observed response rate, median duration of response and overall survival",
7461,NCT03281070,Anastomotic leakage,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7462,NCT00960557,To determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],To determine progression-free survival (PFS).,
7463,NCT03285230,Health outcomes,1990-06-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7464,NCT05893667,Overall survival Disease-free survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],Pathological response through Ryan Tumor Regression Grade,
7465,NCT02829359,HBV reactivation on the recovery of liver function,2012-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7466,NCT04967482,Success rate of conversion to resection,2021-07-09,RECRUITING,INTERVENTIONAL,['NA'],Overall survival (OS),
7467,NCT00419627,,2007-02,UNKNOWN,OBSERVATIONAL,['NA'],,
7468,NCT00003220,,1998-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7469,NCT02025036,OS-2 year,2014-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],pathologic complete response rate,
7470,NCT03475953,Phase II (cohort A'): Assessment of the antitumor activity of regorafenib,2018-05-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II (cohort B): assessment of the antitumor activity of regorafenib,
7471,NCT04813406,Overall survival(OS),2021-03,UNKNOWN,INTERVENTIONAL,['NA'],Disease Control Rate (DCR),
7472,NCT01776307,Disease Control Rate,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Adverse Events and Serious Adverse Events,
7473,NCT02920944,single diagnostic yield of the histologic core,2016-07,COMPLETED,INTERVENTIONAL,['NA'],total diagnostic yield of the histologic core,
7474,NCT05400122,Persistence of donor NK cells,2022-09-09,SUSPENDED,INTERVENTIONAL,['PHASE1'],Clinical Response,
7475,NCT03516942,Change in level of self-reported financial burden,2018-06-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Change in level of self-reported financial burden,
7476,NCT02113683,active tumor growth before and after cancer therapy,2014-05,TERMINATED,OBSERVATIONAL,['NA'],,
7477,NCT03717935,Change in Hepatic Fat Fraction,2018-10-08,COMPLETED,INTERVENTIONAL,['NA'],Change Bile Acid Metabolomics: sphingosine-1-phospate,
7478,NCT02116894,Recommended phase II dose (RPTD) for the combination of PF-03446962 plus regorafenib,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression free survival associated with PF 03446962 plus with regorafenib,
7479,NCT01216813,Patients' opinion of how to manage any of the issues that arise,2010-08,COMPLETED,OBSERVATIONAL,['NA'],Theories and a hypothesis from data collected for use in a future interventional study,
7480,NCT00109226,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7481,NCT01677884,Efficiency of treatment based on objective response rate,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Hepatic metastasis resection rate,Total area under the curve of contrast-enhanced liver ultrasound
7482,NCT03340974,Radiographic Stable Disease (SD) or Better Based on RECIST Criteria,2018-02-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7483,NCT04204577,Progression-Free-Survival(PFS),2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life score(QOL),
7484,NCT02125409,Assessment of the degree of COX-1 acetylation by ASA administered for 1 week.,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Change from baseline in eicosanoid biosynthesis and protein expression of markers of growth and progression of colorectal cancer (such as COX-2, NF-Kb and PI3K/Akt/mTOR pathway).",
7485,NCT03732105,"Recurrence Free Survival,RFS",2019-03-06,RECRUITING,INTERVENTIONAL,['NA'],health related quality of life,
7486,NCT02017002,Overall survival duration,2014-03,UNKNOWN,INTERVENTIONAL,['NA'],Change of lung function after surgery,
7487,NCT00353457,Pathologic complete response,2006-02,TERMINATED,INTERVENTIONAL,['PHASE2'],Disease free survival,
7488,NCT04995809,Reason for attrition,2021-06-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],The number of participants required to take part in a larger multicentre trial which will identify potential therapeutic targets from metabolomic and microbiomic profiling,Microbiomic profiling by bacterial 16S rRNA metabarcoding sequencing
7489,NCT00320749,Maximum Tolerated Dose (MTD),2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Therapeutic Response,
7490,NCT02630056,the grade of acute hematologic toxicity,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,
7491,NCT03975491,Interleukin-6,2019-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Circulating Tumor Cells,Tumor Fraction
7492,NCT05633641,ORR,2022-10-19,RECRUITING,OBSERVATIONAL,['NA'],,
7493,NCT00357422,overall survival rate,2005-10,COMPLETED,INTERVENTIONAL,['NA'],disease free survival rate and recurrence rate,
7494,NCT05704010,Small bowel adenoma,2018-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
7495,NCT03460769,"Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",2017-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
7496,NCT04895709,Incidence of AEs leading to death,2021-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival rate (PFSR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator,
7497,NCT03671265,"Adverse events (AE), Serious Adverse Event(SAE) Adverse events",2018-09-17,UNKNOWN,INTERVENTIONAL,['NA'],OS,
7498,NCT02033538,response rate,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse events,
7499,NCT00536809,Overall Response in Phase II,2007-09-26,COMPLETED,INTERVENTIONAL,['PHASE1'],"Change From Baseline to Study Completion in Aspartate Aminotransferase, Alanine Aminotranferease, and Alkaline Phosphatase",
7500,NCT03184493,Number of participants with tumor recurrence,2017-06-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7501,NCT06206876,CL/F,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,
7502,NCT05687617,Number of patients with peritoneal metastases detected only with ICG.,2022-12-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7503,NCT01766349,"Changes of respiratory muscle performance (MIP/MEP, PFT)from baseline",2011-09,COMPLETED,OBSERVATIONAL,['NA'],Total length of hospital stay,
7504,NCT01727908,The percentage of increasement of endoscopic detection of (pre)malignant for gastric cancer by staining of the gastric mucosa.,2012-11,TERMINATED,INTERVENTIONAL,['NA'],"To determine the psychosocial impact of the screening protocol in this population, measured as the amount of stress and anxiety by use of the Hospital Anxiety and Distress Scale and the amount of cancer-worry by use of the Cancer Worry Scale.",
7505,NCT05535894,Concomitant Analgesic/Narcotic Use,2022-08-10,RECRUITING,OBSERVATIONAL,['NA'],,
7506,NCT00444678,Response Rate for the Combination Treatment,2004-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival,
7507,NCT00522795,Complete Pathologic Response,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7508,NCT03620916,Severity of pain at rest,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative complications,
7509,NCT04911517,pathologic complete response（pCR）,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],3-year overall survival (OS),
7510,NCT00384800,To assess the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma.,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],To evaluate the changes of circulating factors indicating the angiogenesis activity and their correlation with objective tumor response.,
7511,NCT04541875,To use the MAR-Scale to identify the top patient-reported reasons for non-adherence to specific medications indicated to treat these rare diseases.,2021-01,WITHDRAWN,OBSERVATIONAL,['NA'],To perform psychometric analysis of the MAR-Scale questionnaire based on data collected from rare disease patients.,
7512,NCT04574050,Feasibility: the number of patients recruited into this study over a 12-month period,2021-01-11,COMPLETED,INTERVENTIONAL,['NA'],,
7513,NCT05257590,Objective Response Rate (ORR)_mRECIST,2022-05-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Pharmacodynamics analysis for the relationship of AUC and AE,
7514,NCT01155882,To determine range of morbidity and mortality,2010-09-20,COMPLETED,OBSERVATIONAL,['NA'],Effect of occlusion of the splenic vein at the confluence.,
7515,NCT04151719,Overall Survival,2020-02-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
7516,NCT03170310,Progress free survival,2017-02-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
7517,NCT05429697,Progression Free Survival,2022-06-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of Life,
7518,NCT06041490,EFFICACY: One-year recurrence-free survival rate (1-year RFS rate),2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],SAFETY: Incidence of adverse events and serious adverse events,
7519,NCT03050879,Total Number of Retrieved Lymph Nodes,2017-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],3-year overall survival rate,
7520,NCT03611309,Patient quality of life,2018-09-25,COMPLETED,INTERVENTIONAL,['NA'],Caregiver prognostic awareness assessment,
7521,NCT00005591,,1999-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
7522,NCT00662688,Thromboembolic events,2007-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Tolerance of regimens,
7523,NCT05400915,(Phase II) Progression-free survival,2019-07-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Adverse Events That Are Related to Treatment,
7524,NCT03130712,Safety of CAR-T cell infusion mediated by intratumoral injection as measured by number of participants with adverse Events,2017-04-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Serum cytokine levels,
7525,NCT04595266,Objective response rate (ORR),2021-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of patients with liver surgery,
7526,NCT03554395,Objective response rate,2018-04-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Symptom remission rate,
7527,NCT05775120,"To assess the state of the gastric mucosa according to endoscopic and morphological studies using the OLGA system, and their correlation with serological markers of atrophy",2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],To determine the prevalence of H. pylori in the Moscow population according to the serological method - level of IgG antibodies to H.pylori.,Develop recommendations for GC prevention and early detection strategy.
7528,NCT03408665,SBRT efficiency in term of L-PFS for patient who are to be treated with SBRT in patients with primitive hepatic tumor of hepatic metastatis,2019-03-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Estimate the impact of the different SBRT techniques on SBRT efficacy according to OS.,
7529,NCT05759975,Oral Mucositis evaluation according NCI scale,2023-01-13,RECRUITING,INTERVENTIONAL,['NA'],Saliva analysis,
7530,NCT03738280,Lesion borders (smooth or irregular),2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
7531,NCT05263219,Overall survival (OS),2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse Events (AEs),
7532,NCT00183807,To assess the time to progression of CPT-11 and cisplatin in combination with celebrex in patients with metastatic or unresectable carcinoma of the esophagus,2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],"To evaluate the effects of celebrex on a variety of histological and molecular biomarkers of angiogenesis, including in vitro activity assays on endothelial cell proliferation, migration and invasion.",
7533,NCT01661114,The Percentage of Untreated and Previously Treated Patients That Had a Partial Response to Treatment,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival of Previously Treated and Previously Untreated Patients,
7534,NCT02144727,overall survival,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Finding biomarkers predicting lymph node metastasis and recurrence,
7535,NCT03881111,OS in PD-L1 biomarker-positive participants,2019-01-21,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Change from baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Score,
7536,NCT03618758,Overall survival (Phase 2),2018-12-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Conversion surgery ratio,
7537,NCT05629442,Rate of successful pathologic complete response,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Overall Survival (OS),
7538,NCT03435770,To measure side effects and adverse event of EUS-guided RFA,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7539,NCT02504229,Progression free survival,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7540,NCT00274885,Relationship between residual platinum levels in the blood and persistent neurotoxicity,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],Pharmacokinetics,
7541,NCT00002759,,1996-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7542,NCT02040142,Evaluate the technical parameters,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival,Patient Reported Outcomes
7543,NCT02162823,Survival,2007-05,COMPLETED,OBSERVATIONAL,['NA'],Factors influencing survival,
7544,NCT02307500,"activity of regorafenib screening, in terms of 2-months progression free survival rate",2014-12,COMPLETED,INTERVENTIONAL,['PHASE2'],safety profile of regorafenib according to NCI-CTC v.3,
7545,NCT00094861,Number of Participants With Grade 2 or Higher Dysphagia,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Maximal Body Weight Loss,
7546,NCT05970900,Organ preservation,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Anorectal function,
7547,NCT04918992,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system in prediction radiation proctitis,2021-06-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The specificity of AI prediction system in prediction radiation proctitis,The sensitivity of AI prediction system in prediction the radiation proctitis candidates
7548,NCT04688242,Major LARS at 1 years after proctectomy,2021-02-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],Other complications within 1 years after proctectomy,
7549,NCT05278260,Number of participants who develop grade 3 oropharyngeal mucositis,2022-05-25,RECRUITING,INTERVENTIONAL,['NA'],,
7550,NCT00044512,Percentage of Participants for Each Type of Response,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
7551,NCT02787954,Time to progression,2016-01,TERMINATED,OBSERVATIONAL,['NA'],1 year survival,
7552,NCT05592197,Overall Survival (OS),2018-10-01,WITHDRAWN,INTERVENTIONAL,['NA'],ncidence of Adverse Events (AE),
7553,NCT01570075,overall survival,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],disease-free survival,
7554,NCT04559139,Difference in overall survival,2021-02-24,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Difference in progression-free survival,
7555,NCT01096914,Tumor response,2009-01,COMPLETED,INTERVENTIONAL,['NA'],time to local recurrence,
7556,NCT00501306,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],,
7557,NCT02512237,Maximum tolerated dose of ARX788,2016-03,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of subjects developed anti-ARX788 antibody,
7558,NCT00410579,"Comparison of patient-reported outcomes prior to randomization, 1 year after completion of study treatment, and in long-term follow up > 5 years after diagnosis in patients treated in NSABP C-06 or NSABP C-07 trials",2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
7559,NCT04905082,Recall rates of personal genomic results,2021-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Operationalization of contextual guideline concordant care,HOPE-Genomics tool usage
7560,NCT02431715,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
7561,NCT00002533,,1993-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7562,NCT00178763,"Tumor response, disease-free survival",2003-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Allow inoperable pancreatic cancer to be converted to operable disease,
7563,NCT06011772,Immunogencity of vaccine,2023-12-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Progression free survival,
7564,NCT04075305,Toxicity in common toxicity criteria for adverse events (CTCAE).,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
7565,NCT03356158,Incidence of Adverse Events [AEs],2017-11-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],Cancer antigen [CA19-9],
7566,NCT05867810,nutrition assessment,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],Biochemical data,
7567,NCT02843945,Safety of CivaSheet Radiation Treatement,2017-05-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Length of Hospital Stay,
7568,NCT02837159,Body Mass Index,2016-10,WITHDRAWN,INTERVENTIONAL,['NA'],Lower-body flexibility,
7569,NCT02240212,Assessment of PR (vital signs) in Phase I Dose Escalation,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Assessment of composite pharmacokinetics of afuresertib and paclitaxel in expansion cohort,
7570,NCT01673269,the frequency of bacteremia after ERCP with direct cholangioscopic examination of the CBD,2012-07,COMPLETED,INTERVENTIONAL,['NA'],To measure the frequency of fever or sepsis after ERCP with direct cholangioscopic examination of the CBD,
7571,NCT01336985,To determine the safety of hepatic chemoembolization with drug-eluting beads containing 100mg of irinotecan,2011-03-28,TERMINATED,INTERVENTIONAL,['PHASE1'],To determine the serum pharmacokinetics and tumor tissue concentrations achieved following hepatic chemoembolization with irinotecan-eluting beads,
7572,NCT04792684,Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing,2020-12-30,RECRUITING,OBSERVATIONAL,['NA'],,
7573,NCT02840890,episode of nausea and / or vomiting,2015-11-05,COMPLETED,INTERVENTIONAL,['NA'],Quality of life questionnaire(QLQ-C30),
7574,NCT00758186,The primary endpoint was postoperative complication rates.,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],"Secondary outcomes evaluated included type of surgery performed, bowel preservation, presence of a stoma, postoperative bowel function, length of hospital stay, and hospitalization costs.",
7575,NCT04466592,general quality of life,2019-12-13,COMPLETED,INTERVENTIONAL,['NA'],Number of participants maintaining their social activities,
7576,NCT03929666,Objective response rate (ORR) (Part 2),2019-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of lab abnormalities (Part 2),
7577,NCT03033225,Tumor response,2016-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7578,NCT05452668,Pain Assessment,2023-05-16,RECRUITING,INTERVENTIONAL,['NA'],Oral Mucositis Severity:,
7579,NCT01120288,Determine the modulation of HIF-1 alpha mRNA in tumor biopsies pre- and post- administration of EZN-2968.,2010-04-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Assess the safety of EZN-2968 in patients with liver-predominant solid tumors. Determine the modulation of HIF-1 alpha protein levels in tumor biopsies pre- and post-administration of EZN-2968.,
7580,NCT04966611,OS,2021-07-15,RECRUITING,OBSERVATIONAL,['NA'],PFS,
7581,NCT05965921,Number of additional Barrett's neoplasia found on quadrantic biopsies,2023-07-26,RECRUITING,OBSERVATIONAL,['NA'],Impact of AI (WISE VISION) in real-life,
7582,NCT03585530,Overall survival(OS),2018-09-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life(QOL),
7583,NCT02082782,Efficacy,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7584,NCT05929885,The Grade 3-5 Toxicity Rate.,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS).,
7585,NCT00525655,Pilot Test FAP Website (Interviews),2007-08,COMPLETED,INTERVENTIONAL,['NA'],Participant Assessment of FAP Website (Questionnaire),
7586,NCT00199277,Preoperative variations in hemoglobin.,na,UNKNOWN,INTERVENTIONAL,['PHASE4'],Length of hospital stay,
7587,NCT02560779,Overall Response Rate (ORR),2016-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",TRC105 Immunogenicity as Assessed by Anti-Product Antibody (APA),
7588,NCT04739072,Detection of recurrences post completion of curative therapies,2019-11-22,RECRUITING,OBSERVATIONAL,['NA'],Overall survival (OS),"Nature and frequency of detection of incidental non-colorectal cancer related DNA, RNA and / or proteomic alterations"
7589,NCT04192929,Adenomas per colonoscopy,2023-09,WITHDRAWN,INTERVENTIONAL,['NA'],Inspection time,
7590,NCT00835185,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response ),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Kirsten Rat Sarcoma (KRAS) Mutation Status,
7591,NCT00258297,Effect on the signaling pathways by immunohistochemistry after 2-3 weeks of exposure to gefitinib,2004-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7592,NCT06218511,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2022-11-22,RECRUITING,INTERVENTIONAL,['PHASE1'],OS,Assessment of the potential impact of the standard therapy on the natural immune response to peptides contained in IMA970A
7593,NCT00100841,Progression Free Survival Rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7594,NCT01521780,Expression Levels of Beta-catenin Protein From Core Needle Biopsy (CNB) Equivalents of Resected HCC.,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1'],Expression Levels of Low Density Lipoprotein Receptor (LDL-R) in Resected HCC and Adjacent Liver From Whole Tissue Sections.,
7595,NCT03680261,3-year Overall Survival,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse effect (Safety and Tolerability),
7596,NCT03460080,PIVKA-II,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Prothrombin Time (PT) (%),
7597,NCT03097224,Change in cardiorespiratory fitness,2017-04-04,UNKNOWN,INTERVENTIONAL,['NA'],Adherence,
7598,NCT03593681,Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement,2018-08-27,COMPLETED,OBSERVATIONAL,['NA'],"Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy for Subject Level Analysis",
7599,NCT00188305,Colon screening behaviour,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Satisfaction,
7600,NCT01726465,A decrease of 100 UI/L of AST and ALT compared with placebo.,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Difference in blood transfusions.,
7601,NCT00526110,Progression Free Survival,2004-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median Overall Survival,
7602,NCT01570452,,2005-09,COMPLETED,OBSERVATIONAL,['NA'],,
7603,NCT00561548,Relative variation (%) in apoptotic cells calculated according to the formula: (% of induced apoptotic cells) - (% of spontaneous apoptotic cells),2007-05,TERMINATED,INTERVENTIONAL,['NA'],Lymphocyte activation markers and macrophage activation markers,
7604,NCT03594188,cell proliferation,2018-07-23,COMPLETED,INTERVENTIONAL,['NA'],cell metastasis,
7605,NCT05909423,Pathological response,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Analysis of perturbations in the immune activity with a focus on effector and memory CD8+ T cells,
7606,NCT01696695,PFS by Therapeutic Regimens,2011-07,COMPLETED,OBSERVATIONAL,['NA'],Percentage of Participants With Dose Modification of Capecitabine,
7607,NCT01277120,Correlation of the time from the start of chemotherapy to the start of Avastin treatment with progression-free survival,2010-04,TERMINATED,OBSERVATIONAL,['NA'],Safety: Incidence of adverse events,
7608,NCT00661154,Determine whether[18F]-5-Fluorouracil PET/CT scanning can demonstrate a difference in [18F]-5-Fluorouracil tumor uptake before and after the administration of Avastin,2008-02,COMPLETED,OBSERVATIONAL,['NA'],Determine if [18F]-5-Fluorouracil PET/CT imaging demonstrates that there is a difference in maximal [18F]-5-Fluorouracil tumor uptake that is dependent on the time point of post-Avastin scanning,
7609,NCT00909558,Is there any measurable effect upon the underlying cancer as assessed by an increase or decrease in the tumor as measured from baseline using established criteria?,2009-05,SUSPENDED,INTERVENTIONAL,['PHASE1'],"Are the dosages administered during the study safe, as measured by the number of unexpected and serious adverse events associated with the study drug, as defined by FDA regulations and as measured by established criteria?",
7610,NCT00332943,Sensitivity of VAS score vs. ReCon score,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
7611,NCT02316535,disease free survival,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],quality of life,
7612,NCT01116687,Number of Participants With Objective Radiographic Response (ORR),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Related Serious Adverse Events (SAEs),
7613,NCT00661167,Overall response rate,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease control rate,
7614,NCT01034332,To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT,2007-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7615,NCT02932956,Number of Patients with Dose Limiting Toxicity,2018-12-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Median T cell persistence,
7616,NCT00020605,,2000-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7617,NCT01727388,realization of a full digital rectal examination,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Evaluation of the position by the patient,
7618,NCT03046979,Objective Response Rate(ORR),2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events [Safety],
7619,NCT02651415,Number of Participants That Have Any Grade HFSR Toxicity,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Time to Progression Free Survival (PFS),
7620,NCT04926376,Overall Response Rate (ORR) by mRECIST,2021-11-02,COMPLETED,INTERVENTIONAL,['NA'],,
7621,NCT02726854,ORR (Objective response rate),2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by NCI-CTC（V3.0）,
7622,NCT04124601,Incidence of treatment-emergent adverse events (safety and tolerability),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Pathologic therapy response to neoadjuvant treatment,
7623,NCT01925274,Progression Free Survival (PFS) as Assessed by Investigators,2013-11-15,TERMINATED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Functional Assessment of Cancer Therapy-Colorectal (FACT-C),
7624,NCT02532478,Stoma closure rate,2007-02,COMPLETED,OBSERVATIONAL,['NA'],,5-year overall survival
7625,NCT00829465,OS of 1 years; TTP,2008-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
7626,NCT04188145,The Time-to-Treatment Failure (TTF),2020-01-27,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life (QoL),
7627,NCT05782465,Gastric Cancer,2019-08-23,RECRUITING,OBSERVATIONAL,['NA'],,
7628,NCT04418895,complete pathologic response (pCR) rate,2021-08-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Median Neoadjuvant Rectal Score (NAR),
7629,NCT06282016,Asthma,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Area deprivation,
7630,NCT01918527,Two-year disease free survival,2013-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Rate of patients fulfilling the criteria for adjuvant chemotherapy,
7631,NCT02785835,Overall survival,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,
7632,NCT05733611,Objective Response Rate (ORR),2023-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Complete Response Rate,
7633,NCT03719573,30-second chair stand test (30s-CST),2019-02-21,COMPLETED,INTERVENTIONAL,['NA'],doses of adjuvant chemotherapy,
7634,NCT00461708,Overall Survival (OS) During the Study,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Disease Control According to RECIST,
7635,NCT03042000,3y-DFS,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],pCR,
7636,NCT04527939,"Degree of parietal invasion (T),",2020-08-07,UNKNOWN,INTERVENTIONAL,['NA'],,
7637,NCT03648073,Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET,2019-01-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7638,NCT00942266,Disease Control Rate (Stable Disease or Objective Response),2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Fluorouracil Steady-state Pharmacokinetics,
7639,NCT03935763,Overall survival,2019-03-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Quality of life using Patients Reported Outcomes,
7640,NCT00005648,Overall survival of patients with advanced pancreatic cancer after treatment with gemcitabine with or without R115777.,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],The incidence of adverse events with respect to severity and relationship to the study medication as a measure of safety,
7641,NCT00623077,Maximum tolerated dose of tomotherapy up to 12 Gy,2005-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Disease-Free Survival,
7642,NCT01244022,Postoperative changes of serum cytokine levels,2010-08,COMPLETED,OBSERVATIONAL,['NA'],Early postoperative complications,
7643,NCT00003172,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7644,NCT04749381,Postoperative complications,2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],Length of hospital stay,
7645,NCT00565487,To determine optimal dosage for Capecitabine and Tarceva combination in the setting of radiation.,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],To assess treatment efficacy and overall survival.,
7646,NCT00517621,Validation of a french version of FACT-GOG/NTX of peripheral neurotoxicity questionnaire,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],- Incidence of the thrombo-embolic events according to whether the patients are treated or not by EPO,
7647,NCT02951273,Changes in Internal Carotid Artery Blood Flow by Treatment of Anaesthesia-induced Hypotension,2016-12-08,COMPLETED,OBSERVATIONAL,['NA'],Changes in Stroke Volume From Baseline Before Induction of Anaesthesia.,
7648,NCT02292173,Maximum Tolerated Dose (MTD),2015-02-18,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
7649,NCT00652587,overall survival rates,2002-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7650,NCT06129812,Overall survival,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,
7651,NCT00975897,Efficacy of IrMdG with vs without bevacizumab in K-ras mutant tumors,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Attitudes of patients about tests and treatment,
7652,NCT00935779,,2002-10,COMPLETED,OBSERVATIONAL,['NA'],,
7653,NCT01164215,Achievement of targeted AUC using pharmacokinetic (PK)-guided 5 fluorouracil as part of mFOLFOX6 therapy,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Toxicity differences between PK-guided therapy versus non-PK-guided therapy,
7654,NCT06042842,(1) To evaluate the clinical utility of plasma circRNAs (hsa_circ_0004001)by Q-PCR as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders,2023-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7655,NCT05126290,Number of CTNNA1 genotypes associated with a cancer phenotype,2021-03-16,RECRUITING,OBSERVATIONAL,['NA'],,
7656,NCT00005871,,1998-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7657,NCT01497392,"Overall safety profile characterized by type, frequency, severity (according to National Cancer Institute [NCI] CTCAE version 4.0), timing, seriousness and relationship to study treatment",2012-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacodynamic effects of dovitinib lactate and Gem-Cap combination on vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptors (FGFR) dynamics in serum and tumor specimens,
7658,NCT03451773,Duration of Treatment-related Adverse Events (AEs),2018-05-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Progression Free Survival,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
7659,NCT02735057,maximum tolerated dose (MTD),2016-04-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",overall survival,
7660,NCT02862704,Number of patients with adverse event,2016-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Detection of transferred T cells in the circulation using quantitative -PCR,
7661,NCT02777801,Incidence of hepatitis B virus associated hepatitis,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Interruption of chemotherapy due to hepatitis,
7662,NCT01534923,describe doctor-patient communication about CRC screening,2012-02-07,COMPLETED,OBSERVATIONAL,['NA'],examine the association between the quality of doctor-patient communication about CRC screening and low-income patients' screening outcomes,
7663,NCT01989000,"Predictive value of pretreatment DWI, DCE-MRI, T2*, and 18F-HX4-PET/CT on overall survival in patients with pancreatic cancer treated with surgery and adjuvant chemotherapy or with neoadjuvant radiochemotherapy, surgery and adjuvant chemotherapy.",2013-11,COMPLETED,INTERVENTIONAL,['NA'],Immunohistochemically determined parameters of the tumor microenvironment assessed in a pretreatment tumor biopsy to predict overall and recurrence-free survival,Immunohistochemically determined parameters of the tumor microenvironment assessed in pretreatment tumor biopsies and post-surgery resection material correlate
7664,NCT00961077,To evaluate response rate of attenuated SOX as first-line chemotherapy in elderly patients with relapsed or metastatic AGC,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],"To evaluate progression free survival, overall survival, and toxicities of aSOX-regimen",
7665,NCT04524442,Mean change from baseline in serum potassium levels over 24 hours,2021-01-27,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Participants with Notable Changes in Electrolyte and Blood Gas parameters,
7666,NCT00290524,Hospitalisation stay measured in days,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Post-surgery complications,
7667,NCT02114359,comparison of overall survival,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],comparison of quality of life,comprehensive geriatric assessment
7668,NCT01517009,"The number of patients with (serious) adverse events receiving the combination of 4 courses of docetaxel, cisplatin and capecitabine as neoadjuvant chemotherapy and standardized surgery in resectable localized or locally advanced gastric cancer.",2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],The number of patients receiving a D1-extra-resection as protocolized surgery in resectable gastric cancer,
7669,NCT01842971,number of complete surgical procedure,2013-06-07,TERMINATED,INTERVENTIONAL,['PHASE3'],quality of life,
7670,NCT05233332,ORR（by ICR）,2022-02-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Adverse Events,
7671,NCT03531606,Anterior resection syndrome improvement change,2016-12-12,COMPLETED,INTERVENTIONAL,['NA'],Other biomarkers,
7672,NCT01089595,Progression Free Survival,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],"Best Overall Response Using Response Evaluation Criteria in Solid Tumors, Choi Criteria, and Positron Emission Tomography Imaging",
7673,NCT04736485,Pathologic response after pre-operative treatment,2021-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-Related Adverse Events,
7674,NCT04603586,1-year Disease Progression-Free-Survival (DPFS),2020-10-20,UNKNOWN,INTERVENTIONAL,['NA'],Overall Survival,
7675,NCT03935282,Proportion of patients reporting at least one non-ideal or missing CVH topic,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Measure of tool acceptability with Tool Assessment,
7676,NCT02192034,Navigation role in colorectal cancer screening,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,
7677,NCT04380766,Changes in pancreatic cancer management during the COVID-19 pandemic,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7678,NCT03788499,Incidence of severe radioactive oral mucositis,2019-01-11,COMPLETED,INTERVENTIONAL,['NA'],the time at which the radioactive oral mucosa occurred; Difficulty in opening your mouth.,
7679,NCT05637567,Hematogenous metastases-free survival,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of resected lymph nodes,
7680,NCT04411524,Pathologic Complete Response Rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Quality of Life Scale, range 0-60. It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life.",
7681,NCT02245217,RECIST 1.1 Therapeutic Responses to 1 Cycle,2014-12-12,COMPLETED,INTERVENTIONAL,['NA'],,
7682,NCT04759846,Encorafenib AUC(0-inf),2021-01-21,WITHDRAWN,INTERVENTIONAL,['PHASE1'],MRAUC,
7683,NCT05464706,Quality of life after liver surgery,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
7684,NCT02687009,Dose limiting toxicity,2017-11-07,TERMINATED,INTERVENTIONAL,['PHASE1'],Niclosamide blood levels,
7685,NCT03647540,the number of the dissected lymph nodes,2018-08-30,UNKNOWN,INTERVENTIONAL,['NA'],The mean postoperative hospital stay,
7686,NCT05117047,Disease free Survival,2015-02-14,COMPLETED,OBSERVATIONAL,['NA'],Textbook Outcome in liver surgery (TOLS),
7687,NCT01863303,incidence of CRC,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],,
7688,NCT01305980,Evaluating Tumor Response Rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Determine duration of response rate by measuring time to progression,
7689,NCT01834963,Two-year overall survival rate,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],toxicity,
7690,NCT06084897,EFFICACY:1-year overall survival probability,2023-10-16,RECRUITING,INTERVENTIONAL,['PHASE2'],QUALITY OF LIFE: Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants,Biomarkers for the predicting of efficacy
7691,NCT00024375,,2001-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7692,NCT02052557,PCA (Patient Controlled Analgesia) Usage,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Home Oral Narcotic Use,NG (Nasogastric) Placement
7693,NCT06162520,Area under the Receiver Operating Characteristic curve (AUROC) of the diagnostic models for the differential diagnosis of congenital and secondary biliary dilatation and the identification of intrahepatic involvement,2021-12-17,COMPLETED,OBSERVATIONAL,['NA'],Accuracy of the diagnostic models for the differential diagnosis of congenital and secondary biliary dilatation and the identification of intrahepatic involvement,
7694,NCT00397878,Median Progression Free Survival (PFS),2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Time to Progression,Pre- and Post-treatment Expression Values for Each Biological Correlate
7695,NCT00783172,progression measured with CT scan,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7696,NCT05536713,Blood-based test compliant rates,2023-02-09,RECRUITING,OBSERVATIONAL,['NA'],Patient satisfaction with the blood-based test,
7697,NCT02712112,disease control rate,2016-03-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7698,NCT02380131,progression-free survival(PFS),2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],Objective response rate (ORR),The number of Participants with adverse events
7699,NCT00443196,"Complete Response, No Response",2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7700,NCT00598117,To prospectively evaluate the quality of life of patients before and after esophageal cancer resection.,2003-08,COMPLETED,OBSERVATIONAL,['NA'],To describe a cohort of long term survivors of esophageal cancer in order to identify significant features in patients more than 18 months post surgery.,
7701,NCT04002128,Number of the patients with hoarseness,2008-01,COMPLETED,INTERVENTIONAL,['NA'],One year survival and complications,
7702,NCT00501176,Intra-operative measurement of the Culture from the bile.,2006-12,COMPLETED,INTERVENTIONAL,['NA'],"Intraoperative measurements of inflammatory reaction in the liver, hepatoduodenal ligament and around the bile ducts with biopsies. Stent dysfunction and cholangitis after ERCP and pre-operative bile flow relief. Postoperative analysis.",
7703,NCT03357978,Infections in A-T,2016-10-01,UNKNOWN,INTERVENTIONAL,['NA'],Cancer risk,
7704,NCT00777894,Best objective response of target liver lesions (TLLs),2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Serum alpha-fetoprotein level (Phase II),
7705,NCT00440167,TTF2,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],Toxicity,
7706,NCT04993378,EV-Score,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],Survival significance of EV-Score,
7707,NCT02947165,"Incidence of DLTs, AEs, SAEs and dose reductions/interruptions for NIS793 in combination with PDR001",2017-04-25,COMPLETED,INTERVENTIONAL,['PHASE1'],Characterization of tumor infiltrating lymphocytes by immunohistochemistry using markers such as CD8 and PD-L1,
7708,NCT05953337,Incidence of serious adverse events (SAEs),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,
7709,NCT05576909,Downstaging success rate,2023-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
7710,NCT03322995,Completion of all intended neoadjuvant therapy and surgical therapy,2018-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-free survival,
7711,NCT03893695,Dose-limiting Toxicity(DLT),2019-05-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory Biomarker: circulating tumor deoxyribonucleic acid (ctDNA),
7712,NCT02484079,Complete resection rate,2015-05-18,COMPLETED,INTERVENTIONAL,['NA'],Factors explaining the primary outcome,
7713,NCT00149565,134 patients for each of the two treatment arms are needed.,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7714,NCT05970159,Postoperative complications,2023-08,RECRUITING,OBSERVATIONAL,['NA'],Mortality,Days of ICU stay
7715,NCT05498194,The neoantigen landscape of patients with gastric cancer,2022-08-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The ratio of predicted neoantigens being immunogenic.,
7716,NCT02542215,Overall mean Area Under the Curve (AUC) of oral mucositis severity over time,2015-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Mean cumulative radiation dose at time of severe (WHO grade 3 or 4) oral mucositis onset,
7717,NCT04268290,Postoperative hospital stays,2020-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],Morbidity and mortality rates,
7718,NCT02961374,Number of Participants With Grade 2/3 Adverse Event (AE),2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Absolute and Percent Change in Desmoid Tumor Size,Change in Differentially Expressed Genes of Duodenal Polyps and Uninvolved Tissue
7719,NCT05396326,The incidence of treatment related adverse events (TRAE).,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Progressive free survival (PFS),
7720,NCT01386931,Compare the percent of patients with inadequate samples (defined by an absence of cellular elements to account for a mass/lesion) between the two groups,2011-06,COMPLETED,OBSERVATIONAL,['NA'],Compare the percent of patients requiring repeat procedures between the groups,
7721,NCT05251233,Incidence of delayed gastric emptying as measured by Modified Accordion Grading System (MAGS),2022-04-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Marginal ulcer-free survival (MUFS),
7722,NCT01503983,Overall Survival,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],time to response,
7723,NCT05871333,change in severity of intestinal mucositis,2023-07-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Laboratory evaluation of Interleukin-1β level,
7724,NCT00273247,Recurrence Free Survival,1998-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Patient Survival,
7725,NCT03561948,Positive peritoneal lavage,2018-01-09,COMPLETED,INTERVENTIONAL,['NA'],,
7726,NCT00006357,,2000-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7727,NCT00065117,,2003-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7728,NCT04410302,Establish and characterize at least 200 patient-derived cancer xenografts (PDXs),2019-11-12,RECRUITING,OBSERVATIONAL,['NA'],,
7729,NCT03246321,Major toxicity,2017-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Procedure-related characteristics: blood loss,
7730,NCT02243007,Survival Rate at 18 Month,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Local Control Rate,
7731,NCT04987788,Colonoscopy completion,2021-08-19,COMPLETED,INTERVENTIONAL,['NA'],,
7732,NCT01383538,The maximum tolerated dose (MTD) for FOLFIRINOX plus IPI-926 in patients with advanced pancreatic cancer.,2011-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],Objective response rate (ORR) by RECIST criteria,
7733,NCT05476978,The model's ability to differentiate pancreatic cancer from other pancreatic solid lesion,2022-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],"The model's ability to specify the pancreatic solid lesions such as pancreatic cancer, CP, AIP and NET",
7734,NCT00673673,Progression Free Survival,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
7735,NCT03591705,progression-free survival,2018-07-06,RECRUITING,INTERVENTIONAL,['NA'],Downstage hepatectomy rate,
7736,NCT00931840,Response Rate,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),
7737,NCT03189576,ctDNA level,2015-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7738,NCT00059826,Overall survival at 18 months,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Distant disease control,
7739,NCT01506167,Overall Survival,2012-07-06,COMPLETED,OBSERVATIONAL,['NA'],Response to the Burden of Illness Question: Has your cancer resulted in a family member seeking support?,
7740,NCT02692365,Exploratory study for the determination of tissue changes of advanced hepatocellular carcinoma induced by electromagnetic waves amplitude modulated low energy specific frequencies during image MRIstudy.,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,
7741,NCT04136522,2 years recurrence free survival,2020-01-10,RECRUITING,INTERVENTIONAL,['NA'],Recurrence pattern,
7742,NCT03885817,Patient reported peripheral sensory neuropathy,2019-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Overall- and disease free survival,Diagnosed with type 2 diabetes.
7743,NCT02676791,Local carcinoma recurrence,2016-02-16,COMPLETED,INTERVENTIONAL,['NA'],,
7744,NCT00487851,"Primary outcome consist of a composite score (i.e. number of hospitalizations, episodes of cholangitis, degree of jaundice, other complications requiring therapeutic interventions). Secondary outcome are QoL,hospital stay and health economic burden.",2007-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
7745,NCT03578224,Accuracy rate of traditional endoscopic ultrasonography (EUS) with suspicious node biopsy and lymphosonography for sentinel node identification,2018-09-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Number of nodes identified,
7746,NCT03806426,Total Number of Polypectomies (polyps > 5mm in the rectum) conducted during the 24 months study period,2018-12-05,RECRUITING,INTERVENTIONAL,['PHASE3'],Change in score on the InSIGHT Polyposis Staging System (IPSS) at 24 months,
7747,NCT02848443,Changes in ECOG (Eastern Cooperative Oncology Group) performance status as a measure of safety and tolerability for S95005-oxaliplatin,2016-05,COMPLETED,INTERVENTIONAL,['PHASE1'],"PDL-1 expression, tumour-infiltrating CD8 T cell density, for S95005-oxaliplatin + nivolumab",Peripheral blood mononuclear cells
7748,NCT01387373,Response rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,
7749,NCT05162352,Progression free survival (PFS) assessed by investigators according to modified Response Evalutaion Criteria in Solid Tumors (mRECIST).,2021-12-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],DCR assessed by investigators according to RECIST 1.1.,
7750,NCT01861678,Anastomotic leakage rate,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Amount of blood loss,
7751,NCT02807337,Oral mucositis will be assessed daily for all 75 pediatric patients at the oncology ward and at home by use of the Children International Mucositis Evaluation Scale (ChIMES scale) and WHO oral mucositis scale.,2016-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7752,NCT00275210,Every 3 years colonoscopy for polyp free patient,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],"Every 2 weeks clinical and laboratory tests (hematological, creatinine and liver tests) for safety evaluation during treatment then every 6 months neurological examination Date of death for OS",
7753,NCT00738478,Quality of life,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],"complication, hematological data,",
7754,NCT05281926,Area Under the Concentration-Time Curve(ACU 0-22 weeks),2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Area Under the Concentration-Time Curve(ACU 0-24 weeks),
7755,NCT05276973,Incidence of adverse events,2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor response,Tumor response
7756,NCT05995821,Biological specimens obtained from cancer patients,2016-08-25,RECRUITING,OBSERVATIONAL,['NA'],,
7757,NCT02488746,Rate of cases in which a complete macroscopic en bloc resection of the gastric subepithelial tumor could be achieved,2015-03,TERMINATED,OBSERVATIONAL,['NA'],Number of participants with needs of surgical therapy or endoscopic re-resection,
7758,NCT01384994,Progression Free Survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival,
7759,NCT01829178,Urine concentration of NGAL,2013-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Tissue activity of caspase 3,
7760,NCT02167321,Disease free survival (DFS),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Evaluation for rate of various events after surgery,
7761,NCT03248661,Primary endpoint is a received completed FIT kit within 15 months after the participant received results from the original FIT test,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7762,NCT01609504,oncological result in term of local and/or systematic recurrence,1997-04,COMPLETED,INTERVENTIONAL,['PHASE3'],cancer-related mortality,
7763,NCT06228209,The proportion of screened eligible patients,2024-01-26,RECRUITING,INTERVENTIONAL,['NA'],Patient-Reported Goals of Care Discussion (GOCD),
7764,NCT02327494,the central venous oxygen saturation (ScvO2),2015-01,UNKNOWN,OBSERVATIONAL,['NA'],postoperative outcome,
7765,NCT01396707,Overall response rate,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
7766,NCT05498766,3-year DFS rate,2023-10-12,RECRUITING,OBSERVATIONAL,['NA'],"Incidence and severity of adverse reactions, serious adverse reactions, suspicious and unexpected serious adverse reactions",
7767,NCT04595058,Recurrent biliary obstruction (RBO),2020-11-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Survival,
7768,NCT04047771,Occurrence of adverse events (AEs) and serious adverse events (SAEs),2019-09-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (AUC 0-inf),
7769,NCT03468634,Device safety testing (no detectable damage in biopsy samples when reviewed by histopathology),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],Diagnostic model developed (algorithm able to discriminate disease with >50% specificity and >50% sensitivity),
7770,NCT04939051,Mean change Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR) 5+ cells,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety profile of treatment with OCA
7771,NCT03644459,AUC(0-∞) of T1h after Each Subsequent Introduction (multiple dose),2019-04-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],PGA after Each Subsequent Introduction (multiple dose),Half time (t1/2) of T1h after Each Subsequent Introduction (multiple dose)
7772,NCT06233864,"Object Response Rate, ORR",2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events (AE),
7773,NCT06284226,To evaluate the safety and the efficacy,2022-03-25,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],To assess the modulation in tumor markers,
7774,NCT02071069,The progression free-survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Grade 3 and 4 adverse Events as a Measure of Safety and Tolerability,
7775,NCT03006432,progression-free survival,2016-12-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Toxicity events according to NCI-CTC v4.0,
7776,NCT00016952,tumor response rate,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],quality of life,
7777,NCT06324409,First round screening participation,2024-03-22,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall screening participation,
7778,NCT01284413,one year survival rate,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Toxicity and response rate,
7779,NCT00358683,"For ethical reasons, provide the opportunity for patients > 18 years suffering from Crohn's disease who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with certolizum",2007-11,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Incidence of adverse events reported by the patients during the long-term treatment period of the study.,
7780,NCT05171335,Percent Tumor Necrosis,2022-06-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],Explant Biomarkers,
7781,NCT00802555,To evaluate the safety of ARQ 197 when administered in cirrhotic patients diagnosed with HCC,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],"To evaluate dynamic changes of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and soluble c-Met in patients' peripheral blood that are associated with ARQ 197 treatment",
7782,NCT01651949,Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event,2012-10-29,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine,
7783,NCT00039611,,2002-05,COMPLETED,INTERVENTIONAL,['NA'],,
7784,NCT03284684,Change in integrity index of circulating DNA for KRAS gene,2018-01-22,COMPLETED,OBSERVATIONAL,['NA'],Change in plasma concentration of BRAF DNA fragments with V600E mutation,
7785,NCT01693835,Circadian rhythms in urinary excretion of modified nucleosides,2012-08,COMPLETED,OBSERVATIONAL,['NA'],,
7786,NCT01963117,Time to Local Tumor Progression After Combined Hyperthermia and RT,2013-10,TERMINATED,INTERVENTIONAL,['NA'],Overall Survival Rate After Combined Hyperthermia and RT,
7787,NCT04487067,Number of Participants With Grade 3-5 NCI CTCAE v.5 Bleeding/Haemorrhage,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Number of Participants Reporting Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire,
7788,NCT04205097,total dose of remifentanil,2019-12-23,COMPLETED,INTERVENTIONAL,['NA'],,
7789,NCT00004604,Safety,1997-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Immune response,
7790,NCT05121038,Drug Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2021-10-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pathological response rate (PCR) .,
7791,NCT00662246,all cause mortality,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7792,NCT02692911,Cancer/precancer,2017-01-11,COMPLETED,OBSERVATIONAL,['NA'],,
7793,NCT06010225,Total medical costs,2020-05-01,COMPLETED,OBSERVATIONAL,['NA'],adherence to the ERAS protocols,
7794,NCT04128657,Validation of the moroccan arabic version of the Wexner score,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7795,NCT06211933,Survival rate at 12 months after HIFU intervention,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinical benefice rate regarding performance status,
7796,NCT01529164,response rate,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events,
7797,NCT00222898,,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,
7798,NCT05838391,Time to plan and deliver treatment fractions.,2023-05-18,RECRUITING,INTERVENTIONAL,['NA'],Complete Clinical Response Rate,
7799,NCT00410774,Disease-free survival rate at 1 year,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median overall survival rate at 1 and 2 years,
7800,NCT00510627,To evaluate Overall Survival in subjects receiving chemotherapy + RFA compared to chemotherapy alone.,2007-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],To determine if there are differences in the incidence or severity of adverse events in the RFA + chemotherapy arm compared to the chemotherapy only arm.,
7801,NCT04258566,ICG Fluorescene,2022-01-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1'],Exvivo fluorescence,
7802,NCT00588549,To assess if whole body 18F-FDG-PET enhances our ability to detect metastatic colorectal cancer restricted to liver and lung over conventional imaging such as CT and to determine the accuracy of PET in imaging extrahepatic tumors.,1998-07,COMPLETED,OBSERVATIONAL,['NA'],To determine whether PET plays a role in altering clinical management of patients undergoing evaluation for liver resection for hepatic colorectal metastases.,
7803,NCT00693342,Progression-free survival,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Correlation of outcome with antigen-specific immune titers in a limited sampling of patients,
7804,NCT01939275,"Number of HER2 Negative, Positive, or Equivocal Participants With Either Negative or Positive Tumor Readings",2014-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7805,NCT04561453,Success Rate of Obtaining circulating tumor DNA (ctDNA) quantification and Ability to assess change in ctDNA levels across those time points,2020-07-08,RECRUITING,OBSERVATIONAL,['NA'],Predictive Value of circulating tumor DNA (ctDNA) for Response to Medical Therapy,
7806,NCT04379999,Genome-wide expression analyses using RNA-Seq,2018-09-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Acceptability of the pilot study intervention and the willingness of the subject to participate in a similar larger study.,
7807,NCT01633203,Rate of downstaging,2010-08,COMPLETED,OBSERVATIONAL,['NA'],HER 2 expression,
7808,NCT00584129,"To test whether pre-treatment swallowing exercises compared with ""usual care"" (where exercises are taught post-treatment) improves quality of life in patients undergoing chemoradiation therapy for advanced head and neck cancer.",2006-02,COMPLETED,INTERVENTIONAL,['NA'],To test whether pre-treatment swallowing exercises compared with usual care improves secondary outcome measures related to dysphagia in this patient population.,
7809,NCT02253511,Overall survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],Recurrence-free survival,Number of participants with adverse events
7810,NCT02310477,Overall survival (OS),2014-02,COMPLETED,OBSERVATIONAL,['NA'],Progression-free survival (PFS),
7811,NCT03177681,Percentage Change in Firmicutes in Stool from Baseline to Day 12,2022-03-01,WITHDRAWN,INTERVENTIONAL,['NA'],Adherence Rate of Dannon® Oikos® Yogurt Intake,
7812,NCT04161781,Feasibility of 18F-BMS-986229 PET in participants with Gastroesophageal Cancer,2019-11-12,COMPLETED,OBSERVATIONAL,['NA'],,
7813,NCT03008304,Relief degree of tumors,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival（OS）,
7814,NCT02149771,Median survival time,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Time to Disease Progression,
7815,NCT04486378,Disease-free survival (DFS),2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Occurrence of dose reduction and discontinuation of IMP due to a TEAE.,
7816,NCT03192462,Number of Patients Who Received 6 Infusions of multiTAA-specific T Cells,2018-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival Using the Kaplan-Meier Method,
7817,NCT03180411,Development of Decision Tool to Guide Participants in Making Individualized Decisions Regarding Colorectal Cancer (CRC) Surveillance Through the Use of Cognitive Testing Interviews,2017-02-14,COMPLETED,OBSERVATIONAL,['NA'],,
7818,NCT04827732,Maximum tolerated dose (MTD) of reirradiation using hypofractionated IMPT,2021-05-04,RECRUITING,INTERVENTIONAL,['NA'],Frequency of late adverse events as measured by CTCAE v 5.0,
7819,NCT00190554,Disease free survival,2000-05,TERMINATED,INTERVENTIONAL,['PHASE3'],Operative morbidity,
7820,NCT05187312,Diagnostic yield,2022-01-14,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7821,NCT04855448,learning curve of surgicla failure,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],Disease free survival,
7822,NCT05449860,Local tumor progression rate,2020-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Technical success rate,
7823,NCT01378013,Sepsis,2011-08,COMPLETED,OBSERVATIONAL,['NA'],Mortality,
7824,NCT02732483,Rebleeding rate,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Mortalities,
7825,NCT02457624,Detection rate for gastric premalignant lesion,2008-03,UNKNOWN,OBSERVATIONAL,['NA'],Detection rate for gastric dysplasia,
7826,NCT03191487,"The rate of prescriptions for chemotherapy in the outpatient clinic prepared at the latest the day before a session (except for predefined, limited stability products) and administered in full, per patient, during a follow-up period of 6 months",2018-04,WITHDRAWN,INTERVENTIONAL,['NA'],Overall costs,
7827,NCT04673526,Quality of life associated to incontinence as assessed by Faecal incontinence quality of life scale (FIQL),2009-01-01,COMPLETED,INTERVENTIONAL,['NA'],Post-operative complications,
7828,NCT06061263,recurrence-free survival,2022-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7829,NCT00143403,Disease Free Survival (DFS),2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival Rates,
7830,NCT01763489,feeling able to judge the applicability of the trial,2014-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
7831,NCT06233877,Response Rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7832,NCT01919879,Non progression rate at 6 months,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Tolerance of the treatment,
7833,NCT04414306,Change in non-screening cancer prevention behaviors,2020-10-08,COMPLETED,INTERVENTIONAL,['NA'],Uptake of tobacco quitting behaviors,
7834,NCT03812783,Overall Survival (OS),2018-11-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events,
7835,NCT00960518,the progression free survival (PFS),2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],the rate of overall survival,
7836,NCT05688033,Number of Participants Experiencing Adverse Events,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Number of Participants in Who Experienced Tumor Down-staging,
7837,NCT05341622,FIT Completion,2022-05-27,COMPLETED,INTERVENTIONAL,['NA'],FIT Positive Follow-up Completion,
7838,NCT00883792,Comparison of the screening group vs. the control group in an intention-to-treat model after 15 years of follow-up with regard to CRC mortality and CRC incidence,2009-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Mortality from all causes,
7839,NCT04825834,"Accuracy of lung cancer detection measured by sensitivity, specificity, and the AUC of the ROC.",2021-03-22,RECRUITING,OBSERVATIONAL,['NA'],"Accuracy of multi-cancer detection measured by sensitivity, specificity, and the AUC of the ROC and tissue of origin (TOO) accuracy",
7840,NCT00003426,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7841,NCT03949777,Aer-O-Scope Validation of Cecal Intubation,2020-01-06,COMPLETED,INTERVENTIONAL,['NA'],,
7842,NCT05780736,Disease-free Survival (DFS),2023-08-04,RECRUITING,OBSERVATIONAL,['NA'],Participant Treatment History,
7843,NCT01029418,To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combination of AZD6244 and sorafenib in patients with advanced hepatocellular cancer.,2009-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To investigate if the combination sorafenib and AZD6244 increases Time To Progression (TTP) over sorafenib alone in patients with advanced hepatocellular carcinoma patients.,
7844,NCT02934958,Colonoscopy Completion,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,
7845,NCT01522209,Detection of Liver Metastasis during Operation,2011-12,COMPLETED,INTERVENTIONAL,['NA'],Comparison of Specicivity of all imaging modalities,
7846,NCT03662412,overall survival,2018-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Response rate,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
7847,NCT04456218,Image quality evaluation: the light brightness and the imaging sharpness in Likert scale,2020-07-01,COMPLETED,INTERVENTIONAL,['NA'],In biliary stricture arm: Number of the lesions with or without presenting of the specific features for DDx of the benign or malignant stricture,
7848,NCT04411537,Pathologic Complete Response Rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Quality of Life Scale, range 0-60. It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life.",
7849,NCT05046756,"Change of body composition (weight, kg)",2021-05-11,RECRUITING,INTERVENTIONAL,['NA'],The Wexner score,
7850,NCT00114842,Sensitivity/specificity for water versus air for distension of colon in MR colonography,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Sensitivity/specificity of MR colonography versus colonoscopy,
7851,NCT03927495,Objective response rate assessed by investigator based on RECIST 1.1,2019-05-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7852,NCT04330716,Rate of patients who have germline genetic tests,2020-12-01,COMPLETED,INTERVENTIONAL,['NA'],Cascade testing in positives,
7853,NCT00093496,Proportion of Patients Who Experience a Confirmed Response According to Modified RECIST Criteria.,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,
7854,NCT01169220,Quality of colon cleansing,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Patient satisfaction,
7855,NCT02165215,"Maintenance Phase: Percentage of Participants in Remission at Week 62 Among Randomized Participants With a Clinical Response at Week 10, as Determined by the Mayo Clinic Score (MCS)",2014-08-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Maintenance Phase: Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ),
7856,NCT03234465,Efficacy of AG013 Compared to Placebo for Reducing OM as Measured by Duration (in Days) of Severe Oral Mucositis (WHO Grades 3 or 4),2017-07-18,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7857,NCT02287168,elimination,2014-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],dissemination,
7858,NCT05419531,rate of young endurance athletes that have colorectal cancer on screening colonoscopies.,2022-10-18,RECRUITING,OBSERVATIONAL,['NA'],Comparison of the rate of young endurance athletes that have colorectal cancer on screening colonoscopies with that of the historical controls (those in the average risk group).,
7859,NCT05163873,Assessing the feasibility of the trial based on overall QoL reported in intervention group compared with standard care group,2021-12-09,RECRUITING,INTERVENTIONAL,['NA'],,
7860,NCT00464620,6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST),2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Tumors With Mutations in Kinases,
7861,NCT02415829,The tumor regression grade of all the patients enrolled,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events as a Measure of Safety and Tolerability,
7862,NCT03748667,The presence or absence of deep invasion according to the gold standard (histology),2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],Number of genome copies using SNP-arrays,
7863,NCT02645084,"Percentage of all included patients who have received a recommendation for regular surveillance colonoscopies for himself/herself and/or relatives, provided by a clinical geneticist.",2015-02,COMPLETED,INTERVENTIONAL,['NA'],Usability of the questionnaire for health care providers and patients by using a self-created online or paper questionnaire,
7864,NCT01368419,Objective Response Rate (ORR),2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
7865,NCT01381211,Time to Progression (TTP).,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicities and adverse events (recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 3.0),
7866,NCT05950503,Surgery conversion rates,2023-07-10,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
7867,NCT00195585,Relapse-free survival time,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],"Disease-free survival time, survival time, safety",
7868,NCT00354601,Objective Tumor Response,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of Life,
7869,NCT03333265,Cumulative the numbers and diameters of those colorectal adenomas during Berberine hydrochloride or placebo treatment in patients with familial adenomatous polyposis,2017-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7870,NCT05316480,Overall response rate (ORR),2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
7871,NCT05318404,Percentage of body weight loss,2020-12-08,COMPLETED,INTERVENTIONAL,['NA'],Postoperative daily protein intake,
7872,NCT01130701,"To estimate the 3 year progression-free survival of patients with localized, resectable pancreatic cancer",2010-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],To estimate resection rate,
7873,NCT05108428,Feasibility of MRI guided dose adaptive chemoradiation therapy,2021-12-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Number of Participants with Pathological Complete Response (pCR),Number of Participants with Disease-Free Survival (DFS)
7874,NCT00057395,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7875,NCT01839630,Summarized patient characteristics,2013-05-30,COMPLETED,OBSERVATIONAL,['NA'],Treatment pattern of Sorafenib,
7876,NCT02142803,Most Common Related Toxicities That Led to Dose Hold/Reductions,2014-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Number of Patients That Discontinue Study Drugs Due to Treatment Related Toxicity,Mutation Analysis of Tissue From Biopsies of Patients With Ovarian and Endometrial Cancers
7877,NCT00355238,The Number of Participants Experiencing Adverse Events (AEs),2006-12-31,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline to End of Treatment in FHSI-8 Total Score,
7878,NCT04919577,Roux stasis syndrome,2014-03-01,COMPLETED,OBSERVATIONAL,['NA'],Gender,
7879,NCT05670561,Pain Intensity at 12hours after the beginning of TACE operation,2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE4'],Analgesic Consumption,Quality-of-Life Assessment at 24hours after the beginning of TACE operation
7880,NCT01384617,Incidence of pancreatic fistula defined by ISGPF classification,2011-06,COMPLETED,INTERVENTIONAL,['NA'],Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma,
7881,NCT00278863,Response Rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Adverse Events,
7882,NCT00478374,To assess the safety and tolerability of the administration of sorafenib in patients with hepatocellular carcinoma treated with TACE by determining the MTD.,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],changes in the blood concentration of tumor marker AFP,
7883,NCT03797625,Progression Free Survival,2017-05-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7884,NCT05043363,Clinician experience of LumenEye examination,2020-11-14,COMPLETED,OBSERVATIONAL,['NA'],"Diagnostic accuracy of the LumenEye for the detection of rectal pathology including tumour, polyps and inflammation",
7885,NCT02812550,adenoma detection rate in the two different colonoscopies,2015-05,COMPLETED,INTERVENTIONAL,['NA'],colonoscopy withdrawal time,
7886,NCT04696055,Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment,2021-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants With Dose Modification,
7887,NCT05546411,Major pathological response rate (MPR),2023-01-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Median Overall Survival (OS),
7888,NCT02885376,"Incidence of severe oral mucositis, defined as grade 3 or 4 on the World Health Organization (WHO) scale",2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"Use of opioid analgesics for oral mucositis pain, as expressed in morphine equivalents.",
7889,NCT05354856,Difference in gastric perfusion,2022-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Short term outcome,
7890,NCT00267046,Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7891,NCT06157463,Change of FAPI SUV,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Correlation of FAPI SUV,
7892,NCT06085976,Incidence on intraoperative bleeding.,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of postoperative complications,
7893,NCT03070613,Number of dysplastic and cancerous lesions identified under white light and under fluorescence,2017-04-23,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Resection margin of of lesions undergoing TEMS resection under white light and under fluorescence.,
7894,NCT05617872,cfDNA concentration,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],Weight,
7895,NCT05507411,1-year DFS of CCR-Watch and Wait group,2022-08-03,RECRUITING,INTERVENTIONAL,['PHASE2'],EORTC QLQ-30,
7896,NCT05936931,CRC screeningintentions,2024-02,WITHDRAWN,INTERVENTIONAL,['NA'],,
7897,NCT02703545,Proportion of patients and resected lesions with pancreatic cancer in situ (high grade dysplasia) or invasive malignancy,2014-02,COMPLETED,OBSERVATIONAL,['NA'],Calculate survival time from point of diagnosis and treatment,
7898,NCT04923672,Steps per day,2023-02-20,RECRUITING,INTERVENTIONAL,['NA'],Fitness level,
7899,NCT02437851,To determine if the proportion of participants who develop treatment failure by 3 years is less than 25%.,2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"The rate of treatment related adverse events including non-healing ulcer, fissure, persistent pain and bleeding, stricture, incontinence, and colostomy 6 months after excision of SISCCA.",Collection of clinical specimens (composite)
7900,NCT03523546,Utilization of acute and specialty care,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Survival,
7901,NCT01911000,Hyperthermia effect and averse event in RT for HCC with PVTT,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate RT response prediction probability by diffusion-weighted (DW) MRI,
7902,NCT03385434,Evaluation of the adenoma detection rate during screening colonoscopy,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7903,NCT00685763,"Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90 Days of Treatment Start)",2008-03,COMPLETED,INTERVENTIONAL,['NA'],Collect and Analyze Tumor Control Measures,
7904,NCT03649945,3 year disease-free survival rate,2018-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,
7905,NCT05181332,Hepatic decompensation,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
7906,NCT03110328,overall survival,2018-02-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7907,NCT01083537,Time to Resolution of Bowel Obstruction,2010-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Evaluation of Toxicity,
7908,NCT01824953,Newly developed gastric neoplasm,2010-01,COMPLETED,OBSERVATIONAL,['NA'],Degree of gastric atrophy,Helicobacter pylori
7909,NCT04246177,Overall Survival (OS),2020-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],TTP per RECIST 1.1,
7910,NCT00918827,Relapse-free survival,2009-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
7911,NCT02403024,Change in VO2peak,2015-08,COMPLETED,INTERVENTIONAL,['NA'],Change in VO2peak (secondary comparisons),
7912,NCT03238404,Postoperative length of stay,2015-08-01,COMPLETED,INTERVENTIONAL,['NA'],Prealbumin,
7913,NCT03824366,Feasibility of Same-session MRI-only Simulation as Defined as More Than 70% of Patients Receiving at Least 70% of Their Scheduled Treatment Fractions on the First On-table Attempt for Each Respective Fraction.,2019-04-23,COMPLETED,INTERVENTIONAL,['NA'],,
7914,NCT00339560,Gallbladder Cancer,1997-05-16,COMPLETED,OBSERVATIONAL,['NA'],,
7915,NCT06040177,Objective response rate(ORR),2023-02-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
7916,NCT06318234,Evaluation efficacy of tumor regression level,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],SUV,
7917,NCT04101929,Progression Free Survival,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Response Rate,
7918,NCT00276302,To recommend a dose for subsequent studies of IPI-504,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],To explore potential pharmacodynamic (PD) markers of biologic activity of IPI-504 in GIST and STS.,
7919,NCT05070598,ORR (Objective control rate),2021-09-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],OS(Overall survival),
7920,NCT05412706,Progression-Free Survival 1,2023-09-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events,Translational objectives 3 for evaluated association between in vitro drug screening sensitivity on Patient-derived organoids and clinical outcome
7921,NCT04340401,pathologic complete response rate(pCR rate),2020-05-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],Major adverse events,
7922,NCT04923620,Pathological response rate,2021-10-20,RECRUITING,OBSERVATIONAL,['NA'],disease-free survival,
7923,NCT02649348,The proportion of postoperative complications,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,
7924,NCT02186886,Clinical response,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],Calprotectin stool levels,molecular spectral range
7925,NCT04232891,relapse rate in MRD- patients,2019-11-18,UNKNOWN,OBSERVATIONAL,['NA'],minimal residual disease detection rate,
7926,NCT02436395,Superficial incisional surgical site infections,2015-05,UNKNOWN,INTERVENTIONAL,['NA'],,
7927,NCT01074996,Progression Free Survival(PFS),2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],safety and tolerance,
7928,NCT04662346,correlation to post-operative complication,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7929,NCT03485027,PFS,2018-01-24,COMPLETED,INTERVENTIONAL,['PHASE2'],OS,
7930,NCT01490203,Correlation of hepatic extraction fraction (HEF) of future remnant liver function (RLF) obtained from Gd-EOB-DTPA enhanced MRI with postoperative ICG R15 clearance test results,2011-12,COMPLETED,OBSERVATIONAL,['NA'],Exploratory analysis of MRI parameters and ICG R15 derived from potential liver donors,
7931,NCT04639284,Objective response,2020-12-23,UNKNOWN,OBSERVATIONAL,['NA'],"Time to deterioration in patient-reported quality of life, physical functioning, and role functioning",
7932,NCT00002935,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7933,NCT03941626,"Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0",2019-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinical response,
7934,NCT00383695,Pathological complete response rate at time of total mesorectal excision (TME),2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Quality of life, including long-term bowel function",
7935,NCT04707365,overall survival,2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7936,NCT00070213,Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 14 weeks,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Compare health economics in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap,
7937,NCT00875771,Progression free survival (PFS),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Rate of hepatic metastases resection,
7938,NCT05618821,Total Number of Retrieved Lymph Nodes,2022-06-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Intraoperative situation,
7939,NCT04212221,Objective response rate (ORR),2020-04-20,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
7940,NCT01972737,Antibody responses,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Persistent immunological responses,Time to recurrence and disease-free survival and immune responses
7941,NCT02138617,Progression Free Survival,2014-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
7942,NCT03884868,Grade of distress experienced by patients,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],Grade of understanding of the information reported by patients,
7943,NCT03792048,Incidence of anastomotic fistula,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],Incidence of pancreaticojejunostomic stricture,
7944,NCT00561470,Overall Survival (OS),2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay,
7945,NCT03670199,Variation of the Medical Outcome Study Short Form 36 score,2019-01-29,RECRUITING,INTERVENTIONAL,['NA'],Length hospitalization,
7946,NCT04093687,Endoscopist adjusted painful colonoscopy rate change,2019-11,UNKNOWN,INTERVENTIONAL,['NA'],Adjusted painful colonoscopy rate for screening centres (in which assessed endoscopists are working),
7947,NCT05463328,"Rate of postoperative anastomosis leakage(pancreatic,billary and intestinal).",2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Postoperative 30 days mortality rate.,
7948,NCT04183218,Cardiac event rate at 12 months,2019-09-23,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Overall survival,Imaging changes
7949,NCT01472770,Rate of patients progression free at 3 months,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
7950,NCT03754192,Pefusion parameters,2019-01-30,UNKNOWN,INTERVENTIONAL,['NA'],Pathological examination,
7951,NCT00266097,Maximum Tolerated Dose (MTD) of erlotinib hydrochloride and gemcitabine hydrochloride (Part 2),2004-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7952,NCT00006001,,2000-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7953,NCT03986541,Progression free survival,2019-09-23,UNKNOWN,OBSERVATIONAL,['NA'],Disease control rate,
7954,NCT02630108,Overall Survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of participants with adverse events and severe adverse events in TACE alone and TACE combined with ablation groups,
7955,NCT01423604,Overall Survival,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Summary of Clinical Benefit,
7956,NCT02310230,Average minute ventilation in patients cared for using the ExSpiron Respiratory Variation Monitor (RVM) compared to patients with routine monitoring in patients undergoing upper gastrointestinal endoscopy,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],The ability of respiratory parameters with capnography to assess states of hypoventilation between the two groups,
7957,NCT04852679,Clinical Benefit Rate (CBR) of tumour response assessed using RECIST (Version 1.1) and confirmed by Blinded independent central review (BICR),2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE3'],Incidence of Adverse Events (AEs),
7958,NCT05055726,Number of responders,2021-12-06,COMPLETED,INTERVENTIONAL,['PHASE4'],Frequency of adverse events,
7959,NCT02519140,Lift Efficacy,2014-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Dissection Adequacy,
7960,NCT05799443,Objective response rate(ORR),2023-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
7961,NCT00304135,Overall survival,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Biliary complication rate,
7962,NCT06218888,Objective Response Rate（ORR）,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),
7963,NCT05742425,Disease-free survival (DFS),2023-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence rate of adverse events,
7964,NCT06253949,rectal cancer-low anterior resection syndrome (LARS),2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],1-year overall survival,
7965,NCT00550589,Safety and Tolerability of Topical Cidofovir as Assessed by NCI CTCAE v3.0,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in Gene Expression in Perianal HSIL After Exposure to Cidofovir as Assessed by RNA Microarray Analysis,
7966,NCT00288275,Progression Free Survival,2004-07,TERMINATED,OBSERVATIONAL,['NA'],Tumor Response,
7967,NCT01290523,Number of Participants With Adverse Events,2010-05,TERMINATED,INTERVENTIONAL,['NA'],Radiographic Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,
7968,NCT04819958,3-year disease free survival rate,2021-03-31,UNKNOWN,OBSERVATIONAL,['NA'],Duration of postoperative hospital stay,
7969,NCT03816358,Maximum tolerated dose (MTD),2019-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Biomarker analysis,
7970,NCT03597581,RGX-202-01 treatment-emergent adverse events,2018-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],RGX-202-01 area under the curve,
7971,NCT02863107,Adherence score,2012-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7972,NCT03460925,Clinical response to the treatment in terms of resectability,2018-05-02,UNKNOWN,INTERVENTIONAL,['NA'],Quality of life,
7973,NCT02764268,Number of Participants With Dose Interruptions,2016-11-02,COMPLETED,INTERVENTIONAL,['NA'],Disease Control Rate(DCR),
7974,NCT01313377,Quality of life,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Toxicity of adjuvant chemotherapy,
7975,NCT03205501,"Safety: the number of participants with symptoms or changes in vital signs (blood pressure, heart frequency and temperature) and/or (serious) adverse events that are related to administration of EMI-137.",2017-02-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Visualization of the localization and distribution patterns of EMI-137 in the esophagus using ex vivo fluorescence microscopy.,
7976,NCT06217016,secondary catheterization owing to urinary retention,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Postoperative complications,
7977,NCT02311803,Sexual function,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],5-year recurrence pattern,
7978,NCT03632746,The specificity of the Nomogram combining sentinel lymph node in predicting lymph node metastasis in early gastric cancer patients,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA'],The sensitivity of the Nomogram alone in predicting lymph node metastasis in early gastric cancer patients,
7979,NCT04365946,Analysis of microbiome in subtypes of intestinal metaplasia and gastric cancer,2020-04-18,UNKNOWN,OBSERVATIONAL,['NA'],,
7980,NCT03168152,Time to local tumor progression,2017-05-11,WITHDRAWN,INTERVENTIONAL,['NA'],Incidence of intrahepatic failure,
7981,NCT02047500,Number of Subjects Experiencing Dose Limiting Toxicity (DLT),2014-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Subjects With Treatment-emergent Adverse Events (TEAEs),
7982,NCT01787006,Rate of Participants Who Were Alive at 2 Years,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Quality of Life Between Baseline and End of Treatment (After 5 to 13 Weeks),
7983,NCT03150992,Change in incidence of pain,2017-07-19,UNKNOWN,INTERVENTIONAL,['NA'],Nutritional intake,
7984,NCT02973685,Overall survival,2016-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of of Patients developed Adverse Events,
7985,NCT01373320,Proportion of participants reporting the health behavior of interest (depending on which intervention component(s) were selected),2010-03,COMPLETED,INTERVENTIONAL,['NA'],"Retention (i.e., number of participants who complete all planned assessment timepoints)",
7986,NCT06007846,Patients Progression Free Survival at 6 months,2023-07-31,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Change from baseline as assessed by the European Organization for Research and Treatment of Cancer (EORTC-HCC18) over treatment
7987,NCT04367025,Major pathologic response (MPR),2020-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],OSR,
7988,NCT02024841,Maximum tolerated dose and recommended dose,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival,
7989,NCT01203787,Cumulative Dose of Sorafenib,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Subjects With Dose Reductions,
7990,NCT05802485,Predict response to systemic therapies in patients with non-metastatic pancreatic adenocarcinoma,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7991,NCT01458717,2-year survival rate,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",efficacy of imaging study after neoadjuvant chemoradiation,
7992,NCT04465734,tumor assessment,2022-11-15,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
7993,NCT05476432,Overall survival,2022-07-26,RECRUITING,INTERVENTIONAL,['PHASE3'],the predictive power of thymidylate synthase (TYMS),
7994,NCT01336452,characteristic of Perfusion MR,2011-04,UNKNOWN,INTERVENTIONAL,['NA'],,
7995,NCT05593419,TIIC signature,2022-10-31,RECRUITING,OBSERVATIONAL,['NA'],,
7996,NCT00609310,Recurrence rate of neoplasia,2015-05,SUSPENDED,INTERVENTIONAL,['PHASE2'],"Recurrence free survival, Overall survival, Serum-Flavonoid levels of patients",
7997,NCT06037655,Objective response rate (ORR),2023-09-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival (OS),Major Pathological Response Rate (MPR)
7998,NCT01784861,Objective Response Rate (Complete Response + Partial Response) - Phase II,2013-05-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Toxicity - Phase II,
7999,NCT04648020,To demonstrate the efficacy of HCl MBT to prevent SOM in OPC patients receiving CRT.,2021-02-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],
8000,NCT01402401,efficacy of AUY922 in combination with trastuzumab as assessed by RECIST,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8001,NCT05468944,Complication rate,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival rate,
8002,NCT01094600,Primary outcome: correlation between S-MRCP with ePFT,2012-06,WITHDRAWN,INTERVENTIONAL,['NA'],,
8003,NCT05516628,"Recurrence-free-survival (RFS) in relation to the multi-omics (epigenomics, genomics, transcriptomics, proteomics and metabolomics) and spatial TME profiles of both tissue and peripheral blood.",2023-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS).,
8004,NCT02845908,"Progression-Free Survival,PFS",2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival(OS),
8005,NCT05690958,Intended uptake of EAC screening,2023-02-13,RECRUITING,OBSERVATIONAL,['NA'],Views on the organization of EAC screening,Acceptability of screening test accuracy
8006,NCT04606888,S100 calcium-binding protein β,2020-07-01,COMPLETED,INTERVENTIONAL,['NA'],Numeric Rating Scale score,
8007,NCT03156582,Number of participants whose tumoral characteristics on the liver explant were under the criteria of the AFP score,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],Progression free survival after LT for HCC,
8008,NCT04943653,6-month progression free survival (6-month PFS),2021-06-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Ascites response,
8009,NCT04027764,objective response rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,
8010,NCT00059865,Survival after 6 months of treatment,2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Toxicity as assessed by CTC v3 every 4 weeks,
8011,NCT03909997,Number of patients with severe 30-day or in-hospital morbidity,2019-04-05,UNKNOWN,OBSERVATIONAL,['NA'],Median and percentage of patients with long-term survival,
8012,NCT03364621,Utilization rates of characterized genomic and epigenetic features associated with chemotherapy resistance and tumor recurrence in clinical environments,2017-08-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Non-invasive detection of cfDNA methylation profiles by performing cfMeDIP-seq on blood samples,
8013,NCT03869151,increased over all survival,2019-04-05,UNKNOWN,OBSERVATIONAL,['NA'],,
8014,NCT02399033,Hepatocellular carcinoma recurrence rate in the three years after hepatectomy,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],The incidence of adverse reaction.,
8015,NCT04310111,Tumor size,2020-03-01,COMPLETED,INTERVENTIONAL,['NA'],Adverse events,
8016,NCT01598584,quality of life,2012-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",chemotherapy induced nausea and vomiting,
8017,NCT00497497,Incidence and nature of dose-limiting toxicities,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Incidence and severity of infusion reactions,
8018,NCT03792269,Progression-free Survival (PFS),2016-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events (AE),
8019,NCT00042900,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8020,NCT02170090,Disease free survival (DFS),2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],locoregional control (assessed by the rate of patients with hepatic or locoregional recurrence),
8021,NCT03925662,number of patients with tumour response,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
8022,NCT04068896,Number of Patients with Clinically Significant Laboratory Abnormalities:,2019-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Skeletal muscle index during therapy with NGM120,
8023,NCT02570711,Overall Response Rate (ORR),2015-10-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8024,NCT01915589,Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review,2013-09-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events as a measure of safety and tolerability,
8025,NCT00479817,Progression Free Survival,2007-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of the occurence of AMG 386 Antibody formation,
8026,NCT02542436,Overall Survival (OS),2015-09-01,WITHDRAWN,OBSERVATIONAL,['NA'],Percentage of Participants with Adverse Events of Special Interest,
8027,NCT03458975,Objective response for liver metastases,2019-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Dosage of cytokines,
8028,NCT03567629,"Progression-free Survival: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first.",2018-05-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],The incidence of treatment related emergent adverse events（Safety and Tolerance）,
8029,NCT02581215,Progression Free Survival (PFS),2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Characterize Adverse Events (AE),
8030,NCT00419614,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
8031,NCT01711450,Dose of intravenous sedation required during and after the procedure,2012-12,WITHDRAWN,INTERVENTIONAL,['NA'],Complication rate of paravertebral block,
8032,NCT05344924,Progression free survival (PFS),2022-10-12,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse effects,
8033,NCT05753163,1-year recurrence-free survival rate (1-year RFS),2022-08-02,RECRUITING,INTERVENTIONAL,['PHASE2'],health-related quality of life (HRQol),
8034,NCT02543762,"Prevalence and incidence of dysplasia and colitis-associated colorectal cancer in patients with longstanding colonic inflammatory bowel disease (N-IBD), in Spain",2012-02,COMPLETED,OBSERVATIONAL,['NA'],Usefulness of advanced endoscopy in displasia characterization (chromoendoscopy ) for the diagnosis and endoscopic differential diagnosis of NIBD.,
8035,NCT06044142,Assess the impact of photo-bio-modulation low level (LL) laser treatment in managing mucositis,2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8036,NCT06160557,"Disease Free Survival, DFS",2023-11-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
8037,NCT01442649,Progression-free survival (PFS) at 4 months,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
8038,NCT02774187,Overall survival,2016-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of of Patients developed Adverse Events,
8039,NCT05980182,Colorectal Screening Status,2023-08-05,RECRUITING,INTERVENTIONAL,['NA'],Determine the feasibility of the mHealth Application - Sharing Content,
8040,NCT04484909,Recommended phase II dose (RP2D),2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),Resection status
8041,NCT00910494,surgical complication rate,2010-01,TERMINATED,INTERVENTIONAL,['NA'],local control,
8042,NCT05552729,Cognitive function,2022-09-22,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Asthenia,
8043,NCT05383976,Adenoma Detection Rate,2023-02-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8044,NCT01956864,Number of participants on high dose Vitamin D with adverse events,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Changes in the expression of serum and imaging biomarkers,
8045,NCT00136227,colorectal cancer screening initiation rate,2005-10,COMPLETED,INTERVENTIONAL,['NA'],making decisions about colorectal cancer screening that are consistent with their values and preferences,
8046,NCT00253526,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
8047,NCT03602417,Clinical success rate,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
8048,NCT03249727,"Test performance of NK Vue (ability of NK Vue to detect CRC in those subjects in risk categories P2, P3 or P4)",2017-07-05,TERMINATED,INTERVENTIONAL,['NA'],Test performance of NK Vue in combination with FIT,
8049,NCT06304597,Temperature,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluate targeted detection with nivolumab-800CW and durvalumab-680LT of the tumor by ex vivo visualization of the resection specimen with PEARL Trilogy,
8050,NCT03648879,Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1) Germline Mutation Carriers Compared to Current Method of Standard White Light Endoscopy,2019-02-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants Who Have Signet Ring Cells (SRC) Foci Not Identified by Confocal Endoscopic Microscopy (CEM),Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
8051,NCT03136354,Complication,2009-05,COMPLETED,INTERVENTIONAL,['NA'],Disease free survival,
8052,NCT04654494,disease free survival,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
8053,NCT03570996,Pain scores,2018-01-01,TERMINATED,INTERVENTIONAL,['NA'],Hypotension,
8054,NCT00238381,Composite evacuation score after total mesorectal excision,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Morbidity,
8055,NCT01068483,Maximum Tolerated Dose (MTD) of BKM120,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Clinical tumor response in patients with tumors that show PI3K pathway activation,
8056,NCT05002686,1 year Progression Free Survival (PFS),2021-08-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Percentage of pathologic complete response(pCR),Potential biomarker to predict prognosis
8057,NCT04621474,Inter-observer agreement,2019-04-08,UNKNOWN,OBSERVATIONAL,['NA'],Preferred imaging modality,
8058,NCT01627379,Overall Survival,2012-05,TERMINATED,INTERVENTIONAL,['PHASE3'],Quality of life,
8059,NCT01243346,The primary end-point is overall response rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],PKPD analysis,
8060,NCT03722628,The level of Matrix metalloprotinease-1 genotypes polymorphism in the study population,2018-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,
8061,NCT06210971,Pathologic Complete Response,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
8062,NCT03206827,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification,2016-11-29,COMPLETED,INTERVENTIONAL,['NA'],Genotoxicity testing of human fecal water in 2D and 3D cell cultures,
8063,NCT04287868,Best Overall Response (BOR) in Checkpoint Naive and Immune Checkpoint Blockade (ICB) Resistant Disease in Participants With Advanced or Metastatic Human Papillomavirus (HPV) Associated Malignancies,2020-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of Response (DOR),Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
8064,NCT06333769,complete response (CR) rate,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],3y-DFS,
8065,NCT04252456,"Overall survival (OS) according to VEGFR2 levels, evaluating the difference in terms of median OS among patients with high VEGFR2 activity and patients with low VEGFR2 activity",2018-04-23,UNKNOWN,INTERVENTIONAL,['NA'],Angiogenetic factors levels concentration before and during treatment.,
8066,NCT01921283,procedure satisfaction score of propofol addition,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
8067,NCT00327652,Dose-limiting toxicities (DLTs) for 7 days after dosing,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8068,NCT04009265,Overall Survival,2019-08-23,RECRUITING,INTERVENTIONAL,['PHASE3'],Scores of Quality of Life,
8069,NCT02660671,Colonoscopy participation,2016-01,COMPLETED,INTERVENTIONAL,['NA'],Scheduling of colonoscopy,
8070,NCT04695470,PFS(progression free survival) rate at 6 months,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8071,NCT03133286,Obtain pre- and post-irradiation participant-collect blood samples,2017-04-06,UNKNOWN,OBSERVATIONAL,['NA'],,
8072,NCT03461341,Utilisation of routine surveillance imaging across European Centers,2009-06-01,COMPLETED,OBSERVATIONAL,['NA'],Health-related quality of life (HR-QL) as assessed by EORTC QLQ-C30 questionnaire,
8073,NCT00625586,Number of Patients Alive at 8 Months,2008-04-15,TERMINATED,INTERVENTIONAL,['PHASE2'],Cmax,
8074,NCT05608213,Overall survival (OS),2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse Events (AEs),
8075,NCT05894824,PFS rate at 24 weeks,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",adverse events categorized in accordance with CTCAE 5.0 Criteria.,
8076,NCT02222753,Disease-specific survival,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,Disease-free survival
8077,NCT03245190,16 weeks progression-free rate (16W-PFR),2018-04-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",12 months overall survival rate,Screening characteristics of ctDNA measurement (multi-gene analysis).
8078,NCT03432624,Fourfold Table Analysis Indexes,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],Statistical Analysis Indexes,
8079,NCT00936689,survival of all randomized patients at month 24 (favorable event). Mortality by month 24 and withdrawal from the study will be considered to be unfavorable events.,2008-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Radiological tumor response; TTSP; TTP; Overall duration of response; Quality of life; ECOG score; Impact on liver function; No.of treatments administered.,
8080,NCT02857270,Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs),2016-09-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival (OS) (Dose Expansion Arms Only),
8081,NCT02743221,Progression Free Survival (PFS),2016-04-29,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
8082,NCT06172205,ORR,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],conversion rate,
8083,NCT02317471,Number of participants with adverse events related to gp96 immunotherapy,2014-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
8084,NCT02421432,TME quality & circumferential resection margin (CRM),2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of harvested Lymph Nodes,5-year overall survival
8085,NCT06041009,"The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)",2023-12-20,RECRUITING,OBSERVATIONAL,['NA'],"The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)",
8086,NCT02008422,progression-free survival (PFS),2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],overall survival (OS),
8087,NCT05040425,Mucositis pain,2021-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],Body mass index (BMI),Electrical body conductivity
8088,NCT04980950,The impact of immunonutrition on gut microbiota in gastric and colorectal cancer patients.,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],The impact of immunonutrition on intestines in gastric and colorectal cancer patients.,
8089,NCT03646409,VTE- and bleeding incidence,2018-06-11,COMPLETED,OBSERVATIONAL,['NA'],Arterial thromboembolism (ATE) incidence,
8090,NCT00003360,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8091,NCT00084721,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8092,NCT02246634,Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.,2014-08,RECRUITING,INTERVENTIONAL,['NA'],To describe the impact of MR screening on treatment received by patients who are diagnosed with liver metastases.,
8093,NCT04832776,ORR,2021-04-17,RECRUITING,INTERVENTIONAL,['PHASE2'],PFS,
8094,NCT00002692,,1994-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8095,NCT01269255,maximum tolerated dose,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8096,NCT00034827,Overall objective response and clinical benefit response,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],"Time to objective response, duration of response, time to progression and survival",
8097,NCT02458573,soft diet intake after surgery,2015-06-04,COMPLETED,INTERVENTIONAL,['PHASE4'],postoperative pain,
8098,NCT01833286,overall survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],disease-free survival,Morbidity
8099,NCT03067792,response rate,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],progression free survival,
8100,NCT01196000,Rate of conversion to open surgery as an indicator of surgical technical difficulty,2011-12,WITHDRAWN,INTERVENTIONAL,['NA'],Health economics,
8101,NCT02638857,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life,
8102,NCT02613221,Progression Free Survival (PFS) Rate at 6 Months,2015-12-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs),
8103,NCT01545063,Number of catheter related infections,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
8104,NCT02161029,Amount of submucous tissue in gastrointestinal submucosal tumors harvested with a new drill biopsy instrument used with flexible endoscopes.,2014-07-02,COMPLETED,INTERVENTIONAL,['NA'],,
8105,NCT05053386,"Objective Response Rate, ORR",2021-10,UNKNOWN,INTERVENTIONAL,['NA'],"Overall survival, OS",
8106,NCT02556762,Overall survival,2015-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Biomarkers,
8107,NCT02046174,Overall Survival,2014-04-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Pain Assessment,Necrosis Comparison of Tumors Using PET-CT Scan
8108,NCT00005053,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8109,NCT04762953,Incidence of Treatment-Emergent Adverse Events [Safety],2021-02-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Patient Reported Quality of Life Outcomes,Correlation of Plasma and Ascite Exosomal Gene Signature (EXOSIG) to Treatment Response
8110,NCT04202978,R0 resection rate,2020-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",pathologic complete response,
8111,NCT00560846,Length of stay,2007-11,TERMINATED,INTERVENTIONAL,['NA'],Body composition,
8112,NCT00788125,Maximum Administered Dose of Dasatinib (Phase I),2008-09-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8113,NCT03252821,Change in fatigue,2017-08-15,COMPLETED,INTERVENTIONAL,['NA'],Adherence,
8114,NCT03997188,Degree of dysphagia,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8115,NCT04416854,Overall survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],The proportion of surgical intervention in control group,
8116,NCT00576654,Recommended phase II dose (RP2D) of study drugs,2007-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor response,Excision repair cross-complementation group 1 (ERCC1) expression levels
8117,NCT02767752,Disease-free survival (DFS),2016-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of Life,Determination of plasma IL-6
8118,NCT01697488,Safety: Incidence of adverse events,2012-02-02,COMPLETED,OBSERVATIONAL,['NA'],Treatment duration,
8119,NCT03731130,QoL (EORTC QLQCR29) absolute values and change over time,2018-10-05,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
8120,NCT05500027,Differentiation expression of serum sCD58 and TGfbeta1 among pancreatic cancer and other conditions,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
8121,NCT00514761,Progression event count,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],safety and tolerability,
8122,NCT03968406,Maximum tolerated dose (MTD),2019-09-26,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,Overall quality of life as assessed by the FACT questionnaire
8123,NCT01062919,Postoperative functional recovery,2009-07,TERMINATED,INTERVENTIONAL,['NA'],length of hospital stay,
8124,NCT00004867,Proportion of these patients with FDG-PET findings that contraindicate surgery,1999-11,COMPLETED,INTERVENTIONAL,['NA'],The proportion of false positive lesions found by FDG-PET.,
8125,NCT00848094,"Toxicity was graded using the CTCAE 3.0. Dose-limiting toxicity was defined as acute ≥ grade 3 hepatic or gastrointestinal toxicity, or any grade 5 treatment-related adverse event, or late complication of radiation-induced liver disease.",2005-04,COMPLETED,INTERVENTIONAL,['PHASE1'],"1,2 and 3 years survival",
8126,NCT02369939,Improvement of complete remission,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life,
8127,NCT06324357,Dose optimization (Phase II): Objective response (OR),2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Dose optimization (Phase II): Patient-reported outcome (PRO) - EORTC IL19,
8128,NCT01933789,Occurrence of Discussion About Goals of Care at Target Visit,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Palliative Care Consultation and/or Referral - Patients Most Likely to Benefit,Group Differences - Stable Treatment Preference (Filter for Subgroup Analysis of Goal-concordant Care)
8129,NCT04999306,patient adherent to the program.,2023-05-17,RECRUITING,INTERVENTIONAL,['NA'],Quality of life questionnaire-Core 30 (QLQ-C30),
8130,NCT00471146,Overall Survival (OS),2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736),
8131,NCT02568046,"Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence Measured From Baseline to End of Trial Participation, as Assessed by the Common Terminology Criteria for AEs (Version 4.03) (CTCAE v4.03).",2016-03-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8132,NCT05594927,Overall survival (OS),2022-12-12,RECRUITING,INTERVENTIONAL,['PHASE3'],Mean area under the concentration-time curve during the dosing interval (AUC0-t),
8133,NCT04270851,Change in decision making on technical resectability,2020-04,UNKNOWN,OBSERVATIONAL,['NA'],Level of agreement between liver surgeons on technical resectability,
8134,NCT02539225,Progression Free Survival (PFS),2015-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Anti-Ramucirumab Antibodies,
8135,NCT01312467,"Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235)",2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety and Tolerability of Metformin Hydrochloride Treatment,
8136,NCT03102229,Number of patients hospitalized during treatment or within 4 weeks after completing radiotherapy.,2016-07,COMPLETED,INTERVENTIONAL,['NA'],Modified Glasgow Prognostic Score,
8137,NCT02394769,Change in Urinary Prostaglandin Metabolites (PGE-M),2015-07-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Spectral Biomarkers of Colorectal Cancer,
8138,NCT05996458,Cancer or precancerous lesions detected,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
8139,NCT02781532,Evaluation of ingesta,2014-04,COMPLETED,OBSERVATIONAL,['NA'],,
8140,NCT03542422,Progress free survival（PFS）,2018-06-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival,
8141,NCT04054908,Acceptability of specimens for analysis,2018-04-13,COMPLETED,OBSERVATIONAL,['NA'],Change in relative abundance of following gut bacteria that occur with oral fluoropyrimidine therapy,
8142,NCT04069702,Number of Participants With VR Side Effects,2020-03-12,COMPLETED,INTERVENTIONAL,['NA'],Change in Pain Self-efficacy as Measured Using Items Adapted From the Self-efficacy for Pain Management Subscale of the Chronic Pain Self-Efficacy Scale,
8143,NCT00310882,,2006-05,WITHDRAWN,OBSERVATIONAL,['NA'],,
8144,NCT06027242,Change of area of psoas muscle,2023-02-21,RECRUITING,INTERVENTIONAL,['NA'],Change of serum pre-albumin value,
8145,NCT03793725,R0 (resection rate),2019-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],RFS,
8146,NCT00617071,Screening utilization over the 6-month observation period,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Identification of predictors of CRC screening use and screening preference,
8147,NCT02960282,"Best tumor response, defined as a complete response or a clear decrease in tumor burden",2016-10-20,TERMINATED,OBSERVATIONAL,['NA'],,
8148,NCT03353311,Adherance to ERAS protocol,2014-09-01,COMPLETED,OBSERVATIONAL,['NA'],Number of items of the ERAS protol correlated wih adverse events as described by the Clavien Dindo Classification and with a longer hospital stay,
8149,NCT01044511,"HRQoL, EORTC C-30, EOS-18",2010-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8150,NCT00006994,Effectiveness of L-glutamine for mucositis,2001-11,TERMINATED,INTERVENTIONAL,['PHASE3'],Compliance (dose taken) in patients treated with L-glutamine when given with radiation treatment,
8151,NCT03253289,Change in mRNA levels,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],A panel of CAR downstream target genes,
8152,NCT02332499,Overall Survival (OS),2014-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Number of Participants with Adverse Events as a Measure of Safety and Tolerability,
8153,NCT03762590,"Change of genetic testing among family members of mutation positive PDAC patients, among family members of mutation positive individuals with a family history of PDAC and among first-degree relatives of PDAC patients",2019-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"Uptake of surveillance for pancreatic, other associated cancers and health behaviors",
8154,NCT03237130,pathological local lymph node status,2017-02-15,COMPLETED,OBSERVATIONAL,['NA'],,
8155,NCT01483144,Number of Subjects With Any FAP-related Event.,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Improvement in Investigator Lower GI Assessment,
8156,NCT02530398,the grade of adverse events,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8157,NCT03945799,Disease free survival,2019-04-22,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
8158,NCT00010088,,1999-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8159,NCT05420584,Imaging Tumor Regression Rate,2022-11-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Pathological Tumor Regression Rate,
8160,NCT05908838,Overall survival,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Immune function,
8161,NCT05397548,Detection of levels of circulating exosomal lncRNA-GC1,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
8162,NCT02724397,Number of Proximal Serrated lesions and colorectal adenomas in proximal colon,2016-05-01,UNKNOWN,INTERVENTIONAL,['NA'],Improvement of histological diagnosis for serrated lesions and colorectal adenomas using LCI/BLI by comparing with that under white endoscopy,
8163,NCT02548780,Area under the Curve (AUC),2016-04,COMPLETED,INTERVENTIONAL,['NA'],Progression Free Survival,
8164,NCT01158287,Disease control rate after 4 months,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Tolerability and toxicity,
8165,NCT01608841,disease control rate,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],progression-free survival,
8166,NCT03280511,The number of patients with peritoneal recurrence,2017-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],"1-, 3- and 5-year overall survival rate",
8167,NCT04984369,ORR,2021-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
8168,NCT05369234,Management of Oral Mucositis and Esophagitis,2022-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,
8169,NCT06333561,Overall survival,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],Progression-Free-Survival,Objective response rate
8170,NCT04150081,Validation of molecular signatures,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],Sensitivity and specificity of follow-up tests,
8171,NCT01522820,"Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0",2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],NY-ESO-1 specific humoral immunity,Time to disease progression
8172,NCT03422120,Natural Killer Cell Activity (NKA) at baseline compared to POD1 in CRC surgery patients,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],Natural Killer Cell Activity (NKA) in healthy donors (HD) as compared to colorectal cancer (CRC) patients (at baseline),
8173,NCT03403465,Progression free survival (PFS),2018-03-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Measure the potential sparing of radiation dose to critical normal tissue,
8174,NCT06040021,OS,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8175,NCT04327986,Best Overall Response (BOR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) of Bintrafusp Alfa (M7824) & NHS-IL12 (M9241) in Combination With Stereotactic Body Radiation Therapy in Participants With Locally Advanced Pancreas Cancer,2021-06-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Complete Pathological Response Rate(s) For Participants Who Underwent Surgical Resection After Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment,Number of Participants With a Dose-limiting Toxicity (DLT)
8176,NCT03662659,BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests,
8177,NCT01182831,immediate pain relief,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8178,NCT00595972,time to progression,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],toxicity,
8179,NCT05961709,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2025-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8180,NCT06023758,pCR rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival (OS),
8181,NCT03353753,Progression-Free Survival (PFS),2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of Life & Disease-Related Symptoms - EuroQol Visual Analogue Scale,
8182,NCT02852915,Disease free survival,2016-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse events (mortality and morbidity),
8183,NCT01212510,Prediction of tumor progression,2010-10,COMPLETED,INTERVENTIONAL,['NA'],Prediction of tumor response,
8184,NCT04262687,The rate of patients alive and without progression at 10 months after inclusion,2021-04-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Histological response in case of secondary resection,
8185,NCT04774757,3-year DFS,2021-03-10,RECRUITING,INTERVENTIONAL,['NA'],1-year DFS,
8186,NCT04538677,Attitude and satisfaction with video consultation,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],Satisfaction of surgeons: Questionnaire,
8187,NCT04682665,Effect of human faecal samples from patients treated with EPA or placebo on anti-tumour immune response in gnotobiotic mice with colorectal cancer liver metastasis,2021-09-16,RECRUITING,OBSERVATIONAL,['NA'],,
8188,NCT02801500,Bilioenteric anastomotic leakage,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],Bilioenteric anastomotic stricture,
8189,NCT01816607,Presence of metastatic disease 5 years after rectal cancer treatment,2013-10,COMPLETED,OBSERVATIONAL,['NA'],Histomorphological response to preoperative chemoradiotherapy,Detection of regional malignant lymph nodes at time of diagnosis
8190,NCT01191684,Safety and tolerance of modified vaccinia virus ankara vaccine expressing p53 assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4 toxicity scale,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Immunogenicity,
8191,NCT00004002,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8192,NCT02919787,Overall survival 18 month after randomization,2016-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Health economics,
8193,NCT02576548,"Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs) and dose-limiting (DLTs).",2015-09-23,COMPLETED,INTERVENTIONAL,['PHASE1'],Area under the plasma concentration versus time curve (AUC),
8194,NCT00033371,Number of Participants With Adverse Events Occurring at a Frequency of 5% or Grade 3 and Higher,2001-12-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Percent Change in the Area of Plaque-like Duodenal Polyps,Percent Change in Polyp Size in Focal Area(s) of the Colorectum
8195,NCT01876927,the difference in percentage of patients receiving all the planned chemotherapeutic cycles between the two arms.,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Biologcal profile of treatment response,
8196,NCT06249672,Low anterior resection syndrome,2023-01-17,RECRUITING,OBSERVATIONAL,['NA'],,
8197,NCT03280277,Technical feasibility of ultrasmall superparamagnetic iron oxide (USPIO) - magnetic resonance imaging (MRI) of the chest,2018-04-27,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Accuracy of USPIO - MRI,
8198,NCT00155805,,2004-02,UNKNOWN,OBSERVATIONAL,['NA'],,
8199,NCT00568425,Evaluate the late effects of radiation treatment,2005-09,TERMINATED,OBSERVATIONAL,['NA'],,
8200,NCT03358095,Emerged complications related to surgery or preoperative endoscopy within 120 days of surgery,2017-11-26,WITHDRAWN,INTERVENTIONAL,['NA'],,
8201,NCT00976976,"This protocol will evaluate the possible benefit of adjuvant docetaxel, capecitabine, and cisplatin combination chemotherapy in patients with resected gastric cancer pathologic stage IIIB and IV in terms of relapse free survival.",2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],"Investigate the safety profiles, patient tolerance, and overall survival in this population",
8202,NCT00508846,Patient Responses to Questionnaire,2003-05,COMPLETED,OBSERVATIONAL,['NA'],,
8203,NCT01897038,Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs),2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With Anti-therapeutic Antibodies (ATAs) Against Onartuzumab,
8204,NCT05171426,incidental cancer,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8205,NCT00155415,Cleansing level of colon and detected lesion number during colonoscopy,2005-04,COMPLETED,INTERVENTIONAL,['NA'],,
8206,NCT04286711,Dose-Limiting Toxicity [DLT],2020-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival [OS],
8207,NCT00204373,"Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE4'],The Median Survival From the Time of Diagnosis.,
8208,NCT01570010,Overall survival,2012-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Health related quality of life and fatigue,
8209,NCT04222530,Diagnostic accuracy,2020-01-28,UNKNOWN,INTERVENTIONAL,['NA'],Operating time,
8210,NCT01901692,Progression-free survival (PFS) rate,2013-07-29,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Exploratory analysis for overall patient survival rate,
8211,NCT03874559,Exosomal Biomarkers Assessment,2018-02-13,UNKNOWN,OBSERVATIONAL,['NA'],Exosomal Functionality Assessment,
8212,NCT06194877,Part 2: ORR as Assessed by Initial Investigator Review,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Part 2: Number of Participants with Reductions in Dosing with BGB-3245,
8213,NCT03079778,Intrahepatic progression,2019-07-31,WITHDRAWN,INTERVENTIONAL,['NA'],QoL-quality of life,Extrahepatic failure
8214,NCT00869271,overall survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],progression free survival,
8215,NCT00288093,MTD as assessed by the number of patients with dose-limiting toxicity (DLT),2006-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Therapeutic response as assessed using the Response Evaluation Criteria in Solid Tumors (RECIST),
8216,NCT04776590,Pathologic complete response rate,2021-01-28,RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival,
8217,NCT01833832,Intraperitoneal Progression Free Survival (PFS),2013-04-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),
8218,NCT01978717,The changes of peripheral immune cells and cytokines,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
8219,NCT04392050,Successful completion of the key contact interviews and focus groups leading to the development of the culturally tailored educational intervention,2020-01-31,RECRUITING,OBSERVATIONAL,['NA'],,
8220,NCT04104230,Knowledge and Tissue Bank,2012-03-12,RECRUITING,OBSERVATIONAL,['NA'],,
8221,NCT01260168,The primary endpoints are point estimates of the sensitivity of the diagnostic tests for detection of colorectal neoplasms.,2010-10,COMPLETED,OBSERVATIONAL,['NA'],To collect samples from patients diagnosed with colorectal cancers.,
8222,NCT01633333,Pain during colonoscopy,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Dose of medication,
8223,NCT01903694,determination of the tumor according to the evaluation criteria of Response Evaluation Criteria in Solid Tumors,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8224,NCT03297710,Maximum tolerated dose (MTD),2017-12-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time until treatment related grade 3+ toxicity
8225,NCT04595864,OS,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],PFS,
8226,NCT00005864,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8227,NCT01129700,To evaluate the pathologic response,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Acute/ late toxicities,
8228,NCT01781403,Recommended Dose (RD),2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Pathological Complete Response,Disease-free Survival
8229,NCT03415451,The success rates of fiberscope-guided NG tube insertion,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],,
8230,NCT05215899,Mindfulness-based yoga and meditation intervention may reduce fatigue level of colorectal cancer patients,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8231,NCT04411706,Objective Response Rate (ORR),2020-06-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety as measured by the rate of AEs,
8232,NCT02942901,Overall Survival,2015-01,COMPLETED,OBSERVATIONAL,['NA'],Number and sites of metastases detected by PET-CT,
8233,NCT02779608,response rate of ascites,2017-01-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],side effects of chemotherapy,
8234,NCT01306630,"To determine the safety, tolerability, and maximum tolerated dose of tivozanib when administered in combination with capecitabine (Xeloda®) to subjects with advanced solid tumors",2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],"To evaluate the antineoplastic activity of tivozanib and capecitabine, when given together, to slow the growth of or shrink tumor as measured by CT/MRI imaging assessment and according to RECIST criteria.",
8235,NCT05882370,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Median overall survival time (mOS),Treatment-related adverse events
8236,NCT06203327,early gastric neoplasm,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
8237,NCT00899210,Kinetics of postoperative changes of serum matrix metalloproteinases (MMP) and their inhibitors (TIMP),2003-09,COMPLETED,OBSERVATIONAL,['NA'],Correlation of postoperative serum HGF/SF with plasma levels in MMPs,
8238,NCT01082315,Safety,2009-04,COMPLETED,OBSERVATIONAL,['NA'],Clinical efficacy,
8239,NCT04063683,Progress free survival (PFS),2019-10-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Duration of Response(DOR),
8240,NCT06143748,Progression-free survival,2024-03-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Correlation between genetic biomarkers and survival
8241,NCT01327521,Freedom from local progression at 6 months and 12 months,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Serum AFP levels,
8242,NCT03645655,Change of PIVKA-II,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],Change of AFP,
8243,NCT00745134,Number of Participants With Pathologic Complete Response (pCR) Rate,2008-08-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Tumor Downstaging,
8244,NCT02403544,Maximum Tolerated Dose (MTD) for capecitabine and oxaliplatin,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],Tumor response rate including complete response and partial response rates,
8245,NCT00335959,Pathologic Complete Response,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug,
8246,NCT06283134,MTD,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Serum neutralizing antibody level,
8247,NCT05898789,Disability,2023-07-07,RECRUITING,INTERVENTIONAL,['NA'],Physiological measures of performance,
8248,NCT01719549,Progression-free survival,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2'],FGFR2 copy number,
8249,NCT00392470,Pathologic response rate and histological degree of tumor regression as measured by Mandard TRG score,2006-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8250,NCT02057562,Adenoma detection rate,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],Frequency of colon diverticulosis,
8251,NCT03416478,Disease Free Survival,2018-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,
8252,NCT04572633,Primary Safety: Procedure-Related Major Complications,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Secondary Safety: All Adverse Events,
8253,NCT05408897,recurrence,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
8254,NCT02089269,Treatment reality in Germany,2013-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8255,NCT05637268,3-year DFS rate,2020-11-26,RECRUITING,INTERVENTIONAL,['PHASE2'],5 years OS rate,
8256,NCT05194371,Overall survival,2021-06-01,COMPLETED,OBSERVATIONAL,['NA'],Proportion of using chemotherapy or target therapy concurrently with radiotherapy,
8257,NCT00862524,Assess the efficacy of the study drug in combination with gemcitabine in terms of progression-free survival (PFS) at 16 weeks.,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Characterize the safety profile of study drug in combination with gemcitabine in terms of adverse events, clinical laboratory tests and electrocardiograms.",
8258,NCT02786602,"Clinical characteristics (age, sex, tumor location) compared between LRP1 high and low methylation groups.",2016-05,COMPLETED,OBSERVATIONAL,['NA'],,
8259,NCT04143048,Genetic mutations of patients with stromal tumor assessed by next-generation sequencing,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],Genetic mutations of patients with stromal tumor assessed by next-generation sequencing,
8260,NCT04440735,DSP107 Serum Concentration,2020-10-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Preliminary Efficacy (Part 2 only),
8261,NCT05834543,ORR,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of serious adverse events (SAEs),
8262,NCT01568723,Response to therapy,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
8263,NCT02250053,"1. The biological efficacy of aerobic exercise on soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular adhesion molecule-1 (sVCAM-1) prognostic biomarkers.",2015-12,COMPLETED,INTERVENTIONAL,['NA'],Circulating tumor cells measured at baseline and six-months.,
8264,NCT00590278,"This study will evaluate the value of TOMUDEX in combination with a 'standard' course of pelvic radiotherapy for inoperable/recurrent rectal cancer, in terms of response rate and increasing the resectability rate",2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8265,NCT04704960,correlation between circulating tumor DNA (ctDNA) before and after local treatment (surgery or radiation) and recurrence of lung metastases from colorectal cancer,2021-02,UNKNOWN,OBSERVATIONAL,['NA'],mutations related to target drug,
8266,NCT04293458,Primary Efficacy,2020-02-28,COMPLETED,INTERVENTIONAL,['NA'],Secondary Efficacy,Safety of EsoCheck device administration
8267,NCT02624115,FAZA PET uptake in locally advanced rectal cancers prior to and after chemoradiotherapy,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],Correlation of FAZA-PET and blood oxygen level-dependent MRI to Pimonidazole staining in locally advanced rectal cancer,
8268,NCT04198766,MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab,2019-12-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Immunogenicity of INBRX-106,Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab
8269,NCT02919969,Overall Response Rate,2016-10-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events to Evaluate the Safety and Tolerability of Pembrolizumab,
8270,NCT05354817,Assess response rate after 4 cycles of FOLFIRINOX,2021-10-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival,
8271,NCT02584244,"Correlate LUM015 fluorescence in gastrointestinal cancers (pancreatic, esophageal, and colorectal) with pathology results",2016-08-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Number of safety events in humans with colorectal, pancreatic, and esophageal cancer.",
8272,NCT03974594,Bioequivalence based on Peak Plasma Concentration (Cmax),2019-05-21,COMPLETED,INTERVENTIONAL,['PHASE1'],Adverse Event,
8273,NCT03332576,Safety as measured by adverse event reporting (CTCAE),2013-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],Impact on residual tumour,
8274,NCT04422002,Survival,2019-12-01,COMPLETED,OBSERVATIONAL,['NA'],Surgical complications,
8275,NCT04295109,effective bolus times,2020-03-02,UNKNOWN,INTERVENTIONAL,['NA'],postoperative hospitalization days,
8276,NCT01157598,the satisfaction of patients and endoscopist in midazolam and meperidine induced sedation with BIS monitoring during ESD,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],the dose of midazolam and meperidine during ESD with BIS monitoring,
8277,NCT03592550,Difference in liver position after set-up,2018-09,UNKNOWN,OBSERVATIONAL,['NA'],Number of available imaging positions,
8278,NCT00500292,Number of Patients With an Objective Disease Progression Event,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8279,NCT02293954,Tumor Uptake of 64Cu-DOTA-hT4.66-M5A at Day 2,2015-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],The Average Increase of Tumor-to-blood (T:B) Ratio From Day 1 to Day 2,
8280,NCT00426127,Tumor Response Measured by CT Scans After Each Set of 3 Cycles of Chemotherapy,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Safety and Effect of Chemo Regimen on D-Dimer Measured by Drawing D-Dimer Levels Every Cycle,
8281,NCT01831726,Clinical Benefit Rate (CBR),2013-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
8282,NCT05080907,Collection of Biospecimens for Novel Research Uses,2016-07-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Number of subjects enrolled,
8283,NCT02520453,Disease-free survival,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8284,NCT02077881,Overall Survival,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to Progression of Disease,
8285,NCT02007876,Muscle Mass,2013-06,WITHDRAWN,INTERVENTIONAL,['NA'],Effects of Individual MAT Program Segment,Effect of MAT of Hospital Length of Stay
8286,NCT02470559,Toxicity profile of IP and IV HER2Bi-aATC at the MTD or technically feasible dose graded using NCI CTCAE version 4.0,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Progression free survival,
8287,NCT00558051,The primary endpoint of this study is to evaluate the feasibility and safety of semi-continuous intralymphatic vaccination dendritic cells.,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],"The secondary objective of this study is to evaluate the immunity results from either single injections or semi-continuous infusion, intradermal or intranodal, administered immunization with the DC vaccine for colorectal cancer (CRC) patients.",
8288,NCT02703571,Objective Response Rate (ORR),2016-06-29,TERMINATED,INTERVENTIONAL,['PHASE1'],overall survival,
8289,NCT05536427,Tolerance(DLT/ MTD/ OBD),2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
8290,NCT06061445,ORR,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8291,NCT04544046,Proportion of participants requiring a hospital admission or emergency department visit,2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in Instrumental Activities of Daily Living (IADLs),
8292,NCT00149266,overall survival,1995-07,TERMINATED,INTERVENTIONAL,['PHASE3'],quality of life,
8293,NCT03844750,Proportion of patients with a >= 2-fold increase in the tumor-infiltrating cells per unit area (5 high power fields) in post- versus pre pembrolizumab treatment tumor specimens.,2019-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Median Relapse-free survival (RFS) per RECIST 1.1,
8294,NCT01264822,Transition rate to secondary therapy for eradication of Helicobacter pylori,2011-01-13,COMPLETED,OBSERVATIONAL,['NA'],,
8295,NCT01336062,Objective response rate,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",biomarkers,
8296,NCT06263088,Biomarker testing rate of Black participants diagnosed with GI cancer,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Change in Health literacy score among black participants diagnosed with GI cancer,
8297,NCT03396705,Gene expression,2017-09-12,TERMINATED,OBSERVATIONAL,['NA'],,
8298,NCT03391843,Pelvic complete resection rate,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],The incidence of >=3 grade adverse events,
8299,NCT02098239,Patient Survival,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Injection Tolerability,
8300,NCT00948337,Screening behavior for second primary cancer,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Knowledge and attitudes of Secondary cancer screening and dietary supplement,
8301,NCT05203627,Objective measures of patient nutrition - Skeletal mass Index,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
8302,NCT04775862,Progression-free survival (PFS),2021-02-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],Determine the prevalence of RAS G12C mutation via using cfDNA,
8303,NCT03652077,Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only),2018-09-24,COMPLETED,INTERVENTIONAL,['PHASE1'],Immunogenicity of INCAGN02390,
8304,NCT02966223,Primary,2017-08-17,TERMINATED,INTERVENTIONAL,['NA'],Secondary,
8305,NCT04777162,objective response rate,2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,
8306,NCT00037804,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8307,NCT01443065,Progression-free survival at 4 months,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Tolerance of the treatment,
8308,NCT03959839,local recurrence rate,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA'],Short-term local recurrence rate,
8309,NCT00972036,"To determine the safety, toxicity, and maximum tolerated dose of SIR-Spheres® in patients with unresectable metastatic colorectal cancer to the liver (CLM) who have received previous hepatic arterial infusion chemotherapy (HAC).",2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],To obtain preliminary evidence of any clinical efficacy of the SIRT therapy in these heavily pretreated patients with unresectable CLM who have received hepatic arterial infusion pump and have failed at least one line of prior chemotherapy.,
8310,NCT05323929,scar area,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
8311,NCT01688817,Effect of primary care physician's (PCP) counseling on participation rate in primary colonoscopy screening program,2008-05,COMPLETED,INTERVENTIONAL,['NA'],Effect of primary care physician's (PCP) counseling on a patient's decision to choose unsedated colonoscopy (not in sedation).,
8312,NCT05993702,Progression-free Survival (PFS),2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Incidence and severity of adverse events (AE) and serious adverse events (SAE),
8313,NCT01393249,Risk of pancreatitis,2011-07,COMPLETED,OBSERVATIONAL,['NA'],Course of pancreatitis,
8314,NCT02851784,"Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test.",2009-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","disease free survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test","Local tumor progress rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test"
8315,NCT04678011,Advanced neoplasia,2020-11-24,RECRUITING,OBSERVATIONAL,['NA'],Complications,
8316,NCT01640522,Depression,2008-01,COMPLETED,INTERVENTIONAL,['NA'],Fatigue,
8317,NCT05369650,Immediate postoperative plasma lidocaine concentration,2019-07-27,RECRUITING,INTERVENTIONAL,['NA'],Patient satisfaction scores,
8318,NCT02136836,The proportion of HER2 overexpression in gastric cancer patients,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],Gastric cancer specific survival according to HER2 expression in each stage,The practice pattern of Herceptin use in stage IV gastric cancer
8319,NCT05332002,Adverse Event Rates,2022-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8320,NCT06249841,"The primary endpoint of this study is feasibility of percutaneous cryobiopsy in the bile duct, i.e., successful retrieval of at least one cryobiopsy specimen per patient.",2024-03-04,RECRUITING,INTERVENTIONAL,['NA'],"Rate of safety-relevant aspects, like for example bleeding, post-bleeding, perforation, infection and abscess",
8321,NCT02792881,Morbidity,2016-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],The Surgery Task Load Index (SURG-TLX),
8322,NCT04596865,Patterns of disease recurrence,2020-10-12,COMPLETED,OBSERVATIONAL,['NA'],"Determine if/how specific patterns of recurrence (local only, distant only, synchronous local and distant) following pancreaticoduodenectomy for pancreatic head malignancy correlate with the following factors:",
8323,NCT02444572,Incidence of asymptomatic Deep Venous Thrombosis (DVT),2015-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Incidence of both Enoxaparin formulations immunogenicity,
8324,NCT00897832,Determination if a method of extracting and identifying biomarkers from tissues of the quantity obtained from typical biopsy can be applied in the setting of pancreatic cancer,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,
8325,NCT01317433,reduction of Grade > or = 2 acne-like skin rash by 30%,2010-12-29,TERMINATED,INTERVENTIONAL,['NA'],Resectability rate,
8326,NCT00580281,"This pilot study will collect longitudinal data on bone metabolism for patients treated with imatinib. Sixty patients will be followed over a two-year period on this protocol, with bone marker assessments ascertained every 3 months (+2 weeks).",2006-11,COMPLETED,INTERVENTIONAL,['NA'],,
8327,NCT02081755,"Disease free survival (DFS) defined as the time from randomization to the time of tumor recurrence or death, whichever occurs first.",2014-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Hepatic arterial thrombosis,
8328,NCT05711823,Complete response rate,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
8329,NCT02640781,Duration of stent patency between stent insertion and recurrence of obstructive symptoms,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],Number of patients with complications,
8330,NCT02008539,Safety and tolerability as indicated by Common Toxicity Criteria (CTC-AE) of the National Cancer Institute,2013-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8331,NCT03775863,Incidence of recurrent hepatocellular carcinoma after liver transplantation.,2017-11-11,COMPLETED,OBSERVATIONAL,['NA'],Survival in patients with hepatocellular carcinoma after liver transplantation.,
8332,NCT00060411,The relationship between CYP3A4 activity and OSI-774 clearance,2003-06,COMPLETED,INTERVENTIONAL,['PHASE1'],"Pharmacokinetics of OSI-774 given with FOLFOX 4, and Bevacizumab",
8333,NCT00075439,Proportion of patients progression-free at 6 months,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to treatment failure,
8334,NCT02227940,"MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation, defined as the highest dose level at which < 2 of 6 patients experience treatment-related DLT (Arms 2 and 2E)",2015-01-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Response rate as assessed by the RECIST 1.1,Levels of serum and tumor biomarkers
8335,NCT01673334,Diagnostic Yield,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8336,NCT04050462,Objective Response Rate (ORR) of Cabiralizumab or BMS-986253 in combination with Nivolumab in comparison to Nivolumab monotherapy,2019-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8337,NCT03046849,Pathogenic germline mutation,2017-03-08,COMPLETED,OBSERVATIONAL,['NA'],Variant of uncertain significance of germline mutation,
8338,NCT01956149,Disease Control Rate (DCR),2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Correlation of circulating tumor cells with the clinical response,
8339,NCT06276140,Overall morbidity,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Values of different erythrocyte indices,
8340,NCT03257280,Hospital stay,2017-10-20,UNKNOWN,INTERVENTIONAL,['NA'],Impedancemetry,
8341,NCT01068769,"Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease Control",2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free Survival (PFS),
8342,NCT00237185,Best Tumor Response (Core + Extension),2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Progression (Core + Extension),
8343,NCT06010888,Objective Response Rate（ORR）,2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival（OS）,
8344,NCT03301805,Part II: Overall response rate (PR + CR),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Part II: Incidence of grade 3/4 hematological toxicity,
8345,NCT03393234,3-year disease free survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],sexual function,
8346,NCT04331743,Recommended Phase II Dose (RP2D),2021-06-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],Duration of Response (DoR),
8347,NCT00650988,Number of patients that experience toxicity with cryotherapy,2005-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Assess the degree of tumor ablation of inoperable early esophageal cancer,
8348,NCT02163759,"Percentage of Participants in Remission at Week 10 With Etrolizumab as Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28948 Population",2014-11-04,COMPLETED,INTERVENTIONAL,['PHASE3'],"Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Anytime Post-Baseline, GA28948 Population",
8349,NCT06249321,"progression-free survival, PFS",2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],disease control rate (DCR),
8350,NCT04340141,Overall survival (OS),2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Computed tomography (CT)-based radiomics as non-invasive predictors of overall survival,
8351,NCT03816163,Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events,2019-03-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Health Related Quality of Life (HRQoL) measured by the Patient Global Impression of Severity (PGIS) Scale,
8352,NCT01746771,Safety evaluation(phase I),2012-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Efficacy evaluation(Phase II),
8353,NCT03252938,Feasibility rate,2017-08-15,RECRUITING,INTERVENTIONAL,['PHASE1'],Immune response in whole blood and tumor tissue,
8354,NCT01966289,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-04-14,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression Free Survival (PFS),
8355,NCT03768687,Progression free survival,2018-12-20,UNKNOWN,OBSERVATIONAL,['NA'],,
8356,NCT02892721,Difference in sensitivity between arms,2017-04-20,COMPLETED,INTERVENTIONAL,['NA'],Characteristics of radiologists performing well versus those that do not.,
8357,NCT01189929,To determine the maximum tolerated dose of demcizumab (OMP-21M18) when combined with gemcitabine +/- Abraxane®,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],To determine the exploratory biomarker changes of gemcitabine plus demcizumab (OMP-21M18),
8358,NCT01549327,Empowerment,2012-05,COMPLETED,INTERVENTIONAL,['NA'],Cost-effectiveness,
8359,NCT00656838,"To determine the effectiveness and maintenance of a colon-rectal cancer screening patient reminder program.Identify patient, primary care team, and system factors important to implementation success.",2008-04,COMPLETED,INTERVENTIONAL,['NA'],"Create, refine, and disseminate an implementation guide for colon-rectal cancer screening reminder programs by combining the findings from the primary aim.",
8360,NCT03693170,Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments,2019-01-17,COMPLETED,INTERVENTIONAL,['PHASE2'],PGIC Scores Over Time,
8361,NCT02500043,Overall Survival (OS),2016-02-24,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE),EORTC Quality of Life Questionnaire - Gastric-specific Module (EORTC QLQ-STO22): Percentage of Participants With Overall Compliance
8362,NCT05736731,Phase 2: The Overall Response Rate (ORR) for patients,2023-04-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Cytokine analysis,
8363,NCT02632682,Probe-based confocal laser endomicroscopy (pCLE) will be compared to standard histologic analysis in the evaluation of Barrett's esophagus.,2016-02,COMPLETED,OBSERVATIONAL,['NA'],,
8364,NCT06138223,Quality of life (EORTC-QLQ-30) summary score,2023-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Health-related quality of life: fatigue,(Serious) Adverse Events potentially related to the exercise intervention
8365,NCT03043183,complication,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8366,NCT00005639,Minimal Effective Dose (MED) of Azacitidine with Phenylbutyrate,2000-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Gene-re-expression of epigenetic modulation in Peripheral Blood Mononuclear Cells (PBMC) as measured by change in Epstein-Barr Virus (EBV) viral load (number of copies per 1 million cells) after treatment with Azacitidine,
8367,NCT00321685,Pathologic Complete Response Rate,2006-07-25,COMPLETED,INTERVENTIONAL,['PHASE2'],5-year Recurrence-free Survival Rate,
8368,NCT05789433,Whole-Body Intermuscular Adipose Tissue,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
8369,NCT02316496,Objective response rate (ORR),2015-09-23,TERMINATED,INTERVENTIONAL,['PHASE2'],PFS,
8370,NCT05156866,Recommended Phase 2 Dose (RP2D),2022-02-02,RECRUITING,INTERVENTIONAL,['PHASE1'],Accumulation ratio (Rac) of TORL-2-307-ADC,
8371,NCT03445585,Number of participants in the study.,2017-01,RECRUITING,OBSERVATIONAL,['NA'],Number of clinical phenotypes and/or endpoints observed (per category),
8372,NCT01509911,Disease Control Rate as defined by Percentage of patients experiencing a Complete Response or a Partial Response or a Stable Disease according to RECIST measured at 16 weeks after treatment initiation,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival,
8373,NCT02331927,Randomized part: PFS rate at 6 months after first cycle after randomization,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Prognostic value of CAF at baseline and/or during treatment,
8374,NCT00504998,"Clinical toxicity (DLT and MTD) as defined by patient performance status, toxicity assessment score, hematologic, and metabolic profiles.",2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To identify an objective tumor response to Rexin-G,
8375,NCT04605237,Survival,2014-01-01,RECRUITING,OBSERVATIONAL,['NA'],Number of histologically confirmed recurrences,
8376,NCT00764595,Progression-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Types and severities of adverse events,
8377,NCT04315883,Evaluate the efficacy and clinical utility of TARE-Y90 by examining clinical course,2021-02-11,RECRUITING,OBSERVATIONAL,['NA'],,
8378,NCT00838968,5-years survival rate,2008-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
8379,NCT05495776,Frequency of microsatellite instability and Lynch syndrome,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],Impact of the presence of microsatellite instability/deficiency,
8380,NCT02139605,primary endpoint:Overall Survival,2013-07-05,RECRUITING,INTERVENTIONAL,['NA'],Disease-free survival,
8381,NCT00834158,the rate of tumor resection after intervention,2009-01,COMPLETED,INTERVENTIONAL,['NA'],rate of survival,
8382,NCT00960284,1-year progression-free survival (Phase II),2003-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Pattern of relapse,
8383,NCT05854498,Progression Free Survival (PFS),2023-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Efficacy of irinotecan measured by PFS for patients with and without irinotecan containing regimens,
8384,NCT04120935,Number of patients longitudinally monitored,2019-10-15,RECRUITING,OBSERVATIONAL,['NA'],Number of patients triaged in proof-of-concept (POC) clinical trials,Correlation of new prognostic and predictive biomarkers with clinical outcomes
8385,NCT02137343,Overall Survival,2014-07,TERMINATED,INTERVENTIONAL,['PHASE3'],"Incidence of subject adverse events, laboratory abnormalities and immunogenicity",
8386,NCT00003063,,1991-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8387,NCT01897584,arterial oxygenation (PaO2),2013-07,COMPLETED,INTERVENTIONAL,['NA'],cerebral perfusion pressure,
8388,NCT06271109,complete resection of the neoplasm,2021-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],recurrence rate,
8389,NCT06026618,Change in Hemoglobin,2012-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],number of complications related to IVI administration,
8390,NCT03659357,the size in centimeters,2018-09-01,UNKNOWN,OBSERVATIONAL,['NA'],intensity of the neoplasms measured in the CTE in Hu,
8391,NCT05816980,Resection rate,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Comparative dose planning study,
8392,NCT01186081,Disease-free survival,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Treatment related toxicities,
8393,NCT02980510,Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8394,NCT00960609,First outcome was the rate of CVs detectable with e-flow IOUS along clamping of the HV for which resection could be needed.,2008-01,COMPLETED,OBSERVATIONAL,['NA'],"Secondary outcome was safety (morbidity, mortality, blood loss, blood transfusions) of the procedure.",
8395,NCT02005614,Rate of Local Control Over time (RECIST Criteria),2013-11,TERMINATED,INTERVENTIONAL,['NA'],,
8396,NCT00838318,"To look at the knowledge, beliefs, and attitudes toward screening for colorectal cancer among Hispanic colorectal cancer patients and their close relatives.",2004-02,COMPLETED,OBSERVATIONAL,['NA'],To study how these families communicate with each other and health care providers about colorectal cancer risk and screening.,
8397,NCT04984733,Tumour Response to nivolumab,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],The percentage of patients who have achieved response,
8398,NCT03781050,Total load of PJS-related intestinal polyps Total load of PJS-related intestinal polyps Total load of PJS-related intestinal polyps,2018-09-16,UNKNOWN,INTERVENTIONAL,['PHASE4'],Adverse events,
8399,NCT00920868,To determine the maximum tolerated dose(MTD)/recommended phase II dose (RPTD) of capecitabine/oxaliplatin/bevacizumab/dasatinib for patients with advanced solid tumors.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],"To explore any correlation between blood, urine, and paraffin biomarkers and clinical outcomes",
8400,NCT05494086,Early operative morbidity,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],5 year overall survival rate,
8401,NCT01911273,Overall Survival (OS),2013-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Observed Serum Concentration of Circulating Protein,
8402,NCT00010023,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8403,NCT02279134,Disease-free survival (DFS),2014-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall survival (OS),Adverse events
8404,NCT01440959,Disease Control Rate (DCR; OR + Stable Disease),2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
8405,NCT03862378,Predictive value of the nomogram prediction model (APPEAL-GC score),2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Abdominal infection outcome.,
8406,NCT00184834,,1999-06,COMPLETED,OBSERVATIONAL,['NA'],,
8407,NCT02827201,Rate of patients alive without progression 6 months after inclusion,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival:,
8408,NCT02675738,Number of cases with confirmed preoperative diagnosis,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,
8409,NCT05239169,Recurrence free survival at 12 months (RFS@12).,2022-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],QoL EQ-5D-5L,
8410,NCT00009737,Disease-free Survival,1998-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Any Adverse Events and Serious Adverse Events,
8411,NCT02960620,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
8412,NCT00576134,Respiratory evaluation,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Nasofibroscopy,
8413,NCT00356161,Safety of device and regional therapy,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of life,
8414,NCT02726399,Progression Free Survival,2016-03-18,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8415,NCT00885469,"Accuracy parameters (sensitivity, specificity, NPV, PPV) of PillCam ESO 2 in detecting suspected Barrett's Esophagus (BE) as compared to standard EGD, using unblinded EGD as the reference standard.",2007-12,COMPLETED,OBSERVATIONAL,['NA'],Subjects' satisfaction will be assessed by a post procedure questionnaire,
8416,NCT05645198,Ratio of (patient who suffers from) pancreatic fistula,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE4'],,
8417,NCT05440864,Number of greater than grade 3 adverse events (AEs) or immune related adverse events that leads to treatment cessation,2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Rates of R0 resection,Taxonomic profiling of gut microbiome
8418,NCT01643070,R0 resection rate after simultaneous surgery of the rectum and the liver,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8419,NCT03519997,Overall Response Rate,2018-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and Tolerability: rates of adverse events according to the CTCAE,Treatment response
8420,NCT04343456,Disease free survival,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8421,NCT02113202,"Number of fluorescent adenomatous polyps during surveillance endoscopy using the near-infrared fluorescence endoscopy platform in patients with Familial Adenomatous Polyposis (FAP), after administration of the fluorescent tracer bevacizumab-IRDye800CW.",2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Measure the mean fluorescent intensity of adenomas and compare this between the three different dosing groups to determine the best tracer dose for the fluorescence endoscopy procedure.,
8422,NCT00740753,"Tumor response after treatment based on tumor marker and lab results, CT scan and patient's symptoms.",2004-08,COMPLETED,INTERVENTIONAL,['NA'],,
8423,NCT04166240,EPRP Outcome,2018-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
8424,NCT00296335,Relapse-free Survival Rate,2002-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Patients With Adverse Events,
8425,NCT04104139,Proportion of dose limiting toxicity (DLT)s for TAS-102 at the maximum tolerated dose (MTD),2019-12-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of grade 3 or higher treatment emergent adverse events (TEAEs) during FOLFOX or CAPOX treatment,Rate of pathologic complete response after standard total mesorectal excision (TME)
8426,NCT00159471,"To see if patients with advanced pancreatic cancer treated with gemcitabine, docetaxel and capecitabine who bear more favorable genotypes of genes involved in drug metabolisms are more likely to have response and survive longer than those that do not.",2005-02,TERMINATED,INTERVENTIONAL,['NA'],"To assess time to progression, toxicity and to identify other molecular correlates of response, toxicity, and survival.",
8427,NCT03216174,Complete resection,2017-07-11,UNKNOWN,INTERVENTIONAL,['NA'],,
8428,NCT05012540,The overall survival,2013-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
8429,NCT03442569,Overall Response Rate,2018-03-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity of Treatment,
8430,NCT01152645,Antitumor effect,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse events,
8431,NCT01305993,Evaluating Tumor Response Rate,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Determine duration of response rate by measuring time to progression,
8432,NCT03876561,Severity of Low Anterior Resection Syndrome Score (LARS score),2019-05-27,UNKNOWN,INTERVENTIONAL,['NA'],Medico-economic impact of pelvic floor prehabilitation including the fecal incontinence related costs,
8433,NCT02930291,3-year disease free survival rate,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],Visual Analog Score for pain,
8434,NCT02198976,Number of Serious and Non-Serious Adverse Events,2014-04,RECRUITING,OBSERVATIONAL,['NA'],Number of Participants with Serious and Non-Serious Adverse Events,
8435,NCT04825288,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0,2021-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in (CD14+CD16+IL-1⍺+) triple positive tumor associated monocytes in peripheral blood,Cardiotoxicity measured by the number of required ECGs and cardiotoxicity related events summarized by treatment arm and compared over time
8436,NCT00837031,"Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment",2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],"Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death",
8437,NCT00905710,"The primary endpoints of the study are the number of adenomas, advanced adenomas, carcinomas at baseline and the number of the number of adenomas, advanced adenomas, carcinomas and the number of patients requiring colectomy at 2-year follow-up.",2008-09,COMPLETED,INTERVENTIONAL,['NA'],The secondary endpoints of the study are the number of complications from colonoscopy at baseline and at 2-year follow-up.,
8438,NCT04719988,Clinical complete response (cCR) at 10 months,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8439,NCT00042939,Proportion of Patients With Objective Response Evaluated by RECIST (Solid Tumor Response Criteria),2003-12-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Proportion of Patients With Thromboembolic Events,
8440,NCT02562963,"Objective Response Rate (ORR), confirmed by CT or MRI, or confirmed by biopsy",2015-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumor Marker,
8441,NCT00466856,Tumor response,2003-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Patient report of Health-related quality of life (HRQOL),
8442,NCT01449864,Acute Toxicity,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,
8443,NCT04160416,Incidence of adverse events,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8444,NCT02095678,Mean Transit Time (MTT),2013-12-01,COMPLETED,INTERVENTIONAL,['NA'],Minimal Breathhold Time,
8445,NCT04444622,Incidents of Adverse Events (AE),2021-07-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8446,NCT01821105,Detection of Position Accuracy With Handheld Probe on Anatomical Location.,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor Detection,
8447,NCT01458925,safety - transit time (less than 300 hours),2011-11-20,TERMINATED,INTERVENTIONAL,['NA'],"Colon Capsule correlation map (Empirical, qualitative)",
8448,NCT03581773,CTCAE Mucositis,2017-12-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],QOL MDASI,
8449,NCT04180072,Best overall response rate,2020-03-12,RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
8450,NCT05368506,Incidence of adverse events,2023-07-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Overall survival,Cellular and molecular characteristics
8451,NCT03447951,Objective Response Rate (ORR),2018-06-19,RECRUITING,INTERVENTIONAL,['PHASE2'],EQ-5D-5L quality of life score,
8452,NCT01774344,Overall Survival (OS),2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease Control Rate (DCR),Overall Survival (OS)
8453,NCT01767597,Percentage of Patients Appropriately Seeking Care,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
8454,NCT03144843,Progression-free survival (PFS),2017-01-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety (incidence of adverse events) [,
8455,NCT01185483,,2009-11,UNKNOWN,OBSERVATIONAL,['NA'],,
8456,NCT00441337,Percent of Participants With Prostate-Specific Antigen (PSA) Response After the First Dose by Day 85 In Participants With Hormone-Refractory Prostate Adenocarcinoma (HRPC),2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],"Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in in 1mg, 3mg, and 10 mg Cohorts - Safety Population",
8457,NCT04273477,The prediction accuracy of the radiomics prediction model,2020-01-10,UNKNOWN,OBSERVATIONAL,['NA'],The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiomics prediction model,
8458,NCT04726319,Changes in risk-appropriate screening based on family history,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Attitudes towards the FHAMe intervention,
8459,NCT02858206,Adverse events,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Recurrence rate,
8460,NCT01792934,Overall survival,2013-05,RECRUITING,INTERVENTIONAL,['NA'],Safety and efficacy of the additional local treatment measured by number of serious adverse events.,
8461,NCT02200250,Reviewing patients symptoms following resection,2021-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
8462,NCT03682744,Safety of Intraperitoneal CAR-T Cell Infusions as Measured by Number of Participants with Adverse Events,2018-09-13,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Serologic response rates,
8463,NCT03840590,"Adenoma detection rate, ADR",2019-07-10,COMPLETED,INTERVENTIONAL,['NA'],"Polyp detection rate, PDR",
8464,NCT05076305,Assessment of resectability,2021-10-15,UNKNOWN,OBSERVATIONAL,['NA'],Assessment of staging,
8465,NCT03921684,Incidence of Treatment-Emergent Adverse Events (Safety),2019-04,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
8466,NCT05919758,Recurrence rate,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],Health related Quality of Life at follow-up moment for this study,
8467,NCT05990257,pain control,2018-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
8468,NCT01427647,Plasma levels of several cytokines after colorectal cancer surgery,2007-06,COMPLETED,INTERVENTIONAL,['NA'],Incidence of adverse clinical outcomes between groups,
8469,NCT02078245,MRI accuracy,2010-08,RECRUITING,OBSERVATIONAL,['NA'],Outcome of surveillance program,
8470,NCT02178644,pCR Rate,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8471,NCT01303172,Safety and Tolerability.,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival in Metastatic Patients Only,
8472,NCT00972881,Histologically confirmed R0 resection rate,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Local failure-free survival,
8473,NCT04241887,Effectiveness of PVB on pain intensity,2017-09-09,COMPLETED,INTERVENTIONAL,['NA'],Surgeon's satisfaction,
8474,NCT00182611,Overall survival,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Adverse events,
8475,NCT02618850,change from baseline in highest value SUVmax (maximum standardized uptake values in PET/CT scan),2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"prognostic value of metabolic response (SUVmax, SUVmaxsum, TLGmax, TLGsum) and recist response","prognostic value of metabolic response (SUVmax, SUVmaxsum, TLGmax, TLGsum) by different cut off values (other than 50% reduction)"
8476,NCT02979691,Overall survival,2016-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Chemoradiotherapy toxicities,Clinical target contouring guided by MRI or CT simulation
8477,NCT04005742,Serum high-sensitivity C-Reactive Protein concentrations (marker of systemic inflammation),2017-03-13,COMPLETED,OBSERVATIONAL,['NA'],HbA1c in whole blood,Sedentary behaviour assessed using Lifestyle Questionnaire
8478,NCT01521702,progression-free survival,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],complication,
8479,NCT05620485,Long-term complications,2022-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],length of nutritional support in hospital,
8480,NCT05924880,The incidence of Possible related adverse events(PRAE) Grade 3 or 4,2023-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse Events(AEs) resulting in study intervention interruption and discontinuation,
8481,NCT00524186,"Maximum tolerated dose of sunitinib malate when administered with FOLFIRI chemotherapy (i.e., irinotecan hydrochloride, fluorouracil, and leucovorin calcium)",2007-05,TERMINATED,INTERVENTIONAL,['PHASE1'],Correlation of pre- and post-therapy changes in CEC number and VEGF expression with response rate and survival,
8482,NCT01593475,feasibility and compliance,2011-09-05,COMPLETED,INTERVENTIONAL,['PHASE2'],disease-free survival.,
8483,NCT02600481,Troponin T level is set as the marker of myocardial injuries after robot-assisted surgeries,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Chest CT scan is used to determine pulmonary complications,
8484,NCT01777698,Changes in body composition,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
8485,NCT03993327,Percent of known liver lesions per standard staging scans identified on iodine I-124 (I-124) M5A imaging,2020-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of adverse events,
8486,NCT04665947,[177Lu]Lu DOTA-ABM-5G dose escalation therapy,2020-12-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Assessment of organ dosimetry of [177Lu]Lu DOTA-ABM-5G,
8487,NCT03165721,Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST),2017-08-16,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in Distress From Baseline,
8488,NCT05257408,Progression-free Survival as Assessed by BICR,2022-06-29,RECRUITING,INTERVENTIONAL,['PHASE3'],Combined Response According to RECIST v1.1 and GCIG Criteria,
8489,NCT00036790,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8490,NCT02891447,Patterns of tumor recurrence,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
8491,NCT03650517,Clavien Dindo Complication,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],C-Reactive Protein value (CRP) days 1 & 3 postoperative,Pain evaluation
8492,NCT04716062,Clavien Dindo score (post-operative complications),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],Lenght of specimen,
8493,NCT01243398,Overall survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression-free survival,
8494,NCT03177317,Complete response (CR),2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],Complete protection (CP),
8495,NCT01607255,Number of Participants With Detected Proximal Diminutive (<10 mm) Adenoma Detection Rate,2013-05-16,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8496,NCT01657175,Quality of Life,2009-01,COMPLETED,INTERVENTIONAL,['NA'],Contacts with the health care system,
8497,NCT01876069,The rates of diagnostic sufficiency,2013-07,COMPLETED,INTERVENTIONAL,['NA'],The presence of histologic core,Procedure related complications
8498,NCT06326736,Incidence of Treatment Emergent Adverse Events (TEAEs),2024-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Disease control rate (DCR),
8499,NCT05940740,Nightingale Symptom Evaluation Scale,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],Self-Care Needs Evaluation Form,
8500,NCT04303286,Species differential analysis,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
8501,NCT02031536,Disease Free Survival (DFS),2014-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
8502,NCT04177797,Complete pathologic response rate,2020-03-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
8503,NCT01686880,Peri-operative morbidity,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Contra-lateral Lobe Hypertrophy,
8504,NCT06199115,Neuropathic Pain Synptom Inventory : pain,2023-05-31,RECRUITING,INTERVENTIONAL,['NA'],Evaluation of sensitive and motor symptoms,
8505,NCT03415126,"Part B: evaluate the overall response rate (number of Complete Responses + Partial Responses) in subjects receiving ASN007 for the treatment of metastatic melanoma, CRC, NSCLC, or pancreatic cancer.",2018-01-19,COMPLETED,INTERVENTIONAL,['PHASE1'],Calculate the terminal elimination rate (T 1/2).,Evaluate the change from baseline in the amount of circulating tumor DNA
8506,NCT03205176,Incidence of dose-limiting toxicity (DLT).,2017-06-30,COMPLETED,INTERVENTIONAL,['PHASE1'],Clearance (CL).,
8507,NCT05002452,Tumor Response,2021-12-20,RECRUITING,OBSERVATIONAL,['NA'],Distant control,
8508,NCT00969657,Pathological complete response (ypT0N0),2009-08,COMPLETED,OBSERVATIONAL,['NA'],"Several extra outcomes are registered for research: Local relapse at 2 years, metastases free survival, survival and relapse free survival",
8509,NCT06006390,Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability],2023-09-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacodynamics of CEA CAR-T cells[Cell dynamics],Overall survival(OS)of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness]
8510,NCT05771025,Overall survival time,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],Unplanned reoperation rate,
8511,NCT06307548,Changes in carcinoembryonic antigen (CEA) and circulating tumor deoxyribonucleic acid (ctDNA) (Phase II),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Correlation between disease free survival and changes in levels of ctDNA (Phase II),
8512,NCT02943265,Patient Perception of Care (Scale),2017-09-18,COMPLETED,INTERVENTIONAL,['NA'],,
8513,NCT04680104,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2015-11-03,COMPLETED,OBSERVATIONAL,['NA'],economical impact,
8514,NCT02427841,R0 Resection Rate Defined as Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins by Pathologic Assessment,2016-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Response Rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Defined as the Percent of Subjects With Complete or Partial Disease Response as Confirmed Through Tumor Imaging With Computed Tomography (CT),
8515,NCT05253846,complete pathologic response (pCR),2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Rectal Continence,Correlation of FFS and pCR with ctDNA status
8516,NCT00408070,Progression Free Survival Rate at 9 Months,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Determine Tolerability to 12 Months (q 3 Weeks) of Bevacizumab Maintenance Therapy,
8517,NCT05793554,Validation of tissue classification through fluorescence perfusion,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Usability of video sharing and annotation technology in multiple sites,
8518,NCT05061537,Objective response rate in the dose expansion (Part 2) arms,2021-10-20,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall survival (Part 2),
8519,NCT01637805,Objective response rate,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8520,NCT04874259,1 year patient survival,2022-08-22,RECRUITING,INTERVENTIONAL,['NA'],Recurrence,
8521,NCT05103904,Overall response rate (ORR),2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of response (DR),
8522,NCT04464668,Change in Colorectal Cancer Screening Rates - Repeat FIT,2020-06-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Differences in Screening Rates,
8523,NCT02843217,"Colorectal Cancer Screening, beginning age 50",2010-09,COMPLETED,INTERVENTIONAL,['NA'],,
8524,NCT02560376,Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis of Insulinoma and Nesidioblastosis,2014-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Adverse events collection,
8525,NCT01205022,Maximum tolerated dose of yttrium-90 (90Y) M5A anti-CEA antibody when given in combination with FOLFIRI chemotherapy and bevacizumab,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],"Estimation of radiation doses to whole body, normal organs, and tumor through serial nuclear imaging",
8526,NCT05448157,"To evaluate the diagnostic efficacy and the safety of the combined approach with β-probe and 68Ga-DOTA-TOC PET/CT in the correct identification of primary tumor and lymph node metastases, in patients with GEP-NETs candidates to surgery",2022-05-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8527,NCT06154538,pCR rate,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],OS,serious adverse event
8528,NCT04038619,Clinical response/remission of immune-related diarrhea/colitis,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Recurrent immune-related diarrhea/colitis within 3 months post-FMT after initially achieving clinical remission/response,"Frequencies of immune cells (CD4/8 T cells, regulatory T cells [Treg], macrophages, etc.) in tissue/blood/stool samples"
8529,NCT00780117,Annual lumbar-sacral MRI is performed,2008-06,COMPLETED,OBSERVATIONAL,['NA'],Annual serum alpha-foeto protein level monitoring,
8530,NCT03602079,Phase I: Maximum Tolerated Dose,2018-07-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase I Volume of distribution at steady state (Vss).,
8531,NCT04250402,Number of gallstone patients,2020-02-14,RECRUITING,OBSERVATIONAL,['NA'],"Number of physical regurgitation, nausea, vomiting, diarrhea, constipation",
8532,NCT06107920,the success of a full curative therapeutic,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life evaluated using EORTC QLQ-C30 and QLQ-CR29 dedicated to CRC,
8533,NCT03357991,Determine the predictive value of HPV E6/E7 mRNA for the detection of HSIL and its ability to predict incident cases.,2015-01-11,UNKNOWN,OBSERVATIONAL,['NA'],Cost-effectiveness analysis of an anal cancer screening strategy based on HPV E6/E7 mRNA analysis.,
8534,NCT00578721,Rectal Tissue Putrescine Reduction,2008-09-24,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety/Toxicity,
8535,NCT02728193,Death,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
8536,NCT06080204,Disease-free survival time,2008-03,COMPLETED,INTERVENTIONAL,['NA'],Overall survival time,
8537,NCT00045461,Quality of life,2000-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
8538,NCT04258969,Feasibility of Pedaling Concurrent to Chemotherapy Infusion,2020-12,WITHDRAWN,INTERVENTIONAL,['NA'],Symptom Severity,
8539,NCT05339230,Incidence of diarrhoea CTCAEv5.0 ≥ grade 2.,2020-12-15,RECRUITING,INTERVENTIONAL,['NA'],Incidence of adverse events CTCAEv5.0 grade ≥ 3 considered probably related to investigational products/placebo.,Change in liver metastasis tumor blood flow.
8540,NCT02307539,Qualitative interview data,2014-11,COMPLETED,INTERVENTIONAL,['NA'],"Patient/family out of pocket expenses, as measured by the Finances and Out of Pocket Costs Tool",
8541,NCT00002455,Survival rate,1971-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8542,NCT05845294,Anxiety of patients was assessed by Hospital Anxiety and Depression Scale,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
8543,NCT03164655,Curative-intent (R0-R1) resection (and/or ablation) rate (CRR) of CRLM,2018-07-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8544,NCT05879861,Status of frailty,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
8545,NCT05769959,Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs),2023-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Part 1, 2, 3: Overall survival (OS)",
8546,NCT04466267,The molecular mechanism of patients primary or secondary resistance to cetuximab,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
8547,NCT02017600,the R0 resection rate of participants,2013-08,TERMINATED,INTERVENTIONAL,['PHASE2'],1-year overall survival rate of participants,
8548,NCT00637559,"To compare the total percent time during the 24-hour monitoring period that gastric pH is above 4.0 at steady state in patients when taking: esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.",2002-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Compare total percent time distal esophageal pH is above 4.0 at steady state for each treatment period.,
8549,NCT04821843,Overall survival,2002-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Distant metastasis free survival,Radiomics analysis
8550,NCT04161560,relative adverse drug reaction,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8551,NCT05286814,Determine overall response rates,2022-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Determine hepatic progression-free survival (PFS),
8552,NCT01659502,Clinical Benefit Measurement,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),
8553,NCT01722175,Liver free of tumors,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Liver synthetic and transport function,
8554,NCT05232721,Diagnostic performance of advanced neoplasms,2022-02-20,UNKNOWN,OBSERVATIONAL,['NA'],Diagnostic performance of Colorectal Cancer,
8555,NCT02229058,Progression-free survival,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease control rate,
8556,NCT04652440,Measure Tolerability,2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median Disease-free survival (mDFS),
8557,NCT00578279,The Change in Mean Pain Scale Rating in Patients Following Treatment With 10mL or 20mL of Alcohol Injection,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8558,NCT05372198,Progression-Free Survival (PFS),2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],adverse events (AE),
8559,NCT03721744,Overall survival (OS),2018-10-25,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of Life (QoL),
8560,NCT04391049,Dose Limiting Toxicity,2020-06-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival,
8561,NCT03563157,"Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1",2018-05-25,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component",
8562,NCT02027948,feasibility of a nutritional management algorithm,2013-12-23,COMPLETED,INTERVENTIONAL,['NA'],treatment toxicity of chemoradiotherapy,
8563,NCT04628182,post-operative anastomotic leakages,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
8564,NCT03048123,Disease control rate,2015-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events,
8565,NCT02861690,Response rate,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events (Toxicity),
8566,NCT03678428,Overall Response Rate and bilateral 95% confidence interval,2021-12-31,TERMINATED,INTERVENTIONAL,['PHASE3'],"Adverse events, servere adverse events and surgery-related adverse events rates",
8567,NCT04516083,Number of patients who have a somatic mutation at the same time as a germline mutation,2019-12-21,UNKNOWN,OBSERVATIONAL,['NA'],,
8568,NCT05250895,To investigate the variability of hypoxia in HCC at baseline as quantified by immunohistochemistry,2022-04-28,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Treatment response,
8569,NCT02372929,Evaluate the relationship between tightness of esophageal stricture encountered at endoscopy with cancer staging at EUS.,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
8570,NCT02767375,Recurrence Free Survival,2015-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse Events That Are Related to Treatment,
8571,NCT00779688,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious lesions.,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
8572,NCT00486460,,2005-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8573,NCT02887599,Difference of the severity of the pancreatic cancer,2016-08-08,COMPLETED,INTERVENTIONAL,['NA'],Correlation of the cytotoxic immune status,
8574,NCT01052922,Adherence to FOBT test kit,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,
8575,NCT05036486,To perform large-scale NGS analysis for specific populations,2021-10-25,RECRUITING,OBSERVATIONAL,['NA'],"To correlate the clinical characteristics, treatment and outcome of Biliary tract cancer with the genetic profile in Taiwan.",
8576,NCT03856658,Hepatic progression-free survival,2019-02-05,RECRUITING,INTERVENTIONAL,['PHASE2'],EORTC Quality of Life Questionnaire,
8577,NCT01850654,Determine the Incidence of Hereditary Cancer Syndromes among Newly Diagnosed Colorectal Cancer Patients,2012-12-26,COMPLETED,INTERVENTIONAL,['NA'],,
8578,NCT02789371,the overall diagnostic accuracy of modified wet suction technique and 5ml dry suction technique to the solid occupying lesions,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],Blood contamination and cellularity in specimens obtained by modified wet suction technique and 5ml dry suction technique,
8579,NCT01138904,Response rate by RECIST,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival,
8580,NCT00004095,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8581,NCT00647530,Pathological down-staging as measured by depth of extramural spread among patients allocated to preoperative chemotherapy with or without panitumumab,2008-05-15,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse events,
8582,NCT00425841,Clinical response rate as assessed by RECIST criteria,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Histologic response rate,
8583,NCT03171389,clinical benefit rate (CBR),2017-03-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],Fatigue assessment,
8584,NCT01923233,Safety,2014-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Anti-Tumor Response,
8585,NCT05591534,Tolerance,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Surgical morbidity for recurrence,
8586,NCT00898287,To determine the maximum tolerated dose (MTD) of P276-00 administered along with Gemcitabine.,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To characterize toxicities of P276-00 in combination with Gemcitabine.,
8587,NCT03914352,Disease-free survival,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8588,NCT00497263,functioning anastomosis & no occurrence of adverse events related to device use,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8589,NCT02321202,hospital stay (time of hospital stay after surgery),2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],mortality,
8590,NCT00639327,"In phase II part, progressive disease rate will be measured for the safety. In phase III part, overall survival will be measured for the benefit of doublet.",2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Adverse events, response rates, progression free survival, time to treatment failure, change over rates to 3rd line",
8591,NCT00287755,Overall survival rate,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Side effect,
8592,NCT05734300,Change in patient-reported postoperative recovery - Quality of Recovery 15,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],Rate of secondary standard resection,
8593,NCT01405573,overall survival,2011-07,TERMINATED,INTERVENTIONAL,['PHASE3'],progression free survival,
8594,NCT02117557,Early morbidity rate,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Inflammatory and immune response,
8595,NCT05384184,Build the next generation biobank of liver-derived organoids,2019-06-06,RECRUITING,OBSERVATIONAL,['NA'],Evaluate the clinical relevance of the generated organoids,
8596,NCT01754623,Margin-negative (R0) Resection Rate,2013-02,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS) Rate,
8597,NCT06290505,Progression free survival rate is the proportion of patients alive and progression free (the cancer has not worsened) assessed by CT Scan and clinical review.,2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival.,
8598,NCT03920202,Bowel function assessment using Low anterior resection syndrome questionnaire,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],Risk factors: preoperative chemoradiotherapy,
8599,NCT04903548,SPECT CT,2021-04-20,RECRUITING,OBSERVATIONAL,['NA'],,
8600,NCT04379830,Change in Mesorectal Fat Volume (efficacy),2022-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],Intraoperative Adverse Events,
8601,NCT03215017,"Bowel function, Low anterior resection syndrome (LARS)",2017-05-15,COMPLETED,INTERVENTIONAL,['NA'],Quality of Life (QoL),
8602,NCT03086993,Overall Survival,2018-04-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Objective response rate (CR + PR) as determined by the Investigator,Incidence of Treatment-Emergent Adverse Events (Safety)
8603,NCT01621243,Part B: Overall Survival,2012-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Part B: Duration of progression-free survival,
8604,NCT00381862,Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Patients With no Emesis and no Rescue Therapy Within 5 Days of the First Course of Chemotherapy,
8605,NCT03550482,Quality of life improvement,2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Nutritional level,
8606,NCT03827044,Primary End point: Disease Free survival,2018-08-31,TERMINATED,INTERVENTIONAL,['PHASE3'],Secondary End Points: Toxicity of Investigational Medicinal Product according to the NCI-CTCAE (Common Terminology Criteria for Adverse Events) version 4.0.,
8607,NCT02678806,overall survival,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8608,NCT05265169,Local tumor progression free survival at 24 months,2023-01-13,RECRUITING,INTERVENTIONAL,['NA'],Proportion of subjects with CTCAE grade 3 events or greater within 90 days after MWA,
8609,NCT05977764,to identify D-CEUS quantitative parameters useful for characterizing FLLs.,2020-03-13,RECRUITING,INTERVENTIONAL,['NA'],,
8610,NCT04230759,Disease-free survival (DFS),2020-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life questionnaires,
8611,NCT04164797,progression-free survival(PFS),2019-11-25,UNKNOWN,INTERVENTIONAL,['PHASE4'],overall survival (OS),
8612,NCT00002485,Determine why eligible patients are not enrolled on available Pediatric Oncology Group therapeutic clinical trials.,1992-02,COMPLETED,OBSERVATIONAL,['NA'],,
8613,NCT00892255,Measure of the tissue destruction with the MedWaves Microwave Ablation/ Coagulation Ablation System,2009-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
8614,NCT04298021,Disease control rate of AZD6738 + Olaparib cohort,2020-06-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],quality of life measurement of AZD6738 + Olaparib cohort,
8615,NCT04662853,Gut-microbiota-based color-rectal cancer diagnosis.,2017-01-17,UNKNOWN,OBSERVATIONAL,['NA'],Dietary habits,
8616,NCT01791374,Part 2: Dose-limiting toxicities (DLT) for each dose level of rilotumumab in combination with cisplatin and capecitabine (CX) chemotherapy tested,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],"Part 2: Evaluate efficacy based on the treatment effects of rilotumumab in combination with cisplatin and capecitabine as measured by the following: Objective Response Rate, duration of response, progression-free survival, overall survival.",
8617,NCT01686412,Autonomic response monitoring (blood pressure digital and manual monitoring),2012-07,COMPLETED,INTERVENTIONAL,['NA'],Baroreflex sensitivity (by the method of sequence),
8618,NCT04777708,Objective response rate (ORR),2021-10-13,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Incidence of adverse events,
8619,NCT02254889,A 10-cm VAS was used to evaluate pain after ESD.,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,
8620,NCT05875558,ORR,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],OS,
8621,NCT04573738,The distant metastasis rates of rectal cancer,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,
8622,NCT05751733,Progression-Free survival (PFS),2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],Disease Control Rate (DCR),
8623,NCT05001321,Texture of nuclei,2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Recurrence/metastasis,
8624,NCT01657695,Survival,2008-06,COMPLETED,OBSERVATIONAL,['NA'],Response to therapy,
8625,NCT04164069,Incidence of adverse events,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Dasatinib on pharmacokinetics (PK) of oxaliplatin
8626,NCT03129607,Pancreatic fistula,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],Mortality,
8627,NCT05412628,To analyze the similarity of microbiota distribution between the buccal field and the esophageal area in the same patient,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],To analyze the distribution difference of microbiota among the patients with esophageal cancer/oropharyngeal cancer and non-cancer control,
8628,NCT05217446,Progression-free Survival (PFS),2022-07-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Objective Response (OR),
8629,NCT02343692,Presence of pancreatic cyst,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],Preliminary health economics analysis from questionnaires and cost diaries (Self-completed EQ-5D-5L questionnaire and cost diary.),
8630,NCT04098081,response rate,2019-12-12,RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival,
8631,NCT01358812,Response Rate,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Analyses of Potential Predictive Factors,
8632,NCT00226811,Objective Response (Complete Response (CR) or Partial Response (PR)),2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
8633,NCT01566474,Oxidative stress,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],The presence of DNA anomalies (tetraploidy and aneuploidy.,
8634,NCT04588051,Median Progression-free survival (PFS),2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of adverse events according to CTCAE v5.0,
8635,NCT05568095,Overall survival,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence and severity of adverse events (AEs) and serious adverse events (SAEs),
8636,NCT05303740,PFS,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],OS,
8637,NCT04669951,Tumor-to-background ratio,2019-11-18,COMPLETED,INTERVENTIONAL,['NA'],uPAR in patient groups,
8638,NCT00609622,Progression-free Survival (PFS),2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Functional Assessment of Cancer Treatment - Gynecologic Oncology Group Oxaliplatin-Specific Neurotoxicity (FACT&GOG-Ntx) Score,
8639,NCT02970136,Percentage of Participants Who Are Screened for All Conditions,2017-04-11,COMPLETED,INTERVENTIONAL,['NA'],Median Number of Screenings Completed,
8640,NCT00004099,,1999-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
8641,NCT04454151,Evaluation of changes in size of adenomas measured by upper endoscopy,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Evaluation of changes in size of adenomas measured by lower endoscopy,Evaluation of changes in size of desmoid tumors
8642,NCT05081024,Complete clinical response (cCR),2021-09-03,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,Specificity
8643,NCT05268549,"The first recurrence of colorectal cancer with liver metastasis (CRLM) after radiofrequency/microwave ablation, assessed up to 18 months",2022-03-12,UNKNOWN,OBSERVATIONAL,['NA'],"Patients with colorectal cancer with liver metastases (CRLM) developed new metastases after radiofrequency/microwave ablation,assessed up to 18 months",
8644,NCT02359968,Short-term benefit of 2 preoperative regimen: complete resection rate AND severe (grade ≥ 3) postoperative morbidity/mortality according to the Clavien-Dindo classification,2015-02-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluation of the efficacy of both regimen in term of quality of life,Prognostic factor and treatment effect controlling for possible confounding factors
8645,NCT01392352,Change in endothelial dependent function,2011-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in endothelial independent function,
8646,NCT01631539,Feasibility of chemoembolization with DC Bead loaded with Irinotecan,2012-09,WITHDRAWN,INTERVENTIONAL,['NA'],progression-free survival,
8647,NCT04929392,Clinical complete response (CR),2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
8648,NCT05343832,Plasma samples of patients with and without HCC to evaluate test performance(accuracy) of the kit. diagnostic(sensitivity and specificity) of the kit.,2021-11-29,UNKNOWN,OBSERVATIONAL,['NA'],,
8649,NCT06008522,Number of Adverse Device-related Events (ADEs) and Serious Adverse Device-related Events (SADEs) using immuno-OCT,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],validation of OCT system: immunohistochemistry,
8650,NCT05975593,Changes in tumor microenvironment,2023-12-19,RECRUITING,OBSERVATIONAL,['NA'],,
8651,NCT00573404,Maximum tolerated dose of imatinib mesylate in combination with sunitinib malate,2007-07,TERMINATED,INTERVENTIONAL,['PHASE1'],Preliminary data on anti-tumor activity of these drugs as assessed by RECIST,
8652,NCT05141643,Tumor drug uptake within PDAC tumors prior at pre-treatment baseline,2021-11-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],changes in [18F]-FAC drug uptake during or following SOC chemo- and/or radiation therapy.,
8653,NCT04602013,PFS,2020-10-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],HRQoL,
8654,NCT00394602,Longitudinal Quality of Life + Symptom Assessment Data,2004-04-07,TERMINATED,OBSERVATIONAL,['NA'],,
8655,NCT00491140,Association of different biomarkers with Cetuximab sensitivity,2006-12,COMPLETED,OBSERVATIONAL,['NA'],Association of different biomarkers with time to progression and survival,
8656,NCT01970722,Incidence of treatment-related toxicities according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) guidelines,2014-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-free survival (PFS),
8657,NCT03936530,metastasis rate,2019-10-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],3-year DFS,
8658,NCT04348643,Adverse events that related to treatment,2020-02-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Levels of CRP in Serum,
8659,NCT01587872,Cecal intubation rate,2011-10,TERMINATED,INTERVENTIONAL,['NA'],Detection of additional colonic pathology,
8660,NCT00867113,Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE2'],Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months,
8661,NCT01364454,Patient's participation to colorectal cancer screening program,2010-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
8662,NCT01211132,The primary outcome is the prevalence of adenomas in the two groups.,2009-09,UNKNOWN,INTERVENTIONAL,['NA'],"The secondary outcomes are the number of adenomas detected per subject, cecal intubation rate, insertion times, withdrawal times and complication rates in the two arms.",
8663,NCT04408105,"To characterize the association between patient-level knowledge, attitudes, and barriers regarding BE screening.",2020-02-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8664,NCT01739608,Participation rate to FS and CT Colonography,2013-12,COMPLETED,INTERVENTIONAL,['NA'],Type of false positive detections of Computer-aided detection for CTC in a CRC screening program,
8665,NCT02512224,Mortality Calculated From Outcome Section From DPC Database at 90 Days,2012-04,COMPLETED,OBSERVATIONAL,['NA'],Mortality Calculated From Outcome Section From DPC Database at 30 Days,
8666,NCT05520619,Progression-free survival,2022-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Tumor mutational burden at baseline
8667,NCT02259725,PFS,2016-08-16,COMPLETED,INTERVENTIONAL,['PHASE2'],"Incidence of Adverse Events, Assessed According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0",Biomarkers Such as Messenger Ribonucleic Acid (mRNA) Levels or Germline Variations of Genes Related to Angiogenesis
8668,NCT03487939,The ratio of tumor downstaging to stage 0 and stage I,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life (QLQ C30),
8669,NCT05161143,1 year RFS rate,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],AFP,
8670,NCT01821196,Density of PGP9.5 in gastric adenocarcinoma related to TNM stage and survival of stomach cancer,2012-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
8671,NCT00643682,Boston Bowel Preparation Scale Score,2006-02,COMPLETED,INTERVENTIONAL,['NA'],Number of Repeat Procedures Recommended Due to Inadequate Bowel Preparation.,
8672,NCT05879172,success rate of anastomosis,2021-07-01,COMPLETED,INTERVENTIONAL,['NA'],time period of recovery,
8673,NCT04820179,Overall Response Rate or Stable Disease,2021-10-12,RECRUITING,INTERVENTIONAL,['PHASE2'],T2 Signal,
8674,NCT02328677,Recurrence,2007-03,RECRUITING,OBSERVATIONAL,['NA'],Treatment toxicities,
8675,NCT02165800,Sexual function,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],5-year overall survival rate,
8676,NCT00970138,Progression free survival,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Toxicity,
8677,NCT05867966,Change in emotional distress,2024-01-16,RECRUITING,INTERVENTIONAL,['NA'],Change in perception about their fatigue,
8678,NCT02376543,Total Time Comparison,2015-03-06,WITHDRAWN,INTERVENTIONAL,['NA'],Complication Comparison,
8679,NCT00006155,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8680,NCT06112704,Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.,2024-02-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Assess the incidence of anti-drug antibodies (ADAs),
8681,NCT02332551,Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.,Progress free survival(PFS)
8682,NCT00982618,Postoperative functional recovery,2009-07,COMPLETED,INTERVENTIONAL,['NA'],opioid side effects,
8683,NCT05863052,Treatment related Adverse Events,2022-01-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Difference in cancer related mortality,Demographic differences
8684,NCT00035087,Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST),2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
8685,NCT04479111,1-year local recurrence,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],3-year disease free survival,
8686,NCT02711969,Dose-limiting toxicities (DLTs) of Apatinib mesylate in patients with unresectable locally advanced or metastatic gastric cancer,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],"Duration of Response(Stable disease, partial response or Complete response)",
8687,NCT04163627,Technical procedures evolutiveness,2019-11-30,UNKNOWN,OBSERVATIONAL,['NA'],Regional disparities,
8688,NCT05014737,postoperative nausea and vomiting,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
8689,NCT06079554,Metabolomics results of lesions and atrophic gastritis.,2023-10-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],microbiomics of lesions and atrophic gastritis.,endoscopic observation
8690,NCT02482909,The patient survival,2005-07,TERMINATED,INTERVENTIONAL,['NA'],The disease-free survival,
8691,NCT05732493,pCR,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Surgical complications,
8692,NCT00101894,"Part 2 - The overall objective tumor response rate (complete and partial response) in subjects treated with AMG 706 (at the dose determined in Part 1b), with either the FOLFIRI or FOLFOX-4 chemotherapy regimen",2004-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Part 1a - The PK of 5-FU when administered as a part of the FOLFIRI or FOLFOX-4 regimen with panitumumab and AMG 706,
8693,NCT01895790,Complications (Safety),2014-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Survival,
8694,NCT05671822,Phase II: Objective Response Rate (ORR)[,2023-03-14,RECRUITING,INTERVENTIONAL,['PHASE2'],"Occurrence of adverse events (AEs), and serious adverse events (SAEs) （Phase II）",
8695,NCT05877352,Availability of potential primary outcome data,2022-05-18,RECRUITING,INTERVENTIONAL,['NA'],Resource use and cost,
8696,NCT02945267,TTP,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],Adverse Events,
8697,NCT04137289,"Phase Ib - Progression-free survival (PFS) is defined as the time from first treatment administration until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.",2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Phase Ib - AUC0-t2: area under the concentration-time curve of BI 905711 in plasma,
8698,NCT03815461,PFS,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse reaction rate,
8699,NCT00096083,To determine the response rate and duration of response to intra-hepatic infusion of melphalan with subsequent venous hemofiltration in patients with primary and metastatic hepatic malignancies,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],To determine the progression free and overall survival in patients with hepatic malignancies following this therapy,
8700,NCT00494611,Safety of peri operative Cetuximab.,2007-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
8701,NCT04273451,The prediction accuracy of the radiopathomics artificial intelligence model,2020-01-10,UNKNOWN,OBSERVATIONAL,['NA'],The F1 score of the radiopathomics artificial intelligence model,
8702,NCT03355495,Decrease in Cecal Intubation Time,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Increase in Adenoma Detection Rate,
8703,NCT01171300,Pathologic complete response (ypT0N0) rate,2010-10,UNKNOWN,INTERVENTIONAL,['NA'],Quality of mesorectal excision.,
8704,NCT00582829,Phone follow-up interview. Participants will be contacted by study assistant and the survey administered.,2003-06,COMPLETED,OBSERVATIONAL,['NA'],,
8705,NCT02032368,Change of circulating tumor cell(CTC) count at different timepoints,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,
8706,NCT01623206,"Presence or absence of grade 3 or 4 adverse events related to the study drug, in a maximum of 2 out of 6 patients assessed in each dose level.",2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of patients with partial or complete response in clinical endpoints,
8707,NCT01262183,1-year overall survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],CTCs and CECs,
8708,NCT00807313,Metabolic complete remission rate,2008-12,COMPLETED,OBSERVATIONAL,['NA'],Late toxicity,
8709,NCT02074046,The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements,The dose of CSC vaccine
8710,NCT00093652,Response (phase II),2003-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immunohistochemistry,
8711,NCT05839470,Overall Response Rate (ORR),2023-11-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression free survival (PFS),
8712,NCT01605318,Percentage of Participants With Laboratory Abnormalities,2013-02-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change from Baseline in Carcinoembryonic Antigen (CEA) Serum Levels,
8713,NCT04296630,Screening intention,2020-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Post comments,
8714,NCT01831609,Biomarker analyses to predict treatment response in metastatic cancer,2011-08-31,RECRUITING,OBSERVATIONAL,['NA'],,
8715,NCT01035008,"Differentiate between non-mucinous, mucinous non-malignant & malignant pancreatic cysts in vivo",2009-12,COMPLETED,INTERVENTIONAL,['NA'],,
8716,NCT02992340,Phase 2B: Progression Free Survival (PFS),2016-12-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Pharmacokinetics of Gemcitabine, dFdU (gemcitabine metabolite) and Cisplatin (Phase 2B)",
8717,NCT00585637,"Levels of Plasma 25(OH)D at Baseline, 3 Months and 6 Months.",2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in CRP From 0 to 3 Months.,
8718,NCT00081536,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8719,NCT01515046,Overall Survival,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Ascorbate Levels,
8720,NCT00006368,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8721,NCT05461235,Progression-free Survival (PFS),2022-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
8722,NCT04296240,pathologic complete response rate,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicity of neoadjuvant chemotherapy,
8723,NCT00118105,Correlation of clinical outcome with expression of biomarkers and telomere length,2006-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
8724,NCT03335813,Percent Volume of the Tumor Receiving the Prescription Dose (V100),2018-03-06,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants With the Need for Dilation,
8725,NCT00866957,HIF-1alpha bio-marker,2006-02,COMPLETED,OBSERVATIONAL,['NA'],Understand biological behavior of the tumors,
8726,NCT00294827,Survival,2006-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Time to progression side-effects,
8727,NCT00295035,,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8728,NCT03387098,Objective response rate by RECIST,2018-01-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.",
8729,NCT02942238,Disease-free survival,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],The accuracy of preoperative staging with CT,
8730,NCT02514551,Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ,2015-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Anti-Ramucirumab Antibodies,
8731,NCT05313282,The progression-free survival (PFS) by RECIST 1.1,2022-06-15,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
8732,NCT03603756,objective response rate,2018-07-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],treatment-related adverse events,
8733,NCT00816491,"The primary endpoint of the study will be to compare the accuracy of two procedures (FICE with target biopsies only, versus conventional white light colonoscopy)",2008-10,COMPLETED,INTERVENTIONAL,['NA'],To quantify the number of true positive and false positive lesions by comparing the number of targeted biopsies performed for suspicious lesions and the resulting histological findings.,
8734,NCT01477190,postoperative pain,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",opioid side effects,
8735,NCT00025532,,2001-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
8736,NCT05356897,Progression-free survival rate,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
8737,NCT02773459,Progression-free survival (PFS),2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
8738,NCT01515787,DFS,2012-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Neoadjuvant Rectal Score,
8739,NCT00500968,Drain fluid content analyses,2006-11,COMPLETED,INTERVENTIONAL,['NA'],"Co-variables measured in the form of: operation time, complications in relation to diagnosis, duration of hospitalization and cost. Patients receiving a pancreas stent are followed in order to evaluate the natural course of the pancreas stent",
8740,NCT01306058,Phase II: Time to Progression (TTP) for the Combination of TR105 With Sorafenib in Hepatocellular Cancer (HCC),2011-02-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Percentage Signal Change in Response on Magnetic Resonance Imaging (MRI),
8741,NCT00955721,Phase II: Obtain an Estimate of the 9-month Progression-free Survival Rate in Patients With Advanced BTC Receiving the RPTD of the Combination Sorafenib and GEMOX.,2009-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II: Explore Biomarkers of Response to the Combination,
8742,NCT03510858,Proportion of patients which have been tested for CRC,2018-03-14,UNKNOWN,INTERVENTIONAL,['NA'],Intention to prescribe colonoscopy vs. FIT within the next 6 months,
8743,NCT05177068,Surgical complete resection rate (R0),2022-05-06,RECRUITING,INTERVENTIONAL,['PHASE2'],adverse event (AEs),
8744,NCT03791918,Overall survival,2019-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Progression free survival,
8745,NCT05291728,the detection rate of early gastric cancer,2020-10-01,RECRUITING,OBSERVATIONAL,['NA'],"the prevalence of dyspepsia, gastroesophageal reflux disease and precancerous lesions in the natural population of Shaanxi Province, as well as the prevalence of helicobacter pylori infection, radical treatment and recurrence rate.",
8746,NCT05740189,Safety: Incidence of Dose-related SAEs,2023-02-19,RECRUITING,INTERVENTIONAL,['NA'],BE regression,
8747,NCT04733521,preliminary antitumor activity of SC-43,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",overall survival(OS) according to RECIST criteria version 1.1,phosphorylated signal transducer and activator of transcription 3(p-STAT3) status in peripheral blood mononuclear cells (PBMCs) of subjects
8748,NCT00568438,,2000-10,COMPLETED,OBSERVATIONAL,['NA'],,
8749,NCT01997684,Rates of primary colorectal anastomosis,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],Recurrence of colorectal cancer,Clinical success
8750,NCT04517032,Catastrophic Expenditure at 6 months,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Colorectal cancer stage at the time of diagnosis,
8751,NCT01485744,Toxicity,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Response Rate,
8752,NCT00363584,Survival at 2 years,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Health economics,
8753,NCT05129046,DFS,2021-11-15,UNKNOWN,OBSERVATIONAL,['NA'],Surgical Outcomes,
8754,NCT05307835,Relapse Free Survival Rate,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE1'],EORTC QLQ-C30 (version 3),
8755,NCT00296608,,1993-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8756,NCT05471674,Pathological tumour response rate,2020-07-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety and tolerability of nivolumab,Exploratory analyses
8757,NCT00254683,PET/CT specificity and sensitivity for tumor response,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Correlation between PET/CT and complete clinical Response,
8758,NCT03634982,Number of participants with dose limiting toxicities (DLTs),2018-09-28,UNKNOWN,INTERVENTIONAL,['PHASE1'],Duration of Response (DOR),
8759,NCT00091078,"Toxicity defined as any of the following events: regimen-related death, transaminitis, infection, or leukopenia grade 3 or higher using NCI CTCAE version 3.0",2005-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall survival,
8760,NCT05463796,"Identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.",2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],,
8761,NCT05491616,Disease Free survival 18 months,2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival at 2 years,
8762,NCT02520154,Progression-free survival,2016-07-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,Change in biomarker expression level
8763,NCT01747707,overall survival time (OS),2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],safety profile,
8764,NCT02352935,Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,Over Survival (OS)
8765,NCT05300269,Percentage of participants with Pathological complete response ( pCR ),2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease-free survival ( DFS ),
8766,NCT03821545,Concentration of inflammatory markers,2019-01-28,COMPLETED,INTERVENTIONAL,['NA'],Length of hospital stay,
8767,NCT03236883,Survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],Karnofsky Performance Status（KPS）,
8768,NCT01035398,Analyses of dietary factors and Helicobacter pylori infection (previous vs current),2000-04,UNKNOWN,OBSERVATIONAL,['NA'],,
8769,NCT02243384,Survival rate,2014-09-01,COMPLETED,INTERVENTIONAL,['NA'],postoperative complications,
8770,NCT01121939,Objective Response Rate (ORR),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Control Rate,
8771,NCT05723562,Number of Participants with Sustained Complete Clinical Response for 12 Months (cCR12) as assessed by Independent Central Review (ICR),2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants with Anti-Drug Antibodies against Dostarlimab,
8772,NCT05068180,Incidences of POD after general anesthesia in elderly patients undergoing non-cardiac major surgery,2021-10-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],Duration of postoperative delirium,
8773,NCT05971199,Progression-free survival(PFS),2021-11-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to progression(TTP),
8774,NCT05029973,Overall response rate ( ORR),2021-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events (AEs),
8775,NCT04542291,Tolerability as Measured by Number of Participants With Related Adverse Events,2021-02-25,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in Tumor Necrosis,
8776,NCT02365662,Recommended Phase 2 dose of ABBV-221,2015-01-09,TERMINATED,INTERVENTIONAL,['PHASE1'],Objective Response Rate (ORR),
8777,NCT04014465,progression free survival,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Adverse Events,
8778,NCT03193814,Progression-free Survival (PFS) Time,2019-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
8779,NCT02297607,Quality of Life after surgery,2014-11,TERMINATED,INTERVENTIONAL,['NA'],Jejunostomy tube-specific complications,Length of hospital stay
8780,NCT03960008,To compare the duration of disease control in treated lesions when utilizing SBRT versus TACE as a bridging strategy for patients with HCC eligible for liver transplantation,2020-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],To assess 90 day Post-transplant mortality,
8781,NCT03219723,Percentage of Participants Who Had One or More Adverse Drug Reactions,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],H. Pylori Eradication Rate,
8782,NCT04170556,Incidence of Treatment-Emergent Adverse Events,2020-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Serum and tissue marker characterization,
8783,NCT00839111,"Progression-Free Survival (PFS) ,defined as the time from treatment to disease progression or death due to any cause",2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Secondary endpoints are disease control rate, defined as a complete response, partial response, and stable disease; Response rate and overall survival; and safety are also evaluated.",
8784,NCT03527784,Incidence of parastomal hernia,2018-05-03,TERMINATED,INTERVENTIONAL,['NA'],Quality of Life measured by RAND 36,
8785,NCT04413526,The survival rates for one-year to five-year,2020-05-25,COMPLETED,OBSERVATIONAL,['NA'],The Child-Pugh score after therapy,
8786,NCT02407119,Incidence of metachronous gastric cancer,2003-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Overall survival,
8787,NCT00576056,Determine Progression-free Survival in This Patient Population Treated With the Proposed Combination Treatment Modality,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Determine the Overall Survival in Patients Treated With This Combination Regimen,
8788,NCT02571374,Number of participants with colorectal cancer on symbiotic to prevent postoperative infection,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],,
8789,NCT04890015,Anastomotic leakage rate between treatment arms,2017-07-10,UNKNOWN,INTERVENTIONAL,['NA'],Definitive and / or temporary stoma rate after anastomotic leakage,
8790,NCT04795063,Morbidity rates,2021-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Time of digestive tract reconstruction,
8791,NCT04685759,Proportion of patients with a primary GI tumor who complete neoadjuvant treatment and are cleared for surgical resection,2022-04,WITHDRAWN,INTERVENTIONAL,['NA'],Change in quality of life assessment,Mean total Patient Satisfaction score of In-Person Exercise Therapy
8792,NCT03881332,Glomerular filtration rate,2019-12-26,COMPLETED,OBSERVATIONAL,['NA'],,
8793,NCT00806663,"reduction of tumor vessel permeability (TVP) and blood flow (BF) measured by DCE-MRI and DCE-USI, measured on liver metastases.",2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],drug treatment safety,
8794,NCT00723996,The primary outcome will be determined through review of medical records or a telephone follow-up 6 months after enrollment,2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
8795,NCT04883775,Biodistribution of MVT-2163,2021-05-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8796,NCT01141114,completion of colorectal cancer screening,2008-09,COMPLETED,INTERVENTIONAL,['NA'],Comparison of detection of polyps and cancers in intervention vs. control groups,
8797,NCT06195254,progression-free survival (PFS),2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],Pain relief rate (PRR）,
8798,NCT00039273,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8799,NCT05494658,The proportion of postoperative blood glucose>8mmol/L,2022-08-26,RECRUITING,INTERVENTIONAL,['NA'],Postoperative hospital stay,
8800,NCT03520283,Retention Rate,2018-05-29,COMPLETED,INTERVENTIONAL,['NA'],Qualitative Assessment of Changes in Outcomes With Semi-structured Interviews,
8801,NCT04229849,Overall Survival (OS),2020-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Assessment of Health-related quality of life,
8802,NCT04036643,Tumor response assessed by modified the Ryan tumor regression grading system obtained by quantification of the residual cancer cells compared to fibrosis on the surgical specimen,2019-11-27,UNKNOWN,INTERVENTIONAL,['NA'],Calculation of the Net Reclassification Index (NRI) by comparing the sensitivity of [18F] -FDG-PET / MRI and the sensitivity of MRI alone for TRG1,
8803,NCT04878783,Predictive performance of radiomics analysis on the pre-treatment CT scan.,2019-12-20,UNKNOWN,OBSERVATIONAL,['NA'],Association between radiomics and molecular expression in regards to long-term outcomes,
8804,NCT05595473,Number of participants with adverse events (AEs) in part 1 and 2 as graded by NCI-CTCAE,2022-07-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To determine safety and efficacy of RZ-001 by changes in overall survival (OS) of the partipants in Part 1 as graded by RECIST v1.1 and mRECIST,
8805,NCT06326879,Incidence rate ratio of colorectal cancer recurrence,2023-11-30,RECRUITING,OBSERVATIONAL,['NA'],Correlation between socioeconomic characteristics and incidence rate of colorectal cancer recurrence,
8806,NCT00926536,"Cumulative Dose (CD), a Measure of Radiation Dose",2009-04,COMPLETED,INTERVENTIONAL,['NA'],,
8807,NCT00868816,disease-free survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],overall survival liver metastasis-free survival,
8808,NCT01283906,To evaluate the efficacy of MuGard on reducing the symptoms of oral mucositis using an Oral Mucositis Daily Questionnaire (OMDQ),2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],To evaluate the efficacy of MuGard on delaying the onset of oral mucositis symptoms and reducing the impact on health and resource outcomes.,
8809,NCT02221245,"Percentage of samples with identifiable Notch, Wnt and Hedghog pathways in the chemo naive esophageal tumor as well as in cancer stem cell populations (CSC).",2013-04-05,TERMINATED,OBSERVATIONAL,['NA'],,
8810,NCT06153368,Objective response rate (ORR),2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (safety),
8811,NCT01056796,"To evaluate for the occurrence of adverse events related to the use of the CAR™ 27 device, include anastomotic leak, bleeding, ring evacuation and strictures at 6 months.",2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Evaluation of the creation of a functioning CAR™ 27 anastomosis in radiated patients,
8812,NCT05576896,Objective Response Rate (ORR),2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
8813,NCT05941481,pathological complete remission (pCR) rate,2023-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
8814,NCT04168346,The need for blood transfusion,2019-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Use of IV iron after operation,
8815,NCT04006600,Persistence of a stomy 2 years after rectal surgery when stoma was primarily intended to be temporary,2018-03-16,COMPLETED,OBSERVATIONAL,['NA'],,
8816,NCT02351765,Maximum Tolerated Dose (MTD) of Aclerain in combination with Cisplatin,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Exploration of the pharmacokinetic profile for the combination of Acelarin with Cisplatin,
8817,NCT01950442,Safety of gentle dilation,2013-10,COMPLETED,INTERVENTIONAL,['NA'],impact on staging,
8818,NCT00027638,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8819,NCT02747862,Chart Review of Outcomes of Participants with Attenuated Familial Adenomatous Polyposis (AFAP) and Deleterious Familial Adenomatous Polyposis (FAP) Undergoing Endoscopic Surveillance,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
8820,NCT01744821,Other Surrogate Endpoint Biomarkers Markers of Cancer Prevention,2012-10,TERMINATED,INTERVENTIONAL,['NA'],Review of the Differences in the Types and Incidence of Toxicities Associated With Vitamin D3 Replacement.,
8821,NCT05753748,Neoplastic Progression,2023-01-24,RECRUITING,INTERVENTIONAL,['NA'],Patient-Reported Gastroesophageal Reflux,
8822,NCT02110329,Recurence rate according to molecular results,2010-05,COMPLETED,INTERVENTIONAL,['NA'],Survival rate according to molecular results,
8823,NCT01777594,Time to progression,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
8824,NCT05807776,MPR rate,2023-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],AE and SAE,
8825,NCT03203005,Immunogenicity (T-cell response in peripheral blood),2017-09-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
8826,NCT03775980,Local Tumor Control,2019-09-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Treatment specific quality of life,
8827,NCT02559024,Immune Score,2016-03-14,TERMINATED,INTERVENTIONAL,['PHASE1'],,
8828,NCT00856115,Factors that influence appraisal and diagnostic delay,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
8829,NCT02269995,Safety and Tolerability as measured by Adverse Events,2014-03-06,COMPLETED,OBSERVATIONAL,['NA'],Efficacy of DC bead as assessed by embolic performance,
8830,NCT00109954,Toxicity as measured by NCI CTCAE version 3.0,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8831,NCT04080414,Feasibility of home-based high-intensity interval training among colorectal cancer survivors,2019-08-02,COMPLETED,INTERVENTIONAL,['NA'],,
8832,NCT02723604,Number of Participants With Severe World Health Organization [WHO] (Grade 3-4) Oral Mucositis in Patients Treated to a Cumulative Radiation Dose of at Least 5000 cGy,2016-03,COMPLETED,INTERVENTIONAL,['NA'],Time to Onset of Severe (CTCAE v. 4.0 Grade 3-4) Oral Mucositis Following the Initiation of Radiotherapy,Time to Reach Planned Dose of Radiation Therapy
8833,NCT04091620,Incidence rate of achieving a composite of pathologic endpoint indicating adequate surgical resection,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],Direct/indirect medical costs and out-of-hospital economic costs,
8834,NCT01150045,Disease-free Survival,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],Overall Survival,
8835,NCT01484444,Analyzed of DNA mutations,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
8836,NCT02216110,Patient's death,2003-05,COMPLETED,OBSERVATIONAL,['NA'],Development of metachronous cancers,
8837,NCT00845611,Safety(Phase I:toxicities as assessed by NCI CTCAE version3),2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],evaluate immunological responses,
8838,NCT02101099,Peak push force is increased in patients receiving propofol as compared to conscious sedation.,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
8839,NCT01024504,Overall response rate,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
8840,NCT05438108,AEs,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
8841,NCT05660213,ORR,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Incidence and severity of adverse events of special interest (AESI),
8842,NCT03557216,Presence of ACN,2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],Fecal calprotectin test predictive value for ANC detection,
8843,NCT01053923,Primary tumor apparent diffusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI,2009-12,WITHDRAWN,OBSERVATIONAL,['NA'],Change with time from start of radiotherapy course in primary tumor apparent diffusion coefficient from MRI,
8844,NCT01258868,Tabulation of patient toxicities and their grades,2010-12-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of patients of first 20 lung CA patients with cell line development greater than or equal to 5.,
8845,NCT05990231,Objective response rate,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
8846,NCT03035136,Adenoma detection rate,2017-01-15,COMPLETED,OBSERVATIONAL,['NA'],Polyp detection rate,
8847,NCT02409186,Over Survival,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8848,NCT02570516,Number of adenomas and / or adenocarcinoma detected during each procedure (NBI vs Indigo carmine),2015-11,COMPLETED,INTERVENTIONAL,['NA'],Number of subject with adverse events as mesure of safety.,
8849,NCT02293850,"Evaluation of safety parameters (adverse events, laboratory data, EKG, body weight, vital signs) on patient-base.",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],Dose-Limiting Toxicity (DLT) for patients using OBP-301.,
8850,NCT04686747,"Rate of advanced Esophageal, Gastric, Pancreatic and Colorectal cancer in 2020 compared to 2019.",2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],Rate of patient unable to performer adjuvant treatment in 2020 compared to 2019,
8851,NCT02823691,incidence of SAEs and AEs,2016-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],biochemical responses to Lanreotide ATG 120 mg in combination with Metformin,
8852,NCT03241680,Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III),2017-08-02,UNKNOWN,INTERVENTIONAL,['NA'],,
8853,NCT04843397,Define the prevalence of pre-malignant upper GI tract lesions as measured by standardised endoscopy and biopsy protocol,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],Correlation between life-style factors and pathological outcomes,
8854,NCT03801668,Progression-free Survival (PFS),2019-03-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Safety as measured by number and grade of adverse events,
8855,NCT01233544,Local progression-free survival,2010-09,TERMINATED,INTERVENTIONAL,['PHASE3'],Quality of life,
8856,NCT03540953,dysphagia,2015-01-05,TERMINATED,INTERVENTIONAL,['NA'],number of sessions of endoscopic dilations,
8857,NCT00057876,Overall Survival Time,2003-08-29,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Response,
8858,NCT05555901,Progression-Free Survival (PFS),2023-06-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
8859,NCT04232748,Overall survival,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Chemotherapy interruption,
8860,NCT05013125,Adenoma missed rate,2021-08-09,UNKNOWN,INTERVENTIONAL,['NA'],Number of CAD assisted abnormality,
8861,NCT05928897,ORR,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
8862,NCT01348256,Progression Free survival,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
8863,NCT00006786,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8864,NCT04677998,Advanced neoplasia,2020-11-24,RECRUITING,OBSERVATIONAL,['NA'],Surgery,
8865,NCT00954655,response,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,
8866,NCT00521404,Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic Cancer,2007-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment-Emergent Adverse Events Considered by the Investigator at Least Possibly Related to Gemcitabine Experienced by ≥5% of Participants by System Organ Class and Preferred Term,
8867,NCT06043921,Cohort of patients with resectable pancreatic cancer; Success rate of WES assays and selections of personalized genes using tumor tissue specimens obtained by EUS-FNA/FNB,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],Cohort of patients with resectable pancreatic cancer; to investigate the lead time of ctDNA detection of recurrence before detection of recurrence via imaging methods,
8868,NCT02564835,Program Evaluation,2015-09,COMPLETED,INTERVENTIONAL,['NA'],Pro-inflammatory Markers,Beliefs about Treatment
8869,NCT01869725,Compare Specificity of 68Ga-DOTATOC PET/CT With Octreoscan,2013-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8870,NCT01356030,Direct comparison of tissue sampling techniques for patients with suspected pancreaticobiliary cancers.,2011-05,COMPLETED,INTERVENTIONAL,['NA'],,
8871,NCT02595320,Twelve-week Progression Free Survival (cohort 1 only),2015-10-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Grade 3 or higher toxicity (cohorts 1 and 2),Objective response rate (cohorts 1 and 2)
8872,NCT02707159,Change in levels of circulating tumor cells (CTCs) during treatment,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in quality of life during treatment,
8873,NCT02560298,Best ORR defined as the percentage of patients achieving confirmed partial (PR) or complete responses (CR) as per RECIST v1.1,2016-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Sensitivity analysis of ORR,Changes in expression of tumor biomarkers
8874,NCT03783156,Number of participants with presence of adenomatous tissue al the base of polypectomy,2019-02-18,COMPLETED,INTERVENTIONAL,['NA'],Number of participants with Postpolypectomy Complications,
8875,NCT00748449,Percentage of patients who refuse to undergo an examination,2008-06,TERMINATED,INTERVENTIONAL,['NA'],,
8876,NCT04545957,Proportion of patients with QOL decline exceeding 2 x MID,2020-10-14,RECRUITING,INTERVENTIONAL,['NA'],Performance of the synthetic CT in RT planning,
8877,NCT03644511,"Identification of current treatment patterns by means of individual treatment lines in the systemic HCC therapy with regards to Nexavar and Stivarga, i.e. when both drugs are used in ≥ 2nd-line under current practice conditions",2019-01-24,TERMINATED,OBSERVATIONAL,['NA'],Incidence of treatment-emergent adverse events (TEAE),
8878,NCT01815463,Correlation of Adnab-9 stool result with outcome of colonoscopy,2006-08,TERMINATED,OBSERVATIONAL,['NA'],Define the origin of the Adnab-9 bound antigen,
8879,NCT02215837,Progress-free survival,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Severity of adverse events,
8880,NCT02906397,Safety based upon standard laboratory and clinical adverse event monitoring,2017-03-30,COMPLETED,INTERVENTIONAL,['PHASE1'],Promotion of anti-tumor immunity with addition of intervention to SBRT,
8881,NCT01806272,The incidence of grade II and less oral mucositis at the end of treatment,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Tumor response to chemoradiotherapy,
8882,NCT02699073,Tumor response rate at 2 months according Choi Criteria,2016-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Correlation between Baseline cell free DNA and survival outcomes (PFS and OS),
8883,NCT05832892,Objective response rate (RECIST 1.1),2023-10-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Predictive biomarkers,
8884,NCT04115254,Rate of Improvement in Tumor Control-Phase II,2019-10-22,SUSPENDED,INTERVENTIONAL,['NA'],Overall Survival Rate-Phase II,
8885,NCT02480361,Remnant sitz markers in small intestine at postoperative day 7,2013-01,COMPLETED,INTERVENTIONAL,['NA'],hospital stay,serum albumin level in postoperative day 7
8886,NCT01365910,Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15%,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Patients With Each Worst-Grade Toxicity,
8887,NCT01548482,Safety profile of trebananib and temsirolimus as assessed by NCI CTCAE version 4.0,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],PD effects of both drugs when administered in combination,
8888,NCT03904121,Postoperative mortality,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],Functional performance,
8889,NCT01084746,Increase patient completion of colorectal cancer screening (CRCS) among patients ages 50 to 64 years old.,2005-01,COMPLETED,INTERVENTIONAL,['NA'],Secondary goals are to increase understanding of factors that predict completion of CRCS and to assess the cost-effectiveness of the intervention.,
8890,NCT00716820,Objective Response Rate,2008-04,COMPLETED,OBSERVATIONAL,['NA'],Numbers of Participants With Treatment-Related Adverse Events Corresponded to Items for Priority Investigation,Number of Participants With Treatment-Related Adverse Events Grade 3 or Higher in Common Toxicity Criteria for Adverse Events (CTCAE)
8891,NCT03754075,Risk of recurrence,2008-06-01,UNKNOWN,OBSERVATIONAL,['NA'],Number of mesocolic lymph nodes,
8892,NCT00325611,Quality and cost of care,2002-04,COMPLETED,INTERVENTIONAL,['NA'],Lower total costs 6 months past hospitalization,
8893,NCT01778595,"Participation rate, data quality",2013-01-08,COMPLETED,OBSERVATIONAL,['NA'],,
8894,NCT03918369,Rate of Re-interventions,2019-03-07,COMPLETED,INTERVENTIONAL,['NA'],,
8895,NCT02149108,Overall Survival (OS),2014-09-25,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment,
8896,NCT00403052,Occurrence of adverse events,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall survival time,
8897,NCT02850991,Overall Survival,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Progression-free survival,"local control rate, recurrence pattern"
8898,NCT04843306,Effectiveness of motion management for SBRT for pancreatic cancer with real-time coaching for the ABC procedure using an augmented reality platform,2021-06-24,RECRUITING,INTERVENTIONAL,['NA'],Anxiety of patient with the ABC procedure with real-time coaching using an augmented reality platform during SBRT for pancreatic cancer as assessed by patient reported outcome measures (PROMs),
8899,NCT01219543,To investigate the safety and tolerability of AZD1480,2010-11,TERMINATED,INTERVENTIONAL,['PHASE1'],To obtain a preliminary assessment of the anti-tumour activity of AZD1480,
8900,NCT02347618,Incidence of grade 2 or greater toxicity,2014-12,COMPLETED,INTERVENTIONAL,['NA'],Time to death,
8901,NCT02943031,Overall Survival (OS),2016-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],Progression-Free Survival (PFS),
8902,NCT03526328,cell-specific expression patterns of putative intestinal stem cell biomarkers in BE patients; correlation of markers with serum/plasma protein expression and disease progression.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,
8903,NCT02716766,Time to progression (TTP),2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency and severity of adverse events and laboratory abnormalities,Quality of life (QoL)
8904,NCT01379482,Overall survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8905,NCT03243734,Change from baseline dysphagia scale at 14 days post cryotherapy procedure,2017-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Mean change in the amount of residual tumor from baseline to follow-up cryospray delivery session,
8906,NCT05027737,Complications,2022-02-22,RECRUITING,INTERVENTIONAL,['NA'],EORTC QLQ-CR29 score,
8907,NCT00807300,Time to untreatable progression,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
8908,NCT02366286,Rate of HBV vaccination in subjects with negative HBV serology,2010-11,COMPLETED,OBSERVATIONAL,['NA'],Incidence of HCC over the period of the study,
8909,NCT02955901,Score of mucosal visualization,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],Withdrawal time,Patients characteristics questionnaire
8910,NCT03022110,Cyst recurrence rate,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],Complication rate,
8911,NCT01572324,Response rates,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
8912,NCT01362361,progression free survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8913,NCT01609660,Mucosal cytokine,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Short chain fatty acids,
8914,NCT00226941,Dose-limiting Toxicity (DLT) - Number of Participants Affected,2004-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Survival at 5 Years,
8915,NCT04050787,3-year disease free survival rate,2019-07-21,UNKNOWN,INTERVENTIONAL,['NA'],The number of positive lymph nodes,
8916,NCT05447221,The diagnostic performance of AI model to assess the severity of intestinal metaplasia,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],"Accuracy of digital pathological AI models to identify glands, mucosal epithelium, and intestinal metaplasia in non-neoplastic areas",
8917,NCT01967823,Percentage of Participants With a Response,2013-10-24,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of T Cell Receptor (TCR) in Cluster of Differentiation 3 (CD3) + Cells,Number of Participants With Serious and Non-serious Treatment Related Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
8918,NCT05147389,Neoplastic bile duct diagnosis confirmation after one year follow-up,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
8919,NCT03329950,Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetic evaluation,
8920,NCT05115786,Recurrence of colorectal cancer,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
8921,NCT01855724,Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1),2013-06-28,TERMINATED,INTERVENTIONAL,['PHASE2'],Evaluation of potential prognostic and/or predictive biomarkers in tissue and blood samples,
8922,NCT01180959,Progression Free Survival (PFS),2011-04-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
8923,NCT05187338,Duration of remission (DOR),2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
8924,NCT02136069,"Percentage of Participants With Both Clinical Response at Week 10 and Clinical Remission at Week 54, as Determined by the Mayo Clinic Score (MCS)",2014-12-24,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab,
8925,NCT03248375,Number of Participants With Local Tumor Response According to mRECIST,2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants With Treatment-related Laboratory Adverse Events,
8926,NCT03161522,Overall survival (OS),2018-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to local or regional disease recurrence,Time to disease progression
8927,NCT06227871,Complication occurrence,2019-11-01,COMPLETED,OBSERVATIONAL,['NA'],Associated intra-abdominal injuries,
8928,NCT00035919,dose-limiting toxicity and maximum tolerated dose,2002-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",objective tumor response by CT scan or MRI,
8929,NCT04723004,Overall survival (OS),2020-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],ADA,
8930,NCT00026338,Overall survival,2001-10-29,COMPLETED,INTERVENTIONAL,['PHASE3'],Pharmacokinetics,
8931,NCT01009801,Time to progression (Phase II),2010-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to treatment failure (Phase II),
8932,NCT04597268,Ramsy sedation score (RSS),2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
8933,NCT04608786,Recommended phase II dose (RP2D),2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],the number of subjects presenting detectable anti drug antibodies (ADAs),
8934,NCT00410618,Nature and long-term ramifications of CNS injury as a result of cancer treatment,2003-04,COMPLETED,OBSERVATIONAL,['NA'],Relationship between MRI measures and cognitive performance,
8935,NCT00470951,Disease free survival,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life,Immunologic response
8936,NCT04681274,Specific tumor phenotypes,2020-08-31,COMPLETED,OBSERVATIONAL,['NA'],Small lesion detection and characterization,
8937,NCT02375997,Overall survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse event,
8938,NCT02564224,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
8939,NCT03038568,assess the stability (reproducibility) of radiomic measurements obtained from repeat abdominal CT scans,2017-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
8940,NCT03267641,Time to recurrence,2016-05-16,COMPLETED,OBSERVATIONAL,['NA'],Overall Survival,
8941,NCT03344172,Proportion of Grade IIb or Higher Histolopathologic Responses,2017-12-13,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in Coagulation Index (CI),
8942,NCT04888663,"Phase 2: Progression-free survival in patients with HER2-positive gastric cancer receiving trastuzumab, ramucirumab, and paclitaxel combination treatment",2018-02-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE v4.02,
8943,NCT05732129,"Objective response rate of Metastatic Colorectal Cancer,inculdthe proportion of patients with complete response or partial response",2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.,
8944,NCT01930864,Non-Progression at week 12th of treatment,2015-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety,
8945,NCT02778308,Disease Free Survival,2012-01,COMPLETED,INTERVENTIONAL,['NA'],Gastrointestinal system Adverse events,
8946,NCT02485561,Intentions to Get Screened for Colon Cancer,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],Absolute Perceived Susceptibility to Colon Cancer,Perceived Benefits and Barriers of Colorectal Cancer Screening
8947,NCT04601727,16s rRNA pyrosequencing analysis of microbial flora of rectal cancer patients,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],Categorisation of microbial flora against response to neoadjuvant chemoradiotherapy,
8948,NCT04787523,Immun cell infiltrate in pathology sections from the tumour,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
8949,NCT05441163,HRQoL deterioration free survival (QFS),2023-04-08,RECRUITING,INTERVENTIONAL,['NA'],,
8950,NCT03983057,Progression-free survival,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Carbohydrate antigen 19-9,
8951,NCT02363647,Overall response rate (ORR),2015-01,TERMINATED,INTERVENTIONAL,['NA'],Overall survival (OS),
8952,NCT04508452,Reintroduction Rate,2020-05-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],ORR2,
8953,NCT00956436,To evaluate the safety and tolerability of BIIB022 given once every 3 weeks in combination with sorafenib in subjects with advanced HCC.,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],To assess the anti-tumor response in this study population,
8954,NCT03802214,"Analysis of blood and tissue leukocytes (T cells, B cells and Dendritic cells)",2020-10-29,TERMINATED,OBSERVATIONAL,['NA'],Analysis of the serum and tissue concentrations of vedolizumab,
8955,NCT04748744,Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases,2019-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
8956,NCT04296851,Mean percentage change of the number and size of polyps in colon and/or duodenum.,2020-02-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],A qualitative assessment of the total extent of colorectal polyposis,
8957,NCT00280709,"Clinical follow-up every month, starting one month after stent insertion. Clinical and/or laboratory signs of stent dysfunction?",2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8958,NCT06216834,psychosocial status,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
8959,NCT00112086,proportion of clinical complete remission,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival among all enrolled patients.,
8960,NCT01004978,Progression-free Survival (PFS),2009-10-28,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression-free Survival (PFS) Among Patients With Intra-hepatic Progression,To Evaluate the Effects of Intra-hepatic vs. Extra-hepatic Progression on OS.
8961,NCT05289895,Proteomic analysis of blood and urine,2022-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
8962,NCT02296736,Review pre-operative imaging to distinguish the organ of origin of pancreatic head tumours,2014-10,COMPLETED,OBSERVATIONAL,['NA'],Resectabilty of the pancreatic tumour,
8963,NCT04368182,Safety of C-TCR055,2020-04-13,UNKNOWN,INTERVENTIONAL,['PHASE1'],DOR,
8964,NCT02327481,Operating time,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Recurrence patterns,
8965,NCT05981066,Clinically significant abnormal changes in laboratory tests,2023-07-10,RECRUITING,INTERVENTIONAL,['NA'],"Overall Survival, OS",
8966,NCT04564898,activity,2022-01-25,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",survival,Clearance
8967,NCT05658016,Mucositis,2022-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence Adverse Events That Are Related to Treatment,
8968,NCT02299648,molecular screening ( biopsy of their tumor and will be analyzed using cancer panel/nanostring CNV and immunohistochemistry),2014-07-25,COMPLETED,INTERVENTIONAL,['NA'],OS/PFS,
8969,NCT03019588,Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),2017-02-16,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of Participants Who Discontinue Study Treatment Due to an AE,
8970,NCT03639935,Proportion of patients alive and without radiological or clinical progression at 4 months,2019-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS) time as measured from start of 1st line platinum therapy,
8971,NCT01134666,Safety and tolerability evaluated based on the incidence and severity of AEs.,2009-11-30,TERMINATED,OBSERVATIONAL,['NA'],Response rate,
8972,NCT03602677,Anastomosis leakage rate,2018-09-24,RECRUITING,INTERVENTIONAL,['NA'],Hospital costs,
8973,NCT04624282,Metabonomic difference in patients with chronic gastritis and gastric carcinoma,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],Association of different metabolic substances and disease results in chronic gastritis and gastric carcinoma,
8974,NCT00868114,Overall Survival,2006-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8975,NCT05657249,Comparison of alternative surveillance program (alternating focused MRI + US in 6 month interval) and conventional surveillance (biannual US) for HCC detection,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],comparison between false referral rates of biannual US and annual focused MRI,comparison between incidental findings between biannual US and annual focused MRI
8976,NCT02376478,"Number of anogenital warts, anogenital HPV DNA positivity and mucosal HPV seropositivity",2009-12,COMPLETED,OBSERVATIONAL,['NA'],,
8977,NCT01714726,Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 8,2013-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With ADA Positive to MEDI2070 in Open-label Period,
8978,NCT05878977,response prediction in first line immune checkpoint inhibitors treatment in metastatic melanoma assessed by human gastrointestinal microbiome (bacterial and viral) and exosomal mRNA expression of PD-L1 and IFNγ,2022-10-05,RECRUITING,INTERVENTIONAL,['NA'],,
8979,NCT03793322,The accuracy of positive margins of resection detected by ICG fluorescence.,2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8980,NCT04430231,Disease-free overall survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8981,NCT01103492,Number of Participants With Adverse Events,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,
8982,NCT02260440,Objective Response Rate (ORR),2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
8983,NCT05163028,"To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), of HBI-2376 as an oral monotherapy for advanced solid tumors harboring KRAS or EGFR mutations.",2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacokinetic variables including volume of distribution,
8984,NCT00222469,"To determine the overall survival (OS) rate at 1 year in this patient population, treated with the combination therapy of bevacizumab plus gemcitabine and oxaliplatin",2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],To determine the tolerability and toxicity profile of this regimen in this patient population,
8985,NCT01279278,Completion of Fecal Occult Blod Test,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],"Compare the rate of completion of colonoscopy after a positive test (information received by ADECA in the follow-up), according to the specifications.",
8986,NCT00314353,One-year Progression-free Survival (PFS),2006-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Duration of Response,
8987,NCT05243862,Administration safety,2022-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Measured Memory T Cell Immune Response,
8988,NCT03245203,R0 resection rate,2017-08,UNKNOWN,INTERVENTIONAL,['NA'],overall response rate (ORR),
8989,NCT04829032,Number of Hartmann's procedure vs colic resection with primary anastomosis performed in 3-months in urgent or emergency setting for left-sided acute colonic diseases.,2021-03-01,UNKNOWN,OBSERVATIONAL,['NA'],The number of patients treated with Hartmann's procedure with a permanent stoma after one year.,
8990,NCT02927626,Survival rate,2016-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],quality of life(QOL),
8991,NCT05887531,Post-surgical readmisions,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],Strength,
8992,NCT05462470,overall survival,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],Severe complication rate after resection of primary and metastatic lesions,
8993,NCT05546970,Efficacy of the echo-guided TAP Block on analgesia,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
8994,NCT01255007,To establish superiority of Primovist-enhanced liver MRI and DWI to MDCT in the preoperative detection of colorectal liver metastases in patients who have received prior chemotherapy by comparison against pathology or Intra-operative ultrasound.,2010-09,COMPLETED,INTERVENTIONAL,['NA'],To compare accuracies of Primovist-enhanced MRI and DWI to MDCT in the characterization of non-metastatic liver lesions against histopathology or intra-operative ultrasound.,
8995,NCT06085560,Anticipatory Racism,2023-07-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
8996,NCT01809756,severity of esophagitis (NCI Common Terminology Criteria for Adverse Events (CTCAE) 4.0 score),2014-02-25,TERMINATED,INTERVENTIONAL,['NA'],weight loss (NCI CTCAE 4.0 score),
8997,NCT00351572,,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,
8998,NCT00899093,YKL-40 measurements,2007-09,TERMINATED,OBSERVATIONAL,['NA'],,Variability of YKL-40 measurements
8999,NCT05565417,Phase 2a Cohort(s) Overall Response Rate (ORR) based on RECIST 1.1 or Lugano criteria (lymphomas only) to assess anti-tumor activity of IMT-009 in each cohort,2022-11-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2a Cohort(s)- Number of participants with adverse events following administration of IMT-009,
9000,NCT06195904,Genetic variants of pancreatic cysts associated with malignancy assessed by next-generation sequencing,2024-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Genetic variants that differentiate mucinous from serous cysts assessed by next-generation sequencing,
9001,NCT03189992,Complete patient recruitment,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
9002,NCT01887717,Overall Survival (OS) From Time of Randomization,2014-02-27,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of Participants With Treatment Emergent Adverse Events (TEAE),
9003,NCT03444194,Tissue biopsy,2017-05-12,UNKNOWN,INTERVENTIONAL,['NA'],RECIST,
9004,NCT05264688,diagnose accordance rate,2022-01-20,UNKNOWN,OBSERVATIONAL,['NA'],Total Glycolysis (TLG),
9005,NCT04833699,time to the first passage of flatus after surgery,2021-04-05,COMPLETED,INTERVENTIONAL,['NA'],The time to the first bowel movement,
9006,NCT05984342,disease-free survival rate,2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE1'],Rate of adverse events,
9007,NCT03951389,"The correlation between wild type PIK3CA, PIK3CA exon 9 and PIK3CA exon 20 mutations and developing of metastatic disease and overall colorectal patient survival",2012-05-22,COMPLETED,OBSERVATIONAL,['NA'],,
9008,NCT02347852,Amount of physical activity assessed by a pedometer (smartLAB) and an international physical activity questionnaire,2015-01-20,COMPLETED,OBSERVATIONAL,['NA'],"Relation of the amount of physical activity to PFS (Progression Free Survival) data assessed in CORRELATE (NCT02042144, 'Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings')",
9009,NCT00191607,"- Progression free survival (PFS) in patients who have failed one, but no more than two, prior treatments",2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of life,
9010,NCT01290536,Number of Participants With Adverse Events,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Radiographic Response,
9011,NCT01934179,"Incidence of chemotherapy related grade 3 or higher adverse events, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",2013-10,TERMINATED,OBSERVATIONAL,['NA'],Change in TL after chemotherapy,"Association of each geriatric scale, and pro-inflammatory markers to the incidence of chemotherapy related adverse events and TL"
9012,NCT03814369,Adenoma detection rate,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],caecal intubation time,
9013,NCT05811195,Oral mucositis Children's International Mucositis Evaluation Scale (CHIMES),2023-03-10,RECRUITING,INTERVENTIONAL,['NA'],Analysis NET and TSE,
9014,NCT02649153,Time to first peristalsis,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9015,NCT02421185,Number of participants with Objective Response,2015-05-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of Objective Response (DOR),
9016,NCT03144856,Progression-free survival (PFS),2017-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety (incidence of adverse events),
9017,NCT03491709,Pharmacokinetic Parameters: Area Under the Serum Concentration-time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Infusion,2018-07-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Immunogenicity indicators: neutralizing antibodies,
9018,NCT06236594,Image quality rate,2023-09-18,RECRUITING,OBSERVATIONAL,['NA'],Diagnosis accuracy according to image,
9019,NCT00006479,,2000-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
9020,NCT05550974,complication,2022-09,RECRUITING,OBSERVATIONAL,['NA'],number of use for each surgical instruments,
9021,NCT01417000,Overall Survival (OS) in Subjects Receiving Test Treatments (FAS),2011-09-21,COMPLETED,INTERVENTIONAL,['PHASE2'],"To Assess Safety of the Cyclophosphamide, GVAX Pancreas Vaccine, and CRS-207 Treatment Regimen",
9022,NCT01237132,Overall survival of resected patients for HCC,na,COMPLETED,OBSERVATIONAL,['NA'],Disease-free survival of resected patients for HCC,
9023,NCT03003078,Safety / Tolerability of Device according to CTCAE V4.0,2017-03-27,COMPLETED,INTERVENTIONAL,['NA'],Pain Scores,tumour response
9024,NCT05995990,Raman spectroscopy is able to discriminate between healthy liver tissue and colorectal liver metastases.,2020-11-25,COMPLETED,INTERVENTIONAL,['NA'],Tissue sections can be analysed by Raman spectroscopy more time effectively than normal clinical practice.,
9025,NCT04563975,disease control rate,2020-07-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival rate,
9026,NCT04257448,Recommended dose for expansion (RDE),2020-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression free survival (PFS),
9027,NCT06223763,Overall Survival at 5 years,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],Homologous Recombination Deficiency (HRD) deficiency influence,
9028,NCT05365412,"Survival (overall/disease-specific) according to sex, molecular profiles and sex hormone receptors",2019-01-01,RECRUITING,OBSERVATIONAL,['NA'],"Disease-free survival according to sex, molecular profiles and sex hormone receptors",
9029,NCT00262808,Proportion of patients with a change in tumor-associated macrophage VEGF expression,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease-free and overall survival,
9030,NCT05601609,Overall survival outcome in young colorectal cancer (yCRC) and elderly colorectal cancer (eCRC),2020-11-11,COMPLETED,OBSERVATIONAL,['NA'],Cancer-specific survival outcome in young colorectal cancer (yCRC) and elderly colorectal cancer (eCRC),
9031,NCT00985777,Maximum Tolerated Dose (MTD),2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With Adverse Events (AEs),
9032,NCT02619435,the rate of evaluable patients alive and not progressed at 6 months,2015-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival,
9033,NCT00095927,"Median duration of dependence on percutaneous endoscopic gastrectomy (PEG) for adequate nutrition at 8, 12, 24, and 52 weeks after completion of study treatment",2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Swallowing function,
9034,NCT05957822,CRT maximal amplitude,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],re-operation,
9035,NCT04716166,FEV1/FVC ratio,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],,
9036,NCT00065234,,2003-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9037,NCT00081354,Case Control,2004-04-06,COMPLETED,OBSERVATIONAL,['NA'],,
9038,NCT00606788,weaning duration,2005-11,SUSPENDED,INTERVENTIONAL,['NA'],reintubation rate,
9039,NCT00823290,Maximum tolerated dose of LBH589,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Laboratory abnormalities (CTC grade 3 or grade 4 toxicities),
9040,NCT06061874,Correlation of the Ga68-FAPI PET/CT derived PCI (peritoneal cancer index) score with the intraoperative PCI based on histopathology of resected specimen (the reference standard),2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Assessment of the impact of neoadjuvant chemotherapy on the FAPI expression of target lesions at baseline.,
9041,NCT06052202,Receipt of Colorectal Cancer Screening Test at Month 6,2023-12-08,RECRUITING,INTERVENTIONAL,['NA'],Change from Baseline in Colorectal Cancer Knowledge at Month 6,
9042,NCT04248569,Fold change in interferon-producing DNAJB1-PRKACA-specific cluster of differentiation 4 (CD4) T cells at 10 weeks,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
9043,NCT02511756,CTP as predictive marker for efficacy measured by progression-free survival,2015-07,TERMINATED,INTERVENTIONAL,['NA'],Local and distant recurrences,
9044,NCT00292279,Systemic inflammatory response syndrome (SIRS),2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Post operative nutritional cost & total treatment cost,
9045,NCT02090101,Response rate after 2 months in patients with colorectal cancer with liver metastases treated with anakinra and LV5FU2/bevacizumab,2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Rate and safety profile according to NCI-CTCAE v4,
9046,NCT02807844,Phase Ib: Number of Participants With Dose Limiting Toxicities (DLTs) During the First 2 Cycles of Study Treatment,2016-06-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase Ib and Phase II: All Collected Deaths,
9047,NCT05345678,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
9048,NCT05682898,Incidence of surgical complications,2023-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9049,NCT06333392,Proximal sessile serrated lesion detection rate,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Single use accessories for the procedure,
9050,NCT04850716,Progression-Free Survival (PFS),2021-04-27,RECRUITING,OBSERVATIONAL,['NA'],Disease Control Rate (DCR),
9051,NCT04568200,pathological response,2020-06-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
9052,NCT02442362,Tumor respone,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Side-effect,
9053,NCT02015169,complete resection rate (R0 resection rate) (defined as no macroscopic or microscopic residual tumor).,2012-07-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory biomarker analysis,
9054,NCT01736813,"safety as occurence of adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria, that are definitely, probably, or possible related to the administration of the investigational agent",2012-11,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
9055,NCT00904813,Time to Local Recurrence.,1998-11,COMPLETED,INTERVENTIONAL,['NA'],Tumour Regression Based on the Dworak Grading Scoring System,
9056,NCT04071431,Rate change,2019-05-29,UNKNOWN,INTERVENTIONAL,['NA'],,
9057,NCT04563897,Diagnostic performance of contrast-enhanced ultrasound in different liver background and liver turmors by sonazoid,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9058,NCT05190042,The rates of complete closure of mucosal/submucosal defects,2022-01-18,COMPLETED,INTERVENTIONAL,['NA'],Post polypectomy syndrome,
9059,NCT01489865,Dose limiting toxicities,2011-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Objective Response,
9060,NCT01479608,Overall survival,2012-04-11,RECRUITING,INTERVENTIONAL,['NA'],,
9061,NCT02758977,1 Year Disease-free Survival,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],Incidence of posthepatectomy renal failure,
9062,NCT03680183,Average plasma concentration of the drugs (TKIs),2018-05-22,UNKNOWN,OBSERVATIONAL,['NA'],Incidence of adverse reaction caused by TKIs,
9063,NCT05014776,Objective response rate (irORR) using immune Response Evaluation Criteria for Solid Tumors (iRECIST),2022-08-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants experiencing grade 3 or above drug-related toxicities,
9064,NCT02043288,Overall survival (OS),2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of life (QoL) using EORTC QLQ-C30,
9065,NCT06136845,To characterize the microbiota of esophageal cancer patients differentiating it by: - demographic criteria - tumor characteristics,2020-01-13,RECRUITING,OBSERVATIONAL,['NA'],,
9066,NCT03411200,Lower body strength measured with the 30-second chair stand test,2018-04-04,COMPLETED,INTERVENTIONAL,['NA'],Survival,
9067,NCT05292417,Progression-free survival (PFS),2022-03-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety:Percentage of Participants With Adverse Events (AEs),
9068,NCT06048913,Overall Survival,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1'],Toxic side reactions,
9069,NCT00955240,Objective response (complete and partial) according to RECIST criteria at 8 weeks after completion of study treatment,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Duration of objective response,
9070,NCT03868228,Progression free survival assessed by laparoscopy and cross sectional imaging,2019-02-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PIPAC related safety regulation breaches / adverse events in theatre,
9071,NCT04389151,effectiveness of neoadjuvant therapy,2020-03-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9072,NCT02870036,Adverse events (AE),2016-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],accumulative excretion rate,
9073,NCT06261814,False discovery rate,2024-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Ability of the model to predict binary treatment response,
9074,NCT04262635,Efficacy: Maintenance PFS,2021-09-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Overall Survival,Change from Baseline in Mutation Status of Selected Genes tested by Next-Generation Sequencing during Treatment Period
9075,NCT02785783,Number of polyps per patient,2016-05-13,COMPLETED,INTERVENTIONAL,['NA'],,
9076,NCT03852693,Frequency of distant metastases in aNET measuring 1-2 cm,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],Long-term survival after complete resection of aNET measuring 1 - 2 cm with or without oncological right-sided hemicolectomy,
9077,NCT03311750,Evaluation of overall response rate of the addition of panitumumab rechallenge to standard third-line therapy,2018-03-26,TERMINATED,INTERVENTIONAL,['PHASE2'],Mutations analysis on platelet-resorbed tumour RNA (with Real-time PCR) in exon 20 of PIK3CA gene mutations,
9078,NCT03694600,Independent performance measure of sensitivity and specificity of a multi-analyte blood test vs Ultrasound,2019-02-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],To compare the performance (sensitivity and specificity) of ultrasound alone to the multi-analyte Test alone for the detection of liver cancer lesions that are ≤ 2cm in diameter.,
9079,NCT01959087,Length of postoperative hospital stay,2014-01-27,COMPLETED,INTERVENTIONAL,['NA'],Post-operative quality of life,
9080,NCT00436241,Overall response rate,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"AEs, laboratory parameters.",
9081,NCT00881504,Progression-free Survival,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Safety and Toxicity,
9082,NCT00890305,The primary endpoint will be the median progression free survival in patients treated with CT-011 plus FOLFOX compared to that of patients treated with FOLFOX alone.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor and immunological markers.,
9083,NCT03400280,Composite primary endpoint,2018-01-08,UNKNOWN,INTERVENTIONAL,['NA'],Cost-effectiveness,
9084,NCT03471052,Change in surface area of residual inlet patch post ablation,2018-03-06,UNKNOWN,INTERVENTIONAL,['NA'],"Symptomatic response for cough, hoarseness and sore throat using Visual Analogue Scale (VAS)",
9085,NCT01926743,To compare the number of retrieved lymph node in each nodal station after additional application of near infra-red fluorescence imaging,2013-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
9086,NCT00104689,Efficacy in terms of stabilization or improvement by 1 point on Katz's Activities of Daily Living scale,2003-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacokinetics,
9087,NCT02325739,Overall Response Rate (ORR) Based on Local Assessment: Group 3 (Phase II Only),2014-12-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",T1/2 of FGF401: Phase I,
9088,NCT03171428,Short-term outcome: Occurrence of postoperative complications or death after surgery,2007-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9089,NCT04331041,Progression-free survival (PFS),2021-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Local control,
9090,NCT05030870,The incidence of hypoxia,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],The incidence of other adverse events,
9091,NCT01456923,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9092,NCT02678013,Recurrence-free survival,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0,
9093,NCT02247336,Number of Patients With Provider Referral for Risk-appropriate Colorectal Cancer Screening,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],Number of Patients Who Received Referral for Genetic Consultation,
9094,NCT00003544,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9095,NCT00881621,Overall Survival,2009-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Adverse Events,
9096,NCT05859945,Number of hepatocellular carcinoma study participants who remain in clinical trial until completion.,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9097,NCT05267080,Local Tumour Control,2023-01-25,RECRUITING,OBSERVATIONAL,['NA'],Economic aspects,
9098,NCT00265824,Progression-free survival during maintenance therapy,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9099,NCT05965531,Objective response rate,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
9100,NCT05927584,Success rate,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Radical rescue surgery specimen quality,
9101,NCT03198975,Presence of microvascular invasion,2017-06-23,UNKNOWN,OBSERVATIONAL,['NA'],,
9102,NCT00005629,Safety,1999-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Survival,
9103,NCT05084456,The hematological and non-hematological toxicity profile of oral docetaxel in combination with ritonavir,2017-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
9104,NCT01585428,Number of Participants With an Objective Clinical Response,2012-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Serious and Non-serious Adverse Events,
9105,NCT05616403,Textbook outcome,2010-01-18,COMPLETED,OBSERVATIONAL,['NA'],,
9106,NCT01005875,Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma,2009-11,TERMINATED,INTERVENTIONAL,['NA'],The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by ADC (Apparent Diffusion Coefficient).,
9107,NCT01640405,Progression free survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],"Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)",
9108,NCT00037180,Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy,2002-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Health resource utilization (collected data to be evaluated separately from this protocol),
9109,NCT04272619,Change in intentions about communicating with healthcare provider - liver cancer risk,2020-02-11,COMPLETED,INTERVENTIONAL,['NA'],,
9110,NCT01786278,The highest improvement of stricture diameter,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life,Cost analysis
9111,NCT02806648,Activity of palbociclib (PD0332991) considering objective response rate,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],"Positive expression of tumor biomarkers (Cdk4, Cdk6, fosfo-Rb1, D1 cyclin, p53, Ki67)",
9112,NCT00054873,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9113,NCT03330964,Levi sensory nerve toxicity classification standard,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],The quality of life questionnaire(QLQ)-C30,National Cancer Institute(NCI)Common Toxicity Criteria
9114,NCT05133544,Adenoma detection rate,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],Total number of polyp or adenoma per patient.,
9115,NCT06280508,1-year EFS rate,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
9116,NCT03172884,Area Under the Concentration-time Curve of Copanlisib in Plasma Over the Time Interval From 0 to 168 h.,2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Subjects With Treatment-emergent Adverse Events (TEAEs) in Different Severity.,
9117,NCT03823144,"4. Tumor blood flow (velocity, mm/sec)",2019-02-28,COMPLETED,INTERVENTIONAL,['NA'],Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.,
9118,NCT01494012,The rate of grade 3 or greater non-hematologic acute toxicity as graded by the CTCAE v. 4.0,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall survival,
9119,NCT02016391,Patient Satisfaction With Sedation Technique,2013-12,COMPLETED,INTERVENTIONAL,['PHASE4'],Maximal pain intensity,
9120,NCT03770559,Posteroperative length of stay,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],R0 resection,
9121,NCT05657418,RP2D,2022-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],ORR,
9122,NCT02312284,Distant metastasis free survival,2011-01,COMPLETED,OBSERVATIONAL,['NA'],Surgery complication,
9123,NCT03475615,overall survival,2018-03-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
9124,NCT06153394,Number pf participants with hypercoagulability identified via TEG testing,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Disease Free Survival,
9125,NCT01540461,Accumulation index calculated as the ratio: AUC(TAU) at steady-state (Day 8) divided by AUC(TAU) after the first dose (Day 1) [AI] of Brivanib,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Preliminary evidence of anti-tumor activity as measured by objective response rate (ORR) and disease control rate (DCR) in Chinese subjects with advanced HCC treated with Brivanib,
9126,NCT00052962,Progression Free Survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With an Adverse Event,
9127,NCT00496678,"To develop, implement, and evaluate a primary care-based, patient navigation program using specially-trained community health workers. We will investigate the effect of this intervention on timing and quality of cancer-related care.",2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],"Secondary aims examine the impact of navigation on disparities in care, improvement in patient activation and total costs.",
9128,NCT04163068,Treatment burden,2020-01-08,COMPLETED,OBSERVATIONAL,['NA'],,
9129,NCT00032110,Objective response or disease stabilization,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Molecular changes with therapy,
9130,NCT05409482,Progression-free survival（PFS）,2022-08-20,RECRUITING,OBSERVATIONAL,['NA'],Occurence of AE and SAE,
9131,NCT02023593,Disease control rate,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression free survival,
9132,NCT00810719,Progression Free Survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
9133,NCT03612726,Overall survival,2018-07-16,RECRUITING,OBSERVATIONAL,['NA'],Frequency and Severity of Adverse Events,
9134,NCT00003557,Objective Response Rate,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9135,NCT02665299,Utility of plasma ctDNA measurements to detect colon cancer or precancerous conditions.,2016-01,COMPLETED,OBSERVATIONAL,['NA'],Determination of incident rate of new colon or other cancers in patients who underwent initial measurement of ctDNA,
9136,NCT01646554,Progression free survival,2012-12,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Safety,
9137,NCT03619317,• Left ventricular systolic function estimated by 2D longitudinal strain (GLS) and ejection fraction (EF) at rest and peak exercise,2018-06-25,UNKNOWN,OBSERVATIONAL,['NA'],Left ventricular systolic function estimated by 2D longitudinal strain (GLS) and ejection fraction (EF) at rest and peak exercise,
9138,NCT01650766,,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9139,NCT03370198,The occurrence of DLTs until 14 days after the last NKR-2 study treatment administration (Visit Day 43),2017-10-11,TERMINATED,INTERVENTIONAL,['PHASE1'],The overall survival (OS).,
9140,NCT04862260,Characterization of dose-limiting toxicities,2021-10-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],CD36 (Cluster of Differentiation 36) changes in response to the multipathway cholesterol embargo,To explore the feasibility of a larger multicenter trial
9141,NCT06244537,Pathological complete response (pCR),2024-02-29,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
9142,NCT06152276,Overall major complications,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
9143,NCT01462890,Progression Free Survival (PFS),2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Translational Research - Complementary and Alternative Treatment Questionnaires,
9144,NCT03971201,overall survival,2019-09-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],progression free survival,
9145,NCT00556413,Complete response rate,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival,
9146,NCT00653484,Physical activity-energy expenditure,2008-03,COMPLETED,INTERVENTIONAL,['NA'],Body weight and composition,
9147,NCT00940563,tumor response /RecIST criteria),2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"which early predictive factors of tumor response may be of relevance, i.e. conventional pathologic characteristics of tumor and radiological aspects.",
9148,NCT00877045,,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
9149,NCT04451343,"Assess how the patients, their relatives and their family members, face the disease.",2018-07-06,COMPLETED,OBSERVATIONAL,['NA'],,
9150,NCT00602329,"Analysis of tumor blood flow, assessed by DCE-MRI as percentage change in Ktrans, after 2 courses of FOLFOX and bevacizumab or FOLFOX alone compared to baseline value",2006-02,TERMINATED,INTERVENTIONAL,['PHASE2'],"Correlation of markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival",
9151,NCT00189566,Progression-free survival of patients in the three groups,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
9152,NCT01215565,Objective response,2009-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarkers of radiological response,
9153,NCT01635595,,2006-01,COMPLETED,OBSERVATIONAL,['NA'],,
9154,NCT00671996,Neutropenia,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life,
9155,NCT04653701,Technical success,2020-11-14,UNKNOWN,OBSERVATIONAL,['NA'],,
9156,NCT06220045,Incidence of surgical wound infection,2024-01-15,RECRUITING,INTERVENTIONAL,['NA'],Morbidity and mortality rates,
9157,NCT00967291,Progression-free survival at 6 months,2006-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall survival,
9158,NCT05281159,Opening link within SMS Text message,2022-02-21,COMPLETED,INTERVENTIONAL,['NA'],Overall completion of any CRC screening test,
9159,NCT00088894,Grade 3-4 neutropenia in terms of specific single-nucleotide polymorphisms (SNPs) and/or copy number variations that are associated with the prevalence of these events (Clinical endpoint),2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],OS (Clinical endpoint),
9160,NCT05004376,Screening,2022-01-03,COMPLETED,INTERVENTIONAL,['NA'],Phone Interview for refinement of Intervention,
9161,NCT02727309,Progression free survival,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Objective response rates,
9162,NCT01437514,local recurrence,2011-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",short-term complication of the surgery,
9163,NCT04046601,impedance,2019-10-09,COMPLETED,INTERVENTIONAL,['NA'],differences in impedance,
9164,NCT04837833,measurement differences between ultrasound tumor volumes,2021-04-06,RECRUITING,INTERVENTIONAL,['NA'],,
9165,NCT02545751,The proportion of patients with tumor responses after the initiation of treatment.,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"The proportion of patients alive with tumor responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study.",
9166,NCT01590719,Progression-free survival (PFS) in patients with Met-positive tumors,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of response (DOR),
9167,NCT00082862,Changes in quality of life,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Changes in cellular and cytokine immune function,
9168,NCT00195572,Survival time,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],"Response rate, duration of response, time to progression, safety, quality of life",
9169,NCT04034355,Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN),2019-01-07,TERMINATED,INTERVENTIONAL,['PHASE3'],Patients With Disease Free Survival,
9170,NCT03767764,Yliver,2018-12-27,COMPLETED,OBSERVATIONAL,['NA'],AAb AFP,
9171,NCT05963087,Objective response rate (ORR),2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival time,
9172,NCT00575640,The study design calls for an initial phase of dose-escalation in cohorts of 3 patients. There are no intra-patient changes in dose.,2004-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Subsequent to this Phase I scheme, the study will continue with the selected dose-level (on toxicity and tolerability grounds) to accrue patients in a phase II scheme.",
9173,NCT00276705,Event-free and overall survival following tumor resection,2005-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Efficacy and tolerability following course 2 and 4 of pre-operative chemotherapy,
9174,NCT00003926,,1998-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,
9175,NCT05265754,Sujok Therapy's positive cahange in nausea and vomiting Experienced by Patients with Gastrointestinal System Cancer,2022-02-01,COMPLETED,INTERVENTIONAL,['NA'],,
9176,NCT00825110,the primary endpoint is the identification of cases with evidence of loss of the product of one of the four main MMR genes on tumour histology.,2008-11,UNKNOWN,OBSERVATIONAL,['NA'],Secondary outcome measure is the survival and response to treatment of the identified cases.,
9177,NCT02155140,Fatigue,2011-02,TERMINATED,INTERVENTIONAL,['NA'],Health economic analysis,
9178,NCT04190589,Lymph node count,2020-05-18,RECRUITING,INTERVENTIONAL,['NA'],Readmissions,Conversion rate
9179,NCT04160962,EORTC Questionnaire QLQ-C30,2020-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9180,NCT03264898,FIT Result,2017-10-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9181,NCT01640808,Recurrence-free Survival,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Time to Recurrence,
9182,NCT00081094,Relative sensitivity and specificity of positron emission tomography (PET) scanning with carbon-11 acetate and fludeoxyglucose F 18,2003-09,COMPLETED,INTERVENTIONAL,['NA'],Obtain a preliminary estimate of the impact of PET on management of patients with HCC.,
9183,NCT03148119,Incidence of QRH-882260 Heptapeptide administration-related adverse events,2017-03-31,TERMINATED,INTERVENTIONAL,['PHASE1'],Efficacy of QRH-882260 Heptapeptide administration for detection of polypoid and non-polypoid colonic neoplasia,Efficacy of QRH-882260 Heptapeptide administration for detection of dysplasia in the setting of IBD
9184,NCT00467116,Maximum Tolerated Dose,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor response rate,
9185,NCT01375972,Progression-free survival rate at 6 months,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival,
9186,NCT03515356,Sensory neuropathy at 8 weeks,2018-06-13,COMPLETED,INTERVENTIONAL,['NA'],Mood at 8 weeks,MI Fidelity Measure at 9 months
9187,NCT00044031,Survival,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants with Serious and Non-Serious Adverse Events,
9188,NCT00499486,Severity of Adverse Events as Assessed by NCI CTCAE v3.0,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9189,NCT00855348,Clinical/surgical diagnosis of invasive colorectal adenocarcinoma detected by optical colonoscopy and confirmed by histology compared to the Septin 9 Biomarker classification.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],"Detection of adenomatous polyp(s) equal to or greater than 10 mm, flat lesion (s) or non-invasive adenocarcinoma by colonoscopy and confirmed by histology compared to the Septin 9 Biomarker classification will also be described.",
9190,NCT02912559,Disease free survival (DFS),2017-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence of adverse events,
9191,NCT05288205,Number of participants with dose limiting toxicities,2022-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival (PFS),
9192,NCT00793455,Colorectal Cancer Screening Completion.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],Colorectal Cancer Screening Completion,
9193,NCT04795869,Overall objective response rate (ORR),2020-03-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival,
9194,NCT02803515,Changes in serum levels of HSP90 and 70 on peripheral venous samples.,2017-01-16,TERMINATED,INTERVENTIONAL,['NA'],,
9195,NCT01679340,replase free survival,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events as a Measure of Safety and Tolerability,
9196,NCT00335010,differences in microvascular hemoglobinsaturation,2005-05,COMPLETED,INTERVENTIONAL,['NA'],differences in anastomotic stenosis,
9197,NCT03193710,Cancer free survival,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],Colorectal cancer antibodies,Days of hospitalization
9198,NCT02048540,R0 resection rate,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",safety of peroperative treatment and surgery,circulating tumor cell number change
9199,NCT01582750,Endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values,2010-10,UNKNOWN,OBSERVATIONAL,['NA'],,
9200,NCT02510911,Time to first bowel movement,2015-08,TERMINATED,INTERVENTIONAL,['NA'],Consumption of sleep inducing drugs,preoperative caffeine consumption
9201,NCT03479814,complete pathological response (pCR),2016-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Evaluation of PET-response as predictive factor,
9202,NCT05064618,Phase II study; response rate (based on RECIST ver1.1),2021-08-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Response rate （Phase I）,
9203,NCT01249352,Overall survival and assessment of the complete endoscopic response,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Complete clinical response rate,
9204,NCT00628810,Tolerability evaluated by NCI CTC v. 2.0 criteria,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life using the EuroQOL EQ5D questionnaire,
9205,NCT03917017,Postoperative survival,2019-01-01,RECRUITING,INTERVENTIONAL,['NA'],Disease-free survival,Intraoperative blood loss
9206,NCT01301495,Palliation assessment based on Dysphagia Scores,2010-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Assessment of Complications and MD Anderson Dysphagia Score,
9207,NCT03486678,Incidence of Treatment-Emergent Adverse Events,2018-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],OS,
9208,NCT05237921,Number of participants that adhere to a Combined Exercise and Dietary Intervention (CEDI),2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],Number of participants that meet estimated dietary intake and exercise goals,
9209,NCT01183559,Maximum Tolerated Dose of Vandetanib,2008-08-07,COMPLETED,INTERVENTIONAL,['PHASE1'],The Number of Participants With Adverse Events,
9210,NCT05520866,Proportion of days before surgery engaged in prehabilitation,2023-03-14,RECRUITING,INTERVENTIONAL,['NA'],Change in Mean score on the SF-36,Median Satisfaction Scores
9211,NCT04842565,Progression-free survival time (mPFS) (mRECIST),2021-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Time to Progression (TTP),
9212,NCT05568420,genomic analysis of tissue,2022-09-30,RECRUITING,OBSERVATIONAL,['NA'],,
9213,NCT04506138,Major Pathologic Response (MPR),2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Event Free Survival（EFS）,FACT-E questionnaire
9214,NCT01196260,To determine prognosis of patients with metastatic colorectal cancer received the combination of drugs,2004-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",To evaluate the time to progression of metastatic colorectal cancer after treatment,
9215,NCT01697371,Phase I of study: Number of participants with adverse events as a measure of safety and tolerability,2012-08-22,RECRUITING,INTERVENTIONAL,['NA'],Phase II -local control within irradiated fields at 2 years,
9216,NCT02997228,Progression free survival (PFS),2018-01-19,RECRUITING,INTERVENTIONAL,['PHASE3'],Duration of SD,Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected
9217,NCT00525005,overall response rate,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],"safety, progression-free survival, and overall survival",
9218,NCT00969046,To identifymaximum tolerated dose (MTD),2003-11,COMPLETED,INTERVENTIONAL,['PHASE1'],"To evaluate the blood concentrations profile (pharmacokinetics [PK]) of patupilone by multiple blood sampling before, during and after drug administration",
9219,NCT01286818,Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)],
9220,NCT02460991,Overall Survival,2015-11,TERMINATED,INTERVENTIONAL,['PHASE3'],Frequency of Treatment Emergent Adverse Events,FACT-Hep Quality of Life
9221,NCT04744688,The difference between changes in concentration of prothrombin fragment 1+2.,2021-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Incidence of deep venous thrombosis measured by doppler ultrasonography in colorectal cancer patients undergoing cytoreductive surgery with HIPEC,
9222,NCT00920192,Safety and tolerability of foretinib at the MTD as measured by number and severity of AEs,2009-08-12,COMPLETED,INTERVENTIONAL,['PHASE1'],PK profile of foretinib,
9223,NCT06105203,intersphincteric resection (ISR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],3-year defecation function,
9224,NCT01273805,2-month Progression-Free Survival Rate,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Grade 4-5 Treatment-Related Toxicity,
9225,NCT02649491,Change in Olfactory Signatures in patient sample,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],"Changes in the scores of Inflammatory Bowel Questionnaire,",
9226,NCT00657995,the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas,2007-04,COMPLETED,INTERVENTIONAL,['NA'],the total amount of insulin required for glycemic control after pancreatic resection,
9227,NCT05988814,Progression-free survival (PFS),2024-01-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life (QoL),
9228,NCT00226746,One-year overall survival rate,2003-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Occurrence of pathological response or shrinkage of the tumor (becomes resectable),
9229,NCT04409223,Progression-free survival (PFS),2020-09-12,TERMINATED,INTERVENTIONAL,['PHASE3'],Adverse Events and Serious Adverse Events,
9230,NCT01506115,Complications associated with the procedure,2009-09,COMPLETED,INTERVENTIONAL,['NA'],Survival time,
9231,NCT05921942,Progression free survival,2020-04-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Common terminology criteria adverse events (CTCAE 4.0),
9232,NCT04165031,Phase 2: Progression-Free Survival (PFS) Non-Small Lung Cancer (NSCLC Cohorts),2019-11-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Phase 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD",
9233,NCT05353582,Progression free survival,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Hospitalization time,
9234,NCT05557656,Overall survival (OS),2023-01-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Adverse events (AEs),
9235,NCT02272699,Disease-free survival,2014-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.,
9236,NCT05980416,Number of patients with clinically significant changes in laboratory tests,2023-08-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9237,NCT01395537,PHASE II: To Assess the Response Rate to This Regimen.,2011-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To Determine the Overall Survival,
9238,NCT00860691,"Fe, transferrin, ferritin",2008-01,UNKNOWN,INTERVENTIONAL,['NA'],"loss of blood during the surgery, postoperative hospital stay, morbidity, and mortality within 30 days after surgery",
9239,NCT01282333,Maximum-tolerated dose of veliparib in combination with cisplatin and gemcitabine,2011-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Recommended phase II dose,
9240,NCT03777462,Overall time,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease free time,
9241,NCT05249114,Establish the maximal tolerated dose of cabozantinib in combination with Lu-177 dotatae at a standard dose of 7.4 GBg in four 8-week cycles followed by continuation of cabozantinib.,2022-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Establish objective response rate as measured by RECIST 1.1,
9242,NCT02841046,Number of Days Needed for Anal Exsufflation After Surgery,2016-07-27,COMPLETED,INTERVENTIONAL,['NA'],Number of Days in Hospital,Complication After Surgery
9243,NCT00027521,,2000-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
9244,NCT01566942,disease-free survival（DFS）,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],overall survival(OS),
9245,NCT03747588,Intra-abdominal infection,2018-12-01,RECRUITING,INTERVENTIONAL,['NA'],Length of hospital stay (day),progression-free survival
9246,NCT03891654,DCE-CT Perfusion Metrics: Blood Flow,2019-08-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Correlation Between Patient Demographics and Blood Flow: Clinical Stage of Disease,
9247,NCT00133913,,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],,
9248,NCT05357196,To obtain best disease control rate (DCR) data(Phase II),2020-04-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Area under the plasma concentration versus time curve (AUC),
9249,NCT03576872,80% or higher rate of completing at least 3 of 4 nurse-led encounters with participants,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],80% or higher on the index of rates for follow-up phone calls and binder review prior to cycle 2 of chemotherapy,
9250,NCT05404347,Overall Survival,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],RFS,
9251,NCT05184803,Evaluation of R0 resection rate in patients who underwent prior chemotherapy as a clinical trial.,2022-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,
9252,NCT04416490,Overall Survival (OS),2020-03-25,RECRUITING,OBSERVATIONAL,['NA'],Quality of Life Assessment (FACT/GOG-NTX-12),Results on blood pressure
9253,NCT03568669,Neurocognitive Outcomes,2016-01,RECRUITING,OBSERVATIONAL,['NA'],Neourcognitive Outcomes,
9254,NCT00131586,,2003-04,TERMINATED,OBSERVATIONAL,['NA'],,
9255,NCT01277406,Phase II: Progression free survival (PFS),2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Phase II: Pharmacokinetics: AUClast, AUCtau, cmax, tmax, t ½, CL/F of resminostat, Irinotecan (SN-38), 5-FU and folinic acid",
9256,NCT04645251,Map the natural course of PLD,2021-01-21,RECRUITING,OBSERVATIONAL,['NA'],Determine whether rate of liver growth can be used to predict disease progression,
9257,NCT05379972,Objective Response Rate (ORR) of unirradiated tumors,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 during concurrent SBRT/olaparib,
9258,NCT02026583,Progression free survival,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9259,NCT05093907,Objective Response Rate(ORR)(Phase 2) assessed by investigator following administration of BEY1107 in combination with Capecitabine,2021-08-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease control rate(DCR) assessed by investigator following administration of BEY1107 in combination with Capecitabine,
9260,NCT00720668,The Rate of Exacerbation of chronic hepatitis B after RFA,2006-06,UNKNOWN,OBSERVATIONAL,['NA'],mortality,
9261,NCT05547919,Number of patients with identified tumor lesion sites,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],PSMA uptake on 18F-PSMA-1007 PET,
9262,NCT06301828,ORR,2024-02-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events,
9263,NCT03817411,ORR,2019-01-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],DCR,
9264,NCT05664139,Objective tumor response rate (ORR),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse event collection,"Changes of CD4+ cells count, CD8+ cells count, Th1 cells count, Th2 cells count, Treg cells count in peripheral blood"
9265,NCT03382886,Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D),2018-04-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall Survival,
9266,NCT04739722,Colosense specificity for subjects with negative findings,2021-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9267,NCT00137449,Number of Participants With Clinical Benefit Response (CBR) According to RECIST,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Score of EQ-5D (Euro Quality of Life-5 Dimension) Weighted Health Index,
9268,NCT05839951,Cohort R-T or Cohort T-R: Descriptive analysis of biomarker Kirsten rat sarcoma 2 viral oncogene homolog (KRAS),2023-04-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Cohort R-T or Cohort T-R: Overall survival of patients with Regorafenib followed by TAS-102 and vice versa in 3rd line treatment and 4th line treatment,
9269,NCT00609505,Patient satisfaction,2008-08,COMPLETED,INTERVENTIONAL,['NA'],Cost-effectiveness,
9270,NCT02274376,Safety and tolerability: incidence and nature of adverse drug reactions,2008-08,COMPLETED,OBSERVATIONAL,['NA'],Incidence and nature of dose interruptions,
9271,NCT04700410,Boston Bowel Preparation scale (BBPS)-score after cleaning with the Pure-Vu system.,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],Number of adverse events after study intervention,
9272,NCT02985034,Local tumor progression (LTP),2010-10,COMPLETED,OBSERVATIONAL,['NA'],immediate technical success on registration-software assessment,
9273,NCT04810663,Efficacy of Radiotherapy in operated gastric cancer,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9274,NCT00831181,Pathologic Response and Complete Response,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Comparison of Preoperative Stage With Post-treatment Pathologic Stage,
9275,NCT01434485,Number of Adverse Drug Reactions,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,
9276,NCT06262581,pathological complete regression rate,2023-09-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease free survival,
9277,NCT03930888,Progression of the self sufficiency,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],Effect of tumor localization,
9278,NCT05051423,"Correlations with statistical significance between time-intensity curve analysis parameters, immunohistochemical markers of angiogenesis and clinico-pathological parameters.",2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9279,NCT01066741,Rate of occurrence of grade ≥ 3 (RTOG classification) mucositis during irradiation (only the first occurrence will be reported),2009-05,TERMINATED,INTERVENTIONAL,['PHASE3'],Evaluation of the cost of severe mucositis treatment,
9280,NCT04641637,The completeness of coverage of the tumor vasculature by therapeutic agent at the completion of the treatment as evaluated on non-contrast CT scan,2022-06-30,COMPLETED,INTERVENTIONAL,['NA'],Tumor response,
9281,NCT01522573,Safety,2011-11,UNKNOWN,OBSERVATIONAL,['NA'],Survival duration,
9282,NCT02375672,Median Progression Free Survival (mPFS),2015-05-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Grade 3 or Higher Treatment Related Adverse Event,
9283,NCT00689624,Objective Response Rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Q-Twist analysis of Quality of life,
9284,NCT00003834,response rate,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival,
9285,NCT05208372,Expression of ctDNA,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9286,NCT02525952,overall survival,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],Time to recurrence,
9287,NCT04224896,SPECIFICITY OF THE TWO DIAGNOSTIC STRATEGIES,2011-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
9288,NCT06187610,Symptom self-management knowledge,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],Patients engagement while learning,
9289,NCT01304602,Maximum tolerated dose,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Biological half life of BKM120,
9290,NCT01927328,Hemoglobin differences between groups,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],Differences in hematinic markers.,
9291,NCT06172647,Proportion and abundance of bacterial taxa (defined as total percentage of bacterial DNA sequences),2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
9292,NCT04694404,PFS,2016-05-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],The number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
9293,NCT00355004,Rate of colorectal cancer screening,2005-03,COMPLETED,INTERVENTIONAL,['NA'],Number and dates of sigmoidoscopies and colonoscopies scheduled and performed,
9294,NCT00598156,progression-free survival,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],overall survival,
9295,NCT02572050,Number of retrieved lymph nodes in the topographical N2 area,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life,
9296,NCT02745561,response rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
9297,NCT00717990,Objective Response Rate,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
9298,NCT02488577,Overall percent of postoperative complications.,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],Recurrence.,
9299,NCT01582841,Implementation effectiveness,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
9300,NCT00027534,Safety,2002-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Immune response,
9301,NCT04929587,Frailty assessed by Frailty Phenotype (FP),2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],Sleep assessed by Pittsburgh Sleep Quality Index (PSQI),
9302,NCT05007015,EORTC-QLQ-C30,2022-01-15,RECRUITING,INTERVENTIONAL,['NA'],Bowel diaries,
9303,NCT03836131,The percentage of cancer in patients with GM-LSTs treated with endoscopic resection.,2018-12-31,COMPLETED,OBSERVATIONAL,['NA'],,
9304,NCT02650427,Safety (Number of adverse events. Toxicity grade > 3),2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Infiltration of leucocytes in tumor tissue,
9305,NCT02967289,Disease Free Survival (DFS),2017-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],
9306,NCT05872828,Depression score,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Immune variables 8,
9307,NCT01315548,Contrast enhanced harmonic endoscopic ultrasound,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
9308,NCT02045030,A biomarker (in blood or tissue) that may be predictive of level of response to aflibercept,2014-01,TERMINATED,INTERVENTIONAL,['PHASE2'],The quality of life impact of treating with FOLFIRI in combination with Aflibercept,
9309,NCT05957367,Objective response rate (ORR) (Expansion Phase),2023-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Area under the concentration-time curve (AUC),
9310,NCT00747136,"Determine sensitivity/specificity to identify dysplasia/cancer in the esophagus WavSTAT System alone, endoscopist alone/combination of WavSTAT and endoscopist. Sensitivity of the endoscopist will be compared to combination of endoscopist and WavSTAT.",2008-08,TERMINATED,OBSERVATIONAL,['NA'],,
9311,NCT01475331,Number of Participants With the Changing in Cyst Volume,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9312,NCT02325999,DFS,2013-12,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
9313,NCT02465736,Toxicities of neo-adjuvant chemoradiotherapy,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Health Related Quality of Life,
9314,NCT04198337,Complete resection of GIST,2014-08-01,RECRUITING,INTERVENTIONAL,['NA'],technical success in complete resection,
9315,NCT00002828,,1995-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9316,NCT06275165,Change from Baseline in gastrointestinal symptom distress Scale at study day 5(end day),2024-03-27,RECRUITING,INTERVENTIONAL,['NA'],,
9317,NCT01306799,Volumetric bone mineral density as measured by pQCT,2010-01,COMPLETED,OBSERVATIONAL,['NA'],measure vitamin B12 levels at each study visit,
9318,NCT02873195,Progression Free Survival (PFS),2017-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],The Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event Deemed at Least Possibly Related to Treatment (Toxicity),
9319,NCT02347735,Anastomotic leakage,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,
9320,NCT05894694,PFS,2023-06-11,RECRUITING,INTERVENTIONAL,['PHASE4'],1-year PFS rate,
9321,NCT00780988,To assess the feasibility of using an autologous tumor cell vaccine in combination with standard chemotherapy followed by investigational autologous hematopoietic and immune cell rescue in terms of acceptable clinical toxicity.,na,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Ex vivo analysis of immune response,
9322,NCT04865601,Correlation of DNA adduct and DNA repair products,2021-02-15,RECRUITING,OBSERVATIONAL,['NA'],Correlation of DNA adducts with CRC causes,
9323,NCT02933944,Immunological Activation in Tumour Mass by Assessing Number of Patients With Increased Intra-tumoural Lymphocytes.,2016-09,TERMINATED,INTERVENTIONAL,['PHASE1'],Changes in the Tumour Marker Carcinoembryonic Antigen (CEA) Throughout Treatment Will be Assessed by Analysis of Blood Samples to Follow the Evolution of Disease Under Treatment,
9324,NCT00193882,Relief of dysphagia,2003-07-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Time to achieving a complete response i.e. dysphagia score of 0.,
9325,NCT05861336,Resectability rate,2023-06-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life questionnaire (QLQ),
9326,NCT04203459,Animal model experiment: to verify the ability of intestinal bacteria to control anti msln car-t targeted killing pancreatic cancer cells.,2019-10-20,UNKNOWN,OBSERVATIONAL,['NA'],,
9327,NCT01921673,Progression-free survival,2013-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biomarker,
9328,NCT03033719,Global postoperative morbidity in both arms,2017-07-04,UNKNOWN,INTERVENTIONAL,['NA'],Timed Get-up-and-go (TGUG),To compare our molecular classification with the different classifications already published in the literature on colorectal cance
9329,NCT00841282,Increments of medications used for sedation,2008-10,COMPLETED,INTERVENTIONAL,['NA'],willingness to repeat colonoscopy,
9330,NCT05857631,3-year cumulative incidence of grade ≥2 gastrointestinal or genitourinary toxicity,2023-05-29,RECRUITING,INTERVENTIONAL,['NA'],C-MOSES scoring,
9331,NCT03817489,"Change of Week 1 Practice Compliance at Week 2 to 7 of intervention, and 6-month post-intervention",2017-01-04,UNKNOWN,INTERVENTIONAL,['NA'],,
9332,NCT03053999,Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Genome Sequencing,2012-10-09,UNKNOWN,OBSERVATIONAL,['NA'],Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Data Review,
9333,NCT00259922,To compare alvimopan with placebo for efficacy in the treatment of OBD,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],"Safety and tolerability, quality of life, pharmacogenetics (dependent on results from other data)",
9334,NCT03330028,Dose Limiting Toxicity (DLT) of Paclitaxel via Intraperitoneal Route Combined with Fixed Doses of Mitomycin and Cisplatin during Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC),2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9335,NCT00001165,,1978-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9336,NCT00835133,Collection of familial data and biospecimens in a data and tissue repository for familial pancreas research,2002-08,RECRUITING,OBSERVATIONAL,['NA'],,
9337,NCT05879783,Accuracy of pCLE optical biopsy,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],The positive predictive value and negative predictive value of pCLE optical biopsy,
9338,NCT04385316,DNA extraction of tumer tissue samples and high-throughput sequencing,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],"DNA extraction of tumer tissue samples, blood tissue and urine samples and high-throughput sequencing",
9339,NCT05623787,Early peritoneal recurrence,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],Early distant recurrence,
9340,NCT00256932,to compare alvimopan with placebo for efficacy in the treatment of OBD,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],"Safety and tolerability, quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data)",
9341,NCT02300727,Number of Participants With Serious and Non-Serious Adverse Events,2015-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in Health Providers Assessment of Oral Mucositis and Healing Time Measured by the Common Terminology Criteria for Adverse Events (CTCAE) and World Health Organization's (WHO's) Oral Toxicity Scale (OTS),
9342,NCT00019591,Response rate every 3 months for up to a year after completion of study treatment,1999-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9343,NCT00343668,response rate,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],treatment-related toxicities,
9344,NCT00064207,"Overall survival as measured by Logrank every 3 months in years 1-2, and every 6 months thereafter in phase III",2003-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life as measured by Quality of Life Questionnaire Core 30 (QLQ-C30) v3.0 and EORTC QLQ PAN-26 every 3 months in years 1-2 and every 6 months thereafter,
9345,NCT03425773,Incidence of Serious Adverse Events assessed with CTCAE v4.03,2018-02-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Change of tumor burden,
9346,NCT00105443,Time to Symptomatic Progression (TTSP),2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire,
9347,NCT03984578,Immune T-cell infiltration before and after treatment,2019-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of cell viability and cell death at fixed time points (e.g. 24 or 48 hours),
9348,NCT03278106,16-Week Progression-free Survival (PFS) Rate,2017-10-20,COMPLETED,INTERVENTIONAL,['PHASE2'],"Overall Toxicity Rates (Percentages) for Grade 3 or Higher Adverse Events Considered at Least Possibly Related to Treatment, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)",Mutation Status of the Tumor
9349,NCT02662478,Success rate,2008-06,COMPLETED,OBSERVATIONAL,['NA'],Accuracy of classification system,
9350,NCT05161572,Pathological complete regression (pCR) rate,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety of surgery after preoperative therapy include chemo(radio)therapy and PD-1 antibody.,To study the influence of preoperative therapy on the tumor immune microenvironment (TIME) and systemic immune status.
9351,NCT04812054,Model for early graft dysfunction score,2021-04-05,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative complications,Allograft ATP content
9352,NCT03189953,Tumor visualization by 68Ga-NODAGA-exendin-4 PET/CT and standard imaging,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",GLP-1 receptor expression by histology compared to tracer uptake,
9353,NCT04241523,Resection rate,2020-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Exploratory serum biomarker research,
9354,NCT03516708,Phase II Treatment Cohort only: Neoadjuvant Rectal (NAR) Score,2019-10-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase I and Phase II Treatment Cohort only: Complete clinical response rate (cCR),
9355,NCT02292758,6-month and 12-month Progression-free Survival (PFS) Rates,2014-12-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Relative Dose Intensity (RDI),Dynamic Change in Mutation Concentration While the Patient is Receiving Cetuximab Treatment
9356,NCT03738787,Rate of postoperative mortality,2015-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Variation of Body Mass Index after pancreatoduodenectomy,Overall survival
9357,NCT05229900,Number of participants with DLTs by dose level,2022-04-21,TERMINATED,INTERVENTIONAL,['PHASE1'],Combined RECIST/CA-125 overall response rate according to GCIG (subjects with ovarian cancer only),
9358,NCT00785785,Time to Progression Free Survival (PFS),2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9359,NCT00324428,"Pain (visual analog scale, CGI,PGA); Medication use (medication diary)",2006-05,COMPLETED,INTERVENTIONAL,['NA'],Safety (cognitive assessment - neuropsychological battery),
9360,NCT06289712,Correlate 3D numerical simulations of the IRE electric field with patient imaging follow-up,2023-11-23,RECRUITING,OBSERVATIONAL,['NA'],Develop software solutions potentially usable in real-time and tailored for clinical use.,
9361,NCT05934058,Impact of major gastric cancer risk factors on its aetiology in rarer patients subgroups,2023-07-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Development of a genome-wide modelling of Polygenic risk score (PRS) in gastric cancer,
9362,NCT02500004,Brown adipose tissue (BAT) activity measured by PET(-MRI),2015-06,COMPLETED,INTERVENTIONAL,['NA'],"Lean tissue mass measured by MRI, DXA, and doubly labeled water",
9363,NCT01643460,Cyst resolution,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,
9364,NCT02503631,To provide stool and blood specimens to assess new markers for the detection of CRC,2014-10,TERMINATED,OBSERVATIONAL,['NA'],To provide quality control material for use in assessing performance of developed assays,
9365,NCT05954078,ctDNA clearance rate,2023-07,RECRUITING,INTERVENTIONAL,['PHASE3'],Treatment Completion Rate,
9366,NCT06104579,Rate of Organ-space surgical site infection,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9367,NCT04389957,Provider Screening Adenoma detection rate (Sceening colonoscopies only),2020-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Bowel Preparation Quality (provider level),
9368,NCT02595086,"Incidence of Dumping syndrome, assessed by Sigstad score (≥7)",2015-07,UNKNOWN,INTERVENTIONAL,['NA'],Gross and microscopic changes measured by gastroscopy (composite),
9369,NCT05657145,Visualization of papilla,2023-01-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
9370,NCT05910970,Recurrene-free survival,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse events,
9371,NCT05421689,Anterior tongue pressure measured from Iowa Oral Performance Instrument (IOPI),2022-05-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Patient-reported dysphagia symptoms based on Eating Assessment Tool EAT10 score,Patient-reported Quality of Life based on FACT-HN score
9372,NCT00710710,Best Objective Response Evaluated According to the RECIST Criteria by Independent Review,2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Incidence and Intensity of Adverse Events Graded According to Common Terminology Criteria for Adverse Events (CTCAE),
9373,NCT01133951,Gastric cancer incidence,2010-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Histopathological changes,
9374,NCT04684095,Changes of quality of life (QoL) at 1 year after randomization compared with baseline,2021-05-26,RECRUITING,INTERVENTIONAL,['NA'],Patient satisfaction,Economic assessment for ePRO compared to regular follow-up
9375,NCT06131840,Number of participants with DLTs by dose level,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
9376,NCT01389986,Time to first flatus,2011-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Patients' satisfaction,
9377,NCT03854799,The primary objective of this trial is to evaluate the rate of complete pathologic response (pCR),2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Sphincter preservation rate,
9378,NCT02406508,Progression free survival in months of patients receiving Melphalan/HDS treatment followed by Sorafenib,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaires
9379,NCT00614601,The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],We will use overall survival and adverse events rates as secondary endpoints.,
9380,NCT03594630,Time to surgery or death,2024-03-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Pathologic Findings,
9381,NCT04059731,Postoperative complications,2019-06-20,UNKNOWN,INTERVENTIONAL,['NA'],Hospital Stay,
9382,NCT05233540,Overall survival according to circulating tumour DNA status,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],Overall survival according to circulating tumour DNA and immune markers.,
9383,NCT00003617,,1995-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
9384,NCT04823416,Risk Factors for Mortality in cases of obstructed left colonic Carcinoma,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
9385,NCT00756951,Efficacy of Oral Mucositis assessment will be completed by trained site personnel. The WHO score will be the primary measure and NCI CTCAE will be a secondary measure for assessing Oral Mucositis.,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9386,NCT00605800,To determine qualitatively and quantitatively whether bone marrow derived liver associated stem cells are mobilized from the bone marrow in patients undergoing major liver resections (3 or more liver segments).,2006-03,WITHDRAWN,OBSERVATIONAL,['NA'],To determine whether a difference exist in the baseline levels of bone marrow derived liver associated stem cells between normal healthy subjects/ volunteers and cancer patients prior to liver surgery.,
9387,NCT00021268,,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
9388,NCT06134388,Investigating the possible efficacy of sulfasalazine through evaluation of its impact on disease control rate (DCR).,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],"Evaluating the safety and tolerability of sulfasalazine through investigating Renal function test (serum creatinine (mg/dL), blood urea nitrogen (mg/dL) and creatinine clearance (mL/min)).",
9389,NCT02345889,Adenomas Per Colonoscopy,2015-02,COMPLETED,INTERVENTIONAL,['NA'],"Percent of Sessile Serrated Polyps in the Right Side of the Colon, Which Includes the Cecum, Ascending Colon, and Hepatic Flexure.",
9390,NCT01550510,Number of Participants That Experience Serious Adverse Events as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.,2011-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants That Are Alive After 11 Weeks.,
9391,NCT00182715,Overall survival at 2 years,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],Time of disease control at 2 years,
9392,NCT03774589,Bilioenteric anastomotic leakage,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],Bilioenteric anastomotic stricture,
9393,NCT00182130,Hospital rate of local recurrence,2002-05,UNKNOWN,INTERVENTIONAL,['NA'],Quality of life,
9394,NCT00779311,Determination of the Maximum Tolerated Dose (MTD) of Sorafenib When Given in Combination With mFOLFOX6 and Bevacizumab,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Determination of Quality of Life (QoL) as Indicated by Patient Care Monitor (PCM) Data Among Patients on This Regimen,
9395,NCT00685568,Toxicity,2002-11-21,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (plasma drug trough concentrations),
9396,NCT05061017,Objective Response Rate (ORR) - (Cohorts 2 & 3),2021-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],2-year Overall Survival (OS),
9397,NCT05254847,1 year DFS rate,2021-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],AE,
9398,NCT01378507,Short-term result after ESD,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],The safety of ESD procedure,
9399,NCT05514158,The incidence and severity of adverse events (AE),2022-09-28,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-free survival,
9400,NCT00508872,Complete Gross Resection Rate,2005-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9401,NCT03350490,Relief degree of tumors,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall survival（OS）,
9402,NCT00003368,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9403,NCT05424159,2-year cumulative local regional progression rate (LRP),2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],Late toxicity,
9404,NCT01758679,Progression-free survival,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
9405,NCT00033306,"Determine the clinical activity of BMS-247550, as measured by the tumor response rate, in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine and irinotecan.",2002-02,TERMINATED,INTERVENTIONAL,['PHASE2'],"Determine the response duration, time to progression, and survival in patients treated with this drug.",
9406,NCT05242757,The size (tumor diameter) and number (tumor recurrence lesions) of PHC tumors were examined by enhanced abdominal CT,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
9407,NCT02571946,one-year overall survival,2015-08,COMPLETED,INTERVENTIONAL,['NA'],Hepatobiliary phase signal change after proton beam therapy,
9408,NCT04147494,To define and document the biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46) and gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) in normal and cancer tissues of patients with various non-prostate malignancies,2019-11-05,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],evaluate the 68Ga-FAPI-46 biodistribution correlation with 18F-FDG biodistribution,Additional correlation of biodistribution of standard of care tracer
9409,NCT03705754,Number of tumors visualised from peritoneal cavity/number of tattoos visualised form peritoneal cavity,2019-02-06,RECRUITING,INTERVENTIONAL,['NA'],,
9410,NCT02395250,Adverse events attributed to the administration of the anti-GPC3 CAR T cells,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9411,NCT05363722,Objective response rate (ORR),2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Immune Best Overall Response（iBOR）according to iRECIST criteria,
9412,NCT05088304,postoperative complications,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],hospitalization cost,
9413,NCT06022978,Diagnostic accuracy for T1a and T1b staging,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
9414,NCT01943318,"Liver-related outcome: Decompensated liver cirrhosis (ascites, variceal bleeding, hepatic encepahlopathy), occurence of hepatocellular carcinoma",2013-01,COMPLETED,OBSERVATIONAL,['NA'],Liver-related mortality,
9415,NCT00552058,Percentage of Subjects in Clinical Remission at Week 6,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6,
9416,NCT03123432,immunomodulating effects,2011-06-01,COMPLETED,INTERVENTIONAL,['NA'],length of hospital stay after surgery,
9417,NCT04825470,Graft Survival,2022-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Disease free survival,
9418,NCT03636607,Calculating the overall diagnostic sensitivity and specificity and ROC,2018-06-13,RECRUITING,INTERVENTIONAL,['NA'],Calculating the overall diagnostic sensitivity and specificity and summarizing the intrinsic correlations,
9419,NCT04312360,Change in bacterial composition (Exploratory primary outcome 2),2020-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Assessment of any adverse events or side effects regarding the spraying of the right hemicolon with fosfomycin/metronidazole gel in track 2.,
9420,NCT03167125,Increased colorectal cancer screening rates,2017-09-05,COMPLETED,INTERVENTIONAL,['NA'],,
9421,NCT02252926,Reduction of oral and pharyngeal pain measured on Visual Analogue Scale (VAS),2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety: Peak plasma concentrations of bupivacaine,
9422,NCT04400136,Percentage of post-operative GERD based on the trial protocol. Clinical evaluation,2020-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],evaluate in each group of the study (arm type) the endoscopic finding of peptic lesions of the esophagus-gastro-duodenal mucosa at 24 months of follow-up,
9423,NCT02961283,Part B: evaluates the preliminary efficacy of ASN003 in subjects with selected BRAF and PI3 kinase mutated cancers,2016-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Appearance of new tumor lesions,Change in tumor mutational status
9424,NCT00001587,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9425,NCT00005981,Determine the response rate of patients with metastatic colorectal carcinoma treated with O6-benzylguanine and carmustine.,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9426,NCT01105806,To document advance directive (AD)completion,2010-04,COMPLETED,OBSERVATIONAL,['NA'],To longitudinally follow discussions about ADs and nature of hospitalizations,
9427,NCT04177316,disease free survival (DFS),2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
9428,NCT03070262,overall survival (OS),2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],progression-free survival (PFS),
9429,NCT04516681,Objective Response Rate,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Overall Survival,
9430,NCT04894643,Perioperative Mortality and Complications,2020-09-14,RECRUITING,INTERVENTIONAL,['NA'],Quality of Life questionnaire: Brief Pain Inventory,
9431,NCT04280393,adenoma detection rate per patient,2020-02-10,COMPLETED,INTERVENTIONAL,['NA'],Demonstrate the non-inferiority of patient experience when comparing Endocuff Colonoscopy and Standard Colonoscopy,
9432,NCT04739501,Post_TACE hepatic cell failure,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9433,NCT04445532,Collected samples,2020-10-11,RECRUITING,OBSERVATIONAL,['NA'],Multi-omics analysis to further type and find therapeutic targets,
9434,NCT02743065,Progress-free-survival (PFS),2016-09,UNKNOWN,OBSERVATIONAL,['NA'],Objective Response Rates,
9435,NCT00006812,,2001-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9436,NCT01540435,Failure-free survival (FFS@18),2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Pathologic response rate,
9437,NCT01020006,Number of Participants With Treatment Emergent Adverse Events (AEs),2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9438,NCT04488549,Predictive power of respondents' and hospitals' demographics on delaying colorectal cancer care across 6 geographical regions,2020-05-20,COMPLETED,OBSERVATIONAL,['NA'],,
9439,NCT00910819,Course of Antineoplastic Treatment,2006-09,COMPLETED,OBSERVATIONAL,['NA'],,
9440,NCT03322592,EUS-FNB diagnostic accuracy,2018-03-29,COMPLETED,INTERVENTIONAL,['NA'],Macroscopic on-site evaluation [MOSE],
9441,NCT03367611,Colonic lesion.,2018-03-15,COMPLETED,INTERVENTIONAL,['NA'],,
9442,NCT00565682,To measure the amount of rescue medication (opioid) needed to relief,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],To determine the overall analgesic effect using the visual analog scale (VAS),
9443,NCT05279677,ORR,2022-08-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events,
9444,NCT06253611,Objective response rate (ORR) at 4 months,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],1-year and 2-year PFS,
9445,NCT00327457,Medical record verified flexible sigmoidoscopy or colonoscopy,2002-06,COMPLETED,INTERVENTIONAL,['NA'],,
9446,NCT05624099,Objective Response Rate(ORR),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression free survival(PFS),
9447,NCT00978107,Maximal tolerated dose,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor response of injected and non-injected lesions Viral dissemination Proof of concept: 5-FU concentration in plasma and in tumors,
9448,NCT01525069,Dose-limiting toxicities (DLTs),2012-04-03,TERMINATED,INTERVENTIONAL,['PHASE1'],Time to progression (TTP),
9449,NCT05346536,CTC-AXL measurement concordance rate,2022-06-16,RECRUITING,INTERVENTIONAL,['NA'],Evaluation of circulating immune system: platelets,
9450,NCT03906110,Fecal Immunochemical Test (FIT) Use- Time Point 3,2018-04-03,COMPLETED,OBSERVATIONAL,['NA'],,
9451,NCT00957424,Number of Participants Willing to Continue With Preferred HRP,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,
9452,NCT05028725,Proportion of True-Negatives (specificity) detected with the EsoCAN assay after specimen collection using 'EsophaCap' sponge sampling (ESCC cases & controls only),2022-05-16,RECRUITING,INTERVENTIONAL,['NA'],Median Acceptability Scores,
9453,NCT05734820,Diagnostic performance of AI-assisted polyp detector,2020-01-11,RECRUITING,INTERVENTIONAL,['NA'],Adenoma Miss Rate (AMR),
9454,NCT03028831,colonic mucosal proliferation,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],colonic secondary bile acids,
9455,NCT02723253,Number of patients defined as good responders (G1 or G2) according to the Mandard regression grading system.,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],The number of patients still alive at the end of follow-up,
9456,NCT01669109,Health-related quality of life,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Spiritual well-being,Qualitative Interviews
9457,NCT05889325,Progression-Free Survival (PFS),2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Duration of Response (DoR),
9458,NCT04369053,Specificity of the Freenome test,2020-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
9459,NCT03894384,Diagnostic value of trefoil factor family 3 (TFF3) in serum of gastric cancer as non invasive marker,2019-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9460,NCT04902144,Clinical and Patient Reported Outcomes Following Genetic Test Results,2020-08-03,COMPLETED,INTERVENTIONAL,['NA'],,
9461,NCT05677490,Overall survival (OS),2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE3'],Patient reported outcomes,Feasibility and compliance of intervention
9462,NCT00320320,Response rate after FOLFIRI reintroduction,2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall survival,
9463,NCT04547153,hematological response rate (HeRR),2021-01-15,COMPLETED,INTERVENTIONAL,['PHASE2'],quality of life assessed by EORTC QOL C-30 and STO-22 (QoL),
9464,NCT00002515,,1992-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9465,NCT02353858,Pathological complete response rate,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],post operative morbidity,
9466,NCT00265356,proportion of patients who have a change in management resulting from PET,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],prognostic ability of the PET standard uptake value (SUV) in predicting 3-year overall survival,
9467,NCT02772029,time to progression,2016-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",overall survival,
9468,NCT01839539,Progression-free survival (PFS),2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Laboratory findings (The number of CD3+ (or CD8+ or CD4+ or CD56+)T cell),
9469,NCT00436072,"To determine the tolerability and maximum tolerated dose of combining ZD6474, cetuximab and irinotecan in patients with metastatic colorectal cancer refractory to prior cytotoxic chemotherapy.",2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],"Determine response rate, progression-free survival and overall survival of adding ZD6474 to cetuximab and irinotecan in this patient population.",
9470,NCT01653496,Overall compliance to the ERAS program,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Mortality,
9471,NCT05189730,Incidence of adverse events,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival,
9472,NCT00611000,"DNA methylation (overall, p53 coding, p16 promoter, MLH1 promoter) in PBMCs and rectal biopsy cells",2003-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Differential gene expression in colonic and PBMCs by microarray analysis,
9473,NCT02471313,Number of Participants for Which Uptake of [18F]-FMISO Was Successful and Hypoxic Tumors Were Observed During PET Scan Imaging Post TACE Procedure,2015-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9474,NCT03183219,Overall survival（OS）,2017-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9475,NCT04787341,Overall survival,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Objective Response Rate,
9476,NCT00487409,this study will evaluate the surgical approach using the Ligasure device at six weeks post operative.,2006-12,COMPLETED,INTERVENTIONAL,['NA'],Will evaluate the surgical approach using electrocautery with surgical clips and staples,
9477,NCT04619342,Progression Free Survival（PFS）,2020-10-30,UNKNOWN,INTERVENTIONAL,['NA'],Adverse Events,
9478,NCT02569645,To determine the pathological complete response rate in patients with high-risk locally advanced rectal cancer treated with standard neo-adjuvant chemotherapy and radiation in combination with rosuvastatin.,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Dose normalized AUC will be collected as pharmacokinetic data,
9479,NCT02077868,Overall survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life (QoL),
9480,NCT01292369,System performance,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9481,NCT00608595,Change of gene and protein expression pattern from pre- to post-treatment levels,2002-07,TERMINATED,INTERVENTIONAL,['NA'],,
9482,NCT06242470,Number of participants with adverse events (AEs) and serious AEs (SAEs),2024-03-06,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of participants who develop anti-MGC026 antibodies (immunogenicity),
9483,NCT02997241,patients treated with chemotherapy based on clinical prognosis compared to Oncocare detection prognosis,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival at 5 years,
9484,NCT01744353,"Assessment of Toxicities to Define MTD of FOLFOX-Abraxane (A) for Newly Diagnosed, Advanced Pancreatic Cancer.",2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],"Response Rate (if Patient's Tumor(s)Are Progressing or Being Controlled) Following Treatment With FOLFOX-A for Patients With Newly Diagnosed, Advanced Pancreatic Cancer.",
9485,NCT01846520,Effects of FCPCI on psychological distress,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Caregiver out-of-pocket costs,
9486,NCT02127541,Measuring the accuracy of the Tumour-Localisation of 68-DOTA-Exendin-4 PET/CT and 111 In-DOTA-exendin-4 SPECT/CT.,2014-01-06,COMPLETED,INTERVENTIONAL,['NA'],Comparison of the angiogenesis markers with the those of breast carcinoma patients,
9487,NCT05387681,pathological complete response (pCR),2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],pathological partial response(MPR),
9488,NCT02506803,Number of participants with toxicity of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],The R0 resection rate of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,
9489,NCT04985981,Occurrence of Anastomotic leak,2021-04-01,SUSPENDED,OBSERVATIONAL,['NA'],Time to diagnosis of anastomotic leak,Additive curative surgery (no/yes: liver; lung; locoragional relapse)
9490,NCT01740947,anastomotic leakage and/or abscess,2013-01,TERMINATED,INTERVENTIONAL,['PHASE4'],Disease free survival,In hospital and out-of-hospital costs
9491,NCT06002789,pCR rate,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],3 years OS Rate,
9492,NCT05630794,Mean change in human adenoma tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in polyps induced by ONC201,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Proportion and severity of treatment emergent adverse events,Adenoma-derived organoid take rates between samples obtained prior to and following treatment
9493,NCT04357171,The rate of readmissions due to severe dehydratation,2012-01-14,COMPLETED,INTERVENTIONAL,['NA'],The rate of early postoperative complications after stoma closure operation,
9494,NCT00628368,Role of predictive factors in the EGFR signaling pathway in response to treatment,2005-11,UNKNOWN,INTERVENTIONAL,['NA'],Establishment of a tissue bank,
9495,NCT06202183,Gut Microbiome Genomes,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Change in Chemotherapy Toxicity,
9496,NCT05095519,True Negative Rate per lesion.,2021-09-08,RECRUITING,INTERVENTIONAL,['PHASE2'],GLUT-1 expression,
9497,NCT05942768,Overall Survival (OS),2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],Treatment-Related Adverse Events (TRAE),
9498,NCT02511821,Percentage of patients who are able to wear the wristband device for at least 1 week post-operatively,2015-07-22,COMPLETED,INTERVENTIONAL,['NA'],"Suggestions for items that were not covered but should be added, as measured by responses from Satisfaction Tool",
9499,NCT00187109,To evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy.,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9500,NCT04620473,Objective Response Rate（ORR）,2023-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Postoperative complications,
9501,NCT05149807,Phase III : Event-free Survival (EFS),2022-01-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']",30-day postoperative mortality.,
9502,NCT03401294,Rate of liver metastasectomy,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
9503,NCT02056691,Assess the feasibility of carrying out a two week preoperative exercise program in patients with colorectal cancer and assess the effects of preoperative exercise on the proliferation of colorectal cancer cells,2014-10,COMPLETED,INTERVENTIONAL,['NA'],Irisin levels,
9504,NCT05339763,bowel function,2019-08-12,COMPLETED,INTERVENTIONAL,['NA'],fecal incontinence,
9505,NCT03359616,Disease-free survival (DFS),2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],mortality rate,
9506,NCT00513331,"To standardize physician recommendations and provide cutting edge technology to patients with BE and GERD, and establish a Valley Hospital Center for Barrett's Esophagus and GERD",2007-07,COMPLETED,OBSERVATIONAL,['NA'],"To assess clinical outcomes of patients enrolled in The Valley Hospital Center for Barrett's Esophagus and GERD, and modify algorithms as appropriate.",
9507,NCT05022719,"The interference level of detrimental effects on the visualization of the colonic mucosa during CCE, due to use of MB-MMX per colonic segment.",2021-10-04,COMPLETED,INTERVENTIONAL,['NA'],To evaluate the safety of CCE procedure while using MB-MMX.,
9508,NCT01600209,Sensitivity and Specificity of the Exact CRC diagnostic screening test.,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,
9509,NCT04163237,Disease-free Survival,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Overall Survival,
9510,NCT06117241,Stool,2023-10-17,RECRUITING,INTERVENTIONAL,['NA'],,
9511,NCT00003571,disease free survival,1998-08,COMPLETED,OBSERVATIONAL,['NA'],determine the prognostic and predictive values for response to this therapy,
9512,NCT01187641,"The primary endpoint will be the accuracy of MRI and CT in determining T stage using histology as the gold standard, on a per patient basis.",2010-08-18,COMPLETED,OBSERVATIONAL,['NA'],"We will also compare the accuracy of 1.5T against 3.0T MRI scans, and T2 weighted against T1 weighted images",
9513,NCT04683939,Occurrence of dose-limiting toxicities (DLTs) within a patient during the DLT evaluation period,2022-01-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",BNT141 - Duration of response (DOR),
9514,NCT06144827,Feasibility of Quantitative Multiparametric MRI,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Change in Total Liver Volume and Volume of non-irradiated and irradiated lobes,
9515,NCT03904043,Clinical complete response rate,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],Organ preservation rate,
9516,NCT00394992,"3-year disease free survival, defined as the percentage of disease free patients 3 year after randomisation.",2006-12,TERMINATED,INTERVENTIONAL,['PHASE3'],"Overall survival, defined as the percentage of patients alive 5 year after randomisation.",
9517,NCT05021172,Responses to Qualitative Acceptability survey,2021-08-24,COMPLETED,INTERVENTIONAL,['NA'],,Proportion of patients screened for colorectal cancer
9518,NCT00797732,Treatment Compliance Rate,2008-12,COMPLETED,INTERVENTIONAL,['NA'],MDADI Scores,
9519,NCT02601079,Highest proportion (number) of representative biopsies for diagnostic purposes from the tumor tissue.,2016-09,TERMINATED,INTERVENTIONAL,['NA'],Number of fusion genes in tissue harvested from esophageal neoplasms prior to neoadjuvant oncological treatment.,
9520,NCT03919461,Biomarkers in blood samples assessing pro- and anti-metastatic processes,2019-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Fatigue,
9521,NCT01959061,Progression-free survivial,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
9522,NCT02502656,"Concordance regarding the mutation of RAS (yes vs no, dichotomous variable) between the two methods",2015-07,UNKNOWN,OBSERVATIONAL,['NA'],Comparisons of the costs between the two methods,
9523,NCT05477836,Length of colon explored,2022-10-18,COMPLETED,INTERVENTIONAL,['NA'],Perception of difficulty,
9524,NCT04353882,MOR-1 expression by polymerase chain reaction (RT-qPCR) in tumor tissue and adjacent healthy tissue.,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA'],MOR-1 expression by immunohistochemistry in tumor tissue and adjacent healthy tissue.,Concomitant Diseases
9525,NCT02710812,Rate of organ preservation,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29,
9526,NCT02451956,Object response rate (ORR),2015-01-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of subjects with Adverse Events as a Measure of safety and tolerability,
9527,NCT00812240,Progression Free Survival (PFS),2009-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),
9528,NCT01269567,Pelvic sepsis,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Rate of closure of stoma,
9529,NCT01932385,progression free survival and overall survival,2013-08-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",response rate,
9530,NCT05347745,therascreen® KRAS RGQ PCR Kit,2022-01-07,UNKNOWN,INTERVENTIONAL,['NA'],,
9531,NCT00184782,Increase in metabolic activity of liver metastases after resection of the primary tumor compared to the activity of metastases in patients without primary tumor resection,2003-09,UNKNOWN,INTERVENTIONAL,['NA'],,
9532,NCT01975077,safety and tolerability,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",overall survival (OS),
9533,NCT00587184,,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,
9534,NCT01525056,"efficacy of PET, CT-perfusion and MRI to stage patients with rectal cancer",2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9535,NCT04093648,Dose Limiting Toxicity (DLT) Rate,2020-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Response Rate according,
9536,NCT00154700,Response rate,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,
9537,NCT00683241,To determine the feasibility and safety of administering DCVax-L intradermally combined with intravenous bevacizumab and oral metronomic cyclophosphamide in patients with recurrent ovarian or primary peritoneal cancer.,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],"To assess the immunogenicity of DCVax-L administered intradermally in patients with recurrent ovarian or recurrent primary peritoneal cancer, combined with intravenous bevacizumab and oral metronomic cyclophosphamide.",
9538,NCT05923255,3-year disease free survival,2023-05-14,RECRUITING,INTERVENTIONAL,['NA'],5-year overall survival rate (OS),
9539,NCT03453164,Disease control rate,2018-03-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Peak antigen-specific cytotoxic T lymphocyte population,
9540,NCT04166604,Rate of patients free of trifluridine/tipiracil dose reduction or postponement of cycles of > 7 days at 6 months or at progression or death or stop of treatment for another cause than neutropenia if observed in 6 months.,2020-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Clinical or biological factors at baseline associated with the occurrence of grade 3-4 neutropenia,
9541,NCT00837239,Progression Free Survival at 4 Months,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival,
9542,NCT00357942,Use of supplemental analgesics,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],Oral intake of food,
9543,NCT00137761,To determine the response rate of Iressa and docetaxel in patients with advanced pancreatic cancer following failure of gemcitabine-based therapy,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"To determine the safety, radiologic response rate, progression-free survival and overall survival of patients treated with Iressa and docetaxel",
9544,NCT03507140,"Comparison of the relative abundance of pathobionts and symbionts before and 6 months after liver transplantation, in the bile of recipients.",2019-04-16,UNKNOWN,OBSERVATIONAL,['NA'],"Biobanking of blood, saliva, bile, feces and urine for further analyses such as metabolomic studies on blood, urine and feces metagenomic studies on saliva, and immunomonitoring on blood.",
9545,NCT04508764,Number of primary barriers to genetic testing for family members,2021-04-09,RECRUITING,INTERVENTIONAL,['NA'],,
9546,NCT00895323,Tissue distribution,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
9547,NCT03766295,Overall Survival (median),2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression Free Survival,
9548,NCT02177084,LARS score,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],morbidity,
9549,NCT03558724,Safety of bevacizumab-800CW administration by monitoring vital signs and/or (serious) adverse events.,2018-10-29,TERMINATED,INTERVENTIONAL,['PHASE1'],The variation in fluorescence intensity between fluorescence molecular endoscopy before and after neoadjuvant chemoradiotherapy defined as the tumor to background ratio and intrinsic fluorescence.,
9550,NCT00145015,Apoptosis in colonic biopsy samples,2004-12,COMPLETED,INTERVENTIONAL,['NA'],gene transcription,
9551,NCT03260647,Optimization of multidisciplinary care,2017-08-04,RECRUITING,OBSERVATIONAL,['NA'],Evaluate cannabis use in patient population,
9552,NCT06097416,Overall survival,2024-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Progression-free survival,
9553,NCT03022734,complete resection (R0) rate for rectal and liver lesions,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Response rate (RECIST V1.1),
9554,NCT02552745,Pain scores,2014-10,COMPLETED,OBSERVATIONAL,['NA'],Hospital Stay,
9555,NCT03957031,Exposure to a variety of potential sources of GC risk factors,2019-05-31,UNKNOWN,OBSERVATIONAL,['NA'],,
9556,NCT03638206,"Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0",2018-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",CAR-T cells testing,
9557,NCT01271192,5-year disease free survival,2010-12,UNKNOWN,INTERVENTIONAL,['NA'],"Side effect of chemo radiotherapy, postoperative complications, recurrent rate, distant metastatic rate,biomarkers, quality of life, toxic profile, convenience",
9558,NCT00031837,Quality of life as measured by FACT-Hep version 4 every 4 weeks,2002-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Safety as measured by the occurrence of bleeding complications,
9559,NCT00526786,The eradication of LGD and HGD within BE at 24 months after the final treatment. The primary safety endpoint is the incidence of all adverse events.,2007-09,TERMINATED,INTERVENTIONAL,['PHASE4'],1.Eradication of all BE by 24 months after the final treatment. 2.The proportion of lesions that decreased in length by the 24-month follow-up. 3.The proportion of lesions where severity was downgraded by the 24-month follow-up.,
9560,NCT02352259,Evaluation of Safety Related to Electrochemotherapy,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Response to Treatment (Determined by Modified RECIST Criteria).,
9561,NCT02855788,response rate,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,
9562,NCT00475722,Adherence to Dietary Goals,2007-05,COMPLETED,INTERVENTIONAL,['NA'],,
9563,NCT03622229,"EUS-FNB procurement yield of tissue ""core"" using two different FNB needles.",2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],Macroscopic on-site evaluation (MOSE),
9564,NCT06231680,RCCEP response rate at 3 weeks,2024-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Thalidomide treatment-related adverse events,
9565,NCT01833546,Number of Participants Who Experienced Any Dose-Limiting Toxicity (DLT) During First Cycle - Day 1 to 28,2013-04-18,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2,
9566,NCT03760003,Modified Mayo Score,2019-09-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of clinically-significant laboratory abnormalities,
9567,NCT04387695,Progression-free survival (PFS) rate,2020-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],Disease control rate,
9568,NCT03875781,Survival,2019-06-05,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life - physical functioning: QLQ-C30,
9569,NCT05546892,Anastomotic leak rate,2023-02-10,RECRUITING,INTERVENTIONAL,['NA'],Bowel preparation compliance,
9570,NCT05611034,safety as measured by acute lung injury findings,2023-02-06,RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of mechanical ventilation,
9571,NCT01671592,Ability to track the labeled DC vaccine by MRI,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],May assess the disease-free survival and overall survival,
9572,NCT04363801,Part C: Progression Free Survival (PFS) in G/GEJ DKK1 high and overall patients treated with DKN-01 in combination with tislelizumab and chemotherapy vs tislelizumab and chemotherapy as a first-line therapy,2020-07-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Part C:To characterize the frequency of toxicity ≥Grade 3 treatment-related adverse events (TRAE) associated with each of the treatment arms.,Dickkopf-1 (DKK1) concentration in serum and plasma relative to safety and efficacy outcomes in G/GEJ patients treated with DKN-01 in combination with tislelizumab as a second-line therapy
9573,NCT05872295,Objective Response Rate (Part 2),2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluation of the immunogenicity of IKS014 (Part 1 and 2),
9574,NCT04727307,Recurrence-free survival,2021-01-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,
9575,NCT04500548,Incidence of adverse events,2021-01-28,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Overall survival,
9576,NCT01875198,Bleeding amount,2013-04,TERMINATED,INTERVENTIONAL,['NA'],postoperative complication,
9577,NCT02579278,To determine if there is a link between EMVI status and ctDNA,2015-11,RECRUITING,OBSERVATIONAL,['NA'],To investigate the effect of ctDNA status on patient survival outcomes,
9578,NCT06098560,Correlation of ctDNA changes with pCR rate and the duration of cCR,2023-08-16,RECRUITING,OBSERVATIONAL,['NA'],Correlation of ctDNA changes with 2 years PFS,
9579,NCT01116791,Overall survival time (OS) following CRS+HIPC (from surgery to cancer-related death),2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],In-hospital perioperative complications,
9580,NCT00238160,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
9581,NCT05641233,"Hardness of pancreas texture, determined by Durometer measurement",2020-12-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",30-day mortality and in-hospital mortality,
9582,NCT00006245,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9583,NCT02915393,Detection of helicobacter pylori by Urea Breath Test(UBT),2016-09,UNKNOWN,OBSERVATIONAL,['NA'],TCM syndrome type diagnosed by two professional TCM doctors,
9584,NCT06057350,CRC recurrence or sign of lymph nodes or distant metastases,2023-10-27,RECRUITING,INTERVENTIONAL,['NA'],Health related quality of life and functional outcomes after 30 days and one year,Cost-effectiveness
9585,NCT06172036,12-month EFS rate,2024-01-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events,
9586,NCT05396937,"Objective response rate, ORR",2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
9587,NCT02384005,Kappa agreement will be calculated between lay person and nurse practitioner on the anal exam results.,2015-02,COMPLETED,INTERVENTIONAL,['NA'],Number of persons who state they intend to seek subsequent care in the event of an abnormal result to a self-DAE.,
9588,NCT05101265,Total plasma dose-normalized AUC0-∞,2021-03-09,RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacogenetics,
9589,NCT05491889,mortality,2022-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9590,NCT04628780,Objective response rate (ORR) in the Expansion cohorts (Part 2),2020-12-16,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall survival (OS) in the Expansion Cohorts (Part 2),
9591,NCT01151007,Frequency of KRAS mutation,2011-07,COMPLETED,OBSERVATIONAL,['NA'],The incidence of the colorectal carcinoma,
9592,NCT05355662,Recurrence of the primary disease after surgery,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],Post-operative complications in patients who underwent liver transplantation,
9593,NCT04441580,Rate of patients detected with 3 or more adenomas.,2020-05-04,RECRUITING,INTERVENTIONAL,['NA'],Specific contribution of AI,
9594,NCT03630393,Postoperative Pain Medication Use,2019-05-09,TERMINATED,INTERVENTIONAL,['NA'],Discharge Day (Post-operative Day 0 or 1),
9595,NCT04221555,Pathologic complete regression (pCR) rate,2020-05-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease free survival (DFS),
9596,NCT03561142,Clinical complete response rate,2018-06-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
9597,NCT05086250,Feasibility of enrolling subjects which will be measured by the proportion of patients dropping out of study for any reason prior to the end of treatment visit.,2022-10-20,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],"To investigate the tolerability of oral ketamine in patients with pancreatic cancer and anxiety, which will be measured by patient-reported Ketamine Adverse Symptom Checklist and Impact scores.",
9598,NCT03658044,Self empowerment measured by Cancer Behavior Inventory (CBI) scale,2018-12-01,COMPLETED,INTERVENTIONAL,['NA'],Generated Knowledge in Online Discussions,
9599,NCT00629759,"To determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 injected within unresectable solid tumor(s) within the liver",2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],"Secondary objectives include determination of JX-594 pharmacokinetics, replication and shedding, immune response, and injection site tumor responses.",
9600,NCT05319054,Adherence of participants to the treatment programme,2022-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],LARS treatment history,
9601,NCT06166147,Performance of cfDNA methylation-based model for discriminating pancreatic cancer versus non-cancer,2023-12-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Performance of pre-defined model in clinical sub-groups of interest,
9602,NCT05707338,early postoperative complications,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
9603,NCT02573974,Measurement of muscle mitochondrial bioenergetics,2016-01-19,COMPLETED,INTERVENTIONAL,['NA'],Determining the isotopic composition of nitrogen hair,
9604,NCT02677389,Feasibility as defined by recruitment rate,2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],Physical activity as measured by the ActiGraph GT3X+ accelerometer (Arm II),
9605,NCT05510388,The incidence of hypoxia,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Complications related to high-flow nasal cannula,
9606,NCT05118451,Main evaluation indicators,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],Secondary evaluation index,
9607,NCT02870049,Screening completion rate,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,
9608,NCT01409499,Overall survival (OS),2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],cost of treatments,
9609,NCT02661971,Phase III: Overall Survival (OS): time from randomization to death of any cause,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Phase II/III: Subgroup analyses: PFS (medians and rates) according to subgroup (intestinal vs. diffuse/mixed or unknown and GEJ vs. gastric),
9610,NCT04560270,Correlation of the ctDNA level to the response to chemotherapy,2016-04-25,COMPLETED,INTERVENTIONAL,['NA'],Progression free survival,
9611,NCT02606916,Clinical response rate,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],grade 3 or 4 toxicities according to CTCAE4.0,
9612,NCT06199466,Overall Response Rate (ORR) of YL-13027 in combination with gemcitabine and nab-paclitaxel,2024-01-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9613,NCT04420130,6-month PFS rate,2020-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],Incidence of Treatment-Emergent Adverse Events,
9614,NCT01846650,Area Under Curve (AUC),2012-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9615,NCT00165061,Overall survival,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],4.Recurrence of the disease,
9616,NCT06204835,HCC lesions,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9617,NCT03875235,Overall Survival (OS) Rate at 24 Months,2019-04-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Disease Control Rate (DCR) - 48 Weeks,
9618,NCT05990543,Progression free survival,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
9619,NCT01248962,Number of Participants With and Without Hypersensitivity Reaction,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],The Odds Ratio for the Relationship of Baseline Variables to the Carboplatin Hypersensitivity Rate,
9620,NCT02211443,Number of participants with SCT200-related adverse events,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Area Under the plasma concentration versus time curve (AUC) of SCT200,Time to Disease Progression (TTP) of SCT200
9621,NCT02651974,Percentage of individuals who complete FIT screening measured by return FIT kit,2015-09,COMPLETED,INTERVENTIONAL,['NA'],"Pre-post analysis of current results reporting strategy (which will utilize a white envelope for normal results, and a red envelope for abnormal results) to prior generic envelope for FIT result reporting for both normal and abnormal results.",
9622,NCT03586869,Overall Response Rate by RECIST Version 1.1,2018-07-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",ORR by RECIST Version 1.1,Quality of Life by patient-reported outcomes (PROs)
9623,NCT05319145,Short Physical Performance Battery (SPPB),2022-05-01,UNKNOWN,INTERVENTIONAL,['NA'],Days spent at home (number of days),
9624,NCT06050707,Change in locoregional failure (LRF) at Year 2,2023-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life (QOL),
9625,NCT03072641,Changes in microbiota composition after probiotics use,2010-06-03,COMPLETED,INTERVENTIONAL,['NA'],Epigenetic changes after probiotics use,
9626,NCT05831488,"Assess the relationship between Seismofit®-estimated VO2 peak and CPET-measured VO2 peak in HPB, gastro-oesophageal or colorectal cancer patients undergoing preoperative assessment for major surgery.",2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],Assess patient experience of the Seismofit® test using a brief measure that has been used previously in CPET research,
9627,NCT01794793,Incidence of adverse events to evaluate long term safety data,2013-06-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Percentage of patients with clinical benefit as assessed by the investigator,
9628,NCT05754229,False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system,2022-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9629,NCT05978882,Detection rate of Sentinel lymph nodes,2023-08-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],5 year recurrence free survival rate,
9630,NCT01890213,Number of participants with adverse events,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9631,NCT05705791,Objective response rate,2023-02-07,RECRUITING,INTERVENTIONAL,['NA'],Evaluate alternative response evaluation criteria,
9632,NCT00790140,Preservation of body compostition after surgery,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],Reduced immuno-inflammatory response to surgery,
9633,NCT01374074,To examine the association between BE and environmental factors,2011-03,COMPLETED,OBSERVATIONAL,['NA'],To investigate the association between BE and genetic and epigenetic status of Cdx1/Cdx2,
9634,NCT04096118,Survival rates,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
9635,NCT02197351,Detection of Intestinal Metaplasia or Dysplasia,2014-07,RECRUITING,INTERVENTIONAL,['NA'],Helicobacter pyrlori detection,
9636,NCT03473327,Oxidative and immunological gene-expression before and after laparoscopic surgery for colon cancer using whole blood gene expression profiling from blood samples,2016-01,COMPLETED,OBSERVATIONAL,['NA'],Assessement of inflammatory tumor invasion using immunohistochemestry on tumor tissue samples,
9637,NCT01972672,time to progress（TTP）,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Laboratory abnormal findings,Gene expression profiling of blood cells and tumor biopsies
9638,NCT02164240,Number of Participants With Serious and Non-Serious Adverse Events,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Median Progression Free Survival (mPFS),
9639,NCT00547612,Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography,2007-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9640,NCT06316466,OS,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],PFS,
9641,NCT03114085,time to progression,2017-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9642,NCT03031171,Colonoscopy completion,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,
9643,NCT05427669,3-year Disease-free Survival (DFS),2022-10-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],3-year distant metastatic-free survival （DMFS）,
9644,NCT05352542,CAR transgene levels in peripheral blood,2022-05-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of anti-LCAR-H93T antibody,
9645,NCT06022692,disease control rate (DCR),2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",overall survival (OS),
9646,NCT00265850,Overall Survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Duration of Tumor Response,
9647,NCT04011969,Fecal immunochemical test (FIT),2019-07,UNKNOWN,OBSERVATIONAL,['NA'],,
9648,NCT03151642,Number of MRIs,2017-04-05,COMPLETED,OBSERVATIONAL,['NA'],,
9649,NCT01253161,Progression-free Survival (PFS) at One Year,2011-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events Possibly Related to Study Treatment,
9650,NCT03708952,Numbers of participants with polyps,2018-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Numbers of participants with cardiometabolic diseases,Numbers of participants died
9651,NCT05351398,Objective Response Rate,2022-04,UNKNOWN,OBSERVATIONAL,['NA'],R0 resection rate,
9652,NCT02490111,Proportion of patient developing gallstone at 12 month after gastrectomy,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Time to gallstone formation,
9653,NCT02868151,World Health Organization criteria of grading oral mucositis.for head and neck cancer patients,2016-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
9654,NCT05205629,Progression Free Survival,2022-01-30,UNKNOWN,OBSERVATIONAL,['NA'],Conversion rate,
9655,NCT02194387,Change in waist circumference (Pilot II),2014-09-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9656,NCT06043466,To obtain the maximum tolerable dose of C-13-60 cells [Safety and Tolerability],2023-08-11,RECRUITING,INTERVENTIONAL,['PHASE1'],The content of CEA in peripheral blood after infusion of C-13-60 cell [Cell dynamics],Overall survival(OS) of C-13-60 cell treatment in patients with CEA-positive advanced malignancies[Effectiveness]
9657,NCT02985801,Change in Body Weight,2016-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in Body Weight Composition,
9658,NCT00812175,The safety of Nexavar in all patients with unresectable HCC who are candidates for systemic therapy and in whom a decision to treat with Nexavar has been made under real-life practice conditions,2009-01,COMPLETED,OBSERVATIONAL,['NA'],Reports of adverse events,
9659,NCT02404909,to investigate the influence of the liver resection on hemodynamic status in terms of hemodynamic indexes changes,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
9660,NCT06186609,Progression-free survival,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
9661,NCT01091428,Phase 2: Progression-Free Survival (PFS),2010-04-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Phase 2: Number of Participants With Clinically Significant Vital Sign Findings,Banked Tumor Specimens for Candidate Markers of Response to Alisertib and Taxanes
9662,NCT01665625,overall surviva,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],surgical complications,
9663,NCT06013657,Mortality,2021-12-01,COMPLETED,OBSERVATIONAL,['NA'],Length of stay,
9664,NCT00837876,Number of Patients With Progression-free Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Worst Grade Toxicities,
9665,NCT03289273,"Number of patients with treatment emergent adverse events (TEAEs) leading to dose modifications (including reductions, interruptions and permanent discontinuation)",2017-09-13,COMPLETED,OBSERVATIONAL,['NA'],Duration of regorafenib treatment,
9666,NCT04852653,Positivity of the liquid biopsy,2021-09-21,RECRUITING,OBSERVATIONAL,['NA'],Genetic profile of the primary tumor predictive of the response to nCRT,
9667,NCT02246322,Clinical performance of 22G and 25G needles,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],Major complications,
9668,NCT04823754,Evaluate the concordance between the patient's perception of his prognosis and treatment side effects with the one of his treating physician.,2021-07-12,COMPLETED,OBSERVATIONAL,['NA'],Evaluate the association between individual prognosis expectation (patient and physician) and data from the available literature.,
9669,NCT00007618,,1998-01,COMPLETED,OBSERVATIONAL,['NA'],,
9670,NCT03948763,Number of Participants Who Discontinued Study Treatment Due to an AE,2019-06-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Mutant KRAS Specific T cells,T-cell receptor (TCR)
9671,NCT03794193,3-year Disease-free Survival,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Distant organ metastasis rate,
9672,NCT02746224,Anorectal functional outcome at 12 months assessed by LARS scale,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],Distance to surgical margins,
9673,NCT03398291,Real overall survival,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Postoperative mortality,
9674,NCT04231929,Tumor response,2020-05,WITHDRAWN,INTERVENTIONAL,['NA'],Best overall response,
9675,NCT02706782,Number of patients with adverse event,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],Detection of transferred T cells in the circulation using quantitative -PCR,
9676,NCT03642093,Frailty Measurement,2018-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Quality of Life (QoL) Assessment,
9677,NCT00628147,Neoplasm Miss Rate,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Procedure Complications,
9678,NCT00655499,Objective Response Rate (ORR) During the Combination Therapy Phase,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
9679,NCT05861947,Pharmacokinetics: Terminal elimination half life,2023-08-26,RECRUITING,INTERVENTIONAL,['PHASE1'],Laboratory abnormalities,Exploratory endpoint (PD biomarker): IFN-γ level
9680,NCT05002608,change from baseline health insurance literacy to 5-month follow-up,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
9681,NCT05127096,Specificity of the FirstSight test,2020-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,
9682,NCT05419362,"To assess the anti-tumor activity of GEN-001, when administered as combined with avelumab",2022-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),Microbiota
9683,NCT00496509,Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases.,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Assessment of the effectiveness of ZD6474 as measured by objective response rate and progression free survival based on RECIST.,
9684,NCT03647527,the highest grade of oral mucositis,2016-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9685,NCT00264979,Rate of patients with at least one postoperative severe complication within 60 days after each surgery,2006-03-02,TERMINATED,INTERVENTIONAL,['NA'],Two years recurrence rate,
9686,NCT06314958,Recurrence-Free Survival,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],Overall Survival,
9687,NCT01451658,Rebleeding,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],complication survival,
9688,NCT01712971,intra-operative blood loss,2012-11,WITHDRAWN,OBSERVATIONAL,['NA'],hospital costs,
9689,NCT01921699,proliferation and migration of PANC1 cell line in the tested groups.,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],To determine whether direct cell-to-cell interaction or soluble factors participate in MIC.,
9690,NCT03668431,"Number of participants with grade 3, 4 and 5 adverse events",2018-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],"Mechanisms of response and resistance to dabrafenib, trametinib, and PDR001",
9691,NCT02559687,Objective Response Rate (ORR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR),2015-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
9692,NCT00278889,Progression Free Survival,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],QOL: Time to Worsening of FACT Colorectal Cancer Symptom Index(FCSI),
9693,NCT00922181,Variability of ablation diameters,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,
9694,NCT00677612,safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To evaluate immunological responses,
9695,NCT01519999,Change in colorectal cancer screening adherence,2012-05,COMPLETED,INTERVENTIONAL,['NA'],Providers'/staff shared decision-making experience,
9696,NCT03601156,Pathological Complete Response (pCR),2014-06,UNKNOWN,INTERVENTIONAL,['NA'],Number of Postoperative Complication,
9697,NCT05256381,Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),2022-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants with Anti-drug Antibodies (ADAs),
9698,NCT03706248,"Sensitivity, specificity, positive predictive value and negative predictive value",2018-07-28,COMPLETED,OBSERVATIONAL,['NA'],,
9699,NCT03228043,Number of Participants overall survival,2020-03-01,WITHDRAWN,INTERVENTIONAL,['NA'],Number of Participants overall survival,Number of Participants overall survival
9700,NCT02204332,"The efficacy of cabazitaxel measured by estimating the overall response rate (ORR), as the percentage of individuals who achieve a complete tumor response (CR) or partial tumor response (PR) in each arm and between arms.",2013-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression-free survival (PFS),"Safety and toxicity in the experimental arm. Toxicity is graded according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE, v 4.0)."
9701,NCT02251977,rates of grade 2 or more chronic cumulative neurotoxicity of both arms,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],rates of 3 year disease free survival of both arms,genetic polymorphisms of oxaliplatin induced severe and cumulative neurotoxicity
9702,NCT00579163,To establish a bank of DNA and frozen lymphoblastoid cell lines for the purpose of facilitating genetic epidemiology investigations of familial cancers.,1994-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],A related goal is to provide patients with cancer and their living relatives the opportunity to preserve DNA samples so that they may be used for future genetic counseling regarding inherited cancer risk.,
9703,NCT04943406,Prognostic impact of ctDNA positivity,2020-05-08,RECRUITING,OBSERVATIONAL,['NA'],Prognostic impact of ctDNA positivity in peritoneal lavage and peripheral blood on the risk of peritoneal and distant metastases,
9704,NCT02869152,2nd Phase: Detection rate of refined protocol in identifying SLN,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],Ergonomic optimization of the protocol as measured by surgeon satisfaction,
9705,NCT00867126,"Changes in symptoms and quality of life as measured by the validated FACT-Hep scale version 4 questionnaire at baseline, every 4 weeks during therapy, and then at the completion of therapy",2009-03-02,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Time to disease progression,
9706,NCT05279287,Number of errors in an operation using validated methodology- Objective Clinical Human Reliability Analysis (OCHRA),2023-02-01,RECRUITING,OBSERVATIONAL,['NA'],Application of Machine learning and Artificial Intelligence to video analysis,
9707,NCT03973112,ORR,2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],DOR,
9708,NCT05843188,Overall response rate,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidences and severity of adverse events,
9709,NCT02196935,Successful ERCP or EUS,2010-09,RECRUITING,OBSERVATIONAL,['NA'],Definitive Diagnosis,
9710,NCT03675737,Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10,2018-11-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE),
9711,NCT05038098,Safety of endoscopic peritumoral gastric injection of FerroTrace,2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
9712,NCT06229041,The PCR rate between total neoadjuvant treatment ±immunotherapy,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,
9713,NCT03636893,Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour,2018-08-24,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS) Disease Free Survival (DFS),
9714,NCT00483080,Progression Free Survival (PFS),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety according to NCI-CTCAE criteria (version 3),
9715,NCT00417287,Determine if there is a difference in effect on circulating Trx-1 protein levels between two dose levels of PX-12,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Assess the effects of metabolic excretion of PX-12,
9716,NCT03316677,the predictive value of intraoperative anastomosis testing on anastomotic leak.,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],The sensitivity of the 2 methods of intraoperative anastomosis testing.,
9717,NCT00225784,Objective Response of Tumor by RECIST 1.0 Criteria,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Pattern of Failure After Therapy,
9718,NCT01596634,Change in the Taste Visual Analog Scale (VAS) and taste and smell questionnaire responses,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Quality of life as quantified by the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) questionnaire,
9719,NCT05001009,Percent of patients with a goals of care conversation note documented in Stage 2,2022-09-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Percent of patients with a goals of care conversation note documented in Stage 1,
9720,NCT01752933,Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
9721,NCT06124001,Phase IIa:ORR,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase Ib and Phase IIa: herpes simplex virus type I antibodies,
9722,NCT04753879,Progression-free Survival (PFS) after 6 months according to IRECIST criteria.,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants experiencing grade 3 or above drug-related toxicities,
9723,NCT01764802,"Sexual pain graded using the International Pelvic Pain Society Pelvic Pain Assessment, patient/physician version",2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Body change stress graded according to the Impact of Treatment Scale (ITS),
9724,NCT04989387,"Evaluation of Recommended Dose for Expansion (RDE) of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by safety, PK and PD data",2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Duration of Response (DOR) from earliest date of disease response until earliest date of disease progression as determined by radiographic disease assessment, or death if occurring sooner than progression",
9725,NCT03718221,Patient-level Colorectal Cancer (CRC) Screening,2018-08-30,COMPLETED,INTERVENTIONAL,['NA'],Neighborhood-level Screening,
9726,NCT03768531,Number of participants experiencing study drug-related toxicities,2019-06-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Disease free survival (DFS),
9727,NCT00132041,Proportion of Participants With Successful Control of Disease at 18 Months,2005-12,COMPLETED,INTERVENTIONAL,['NA'],Remote Tumor Occurrence Rates,
9728,NCT03189914,Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2),2017-10-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15,Quality of Life (QOL) (Phase 1 and 2)
9729,NCT02611700,Median time of overall survival(OS),2015-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Incidence of adverse events,
9730,NCT04694794,Utility of Educational Brochure assessment,2021-03-24,COMPLETED,INTERVENTIONAL,['NA'],Baseline Educational Assessment,Feasibility Assessment
9731,NCT02611661,Safety and tolerability of administering hepatic locoregional therapy following radioembolization as measured by occurrences of grade 3 or higher toxicities of interest,2016-01-19,TERMINATED,INTERVENTIONAL,['PHASE1'],Response rates associated with radioembolization followed by dosimetry-guided subsequent hepatic locoregional therapy,
9732,NCT05722223,To explore the feasibility of a trimodal prehabilitation program in the hospital setting,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],Anxiety and depression,Circulating tumor DNA and mutational variations
9733,NCT03426514,Early morbidity rate,2018-03-25,RECRUITING,INTERVENTIONAL,['NA'],5-year overall survival rate,
9734,NCT00775073,Time to Progression,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
9735,NCT05850559,Assessment of the Diagnostic Role of Serum Insulin-like Growth Factor Binding Protein-3 as a Potential Biomarker for Colorectal Cancer (CRC) in Egypt,2023-10-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9736,NCT02069041,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]),
9737,NCT05668793,validity,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],reliability,
9738,NCT04825574,Safety as assessed by the number of serious adverse events and adverse events of special interest,2021-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
9739,NCT06255379,Progression Free Survival (PFS),2024-03-22,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],adverse events (AE),
9740,NCT05952947,Adverse events and serious adverse events,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Concentration of Cytokines (IL-2、IL-6、IL-10、TNFα、IFNγ),T cell subgroup in peripheral blood
9741,NCT01559844,Number of Participants Who Died,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Proportion of Participants With Virologic Failure Prior to Transplant,
9742,NCT04736043,Overall survival rate,2021-01-31,RECRUITING,OBSERVATIONAL,['NA'],,
9743,NCT03153332,The primary outcomes was the precise allocation of hepatic disease,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],Time spent to judge tumor location,
9744,NCT01542177,Measure the hypoxia level in Patients with Pancreatic Cancer using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA).,2012-02,COMPLETED,OBSERVATIONAL,['NA'],Determine the feasibility of using dynamic and static PET imaging of FAZA uptake in patients with pancreatic cancer.,
9745,NCT04616950,Hospital course of patients with cancer of the digestive system,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],Modeling of the hospital journey based on observations made during the period preceding the COVID-19 epidemic,
9746,NCT05640609,the objective Response Rate (ORR) of the experimental group.,2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",disease control rate (DCR),
9747,NCT05220020,Two-Years Overall Survival Rate,2022-05-18,RECRUITING,INTERVENTIONAL,['PHASE3'],"Evaluate the patients cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30.",
9748,NCT04138654,Change in whole genome gene expression analyses in colonic biopsies and blood between baseline levels and each intervention period (transcriptomics),2014-04-17,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in the microbiome in feacal samples and in saliva between baseline levels at the start of the intervention and each intervention period,Change in O6-MeG in colonic biopsies between baseline levels at the start of the intervention and each intervention period
9749,NCT03944252,Primary endpoint is Objective Response Rate (ORR).,2018-09-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9750,NCT01581840,Response to treatment,2012-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
9751,NCT05615818,Progression-free survival (PFS),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Percentage change in tumour size,Incidence of Adverse Events
9752,NCT02530437,Pathologic Complete Response Rate (Phase II),2017-03-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
9753,NCT01271712,Progression-free Survival,2011-01-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Duration of Response (DOR),
9754,NCT00484211,Antitumour activity defined as progression free survival (PFS),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Experimental imaging study (DCE-MRI),
9755,NCT06097078,Rate of patients with anastomotic leakage,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Rate of intraluminal hemorrhage,
9756,NCT05651672,Overall response rate (ORR),2022-12-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events (AEs),
9757,NCT01703585,Patient recruitment for paired core and fine needle biopsy greater than or equal to 50% of those screened or approached.,2012-10-04,COMPLETED,OBSERVATIONAL,['NA'],Actionable genomic result analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 30%,
9758,NCT02051868,Best overall response rate by 24 weeks post treatment,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Identification of potential tumour biomarker,
9759,NCT04544852,The proportion of participants that completed the FIT test within three months post enrollment.,2017-12-04,RECRUITING,INTERVENTIONAL,['NA'],,
9760,NCT02282722,Number of Patients With Accurate Understanding of Chemotherapy Benefits,2015-06-10,COMPLETED,INTERVENTIONAL,['NA'],Patient-Reported Prognostic Understanding in Median Years,
9761,NCT06242067,progression-free survival(PFS),2023-04-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of Response (DOR),
9762,NCT06330441,Number of participants with newly diagnosed pancreatic ductal adenocarcinoma,2022-01-07,RECRUITING,INTERVENTIONAL,['NA'],KRAS mutation status evaluation,
9763,NCT03412877,Response rate,2018-09-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerance,
9764,NCT03113318,5-year overall survival,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],30-day mortality,
9765,NCT03044743,Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients,2017-04-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Th1/Th2 change in the peripheral blood,
9766,NCT00437502,Date of first objective finding will be used to define the date of relapse,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9767,NCT00545545,To determine safety and maximum tolerated dosage of Imprime PGGwhen used in combination with cetuximab with and without irinotecan therapy in patients with recurrent/progressive colorectal carcinoma previously treated with a 5-FU regimen.,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","To determine the tumor response rates (complete response, partial response, stable disease, overall response rate), time to progression, duration of overall tumor response, and the duration of stable disease in patients receiving the combination therapy.",
9768,NCT03516071,Time to Progress (TTP),2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
9769,NCT00449995,diagnostic accuracy of confocal laser scanning microscopy for detection of metaplasia or neoplasia in Barrett´s esophagus,2007-03,COMPLETED,INTERVENTIONAL,['NA'],inter- and intra observer variability for confocal laser scanning microscopy,
9770,NCT04344847,Excision of GIST during LSG,2016-12-12,UNKNOWN,INTERVENTIONAL,['NA'],,
9771,NCT00398086,Number of Participants With Dose-limiting Toxicities,2006-11-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Maximal Degree of Anemia,
9772,NCT00407186,overall survival,2007-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],health-related quality of life,
9773,NCT02972541,Rate of stoma formation,2016-09-30,UNKNOWN,INTERVENTIONAL,['NA'],Chemotherapy related complication,
9774,NCT03259867,Overall Response Rate,2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
9775,NCT06230471,Objective response rate,2024-01-09,RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival rate,
9776,NCT03829852,"Effectiveness of regorafenib use in routine clinical practice setting, assessed by tumor response",2019-02-11,COMPLETED,OBSERVATIONAL,['NA'],"Eligibility of subsequent therapies and the outcome, assessed by PFS","Exploratory outcome: Image pattern as the potential predictive factor for regorafenib treatment outcome in overall cohort and long-term responders, assessed by changes in image patterns"
9777,NCT01868971,The primary endpoint is reaching the cecum of the colon with the ENDORINGS™.,2013-04,COMPLETED,INTERVENTIONAL,['NA'],7. Patient satisfactory.,
9778,NCT00824785,Overall survival,2008-05,TERMINATED,INTERVENTIONAL,['PHASE3'],"response rate, toxicity, quality of life and PFS",
9779,NCT00238212,Response probability (confirmed complete and confirmed partial responses),2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to progression,
9780,NCT06006026,The safety profile of combining ropivacaine and lidocaine,2023-08-28,COMPLETED,INTERVENTIONAL,['NA'],The plasma concentration of lidocaine,
9781,NCT02746432,The anti-inflammatory effects of intraoperative hyper-insulinimic euglycemic therapy in patients undergoing colorectal cancer surgery.,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],The immunomodulatory effect of intraoperative hyper-insulinimic euglycemic infusion.,Thirty days post-operative mortality
9782,NCT03138720,CA19-9 value,2017-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
9783,NCT01460888,Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],Exploration of blood and tissue borne pharmacodynamic markers to establish the biological efficacy of the addition of Olaparib to radiotherapy.,
9784,NCT02349958,measure treatment response to HIPEC and tumor debulking,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicity Monitoring,QOL
9785,NCT03621982,Part 1 Combination Therapy: Number of Patients who Experience a Dose Limiting Toxicity (DLT),2018-11-09,TERMINATED,INTERVENTIONAL,['PHASE1'],Part 2 Combination Therapy: Number of Patients with Confirmed Positive Anti-drug Antibody (ADA) Responses,
9786,NCT00260559,Change from baseline in SF36 Quality of Life Questionnaire at 36 month,1999-05,RECRUITING,OBSERVATIONAL,['NA'],,
9787,NCT03187951,Change in 6 Minute Walk Test (6MWT),2017-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9788,NCT04174079,Disease-free survival,2019-12-11,RECRUITING,INTERVENTIONAL,['NA'],overall survival,
9789,NCT00382720,Time to Progression,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
9790,NCT05010681,Objective Response Rate (ORR),2021-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
9791,NCT05266300,Adverse events,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],Rate of discontinuation of fluoropyrimidines due to adverse events,
9792,NCT04923529,16-week progression-free survival (PFS) rate,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety outcome measures,
9793,NCT03031691,Percentage of patients with anti-brontictuzumab antibodies,2017-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival,
9794,NCT02465060,Objective response rate,2015-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Progression free survival,
9795,NCT00220064,Disease stabilization rate or tumour marker response,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9796,NCT02276768,Mean visceral pain intensity score following dosing with GIC-1001 375 mg TID,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],"Standard laboratory measures (biochemistry, hematology, urinalysis)",
9797,NCT05057052,Objective Response Rate (ORR),2021-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
9798,NCT04973306,Overall survival(OS),2022-03-02,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Correlation between genetic profile and tumor response,
9799,NCT00003186,,1997-04,COMPLETED,INTERVENTIONAL,['NA'],,
9800,NCT04315311,Change In Coefficient Of Fat Absorption (CFA) From Baseline,2020-05-06,WITHDRAWN,INTERVENTIONAL,['PHASE4'],Change In Gastrointestinal Quality Of Life Index (GIQLI) From Baseline,
9801,NCT06039280,Prevention of post-embolization syndrome,2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adverse events of Dexamethasone and NAC in patients undergoing transarterial chemoembolisation for HCC,
9802,NCT00305877,Proportion of Patients With Specific Protocol Defined Adverse Event at Conclusion of All Therapy,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Two-year Disease-free Survival (DFS),
9803,NCT01868347,evaluation of arterial oxygenation,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],evaluation of difference between arterial end-tidal partial pressure of carbon dioxide,variation of gas exchange in post operative period
9804,NCT06178926,Sedation efficacy,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],Injection pain,
9805,NCT00006006,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9806,NCT00297128,feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"collection of response rate (T-downstaging, pCR), correlation of responsiveness with EGFR-status",
9807,NCT04168944,Tumor free survival rate,2019-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall survival rate,the side effects
9808,NCT02694562,Local Tumor Control,2013-11,COMPLETED,INTERVENTIONAL,['NA'],Time To Tumor Progression,
9809,NCT02381561,Maximum tolerated dose (MTD) defined as the dose below which 2 or more of 6 patients experience dose-limiting toxicity,2016-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor response relationship to the %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation using Response Evaluation Criteria in Solid Tumors (RECIST) criteria based on high-pressure liquid chromatography (HPLC) and flow cytometry measurements,
9810,NCT01213004,To determine whether motion-corrected cone-beam CT (CBCT) can visualize and localize abdominal tumors using intravenous contrast enhancement.,2010-09,COMPLETED,INTERVENTIONAL,['NA'],To determine whether tumor and organ-at-risk positions localized in cone-beam CT (CBCT),
9811,NCT03606317,Prognosis and practice patterns in the management of cachexia and its associated symptoms.,2013-11-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
9812,NCT03258398,Part 2: Overall Response Rate,2017-09-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9813,NCT02563158,Serum total bilirubin on postoperative day 5,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Long-term survival,
9814,NCT01003600,"Assess colorectal cancer survivors' basic knowledge of their own cancer history, including date of diagnosis, stage, and treatments received.",2009-10,COMPLETED,OBSERVATIONAL,['NA'],Assess whether survivors who had concerns about working after cancer treatment spoke with health care professionals about their concerns.,
9815,NCT00002664,,1995-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
9816,NCT05025826,Demonstrate a 50% decrease of the grade> or = 2 neurotoxicity at 4 months after oxaliplatin-based chemotherapy start in the PHYCOCARE arm,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],Comparison between the two arms of Neurological toxicities,
9817,NCT01472029,"Rate of complete pathological responses (percentage of patients with pCR referring to the total number of enrolled and eligible patients), as evaluated centrally by a reference pathologist.",2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
9818,NCT03347630,diagnostic performance for staging,2017-10-02,UNKNOWN,INTERVENTIONAL,['NA'],Diagnostic performance to assess tumor response,
9819,NCT00364364,"For patients who undergo surgery after the 111In-hPAM4 study, targeting will be correlated against surgical findings.",2007-05,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],"Targeting with 111In-hPAM4 will be compared to other radiological (e.g., CT) and nuclear (FDG-PET; optional)findings.",
9820,NCT04638959,differences in abundance of gut microbiota,2019-09-30,UNKNOWN,OBSERVATIONAL,['NA'],evidence of gastric carcinoma,Basic information of patients with different clinical outcomes
9821,NCT00031694,Response Rate of at Least 30%,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,Bryostatin 1 Pharmacokinetics
9822,NCT03866525,The anti-tumor activity of OH2 monotherapy and in combination with irinotecan or HX008,2019-04-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The immunogenicity of OH2,
9823,NCT01474642,response rate,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],predictive marker,
9824,NCT03300570,"Pharmacological Effect on Cyclic Guanosine Monophosphate (cGMP) Levels for Dolcanatide Arm Versus (vs.) Placebo, as Measured by the Differences in Mean cGMP Levels After 7 Days of Intervention",2018-07-27,COMPLETED,INTERVENTIONAL,['PHASE1'],Percentage of Participants With Grade 3 or Higher Diarrhea Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0,
9825,NCT00892593,"rate of significant colon neoplasia among those who enter a screening or surveillance program with FIT testing added at yearly intervals vs. that of ""usual care"" patients in the same patient population.",2009-05,UNKNOWN,INTERVENTIONAL,['NA'],the pathology found at repeat colonoscopy in each group.,
9826,NCT00994903,Total complications,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Change in functional recovery,
9827,NCT01605734,Time to Progression,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],AFP,
9828,NCT04316000,Initial Fear of Cancer degree,2019-11-22,SUSPENDED,OBSERVATIONAL,['NA'],Long-term Fear of Cancer degree,
9829,NCT00590239,Pathologic and Clinical Outcomes,2007-05-15,RECRUITING,OBSERVATIONAL,['NA'],Efficacy of endoscopic detection of early esophageal lesions,
9830,NCT03171298,intraoperative complication,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],Mesorectal completeness,
9831,NCT05172635,Pathological response of the primary tumour,2014-06-01,COMPLETED,OBSERVATIONAL,['NA'],90 day mortality,
9832,NCT05188209,Adverse Events (AEs),2021-05-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],The proportion of patients with positive of anti-drug antibody (ADA),
9833,NCT04984980,objective response rate,2020-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival,
9834,NCT01712347,Overall survival from the time of starting first-line therapy,2012-10-11,COMPLETED,OBSERVATIONAL,['NA'],Number of participants with adverse events,
9835,NCT05226169,Maximum change of Hb concentration,2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE3'],OS,
9836,NCT05512520,1-year progression-free survival,2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,
9837,NCT02997293,Hospital length of stay,2017-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
9838,NCT03474354,CORRELATION OF LUMI DISTRIBUTION WITH NECROSIS,2018-05-02,COMPLETED,OBSERVATIONAL,['NA'],Distribution of radiopaque beads and correlation with necrosis,
9839,NCT00415155,Phase 2: Time to progression,2008-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Safety,
9840,NCT06323382,Progression-Free-Survival (PFS),2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],Adverse events,
9841,NCT06051695,Phase 2: The Overall Response Rate (ORR) for patients,2024-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Cytokine analysis,
9842,NCT00353262,AUC0-inf for Free Platinum,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Marked Laboratory Abnormalities,
9843,NCT00535353,"Correlation, if any, between the toxicity profile and pharmacokinetics",2008-01-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacodynamic outcomes,
9844,NCT00003381,Evaluate the quality of life of patients,1998-07,TERMINATED,OBSERVATIONAL,['NA'],,
9845,NCT04203641,Adverse events (as per CTCAE v. 5.0),2019-12-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Proportion of patients expressing anti-L-DOS47 antibodies,
9846,NCT01528501,objective response rate within the first six treatment cycles,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Safety and tolerability of LBH 589,
9847,NCT03343301,Number of Participants With Dose Limiting Toxicities (DLTs),2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With Treatment Induced Anti-bemarituzumab Antibodies,
9848,NCT04446793,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
9849,NCT03401827,survival rate,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],adverse event,
9850,NCT03699371,Long-term quality of life at 6 months,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],Antibiotic-free days,PCS SF-36 change
9851,NCT02489214,Number of Participants with Adverse Events,2016-05-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival time,
9852,NCT02442323,Patient-reported outcome of quality of life,2013-08-09,COMPLETED,INTERVENTIONAL,['NA'],,
9853,NCT04689347,"To evaluate the safety and to determine the recommended phase 2 dose of the combination of FLIRT- bevacizumab in patients with MGMT silenced and MSS mCRC, previously untreated for advanced disease",2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Quality of life as assessed using the Euro Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L),OS of FLIRT bevacizumab
9854,NCT05718115,Predict response to anti-HER2 directed therapy using DLR,2023-02-15,RECRUITING,OBSERVATIONAL,['NA'],,
9855,NCT00878657,Disease-free survival (Phase II),2009-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,
9856,NCT02069704,AUC at Steady State (AUCss) of BEVZ92 and Avastin®,2014-10-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Volume of Distribution (Vd) of BEVZ92 and Avastin®,
9857,NCT02256514,Effect of hepcortespenlisimut-L (V5) immunotherapy on tumor size or clearance,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Effect of hepcortespenlisimut-L (V5) immunotherapy on patients' performance,
9858,NCT03437200,12-Month Progression-free survival using RECIST 1.1,2019-01-17,TERMINATED,INTERVENTIONAL,['PHASE2'],Relative dose intensity of 5FU,
9859,NCT01364805,Determine safety of combined gemcitabine chemotherapy with IV ascorbate.,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Assess pharmacokinetic and pharmacodynamic interactions when adding IV AA to front-line gemcitabine chemotherapy in the treatment of locally advanced or metastatic pancreatic cancer not eligible for surgical resection.,
9860,NCT03042169,Overall survival,2021-08-25,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of interventional palliative procedures per patient,
9861,NCT05829057,Number of participants with physical examinations,2023-05-23,RECRUITING,INTERVENTIONAL,['PHASE1'],changes of cytokines relative to the baseline,
9862,NCT02664077,"Disease-free survival (DFS) - time from randomization until first colon cancer recurrence, second primary colon cancer, or death due to any cause.",2016-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Compare the symptoms experienced by patients receiving regorafenib to patients receiving placebo during treatment as measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE),
9863,NCT03777475,OS,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA'],PFS,
9864,NCT03839706,18F-FDG PET/MRI results can identify aggressive HCC behavior and recurrence post transplant,2018-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],18F-FDG PET/MRI are related to presence of circulating tumor DNA in plasma,
9865,NCT05059717,Magnetic Resonance Displacement Encoding with Stimulated Echo (MR DENSE) imaging data of patients treated with chemotherapy prior to resection of metastases to explore its utility in detecting sinusoidal liver injury.,2018-07-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
9866,NCT01770405,performance evaluation,2013-09,COMPLETED,OBSERVATIONAL,['NA'],Safety and feasibility evaluation,
9867,NCT04152889,DFS,2020-04-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9868,NCT04525313,response rate,2020-08,UNKNOWN,OBSERVATIONAL,['NA'],progression free survival,
9869,NCT04039360,stoma rate,2014-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
9870,NCT05530746,Detection of advanced colorectal adenoma,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],Detection of non-advanced colorectal adenoma,
9871,NCT01659424,Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy (BT) Improve Compliance,2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],4) Quality of Life,
9872,NCT05594914,AE,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
9873,NCT01467921,disease-free survival,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9874,NCT00002615,,1994-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9875,NCT03072472,Adenoma Detection Rate,2017-02-14,COMPLETED,INTERVENTIONAL,['NA'],Compare the baseline ADR of each colonoscopist prior to trial recruitment with their individual ADR in patients where EndocuffTM Vision was not used.,
9876,NCT01214343,Overall survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Biomarker predicting the efficacy,
9877,NCT01725490,the mean percentage change of the number and size of polyps in colon and/or duodenum.,2013-02-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9878,NCT02837263,Recurrence rate at 1 year,2016-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival estimated using the Kaplan-Meier method,Expression levels of PDL1
9879,NCT05432193,Treatment emergent adverse events,2022-07-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Uptake of [Ga-68]-PNT6555 in tumor lesions,Uptake of the [Ga-68]-PNT6555 imaging agent and optimal scanning specifications for future studies
9880,NCT04180761,Incidence of peritoneal metastases and proportion of patients free from peritoneal metastasis after one year after HIPEC.,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by grading according to CTCAE v5.0 and Clavien-Dindo.,
9881,NCT02176746,The number of participants with adverse events,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements,The dose of CSC vaccine
9882,NCT00971126,"Terms of efficacy assessment: objective tumor response, overall survival, progression-free survival. Terms of safety assessment: adverse effects, laboratory values.",2009-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9883,NCT01853319,Progression-Free Survival (PFS),2013-07-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9884,NCT01110798,Major anastomotic leak rate,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],"Bowel function, fecal incontinence, and quality of life, evaluated with validated questionnaires",
9885,NCT03676075,Sensitivity and specificity of the model in the diagnosis of colorectal cancer and adenoma,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9886,NCT05520385,"an association between occurrence of CRC and blood group A+ , O + .",2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],an association between occurrence of CRC and overweight and class І obesity patients,
9887,NCT04704934,Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel,2021-05-21,RECRUITING,INTERVENTIONAL,['PHASE3'],Percentage of Participants Who Have Treatment-emergent ADAs,
9888,NCT05694338,Percent of patients considered frail assessed by Clinical Risk Analysis Index (RAI-C) Scores of 21 or higher,2023-03-13,RECRUITING,OBSERVATIONAL,['NA'],Adverse outcomes after major surgery,
9889,NCT00188110,To evaluate the performances of the WE-CT in patients suspected of having a colon tumor,2003-03,UNKNOWN,INTERVENTIONAL,['NA'],To demonstrate the advantages of the WE-CT compared to the CT and magnetic resonance (MR) colonography for the diagnosis and local staging of colon tumors,
9890,NCT06311396,Omics studies and functional morphological studies,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
9891,NCT04131192,Rate of dose limiting toxicities of each subject,2019-11-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
9892,NCT04177602,Rate of pathological complete remissions (pCR)/Phase 2 part,2019-11-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Rate of perioperative complications,
9893,NCT02954913,Comprehensive Complication Index,2017-02-14,COMPLETED,INTERVENTIONAL,['NA'],Cost Analysis,
9894,NCT04625803,Tumor regression rate of MSS/pMMR patients,2021-01-04,RECRUITING,INTERVENTIONAL,['PHASE2'],mortality rate,
9895,NCT00769782,Recurrence-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Types and severities of adverse events,
9896,NCT05051358,Safety of procedure,2021-02-11,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Cost Effectiveness,
9897,NCT05323409,Instrument to measure Self-Management (IMSM),2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],Supportive Care Needs Survey (SCNS),
9898,NCT00274209,Prevalence of dysplastic lesions by white light vs. chromoendoscopy,2005-12,COMPLETED,OBSERVATIONAL,['NA'],,
9899,NCT02140463,feasibility,2014-02,COMPLETED,OBSERVATIONAL,['NA'],response rate,
9900,NCT04949672,Completeness of mesorectal fascia and specimen quality (specimen integrity after rectal resection),2017-01,COMPLETED,OBSERVATIONAL,['NA'],Cancer specific survival (CSS),
9901,NCT02714374,Number of participants with treatment-related adverse events as defined by CTCAE v4.03.,2016-03-25,TERMINATED,INTERVENTIONAL,['PHASE1'],Amount of lymphocyte infiltration in pre-treatment biopsy and post-treatment resected tumor tissue,
9902,NCT00267020,Overall Survival (OS),2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Experiencing Serious Adverse Events (SAEs) and Adverse Events (AEs) (Toxicity),
9903,NCT03976739,corelation between the bile reflux and gastric mucosa diseases,2019-06-17,COMPLETED,OBSERVATIONAL,['NA'],the risk factors of primary bile reflux gastritis,
9904,NCT04552093,Completion of 2 combined chemotherapy cycles (feasibility),2020-09-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Conversion rate colorectal liver metastases (CRLM),Quality of life assessment
9905,NCT04521491,Recurrence free survival(RFS),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival(OS),
9906,NCT03609268,progression free survival,2018-06-30,UNKNOWN,INTERVENTIONAL,['NA'],overall survival,
9907,NCT02636088,Local tumour Control,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life,
9908,NCT01521104,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
9909,NCT01802203,Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings.,2013-04,COMPLETED,OBSERVATIONAL,['NA'],Collect safety data related to the use of trūFreeze® spray cryotherapy for treatment in the pulmonary and gastrointestinal settings.,
9910,NCT01802320,Overall Response Rate (CR+PR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free Survival (PFS),Validation of the Enrichment Biomarker Signature in Metastatic Sites
9911,NCT02070822,tumor response,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],change of baseline MRI parameters,
9912,NCT04450732,Maximum Tolerated Dose (MTD) or Dose Recommended for Dose Expansion (DRDE),2020-07-07,RECRUITING,INTERVENTIONAL,['PHASE1'],Preliminary Efficacy,
9913,NCT01505972,Participation rate,2011-03,COMPLETED,INTERVENTIONAL,['NA'],Response rate in FOUR&TWO group,
9914,NCT05613621,clinical outcomes of MAFLD vs. non-MAFLD.,2022-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9915,NCT02191566,"3-year recurrence-free survival, RFS",2015-05,TERMINATED,INTERVENTIONAL,['PHASE2'],"5-year overall survival, OS",compliance for chemotherapy
9916,NCT06111326,Phase II: Dose Expansion Part-objective response rate (ORR),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9917,NCT05641896,Positive predictive value will be determined on a per-lesion basis for all lesions with tissue available for FAP analysis.,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Further characterize the safety profile of [18F]FAPI-74 in subjects utilizing Common Terminology Criteria for Adverse Events (CTCAE v5),
9918,NCT01662609,Number of Abnormalities Detected by EUS,2007-08-23,COMPLETED,OBSERVATIONAL,['NA'],,
9919,NCT06260293,Shorts Physical Performance Battery(SPPB),2023-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9920,NCT03841799,Characterization of colorectal tissue microenvironment of patients with locally colorectal neoplasia.,2019-05-02,RECRUITING,OBSERVATIONAL,['NA'],Identification of potential molecular abnormalities in cancer cells from colorectal tissue and from blood samples.,
9921,NCT01876407,Evaluate the effectiveness of using low-intensity laser compared with placebo as preventive and therapeutic intervention of oral mucositis induced by radiation therapy and chemotherapy.,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Assess the intervention tolerance and side effects of it.,
9922,NCT00176735,,2001-12,TERMINATED,INTERVENTIONAL,['NA'],,
9923,NCT05067153,Prothrombin fragment F1+2,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4'],Mortality,
9924,NCT01262040,"Determine the feasibility of Narrow Band Imaging (NBI) at the time of thorascopic, laparoscopic or robotic surgery.",2010-12-14,COMPLETED,INTERVENTIONAL,['NA'],Determine what percentage of patients have surface metastasis identified with NBI that were not seen on white light imaging.,
9925,NCT00625573,"To evaluate the efficacy by means of response rate of Abraxane and capecitabine in combination, in the treatment of patients with colorectal cancer in the 2nd or 3rd line metastatic setting following failure of irinotecan or oxaliplatin based therapy",2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"To evaluate overall survival, time to progression, response duration, time to response and safety of this combination",
9926,NCT06148636,Determine recommended therapeutic dose of [212Pb] VMT-α-NET,2023-11-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Maximum tolerated radiation dose for kidneys,
9927,NCT01456455,HER2 Status,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],Outcome according to HER2 Status,Outcome according to ethnicity of patients
9928,NCT00081289,Pathologic Complete Response Rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Two Years,
9929,NCT02785380,Overall survival,2016-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Recurrence-free survival,Number of Participants With Treatment-Related Adverse Events as Assessed by
9930,NCT06054308,pathologic response,2024-02-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Disease free and overall survival,
9931,NCT01438437,Local tumor response,2001-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],Change from baseline in Child status at 1 year,
9932,NCT04454476,Safety of Trametinib treatment: adverse events,2022-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
9933,NCT06006923,"Progression-free Survival (PFS), Randomize Phase",2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Objective Response Rate (ORR), Randomized Phase",
9934,NCT03111823,Total number of minutes exercised per week with >80% total weekly minutes (48/60 minutes) completed,2016-07-07,TERMINATED,INTERVENTIONAL,['NA'],Change in QOL,Change in endothelial function
9935,NCT04486651,Overall Survival (OS) in Participants With PD-L1 CPS≥1,2020-09-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),
9936,NCT05145647,To estimate the local control rate at primary tumor site,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Treatment toxicity grading according to the CTCAE,Overall survival (OS)
9937,NCT04195373,Determine MTD and dose for phase II,2020-11-23,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Efficacy of therapy assessed by changes in tumor marker level,
9938,NCT01998152,Change in skeletal muscle area (cm2) between individualized nutritional counselling versus usual nutritional care,2013-11,COMPLETED,INTERVENTIONAL,['NA'],"Associations of (changes in) muscle area with (changes in) mid-upper arm muscle circumference, whole body fat free mass (BIA) and whole body lean body mass (DEXA).",
9939,NCT03563326,EpCAM CAR-T cells treatment related adverse events,2018-08-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],Progress free survival outcome,
9940,NCT00005030,,1999-09-29,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
9941,NCT01915225,"Collection of biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets",2013-07-21,RECRUITING,OBSERVATIONAL,['NA'],"Collection of detailed history, demographic, treatment data, and perioperative outcomes data related to surgical quality and safety in order to categorize and track the specific procedures.",
9942,NCT04768218,To externally validate the EGGIM score classification using BLI,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
9943,NCT01032967,Overall survival and disease-free survival,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of life and function outcomes,
9944,NCT00997685,To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],To evaluate the safety profile of XELOX peri-operative treatment,
9945,NCT01198548,Rate of Sufficient Cholecalciferol,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],PFS of Patients Receiving Study Treatment,
9946,NCT03542877,12-Week Progression Free Survival,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS) by PIK3CA Mutation Status,
9947,NCT04868227,GENE EXPRESSION CHANGE,2014-03-28,COMPLETED,INTERVENTIONAL,['NA'],VITAMIN D STATUS CHANGE,
9948,NCT02958163,Objective response rate at 6 months,2017-02-20,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall response rate based on the MRI evaluation in Child Pugh B7 patients,MRI description of tumors at the hepatobiliary phase at 6 months after treatment
9949,NCT03348241,The effect of Gum Arabic to prevent Chemotherapy-induced Oral Mucositis was the primary outcome that assessed using World Health Organization Mucositis Scoring.,2015-10-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9950,NCT05156788,R0 resection rate,2021-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],RFS,
9951,NCT00125021,To assess the response rate associated with capecitabine and OSI-774 in patients with advanced pancreatic cancer,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],to estimate the time to progression and overall survival of patients with advanced pancreatic cancer treated with capecitabine and OSI-774,
9952,NCT03604991,Disease-free survival (DFS) (Step 2),2019-05-03,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",DFS,Percent change in mean volumetric apparent diffusion coefficient (ADC)
9953,NCT05225844,progression-free survival（PFS）,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease control rate(DCR),
9954,NCT02705651,Growth rate of the tumor in mm,2019-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Documentation of lymph node and/or distant metastases,
9955,NCT04001101,Out-of-field ORR improvement,2019-10-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Quality of life score,
9956,NCT05583292,rate of mortality,2023-02-11,COMPLETED,OBSERVATIONAL,['NA'],,
9957,NCT00054912,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9958,NCT00361231,Median Progression Free Survival,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Response Rate,
9959,NCT01099527,To assess response rate in phase II,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9960,NCT02350166,30-day complications,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],C-reactive protein,
9961,NCT01188109,Recurrence-free Survival as Measured by CT Scan,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Immunohistochemistry to Determine Status of Excision Repair Cross Complementation Gene-1 (ERCC1) Expression,
9962,NCT05718882,Progression free survival,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],Safety endpoint,
9963,NCT00053924,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9964,NCT02235324,Progression-free survival during the second phase of the study,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of adverse events graded according to NCI CTCAE version 4.0,"mRNA level of VEGFR1, VEGFR2, and VEGF-A"
9965,NCT01652196,Proportion of patients alive and progression-free,2012-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],Proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial,
9966,NCT03757455,Days until discharge from university hospital,2020-09-01,TERMINATED,INTERVENTIONAL,['NA'],Readmission frequency,
9967,NCT05305001,BRCA 1/2 germline mutation prevalence,2020-09-09,COMPLETED,OBSERVATIONAL,['NA'],Clinical and pathological characteristics,The proportion of germline mutation carriers who accept pancreatic cancer surveillance.
9968,NCT05049317,Incidence of urinary dysfunction,2021-11-24,RECRUITING,INTERVENTIONAL,['NA'],Incidence of urinary dysfunction,
9969,NCT00502177,PedsQL 4.0 Generic Core Scale,2007-06-19,COMPLETED,OBSERVATIONAL,['NA'],,
9970,NCT00695227,The primary aim of the study is to establish that patients with symptoms of LPR who are referred to an otolaryngology clinic have a prevalence of Barrett's metaplasia equivalent to that of a population with GERD symptoms.,2004-05,COMPLETED,INTERVENTIONAL,['NA'],,
9971,NCT05449847,Relation between MicroRNA and HCV,2021-05-13,COMPLETED,OBSERVATIONAL,['NA'],,
9972,NCT01409005,8-weeks progression free survival rate (PFS rate),2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Patients with Adverse Events,
9973,NCT03579199,Histological analysis of explanted liver parts,2019-03-18,UNKNOWN,INTERVENTIONAL,['NA'],bilirubin and prothrombin levels,
9974,NCT01721941,Maximum tolerated dose of TH-302 use in TACE,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],Objective response rate,
9975,NCT05314946,Feasibility of the trial,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Post-operative mortality,
9976,NCT04727151,Phase 2: Evaluate Progression-Free survival (PFS) or Time to progression (TTP),2021-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1 and Phase 2: Cytokine level detection,
9977,NCT00342472,PAH exposure,1998-02-12,COMPLETED,OBSERVATIONAL,['NA'],,
9978,NCT04397601,Overall Survival (OS).,2020-05-11,RECRUITING,OBSERVATIONAL,['NA'],Progression-free survival (PFS).,Serum level of PlGF (Placental Growth Factor).
9979,NCT02012699,Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC),2013-11-01,RECRUITING,OBSERVATIONAL,['NA'],Procurement and banking of excess biological material for future analysis,"Collection and banking of blood, DNA, and urine samples for future analysis that will be proposed in future studies"
9980,NCT04294160,Dose intensity,2020-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments,
9981,NCT01047293,"Evaluate Safety of the Combination at a Daily Dosing of 2.5mg RAD001, 5 mg RAD001 or 10 mg RAD001 (Phase 1 Part)",2010-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9982,NCT00822991,Size of HCC which is detected first,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],The improvement of prognosis of patients who are diagnosed in this study,
9983,NCT05992584,Progression free survival (PFS) according to mRECIST,2023-08-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events (AEs),
9984,NCT06079229,Evolution in the ADL questionnaire score between pre-operative and post-operative 3 to 30 months after surgery.,2023-11-06,RECRUITING,OBSERVATIONAL,['NA'],,
9985,NCT02702986,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Disease specific survival (DSS),
9986,NCT02384759,Radiological progression-free survival according to the investigator,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],progression-free survival,
9987,NCT03959774,demonstrate that the adherence rate of digital follow-up is greater than 70% in a population of elderly patients.,2020-12-30,UNKNOWN,INTERVENTIONAL,['NA'],,
9988,NCT03653052,Clinical response to therapy (durvalumab),2018-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Ex-vivo effect of compounds on tumour/cell models
9989,NCT00021320,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9990,NCT04798781,Progression-free survival,2021-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence and severity of adverse events,
9991,NCT03229096,Objective response rate (ORR),2017-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],3-year overall survival rate,
9992,NCT06050447,Mortality rate,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],Recurrence-free survival,
9993,NCT00940303,Progression-free survival,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],"Proportion of patients with NCI-CTC grade 3-5 adverse events; adverse events, laboratory parameters, ECOG performance status.",
9994,NCT03797326,Percentage of Participants Receiving Lenvatinib Monotherapy who Discontinue Study Treatment Due to an Adverse Event (AE),2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Plasma Concentration of Lenvatinib,
9995,NCT03099564,Progression free survival (PFS),2017-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Estimate overall survival (OS),
9996,NCT04295811,Primary Efficacy,2020-06-18,RECRUITING,INTERVENTIONAL,['NA'],Secondary Efficacy,"Safety outcome of EsoCheck Device (510k cleared, non-invasive, esophageal cell collection device) on all patients who undergo the device procedure."
9997,NCT06269341,Overall Survival,2010-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
9998,NCT01487343,adherence to oral chemotherapy,2011-11,COMPLETED,OBSERVATIONAL,['NA'],improve the care of patients,
9999,NCT02319928,Colorectal cancer incidence,2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
10000,NCT05610904,Accuracy of stoma implementation,2022-12-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Rate of stoma reverse,
10001,NCT00108953,Time to Progression (TTP),2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants for Whom Disease Control Was Achieved,
10002,NCT05158621,Primary,2021-12-14,COMPLETED,OBSERVATIONAL,['NA'],,
10003,NCT00626639,Pharmacokinetics of Palifermin,2005-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
10004,NCT05038813,Objective Response Rate(ORR),2022-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival(OS),
10005,NCT04151394,Overall survival,2019-01-31,COMPLETED,OBSERVATIONAL,['NA'],,
10006,NCT01314027,Progression-free survival,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3'],feasibility of adjuvant chemotherapy,
10007,NCT06227325,pathological complete response (pCR) rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of Participants who experience one or more adverse events (AEs).,
10008,NCT05975749,Disease-free survival,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Side effects,
10009,NCT01402089,Steady-state partial area-under the plasma concentration-time curve over 24 hours (AUC24h) of sunitinib and erlotinib and CYP3A4/1A2-phenotype activity as defined in the protocol,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],"Concentrations of Sunitinib, Erlotinib and probe drugs (Midazolam, Caffeine) in whole blood, sampled from patient's dried blood spots (DBS)",
10010,NCT02821559,Evolution of Raltitrexed plasma levels,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival (OS),
10011,NCT04877340,Compare the diagnostic yield,2020-11-26,UNKNOWN,INTERVENTIONAL,['NA'],adverse event rate,
10012,NCT02836977,Disease free survival,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,
10013,NCT04167436,Changes in immunological function,2019-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Remission and cancer free survival,
10014,NCT02274753,Relapse in relation with the immunoscore determined on a tumor section and criteria defined in the monitoring of patients,2015-03-11,UNKNOWN,OBSERVATIONAL,['NA'],Relapse in relation with the immunoscore on biopsies,
10015,NCT06168812,Change in mean interstitial glucose level for Cohort 1 participants before and after initiation of glipizide,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10016,NCT05291156,OS,2022-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of treatment-related adverse events as assessed by CTCAE v5.0,
10017,NCT01091558,"L-Arginine (L-Arg) availability in ulcerative colitis (UC) patients and normal control subjects, and correlate with disease activity",2009-09,COMPLETED,OBSERVATIONAL,['NA'],L-Arg intake in the diet of UC patients and control subjects,
10018,NCT05640830,Progression-free survival,2023-01-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10019,NCT01611506,Dose limiting toxicity,2012-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Toxicity (according to NCI-CTCAE, Version 4.0)",
10020,NCT00474903,Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,
10021,NCT02909114,local control assessed by RECIST,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,
10022,NCT02836535,Number of complications,2016-07,COMPLETED,OBSERVATIONAL,['NA'],,
10023,NCT00911196,Expression of c-MET in the same hepatocellular carcinoma tumor samples,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
10024,NCT02326948,Number of participants with alcohol consumption,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with polypoid lesions of gallbladder
10025,NCT00507598,"•Perform metabolic profiling of tissue,serum & urine from pts w/ colorectal cancer (stages I-IV), healthy controls & pts w/ colorectal polyps & correlate results.",2007-07,COMPLETED,OBSERVATIONAL,['NA'],"Correlate changes of serum & urine biomarkers /p trt to predict response or toxicity,& correlate w/other treatment outcomes. Compare the metabolic profile between pts w/various stages of colorectal cancer.",
10026,NCT00033319,,1997-05,UNKNOWN,INTERVENTIONAL,['NA'],,
10027,NCT03819387,Number of patients with treatment-related adverse events as assessed by CTCAE v5.0,2019-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Additional pharmacokinetic parameters for siRNA,To evaluate correlation between KRAS mutations and clinical outcome
10028,NCT02274012,Change of tumor burden (in centimeters) for participants during protocol therapy,2014-05-29,WITHDRAWN,INTERVENTIONAL,['PHASE2'],ErbB2 levels benefit during therapy.,
10029,NCT02958059,Rate of complication that related with infection.,2016-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Grade of post-ERCP infectious complication,
10030,NCT00966251,To assess the safety and tolerability of CT-011 in patients with Primary Hepatocellular Carcinoma,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10031,NCT02630004,Number (percentage) of patients who develop severe oral mucositis (grade 3-4 according to the RTOG scale),2015-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacokinetics evaluation [Clearance],Number (percentage) of patients with progression disease using the RECIST 1.1 criteria
10032,NCT05732389,Complete clinical response,2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in Quality of life (EORCT QLQ-CR29),
10033,NCT03722875,Overall survival(OS),2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10034,NCT01933958,Number of Patients with serious adverse drug reactions (SADRs) from the first administration of Regorafenib,2013-09-04,COMPLETED,OBSERVATIONAL,['NA'],Integration analysis for safety in drug use investigations (DUIs) for both colorectal cancer and gastrointestinal stromal tumor.,
10035,NCT03872908,Cohort 2: Efficacy of compression induced by surgical gloves vs peripheral neuropathies development in patients treated by oxaliplatine after a cumulative dose of 595 mg/m2,2019-09-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Cohort 2: Evaluation of the peripheral neuropathies percentage for each hand,
10036,NCT01367275,Number of Participants With Median Progression-Free Survival (PFS),2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10037,NCT02874885,Change in circulating tumor cells status,2013-09-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10038,NCT04233151,Progression-free Survival（PFS）,2020-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10039,NCT04222413,To determine the Objective Response Rate (ORR) according to Evaluation Criteria (RECIST 1.1) in patients treated with metarrestin at the MTD,2020-10-27,RECRUITING,INTERVENTIONAL,['PHASE1'],To assess safety and tolerability of metarrestin in subjects with metastatic solid tumors,
10040,NCT00452205,,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],,
10041,NCT04171141,Objective Response - Number of Participants With Objective Response for Dose Expansion (Part 2),2019-11-19,TERMINATED,INTERVENTIONAL,['PHASE1'],Change from baseline of immune cells from tumor biopsies,
10042,NCT06329869,Overall objective response rates (ORR),2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Biomarkers-related endpoints
10043,NCT01624363,Prevalence of Pancreatic Cysts During Routine EUS,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,
10044,NCT02953743,Mean area under the concentration-time curve over the dosing interval on multiple dosing (AUC(0-τ)),2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs),
10045,NCT02364154,metabolic phenotype of colorectal cancer,2014-12,COMPLETED,OBSERVATIONAL,['NA'],tumor stage,
10046,NCT03630068,Recurrence-free survival,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],Clinical and radiological complications,
10047,NCT05908916,Progression-free survival,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10048,NCT00672828,Self-reported colorectal cancer (CRC) screening adherence with medical record verification of screening test completion,2008-01,COMPLETED,INTERVENTIONAL,['NA'],Self-reported stage of CRC screening test adoption,Clinic variables as CRC screening predictors
10049,NCT05114798,Weight change (% kg),2022-05-17,RECRUITING,INTERVENTIONAL,['NA'],Saliva microbiota,
10050,NCT05228743,R0 resection rate,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA'],1 year overall survival,
10051,NCT04734249,Objective response rate (ORR),2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Assess the anti-tumor activity:DCR,
10052,NCT05989789,Procedure-Safety (No residual source of radiation),2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],Number of patients without side effects,
10053,NCT05759741,Wexner incontinence score,2023-01-17,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Rate of postoperative complications,
10054,NCT00003486,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
10055,NCT00168155,disease free survival,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10056,NCT02020928,Incidence of Oral Mucositis,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Degree of mucositis,
10057,NCT00958737,Disease-free survival (DFS),2009-05-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Treatment compliance,
10058,NCT02561546,glycosylated hemoglobin (A1C),2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],postprandial glucose (PPG),
10059,NCT05293041,Blood loss,2022-03-27,RECRUITING,INTERVENTIONAL,['PHASE4'],I-FABP (change in organ damage markers),
10060,NCT03707574,Obtaining tumor tissue and blood specimens,2019-04-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Genomic analysis,
10061,NCT03693677,The progression free survival at 6 months according to the RECIST 1.1 criteria,2018-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment safety,
10062,NCT01574677,Performance characteristics of the Septin 9 biomarker among patients who have a positive FIT result,2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],Concordance and discordance (Kappa scores) between Septin 9 test results and colonoscopy findings associated with specific medication use practices.,
10063,NCT00031941,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10064,NCT02587689,Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR T cells,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10065,NCT00613665,Safety measures: injection site and systemic reactions,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Immunogencity measures: antigen-specific antibodies and cellular immune response,
10066,NCT05528952,objective response rate (ORR),2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],disease control rate (DCR),
10067,NCT03962478,6-month survival rate,2019-05-31,COMPLETED,INTERVENTIONAL,['NA'],Stent dysfunction free survival,
10068,NCT01200121,paracentesis-free survival (ParFS),2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in laboratory values and vital signs.,
10069,NCT02163785,Assessment of the circumferential resection margin,2014-06,TERMINATED,INTERVENTIONAL,['NA'],Histopathological quality of surgical specimen,Morbidity of the perineal incision.
10070,NCT04242199,Number of treatment-emergent adverse events,2020-09-04,RECRUITING,INTERVENTIONAL,['PHASE1'],Vz/F of INCB099280,
10071,NCT00427713,Disease-free survival at 3 years,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Toxicity,
10072,NCT02768428,knowledge about TACE (A 40-item exam is performed to test the patients' knowledge),2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,
10073,NCT00043199,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10074,NCT06261008,adherence rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],qualitative factors associated with repeat FIT adherence,
10075,NCT05007613,Overall response rate,2021-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety,
10076,NCT03039322,Golgi protein correlated with presence of HCC,2014-12-22,COMPLETED,OBSERVATIONAL,['NA'],,
10077,NCT04034459,Overall Response Rate (ORR),2016-11-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],
10078,NCT05308732,Maximum tolerated dose,2021-05-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of Oral Mucositis,
10079,NCT02459652,R0 resection rate,2012-12-28,COMPLETED,INTERVENTIONAL,['PHASE2'],R0 resection rate in borderline resectable pancreatic cancer,
10080,NCT05635929,"Quality of life evaluation of radiotherapy, with or without chemotherapy, long-term symptoms (6 months) after 1 month of use of the tested composition in head & neck cancer patients.",2022-10-11,COMPLETED,INTERVENTIONAL,['NA'],Comparison between oral mucositis severity in patients receiving radiotherapy with patients receiving radiotherapy plus chemotherapy.,
10081,NCT01099085,Progression free survival of XP ± simvastatin,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10082,NCT00753675,Progression Free Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
10083,NCT00160030,Percentage of patients having completed the full treatment and Endoscopic complete response rate,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity profile (NCI-CTC).,
10084,NCT03903185,Measurement of the pharmacokinetics of LDV\SOF,2019-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Measurement of the number of participants with sustained virological response (SVR12), 12 weeks after discontinuation of therapy with ledipasvir-sofosbuvir (LDV-SOF).",
10085,NCT01326000,Progression-free survival: tumour assessments by CT scan or MRI according to RECIST criteria,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect of concomitant FOLFIRI on pharmacokinetics of RO5083945 and vice versa,
10086,NCT05644249,Objective tumor response according to RECIST v 1.1 after second PIPAC,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],Adverse events of chemotherapy drugs,
10087,NCT03027401,Identify incidental and secondary findings in germline DNA and actionable somatic mutations for reporting clinical results from a CLIA-certified lab into CRIS medical records.,2017-01-10,WITHDRAWN,OBSERVATIONAL,['NA'],Assessment of effects of the informed consent process,
10088,NCT05875402,Adverse Events (AE),2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
10089,NCT05340569,Unexpected abortion,2022-03-28,RECRUITING,INTERVENTIONAL,['NA'],Early distant recurrence,
10090,NCT05535998,Progression-free survival,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],Conversion rate,
10091,NCT02582918,Patient satisfaction and acceptability,2018-03-26,COMPLETED,INTERVENTIONAL,['NA'],Repeat Screening,
10092,NCT02489916,Number of participants with Adverse Events,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression Free Survival,Area under the plasma concentration versus time curve (AUC)
10093,NCT04913233,Colorectal cancer screening sensitivity,2021-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
10094,NCT00041262,Survival,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life,
10095,NCT03368131,The pathological complete response rate(pCR),2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events,
10096,NCT04484311,Residual neoplasia,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10097,NCT02301962,Number of subjects with adverse event.,2015-07-28,UNKNOWN,INTERVENTIONAL,['PHASE4'],Duration of response.,
10098,NCT04095195,"This clinical study will assess the diagnostic yield of a clinical surveillance program for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals",2019-08-20,RECRUITING,OBSERVATIONAL,['NA'],"This study will investigate possible risk factors for the incidence or the progression of for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals",
10099,NCT03029793,Pathologic Response,2016-05,UNKNOWN,OBSERVATIONAL,['NA'],Overall Survival,
10100,NCT04798820,Change from preoperative weight change at postoperaive 18 months in SE and IE groups.,2021-03-09,RECRUITING,INTERVENTIONAL,['NA'],Quality of life of the patients,
10101,NCT05427227,Tumor associated proteins expression level of exosomes,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
10102,NCT04602611,Overall Survival,2020-11-03,COMPLETED,INTERVENTIONAL,['NA'],Oncology Nurse Navigation Comparison for Satisfaction,Oncology Nurse Navigation Provider Comparison for Outcomes
10103,NCT00002711,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10104,NCT03200834,5-year survival,2017-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Disease free survival 5 years after initial surgery,
10105,NCT00077545,Objective response rate (CR + PR),2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of improvement of dysphagia,
10106,NCT05125094,Overall Survival,2021-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],tumor response,
10107,NCT03457844,Progression Free Survival(PFS),2018-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease Control Rate(DCR),
10108,NCT05132244,Frequency of glucose levels maintained within range in Arm 1 compared to Arm 2,2024-02,RECRUITING,INTERVENTIONAL,['NA'],Overall survival (OS) in each study arm from the initiation of FOLFIRINOX,"Amount of circulating biomarkers, measured in molar, for participants in each study arm from screening until the end of study visit"
10109,NCT01395459,Change in population level cancer screening level at the health clinics involved.,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,For the substudy: return rate of gFOBT kits vs. FITs
10110,NCT00882310,Number of Subjects Who Experience Dose Limiting Toxicities (DLTs),2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Score on FACT-Hep (Version 4),
10111,NCT01087268,Gastrointestinal symptoms score using the IBDQ quality-of-life questionnaire,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Health economics data,
10112,NCT00910143,"Local recurrence, recurrence-free survival, overall survival",1993-01,COMPLETED,OBSERVATIONAL,['NA'],Percentage of patients undergoing transcatheter arterial embolisation,
10113,NCT05953961,Disease Progression,2023-08-08,RECRUITING,INTERVENTIONAL,['NA'],Duration of Response,
10114,NCT05569668,OS(overall survival),2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],DFS(disease-free survival),
10115,NCT04157322,clinically detectable recurrence at 1 year after surgery.,2019-08-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10116,NCT01858805,overall survival,2010-04,COMPLETED,OBSERVATIONAL,['NA'],recurrence-free survival,
10117,NCT01476592,Notch1 activation in post-treatment tumor biopsy specimens when compared to pretreatment levels,2011-12,COMPLETED,INTERVENTIONAL,['NA'],Describe the effect of resveratrol on tumor growth as demonstrated by standard cross sectional imaging and tumor markers.,
10118,NCT03046745,Prediction of risk factors for gastric cancer and definition of optimal endoscopic screening interval,2016-08,UNKNOWN,OBSERVATIONAL,['NA'],Reservation of frozen serum for novel gastric cancer serologic marker analysis,
10119,NCT00004547,Number of Participants With Adverse Events,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Signal Transduction Pathways in Tumor Tissue Versus Normal Tissue,
10120,NCT04807673,Event Free Survival (EFS),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life differences (EORTC QLQ-OES18),
10121,NCT01423799,"Quality of Life (QOL), measured with the EORTC QLQ-C30",2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],QOL assessed by the EORTC QLQ-OG 25,
10122,NCT00819754,"Phase II: Using the RD established in phase I, assess efficacy of the IXO with bevacizumab combination as measured by progression-free survival",2003-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Qualitative and quantitative toxicity,
10123,NCT02246153,Postoperative complication rate,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],Postoperative recovery index,
10124,NCT01047618,To evaluate the incidence of VTE in advanced gastric cancer with chemotherapy and to identify risk factors and biomarkers for VTE in this population,2009-12,COMPLETED,OBSERVATIONAL,['NA'],To investigate the significant impact of VTE on overall survival and in this population,
10125,NCT01486134,Rate of complete ablation one month after one RFA procedure,2012-06-20,TERMINATED,INTERVENTIONAL,['NA'],Agreement of 2D and 3D measurements of ablations zones on IRMT° images and those measured on conventional magnitude MR images.,
10126,NCT03550885,Change in the mucosal abundance of bacterial genes associated with sulfur and bile acid metabolism,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in colonocyte proliferation,
10127,NCT00942383,Comparison of transverse ablation diameter between intraoperative ultrasound elasticity imaging (USEI) and postoperative cross-sectional imaging (CT or MRI).,2007-09,TERMINATED,OBSERVATIONAL,['NA'],Feasibility of image processing and image segmentation using this clinical free-hand system.,
10128,NCT05845268,cCR rate,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],immune-related adverse event rate,
10129,NCT05420909,Duration of Systemic Treatment,2019-01-28,COMPLETED,OBSERVATIONAL,['NA'],,
10130,NCT00375024,Questionnaire Results Regarding Time to Diagnosis,2007-05,COMPLETED,INTERVENTIONAL,['NA'],Questionnaire Results Regarding Patient Navigators,
10131,NCT01790425,Cecal intubation,2011-08,COMPLETED,INTERVENTIONAL,['NA'],Amount of opiate and benzodiazepines used for sedation.,Patient discomfort Patient pain rating during and after procedure
10132,NCT02682394,Blood levels of free DNA,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,
10133,NCT00909402,"Use National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) to establish the MTD, Dose Limiting Toxicity (DLT(s)) and safety profile of BMS-833923 administered in combination with Cisplatin and Capecitabine",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],The pharmacokinetic parameters that will be assessed include: AUC(TAU) (Area under the concentration-time curve in one dosing interval),
10134,NCT01329809,Delivery to and replication within tumors,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicity: Grade I-IV Adverse Events (according to CTCAE),
10135,NCT04936581,Vaizey score,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],Postoperative complications,
10136,NCT03361150,Oxygen consumption (VO2),2016-01,COMPLETED,INTERVENTIONAL,['NA'],Hospital Anxiety and Depression Scale (HADS) score,
10137,NCT03585166,"The survival rate of primary liver cancer treated by laparoscopic hepatectomy and laparoscopic hepatectomy,Telephone pays a return visit",2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],Comparison between laparoscopic hepatectomy and laparoscopic hepatectomy in primary hepatocellular carcinoma Unit: times,
10138,NCT00553813,Survival,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Evaluate the gene expression profile in relation to clinical outcomes,
10139,NCT01658813,Progression Free Survival,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Survival,
10140,NCT01270698,Safety,2011-05,COMPLETED,INTERVENTIONAL,['PHASE1'],efficacy,
10141,NCT01198392,Time to progression,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],Response rate,
10142,NCT01735968,Characteristics of dose limiting toxicities (DLTs),2013-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],Effect of basic PK parameter: CL/F,
10143,NCT00373347,Identify new blood markers of liver cancer,2004-11,RECRUITING,OBSERVATIONAL,['NA'],,
10144,NCT05417230,ORR,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],AEs,ctDNA
10145,NCT02499783,Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4,2015-08-17,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in Fecal Calprotectin Level Over Time (Any Adalimumab Set),
10146,NCT05541445,Major pathologic response,2022-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
10147,NCT03981679,AUC,2018-06-05,COMPLETED,INTERVENTIONAL,['NA'],Intplex parameters,
10148,NCT04130399,Local control rate among PDAC patients treated with neoadjuvant chemotherapy followed by SBRT,2019-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Rate of grade 3-4 non hematological toxicity rates,
10149,NCT01478373,Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],DCR (CR+PR+SD) at the End of Treatment,
10150,NCT00173277,,2003-06,UNKNOWN,OBSERVATIONAL,['NA'],,
10151,NCT04223635,Volume of Distribution in the Terminal Phase (Vz/F) Following a Single Dose in Participants With Moderate Hepatic Impairment Compared to Healthy Participants,2020-01-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Number of Participants Reporting Treatment-Emergent Adverse Events (TEAE) by System Organ Class and Preferred Term Following a Single Dose of Pexidartinib in Participants With Moderate Hepatic Impairment Compared to Healthy Participants,
10152,NCT02591082,Survival,2015-12,COMPLETED,OBSERVATIONAL,['NA'],Tumor response,
10153,NCT05541601,Positive/Negative predictive values of novel diagnostic approaches for the early diagnosis of HCC in enrolled patients who are diagnosed with HCC by conventional approaches.,2022-02-23,RECRUITING,OBSERVATIONAL,['NA'],To better understand the incidence of HCC in a UK population stratified by underlying cirrhosis aetiology,
10154,NCT04198051,The change of concentration of P-hydroxyphenylalanine metabolites in urine during chemotherapy,2019-12-20,UNKNOWN,INTERVENTIONAL,['NA'],The change of the number of tumor necrosis factor(TNF)-α in blood during chemotherapy,
10155,NCT05620706,AE/SAE,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],ORR,
10156,NCT04899739,Rate of lymph nodes wrongly categorised by ultrasound endoscopy. (Specificity),2021-12-05,RECRUITING,INTERVENTIONAL,['NA'],Development of an algorithm capable of characterizing lymph nodes metastases by the mean of artificial intelligence,
10157,NCT00004258,To evaluate the safety and tolerability of escalating doses of twice weekly EMD 121974 in patients with cancer.,1999-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10158,NCT04801355,R1 resection rate,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],The incidence and structure of postoperative complications,
10159,NCT00798447,reduction of pro inflammatory activity,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10160,NCT05971108,Stage of hepatocellular carcinoma at diagnosis,2024-01-08,RECRUITING,INTERVENTIONAL,['NA'],Survival rates,
10161,NCT06186700,The incidence of mucositis in the two groups using WHO grading of oral mucositis,2023-12-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],The incidence of adverse effects,
10162,NCT04707560,Quantification of tissue quality,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Diagnostic performance between different suction method,Complication
10163,NCT01762254,pain score,2009-06,COMPLETED,INTERVENTIONAL,['NA'],wound complication,length of hospital stay
10164,NCT00858338,toxicity of IP FUDR after surgery prior to chemoradiation,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],"Time to relapse, disease specific survival",
10165,NCT00503035,13-HODE Colonic Tissue Levels,2003-08-20,COMPLETED,INTERVENTIONAL,['PHASE2'],PGE2 Colonic Tissue Levels,
10166,NCT02694536,Percentage of Participants With Adverse Events (AEs),2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression-Free Survival (PFS) According to RECIST,
10167,NCT03917966,Major pathological response（MPR）,2020-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],R0 resection rate,
10168,NCT01490866,Progression-free Survival,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency of Adverse Events as a Measure of Safety,
10169,NCT00310076,Time to Progression,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Events of Toxicity Graded 3 and 4,
10170,NCT01671683,,2010-07,COMPLETED,OBSERVATIONAL,['NA'],,
10171,NCT02951091,progression free survival,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10172,NCT03974672,Measuring severity of complications with the Dindo Clavien complications scale,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10173,NCT01863862,The final three-year rate of local and distant recurrences taking into consideration results of rescue surgery for pelvic recurrence.,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],Multivariable analysis of prognostic factors associated with clinical complete response.,
10174,NCT03350412,Thoroughness to report molecular profiling,2015-10,UNKNOWN,OBSERVATIONAL,['NA'],Percentage of complete data capture for treatment-related check-point events,
10175,NCT02278133,Overall response rate in phase II,2014-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of participants with dose interruptions and dose reductions (phase Ib/II),
10176,NCT03583528,Sensitivity of 68Ga-DOTATOC PET/CT in the diagnosis of SSTR positive tumors.,2018-07-11,RECRUITING,OBSERVATIONAL,['NA'],Total number of lesions per anatomic location identified by 68Ga-DOTATOC PET/CT,
10177,NCT02788669,LRP1 molecular expression,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,
10178,NCT01333475,pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced Colorectal Cancer,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events,
10179,NCT06316401,Safety of ESD under SA,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],Median ESD duration,
10180,NCT00427492,Time to defecation after colonic resection,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
10181,NCT02117466,Clinical Benefit Rate,2014-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life (QoL) and health related QoL,
10182,NCT04319302,Bile drainage,2005-01,COMPLETED,OBSERVATIONAL,['NA'],Complications of procedure,Complications
10183,NCT04194775,Overall survival (OS),2019-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],"Time to deterioration (TTD), defined as the time from randomization to the first deterioration of European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) scale",
10184,NCT03558048,Relationship between IBD and PSA,2019-08-01,RECRUITING,OBSERVATIONAL,['NA'],Location of disease,
10185,NCT02468076,Feasibility (ratio of technically successful RFA-applications to all examinations in which RFA-use was intended),2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],safety (number and type of adverse events),
10186,NCT05426850,Relationship between ctDNA status after chemoradiotherapy and relapse.,2021-06-01,RECRUITING,OBSERVATIONAL,['NA'],"Relationships between radiomics features, ctDNA status and relapse.",
10187,NCT04813627,Occurrence of ctDNA positivity in the first post-AdCTx blood sample,2021-07-02,RECRUITING,OBSERVATIONAL,['NA'],Transfer of participants from the BNT000-001 study to the BNT122-01 clinical trial,
10188,NCT00385177,Pharmacokinetic parameters for SN2310 and SN-38,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10189,NCT03323944,Number of study subjects with treatment-related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03,2017-09-15,RECRUITING,INTERVENTIONAL,['PHASE1'],Objective response rate,
10190,NCT05721300,Incidence of early liver cancer,2023-02-10,RECRUITING,INTERVENTIONAL,['NA'],,
10191,NCT02864043,Performance of manually identified VLE features in predicting biopsy defined dysplasia,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],Per Biopsy performance of VLE compared to standard-of-care for detecting dysplasia,
10192,NCT05692037,Progression Free Survival Rate of Liver Target Lesions,2022-12-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease control rate (DCR),
10193,NCT00823810,Survival,2008-12,TERMINATED,INTERVENTIONAL,['NA'],Time to progression,
10194,NCT03113955,Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging),2017-10-24,COMPLETED,INTERVENTIONAL,['NA'],Kaplan-Meier Analyses the Percent of Participants for Time to Extrahepatic Spread,
10195,NCT01600196,Survival time,2006-01,TERMINATED,INTERVENTIONAL,['PHASE4'],Number of Adverse Events,
10196,NCT02911363,Histological quality of the EMR specimen obtained during the procedure will be analyzed and compared to cassette vs. no cassette for pathology review.,2016-01,COMPLETED,INTERVENTIONAL,['NA'],Ease of use of the Captivator tissue cassette will be comparable to Standard of Care.,
10197,NCT04202601,Arms 3:≥second-line therapy group,2019-12-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Arms 3:≥second-line therapy group,
10198,NCT02511223,Objective Response Rate (ORR) by using RECIST 1.1,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10199,NCT01629004,Uptake of appropriate CRC screening,2011-04,COMPLETED,INTERVENTIONAL,['NA'],Uptake of lower gastrointestinal investigations,
10200,NCT04291976,detection rate of neoplasia for each technique,2020-03-13,COMPLETED,INTERVENTIONAL,['NA'],Size of the lesion in mm,
10201,NCT06278701,Albumin rising,2023-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Improved quality of life,
10202,NCT01333033,Complete Pathological Response (pCR) of PET/CT Non-responders,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS) Among PET/CT Non-responders Within Each Induction Treatment Group,
10203,NCT05193253,Disease-free survival (DFS).,2000-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
10204,NCT04518579,anti tumour immunity,2018-04-15,COMPLETED,INTERVENTIONAL,['NA'],change in pain intensity,
10205,NCT02835924,Percentage of patients with G3/G4 treatment-related AEs in each arm according to CTCAE v4.03 criteria.,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
10206,NCT06305728,Sensitivity of ImmunoPET to identify presence or absence of adenocarcinoma,2024-03-04,RECRUITING,OBSERVATIONAL,['NA'],,
10207,NCT05093608,Maximum Tolerated Dose,2021-11-03,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall Survival,
10208,NCT00471965,Overall survival,2007-03,COMPLETED,INTERVENTIONAL,['PHASE3'],"Response rate, secondary resection rate, quality of life",
10209,NCT03291951,Number of moderate and severe chemotherapy-associated toxicities,2018-02-23,COMPLETED,INTERVENTIONAL,['NA'],,
10210,NCT00014079,Determine the clinical and pathologic significance of unstable DNA elements,1997-09,COMPLETED,OBSERVATIONAL,['NA'],Determine the clinical and pathologic significance of loss of heterozygosity,
10211,NCT06310902,Bioinformatics analysis of single-cell sequencing results,2024-03-01,RECRUITING,OBSERVATIONAL,['NA'],,
10212,NCT00499395,Sensitivity and specificity of fludeoxyglucose F 18 (FDG)-PET imaging in early diagnosis of residual disease,2005-07,COMPLETED,INTERVENTIONAL,['NA'],Findings on day 7 after RFA using FDG-PET imaging,
10213,NCT00008398,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10214,NCT03740360,Mutations in pancreatic cystic neoplasm,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],Relation between pancreatic fluid and serum molecular analysis,
10215,NCT01383746,Progression -free survival at 6 months (from date of inclusion),2011-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Safety of RADIOEMBOLIZATION using the NCI-CTCAE V3.0 classification.,
10216,NCT03116945,"Uptake of positron emitting radiotracer, 68Gallium Citrate will be measured in the lesions of hepatocellular carcinoma.",2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10217,NCT01385956,Number of Participants With Serious Adverse Events,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With Overall Survival (OS),
10218,NCT02866344,Local disease control at the site of intervention,2016-08,TERMINATED,INTERVENTIONAL,['NA'],Postoperative mortality,
10219,NCT05592925,Postoperative pathological results of tumor N stage.,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10220,NCT03601988,DFS,2018-07-28,UNKNOWN,INTERVENTIONAL,['PHASE3'],OS,
10221,NCT00540579,"The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0",2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10222,NCT00355862,Recurrence free survival,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10223,NCT02527772,Progression-Free-Survival,2015-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Time-to-Progression,
10224,NCT05537402,Progression-free survival,2023-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to deterioration of quality of life,
10225,NCT00917384,Overall Survival (OS),2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants Who Developed Antibodies Against IMC-1121B,
10226,NCT00919009,Time to progression (TTP) in patients treated with TACE plus sorafenib,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall response rate will be evaluated,
10227,NCT05770635,Objective response rate (ORR) 1 month after the last TACE -mRECIST evaluation,2022-12-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
10228,NCT02756468,Specificity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],PCT and CRP cuts-off in 5th POD with a good NPV for AL,
10229,NCT01789073,Overall postoperative complications after major gastrointestinal (GI) elective surgery.,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Length of hospital stay after major gastrointestinal (GI) elective surgery,"Weight stability, functional capability and patients´ satisfaction with the overall study course."
10230,NCT06133062,Progression free survival (PFS),2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence and severity of adverse events,
10231,NCT05515315,progression free survival,2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
10232,NCT05139199,Quality of Life (EORTC QLQ-PAN26 ),2022-02-23,COMPLETED,INTERVENTIONAL,['NA'],Physical Activity(Exercise Counseling and Programming Preferences),
10233,NCT04380506,Validate the ability of the diameter (in cm) of abdominal collection detected during the contrast-free abdomen CT in POD3 to predict risk of biliary fistula,2020-03-15,UNKNOWN,INTERVENTIONAL,['NA'],,
10234,NCT06099119,Change in body weight over study period.,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,
10235,NCT03083002,Transcriptomics characterization of liver tissue: the purpose is molecular evaluation of possible predisposing factors to development of hepatocellular carcinoma in patients with cirrhosis.,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],Transcriptomics characteristics of newly diagnosed hepatocellular carcinoma: the purpose is to verify if we can predict the survival of patients considering the molecular features of HCC at first diagnosis.,
10236,NCT04466254,Best of Response (BOR),2020-12-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Deepness of Response (DpR),
10237,NCT03287375,"Number of patients with major/complete histologic response (PRGS 1+2) peritoneal biopsies, within a series of three PIPAC procedures.",2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of patients where MRI is accurate in describing PM distribution and progressive/regressive disease,
10238,NCT04809142,Overall survival (OS),2021-02-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],Overall survival at 12 months,
10239,NCT01434199,caecal intubation rate,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Caecal intubation time,
10240,NCT06223230,Median progression-free survival time,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],Duration of Response,
10241,NCT03546998,Detection of epidermoid carcinoma of the esophagus,1973-01-01,RECRUITING,OBSERVATIONAL,['NA'],Result of achalasia treatment by investigating dysphagia and gastro-esophageal reflux,
10242,NCT03108885,Esophageal Cancer Mutation,2017-10-01,TERMINATED,OBSERVATIONAL,['NA'],Marker for Recurrence,
10243,NCT04408859,Quality of life index,2018-04-17,UNKNOWN,OBSERVATIONAL,['NA'],,
10244,NCT00973609,Time to failure of maintenance and reinduction treatment strategy measured from randomization,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],"TFS, Toxicity, QoL, PFS 1, PFS 2, ORR (first induction), ORR (reind. treatm.), Treatment free interval/duration of maintenance therapy, second. Resection rate, Reasons for discontinuation, OS, Translational research.",
10245,NCT04021056,Evaluate the recurrence free survival rate of HCC patients after curative treatments,2011-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10246,NCT04074538,Adenoma or advanced adenoma incidence,2013-01-01,RECRUITING,OBSERVATIONAL,['NA'],Second primary cancer incidence,
10247,NCT02595931,"Recommended phase 2 dose (RP2D) of ATR kinase inhibitor M6620 (VX-970, berzosertib) and irinotecan hydrochloride",2016-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Pharmacodynamic parameters of M6620 (VX-970, berzosertib) in combination with irinotecan hydrochloride",Change in biomarker levels
10248,NCT05163977,Post-Operative Pancreatic Fistula,2021-06-12,UNKNOWN,INTERVENTIONAL,['NA'],primary or reactionary hemorrhage,
10249,NCT02817308,correlation of CA19-9 levels in urine and saliva with those in the serum,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],Number of participants needed to standardize the measurements in urine and saliva according to those measured in the serum.,
10250,NCT00005874,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10251,NCT03384316,Recommended Phase 2 Dose (RP2D),2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),Number of Dose Limiting Toxicities (DLTs)
10252,NCT04752215,Number of patients with dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period,2021-05-06,RECRUITING,INTERVENTIONAL,['PHASE1'],Objective response based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1) in patients with measurable disease,
10253,NCT00844077,Conversion from Barrett's intestinal metaplasia to dysplasia or esophageal adenocarcinoma.,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
10254,NCT04817813,Survival and disease-free survival at 5th year.,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA'],Follow up- Date of death,
10255,NCT01006577,Side-to-end anastomosis is not inferior not colon J pouch in terms of fecal incontinence. fecal incontinence (Wexner score),2010-06,UNKNOWN,INTERVENTIONAL,['NA'],cancer related deaths,
10256,NCT00183872,"Objective Response (Complete, Partial, Stable and Progression)",2005-04-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival,
10257,NCT01953406,Time-to-progression(TTP)of lung metastasis,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Disease control rates (CR + PR + SD)of lung metastasis,Adverse Events
10258,NCT03961373,Overall survival analysis,2018-11-05,RECRUITING,INTERVENTIONAL,['PHASE3'],Percentage of completion of protocol treatment,
10259,NCT00016042,,2001-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
10260,NCT01442935,The main objective is to compare resection rates (R0 or R1) for hepatic metastases,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
10261,NCT03071237,Distribution of IPA origin,2017-03-04,COMPLETED,OBSERVATIONAL,['NA'],Reconstruction rate of IPA by CT scan,
10262,NCT00107315,Time to Progression,2004-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Toxicity,
10263,NCT05210322,Tube free survival,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],Complication rate,
10264,NCT02585479,Progression-Free-Survival,2015-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Time-to-Progression outside the liver,
10265,NCT03801876,"Incidence of specific grade 3+ cardiopulmonary adverse events (AEs) that are definitely, probably, or possibly related to protocol treatment",2019-03-15,RECRUITING,INTERVENTIONAL,['PHASE3'],Cost-benefit economic analysis of treatment,
10266,NCT01238055,time to progression,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression free survival,
10267,NCT02525237,Safety will be assessed by incidence of adverse events,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life (QoL),
10268,NCT03375320,Progression-free survival (PFS),2018-10-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Radiographic response rate,
10269,NCT03989310,Disease control rate (DCR),2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of participants with laboratory test abnormalities,
10270,NCT04028375,MSCT and MRI staging in Gastric Cancer.,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],MSCT and MRI prediction of prognosis in gastric cancer,
10271,NCT00559676,Pharmacogenetic and pharmacokinetic predictors of therapeutic response and toxic effects,2005-03,COMPLETED,INTERVENTIONAL,['PHASE4'],Predictive value of pharmacogenetic and pharmacokinetic parameters on disease-free and overall survival,
10272,NCT03275376,Overall survival,2017-12-21,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression free survival,
10273,NCT00769106,Time to recurrence (TTR),2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],AEs and SAEs,
10274,NCT04678583,Intrahepatic disease-free survival (iDFS),2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],"Assessment of additional oncological and perioperative outcomes: Assessment of ""Quality of life"" (QoL)",
10275,NCT02862613,Progress-free survival,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life,
10276,NCT01318161,Long-term (up to 5 yrs) all-cause mortality,2011-03,TERMINATED,INTERVENTIONAL,['PHASE3'],Cancer recurrence detected by MRI; perioperative complications,Postoperative pain and early recovery
10277,NCT00271011,Percentage of Patients With an Objective Response,2005-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Proportion of Patients Experiencing Hematologic and Non-hematologic Adverse Events,
10278,NCT03199144,patient overall survival,2017-04-20,WITHDRAWN,INTERVENTIONAL,['PHASE2'],CEA level post operatively at one month,
10279,NCT00318903,The determination of pathologic response in patients who undergo surgical resection.,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess the toxicities associated with this treatment and any impact on surgery.,
10280,NCT05959226,3-year overall survival rate,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],QLQ-C30 assessment,
10281,NCT01254617,"Maximum-tolerated dose of lenalidomide with cetuximab, defined as the highest dose level at which 0 or 1 patients out of 6 experiences a dose limiting toxicity graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2011-02-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Natural killer cell activation,Immune cell activation
10282,NCT02751606,Sensitivity and specificity of 7 Tesla MRI in combination with ferumoxtran-10 on nodal level.,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],Comparison of 7 Tesla and 3 Tesla MRI,
10283,NCT01198522,Maximum tolerated dose and the preliminary tolerability profile.,2007-06,TERMINATED,INTERVENTIONAL,['PHASE1'],Antitumor activity,
10284,NCT03628651,Biomarker Identification,2018-04-02,COMPLETED,OBSERVATIONAL,['NA'],,
10285,NCT02623153,response rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
10286,NCT01796145,Overall survival,2013-02-27,RECRUITING,INTERVENTIONAL,['NA'],Liver stiffness (kPa),
10287,NCT05720195,Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI),
10288,NCT00034216,"Collection of tissue, urine, saliva, stool and blood components, which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and circulating tumor cells (cTC), of human subjects.",2002-07-16,RECRUITING,OBSERVATIONAL,['NA'],,
10289,NCT00519324,To Assess disease control rate (DCR) as defined CR + PR + SD assessed by RECIST criteria,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],"To describe the safety profile (incidence and severity of adverse events, serious adverse events) assessed by NCI CTCAE version 3.0",
10290,NCT03656627,Dose-Limiting Toxicity (DLT),2019-06-27,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall Survival,
10291,NCT02861430,Concordance between immunochemistry and molecular biology,2014-04,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival,
10292,NCT01746043,Proportion of Patients Under Each Treatment Arm Who Experienced a Mean Symptom Increase of 2 Units or More From Baseline to 6 Weeks.,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10293,NCT04293315,Effective Screening,2018-06-09,UNKNOWN,INTERVENTIONAL,['NA'],Implementation outcomes according to the RE-AIM framework,
10294,NCT02078726,Adenoma Detection Rate (ADR) During Colonoscopy Procedure,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
10295,NCT05192460,Objective Response Rate (ORR),2022-03-28,RECRUITING,INTERVENTIONAL,['NA'],The concentration of Lymphocyte,
10296,NCT06096493,Disease free survival.,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
10297,NCT06258434,Sensitivity and specificity of the multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo) with comparison to colonoscopy,2024-02-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],"Sensitivity of the multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo) with comparison to FIT, with respect to advanced adenoma (AA) and CRC",
10298,NCT03567863,cumulative length of tissue core biopsies per needle pass,2018-06-24,COMPLETED,INTERVENTIONAL,['NA'],intra-observer evaluation of the anatomopathological criteria used,
10299,NCT04906382,T-cell receptor (TCR) diversity,2021-07-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Incidence of adverse events,
10300,NCT01483638,progression-free survival,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],Adverse events,
10301,NCT02736552,Disease-free survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Side effects,Treatment expense
10302,NCT01801163,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2012-02,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Time from start of treatment until death from any cause or date of last patient contact.,"3.2.4 To evaluate biologic markers such as VEGF, eNOS and HIF1-alpha, VEGF-R2 genetic polymorphisms as well as serum VEGF and soluble VEGFR2 levels and correlate with efficacy outcomes."
10303,NCT06139042,"The sensitivity and specificity of the cfDNA methylation model in detection of liver, biliary tract and pancreatic cancers.",2023-11-01,RECRUITING,OBSERVATIONAL,['NA'],"The sensitivity and specificity of the combined model in detection of different stages of liver, biliary tract and pancreatic cancers.",
10304,NCT05241899,Progression free survival (PFS),2022-05-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Safety and tolerance evaluated by incidence, severity and outcomes of AEs",
10305,NCT02166255,Overall survival,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10306,NCT03349255,Toxicity profile of ET1402L1-CART-cell treatment,2017-10-06,TERMINATED,INTERVENTIONAL,['PHASE1'],AUC of serum cytokine levels,
10307,NCT03720678,Incidence of dose-limiting toxicities (DLTs) during dose escalation phase,2018-11-18,COMPLETED,INTERVENTIONAL,['PHASE1'],Immunomodulatory activity in subsets for AB928 in combination with mFOLFOX,
10308,NCT01914692,fistula of pancreas,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],infection of incisional wound,postoperative pancreatitis
10309,NCT03602703,Pattern of immunity in patients with de novo HCC develped after treatment with DAAs,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
10310,NCT03519308,Number of Adverse Events,2020-07-29,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Proportion of Margin Negative Surgical Resections,
10311,NCT03819920,Screening Behavior: Differences in colorectal cancer screening completion rates between usual care (UC) and CCRAT,2015-10-06,COMPLETED,INTERVENTIONAL,['NA'],Colorectal cancer screening rates at 12 months as a function of CCRAT score,Fear: Health Belief Model Likert Scale
10312,NCT04797507,ORR based on RECIST v1.1,2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
10313,NCT06232395,The performance of the new biomarkers in the post-operative monitoring of gastric cancer,2024-02-18,RECRUITING,OBSERVATIONAL,['NA'],The performance of the new biomarkers as prognostic biomarkers,
10314,NCT00290485,Patient response rate according to RECIST criteria,2005-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Evaluate whether the response rate can predict survival,
10315,NCT00885950,Histologically proven hepatic sinusoidal injury,2008-01,COMPLETED,OBSERVATIONAL,['NA'],90-day morbidity and mortality,
10316,NCT04015245,Series changes of Prothrombin Time-Intemrnational Normalized Ratio,2018-04-12,COMPLETED,INTERVENTIONAL,['PHASE4'],Series changes of blood pressure levels before and after TACE,
10317,NCT05718232,Overall Survival (OS),2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Time to Progression （TTP）,
10318,NCT04607421,Cohort 3: Objective response rate by blinded independent review,2020-12-21,RECRUITING,INTERVENTIONAL,['PHASE3'],Cohort 3: Trough concentrations of encorafenib and its metabolite LHY746,
10319,NCT05628194,MSM awareness of strategies to decrease anal cancer risk,2023-06-08,RECRUITING,OBSERVATIONAL,['NA'],,
10320,NCT00303927,Toxicity,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Response rate,
10321,NCT01188876,Best Overall Response,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Area Under the Plasma Drug Concentration-Time Curve (AUC),
10322,NCT06217250,Success rate of resection defined as absence of residual/recurrence in SC1 and/or SC2,2024-02-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Avarage time of procedure and polyp resection time,
10323,NCT05620537,postoperative overall survival,2022-11-10,COMPLETED,OBSERVATIONAL,['NA'],,
10324,NCT03001518,immune response,2017-05-04,COMPLETED,OBSERVATIONAL,['NA'],disease-free survival,
10325,NCT02135757,The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting,2014-08,COMPLETED,OBSERVATIONAL,['NA'],Identification of blood biomarkers that confer significant improvement in progression-free survival in patients treated with panitumumab.,
10326,NCT03243916,overall survival(OS),2017-08-15,UNKNOWN,INTERVENTIONAL,['NA'],Quality of life (QOL),
10327,NCT05122221,"Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).",2022-07-17,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-Free Survival（PFS）,Negative conversion rate among HPV-16 positive patients detected by tissue biopsy
10328,NCT06096779,Percentage of Participants with Adverse Events,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Change From Baseline in IL46 Scores,
10329,NCT06185556,Local control,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Cost-effectiveness ratio (ICER) per patient,
10330,NCT01710215,Cost: Cost per-patient effectively screened.,2013-04,COMPLETED,INTERVENTIONAL,['NA'],Cost: Incremental costs for the FIT and Colo strategies relative to the Usual Care strategy.,
10331,NCT01877096,Screening colonoscopy completion,2013-08,COMPLETED,INTERVENTIONAL,['NA'],Psychological mediators,
10332,NCT02269904,DFS (Disease Free Survival),2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse event,
10333,NCT00418938,Progression-free Survival (PFS),2006-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response,
10334,NCT01396668,Time to progression,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],clinical benefit rate,
10335,NCT04747600,the incidence of the pancreatic fistula,2014-06-01,COMPLETED,OBSERVATIONAL,['NA'],recurrence rate in percentage,
10336,NCT05169528,6-minute-walk-test,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],Patient Satisfaction Survey,
10337,NCT06272214,2-year DFS,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Recurrence,
10338,NCT00887822,Overall Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Cycle 1 in EORTC QLQ-STO22 Scale Over Time,
10339,NCT01995396,Rates ot postoperative surgical complications within 30 days.,2014-02,TERMINATED,INTERVENTIONAL,['NA'],Other postop complications,Late complications after surgery
10340,NCT02872519,Number of lesions detected by (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET imaging before and after neoadjuvant chemotherapy treatment,2018-06,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Conditional predictive models of imaging performance and agreement,
10341,NCT06260943,Proportion of Participants Enrolled in Clinical Research,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10342,NCT01843400,Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.,2013-04-22,COMPLETED,OBSERVATIONAL,['NA'],Tumor response assessed by RECIST or physicians own evaluation,
10343,NCT01705002,Pharmacokinetic (PK) profile of PROMITIL,2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Toxicity profile of PROMITIL,
10344,NCT05176860,CBCT Image Quality,2022-12-20,COMPLETED,INTERVENTIONAL,['NA'],Patient Experience,
10345,NCT05171075,"Time to first event of centrally adjudicated VTE recurrence consisting of new proximal deep venous thrombosis, new pulmonary embolism (PE) or fatal PE, including unexplained death for which PE cannot be ruled out",2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE3'],"Net clinical benefit defined as survival without VTE recurrence, or major or CRNM bleeding",
10346,NCT04999072,Relapse free survival,2020-04-19,UNKNOWN,OBSERVATIONAL,['NA'],,
10347,NCT00610389,Response rate,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Immunological response,
10348,NCT04140552,Overall Survival,2008-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10349,NCT06265883,Time to progression (TTP),2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],treatment-related adverse events (TRAEs),
10350,NCT04713618,Change in sexual function,2021-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Change in vaginal microbiome,
10351,NCT02702401,Overall Survival (OS),2016-05-26,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE),
10352,NCT04589975,Conversion to open rate: predictive factors oncological outcomes,2000-01,COMPLETED,OBSERVATIONAL,['NA'],,
10353,NCT05967910,Effect of Chronic stress on efficacy of immune checkpoint inhibitors,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],Effect of chronic stress on quality of life,The correlation between peripheral immune cells signature and chronic stress and the efficacy of ICIs
10354,NCT03366155,Response rate (RR),2019-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Extra-hepatic progression-free survival,
10355,NCT01360541,Prevalence of low grade dysplasia 3 years after randomization,2010-12-22,COMPLETED,INTERVENTIONAL,['PHASE2'],Detection rate of dysplasia and Barrett's oesophagus with the confocal endomicroscopy technique,
10356,NCT05701553,Incidence of adverse events,2023-01-26,RECRUITING,OBSERVATIONAL,['NA'],12-month survival rate,
10357,NCT05920928,Clinical complete response,2023-09-23,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10358,NCT03627728,PFS1,2018-06-13,RECRUITING,INTERVENTIONAL,['PHASE2'],biomarker evaluation,
10359,NCT05458388,Early gastric cancer detection rate,2022-07-12,RECRUITING,INTERVENTIONAL,['NA'],,
10360,NCT01886287,Number of Participants With Improved Frequency of Diarrhea,2013-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Rate of Progression Free Survival (PFS) at 6 Months,
10361,NCT00562380,Pharmacokinetic profile,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Circulating levels of IGF-1R and IGF-BP3,
10362,NCT01395667,Maximally tolerated dose,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Improved rate,
10363,NCT03244787,Percentage of patients in intervention and control groups who completed any colorectal cancer screening during the six-month study period,2017-01,COMPLETED,INTERVENTIONAL,['NA'],Number of polys found in intervention polyps (histology),
10364,NCT01783171,MTD of dinaciclib in combination with Akt inhibitor MK2206 defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients,2013-01-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression-free survival,Protein expression in serum as measured by fluorescence activated cell sorting (FACS)
10365,NCT01934634,Percentage of patients with Dose-Limiting Toxicities,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],Objective Response Rate,
10366,NCT01534637,Number of Patients With Gastrointestinal Toxicities (Grade 3 and 4 Nausea and Vomiting) Associated With Delivering Fluorouracil/Gemcitabine Hydrochloride-based Chemotherapy With Upper Abdominal Radiation,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Impact of Aprepitant/5HT-3 Antagonist Therapy on the Patient Quality of Life as Measured by the Number of Patients Taking Anti Nausea Drugs,
10367,NCT03071458,Genetic and transcriptomic landscape,2008-01,COMPLETED,OBSERVATIONAL,['NA'],Validation of the molecular classification by integrative analysis,
10368,NCT00869570,Pathological near complete or complete tumor response (Dworak grade 3 and 4) (Phase II),2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse events as assessed by NCI CTCAE v3.0,
10369,NCT02639065,Percentage of Participants With One-Year Relapse Free Survival (RFS) With Post-Operative Durvalumab,2016-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Adverse Events as a Measure of Safety and Tolerability,
10370,NCT04730388,predictive factor for progression-free survival,2021-01-18,UNKNOWN,OBSERVATIONAL,['NA'],,
10371,NCT05840263,Extract key themes to integrate into preliminary drafts,2023-05-31,RECRUITING,OBSERVATIONAL,['NA'],,
10372,NCT05162755,Assessment of antitumor activity using RECIST v1.1 (Dose expansion part),2021-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival (OS) (Dose escalation and dose expansion parts),
10373,NCT04970056,Development of PDAC,2020-09-18,RECRUITING,OBSERVATIONAL,['NA'],,
10374,NCT01992406,Transanal specimen extraction possible or not,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],quality of life,
10375,NCT01473303,Convergent validity of each selected PRO-CTCAE item (phase II),2012-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Responsiveness (sensitivity to change) of PRO-CTCAE (phase II),
10376,NCT03955224,Rate of patients who didn't need a dose increase or introduction of new analgesics for mouth pain during the study compared to baseline,2021-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Frequency of adverse events related to the LLLT using the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) version 5.0,
10377,NCT06185907,Duration of stay,2021-04-15,COMPLETED,OBSERVATIONAL,['NA'],,
10378,NCT00114244,Objective Response (OR = CR or PR) as Determined by the RECIST Criteria,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free Survival,
10379,NCT00006046,Number of Patients With Dose-limiting Toxicities (DLTs),2000-07-12,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Patients With Tumor Responses,
10380,NCT03719924,survival at 9 months,2019-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life (questionnaires),
10381,NCT02652663,Disease free survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10382,NCT00867334,Number of Patients With Adverse Events,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Stabilization or Reduction in Tumor Size,
10383,NCT02485834,Overall Survival,2015-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants Who Reported Grade 3 or Higher Adverse Events,Change in FDG-PET SUV Measures
10384,NCT06016400,Within two months from the start of chemotherapy,2021-06-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Length of hospital stay of patients in vitamin D treatment group and placebo group,
10385,NCT01483014,Objective response using the RECIST criteria,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
10386,NCT02789709,Disease-free survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],Postoperative mortality,
10387,NCT04281290,Evaluation of feasibility and safety,2020-07-13,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall Survival,
10388,NCT04292366,Number of residents participating in colorectal cancer screening,2020-10-02,COMPLETED,INTERVENTIONAL,['NA'],,
10389,NCT02218801,Number of post-operative complications,2015-05,COMPLETED,OBSERVATIONAL,['NA'],Number of post-operative complications in the first 50 patients compared to the second 50 patients,
10390,NCT02475772,Adverse events according to CTCAE criteria,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Clinical benefit according to RECIST criteria,Plasma concentrations of cisplatin and doxorubicin
10391,NCT03598998,Overall response rate (ORR) according to Lugano classification (Phase II),2019-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of unacceptable toxicity assessed by NCI CTCAE version 5.0,
10392,NCT03272659,fluorescence with photodynamic diagnostics (PDD) in colorectal cancer,2018-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Detect malignant lesions,Accurate depiction of the extent of disease burden by correlating pre-and post surgical results after neoadjuvant chemotherapy and radiation.
10393,NCT04889742,Local tumor recurrence,2024-05-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Patient reported quality of Life,
10394,NCT06256705,"Clinical response defined by the PFS as the time measured from the day of first administration of PRRT to first progression or death at 18 months, whichever occurs first",2024-03-25,RECRUITING,INTERVENTIONAL,['NA'],,
10395,NCT06241079,Overall survival,2003-03-31,COMPLETED,OBSERVATIONAL,['NA'],,
10396,NCT01428752,prevalence of colorectal adenoma(any size),2011-09,UNKNOWN,OBSERVATIONAL,['NA'],prevalence of advanced adenoma,
10397,NCT03388047,Level of confidence in delineating the area of interest by multispectral imaging,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],Correlation with molecular biomarkers,
10398,NCT02264886,"Feasibility of the online, adaptive, MRI-guided SBRT",2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Patient-reported quality of life,
10399,NCT00107341,Confirmed tumor response rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of response,
10400,NCT00733746,Overall Survival at 2 Years,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Response Rate,
10401,NCT05003700,Objective response rate (ORR),2021-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,
10402,NCT05195502,Evaluation of metabolic profile,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Colonic biofilm,
10403,NCT01653327,Change in Pain Score,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Analgesic Effect,
10404,NCT04137107,Chronic neuropathic pain response (Phase III),2020-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Incidence of adverse events, including duloxetine side effects of nausea, dry mouth, dizziness, somnolence, fatigue, and insomnia (Phase III)",
10405,NCT06048458,Change in myocardial blood flow from baseline with adenosine stress assessed by quantitative perfusion cardiac MRI,2022-05-18,RECRUITING,OBSERVATIONAL,['NA'],Change in retinal vessel density,
10406,NCT04354662,Pathological complete response rate (pCR),2019-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],5-year Survival Rate,
10407,NCT04044313,Progression free survival rate at 6 months,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse events,
10408,NCT03459235,assessment of quality of life of patients operated for a rectal cancer (rectal resection) - Sexual sequelae (for men),2018-03-20,UNKNOWN,INTERVENTIONAL,['NA'],,
10409,NCT06320301,the effectiveness of first-line treatment with Adebrelimab and a tyrosine kinase inhibitor (TKI) in combination with gemcitabine and oxaliplatin (GEMOX) in patients with advanced BTC,2024-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],To evaluate the overall survival (OS).,The DoR based on an immunomodified RECIST (imRECIST）
10410,NCT05319314,Recommended Phase 2 dose (RP2D) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation study,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Tmax: The time to reach maximum(peak) in peripheral blood or other body fluid drug concentration after single dose administration (days),
10411,NCT01933945,Overall survival (OS),2013-10-28,COMPLETED,OBSERVATIONAL,['NA'],TTP from initiation of sorafenib,Duration of treatment of sorafenib after TACE
10412,NCT04332705,Prevalence of Cryptosporidium,2020-06-30,RECRUITING,OBSERVATIONAL,['NA'],Rate of development of a neoplastic lesion in the human explants,
10413,NCT01084629,detection of dysplasic areas,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
10414,NCT05007548,Correlation of the ICGR15 with the conventional liver function tests,2021-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Comparison of CTV and Ga68-Dolacga PET parameters in patients with PHLF,
10415,NCT03334890,mSEPT9 level,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA'],"CR,PR,SD,PD",
10416,NCT04466124,Establish a cohort of liver cancer patients treadted with proton beam therapy.,2018-09-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
10417,NCT03969784,percentage of microparticule,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10418,NCT00601510,Overall tumor response as assessed by RECIST,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Quality of life,
10419,NCT01230697,Identify the value variations of hormones involved in phosphate homeostasis during sorafenib administration,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],Identify correlations between phosphate related hormones variations and patients outcome (TTP and overall survival),
10420,NCT00016250,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10421,NCT02556619,Change in Health-Related Quality of Life (HRQoL),2019-04-02,UNKNOWN,INTERVENTIONAL,['NA'],Cost Utilization,
10422,NCT01853813,Response Rate,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],"evaluation of serum IL-8, bFGF, HGF, PlGF, SDF-1, MCP-3",RECIST criteria and those defined by Chun
10423,NCT00625625,Disease-free survival,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10424,NCT00999882,Evaluate the pharmacokinetics of AZD8055 following both single and multiple dosing,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],To collect and store DNA for future exploratory research that may influence response to AZD8055,
10425,NCT05179837,Proportion of participants that have a lesion that can be adequately evaluated with OCT,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],Weighted kappa,
10426,NCT03419481,Response rate (RR) according to RECIST1.1,2018-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
10427,NCT05083247,R0 Resection rate,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Technical and quality success rate of EUS-delivered fiducials.,
10428,NCT00006038,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10429,NCT05855200,Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR),2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of Participants with Anti-Drug Antibodies against Dostarlimab,
10430,NCT04963088,ORR,2021-03-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival,
10431,NCT05716594,Disappearance rate of pseudocyst（PDR） after stent implantation,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Time of disappearance of pseudocyst after stent implantation,
10432,NCT06151223,Collection of radiology images and videos,2021-07-13,RECRUITING,OBSERVATIONAL,['NA'],,
10433,NCT00265798,Objective Response Rate,2005-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
10434,NCT06328101,Standardized incidence ratio (SIR) of first invasive cancer,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Risk factor associated with cancer diagnosis.,
10435,NCT02025842,risk for hepatocellular carcinoma,2000-01,COMPLETED,OBSERVATIONAL,['NA'],survival,
10436,NCT04039607,Overall Survival (OS),2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Time to Symptom Deterioration (TTSD),
10437,NCT01236300,NPV (Negative Predictive Value),2010-07,COMPLETED,INTERVENTIONAL,['NA'],Overall Complication Rate,
10438,NCT04241835,"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, fu: unbound fraction of drug in plasma",2020-01-28,RECRUITING,INTERVENTIONAL,['PHASE1'],To evaluate the number of participants with adverse events (AEs) as assessed by CTCAE v5.0,
10439,NCT00122720,"The functional capacity measured by postoperative fatigue, work capacity, balance, and quality of life",2003-06,COMPLETED,INTERVENTIONAL,['PHASE4'],Postoperative complications,
10440,NCT03885219,6-month progression-free survival (PFS),2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Objective Response Rate (ORR),
10441,NCT04499924,Incidence of dose modifications (Phase 2 only),2021-03-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Utility index values as assessed by the EQ-5D-5L,
10442,NCT01275222,Progression-free Survival (PFS) - Phase II,2002-11-13,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Relationship Between Drug-induced Changes in Tumoral Metabolism, as Shown by Functional Imaging With 18F-fluorodeoxyglucose Positron Emission Tomography (FDC-PET), With Clinical Outcome and Changes in Molecular Pathology.",
10443,NCT03524677,Early recurrence,2019-01-23,UNKNOWN,OBSERVATIONAL,['NA'],N stage,
10444,NCT06024980,Swallowing ability to four different textures,2023-01-03,RECRUITING,INTERVENTIONAL,['NA'],The time in weeks of nasogastric feeding,
10445,NCT04562727,DFS,2021-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Tumor reactivity assessment,
10446,NCT05568017,objective response evaluation,2020-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],analysis of tumor specific circulating NET transcripts,
10447,NCT00056537,Maximum Tolerated Dose (MTD) as a function of pre-treatment anti-SEA/E-120 levels,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to progression and Survival,
10448,NCT03834701,Incidence of adverse events (AEs) after EUS-guided radiofrequency ablation (RFA),2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],Rates of secondary surgery,
10449,NCT02730663,Number of Participants With Clinical Success,2016-03-21,COMPLETED,INTERVENTIONAL,['NA'],Other Adverse Events,
10450,NCT00861094,Progression-free survival (Phase III),2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life as assessed by EORTC QLQ-C30 (version 3) and EORTC QLQ-OES18 (Phase III),
10451,NCT01718873,Objective Response Rate,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Toxic Effects,
10452,NCT04595604,Change in preoperative functional status - FVC by the end of rehabilitation,2020-09-07,SUSPENDED,INTERVENTIONAL,['NA'],Change of alpha- and beta-diversity of fecal microbata,
10453,NCT04150120,Cost-utility ratios,2019-10-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],EQ-5D-3L,
10454,NCT01375088,NCI.CTC Scale,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],hyposalivation scale,
10455,NCT05229003,ORR,2022-03-09,RECRUITING,INTERVENTIONAL,['PHASE2'],AEs,
10456,NCT00981162,Maximum tolerated dose of everolimus (Phase I),2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Toxicity and adverse events as assessed by NCI CTCAE v3.0,
10457,NCT05572788,Rate of post-procedure pancreatitis following EUS-guided fine needle aspiration of pancreatic cysts,2022-09-26,RECRUITING,INTERVENTIONAL,['NA'],Length of hospitalization in any patient hospitalized with acute pancreatitis,
10458,NCT05010434,ORR (objective response rate),2021-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse effects,
10459,NCT00449137,Thymidylate synthase expression,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10460,NCT01556815,Effectiveness of sorafenib in increasing the effectiveness of transarterial chemoembolization (TACE),2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Survival in the two treatment groups,
10461,NCT02029157,Progression-free survival (PFS),2014-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall survival,
10462,NCT04003181,Serum concentration of FGF19,2017-09-28,COMPLETED,INTERVENTIONAL,['NA'],Quality of life after treatment with antibiotics or bile acid binder,
10463,NCT01341756,Response of bleeding to radiotherapy,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Number of patients who develop anorexia, nausea, vomiting as per common toxicity criteria v3.0",
10464,NCT03749083,One year local recurrence rate in participants that test positive for ctDNA compared to participants that tested negative for ctDNA,2019-12-31,WITHDRAWN,OBSERVATIONAL,['NA'],Median Fecal Incontinence Severity Index (FISI) score,
10465,NCT00084773,Safety profile,2004-03,COMPLETED,INTERVENTIONAL,['NA'],Activity in terms of pathological complete response rate,
10466,NCT05153746,Adenoma detection rate,2022-02-10,RECRUITING,INTERVENTIONAL,['NA'],Flat adenoma detection rate,
10467,NCT05364918,Acute radiotherapy-induced oral mucositis,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE3'],Oral pain,
10468,NCT04503967,Objective response rate,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
10469,NCT00055250,6-month survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],PK,
10470,NCT06126120,Participant non-adherence to 2-yearly colonoscopy check-up.,2024-01-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],The four most important challenges to having colonoscopy check-up for participants.,
10471,NCT01647776,Efficacy of sDNA testing for the detection of advanced adenomas,2012-04-01,COMPLETED,OBSERVATIONAL,['NA'],"To investigate the association of activated (phosphorylated) IRS1, AKT and mTOR with colon adenomas.",
10472,NCT00817895,disease free survival,2008-12,COMPLETED,INTERVENTIONAL,['NA'],overall survival,
10473,NCT04079049,Survival,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10474,NCT05135364,Progression-free survival (according to mRECIST),2021-11-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease control rate (according to mRECIST and RECIST 1.1),
10475,NCT00630890,To determine the maximal tolerated dose of the Cyberknife radiosurgery boost,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],To estimate disease specific and overall survival,
10476,NCT00809081,To evaluate the impact of early postoperative enteral feeding,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],To evaluate the nutritional status,
10477,NCT01927016,To identify predictors of recurrence after esophageal cancer surgery,2012-07,COMPLETED,OBSERVATIONAL,['NA'],"Impact of patient preconditioning (such as nutritional support, esophageal prosthesis, mini-invasive approach…) on outcomes",
10478,NCT03045497,Ability of contrast-enhanced ultrasound to predict response to transarterial chemoembolization with drug eluting beads,2012-12-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Changes in contrast fill time,
10479,NCT04606992,Resection margin,2020-02-10,COMPLETED,INTERVENTIONAL,['NA'],Complication rate,
10480,NCT01355107,measurement of selenium levels in hcv- infected patients,2011-04,COMPLETED,OBSERVATIONAL,['NA'],selenium levels and MELD(Na)score,
10481,NCT00891332,Overall Response Rate (ORR),2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacokinetics,
10482,NCT00570713,Overall Survival (OS),2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Best Overall Response Rate,
10483,NCT05985798,Overall survival (OS),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse Events (AEs),
10484,NCT00436657,Maximum Tolerated Dose (MTD) of continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin in children with peritoneal cancer,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10485,NCT04472767,Complete Response Rate,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Conversion Rate to Resectable,
10486,NCT06313268,Adverse events,2022-04-21,RECRUITING,OBSERVATIONAL,['NA'],,
10487,NCT03239158,Relief degree of tumors,2017-09-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall survival（OS）,
10488,NCT00003298,Grade 3 or Higher Toxicity Incidence on Step 1,1999-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival,
10489,NCT00828984,Difference (After Treatment Minus Before Treatment) of EGFR Expression,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in E-cadherin Expression as Measured in Endoscopically Normal (Non-ACF) Mucosal Biopsies,
10490,NCT00237900,"Parts 2 and 3: Safety and tolerability of gefitinib in combination with 5-FU, LV and radiotherapy",2003-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Exploratory outcome: Parts 2 and 3: sVEGF levels, EGFR activation, Biomarkers such as cyclin D1, IL-1, GI-associated TOP2A, GAS, EST AA552509",
10491,NCT01150916,diagnostic accuracy of BNP for the diagnosis of ascites due to heart failure,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
10492,NCT00134589,Completion of colorectal cancer screening,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Patient's intention to ask/patient asking medical provider for colorectal cancer screening,
10493,NCT02080260,Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects,2014-06-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Control,
10494,NCT03623464,Readmission rate,2017-05-31,RECRUITING,INTERVENTIONAL,['NA'],Quality of life: Return to Baseline Function-Activities of Daily Living (ADLs),
10495,NCT03449030,Recommended Phase 2 Dose (RP2D) of TAK-164,2018-04-23,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants With Positive Antidrug Antibody (ADA) Levels in Serum,
10496,NCT01048580,"Safety and tolerability of the combination of perifosine and capecitabine (i.e., dose limiting toxicity)",2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetic (PK) data for the combination of perifosine and capecitabine,
10497,NCT02534142,Variables related to non-completion of colonoscopy following a positive fecal occult blood test,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,
10498,NCT01643447,the overall survival rate of each group,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
10499,NCT01377220,,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10500,NCT02081547,IPC status,2012-04,UNKNOWN,OBSERVATIONAL,['NA'],Survival,
10501,NCT02117674,polyp detection rate,2014-04,COMPLETED,INTERVENTIONAL,['NA'],patients' satisfaction,
10502,NCT01229813,To demonstrate that maintenance treatment with bevacizumab + erlotinib following first line chemo- and anti-angiogenetic therapy results in a significant increase in progression free survival (PFS) compared to treatment with only bevacizumab.,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],To explore the activity of bevacizumab and low dose metronomic capecitabine in patients with KRAS mutated tumors.,
10503,NCT05874726,Tissue sample repository,2023-07-19,RECRUITING,OBSERVATIONAL,['NA'],,
10504,NCT01372527,Cancer completion for all eligible cancers,2011-06,COMPLETED,INTERVENTIONAL,['NA'],TopCare system measures (intervention practices),
10505,NCT01549795,Time to recurrence after liver transplant,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],Complication rate due to radiotherapy (Hepatic artery thrombosis and Portal vein thrombosis),
10506,NCT06321913,vital signs,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),CLDN18.2 expression level
10507,NCT05374369,Tumor detection rate in the positive screening results,2022-03-29,COMPLETED,OBSERVATIONAL,['NA'],,
10508,NCT00436410,Comparison of the impact of distribution time and histology on accumulation of treatment particles in tumor vs normal tissues,2006-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Long-term toxicity of treatment as assessed by CTCAE v3.0,
10509,NCT01895257,Time to progression (TTP1 overall),2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),SIR-spheres treatment
10510,NCT02537171,Progression-free survival (PFS),2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse Events(AEs),
10511,NCT02425735,Reduced size of the tumors,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10512,NCT05935384,Sensitivity of ctDNA to Detect Disease Progression,2023-10-25,RECRUITING,OBSERVATIONAL,['NA'],Lead Time,
10513,NCT05415709,Incidence of chemotherapy-related adverse events,2022-06-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Quality of life (QOL) assessment EORTC QLQ-C30,
10514,NCT06248528,Overall survival,2019-12-01,RECRUITING,INTERVENTIONAL,['NA'],Adverse effects,
10515,NCT06283121,Objective response rate (ORR),2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
10516,NCT02287597,"Effectiveness: Second-line time to progression, in months",2014-11-13,COMPLETED,OBSERVATIONAL,['NA'],"Safety (composite outcome measure): Incidence, nature and severity of all serious adverse events reported in second line mCRC treatment with Avastin plus chemotherapy and information on outcome and action taken with the drug",
10517,NCT02867592,Objective Response (Osteosarcoma Stratum),2017-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),Change in Immune Biomarkers
10518,NCT04239261,Development of Oral Mucositis during ChemoRadiation Treatment,2020-01-17,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in Bowel Movements,
10519,NCT00001332,,1992-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10520,NCT03403296,overall survival(OS),2016-07-13,COMPLETED,OBSERVATIONAL,['NA'],,
10521,NCT04616495,five year overall survival (OS),2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],Quality of life using EORTC questionnaires: QLQ-C30,
10522,NCT06138769,Progression-free survival,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
10523,NCT02799212,presence of postoperative ascites during the postoperative course,2018-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Postoperative morbidity on Renal failure,
10524,NCT03135652,Disease free survival,2017-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Toxicities,
10525,NCT03632850,Decisional Conflict Scale,2019-02-19,COMPLETED,OBSERVATIONAL,['NA'],Usability: System Usability Scale (SUS),
10526,NCT01609075,Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events,2012-06,COMPLETED,OBSERVATIONAL,['NA'],Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes),
10527,NCT03503630,The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then mFOLFOX-6/COMPOUND 2055269,2018-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life of the patients in a neoadjuvant setting with COMPOUND 2055269 as assessed by FACT-C questionnaire,
10528,NCT04314349,Correlation of radiogenomics,2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],Treatment response and survival,
10529,NCT01510730,Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of gastric tumor.,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],effect of eradication of Helicobacter pylori on incidence of High grade dysplasia development after endoscopic resection of gastric tumor.,
10530,NCT05458791,Quantification of Parameters for Intra-arterial Perfusion,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],Impact of low dose radiation technique on intra-arterial perfusion parameters,
10531,NCT01197664,"Toxicity and tolerability of the paricalcitol regimen, as measured by calcium levels",2010-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Patterns of gene expression in tumor samples of patients who receive chemoradiation with and without paricalcitol,
10532,NCT04485286,Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury.,2020-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10533,NCT01539824,Disease stabilisation rate,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumour Markers,
10534,NCT02981719,Safety (number of adverse effects),2016-10-01,COMPLETED,INTERVENTIONAL,['NA'],Technical success of ablation,
10535,NCT02677597,PFS,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10536,NCT00956254,Cmax of Fentanyl,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],AUC0-last of Fentanyl,
10537,NCT00956241,Primary endpoint was the function of the neo-rectum as assessed by a validated functional outcome questionnaire at 4 months.,2002-04,COMPLETED,INTERVENTIONAL,['NA'],Quality of life,
10538,NCT01991379,Best Response Rate (phase II portion),2013-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",RR by EORTC criteria,
10539,NCT04054713,Comparing the incidence of dysplasia by directed biopsies with acetic acid chromoendoscopy against taking non-directed protocolized biopsies( Seattle protocol) in patients with Barrett's esophagus.,2019-07-03,RECRUITING,INTERVENTIONAL,['NA'],,
10540,NCT05924282,5-year overall survival,2010-07-01,COMPLETED,OBSERVATIONAL,['NA'],Readmission,
10541,NCT04721470,AFP variation rate,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
10542,NCT00955149,To examine the safety and tolerability of Tarceva (Erlotinib) in patients with primary sclerosing cholangitis and trisomy 7 on biliary cytology.,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],To assess among patients with primary sclerosing cholangitis and trisomy 7 the resolution of this cytologic abnormality following treatment with Tarceva (Erlotinib).,
10543,NCT00162110,Evaluate the efficacy of Erbitux in the treatment of mucinous gastrointestinal adenocarcinoma involving the peritoneal surfaces based on clinical response rate.,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"To evaulate surgically resected tumor specimens of the EGF receptor, mucins 1-6, and anglogenic indices such as vessel counts, VEGF expression, and Ki-67 expression. To evaluate the safety of Erbitux monotherapy in this patient population.",
10544,NCT05426005,Objective response rate (ORR),2023-02-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Toxicity assessed using the The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.",
10545,NCT03899415,Safety evaluation based in Incidences of adverse events/serious adverse events,2019-04-20,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival rate,
10546,NCT05658679,5-year survival rate,2016-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10547,NCT01766479,"Number of patients in whom colorectal polyps and colorectal neoplasia have been detected by CT colonography, by adopting colonoscopy as gold standard, as a measure of efficacy.",2009-05,COMPLETED,INTERVENTIONAL,['NA'],,
10548,NCT00594529,Curative resection rates of liver metastases,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Completion rates of neoadjuvant chemotherapy,
10549,NCT05964361,Safety of IL15/IL15Ra/WT1 DC vaccine administration: total (S)AEs (grade),2023-12-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Evaluation of changes in quality of life: How patient-reported quality of life evolves over time,
10550,NCT04597970,Progression free overall survival，PFS,2020-10-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival， OS,
10551,NCT01493206,clinical outcomes,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],toxicities,
10552,NCT02066064,G-EYE™ colonoscopy detection rate of adenomas and serrated lesions compared to the standard colonoscopy detection rate of the same.,2013-11,COMPLETED,INTERVENTIONAL,['NA'],"polyp and adenoma detection, procedure times and safety",
10553,NCT04008511,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2019-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall response rate (ORR),
10554,NCT03817866,Disease Progression,2019-01-29,COMPLETED,OBSERVATIONAL,['NA'],,
10555,NCT03206151,Progression-free Survival (PFS),2017-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence of anti-CMAB009 antibody,
10556,NCT05869097,Overall Survival (OS),2020-11-01,COMPLETED,OBSERVATIONAL,['NA'],Treatment-Related Adverse Events (TRAE),
10557,NCT00763425,Complete removal rate of colorectal polyps,2008-09,COMPLETED,INTERVENTIONAL,['NA'],Complication rate,
10558,NCT00434161,Incidence of Cataract Development or Progression at Month 12.,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Incidence of Second Primary Malignancies or Other Malignancies,
10559,NCT04072224,Description of volume of in vivo ablation,2018-10-23,COMPLETED,OBSERVATIONAL,['NA'],liver response,
10560,NCT01161316,progression-free survival,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse events,
10561,NCT03399110,DFS,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],OS,
10562,NCT02987699,Tumor response,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of of Patients developed Adverse Events,
10563,NCT01106066,MTD/pathologic CR,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10564,NCT00712790,Tumour response rate (liver ± any site).,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Rate of downstaging to surgical resection or ablative therapy.,
10565,NCT05028933,Adverse Event(AE),2021-09-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of circulating tumor cells (CTC) in peripheral blood,
10566,NCT03700398,detect rate,2017-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10567,NCT03729687,Pathological complete response (pCR) rate and clinical complete response (cCR) rate,2016-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Long-term Adverse Events,
10568,NCT02273167,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Polyp Detection Rate (Overall Colon),
10569,NCT00454116,Number of Patients With an Objective Disease Progression Event,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10570,NCT00379639,Best Overall Response,2006-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10571,NCT00263055,Occurrence of dose-limiting toxicity,2004-08,COMPLETED,INTERVENTIONAL,['PHASE4'],Long term toxicity,
10572,NCT05847855,Sensitivity and specificity,2023-04-27,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Sensitivity and specificity in distinguishing different AJCC stages,
10573,NCT00591045,5 year overall survival,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],R0 resection rate,
10574,NCT00854971,Determine response rate,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Determine safety of combination,time to treatment failure, overall survival time",
10575,NCT04771520,Overall response rate (ORR),2021-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
10576,NCT03985891,ORR,2020-12-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",OS,
10577,NCT05517239,Progression free survival,2015-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
10578,NCT00962494,Health Behaviors,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Satisfaction with intervention,
10579,NCT05643677,Progression-free survival (PFS),2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival（OS）,
10580,NCT00530010,Patient Completion,2004-12,COMPLETED,OBSERVATIONAL,['NA'],,
10581,NCT05589480,Recurrence-free survival,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
10582,NCT04979663,Safety: the incidence of adverse events and serious adverse events,2020-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
10583,NCT00441311,Colorectal cancer screening recommendations,2003-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,
10584,NCT00582452,To assess levels of intention in prophylactic colectomy among individuals at increased familial risk of colorectal cancer and to identify distinctive decision types based on profiles of perceived pros and cons of prophylactic colectomy;,2004-11,COMPLETED,OBSERVATIONAL,['NA'],,
10585,NCT03731442,"1-, 2-, 3-year overall survival",2018-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],"Toxicities according to RTOG and CTCAE criteria, including hematological and non-hematological toxicities",
10586,NCT02264665,Number of Participants With Adverse Events Leading to Death - Based on Treatment Received At-least Once During the Study,2015-05-12,COMPLETED,OBSERVATIONAL,['NA'],Number of Participants With Types of Main Lines of Treatment Received During the Follow-up - Based on Targeted Therapy Group and Other Treatments Group at Inclusion,
10587,NCT05408182,Postoperative pain score,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Readmission rate,
10588,NCT00030342,Safety as measured by NCI common toxicity table at study completion,2001-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10589,NCT04712604,Acceptability of the intervention,2021-03-14,COMPLETED,INTERVENTIONAL,['NA'],Change in quality of life,
10590,NCT05093231,Objective Response Rate (ORR),2022-03-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],European Organisation for Research and Treatment of Cancer Pancreatic Cancer Quality of Life Questionnaire (EORTC PAN26),
10591,NCT03387982,Difference in pain quality 4 weeks post-procedure for subjects receiving Balloon Cryotherapy or Radiofrequency Ablation via the Pain Quality Assessment Scale (PQAS),2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
10592,NCT05104268,Change in Patient-Reported Oral Mucositis Symptom (The Modified PROMS Questionnaire) Pain Score,2024-11-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],"Change of oral mucositis grade in the World Health Organization Grade,(WHO Mucositis Grade)",
10593,NCT01285557,Overall Survival (OS),2011-04-14,TERMINATED,INTERVENTIONAL,['PHASE3'],Time to Tumor Response (TTR),
10594,NCT05318027,Number of triage visits,2023-05-22,RECRUITING,INTERVENTIONAL,['NA'],Quality of Life scores,
10595,NCT05355168,Major pathological remission rate,2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","1-, 2-, 3-year Disease-free survival rate (DFS).",
10596,NCT00153998,"Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population",2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Molecular predictive markers for response and toxicity,
10597,NCT00807911,disease-free survival,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],"overall survival, pattern of failure,safety, quality of life",
10598,NCT02671357,The incidence of severe complications,2016-03,COMPLETED,OBSERVATIONAL,['NA'],"Postoperative in-hospital, 30-day and 90-day mortality",Delayed gastric emptying (DGE) rate
10599,NCT03058289,Rate and severity of treatment-emergent adverse events ≥ grade 3 attributed to study drug using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5),2017-02-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Key pharmacokinetic parameters, half live (hours) of each of the 3 main components of INT230-6.",Exploratory: Overall Subject Outcome
10600,NCT02751736,Low Anterior Resection Syndrome score,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative complication,
10601,NCT04996914,1-year local control rate,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Quality of life based on EORTC QLQ-HCC18,
10602,NCT02238847,"Sustained Biliary Drainage, Defined as Absence of Reinterventions for the Management of Biliary Obstructive Symptoms",2015-03-24,COMPLETED,INTERVENTIONAL,['NA'],"For Participants Not Undergoing Curative Intent Surgery, Sustained Biliary Drainage to One Year After Stent Placement",
10603,NCT06278883,Uptake of genetic testing recommendations by the provider,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10604,NCT00462501,Complete Pathologic Response,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,
10605,NCT00117299,Response rate,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10606,NCT02844075,complete pathologic response rate,2017-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of adverse event based on CTCAE 4.0.,
10607,NCT00479050,overall survival,2001-01,COMPLETED,INTERVENTIONAL,['PHASE1'],tumor response,
10608,NCT00054262,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10609,NCT01643824,local progression-free survival,2012-06-07,COMPLETED,INTERVENTIONAL,['NA'],overall survival,
10610,NCT06199895,Objective Response Rate,2023-11-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
10611,NCT05755607,Rate of long-term Survival,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Incidence of postoperative complications,
10612,NCT00849979,Validation of M. D. Anderson Symptom Inventory - Gastrointestinal (MDASI-GI) Questionnaire (Response),2008-07,COMPLETED,INTERVENTIONAL,['NA'],,
10613,NCT03466593,PaO2,2017-12-18,COMPLETED,INTERVENTIONAL,['NA'],Lenght of stay,
10614,NCT01473121,Descriptive analysis of clinical profile of newly diagnosed HCC patients,2012-08-13,COMPLETED,OBSERVATIONAL,['NA'],Descriptive analysis of tumor properties,
10615,NCT00020761,To determine the antitumor activity of irinotecan and paclitaxel in patients with unresectable adenocarcinoma of the esophagus and gastric cardia.,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate the toxicities of irinotecan and paclitaxel in this patient population.,
10616,NCT03257163,Recurrence-free survival (RFS) rate,2017-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10617,NCT02006030,Determine time to tumor progression (TTP),2014-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor response rates,
10618,NCT00677924,Number of Participants With Adverse Events (AEs),2008-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Best Overall Tumour Response (BOR),
10619,NCT05760430,Conversion rate,2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
10620,NCT01508000,Progression free survival,2013-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Safety,
10621,NCT05316818,Rate of adverse events,2018-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival time (OS),
10622,NCT05561907,Time to initiation of solid oral intake without symptoms of GOO,2022-10-28,RECRUITING,INTERVENTIONAL,['NA'],Chemotherapeutic regimen tolerance,
10623,NCT00746317,Determine the safety and tolerability of escalating doses of GC33,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Perform a preliminary assessment of anti-tumor activity of GC33,
10624,NCT04975620,Comparison of EUS-FNB sensitivity using two types of FNB needles,2021-08-01,COMPLETED,INTERVENTIONAL,['NA'],Comparing the score of blood content n for each pass in two types of FNB needles.,
10625,NCT04053985,PFS,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],DCR,
10626,NCT04152356,Disease-free Survival,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall Survival,
10627,NCT00072553,Response rate,2003-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life,
10628,NCT00076609,"Alphafetoprotein measurements every 3 weeks for first 3 courses, then every 6 weeks thereafter",2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Survival follow-up every 2 months,
10629,NCT02910960,Total area of procured tissue between the two FNB needles,2016-12,COMPLETED,INTERVENTIONAL,['NA'],Diagnostic adequacy between the two FNB needles,
10630,NCT04603040,Objective response rate (ORR),2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],OS rates at 9 months and 12 months,JS001 anti-drug antibody assessment
10631,NCT00420394,Feasibility of the study regimen.,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall and progression free survival following the study treatment plan,
10632,NCT00080002,,2003-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10633,NCT05503381,disease-free survival rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10634,NCT04673968,Body composition,2020-02-25,RECRUITING,INTERVENTIONAL,['NA'],Mitochondria functionality,
10635,NCT00437268,Percentage of Participants With Progression-Free Survival (PFS) at 6 Months (PFS Rate),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events (AEs) or Who Died,
10636,NCT04597294,Peritoneal recurrence rate,2021-08-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Treatment-related quality of life assessed by Quality of Life Questionnaire-Stomach (STO22),
10637,NCT04535414,Determine if Bethesda protocol provides improved sensitivity for detection of early stage gastric cancer in CDH1 germline mutation carriers compared to the Cambridge method,2023-06-22,RECRUITING,INTERVENTIONAL,['PHASE2'],To estimate and compare the difference in crude cancer detection rates between endoscopy using the Bethesda protocol and the Cambridge method,
10638,NCT01196130,Rate of Successful Biomarker Determination,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,
10639,NCT04395118,Hepatitis C Screening,2020-08-15,WITHDRAWN,INTERVENTIONAL,['NA'],Cost Per HCV Diagnosis,
10640,NCT02045368,Maximum Tolerated Dose (MTD),2014-01-28,COMPLETED,INTERVENTIONAL,['PHASE1'],Disease Response based on RECIST Criteria,
10641,NCT02902484,Maximum Tolerated Dose (MTD),2017-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10642,NCT05625893,Incidence of adverse event assessed according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0),2022-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Local tumor progression rate,
10643,NCT03069950,Resection rate assessed using RECIST (version 1.1),2017-02-28,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
10644,NCT00056446,Overall survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Tolerability and safety profile,
10645,NCT06086002,Technique efficacy,2023-09-18,RECRUITING,INTERVENTIONAL,['NA'],,
10646,NCT01440855,Reported uptake of behavioral actions recommended in Facing Forward,2005-02,COMPLETED,INTERVENTIONAL,['NA'],Usability of Facing Forward,
10647,NCT01982227,Sensitivity (true positive) of the fluorescence ex vivo compared to histological analysis s detected by fluorescence ex vivo,2013-03,COMPLETED,OBSERVATIONAL,['NA'],Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence,
10648,NCT03693807,% frequency liver toxicity,2018-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],progression free survival,
10649,NCT01526200,new colorectal liver metastases detected at contrast-enhanced intraoperative ultrasonography,2007-10,COMPLETED,OBSERVATIONAL,['NA'],new colorectal liver metastases detected during 6-month postoperative follow-up,
10650,NCT05291338,Interleukin 28 B (IL28B) rs12979860.,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10651,NCT02056548,Cumulative incidence rate of hepatitis B viral reactivation,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],Severity of reactivation of hepatitis B,
10652,NCT05858736,Incidence of treatment emergent adverse events (TEAE),2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],"Overall survival (OS),",
10653,NCT01182272,Significant pathological changes,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Tolerance of liver resection after sorafenib tosylate treatment,
10654,NCT02103322,AUC0-tau,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Fluctuation Rate,
10655,NCT05965817,To assess the feasibility of simultaneous use of ICG and SGM-101 for intraoperative imaging of colorectal liver metastases.,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10656,NCT04058600,Hospital Anxiety and Depression Scale (HAD),2018-04-11,COMPLETED,INTERVENTIONAL,['NA'],,
10657,NCT01472419,Overall Survival,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
10658,NCT03100409,Changes in food intake,2017-02-01,TERMINATED,INTERVENTIONAL,['NA'],Change in quality of life for cervical cancer patients: (European Organization for Research and Treatment of Cancer Cervical cancer module- EORTC QLQ-CX 24),
10659,NCT05424692,The difference of 3-year disease-free survival rate of patients in both group,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],The difference of OS of patients in both group,
10660,NCT04703101,Complete clinical response rate,2021-02-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Prediction of complete clinical response rate status by radiomics,
10661,NCT05362617,ORR（objective response rate）,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],QoL（quality of life）,
10662,NCT03806244,"Accuracy of Surgical stereotactic navigation defined as the distance, in millimetres, between the position of the surgical landmark and the position determined by the navigation system",2019-07-17,TERMINATED,INTERVENTIONAL,['NA'],Number of intra and/or postoperative complication,
10663,NCT05988645,Number of mural injuries.,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],Perception of difficulty.,
10664,NCT02010801,Complete treatment,2012-04,COMPLETED,INTERVENTIONAL,['NA'],adverse effect,
10665,NCT00019019,,1994-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10666,NCT00660426,"To define the maximum tolerated dose of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.",2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],To perform correlative pharmacogenomic and pharmacokinetic tests for this novel regimen.,
10667,NCT02017366,overall survival from day of surgery,2018-10,WITHDRAWN,INTERVENTIONAL,['NA'],postoperative weight loss,
10668,NCT01843218,assess erectile dysfunction,2008-03,TERMINATED,INTERVENTIONAL,['NA'],Evaluate objectively the presence of erectile dysfunction before and 12 months after the medico-surgical treatment of rectal cancer,
10669,NCT01637350,,2012-08,UNKNOWN,OBSERVATIONAL,['NA'],,
10670,NCT05225038,"Change in participants physical capacity, as represented by hand grip strength",2022-06-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Physical capacity as represented by 6-Minute Walk Test,
10671,NCT03500068,Developing organoids from advanced pancreatic cancer patients that predict non response or response,2017-09-04,UNKNOWN,INTERVENTIONAL,['NA'],Functional studies will be done with the patient derived organoids to find biomarkers that correlate with response in organoids and patients.,
10672,NCT01076517,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
10673,NCT03520790,Overall survival,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression free survival,
10674,NCT03450447,The first day of food intake of enrolled patients,2018-03-10,UNKNOWN,OBSERVATIONAL,['NA'],The severity of stenosis,
10675,NCT02933307,Expectations & experiences of care givers,2015-04,COMPLETED,INTERVENTIONAL,['NA'],System usability Scale,Performed surgical procedure
10676,NCT04012021,Evaluate the correlation between the characteristics detected by the MRI equipment and the histological composition of ex-vivo specimens from hepatic and pancreatic tissues and lesions,2019-05-24,UNKNOWN,INTERVENTIONAL,['NA'],,
10677,NCT05628857,Objective Response Rate (ORR),2022-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Terminal elimination half life,
10678,NCT00033540,Response,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Survival Time for Participants With Relevant Biologic Markers,
10679,NCT02728596,Incidence of Febrile Neutropenia Among Intermediate Risk Participants,2016-10-07,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival (OS),Differences Among Cohort Components and Intervention and Usual Care Components
10680,NCT00070265,Rate of complete resection (R0 resection),2003-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Positron emission tomography response rate,
10681,NCT00995202,Overall survival rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease-free survival rate,
10682,NCT00448682,Number of Patients Achieving Clinical Response,2005-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants Experiencing Adverse Events,
10683,NCT01887158,quality of bowel preparation rated according to a modified Ottawa bowel preparation scale,2013-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Lesion detection (type and lesion detection rate/patient),
10684,NCT05148572,Metabolome profiling for recurrence prediction.,2021-11-10,RECRUITING,OBSERVATIONAL,['NA'],,
10685,NCT03291054,Overall Response Rate,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
10686,NCT05361161,OS,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10687,NCT00881036,,2006-08,COMPLETED,OBSERVATIONAL,['NA'],,
10688,NCT05806931,Disease control rate (DCR):,2023-05-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of Response,
10689,NCT05977478,Correlating tissue biochemical composition with the Raman spectra and histopathologic results to differentiate between the gastric disease states based on distinct features in the biochemical composition of pre-cancerous / cancerous lesions.,2022-10-27,RECRUITING,INTERVENTIONAL,['NA'],,
10690,NCT02453464,Maximum Tolerated Dose (MTD),2015-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
10691,NCT05396755,"occurrence of cholangiosepsis (defined by SEPSIS-3 criteria and diagnosis of acute cholangitis according to the Tokyo Guidelines), whatever occurs first.",2022-11-14,TERMINATED,INTERVENTIONAL,['NA'],Occurrence of unplanned hospital admissions (necessity and days free of hospital care within 6 months),occurrence of serious adverse events
10692,NCT02268825,Safety of combination mFOLFOX and MK-3475,2015-01-23,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10693,NCT04223141,Mortality,2020-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Medical complications,
10694,NCT03759548,Impact in Quality of Life during pharmacological treatments,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],Pharmacological treatment-related adverse events,
10695,NCT04162158,Overall survival,2019-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease control rate,
10696,NCT00239200,"Primary Objective: To determine the response rate of metastatic or recurrent squamous cell carcinoma of the esophagus, when treated with lapatinib (GW572016)",2005-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Secondary Objective: To determine the toxicity of this regimen,
10697,NCT05359042,Change in overall score of EQ-5D,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Predictive value of ED Visit and/or hospital admission,
10698,NCT03374293,Local control,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
10699,NCT05238558,Summary of Adverse Events,2022-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10700,NCT00019760,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10701,NCT05621629,Pena's questionnaires score before treatment,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
10702,NCT01798251,Progression Free Survival (PFS),2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events (AE),K-ras gene type
10703,NCT02301286,5 year overall survival,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Time to Treatment Failure,
10704,NCT04949282,Overall response rate (ORR),2021-05-10,RECRUITING,OBSERVATIONAL,['NA'],Health-related Quality of Life (HRQoL),
10705,NCT02184663,Health-related quality of life (HRQoL) at 16 weeks,2014-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],anxiolytic / antidepressant consumption,
10706,NCT00737373,response (WHO criteria),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10707,NCT05743426,Disease-free survival,2023-03-17,RECRUITING,OBSERVATIONAL,['NA'],Quality of life Toronto Extremity Salvage Score (TESS),
10708,NCT00002984,Number of subjects experiencing adverse events,1997-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Efficacy of treatment,
10709,NCT04875793,The enrollment rate of individuals who underwent CRC screening in the intervention group vs. control group,2021-06-10,COMPLETED,INTERVENTIONAL,['NA'],The percentage of individuals who screened positive and enrolled in colonoscopy for follow-up in the intervention group vs. control group.,
10710,NCT02495051,presence of gastric and / or intestinal metaplasia diagnosed at histology,2010-02,COMPLETED,OBSERVATIONAL,['NA'],"evaluation of actual other symptoms (respiratory, dysphagia)",
10711,NCT00386594,Elimination of high-grade dysplasia in Barrett's esophagus,2006-10,TERMINATED,INTERVENTIONAL,['NA'],,
10712,NCT05991102,Overall response rate (ORR),2023-12-15,RECRUITING,INTERVENTIONAL,['NA'],Acute and late toxicity,
10713,NCT03314532,disease-progression-free period,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],overall survival period,
10714,NCT00041691,,na,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10715,NCT02879227,Feasibility of treatment: Number of patients with completed treatment,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
10716,NCT03223142,Local control rate,2017-07,UNKNOWN,INTERVENTIONAL,['NA'],Complication rate,
10717,NCT03132740,Impact on complication of three dimensional visualization technique,2017-03-15,UNKNOWN,OBSERVATIONAL,['NA'],Postoperative results of paraffin wax and immunohistochemical index,
10718,NCT03469258,Effect of Pancreatic Enzyme Replacement Therapy on the Completion Rate of Adjuvant Chemotherapy and Radiation After Surgery for Early Stage Pancreatic Cancer,2018-04-13,TERMINATED,INTERVENTIONAL,['PHASE2'],Measure Grip Strength Before and After Surgery and Adjuvant Treatment for Early-stage Pancreatic Cancer,
10719,NCT01710293,Median Time from Initial Follow-up Delay to Follow-up Action,2017-01-27,WITHDRAWN,INTERVENTIONAL,['NA'],,
10720,NCT04954521,OS,2021-06-30,RECRUITING,OBSERVATIONAL,['NA'],PFS,
10721,NCT02541149,"serum Annexin A2 in patients with hepatocellular carcinoma, chronic liver disease and healthy subjects",2014-06,COMPLETED,OBSERVATIONAL,['NA'],,
10722,NCT01671488,"To Evaluate the 6-month Clinical Complete Response Rate for Patients With Anal Cancer Treated With ADXS11-001 Mitomycin, 5-FU and IMRT.",2013-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","To Evaluate Progression-free and Overall Survival for Patients With Anal Cancer Treated With ADXS11-001, Mitomycin, 5-FU and IMRT.",
10723,NCT01400620,Proportion of WHO score 3-4 Oral Mucositis at a Cumulative Radiation Dosage of 50 Gy in the active and Placebo Groups,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of grade 2-3-4 Oral Mucositis as measured by the WHO scale at increasing increments of cumulative radiation exposure,
10724,NCT05068206,Disease Control Rate (DCR),2021-10-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of disease remission (DOR),
10725,NCT03844347,Manifestations of Psychological Well-being Measurement,2019-10-21,RECRUITING,INTERVENTIONAL,['NA'],Physical activity evaluation,
10726,NCT02775461,Number of individuals with pancreatic diseases,2013-03-01,RECRUITING,OBSERVATIONAL,['NA'],,
10727,NCT00324987,Progression Free Survival,2008-04,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug,
10728,NCT04882423,Hydroxylated PhlP profile with both cruciferous and apiaceous vegetables,2013-09-19,TERMINATED,INTERVENTIONAL,['NA'],,
10729,NCT04179084,Objective Response Rate (ORR),2019-08-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression-free survival (PFS),
10730,NCT02147301,Number of Patients Who Developed New Severe Adverse Events,2014-12-17,TERMINATED,INTERVENTIONAL,['NA'],Median Area Under Curve (AUC),
10731,NCT01047475,The Primary Efficacy Endpoint of This Study is the Best Overall Response (Complete Response + Partial Response),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10732,NCT05893056,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-06-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,
10733,NCT05725473,Clinical efficacy,2023-01-12,RECRUITING,INTERVENTIONAL,['NA'],,
10734,NCT02834169,Incidence of rare peritoneal surface malignancies,2010-10,UNKNOWN,OBSERVATIONAL,['NA'],Impact of specific treatment strategies,
10735,NCT00059930,"Correlate thymidylate synthase, dihydropyrimidine dehydrogenase, and ERCC-1 with survival and recurrence as measured by normal and tumor liver tissue",2003-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
10736,NCT04774952,Number of participants with dose limiting toxicities (DLTs),2021-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Duration of Response (DOR),
10737,NCT04105062,Phase II only: Ability of LS301 to predict presence of positive margins,2021-12-31,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10738,NCT05498051,Safety of SLN identification,2022-09-01,COMPLETED,INTERVENTIONAL,['NA'],number of SLNs identified,
10739,NCT00123318,The percentage of major radiotherapy protocol violations,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Median survival and overall survival at 3 years,
10740,NCT02924714,Progression free survival (PFS),2017-01,SUSPENDED,INTERVENTIONAL,['NA'],Quality of Life (QoL),
10741,NCT01625702,circulating tumor cells in blood,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,
10742,NCT00316914,Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in Quality of Life (QOL) at One Month,
10743,NCT05976282,Acceptability of Participants Who Feel FIT is an Acceptable Method of Screening,2016-03-15,COMPLETED,INTERVENTIONAL,['NA'],,
10744,NCT04611165,Progression-free survival (PFS),2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10745,NCT02702323,Progress Free Survival,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Toxicity as measured by CTCAE V4.0,
10746,NCT01727921,Diagnostic accuracy,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Technical success,Complications
10747,NCT05257057,Lynch Syndrome Screen Positive Rate,2019-05-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10748,NCT06314971,Recurrence-free Survival,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],,
10749,NCT01160367,family decision-making self-efficacy,2010-08-26,COMPLETED,INTERVENTIONAL,['NA'],"family psychological outcomes (depression, caregiver burden, decision making distress)",
10750,NCT05828381,The pathological complete response rate,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The disease free survival rate,
10751,NCT00041340,Response rate,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10752,NCT05983315,Correlation between endoscopic CONECCT's classification,2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
10753,NCT03792347,Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events),2019-01-21,COMPLETED,INTERVENTIONAL,['PHASE1'],Radiographic Response,
10754,NCT04231552,Pathological complete response,2019-11-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",3-year overall survival rate,
10755,NCT05034627,Incidence of dose-limiting toxicities (DLTs),2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],Mean plasma asparaginase activity,Therapy induced changes in the tumor and tumor ecosystem
10756,NCT00711672,"Correlation of degree of ""narrative agreement"" with validated quality of life measures",2008-07,COMPLETED,OBSERVATIONAL,['NA'],,
10757,NCT05587088,Safety and efficacy,2022-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Survival,
10758,NCT02919553,Rate of core tissue acquisition adequate for histologic analysis.,2018-01,WITHDRAWN,INTERVENTIONAL,['NA'],"Cell block will be assessed of presence of any core tissue with intact architecture with this scale: graded 0 = none, 1 = present but marginal adequacy, 2 = present and adequate. Dimensions of the largest core will be noted if possible.",
10759,NCT00414492,,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,
10760,NCT05305820,Change in Cardiorespiratory Fitness,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in Nutritional Status- Blood Screening,Change in Smoking Status
10761,NCT02185443,Local Progression Free Survival,2014-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity,
10762,NCT00902759,FACIT (Facit Fatigue Scale) and Medical Outcomes Study Short Form-36 (MOS-SF-36) questionnaires,2009-01-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
10763,NCT01991873,Progression-free survival,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Health and skin related Quality of life,
10764,NCT06315855,oral health related quality of life,2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],comorbidities,
10765,NCT01871545,SubStudy 2: Perfusion Fraction (PF),2013-06,COMPLETED,INTERVENTIONAL,['NA'],Tumor Response,
10766,NCT05174156,Objective Response Rate (ORR),2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (AEs),
10767,NCT02261714,Patients' Immune Response,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinical Efficacy,Relationship Between (KRAS) Status and Clinical Efficacy
10768,NCT04460352,Eating restrictions,2020-11-27,RECRUITING,INTERVENTIONAL,['PHASE3'],Gender stratified analyses of all endpoints,
10769,NCT01293942,conversion to resectability during downsizing therapy with IXO+A patients with initially unresectable liver-only metastases associated with colorectal cancer,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"R0, R1, R2 resection rate after up to 8 cycles of downsizing therapy with IXO+A",
10770,NCT01807936,Overall survival,2013-03-20,COMPLETED,INTERVENTIONAL,['NA'],Disease free survival,locoregional recurrence and recurrence pattern
10771,NCT04374175,Serum adiponectin concentration,2020-04-01,RECRUITING,OBSERVATIONAL,['NA'],Serum adiponectin concentration,
10772,NCT02320123,Intent to Discuss Hospice Care (Based on the Transtheoretical Stages of Change Model),2016-05-23,COMPLETED,INTERVENTIONAL,['NA'],Health Care Utilization: Mean Number of Hospitalizations in Six Months by Group,
10773,NCT05261113,Outcome relevance of CE-IOUS,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],Sensitivity and Specificity of CE-IOUS compared to other imaging methods,
10774,NCT00905047,patients preference after randomization and cross-over,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],safety of each treatment,
10775,NCT05263336,Anastomotic leak,2021-01-03,RECRUITING,INTERVENTIONAL,['NA'],Postsurgical Ileus,
10776,NCT05641129,Primary outcome,2023-01-16,COMPLETED,OBSERVATIONAL,['NA'],Secondary outcome 9,
10777,NCT04389632,Number of participants with dose-limiting toxicities (DLTs),2020-06-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of participants with antidrug antibodies (ADAs),
10778,NCT03297255,Time of Death,2013-01-01,RECRUITING,OBSERVATIONAL,['NA'],Time of metastasis,
10779,NCT04643366,Three-year disease free survival (DFS),2021-01-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of patients who do not require an ostomy at time of surgery,
10780,NCT04097795,Costs,2019-07-01,TERMINATED,OBSERVATIONAL,['NA'],Care-related burden among informal caregivers,
10781,NCT04813861,Lesion Response,2010-01-04,COMPLETED,OBSERVATIONAL,['NA'],Delayed Lesion Response,
10782,NCT03998202,Number of Chemotherapy Toxicities (Grade 3 - 5),2019-09-23,RECRUITING,OBSERVATIONAL,['NA'],Overall Survival,
10783,NCT02340975,Progression Free Survival at 6 (PFS-6) Month in Phase 2,2015-03-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Percentage of Participants With Objective Response in Phase 2 by Programmed Death-ligand (PD-L1) Status,
10784,NCT00959738,Severe stoma specific morbidity rate,2008-08,TERMINATED,INTERVENTIONAL,['NA'],Predictive factors for stomal complications,Number of stoma bags and self-adhesive plates needed in the first month after the operation
10785,NCT04823715,Disease-free survival of the patient after start of treatment,2020-10-15,COMPLETED,OBSERVATIONAL,['NA'],,
10786,NCT00003237,,1998-06-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10787,NCT05810714,Number of Participants to Return Fecal Immunochemical Test (FIT),2021-11-20,COMPLETED,INTERVENTIONAL,['NA'],,
10788,NCT02430662,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Overall survival (OS),
10789,NCT05938504,Skeletal Muscle Index (SMI) change rate,2023-03-14,RECRUITING,INTERVENTIONAL,['NA'],Oral nutritional supplement (ONS) sensory evaluation,
10790,NCT01540344,Progression-free survival (PFS),2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Pathohistological regression,
10791,NCT04242342,local control at 2 years,2020-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
10792,NCT00675012,To determine the feasibility and safety of NGRhTNF administered at low (0.8 mcg/sqm) and high (45 mcg/sqm) doses in combination with a standard oxaliplatin-based regimen in two sequential cohorts of patients with metastatic colorectal cancer.,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate the pharmacokinetic profile of NGRhTNF and to measure plasma levels of sTNF-RI and sTNF-RII,
10793,NCT03791073,Predictive value of each protein contained in Cytolyt® for the positive diagnosis of pancreatic ductal adenocarcinoma,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],"Biomarkers that are prognostically significant on disease free or overall survival in patients with pancreatic cancer, identified using the survival analysis",
10794,NCT01862562,Early complication rate,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Health-related QOL score,
10795,NCT05485909,Objective response rate (ORR),2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to disease progression (TTP),
10796,NCT04002479,Safety - Adverse events,2020-10-20,RECRUITING,INTERVENTIONAL,['NA'],Change in quality of life: QLQ-PAN26,
10797,NCT05975463,Objective response rate (ORR),2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),
10798,NCT00516230,,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10799,NCT02209415,Number of patients eligible for treatment,2011-04,UNKNOWN,INTERVENTIONAL,['NA'],,
10800,NCT04583488,Maximum Tolerated Dose (MTD),2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-Free Survival,
10801,NCT05329597,Genotyping,2020-06-24,UNKNOWN,OBSERVATIONAL,['NA'],,
10802,NCT01360255,"comparison of liver cancer markers AFP, AFP-L3% and DCP before and after TACE",2010-05,COMPLETED,OBSERVATIONAL,['NA'],progression- free - time,
10803,NCT04089657,Disease control rate(DCR),2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events（AE）,
10804,NCT06184555,postoperative complication,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10805,NCT02120911,% of patients completing trastuzumab and pertuzumab treatment.,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacokinetics of pertuzumab and trastuzumab,SUV of pre-treatment trastuzumab-PET
10806,NCT01079780,Progression-free Survival,2011-01-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
10807,NCT00513266,Pathological complete response rate of lesions of less than or equal to 30 mm in size assessed by pathologic examination in resected specimens,2007-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicity as assessed by NCIC criteria,
10808,NCT02721563,Objective response rate,2016-02-25,COMPLETED,INTERVENTIONAL,['PHASE4'],Progression free survival,
10809,NCT00338988,Number of Participants With Objective Response,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10810,NCT03334591,progress free survival(PFS),2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
10811,NCT00268840,Overall response rate,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate the frequency and severity of the adverse events related to the combination of gemcitabine and docetaxel,
10812,NCT02824185,Specificity of FCH-PET/MRI for the detection of preoperative lesions,2017-06-14,COMPLETED,INTERVENTIONAL,['NA'],Costs avoided and induced by performing FCH-PET/MRI,
10813,NCT05402124,Measurement of Adverse Events,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Factors related to uptake, in-study adherence and post-study maintenance using measurement of chemoprevention knowledge",
10814,NCT04402424,Colorectal Cancer,2019-07-16,COMPLETED,OBSERVATIONAL,['NA'],Other Significant Colorectal Disease,
10815,NCT01733147,Change in Esophageal Tissue PGE2 Levels,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4'],Change in Esophageal Macrophage Markers,
10816,NCT04381130,Overall survival,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in quality of life assessed with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 version 3.0,
10817,NCT03572101,Quality of life (EQ-5D-5L scores),2018-01-11,COMPLETED,OBSERVATIONAL,['NA'],"Patient-reported concerns (emotional, social/family/spiritual, practical, physical, mobility, nutrition, informational, other)","Overall level of support received by patients/caregivers from homecare, cancer centre, long term care, hospital and hospice services at end of life"
10818,NCT02897375,Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin,2016-10-24,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax),
10819,NCT00503932,Maximum Tolerated Dose (MTD),2007-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10820,NCT00006103,overall survival,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10821,NCT02141906,Response,2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression,
10822,NCT03548844,DFS,2018-05-24,UNKNOWN,INTERVENTIONAL,['NA'],Quality of life,
10823,NCT00190385,Incidence of small hepatocellular carcinoma (HCC),2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Clinical value of serum alfa-fetoprotein assay,
10824,NCT00003344,,1998-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10825,NCT01668849,Pain caused by oral mucositis,2012-08-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Level of immune biomarkers in mucosal tissue,
10826,NCT05795595,Phase 2 (Cohort Expansion): Objective response rate (ORR),2023-03-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10827,NCT01836926,Early Complications number,2013-04,COMPLETED,INTERVENTIONAL,['NA'],Clinical functional outcome,
10828,NCT00414271,Number of Participants With Pathological Response,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Correlation of CGH and Gene Expression Profile and Their Changes After Chemotherapy With the Same Clinical Outcomes,
10829,NCT04874519,Build a Fibrolamellar Cancer/FLC registry,2021-11-24,RECRUITING,OBSERVATIONAL,['NA'],,
10830,NCT02503696,Sensitivity and Specificity of the Exact CRC diagnostic screening test.,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,
10831,NCT00711243,Response Rate in Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction (Phase II),2005-04-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Toxicity Profile,
10832,NCT04210115,Overall Survival (OS),2020-02-28,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of participants discontinuing study treatment due to an adverse event (AE),
10833,NCT01236690,"The evaluation of the patient's respondence for the therapy is carried out every phase, according to RECIST:CR,PR,SD and PD.",2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10834,NCT00963352,3-year disease free survival (DFS),2007-01,UNKNOWN,OBSERVATIONAL,['NA'],5-year overall survival (OS),
10835,NCT00162669,"The main response parameter will be the disease control rate, defined by the objective response and stable disease rate (Response Evaluation Criteria in Solid Tumors [RECIST criteria]) after two consecutive tumor evaluations during treatment.",2005-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Evaluation of vascular changes will be performed using Doppler ultrasound with injection of sonographic contrast agent,
10836,NCT06006650,Pathologic complete response rate (pCR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival(OS),
10837,NCT04120701,3-year Disease-Free Survival in ctDNA positive patients,2020-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10838,NCT01703390,Response,2012-12-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of adverse events during study treatment,
10839,NCT04152018,Duration of Response (DR) for Dose Expansion,2019-11-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival,
10840,NCT00349336,Weekly Steady-state Exposure of Bevacizumab,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Terminal Half-life of Bevacizumab,
10841,NCT03627390,Sum CTC score,2014-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of registered adverse events,
10842,NCT04005339,"The efficacy of fluorouracil, leucovorin, and nanoliposomal irinotecan in advanced biliary tract cancers following progression on or intolerance of gemcitabine and platinum chemotherapy.",2019-07-29,RECRUITING,INTERVENTIONAL,['PHASE2'],"Maximum change in tumor marker, CA19-9.","Archived tumor tissue using next-generation sequencing (NGS) and immunohistochemistry (IHC) in order to elucidate potential mutational biomarkers predictive of response to fluorouracil, leucovorin, and nanoliposomal irinotecan."
10843,NCT00256321,Determine time to progression,2004-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Evaluate the expression of the Cox-2 on paraffin-embedded tumor sections from patients enrolled on the study and correlate expression with clinical response,
10844,NCT00531297,Recurrence rate,2005-12-01,TERMINATED,INTERVENTIONAL,['NA'],Perioperative mortality,
10845,NCT00573131,Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10846,NCT02424838,Proportion of diagnostic cell block specimens obtained according to needle size and the use of suction.,2014-07-28,COMPLETED,INTERVENTIONAL,['NA'],Rate of complications,
10847,NCT05575765,"Tumor images of multimodal digestive endoscopy, combination of high-definition white light endoscopy, endoscopic cerenkov luminescence imaging (ECLI) and probe-based confocal laser endomicroscopy (pCLE)",2023-08-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
10848,NCT03173729,Sensitivity and specificity of a point of care device to diagnose colorectal cancer and polyps,2017-02-11,RECRUITING,OBSERVATIONAL,['NA'],Cost per patient of point of care urine test for diagnosing patients with colorectal cancer and polyps.,
10849,NCT01665274,3-year DFS,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2'],overall survival,
10850,NCT05572684,Define a recommended Phase 2 dose (RP2D) of NC410 when combined with standard dose Pembrolizumab,2022-10-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free Survival (PFS) per RECIST,
10851,NCT06236321,To assess if subsets of Rectal Cancers can be correlated with FFC scan hydrogen ion dissociation curves,2022-11-04,RECRUITING,INTERVENTIONAL,['NA'],To determine correlation between faecal microbial composition and response to neoadjuvant chemoradiotherapy,
10852,NCT02414009,Progression-free survival of FOLFIRI versus CAPTEM,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life measured by EORTC FACT-C,
10853,NCT02849717,The primary outcome measure for this study is fatigue assessed by the FACIT-F fatigue subscale..,2016-03,COMPLETED,INTERVENTIONAL,['NA'],Quality of Life (QOL) on self reported psychological distress questionnaires: Spielberg State/Trait Anxiety Inventory (STAI Form Y-1).,
10854,NCT04540159,Immune Checkpoint levels,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10855,NCT00587067,Number of Patients With Treatment Related Toxicity,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Survival,
10856,NCT05340231,PFS,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Pathological response rate (PCR+MPR),
10857,NCT00049322,Neovessel Formation as Measured by Angiogram at 14 Weeks,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Measure (Vascular Endothelial Growth Factor)VEGF Before and After TACE With and Without Bevacizumab,
10858,NCT06328361,Disease-free survival,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Complication rates,
10859,NCT05794841,Diagnostic performance of positive predictive value (PPV) and negative predictive value (NPV).,2023-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
10860,NCT03131921,Resting energy expenditure,2016-04-05,COMPLETED,OBSERVATIONAL,['NA'],Total energy expenditure,
10861,NCT04683731,"Decision Quality assessed using the multi-dimensional measure of informed consent (MMIC) which incorporates knowledge, intent, and behavior.",2021-01-19,COMPLETED,INTERVENTIONAL,['NA'],Number of providers who open their provider notification,
10862,NCT01362790,Recommended Phase 2 Dose (RP2D) in Drug Lot FIL129J01,2011-05-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of Response,Count of Participants SS1P Cycles Received Following Onstudy
10863,NCT05563922,Organ preservation rate at 3 years,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],5-year overall survival（OS） rates,
10864,NCT02185937,imatinib area under the curve,2014-08,TERMINATED,INTERVENTIONAL,['PHASE1'],number of adverse events,
10865,NCT00177307,Progression Free Survival (PFS),2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],"1-, 2-, and 3-year Overall Survival",
10866,NCT02905188,Number of Patients with Dose Limiting Toxicity,2019-03-28,COMPLETED,INTERVENTIONAL,['PHASE1'],Median T cell persistence,
10867,NCT05359861,"Progression Free Survival (PFS) according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)",2022-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Serum concentrations of atezolizumab,
10868,NCT03612674,Adenoma Detection Rate (ADR),2018-04-04,UNKNOWN,INTERVENTIONAL,['NA'],Colonoscopists' ADR in the previous year,
10869,NCT05585814,Tumor regression grade (TRG),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life score (QoL score),
10870,NCT03404921,The procedure time,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],The rate of injury to the muscular layer,
10871,NCT06248879,Body Mass Index,2024-02-28,WITHDRAWN,INTERVENTIONAL,['NA'],Feeding amount,
10872,NCT05786716,Durable Clinical Benefit (DCB),2023-03-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Mean change from baseline in the PedsQL 4.0 Standardised Area Under total Scale Score Curve (PedsSAUC) in parents from paediatric participants,
10873,NCT03209076,Urinary dysfunction,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],Costs,
10874,NCT05200611,The efficacy of fecal immunochemical test to detect advanced adenoma,2022-01-04,UNKNOWN,OBSERVATIONAL,['NA'],The efficacy of fecal immunochemical test to detect colorectal neoplasms,
10875,NCT04783844,Accuracy,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10876,NCT01674907,Clinical/demographic patient characteristics at baseline,2010-03,COMPLETED,OBSERVATIONAL,['NA'],Relationship between termination of Avastin treatment and time point of progression,
10877,NCT03191604,Altered chosen treatment modality due to NBI,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],Differences in pathology identification between subgroups,
10878,NCT01267695,Rate of disease recurrence at 2 years,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine the safety and tolerability of this drug in these patients.,
10879,NCT00033748,Recurrence free survival,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,
10880,NCT06293014,Time to treatment failure (TTF),2024-02-23,RECRUITING,INTERVENTIONAL,['PHASE2'],European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30),
10881,NCT03494543,technical success,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],concordance of histology pre- and post endoscopi papillectomy,
10882,NCT03263663,Progression-free-survival,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10883,NCT02138422,Response Rate,2014-07-31,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10884,NCT00834028,tumor progression,2007-02,COMPLETED,OBSERVATIONAL,['NA'],,
10885,NCT00827554,time-to-progression(TTP),2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Progression Free Survival (PFS),
10886,NCT01251666,Ratio of sensitivities (RSN) for detection of advanced neoplasias,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Positivity rate,
10887,NCT03649035,Number of participants with feasible EUS-guided Cryothermal Ablation,2018-07-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Number of participants with treatment-related adverse events,
10888,NCT06071507,Clinical Success,2023-11-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Nutritional status,Overall Survival
10889,NCT03577808,Response of the rectal cancer organoids to irradiation and the same chemotherapy drugs as the corresponding patient.,2018-08-17,UNKNOWN,OBSERVATIONAL,['NA'],Response of the rectal cancer patients to neoadjuvant chemoradiation.,
10890,NCT03206866,serum regucalcin in HCC patients,2016-12-30,UNKNOWN,OBSERVATIONAL,['NA'],,
10891,NCT06187597,Progression-free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Correlation between serum cytokines and overall survival and immune-related adverse events
10892,NCT04985071,Pancreatic fistula,2021-08-18,RECRUITING,OBSERVATIONAL,['NA'],Bleeding complication,
10893,NCT02112162,Radiosensitivity index,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10894,NCT02374931,Standard uptake value (SUV) measured as percent injected dose per cc,2015-04,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],IHC staining intensity in tissue samples,
10895,NCT04466189,Establish a cohort of Pancreatic cancer patients treadted with proton beam therapy.,2018-09-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
10896,NCT00005910,,2000-06,COMPLETED,INTERVENTIONAL,['NA'],,
10897,NCT01747096,Detection of Gastroenteropancreatic Neuroendocrine Tumors lesions in the initial assessment or during the search of recurrence.,2012-11,COMPLETED,INTERVENTIONAL,['NA'],Compare the diagnostic performance of PET / CT with 68Ga-DOTANOC with the standard process,Tolerance of 68-Ga-DOTANOC
10898,NCT03689231,Could the evolution of the initial liver tumor volume (on two follow-up CT scans / MRI over a period of 3 to 6 months) be predictive of progression-free survival according to the RECIST criteria?,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],Could the evolution of the initial liver tumor volume (on two follow-up CT scans / MRI over a period of 3 to 6 months) be predictive of progression-free survival according to the RECIST criteria?,
10899,NCT03606863,morbi-mortality,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10900,NCT00008060,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10901,NCT00241722,To compare alvimopan with placebo for long-term safety and tolerability,2005-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],"Quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data)",
10902,NCT03674801,"Percentage of different managements according to the described method : The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon (Gastrointest. Endosc. 58, S3-43 (2003)",2019-02-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],"""SF36"" questionnaire",
10903,NCT02089373,The percentage of cancer cells in biopsy samples,2014-03,COMPLETED,INTERVENTIONAL,['NA'],,
10904,NCT06125262,Overall survival and disease-free survival.,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],Event-free survival,
10905,NCT05010226,To evaluate clinical benefit response (CBR),2021-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Impact on Quality of Life and Cost
10906,NCT00790569,CO-confirmed 7-day Abstinence,2008-09,COMPLETED,INTERVENTIONAL,['NA'],Change in Cigarettes Per Day,
10907,NCT00544362,Tolerance to neoadjuvant therapy,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Mortality,
10908,NCT04011982,Determination of the correlation between clinical characterizations and biological characterizations of patients suffering from exocrine pancreatic cancer,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],Comparison of healthy tissu and tumor stroma from primitive tumor versus from metastases,
10909,NCT03458949,variation of the rate of participation in colorectal cancer screening,2018-06-18,UNKNOWN,INTERVENTIONAL,['NA'],,
10910,NCT00006468,,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10911,NCT01966081,Measure of polyunsaturated fatty acids in adipose tissue lipids.,na,UNKNOWN,INTERVENTIONAL,['NA'],,
10912,NCT03474341,Histopathologic response,2018-04-09,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival.,
10913,NCT02581059,Subject Fatigue Assessment,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Evaluate Overall Survival (OS),
10914,NCT02071043,The primary study end point was the response rate of preoperative XELOX followed by surgery in gastric cancer patients with PAN involvement,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Grade 3 or 4 Adverse Events as a Measure of Safety,
10915,NCT05363007,12W-PFS,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10916,NCT02899325,Sensitivity of 18F-FDGal in the diagnosis of HCC on per-patient basis,2019-10,WITHDRAWN,OBSERVATIONAL,['NA'],Specificity of 18F-FDGal in the diagnosis of HCC,
10917,NCT01321957,progression free survival rate,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life evaluated by questionnaire,
10918,NCT00873756,Incidence and nature of dose-limiting toxicities,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Incidence of anti-dulanermin antibodies,
10919,NCT03127007,Rate of complete pathological response,2017-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10920,NCT04812912,"Change in testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH in young male patients (<50y) undergoing therapy for colorectal cancer",2021-03-18,RECRUITING,OBSERVATIONAL,['NA'],,
10921,NCT06258824,Diagnostic Value as measured by Area under the Curve (AUC) for candidate miRNAs,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10922,NCT01335958,Nature of dose-limiting toxicities (DLTs) graded per NCI CTCAE v4.0,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Volume of distribution,
10923,NCT00460603,Percentage of Participants With Objective Response: Phase 2,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2,
10924,NCT01762813,Cancer-specific survival,2013-01-01,RECRUITING,OBSERVATIONAL,['NA'],Recurrence-free survival,
10925,NCT02853500,Capillary permeability (Ktrans) calculated by software that analyzes enhancement on post-contrast MRI.,2016-07,RECRUITING,INTERVENTIONAL,['NA'],Time To Tumor Progression,
10926,NCT04185779,Occurrence of colorectal neoplasia,2019-12-13,RECRUITING,OBSERVATIONAL,['NA'],Number of participants who consent for future contact,
10927,NCT00555620,Number of Participants With First-cycle Dose Limiting Toxicities (DLTs),2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression-Free Survival (PFS),
10928,NCT05018156,Genetics referrals,2021-11-10,COMPLETED,INTERVENTIONAL,['NA'],Genetic testing,
10929,NCT05245474,pCR rate,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],quality of life score,
10930,NCT01831531,3-yr local control rate,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
10931,NCT01462513,Comparative evaluation of recurrence-free survival (RFS) time and 3 year overall survival (OS) time between the treatment groups (L-BLP25 plus cyclophosphamide versus placebo and saline infusion).,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival time in a subgroup of MUC1 positive cancers,
10932,NCT05442749,Efficacy of niraparib in patients with HR-deficient pancreatic cancer,2022-10-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerability of niraparib in pancreatic cancer patients,PD biomarkers of response and resistance to niraparib
10933,NCT03469557,Host immunogenicity: BGB-A317 anti-drug antibody (ADA),2017-07-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10934,NCT06026800,Number of Participants with Adverse Events (AEs) [safety and tolerability],2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Cytokines Level [immunogenicity],
10935,NCT00044863,"Determine the response rate of cetuximab in patients with EGFR-positive, metastatic carcinoma",2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10936,NCT00516945,incidence of chemotherapy interruptions,2004-09,COMPLETED,INTERVENTIONAL,['NA'],chemotherapy dose intensity reduction due to hepatitis B reactivation,
10937,NCT06049511,World Health Organization Oral Mucositis Toxicity Scale,2021-08-15,COMPLETED,INTERVENTIONAL,['NA'],Oral assessment guide,
10938,NCT02870582,Overall Survival (OS),2016-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety variables will be summarized using descriptive statistics based on adverse events collection,
10939,NCT05494320,neurotoxicity,2021-08-15,RECRUITING,OBSERVATIONAL,['NA'],,
10940,NCT02296203,percentage of patients achieving a decrease equal or more than 30% in the sum of the longest diameters of target lesions,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10941,NCT04506840,Strength,2020-01-21,RECRUITING,INTERVENTIONAL,['NA'],Depression and anxiety,
10942,NCT03355612,Disease Free Survival(DFS),2017-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Adverse Events,
10943,NCT04736472,Penetrance: proportion of pharmacogenetic tests ordered by providers,2021-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Grade 3 or higher toxicity,
10944,NCT00483834,Objective Response Rate,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10945,NCT01775514,"Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region",2012-10,COMPLETED,OBSERVATIONAL,['NA'],Percentage of Participants Categorized by Tumor Localization,
10946,NCT03899636,Overall Survival,2021-02-23,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10947,NCT05450484,2) Incidence of (severe) adverse events (SAE/AEs) related to administration of durvalumab-680LT assessed by CTCAE,2023-04-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,
10948,NCT04278274,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system and expert radiologists in prediction tumor response,2020-02-08,RECRUITING,OBSERVATIONAL,['NA'],The sensitivity of AI prediction system and expert radiologists in prediction tumor response,
10949,NCT02173756,change in pain of mucositis before and after meal,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],Evaluation of the local tolerance and other topical treatment taken throughout the mucositis,
10950,NCT04225364,Pathologic complete remission (PCR),2020-01-17,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),perioperative adverse events
10951,NCT02861300,PHASE 2: Number of patients with response to treatment,2016-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE 1: proportion of patient who respond to treatment,
10952,NCT04835402,Serious adverse reaction (SAR) rate according to CTCAE v5,2021-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Adverse event rate (CTCAEv5, all grades)",
10953,NCT05497739,The incidence of peritoneal metastasis,2022-06-28,RECRUITING,INTERVENTIONAL,['PHASE2'],The safety,
10954,NCT01806649,disease control rate,2013-07-01,TERMINATED,INTERVENTIONAL,['PHASE2'],overall survival,
10955,NCT00272051,Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment : Q2W ; response rate using RECIST criteria : Q8W,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety : Q2W ; Nerve conduction studies : Baseline + cycle 12 ; Progression Free Survival : Q8W ; Survival,
10956,NCT05782608,Assessment of Pain,2023-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
10957,NCT03151759,Matrilysin levels,2002-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
10958,NCT06060106,Recurrence free survival (RFS),2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],Post-operative hospitalization days,
10959,NCT03069833,"Sensitivity, Specificity, False Positive, False Negative",2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10960,NCT02806037,localization rate of liver tumor,2015-11,COMPLETED,OBSERVATIONAL,['NA'],,
10961,NCT03958032,Postoperative complications,2016-12-03,COMPLETED,OBSERVATIONAL,['NA'],Major complication,
10962,NCT02767557,Overall survival at 6 months,2017-01-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life (Quality of Life Questionnaire C30 (QLQ-C30) Version 3.0).,
10963,NCT01488045,Patient Satisfaction Scores (Absolute Value),2011-06,COMPLETED,INTERVENTIONAL,['NA'],Physician Perceptions (Absolute Value),
10964,NCT03517176,Optimal Biological Dose (OBD) of CEND-1 when given in combination,2018-07-31,COMPLETED,INTERVENTIONAL,['PHASE1'],Preliminary evidence of anti-tumor activity of CEND-1 when given in combination with nabpaclitaxel bound and gemcitabine by objective radiographic assessment according to RECIST 1.1,Immunohistochemical assessment of tumor biopsies for the expression of Neuropilin-1 in order to study if the response to CEND-1 therapy can be predicted based on the Neuropilin-1 expression level
10965,NCT00171977,To evaluate the relapse-free survival (RFS) in patients receiving postoperative adjuvant therapy,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Safety,
10966,NCT00135005,To determine the MTD which will be the Phase II dose of AMN107 when given in combination with Imatinib. The MTD is defined to be the highest dose of AMN107 in combination with Imatinib given for at least 21 days in the first treatment cycle,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],patients showing progression of disease on Imatinib. The patient will be followed-up for at least 4 cycles (28 days for one cycle),
10967,NCT00022373,,2000-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10968,NCT02965521,Adherence,2017-04-10,COMPLETED,INTERVENTIONAL,['NA'],Change in fasting glucose,
10969,NCT05862181,Overall Survival (OS),2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],Duration of Response (DoR),
10970,NCT05036265,Prognostic factors,2011-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
10971,NCT06178809,The advance time of ctDNA dynamic detection compared with AFP+ imaging in monitoring of primary hepatocellular carcinoma recurrence or progression,2023-12-25,RECRUITING,OBSERVATIONAL,['NA'],,
10972,NCT05785325,Objective Response Rate,2023-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Overal survival,
10973,NCT01442506,diagnostic yield of targeted biopsies with high definition endoscopy using i scan virtual chromoendoscopy and acetic acid guided biopsies,2009-04,UNKNOWN,OBSERVATIONAL,['NA'],,
10974,NCT04609592,Measure Complication free Surgery,2021-03-17,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
10975,NCT01896986,Immunogenicity to HPV Vaccine Gardasil,2012-03,TERMINATED,OBSERVATIONAL,['NA'],,
10976,NCT03840239,Rate of clinical complete response,2018-12-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],5 year overall survival,
10977,NCT04181931,"Progression-free survival, PFS",2019-12-16,RECRUITING,INTERVENTIONAL,['NA'],"Overall survival, OS",
10978,NCT05414448,ADR,2023-03-07,RECRUITING,INTERVENTIONAL,['NA'],False positive rate,
10979,NCT04616183,Best overall response (complete response [CR] + partial response [PR]),2020-12-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of adverse events,
10980,NCT00410462,"Six-month progression-free survival, in terms of complete response, partial response, or no change",2006-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
10981,NCT06048133,"Estimate the progression free survival (PFS) with gemcitabine, cisplatin, quemliclustat (AB680) and zimberelimab (AB122) in patients with advanced BTCs.",2024-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Evaluate safety of the proposed drug combination.,
10982,NCT00670553,Establish Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD),2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety profile of oral LBH589 when given in combination with standard Radiotherapy,
10983,NCT03191110,Quality of life (EORTC QLQ-C30),2010-08-03,RECRUITING,OBSERVATIONAL,['NA'],Co-morbidities,
10984,NCT04364373,5-year overall survival,2020-03-31,RECRUITING,INTERVENTIONAL,['NA'],Late postoperative complications rate,
10985,NCT01874665,Clinical Benefit Rate (CBR) in Cohort A,2013-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],"Cmax, SS: Maximum Observed Plasma Concentration at Steady State for Ponatinib",
10986,NCT04768686,Overall response rate in subjects treated with FLX475 in combination with pembrolizumab,2021-05-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10987,NCT01663272,Maximum Tolerated Dose,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Median Progression-free Survival (PFS),
10988,NCT01049880,"Blood cell counts (neutropenia, thrombocytopenia) and serum chemistries (liver function tests, creatinine)",2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Survival,
10989,NCT04115163,Overall response rate (ORR),2020-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
10990,NCT00352755,Safety and Tolerability of the Planned Treatment Regimen as Measured by Number of Participants With Grade 3 or Higher Adverse Events,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
10991,NCT03652896,prognosis,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],hospital stay,volume of transfusion
10992,NCT01334112,Response rate,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events as a Measure of Safety,
10993,NCT05870969,Early diagnosis rate of HCC patients,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],The 3-year cumulative incidence of liver cancer in each subject category according to the risk stratification at the time of initial diagnosis,The compliance rate of each risk group defined at the initial risk stratification
10994,NCT05366881,Detection of cancer,2022-05-03,RECRUITING,OBSERVATIONAL,['NA'],Clinical outcomes,
10995,NCT03373188,Evaluate treatment effects of the study drugs on tumor cluster of differentiation 8+ (CD8+) T cell infiltration between the treatment groups.,2017-12-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events scale version 4.0,
10996,NCT03320317,Length of stay,2018-03-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Complication rate,
10997,NCT02800005,postoperative complications,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],Change of the postoperative AFA,
10998,NCT00438256,Number of Participants With Grade 3 or Greater Toxicity in Phase II,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Treatment Related Serious Adverse Events,
10999,NCT03099629,Changes of forced vital capacity (FVC),2015-03,COMPLETED,INTERVENTIONAL,['NA'],Changes of dyspnea using Modified Borg Dyspnea score,
11000,NCT05111860,Peri-operative complications,2022-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
11001,NCT04756648,Adverse Event of Special Interest （ AESI）,2021-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Antitumor efficacy-Duration of disease control (DDC),
11002,NCT00692770,Recurrence Free Survival (RFS) by Independent Assessment,2008-08-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - MET
11003,NCT02360605,Repeat Screening,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,
11004,NCT05700656,Objective response rate (ORR),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","RNA sequencing, THG-b signaling, other",
11005,NCT04066894,Sacral Nerve Stimulation (SNS) Success,2019-04-12,TERMINATED,INTERVENTIONAL,['PHASE2'],European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal 29,
11006,NCT06173375,Proportion of Follow-up colonoscopy after abnormal stool blood test result,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Number of colorectal cancer cases detected,
11007,NCT01507545,Progression-Free Survival (PFS),2012-03-27,TERMINATED,INTERVENTIONAL,['PHASE2'],"Biomarkers Based OS, Within Treatment Group",
11008,NCT02868632,Overall Survival,2016-08-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Immune-related Response Criteria (irRC),
11009,NCT03708705,relapse rate of tumor,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA'],,
11010,NCT00565370,Progression-free Survival,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Toxicity Profile (According to National Cancer Institute Common Terminology Criteria for Adverse Event Version 3.0),
11011,NCT00025129,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11012,NCT02181556,Rate of Patients Alive and Progression-free 6 Months After Inclusion.,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free Survival,
11013,NCT02425657,MCSAT (Mayo Clinical Skills Assessment Tool),2016-09-14,UNKNOWN,OBSERVATIONAL,['NA'],Endoscopy training computer generated data - Total score,
11014,NCT04219332,Total Number of Retrieved Lymph Nodes,2019-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],3-year overall survival rate,
11015,NCT02852161,Diagnostic accuarcy,2016-07,COMPLETED,INTERVENTIONAL,['NA'],comfort,
11016,NCT04086888,OS (overall survival),2016-12-12,UNKNOWN,OBSERVATIONAL,['NA'],progression-free survival (PFS),
11017,NCT01527409,"Changes from Baseline in Exercise, Diet, and Posttraumatic Growth Inventory(PTGI)",2012-02,UNKNOWN,INTERVENTIONAL,['NA'],Cancer Belief System(CBS),
11018,NCT03849352,"To evaluate whether patients who have undergone CRC treatment are able to comply with remote follow-ups using telephone reviews and digital technology to help promote and track individual healthy lifestyle, diet and PA changes.",2019-03-18,UNKNOWN,INTERVENTIONAL,['NA'],To ascertain whether there was any change in diet and lifestyle factors from baseline to end of intervention (2 months),
11019,NCT00680420,Gene expression profile is 95% accurate in diagnosis of malignancy,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
11020,NCT00091286,Number of patients with an immune response to the peptides,2003-03-24,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Immunogenicity of the peptide mixture measured in the peripheral blood,
11021,NCT03645148,Number of participants experiencing clinical and laboratory adverse events (AEs),2017-10-24,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression Free Survival,Peripheral blood T cell receptor sequencing analysis
11022,NCT05559151,mortality rate,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
11023,NCT00698451,The Primary Efficacy End Point is the Number of Patients With an Objective Response.,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],The Secondary Efficacy Endpoints is Duration of Objective Response.,
11024,NCT02526953,3-year disease-free survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Late toxicity measured according to Radiation Therapy Oncology Group (RTOG) criteria,Quality of life according to European organization for research and treatment of cancer (EORTC) Quality of Life questionnaire (QLQ)-C30 (v.3) scale
11025,NCT02828865,Tumor response,2012-11,COMPLETED,INTERVENTIONAL,['NA'],Assess for presence of adverse events,
11026,NCT00309517,Overall survival,1997-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11027,NCT01536054,"Safety of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine in combination with varying dose levels and schedules of sirolimus, assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4",2012-08-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to disease progression,
11028,NCT00188292,,2002-08,COMPLETED,OBSERVATIONAL,['NA'],,
11029,NCT00893295,Intervention impact on colorectal cancer (CRC) screening utilization over the 6-month observation period,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Intervention impact on population health-management representations related to CRC screening, as assessed by perceived salience and coherence and self-efficacy-related CRC screening measured with 6 to 10 Likert-type items on both the baseline and end ...",
11030,NCT04497038,Maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D),2021-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacokinetic (PK) profile: Elimination clearance (L/hr),
11031,NCT04062058,PCR rate,2019-11-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],R0 resection rate,
11032,NCT00207298,Change in management based on PET procedure,2005-06,COMPLETED,OBSERVATIONAL,['NA'],Safety of 18F-FDG,
11033,NCT04183088,Randomized cohorts: Progression-free survival (PFS) (co-primary),2020-12-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Randomized cohort: progression-free survival (PFS),
11034,NCT04008407,Rate of surgical referral,2017-08-14,RECRUITING,INTERVENTIONAL,['NA'],Adenoma recurrence rate,
11035,NCT02174575,Postoperative acute kidney injury,2014-07,WITHDRAWN,INTERVENTIONAL,['PHASE4'],Urine albumin concentration,
11036,NCT02867865,Overall Survival,2016-09-06,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Deterioration free rate of quality of life (QOL) scores at baseline and three monthly,
11037,NCT02544737,"The proportion of patients with response (CR, PR, SD and PD based on RECIST version 1.0) assessed at 5-6 weeks after the initiation of treatment.",2015-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],"The proportion of patients alive (overall survival rate) from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study.",
11038,NCT05216237,Objective Response Rate (ORR),2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (AEs),
11039,NCT06302400,"The incidence of adverse and serious adverse events in patients receiving individualized treatment with 166Ho- microspheres, using National Cancer Institute CTCAE v5.0.",2024-02-22,RECRUITING,INTERVENTIONAL,['NA'],"The rate of efficacy as defined as overall response rate (ORR) in patients receiving individualized treatment with 166Ho- microspheres, using modified RECIST (mRECIST) response evaluation criteria.",
11040,NCT00341575,,2005-09-28,COMPLETED,OBSERVATIONAL,['NA'],,
11041,NCT02534246,Direct Comparison of pancreatic mass histologic tissue adequacy using two EUS guided fine needle biopsy needles,2016-08,WITHDRAWN,INTERVENTIONAL,['NA'],,
11042,NCT03448757,non-invasive hemodynamic parameter measurements during exposure AM RF EMF,2018-02-15,RECRUITING,INTERVENTIONAL,['NA'],Hemodynamic alteration´s comparison among advanced cancer patients and healthy controls,Searching for cancer-specific frequency modulation
11043,NCT00331786,Effects of nitric oxide-releasing acetylsalicyclic acid (NCX 4016) on aberrant cryptic foci (ACF) multiplicity after the second dose at 6 months,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety and tolerability of long-term oral administration of NCX 4016 as measured by NCI CTCAE v3.0,
11044,NCT02753465,disease-free survival rate,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],30-day mortality rate,
11045,NCT00327496,,2005-06,UNKNOWN,INTERVENTIONAL,['NA'],,
11046,NCT00737230,"Improvement in gastrointestinal symptoms as measured by the modified IBDQ-B score, Rockwood Fecal Incontinence Quality of Life score, St Mark's Incontinence score, and the LENTSOMA score at baseline, 6 months, and 1 year",2007-04,COMPLETED,INTERVENTIONAL,['NA'],Other unmet healthcare needs as a direct result of pelvic radiotherapy,
11047,NCT02221778,Local Progression Free Survival,2014-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
11048,NCT01189942,To the determine the maximum tolerated dose of OMP-21M18 plus FOLFIRI,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],To determine the preliminary efficacy of FOLFIRI plus OMP-21M18,
11049,NCT04318756,Syntactic and semantic equivalence of Cancer worry scale' items between English and Italian language and vice versa,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA'],Exploratory comparison between Patients Health Questionnaire and Irritability Depression Anxiety Scale and cancer worry scale,
11050,NCT06162650,Complete response (CR) rate,2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety profiles,
11051,NCT05420064,Comparison of participant perceived quality of care,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
11052,NCT05621499,1-year DFS rate,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adverse Events (AEs),
11053,NCT04137822,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
11054,NCT01909362,number of drug targetable genetic changes found in tumor tissue sample,2013-07,COMPLETED,OBSERVATIONAL,['NA'],number of physicians who took into consideration regimens that were suggested by the results of the sequencing analysis when deciding their patients' next line of therapies.,
11055,NCT04116073,Disease Control Rate (DCR) at 4 months using RECIST 1.1,2020-04-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants experiencing study drug-related toxicities,
11056,NCT03433014,measure pain scores (Visual Analog Scale) in the postoperative period,2018-03-31,COMPLETED,INTERVENTIONAL,['NA'],objective is to compare the VAS scores between the two types of technique used for specimen retrieval incision,
11057,NCT00767377,Time to progression,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,PET Scan response
11058,NCT04135313,3-year disease-free survival,2019-10-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],Sphincter preservation rate,
11059,NCT05193162,16sRNA and metagenomics,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
11060,NCT01686971,,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,
11061,NCT02519075,Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing TARE for HCC,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
11062,NCT00658801,all cause mortality,2007-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
11063,NCT02075385,Swallowing function,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11064,NCT03040180,Histopathologic tumor regression following electrochemotherapy,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Tumor Immunologic response following electrochemotherapy,
11065,NCT03439761,Disease Control Rate (DCR),2018-03-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",AE,
11066,NCT00196105,Time to Death,2003-09,COMPLETED,INTERVENTIONAL,['NA'],,
11067,NCT02632305,Overall response rates,2016-07-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
11068,NCT06076252,The rate of POPF,2023-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11069,NCT04143516,Tumor response,2019-10-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11070,NCT00622804,Bile reflux by Dual scintigraphy,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Morbidity and Mortality,
11071,NCT00919061,Median PFS,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11072,NCT00955019,,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
11073,NCT02374255,Number of Patients Perception of Improved Goals of Care Discussions,2016-03-15,COMPLETED,INTERVENTIONAL,['NA'],Communication Skills Training,
11074,NCT00494221,Progression Free Survival,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
11075,NCT01392131,Number of patients who have prolonged survival after receiving Oncoxin,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Reduction in serum alpha-fetoprotein level and decrease in tumor size,
11076,NCT02471170,Collection of blood and tissue samples from subjects with pancreatic diseases,2015-09-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
11077,NCT03834272,Initial efficacy of LUM015 in labeling peritoneal surface malignancies by molecular imaging by comparing imaging results with pathology,2019-03-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of patients with reported adverse events,
11078,NCT02681796,Total consumption of morphine or morphine-equivalent in patients undergoing pancreatic resections in the control group compared with the study group,2016-06-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Effect of epidural analgesia during the initial post-operative period as measured by relative ratios of blood level inflammatory markers,
11079,NCT01539681,Efficacy (analyzed by overall survival rate) of sorafenib under real-life practice conditions in patients with Hepatocellular Carcinoma.,2012-02,COMPLETED,OBSERVATIONAL,['NA'],Time to Progression,
11080,NCT02564887,Tongue Pressure Generation (i.e. Tongue Strength) in Kilopascals (kPa) Using the IOPI Device,2016-01,TERMINATED,INTERVENTIONAL,['NA'],Swallowing Impairment-Objective,
11081,NCT00742729,Receipt of a colorectal cancer screening test,2004-09,COMPLETED,INTERVENTIONAL,['NA'],Knowledge and attitudes regarding CRC screening.,
11082,NCT00927485,Size of Polyps,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,
11083,NCT01301417,Rate of anastomotic leakage,2011-02,COMPLETED,OBSERVATIONAL,['NA'],Rate of other device related complications and measures during hospitalization and post procedure:,
11084,NCT05638698,Molecular disease control rate,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between molecular response and disease free survival,
11085,NCT01470742,Overall survival of XELOX(XELODA/oxaliplatin) vs X(XELODA),2010-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],response rate,
11086,NCT01294826,Incidence of dose limiting toxicity (DLT),2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival of patients treated with AUY922.,
11087,NCT02528175,Acute toxicities,2015-04,COMPLETED,INTERVENTIONAL,['NA'],Assessment of radiologic response following treatment.,
11088,NCT00165217,To assess the anti-tumor activity of capecitabine and thalidomide when administered to patients with previously treated metastatic colorectal cancer.,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate the safety of capecitabine and thalidomide in this patient population.,
11089,NCT03380689,Maximum tolerance dose,2018-01-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Overall survival,
11090,NCT04879953,Overall survival at 6 months,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],overall survival from the diagnosis of carcinomatosis and from the diagnosis of the primary tumour.,
11091,NCT01721174,Stent patency rate,2012-11,TERMINATED,INTERVENTIONAL,['NA'],Unscheduled readmission rates,
11092,NCT03265418,Positional stability of BioXmark liquid fiducial markers during the treatment course,2018-01-02,COMPLETED,INTERVENTIONAL,['NA'],Potential BioXmark induced alterations in the surgical specimen,
11093,NCT02168608,survival rate,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],complications,
11094,NCT04518280,Complete response (CR) rate,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Scores of Quality of Life,
11095,NCT02015754,"Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer",2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],One-year Survival Percentage,Exploratory Endpoint - Angiogenesis
11096,NCT01609231,Assessment of Progression-free Survival (PFS),2012-07-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Objective Response Rate (ORR),
11097,NCT00897819,Correlation of MSI and LOH to outcome and response,2007-01-03,COMPLETED,OBSERVATIONAL,['NA'],,
11098,NCT00003798,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11099,NCT00824707,time-to-progression(TTP),2008-12,COMPLETED,INTERVENTIONAL,['NA'],The overall response rate,
11100,NCT05009550,Numeric Pain Scale assesment,2021-05-15,UNKNOWN,INTERVENTIONAL,['NA'],Incidences of adverse effects (like nausea and vomiting),
11101,NCT02087878,Collection of Samples,2014-03-31,WITHDRAWN,OBSERVATIONAL,['NA'],,
11102,NCT05808712,Rate of supportive care needs in cancer,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],,
11103,NCT01497444,Overall response rate (Phase II),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],AFP response rate (Phase II),
11104,NCT00082082,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11105,NCT02728804,Cumulative Incidence Rate of Treatment-related Major Financial Hardship,2016-06-22,COMPLETED,OBSERVATIONAL,['NA'],"Financial Stress (Patient, Caregiver, or Bereaved Caregiver)",
11106,NCT05918094,Progression-Free Survival (PFS),2023-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-STO22 (EORTC QLQ- STO22),
11107,NCT05465512,AUC for BNCISS,2022-01-04,COMPLETED,OBSERVATIONAL,['NA'],disease free survival,
11108,NCT03107416,estimate the local tumor progression (LTP) rates (phase II),2017-04-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11109,NCT02558959,Progression Free Survival,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
11110,NCT05764551,The correlation between serum DNA methylation and HCC recurrence or treatment response,2023-03-28,RECRUITING,INTERVENTIONAL,['NA'],,
11111,NCT02696408,prevalence of grade 3 mucositis and more,2016-06-27,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety,
11112,NCT00445653,"Polymorphisms in DNA repair genes or the p53 pathways (e.g., ERCC2, XRCC1, p53, p73, CCND1, p21)",2005-08,COMPLETED,OBSERVATIONAL,['NA'],,
11113,NCT06134089,Number of messages generated by participants,2023-12-05,COMPLETED,OBSERVATIONAL,['NA'],,
11114,NCT01693419,Objective response rate,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity profiles,
11115,NCT02027545,Number of Participants With CRC Screening Ordered,2015-11-20,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants With CRC Screening Utilized,
11116,NCT06307080,Safety and efficacy assessment,2023-10-08,RECRUITING,INTERVENTIONAL,['NA'],Survival benefit,The application of medical-mechanical combination therapy mode
11117,NCT01308840,The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response Evaluation Criteria In Solid Tumors (RECIST) Criteria.,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],The Number of Participants Who Experience an Adverse Event,
11118,NCT03962088,Change in expression levels of plasma miRNA,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA'],miRNA expression and surveillance,
11119,NCT00892658,Determine the MTD of sorafenib and RT in patients with hepatocellular carcinoma using an iso-toxicity radiation dose allocation scheme. Determine the acute toxicity (< 3 months) of sorafenib when combined with RT.,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],"Determine late toxicities, in-field local control at 3 months, overall survival, progression time, and progression free survival. Quantify alteration in perfusion parameters.Assess serum and tissue biomarkers. Assess quality of life in these patients.",
11120,NCT04391348,Demonstrate that the identification of new tumour lesions by an experimental procedure combining PET-TDMs with 18F-FDG and 18F-Fluorocholine in patients with HCC modifies the initially planned therapeutic strategy,2020-07-17,COMPLETED,INTERVENTIONAL,['NA'],Number of patients who had an additional examination proposed by the MCM (multidisciplinary consultation meeting) following the PET-TDMs performed,
11121,NCT05720910,Quality of life assessed by the EORTC quality of life questionnaire (EORTC QLQ-C30 ),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],GERONTE patient-centered system implementation and usage,
11122,NCT03163186,To assess potential patient preference for the performance of hepatic embolization procedures via transradial versus transfemoral approach.,2015-12-01,COMPLETED,OBSERVATIONAL,['NA'],To identify potential risk factors for complications in transradial approach.,
11123,NCT02562976,Number of patients with severe gastric atrophy and/or intestinal metaplasia in early gastric cancer and non-early gastric cancer,2013-05,COMPLETED,OBSERVATIONAL,['NA'],"correlations between Helicobacter pylori infection and moderate-to-severe EGA classification, OLGA stage III-IV, OLGIM stage III-IV",
11124,NCT02615574,overall survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],immune-related Progression-Free Survival (irPFS),Changes of tumor microenvironment
11125,NCT04581473,"Phase II: Progression-free survival (PFS), as assessed by IRC, of CT041 autologous CAR T-cell injection versus Physician's Choice",2020-10-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Phase II: Disease control rate (DCR), as assessed by IRC and by Investigators",
11126,NCT01927965,To establish the dose of Minnelide™ recommended for future phase 2 protocol,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],To determine pharmacodynamic effect of Minnelide™ on HSP70 levels. And to explore pharmacodynamics effect of Minnelide™ on PET Scans and using Choi criteria on the CT scans.,
11127,NCT02039336,Progression free survival,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
11128,NCT00001576,,1997-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11129,NCT04547166,PFS,2021-03-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",DCR,
11130,NCT03950102,Rate of transplant complication,2015-07-01,UNKNOWN,INTERVENTIONAL,['NA'],Rate of dropout from transplant waitlist,
11131,NCT03996681,Disease control rate (DCR),2019-07-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],Adverse Events,
11132,NCT04929912,Incidence of Treatment-Emergent Adverse Events (CTCAE),2021-06-24,RECRUITING,OBSERVATIONAL,['NA'],Modified FACE-Q evaluation for Skin Cancers,
11133,NCT01704651,Postoperative Length of Hospital Stay,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Postoperative Ileus Incidence,
11134,NCT00006467,overall survival at 6 months,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],response rate,
11135,NCT01171651,Determine safety and tolerability of intravenous infusion of JX-594 followed by intratumoral injections with JX-594 prior to standard sorafenib therapy,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine overall survival time,
11136,NCT03676478,Functional recovery (6mWD - 6-minute Walked Distance),2019-03-25,RECRUITING,INTERVENTIONAL,['NA'],Global Health status score,Levels of Haemoglobin A1c (HbA1c)
11137,NCT05743504,Pathological complete response rate,2023-09-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of participants with delay in planned radical esophagectomy,
11138,NCT04368078,Objective Response Rate (ORR),2020-07-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (AE),
11139,NCT00907166,"To determine the safety and MTD of CPI-613, when used in combination with Gemcitabine, in cancer patients.",2009-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To compare the safety and efficacy of CPI-613 Gemcitabine combination vs. Gemcitabine alone in patients with carcinoma of the pancreas.,
11140,NCT06311851,Objective response rate,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse event,
11141,NCT05518201,Number of subjects with Severe adverse events (SAE),2022-09-23,RECRUITING,INTERVENTIONAL,['PHASE1'],The immunogenicity of subjects receiving 3 doses of vaccination was assessed by IgG antibodies and neutralizing antibodies,
11142,NCT00365144,Safety and Toxicity,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Proportion of Patients With ≥ 25% Decline in Serum CA19-9 Biomarker,
11143,NCT00281736,Efficacy,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Response,
11144,NCT05529615,3-year disease-free survival rate,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
11145,NCT00668161,Proliferation rate in the upper part of colon and rectal mucosa crypts.,2001-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",quality of life (measured by standardized self-report instruments) and sleep quality,
11146,NCT01895673,Local site recurrence (LSR) detection,2013-06,COMPLETED,OBSERVATIONAL,['NA'],Patients experience with PET-CT and PET-MRI,
11147,NCT01579071,Abdominal pain related to each insufflation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Participants with Adverse Events as a Measure of Safety and Tolerability,
11148,NCT01238042,Optimal Light Dose,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Resolve Barrett's mucosa,
11149,NCT02438436,xerostomia,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11150,NCT03034473,Number of patients with histopathologically confirmed complete remission (pCR) (ypT0N0 R0) after preoperative RCTx related to pretherapeutically determined gene expression signature predicting tumor response to RCTx.,2011-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Wexner-Score-Questionnaire,
11151,NCT03687515,"Clinical responses including 4 major symptoms(nasal obstruction, rhinorrhea, loss of smell,and headache/facial pain)",2015-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Physicians' assessment of nasal polyp size reduction,
11152,NCT06043999,Three years disease-free survival rate,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],Urinary function,
11153,NCT02188927,Participation rate,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],Response rate,Cost of including Advance Notification Letter
11154,NCT00293124,Time to Disease Progression,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Survival,
11155,NCT05966246,Quantitative intestinal motility measurement using radio-opaque markers,2022-01-25,COMPLETED,INTERVENTIONAL,['NA'],"Measurement of the amount of food intake, first flatus time and first defecation time",
11156,NCT00112528,Survival at 6 months,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
11157,NCT00417976,Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Response Rates Defined by RECIST 1.0,
11158,NCT01457599,Sensitivity,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,
11159,NCT04160650,"The rate of self care activation (Patient Activation Measure PAM, Insignia Health; Hibbard et al. 2004)",2019-10-21,COMPLETED,INTERVENTIONAL,['NA'],"The rate of quality of life (The Functional Assessment of Cancer Therapy Scale - Colorectal, FACT-C, Cella et al. 1993)",Incidence of morbidity
11160,NCT02966509,Number of Participants With Completed Goals of Care Documentation. We Will Evaluate if 75% of Patients in the Intervention Arm Have a Documented Goals of Care Titled Medical Note Within 6 Months of Patient Enrollment in the Study.,2013-08,COMPLETED,INTERVENTIONAL,['NA'],Patient Satisfaction With Decision-Making Using the Satisfaction With Decision Survey,
11161,NCT05690035,Objective Response Rate (ORR),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events,
11162,NCT00176813,"To determine the overall survival time in patients with metastatic pancreatic cancer treated with the combination of gemcitabine, cisplatin and celecoxib.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],To determine the influence of therapy on the blood levels of prostaglandins and angiogenesis,
11163,NCT00003434,Progression Free Survival,1998-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
11164,NCT04995354,WHO grade of mucositis,2022-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11165,NCT04425226,Recurrence-Free Survival (RFS),2020-08-06,RECRUITING,INTERVENTIONAL,['NA'],Objective Response Rate (ORR),
11166,NCT01098344,Adverse event and severity according to NCI CTCAE Version 4.02,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Plasma concentrations of MK0752,
11167,NCT02837679,Change in Quality of life,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Length of hospital stay,Health costs per patient
11168,NCT01591798,Quality of mesorectal excision,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Long-term outcome,
11169,NCT01784900,Progression Free Survival,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression Free Survival,
11170,NCT05862337,Recurrence-free survival (RFS),2023-05-10,RECRUITING,INTERVENTIONAL,['PHASE3'],Objective response rate (ORR) after first recurrence,
11171,NCT02305615,Progression-Free Survival (PFS),2015-01-13,COMPLETED,OBSERVATIONAL,['NA'],Percentage of Participants with Adverse Events (AEs) and Serious AEs,
11172,NCT01212718,Best response to first-line chemotherapy (recist),2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],"overall survival, toxicity, treatment related complications, time to progression",
11173,NCT04069455,CR29 scores,2019-10-01,RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
11174,NCT02409849,PFS,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],OS,
11175,NCT04734691,Progression free survival,2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life C30,
11176,NCT01379612,Tumor regression grade,2010-05,COMPLETED,OBSERVATIONAL,['NA'],,
11177,NCT04724291,Comparison to EGD in Identifying Lesions.,2021-02-10,COMPLETED,INTERVENTIONAL,['NA'],Safety of MCC Compared to EGD. Documentation of Any Adverse Event Patient Encounters up to the 30 Day Follow-up.,
11178,NCT02385617,Ad libitum calorie intake,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Subjective symptom scores,
11179,NCT02558881,Acceptance rate of colonic capsule versus virtual colonoscopy.,2014-06,COMPLETED,OBSERVATIONAL,['NA'],Additional costs generated by the implementation of a complementary action of screening for patients with a positive FOBT and did not realize optical colonoscopy,
11180,NCT06190665,Disease control rate (DCR) for target lesions 1 month after the last TACE treatment,2023-12-19,RECRUITING,INTERVENTIONAL,['NA'],Number of TACE treatments for target lesions,
11181,NCT05880446,Mean Delta of EORTC Proctitis Module (PRT20) score,2023-10-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Mean Delta of EORTC Quality of Life Questionnaire (QLQ-C30) score,Low Physical Activity Level prevalence and its association with PRT20 and QLQ-C30 Delta
11182,NCT03039309,Curative resection rate,2016-08-05,RECRUITING,OBSERVATIONAL,['NA'],Mortality rates,
11183,NCT00655655,"Efficacy outcomes in patients with metastatic kidney cancer, neuroendocrine carcinoma, non-small cell lung cancer, or melanoma (Cohort II)",2004-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11184,NCT00829335,Technical feasibility,2007-01,COMPLETED,OBSERVATIONAL,['NA'],Morbidity and mortality,
11185,NCT04361227,Closure time after ESD,2020-07-02,COMPLETED,OBSERVATIONAL,['NA'],Clips used post-ESD,
11186,NCT02220062,percentage of participants with 50% decrease or less than 3 points in Pain Visual Analogue Scale (VAS),2014-08,UNKNOWN,INTERVENTIONAL,['NA'],,
11187,NCT03741166,Blood-based biomarkers associated with genetic and epigenetic alterations.,2018-11-08,COMPLETED,OBSERVATIONAL,['NA'],,
11188,NCT00040820,,2002-01,COMPLETED,INTERVENTIONAL,['NA'],,
11189,NCT00678535,Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Safety - Number of Participants With Adverse Events (AEs),
11190,NCT06243393,Progression Free Survival (PFS),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall Survival (OS),
11191,NCT04027556,HCC conspicuity,2019-06-27,COMPLETED,INTERVENTIONAL,['NA'],Radiation dose,
11192,NCT04337333,Cumulative patency of inner covered stent and Two-in-one stent,2016-05-01,UNKNOWN,INTERVENTIONAL,['NA'],Stent dysfunction-free patient survival,
11193,NCT04001478,Determine the diagnostic accuracy of breath test for detection of early oesophageal cancer and Barrett's high grade dysplasia,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],Diagnostic validation study of the breath profile for prediction of early oeosphageal cancer and high grade dysplasia,
11194,NCT02948348,Pathological complete response,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",macroscopic evaluation of (rectal cancer) resected specimen,
11195,NCT00655785,toxicities as assessed by NCI-CACAE ver3),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Survival,
11196,NCT01054924,,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,
11197,NCT01269060,Harvested numbers of lymph node,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],"Postoperative mortality, morbidity",
11198,NCT00467974,progression free survival,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],consumption of hospital resources,
11199,NCT02959541,THF - adjacent mucosa,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],Gene expression - correlation adjacent mucosa tissue concentration of the reduced folates,
11200,NCT04238637,Objective Response rate (ORR) according to RECIST 1.1,2019-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),Translational research
11201,NCT00238147,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11202,NCT05447611,"The main objective of the EMPACOL project is to investigate, in non-metastatic CRC patients, a possible correlation, between perceived HCP's empathy and survival (OS and DFS).",2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],"The relationship between caregiver empathy, as perceived by the patient, and quality of life (QoL) will be studied.",
11203,NCT03598348,PFS,2018-01-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],OS,
11204,NCT03816345,Clinical measures of interest,2019-07-16,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11205,NCT01549067,,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
11206,NCT03175679,Incidence of Treatment-Emergent Adverse Events [Safety],2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Biological activity of infused iNKT cells,Disease Control Rate (DCR)
11207,NCT03092518,Overall survival,2017-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],morbidity,
11208,NCT05052086,"Accuracy of mesorectal lymph node diagnosis with MMUS, compared with preoperative MRI",2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
11209,NCT00714077,3-year disease free survival rate,2008-04,UNKNOWN,OBSERVATIONAL,['NA'],safety,
11210,NCT05726188,Recurrence,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],Cancer-related survival,
11211,NCT00109070,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11212,NCT02127645,incidence of local and distant recurrence,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],anorectal function,
11213,NCT04264962,Recurrance rate,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],quality of life (QOL) questionnaire,
11214,NCT05313191,To determine the cumulative rate of CTCAE v5.0 Grade ≥3 acute and late treatment related adverse events within 1 year of definitive reirradiation completion using proton therapy for recurrent or second primary tumor.,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],To characterize patient reported outcomes within 1 year of reirradiation using the MDASI SP form for spinal tumors.,
11215,NCT02153398,Aggravation of Regurgitation at Week 8 by Investigators,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Apparent Volume of Distribution (Vz/F) of Esomeprazole After at Least 5 Days of Repeated Dose,
11216,NCT00009906,"Toxicity defined as any grade 3 or greater organ toxicity, or any grade 4 or greater hematological toxicity as assessed by CTCAE version 2.0",2000-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11217,NCT04037319,"Incidence of atrial fibrillation within 90 days of colorectal cancer surgery, defined as ≥30 seconds of atrial fibrillation identified on a 24-hour cardiac monitor OR absence of p waves and irregularly irregular rhythm on an electrocardiogram",2020-01-16,UNKNOWN,OBSERVATIONAL,['NA'],Number of events of use of health services for atrial fibrillation or sequelae of atrial fibrillation,
11218,NCT03220711,"Depth-imaging capability of the confocal endomicroscope using an imaging contrast agent, fluorescein",2017-07-28,TERMINATED,INTERVENTIONAL,['NA'],,
11219,NCT05276037,Survival,2019-01-01,RECRUITING,OBSERVATIONAL,['NA'],FDG PET-CT value in Milan-in patients,
11220,NCT04081831,Incidence rate ratio of esophageal cancer among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed),2019-07-31,COMPLETED,OBSERVATIONAL,['NA'],Case-fatality and survival rate,
11221,NCT01914068,Change in physical fitness measured by CPET (ml/kg/min),2013-08,COMPLETED,INTERVENTIONAL,['NA'],Physical activity,TNM Staging
11222,NCT03101475,Best overall immune response rate (iBOR) of lesions not treated by ablation/radiotherapy including the extrahepatic lesions according to iRECIST (with response confirmation),2018-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety: Safety analyses will be performed on the Safety population. The worst toxicity grade per patient over the treatment period according to the CTCAE criteria version 4.0 will be displayed.,
11223,NCT05208775,2-year disease-free survival rate,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Esophageal stenosis rate at 3 months,
11224,NCT01522612,Progression free survival,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2'],"Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by social situation questionnaire",
11225,NCT06069778,Phase 2 - Disease-free survival (DFS),2024-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2 - Occurrence of abnormal laboratory parameters,
11226,NCT00570531,Disease Free Survival Time,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],The Proportion of Toxicities Experienced by Participants,
11227,NCT02969096,Rate of complete tumor ablation,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events,
11228,NCT05892289,The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Proportion of participants need to rehospitalized after surgery,
11229,NCT03820531,Pancreas cyst with HGD or carcinoma,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
11230,NCT00064259,Maximum Tolerated Dose (MTD) of Oblimersen in Combination With Cisplatin and 5-FU,2003-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Microarray Data,
11231,NCT03551951,Quantity of cfDNA in bone marrow,2016-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
11232,NCT03865563,"Safety as measured by number of participants with Grade 3, 4, and 5 toxicities",2019-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Efficacy as assessed by change in levels of gemcitabine and dFdu in peripheral blood samples,
11233,NCT01512745,Overall Survival(OS),2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Adverse Events,
11234,NCT01375816,Tumor response,2011-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Correlation of UGT1A family polymorphism and the toxicity of liposome-encapsulated irinotecan hydrochloride PEP02 or irinotecan hydrochloride,
11235,NCT01612325,Target lesions tumour response,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity according CTC v 4 criteria,
11236,NCT03237325,Duration of Severe Oral Mucositis (SOM),2017-12-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11237,NCT01890291,To evaluate recurrence-free survival,2013-06,COMPLETED,OBSERVATIONAL,['NA'],To determine the response rate to evaluate overall survival and cause specific survival and changes of Alpha feto protein (AFP) figures from baseline to the last observation date.,
11238,NCT02717949,Number Subjects Who Experience Adverse Events on HCV Treatment as Assessed by Division of AIDS (DAIDS) Adverse Event (AE) Grading Table Version 2.0.,2016-02-25,TERMINATED,INTERVENTIONAL,['PHASE4'],Number of Subjects Who Have a Change in Lymph Node Size From Baseline After HCV Treatment,
11239,NCT04678349,ileostomy stoma output,2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],dietary intake,
11240,NCT04512508,Percentage of positive results for Anal Test system versus anal liquid cytology and anoscopy for the presence of high-risk human papillomaviruses,2020-08-30,UNKNOWN,INTERVENTIONAL,['NA'],Number and percentage of patients to have a positive opinion to use Self-Test system.,
11241,NCT06090643,Return rate of completed FIT kits,2019-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
11242,NCT00207155,Prediction of response to Erbitux in subjects with metastatic colorectal cancer,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Radiographic Response,
11243,NCT02950064,Part 2 - Progression-free survival (PFS) measured as the time from the date of initiation of BTP-114 treatment to the documented disease progression (PD) or death from any cause.,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Part 1 - Plasma Pharmacokinetics (PK) estimates of platinum concentration Half-life (T1/2).
11244,NCT02582970,Percentage of Participants With Adverse Events,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4'],Mean Direct Medical Cost for Cancer Related Medical Care Utilization,
11245,NCT05969444,High grade dysplasia/Gastric adenocarcinoma,2015-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
11246,NCT02423174,Intraoperative Serious Adverse Events as a Measure of Safety and Feasibility,2016-01,WITHDRAWN,OBSERVATIONAL,['NA'],Evaluation of post-operative complications,
11247,NCT01378143,Overall survival (OS),2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of response (DR),
11248,NCT02203409,Safety of the procedure defined as the incidence of postoperative complications and mortality,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],survival rate,
11249,NCT00217555,Quality of life,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
11250,NCT01668017,Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT),2012-09-30,TERMINATED,INTERVENTIONAL,['PHASE1'],Percentage of Subjects With Disease Control,
11251,NCT04054518,Six-month progression-free survival,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of distant progression,Six-month progression-free survival according to immune biomarkers
11252,NCT05055323,Incidence of dose limited toxicity (DLT),2021-07-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Fatty tissue accumulation of PP,
11253,NCT00012246,Frequency and severity of toxic effects,2002-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11254,NCT04748380,Change in CRC Screening Intentions,2023-01-18,RECRUITING,INTERVENTIONAL,['NA'],Feelings of usefulness of the decision aid,
11255,NCT00003843,,1998-10,TERMINATED,OBSERVATIONAL,['NA'],,
11256,NCT01187212,Progression-free survival,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarker for sorafenib,
11257,NCT03813784,Overall survival (OS) of SHR-1210 in combination with capecitabine + oxaliplatin sequenced by SHR-1210+apatinib versus capecitabine + oxaliplatin in all subjects or programmed cell death ligand 1 (PD-L1) positive participants,2019-03-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of Subjects with treatment-related adverse events (AEs),
11258,NCT02392637,Median Progression Free Survival (PFS),2015-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment Response Rate,
11259,NCT04150042,Overall incidence rate of Grade 3-5 adverse events,2021-01-13,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-Free Survival,
11260,NCT02146703,Objective reponse rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],"Progression free survival, median overall survival, disease control rate, and over grade 3 hematologic toxicities (neutropenia, thrombocytopenia, and febrile neutropenia)",
11261,NCT05000697,Decision to Watch and Wait due to clinical complete response,2021-07-14,RECRUITING,INTERVENTIONAL,['NA'],Colostomy-free survival at 3 years,
11262,NCT01876511,Progression Free Survival (PFS) at 20 Weeks in MSI Positive Solid Tumor Malignancies Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1),2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Does MSI as a Marker Predict Treatment Response,
11263,NCT03295500,Overall survival rate,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],the value of ICG R15,
11264,NCT03954756,Overall survival rate,2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
11265,NCT06177522,pCR rate,2023-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
11266,NCT00919282,overall survival,1997-09,COMPLETED,INTERVENTIONAL,['PHASE2'],safety of treatment,
11267,NCT04196816,Overall survival,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],Progression-free survival,
11268,NCT05378919,disease-free survival,2015-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
11269,NCT02632201,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life,
11270,NCT03503162,The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System,2018-05-17,COMPLETED,INTERVENTIONAL,['NA'],,
11271,NCT04643041,1 year DFS rate,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],3 years OS rate,
11272,NCT02589496,Response Rate,2016-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11273,NCT03500380,Progression-free Survival (PFS) as Assessed by an IRC,2018-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall Survival,
11274,NCT05203549,Establishment of patient-derived organoids,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],Correlation between results of the drug sensitivity tests in patient-derived organoid models and clinical outcomes,
11275,NCT00026299,Recommended dose of ZD1839 in combination with oxaliplatin,2001-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11276,NCT04761614,Dose limiting toxicities (DLTs),2021-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacokinetic (PK) profile of riluzole (AUC),Change in levels of circulating cytotoxic T cells
11277,NCT00613730,Overall Survival at 1 Year,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Overall Response,
11278,NCT02779465,Change in serum levels of 25-hydroxy vitamin D,2016-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Number of participants on Vitamin D treatment with adverse events,
11279,NCT00987766,Maximum tolerated dose and recommended phase II dose of erlotinib hydrochloride in combination with gemcitabine hydrochloride and oxaliplatin,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],"E-cadherin, vimentin, fibronectin, amphiregulin, and Kras status in the tumors and their relationship to response",
11280,NCT02086656,Pathological response rate,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2'],RECIST Response rate,
11281,NCT04753203,Progression Free Survival,2021-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of response,
11282,NCT04005118,Rate of prolonged postoperative ileuss,2019-05-28,UNKNOWN,OBSERVATIONAL,['NA'],Expression intensity in cytoplasm of protein ligase HACE1 in tumoral and non-tumoral tissues,
11283,NCT01319877,Percentage of Participants With Bevacizumab-related Serious Adverse Events,2011-03,COMPLETED,OBSERVATIONAL,['NA'],Quality of Life: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire,
11284,NCT06173726,Dose-Limiting Toxicity,2023-12-05,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
11285,NCT01837381,overall survival and treatment-related toxicity,2007-02,COMPLETED,INTERVENTIONAL,['NA'],Tumor response,
11286,NCT03740503,Genomic Characterization of Tumor Samples,2013-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
11287,NCT03678883,Part 3 Arm B,2019-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
11288,NCT04779125,Complications,2021-03-19,COMPLETED,INTERVENTIONAL,['NA'],Gluteus muscle function measured by time stands test,
11289,NCT01992705,Rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy.,2014-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Survival status (disease-free-survival vs. overall survival) time to recurrence and site of recurrence in patients with borderline resectable pancreatic cancer receiving preoperative FOLFIRINOX followed by SBRT,Quality of life through and after treatment
11290,NCT04382079,oral mucositis,2020-04-08,UNKNOWN,INTERVENTIONAL,['NA'],"IL-1, IL-6, IL-10,TNF",
11291,NCT05013216,Maximal percentage of change of interferon (IFN-γ) producing mutant-KRAS-specific CD8 and CD4 T cells,2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 17 weeks.,
11292,NCT03914820,Local recurrence free survival (LRFS),2020-06-19,RECRUITING,INTERVENTIONAL,['NA'],mortality at 30 and 90 days from surgery,
11293,NCT03061708,Objective response rate (ORR) by RECIST 1.1,2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11294,NCT00003786,Clinical Response Rate,1999-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
11295,NCT05760599,DCR per RECIST 1.1,2023-02-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers such as PD-L1 expression,
11296,NCT03320733,Negative predicative value,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],Parameters optimization keV,
11297,NCT00016900,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11298,NCT03941093,Overall Survival (OS),2019-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],"Best Overall Objective Response Rate (ORR), as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
11299,NCT01188785,Number of Participants with Adverse Events,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11300,NCT03028311,Incidence of adverse event assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2017-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11301,NCT03764137,Image Quality,2019-03-14,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11302,NCT06002425,Influence Rate of ChatGPT on Treatment Plans,2023-08-29,RECRUITING,INTERVENTIONAL,['NA'],3-year Progression-Free Survival (PFS) Rate,5-year Overall Survival (OS) Rate
11303,NCT04037046,Acceptance of the interventions,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],Effectiveness of each strategy: rate of HCV positivity,
11304,NCT01587534,the change in body weight at eight weeks after the randomisation,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency of bowel movements per day,
11305,NCT03274804,Feasibility Rate of a Combined Therapy,2018-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival,
11306,NCT01231347,To determine if AMG 479 in combination with gemcitabine improves overall survival as compared with placebo in combination with gemcitabine in subjects with metastatic adenocarcinoma of the pancreas,2011-04,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of subjects with adverse events,
11307,NCT00147550,"Objective Response Rate, Safety.",2004-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Time to progression, overall survival, patient reported outcomes.",
11308,NCT04403022,Adverse Events Rates,2021-06-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
11309,NCT03395938,The proportion of siblings that contacted the study team within 4 weeks from point of engagement by the index colorectal cancer patient.,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,
11310,NCT01093755,Change in Esophageal Inflammation Biomarker COX-2 Gene Expression,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,
11311,NCT01550055,Overall response rate,2009-05-31,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Progression-free Survival,
11312,NCT00475293,objective response rate,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],adverse events,
11313,NCT00787787,Median Progression-free Survival,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Median Overall Survival,
11314,NCT01782573,"the positive rate of the baseline culture , the preoperative culture , and the postoperative culture",2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],the post - operative surgical site infection,
11315,NCT04560712,Retention,2020-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Satisfaction of pain control,Postoperative length of stay
11316,NCT04693546,"Sensitivity and specificity for the LifeKit Prevent Colorectal Neoplasia Test for adenoma, including advanced adenoma",2021-06,UNKNOWN,OBSERVATIONAL,['NA'],Sensitivity of the LifeKit Prevent Colorectal Neoplasia Test is superior to that of FIT for advanced adenoma,
11317,NCT05801211,Stoma rate at 1 year after tumor resection,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],type of chemotherapy regimen,
11318,NCT04034953,Breast cancer detection rate,2018-08-06,UNKNOWN,INTERVENTIONAL,['NA'],,
11319,NCT01701310,To determine if the use of intravenous ferric carboxymaltose can reduce the need for allogeneic blood transfusion compare to oral ferrous sulphate in patients with colorectal adenocarcinoma related anaemia,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],To determine differences in anemia symptomatology response between groups.,
11320,NCT03281382,Toxicity of the gene therapy,2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],PET imaging,
11321,NCT03027895,clinical success,2018-09,UNKNOWN,INTERVENTIONAL,['NA'],technical success,
11322,NCT05711433,incidence of postoperative pancreatic fistula,2014-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
11323,NCT00467194,Maximum tolerated dose,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in DCE-CT scan assessment of angiogenesis,
11324,NCT00554905,Overall Survival,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],Recurrence rates,
11325,NCT05596630,Local control rate（LC）,2023-05-08,RECRUITING,INTERVENTIONAL,['NA'],Progression-free survival (PFS),
11326,NCT03687853,Death,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
11327,NCT05375370,Change in tcDNA dosage between baseline and 3 Months,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Survival at 2 years,
11328,NCT06132087,R0 resection rate,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],Time to distant metastases,
11329,NCT04899908,Local Recurrence,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Neurocognitive function: cognitive impairment,
11330,NCT04526483,The success rate of laparoscopic gastric surgery,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA'],Lymph node dissection rate,
11331,NCT03295591,Cutoff value of CTC counts,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,
11332,NCT03944304,Disease control rate,2019-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,
11333,NCT03788226,3-year disease-free survival,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],safety (The incidence of chemotherapy related adverse events),
11334,NCT02333721,3-year disease free survival rate,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],Technical performance,
11335,NCT01103323,Overall Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Tumor Response,
11336,NCT01639911,Optimally Tolerated Dose,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE1'],Toxicity Profile,
11337,NCT05237193,Assess the value of UCAD for malignant biliary obstruction patient follow-up,2021-09-03,RECRUITING,OBSERVATIONAL,['NA'],Comparison of the sensitivity and specificity of the UCAD analysis versus bile cytology,
11338,NCT02686372,To Evaluate safety of the TCR-T treatment,2018-05-16,COMPLETED,INTERVENTIONAL,['PHASE1'],To evaluate objective response rate,
11339,NCT01132469,5-year disease(gastric cancer)-free survival rate after ESD procedure,2010-05,UNKNOWN,INTERVENTIONAL,['NA'],The safety of ESD procedure,
11340,NCT00001241,,1989-01-27,COMPLETED,OBSERVATIONAL,['NA'],,
11341,NCT03853772,Demographic and clinical data obtained via chart review and questionnaires,2019-04-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
11342,NCT02237157,Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],CA19-9 Tumor Reduction,
11343,NCT04254939,Phase II: ORR based on mRESIST 1.1,2019-08-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11344,NCT05603039,Objective remission rate (ORR),2021-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of remission (DOR) Duration of remission (DOR) Duration of remission (DOR) Duration of remission (DOR),Overall survival (OS)
11345,NCT05665868,Anxiety tendency of patients in the past week assessed by self rating anxiety scale,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
11346,NCT03957486,difference between SpHb value and SaHb value (SpHb - SaHb) in g/dL,2019-05-14,COMPLETED,INTERVENTIONAL,['NA'],,
11347,NCT00947206,ever had a CRC screening test,2009-09,COMPLETED,INTERVENTIONAL,['NA'],up-to-date for CRC screening,
11348,NCT01760694,Efficacy - Progression Free Survival,2013-01,TERMINATED,INTERVENTIONAL,['NA'],Safety,
11349,NCT01535326,Proportion of Patients Without Pain,2012-02,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants With at Least One Adenoma,Post-procedure Discomforts and 30 Day Complication Rate
11350,NCT05104567,Objective Response Rate (ORR),2021-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Cend of infusion of cetuximab,
11351,NCT00126542,Response rate of patients treated with the combination of bevacizumab and OSI-774,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
11352,NCT04612309,effectiveness,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],,
11353,NCT03466424,Pathological complete response(pCR) rate,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],Incidence of acute toxicities during radiation or chemotherapy,
11354,NCT01661270,Progression-free Survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Objective Response,
11355,NCT01273493,Pharmacokinetics of trabectedin,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate survival data,
11356,NCT00165854,"to determine the safety, tolerability and efficacy (in terms of response rate and progression-free survival) of the combination in patients with metastatic CRC.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],measure duration of response and stable disease; to measure median and one year survival.,
11357,NCT03787537,Change in nutritional status,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],length of hospital stay,
11358,NCT05727007,Diagnostic accuracy in T stage,2019-01-23,COMPLETED,INTERVENTIONAL,['NA'],Diagnostic accuracy in peritoneal or nearby organ infiltration,
11359,NCT02525380,The rate of Time to progression of hepatocellular carcinoma 30 patients.,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
11360,NCT02688114,Change in the Percent of Mucosa Healed by Neosquamous Epithelium,2017-10-18,COMPLETED,INTERVENTIONAL,['NA'],Change in inflammatory cell infiltrate,
11361,NCT02738606,Overall survival,2016-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Patients who abandon treatment,
11362,NCT00527111,Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],KRAS Mutation Rate,
11363,NCT04112836,Percent of planned chemotherapy delivered,2019-03-15,UNKNOWN,OBSERVATIONAL,['NA'],Factors associated with the percent of chemotherapy received,
11364,NCT01333631,Number of the patients with side effects,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of the patients survived,
11365,NCT03260712,Detection of progression-free survival (PFS) rate at 6 months defined according to RECIST 1.1.,2020-01-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression free survival rate at 6 months according to iRECIST,"Biomarkers predictive of response and toxicity (protein profiling, HLA typing)"
11366,NCT01662752,Subjects in Which the SLN(s) Are Identified,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Sensitivity and Specificity of Tumour-bearing Status of SLN(s) as a Measure of Lymph Node Status When Assessed by Standard Techniques,Frequency and Tumour-bearing Status of Aberrant SLN(s
11367,NCT00544193,Measurement of biochemical parameters in tumors that may correlate with the effectiveness of therapy,1997-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11368,NCT01124994,Accuracy of CLE-EMR,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,
11369,NCT00754468,Depth of Injury,2009-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Side Effects of Subjects Receiving Cryospray Therapy.,
11370,NCT05058846,Proportion of participants with of abnormal magnetic resonance imaging (MRI) findings,2022-01-20,RECRUITING,OBSERVATIONAL,['NA'],Proportion of participants who have additional medical procedures,Change in scores on the Disease Specified Perceived Risk Survey
11371,NCT03923335,disease free survival,2019-04-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11372,NCT00585728,The utility of CT virtual proctoscopy (CTVP) for evaluation of rectal cancer.,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
11373,NCT04664504,R0 resection rate,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],3yLRRFS,
11374,NCT02707328,Maximum tolerable dose,2015-01,TERMINATED,INTERVENTIONAL,['PHASE1'],quality of life,
11375,NCT05070247,Dose Expansion: Overall Response Rate (ORR),2022-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Dose Expansion: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations,
11376,NCT05177484,"the feasibility of running the study, to see if it could be run as a large multi-centre study",2022-05-30,RECRUITING,INTERVENTIONAL,['PHASE3'],postoperative allogenic red blood cell transfusion rates,
11377,NCT01366586,,2011-05,COMPLETED,OBSERVATIONAL,['NA'],,
11378,NCT01670110,Change in Kidney Volume,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Quality of Life,
11379,NCT05139082,Overall response rate (ORR),2021-11-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
11380,NCT03899649,Overall Survival,2019-05-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
11381,NCT03919383,6 months progression free survival rates,2019-04-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse Events,
11382,NCT03346915,HPV vaccine series start and completion,2018-08-14,COMPLETED,INTERVENTIONAL,['NA'],Wheel of Wellness (WoW) feasibility,
11383,NCT01441336,3 year recurrence free survival,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11384,NCT02867280,Recurrence free survival,2016-06-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Incidence of dose modification of sorafenib due to adverse events.,
11385,NCT00373737,,1999-05,COMPLETED,OBSERVATIONAL,['NA'],,
11386,NCT03748680,DFS,2018-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],TR,
11387,NCT00066677,Progression-free Survival,2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Thromboembolic Events,
11388,NCT03450512,the arisen of EC in the CT scan,2019-01-14,RECRUITING,OBSERVATIONAL,['NA'],,
11389,NCT03410758,Overall survival,2016-02-15,COMPLETED,OBSERVATIONAL,['NA'],,
11390,NCT01865565,progression free survival,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],Overall survival (OS),
11391,NCT01266707,Toxicities as assessed by NCI-CACAE ver3,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],Survival,
11392,NCT05704413,"Relation between biological parameters and outcomes of digestive disease (IBD, CRC)",2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],Brain-microbiota interaction,
11393,NCT00933816,Dose limiting toxicity in phase I and Time to progression in Phase II,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase I and II: Adverse effect (AE),
11394,NCT02632019,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life,
11395,NCT05619016,Percentage of HER2-positive lesions,2022-11-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety aspects of ABY-025,Dynamic PET parameters
11396,NCT03416244,Overall survival,2018-02-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events,
11397,NCT04417010,local tumor progression,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11398,NCT02776878,"Progression-free survive, calculated from registration until progression or death",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],"Tumor control probability, defined as CR＋PR＋SD, determined according to RECIST 1.1 criteria",
11399,NCT03517618,Disease Control Rate (DCR),2014-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],"Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]",
11400,NCT04047004,Surgical complications,2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Adjuvant chemotherapy,
11401,NCT05886465,Progression free survival rate at 6 months,2023-05-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
11402,NCT03221400,"Phase 2a: Efficacy of PEN-866 in patients with squamous cell carcinoma of the genitalia (anus, cervix, vulva, or penis) using best overall response rate",2017-08-29,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2a: Overall survival,
11403,NCT05801783,Systemic immune response,2022-12-02,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Quality of Life Assessment,
11404,NCT04170179,Progression free survival rate at 6 months,2019-11-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events,
11405,NCT05171530,Maximum tolerated dose of lenvatinib,2022-01-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],Overall survival (OS),Exploratory Outcome
11406,NCT01626001,Patient Percentage with 4DCT Acquisition Artifacts,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Artifact Reproducibility Reducing 4DCT Acquisition,
11407,NCT05916014,Specificity of AI model to diagnose the Kimura-Takemoto classification,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],The MIOU value of AI model in semantic segmentation of endoscopic atrophy picture,
11408,NCT00036517,,2002-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11409,NCT02862015,European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30 score change,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse effect,
11410,NCT03755791,Duration of Overall Survival (OS) for the experimental arm vs. the control arm,2018-06-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Duration of Progression Free Survival (PFS) for the single-agent arm vs. the control arm,
11411,NCT00559858,Incidence of capecitabine dose modifications (dose delay and dose reductions) due to toxicity,2004-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],Measurement of biomarkers that might predict the occurrence of HFS,
11412,NCT05797467,median of disease-free survival,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Complications,
11413,NCT05738772,Serum level of Soluble PDGFRβ,2023-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11414,NCT01844908,Incidence of prolonged ileus,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],30-day mortality rate,
11415,NCT05445778,Assess Progression-free survival (PFS),2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE3'],Patient-reported outcome health-related quality of life (HRQoL) of disease-related symptoms using the NCCN-FACT Ovarian Symptom Index (NFOSI-18) DRS-P (disease-related symptom subscale - physical).,
11416,NCT00989651,Incidence of DLTs occurring in the first 4 courses of treatment (feasibility phase),2009-10-28,COMPLETED,INTERVENTIONAL,['PHASE1'],"Incidence of toxicity, graded according to National Cancer Institute CTCAE version 4.0",Genomic BRCA mutation status
11417,NCT05069766,Registration of treatment related side effects assessed by CTCAE V 5.0,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],,
11418,NCT00439517,Progression-free Survival (PFS),2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety - Number of Patients Experiencing Any Adverse Event,
11419,NCT00006389,Observed Response Rate.,2000-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free Survival,
11420,NCT00389610,Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity,2006-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease-free Survival (DFS),
11421,NCT05497271,diagnostic accuracy by cystic fluid analysis,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],DNA mutation profile of cystic fluid,
11422,NCT01694277,Overall Survival (OS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression Free Survival (PFS),
11423,NCT03075553,Response Rate for Participants Who Achieve a CR or PR [CT-based Response],2017-05-17,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events,
11424,NCT01017822,Overall survival (Phase II),na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Response rate (Phase II),
11425,NCT02399813,Progression Free Survival,2016-06-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events,
11426,NCT01102569,Frequency of Three BRCA1/2 Mutations in Ashkenazi Jewish Patients,2008-01,RECRUITING,OBSERVATIONAL,['NA'],Frequency of disease modifying mutations,
11427,NCT03225560,Quality of Bowel Preparation,2018-11-21,COMPLETED,INTERVENTIONAL,['NA'],Patient reported adherence to bowel preparation instructions,
11428,NCT05580393,The number of cases with subtypes of human Blastocystis isolates in Sohag,2022-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The number of cases with Blastocystis infection is recorded.,
11429,NCT00474994,Overall Objective Response,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11430,NCT03780049,Overall survival (OS),2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Conversion rate to resection,
11431,NCT03259763,Rate of gastric outlet obstruction recurrence,2020-10-26,RECRUITING,INTERVENTIONAL,['NA'],Duration of stent patency,
11432,NCT01373047,Determine the safety of modified T cells delivered into the hepatic artery by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Designer T cell survival and phenotype following infusion,
11433,NCT00669136,Immunological response rate in PBMC as indicated by the ELISPOT assay,2009-06,TERMINATED,INTERVENTIONAL,['PHASE1'],Immunological response rate in lymph nodes as indicated by the ELISPOT assay,
11434,NCT04185454,Osteocalcin ratio,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],Lipid profil 2,
11435,NCT00490373,To evaluate the efficacy.,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],To characterize the quantitative and qualitative toxicities of pemetrexed in this population of pancreatic cancer patients.,
11436,NCT03370432,Incidence of colorectal cancer in the DCH cohort,1993-12,COMPLETED,OBSERVATIONAL,['NA'],,
11437,NCT01149304,HDR-brachytherapy isodose (measured in Gy) that corresponds to the irradiated liver tissue without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety of the study drugs.,
11438,NCT00055692,To Collect Information on Hepatic Function and Hepatitis Viral Activity in Cirrhosis and Upon Potential Alterations in the Setting of VEGF-inhibition,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Stability
11439,NCT03609489,Progression-free survival,2018-09-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease Control rate,
11440,NCT04647045,Serum cytokine level,2017-05-02,COMPLETED,INTERVENTIONAL,['NA'],Constipation related symptoms,
11441,NCT01315522,The stent patency,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],adverse events,
11442,NCT02325453,Compare the three treatment arms in terms of tumor recurrence after treatment. (Disease-free survival),2015-05,UNKNOWN,OBSERVATIONAL,['NA'],"Verify whether robotic gastrectomy, compared with laparoscopic or open techniques, is capable of improving postoperative surgical stress. (Granulocyte-to-lymphocyte ratio.)",
11443,NCT00606944,Recovery,2007-06,COMPLETED,INTERVENTIONAL,['NA'],Postoperative Complication,
11444,NCT02588560,Increase (log) of HCV Viral Load between Baseline and after Chemotherapy,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],Number of Participants with Early Stop of Chemotherapy due to Hepatotoxicity,
11445,NCT00267787,"Genetic analysis of blood sample as well as tissues , will provide us with any possible tumor marker for a better prognostic indicator.",2004-09,TERMINATED,OBSERVATIONAL,['NA'],,
11446,NCT01843725,To determine the maximum tolerated dose and the recommended phase II dose of capecitabine in association with aflibercept,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],"The secondary endpoint is preliminary data on efficacy, and this will be evaluated using CT scan or MRI using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1",
11447,NCT03843554,Oral mucosal severity,2019-09-23,TERMINATED,INTERVENTIONAL,['NA'],Overall survival,
11448,NCT03064490,Number of Participants With Pathologic Complete Response (pCR),2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety of the Combined Drug Therapy With Radiation Therapy.,
11449,NCT00925769,Part 1: PRD of Bevacizumab for Part 2,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Part 2: Overall Survival,
11450,NCT05257122,progression free survival (PFS),2022-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],safety: the potential side effects,
11451,NCT04747951,The rate of complete responses,2020-10-30,UNKNOWN,INTERVENTIONAL,['PHASE4'],rate of intraoperative and postoperative complications,
11452,NCT03405272,Objective response rate,2018-02-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
11453,NCT02713269,Local tumor control rate,2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE2'],Changes in quality of life (QOL) assessed by SF-12 healthy survey (v2),
11454,NCT05545293,Postoperative nutritional status and quality of life,2022-09-14,RECRUITING,OBSERVATIONAL,['NA'],Postoperative intestinal function recovery time,
11455,NCT06265285,Change in patient-reported rating of Cancer CARE Cancer Connected Access and Remote Expertise (CARE) after 8 weeks,2024-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
11456,NCT00454636,Percentage of Participants With Grade 3 Hand-Foot Syndrome (HFS),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Response,
11457,NCT02129257,Progression-Free Survival (PFS) rate at 1 year,2014-05-26,COMPLETED,INTERVENTIONAL,['PHASE2'],"Enzyme-linked immunosorbent assay (ELISA) plasma concentrations of VEGFA, soluble VEGFR1, soluble VEGFR2, VEGF-B, PlGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF). Predictive significance for response rate, PFS, OS.",
11458,NCT03676426,New documentation of advance care planning in the EHR,2018-10-15,COMPLETED,INTERVENTIONAL,['NA'],Surrogate preferences,
11459,NCT03549338,"Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence.",2018-11-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11460,NCT01183156,Attendance to screening colonoscopy,2010-08,UNKNOWN,INTERVENTIONAL,['NA'],Response rate to the re-invitation letter or invitation to the educational meeting,
11461,NCT05383066,Progression-Free Survival,2022-05-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],disease control rate,
11462,NCT04390958,Pathological complete response (pCR) rate,2020-05-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],Surgical complications,
11463,NCT05259488,LOS,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],Time of tolerated food intake,
11464,NCT02919878,Estimate the rate of pathological complete response following neoadjuvant combined-modality therapy using weekly Gemcitabine and radiation therapy in rectal cancer.,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],R0 resection rate,
11465,NCT05442502,The rate of early postoperative complications.,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],Time of esophagojejunostomy,
11466,NCT05382442,Number of participants with adverse events (AEs),2022-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
11467,NCT00816777,Progression Free Survival,2008-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
11468,NCT04139967,Number of participants who experience a grade 2 adverse event,2020-01-20,TERMINATED,INTERVENTIONAL,['NA'],Number of participants with improved symptoms,
11469,NCT05906615,Pain score,2021-01-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Dose reduction of opioids,
11470,NCT05098197,Overall Survival (OS),2021-09-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Change in Quality of Life,
11471,NCT03127111,Time to recurrence (TTR),2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Overall survival (OS),
11472,NCT05178043,The Objective Response Rate (ORR) (confirmed) as evaluated by an Independent Review Committee (IRC) according to RECIST v1.1,2021-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Presence of Anti-Drug Antibodies (ADAs) to GT90001 and Nivolumab during the study relative to the presence of ADAs at baseline,
11473,NCT06287788,The AUC of the predictive model,2024-03-01,RECRUITING,OBSERVATIONAL,['NA'],The important predictors of severe oropharyngeal mucositis in the predictive model,
11474,NCT00261092,Overall response rate based on RECIST criteria,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
11475,NCT04558684,Clinical complete response rate (cCR),2019-11-01,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of adverse events (AEs),
11476,NCT02305290,Observed procedural data,2014-08,RECRUITING,OBSERVATIONAL,['NA'],Analysis of the costs of this procedure compared to previous treatments,
11477,NCT02841436,Tumor response,2012-11,COMPLETED,INTERVENTIONAL,['NA'],Assess for presence of adverse event,
11478,NCT04357587,Treatment response as measured by Carcinoembryonic antigen (CEA) blood test,2020-08-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11479,NCT03191123,3-year overall survival,2016-07-05,UNKNOWN,INTERVENTIONAL,['NA'],Recurrence rates,mortality
11480,NCT06214611,Accumulated dose distribution in CTV,2023-11-15,RECRUITING,INTERVENTIONAL,['NA'],Side effects (CTC AE),
11481,NCT00768937,Safety of Sorafenib in combination with TACE,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11482,NCT00599924,Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs),2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Initial Area Dnder the Contrast Agent Concentration-Time Curve (IAUC) of Tumors in a Selected Group of Subjects Assessed by DCE-MRI,
11483,NCT00324753,Communication Content,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,
11484,NCT02308384,The positive predictive value for detecting colorectal cancer in relation to indications of using iFOBT,2015-09,COMPLETED,INTERVENTIONAL,['NA'],The rate of performed colonoscopies,
11485,NCT02069561,Changes of apoptosis,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Change of Microbiota composition from baseline,
11486,NCT02748304,Overall survival,2016-04,TERMINATED,INTERVENTIONAL,['NA'],Number of patients with treatment-related bleedings who use aspirin,
11487,NCT01348412,progression-free survival,2010-12-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Estimate the quality of life (QLQ C30) and the fatigue MFI20,
11488,NCT03619681,The proportion of patients experiencing dose limiting toxicities.,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression free survival according to RECIST 1.1 criteria.,
11489,NCT05520840,Number of patient with presence of best isolated serum biomarkers selected from different candidates,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Number of patient with presence of other isolated serum biomarkers selected from different candidates,
11490,NCT04024358,PNI and VI correlation with DFS,2015-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Correlation of neurotoxicity with PNI,
11491,NCT05764720,Acute Grade 3+ treatment related GI toxicities,2023-05-14,RECRUITING,INTERVENTIONAL,['NA'],Progression Free Survival,
11492,NCT02332213,VOCs differentiating the study groups,2014-01,COMPLETED,OBSERVATIONAL,['NA'],Groups of gastrointestinal microbiota correlating to VOCs,Gastrointestinal microbiome in cancer patients
11493,NCT02078843,Number of patients correctly identified as not having GEP-NET by using Gallium-68-DOTATATE PET/CT and Indium-111-pentetreotide scintigraphy (SPECT/CT),2014-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of patients with adverse events,
11494,NCT05201352,Overall survival,2022-10-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11495,NCT04163900,Overall Survival (OS),2019-12-24,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11496,NCT00685828,Progression-free survival,2001-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Toxicity as assessed by NCI CTC v2.0,
11497,NCT05719480,Achieve the expected number of enrolled cases,2022-11-20,RECRUITING,OBSERVATIONAL,['NA'],,
11498,NCT01697943,Change in QOL (Quality of Life),2012-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],Nutritional status of patients,
11499,NCT02686944,Adverse events according to CTCAE v 4.03,2016-06-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Levels of alloimmunization parameters,
11500,NCT05229822,Change in number of Participants with Post-operative infectious and inflammatory complications,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],16s rRNA in mesenteric lymph nodes,
11501,NCT02291289,Progression-Free Survival (PFS),2015-04-17,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score,
11502,NCT06248554,Disease-free survival,2019-12-01,RECRUITING,INTERVENTIONAL,['NA'],Adverse effects,
11503,NCT00927680,"We will recruit individuals with colorectal cancer with and without family history of CRC and their immediate family members and obtain the following: paraffin-embedded tumors blocks, blood samples, risk factor and food frequency questionnaires.",2007-07,RECRUITING,OBSERVATIONAL,['NA'],"We will study the following parameters that we help us plan the larger population-based study such as: response rate of probands and their selected relatives, response rate of participants (probands and relatives), etcetera.",
11504,NCT01308723,Part II: Safety/tolerability: Incidence of adverse events,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety: additional anti-drug antibodies sampling after termination of study drug treatment,
11505,NCT03192735,Radical surgical resection rate,2017-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],adverse event,
11506,NCT06173037,Overall Response Rate (ORR) by Independent Review Committee (IRC),2023-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Expression of MSLN using IHC,
11507,NCT06166576,Duration of response according to localized mRECIST,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in ECOG (Eastern Cooperative Oncology Group) performance status scale,Post-treatment dosimetry based on Y90 PET-CT
11508,NCT00964171,Non-morphological progression as defined by RECIST criteria,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Tolerability and safety as assessed by NCI CTCAE v 3.0,
11509,NCT03905967,Overall survival,2019-06-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],Time to progression,
11510,NCT00865189,Percentage of Participants With Tumor Sterilization Defined by ypT0-N0,2007-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Surgery,
11511,NCT05399394,Incidence of Treatment-Emergent Adverse Events,2016-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Local-regional Tumor Control,
11512,NCT02415036,Objective response rate in percentage of Melphalan/HDS treatment,2014-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression free survival in months of patients receiving Melphalan/HDS treatment.,
11513,NCT00094003,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11514,NCT00286000,Response rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],TTP,
11515,NCT03691090,OS,2018-12-03,COMPLETED,INTERVENTIONAL,['PHASE3'],AE,Antidrug Antibodies (ADAs)
11516,NCT01880554,Clinical Utility of Intraoperative Contrast Ultrasound in the Surgery of Colorectal Cancer Liver Metastases.,2011-06,COMPLETED,INTERVENTIONAL,['NA'],Performance Evaluation of Intraoperative Ultrasound Contrast Per Lesion: Characterisation Rate,
11517,NCT00142428,Progression free survival in patients treated with cetuximab for unresectable or metastatic hepatocellular carcinoma,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate,
11518,NCT02966821,Progression-free survival (PFS) rate at Week 16,2017-01-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
11519,NCT03139942,Diagnostic accuracy of hyperplastic vs adenoma classification,2017-03-14,COMPLETED,INTERVENTIONAL,['NA'],Mean time added to endoscopy due to additional imaging,
11520,NCT04724551,Incidence of clinically relevant pancreatic fistula,2012-06-01,COMPLETED,OBSERVATIONAL,['NA'],Biological markers,
11521,NCT02697084,time of disease-free survival,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],best treatment response criterion: complete or partial metabolic response according to EORTC or PERCIST criteria,
11522,NCT00691054,Overall Survival Rate at 6 Months,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival of Participants,
11523,NCT02613728,Cumulative Hospital Length of Stay (LOS),2016-05-13,COMPLETED,INTERVENTIONAL,['NA'],Patient Satisfaction,
11524,NCT03273608,Overall survival,2016-09-14,UNKNOWN,OBSERVATIONAL,['NA'],Adverse Event (AE),"Exploratory Objectives, Downstaging"
11525,NCT06145074,Overall survival 5-years after surgery,2024-03-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety of 40 mg propranolol twice daily on heart rate.,Feasibility of implementing preoperative propranolol in the preoperative setting for patients with pancreatic cancer using the APEASE framework.
11526,NCT00526331,Length of Hospital Stay (LOS) by Participant,2007-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,
11527,NCT04617522,Percentage of Participants who Develop Positive Anti-Sacituzumab Govitecan-hziy Antibodies,2021-04-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11528,NCT03475680,Postoperative 30-day surgical site infection (SSI).,2018-08-08,TERMINATED,INTERVENTIONAL,['PHASE3'],Date of adjuvant chemotherapy beginning,
11529,NCT05336539,Application value of polygene methylation detection in colorectal cancer in community population,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
11530,NCT00006348,response,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11531,NCT06244446,"Objective response rate (ORR), which is defined as the proportion of patients with complete response (CR) and partial response (PR) at 6 months . CR or PR is assessed in accordance with mRECIST.",2024-02-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],"Number of Participants with biomarkers change ( AFP , PIVKA II) in both groups.",
11532,NCT00101582,Number of Participants With Severe (Grade 3 or 4) Oral Mucositis,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Unplanned Breaks in Radiotherapy,
11533,NCT00607828,Maximum tolerated dose,2007-11-16,COMPLETED,INTERVENTIONAL,['NA'],,
11534,NCT04735198,To evaluate the rate of biliary stone disease associated to patients with midgut NET that have gone through primary tumor surgery.,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],To compare quality of life in patients who went through a prophylactic cholecystectomy against those who did not.,
11535,NCT01511653,Measure the sensitivity of a blood based panel of biomarkers relative to fecal immunochemical testing,2011-10,COMPLETED,OBSERVATIONAL,['NA'],To measure the sensitivity and specificity of a combined panel of blood and stool based biomarkers for the detection of colorectal cancer,
11536,NCT06001567,Proportion of patients with PLT >75×10^9/L or doubling from baseline,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (AEs),
11537,NCT02037399,present pain intensity (PPI),2013-07,UNKNOWN,INTERVENTIONAL,['NA'],,
11538,NCT02232490,changes in plasma AFP,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],CT scan,adverse effects
11539,NCT05287165,Incidence of Treatment Related adverse events (AEs),2022-03-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood),
11540,NCT03430635,Identification of PET/CT parameters that can be predictors of survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11541,NCT04499586,ORR(Objective Response Rate) includes CR(Complete Rate) and PR(Partial Rate),2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0,
11542,NCT05901779,postoperative infectious complications,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],total bilirubin,
11543,NCT03063554,Efficacy of Stent Patency,2016-10-18,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life,
11544,NCT01572428,Number of Serrated Lesions Proximal to the Sigmoid Colon Per Patient,2011-04,COMPLETED,INTERVENTIONAL,['NA'],Patients With 1 or More Conventional Adenomas,
11545,NCT00002570,Survival,1994-07-15,COMPLETED,INTERVENTIONAL,['PHASE3'],response duration,
11546,NCT05125614,Overall survival,2020-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
11547,NCT04709055,Percentage of patients with postoperative complications of grade II or higher in the Clavien-Dindo,2021-01-14,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Patient and professionals experience (ancillary study using semi-directive interviews),
11548,NCT00001228,,1988-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11549,NCT05220046,Retention Rate,2023-04-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Change in Demoralization Scale (D-II) total score from Baseline to 1 week post-dose,
11550,NCT05855291,Overall survival,2018-01-22,COMPLETED,INTERVENTIONAL,['NA'],,
11551,NCT03359187,Change of mucositis grading,2016-02,COMPLETED,INTERVENTIONAL,['NA'],Patient satisfaction with the mouth wash,
11552,NCT02350530,The conversion rate of liver metastases,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life (QLQ C30),
11553,NCT00433576,Concentrations of biomarkers,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11554,NCT05385250,Rate of PIFs,2021-08-23,RECRUITING,INTERVENTIONAL,['NA'],Quality of Life measures (EORTC),
11555,NCT00028626,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11556,NCT04527861,3-year disease free survival rate,2021-04-08,RECRUITING,INTERVENTIONAL,['NA'],5-year overall survival rate,
11557,NCT05685602,Dose limiting toxicity rate,2023-06-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),Pharmacokinetics (PK) of both CA-4948 and nab-paclitaxel
11558,NCT02882620,Annual Completion of the FIT Kit,2016-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Change in Self-Efficacy,
11559,NCT05913674,Feasibility of mEPIC,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Satisfaction of care team,
11560,NCT03130634,GI associated adverse events,2016-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
11561,NCT00323583,Quality of life,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Tolerance and Safety NCI-CTC version 2,
11562,NCT04880811,Objective response rate,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
11563,NCT05606848,Change in serum prealbumin,2022-11-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Energy intake in kcal / kg BW,
11564,NCT05444686,SUV of primary and metastases lesions,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
11565,NCT02311465,Functional Assessment of Cancer Therapy: General (FACT-G) Health Related Quality of Life Questionnaire,2015-12,WITHDRAWN,INTERVENTIONAL,['NA'],Hospitalizations,
11566,NCT01678664,Rate of hepatic progression free survival at 24 months,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicities treatment,
11567,NCT05791448,Incidence of adverse events,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacokinetics evaluation - Peak time (Tmax),
11568,NCT01216189,Change in Sexual Function (Total FSFI Scores) Between Baseline and 2 Years Follow-up.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
11569,NCT02795104,Percentage of Participants Who Received All Needed Screening and Any Needed Screening Across the Three Randomized Arms,2016-11,COMPLETED,INTERVENTIONAL,['NA'],Cost of the Interventions,
11570,NCT03471273,recur or not in 2 years after endoscopic surgical procedure or surgery,2017-09-18,UNKNOWN,INTERVENTIONAL,['NA'],,
11571,NCT04815746,The Gastrointestinal Symptom Rating Scale (GSRS),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
11572,NCT03251612,Progression free survival 8 weeks after start of treatment,2017-09-22,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life as measured by questionnaire EQ-5D-5L,
11573,NCT05350384,funduscopic examination,2021-06-18,COMPLETED,OBSERVATIONAL,['NA'],abdominal CT-scan,Therapy
11574,NCT01661088,The Percentage of Patients That Underwent an R0 Resection,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival Time,
11575,NCT04227886,Toxicities,2019-12-01,UNKNOWN,OBSERVATIONAL,['NA'],pCR,
11576,NCT06192719,Gallbladder Cancer/Dysplasia development,2019-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
11577,NCT00539318,there is no primary outcome measures in this study,2007-08,TERMINATED,OBSERVATIONAL,['NA'],,
11578,NCT00054457,Proportion of successes,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Quality of life as measured by the LASA, FACT-E and Patient Uniscale Swallowing questionnaires",
11579,NCT04336839,Progression-Free Survival,2020-05-01,UNKNOWN,OBSERVATIONAL,['NA'],Histology predictive value,
11580,NCT00845247,Quality of Life measures(questionnaire),2009-03,COMPLETED,INTERVENTIONAL,['NA'],Care process measures in terms of monitoring of data from the National Patient Registry,
11581,NCT04717765,"Treatment of osteonecrosis of the jaws with LLL phototherapy, evaluation using Notani scale - grade 1 to 3 - Radiotherapy",2021-02-10,COMPLETED,INTERVENTIONAL,['NA'],Pain assessed by EVA - score 0 to 10 - all patients,
11582,NCT03717298,Quality of Life: EORTC QLQ-C30,2018-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],Compliance with the treatment with chemotherapy (CT) and Immunotherapy (IT) test,
11583,NCT04977739,signal intensity of the probes,2021-08-03,COMPLETED,OBSERVATIONAL,['NA'],,
11584,NCT01356264,six minute walk test,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Fatigue,
11585,NCT05726864,Phase 2: Compare ELI-002 7P versus standard of care (SOC; observation) in DFS (disease free survival),2023-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Determine the objective response rate (ORR) in subjects who crossover from Observation to ELI-002 7P treatment after confirmed progressive disease according to iRECIST,
11586,NCT03364582,Colorectal cancer risk,2016-06-01,COMPLETED,OBSERVATIONAL,['NA'],Mortality,
11587,NCT03486418,Optical diagnosis of each colorectal polyp,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11588,NCT04844970,Weight change,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],AEs,Chemotherapy Dose change
11589,NCT00655876,Overall Survival (24-month Rate Reported),2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],"Quality-adjusted Survival (Using EQ-5D), Only if Primary Hypothesis is Supported",
11590,NCT03303833,Overall cancer diagnoses,2006-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
11591,NCT02292745,overall survival,2014-12-02,COMPLETED,INTERVENTIONAL,['NA'],predictive value of a set of biological markers for treatment response,
11592,NCT00114231,3-Year Disease-free Survival,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Local Recurrence Rate,
11593,NCT01693523,Average Area Under the Curve (AUC) of Apriori Selected MDASI Symptoms,2013-01-28,COMPLETED,INTERVENTIONAL,['PHASE2'],"Relationship Between Dynamic Changes in Inflammation Biomarkers and Symptom Outcomes, Controlling for the Grouping Variables (Tumor Markers, Weight Loss), Evidence of Infection, ECOG PS, Age and Gender Examined",
11594,NCT04897854,Quality adjusted overall survival,2021-04-22,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of patients with adverse events,Level of CA 19.9
11595,NCT04191551,Progression of intestinal metaplasia,2018-07-30,RECRUITING,OBSERVATIONAL,['NA'],,
11596,NCT06122636,Quality of life rate,2022-10-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11597,NCT05627414,R0 resection rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],safety profile,
11598,NCT00844883,Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the Study Treatment.,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Efficacy - Factors Associated With Overall Survival (OS) After Combination Treatment With Sorafenib and TACE,Median Overall Survival OS Stratified by BCLC Criteria
11599,NCT04976634,Confirmed Objective Response Rate (ORR) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR),2021-08-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Arm 2: Number of Participants Who Discontinued Study Treatment Due to an AE,
11600,NCT04618367,Progression free survival rate at 6 months,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],Adverse events,
11601,NCT00841607,pancreatic leak/fistula,2006-08,COMPLETED,INTERVENTIONAL,['NA'],overall morbidity,
11602,NCT06099951,Complete tumor response rate.,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Sphincter preservation rate,
11603,NCT02616692,"Preference weight scores for 13 selected HCC treatment attributes associated with Sorafenib, repeated TACE, and HAIC",2016-05-09,COMPLETED,OBSERVATIONAL,['NA'],Maximum acceptable risk of life-threatening side effect willing to take for oral anti-cancer therapy (Sorafenib) therapy that will stop cancer from getting worse for a specified period of time,
11604,NCT02223078,Antibody Levels,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Serious and Non-Serious Adverse Events,
11605,NCT04592289,Incisional surgical site infection (SSI) rate,2020-10-30,RECRUITING,INTERVENTIONAL,['NA'],Bowel preparation compliance,
11606,NCT00561418,Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to Progression,
11607,NCT03826862,postoperative complication,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],disease-free survival,
11608,NCT00348699,Plasma area under the curve (AUC) of AFP464,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Percent change in CYP1A1,
11609,NCT02658214,Tumor assessment based on RECIST 1.1 (for cohort 6 only),2016-04-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11610,NCT03651154,Packed Red Blood Cell Transfusion Rates,2018-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Changes in physiologic parameters (Pulse Pressure Variation),
11611,NCT02425059,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Percentage of lesions that show no sign of recurrence 12 months after IRE,Overall survival (OS)
11612,NCT05025033,Progression Free Survival,2019-05-30,COMPLETED,INTERVENTIONAL,['PHASE2'],adverse events,biomolecular markers
11613,NCT02419716,Positive and Negative Predictive Value,2015-04,COMPLETED,OBSERVATIONAL,['NA'],Colorectal Cancer Incidence,The adverse event rate (events occurring between collection kit distribution and sample submission)
11614,NCT06300463,"Mean CD8:Treg ratio, as determined by flow cytometry of tumor tissue, at time of surgical resection in each treatment arm",2024-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants Per Arm with ctDNA Clearance,
11615,NCT00941655,Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE3'],Patterns of Disease Recurrence Between the Two Therapeutic Approaches and Their Clinical Implications,
11616,NCT04025567,To evaluate the effect of oral vancomycin therapy in the relative CXCR6 gene expression levels in the liver,2020-03-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
11617,NCT05184283,Change in mean muscle fat,2022-06-16,TERMINATED,OBSERVATIONAL,['NA'],Delta HOMA-IR,
11618,NCT05263830,evaluate concentration of circulating GPC-3,2023-09-08,RECRUITING,OBSERVATIONAL,['NA'],Evaluation of the HCC response to treatment on Imaging assessment (CT-scan and MRI) every 3 months according to the miRECIST criteria (combination of mRECIST and iRECIST criteria),
11619,NCT03214835,Efficacy of EndoCDx brush,2018-02-01,WITHDRAWN,INTERVENTIONAL,['NA'],Assessment of pain,
11620,NCT00587652,Any dysplasia or adenocarcinoma detected over all biopsies using each method.,2002-12,COMPLETED,OBSERVATIONAL,['NA'],The association between staining patterns and histologic grade of the biopsies obtained using methylene blue will be assessed.,
11621,NCT02412683,Oxaliplatin-Specific Neurotoxicity Scale,2014-01,COMPLETED,OBSERVATIONAL,['NA'],Sense of Coherence scale (SOC-scale),
11622,NCT03210948,Diagnostic accuracy,2019-01-23,UNKNOWN,INTERVENTIONAL,['NA'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
11623,NCT05870800,"Determine the rate of complete histopathologic response to neoadjuvant immunotherapy with neoadjuvant chemotherapy in pMMR resectable, non-metastatic colon cancer.",2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Assess short and long-term quality of life through Patient-Reported Outcomes (PROs),
11624,NCT06311565,Healthy lifestyle behaviors scale II,2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
11625,NCT00020150,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11626,NCT05546619,RFS,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],OS,
11627,NCT01918683,Progression Free Survival,2013-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
11628,NCT06061276,Objective response rate (ORR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Progression free survival (PFS),Overall survival (OS)
11629,NCT01249521,Disease control (ie non progression) at 6 months,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Response rate,
11630,NCT04395352,Adenoma detection rate (ADR),2018-11-01,COMPLETED,OBSERVATIONAL,['NA'],Number of patients with delayed adverse events,
11631,NCT06071052,"Time to progression, TTP",2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Safety evaluation,
11632,NCT03908671,Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,2019-10-18,RECRUITING,INTERVENTIONAL,['NA'],Overall Survival (OS),
11633,NCT04264676,"Disease Free Survival, DFS",2020-03-31,RECRUITING,INTERVENTIONAL,['PHASE2'],"Recurrence Rate, RR",
11634,NCT01032044,"Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of ""Optimally Treated""",2010-02,COMPLETED,INTERVENTIONAL,['NA'],,
11635,NCT02005484,Percentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Time to Progression,
11636,NCT00368329,Patients' responses to therapy will be evaluated clinically after completion of their neoadjuvant chemoradiation.,2006-06,TERMINATED,INTERVENTIONAL,['PHASE1'],Patterns of failure and the 2-year progression-free survival (PFS) rate.,
11637,NCT01815307,1 year recurrent free survival rate,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of overall survival,
11638,NCT03279601,Overall response rate (ORR),2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events （Safety and Tolerability）,
11639,NCT05586061,objective response rate (ORR),2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],duration of response (DOR),
11640,NCT06084884,"1. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phase",2023-11-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",12. Pharmacokinetics - Exposure of AZD5851,
11641,NCT03175705,Incidence of Treatment-Emergent Adverse Events [Safety],2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Biological activity of infused T cells,Disease Control Rate (DCR)
11642,NCT01775644,Median Progression-Free Survival Time in Defined Participant Subgroups as Assessed by Response Evaluation Criteria In Solid Tumors (RECIST),2012-12-14,COMPLETED,OBSERVATIONAL,['NA'],Percentage of Participants in Defined Participant Subgroups Showing Overall Response in Daily Routine Practice as Assessed by RECIST,
11643,NCT02534389,Check effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on Glasgow Prognostic Score (GPS).,2015-01,COMPLETED,INTERVENTIONAL,['NA'],Check for effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on pathological response.,
11644,NCT04308174,Ro resection rate,2020-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Response rate,
11645,NCT03638193,Safety of CART-meso infusion: number of adverse events,2018-07-11,UNKNOWN,INTERVENTIONAL,['NA'],CAR-T cell detection,
11646,NCT03001362,"Feasibility of a ""wait and see"" approach",2015-03,RECRUITING,INTERVENTIONAL,['NA'],,
11647,NCT04443985,Lymph node,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
11648,NCT03245788,Rates of unplanned hospitalization and ER visits,2017-02-15,COMPLETED,INTERVENTIONAL,['NA'],Utilization of non-treatment-related cancer services,
11649,NCT03322267,1-year relapse-free survival (RFS) rate.,2018-10-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),Blood-based biomarkers
11650,NCT02646137,Number of patients with successful ablation,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
11651,NCT03858855,Effects of essential oils on nausea and anxiety,2019-02-18,COMPLETED,INTERVENTIONAL,['NA'],Acceptability of using a personal inhalation bottle for inhalation of essential oils - perception of benefit of essential oil for symptoms,
11652,NCT03982407,Evaluation of PSMA PET-MR for identification of intra and extrahepatic hepatocellular carcinoma in patients,2019-06-27,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
11653,NCT02385604,Disease-free survival,2014-01,COMPLETED,OBSERVATIONAL,['NA'],Histopathologic response,
11654,NCT05390398,Change in cancer-related fatigue,2022-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Cost-effectiveness evaluation,Clinical parameters
11655,NCT01307956,Complete Pathological Response (pCR) Rate,2011-02-28,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Patients Who Can Undergo Resection,Overall Survival
11656,NCT03958747,Tibial Nerve Cross-Sectional Area Comparison,2019-12-17,RECRUITING,INTERVENTIONAL,['NA'],Reduction of Intraepidermal Nerve Fiber Density,
11657,NCT03146520,Clinical performance of EarlyTect Colon Cancer to detect colorectal cancer,2016-12-13,COMPLETED,OBSERVATIONAL,['NA'],Positive ratio of SDC2 methylation in other cancers,
11658,NCT00079261,Complete response as assessed by Cheson criteria,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Freedom from treatment failure as assessed by Cheson criteria,
11659,NCT04300959,12 months OS rate,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent 3/4 Adverse Events,
11660,NCT03236649,Overall survival (OS),2017-09-20,TERMINATED,INTERVENTIONAL,['PHASE3'],Assessment on Quality of life 2,"Genome level (DNA, mRNA, miRNA) biomarker analysis"
11661,NCT01444456,Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL,2011-10,COMPLETED,OBSERVATIONAL,['NA'],Percentage of Participants With Increase in Hemoglobin ≥ 1 g/dL at Any Time,
11662,NCT05793593,number of people beyond the index participants who complete FIT screening,2023-03-17,RECRUITING,INTERVENTIONAL,['NA'],,
11663,NCT06118762,Progression free survival (PFS),2023-10-20,RECRUITING,INTERVENTIONAL,['PHASE4'],Security,
11664,NCT05472896,Progression-free survival (PFS) by Independent Review Committee,2022-06-09,RECRUITING,INTERVENTIONAL,['PHASE3'],2 year survival rate,Adverse event/ serious adverse event
11665,NCT06017297,Incidence of related treatment emergent adverse events,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Event Free Survival (EFS),
11666,NCT05810805,Concentrations of different gas in digestive tract,2023-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The correlation between the severity of gastrointestinal symptoms and gas concentrations in various parts of the digestive tract.,
11667,NCT05783570,Development of anti-drug antibodies (ADA),2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE1'],OS,Immunological assessment
11668,NCT04194359,Adverse Events and Serious Adverse Events,2021-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Progression free survival,
11669,NCT01088204,noncompliance rate,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],3-year disease free survival,
11670,NCT02686424,overall survival,2010-03,SUSPENDED,OBSERVATIONAL,['NA'],,
11671,NCT02777814,Incidence of hepatitis B virus associated hepatitis,2015-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Interruption of chemotherapy due to hepatitis,
11672,NCT06103890,pCR,2023-05-22,RECRUITING,OBSERVATIONAL,['NA'],OS,
11673,NCT01879943,Number of patients with full colonic exploration and detection of lesions,2013-10-18,TERMINATED,INTERVENTIONAL,['NA'],Health-economic assessment,
11674,NCT02002806,Pain Control,2012-01,COMPLETED,INTERVENTIONAL,['NA'],"Disease-specific, recurrence-free survival",
11675,NCT06315361,Prevalence of significant fibrosis by non invasive tests,2019-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Identification of MACE,
11676,NCT01433146,Temperament in non-metastatic colorectal cancer patients,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,
11677,NCT00924092,To determine the safety and tolerability of escalating doses of a heated-killed yeast-based vaccine that targets tumors that express CEA.,2009-03-13,COMPLETED,INTERVENTIONAL,['PHASE1'],"To evaluate CD4 and CD8 immunologic response. To evaluate humoral immune response to yeast antigen. To evaluate evidence of clinical benefit such as PFS, OR, &amp; decreases in circulating tumor cells &amp; tumor markers.",
11678,NCT06146946,3-year disease free survival rate,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],3-year overall survival rate,
11679,NCT03451643,POSTOPERATIVE MORBIDITY,2013-02,UNKNOWN,INTERVENTIONAL,['NA'],QUALITY OF LIFE,
11680,NCT05366829,Safety as assessed by number of participants experiencing adverse events,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Response and progression will be evaluated in this trial using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee (v1.1).,
11681,NCT05009927,Progression-free-rate at 6 months (PFR 6m),2022-01-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of response (DOR),
11682,NCT01998347,median overall survival,2013-11,WITHDRAWN,INTERVENTIONAL,['PHASE3'],median progression free survival,time to progression
11683,NCT01755767,Overall Survival (OS) Rate At Different Time Points Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy,2012-12-27,COMPLETED,INTERVENTIONAL,['PHASE3'],Treatment-Emergent Adverse Events Reported (>20% in Tivantinib Cohort) Following Treatment With Tivantinib Compared With Placebo in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy,
11684,NCT05518643,Rate of Postoperative Pancreatic Haemorrhage (PPH),2022-07-15,RECRUITING,OBSERVATIONAL,['NA'],Cancer recurrence rate,
11685,NCT02340065,number and rate of missed adenomas,2015-01,COMPLETED,INTERVENTIONAL,['NA'],mean number of adenomas per procedure,
11686,NCT06161233,Change in health-related QoL outcomes in RCC patients,2023-05-16,COMPLETED,INTERVENTIONAL,['NA'],User experience of the CAPABLE system in other cancer types patients,
11687,NCT04158635,Compliance,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Time to treatment failure (TTF),Quality of life assessment
11688,NCT01528683,Safety and Efficacy,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
11689,NCT00855452,CR:disappearance of disease.PR:<50% decrease in the total tumor load of the lesions SD:<50% reduction and 25% increase in the sum of the products of the longest perpendicular diameters of the measured lesions.PD:>25% increase in the size of lesion.,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11690,NCT02184182,Percentage of R0 resections,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],hepatic diesease free survival,
11691,NCT00131638,Incidence percentage of severe oral mucositis (Grades 3 or 4 on the WHO oral mucositis scale),2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Incidence of >/equal to 5 missed consecutive fractions of scheduled RT (to include discontinuations of RT),
11692,NCT02904031,"Progression Free Survival (PFS). PFS is defined as the time from randomization to the first documentation of objective disease progression or death due to any cause, whichever occurs first.",2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
11693,NCT04000529,"Dose interruptions, reductions and dose intensity, by treatment",2019-07-30,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall Survival,
11694,NCT00410956,"Antitumor efficacy (complete and partial response, stable and progressive disease)",2007-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity as measured by NCI Common Toxicity Criteria,
11695,NCT03931980,Conversion to open surgery,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],Time of surgery,
11696,NCT06134193,Progress free survival (PFS) per RECIST v1.1,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence rate of adverse events,
11697,NCT05101629,Objective response rate (ORR) according to RECIST 1.1 criteria,2022-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and toxicity,
11698,NCT02206360,Premalignant or malignant pancreatic conditions found with alternating EUS and MRI testing.,2014-04,RECRUITING,OBSERVATIONAL,['NA'],Non-Pancreatic cancers diagnosed while on this protocol,
11699,NCT05495529,Clinical success,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],Progression free survival,
11700,NCT06059170,Frequency of LARS,2017-03-17,COMPLETED,INTERVENTIONAL,['NA'],,
11701,NCT02280278,Disease free survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],toxin-side effect,
11702,NCT00790322,Compare the proportion of patients in the two arms who develop severe oral mucositis,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11703,NCT06280495,3-year Progression-Free Survival Rate,2024-02-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Treatment-related adverse events,
11704,NCT00002631,,1995-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11705,NCT00867750,Health-related quality of life (HRQL),2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmaco-economic assessment,
11706,NCT03179579,Median overall survival,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Risk factors for morbidity and mortality,
11707,NCT06313567,Disease-free survival,2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE3'],Side effects,
11708,NCT03133650,Maximum tolerated laser fluence rate,2017-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11709,NCT02024087,Number of Participants With Adverse Events as a Measure of Safety and Tolerability.,2014-08-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Disease Control Rate (DCR),
11710,NCT00241020,Overall Survival,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],· Safety,
11711,NCT03964753,OS,2019-04-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of Adverse Event,
11712,NCT00743678,To evaluate overall R0 resection rates following neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],"Correlative analyses between pretreatment EGFR, KRAS mutation and response rate/survival",
11713,NCT05800418,Area under drug concentration - time curve (AUC0-t),2019-11-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Apparent volume of distribution (Vd),
11714,NCT04755036,Measurement of consensus in therapeutical decisions in pancreatic cancer between low/mid vs high volume hospitals,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11715,NCT06056804,pCR rate,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],irAE,The expression of CD8
11716,NCT01397747,"Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer.",2011-06,COMPLETED,OBSERVATIONAL,['NA'],,
11717,NCT01613469,To assess the complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer.,2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],The proportion of subjects with complete pathological response at surgical resection,
11718,NCT03457454,Assess the care coordination and communication with primary care providers by colonoscopy clinics/practitioners,2017-09-08,COMPLETED,OBSERVATIONAL,['NA'],,
11719,NCT05957640,Objective response rates (ORR),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE1'],Resection rate of liver target lesions,
11720,NCT04996459,overall response rate,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA'],Safety (the incidence of adverse events and serious adverse events),
11721,NCT00020267,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11722,NCT02949947,Complete Response Rate in Hemoglobin (HGB),2017-12-18,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11723,NCT06074029,Progression free survival,2021-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to treatment discontinuation,
11724,NCT06219941,Objective Response Rate (ORR).,2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],"ADA status will be determined along with prevalence and incidence of anti-drug antibodies to AZD0901, and titer established.",
11725,NCT04328740,Determine recommended Ph2 dose (RP2D) of TP-1454,2020-07-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Determine antitumor activity of TP-1454.,
11726,NCT05322577,Part 2: Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1),2022-05-17,RECRUITING,INTERVENTIONAL,['PHASE1'],Part 2: OS,
11727,NCT01124630,Progression Free Survival,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Serum concentrations,
11728,NCT02342847,Change from baseline of the Karnofsky index,2014-12-10,COMPLETED,OBSERVATIONAL,['NA'],Physical examinations,
11729,NCT01595256,Exploration the Effect of Walking Program in Patients With Colorectal Cancer.,2011-10,COMPLETED,INTERVENTIONAL,['NA'],,
11730,NCT04479436,Objective Response Rate (ORR) As Assessed By Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer,2020-09-14,TERMINATED,INTERVENTIONAL,['PHASE2'],Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) of analytes of U3-1402 Following Administration In Participants with Advanced or Metastatic Colorectal Cancer,
11731,NCT05794971,Overall Survival (OS),2023-06-10,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse enents,
11732,NCT01567930,Disease Progression,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Circulating tumor cells levels,
11733,NCT02424955,Changes in Blood Perfusion (Relative Blood Flow),2014-11-18,COMPLETED,INTERVENTIONAL,['NA'],,
11734,NCT00898846,mRNA levels,2006-10,COMPLETED,OBSERVATIONAL,['NA'],Histopathological examination,
11735,NCT05446129,Composite endpoint: Proportion of patients with at least one occurrence of a safety or feasibility event,2022-09-27,TERMINATED,INTERVENTIONAL,['PHASE1'],"Radiographic response on pre-surgical imaging, following receipt of the neoadjuvant therapy, as per response evaluation criteria in solid tumors (RECIST) v1.1",
11736,NCT00041639,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11737,NCT03016026,Rehabilitative rate,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Mortality rates,
11738,NCT04749303,Adenoma Detection Rate (ADR),2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],Severe adverse events,
11739,NCT02575300,Overall Radiographic Response Rate (ORR),2015-10-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response,
11740,NCT02329860,Overall Survival,2014-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease Control Rate,
11741,NCT04389892,Differentiation between murale nodules and mucus clots or debris,2018-04-01,COMPLETED,INTERVENTIONAL,['NA'],Guiding EUS-FNA by the enhancement pattern,
11742,NCT03318380,Negative Predictive Value of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval,2018-01-19,COMPLETED,INTERVENTIONAL,['NA'],,
11743,NCT00085163,"Disease-free survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter",2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],"Toxicity as measured by CTC AE version 2.0 every 3 months in year 1, every 6 months in years 2-3, and annually thereafter",
11744,NCT03957135,2 year survival,2019-05-20,RECRUITING,INTERVENTIONAL,['NA'],,
11745,NCT00501410,"Maximum Tolerated Dose (MTD) of Dasatinib, Cetuximab and FOLFOX",2007-04-23,COMPLETED,INTERVENTIONAL,['PHASE1'],Response-Rate of Dasatinib and Modified FOLFOX6 With or Without Cetuximab,
11746,NCT01032928,Optimal Respiratory - Swallow Phase,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Impairment According to the Penetration-Aspiration Scale,
11747,NCT04084158,PFS,2019-09-07,SUSPENDED,INTERVENTIONAL,['PHASE2'],TTDM,
11748,NCT02952859,Time from diagnosis to death for any reason,2017-01,TERMINATED,OBSERVATIONAL,['NA'],,
11749,NCT06047015,Abscopal effect: percent change in non-treated colorectal liver metastasis.,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life questionnaire,
11750,NCT01338558,Progression-free survival: native versus mutated K-RAS; tumour assessments according to RECIST criteria,2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Progression-free survival: comparison of the two treatment regimens in the native K-RAS arms,
11751,NCT04508140,Safety: Adverse Events,2020-06-17,TERMINATED,INTERVENTIONAL,['PHASE2'],Survival Rate,
11752,NCT00436215,Clinical Response Rate.,2006-12-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events,
11753,NCT04227041,Progression-free survival (PFS),2020-01-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of Treatment-Emergent Adverse Events [Safety],
11754,NCT03384940,Number of Participants With Objective Response Rate Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Advanced Colorectal Cancer,2018-02-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Treatment-Emergent Adverse Events (TEAEs) Reported By ≥20% Of Participants Following Treatment With DS-8201a in Participants With HER2-expressing Advanced Colorectal Cancer,
11755,NCT05580224,Local tumor progression rate,2022-10-04,RECRUITING,INTERVENTIONAL,['NA'],Recurrence-free survival,
11756,NCT06302660,Identify microbiome dysbiosis in stool associated with long-term functional symptoms.,2022-03-09,RECRUITING,OBSERVATIONAL,['NA'],Propose a strategy for treatment of long-term symptoms in oesophageal adenocarcinoma survivors.,
11757,NCT04196062,Complete (R0) resection,2020-05-01,COMPLETED,INTERVENTIONAL,['NA'],Technical Success,
11758,NCT00489268,Percentage of Participants With Histological Clearance of Barrett's Metaplasia,2003-11,COMPLETED,INTERVENTIONAL,['NA'],Percentage of Participants With Sub-squamous Intestinal Metaplasia,
11759,NCT00931203,"The primary objective is to determine the pathological complete response (pCR) of combining preoperative tegafur-uracil, folinate, radiation and celecoxib for locally advanced rectal cancer.",2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Sphincter preservation rate.,
11760,NCT06311929,Disease-free survival,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Overall survival,
11761,NCT05723978,Disease-free survival (DFS),2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11762,NCT04248452,Overall survival,2020-05-26,RECRUITING,INTERVENTIONAL,['PHASE3'],Progression-free survival,
11763,NCT03978702,"Measurement of immune effectors (Tcells, NK) levels after pancreatectomy",2021-02-24,UNKNOWN,INTERVENTIONAL,['NA'],,
11764,NCT01872104,Survival rate,2013-08,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Progression-free survival,Quality of life
11765,NCT03697239,Disease Control Rate,2019-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Changes in patient's self-reported pain levels,
11766,NCT05907772,Overall survival,2022-08-27,COMPLETED,OBSERVATIONAL,['NA'],,
11767,NCT04319484,3 years recurrence-free survival rate,2020-05-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",5 years overall survival rate,
11768,NCT03579784,Disease control rate,2018-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerability as measured by number and grade of toxicity events,
11769,NCT00516269,Mean Difference Between Post-Methylphenidate and Post-Placebo Measurement,2004-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11770,NCT02288611,Change from baseline in large intestinal microbiota composition verses control intervention (0-3 months),2012-05,COMPLETED,INTERVENTIONAL,['NA'],Change from baseline in Bowel function verses the control intervention (0-3 months,
11771,NCT04010227,Short-form of Zarit Burden Interview,2019-09-16,COMPLETED,INTERVENTIONAL,['NA'],Value Progress Subscale of the Valuing Questionnaire.,
11772,NCT03110926,Disease-free survival rate,2017-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall disease-free survival,
11773,NCT01812577,Intensity of postoperative pain after radiofrequency ablation of liver lesion,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],Consumption of post-operative opioid,Satisfaction of patient and of the operator
11774,NCT05068193,Cmax,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11775,NCT02981862,Assessement of CaptHPV method,2016-12-19,COMPLETED,INTERVENTIONAL,['NA'],,
11776,NCT03390517,Anastomotic Leak Rate,2017-11-09,COMPLETED,INTERVENTIONAL,['NA'],,
11777,NCT05025631,PFS,2020-11-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Correlation between geriatric assessment and efficacy and safety,
11778,NCT04067986,Objective response rate,2019-08-20,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of Treatment-Emergent Adverse-Events,
11779,NCT03081494,Incidence of Dose-limiting toxicity (DLT),2017-06-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Severity of AEs and SAEs,
11780,NCT01621217,To establish maximum tolerable dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab and radiotherapy in patients with locally advanced cancer in the anal region,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11781,NCT01219920,Response rate (RR),2001-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of life (QoL),
11782,NCT00693290,Clarity of the mucosa evaluated by the Ottawa Scale.,2008-06,UNKNOWN,INTERVENTIONAL,['NA'],Concordance with the bowel preparation.,
11783,NCT03907579,Number of Participants With Varying Levels of Behavioral Intentions Related to Colorectal Cancer Screening and Prevention,2017-03-11,COMPLETED,INTERVENTIONAL,['NA'],,
11784,NCT01150877,"The metabolic consequences, including tolerability and toxicity, of prolonged, high-dose physiological vitamin D in patients with colorectal cancer.",2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Patient survival with regards to high-dose vitamin D supplementation.,
11785,NCT03539822,Phase II- Overall Response Rate (ORR),2018-10-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
11786,NCT02509169,overall survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],progression free survival,
11787,NCT04665687,Indentify prognostic biomarkers for predicting recurrence of early gastric cancer and precancerous adenoma lesion.,2020-12-17,UNKNOWN,OBSERVATIONAL,['NA'],"Change in the tumor's molecular profile on serial biopsies at the time of initial treatment, 2 months after treatment, 1 year after treatment, or recurrence.",
11788,NCT04878185,Change in maximal walking distance,2021-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Mortality,
11789,NCT02338297,APS improvement,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],Response Rate,
11790,NCT05452473,Gastric lesion detection rate,2022-07-06,RECRUITING,INTERVENTIONAL,['NA'],Lesion classification accuracy,
11791,NCT03491540,Postoperative 30-day surgical site infection (SSI).,2018-09-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Temporary stoma closure rate,
11792,NCT05242237,Time to progression or death (months),2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11793,NCT00766636,Difference in Positive Margin Resection (R1) Rate in Patients Undergo Surgery Between the Two Treatment Groups.,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11794,NCT05647122,Proportion of patients with radiological response (ORR),2022-12-22,RECRUITING,INTERVENTIONAL,['PHASE1'],Immunogenicity of AZD9592: Anti-Drug Antibodies (ADA),
11795,NCT01112280,Adenoma detection rate,2010-04,COMPLETED,INTERVENTIONAL,['NA'],Surveillance,
11796,NCT03008278,Objective response rate (Phase II),2018-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of adverse events,"Tumor cells for PDX model, and biobanked tumor tissue and peripheral blood"
11797,NCT01685632,heat shock protein expression (blood/cell ratio)compared to baseline values,2012-09,TERMINATED,INTERVENTIONAL,['NA'],,
11798,NCT00435097,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
11799,NCT00393822,Incidence of Grade ≥ 2 (WHO scale) oral mucositis,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of grade ≥ 2 (WHO scale) oral mucositis,
11800,NCT02025244,To compare the yield and success of KHB and EUS-FNA in cytological / histological and immunohistochemical diagnostics of Upper Gastrointestinal Submucosal Tumors.,2010-11,UNKNOWN,INTERVENTIONAL,['NA'],Detection of mitotic activity in case of Gastrointestinal Stromal Tumors,
11801,NCT04612504,The response rate of patients with HCC receiving SynOV1.1,2022-06-23,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,
11802,NCT05438836,"Early Rate of Common Terminology Criteria for Adverse Events (CTCAE) Gastrointestinal Toxicity grade 2 or more (scale from 0-5, 5 being the highest)",2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],Treatment Related Hospitalization,
11803,NCT03946852,Ischemic Cholangiopathy,2019-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Graft survival,Re-operation rate
11804,NCT03340558,Change in CD8 T cell immune infiltrates,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall Survival,
11805,NCT02021110,Effect of UDCA on total liver volume,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect of UDCA on absolute total kidney volume,Adverse events as a measure of tolerability and safety of UDCA
11806,NCT01743469,"Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts).",2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Further Cancer-related Treatment During Follow-up Period (All Cohorts).,
11807,NCT01423708,Everolimus monotherapy,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
11808,NCT05233787,Quality of life over the 12 months after surgery,2022-03-24,RECRUITING,INTERVENTIONAL,['NA'],Changes in microbiome composition and diversity from baseline to 1 month,
11809,NCT03863236,Postoperative complications,2019-04-01,RECRUITING,INTERVENTIONAL,['NA'],Hospital stay,
11810,NCT06172049,Survival,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11811,NCT04866108,Objective Response Rate (ORR),2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of Life (QoL),
11812,NCT05731336,"Overall Survival, OS",2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],"Adverse events, AEs",
11813,NCT02454647,R0 resection rate,2013-09,COMPLETED,OBSERVATIONAL,['NA'],Adverse events are assessed according to CTC criteria v 4.0,
11814,NCT00577902,"To study baseline antioxidant capacity (ORAC), selected biomarkers of nutritional status and nutritional risk of patients beginning therapy for head and neck cancers.",2005-06,COMPLETED,OBSERVATIONAL,['NA'],"To assess antioxidant capacity, nutritional biomarkers and nutritional risk of patients during and after concurrent radiation and chemotherapy.",
11815,NCT04868747,serum concentration of NET(neutrophil extracellular trapping)-related biomarker,2021-04-01,WITHDRAWN,INTERVENTIONAL,['NA'],survival of patients,
11816,NCT04085211,"Sensitivity, specificity, positive predictive value of specific endoscopic image enhancement findings to diagnose or stage the severity of different gastrointestinal conditions",2019-07-01,UNKNOWN,OBSERVATIONAL,['NA'],median duration for image enhanced endoscopy procedures,
11817,NCT05714475,Disease free survival,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],Disease free survival (12),
11818,NCT02324556,Number of specimens with grade I specimen according to Quirke,2015-01,TERMINATED,OBSERVATIONAL,['NA'],Postoperative complications scored according to Clavien-Dindo within the first 12 months,
11819,NCT02301143,Kaplan-Meier Estimates for Time to Treatment Failure (TTF),2015-04-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Participants With Treatment Emergent Adverse Events (TEAEs),
11820,NCT05835778,Incidence of ADRs,2023-06-07,RECRUITING,OBSERVATIONAL,['NA'],,
11821,NCT04907591,"Change of body composition (weight, kg)",2021-05-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"Muscle mass (lumbar 2,㎠)",
11822,NCT00411151,Objective Response Rate (ORR),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety and Tolerability: Adverse Events in ≥10% of Patients,
11823,NCT04717648,Early predictive factors of anastomotic leakege,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11824,NCT03291288,Overall Summary of Treatment-emergent Adverse Events,2018-02-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetic Analysis: Metabolite to Parent Ratio (MPR) for Midazolam,
11825,NCT00003912,Resection rate,1998-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11826,NCT06083974,OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.,
11827,NCT04982939,Pathological complete response (pCR) rate,2021-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),
11828,NCT03699761,Grade III-IV complications,2020-09-01,RECRUITING,INTERVENTIONAL,['NA'],Treatment cost,
11829,NCT05165446,Novel MRE technique to assess tissue viscoelasticity as a risk factor for liver cancer,2022-01-27,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Studies on liver injury and glycemic control.,
11830,NCT05170282,The diagnostic accuracy of infantile liver tumors with deep learning algorithm,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],The diagnostic negative predictive value of infantile liver tumors with deep learning algorithm,
11831,NCT03615170,Disease free survival,2017-07-19,UNKNOWN,OBSERVATIONAL,['NA'],,
11832,NCT04561791,Prevalence of Barrett's esophagus within the single Primary Care Practice cohort.,2019-01-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11833,NCT05277766,Maximally tolerated dose (MTD) of Nal-IRI,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall treatment response,Exploratory outcome: Expression of human carboxylesterase 2 (hCE2)
11834,NCT03668158,recurrence rate,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA'],,
11835,NCT06126575,AUC from time zero to infinity (AUC0-∞),2024-01-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11836,NCT02814864,Decrease of one grade on the LENT SOMA,2021-04-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],Frequency of diarrhea,
11837,NCT06035731,Patient Centricity Questionnaire (PCQ): Patient reported outcome: impact of supportive care,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Anxiety,
11838,NCT02193594,The patient's survival time and recurrence time,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The number of patients with complications,The pathologic profiles and the pathologic response rates
11839,NCT01205828,Clinical Benefit Rate,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarker Analysis,
11840,NCT02226224,the consistency between EUS and pathologic determination of tumor depth,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,
11841,NCT04198025,Number of post operative complications (Clavien-Dindo grade 3-4) during inpatient hospital stay.,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Post operative complications beyond hospital discharge.,
11842,NCT00516841,Efficacy as measured by objective response rate (ORR). Tumor response based on RECIST criteria.,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11843,NCT00089401,Duration of response,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
11844,NCT02964260,Overall survival,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],Times of interventional procedures,
11845,NCT04889495,Safety profile,2024-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Efficacy profile,
11846,NCT02070146,Progression free survival,2013-05,RECRUITING,OBSERVATIONAL,['NA'],Work Ability Index (WAI),
11847,NCT04460066,major pathologic response rate,2020-11-18,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",adverse events rate,
11848,NCT01304160,Number of participants with adverse events,2010-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",overall survival,
11849,NCT04699487,Percentage of patients with at least one OM grade >2 at any time during radiotherapy.,2021-05-10,COMPLETED,INTERVENTIONAL,['NA'],Evolution of body weight over time,"For each neck dermatitis lesion: date of onset, location and CTCAE v5 grade"
11850,NCT03080701,CRC Screening Within 6 Months Following Randomization,2017-03-23,COMPLETED,INTERVENTIONAL,['NA'],,
11851,NCT01042743,surgical quality based on pathological examination,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],complication,
11852,NCT02791503,Overall survival,2016-05-30,COMPLETED,INTERVENTIONAL,['NA'],Tumor marker CA 19.9,
11853,NCT02248805,Characterize dose limiting toxicity and establish a maximum tolerated dose and schedule,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Describe any evidence of anti-tumor activity,
11854,NCT01570582,24month progression free survival,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicity Profile,
11855,NCT03913962,Maximal lipid oxidation rate during submaximal incremental exercise,2019-05-02,RECRUITING,INTERVENTIONAL,['NA'],Blood sample calprotectin,
11856,NCT02626091,Correlation between the perfusion evaluated by the ICG fluorescence-based enhanced reality and the metabolic state of the intestine,2016-09-14,COMPLETED,INTERVENTIONAL,['NA'],Distance between the resection site based on the surgeon's appreciation and the resection site based on the digital analysis and the peri-operative samplings,
11857,NCT05079503,Immune modulation in tissue,2021-12-15,UNKNOWN,INTERVENTIONAL,['NA'],Identify predictive biomarkers for pathologic responders,
11858,NCT02718859,Relief degree,2016-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival（OS）,
11859,NCT01175447,Maximum tolerated dose (MTD) of s-1 in combination with thoracic radiotherapy in elderly patients (> 70 years old) with esophageal Cancer,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],"Objective response rate (e.g. complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PD]).",
11860,NCT04893252,Objective response rate,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
11861,NCT06321055,Time to Next Therapy (TTNT) therapy after regorafenib,2024-03-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Number of patients with evidence of surgery on or after the index date during the follow-up period using Current Procedural Terminology (CPT) codes and International Classification of Disease 9/10 Procedure codes (ICD-PC).,
11862,NCT03013972,Cancer-related fatigue evaluation by brief fatigue inventory-Taiwanese form(BFI-T),2015-11,UNKNOWN,OBSERVATIONAL,['NA'],Quality of life assessments by functional assessment of cancer therapy-general 7 (FACT-G7),
11863,NCT03561350,MSI status in blood sample,2017-09-28,UNKNOWN,OBSERVATIONAL,['NA'],,
11864,NCT02651701,the concordance rate between rectal cancer staging performed by WB MR-PET and the current standard of care (chest/abdominopelvic CT and rectal MRI,2016-01,COMPLETED,OBSERVATIONAL,['NA'],concordance rate of clinical stagings and true M staging obtained by biopsy or follow-up,Transient dyspnea
11865,NCT05286099,Effective detection of early hepatocellular carcinoma,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,
11866,NCT05571956,simultaneous establishment of pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
11867,NCT03381352,Response rate,2015-12-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events,
11868,NCT03736824,Correlation of endoscopic findings and symptoms,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],The infection rate of Helicobacter Pylori,
11869,NCT03867799,Disease Control Rate (DCR),2019-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
11870,NCT04660760,Progression-free survival,2021-06-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
11871,NCT00088660,,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
11872,NCT03211598,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],FACT Hep4 Questionnaire,
11873,NCT01732783,Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay,2012-12-10,COMPLETED,OBSERVATIONAL,['NA'],Type of Post-Panitumumab Anti-cancer Treatment,
11874,NCT03506529,CT scan with measurement,2018-09-17,COMPLETED,OBSERVATIONAL,['NA'],,
11875,NCT03123042,detection rate (%),2017-03-20,RECRUITING,INTERVENTIONAL,['NA'],False negative rate,
11876,NCT04789486,Compare Local Control at 12 months of Maximum tolerated dose MTD - Phase 2,2021-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of Life (QoL)-Completion of Daily Activities utilizing PROMIS Physical and Mental Health batteries,
11877,NCT00156975,Disease free survival,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Secondary outcomes:overall survival,acute- and longtime toxicity of chemotherapy, molecular predictive markers for the risk of relapse and toxicity",
11878,NCT03027427,Clinical and laboratory evaluation and molecular profiling of tumor tissue,2017-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
11879,NCT02090153,Overall Response Rate (ORR),2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events (AEs),
11880,NCT03753399,Average trajectory of C-ESAS over time,2019-01-04,COMPLETED,INTERVENTIONAL,['NA'],Number of Circulating tumor cells detected using microfluidic chip,
11881,NCT05800054,Body weight and body mass index (BMI),2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],ORR,
11882,NCT03505229,freedom of local failure,2018-12-18,RECRUITING,INTERVENTIONAL,['NA'],Feasibility of Using Kilovoltage Intra-fraction Monitoring (KIM) to determine pancreas motion,
11883,NCT01335945,Abdominal pain reduction following cryoablation of the celiac plexus,2011-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Safety assessment,
11884,NCT00352131,Maximum tolerated dose,2005-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Antitumor activity,
11885,NCT00433550,Confirmed Tumor Response Rate (Proportion of Participants With Complete Response),2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Treatment Failure,
11886,NCT05189171,MOS generation,2022-10-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
11887,NCT01525940,To evaluate the completeness of colonic exploration in patients with a previous incomplete conventional colonoscopy due to technical failure (not due to inadequate cleansing level).,2011-11,COMPLETED,INTERVENTIONAL,['NA'],To evaluate the difference in terms of accuracy and completeness between PCCE and CT-colonography,
11888,NCT05039177,Adverse Events,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of Response (DOR),
11889,NCT03042780,Objective Radiographic Response Rate (ORR),2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),Treatment Related Morbidity
11890,NCT00514228,Progression-free survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Serum alpha fetoprotein level,
11891,NCT01830582,determine the best MR imaging schedule,2013-04-09,COMPLETED,INTERVENTIONAL,['NA'],Determine if the best imaging schedule for DCE is the same as for DWI,
11892,NCT02405416,Normalized transection-related blood loss,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative mortality,
11893,NCT03509298,Objective response rate,2018-04-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Symptom remission rate,
11894,NCT02448173,Disease-Free Survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],Recurrence-Free Interval,
11895,NCT04517227,Discontinue rate caused by any AEs,2021-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
11896,NCT03553004,Objective Response Rate (ORR),2019-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of participants with adverse events (AEs),
11897,NCT04566614,PREVAIL ctDNA Part 2 Study,2020-06-18,RECRUITING,OBSERVATIONAL,['NA'],PREVAIL ctDNA Part 2 Study secondary end point 6d,
11898,NCT03837782,overall survival,2019-02-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11899,NCT00385021,The primary objective is to determine if the rate of adverse events among patients receiving chronoFOLFOX plus Avastin is acceptable compared to that in previous studies using the FOLFOX4 regimen.,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11900,NCT00930410,The principal outcome is the percentage of successful in vivo examination according to the localisation of the stenosis. A successful examination is defined by the obtention of exploitable image for the anatomopathology.,2008-09,COMPLETED,INTERVENTIONAL,['NA'],Frequency and grade of adverse effects induced by the confocal endomicroscopy,
11901,NCT00036959,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11902,NCT01055743,To assess the clinical benefit of fluorouracil implants regional chemotherapy during the radical resection in early stage hepatocellular carcinoma patients. The primary endpoint is disease-free survival (DFS).,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events,
11903,NCT03082053,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) or Recommended Phase II Dose (RP2D) in Phase I setting.,2017-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],"Pharmacokinetics: varlinitib, capecitabine and 5-FU metabolites levels in terms of Elimination half-life of Phase β (t1/2β)",
11904,NCT04920032,Percentage of ctDNA positivity in treatment cohort after 6 cycles or at least 3 months of adjuvant treatment,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE1'],Percentage of Grade 3-5 Adverse Events,
11905,NCT03712774,Quality of life,2018-10-12,RECRUITING,OBSERVATIONAL,['NA'],late toxicity,
11906,NCT04103398,Overall Survival,2019-10-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Scoring of Quality of Life,
11907,NCT03447106,cost of treatment,2018-02-28,UNKNOWN,INTERVENTIONAL,['NA'],the operation time,"the all number of postoperative complications（ frequency,reflux esophagitis and bile reflux gastritis）"
11908,NCT02305043,Percentage of Participants With Objective Response,2014-03,COMPLETED,OBSERVATIONAL,['NA'],overall survival,
11909,NCT05179889,Disease free survival (DFS),2021-07-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of treatment-related adverse events,
11910,NCT01259024,Monitor Safety After Treatment of DEB by Measuring Liver Function Tests and Assessing Performance Status.,2011-12,TERMINATED,INTERVENTIONAL,['NA'],To Track Survival Following Treatment With DEB to Confirm That Any Gains in Response Are Associated With an Increase in Survival.,
11911,NCT06202014,ORR,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of grade 3 and above adverse events,
11912,NCT01092481,disease-free survival,2010-01-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],safety profiles,
11913,NCT03565354,Preoperative change in serum ferritin (mcg/L),2018-07-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Days (alive and) at home within 30 days of surgery (DAH30),Median waiting time to surgery (days)
11914,NCT05914610,Surgical conversion rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life (QOL),
11915,NCT00825240,Colorectal Cancer Patients' Concerns + Behavior Changes Post Treatment,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,
11916,NCT05101889,Severe oral mucositis graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 criteria,2013-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival (OS),
11917,NCT00253617,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
11918,NCT05514171,Disease free survival,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11919,NCT03508570,Maximum tolerated dose (MTD)/recommended phase II dose (RP2D) of intraperitoneal (i.p.) nivolumab in combination with ipilimumab,2018-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11920,NCT05871567,survival rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],recurrence rate,
11921,NCT02424279,Change from baseline pain intensity at 1 year (BPI questionnaires),2014-09,UNKNOWN,INTERVENTIONAL,['NA'],"Quality of life and pain intensity measurement (measured with the QLQ- C30, FACIT and BPI questionnaires)",
11922,NCT04831528,Objective response rate,2021-04-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],duration of response,
11923,NCT01340755,Adequacy of the total mesorectal excision based on standard guidelines on pathologic evaluation of TME specimens.,2011-03,COMPLETED,INTERVENTIONAL,['NA'],Oncologic outcomes in subjects receiving transanal endoscopic rectosigmoid resection,
11924,NCT00922688,"The effect of intravenously and enterally administered dipeptide alanyl-glutamine preoperatively on postoperative insulin resistance in colon cancer patients.given, on postoperative insulin resistance in colon cancer patients.",2010-12,UNKNOWN,INTERVENTIONAL,['NA'],The effect of dipeptide alanyl-glutamine on key enzymes involved in glucose production.,
11925,NCT01676922,Treatment duration in patients receiving chemotherapy with Avastin as first-line therapy in daily clinical practice,2011-08,COMPLETED,OBSERVATIONAL,['NA'],Correlation between Comprehensive Geriatric Assessment (CGA) scores and initial treatment,
11926,NCT04227951,30 day reoperation AND/OR additional drain placement,2019-12-17,COMPLETED,INTERVENTIONAL,['NA'],Drain related complications,
11927,NCT00002893,,1995-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
11928,NCT04678492,Helicobacter pylori eradication,2020-12-20,COMPLETED,INTERVENTIONAL,['PHASE4'],adverse events,
11929,NCT03847753,Risk of Cancers,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11930,NCT01839981,Overall Survival,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety profile assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,
11931,NCT00661882,"Development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure as a repository for socio-demographic, environmental, clinical, and family history data",2003-02,COMPLETED,OBSERVATIONAL,['NA'],,
11932,NCT00464295,To evaluate response rate and overall survival after completing minimum of three cycles of Capecitabine in Advance HCC,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],"To evaluate the time to progression, toxicity and quality of life for patients on chemotherapy",
11933,NCT00429858,Correlate Intratumoral Expression Level of Ribonucleotide Reductase Subunit 1 (RRM1) With Response to Gemcitabine in Patients With Advanced Pancreatic Cancer.,2007-01-22,TERMINATED,INTERVENTIONAL,['PHASE2'],Percentage of Patients With at Biomarker Response,
11934,NCT01481545,Percentage of Patients With Complete Tumor Regression Rate (TRG1),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Patients With Metastatic Lymphnodes at Pathology Exam After Surgery,
11935,NCT05029453,Progression Free Survival [PFS],2021-08-26,UNKNOWN,INTERVENTIONAL,['PHASE4'],Adverse Events [AEs],
11936,NCT06317272,Reproducibility DIBH,2021-02-10,TERMINATED,INTERVENTIONAL,['NA'],,
11937,NCT04591821,QoL,2018-02-15,COMPLETED,OBSERVATIONAL,['NA'],Correlation LARS score QoL,
11938,NCT01801852,Occurrence of study related adverse events,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],Anti-tumor responses to NKT cells infusions,
11939,NCT02852096,The positive rate of cohort using dual or multiple tumor tissue paraffin blocks,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,
11940,NCT04894370,Progression-Free Survival (PFS) rate at 1 year.,2022-06-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-Free Survival (PFS) median.,
11941,NCT04246970,Progression in the activities of daily life (ADL),2021-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Change in Quality of life,
11942,NCT00848237,Adverse Event Incidence,2007-07,COMPLETED,INTERVENTIONAL,['NA'],,
11943,NCT02675946,Number of participants with adverse events and/or abnormal laboratory values that are related to treatment,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],CGX1321 half-life,
11944,NCT05887661,The proportion of allogeneic red blood cell products transfusion,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],Number of Participants with postoperative complications (overall),
11945,NCT01609309,3-year disease free survival rate,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],Inflammatory and immune response,
11946,NCT01841294,Dosage of NKs activity after surgery,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Major adverses events,
11947,NCT06152471,Occurrence of Abemaciclib induced diarrhea - STIDAT,2023-06-07,RECRUITING,INTERVENTIONAL,['PHASE3'],Breast cancer recurrence,
11948,NCT03497819,The Percentage of Adverse Events (AEs) ≥ grade 3 assessed through MedDra and CTCAE v4.03 [Time frame: from infusion to 3 month afterward],2017-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Overall Response Rate defined as any improvement measured by imaging following RECIST 1.1 [Time Frame: Day 14 and 1 month after infusion],
11949,NCT03858712,ePRO Oral Response Rate,2019-03-13,COMPLETED,INTERVENTIONAL,['NA'],ePRO oral ease of use,
11950,NCT04562428,FACT-G,2020-11-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],pulse diagnosis,
11951,NCT00396487,Response according to RECIST criteria.,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3'],Toxicity,
11952,NCT05730673,"Overall response rate (ORR, defined as Complete Response (CR) + Partial Response (PR)) in subjects with CCR5+ mCRC treated with Leronlimab (PRO 140) and Regorafenib.",2022-09-20,WITHDRAWN,INTERVENTIONAL,['PHASE2'],The change from baseline in circulating tumor cells (CTC) in the peripheral blood.,"Measure serum level of CCL2, CCL3, CCL4 and CCL5 and correlate with therapeutic benefit (PFS) in patient with mCRC."
11953,NCT04803994,Time to failure of treatment strategy,2021-07-06,RECRUITING,INTERVENTIONAL,['PHASE3'],QoL (EORTC QLQ-C30 and HCC18 sub-questionnaire),Exploratory endpoint - PD-L1 expression
11954,NCT00001823,Results of screening tests,1999-07-11,RECRUITING,OBSERVATIONAL,['NA'],,
11955,NCT05678257,Number of patients achieving progress-free survival (PFS),2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of patients reporting treatment-emergent adverse events (TEAEs),
11956,NCT00254267,The objective response rate as assessed by modified RECIST,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"Duration of response, progression-free survival, time to response, overall survival, PK and safety profile",
11957,NCT01599052,Social cognitive performance,2011-03,COMPLETED,OBSERVATIONAL,['NA'],Influence of Biographical/Medical characteristics,
11958,NCT00324415,Local Failure Rate at 3 Years,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate (Complete and Partial),
11959,NCT02120885,QoL(quality of life),2014-03-14,COMPLETED,INTERVENTIONAL,['PHASE3'],nutrition condition,
11960,NCT02956876,Number of side effects of chemotherapy for WHO grade greater than 2,2016-12-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of provisional chemotherapy orders,
11961,NCT03218423,Detection of colorectal cancer,2017-08-18,UNKNOWN,OBSERVATIONAL,['NA'],Assay Failure Rate,
11962,NCT06135649,Metastatic involvement of second nodal echelon,2013-01,RECRUITING,OBSERVATIONAL,['NA'],Recurrence-free survival,
11963,NCT00587236,Compare the dysplasia detection rate between scope modalities and biopsy type; surveillance or targeted biopsies in CUC patients with concurrent PSC.,2006-03,COMPLETED,OBSERVATIONAL,['NA'],Assess the impact of patient related factors on the difference in dysplasia detection rate between while light colonoscopy and the AFI and NBI techniques in patients with CUC and concurrent PSC.,
11964,NCT05927857,To evaluate disease objective response rate (ORR),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",•To study the blood biomarkers,
11965,NCT05786924,Dose Expansion: Progression-free survival (PFS),2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE1'],Dose Escalation/Expansion: Overall survival,
11966,NCT04348058,Participation rate to screening colonoscopy within PCSP per recruitment strategy,2020-08-20,UNKNOWN,INTERVENTIONAL,['NA'],Response rate to invitation to screening colonoscopy,
11967,NCT03778957,Progression Free Survival (PFS) for Arm B vs Arm C,2018-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Disease-related symptoms measured by European Organization for Research and Treatment of Cancer (EORTC) 18-item hepatocellular cancer health-related quality of life questionnaire (QLQ-HCC18),Pharmacokinetics (PK) of Durvalumab and Bevacizumab as determined by peak serum concentrations
11968,NCT05176665,Clinical benefit rate(CBR) as assess by RECIST v1.1,2021-10-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinical benefit rate(CBR) as assess by RECIST v1.1,
11969,NCT00005594,The primary outcome measure of this study is to estimate the response rate and observe the time to tumor progression of the patients treated on this study.,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine the duration of response in responding patients. Further characterize the safety profile of ISIS 2503 at the recommended dose and schedule.,
11970,NCT02971631,Nadir Blood Glucose,2017-08-10,COMPLETED,INTERVENTIONAL,['NA'],Total Meal Consumption,
11971,NCT06282575,Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],"TDD for all participants in patient-reported symptoms scores as measured by the EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain, and Pruritis)",
11972,NCT04790695,Overall survival,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11973,NCT03510416,Time To Progression,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival,
11974,NCT01651026,"list of diagnostic procedures used in clinical practice, according to participating Institute",2011-01,RECRUITING,OBSERVATIONAL,['NA'],,predictive factors for response to treatment
11975,NCT06173986,Treatment completion rate,2023-01-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of Adverse events (AE) or severe adverse events (SAE),
11976,NCT04305730,Rate of return of bowel function,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],Length of time under general anesthesia,
11977,NCT01972919,Overall Survival,2015-12-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Efficacy of dose escalation,
11978,NCT03776487,Incidence of adverse events,2019-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease-free survival,
11979,NCT03934606,baseline to post-results change in distress levels,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
11980,NCT01648504,Completion rate of colonoscopy procedure,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Patient satisfaction,Feasibility of intervention in practice
11981,NCT05045911,The technical success rate,2021-09-20,UNKNOWN,INTERVENTIONAL,['NA'],Clips used post-ESD,
11982,NCT05606523,Body weight changes in mice after fecal material transplantation.,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],GALT function and systemic inflammation,
11983,NCT02311595,Compliance rate (Japanese Research Society of Gastric Cancer (JRSGC) lymph node grouping),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
11984,NCT03807687,Overall survival,2016-12-01,RECRUITING,OBSERVATIONAL,['NA'],Postoperative morbidity,
11985,NCT01983878,Percentage of Participants Who Are Progression-Free at 12 Weeks (Progression-Free Survival [PFS] Rate at 12 Weeks),2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],PK: Area Under the Curve Time Zero to Infinity (AUC[0-∞]) of Ramucirumab,
11986,NCT01478685,Number of participants with adverse events,2011-11-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Duration of Response,
11987,NCT05655949,Incidence of Grade 3 or Higher Treatment-Related Toxicity,2024-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease Control Rate (DCR),
11988,NCT03838029,Biomarkers in blood samples,2019-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Fatigue,
11989,NCT02935309,Maximum Tolerated Dose (MTD),2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE1'],Occurrence of Treatment Related Adverse Events,Radiosensitivity Index (RSI)
11990,NCT02977702,overall survival,2015-12,COMPLETED,OBSERVATIONAL,['NA'],,
11991,NCT04442984,Progression-Free Survival,2019-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment associated toxicities,
11992,NCT00032123,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11993,NCT06179459,Treatment outcomes in patients undergoing endoscopic treatment of pancreatic fluid collections.,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],Timing of intervention,
11994,NCT01273051,Response,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],The number of sphincter saving procedures,
11995,NCT01463605,Safety of Nimotuzumab combined with Radiotherapy for older patients,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Efficacy of Nimotuzumab combined with Radiotherapy for older esophageal cancer patients,
11996,NCT06021015,Disease control rate (DCR) of target lesions 1 month after the last TACE treatment,2023-09-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Equipment performance evaluation,
11997,NCT03291379,Concentration of N-desmethyl Vandetanib in Resected Liver Tissue Following Treatment With BTG-002814,2017-05-17,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],"Assessment of Changes in Blood Flow on Dynamic Contrast-Enhanced (DCE) MRI Following Treatment With BTG-002814. The Following Parameters Will be Derived From DCE-MRI Images: Ktrans, Kep and Ve.","Study Tissue Biomarkers to Explore Key Immune, Inflammatory and Drug Related Mechanisms"
11998,NCT03281369,For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Percentage of Participants With ADA to BL-8040,
11999,NCT05411926,4) the dose and drug concentration of tacrolimus after liver transplantation in patients with hepatocellular carcinoma;,2021-03-17,UNKNOWN,OBSERVATIONAL,['NA'],5) the overall survival (OS) and relapse-free survival(RFS) after liver transplantation in patients with hepatocellular carcinoma.,
12000,NCT00901901,Overall Survival,2009-05-21,COMPLETED,INTERVENTIONAL,['PHASE3'],Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS,Tumor Response
12001,NCT02354560,Evaluation of changes in size of desmoid tumors,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
12002,NCT01398306,"Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls.",2011-07,COMPLETED,OBSERVATIONAL,['NA'],Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours with and without medication.,
12003,NCT01997957,Time to progression(TTP),2013-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],Number of Participants with Serious and Non-Serious Adverse Events,
12004,NCT05564403,Overall survival (OS),2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,Detection of mutations as well as prediction of outcomes
12005,NCT06068257,"To Identify and test thresholds, specificity and sensitivity for FGF19, (and associated markers) for detection in human blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls.",2023-06-06,RECRUITING,OBSERVATIONAL,['NA'],,
12006,NCT01972451,Procedure time and withdrawal time,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of people attending the screening,Colonoscopy procedure completeness
12007,NCT06089330,Incidence and severity of adverse events (AE) and serious adverse events (SAE),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
12008,NCT00630786,Number of Participants With an Objective Response,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Post-baseline Laboratory Values Grade 3 or Higher,
12009,NCT02847468,Vital status,2017-03-27,TERMINATED,INTERVENTIONAL,['NA'],Questionnaire of quality of life (EORTC QLQ-C30),
12010,NCT00002968,Survival,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease-free survival,
12011,NCT04767750,"Measurement of the gene expression levels of LncRNA H19 & IGF-1R mRNA, normalized to the housekeeping gene GAPDH expression level, in HCC and T2DM in comparison with healthy controls using Real-Time Quantitative PCR (by the 2^-ΔΔCT method).",2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12012,NCT05009979,Positive predictive value,2023-01-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in 18F-DCFPyL PET/CT uptake between pre- and post-treatment,
12013,NCT02028442,Phase 1b - Selection of suitable schedule for repeat cycle IV administration,2012-09-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12014,NCT05972655,Pathological complete response (pCR) rate,2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Validation of the Wexner score,
12015,NCT05095467,"3-year Overall Survival, OS",2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],NCI CTC Adverse Events Version 4.0,
12016,NCT05174169,Disease-Free Survival (DFS),2022-03-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Compliance with adjuvant chemotherapy,
12017,NCT04393220,OS,2020-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12018,NCT04977401,Increase the dissection speed of the ESD procedure,2021-09-21,TERMINATED,INTERVENTIONAL,['NA'],Total procedure duration,Adverse events
12019,NCT00820157,the overall survival rate of each group,2008-11,COMPLETED,INTERVENTIONAL,['NA'],the disease-free survival rate of each group,
12020,NCT00843934,response rate,2009-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
12021,NCT04367805,Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France,2020-04-27,RECRUITING,OBSERVATIONAL,['NA'],,
12022,NCT00459901,To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer,2004-06,TERMINATED,INTERVENTIONAL,['PHASE2'],To determine the qualitative and quantitative toxicity of this combination and sequence of drug administration,
12023,NCT05518929,Incidence of hypoxia and severe hypoxia,2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE4'],Proportion of corrective hypoxic measures,
12024,NCT01996540,Quality of Life (QoL),2012-08,COMPLETED,INTERVENTIONAL,['NA'],Overall survival (OS),
12025,NCT02430298,"Percentage of occurrence of mucositis level 3 or more by using the criteria of CTCAE version 4.0, World Health Organization scale and MTSscores",2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life (FACT- H&N Version 4),
12026,NCT06254248,Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center),2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Donor Specific Antibodies (DSA) median,
12027,NCT02662959,Overall Survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of Adverse Events,
12028,NCT04901741,Go/no-go decision for a randomized expansion study,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Time-to-next-anticancer-treatment (TTNT),
12029,NCT01420588,Discrimination between Malignant and Benign Gastric Lesions with Na-nose,2011-08-01,COMPLETED,OBSERVATIONAL,['NA'],Geographical comparison of VOCs between China and Latvia,Proof seeking from metabolomics and transcriptomics
12030,NCT03049215,Decrease in Pancreatic Fluid Collection (PFC),2017-11-06,TERMINATED,INTERVENTIONAL,['NA'],Incidence of Early (<30 Days) Endoscopic Reintervention,
12031,NCT00042510,To evaluate the effects of G17DT in combination with cisplatin and 5-FU chemotherapy on tumor response assessed by radiographic means.,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2'],"To evaluate the clinical efficacy of G17DT in combination with cisplatin and 5-FU chemotherapy as measured by time to disease progression, best overall response and survival.",
12032,NCT04276857,1 year progression free survival rate of patients with locally advanced pancreatic cancer who are treated with IRE and combination chemotherapy.,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Prognostic bio-markers,
12033,NCT00225290,overall survival,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,
12034,NCT00242190,Occurrence of dose limiting toxicity up to three weeks following the second cycle of chemotherapy.,2004-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Characterize pattern of responses, progression free survival, and survival after treatment",
12035,NCT03426371,Progression Free Survival (PFS) Time,2018-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],quality of life score,
12036,NCT04427761,Extent of the change experienced by patients with pancreatic cancer,2020-06-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
12037,NCT00289003,"To assess actual grade of mucositis upon completion of radiotherapy or chemoradiotherapy and after prophylactic treatment with soluble beta-1,3/1,6-glucan or placebo.",2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess the safety of the investigational product,
12038,NCT00897741,Gene expression profiles,2004-12,COMPLETED,OBSERVATIONAL,['NA'],,
12039,NCT04339374,Area under the receiver operating curve (ROC),2017-07-19,RECRUITING,OBSERVATIONAL,['NA'],Performance characteristics of the novel endorectal ultrasound probe as measured by variability in image production,
12040,NCT04358185,To assess efficacy of Itacitinib by overall response rate: objective response rate (ORR),2018-12-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Efficacy of Itacitinib by overall survival,Correlation of JAK1 mutations with treatment
12041,NCT03225781,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2017-07-01,TERMINATED,INTERVENTIONAL,['NA'],Immunomonitoring,
12042,NCT01802684,Progression free survival at 6 months,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Curative salvage surgery,
12043,NCT05939661,Pathological complete response (pCR),2023-05-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,
12044,NCT05584137,Objective Response Rate (ORR) per RECIST 1.1 as Assessed by Investigator (the second stage),2023-06-15,SUSPENDED,INTERVENTIONAL,['PHASE2'],Duration of Response (DOR) per RECIST 1.1 assessed by Investigator,
12045,NCT01474187,toxicity,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],pathological complete response (pCR),
12046,NCT00004861,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12047,NCT03959800,Tumor infiltrating cells which express immune checkpoints,2015-06-22,RECRUITING,OBSERVATIONAL,['NA'],Response to chemotherapy,
12048,NCT06165094,Overall survival,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12049,NCT00606398,two-year disease free survival (DFS),2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],"Overall survival rate (OS), patterns of treatment failure, treatment efficacy (R0 resection rate), peri-operative morbidity and mortality rates, health related quality of life, hospital length of stay",
12050,NCT02150408,"interest of the realization of 68Ga-DOTATATE PET-CT in the detection of tumor sites in TNE diagnosis, staging and restaging",2014-04-22,COMPLETED,INTERVENTIONAL,['NA'],"therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT","therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT"
12051,NCT01540968,Quality of life,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,
12052,NCT05085548,Determine Recommended Phase 2 Dose (RP2D),2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Assess serum tumor marker CA19-9 or appropriate tumor specific marker.,
12053,NCT02639403,Change of the obstructive symptoms,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Obstruction/colostomy-free survival,
12054,NCT03784326,Pathological complete response (PathCR),2019-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor regression determined by CT or MRI,
12055,NCT05022654,Optimal combination dose (only IIa),2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],ADA,
12056,NCT01531452,Progression Free Survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],number of participants with adverse events,
12057,NCT03058926,"Protocol and Regulatory Compliance for Consortium Studies for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",2017-01-19,UNKNOWN,OBSERVATIONAL,['NA'],,
12058,NCT04707547,Analysis of the number of CD8+ T,2019-10-16,COMPLETED,INTERVENTIONAL,['PHASE4'],,
12059,NCT00582062,The primary objective of this pilot trial is to investigate the ability of quantitative RT-PCR to detect cancer cells in peritoneal washings of patients undergoing laparoscopy for gastric or pancreatic cancer.,2006-03,COMPLETED,OBSERVATIONAL,['NA'],"The secondary objective of this pilot study is to estimate the sensitivity, specificity, false positive, and false negative rate of peritoneal cancer cell detection by quantitative RT-PCR.",
12060,NCT01652976,Progression Free Survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],"Quality of Life, as Measured by the Functional Assessment of Chronic Illness Therapy; Hepatobiliary Cancer (FACT-Hep) Questionnaire (Version 4.0)",
12061,NCT00520013,Consolidation Treatment-related Toxicity Rate,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Consolidation Objective Response Rate,
12062,NCT01882218,Morbidity,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE4'],Cytokine levels,
12063,NCT04096417,Overall Response Rate (ORR),2020-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
12064,NCT03395847,Objective response rate (ORR),2018-02-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Incidence of adverse events,
12065,NCT02967107,Number of participants with residual or recurrent adenoma as assessed at surveillance endoscopy,2016-06,COMPLETED,INTERVENTIONAL,['NA'],Number of participants with pain after EMR as assessed by VAS score and telephone interview at 2 weeks,
12066,NCT04593277,Proportion of HCA-cancer surveillance (SM),2022-10-23,RECRUITING,INTERVENTIONAL,['NA'],Proportion of healthcare adherence (HCA)-all,
12067,NCT01846611,Overall Survival (OS),2013-10-16,COMPLETED,INTERVENTIONAL,['PHASE3'],Objective Response Rate (ORR),
12068,NCT05788744,Sub-study 2 eccDNA,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
12069,NCT03581344,TRG (Tumor Regression Grade),2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],Impact of therapy on quality of life (QoL),
12070,NCT06253897,Qualitative interview: patients' injection experiences and satisfaction with the Ipsen lanreotide syringe and with the Pharmathen lanreotide syringe;,2024-03-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Qualitative interview: experiences that are unique to patients between disease indications,
12071,NCT01447199,Time to Onset for Colorectal Cancer,1994-09,UNKNOWN,OBSERVATIONAL,['NA'],,
12072,NCT06256328,Progression-free survival (PFS) (site investigator assessment),2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse event (AE),
12073,NCT00040898,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12074,NCT02727179,Overall survival,2005-02,COMPLETED,INTERVENTIONAL,['NA'],Morbidity,
12075,NCT00608361,Pharmacokinetic parameters of dasatinib,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Liver dysfunction data
12076,NCT03257761,Tumor response (dose expansion),2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-free survival,
12077,NCT01855854,Objective response rates,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
12078,NCT00103545,The primary endpoint is drop-out due to toxicity as the overall measure of feasibility,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration and strength of the immune response induced by ACA 125 vaccination,
12079,NCT02135887,"The primary endpoint is the incidence of grade 4 neutropenia during the chemotherapy period, defined as an absolute neutrophil count (ANC) <500/mm3.",2013-11-04,UNKNOWN,OBSERVATIONAL,['NA'],Increase in Body Weight,
12080,NCT03582618,Objective Response Rate (ORR),2018-07-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Pharmacodynamics analysis for the relationship of AUC and Adverse Event (AE),
12081,NCT03256201,Adherence,2016-02-01,RECRUITING,INTERVENTIONAL,['NA'],Assessment of Symptoms,
12082,NCT04283994,EHR documentation of Goals of Care discussions,2021-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Goal concordance,Key Implementation Factors
12083,NCT00785889,Increments of medications used for sedation,2008-03,COMPLETED,INTERVENTIONAL,['NA'],willingness to repeat colonoscopy,
12084,NCT00344552,Safety,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to progression (TTP),
12085,NCT03524274,Objective response rate,2018-04-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Symptom remission rate,
12086,NCT02489422,Fatigue Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS),2016-08,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants With Successful Qualitative Data Collection,
12087,NCT05108753,incidence of anastomotic leakage,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],incidence of positivecircumferential resection margin,
12088,NCT01193517,"Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)",2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Response Rate of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX)",
12089,NCT06118437,Overall detection rate of gastrointestinal cancer,2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12090,NCT04920422,Percentage of patients that follow each dosing patterns during first two cycles of treatment,2021-07-15,COMPLETED,OBSERVATIONAL,['NA'],Percentage of patients that start cycle 3 based on dosing patterns.,
12091,NCT04179305,Change in Prognostic Understanding,2020-10-25,COMPLETED,INTERVENTIONAL,['NA'],Patient Performance Status,
12092,NCT02115542,Overall Survival (OS) at 6 Months,2014-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),
12093,NCT05396300,Obtain the maximum tolerated dose of CEA-CAR-T cells[Safety and Tolerability],2022-05-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacodynamics of CEA-CAR-T cells[Cell dynamics],Changes in the number of tumor-infiltrating immune cells of CEA- CAR-T treatment in patients with CEA-positive
12094,NCT03970616,Incidence of Treatment Emergent Adverse Events (TEAEs),2019-09-30,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),
12095,NCT04503902,Objective response rate（ORR） as determined by the Invertigator using RECIST V1.1,2020-10-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression free survival (PFS),
12096,NCT01447667,Number of patients who experienced HCC recurrence after RFA,2011-10,COMPLETED,INTERVENTIONAL,['NA'],Sensitivity and specificity of each indicator of hepatic fibrosis compared to the gold-standard histology score,
12097,NCT01964001,Antioxidant capacity,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Inflammation markers,
12098,NCT03774134,Risk of recurrence,2008-06-01,UNKNOWN,OBSERVATIONAL,['NA'],Mesocolic lymph nodes yield,
12099,NCT01365169,ECOG Performance Status,2011-05-25,RECRUITING,INTERVENTIONAL,['NA'],"CYCORE Data availability for clinicians and researchers in order to be able to daily monitor patients using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales).",
12100,NCT00290693,Rate of Participants Achieving Complete Response or Partial Response to Therapy.,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Study Participants Experiencing Toxicity After Receiving Protocol Therapy,
12101,NCT04595747,Objective radiographic response,2021-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,"Banking of tumor material, germline deoxyribonucleic acid, and peripheral blood"
12102,NCT00202787,Determine confirmed objective response rate,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],"determination of polymorphisms of the intron 1 of the EGFR gene, TS, XRCC1, XPD, serum levels of EGFR and ATP7A and ATP7B, nº of copies of EGFR gene, the levels of PTEN, EGFR, AKT y MAPK proteins, and mutations at EGFR, PI3KCA, K-RAS y B-RAF genes",
12103,NCT00373906,to induce objective/histologic responses in patients with MALT-Lymphoma,na,COMPLETED,INTERVENTIONAL,['PHASE2'],to evaluate the impact of bortezomib on progression free survival,
12104,NCT03044977,absolute neutrophil count decreased,2017-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Overall survival (OS),
12105,NCT05334251,sPO2,2022-04,UNKNOWN,OBSERVATIONAL,['NA'],,
12106,NCT05683470,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
12107,NCT01682031,Incidence of >= Grade 3 Mucositis,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Plasma Cisplatin and Selenium PK and PD Markers (NZ Only),
12108,NCT01444547,Overall response rate (ORR),2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Time to event efficay,
12109,NCT03992599,3 year disease-free survival (DFS),2019-08-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Distribution of metastatic LNs,
12110,NCT05489419,Efficacy of a multimodal prehabilitation,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],Evaluation of complications severity,
12111,NCT02074124,Change in arterial flow during adenosine vasodilation test (CT perfusion parameter),2012-10,COMPLETED,OBSERVATIONAL,['NA'],Change in Permeability (CT perfusion parameter) during adenosine vasodilation test.,
12112,NCT01286064,Colorectal cancer detection by means of optical fluoroscopy,2010-10,UNKNOWN,INTERVENTIONAL,['NA'],,
12113,NCT03155542,colorectal cancer diagnosis,2016-12,COMPLETED,OBSERVATIONAL,['NA'],,
12114,NCT02041065,Peroperative bloodloss,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Hospital stay in days,
12115,NCT00524316,Progression-free Survival,2007-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Tumor Marker Response (AFP),
12116,NCT04729205,Evaluate Disease Control Rate,2021-01-13,TERMINATED,INTERVENTIONAL,['PHASE1'],Plasma MLP level after Promitil infusion,
12117,NCT05150691,Phase 2: Percentage of Objective Response Rate (ORR) as assessed by RECIST 1.1.,2022-01-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2 Cohort b only: Overall Survival,
12118,NCT00019773,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12119,NCT01939210,Changes in the length of the end expiration or end inspiration defined as when the breathing trace or internal motion change direction,2010-02,TERMINATED,INTERVENTIONAL,['NA'],"Change in patients' self-reported levels of psychological distress, physical pain and discomfort, and post-traumatic stress associated with cancer diagnosis and radiation treatment",
12120,NCT05836584,Event-free survival (EFS),2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Circulating tumor-derived deoxyribonucleic acid (ctDNA),
12121,NCT01409733,Proportion of patients completing scheduled treatment plan,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12122,NCT01851174,Overall Survival Based on Toxicity Profile of Adverse Events.,2013-02,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression Free Survival Time,
12123,NCT02834546,Adverse events related to Sorafenib needing a dose adjustment or a symptomatic medication,2017-07-25,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
12124,NCT04109755,Tumour regression grade,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],EORTC QLQ-CR29,
12125,NCT01272557,Time to progression (TTP) according to RECIST 1.1 criteria,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],"• Assessment of overall survival (OS) of disease control rate (CR, PR, SD) to RECIST 1.1 criteria and to EASL criteria • Assessment of safety and quality of life (FACT-Hep) and potential of biomarkers to predict the tumor response",
12126,NCT02795988,Clinical efficacy of IMU-131 (Phase 2),2017-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of TEAE's (Phase 2),Exploratory Outcome (Phase 2): Measurement of immunological and biochemical markers
12127,NCT00172757,,2002-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12128,NCT01051284,To demonstrate that radiation treatments can be reproduced as determined by evaluation of the prescription isodose curves,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],The feasibility of measuring pancreatic cancer stem cell populations by analysis of fine needle aspirate specimens,
12129,NCT06044506,Optimal treatment dosage,2022-08-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-free survival,
12130,NCT00138242,Reduction rate of myelosuppression,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to disease progression,
12131,NCT02915432,Objective response rate (ORR) evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1),2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb,Correlation of the changes of TBNK lymphocytes subgroup in patients receiving chemotherapy combined with JS001 and its correlation with the anti-tumor activity
12132,NCT03283527,Response prediction by EC-PDO,2017-12-01,RECRUITING,OBSERVATIONAL,['NA'],Overall survival (OS) in months,
12133,NCT03502343,Disease control rate,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse event,
12134,NCT02734680,Overal survival,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],Local control rate,
12135,NCT03350763,"Stent failure rate, and need for re-procedure before pancreaticoduodenectomy.",2017-11-18,WITHDRAWN,INTERVENTIONAL,['NA'],"Other complications related to preoperative biliary decompression, and post-surgical complications",
12136,NCT04431076,Pancreatic fistula,2020-05-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Return to preoperative exercise capacity,
12137,NCT05106244,Degree of satisfaction of patients and their families,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
12138,NCT02038296,overall survival,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12139,NCT05848843,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-04-25,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
12140,NCT00431925,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
12141,NCT00312000,Overall survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Toxicity profile,
12142,NCT05750329,Three-year overall survival rate after surgery,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Postoperative tumor-free survival period,
12143,NCT02918162,Pathologic Complete Response (pCR) Rate,2017-11-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Response Rate (ORR),
12144,NCT00494806,Time to First Postoperative Flatus in Days Was the End of Postoperative Ileus (POI) Indicator.,2005-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12145,NCT01870817,Participant recruitment and retention rates,2012-07,COMPLETED,INTERVENTIONAL,['NA'],Nutritional parameters,
12146,NCT01075113,Determine the appropriate Doses for the combination of sorafenib tosylate and vorinostat appropriate for phase II study in hepatocellular carcinoma (HCC).,2010-08-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Anti-tumor effects of the combination of sorafenib tosylate and vorinostat,
12147,NCT04224363,Image Quality,2020-01,UNKNOWN,INTERVENTIONAL,['NA'],Tolerance,
12148,NCT03126708,Progression free survival,2017-04-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
12149,NCT00101686,Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Relative Dose Intensity of Irinotecan,
12150,NCT01152853,progression-free survival at 4-months (PFS4mo),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],toxicity,
12151,NCT05877001,Safety profiles by NCI-CTCAE version 5 .0,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression free survival (PFS),
12152,NCT04969874,patient attendance at monthly remote monitoring,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],felt swallowing,
12153,NCT03168737,Incidence of adverse events per Common Terminology Criteria for Adverse Events version 4.03,2017-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12154,NCT04601428,HCC blood flow,2021-01-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Determine tumor response to intra-arterial infusion of CSR02-Fab-TF,
12155,NCT00961129,supportive cancer care needs,2009-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12156,NCT04434508,the number of lymph nodes (LNs) harvested among both groups,2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],post-operative complications,
12157,NCT01670409,Toxicities,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Complete blood count,
12158,NCT00671463,Pancreatic leak,2008-04,WITHDRAWN,INTERVENTIONAL,['NA'],Clinical outcomes,
12159,NCT06091683,Safety of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC),2021-04-30,RECRUITING,INTERVENTIONAL,['NA'],Peritoneal disease-free survival,
12160,NCT03185429,Proportion of the number of cases that has produced tumor-specific antigen-specific T cells in peripheral blood.,2017-12,UNKNOWN,INTERVENTIONAL,['NA'],Quality score of life improvement,
12161,NCT02156505,The patency rate at 8 weeks after placement.,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],migration rate,
12162,NCT03323489,Change in Pain level from baseline - as measured using BPI,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],hand grip strength,
12163,NCT03098108,local control rate at 3-year,2017-02-09,UNKNOWN,INTERVENTIONAL,['NA'],Colonrectum Quality of life (QOL-CR) assessment,
12164,NCT03940001,"major pahological response, MPR",2019-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
12165,NCT04623515,Urinary Dysfunction - International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS),2021-05-05,TERMINATED,OBSERVATIONAL,['NA'],Short Form-12 Questionnaire - General Health and Well Being,
12166,NCT01515748,"Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1",2011-12-30,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Shift of Laboratory Parameters (Creatinine Clearance [Chronic Kidney Disease]) From Baseline Grade to Worst NCI-CTCAE Grade >=3,
12167,NCT03328234,Overall survival (OS),2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse events,
12168,NCT03698825,Maximum Tolerated Dose (MTD),2018-08-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",pharmacokinetics of TEW-7197,pSMAD as a pharmacodynamic marker
12169,NCT02309788,overall survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12170,NCT06008288,Objective response rate (ORR) by independent central radiological review (IRC) according to RECIST 1.1.,2023-10-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events,
12171,NCT03798626,Part 2 (Expansion) and Part 1b (Safety run-in): Progression free survival (PFS) rate [Cohort C subjects at RDE level],2019-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Number of patients with anti-drug antibodies for ramucirumab in the combination regimens,
12172,NCT00004233,Six month survival,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],evaluate quantitative and qualitative toxicities,
12173,NCT00137878,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12174,NCT06018142,Perfusion ratio,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
12175,NCT03258034,3 year OS,2017-08-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
12176,NCT01793168,"To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.",2010-07,RECRUITING,OBSERVATIONAL,['NA'],,
12177,NCT02997553,Non-inferiority of indocyanine green guided sentinel lymph node biopsy,2017-11-29,COMPLETED,INTERVENTIONAL,['PHASE3'],fluorescence imaging,
12178,NCT04627363,Progression free survival rate at 6 months,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events,
12179,NCT03025152,Changes from baseline in total scores of Spleen Qi Deficiency Symptoms Grading and Quantifying Scale (Units on a scale),2016-11-11,TERMINATED,INTERVENTIONAL,['NA'],Incidence of withdrawn due to adverse events,
12180,NCT01703650,Evaluation of the correlation between the initial perfusion parameters of the tumor and response of the chemotherapy,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],comparison of perfusion parameters among the pancreas tumors and parenchyma,
12181,NCT04631445,Progression-free survival per RECIST 1.1,2020-12-02,RECRUITING,INTERVENTIONAL,['NA'],To compare quality of life between arms via the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire QLC-C30 (EORTC QLQ-C30) assessment.,
12182,NCT04949256,Part 2 (Main Study): Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in all Participants,2021-07-28,RECRUITING,INTERVENTIONAL,['PHASE3'],Part 2 (Main Study): TTD in HRQoL Score Using EORTC QLQ-OES18,
12183,NCT03269526,Overall survival,2017-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Examine tumor tissue for immune system cells, cytokines and proteins to estimate whether the type and number of immune cells correlates with clinical responses",
12184,NCT02413853,Progression free survival (PFS),2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Survivin mRNA expression levels,Intratumoral gene expression of Wnt related biomarkers
12185,NCT04324476,Progression Free Survival 1 (PFS 1),2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],The occurrence of adverse reactions (AEs),
12186,NCT00154752,oncologic results,1999-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],functional results,
12187,NCT05100082,Number of Participants with Grade 3 or higher Adverse Events,2021-11-17,RECRUITING,OBSERVATIONAL,['NA'],Overall Survival (OS),
12188,NCT04755920,To determine the feasibility of SGM-101 for intraoperative imaging of colorectal brain metastases.,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12189,NCT04443478,The number of lower mediastinal lymph nodes retrieved,2020-08-01,RECRUITING,OBSERVATIONAL,['NA'],Overall survival in 3 years,Number of patients that can be screened and successfully recruited
12190,NCT01697917,Change in QOL (Quality of Life),2012-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],Nutritional status of patients,
12191,NCT01079533,Colorectal Cancer Screening,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,
12192,NCT02079363,Number of methylated genes for each participant.,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],Number of methylated genes for each participant related to prognosis,Number of methylated genes in patients with chronic pancreatitis.
12193,NCT05304572,feeding vessels detectability,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],inter-observer agreement,
12194,NCT02585271,Creation of stoma,2015-10-01,TERMINATED,INTERVENTIONAL,['NA'],Overall survival,
12195,NCT02628665,Partial remission rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],The recent incidence of adverse reactions,
12196,NCT01247298,Local Recurrence Rate,2010-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Percentage of Participants With Local Failure Patterns,
12197,NCT01590732,Incidence of adverse events,2012-10-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Complete response,
12198,NCT02781012,Berg's Interrogative Biology® Platform,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12199,NCT04435197,Pathologic complete response,2020-08-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
12200,NCT01862198,The stent patency rate,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],Complication rate related to the hybrid stents,
12201,NCT05281003,Major hypoxia signals in baseline or post-treatment tumor samples from all eligible participants with locally advanced ESCC,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Cell lineage-specific hypoxia signals in baseline or post-treatment tumor samples from all eligible participants with locally advanced ESCC,"EFS in eligible participants with locally advanced ESCC, stratified by PD-L1 biomarker expression (CPS ≥10, ≥1 and <1)"
12202,NCT02973672,Number of patients with treatment-related adverse events,2016-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Serum SGM-101 concentrations,
12203,NCT04809870,Long-term survival,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],Pulmonary complications,
12204,NCT00489359,Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate),2005-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2 - Progression-Free Survival,
12205,NCT03087591,Incidence of adverse events Common Terminology Criteria for Adverse Events version 4.0,2017-04-28,COMPLETED,INTERVENTIONAL,['PHASE1'],Survival as assessed by RECIST,
12206,NCT00453661,Screening Rates,2007-03,COMPLETED,OBSERVATIONAL,['NA'],Compliance Rate Across 5 Cancer Types,
12207,NCT02991092,recovery time of intestinal function,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],hospitalization time after operation（day）,body weight（Kg）
12208,NCT04561830,feasibility of procedure,2015-04,COMPLETED,INTERVENTIONAL,['NA'],recurrence,
12209,NCT02815436,Rate of completion of FOBT in the year of receiving the interventions/control,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Rate of return of FOBT tubes in the year of receiving the interventions/control,
12210,NCT04459468,Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for overall survival in hepatocellular carcinoma patients,2022-11-04,RECRUITING,OBSERVATIONAL,['NA'],Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for Progression free survival in Hepatocellular carcinoma patients.,
12211,NCT01157013,Response to sorafenib therapy shown in PET Scans,2009-01,COMPLETED,INTERVENTIONAL,['NA'],Tumor response evaluated by CT and MRI,
12212,NCT02057874,"Correlation of Changes in Imaging Biomarkers (Ktrans, ADC, MTR, and APTasym) as Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively, With Changes in Tumor Volume (mRECIST).",2014-02,TERMINATED,INTERVENTIONAL,['NA'],"Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Overall Survival (OS)",
12213,NCT02277158,Maximum Tolerated Dose (MTD),2014-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],Quality of Life,
12214,NCT01988493,Phase 2: Time to Progression (TTP) Based on Tumor Assessment by an Independent Review Committee (IRC),2014-01-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Percentage of Participants With Disease Control Based on Tumor Assessment by Investigator According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria,
12215,NCT00498225,Over all survival(OS),2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],"progression-free survival (PFS), response rate (RECIST, if measurable), incidence rate of adverse events, incidence rate of adverse drug reactions, QOL (EQ-5D)",
12216,NCT01744509,Sensitivity of PillCam Colon Capsule 2 (R) in identifying significant colonic polyps,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],to evaluate the tolerability of PCC2 as compared to optical colonoscopy (OC) and CT-colonography (CTC).,
12217,NCT05484024,Disease-free survival rate,2022-08-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life (QoL),
12218,NCT03551444,Recurrence rate,2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Identifications of predictive factors of HCC recurrence,
12219,NCT05965843,All-cause mortality in patients with underline disease after Covid-19 infection.,2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Severe disease in patients with underline disease after Covid-19 infection.,
12220,NCT02136277,Changes in microvascular blood flow during colorectal surgery,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12221,NCT00456599,Two-year Disease Free Survival.,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
12222,NCT01056601,Progression-Free Survival,2010-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Duration of Response,
12223,NCT00551213,Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism: Fluorodeoxyglucose (FDG) Standardized Uptake Value (SUV) in the Target Lesion,2007-11-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Tumor Growth Rate,
12224,NCT04746469,Overall colorectal cancer screening uptake (any modality),2020-09-02,COMPLETED,INTERVENTIONAL,['NA'],Colorectal cancer screening uptake by modality,
12225,NCT01387932,Median Overall Survival,2011-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Objective Response Rates (ORR),Number of TACE-Related Adverse Events in Subjects Treated With HepaSphere/QuadraSphere vs Subjects Treated With Conventional TACE.
12226,NCT01924819,Overall survival,2009-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Surgical complete resection rate (R0),
12227,NCT02349867,Recommended phase 2 dose and schedule,2015-01-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival,
12228,NCT04645160,Phase I: Determine safety and establish the recommended Phase II dose (RP2D) of tivozanib in patients with cholangiocarcinoma who were previously treated with first-line chemotherapy.,2022-03-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Evaluate disease control response (DCR- complete response [CR] plus partial response [PR] plus stable disease [SD]) in patients with cholangiocarcinoma treated with tivozanib,
12229,NCT02080221,Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone.,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Response of Patients With Metastatic Pancreatic Cancer Who Receive the FOLFOX-A Regimen,
12230,NCT00619814,,2003-09,COMPLETED,INTERVENTIONAL,['NA'],,
12231,NCT00458809,Maximum tolerated dose,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in the phenotypic expression of proteins involved in the apoptotic and heat-stress inducible pathways,
12232,NCT01908504,The number of subjects with benefit from an intra-treatment PET-CT,2012-01,COMPLETED,INTERVENTIONAL,['NA'],Measure late toxicities,
12233,NCT03484962,Objective response rate,2018-03-25,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Symptom remission rate,
12234,NCT05542030,Lesions recurrence in a three-month follow-up after EMR,2022-09-12,RECRUITING,INTERVENTIONAL,['NA'],Recurrence risk after EMR,
12235,NCT02725996,Overall Survival(OS) :Overall survival was measured from the date of randomization until death from any cause.,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12236,NCT02000050,Complete pathological response (pCR),2013-10-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Intention-to-treat (ITT) population,
12237,NCT00019513,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12238,NCT05610332,Objective response rate,2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],"The prediction performance of Exosome contents (including proteins, nucleic acids)",
12239,NCT00873275,Pharmacokinetics of ursodiol,2009-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12240,NCT04108936,Overall survival,2016-10,RECRUITING,OBSERVATIONAL,['NA'],Quality of life (Questionnaire-WHOQOL-BREF),
12241,NCT03835663,Difference in the amount of bacteria of the gastric mucosa between the three previously described groups.,2018-06-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
12242,NCT06243757,Appetite level score according to the MDASI-GI,2024-01-08,RECRUITING,OBSERVATIONAL,['NA'],,
12243,NCT04912765,Induced immune response against vaccinated NAs,2021-04-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival,
12244,NCT05499195,Disease-free Survival (DFS),2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12245,NCT01237665,Pathological complete response (pCR),2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],OS,
12246,NCT00848952,Report of proportion of the positives truths and the positive wrong for an examination,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,
12247,NCT01035437,Determine the toxicity of sequential PDT and chemoradiation in obstructing esophageal cancer,2009-12,WITHDRAWN,INTERVENTIONAL,['NA'],Evaluate the efficacy of PDT in palliation of dysphagia,
12248,NCT05475366,Objective Response Rate (ORR) at 4 months based on thorax-abdomen-pelvis (TAP) CT scan every 8 weeks according to RECIST v1.1.,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],Feasibility of study procedure,
12249,NCT01973725,Disease control rate,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],EORTC QLQ-C30 and QLQ-OES18,
12250,NCT02982694,Overall Response Rate,2017-11-24,TERMINATED,INTERVENTIONAL,['PHASE2'],Safety and tolerability (adverse event assessment according to CTCAE v 4.0),
12251,NCT05489458,The evolution of the degree of vascular involvement in 64-MDCT scans,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The Resection Rate at the end of the observation period.,
12252,NCT03097848,Disease free survival,2017-05-04,UNKNOWN,INTERVENTIONAL,['NA'],mortality,
12253,NCT02431078,three-year disease free survival rate,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],baseline detection of ZEB1 expression,
12254,NCT00666978,Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Slow and Fast Metabolizers by Genotype,
12255,NCT05557838,≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE3'],Duration of response (DoR) per RECIST 1.1/mRECIST,
12256,NCT03460197,The classification of Papanicolaou was used for the terminology in pancreatobiliary cytological evaluation of biopsy samples.,2018-04-20,COMPLETED,OBSERVATIONAL,['NA'],,
12257,NCT00110721,frequency of stable disease,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],safety of GM-CT-01 plus 5-FU,
12258,NCT05200442,Phase 2 Primary Objective: Objective Response Rate of Participants Who Take Phase I /MTD Dose of VS-6766 combined with Cetuximab,2022-08-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II Objective: Stable Disease,
12259,NCT06204523,"Investigate pathways of interest at a deeper level, as well as identify other potential pathways/functions impacting clinical outcomes.",2018-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
12260,NCT05622136,Proportion of patients who complete 4 cycles of treatment,2023-09-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Score in the The 5-level EuroQol EQ-5D-5L questionnaire,
12261,NCT03790553,Overall survival in ITT population,2018-10-15,RECRUITING,INTERVENTIONAL,['PHASE3'],Questionnaire EORTC-QLQ-OES18,
12262,NCT01461915,Number of Patients who Achieved Progression-Free Survival,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Proportion of Patients who Achieved Overall Survival,
12263,NCT03102047,Median modified Neoadjuvant Rectal (mNAR) Score,2018-05-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency of adverse events assessed by CTCAE 4.0,
12264,NCT05065801,Progression-free survival,2022-01-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Collection of circulating tumor DNA (ctDNA),
12265,NCT02761356,Visual assesment of Tc-99m-MAA in liver lesions compared to visual assesment of Y-90 sirtex.,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
12266,NCT05856188,Change in the level of salivary transforming growth factor beta 1 during radiotherapy.,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Change in Pain visual analog scale during radiotherapy.,
12267,NCT05865756,acoustic cough features in HNC patients as biomarkers for dysphagia/aspiration.,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
12268,NCT02272894,overall survival,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],disease free survival,
12269,NCT01329718,Effectiveness of the Epi proColon test,2011-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12270,NCT03772132,Progression Free Survival,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],percentage of patients with Clinical Benefit Response,
12271,NCT01969292,%Clear,2013-09,TERMINATED,INTERVENTIONAL,['NA'],Ottawa Stool Score,
12272,NCT01483443,Overall survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease free survival,
12273,NCT04785820,"Overall Survival, Defined as the Time from Randomization to Death from Any Cause",2021-06-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Baseline PDL1, CD8+PD1+, CD8+TIM3+, and CD8+LAG3+ Expression in the Tumor Microenvironment",
12274,NCT03300414,Associate viral sequences and host gene expression signatures with established HCC risk factors in Asian Americans.,2017-03-20,COMPLETED,OBSERVATIONAL,['NA'],,
12275,NCT05238831,Proportion of participants who receive an ACT therapy based an ACT Tumor Board recommendation.,2023-01-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Overall survival,
12276,NCT05086601,Disease-free survival time,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],Pathological TNM stage,
12277,NCT02305810,"Circulating angiogenic factors, molecular imaging and tumor tissue factors changes during treatment with RAD001 at baseline, week 4, week 12 and at disease progression.",2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"TTP, time to progression",
12278,NCT01814501,Progression free survival(PFS),2013-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
12279,NCT02557503,Progression-free survival (PFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],overall survival (OS),
12280,NCT03837132,Impact of early palliative care on quality of life in patients with advanced pancreatic cancer,2018-10-15,COMPLETED,OBSERVATIONAL,['NA'],"To explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer",
12281,NCT05488587,Serum level of Zinc in cirrhotic patients and HCC,2022-08,RECRUITING,OBSERVATIONAL,['NA'],serum level of Zinc and the Barcelona clinic classification,
12282,NCT06152978,Event-free survival (EFS),2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],adverse events,
12283,NCT05497453,Duration of Response (DOR) (for Part 1 and Part 2 expansion),2022-08-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12284,NCT02216578,Progression Free Survival (PFS),2017-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Occurence of adverse events,circulating plasma DNA
12285,NCT01465425,"Rates of Follow Up Imaging, Hospitalization, Intervention",2011-09,UNKNOWN,OBSERVATIONAL,['NA'],Estimate Differences in Cost,
12286,NCT05410977,Specificity of mt-sDNA 2.0 test to detect colorectal dysplasia,2022-03-30,RECRUITING,OBSERVATIONAL,['NA'],,
12287,NCT02140021,Sensitivity and specificity of the combination of anal pap testing + anal HPV testing to diagnose anal dysplasia,2014-10-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12288,NCT02106910,Mean Procedure Preference Rating,2014-10-27,COMPLETED,INTERVENTIONAL,['NA'],Cytosponge™ Operating Characteristics,
12289,NCT03779464,PFS,2019-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety profile :Adverse events of nab-Paclitaxel plus S-1,
12290,NCT03255070,Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1.,2018-03-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Immunogenicity profile of ARX788,
12291,NCT04437953,"Number of patients who achieve platelet counts of ≥ 100,000/mcL",2020-05-27,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Number of patients who can undergo systemic cancer therapy without more than one dose delay or dose reduction,
12292,NCT01991847,Target sample size,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Adverse and serious adverse events,
12293,NCT00577109,Progression-free survival,2007-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"AEs, laboratory parameters.",
12294,NCT05637788,"Evaluate the association between different radiomics and computer-vision features, and the survival after surgery",2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],"Evaluate the association between different radiomics and computer-vision features, and the short-terms results after surgery",
12295,NCT01411189,The proportion of patients had no or mild peristalsis during the therapeutic procedures,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Adverse events and adverse drug reactions,
12296,NCT06134687,Total Procedure Time,2024-03-18,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],User-feedback post-procedure,
12297,NCT06030934,Objective Response Rate (ORR),2022-10-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],Adverse Events (AEs),
12298,NCT00003276,objective tumor response rate,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],time to progression,
12299,NCT02282059,Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs),2014-12-12,COMPLETED,OBSERVATIONAL,['NA'],Progression-free survival by clinical judgment,
12300,NCT03467529,Concordance between FFOCT findings and pathology based on the Paris classification of superficial esophageal cancer in pathology,2018-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
12301,NCT00294359,Phase III: - progression free survival,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",- cost of therapy and assessment of gain in quality-adjusted progression free survival,
12302,NCT02540850,Ct Value (Ct Values From PCR Reaction),2014-02,COMPLETED,OBSERVATIONAL,['NA'],Consistency (the Overall Ratio of True Positive and True Negative),
12303,NCT03295084,Maximal Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of oral Irinotecan based on incidence of Treatment-Emergent Adverse Events,2015-07-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Objective tumor response to treatment based on RECIST 1.1 criteria,
12304,NCT00599378,"Follow up survey to assess participant compliance with CRC screening. For those non compliant participants, randomized to either Control group or CPI2 group - active intervention with implementation intentions-based communication concepts",2007-09,COMPLETED,INTERVENTIONAL,['NA'],120 day followup survey to assess perceived barriers and screening decisional stage,
12305,NCT01661049,,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
12306,NCT01123811,objective response rate,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival,
12307,NCT01519232,Changes in hepatobiliary single photon emission tomography (SPECT) after radiation therapy,2008-08,COMPLETED,OBSERVATIONAL,['NA'],"measuring values between regional radiation dose and local hepatic function as measured by hepatobiliary SPECT, in normal liver parenchyma",
12308,NCT04654975,Odds ratio (OR) for brain metastasis,2020-06-02,UNKNOWN,OBSERVATIONAL,['NA'],Characteristics of brain metastases,
12309,NCT00808743,Change in number and size of duodenal adenomas (assessed directly and by evaluation of video and photographic material from endoscopic procedures),2009-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Biliary acid profile (if present),
12310,NCT04183478,overall survival,2017-09-26,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",QOL,Hematology Index
12311,NCT02163187,Change in Bowel Function,2014-06-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of Life,
12312,NCT01259193,numbers of adverse events,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Overall survival (OS), time to progression (TTP)",
12313,NCT04652947,"compare diagnostic MRI performance of gadoteric acid, gadoxetic acid and P03277 for suspected CHC nodules",2016-12-07,COMPLETED,OBSERVATIONAL,['NA'],,
12314,NCT02533271,Disease-free survival rate,2015-08,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life (QoL),
12315,NCT00303628,5-year Overall Survival Rate,2006-05-11,TERMINATED,INTERVENTIONAL,['PHASE3'],Proportion of Patients Who Completed 12 Cycles of Treatment,Change in Oxaliplatin-related Neurotoxicity Between Baseline and 12 Months
12316,NCT04584996,circRNAs for diagnosis,2020-10-04,UNKNOWN,OBSERVATIONAL,['NA'],Bioinformatics,
12317,NCT06231160,overall survival,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Pain relief rate,
12318,NCT01128803,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Analysis of T lymphocytes,
12319,NCT01751880,"changes of result of blood sample test, cardio pulmonary function test and vital signs reflecting of inflammation level and nutrition condition in patients with minimally invasive gastrectomy",2012-08-08,COMPLETED,INTERVENTIONAL,['NA'],,
12320,NCT03393403,analgesic effect - pain intensity,2017-12-23,UNKNOWN,INTERVENTIONAL,['NA'],analgesic effect - opioid consumption,
12321,NCT01530503,Progression Free Survival (PFS),2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
12322,NCT05594381,Pathological complete response rate (pCR),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events（Safety）,Genomic changes of ctDNA
12323,NCT04053972,RFS,2018-01-31,UNKNOWN,INTERVENTIONAL,['PHASE3'],recurrence rate,
12324,NCT01963702,objective response,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],progression free survival (PFS),overall survival(OS)
12325,NCT05978141,Number of participants populating the T-cell Lymphoma Master Repository/TCLMR,2023-07-27,RECRUITING,OBSERVATIONAL,['NA'],,
12326,NCT01348009,Progression-free survival rate (in Phase 2 portion of study),2011-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Percentage of patients with adverse events (in Phase 1 and Phase 2 portions),
12327,NCT01575730,Area under the plasma concentration versus time curve (AUC) of platinum,2012-05-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Tissue Concentration (Cmax) of Platinum,
12328,NCT03359681,Expression of Ki67 on tumor samples,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE2'],microbiota,
12329,NCT03699410,Negative Prognostic Value (NPV),2018-08-28,TERMINATED,OBSERVATIONAL,['NA'],,
12330,NCT01305200,Duration of Severe Oral Mucositis (WHO Grade 3 or 4),2011-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Severity of Mucositis,Ancillary Validation Study of ChIMES
12331,NCT05187182,Expansion dose of CA-4948 in combination with FOLFOX/PD-1 inhibitor with/without trastuzumab,2023-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
12332,NCT04027543,Overall survival (OS),2018-11-14,COMPLETED,OBSERVATIONAL,['NA'],30-day postoperative or in-hospital mortality,
12333,NCT02054533,Post-Operative Infection,2014-02,COMPLETED,OBSERVATIONAL,['NA'],Hypomotility complication,
12334,NCT01322633,Incidence Rate of Gastric Cancer,2004-07,COMPLETED,OBSERVATIONAL,['NA'],Incidence Rate of Overall Cancer,
12335,NCT01472198,Progression free survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective response,
12336,NCT03092895,The safety and tolerability,2017-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
12337,NCT02063412,"Composite preparation, dispensing, and administration time",2013-08,WITHDRAWN,OBSERVATIONAL,['NA'],,
12338,NCT02704520,To show that patients can successfully avoid surgery after achieving a good response to treatment as measured on MRI (mrTRG).,2016-03,RECRUITING,INTERVENTIONAL,['NA'],To assess whether the detection of ctDNA predicts for relapse in patients with locally advanced rectal cancer,
12339,NCT00073905,Ability of palliative capecitabine and gemcitabine,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Clinical benefit response alone as measured after 3 courses,
12340,NCT04174781,Progression Free Survival (PFS) per mRECIST,2019-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (AEs),
12341,NCT01181557,"Questionnaire number 1, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma",2008-09,COMPLETED,OBSERVATIONAL,['NA'],"Questionnaire number 3, to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma",
12342,NCT04084249,FCI,2020-01-01,RECRUITING,INTERVENTIONAL,['NA'],CE,
12343,NCT05716477,Beliefs about colorectal screening,2022-12-23,RECRUITING,OBSERVATIONAL,['NA'],,
12344,NCT03895008,Disease Free Survival（DFS）,2019-07-08,RECRUITING,OBSERVATIONAL,['NA'],Overall survival(OS),
12345,NCT00754494,Change in ACF pERK Levels,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Reported at Least 1 Diarrhea Side Effect During the Study,
12346,NCT01622803,The time taken to insert bilateral stent,2011-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
12347,NCT06027086,Objective response rate (ORR) using immune Response Evaluation Criteria for Solid Tumors (RECIST 1.1),2024-02-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
12348,NCT04732286,Incidence of Treatment Discontinuations of Atezolizumab and/or Bevacizumab Due to Adverse Events of Grade ≥ 3,2021-05-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Albumin-Bilirubin (ALBI) Assessment Grades of 1 to 3,
12349,NCT00439608,Reponse Rate at Time of Surgery by Tissue,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"Number of Participants With Grade 2 and/or 3 Rash in Patients With Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus, Gastroesophageal Junction, or Stomach.",
12350,NCT03460483,Incidence of tumors with microsatellite instability and/or somatic POLE mutations,2018-03-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12351,NCT03414983,Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR),2018-02-20,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Disease Control Rate (DCR) Per Investigator,
12352,NCT05453383,Objective response rate,2022-07-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-free survival,
12353,NCT00686166,Pathologic Complete Response Rate,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to This Regimen.,
12354,NCT06301399,ORR,2024-03-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],DCR,
12355,NCT01507740,Progression free survival under antiangiogenic therapy,2009-07,TERMINATED,OBSERVATIONAL,['NA'],,
12356,NCT05730361,Objective Response Rate (ORR),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Detection of Lentivirus Copy Number,
12357,NCT03964064,Progression-free survival (PFS),2019-06-11,UNKNOWN,INTERVENTIONAL,['NA'],Adverse reactions,
12358,NCT05007132,Objective response rate,2021-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-free survival,
12359,NCT01839500,"Cohort III, V: Disease-Free Survival (DFS), as Assessed by the Investigator Using RECIST V1.1 Criteria",2013-04-25,COMPLETED,OBSERVATIONAL,['NA'],Cohort II: Percentage of Participants Who Decline to the Recommendation Categorized by Reasons,
12360,NCT06096623,Electronic patient-reported outcome (ePRO) confirming treatment initiation,2023-11-06,RECRUITING,INTERVENTIONAL,['NA'],Time to treatment in days,
12361,NCT04642924,Resection status,2019-10-22,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
12362,NCT06236633,Safety of endovascular inferior mesenteric artery embolisation prior to surgical resection of the rectum in patients with tumours of the lower and middle rectum.,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Markers of epithelial-mesenchymal transition : transcription factors,Operative data
12363,NCT00496704,Overall response rate as assessed by RECIST criteria,2007-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to response,
12364,NCT04710758,Overall survival,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],Postoperative recovery course,
12365,NCT05025748,Self-efficacy in managing patient-physician interactions,2021-08-25,COMPLETED,INTERVENTIONAL,['NA'],Perceptions of the Question Prompt List,
12366,NCT02711033,Early complication rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Metastasis rate of lymph nodes posterior to splenic vessel,
12367,NCT03212625,Cumulative incidence of Hand-Foot Skin Reaction(HFSR) on each group,2016-01-28,COMPLETED,INTERVENTIONAL,['PHASE4'],"Incidence of HFSR on 2, 4, 8, and 12 weeks on each group",
12368,NCT00028015,,2001-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12369,NCT04016948,Accuracy of optical biopsy,2017-06-28,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative function recovery,
12370,NCT03900871,disease free survival,2019-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
12371,NCT04191889,Objective response rate (ORR) by RECIST 1.1,2020-04-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory outcome measure: The quality of life (QoL),
12372,NCT03042611,Overall Survival (OS),2017-03-14,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants Per QOL Dimension Response as Measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire,
12373,NCT00999843,The safety and tolerability of maintenance Sorafenib.,2009-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Time to progression (TTP), progression-free survival (PFS) and overall survival (OS)",
12374,NCT04170530,MFS,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Reported Adverse events,
12375,NCT00359320,The primary endpoint will be the pancreatic fistula rate.,2006-05-25,TERMINATED,INTERVENTIONAL,['NA'],Death,
12376,NCT00833625,Pathologic Response,2009-02,COMPLETED,INTERVENTIONAL,['NA'],,
12377,NCT01226979,Number of Participants With Pathologic Complete Response,2010-10-26,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants With Acute Gastrointestinal Toxicity Associated With High-Dose-Rate Endorectal Brachytherapy (HDRBT) as Assessed by CTCAE v4.0,
12378,NCT01061840,To determine safety following the administration of bi-shRNAfurin and GMCSF autologous tumor cell (Vigil™) vaccine in advanced solid tumor patients who have no acceptable form of standard therapy with curative intent.,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],To determine time to progression. To evaluate the effect of Vigil™ vaccine on immune stimulation. To evaluate whether lower cell doses would activate ELISPOT responses and to compare durability of dose elicited responses.,
12379,NCT05772546,Response Rate of CIT Treatment in Placebo Group,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of Serious Treatment-Emergent Adverse Events (TEAEs) in Placebo Group,
12380,NCT00021281,,2000-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
12381,NCT02731313,Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments,2012-07,COMPLETED,OBSERVATIONAL,['NA'],Weighted Kappa Coefficient Between Immunohistochemistry (IHC) 4B5 and Silver in Situ Hybridization (SISH) Techniques for HER-2 Testing in Centralized Laboratories,
12382,NCT05374044,pathological tumor regression grade(pTRG),2020-05-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],local recurrence,
12383,NCT02452853,Number of Complications reported using the National Cancer Institute Common Toxicity Criteria grading version 4.0,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
12384,NCT01563484,"Change from Baseline in serum creatinine, blood urea nitrogen, direct bilirubin, indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, lactate dehydrogenase, alkaline phosphatase, cholinesterase.",2012-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12385,NCT05675059,Malnutrition: Low Skeletal Muscle Mass,2022-12-21,RECRUITING,INTERVENTIONAL,['NA'],,
12386,NCT03086642,Maximum Tolerated Dose (MTD),2017-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
12387,NCT04996355,"The accuracy, specificity and sensitivity of organoids-on-chip for drug sreening",2021-05-31,RECRUITING,OBSERVATIONAL,['NA'],,
12388,NCT02249650,Dose limiting toxicities (DLTs),2017-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12389,NCT01834742,Primary Variable,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety profile,
12390,NCT05401318,"Induction of immunotherapy efficacy by chemotherapy in colorectal cancer, measured by advanced imaging analysis",2022-03-28,RECRUITING,OBSERVATIONAL,['NA'],,
12391,NCT06326619,Survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12392,NCT00388206,,2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
12393,NCT03411915,Identify the maximum tolerated dose (MTD) and/or recommended dose (RD) and schedule of XmAb18087,2018-01-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12394,NCT05101772,The acquisition rate of the core tissue sample,2021-09-24,UNKNOWN,OBSERVATIONAL,['NA'],the incidence of adverse events and the incidence of device defects,
12395,NCT05721872,Response to D-isoascorbic Acid (D-VC) in combination with arsenic trioxide (ATO),2023-02-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change from baseline number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 24 hours,
12396,NCT03803553,Clearance rate of ctDNA,2020-04-16,RECRUITING,INTERVENTIONAL,['PHASE3'],Clearance rate of Arm 6: Herceptin/Perjeta,
12397,NCT01199250,"Role of FGFR2 mutations in low, intermediate and high risk endometrial cancers (Project 1)",2100-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12398,NCT00624546,gene expression,2009-01,TERMINATED,OBSERVATIONAL,['NA'],,
12399,NCT02295956,Feasibility of Prehabilitation Program Among Pancreatic Patients,2015-02-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12400,NCT03300401,Local tumor response to therapy,2017-11-07,WITHDRAWN,INTERVENTIONAL,['NA'],,
12401,NCT03975452,The reduction of gastrointestinal (GI) toxicity,2007-11,UNKNOWN,INTERVENTIONAL,['NA'],The disease-free survival (DFS),
12402,NCT04017845,Performance Indicators of Colonoscopic Examination,2015-04-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,safety and tolerance of colonoscopy.
12403,NCT01476553,Peritoneal Conversion Rate (PCR),2011-02,TERMINATED,INTERVENTIONAL,['NA'],Perioperative in-hospital morbidity,
12404,NCT04965714,Necrosis of tumors,2022-04-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),Immune biomarker analysis
12405,NCT04177810,Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria,2020-11-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities,
12406,NCT03291574,Gastrointestinal function score,2017-07-29,UNKNOWN,INTERVENTIONAL,['NA'],Physical fitness index,
12407,NCT06234072,Objective response rate (ORR),2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of participants with R0 resection,
12408,NCT02583659,Overall survival(OS) . overall survival Overall survival(OS),2013-01,UNKNOWN,OBSERVATIONAL,['NA'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
12409,NCT05694936,Progression free survival,2023-01-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Quantification of the incidence of treatment-emergent adverse events according to CTCAE V5.0,Quantification of total circulating tumour DNA (ctDNA)
12410,NCT00714701,This clinical study will assess the diagnostic yield of a clinical screening program for early pancreatic neoplasia in high risk individuals.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
12411,NCT06090916,Calorie intake from Myfitness Pal,2023-01-17,RECRUITING,INTERVENTIONAL,['NA'],,
12412,NCT03314896,Overall survival,2016-10,RECRUITING,INTERVENTIONAL,['NA'],Adverse events (mortality and morbidity),
12413,NCT01670851,Perineal wound healing,2013-03,COMPLETED,OBSERVATIONAL,['NA'],Incidence of parastomal hernia,
12414,NCT00026130,Overall Survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,
12415,NCT02014116,Maximum Tolerated Dose (MTD) of LY3009120,2013-11-26,TERMINATED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the End of Dosing Interval at Steady State (AUC[0-τ]) of LY3009120 Cycle 1 Day 28,
12416,NCT05900648,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-05-17,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12417,NCT04594655,MPI and major morbidity,2017-10-01,COMPLETED,OBSERVATIONAL,['NA'],Prediction of complication,
12418,NCT00173472,,2002-07,UNKNOWN,OBSERVATIONAL,['NA'],,
12419,NCT00305188,Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment,2005-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Other: progression free survival and survival,
12420,NCT03140592,Successful generation of pancreatic organoids,2015-01-14,UNKNOWN,OBSERVATIONAL,['NA'],,
12421,NCT05033522,overall survival,2023-08-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Time to Symptomatic Progression,
12422,NCT02232152,"MTD of 6,8-bis(benzylthio)octanoic acid in combination with fluorouracil based on the incidence of dose-limiting toxicities graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",2015-01-06,COMPLETED,INTERVENTIONAL,['PHASE1'],"PK parameters (maximum observed concentration, area under the curve, half-life, elimination rate constant, drug clearance, and volume of distribution) of 6,8-bis(benzylthio)octanoic acid in plasma samples","Disease control rate (DCR) (i.e., sum of CR, PR, and stable disease)"
12423,NCT00929097,The number of colorectal cancer patients following the most optimal follow up program according to the guidelines.,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],Costs of the implementation procedure,
12424,NCT04187352,Overall survival (OS),2019-12-19,COMPLETED,INTERVENTIONAL,['PHASE3'],Duration of response (DoR) assessed by BICR and investigators according to RECIST v1.1,
12425,NCT05973266,quality of bowel preparation,2021-06-03,RECRUITING,INTERVENTIONAL,['NA'],Anxiety,
12426,NCT02519348,Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events,2015-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
12427,NCT02031952,Recurrence-free survival,2005-12,COMPLETED,INTERVENTIONAL,['NA'],Post-operation complication,
12428,NCT04871399,Disease-free survival at 3 years,2020-07-13,RECRUITING,INTERVENTIONAL,['NA'],Other Oncologic outcomes.,
12429,NCT01615653,Pain assessed using a numerical rating scale (NRS) from 0 to 10.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,
12430,NCT03222557,GI-2 recovery,2017-11,UNKNOWN,INTERVENTIONAL,['NA'],Adverse events related to EA/SA,
12431,NCT01813994,Proportion of the patients with high-risk (III/IV) OLGA stages,2014-11,COMPLETED,INTERVENTIONAL,['NA'],,
12432,NCT03766178,Objective Response Rate (ORR),2021-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],12-month survival rate,
12433,NCT03094884,Rate of severe acute esophagitis in patients with lung cancer and esophageal cancer treated with concurrent CRT using PLDR technique.,2017-02-24,RECRUITING,INTERVENTIONAL,['PHASE1'],Response rate based,
12434,NCT03895970,Progression-free Survival (PFS),2019-04-20,COMPLETED,INTERVENTIONAL,['PHASE2'],Stable Disease,Incidence of Treatment-Emergent Adverse Event
12435,NCT02387203,Overall survival,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Progression-free survival measured by no evidence of disease progression, i.e. tumor markers within normal limits, no radiographical evidence of disease",Analyze number of live bacteria in PMP tumor and mucin
12436,NCT04475159,Best Overall Response Rates (BORR),2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Recurrence free survival (RFS),
12437,NCT03984214,Standardized area under the curve of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 symptom summary score over the on-treatment period.,2019-12-16,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall survival (OS),
12438,NCT05662644,Nature of gross picture of specimen,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Occurence of ostoperative reflux,
12439,NCT00159432,Median Time for Progression Free Survival,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Grade 3 or Higher Toxicity,
12440,NCT02521649,Measurable Antibody Titer,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Injection Site Reaction,
12441,NCT04740307,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR),2021-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],TTP per mRECIST as assessed by BICR,
12442,NCT00756509,"To evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as the proportion of patients showing stable disease (SD), partial response (PR) or complete response (CR) during the",2008-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],population pharmacokinetics of Nilotinib,
12443,NCT05311176,Objective Response Rate of HER-Vaxx in combination with chemotherapy or pembrolizumab,2022-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of Response,"Exploratory Outcome: Associations between clinical outcome and HER2/neu, PD-L1 expression"
12444,NCT04567615,Overall response rate (ORR) assessed by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2021-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
12445,NCT00209729,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2005-04,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determine the OS(Overall Survival) and DFS(Disease Free Survival).,
12446,NCT01382407,Relationship between acne and skin rash,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,
12447,NCT05516394,Postoperative complications,2020-07-01,RECRUITING,OBSERVATIONAL,['NA'],Number of patients readmitted to hospital after discharge,
12448,NCT02005315,Phase 1b: Safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (PK) of vantictumab when administered in combination with nab-paclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer,
12449,NCT01314105,Dose Limiting Toxicities During Treatment Course 1,2011-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Change From Baseline in Safety Laboratory Parameters,
12450,NCT01073384,Preliminary Efficacy,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12451,NCT02200055,Bioimpedance Assessment,2012-05,COMPLETED,INTERVENTIONAL,['NA'],Amount of Intraoperative Fluids,
12452,NCT04299919,Three-year recurrence,2007-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Progression-free survival,
12453,NCT04818476,overall mortality,2020-02-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12454,NCT04905329,Relative dose-intensity (RDI) of the myelosupressive therapy course,2020-04-28,UNKNOWN,OBSERVATIONAL,['NA'],Serious adverse events frequency,
12455,NCT05141149,PART 1 (PHASE 1): Determine the recommended Phase 2a dose (R2PD) of PBP1510,2023-06-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PART 2 (PHASE 2a): Presence of ADA and NAb against PBP1510 administered in combination with gemcitabine.,PART 2 (PHASE 2a) Exploratory Endpoint: Analysis of PAUF in tumour tissue pre-treatment and after treatment with PBP1510 administered in combination with gemcitabine.
12456,NCT05882396,Total Neuropathy Score,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The 4-Stage Balance Test,
12457,NCT02385552,Adenoma detection rate,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],Colonoscopy quality indicators,
12458,NCT01994213,Objective Response Rate,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Percent of Participants with OS of one year,
12459,NCT01383252,Success of colonoscopy,2010-02,COMPLETED,INTERVENTIONAL,['NA'],Polyp detection,
12460,NCT02281266,Recurrence-free Survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],"number of patients with abnormal laboratory value, vital signs and ECG result",
12461,NCT01804790,disease-free survival,2012-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Overall survival,
12462,NCT05516641,Gut Flora modulation,2022-07-25,RECRUITING,INTERVENTIONAL,['NA'],Immune Profile,
12463,NCT03599154,Overall survival,2018-01-30,COMPLETED,OBSERVATIONAL,['NA'],,
12464,NCT03725254,Progression-free survival,2018-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],local control rate,
12465,NCT06093009,Disease-free survival,2002-06,COMPLETED,OBSERVATIONAL,['NA'],,
12466,NCT04085055,Degree of cellularity in biopsy sample,2019-09-09,UNKNOWN,INTERVENTIONAL,['NA'],Diagnostic operating characteristics,
12467,NCT00185874,To determine the toxicity of this regimen,2004-01,TERMINATED,INTERVENTIONAL,['PHASE1'],To evaluate the immune response of patients treated with RFA + DC based on the presence and characterization of tumor infiltrating white blood cells,
12468,NCT04351009,Upstaging rate,2020-06-08,COMPLETED,INTERVENTIONAL,['NA'],Aberrant lymph node drainage,
12469,NCT05461794,Arms A and C: Overall Response Rate (ORR),2022-10-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of participants with clinically significant changes from baseline in vital signs,
12470,NCT03284879,Change from baseline activity for arthritis,2017-09-05,COMPLETED,OBSERVATIONAL,['NA'],,
12471,NCT05402891,Change in clone size distribution positive for NOTUM.,2022-06-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],"Safety outcomes by analysing reported adverse events, physical examination and laboratory findings.","History of smoking, if yes number of pack years"
12472,NCT02772965,Percent of Participants Experiencing Treatment Failure,2016-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Percent of Patients With Positive Anti-TNF Antibody,
12473,NCT02041312,Cholesterol level in paitents with and withoutgastric neoplasm,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],Degree of decresed serum cholesterol levels in paitents with gastric neoplasm,
12474,NCT05105815,DFS,2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],EORTC-QLQ30,
12475,NCT05635149,Progression-Free Survival (PFS),2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],Gut microbiome analysis,Exploratory endpoint
12476,NCT00579865,"To determine how surgical or percutaneous drainage affects HRQL scores in patients with MBO, and to determine if these changes are sustained or change over time.",2005-05,COMPLETED,OBSERVATIONAL,['NA'],"To identify factors associated with changes in HRQL after drainage(e.g. diagnosis, level of obstruction, degree of pruritus)",
12477,NCT03279198,"Primary Outcome:differences in stage of adoption (precontemplation, contemplation, action) when controlling for adherence to BC screening at baseline, among women who are randomized to 1) usual care; 2) a TIWeb; 3) a CSC, and 4) a TIWeb plus a CSC.",2010-07-22,COMPLETED,INTERVENTIONAL,['NA'],Secondary outcome:Intervention Costs,
12478,NCT04220944,Progression Free Survival (PFS),2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V5.0 (Safety and Tolerability),
12479,NCT00003687,,1998-06-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12480,NCT00442637,Progression-free survival after re-introduction of MTD chemotherapy and bevacizumab (PFS2),2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Translational research,
12481,NCT00636610,Progression-free Survival (PFS),2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free Survival (PFS) in Patients With Various Degrees of Hedgehog Antigen Tumor Expression,
12482,NCT03839277,"Adenoma detection rate, ADR",2019-06-12,SUSPENDED,INTERVENTIONAL,['NA'],"Polyp detection rate, PDR",
12483,NCT04314401,Percentage of minority and underserved study participants accrued,2020-11-11,RECRUITING,OBSERVATIONAL,['NA'],Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository,
12484,NCT00537121,Recommended phase II dose (RPTD) of SAHA when administered continuously and intermittently with standard doses of FOLFIRI,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival,
12485,NCT02784262,adverse events,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],change in quality of life expressed by Patients' Global Impression of Change (PGIC),
12486,NCT00028496,"Maximum tolerated dose of recombinant fowlpox-CEA(6D)/TRICOM vaccine determined by dose-limiting toxicities graded according to NCI Common Toxicity Criteria, version 2.0",2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12487,NCT05943210,Number of research specimens obtained at the time of surgery.,2023-05-22,RECRUITING,INTERVENTIONAL,['NA'],Comparing levels of cell death related to radio responsiveness will be measured by quantifying cleaved caspase-3,
12488,NCT02378389,The maximum-tolerated dose (MTD) of Pyrotinib and that of Pyrotinib with Docetaxel in patients with HER2 positive advanced gastric cancer,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],preliminary antitumor activity for the regimen,
12489,NCT03196232,Progression-free Survival (PFS),2017-09-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Treatment Delay or Reduction,
12490,NCT01554969,Tumor response and disease progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST).,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12491,NCT02833363,Difference of Gastric Microbiota in the Process of Correa's Model.,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],Difference of Gastric Microbiota in the Process of Correa's Model.,
12492,NCT03888638,Survival,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12493,NCT02865811,Clinical Benefit Rate [CBR],2016-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
12494,NCT06301763,Body Mass Index Level,2022-06-01,COMPLETED,INTERVENTIONAL,['NA'],Penetration-Aspiration Scale,
12495,NCT00657371,Number Polyps Detected With the Standard Colonoscope and Third Eye Retroscope (TER),2008-03,COMPLETED,INTERVENTIONAL,['NA'],Number Participants With Polyps Who Would Have Incorrectly Been Classified as Polyp-free Had the Third Eye Retroscope Not Been Used.,
12496,NCT03320629,Progression free survival,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Side effects,
12497,NCT04008537,"Feasibility of the device as measured by successful completion of the full CBCT-guided online ART workflow, from volumetric imaging through phantom delivery in at least 90% of attempted fractions",2019-09-04,COMPLETED,INTERVENTIONAL,['NA'],,
12498,NCT05034887,Major pathological response [MPR] rate: by central assessment,2022-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],AE rate,AE rate in the Exploration Part
12499,NCT03875612,Specificity of registered level of tie,2016-12-12,COMPLETED,OBSERVATIONAL,['NA'],Cancer recurrence by tie level,
12500,NCT02249975,Presence of residual Barrett's Esophagus,2015-01,COMPLETED,INTERVENTIONAL,['NA'],Device Performance,
12501,NCT06195111,PFS (Progression-free survival),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Quality of life: EORTC QLQ-C30,
12502,NCT00709462,"To establish the safety and tolerability profile of CDX-1307 in patients with incurable breast, colorectal, pancreatic, ovarian or bladder cancer, alone and in combination with adjuvants.",2004-03,COMPLETED,INTERVENTIONAL,['PHASE1'],"To evaluate dose-limiting toxicities, immune response, and clinical activity (tumor response and time to progression)",
12503,NCT02445456,Number of Operations Where There Was Any Surgical Difficulty Due to Tracer Injection Based on Qualitative Assessment by Surgeon,2016-12,TERMINATED,INTERVENTIONAL,['NA'],Number of TEM Operations Where the Sentinel Lymph Node Can be Identified and Removed,
12504,NCT05651971,The distance from LCA to IMA and IMV,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],postoperative anastomotic leakage rate,
12505,NCT01889680,The time to disease progression,2014-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],The severity of adverse events,
12506,NCT05222204,overall survival,2021-07-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12507,NCT00997022,Maximum tolerated dose of daily sorafenib,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Duration of progression free survival,
12508,NCT04200027,oncological outcomes RLAR vs TaTMe,2021-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12509,NCT04585516,Presence of upper GI pathology,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],patient characteristics of colorectal cancer 7,Patients characteristics in patients < 50 years who were admitted for a gastroscopy 9
12510,NCT00102752,Overall objective response rate,2004-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Serum CA-19-9,
12511,NCT00718055,,2006-11,WITHDRAWN,OBSERVATIONAL,['NA'],,
12512,NCT04068194,Objective response rate (ORR) (Phase 2),2020-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Differential response to therapy (Phase 2),T cell receptor (TCR) clonality
12513,NCT01207895,Utility of [18F]-FLT PET to assess cellular proliferation in neoadjuvant trials of patients with rectal cancer,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Correlative biology,
12514,NCT02529878,radical resection rate,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],reaction rate,
12515,NCT01738139,Maximum tolerated dose (MTD),2013-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12516,NCT02004782,Rate of symptomatic stricture formation,2022-03,WITHDRAWN,INTERVENTIONAL,['PHASE4'],Recurrence,Cost
12517,NCT02123407,the number of harvested lymph nodes,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],the diameter of harvested lymph nodes,
12518,NCT00858429,Time to tumor progression,2009-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12519,NCT01683422,One-year Survival Rate,2013-01-02,TERMINATED,INTERVENTIONAL,['NA'],,
12520,NCT04258657,DFS,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],OS,
12521,NCT03101566,The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment,2017-09-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Response Rate (ORR),
12522,NCT05785780,Up-to-date CRC screening,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],Rate of CRC Screening Uptake by Glucose Control (Controlled vs. Uncontrolled) Among Participants with Type 2 Diabetes,Implementation Fidelity
12523,NCT01975454,Progression-free survival(PFS),2012-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse events,
12524,NCT06212700,Acceptability of the virtual multimodal hub.,2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Implementation Outcome: Maintenance,
12525,NCT00307723,to determine the survival of patients treated with this regimen.,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",to evaluate the toxicities.,
12526,NCT05961969,Completion of transabdominal ISR,2022-02-21,RECRUITING,OBSERVATIONAL,['NA'],Fecal incontinence,
12527,NCT05992220,progression-free survival rate,2022-10-22,RECRUITING,INTERVENTIONAL,['PHASE2'],"Tumor marker response (AFP, PIVKA-II)",
12528,NCT04782791,Adverse events,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],R0 rate,
12529,NCT05669482,To determine the efficacy of the RP2D identified in Part A,2023-03-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of abnormal laboratory values,
12530,NCT02083653,Overall Survival (OS) Time,2014-03-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life Assessed by FACT-EGFRI-18 for Skin Rash,
12531,NCT04231175,Number of preventable unnecessary laparoscopies and explorative laparotomies defined as,2019-10-28,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life between diagnostic arms by EQ5D5L,
12532,NCT03255434,Evaluation of neurotoxicity associated with Oxaliplatin,2017-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12533,NCT02829385,Objective Response Rate (ORR),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
12534,NCT05188586,Specificity,2022-12-06,RECRUITING,INTERVENTIONAL,['NA'],Stage Shift,
12535,NCT00716209,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
12536,NCT04659603,Incidence of dose-limiting toxicites (DLTs)- Cohort C Part 1,2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Maximum concentration observed after infusion (Cmax) of gemcitabine metabolite,
12537,NCT01105377,Confirmed Tumor Response,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Progression,
12538,NCT06263205,Rate of Postoperative Wound Healing Complications,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Medical Costs Associated with Wound Care,
12539,NCT02037048,Recurrence Free Survival (RFS) compared to historical averages,2014-02-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Loco-regional control (LRC),"Prognostic effect of CTCs, Ki-67, and HER2 overexpression on pathologic response"
12540,NCT05354674,progression free survival,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],overall survival,
12541,NCT00476970,Percentage of Eligible Patients In Study and Control Groups Who Undergo CRC Screening,2007-09,COMPLETED,INTERVENTIONAL,['NA'],Number of Polyps and Cancers per 100 Patients in the Study vs Control Group,
12542,NCT05561504,H. pylori resistance profiles,2021-03-31,RECRUITING,OBSERVATIONAL,['NA'],risk factors for gastric cancer,
12543,NCT00352261,Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients by evaluation of the percentage of time that intragastric pH is >4.0 over a 24 hr period steady state,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg bid in controlling intragastric pH in BE patients by evaluation of the % of time intragastric pH is >4.0 over 24 hr period at steady state,
12544,NCT02423343,Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab,2015-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Overall Survival (OS),
12545,NCT03010722,"disease control rate (DCR), measured in months",2015-01,COMPLETED,OBSERVATIONAL,['NA'],Median values of volume transfer constant (Ktrans) and enhancing fraction (EF) and their product KEF (product of summarised median values of Ktrans x EF/100) will be compared at baseline and on day 15,
12546,NCT02159339,Metastasis and/ or recurrence of gastric carcinoma,2012-12,COMPLETED,OBSERVATIONAL,['NA'],Disease-free (Recurrence/metastasis-free) survival (DFS) and overall survival (OS) of patients with gastric carcinoma after surgical resection,
12547,NCT02946138,Progression-free survival of all patients,2016-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Objective responses rate,
12548,NCT02762266,Number of Participants With a Local Progression Event,2016-02-27,TERMINATED,INTERVENTIONAL,['PHASE3'],The Impact of Elevated Serum Alpha-Fetoprotein Level (AFP) on Overall Survival (OS),
12549,NCT01471743,Number of participants with post-op Infections,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,
12550,NCT02092948,Assess the safety of [124I] PSCA-Minibody,2013-08-22,COMPLETED,INTERVENTIONAL,['PHASE1'],Compare the sensitivity and specificity of [124I] PSCA-Minibody with conventional imaging,
12551,NCT00905918,"Presence in colon tissue of α-, γ-, and δ-tocopherols, cell proliferation and apoptosis indicators, β-catenin localization, RXR expression, and cyclooxygenase-2, 8-OHdG, and 3-nitrotyrosine levels",2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12552,NCT02181075,Patients Demonstrating >Two-fold Increase in the Amount of Intratumoural Doxorubicin Before and After Focused Ultrasound,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Patients With Significant (Grade 3-5) Adverse Event(s) Deemed Related to FUS Procedure,
12553,NCT04855331,Postoperative complications,2021-04-15,RECRUITING,INTERVENTIONAL,['NA'],The 90 days mortality rate after operation,Postoperative quality of life
12554,NCT05831150,Number of study participants who remain in clinical research until completion.,2024-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12555,NCT04523467,Progression-free survival (PFS),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Adverse events,Conversion rate
12556,NCT01892072,"the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.",2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12557,NCT03015389,Detection rate of Barrett's associated high grade esophageal dysplasia and esophageal adenocarcinoma (HGD/EAC) using WATS3D and random 4 quadrant forceps biopsies taken at 2 cm intervals.,2017-09-27,COMPLETED,OBSERVATIONAL,['NA'],Number of participants with Barrett's related dysplasia and adenocarcinoma diagnosed with random forceps biopsies and WATS3D biopsies used in alternating fashion.,
12558,NCT06329102,Surgical complications defined by Calvien Dindo II to V,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],Quality of life after surgery measured with the 15D instrument,
12559,NCT00583674,Progression Free Survival (PFS),2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Patient Reported Outcomes,
12560,NCT03777813,cPFS (centrally reviewed cPFS),2018-12-05,RECRUITING,INTERVENTIONAL,['PHASE2'],"Quality of Life OES18, used for patients with oesophageal cancer always complemented by the QLQ-C30 measuring 5 functional scales (physical, everyday activity, cognitive, emotional and social) and 3 symptoms scales (fatigue, pain, nausea and vomiting)",
12561,NCT00033384,,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12562,NCT04415385,ORR,2020-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events (AEs) in the treatment of Camrelizumab in combination with apatinib,
12563,NCT03600831,Disease-free survival (DFS),2018-08-20,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life(QOL),
12564,NCT02260505,Disease Free Survival (DFS),2014-12-24,COMPLETED,INTERVENTIONAL,['PHASE3'],Patient's Quality of Life (QoL),
12565,NCT01479894,Compare the prognosis of colon cancer patients compared to gene expression.,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
12566,NCT02420691,Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1,2015-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),Change in Ki-67 With Treatment
12567,NCT05922358,Completion rate of 3 cycles of re-chemotherapy with oxaliplatin,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Concordance rate between oxaliplatin skin test results and clinicians' judgment,
12568,NCT02813928,The presence of recurrences detected for patients curatively treated for a CRC stages II and III within the 3 years of follow-up.,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,
12569,NCT00480298,endoscopic evaluation of the nasal polyp size compared to baseline,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"Nasal Polyp score: endoscopic evaluation of the nasal polyp size compared to baseline. Nasal polyposis signs and symptoms including nasal discharge, nasal congestion, postnasal drip, sense of smell,olfactory test (sites Gent, Stockholm and Huddinge) and",
12570,NCT00681252,safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To evaluate immunological responses,
12571,NCT03541304,clinical response rate,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],overall survival,
12572,NCT02266056,intra-abdominal pressure,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,
12573,NCT00003287,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12574,NCT01821963,Number of Participants With Undetectable Viral Load 12 Weeks Post-transplant,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3'],Sustained Virological Response (SVR),
12575,NCT04342910,Overall Survival (OS) in PD-L1 Positive Participants.,2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE3'],Plasma concentration of apatinib,
12576,NCT05389527,Major pathological response (MPR),2022-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse event (AE),
12577,NCT04021589,progression free survival,2019-07-11,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival,
12578,NCT00725335,Disease free survival,2008-09,COMPLETED,INTERVENTIONAL,['NA'],"overall survival,morbidity,postoperative mortality;blood loss,Liver function test,etc",
12579,NCT06325410,type of resected tumor,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
12580,NCT01285778,Three-year disease-free survival rate,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Predictive potential of different biomarkers,
12581,NCT05064553,To demonstrate that Oncoguard™ Liver HCC specificity exceeds 82%,2021-07-26,RECRUITING,OBSERVATIONAL,['NA'],To determine a point estimate and 95% confidence interval for Oncoguard™ Liver overall HCC sensitivity,
12582,NCT03710486,Number of Participants With Change From Baseline in Endoscopic Findings,2019-02-19,COMPLETED,OBSERVATIONAL,['NA'],Number of Participants with AE Outcome,
12583,NCT01343901,Percentage of Participants Without Detectable Metastatic Disease After a Complete Response Without Surgery,2010-09-30,COMPLETED,OBSERVATIONAL,['NA'],Percentage of Participants With Unresectability Criteria,
12584,NCT04137536,Evaluate toxicity,2019-10-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12585,NCT04222114,Overall survival (OS),2020-10-06,RECRUITING,INTERVENTIONAL,['PHASE3'],Tendency of theperipheral blood lymphocyte counts change associated with the intra-peritoneal infusion of catumaxomab,
12586,NCT06123494,Overall survival (OS),2024-01-09,RECRUITING,INTERVENTIONAL,['PHASE3'],Serum concentrations of SHR-A1811 toxin-binding antibodies and free toxin SHR169265,
12587,NCT00003254,Confirmed Response Rate,1998-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicities,
12588,NCT01745107,Disease-free survival time,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],overall survival time,
12589,NCT03109301,Efficacy,2017-04-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12590,NCT03520088,Changes in sexual dysfunction pre- and post-Total Mesorectal Excision,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA'],,
12591,NCT02272244,Overall Screening Adherence,2014-10-01,COMPLETED,INTERVENTIONAL,['NA'],Screening Knowledge and Perceptions,
12592,NCT02900677,Self-report Questionnaire,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
12593,NCT04137679,Disease-free survival,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment,
12594,NCT05779917,Number of Patients with Dose Limiting Toxicity,2023-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Median CAR-T cell persistence,
12595,NCT00862082,Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group),
12596,NCT02970916,FOLFIRI+aflibercept efficacy in terms of Progression-free survival (PFS) with or without ACE polymorphisms.,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events as assessed by CTCAE v4.0.,"Other biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with tumour-efficacy parameters (ORR, PFS and OS)"
12597,NCT02935634,Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks,2016-11-29,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Laboratory Abnormalities in Specific Liver Tests,
12598,NCT01628913,Progression Free Survival (PFS),2012-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Time to Treatment Failure (TTF),
12599,NCT00005869,,1998-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
12600,NCT01430052,Two year survival rate,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Response rate,
12601,NCT02724267,Overall Survival,2012-11,COMPLETED,INTERVENTIONAL,['NA'],Time to Progression,
12602,NCT01219985,Number of Detected Uptakes on PET Images,2008-04,COMPLETED,INTERVENTIONAL,['NA'],Lesions Uptake Measurement (SUVmax),
12603,NCT00626054,"Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms",2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],"Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation",
12604,NCT05412355,long-term survival,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],Postoperative complications,
12605,NCT02588248,Adenoma Detection Rates,2017-04-27,TERMINATED,INTERVENTIONAL,['PHASE3'],Patient Comfort Level Recorded on Post-procedure Survey,
12606,NCT00276861,Response Rate as Measured by RECIST Criteria,2005-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Time to Progression as Measured by the Kaplan Meyer Curve at Completion of Study Treatment,
12607,NCT05883800,Incidence of acute gastro-intestinal toxicity equal or higher than grade 2,2023-06-22,RECRUITING,INTERVENTIONAL,['NA'],Incidence of late gastro-intestinal toxicity equal or higher than grade 2,Patient reported bowel-related outcome measures
12608,NCT05631873,Implement a new process using a structured result letter template to set the electronic health record follow-up interval after a screening colonoscopy.,2022-11-18,COMPLETED,INTERVENTIONAL,['NA'],,
12609,NCT01764477,The Maximum Tolerated Dose (MTD) of PRI-724 + Gemcitabine measured by the number of dose limiting toxicities (DLTs) that occur.,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Gene expressions in hair follicle epithelial cells,
12610,NCT05502666,Colorectal Cancer Screening,2017-07-08,COMPLETED,INTERVENTIONAL,['NA'],,
12611,NCT06040801,Assess the level of quality of life in frail and non-frail patient groups before and after treatment using EORTC QLQ-C30 v3 and EORTC QLQ-ELD14.,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
12612,NCT06305364,Primary Efficacy Endpoint - Gixam's diagnostic accuracy,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
12613,NCT03456206,CID diagnosis,2018-11-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12614,NCT00641147,Polyp Number,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Apoptosis Index Levels,Change in Akt Phosphorylation Levels
12615,NCT02863172,Variations in Clinical Features Compared Between Proband Group and Family Member Group,2012-05-22,RECRUITING,OBSERVATIONAL,['NA'],Variations in the Overall Disease Phenotype Between Proband Group and Family Member Group,
12616,NCT02140593,Surgical Rating Score,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],The Surgical Rating Score During Fascial Closure,
12617,NCT05128825,Overall Response Rate defined by the revised RECIST v1 .1. and assessed by ICR.,2022-02-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Time To Response as defined by the revised RECIST v1 .1. and assessed by ICR and the Investigator.,
12618,NCT01201655,,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12619,NCT06116864,Adenoma detection rate,2023-10-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Procedure complication (bleeding or perforation) by the end of the procedure. (Following lexicon for endoscopic adverse events methods),
12620,NCT02053324,Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03),2013-11-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Adverse Events,tumor response
12621,NCT03486574,Genes with logarithm of odds (LOD)>2 in linkage analysis,2016-12-07,COMPLETED,OBSERVATIONAL,['NA'],,
12622,NCT05350917,Objective Response Rate (ORR),2022-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Study on the mechanism of drug resistance after progression,
12623,NCT02672917,Group F - Determine the MTD and/or the RP2D of MVT-5873 administered in combination with the modified FOLFIRINOX regimen (mFOLFIRINOX) in the PDAC adjuvant setting,2016-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Group F - Evaluate time to recurrence,
12624,NCT02631590,Progression Free Survival (PFS),2016-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
12625,NCT00191412,Antitumor activity as measured by Response Evaluation Criteria in Solid Tumors,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival: Enroll. to death of any cause,
12626,NCT04676633,Limited Dose Toxicity (LTD),2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12627,NCT00254436,Patient Iron Levels,2001-10-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,
12628,NCT00003862,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12629,NCT05390112,Radiological response at 1 month according to mRECIST and ctDNA detection,2021-05-20,RECRUITING,OBSERVATIONAL,['NA'],Progression-free survival and overall survival,
12630,NCT01831037,Hepatocellular carcinoma,2015-07,WITHDRAWN,OBSERVATIONAL,['NA'],Profile with lowest risk for hepatocellular carcinoma,Regression of liver fibrosis
12631,NCT00260884,We expect to enter 50 patients per year and finish accrual of patient within 2.5 years.,1993-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12632,NCT02729298,Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events,2016-12-14,COMPLETED,INTERVENTIONAL,['PHASE1'],Objective response rate using RECIST v1.1 and iRECIST,
12633,NCT04298008,disease control rate (DCR) of AZD6738 and Durvalumab combination,2020-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],quality of life measurement,
12634,NCT05345054,A database linking socioecological determinants of health with nationally validated surgical outcomes.,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
12635,NCT04111172,Antigen-specific T-cell response to guanylyl cyclase C (GCC),2020-11-10,SUSPENDED,INTERVENTIONAL,['PHASE2'],,
12636,NCT02446925,Y-90 distribution and concentration as determined by post embolization PET-CT,2015-05-01,TERMINATED,INTERVENTIONAL,['NA'],Secondary outcome (time to death from first treatment),
12637,NCT05468008,Evaluate the utility of ESD for treatment of gastrointestinal lesions,2022-02-04,RECRUITING,OBSERVATIONAL,['NA'],Safety- Adverse Events,
12638,NCT01319942,Response rate,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],Time-to radiological progression interval,
12639,NCT05194995,Dose Expansion phase: Overall response rate (ORR),2022-02-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Dose Expansion phase: Progression-free survival (PFS),
12640,NCT03047837,NFκB,2017-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Metformin concentration,
12641,NCT02898077,Overall Survival (OS),2017-03-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score,
12642,NCT03307408,Dosage of the inflammatory cells in liver,2017-02-28,UNKNOWN,OBSERVATIONAL,['NA'],Dosage of the glucose,
12643,NCT00384878,"The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors).",2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],"The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities.",
12644,NCT00098982,Maximum tolerated dose and recommended dose of bortezomib as measured by CTC v3.0,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to progression as measured by Kaplan Meier and RECIST every 8 weeks,
12645,NCT00844623,Adverse Events,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor response by WHO criteria,
12646,NCT04843644,oral mucositis,2021-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Microbiota,
12647,NCT05086627,Pathological complete response rate,2022-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],
12648,NCT00482625,Reduction in Number of Positive IPMN Celss and Staining Intensity After Treatment,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants Reported at Least 1 Adverse Event With a Grade of 3 and Above,
12649,NCT02830620,chimiokine MCP1 expression,2012-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
12650,NCT03204994,Number & location of lymph nodes identified with and without fluorescent probe during rectal cancer surgery,2017-08-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of lymph nodes lying outside the CRM identified by fluorescence,
12651,NCT05265221,Resection speed,2022-03-01,COMPLETED,OBSERVATIONAL,['NA'],Complication rate,
12652,NCT03568110,90-day mortality,2019-03-05,COMPLETED,OBSERVATIONAL,['NA'],Health-related Quality of life at 12 months (EORTC-QLQ-STO22),
12653,NCT05086614,3-year disease-free survival rate,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],rate of adverse events related to thymosin-alpha 1,
12654,NCT05162898,RFS,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],2-year OS%,
12655,NCT00006039,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12656,NCT01580410,"The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments",2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G),
12657,NCT00020826,psychometric validity of the STO22 module,2001-04,COMPLETED,OBSERVATIONAL,['NA'],debriefing questionnaire information,correlation between QLQ-C30 and STO22 scores
12658,NCT02620228,Difference in mean between measured bioimpedance spectra from tumorous and nontumorous tissue,2016-06-09,COMPLETED,INTERVENTIONAL,['NA'],,
12659,NCT05245565,Postoperative anal function assessed by Vaizey scale,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
12660,NCT04977882,Tolerance to solid diet,2020-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],C-Reactive Proteine,
12661,NCT04323618,Improvement in reproducibility of respiratory-related tumour motion (via fiducial maker surrogacy) for liver cancer patients treated with the AV biofeedback respiratory guidance system.,2014-04,COMPLETED,INTERVENTIONAL,['NA'],,
12662,NCT04133324,CRP_D4/CRP_D2 Colorectal,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA'],CRP_D2 colorectal,
12663,NCT04457284,Response,2020-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12664,NCT01138124,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,
12665,NCT05346146,R0-surgery resection rate,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],All the adverse events by NCI CTCAE v 5.0,Biomarkers predictive of response and toxicity
12666,NCT00321828,Major Morbidity Related to the Intact Primary Tumor,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival as Measured by Death From Any Cause,
12667,NCT01020812,Freedom From Local Progression of TACE and SBRT at 12 Months,2009-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median Progression Free Survival,
12668,NCT01479907,"Assessment of gastrointestinal function-related quality of life at 1, 3 and 6 months postoperatively",2010-11,COMPLETED,INTERVENTIONAL,['NA'],,
12669,NCT01912443,Laboratory parameters,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival (OS) of treatment line,
12670,NCT04166383,Best Overall Response (BOR),2020-08-09,COMPLETED,INTERVENTIONAL,['PHASE2'],6-month Progression-free Survival (PFS),Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
12671,NCT01363843,Incidence of Complete Resection,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate the Toxicity of Study Therapy,
12672,NCT03563352,The way patients with cancer choose and obtain nutritional supplements to support medical management,2018-08-30,WITHDRAWN,OBSERVATIONAL,['NA'],Associations of gastrointestinal side effects with specific diagnoses and respective medical therapies,
12673,NCT02066688,"The primary objective of this study is to investigate the incidence of colorectal adenoma (CRA) after Folic acid, calcium and vitamin D intervention.",2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",differences in Histological types of CRA OR CRC,"Changes in routine blood count, urine and stool routine test, liver and kidney functions"
12674,NCT04600154,Change in cachexia staging score from baseline,2021-08-10,RECRUITING,INTERVENTIONAL,['NA'],QLQ-C30 Global health status/QoL,Progression free survival
12675,NCT02631564,number of adverse events,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],Time to progression,
12676,NCT00066404,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12677,NCT00103103,Response rate as measured by RECIST every 8 weeks,2005-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Molecular correlates on and off study treatment,
12678,NCT03127072,Overall survival in subjects receiving RFA plus chemotherapy ± target therapy compared to chemotherapy ± target therapy alone was assessed from the date of study entry until death from the disease.,2017-04-30,UNKNOWN,INTERVENTIONAL,['PHASE4'],The differences in the incidence or severity of adverse events in the RFA plus chemotherapy ± target therapy arm compared to the chemotherapy ± target therapy only arm were was assessed by of complications after therapy.,
12679,NCT06134024,Rate of safety of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of double pigtail plastic stents introduced through the LAMS.,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Rate of long-term success of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of double pigtail plastic stents introduced through the LAMS.,
12680,NCT00660153,"To determine the safety, tolerability, and maximum tolerated dose of tivozanib (AV-951) in combination with FOLFOX6 chemotherapy.",2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],"To characterize the pharmacokinetic profile of tivozanib (AV-951) and FOLFOX6 chemotherapy when administered together, and to assess the antineoplastic activity of the combination of tivozanib (AV-951) and FOLFOX6 chemotherapy.",
12681,NCT01767675,determine the proportion of patients who are without evidence of disease progression,2013-01-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],pharmacokinetics,
12682,NCT02702960,1 year disease-free survival (at 1 year after BMT),2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Liver allograft failure,Efficacy measure- proportion off immunosuppression without graft versus host disease (GVHD) or liver rejection
12683,NCT03902899,Proximal serrated polyp detection rate (PSPDR),2014-01-01,COMPLETED,INTERVENTIONAL,['NA'],Adenoma detection rate (ADR),
12684,NCT03172572,Major morbidity,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
12685,NCT02000180,Difference Between Progressive and High-Fidelity Groups on Clinical Colonoscopy Peformance (JAG/DOPS),2013-06,COMPLETED,INTERVENTIONAL,['NA'],"Colonoscopy Specific Performance, Communication Skills, and Global Performance on an Integrated Scenario",
12686,NCT06238843,overall survival(OS),2024-03-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],neutralizing antibody (NAb),
12687,NCT00275119,Progression-free survival,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Locoregional and metastatic progression-free survival,
12688,NCT00433602,"Incidence of symptomatic pulmonary embolism as assessed by ventilation/perfusion lung scan, pulmonary angiogram, or CT lung scan within 72 hours of detection of symptoms or during autopsy (during the 3-month observation period)",2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
12689,NCT02606097,Overall clinical benefit rate,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),Changes in vital signs by body temperature
12690,NCT01626781,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
12691,NCT05052931,AE,2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
12692,NCT05552651,Rate of pCR,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of MPR,Rate of SAE
12693,NCT00675636,Identification of patients at high risk of developing hereditary colorectal cancer,2007-01,COMPLETED,OBSERVATIONAL,['NA'],Establishment of a tissue and data repository,
12694,NCT04123340,Feasibility of the use of co-registration software (>80%),2019-08-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Quantitatively assessed ablation margin,
12695,NCT03104439,Disease Control Rate,2017-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Median Overall Survival,
12696,NCT04212598,Percentage of patients with disease progression within 2 years after treatment,2020-08-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of patients who died within 2 years after treatment,The number of patients with treatment-related toxicity between the treatment period and half a year after treatment
12697,NCT02486094,"Apoptotic index, Ki67 and Geminin in cells per mm cubed from resected tumour",2015-06,COMPLETED,OBSERVATIONAL,['NA'],Overall Survival (OS),
12698,NCT02024633,The number of patients who suffer adverse events,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],Progression-free survival,
12699,NCT00590031,Pathologic Complete Response,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate Toxicity and Tolerability Including Surgical Morbidity and Mortality,
12700,NCT00004142,Patient Tumor Response Rate,1998-08-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12701,NCT06125145,Describe the percentage of participants that complete 2 out of 3 study visits,2024-03-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Quality of Life,
12702,NCT00952926,Frequency of local recurrence,2009-10,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
12703,NCT04653389,Event Free Survival（EFS）,2020-12-26,TERMINATED,INTERVENTIONAL,['PHASE2'],Tumor biomarker,
12704,NCT05827796,To evaluate the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in subjects with advanced pancreatic cancer.,2022-12-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of Treatment-Related AEs,
12705,NCT01051479,To evaluate our ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer (pre- and post- chemotherapy).,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Perform semi-quantitative analysis of tracer uptake using standard uptake values (SUV) and qualitative analysis using pure visual analysis.,
12706,NCT03519412,Overall response rate (ORR),2019-01-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and Tolerability,
12707,NCT01839877,Progression-free survival rate at 9 months,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
12708,NCT00912847,,1997-10,COMPLETED,OBSERVATIONAL,['NA'],,
12709,NCT00294476,"and Serum tumor markers as appropriate CEA, PSA. Additionally, ECOG performance status is evaluated before each treatment cycle",2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety assessments include Adverse events and laboratory values which are measured and evaluated before every treatment cycle,
12710,NCT04482309,Objective Response Rate (ORR),2020-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],The immunogenicity of T-DXd assessed by the presence of ADAs for T-DXd,
12711,NCT02849106,Number of interpretable chemogram,2011-05,COMPLETED,INTERVENTIONAL,['NA'],time to obtain chemogram,
12712,NCT02834052,Phase 1 and 2: Determine the response rate of metastatic MRP colon cancer (that has progressed following two lines of therapy in the metastatic setting) to the combination of pembrolizumab and poly-ICLC,2018-01-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determine the duration of response of recurrent metastatic MRP colon cancer to the combination of pembrolizumab and poly-ICLC,
12713,NCT01060501,overall survival,1992-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Toxicity (WHO),
12714,NCT05841134,Percentage of Participants With Pathological Complete Response (pCR),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events during the treatment and follow-up (safety),
12715,NCT02703142,"Number of participants with the major complications of gastric conduit (strictures, leakage, necrosis)",2015-10,COMPLETED,OBSERVATIONAL,['NA'],Biological examination of gastric conduit as assessed by the Mitochondrial DNA copy number,
12716,NCT04500171,ColoCARE Completion Efficacy,2020-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12717,NCT04771988,Response to radioembolization,2013-05-08,COMPLETED,OBSERVATIONAL,['NA'],Progression-free survival,
12718,NCT03043664,Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),2017-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",ORR as Measured by Immune-related Response Criteria (irRC),
12719,NCT04986085,Risk of malnutrition in GEP NET,2021-02-24,RECRUITING,OBSERVATIONAL,['NA'],Subjective Global Assessment (SGA) rates,
12720,NCT00636298,Progression-free survival,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Response rate,
12721,NCT05468138,3 year Disease Free Survival,2022-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],5 year Overall Survival,
12722,NCT04826406,Objective Response Rate (ORR),2021-02-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Safety as measured by the rate of AEs, SAEs and laboratory abnormalities",
12723,NCT02304289,"Pharmacokinetic analysis of Cmax, Cmin, Tmax, and AUC.",2014-11,TERMINATED,INTERVENTIONAL,['PHASE1'],"Quality of life based on the ""Functional Assessment of Cancer Therapy Hep-30 scale"" (FACT-Hep-30)",
12724,NCT05984602,Number of patients who proceeded to surgical resection,2023-07-14,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of changes in outcome of surgery that is attributed to study drug,
12725,NCT05318794,Feasibility and safety of combined neoadjuvant systemic chemotherapy and pressurised intraperitoneal aerosol chemotherapy (PIPAC),2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease recurrence and survival,
12726,NCT02539212,"Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and RFA was done by the log-rank test.",2008-10,COMPLETED,INTERVENTIONAL,['NA'],Wilcoxon test was used for comparing liver function between MWA and RFA.,
12727,NCT03759756,the diagnosis efficiency of the AI model,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
12728,NCT00429078,,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
12729,NCT04486131,Lateral local recurrence,2020-10-06,RECRUITING,OBSERVATIONAL,['NA'],Quality of life as assessed by the QLQ-C30,
12730,NCT06063941,Visual analogue scale scores at 30 minutes after chromoendoscopy,2023-10-10,RECRUITING,INTERVENTIONAL,['NA'],Associated factors for visual analogue scale scores,
12731,NCT01804166,Number of Samples Collected for the Identification of Biomarkers for Early Evaluation of Risk of Developing Hepatosplenic T-cell Lymphoma (HSTCL),2013-03-21,COMPLETED,INTERVENTIONAL,['PHASE4'],,
12732,NCT05360277,Disease-free survival,2023-08-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
12733,NCT06335420,Number and size of polyps found at the one-year follow up colonoscopy,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Acceptability of treatment,
12734,NCT02625623,Overall Survival (OS),2015-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22) Questionnaire Scores at End of Treatment (EOT),
12735,NCT00280176,Dose-limiting toxicity,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Gene expression pattern of tumors as assessed by cDNA microarray analysis pre- and post-treatment,
12736,NCT00149279,overall survival,1995-07,COMPLETED,INTERVENTIONAL,['PHASE3'],quality of life,
12737,NCT02041819,response rate,2014-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse events,
12738,NCT05113186,One-year local recurrence-free survival,2022-02-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Per nodule assessment of local recurrence,"Consittution of a sequential biobank comprising peripheral samples (serum, plasma)"
12739,NCT05770102,Durable Clinical Benefit (DCB),2023-10-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Mean change from baseline in the PedsQL 4.0 Standardised Area Under total Scale Score Curve (PedsSAUC) in parents from paediatric participants.,
12740,NCT00778830,Percentage of Subjects With Best Overall Confirmed Response Rate (BORR),2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation and TEAEs Leading to Death",
12741,NCT02018367,The diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRME with directed biopsy,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],"The diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of HRME for the in-vivo diagnosis of neoplasia.",The clinical impact of HRME on the diagnosis and endoscopic surveillance of BE- associated neoplasia
12742,NCT04915144,Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with Choi criteria.,2023-01-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Correlation of QoL scores (EQ-5D) to ctDNA,PFS and QoL scores to ctDNA levels
12743,NCT05599347,Anti-drug antibody development,2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Endoscopic remission,
12744,NCT03345563,Functional Assessment of Chronic Illness (FACIT)-Fatigue Scale,2019-07-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Consensus Sleep Diary,
12745,NCT01930630,Number of participants with adverse events,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],Efficacy of extraesophageal saline separating esophagus from adjacent organs detected by EUS or computerized tomography (CT) just after ESI,
12746,NCT00760604,"Disease free survival defined as the time from surgical resection to the time of recurrent disease, death from esophageal cancer, or death from any cause.",2008-09,TERMINATED,INTERVENTIONAL,['PHASE3'],To determine mortality and morbidity in arm A vs. arm B,
12747,NCT05575635,pCR,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],TRAEs,
12748,NCT04509635,disease control rate,2020-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],overall survival,
12749,NCT02469480,Rise or normalization of hemoglobin,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
12750,NCT04135664,5-year overall survival rate,2019-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life differences (EORTC QLQ-OES18),
12751,NCT02732860,Rate of pPDX engraftment,2015-12,RECRUITING,OBSERVATIONAL,['NA'],Correlation between pPDX and organoid drug sensitivities,
12752,NCT00325494,"Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs",2006-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Objective Tumor Response Rate Assessed by Investigator,
12753,NCT01891539,tumor response,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],time to progression,
12754,NCT06305169,Measurement of the specificity and negative predictive value of serum biomarkers in gastric cancer,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Creating a scoring system for patients that warrant urgent endoscopy on the cancer pathway,
12755,NCT04739046,Objective Response Rate,2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
12756,NCT00606983,Re-insertion rate of urinary catheter after removal,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Scores of IPSS (International Prostatic Symptom Score) and the results of uroflowmetry,
12757,NCT04584775,Change from baseline in FACT-G at week 4,2021-02,UNKNOWN,INTERVENTIONAL,['NA'],Change from baseline in FAMCARE-2 at week 4 and 8,Overall survival
12758,NCT05875584,"Evaluating the sensitivity, specificity, and accuracy of rbcDNA in colorectal cancer screening",2023-05-18,COMPLETED,OBSERVATIONAL,['NA'],"Sensitivity of the rbcDNA screening test with comparison to FIT, with respect to advanced adenoma (AA) and CRC",
12759,NCT02022852,Disease free survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Pathologic complete response,Compliance
12760,NCT03340636,occurrence of severe adverse effects (grades 3-5),2018-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12761,NCT03511183,Time to failure of strategy（TFS）,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Time to failure of strategy（TFS）,
12762,NCT02109341,Dose finding safety and activity,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Safety profile,
12763,NCT00395252,disease free survival,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
12764,NCT03702998,Incidence of HCC,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],Mortality due to HCC or liver-related conditions,
12765,NCT00160875,pathological complete response,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PET scan parameters (radiological),
12766,NCT04099641,Objective Response Rate (ORR),2019-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12767,NCT02384811,Local control rate,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety: Frequencies of treatment-related adverse event categories by NCI-CTC,
12768,NCT02002416,Overall survival,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],Positive rate of C-met,
12769,NCT05410197,Objective Response Rate (ORR),2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events (AE),
12770,NCT01733004,Severity and number of adverse events related to escalating doses of MM-141,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12771,NCT05625529,Clinical performance of ExoVerita™ assay,2022-12-19,RECRUITING,OBSERVATIONAL,['NA'],Stage Shift,
12772,NCT04906044,The incidence of serious adverse events,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Wexner score,
12773,NCT01980238,"anastomotic leakage, reoperation and mortality rate",2011-01,UNKNOWN,INTERVENTIONAL,['NA'],ileus rate,hospital stays and costs
12774,NCT01814345,Incidence of Her2 testing in Gastric cancer,2013-06,TERMINATED,OBSERVATIONAL,['NA'],,
12775,NCT04856787,Phase 3:PFS,2021-06-22,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Duration of response,
12776,NCT01212822,Disease-free Survival,2011-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival,Change in Biomarker Levels
12777,NCT03323866,Disease specific quality of life questionnaire,2017-05-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Endoscopic evaluation of the nasal cavities,
12778,NCT06033716,depression,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12779,NCT03809403,Presence of ctDNA,2019-02-05,UNKNOWN,OBSERVATIONAL,['NA'],MSI status,
12780,NCT00341523,esophageal squamous dysplasia and cancer,2016-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Death from any cause,
12781,NCT01126866,surgically complete resectability; S-CR,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Survival rate (OS) and progression free survival (PFS),
12782,NCT02472249,Liver blood flow,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
12783,NCT00591279,evaluate strategies for the surveillance of post-polypectomy patients,1981-02,COMPLETED,OBSERVATIONAL,['NA'],,
12784,NCT00003748,To determine the antitumor activity of irinotecan hydrochloride (CPT-11) in patients with unresectable adenocarcinoma of the esophagus and gastric cardia who have failed prior chemotherapy,1998-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate the toxicities of irinotecan hydrochloride (CPT-11) in the patient population,
12785,NCT00712855,"Type, frequency, and severity of adverse events.",2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12786,NCT05649969,Efficacy of STRONG Program on Treatment Outcomes,2022-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12787,NCT04913662,Recommended dose,2021-04-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
12788,NCT01662869,OS in the Intent-To-Treat (ITT) Population,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Score,
12789,NCT03358849,Maximum Tolerated Dose,2017-10-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12790,NCT00601627,One Year Survival Rate,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Treatment Failure,
12791,NCT02448810,Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT),2015-06-15,TERMINATED,INTERVENTIONAL,['PHASE2'],Change From Baseline for Quality of Life (QoL) Measure - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30),
12792,NCT00397904,Complete and Partial Response Rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12793,NCT03763526,postoperative complications,2018-12-20,COMPLETED,OBSERVATIONAL,['NA'],operative nutrition status,Length of hospital stay
12794,NCT02665702,Progression Free Survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12795,NCT00766220,Progression Free Survival,2009-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12796,NCT02435758,Sexual function,2015-04,COMPLETED,INTERVENTIONAL,['NA'],Urinary function,
12797,NCT00019435,,1998-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12798,NCT00797251,The primary outcome is the safety of the anatomical right posterior sectionectomy performed IOUS-guided finger compression.,2007-09,UNKNOWN,OBSERVATIONAL,['NA'],The secondary outcome is the efficacy of the anatomical right posterior sectionectomy performed by IOUS-guided finger compression.,
12799,NCT04741165,Objective Response Rate (ORR),2021-01-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events (AEs),
12800,NCT01308086,Relapse Free Survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Safety Profil according to NCI-CTAE v 3.0,
12801,NCT04401800,Overall Response Rate (ORR) as assessed by Central Imaging Facility based on RECIST v1.1,2020-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-Free Survival (PFS),
12802,NCT02980861,Number of group Splenic Hilum (No.10) lymph nodes harvested,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life,
12803,NCT01531621,Resectability,2012-02,RECRUITING,OBSERVATIONAL,['NA'],Radiological assessment,
12804,NCT00238407,Proportion of patients without local failure measured 6 months after completion of study treatment,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Dysphagia as measured 6 months after completion of study treatment,
12805,NCT01857726,Overall survival,2013-07,WITHDRAWN,INTERVENTIONAL,['NA'],Progression-free survival,
12806,NCT03210298,Overall survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],Quality of life according to QLQ-30 of EORTC,
12807,NCT05984511,Overall survival (OS),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adverse events (AEs),
12808,NCT00372567,Progression-Free Survival (PFS),2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS) - Imatinib Treatment Arm,
12809,NCT04416685,peri-operative or postoperative complication,2014-05-01,COMPLETED,INTERVENTIONAL,['NA'],hospital stay,in hospital mortality
12810,NCT03694080,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2018-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Cell proliferation as a marker for metastatic ability,
12811,NCT03484949,Diagnostic rate of patients with early gastric cancer,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Characterization of the high-rik individual for gastric cancer,
12812,NCT03488446,Pathological lymph node status of every station,2017-08-30,UNKNOWN,OBSERVATIONAL,['NA'],Lymph node stage (N stage),
12813,NCT02188615,Overall survival rate,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Mortality of perioperation,
12814,NCT01898104,number of patients with complete pathological tumor regression,2012-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",changes in quality of life from baseline,predictive and prognostic factors of tumor and circulating cells
12815,NCT03853928,Number of patients developing Hepatocellular carcinoma,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA'],Adverse events found in cirrhosis with or without treatment with probiotics.,
12816,NCT02607826,Response to therapy on MRI or CT scancs will be measured using the RECIST criteria version 1.1.,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,
12817,NCT01641783,progression free survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],biomarkers,
12818,NCT04910789,3-year disease-free survival,2019-12-11,RECRUITING,INTERVENTIONAL,['NA'],The incidence of perioperative mortality,
12819,NCT05102110,Correlation of SNP allele frequency in genes associated with known aero-digestive cancers in paired samples of tumour type and rectal mucus.,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
12820,NCT04890054,Likelihood of any colorectal cancer (CRC) screening (for study-eligible patients),2021-05-14,RECRUITING,INTERVENTIONAL,['NA'],Colonoscopy referral,
12821,NCT02222259,Quality of life,2014-09,COMPLETED,INTERVENTIONAL,['NA'],Functional status,
12822,NCT05943288,Positive Predictive Value (PPV),2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],Endoscope withdrawal time,Non-neoplastic resection rate
12823,NCT03981146,Durable Clinical Benefit,2019-08-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival Time,
12824,NCT00400114,"To determine the feasibility and efficacy of adjuvant Sutent therapy after concurrent neoadjuvant therapy with Irinotecan, Cisplatin, external beam conformal radiotherapy plus surgery for potentially resectable esophageal cancer.",2006-09-25,COMPLETED,INTERVENTIONAL,['PHASE2'],To determine the pattern of relapse (local versus distant) with the addition of adjuvant targeted therapy to esophageal cancer multimodality therapy,
12825,NCT04070898,Development of acute urine retention after removal of the bladder catheter after colon surgery.,2019-09-15,UNKNOWN,INTERVENTIONAL,['NA'],Morbidity changes,
12826,NCT00726622,Comparing Laparoscopic-assisted Resection to Open Rectal Resection for Rectal Cancer as Measured by the Percentage of Patients With Successful Resection Based on Pathological Evaluation.,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Bowel and Stoma Function,
12827,NCT04853784,Incidence of postoperative complications,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],5-year overall survival OS,
12828,NCT05059821,Assessment of immunological response,2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression free survival and overall survival time,
12829,NCT05620004,"Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0.""",2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in tumor volume before and after treatment,
12830,NCT03648632,Resection rate for all patients starting SBRT,2018-08-22,COMPLETED,INTERVENTIONAL,['NA'],Mortality,
12831,NCT01412684,Splenic function,2011-09,WITHDRAWN,OBSERVATIONAL,['NA'],Lymph node retrieval,
12832,NCT04722341,Patient-reported outcomes (PROs),2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Sleep,
12833,NCT03533582,Response rate for Group F patients,2018-05-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Percentage of participants with adherence to surgical guidelines
12834,NCT06163729,Pathologic complete response (PCR),2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE2'],R0 resection rate,
12835,NCT03485105,overall survival,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12836,NCT03592407,Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0,2018-07-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
12837,NCT03781323,Proportion of Patients With a Complete Clinical Response.,2019-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of Patients With Survival,
12838,NCT05275530,Overall completion of any Colorectal Cancer Screening test,2022-02-21,COMPLETED,INTERVENTIONAL,['NA'],Colorectal cancer screening uptake by modality,
12839,NCT04348188,Changes in Health Related Quality of Life: EORTC QLQ-30,2020-06,UNKNOWN,INTERVENTIONAL,['NA'],Valuation of the measured force,
12840,NCT02226107,Colonoscopy Completion,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,
12841,NCT06264921,Objective Response Rate (ORR),2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Accumulation ratio (AR),
12842,NCT00770991,Change in Burden of Rectal Polyps,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Apoptosis and Cell Proliferation Measured by Percent Difference in Staining.,
12843,NCT04937647,neoplasia detection rate,2021-06-16,RECRUITING,OBSERVATIONAL,['NA'],Endoscopist neoplasia detection rate,
12844,NCT06109272,Stage 2: Overall Survival (OS),2024-01-11,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Change from Baseline in Global Health Status (GHS)/Quality of Life (QoL) Domain as Measured by the GHS/QoL Domain of the EORTC QLQ-C30,
12845,NCT05507112,Pathological complete response (pCR) rates,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Patient reported outcome: Functional outcome according to Wexner score,
12846,NCT01827553,Overall survival,2013-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Changes in Quality of life,
12847,NCT05866172,overall survival,2023-05-10,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse Events,
12848,NCT05497336,Objective response rate (ORR),2022-08-18,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of participants with abnormality in ECG parameters,
12849,NCT00717756,Response Rate by Recist Criteria,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12850,NCT01683240,Efficacy of cholangioscopy in gallstone therapy and stricture diagnosis,2011-02,COMPLETED,INTERVENTIONAL,['NA'],Stricture diagnostic,
12851,NCT00495924,,2006-10,COMPLETED,OBSERVATIONAL,['NA'],,
12852,NCT01840436,Incidence of grade 2 or higher oral mucositis,2013-03,COMPLETED,INTERVENTIONAL,['NA'],Weight curve,
12853,NCT02647125,Local control rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],progress-free survival,
12854,NCT03484221,The ratio of tumor downstaging to stage 0 and stage I,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life (QLQ C30),
12855,NCT00022477,Response rate of BMS-247550 in colon cancer,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12856,NCT06084481,Objective Response Rate (ORR),2023-11-09,RECRUITING,INTERVENTIONAL,['PHASE1'],Neutralizing Antidrug Antibody (nADA),
12857,NCT01938300,Change of MCF of EXTEM,2011-06,COMPLETED,INTERVENTIONAL,['NA'],Change of Fibrinogen,
12858,NCT02945566,Phase III Primary Outcome: Organ Preservation,2017-06-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Phase III: For analyses incorporating the non-randomised standard surgery comparator - Decision Regret,
12859,NCT02084524,Perioperative nutritional management,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],Evolution of the activities of daily living,
12860,NCT06030622,Primary Outcome: Safety and tolerability,2023-12-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Secondary Outcome: Biomarkers,
12861,NCT01195415,Median Percent at Baseline and 3 Weeks in CD44+/ CD24+/ ESA+ Cells From Needle Biopsy Calculated Using FACS,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Treated Patients Experiencing Grade 3+ Toxicity Per National Cancer Institute Common Toxicity Criteria (CTC) Version 3.0,
12862,NCT03351959,Overall Survival,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Molecular Profile of N+,
12863,NCT04651634,Incidence of severe OM,2021-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Analgesic use for OM,
12864,NCT04763707,serum Visfatin & serum Vaspin levels,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
12865,NCT00220142,,2003-11,COMPLETED,OBSERVATIONAL,['NA'],,
12866,NCT04773626,Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient.,2021-06,UNKNOWN,OBSERVATIONAL,['NA'],,
12867,NCT01523457,Progression Free Survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"Correlate Time to Progression, Objective Response, and Overall Survival With Early Changes in Glucose Metabolism Using FDG-positron Emission Tomography (PET) Scanning",
12868,NCT02988440,Dose intensity,2017-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Area Under the Plasma Concentration-time Profile (AUCtau) of sorafenib,
12869,NCT03958188,Standardization of a reading grid for PreOPerative Imaging of NeuroEndocrine Tumors,2019-03-31,UNKNOWN,OBSERVATIONAL,['NA'],,
12870,NCT04598984,The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients with Rectal Cancer,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
12871,NCT00247676,Objective Response (CR or PR),2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma Concentration of Soluble KIT (sKIT),
12872,NCT00493883,Survival time,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12873,NCT00581724,Descriptive statistics will be generated to describe the prevalence of pain and its psychosocial correlates.,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,
12874,NCT05475301,Overall survival of patients with locally recurrent rectal cancer,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12875,NCT01847495,Number of participants with adverse events related to toxicities from concurrent SBRT and irinotecan,2013-10,WITHDRAWN,INTERVENTIONAL,['NA'],Overall survival,
12876,NCT04720924,Detection rate of early cancer and precancerous lesions on upper gastrointestinal tract confirmed by pathological examination,2021-01-16,UNKNOWN,INTERVENTIONAL,['NA'],"Detection rate of early cancer and precancerous lesions on upper gastrointestinal tract from senior, intermediate and primary endoscopist with assistance of AQCS.",
12877,NCT02608879,Oral Mucositis Severity - NCI Scale,2014-03,COMPLETED,INTERVENTIONAL,['NA'],Change in Quality of Life as Measured by the Composite Score of the EORTC,
12878,NCT01718626,Progression-free survival(PFS),2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival(OS),
12879,NCT03948100,Patient 6-minute walk test (6MWT),2018-12-20,RECRUITING,INTERVENTIONAL,['NA'],Patient and caregiver quality of life (QOL),
12880,NCT00763776,Intra-operative blood loss during liver transection (ml).,2008-07,TERMINATED,INTERVENTIONAL,['NA'],60-day postoperative complications,
12881,NCT02280694,The median progression free survival (mPFS),2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12882,NCT02443324,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs),2015-07-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab,
12883,NCT05225116,Number of patients who complete pre-op treatment and proceed to surgery,2023-01-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Recurrence free survival(RFS),
12884,NCT01350648,Progression of liver disease in patients with HBV,2011-08-23,COMPLETED,OBSERVATIONAL,['NA'],,
12885,NCT02683824,Dosimetry of [18F]FP-R01-MG-F2 (mSv/MBq),2016-01-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12886,NCT02298010,Topographic pattern of metastasis to regional lymph node stations,2016-01,COMPLETED,OBSERVATIONAL,['NA'],recurrence pattern,
12887,NCT04517708,Change of quality of life after 8 weeks: European Organisation for Research and Treatment of Cancer (EORTC) version 3.0,2016-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
12888,NCT04997850,Conversion resection rate,2020-05-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE1', 'PHASE2']",OS,
12889,NCT03749005,Impact on operation strategy of three dimensional visualization technique,2017-04-18,UNKNOWN,OBSERVATIONAL,['NA'],1-year disease free survival rate,
12890,NCT05755685,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2023-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],the recurrence rate of metastasis and long-term survival of participants accepted the treatment of rmhTNF in the treatment of peritoneal metastases in colorectal cancer.,
12891,NCT04115618,Toxicity Effect,2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],OS,
12892,NCT01741597,Change in volume transfer coefficient (Ktrans) during DCE-MRI with tumor-homing peptide iRGD compared to a baseline DCE-MRI without tumor-homing peptide iRGD,2014-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],The potential for tumor-homing peptide iRGD to enhance uptake of key anti-cancer agents,
12893,NCT00003057,,1997-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12894,NCT04658147,Number of patients who complete pre-op treatment and proceed to surgery,2021-05-28,RECRUITING,INTERVENTIONAL,['PHASE1'],Disease free survival (DFS) at 5 years,
12895,NCT05506696,25OHD level,2012-09-24,COMPLETED,INTERVENTIONAL,['NA'],,
12896,NCT05774964,Progression Free Survival (PFS),2023-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12897,NCT06152289,Develop an artificial intelligence solution to help with diagnosis in VCE,2023-02-10,RECRUITING,OBSERVATIONAL,['NA'],Evaluation of the diagnostic performance of the A.I. solution in terms of quality of preparation of the various segments of the digestive tract,
12898,NCT01882920,rate of abdominal complications,2010-06,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival,length of hospital stay
12899,NCT04907539,RXC004 + nivolumab Combination: Objective response rate (ORR) using each patients BOR according to RECIST 1.1,2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of patients with adverse events (AEs),
12900,NCT00005938,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12901,NCT01065805,Phase II: To determine general biodistribution of 18F-FLT and correlate 18F-FLT uptake with hENT1 expression and Ki-67 scores.,2009-03-20,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Phase II: to correlate 18F-FLT uptake with patient outcomes (treatment response, progression-free survival, overall survival), over the first 12 months of follow-up after completion of tx, subsequently over the remainder of the disease course",
12902,NCT05035108,The incidence of adverse events (safety and tolerability).,2020-11-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Electrolyte level,
12903,NCT04615312,To determine the maximum tolerated dose of a CDK4 / 6 inhibitor and a MEK inhibitor therapy,2020-11-14,UNKNOWN,INTERVENTIONAL,['PHASE1'],ORR,
12904,NCT00209716,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.,
12905,NCT04338685,Number of Participants with Adverse Events (AEs) According To NCI CTCAE v5.0,2020-07-16,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
12906,NCT05664906,Comparison of the proportion of the most severe modified WHO Mucositis Grades,2023-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of analgesic and antibiotics use daily,
12907,NCT02647047,Assessment of postoperative pain control by mean of the visual analog scale at hospital discharge,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Ready to discharge status,
12908,NCT01952353,overall survival time,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of Adverse Events,
12909,NCT02089386,Extent of Barrett's involvement and changes in histology,2014-07-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Changes in the length of Barrett's esophagus involvement,
12910,NCT05579340,Change in peak oxygen consumption (VO2peak),2023-04,RECRUITING,INTERVENTIONAL,['NA'],Postoperative complications,
12911,NCT05703555,intratumoral DM4 concentration,2024-02-16,WITHDRAWN,INTERVENTIONAL,['PHASE2'],features in tumor micro-environment,
12912,NCT01225744,Objective response rate (according to RECIST criteria),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to progression (TTP),
12913,NCT00044343,Tumor response rate (complete or partial).,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to response duration of response time to progression 4-month progression-free survival 6-month progression-free survival overall survival safety data biomarkers,
12914,NCT05631015,The accuracy of recommentions for different disease with deep learning algorithm,2012-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],The F-score of gastric diseases with deep learning algorithm,
12915,NCT01608464,Pathological Complete Response ( regression score 1a- see response assessment) in each treatment group,2012-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Rate of conversion from PET non responder to responder with each type of salvage therapy,
12916,NCT04439812,evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.,
12917,NCT01417494,"Tolerance, in terms of no grade 4 arterial hypertension, grade 3-4 thromboembolic event, grade 3-4 cardiac insufficiency, and hospitalization not related to chemotherapy",2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival with no deterioration of autonomy,
12918,NCT00752570,To estimate the treatment effect as measured by progression free survival (PFS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo.,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"To evaluate patient reported outcomes (PROs), relative dose intensity, incidence of anti AMG 386 antibody formation, pharmacokinetics of AMG 386 (Cmax and AUC) and safety (incidence of AEs and significant laboratory changes)",
12919,NCT03286920,Percentage of 5% body weight loss on Day 30,2017-09-20,UNKNOWN,OBSERVATIONAL,['NA'],Re-hospitalization ratio,
12920,NCT03455595,Evaluation of the CONECCT endoscopic score so as to improve colon therapeutic treatment polyps,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
12921,NCT03263741,Objective response rate(ORR),2017-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease control rate(DCR),
12922,NCT00335595,Determine the free time to disease progression,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Prognostic factor of the K-Ras gene mutation,
12923,NCT02929082,Tumoral environment invasion assessed by the presence of microvascular invasion of the tumor capsule after pathological examination of the surgical pieces,2018-01-23,COMPLETED,INTERVENTIONAL,['NA'],Interstitial force and traction force at the cell/tumor interface assessed by FRM,
12924,NCT02576080,Rate of metastatic relapse in GIST patient,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Patients' quality of life,
12925,NCT01586117,Acute radiation-induced toxicity: daily diarrhea frequency,2012-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12926,NCT00183846,"To determine the maximum tolerated dose of irinotecan when administered as a 5-day continuous infusion with concomitant radiation therapy in patients with upper gastrointestinal tumors (pancreas, stomach, duodenum, and common bile duct)",2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],To obtain preliminary information related to the efficacy of this combination,
12927,NCT03992456,Overall survival (OS),2020-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Patient-reported quality of life,Tumor tissue studies
12928,NCT03867916,Rate of Participation,2018-12-13,COMPLETED,INTERVENTIONAL,['NA'],Patient Acceptability,
12929,NCT02711553,Progression Free Survival (PFS),2016-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change From Baseline in Participant-Reported EQ-5D-5L Visual Analog Scale (VAS) Score,
12930,NCT01505413,Response rate,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
12931,NCT03051464,TME-free survival,2017-04-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall Quality of life,
12932,NCT01995227,Safety,2013-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumor Biomarker Status,Overall Survival (OS)
12933,NCT00338039,Median Overall Survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12934,NCT02117895,Overall survival,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Disease-specific, recurrence-free survival",Pain Control
12935,NCT04636008,Adverse reaction,2020-08-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of life questionnaire,
12936,NCT00281996,Overall survival at 6 months,2005-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
12937,NCT04190121,infective complications,2019-03-26,UNKNOWN,INTERVENTIONAL,['NA'],length of stay in the ICU,patient's serum albumin changes
12938,NCT05573217,Evaluate efficacy,2021-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
12939,NCT01918852,Incidence of HFS in first line treatment,2013-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Response rate,
12940,NCT02339116,Progression Free Survival 2 (PFS2),2015-02-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],Toxicity Rate,
12941,NCT01626963,Operative Time,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",CRP,
12942,NCT01655641,Primary objective of the study is to compare transfusion requirements and Mortality in patients receiving Tranexamic acid (Cyklokapron®) and those not receiving it.,2012-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Secondary outcome measure,
12943,NCT04523662,PFS,2020-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12944,NCT04913896,Predictive value of CT and MRI after the neoadjuvant treatment for developing a pCR at surgery,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],Prediction model based on CT and MRI of response in AGC,
12945,NCT03078348,Rate of Fecal Immunochemical Test (FIT) Kit Return Per Study Arm,2011-12-05,COMPLETED,INTERVENTIONAL,['NA'],Rate of Diagnostic Colonoscopy,
12946,NCT00178698,Survival,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of Life,
12947,NCT04391426,Composition of the biliary microbiota,2021-06-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12948,NCT03556345,Objective Response Rate （ORR）,2018-07-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival(OS),
12949,NCT05883644,Objective response rate (ORR),2023-06-27,RECRUITING,INTERVENTIONAL,['PHASE3'],Change from baseline in HRQoL as assessed by EORTC QLQ-HCC18,
12950,NCT05481463,Progression-Free Survival (PFS),2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE2'],adverse events (AE),
12951,NCT01859442,Exponential rate constant of post-chemoradiotherapy and post-exercise phosphocreatine recovery.,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Alterations in mitochondrial energetics post-chemoradiotherapy and exercise,
12952,NCT05356039,Resection,2022-04-19,RECRUITING,OBSERVATIONAL,['NA'],Quality of Life at 24 months after inclusion,
12953,NCT04415567,Disease-free survival (DFS),2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],Overall survival (OS),3-year Recurrence rate (RR)
12954,NCT04743479,Hazard ratio (HR),2020-12-01,RECRUITING,OBSERVATIONAL,['NA'],Diagnostic yield,
12955,NCT05078866,Rates of grade 2/3 adverse events and symptom reactivity following revaccination (Cohort II),2022-11-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Mismatch repair and/or microsatellite instability status of polyps (and adjacent normal mucosa as control),
12956,NCT01443377,Histopathological complete response rate (pCR),2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival,
12957,NCT05379205,Post-surgery complications.,2022-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Fecal microbiota analysis,
12958,NCT03273231,natural killer cell cytotoxicity,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],metastasis,
12959,NCT04095299,Rectal preservation at two years,2020-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Frequency of grade 3-4 toxicity according to CTCAE v4,
12960,NCT04856423,The accuracy of us-qFIT to diagnose colorectal advanced adenoma.,2021-04-19,UNKNOWN,OBSERVATIONAL,['NA'],Develop a predictive model of advanced colorectal neoplasms which includes the value of us-qFIT.,
12961,NCT00030563,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12962,NCT02002299,invasive front growth pattern,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],,
12963,NCT03150628,Mortality,2017-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Readmissions,
12964,NCT01300858,Tumor Growth Assessment by X-ray/CT,2011-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of study subjects with adverse events,
12965,NCT00052559,Maximum tolerated dose of bevacizumab when administered concurrently with 5-fluorouracil (5-FU) and external beam radiation therapy (EBRT) in patients with cT3 and T4 rectal cancer prior to surgery,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival,
12966,NCT00004150,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12967,NCT01375699,The difference in left ventricular ejection fraction (LVEF) between arms,2011-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Comparison of candidate early markers of cardiac injury,
12968,NCT02652702,colostomy associated complications,2016-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,
12969,NCT06190730,SASSI,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
12970,NCT03943173,Feasibility of olaparib,2019-06-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Symptom burden and health status,
12971,NCT03041662,death,2011-10-31,COMPLETED,OBSERVATIONAL,['NA'],biliary dysplasia,
12972,NCT00054951,,2001-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12973,NCT02146313,Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs),2014-06-22,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression-free Survival (PFS) as Assessed by RECIST v1.1,
12974,NCT01372787,"Prevalence and severity of patient-reported symptoms as measured by the NFOSI-18, the FACIT-F subscale, and the FACT/GOG-AD and NTX subscales",2011-04-12,UNKNOWN,OBSERVATIONAL,['NA'],,
12975,NCT04947930,Sensitivity and specificity of the screening tool generated from fecal metagenomics and metabolomics data.,2021-07,UNKNOWN,OBSERVATIONAL,['NA'],,
12976,NCT02387268,Safety as Measured by Number of Serious Adverse Events and Major Complications.,2015-05,COMPLETED,INTERVENTIONAL,['NA'],Percentage of Participants in Whom the Cecum Was Reached,
12977,NCT04710641,Progression free survival (PFS),2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
12978,NCT00792285,colorectal cancer screening,2005-03,COMPLETED,INTERVENTIONAL,['NA'],colonoscopy screening,
12979,NCT03413605,Colorectal Cancer Screening Rate,2016-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
12980,NCT06092112,The objective response rate based on mRECIST,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Overall Survival,The impact of CD-801 treatment on immune cell profiling in serum after treatment.
12981,NCT02906943,Utilization rates of molecular profiling information provided to treating physicians in guiding future treatment decisions,2016-08,RECRUITING,OBSERVATIONAL,['NA'],Concordance between administrative data and clinically abstracted data comparing variables using 2x2 concordance tables,
12982,NCT04566848,Immune Checkpoints,2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
12983,NCT03008512,Progression-free survival rate at 6 months,2016-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Adverse events,
12984,NCT01075399,Reproducibility of [F18]HX4 PET Imaging in Measuring Hypoxia in Tumors,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12985,NCT02457299,The number of participants with gastric conduit failures as a measure of safety and tolerability in the one-stage esophagectomy as compared with the two-stage esophagectomy.,2015-05,TERMINATED,INTERVENTIONAL,['NA'],Quality of Life (QOL) scores of patients in both arms,
12986,NCT02644408,Quality of Life (QoF),2014-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],adverse events,
12987,NCT00526669,Percentage of Participants (Par.) With 5-month Progression-free Survival (PFS),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"Number of Participants With Change From Baseline (Measured as AGI, ItoG3, and ItoG4) in Toxicity Grades for White Blood Cell (WBC) Count at the Indicated Time Points",
12988,NCT04659005,HCC screening uptake rates,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],Decisional conflict scale,
12989,NCT03120572,Change of forced vital capacity (FVC),2013-08,COMPLETED,OBSERVATIONAL,['NA'],Change of dyspnea,
12990,NCT00454376,"Reliability, scaling, scale correlation, and clinical validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21)",2006-10,UNKNOWN,OBSERVATIONAL,['NA'],Response to change after various treatments,
12991,NCT00691691,Response rate to SBRT,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Treatment Related Toxicity,
12992,NCT03487484,Change in quality of life specific for the gastrointestinal tract,2018-03-22,TERMINATED,OBSERVATIONAL,['NA'],Change in faecal Incontinence,
12993,NCT05513144,The sensitivity and specificity of ctDNA detection. Profiling of the most frequently detected gene mutations and level of mutations in ctDNA,2021-12-24,RECRUITING,OBSERVATIONAL,['NA'],Relative frequency of targetable mutations (incl. TMB and MSI status).,
12994,NCT03777657,Overall Survival (OS),2018-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],time to response (TTR),
12995,NCT00593866,The Maximum Tolerated Radiation Dose,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The Percentage of Participants Free From Local Progression at 2 Years,
12996,NCT04161755,Drug related toxicity,2019-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12997,NCT00059618,Maximum Tolerated Dose (MTD) of Bortezomib with Carboplatin Chemotherapy,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12998,NCT06159634,Dissection speed,2023-12-05,RECRUITING,INTERVENTIONAL,['NA'],Abdominal pain,
12999,NCT05909410,Perception about the impact of CHCs on favoring/contrasting specific symptoms onset,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13000,NCT01238094,Progression free survival,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13001,NCT05686226,Tumor response,2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
13002,NCT02843750,Postoperative Pneumonia,2016-06,WITHDRAWN,INTERVENTIONAL,['NA'],Postoperative Pulmonary Complications,Quality of Life
13003,NCT03563651,"Detection rates of Kras, Braf, or PI3K tumor DNA extracted from urine in patients without pre-existing mutations",2014-02-06,COMPLETED,OBSERVATIONAL,['NA'],,
13004,NCT04008056,Authorization for preparation of chemotherapy based on patient reported outcome (decision 3),2019-11-16,COMPLETED,OBSERVATIONAL,['NA'],Patient satisfaction with the patient reported outcome questionnaire,
13005,NCT03458689,"Use of analgesics - ""change"" is being assessed",2018-02-28,UNKNOWN,INTERVENTIONAL,['NA'],"Sedation scores - ""change"" is being assessed",
13006,NCT06056908,"Provide education on the diagnosis, medical management, and treatment of SDS/SDS-Like conditions for patients, families, and the medical/scientific community.",2016-01-19,RECRUITING,OBSERVATIONAL,['NA'],,
13007,NCT00185588,Time-to-Treatment Failure (Intent-To-Treat Analysis),2004-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Time-to-Progression, Evaluable Patients",
13008,NCT06206382,Mortality,2024-01-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Morbidity,
13009,NCT02513199,Number of Participants With Objective Response Rate,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Child-Turcotte-Pugh (CTP) Score,
13010,NCT01642953,Drop rate from critical pathway,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Recovery after surgery,
13011,NCT00084617,Response Rates (RR) in Metastatic Gastric/GE Junction Tumors,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
13012,NCT02509507,Part 2 Only: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE),2016-02-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13013,NCT02952989,Incidence of dose-limiting toxicities (DLTs),2017-02-23,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall survival,
13014,NCT04456933,Percentage of anastomotic leak (AL),2020-06-29,UNKNOWN,OBSERVATIONAL,['NA'],Rate of Re-interventions,
13015,NCT02945033,"Number of patient with local or distant recurrence or second colorectal cancer or death from any cause, whichever occurred first",2018-07-12,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of participants with treatment-related adverse events,
13016,NCT05111626,Part 2: Overall Survival in FGFR2b ≥ 10% 2+/3+ Tumor Cell Staining Participants,2022-03-14,RECRUITING,INTERVENTIONAL,['PHASE3'],Part 2: Number of Participants With Anti-Bemarituzumab Antibody Formation,
13017,NCT04587128,Cohort B Progression Free Survival (PFS),2020-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),Circulating Tumor DNA (ctDNA) at time of Progression
13018,NCT02730546,Pathological Complete Response (PathCR) Rate,2016-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of Dose-limiting Toxicities (DLTs) Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0,
13019,NCT03476122,Detection of circulating tumor cells,2018-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,
13020,NCT01860742,Progression Free Survival (PFS),2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],"Tumor 18FDG PET/CT and 68Ga-octreotate PET/CT uptake at baseline, at mid and end of treatment",
13021,NCT00190801,Response rate according to RECIST criteria,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],The quantitative and qualitative toxicity of pemetrexed plus cisplatin in this patient population,
13022,NCT03074461,Stool frequency,2017-04-05,UNKNOWN,INTERVENTIONAL,['NA'],Antimotility drug usage,
13023,NCT02541461,Change in body composition (changes in lean tissue mass and fatty tissue mass Using DEXA machine produced by Hologic),2015-05,COMPLETED,INTERVENTIONAL,['NA'],Changes in lipid profile,
13024,NCT05964530,Overall disease-free survival,2023-04-19,RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
13025,NCT00376948,Median Overall Survival Estimate,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],pAKT (Pichia Anomala Killer Toxin) and NF (Nuclear Factor)-kappaB Activation,
13026,NCT01677312,Median Number of Passes to Establish Diagnosis,2012-08,COMPLETED,INTERVENTIONAL,['NA'],Complications,
13027,NCT05169177,Standard deviation of difference between software and ground truth measure,2022-10-17,RECRUITING,OBSERVATIONAL,['NA'],Modelling of patient or treatment features that contributed to the success or failure of the KIM method,
13028,NCT03291938,Maximum tolerated dose,2017-11-13,COMPLETED,INTERVENTIONAL,['PHASE1'],Duration of response,Pharmacodynamic and predictive biomarkers of activity of IACS-010759
13029,NCT04520906,Complete tumor ablation rate,2020-12-17,UNKNOWN,INTERVENTIONAL,['NA'],Complete ablation rate of lesions,
13030,NCT04323813,Assessments of diagnosis of CRC by EMT-TF mRNA levels in blood,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],Prediction of prognosis of CRC by EMT-TF mRNA levels in blood,
13031,NCT05933980,ORR,2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE2'],DoR,
13032,NCT05664607,Harris Benedict Equation,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
13033,NCT00003103,,1997-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13034,NCT03431428,OS,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],QOL,
13035,NCT04324307,ORR,2019-11-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",OS,
13036,NCT00436423,Response rate by RECIST criteria,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"Evaluate the following efficacy measure Duration of response,Time to treatment failure,Time to documented disease progression, Overall survival",
13037,NCT02291744,"TFS time of failure of strategy (the second progression time after induction therapy, or time to the use of second line strategy (if no reapplication of induction therapy) or time to no further treatment)",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13038,NCT02403531,overall response rate (clinical complete response and partial response),2015-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival,
13039,NCT02240771,Survival rate-,2006-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Tumor response,
13040,NCT02545556,Number of participants with Adverse events,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
13041,NCT06065891,Prevalence of paraaortic lymph nodes in pancreatic cancer in patients submitted to a tentative curative resection,2023-09-05,RECRUITING,INTERVENTIONAL,['NA'],To address the question of how to optimize the frozen section analyses (lgll station 16) as related to the final pathology report?,
13042,NCT01681472,Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of AEs Per Severity,
13043,NCT06134973,Application prospect of liquid biopsy technique in monitoring HCC in high risk population,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
13044,NCT05485974,"adverse events (AEs), and serious adverse events (SAEs) overall",2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacokinetic variables including volume of distribution,
13045,NCT05420558,early postoperative recurrence,2022-06-23,RECRUITING,OBSERVATIONAL,['NA'],diagnostic performance,
13046,NCT05707598,Hospital stay after surgery,2023-01-01,COMPLETED,OBSERVATIONAL,['NA'],Disease-free survival,
13047,NCT02038283,Direct Health Care Costs for each CRC screening strategy,2009-10,COMPLETED,OBSERVATIONAL,['NA'],Factors Associated with HRQOL,
13048,NCT00470340,Survival without recurrence at 2 years,2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Morbidity and mortality following adjuvant treatment,
13049,NCT02583087,Rate of histologically complete (R0) resection of esophageal adenocarcinoma or high grade dysplasia,2016-01-02,UNKNOWN,OBSERVATIONAL,['NA'],rate of buried glands,
13050,NCT03176680,Postoperative complications,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA'],Inflammatory markers,
13051,NCT05107661,: Colorectal Screening Strategies in the High Risk Medically Underserved Population in a Hospital-based Community Outreach Program,2021-09-26,TERMINATED,OBSERVATIONAL,['NA'],Colorectal Screening Strategies in the High Risk Medically Underserved Population in a Hospital-based Community Outreach Program,
13052,NCT05302557,Ileus,2021-12-09,RECRUITING,INTERVENTIONAL,['NA'],Hospital readmission,
13053,NCT00273312,Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST),2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
13054,NCT04053725,the proportions of patients with positive serum ctDNA that have postoperative relapse,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],The proportion of ctDNA content decreased in patients with good therapeutic effect,
13055,NCT05759858,Disease-free survival,2022-12-14,RECRUITING,OBSERVATIONAL,['NA'],"The incidence and mortality of postoperative hemorrhage, bile leakage and other complications.",
13056,NCT00577031,PFS: Time to Event,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score,
13057,NCT03997162,Rate and type of post-operative complications,2018-10-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],QoL after stomach cancer surgery,Overall survival of enrolled patients
13058,NCT02350517,Progression free survival,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life,
13059,NCT01236053,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,
13060,NCT05170438,Overall response rate,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-free survival (PFS),
13061,NCT02798224,CRC Screening use,2017-06-14,COMPLETED,INTERVENTIONAL,['NA'],,
13062,NCT00375661,Incidence of adverse effect of interferon,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13063,NCT03637647,Fitness,2012-06-01,COMPLETED,OBSERVATIONAL,['NA'],Sarcopenia defined by skeletal muscle radiation attenuation,
13064,NCT03199586,Establish the safe recommended phase 2 dose,2017-12-21,COMPLETED,INTERVENTIONAL,['PHASE1'],Cmax,
13065,NCT01361061,development of HCC,2010-06,COMPLETED,OBSERVATIONAL,['NA'],"comparison of these liver cancer markers (AFP, AFP-L3% and DCP) between different etiologies",
13066,NCT04751149,to compare the incidence of acute urine retention after removal of the urinary catheter in the postoperative period of rectal resection.,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA'],Incidence of postoperative complications,
13067,NCT05836870,Safety and adverse events (AEs),2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE3'],,
13068,NCT01883297,Number of occurrences and severity of side effects,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Number of patients with an immunity and no immunity to the study treatment,
13069,NCT02240433,Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT),2014-11-12,COMPLETED,INTERVENTIONAL,['PHASE1'],"The Number of Participants with Best Response of Partial Response (PR), Complete Response (CR), Stable Disease (SD), or Progressive Disease (PD)",
13070,NCT05573035,Determine recommended Phase 2 Dose Range (RP2DR),2022-12-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
13071,NCT04709380,TTP,2021-03-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence of grade 3 and above adverse events,
13072,NCT00826579,To assess the extent of upstaging due to the SLN procedure for colon cancer.,2000-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To evaluate the accuracy of the SLN procedure for colon cancer. To identify factors influencing the success of the procedure. To correlate SLN results with the presence of colon cancer cell in bone marrow aspirates. To assess OS and DFS.,
13073,NCT00397787,Response (CR/PR/stable disease) as measured by RECIST criteria,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
13074,NCT03843229,tumor size,2019-01-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],"Interleukin(IL)-2,Interleukin(IL)-4,Interleukin(IL)-6,tumor necrosis factor(TNF)-α，interferon(INF)-γ in blood",
13075,NCT02286492,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
13076,NCT04840186,Median overall survival,2021-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life,
13077,NCT02858778,The difference in the percentage of patients with a completed advance directive (AD) in Ig vs.Cg,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],Time to consultation in Ig vs. Cg groups,
13078,NCT05802420,Progression-free survival,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],Overall survival,The prognostic role of targeted therapy selected based on MRD
13079,NCT05259384,Complication Rate,2021-04-17,RECRUITING,INTERVENTIONAL,['NA'],The rate of spleen-preservation,
13080,NCT00098527,Radiographic response rate (complete response & partial response),2004-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in plasma and urine TGFB levels,
13081,NCT00003365,,1996-08,TERMINATED,INTERVENTIONAL,['NA'],,
13082,NCT05066048,Species composition of fecal microbial,2021-04-30,UNKNOWN,OBSERVATIONAL,['NA'],age in year,
13083,NCT01628458,Safety,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Chemotherapy,
13084,NCT02391662,Efficacy of treatment through 3-months deterioration free rate,2015-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],CA 19.9 biomarker response,
13085,NCT04181333,The incidence of adverse drug reactions in this surveillance,2023-08-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Assessment of tumor response: Assess the tumor response according to RECIST Ver. 1.1.,
13086,NCT02350400,Establish safety and toxicity profile of the irinotecan loaded DEBIRI beads (number of patients with adverse events according to Health Science Authority's Safety Reporting for Clinical Trials),2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumour response (measured by mRECIST),
13087,NCT06088940,Effects of probiotic on depression symptoms,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Probiotic effects on gut microbiota differential taxonomic abundance,Relationships between bacterial taxa and symptoms
13088,NCT05853172,R0 surgical conversion rate,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse event (AE),
13089,NCT03418922,Part 1 and Part 2: Number of Participants with Any Serious and/or Non-serious Adverse Event,2018-01-30,COMPLETED,INTERVENTIONAL,['PHASE1'],Part 1 and Part 2: Serum Concentration of Nivolumab,
13090,NCT05074264,Most efficient algorithm for detection of anogenital human papillomavirus (HPV)-related cancers and high-grade squamous intraepithelial lesions (HSIL),2021-11-30,RECRUITING,INTERVENTIONAL,['NA'],,
13091,NCT01170754,Boston Prep Scale,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Phosphorus Level in mg/dl,Boston Prep Scale (Per Protocol Analysis)
13092,NCT00506623,Pathologic stage Tumor regression grade,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicity,
13093,NCT04616768,Patient perceptions of symptom management,2020-11-19,COMPLETED,INTERVENTIONAL,['PHASE3'],Fitbit step data,Additional analysis of the primary outcome between different arms (3 month) (exploratory)
13094,NCT00055822,,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13095,NCT01320241,Overall Mean Survival and Median Survival,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"Number of Participants with Adverse Events as a Measure of Technical Success, Clinical Success, Safety (including WBC and Immunological changes of lab, Leakage of the radioactive seeds and Complications related to the procedure.",
13096,NCT03047226,Pathogenic germline mutation,2017-02-28,COMPLETED,OBSERVATIONAL,['NA'],Variant of uncertain significance of germline mutation,
13097,NCT00879385,Evaluate safety & feasibility of sequential use of a DNA methyltransferase (DNMT) inhibitor (decitabine) with targeted biological agent against EGFR (panitumumab) for KRAS wild type tumors in second or third line treatment of colorectal cancer.,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Measure CEA levels at the beginning of each cycle to examine if they correlate with treatment response or disease progression.,
13098,NCT04960943,Objective Response Rate (ORR),2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),Safety and Tolerability
13099,NCT03336229,Change in cardiorespiratory fitness,2018-04,UNKNOWN,INTERVENTIONAL,['NA'],Survival,Feasibility of home-based exercise
13100,NCT04025840,2-year overall survival,2019-09-11,RECRUITING,INTERVENTIONAL,['PHASE4'],2-year progression-free survival,Time to oral intake after surgery.
13101,NCT02931825,Comparison of the performed colonoscopy rate within 12 months following randomization / send letter in the 2 arms,2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],,
13102,NCT01924897,postoperative morbidity,na,UNKNOWN,INTERVENTIONAL,['NA'],Admission to HDU/ITU,Feasibility outcomes for exercise training
13103,NCT04838327,Feasibility and translational analysis,2021-08-16,RECRUITING,OBSERVATIONAL,['NA'],Quality of Life by EORTC QLQ-C30,
13104,NCT03608631,Progression-free survival (PFS),2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13105,NCT03898102,Difference in grade 2 or worse HFSR incidence within the first 8 weeks of regorafenib treatment between mCRC patients who receive regorafenib treatment with or without zinc supplementation,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of treatment of regorafenib (DoT),Percentage of patients with adverse events (graded by NCI-CTCAE v4.03)
13106,NCT01254591,"Prognosis (6-month, 1-year, 3-year, and 5-year mortality including local/distance recurrence rates)",2006-11,UNKNOWN,INTERVENTIONAL,['NA'],,
13107,NCT00687830,"Comparing All Morning Bowel Prep to Evening Bowel Prep for Patients Undergoing Afternoon Colonoscopies. (Using Ottawa Scale Scores, Range 0-14) Lower Score Indicates a Better Outcome.",2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],"Patient Satisfaction in the Two Groups, All Morning Prep vs. All Evening Bowel Prep.",
13108,NCT03742596,The Level of C-reactive protein (CRP),2018-11-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The gastrointestinal toxicity,The level of neutrophils
13109,NCT02685046,Effects of treatment on the mesenchymal gene expression profile,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events as assessed by CTCAEv4.02,
13110,NCT04273100,objective response rate (ORR),2019-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,conversion rate of hepatectomy
13111,NCT02395471,Number of Participants With Adequate Cytosponge™ Sample,2015-08,COMPLETED,INTERVENTIONAL,['NA'],Ongoing Safety Measures,
13112,NCT02419586,Time to first flatus,2015-01,COMPLETED,INTERVENTIONAL,['NA'],Length of stay,
13113,NCT00005833,Confirmed complete and partial response rate to R115777,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency & severity of toxicities,
13114,NCT02072356,Adverse experiences,2010-10-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
13115,NCT04710589,Progression free survival time (PFS),2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival time (OS),Side effects
13116,NCT05271110,Feasibility of treatment,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Quality of life after surgery,
13117,NCT00098787,Objective Response Rate,2005-09-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
13118,NCT02355119,Disease free survival (DFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Number of Participants with Adverse Events as a Measure of Safety and Tolerability,
13119,NCT03236636,Overall survival (OS),2017-09-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Assessment on Quality of life 2,"Genome level (DNA, mRNA, miRNA) biomarker analysis"
13120,NCT06016855,Gene mutations,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE4'],,
13121,NCT02277548,Average/Cumulative Opioid Dose,2014-05,COMPLETED,INTERVENTIONAL,['NA'],,
13122,NCT02909452,Changes from baseline in ECG results,2016-09-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Vd (clearance and volume of distribution) of entinostat when given in combination with pembrolizumab,Best overall tumor response
13123,NCT02210364,Recommended dose of PM01183 in combination with capecitabine,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13124,NCT05589597,Safety and tolerability of EO4010 in combination with nivolumab,2023-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up,
13125,NCT00278694,Number of patients obtaining pCR,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],"Clinical, radiological and molecular response to treatment",
13126,NCT02817685,The incidence of Hepatocellular carcinoma,2016-05,UNKNOWN,OBSERVATIONAL,['NA'],,
13127,NCT00537823,All-cause Mortality,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in Tumor Size From Pretreatment to Preoperative CT Scan,
13128,NCT02416635,The number of Circulating Tumor Cells (CTCs),2013-06,COMPLETED,OBSERVATIONAL,['NA'],,
13129,NCT00399009,Clinical anastomotic leak,2004-01,TERMINATED,INTERVENTIONAL,['NA'],,
13130,NCT04188158,Disease-free survival (SLE) at 2 years,2017-03-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],To compare the postoperative morbidity and mortality of the neoadjuvant treatment in relation to the standard treatment,
13131,NCT01340105,Complete ablation rate,2011-04,COMPLETED,INTERVENTIONAL,['NA'],Hospital stay,
13132,NCT02967523,Objective tumor response,2016-05,TERMINATED,OBSERVATIONAL,['NA'],Changes in alpha-fetoprotein (AFP) blood levels,
13133,NCT01294358,MTD (Maximum Tolerated Dose),2011-01-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With Serious and Non-Serious Adverse Events,
13134,NCT03253133,Maximum tolerated dose,2016-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Area Under the Curve (AUC),
13135,NCT01387503,For Phase III - Overall Survival,2011-01,COMPLETED,INTERVENTIONAL,['NA'],Validation of the Metroticket model for the prognosis of survival after liver transplantation in patients exceeding Milan Criteria,
13136,NCT05855278,Overall survival,2019-08-13,COMPLETED,INTERVENTIONAL,['NA'],,
13137,NCT04879927,Rate of Treatment Interruption,2021-05-17,COMPLETED,INTERVENTIONAL,['NA'],,
13138,NCT03329690,Percentage of Participants With Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set),2017-11-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Summary of Most Common Treatment-Emergent Adverse Events (TEAEs) ≥20% of Any Grade by Preferred Term Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Safety Analysis Set),
13139,NCT01668134,Stereotactic radiation therapy (either photon or proton) can be delivered to the liver with a less than 10% 3-month incidence of Grade 4 study related toxicity.,2009-12-16,COMPLETED,INTERVENTIONAL,['PHASE1'],Measure the response rates associated with using SBRT in patients with resectable HCC and IHC,
13140,NCT02649647,Incidence of major bowel dysfunction,2016-02,RECRUITING,INTERVENTIONAL,['NA'],Quality of life impairment,Postoperative hospital stay by days
13141,NCT02705118,Registration accuracy,2015-12,COMPLETED,INTERVENTIONAL,['NA'],Registration time,
13142,NCT03598231,Proportion of Responders of Low Anterior Resection Syndrome,2018-05-25,COMPLETED,INTERVENTIONAL,['NA'],Urinary function,
13143,NCT03857763,The pathological complete response rate(pCR),2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events Toxicity,
13144,NCT00043043,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13145,NCT03256084,Evaluation of CTC features,2017-07-17,RECRUITING,INTERVENTIONAL,['NA'],,
13146,NCT05385809,Surgical conversion rate,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],adverse event (AEs),
13147,NCT02441153,Disease-free survival,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,
13148,NCT04588909,Early post operative mortality,2020-03-23,UNKNOWN,OBSERVATIONAL,['NA'],Rate of hospital acquired SARS CoV 2 infection among operated patients.,
13149,NCT00265720,"Colorectal Cancer Screening Rate; This measurement(Impact) is taken 90 days from last intervention session. If a person is not screened, an additional measurement(Post-Impact) is taken 90 days from the Impact.",2003-03,COMPLETED,INTERVENTIONAL,['NA'],"Knowledge, Attitudes and Beliefs; this measurement is taken at baseline and post intervention session. Sessions vary by intervention group after the initial recruitment sessions:",
13150,NCT00113776,Incidence of HAHA formation,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13151,NCT03396926,Overall response rate (ORR) (Expansion Cohort),2018-04-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival (PFS) (Expansion Cohort),
13152,NCT03054987,Rates of death attributable to the procedure.,2016-09,COMPLETED,INTERVENTIONAL,['NA'],Reintervention,
13153,NCT00911391,Post-operative functional recovery,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Perioperative Complications,
13154,NCT02447263,Number of participants with Adverse events,2015-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
13155,NCT05523154,Reduction in surgical site infections,2023-01-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Timeliness of sample analysis,
13156,NCT06269445,Progression-free survival(PFS),2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],Quality of life of the patients,
13157,NCT03814629,Clinical symptom score is assessing a change,2015-08-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],kidney function test,
13158,NCT00154726,Response rate,1997-04,COMPLETED,INTERVENTIONAL,['PHASE2'],overall survival,
13159,NCT01322815,Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients),2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13160,NCT02788955,Change/maintenance in muscle mass,2016-04,COMPLETED,INTERVENTIONAL,['NA'],Change in physical function,
13161,NCT04106167,Overall Survival (OS) post-Infusion,2019-06-11,TERMINATED,OBSERVATIONAL,['NA'],,
13162,NCT03340844,Patient survival,2017-12-15,UNKNOWN,INTERVENTIONAL,['NA'],Morbidity,
13163,NCT04945720,One-Year Overall Survival Rate,2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE2'],"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-HCC18.",Exploratory study endpoints
13164,NCT05837598,Patient satisfaction assessed by patient feedback questionnaire.,2023-05-31,RECRUITING,INTERVENTIONAL,['NA'],Tumor board participant satisfaction assessed by in-session feedback questionnaire.,Patient receipt of mental health care assess by electronic medical record review.
13165,NCT01316679,,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
13166,NCT02488707,Hospital stay,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13167,NCT00983268,Maximum tolerated dose of vorinostat when given in combination with capecitabine and radiotherapy,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Biological effect,
13168,NCT05489237,Phase 1b - Objective Response Rate (ORR) mRESIST v1.1,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Phase 1b - Overall survival,
13169,NCT04661150,Pathological Complete Regression (pCR) Rate,2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Adverse Events,
13170,NCT03873532,Overall survival (OS),2018-07-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Duration of response (DOR),Detection of biomarkers
13171,NCT03271047,Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1,2017-10-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Concentration Versus Time Summary of Plasma Concentration of Binimetinib,
13172,NCT00968604,Dose-Limiting Toxicity (DLT),2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
13173,NCT05804331,Long term outcomes: recurrent and residual disease,2023-03-14,RECRUITING,OBSERVATIONAL,['NA'],Patient interviews/questionnaires,
13174,NCT04708470,Determine RP2D of entinostat,2021-10-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Duration of Response (DoR),
13175,NCT04440943,Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0,2020-08-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetic Evaluation,
13176,NCT02999295,Progression free survival rate after 6 months,2017-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression free survival (PFS),
13177,NCT03333785,Team/Cross Boundary Continuity subscale of the Nijmegen Continuity Questionnaire,2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],Patient experience of the care process,Team/Cross Boundary Continuity subscale of the Nijmegen Continuity Questionnaire
13178,NCT03301493,Timing of molecular profiling,2017-03-30,RECRUITING,OBSERVATIONAL,['NA'],Outcome of treatment,
13179,NCT01915602,Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review,2013-09-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events as a measure of safety and tolerability,
13180,NCT02340117,Objective response rate (ORR),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events,
13181,NCT03940976,Objective response rate,2019-04-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
13182,NCT02070705,Change in tumor margins in patients who have undergone chemotherapy for pancreatic cancer (Group III),2014-01-31,RECRUITING,INTERVENTIONAL,['NA'],DCE- MRI imaging parameters and descriptional analysis of normal pancreas DCE- MRI images (Group IV),
13183,NCT04671862,Rate of occurence of radiation mucositis,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],Radiation dermatitis,
13184,NCT03436719,Rate of Surgical Site Infection,2017-11-06,UNKNOWN,INTERVENTIONAL,['NA'],,
13185,NCT01394120,Overall Survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13186,NCT02451553,Recommended phase 2 dose (RP2D) (Phase Ib),2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to progression,
13187,NCT01624220,Assess Use of Implanted Fiducial Markers in Treatment Planning and Delivery Workflow for Frame-Based Spinal Stereotactic Body Radiation Therapy (Spinal SBRT),2012-06-18,COMPLETED,INTERVENTIONAL,['NA'],Esophageal Tolerance to Hyperfractionation,
13188,NCT01494155,Progression-free survival,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Measure utilization of health services,
13189,NCT05117957,Safety (Adverse events),2022-02-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],Disease control rate (DCR),
13190,NCT06209983,Length of hospital stay,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Complication rates,costs of hospitalization
13191,NCT02498041,Endoscopic Diagnostic Accuracy for Barrett's esophagus,2009-04,COMPLETED,INTERVENTIONAL,['NA'],Adverse events,
13192,NCT01916447,"Safety monitoring including adverse events, vital signs, and laboratory assessments",2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Document any preliminary antitumor activity of TAS-102 administered in combination with CPT-11 and in combination with CPT-11 and Bevacizumab.,
13193,NCT05938309,Overall postoperative morbidity,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],3-year recurrence pattern,
13194,NCT00753844,Safety(Phase I:toxicities as assessed by NCI CTCAE version3),2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],evaluate immunological responses,
13195,NCT02586753,Overall survival (OS),2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression-free survival (PFS),
13196,NCT01012804,,2000-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
13197,NCT03961945,Aim 3 - Dysplasia Detection Sensitivity and Specificity,2021-07-01,RECRUITING,INTERVENTIONAL,['NA'],Aim 3 - Dysplasia Detection Rate of Missed Dysplasia,
13198,NCT01053390,"(Response Evaluation Criteria in Solid Tumors, RECIST,2009 ), CR(complete response) and PR(partial response)",2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],"A: KPS (karnofsky performance score) B:Laboratory tests: Reexamination of CA19-9（Carbohydrate Antigen 19-9）、 CEA（ carcinoembryonic antigen）, especially for those which are abnormal prior to chemotherapy",
13199,NCT02027311,Number of Intervention,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Event of Hypoxia,
13200,NCT05994521,Rate of gastric outlet obstruction (GOO),2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Nutritional status,
13201,NCT04161911,Overall Survival,2018-10-29,COMPLETED,OBSERVATIONAL,['NA'],,
13202,NCT00102700,Document progression free survival after treatment with ARQ 501 and gemcitabine,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Document safety and efficacy of ARQ 501 in combination with gemcitabine,
13203,NCT06024343,Incidence of Clinically Relevant Postoperative Pancreatic Fistula,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Recurrence-free survival (RFS),
13204,NCT00061932,True Response Rate Evaluated for the Combination of Irinotecan and PS341 by Response Evaluation Criteria in Solid Tumors (RECIST),2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Patterns of Gene Expression Pre- and Post-treatment Performed by GeneChip Analysis,
13205,NCT00252889,"Subjective parameters including ECOG performance status, specific symptoms, and side effects are graded according to standard Common Terminology Criteria for Adverse Events (CTCAE) v.30 criteria.",2004-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13206,NCT05266820,Progression-free survival (PFS),2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events,
13207,NCT05493033,Anastomotic leak,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Incision herniation,
13208,NCT03785873,Phase II: Median Progression-Free Survival (PFS),2019-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median Overall Survival (OS),
13209,NCT03005002,Incidence of adverse events assessed by NCI CTCAE version 4.03,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall response rate (both hepatic and extrahepatic disease) assessed by RECIST 1.1,Tumor immune profiling
13210,NCT01714466,Cleansing success rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],PEG3350 concentration,
13211,NCT00019331,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13212,NCT04248816,HCC Screening Completion,2020-11-19,COMPLETED,INTERVENTIONAL,['NA'],HCC Screening Method,
13213,NCT01228045,Overall Response Rate (ORR),2011-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety Evaluations,
13214,NCT01667198,Screening centre leader's adenoma detection rate,2012-07,COMPLETED,INTERVENTIONAL,['NA'],Screening centre leader's withdrawal technique,
13215,NCT00430027,Overall Toxicity,2006-11,TERMINATED,INTERVENTIONAL,['NA'],,
13216,NCT04450836,To evaluate the feasibility of treatment sequence (R-TT or TT-R),2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],To evaluate the safety (Treatment-Emergent Adverse Events) during treatment,
13217,NCT03787667,Sensitivity,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13218,NCT01264432,Maximum tolerable dose defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,2011-01-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Proportion of toxicities of the combination of veliparib and LDRWAR as graded by the NCI CTCAE version 4.0,
13219,NCT02151123,False negative rate of test for colon cancer,2019-03,UNKNOWN,OBSERVATIONAL,['NA'],,
13220,NCT00118339,,2003-07,COMPLETED,INTERVENTIONAL,['NA'],,
13221,NCT00252161,overall survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],adverse events,
13222,NCT00701857,The maximum tolerated dose (MTD) of pemetrexed,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],"Response (complete response, partial response, progressive disease, and stable disease) as measured by RECIST criteria",
13223,NCT03445416,Change in vaccine awareness,2018-09,WITHDRAWN,INTERVENTIONAL,['NA'],Change in healthcare engagement,
13224,NCT05112016,"Quality of life, including functional and symptom scales, incontinence scores, sexual function",2007-01-01,RECRUITING,OBSERVATIONAL,['NA'],Costs,
13225,NCT03482609,The incidence of postoperative referred pain in the left shoulder within 1 month,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA'],inflammatory and immune response,
13226,NCT06206733,Progression Free Survival (PFS),2024-01-25,RECRUITING,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),Number of anti-drug antibody (ADA) Positive Participants
13227,NCT03976960,Number of biological risk factors for colorectal cancer,2018-09-19,RECRUITING,INTERVENTIONAL,['NA'],,
13228,NCT00039208,Peak delivery time for CPT11 tolerability over the first 3 courses of treatment in patients who started therapy,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
13229,NCT05098847,Objective Response Rate,2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
13230,NCT00658840,all cause mortality,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13231,NCT03392584,Monitoring intermediate metabolites in the remnant muscular tissue of the pelvis floor with microdialysis catheters after neoadjuvant CRT and subsequent APR for LARC.,2016-10-01,COMPLETED,OBSERVATIONAL,['NA'],Measure intermediate metabolites and inflammatory mediators after neoadjuvant CRT and subsequent APR for LARC with reconstruction of the perineum with VRAM.,
13232,NCT03008980,Outcomes of patients undergoing WATS sampling. Specifically incremental yield for Barrett's Esophagus and Esophageal Dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings.,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,
13233,NCT00711997,Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumor Resectability,
13234,NCT02250638,A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients with Pancreatic Cancer,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,
13235,NCT01344304,"Patient diary recording nausea, emesis, food ingestion, and rescue therapy",2011-04,COMPLETED,INTERVENTIONAL,['NA'],,
13236,NCT03798951,Post-operative complications,2019-06-05,TERMINATED,INTERVENTIONAL,['NA'],,
13237,NCT03606785,reduction in blood loss,2018-08-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13238,NCT04715581,Recurrence-free survival after surgery.,2021-11-25,RECRUITING,INTERVENTIONAL,['NA'],Physical activity at 30 days after surgery (sub-study).,"Physical activity at 3 months, 6 months and 1 year after surgery."
13239,NCT03350477,Relief degree of tumors,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall survival,
13240,NCT03109262,Image Quality for 90-Y PET/CT Scans,2017-02-15,COMPLETED,INTERVENTIONAL,['NA'],Radiopharmaceutical Dosimetry Accuracy for 90-Y PET/CT Scans and 99mTc-MAA SPECT/CT Scans,
13241,NCT00193219,"Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment",2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Adverse Events as a Measure of Safety With FOLFOX6 Combined With Bevacizumab and Cetuximab,
13242,NCT03977077,Progression free survival (PFS),2019-06-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,
13243,NCT02391207,the safety of HV-sparing surgery in terms of operative mortality and morbidity,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
13244,NCT01733719,Recruitment rate and retention,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Quality of life,
13245,NCT00422409,Change/improvement i Quality of life,2006-10,COMPLETED,INTERVENTIONAL,['NA'],Death,
13246,NCT05617469,Tumor regression grade,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
13247,NCT02188264,Incidence of DLT defined as any grade 3 non-hematological toxicity or grade 4 hematological toxicity attributed to selumetinib or cyclosporine graded per National Cancer Institute (NCI) CTCAE version 4.0,2014-08-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Progression-free survival (PFS),Change in expression of phosphorylated-mitogen-activated protein kinase 1
13248,NCT02158988,The primary outcome measure is overall survival,2014-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],quality of life,frequency of necessary secondary surgical procedures and the length of hospitalisation
13249,NCT02716012,Part 2 - Change in tumour size from baseline using RECIST 1.1 and mRECIST in patients treated with MTL-CEBPA in combination with sorafenib,2016-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Part 2 - Safety and tolerability of co-administering MTL-CEBPA with sorafenib assessed using frequency of adverse events graded according to toxicity criteria (NCI CTCAE v 5.0) and categorised by body system,
13250,NCT00911170,Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy,2009-11-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants With Adverse Events (AEs),
13251,NCT02113384,Overall survival,2012-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
13252,NCT02685553,Number of hypervascular pancreatic neoplasms detected intraoperatively by NIR,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13253,NCT00215462,To assess the anti-tumor activity of vinorelbine when administered to patients with locally advanced or metastatic esophageal or gastric adenocarcinoma.,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate the toxicities of vinorelbine in this patient population.,
13254,NCT05871762,3-year OS,2023-06-04,RECRUITING,OBSERVATIONAL,['NA'],30-day mortality,
13255,NCT03149679,Objective response rate (ORR),2017-05-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Safety and tolerability of the study treatment including recording of number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
13256,NCT04268121,Relapse-free survival (RFS) - prospective cohort,2021-01-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0 - Prospective cohort,
13257,NCT02291198,NK cell activity,2014-10,COMPLETED,INTERVENTIONAL,['NA'],,
13258,NCT04199832,Body Weight Change from baseline to the end of treatment,2019-12-20,COMPLETED,OBSERVATIONAL,['NA'],Overall Survival,
13259,NCT00541047,Freedom from distant metastases (any distance metastases or prostate cancer death) (RADICALS-RT),2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Freedom from biochemical progression (RADICALS-RT),
13260,NCT02573220,Maximum Tolerated Dose (MTD),2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],metastectomy (with curative intent) rate,
13261,NCT05844514,Validation and further discovery of VOC biomarkers for CRC.,2022-09-23,RECRUITING,OBSERVATIONAL,['NA'],Exploratory comparison between the breath test and FIT.,
13262,NCT01473290,Average area under the curve (AUC) of the FACIT-D diarrhea subscale score assessed weekly during treatment and for two weeks following the completion of RT,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Disease-free survival,
13263,NCT00495846,Prolongation of the survival curve (>6 months),2007-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Improvement of quality of life according with SF36 questionnaire,
13264,NCT05035446,Rate of complications,2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],pain intensity,
13265,NCT02030561,Time-to-Event Outcome Measure,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13266,NCT06077591,tumor response,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],rate of grade III/IV toxicities.,
13267,NCT02546596,"T stage (0 - 4), N (0 - 3) stage, tumor regression grade (0 - 4)",2014-03-25,UNKNOWN,INTERVENTIONAL,['NA'],Treatment toxicity (grade 0 - 5),
13268,NCT05780684,Proportion of patients that receive dose intensified infusional 5-FU in Cycle 6 of the FOX regimen,2023-07-14,RECRUITING,INTERVENTIONAL,['NA'],5-FU drug exposure,
13269,NCT02075905,Risk Stratification,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
13270,NCT02607332,Disease control rate,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13271,NCT04616196,Objective Response Rate (ORR) by RECIST 1.1 of NKTR-255 in combination with Cetuximab in R/R metastatic HNSCC or CRC for Phase 2 Dose Expansion,2020-10-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The development of anti-drug antibodies (ADA) against NKTR-255 and cetuximab,
13272,NCT03383458,Recurrence-free Survival (RFS),2018-04-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Time to recurrence (TTR),
13273,NCT05213741,Safety of magnetic-assisted colonoscope system,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
13274,NCT04886635,"Safety of active surveillance (including delayed surgery), measured by the number of patients with adverse events",2021-03-09,RECRUITING,OBSERVATIONAL,['NA'],The number of biopsies taken and quality of the biopsies,
13275,NCT05137782,Operationalization as measured by the creation of a manual of operating procedures and web-based data collection forms,2023-01-03,COMPLETED,INTERVENTIONAL,['NA'],Acceptability as measured by willingness to recommend study participation to others.,
13276,NCT00955188,Adherence to colorectal cancer screening at 12 months post-intervention,2004-08,COMPLETED,OBSERVATIONAL,['NA'],Intention to get screened,
13277,NCT03161535,Quality of life (EORTC QLQ-OES 18 ),2017-09-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Circadian rhythms,
13278,NCT01859806,Postoperative pancreatic fistula (POPF),2011-01,COMPLETED,INTERVENTIONAL,['NA'],hospital stay,
13279,NCT03766555,Overall survival,2018-05-21,RECRUITING,INTERVENTIONAL,['NA'],Hospital stay,
13280,NCT05841420,PFS (Progression Free Survival),2023-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Cumulative worst toxicity during treatment,
13281,NCT03385213,Transcriptional changes in gut microbiota,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],Epigenetic changes,
13282,NCT01130233,Bladder function,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life,
13283,NCT02047994,Gastric cancer mortality,2013-03,RECRUITING,INTERVENTIONAL,['PHASE4'],Incidence of- and mortality from other medical conditions,
13284,NCT04340440,Operative mortality rate,2014-12,COMPLETED,INTERVENTIONAL,['NA'],2 years Overall survival rate,
13285,NCT02350686,Progression-free survival,2015-05-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events as a Measure of Safety and Tolerability,
13286,NCT01072851,Comparison of the acceptance of colorectal cancer screening by patients who view print or multimedia educational tools,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Comparative knowledge of colorectal cancer screening by patients who view the print or multi-media educational tools.,
13287,NCT01157806,percentage of patients not requiring palliative surgery during the follow-up,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Determination of prognostic factors indicating the need for immediate palliative surgery.,
13288,NCT04519905,overall survival difference of definitive radiotherapy and chemoradiotherapy groups,2020-01-06,RECRUITING,INTERVENTIONAL,['NA'],cancer specific survival,
13289,NCT03607643,Response rate,2019-01-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality-of-life assessment in patients using clinician-reported outcomes (ClinRO) data.,
13290,NCT00828048,Identify clinical and morphological predictors of cancer or high grade dysplasia in patients with IPMN. Identify predictors of progression to cancer or high grade dysplasia among patients who are followed in surveillance programs.,2008-03,COMPLETED,OBSERVATIONAL,['NA'],,
13291,NCT05635266,Biospecimen & Clinical Data Collection,2021-10-26,RECRUITING,OBSERVATIONAL,['NA'],,
13292,NCT01321658,Postoperative complications,2011-02,COMPLETED,INTERVENTIONAL,['NA'],Living at home or in institution,
13293,NCT02958592,Stage of hepatic fibrosis,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
13294,NCT03138031,Overall survival rate,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],Tumor response rate,
13295,NCT05047926,Adherence to each prehabilitation component based on patient reported adherence (Cohorts 2 & 3),2021-10-01,RECRUITING,INTERVENTIONAL,['NA'],Acceptability of remote setting in Cohort 3,
13296,NCT06260150,Incidence rate of DVT,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Amount of bleeding during surgery,
13297,NCT05356156,The incidence of internal hernia within 3 years after surgery,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival at 3 years after surgery,
13298,NCT04000737,Progression free survival (PFS),2020-01-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Effects of YIV-906 on mean t½ (Hr) of sorafenib in blood,
13299,NCT06202105,3 year relapse-free survival by Kaplan Mayer,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],hospital stay,
13300,NCT04616131,Number of patients with circulating tumor DNA (ctDNA) levels as not detectable in their blood compared to number of patients with ctDNA detected.,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],"Investigators will look for statistically significant correlations of ctDNA blood levels with clinical treatment responses of tumor grades, CA 19-9 units/milliliter blood level, and radiologic response by RECIST categories of complete response.",
13301,NCT00660348,Number of Subjects Per Arm With Decrease in Pain Scores,2008-03,TERMINATED,INTERVENTIONAL,['NA'],,
13302,NCT03240679,Completeness of EMR Site Healing at Follow up Endoscopy,2017-03-22,TERMINATED,INTERVENTIONAL,['NA'],Presence of Stricture Formation at Follow up Endoscopy,
13303,NCT05883345,Validity of blood tests for gastric cancer screening and gastritis type,2023-04-24,RECRUITING,OBSERVATIONAL,['NA'],,
13304,NCT01220063,tumor response accoording to recist criteria,2007-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13305,NCT01872988,overall survival,2012-09,TERMINATED,INTERVENTIONAL,['PHASE3'],time to liver decompensation,
13306,NCT04040842,LARS score change comparing before surgery and 1 year after the surgery.,2019-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
13307,NCT01891344,Objective Response Rate (ORR) by RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study),2013-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],Steady State Trough (Cmin) Level Rucaparib Concentrations,
13308,NCT01310985,"Evaluate the safety of pre-operative concurrent chemotherapy with capacitabine (Xeloda), weekly cetuximab (Erbitux), and external beam radiation.",2008-03,COMPLETED,OBSERVATIONAL,['NA'],"Evaluate efficacy of sphincter preserving surgery rate, local recurrence rate and the disease free and overall survival in patients.",
13309,NCT02999672,Best Overall Response (BOR) Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1).,2016-12-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma/Serum Concentrations of Trastuzumab Emtansine,
13310,NCT03534843,Overall survival of all patients,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],Short-term mortality of non-surgical subgroup,
13311,NCT05866783,Disease-free survival,2023-04-28,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
13312,NCT01808599,Complete remission rate,2013-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Event-free-survival (EFS),
13313,NCT02333279,Number of solid cancers,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,
13314,NCT06164691,Clinical Complete Response,2022-08-14,TERMINATED,INTERVENTIONAL,['NA'],Prealbumin Level,
13315,NCT00774501,To assess safety & feasibility of single dose image-guided intensity modulated radio (IG-IMRT) using gen anesthesia with apneic oxygenation & controlled ventilation to temp suspend respiratory motion for tx of mets liver disease during localization & tx.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,
13316,NCT00603577,"Neurological sensory assessment using the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE, Version 3.0)",2008-01,TERMINATED,INTERVENTIONAL,['PHASE3'],"AE graded with NCI-CTCAE (Version 3.0) and coded using Medical Dictionary for Regulatory Activities (MedDRA, version 9.1)",
13317,NCT03076957,Maximum Tolerated Dose(MTD),2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Number of participants with toxicity as assessed by CTCAE v4.03 through study completion, an average of 1 year",
13318,NCT03231917,Adenoma Miss Rate,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],Adenoma < 6mm Detection Rate,
13319,NCT00003055,,1997-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13320,NCT02810418,Maximum Tolerated Dose (MTD) of Continuous Infusion LMB-100,2016-08-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).,Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2
13321,NCT03635021,Progression-free survival rate at 35 months,2018-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence and severity of AEs CTCAE v4.03 criteria,clinical impact of clonal dynamics by longitudinal analysis of circulating tumour deoxyribonucleic acid (ctDNA) in plasma
13322,NCT01397019,2 year survival rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13323,NCT00238199,Time to progression,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in pancreatic cancer-induced pain,
13324,NCT05369117,Three-year disease-free survival rate,2022-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],operative mortality,
13325,NCT03896399,Number of participants with a grade 2 or higher complication after laparoscopic ischemic conditioning,2019-04-09,UNKNOWN,INTERVENTIONAL,['NA'],Redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography,
13326,NCT01820091,Optimal dose and Schedule of Fusilev to prevent or reduce Oral Mucositis,2013-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Impact of Fusilev on number of Folotyn doses delivered,
13327,NCT05493215,Incidence of Grade 3/4 adverse events attributable to imatinib per CTCAE v5.0,2024-03-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Average dose of imatinib required to achieve therapeutic levels and drug dose over 3 years,
13328,NCT00112580,Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR),2005-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13329,NCT02042443,Overall Survival,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free Survival,
13330,NCT05743842,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-03-14,RECRUITING,INTERVENTIONAL,['NA'],,
13331,NCT02506842,Overall survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life,
13332,NCT02562755,Overall Response Rate (ORR),2015-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13333,NCT01326390,"Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)",2010-05,TERMINATED,OBSERVATIONAL,['NA'],,
13334,NCT01286155,The primary outcome from the survey will be the proportion of patients willing to undergo an esophageal capsule study compared to those willing to undergo an endoscopic procedure (Esophagogastroduodenoscopy or transnasal endoscopy),2010-01,COMPLETED,OBSERVATIONAL,['NA'],"Study established (age, gender, ethnicity, reflux) and potential risk factors (sleep apnea, visceral adiposity, Helicobacter pylori infection, Metabolic Syndrome)to develop a clinical risk factor model for diagnosis of Barrett's esophagus(BE).",
13335,NCT02644603,Treatment related complications,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],Serum complement,
13336,NCT01521091,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
13337,NCT04456699,Progression Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR).,2020-08-19,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants Discontinuing Study Intervention Due to an AE,
13338,NCT00303940,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13339,NCT06219031,CR、PR、SD、PD,2023-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
13340,NCT04674696,Evaluate MRI good response rate after the total neoadjuvant treatment,2020-11-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Describe the safety and tolerability of total neoadjuvant treatment.,
13341,NCT06199297,progression free survival，PFS,2021-03-02,COMPLETED,OBSERVATIONAL,['NA'],"overall survival, OS",
13342,NCT00701012,Assessment of bowel function,2008-01,COMPLETED,INTERVENTIONAL,['NA'],comparison of leakage rate,
13343,NCT03763214,Stent migration,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Survival rate,
13344,NCT02311205,Overall survival (OS),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease control rate (DCR),
13345,NCT04109495,EORTC Questionnaires - Quality of Life,2017-02-22,COMPLETED,INTERVENTIONAL,['NA'],Skeletal muscle index change,
13346,NCT05223088,Total/moderate tumor regression rate under pathology,2021-10-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
13347,NCT03587480,3-year disease-free survival,2018-12-17,RECRUITING,INTERVENTIONAL,['NA'],the score of quality of life,
13348,NCT04959617,Specificity of quantitative FIT,2019-01-06,UNKNOWN,OBSERVATIONAL,['NA'],,
13349,NCT05653427,Objective Response Rate (ORR),2022-12-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants with Anti-amivantamab Antibodies,
13350,NCT00848510,Whole Tumor Volume and Enhancing Tumor Volume,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression-Free Survival (PFS) Time,
13351,NCT04905030,(Long Term) Posterior beliefs about false risks of the HPV vaccine,2021-04-28,UNKNOWN,INTERVENTIONAL,['NA'],Subjective vs Objective vaccination measure (binary indicators),
13352,NCT02518373,Change in plasma gastrin level.,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13353,NCT03015298,The results of the PET/MRI and PET/CT examination,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],Follow-up data,
13354,NCT02833506,Incidence of adverse events defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03,2017-12-08,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Time to disease progression as documented by Response Evaluation Criteria in Solid Tumors version 1.1,
13355,NCT00152906,Phase II: To determine with more confidence the rate and spectrum of all toxicities that occur at the maximally tolerated dose of radiation.,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To determine whether serum cytokines and P-III-P can help predict RILD.,
13356,NCT04921488,Estimation of the sensitivity of the automatic characterization system CAD EYE.,2021-10-21,COMPLETED,INTERVENTIONAL,['NA'],"Compare the diagnostic performance to determine the malignancy of polyps between the automated colonic polyp detection device by the CAD EYE system, and the investigator performing the colonoscopy for colorectal cancer screening.",
13357,NCT05745415,Progression free survival,2018-03-29,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
13358,NCT05429190,Increased sensitivity for HCC detection,2023-11-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Cost-effectiveness analysis of SMS protocol,Patients acceptance of the SMS protocol (through a questionnaire)
13359,NCT01139229,the incidence of anastomotic stricture,2007-11,COMPLETED,INTERVENTIONAL,['NA'],the clinicopathological parameters in relation to postoperative complications,
13360,NCT01179750,amount of blood loss,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],drainage from peritoneal cavity during hospital,
13361,NCT06026943,"Safety- Adverse events, Safety will be determined according to the overall incidence of device-related SAE's graded according to CTCAE v5.0 criteria",2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Efficacy- Alpha DaRT seeds,Exploratory Objective -to evaluate the changes in the immune markers by Blood samples for immune response
13362,NCT02594696,Feasibility of implementing the intervention in patients with SMI and cancer,2015-11-09,COMPLETED,INTERVENTIONAL,['NA'],Change in alliance with the oncology clinician,
13363,NCT00005597,"Assess response (confirmed & unconfirmed, complete & partial response)",2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicities,
13364,NCT02043730,Progression Rate,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
13365,NCT06140823,Performance metrics for LIRIC model risk quantiles,2023-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Tumor stage at HCC diagnosis,
13366,NCT00118755,Progression-free Survival (PFS),2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Overall Clinical Response (CR or PR),
13367,NCT00094445,Six-Month Participant Survival,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13368,NCT01652482,Progression-free Survival (PFS) According to Modified RECIST v1.1 Criteria,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Minimum Observed Serum Concentration (Cmin) of MEHD7945A,
13369,NCT04134104,Sexual Dysfunction,2014-12,COMPLETED,OBSERVATIONAL,['NA'],,
13370,NCT05091528,Number of Participants With an Objective Response Rate,2022-02-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Proportion of Participants With Clinical Benefit Rate,
13371,NCT02520141,Progression Free Survival of Ramucirumab in Advanced Biliary Cancers,2015-12-29,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Disease Control Rate,
13372,NCT04567459,5)Sarcopenia assessment,2021-01-27,UNKNOWN,INTERVENTIONAL,['NA'],,
13373,NCT04600518,Prognostic equivalence,2020-10-07,COMPLETED,OBSERVATIONAL,['NA'],Multivariate analysis,
13374,NCT03086538,Overall Response Rate,2017-05-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13375,NCT05610592,5-year event-free survival rate,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],Local recurrence,
13376,NCT04619329,Median Overall Survival (mOS),2020-10-30,UNKNOWN,INTERVENTIONAL,['NA'],Adverse Events,
13377,NCT02859064,Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability,2017-07-28,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
13378,NCT01006369,Progression-free Survival,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
13379,NCT00439179,Toxicity (Number of Patients Who Experiened DLTs),2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Patients Who Experienced a Partial Response,
13380,NCT06113796,Costs of treatment,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],30-days Readmission,
13381,NCT01434459,The maximum tolerated dose of gemcitabine when given in combination with therasphere,2011-09,TERMINATED,INTERVENTIONAL,['PHASE1'],The progression free of patients treated on the trial,
13382,NCT04406311,Lars score,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],Single question on QoL,
13383,NCT01125111,The difference in 1 month between two surgical methods in terms of Bladder function.,2009-06,COMPLETED,OBSERVATIONAL,['NA'],"The serial change of Bladder and sexual function according to times, in each operation method.",
13384,NCT05387005,Detection rates of H. pylori infection,2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The compliance(/adherence) of screening tests for H. pylori infection in the two randomized groups,
13385,NCT06159049,SUVmaxFAPI and SUVmaxFDG for each target (Standardized Uptake Value),2022-07-21,COMPLETED,OBSERVATIONAL,['NA'],,
13386,NCT00483405,Disease Response Rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Progression,
13387,NCT06046963,Ascites objective response rate (ORR),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Changes of ascite cell subsets in patients,
13388,NCT05964621,VTE incidence in primary pancreatic cancer resection,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
13389,NCT00154713,evaluate the clinical responses of vaccinated patients 6 weeks after the first injection,2005-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",evaluate the safety of this treatment and the immune responses against CEA before and after the treatment 6 weeks after the first injection,
13390,NCT05411432,SUV of organs,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],radioactivity of blood sample,
13391,NCT04622176,Accuracy of lymph node diagnosis compared to MRI,2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],,
13392,NCT04523818,Incidence of adverse events,2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
13393,NCT04977453,Objective Response Rate (ORR) according to RECIST version 1.1,2021-08-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",DCR per iRECIST guidelines,Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points
13394,NCT05980624,Nutrition status - scored Patient-Generated Subjective Global Assessment (PG-SGA),2023-07-20,RECRUITING,INTERVENTIONAL,['NA'],common adverse effects,
13395,NCT05863195,Overall survival (OS),2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence of adverse events,
13396,NCT02277093,Progression-free Survival (PFS),2015-09-22,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
13397,NCT06089590,"Number of SAE declared by patients (cancer, serious infections, arterial and venous thrombotic events)",2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],"Number and duration of hospitalization, surgery, endoscopy and other imaging",
13398,NCT02685228,overall survival,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],Evidence of the size of the lesion in pancreas confirmed by non-investigational CT or MRI,
13399,NCT01137084,patient and graft survival,2005-01,COMPLETED,INTERVENTIONAL,['NA'],Postoperative complications,
13400,NCT04202848,The change of concentration of P-hydroxyphenylalanine metabolites in urine,2019-12-20,UNKNOWN,OBSERVATIONAL,['NA'],The change of the number of Gastrin in blood during the therapy,
13401,NCT06094140,The proportion of patients receiving at least 80% of planned neoadjuvant treatment.,2022-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Objective response rate.,Analysis of tumour tissue (baseline and surgical resection) for molecular changes and gene expression profile.
13402,NCT02033551,Number of subjects with adverse events,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor Assessment,
13403,NCT00646607,disease free survival (DFS),2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],"overall Survival (OS), Toxicity and incidence of adverse events",
13404,NCT02221700,"Completion Rates of Two Massage Treatment Protocols for Patients With Chronic, Oxaliplatin-Induced Peripheral Neuropathy",2015-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Baseline treatment expectations,
13405,NCT05866510,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants,2023-05-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Related Adverse Events,
13406,NCT01760070,Procedure time for ESD,2012-12,COMPLETED,INTERVENTIONAL,['NA'],Bleeding Rate,
13407,NCT04008797,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),2019-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Duration of Response (DOR),
13408,NCT00002884,,1996-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13409,NCT03427346,Eradication rate of neoplastic Barrett's Esophagus,2016-12,RECRUITING,INTERVENTIONAL,['NA'],Intervention time,
13410,NCT03663114,Number of Participants With Hepatic Encephalopathy Risk Factors,2018-07-02,COMPLETED,OBSERVATIONAL,['NA'],Number of Participants with Hepatic Encephalopathy,
13411,NCT00004189,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13412,NCT04220151,Percentages of methylation of DNA in patients with HCC,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13413,NCT00963794,"Electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.",2008-01,COMPLETED,INTERVENTIONAL,['NA'],,
13414,NCT05010850,Safety Major Complications,2022-01-17,SUSPENDED,INTERVENTIONAL,['NA'],,
13415,NCT05606094,Percentage of Participants Receiving Locoregional Treatment for Localized Disease and Metastasis (Radiotherapy and/or Surgery),2023-03-09,COMPLETED,OBSERVATIONAL,['NA'],Number of Participants with Adverse Events of Special Interest (AESI) In Each Line of Treatment,
13416,NCT02179970,Safety of Investigational Medicinal Product (IMP),2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics of the Investigational Medicinal Product (IMP) within the body.,Disease status
13417,NCT00408564,Progression-free Survival at 6 Months,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine the Biomarker Response of CA 19-9 to Therapy,
13418,NCT04524702,Change from baseline tumor size as measured by cross sectional imaging at 8 weeks.(every 8 weeks),2020-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,Changes in selected biomarkers in tumor microenvironment and circulation
13419,NCT06217042,Disease-free survival (DFS),2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],5-year overall survival rate,
13420,NCT05417386,R0 Resection Rate,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],Resection rate,
13421,NCT04102436,Response rate,2024-03-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Immune monitoring,
13422,NCT00035334,,2001-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13423,NCT04044326,the efficacy of microwave ablation for the treatment of primary or secondary liver cancers: modified RECIST criteria,2019-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],safety and local tumor recurrences,
13424,NCT06244225,Progression free survival (PFS) per RECIST v1.1,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],The treatment-related adverse events (TRAEs）,
13425,NCT06222255,The LARS (Low Anterior Resection Syndrome) Score with Night symptoms,2023-12-06,RECRUITING,INTERVENTIONAL,['NA'],European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - CR29,
13426,NCT06182072,Determine a single ideal dose which will be selected for further investigation in the dose escalation cohort.,2023-12-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluate patient tumor response.,Evaluate patient tumor blood perfusion pre and post treatment with ProAgio.
13427,NCT00003321,,1998-02,COMPLETED,OBSERVATIONAL,['NA'],,
13428,NCT01401907,Functional Assessment of Cancer Therapy (Quality of Life Measure),2011-05,COMPLETED,INTERVENTIONAL,['NA'],Coping (Brief Cope),
13429,NCT04153721,"Change, during the preoperative phase, of the psychological condition of the patients, assessed by GAD7 questionnaire scoring.",2020-03-11,COMPLETED,INTERVENTIONAL,['NA'],Evaluation of the number of postoperative critical values,
13430,NCT06274879,Any grade 3 or 4 adverse events (AE) leading to chemo-immune checkpoint inhibitor-therapy (CICI) discontinuation up to six months after enrolment.,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Total dose of CICI applied,Overall survival
13431,NCT00260364,Part B (Phase II): Overall response rate (complete response and partial response),2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",and Assessment of pain,
13432,NCT00614913,Median Survival Without Tumor Progression,1998-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13433,NCT06120803,Grade 2 or higher radiation induced esophagitis,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
13434,NCT02868255,evaluation of the SIRP/CD47 expression,2016-01-03,COMPLETED,OBSERVATIONAL,['NA'],,
13435,NCT04538313,Progression-Free Survival,2020-08-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",EQ-5D score,
13436,NCT04297254,Number of Participants with Grades 1 and 2 Treatment-emergent Adverse Events (TEAEs),2021-02-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Time to First Dose Reduction,
13437,NCT03158103,Recommended phase II dose (RP2D),2017-04-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of participants with partial response,
13438,NCT00004885,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13439,NCT01149642,The rate of grade 3 and 4 acute mucosal toxicity,2009-11,COMPLETED,INTERVENTIONAL,['NA'],overall survival rates,
13440,NCT05806151,Progression/Recurrence,2023-01-17,RECRUITING,OBSERVATIONAL,['NA'],,
13441,NCT00463840,Resectability After Chemoradiation,2004-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median Overall Survival,
13442,NCT02078362,Percentage of cell lysis,2013-09,UNKNOWN,OBSERVATIONAL,['NA'],,
13443,NCT06023966,hepatic metastasis,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],interval between the surgery and hepatic metastasis,
13444,NCT04288323,Reader reliability of screening modalities,2018-04-27,RECRUITING,INTERVENTIONAL,['PHASE4'],,
13445,NCT02462564,Incidence for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy,2014-06,COMPLETED,OBSERVATIONAL,['NA'],Risk factor for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy,
13446,NCT02332863,Procedure Duration Required for Placing the Fiducial Markers,2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],Number of Fiducials Placed,
13447,NCT04938336,Assessment of the usability of the decision aid tool through individual interviews,2022-04-22,RECRUITING,OBSERVATIONAL,['NA'],,
13448,NCT02072317,Progression-free survival (PFS),2013-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13449,NCT06196554,Predictive specificity of drug sensitivity,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],Concordance between organoids and source tumor tissue,
13450,NCT00197470,,2000-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13451,NCT05270824,The number of CD8+ tumor-infiltrating lymphocytes in tumor tissue and adjacent tissue before and after treatment,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Surgical safety,
13452,NCT06191120,Tumor-level CMS4 status as assessed by the current RNA-sequencing based CMS4 status reference standard performed on fresh-frozen tissue samples following surgery.,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],10-120 minutes post-injection dynamic [18F]-ALF-FAPI-74 uptake levels in tumor lesions and reference organs,RNA-sequencing derived gene-expression levels per tumor lesion
13453,NCT00756977,Efficacy - Preparation Quality Using a 4 Point Scale,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Serum Chemistry Results (Osmolality),
13454,NCT01270178,The survival rate and recurrence rate between patients receiving ETV therapy and those in historical control,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],"HBV reactivation, incidence of ALT normalization, reduction of serum HBV DNA level, HBsAg loss and HBsAg seroconversion to anti-HBsAb, emergence of resistance.",
13455,NCT05007106,PFS per RECIST 1.1 as Assessed by Investigator at 12 months,2021-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants Who Discontinued Study Intervention Due to an AE,
13456,NCT04414956,HCC occurrence,2016-07-01,RECRUITING,INTERVENTIONAL,['NA'],Early HCC occurrence,
13457,NCT01918644,Incidence of dose-limiting toxicity defined as any grade 3-4 non-hematologic toxicity or grade 5 toxicity attributable to combination chemo-radiotherapy per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2014-04-08,COMPLETED,INTERVENTIONAL,['PHASE1'],OS,
13458,NCT00972751,"Correlation of expression of these proteins with tumor stage, disease-free survival, overall survival, and risk of recurrence",2009-02,COMPLETED,OBSERVATIONAL,['NA'],,
13459,NCT05677048,Measure response rate to baseline and follow-up surveys by probands and at-risk relatives,2023-04-14,RECRUITING,INTERVENTIONAL,['NA'],,
13460,NCT02820077,mortality,2016-08-06,TERMINATED,INTERVENTIONAL,['NA'],Hospital length of stay,
13461,NCT01894269,overall survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],HBV reactivation,HBV resistance to lamivudine or entecavir
13462,NCT00563095,regression of tumour size,2004-03,UNKNOWN,INTERVENTIONAL,['NA'],side effects,
13463,NCT04646772,Postoperative mortality,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease Free Survival,
13464,NCT02768532,Vedolizumab concentration at week 6,2016-07-01,TERMINATED,INTERVENTIONAL,['PHASE4'],Specific antibodies (anti-integrins) level at week 54,
13465,NCT03941561,DFS,2019-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],OS,Side effects
13466,NCT02687113,RFA feasibility rates on planning USG with/without fusion CT/MR and US,2013-03,COMPLETED,INTERVENTIONAL,['NA'],Number of patients with safety access route on planning USG with/without fusion technique,Anticipated number of overlapping of RFA electrodes on planning USG with/without fusion technique
13467,NCT03864640,Content validity of Mediterranean Colorectal Cancer Registry: answering multiple-choice items,2019-02-27,COMPLETED,OBSERVATIONAL,['NA'],Face validity of Mediterranean Colorectal Cancer Registry: the major reason behind the negative response,
13468,NCT03494946,Overall Survival,2016-12-05,RECRUITING,INTERVENTIONAL,['NA'],,
13469,NCT05021029,Pre-malignant progression,2021-07-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Recruitment response rates,
13470,NCT00558207,Evaluate progression-free survival (PFS) in patients receiving ARQ 197 versus gemcitabine.,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Further characterize the safety profile of ARQ 197,
13471,NCT02678832,Social norms and cognitions toward self-management strategies of cancer patients as assessed by the variables of the theory of planned behavior (TPB),2015-12,COMPLETED,OBSERVATIONAL,['NA'],Physical activity as assessed with SQUASH,
13472,NCT03997435,Rate of pathologic complete response,2019-09-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of response to neoadjuvant therapy,
13473,NCT01972503,3 years disease-free survival,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],3 years overall survival and metastasis-free survival,
13474,NCT00677287,safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To evaluate immunological responses,
13475,NCT04412161,overall and disease free survivals,2006-04-19,COMPLETED,OBSERVATIONAL,['NA'],,
13476,NCT04971304,Number of patients who develop febrile neutropenia,2015-03-01,COMPLETED,OBSERVATIONAL,['NA'],Number of patients who develop G-CSF associated adverse events,
13477,NCT01388257,Percentage of patients having a clinical healing of their anoperineal fistulas in Crohn disease,2011-10,UNKNOWN,INTERVENTIONAL,['NA'],Change in discomfort and impact assessed by the patient using a visual analog scale (VAS),
13478,NCT04766736,Netrin-1 expression patterns in HCC samples,2019-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13479,NCT01861483,R0 resection rate,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,
13480,NCT02102646,Change in hepatic fat content,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Correlation between Hepatic fat content and baseline androgen status,
13481,NCT05080621,Expansion Phase Only: Evaluate the objective response rate (ORR) of ripretinib in combination with binimetinib by modified RECIST,2021-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Evaluate the time to response (TTR) of ripretinib in combination with binimetinib,
13482,NCT01964430,Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee,2014-03-28,COMPLETED,INTERVENTIONAL,['PHASE3'],The Number of Participants With Clinical Chemistry Laboratory-Detected Abnormalities (Grade 3-4),
13483,NCT06277908,the type of complications and the incidence of it,2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13484,NCT02308631,Safety and Tolerability of the procedure,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of animals with Adverse Events in the colostomy.,
13485,NCT04755543,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2019-06-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],Serum concentration of the antibody against LP002 within 1 hour prior to each administration,
13486,NCT03329248,Objective response rate by RECIST,2017-11-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Patient-reported outcomes of pancreatic cancer symptoms,
13487,NCT03366961,3-year overall survival,2017-12-01,WITHDRAWN,INTERVENTIONAL,['NA'],Response rate of chemotherapy,
13488,NCT00899158,Urinary 3-methylhistidine levels,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,
13489,NCT06282445,Progression-free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],TRAEs,
13490,NCT02312167,"The number of participants with adverse events, their type and severity",2014-10,COMPLETED,INTERVENTIONAL,['NA'],The ease of manipulation of the robotized probe (grade 1 to 5),"number of interpretable images per organ, per contrast agent and per pathology"
13491,NCT01206218,Progression-free Survival,2010-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Response Rate,
13492,NCT05352646,dose-limiting toxicity (DLT),2022-07-26,RECRUITING,INTERVENTIONAL,['PHASE1'],recurrence-free survival(RFS) rate,
13493,NCT04965870,Progression Free Survival,2021-06-30,COMPLETED,OBSERVATIONAL,['NA'],Disease Control Rate,
13494,NCT02777437,Disease free survival,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The proportion of completion of laparoscopic surgery,
13495,NCT04769713,Changes in narcotic use after a hepatic hilar nerve block during and immediately after liver chemoembolization,2021-11-23,RECRUITING,INTERVENTIONAL,['PHASE4'],Differences in disease response post liver tumoral chemoembolization between patients with hepatic hilar nerve block and those with sham procedure,
13496,NCT02521285,Differences in the Activation Status of NF-kB by Assessing Levels of Total and Phospho-p65 and Cytoplasmic to Nuclear Translocation of Phospho-p65 at 12 Months (Location C),2016-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Differences in the Change of a13pge2 at 12 Months (Location C),Incidence of Barrett's Esophagus (BE) Recurrence
13497,NCT01845454,Efficacy of Spray Cryotherapy Dose: Percent Regression of Disease Following Baseline Spray Cryotherapy,2013-04,TERMINATED,INTERVENTIONAL,['NA'],Safety Outcomes,
13498,NCT04392700,Recurrence of HCC,2019-07-25,RECRUITING,INTERVENTIONAL,['PHASE3'],The number of overall patients,
13499,NCT00671372,The safety and tolerability of dulanermin administered in combination with FOLFIRI (with or without Bevacizumab),2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13500,NCT00842647,,2006-07,UNKNOWN,OBSERVATIONAL,['NA'],,
13501,NCT02039635,Area Under Curve (AUC) of Brief Fatigue Index (BFI) on the intake trial drugs up to 16 weeks,2013-12,COMPLETED,INTERVENTIONAL,['NA'],adverse events,"Change in blood cytokine(IL-2, IL-8, IL-10) level after 16 weeks of trial drug intake"
13502,NCT01786200,Klintrup-Makinen immune score,2013-02,UNKNOWN,INTERVENTIONAL,['NA'],Local inflammatory response,
13503,NCT01134640,Safety and toxicity of Erbitux in clinical practice,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
13504,NCT03601689,Distant recurrence rate,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],Predictive factors of disease free survival,
13505,NCT00598975,Number of Patients With Dose Limiting Toxicities,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Overall Response,
13506,NCT00862784,Progression-Free Survival (PFS),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Serum Anti-IMC-1121B (Immunogenicity) at Day 1,
13507,NCT00764140,mortality,2007-01,COMPLETED,OBSERVATIONAL,['NA'],distant metastasis,
13508,NCT00380588,Percentage of Patients Alive at 1 Year (1-Year Survival Rate),2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival,Survival Time
13509,NCT01132534,"To compare the detection rate of premalignant lesions(intestinal metaplasia, gastric atrophy, dysplasia) and early neoplasia of stomach between combined AFI/NBI endoscopy versus standard endoscopy",2007-06,COMPLETED,OBSERVATIONAL,['NA'],To assess the diagnostic accuracy AFI and NBI imaging,
13510,NCT04532736,Lund-Kennedy endoscopic grading system (NPS),2017-09-02,COMPLETED,INTERVENTIONAL,['PHASE2'],"Presence of peripheral eosinophilia (PE, > 500/mcl) in blood samples",
13511,NCT03208335,progress-free survival(PFS),2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life (QOL),
13512,NCT01371240,Pancreatic tumor conspicuity on MRI,2011-06,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],post-injection complications and side effects of secretin,
13513,NCT02783261,liver hypertrophy,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,
13514,NCT06091592,Serum autotaxın level,2020-12-30,COMPLETED,OBSERVATIONAL,['NA'],tumor differentiation grade,
13515,NCT00339742,Esophageal Cancer,2003-03-25,COMPLETED,OBSERVATIONAL,['NA'],,
13516,NCT06233981,Median Overall Survival,2024-01-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Toxicity,
13517,NCT06008054,Recommended Phase II Dose (RP2D),2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-Emergent Adverse Event (TEAE),
13518,NCT05884255,Progression-free survival (PFS) assessed by BICR,2023-07-06,RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence and severity of AE and SAE,
13519,NCT02307812,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
13520,NCT05486572,Hepatocellular Carcinoma Mortality,2023-11-03,RECRUITING,INTERVENTIONAL,['NA'],Overall Survival,
13521,NCT05578430,Major Pathological Response Rate (MPR rate),2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events (AE),
13522,NCT05701436,The one-year DFS rate,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse events,
13523,NCT05030090,Evaluate nutritional status indicators change,2021-06-25,COMPLETED,INTERVENTIONAL,['NA'],Evaluate quality of life indicators change,
13524,NCT05487924,postoperative complication,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],time to first flatus,
13525,NCT03026803,Response Rate,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13526,NCT01361035,"Change in cervical, breast and colorectal cancer screening rates",2008-06,COMPLETED,INTERVENTIONAL,['NA'],Change in standardized patient ratings of physician communication behaviors,
13527,NCT02399059,Global survival,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Disease free survival,
13528,NCT05394415,Treatment safety,2022-05-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
13529,NCT00638612,Incidence of treatment emergent adverse events,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Functional Assessment of Cancer Therapy - Pancreas (FACT-Hep),
13530,NCT03380052,The evaluation of OLGA and OLGIM stage systems with serum pepsinogen for prediction of gastric cancer risk,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,
13531,NCT03622437,Health-related quality of life and symptom burden,2016-02-26,COMPLETED,INTERVENTIONAL,['NA'],Cost-benefit - QALY's,
13532,NCT04032353,"the incidence of upper gastrointestinal cancers, including gastric cancer and esophageal cancer.",2018-12-31,UNKNOWN,INTERVENTIONAL,['NA'],tthe focal lesions of upper gastrointestinal tract,adverse events
13533,NCT00077389,Rate of complete remission after completion of study therapy,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Event-free survival,
13534,NCT02352831,Progression-free Survival (PFS) Rate,2015-08-31,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With a CA19-9 Response,
13535,NCT00030082,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13536,NCT03041571,Patient provider orientation scale score (PPOS),2017-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],Medical honors students focus group,
13537,NCT01863420,Hematologic toxicity,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],Conformity and Homogeneity of IMRT plan,
13538,NCT05214222,Objective Response Rate (ORR),2022-09-02,RECRUITING,INTERVENTIONAL,['PHASE2'],The 3-year OS rate,
13539,NCT04151030,Technical success of endoscopic vs radiographic Push-PEG placement in patients who are not candidates for a Pull-PEG placement,2019-06-28,COMPLETED,INTERVENTIONAL,['NA'],Procedure duration between endoscopic push PEG placement and IR guided push PEG placement,
13540,NCT06038552,Overall survival,2002-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13541,NCT00493857,The primary goal is to assess the Objective Response Rate (ORR) that the combination of irinotecan and nimotuzumab will produce in patients with irinotecan-refractory metastatic colorectal cancer,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],"Assess the incidence of acneiform rash,drug reaction,adverse events, the assessment of progression-free survival,stable disease,time to disease progression, overall survival, objective response rates, safety and trough levels in the serum of patients.",
13542,NCT05489250,Tumor mutations and their impact on treatment decisions in gastrointestinal cancer patients,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],QoL via EORTC QLQ-STO22 questionnaire in genetically defined cohorts of EC/GC patients,"Feasibility of the PLATON WebApp - an interactive platform that connects the participating physicians on cases, cancer types, mutations, protein expressions and therapies, possible trials and discussion options for medical professionals"
13543,NCT03985670,Pathological complete response rate,2019-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],disease-free survival rate,
13544,NCT05830890,Accuracy,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Sensitivity,
13545,NCT03112837,the incidence of Radiation Therapy Oncology Group grade 3 mucositis,2017-03-10,UNKNOWN,INTERVENTIONAL,['NA'],,
13546,NCT04712643,Overall Survival (OS),2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Adverse Events,
13547,NCT03528941,Number of patients with hepatitis B reactivation,2018-11-28,COMPLETED,OBSERVATIONAL,['NA'],Rate of adverse events during ibrutinib treatment,
13548,NCT00003594,time to progression,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],quality of life,
13549,NCT00903565,To validate the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage II colorectal cancer.,2008-09,UNKNOWN,OBSERVATIONAL,['NA'],• Compare the ColoPrint results from fresh RNARetain colorectal tumor specimens to the matched formalin-fixed paraffin-embedded tissue (FFPE) colon tumor specimens for concordance.,
13550,NCT03052556,Prevalence of HPV carriage,2017-03-08,COMPLETED,INTERVENTIONAL,['NA'],Rate of worsening of cervical dysplasia,
13551,NCT04307654,Postoperative complications,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
13552,NCT02954094,"Establish a longitudinal observational cohort to understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice",2016-12,RECRUITING,OBSERVATIONAL,['NA'],Establish a Biorepository Specimen Bank (BSB),
13553,NCT02021422,The Number of Participants with SAEs and AEs.,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],Gather preliminary information on the immune modulation and clinical activity of this therapy,
13554,NCT04761185,tolerable dose,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
13555,NCT02739698,"The Grouped Miller and Payne (MP) System for Pathological Response: G1 (Minimal Changes and < 30% Cells Tumour Reduction That Includes MP G1-G2), G3 (Microscopic Foci, Cells Tumour Reduction up to >90% That Includes MP G3-G4) and G5 (no Residual Tumour)",2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13556,NCT05440565,Detection rate,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
13557,NCT01999634,anastomotic leaks rate,2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE3'],functional success of microdialysis,
13558,NCT00505024,"To study the effectiveness of the interactive voice response system (IVRS), which is designed to send a report to a patient's doctor about severe symptoms they are experiencing.",2006-07,COMPLETED,INTERVENTIONAL,['NA'],"To study if systematic symptom assessment (by the use of IVRS) is another way to report symptoms rather than the usual method, which is calling the doctor when there is a problem.",
13559,NCT00720512,Progression-free survival,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Safety,
13560,NCT02272036,Bowel cleanness measured by Boston Bowel preparation Scale,2015-12,COMPLETED,INTERVENTIONAL,['NA'],Patient satisfaction and compliance,
13561,NCT03524716,Text message response rate,2018-03-06,COMPLETED,INTERVENTIONAL,['NA'],Social support,
13562,NCT04975256,Establish Maximum Tolerated Dose,2021-08-12,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate preliminary clinical activity of the combination regimen,
13563,NCT04728750,Complete enucleation of a tumor in the pancreas,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
13564,NCT05729230,Perception of prognosis and treatment side effects,2021-04-05,COMPLETED,OBSERVATIONAL,['NA'],Evaluation of patient satisfaction with the information received during the consultation,
13565,NCT04764643,Mean Visual analogue scale change,2020-02-01,COMPLETED,INTERVENTIONAL,['NA'],exam time,
13566,NCT00514020,"Number of Patients With Each Response in ""Good Risk"" Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression])",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13567,NCT01247246,Efficacy,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety,
13568,NCT03937440,Difference of stress responses between deep block and moderate block,2019-07-03,COMPLETED,INTERVENTIONAL,['NA'],,
13569,NCT02215642,Disease-specific survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,Disease-free survival
13570,NCT05228587,To identify IGT PDR cut-off level below which the liver graft is not to be used for solid organ transplantation,2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],To identify IGT PDR cut-off level(s) below which post-LT organ recovery is impaired (early allograft dysfunction).,
13571,NCT03117556,Daily Narcotic Requirements,2017-08-31,WITHDRAWN,INTERVENTIONAL,['NA'],Use of Anti-emetics,
13572,NCT01883908,Number of Patients Completing Acupuncture Treatment,2012-12,TERMINATED,INTERVENTIONAL,['NA'],,
13573,NCT03851887,ORR,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],DCR,
13574,NCT02241551,"Safety and Efficacy Using Neo-adjuvant Gemcitabine Plus Nab-paclitaxel in Patients Receiving SBRT and Surgery for Borderline Resectable Pancreatic Cancer, Using Neo-adjuvant mFOLFIRINOX as a Control",2014-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of Life Effects of Chemotherapy on Patients Receiving Chemotherapy and SBRT,
13575,NCT02557932,H. pylori eradication rate,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Factors associated with H. pylori reinfection,
13576,NCT00684801,Caregiver's satisfaction with end-of-life care,2007-08,COMPLETED,OBSERVATIONAL,['NA'],,
13577,NCT04913376,Time until Grade 2 or higher patient-reported peripheral neuropathy after start of treatment in the first 12 weeks,2021-05-17,UNKNOWN,INTERVENTIONAL,['NA'],Secondary Outcome Measures regarding comfort hilotherapy,
13578,NCT05667064,Incidence of ADRs,2023-05-10,RECRUITING,OBSERVATIONAL,['NA'],,
13579,NCT01263171,Proportion of patients who commence neoadjuvant chemotherapy and radiotherapy and then undergo surgical resection,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"Local recurrence-free, distant metastasis-free, and overall survival at 1 year after surgery",
13580,NCT03277144,incidence of duodenal stump leak,2017-09-11,UNKNOWN,INTERVENTIONAL,['NA'],Frequency of DSF by surgical volume,
13581,NCT03825861,Pathologic Complete Response (pCR),2017-02-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of Disease Progression,
13582,NCT05937919,Standardized uptake value,2023-05-28,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Number of participants with drug-related adverse events,
13583,NCT05751343,Objective response rate,2023-03-09,RECRUITING,INTERVENTIONAL,['PHASE2'],progress-free survival,
13584,NCT00006117,,1999-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13585,NCT00826540,Progression-free Survival Rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Feasibility of Study Treatment,
13586,NCT03374254,Percentage of participants with a dose limiting toxicity (DLT),2018-02-16,COMPLETED,INTERVENTIONAL,['PHASE1'],Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),
13587,NCT00705731,"Adherence to colorectal cancer (CRC) screening, defined as completion of the screening strategy (the subject agrees to pursue/scheduled by the primary care provider).",2007-03,COMPLETED,OBSERVATIONAL,['NA'],Identification of variables in the survey (based on the Health Belief Model) which are associated with non-adherence to screening.,
13588,NCT04850157,Relapse-free survival( RFS),2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events (AEs),
13589,NCT01494363,Response rate,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
13590,NCT06064344,The cumulative occurrence rate of complications of grade ≥2 within 2 years after the start of treatment,2023-10-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],2-year overall survival rate,
13591,NCT04841616,False negative rate,2021-07-01,RECRUITING,INTERVENTIONAL,['NA'],the need to repeat procedure,
13592,NCT01097018,Overall Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Progression-free Survival,
13593,NCT05844046,ORR,2023-04-06,RECRUITING,INTERVENTIONAL,['PHASE2'],ORR-BICR,QOL
13594,NCT01637194,Number of patients with dose limiting toxicity,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacodynamic effects of this regimen on post-therapy tumor and/or skin specimens,
13595,NCT00757614,Evaluation of interactions between polymorphisms in predisposition genes and potential lifestyle risk factors,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],,
13596,NCT05842525,Objective response rate (ORR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Progression-Free Survival (PFS),Disease Control Rate (DCR)
13597,NCT05198856,progression-free survival (PFS),2022-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Percentage of Participants With Adverse Events (AEs),
13598,NCT04643405,Overall Response Rate (Applicable for: phase II stage) .,2021-03-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse events,
13599,NCT03942328,Progression-free survival rate at 2 years (Phase II),2019-09-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival,Change in immunologic correlates before and after vaccination treatment
13600,NCT04931654,Preliminary anti-tumour activity of AZD7789,2021-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Preliminary anti-tumour activity of AZD7789: Changes in circulating tumor DNA (ctDNA),
13601,NCT02072720,Change of VEGFR2 phosphorylation with IHC,2014-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Changes in vascular parameters in the tumor tissue to asses ongoing angiogenesis,
13602,NCT05848947,Effective dose (Gy) for the whole body,2023-04-25,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13603,NCT02705196,Number of patient with dose-limiting toxicities (DLTs) as evaluated accordingly to CTCAE 4.0,2016-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
13604,NCT03052335,Negative predictive value (NPV) of the CCE2 for large polyps (≥ 10 mm),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Cost-effectiveness analyses: cost reduction of preventive colonoscopies spared,
13605,NCT02205463,Maximum Tolerated Dose (MTD),2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Pharmacokinetics of KD019,
13606,NCT00005876,,2000-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13607,NCT00767273,Evaluate the performance of the novel imaging methods,2006-10,COMPLETED,INTERVENTIONAL,['NA'],Correlate FLT activity with clinical outcomes,
13608,NCT00677456,"Patients should live for 6 months at least, and with acceptable life quality",2008-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],There are significant differences among life qualities of the four reconstructions,
13609,NCT01594125,Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With Response by Alpha Fetoprotein (AFP),
13610,NCT02130427,Tumor Volume,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,
13611,NCT02210260,Neuroendocrine response to surgery,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Inflammatory pathway,
13612,NCT01091207,Disease-control rate,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Response rate,
13613,NCT04529850,Incidence of Treatment Emergent AE's,2020-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],Cumulative Incidence of Severe OM,
13614,NCT04291651,Indolency,2019-10-08,RECRUITING,OBSERVATIONAL,['NA'],,
13615,NCT04361708,The maximum dose tolerated,2020-05-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival rate,
13616,NCT00615420,Severity of Mucositis According to the Radiation Therapy Oncology Group (RTOG) for Patients Who Had a Minimum of 2 Mucositis Assessments,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13617,NCT02921646,Resting energetic expenditure measurement by indirect calorimetry,2017-07-10,TERMINATED,INTERVENTIONAL,['NA'],,
13618,NCT05103007,FLR,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],Progression-free survival (PFS),
13619,NCT03033446,Response Rate,2016-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events from the combination of RE and nivolumab assessed by NCI CTCAE v4.0,
13620,NCT00002842,2 Year Disease-free Survival .,1994-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13621,NCT00077441,"Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 6 weeks apart",2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to treatment failure,
13622,NCT02549053,Research of HPV DNA in esophagus biopsies using real time polymerase chain reaction (PCR),2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
13623,NCT01898091,Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily Questionnaire*.,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13624,NCT00478010,Decision satisfaction,2007-01-19,COMPLETED,INTERVENTIONAL,['NA'],,
13625,NCT01759901,Post-operative surgical complications,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Recurrence rate of hepatocellular carcinoma,
13626,NCT05544253,recurrence-free-survival,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13627,NCT00514163,response rate,2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],clinical benefit response,
13628,NCT04326296,"Safety, Tolerability",2020-05-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
13629,NCT03349957,tumeur response,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
13630,NCT03568019,A retrospective review to determine if PET can be used to identify cachexia-inducing lung and gastrointestinal tumors,2013-11-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
13631,NCT02298946,Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to Maximum Observed Plasma Concentration (Tmax) of AMP-224,
13632,NCT03604653,Disease-free Survival,2018-05-15,COMPLETED,OBSERVATIONAL,['NA'],Toxicity as measured by treatment related adverse events according to the NCI CTCAE v 4.0,
13633,NCT04304131,sensitivity and specificity of EarlyTect,2020-06-07,COMPLETED,INTERVENTIONAL,['NA'],,
13634,NCT05224518,Quality of life of cancer patients(EORTC QLQ-CR29),2022-02-21,RECRUITING,INTERVENTIONAL,['NA'],Exercise Counseling and Programming Preferences,
13635,NCT03988712,Diagnostic yield of colorectal cancer,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
13636,NCT02730611,Blood bile acids (micromols per liter),2016-03,COMPLETED,OBSERVATIONAL,['NA'],Hepatic FXR expression,
13637,NCT02843581,Relief degree,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival（OS）,
13638,NCT00654212,successful one-stage operation,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4'],"cumulative operative time, cumulative blood loss, conversion rate, post-operative pain, cumulative length of hospital stay, operative mortality, post-operative complications, ates of permanent stoma creation,disease recurrence, survival",
13639,NCT01952847,Severity of Oral Mucositis for mTOR Inhibitor Patients,2014-07-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Summary of Adverse Events by Grade and Relationship - mTOR Inhibitor Cohort,
13640,NCT00909350,miR expression between tissue from Barrett's esophagus and that from normal tissues,2008-04,COMPLETED,OBSERVATIONAL,['NA'],expression of miR in Barrett's esophagus patients with cancer in comparison to those who do not progress to cancer,
13641,NCT05927142,Phase II: Determine the clinical benefit rate of combination therapy with durvalumab and rintatolimod.,2024-01-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Determine the clinical effect of combination therapy on quality of life using questionnaires,
13642,NCT00055809,Tumor response rate (CR + PR) as measured by RECIST criteria,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity graded according to CTC v3.0 criteria for adverse outcomes,
13643,NCT04589884,To collect human tissue spectral features to build a spectral tissue library and build successively machine learning algorithm to enable real-time automated tissue recognition,2020-09-22,TERMINATED,OBSERVATIONAL,['NA'],To correlate HSI values with pathological data obtained as standard of care,
13644,NCT04407247,Treatment-related adverse events,2020-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Recurrent immune-related diarrhea/colitis,Change in frequencies of immune cells in tissue/blood/stool samples
13645,NCT04588805,ncidence Rate of Perioperiative VTE,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13646,NCT00634725,Overall survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],tolerance to erlotinib,
13647,NCT06047158,Immune related index,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],Hospitalization related,
13648,NCT00077337,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13649,NCT04247503,Incidence of cancer in the risk cohort,2019-12-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Measurement of test accuracy of biomarkers to detect pancreatic cancer,
13650,NCT05963191,to evaluate the effectiveness of the CAD EYE system in screening for neoplastic lesions in Lynch syndrome.,2023-10-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Time of Colonoscopies,
13651,NCT04673136,Detection of advanced lesions,2021-04-01,COMPLETED,INTERVENTIONAL,['NA'],Characteristics of GI-GENIUS,
13652,NCT00897442,Make available tissue and blood for proposed projects,1992-06,COMPLETED,OBSERVATIONAL,['NA'],,
13653,NCT00820339,Overall survival,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications",
13654,NCT00867464,Increase in the rate of cervical lesions associated with other carcinogenic HPV types that the vaccine does not protect against from prevention of HPV-16/18 associated cervical lesions through vaccination,2009-03-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
13655,NCT05226221,30-day morbidity rate,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],Emergency Surgical Frailty Index (EmFSI),
13656,NCT05239546,Major Clinical Response (MCR) Rate,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Response Rate (ORR),
13657,NCT03787056,ROC curve AUC regarding diagnostic accuracy of progastrin levels at baseline in cancer patients compared to non-cancer controls,2018-12-04,RECRUITING,INTERVENTIONAL,['NA'],"Comparison of the initial values and of the kinetics of other serum tumor markers (CA15-3, CA 19-9, CA125, CEA, PSA, AFP) with those of progastrin",
13658,NCT05526339,The incidence of hypoxia,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The incidence of other adverse events,
13659,NCT00122187,Percent of Patients Receiving GI Consult Plus Anatomic Workup for FOBT+ Results,2005-08,COMPLETED,INTERVENTIONAL,['NA'],,
13660,NCT01909830,Objective Response Rate (ORR),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
13661,NCT05447234,Overall Survival,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],AEs,
13662,NCT05287880,Comparison of BP between MLN and BLN.,2022-03-10,UNKNOWN,OBSERVATIONAL,['NA'],,
13663,NCT03708328,"Expansion: Progression Free Survival, Assessed According to RECIST v1.1",2018-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Dose Escalation: Progression Free Survival, Assessed According to RECIST v1.1",
13664,NCT05792735,Pathological Complete Response Rate,2023-04-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of participants with treatment-related adverse events (TRAE) as assessed by CTCAE v5.0,Quality of life (QoL)
13665,NCT03345225,Comparing the change in the Lencioni score between the SureFire infusion system and a standard endhole microcatheter,2018-05,WITHDRAWN,INTERVENTIONAL,['NA'],Number of Adverse Event,
13666,NCT05388513,Survival,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
13667,NCT03998644,"Gut microbiota structure and function difference between colorectal cancer, precancer and healthy controls",2015-12,RECRUITING,OBSERVATIONAL,['NA'],"Metabolic difference of blood samples between colorectal cancer, precancer and healthy controls",
13668,NCT02993731,Overall Survival,2016-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Mean Change From Baseline for Global Quality of Life (QoL) at 8 Weeks.,Overall Response Rate in Biomarker Positive Patients
13669,NCT01919463,Mean Intubation Time (MIT),2015-03,UNKNOWN,INTERVENTIONAL,['NA'],Polyp Detection Rate (PDR),
13670,NCT00751036,Progression-free Survival (PFS),2009-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),
13671,NCT03480152,Number of Non-Serious Adverse Events Probably Related to Treatment,2018-05-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With an Increase in the Quantity and Quality of Circulating Antigen-specific T Cells,Maximum Tolerated Dose (MTD
13672,NCT00766480,Complete histological response,2007-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13673,NCT05884723,Perioperative blood transfusion,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Cancer-related mortality,
13674,NCT02046356,Technical success,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],IDR-free survival,RFA complications
13675,NCT02775227,Comprehensive Complication Index,2016-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Readmissions,Disease specific survival
13676,NCT01586416,Number of participants who withdraw from study after enrollment,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],Proportion of each chemotherapy component administered during the treatment regimen relative to the total planned amount,
13677,NCT02911961,APAP-CYS Concentrations Over Time - Acetaminophen Group,2021-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],Relationship between APAP-CYS and other biochemical markers of liver function,
13678,NCT05381038,CURATE.AI applicability: percentage of participants in whom the investigators successfully apply CURATE.AI profile.,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinically significant dose changes,ctDNA Analysis
13679,NCT02657330,Maximum tolerated dose of SBP-101,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Plasma drug half-life,
13680,NCT00007930,Local recurrence at 3 years,1999-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Disease-free and overall survival at 5 years,
13681,NCT01695863,Bowel Prep Efficacy - Boston Bowel Preparation Scale (BBPS),2012-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Renal Function Pre and Post Bowel Prep - Continued (mmol/L),Non-Serious Adverse Events on Self Report Scale
13682,NCT05628441,Combined performance of endoscopist + CADe system in terms of per-patient sensitivity and specificity,2022-05-16,COMPLETED,OBSERVATIONAL,['NA'],Stand-alone performance of CADe system in terms of per-patient sensitivity and specificity,
13683,NCT02973490,postoperative complications,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13684,NCT05738616,Overall survival at 2 years,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life assessment,
13685,NCT01755585,all cause mortality,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],,
13686,NCT00267696,Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or Responding.,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival for Patients Treated With the Regimen.,
13687,NCT04310540,Association between prostate specific membrane antigen (PSMA) uptake in hepatocellular carcinoma at PET with tissue PSMA expression,2020-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
13688,NCT03926338,Pathological complete response (pCR) rates,2019-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Surgery feasibility,
13689,NCT04166721,Main phase IIB (efficacy) phase: Best objective response rate (ORR) using RECIST 1.1 criteria,2020-02-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
13690,NCT04949737,Estimation of the prevalence of Helicobacter pylori,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13691,NCT00100815,Progression-free Survival,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
13692,NCT00192114,Percentage of Participants With Progression Free Survival (PFS) at 6 Months,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Carcinoembryonic Antigen (CEA) Response at Each Cycle,Change From Baseline in Vascular Endothelial Growth Factor (VEGF) to Cycle 2 and Cycle 3
13693,NCT01216527,Overall survival rate,2007-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],Disease free survival rate,
13694,NCT00788697,Specificity: Percentage of True Negative Lesions Among All Malignant Lesions Per Truth Standard,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Inter-reader Agreement,
13695,NCT04149015,Pathological complete and subtotal regression (TRG1a/b by Becker),2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13696,NCT04697186,Helicobacter pylori eradication,2021-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],adverse events,
13697,NCT05450029,Pathological complete response,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between minimal residual disease (MRD) and survival,
13698,NCT01832116,The in vivo biodistribution measured in SUV values and organ pharmacokinetics (PK) of 89Zr-MMOT0530A,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of patients with adverse events after 89Zr-MMOT0530A injection as a measure of safety and tolerability,
13699,NCT03035253,Incidence of dose limiting toxicities,2016-12,TERMINATED,INTERVENTIONAL,['PHASE1'],Progression Free Survival,
13700,NCT03220009,Recurrence free survival (RFS),2017-11-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Rate of delayed surgery,T cell inflammation
13701,NCT04175756,Total operative time,2020-01-02,COMPLETED,OBSERVATIONAL,['NA'],Quality of excision: M.E.R.C.U.R.Y. criteria,
13702,NCT00081627,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13703,NCT02653313,Shedding of viral genomes [Vg],2015-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Clinical outcome,
13704,NCT00268411,Objective response rate,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],Progression-free and overall survival,
13705,NCT00088868,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13706,NCT01292330,postoperative complications,2010-01,UNKNOWN,INTERVENTIONAL,['NA'],hospitalization expenses and length of stay,
13707,NCT04239001,Incidence of degree 3-4 neutropenia in each cycle of chemotherapy,2020-02,UNKNOWN,INTERVENTIONAL,['NA'],The proportion of patients receiving antibiotics during the entire chemotherapy period.,
13708,NCT06204484,Relapse-free survival (RFS) time in MRD-negative groups,2023-07-26,RECRUITING,INTERVENTIONAL,['NA'],OS time in MRD+ groups,Performance of landmark MRD status and longitudinal MRD status in prediction of recurrence.
13709,NCT00932438,Tumor Response,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Serious Adverse Events,
13710,NCT04380545,Incidence of adverse events,2021-01-13,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival (PFS),Tissue and blood immunohistochemistry
13711,NCT04902872,Phase 2: Overall response rate (ORR),2021-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Incidence of TEAEs,
13712,NCT03603366,Patients' benefit/risk trade-offs,2019-08-14,COMPLETED,OBSERVATIONAL,['NA'],Preferences of aspirin using in different subgroups,
13713,NCT02023021,Recurrence-free survival at one year after curative resection,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],CA199 level after curative resection,
13714,NCT05002855,Evaluate the effect of the implementation of this protocol on 3-year overall survival.,2021-01-20,COMPLETED,OBSERVATIONAL,['NA'],,
13715,NCT01739439,MTD defined as the dose level in which 1 out of 6 patients observes dose-limiting toxicity (DLT) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,2013-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
13716,NCT06042998,3-year disease-free survival,2023-07-07,RECRUITING,INTERVENTIONAL,['NA'],postoperative recovery course,
13717,NCT04207489,The imaging effect of indocyanine green,2020-04-15,UNKNOWN,OBSERVATIONAL,['NA'],,
13718,NCT01150630,Event-free survival at 1 year (phase II),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Lymph node status,
13719,NCT03595345,Tumour-specific death,2016-12-15,COMPLETED,OBSERVATIONAL,['NA'],Drop-out,
13720,NCT00006010,six-month overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],time to progression,
13721,NCT00005049,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13722,NCT06143605,DFS,2013-01-30,COMPLETED,OBSERVATIONAL,['NA'],,
13723,NCT05326152,Immediate adverse effects,2020-11-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Recurrence,
13724,NCT02430636,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Overall survival (OS),
13725,NCT00738790,The rate of patients with downstaging after radiotherapy to pathological complete response or ypT1 disease with negative margins.,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],"The rate of local control, overall survival and disease-free survival and toxicity.",
13726,NCT03667495,Colorectal cancer or adenoma recurred,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13727,NCT00946153,Phase 2: Time to Progression (TTP) by Independent Review Assessment,2009-07-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Overall Survival (OS),
13728,NCT01962168,Freedom from symptomatic recurrent biliary obstruction requiring reintervention,2013-12,COMPLETED,OBSERVATIONAL,['NA'],Ease of use,
13729,NCT05434026,the rate of postoperative complications,2022-08-03,RECRUITING,OBSERVATIONAL,['NA'],,
13730,NCT03420443,Action of synbiotics on irradiated GI mucosa in rectal cancer treatment,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
13731,NCT00216086,Pathological Complete Response (pCR) Rate,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Disease-Free Survival,
13732,NCT01415609,Ease of use of the overall procedure and Time of procedure.,2010-08,COMPLETED,OBSERVATIONAL,['NA'],Complications and Rate of Completion,
13733,NCT00005860,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13734,NCT00746655,To evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.,2009-07,WITHDRAWN,INTERVENTIONAL,['NA'],To determine if SBRT and TACE will be able to bridge patients to transplant that were initially ineligible.,
13735,NCT00921531,Overall survival,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],time to progression,
13736,NCT04080024,Number of treatment related adverse events (AEs),2019-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetics as measured by apparent volume of distribution at steady state (Vss) for Mn (L) the terminal phase half-life (T½) for manganese (Mn),Visualization of the pancreatic duct
13737,NCT02103062,Progression Free Survival (PFS) Rate as Measured at Week 8,2014-05-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events,Kaplan Meier Estimate of PFS by Investigator Assessment
13738,NCT05331131,Assessing Pain Response,2022-09-19,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse events,
13739,NCT02777463,The statistical analysis of the correlation between pretreatment ADC value of diffusion MRI and pathologic response evaluated by Evans grade in patients with borderline resectable pancreatic carcinoma (BRPC) who undergo neoadjuvant therapy.,2016-06,COMPLETED,OBSERVATIONAL,['NA'],The statistical analysis of the correlation between tumor's limb sign in diffusion MRI and the rate of tumor cell destruction more than 10%.,
13740,NCT01929421,Response rate,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],number of participants with adverse events,
13741,NCT06028737,Histopathological tumor response rate (Becker regression criteria).,2023-08-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Correlation between the pathohistological response and overall and disease-free survival.,
13742,NCT01097083,,2010-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13743,NCT00913757,Large-scale molecular profiling study to identify HCC biomarkers for early diagnosis and prevention.,2009-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
13744,NCT00915850,Safety (Phase I: toxicities as assessed by NCI CTCAE version3) and efficacy (Phase II: Feasibility as evaluated by RECIST),2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",median survival time (Phase II),
13745,NCT00268437,Pathologic Complete Response Rate,2006-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
13746,NCT02717091,R0 resection rate,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of the tumor,
13747,NCT05797077,5-years Progression Free Survival,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE3'],Complication,
13748,NCT00786747,Up to date colorectal cancer screening status,2010-02,COMPLETED,INTERVENTIONAL,['NA'],Readiness to undergo colorectal cancer screening,
13749,NCT03256344,Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT),2018-03-19,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
13750,NCT03368651,Overall survival (OS),2016-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],recurrence rate,
13751,NCT04713007,Perception of Care Coordination Caregiver,2021-06-03,RECRUITING,INTERVENTIONAL,['NA'],,
13752,NCT01596361,Verify the differences observed in the frequency of germline pharmacogenetic variants related to chemotherapy between Asian and Caucasian CRC patients,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],Characterise the deletion status of heat shock protein molecules and determine the association between heat shock protein deletion status and clinico-pathological outcomes in Asian and Caucasian patients with CRC,
13753,NCT04462042,Acute grade >2 hematological side effects,2021-04-07,RECRUITING,INTERVENTIONAL,['NA'],Overall survival,Cost-utility analysis
13754,NCT01347645,Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),2011-09-30,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Percentage of Participants With Overall Response,
13755,NCT04990895,Assessment of the Quality of Life of Colorectal Cancer Patients Using EORTC-QLQ CR29 Questionnaire,2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE3'],Patient self-efficacy,
13756,NCT05976568,Overall Survival (OS) (Phase III),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Time to progression (TTP),
13757,NCT06222944,ORR,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
13758,NCT04792801,Rate of patients reclassified for lymph node fixation (N +) and / or extrahepatic extension (M +) after PET TDM FDG-Choline,2021-06-22,RECRUITING,OBSERVATIONAL,['NA'],Binding intensity (SUV) of PET TDM FDG-Choline and the last aFP value before transplantation or WL dropout.,
13759,NCT02297269,the incidence of DVT,2014-12,UNKNOWN,OBSERVATIONAL,['NA'],incidence of incision infection,
13760,NCT00397540,"1,3,5 Year-Disease Free Survival (or Recurrence Free Survival)",2004-10,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival,
13761,NCT03575637,time to treatment failure,2018-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Progression free survival time (PFS), overall survival time (OS).",
13762,NCT03117972,Progression Free Survival,2017-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
13763,NCT00967603,6-month progression-free survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],pharmacodynamics,
13764,NCT02742597,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,2016-01-12,COMPLETED,INTERVENTIONAL,['NA'],Evaluation of Intervention Effectiveness - Change in Demographics,
13765,NCT02461407,Overall Survival (OS),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Disease Control Rate (DCR),
13766,NCT06293625,DFS (disease Free Survival),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
13767,NCT02720666,The maximum-tolerated dose (MTD) of K-001,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Clinical efficacy of K-001 assessed by disease control rate (DCR) according to RECIST V 1.0 criteria,
13768,NCT04019808,H. pylori prevalence and drug resistance,2019-07-30,UNKNOWN,OBSERVATIONAL,['NA'],,
13769,NCT03894618,Maximum Tolerated Dose (MTD) of SL-279252,2019-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Volume of distribution,
13770,NCT03311152,Presence of hepatocellular carcinoma.,2018-02-12,RECRUITING,INTERVENTIONAL,['NA'],Presence of early hepatocellular carcinoma. Early hepatocellular carcinoma will be defined as a tumor smaller than 30 mm according to Kudo M (Liver Cancer. 2013;2:69-72).,
13771,NCT00003851,,1999-03,TERMINATED,INTERVENTIONAL,['NA'],,
13772,NCT01560260,Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"Correlations Between Glucose, Insulin, Tumor Tissue and Blood Biomarkers With FDG-PET Metabolic Response.",Determine the Number of Participants With Tumor Metabolic Response Correlating With Anatomic Response and Clinical Benefit.
13773,NCT01426074,Pathologic Complete Response (pCR),2011-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
13774,NCT02414100,"Identification of germline mutations in known cancer genes from whole blood genomic deoxyribonucleic acid, and somatic mutations in conditionally reprogrammed cells derived from pre-treatment and post-treatment (e.g., resistant) tumors",2013-12-12,WITHDRAWN,OBSERVATIONAL,['NA'],,
13775,NCT01815359,disease-free survival,2013-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],chemotherapy toxicity grade 3 to 5,
13776,NCT02164292,Feasibility of the procedure defined as percentage of patients that complete both surgical stages.,2011-06,COMPLETED,OBSERVATIONAL,['NA'],Risk factors for a reduced kinetic growth rate of the future liver remnant (<35 cc/day),
13777,NCT02007954,Collection of Adverse Events Related to Study Device as a Measure of Safety,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],AFP Tumor Marker Pre- and Post-treatment,Exploratory Endpoint - Tmax of Doxorubicin and Doxorubicinol Post DEBDOX-M1 TACE
13778,NCT05489211,PSA50 response (Substudy 3 only),2022-09-06,RECRUITING,INTERVENTIONAL,['PHASE2'],CA-125 response (Substudy 4),
13779,NCT01412957,Overall Survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Maximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval,
13780,NCT03626922,Objective Response Rate to pembrolizumab and pemetrexed plus oxaliplatin,2019-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival,
13781,NCT03924349,Success rate of localization,2019-07-08,COMPLETED,INTERVENTIONAL,['NA'],Number of Participants with Complication,
13782,NCT01710592,"Determine in a randomised study if the response rate to docetaxel and oxaliplatin (ElTax) is comparable to epirubicin, oxaliplatin and capecitabine (EOX) and warrants further evaluation in advanced gastro-oesophageal cancer",2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],To examine the effect of treatment on Quality of life.,
13783,NCT00274872,Pharmaco-economic evaluation,2004-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13784,NCT01783158,To detect early synchronous second primary esophageal carcinoma,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,
13785,NCT00460174,Response rate,2005-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity profile of bevacizumab and gemcitabine with radiation therapy,
13786,NCT04345978,Disease-free Survival,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],"IL-1β，IL-2,IL-4,IL-5,IL-6,IL-8,IL-10,IL-17A,IL-17F,TNF-α，TNF-β，",
13787,NCT01216930,,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,
13788,NCT02877056,Predictive Tumor Cell Biomarkers After Chemoradiation Treatment for Colorectal Cancer,2005-08,UNKNOWN,OBSERVATIONAL,['NA'],,
13789,NCT02508467,"Number of patients with adverse events, serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findings",2015-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Preliminary evidence of fisogatinib (BLU-554) antineoplastic activity,
13790,NCT06011330,overall survival (OS),2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],progress-free survival (PFS),Treatment-Related Adverse Events (TRAE)
13791,NCT01591590,Mortality,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Tumour Progression,
13792,NCT03711058,6-month Objective Response Rate (ORR) of Patients Treated With Copanlisib and Nivolumab,2019-01-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants Experiencing Study Drug-related Toxicities,
13793,NCT00026091,Response rate (CR or PR),2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Molecular change,
13794,NCT02812641,Pathological complete response rate (randomized phase),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,Serum biomarker (VEGF-A)
13795,NCT05427396,The incidence of adverse events (AE) and serious adverse events (SAE) were assessed,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],TTP,PFS
13796,NCT05227261,Sensitivity and specificity of the test in early detecting cancers,2022-04-10,RECRUITING,OBSERVATIONAL,['NA'],Rate of cancer development in the high-risk group as compared to the moderate-risk population,
13797,NCT04644315,"Confirmed Objective Response Rate (ORR) as Determined by the Investigator Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",2021-05-24,TERMINATED,INTERVENTIONAL,['PHASE2'],OS in Participants With Primary CNS Tumors,
13798,NCT05400018,Ct Value (Ct Values From PCR Reaction),2020-11-20,COMPLETED,OBSERVATIONAL,['NA'],Kappa coefficient,
13799,NCT05479240,Pathological complete response rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
13800,NCT00499369,Progression-free Survival (PFS),2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Toxicity,
13801,NCT05815290,complete response rate,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],pCR rate,
13802,NCT02625272,the content RNA of CEA and CK20 in circulating tumor cells and ascites,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],3-year local recurrence,
13803,NCT01619696,acceptation rate of the entire sequence by eligible patients,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],"radiological changes while on chimiotherapy, to tumour regression, and prognosis",
13804,NCT01824459,Overall Survival,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Adverse events (AE),
13805,NCT03205735,progression free survival,2017-06-29,UNKNOWN,OBSERVATIONAL,['NA'],toxicities evaluation,
13806,NCT04525833,The incidence of a new diagnosis of any event of liver cirrhosis complications,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13807,NCT05933785,anal preservation rate,2018-01-02,COMPLETED,OBSERVATIONAL,['NA'],incidence of positive distal resection margin,
13808,NCT00718913,The proportion of patients completing protocol therapy (feasibility),2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
13809,NCT01111604,Progression-Free Survival (PFS),2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events,
13810,NCT05952661,Correlations of minimal residual disease (MRD) and efficacy,2023-02-22,RECRUITING,OBSERVATIONAL,['NA'],The timing of MRD advance warning of recurrence in patients ahead of imaging cues,ctDNA mutation profiles in ESCC patients undergoing adjuvant immunotherapy.
13811,NCT01070290,Compare the progression-free survival (PFS) of ARQ 197 versus investigator's choice of second-line chemotherapy in patients with advanced gastric cancer who have failed first-line treatment.,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Further characterize the safety profile of ARQ 197,
13812,NCT00114829,Sensitivity in determining malignant or benign diagnose,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],Sensitivity/specificity of MR colonography,
13813,NCT00865982,R0-resection rate,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Event free survival rate,
13814,NCT02757391,Incidence of toxicity defined as grade 3 or 4 non-hematologic or grade 4 hematologic toxicity per Common Terminology Criteria for Adverse Events version 4.0,2019-08-09,TERMINATED,INTERVENTIONAL,['PHASE1'],Overall survival,
13815,NCT02960061,Number of survival participants will be assessed according to the data collected by the followed up office.,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Progression Free Survival,
13816,NCT00086931,Complete pathological response rate at time of surgery,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Disease-free survival, safety, and overall survival at 5 years",
13817,NCT00005804,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13818,NCT04902261,1-Year Survival Rates,2020-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events (AEs),
13819,NCT02058849,Endurance,2014-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Muscle Strength,Total Body Mass
13820,NCT01853774,Primary Outcome is Clinic Attendance,2012-04,COMPLETED,INTERVENTIONAL,['NA'],The Secondary Outcome is Participant Completion of a CRC Screening Test.,
13821,NCT06335966,Patient acceptability: Number of patients interested in being screened via SECD at other care centers,2024-01-25,RECRUITING,OBSERVATIONAL,['NA'],Access: time to full diagnostic work up for patients with positive SECD results,
13822,NCT05803746,MPR,2022-07-15,RECRUITING,INTERVENTIONAL,['NA'],PFS,
13823,NCT03717038,Overall survival (OS) time following treatment with Sym004 versus TAS-102.,2019-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Pharmacokinetic (PK) Parameters of Sym004: Maximum Concentration (Cmax),
13824,NCT05171660,Progression free survival time,2022-02-08,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse Events,
13825,NCT06272656,"comparison of liver cancer markers AKR1B10, AFP, AFP-L3% and DCP before and after TACE",2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],progression- free - time,
13826,NCT03269994,Compare the effectiveness of cefoxitin with piperacillin-tazobactam as surgical antibiotic prophylaxis in decreasing the overall rate of postoperative surgical site infections in participants undergoing pancreatoduodenectomy,2017-11-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,
13827,NCT02694718,Percentage of Participants With Pathological Complete Tumor Response,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Any Adverse Events and Serious Adverse Events,
13828,NCT05290220,PFS,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],DOR,
13829,NCT05811481,Overall survival,2022-12-27,RECRUITING,OBSERVATIONAL,['NA'],Progression-free survival for the first subsequent treatment PFS 2,
13830,NCT03851913,OS,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],PFS,
13831,NCT02028806,Disease control rate,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],EORTC QLQ-C30,
13832,NCT04524260,Change of Anxiety,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA'],Change of Health related quality of life - SF-12,Socio-economic: ability to return to work
13833,NCT05911633,Technical success,2024-02-29,RECRUITING,INTERVENTIONAL,['NA'],Best overall response,
13834,NCT01161186,"to establish the maximal tolerated dose (MTD) of the AGX combination in patients with previously untreated, metastatic pancreatic adenocarcinoma.",2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],"To obtain a preliminary assessment of the clinical efficacy of AGX as measured by time to tumor progression, overall survival, objective radiographic response (ORR), and CA 19-9 biomarker response",
13835,NCT05147545,Change in circulating DNA induced by moderate effort in subjects free of malignacy,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Change in circulating DNA induced by hyperlipidic meal in patients with colon cancer,
13836,NCT03679429,Accuracy optical biopsy,2018-11,UNKNOWN,OBSERVATIONAL,['NA'],Adenoma detection rate,
13837,NCT05639413,Overall Survival (OS),2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],Correlation between predictive biomarkers and response to treatment,
13838,NCT03851471,Overall Survival,2019-04-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],10cm-VAS of the pain,
13839,NCT03307603,Phase II: Response rate,2018-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase II: Overall survival,
13840,NCT05886257,ORR per RECIST 1.1,2022-12-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],PD-L1 Biomarker,
13841,NCT01638533,Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method,2012-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria,
13842,NCT02543411,Fentanyl consumption during sedation,2015-09,COMPLETED,INTERVENTIONAL,['NA'],Incidence of nausea and vomiting,
13843,NCT03947775,The proportion of participants in each arm with biopsy-proven HGAIN (AIN-2/3).,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"The geometric mean titres (GMT) of antibody to each vaccine type above a pre-specified, validated cut-off. F",Change in anal carriage of vaccine HPV types. Repeated detection of anal HPV will indicate the duration of carriage. This will be compared between the early and delayed vaccine groups.
13844,NCT01864070,Dose Limiting Toxicities (DLT) for Combination of TheraSphere and Everolimus,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
13845,NCT01105169,Expression of Cox2 in rectal epithelia,2010-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Urine excretion of prostaglandin E2 metabolite (PGE-M),
13846,NCT02575508,Overall survival (Phase II),na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Potential associations between response rate and tumor biomarkers (Phase II),
13847,NCT01455311,Rank The Diagnostic Accuracy of Specimen,2010-09,TERMINATED,OBSERVATIONAL,['NA'],Cataloging Proteins,
13848,NCT00732836,Maximum Tolerated Dose (MTD) of HAI Abraxane,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13849,NCT02595424,PFS,2016-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Response rate (complete response or partial response) by RECIST 1.1,Prognostic significance of well differentiated non-small cell gastroenteropancreatic neuroendocrine tumors
13850,NCT00005085,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13851,NCT00440310,Overall Survival,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13852,NCT05480280,Objective Response Rate (ORR),2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
13853,NCT04591431,OVERALL RESPONSE RATE (ORR),2020-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
13854,NCT03708445,The usefulness of new staining method,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
13855,NCT03548961,number of patients whose tumor can be resected by local excision with negative margins,2018-05-11,SUSPENDED,INTERVENTIONAL,['PHASE2'],Disease-free survival (DFS) of patients,
13856,NCT05609149,3-year event-free survival rate,2016-10-30,COMPLETED,OBSERVATIONAL,['NA'],Local recurrence,
13857,NCT05615103,Pathologic complete response rate (pCR),2022-11-08,RECRUITING,OBSERVATIONAL,['NA'],Safety as measured by number of participants with Grade 3 and 4 adverse events,
13858,NCT02409524,To evaluate survival compared to historical controls,2016-07,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate safety in advanced HCC (adverse events),Tumor-Specific Immunity
13859,NCT03504293,Diagnostic accuracy,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],Adverse event rate,
13860,NCT00036712,Proportion of patients not experiencing ulcerative mucositis within the first 14 days posttransplant,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Time to heal,
13861,NCT02196688,Progression Free Survival (PFS),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Over Survival (OS),
13862,NCT05591053,Usability of the device by surgeon and support personnel satisfaction;,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],Ability of ActivSightTM to display blood vessels.,
13863,NCT03875690,frequency of patients with postoperative major complications occurring within 30 days after surgery,2019-07-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,
13864,NCT06192680,Progression free Survival,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
13865,NCT06265350,Objective response rate (ORR),2024-02-02,RECRUITING,INTERVENTIONAL,['NA'],Overall survival (OS),
13866,NCT05053750,To assess macrophage counts by image cytometry in women with platinum resistant ovarian cancer treated with weekly paclitaxel/bevacizumab and ZA relative to weekly paclitaxel/bevacizumab,2021-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
13867,NCT04195438,Measure the extent of HO-1 induction by measuring endogenous CO production in relationship to the extent of hepatic resection,2014-05-07,RECRUITING,INTERVENTIONAL,['NA'],Measure the relationship between HO-1 induction and the quality of post-hepatectomy liver regeneration,
13868,NCT01715532,Progression free survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
13869,NCT06274190,Responsiveness of the newly developed bowel e-diary in patients after rectal surgery for rectal cancer. The newly validated e-diary is the primary outcome.,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13870,NCT00470535,Progression-free Survival,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],"Correlation of Response, QOL, and Survival With EGFR, E-cadherin, P-cadherin, Vimentin, Cytokeratin, ki67, and Fibronectin and With Other Prognostic Variables, Such as Age and Tumor Grade",
13871,NCT02518529,Measurable Gastrin-17 Antibody Titer,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival from date of randomization to death or end of study,
13872,NCT01348217,Survival without locoregional relapse at 2 years (time elapsed between date of randomisation and onset of local relapse and/or lymph node involvement),2011-05-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Evaluation of the post-operative morbi-mortalities,
13873,NCT04865471,Percent of transplanted patients receiving second stage hepatectomy within 4 weeks of segment 2/3 transplantation,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],Complication rate,
13874,NCT01164150,Reduction in the incidence of ≥ grade 2 acute genitourinary (GU) and gastrointestinal (GI) toxicity according to NCI CTCAE v.3.0,2010-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall survival rate,
13875,NCT04645797,Primary Outcome Measure,2021-01-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Secondary Outcome,
13876,NCT06031818,Clinical effectiveness of the explanation framework,2023-12-10,RECRUITING,OBSERVATIONAL,['NA'],Usability of the explanation framework,
13877,NCT03718078,malignant pCLE criteria,2019-03,UNKNOWN,INTERVENTIONAL,['NA'],pCLE criteria diagnostic performance,
13878,NCT06035250,Accuracy of TRG prediction by the AI model,2023-09-10,RECRUITING,OBSERVATIONAL,['NA'],Overall Survival (OS) at 5 years,
13879,NCT01584336,The incidence of postoperative morbidity and mortality,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],the surgical outcomes according to the method of reconstruction,
13880,NCT02575391,Measurement of Tolerability,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Treatment Break Measurement,
13881,NCT03978481,Overall survival,2019-01-30,COMPLETED,OBSERVATIONAL,['NA'],Metachronous cancer (remnant stomach cancer),
13882,NCT04571047,Overall survival,2020-10-15,COMPLETED,OBSERVATIONAL,['NA'],Radical surgery,
13883,NCT02175095,[18F]FLT-PET SUV_MAX,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],Response evaluation by RECIST 1.1,
13884,NCT00216372,Percentage of responder patients (patient with 1 or less vomiting episode per day during at least 3 consecutive days or in whom nasogastric tube (NGT) has been removed during at least three consecutive days without vomiting recurrence),2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],Symptom relief duration,
13885,NCT02594150,Increase in return rate of completed FIT,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,
13886,NCT00197873,Effect on the treatment-related grade 2 to 4 diarrhoea,2005-09,COMPLETED,INTERVENTIONAL,['NA'],Effect on resectability of liver metastases,
13887,NCT04513431,Adverse events that related to treatment,2020-08-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Maximum tolerated dose (MTD) of CEA targeted CAR T cells,
13888,NCT04174339,Objective response rate(ORR),2019-12-10,UNKNOWN,INTERVENTIONAL,['NA'],Disease control rate(DCR),
13889,NCT00265811,Disease-free survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall survival,
13890,NCT03227510,MicroRNAs and its Correlation to Development and prediction of HCC,2017-11,UNKNOWN,OBSERVATIONAL,['NA'],,
13891,NCT01393093,Time to progression,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],remission rate,
13892,NCT06241326,Adverse events,2024-02-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
13893,NCT03377400,Progression-free survival,2017-12-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13894,NCT02970539,Maximum tolerated dose (MTD),2016-12-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],Preliminary activity of Oraxol plus ramucirumab as determined by overall survival,
13895,NCT05461248,Incidence of low anterior resection syndrome,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Quality of life score,
13896,NCT06019455,Incidence of >=Grade 3 toxicities,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],Progression-free survival,
13897,NCT00314678,Recurrence-Free Interval,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Examine the toxicity of therapy and to develop suitable strategies for dose modification.,
13898,NCT01089413,Duration of Bevacizumab Treatment,2010-01,COMPLETED,OBSERVATIONAL,['NA'],Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status,
13899,NCT03141437,Patients' decisional conflict (Part 2),2017-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Patients' decision-making process (Part 2),Feasibility of the multicomponent DS intervention and research methods (Part 2)
13900,NCT01580540,Non-inferiority of Epi proColon test result compared to FIT result using a 95% confidence interval for difference in sensitivities and differences in specificities below a strictly defined margin.,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
13901,NCT03245892,number of patients with dose limiting toxicities weekly paclitaxel/carboplatin plus nivolumab and ipilimumab,2017-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13902,NCT04455737,retrieved lymph nodes,2013-10,COMPLETED,OBSERVATIONAL,['NA'],survival,
13903,NCT01299493,Practice-level colon cancer screening rate,2012-06-19,COMPLETED,INTERVENTIONAL,['NA'],,
13904,NCT00631410,Number of Participants With Adverse Events,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Sunitinib Relative Dose Intensity in the Treatment Arm B,
13905,NCT04162665,Complete pathologic response (pCR - primary and nodal) rate,2020-02-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of patients able to complete a full course of total neoadjuvant chemotherapy,Average percent difference in coverage of planning target volume (PTV) by 95% isodose line
13906,NCT01589900,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
13907,NCT02973204,Concordance between specific DNA mutations found in patient biopsies and plasma circulating tumor DNA,2016-11,COMPLETED,OBSERVATIONAL,['NA'],Correlations between mutations fund in circulating DNA and circulating tumor cells,
13908,NCT01034670,Detection of neoplasia,2009-06,RECRUITING,INTERVENTIONAL,['NA'],,
13909,NCT05164315,Overall Survival (OS),2022-01-03,RECRUITING,INTERVENTIONAL,['NA'],defecation function,
13910,NCT04294264,Overall response rate,2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
13911,NCT00782834,Response Rate,2008-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13912,NCT05031949,Progression-free survival based on RECIST v1.1,2021-10-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of Subjects with one or more adverse events as assessed by CTCAE 5.0,
13913,NCT00409292,To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy.,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],to Assess Overall Survival Associated With RAD001 in This Patient Population.,
13914,NCT00093444,"Pharmacokinetics and pharmacodynamics of heat-activated doxorubicin HCL liposome at 15, 30, 45, 60, 75, and 90 minutes; 2, 3, 4, 6, 24, and 46 hours; and 4 and 8 days following infusion",2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Effects of ablative therapy on tumor blood flow and tumor vascular density as measured by MRI at 28 days following study completion,
13915,NCT01773980,Number of participants with improved cancer screening,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,
13916,NCT04318834,Number of participants with tumour whole genome sequencing returned within 8 weeks,2020-04-01,RECRUITING,INTERVENTIONAL,['NA'],Number of patients who received a targeted therapy (after first-line treatment),
13917,NCT01451632,To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Immunogenicity,
13918,NCT01023633,DDC: Duration of Disease Control,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],"OS, RR, PFS, DCR, safety,",
13919,NCT03036436,Change in quality of life,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13920,NCT00820456,To determine the alteration in tumor vascularity (assessed by percentage change in tumor Ktrans) in Arm A participants with metastatic colorectal cancer to the liver after one cycle of chemotherapy including bevacizumab compared to baseline Ktrans value.,2008-04,TERMINATED,OBSERVATIONAL,['NA'],To determine the functional status as a predictor of response or disease-free survival in participants in Arm A.,
13921,NCT02310971,"Assessment of safety and tolerability of CVac. (adverse events, vital signs, 12 lead ECG, relevant changes in physical examination)",2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Assessment of Progression-Free Survival (PFS) and Overall Survival (OS) following the initiation of Cvac in this patient population,Assessment of the change in quality of life (QoL) following the initiation of Cvac in this patient population
13922,NCT03965325,Assess the most accurate trend of the Global Health Status (Quality of Life evolution) over time in colorectal cancer patients evaluated by the EORTC-QLQ-C30 questionnaire.,2019-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Measure healthcare costs during the study period,
13923,NCT05746182,Rate of overall pathogenic germline mutations,2023-04-07,RECRUITING,OBSERVATIONAL,['NA'],Rate of completion of testing,
13924,NCT01858207,The rate of complete necrosis (CN),2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Major complication,
13925,NCT05197504,collected blood samples,2021-12-20,RECRUITING,OBSERVATIONAL,['NA'],Biomarkers on the efficacy of Atezolizumab+Bevacizumab for advanced HCC,
13926,NCT03564938,Change in heart rate (beats/min),2018-07-30,COMPLETED,INTERVENTIONAL,['PHASE4'],Overall survival (OS),
13927,NCT03060720,"We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool",2017-02-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Number of patients who disclose genetic testing results to relatives,
13928,NCT03064646,Percentage of organ preservative strategies after neoadjuvant treatment in locally advanced rectal cancer,2017-03-10,RECRUITING,INTERVENTIONAL,['NA'],Quality of Life in patient with rectal cancer,Colostomy free survival
13929,NCT01524575,6 month overall survival,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Duration of overall response,
13930,NCT04212273,"The sensitivity, specificity and accuracy of Sonazoid-CEUS and EOB-MRI",2019-12-21,RECRUITING,INTERVENTIONAL,['NA'],The detection rate of the additionally found HCC,
13931,NCT01074216,To Achieve Target Vitamin D Level,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13932,NCT01191138,Gastric Emptying assessed clinically and correlated objectively with liquid and solid emptying of radionucleotide,2009-01,COMPLETED,INTERVENTIONAL,['NA'],Correlation of pancreatic duct leak with gastric emptying,
13933,NCT02259647,Overall Survival,2014-10-01,COMPLETED,INTERVENTIONAL,['NA'],Safety,
13934,NCT04543695,The rate of tumor down-staging,2020-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of surgical complications,
13935,NCT01507064,Effectiveness of sorafenib in increasing the effectiveness of laser ablation (LA),2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival in the two treatment groups,
13936,NCT03649971,Percentage Change from Baseline in Rectal/pouch Polyp Burden at Week 24,2018-11-19,COMPLETED,INTERVENTIONAL,['PHASE1'],Relative Changes to Baseline in Levels of Interleukin (IL)-23 Effector Proteins in Biopsy Tissue,
13937,NCT00510796,Feasibility to perform both colon and endometrial cancer screening at the time of colonoscopy in women at high risk for colon and endometrial cancer.,2002-03,COMPLETED,OBSERVATIONAL,['NA'],,
13938,NCT04646915,Incidence of transfer to inpatient ward,2019-12-15,UNKNOWN,OBSERVATIONAL,['NA'],Mortality,
13939,NCT05065957,To assess disease control rate (DCR),2022-03-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",To assess overall survival (OS),
13940,NCT04522687,Overall Survival,2012-01-01,RECRUITING,OBSERVATIONAL,['NA'],Progression Free Survival,
13941,NCT00640913,Reversal of defunctioning loop stoma on postoperative day 14 following low anterior resection of the rectum for cancer with or without preoperative adjuvant treatment,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],Postoperative 30 day morbidity. Postoperative ano-rectal function at 1 and 6 months.,
13942,NCT04918472,The combined diagnostic accuracy of MCCE and UBT as gold standard,2021-08-06,COMPLETED,INTERVENTIONAL,['NA'],"Adverse events up to 2 weeks after UBT, MCCE, UGI endoscopy",
13943,NCT00154817,"The primary objective is to evaluate response rate, tolerability and failure pattern of local radiotherapy for the treatment of locally advanced HCC.",2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],The second objective is to correlate parameters of tumor perfusion assessed by dynamic contrast enhanced MRI (DCEMRI) and serum cytokine levels with clinical outcomes.,
13944,NCT05059444,Distant Recurrence Free Interval (D-RFi),2021-09-07,RECRUITING,OBSERVATIONAL,['NA'],Lead Time,Rate of ctDNA clearance with adjuvant chemotherapy
13945,NCT01385579,Completion of a Colorectal Cancer Screening,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,
13946,NCT02734849,Change in Total Polys Score (TPS),2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13947,NCT04929028,Incidence of adverse events (High-risk stratum),2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in combination antiretroviral therapy (cART) adherence,Impact of reduced intensity CRT on quality of life
13948,NCT00003648,frequency of defective DNA mismatch repair in individuals with familial colon cancer versus all colon cancers by using antibodies to the hMSH2 and hMLH1 protein products,1998-07,COMPLETED,OBSERVATIONAL,['NA'],,
13949,NCT03318562,Level of biomarkers of antitumor activation,2017-11-21,TERMINATED,INTERVENTIONAL,['PHASE2'],PK plasma concentrations,
13950,NCT01595243,12-Item Short Form Survey,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,
13951,NCT00764621,Primary variable is the proportion of patients in each of the three treatment groups for whom further imaging is required after initial imaging to come to a therapy decision.,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],"Proportion of patients with intra-operatively modified surgical plans based on initial imaging with either Primovist-, ECCM-MRI or CE-CT",
13952,NCT01906008,Average Area Under the Curve (AUC) for Numbness/Tingling Over 4 Months,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Average Area Under the Curve (AUC) for Fatigue Over 4 Months,
13953,NCT05846295,"Participant entered rate of accurate polyp size classification into diminutive (1-5 mm), small (6-9 mm), or large (≥10 mm) category on 40 question polyp sizing test.",2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Proportion of participant responses that underestimate actual polyp size category versus overestimate actual polyp size category on the 40-question polyp sizing test.,
13954,NCT01210313,feasibility of physical activity,2010-10,COMPLETED,OBSERVATIONAL,['NA'],gen- and metabolic signs,
13955,NCT02567331,"Response rate, ie, percentage of participants with complete, partial, and overall response",2004-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Pharmacoeconomic analysis: Treatment-related and AE-related spending/savings\n,
13956,NCT03113942,Histological High Grade Squamous Intraepithelial Lesions (HSIL) clearance at 6 months of therapy,2017-06-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],effect of pomalidomide on self-reported health related quality of life and cancer anxiety during and after therapy,
13957,NCT04089631,Disease free Survival (DFS),2020-06-26,RECRUITING,INTERVENTIONAL,['PHASE3'],Frequency of adverse events from start of chemotherapy until 30 days after chemotherapy,
13958,NCT01359410,Clinically Significant Postoperative Pancreatic Leak at Any Time as Defined by the ISGPF Pancreatic Leak Grading System,2007-06,TERMINATED,INTERVENTIONAL,['NA'],Number of Non-pancreatic Adverse Events,
13959,NCT00813137,Time to progression,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13960,NCT03481920,To assess the safety of this combination in patients with PDAC.,2018-01-10,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],"Changes in CA 19,9 leves",Immune infiltrate.
13961,NCT06192212,perioperative 90-day mortality.,2023-12-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Albumin loss rate,
13962,NCT00052585,Response rate,2002-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13963,NCT01078415,Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,2010-02,COMPLETED,INTERVENTIONAL,['NA'],Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.,
13964,NCT04847726,Diagnostic accuracy for HCC: non-inferiority test,2020-06-09,COMPLETED,INTERVENTIONAL,['NA'],Diagnostic performance of perfulorobutane enhanced USG using different definition of washout,Role of perfluorobutane enhanced USG in EASL diagnostic algorithm of HCC
13965,NCT01607957,Overall Survival,2012-06-17,COMPLETED,INTERVENTIONAL,['PHASE3'],"Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths",
13966,NCT05341206,Change of CTCAE 4.0,2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Change of common aerobic culture,
13967,NCT02485015,Overall Survival(OS),2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Disease-free survival,Adverse events
13968,NCT00990535,Tumor stabilization,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Decrease of chromogranin-A,
13969,NCT00199862,Toxicity defined by NCI Common Toxicity Criteria,2004-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],HAHA levels - measured by plasmon resonance surface (Biacore®) assay,
13970,NCT03556956,Overall survival,2015-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Progression Free Survival (PFS),
13971,NCT03821025,Number of patients without stent failure,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Cost,
13972,NCT05689918,Level of awareness of esophageal cancer risk factors and alarm symptoms,2022-12-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Beliefs about esophageal cancer,
13973,NCT06148155,Complete PET imaging,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
13974,NCT04286984,Transfusion Rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],Percentage of failure-to-rescue,
13975,NCT06128785,Time of first postoperative exhaust,2023-11-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Biochemical indexes 3,Adverse Event Assessment
13976,NCT01039519,Percentage of Participants Showing Clinical Benefit Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Count of Participants With Treatment-Emergent Adverse Events (AEs),
13977,NCT00501813,Overall survival rate,2006-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of live,
13978,NCT04764227,Local control rate,2020-05-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
13979,NCT04435652,Overall survival（OS）（stage 2）,2020-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Immunogenicity（stage 1 and 2）,
13980,NCT04123925,Predictive Biomarkers,2018-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Metabolic Response,
13981,NCT04149093,Long-term outcomes (Quality of life questionnaire),2020-05-01,UNKNOWN,OBSERVATIONAL,['NA'],Functional outcomes,
13982,NCT04920435,Prediction of the complete response (pCR) to neoadjuvant chemoradiotherapy,2019-01-02,COMPLETED,OBSERVATIONAL,['NA'],,
13983,NCT05006092,adenoma detection rate,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],Boston Bowl Preparation Score,
13984,NCT03826446,Recurrence rate in open and laparoscopic complete mesocolic excision groups in right cancer colon,2016-01-13,COMPLETED,INTERVENTIONAL,['NA'],,
13985,NCT05247515,Severe post-resection bleeding rate up to Day 30,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Rate and duration of hospitalizations,
13986,NCT05240040,time to recurrence,2016-04-26,UNKNOWN,OBSERVATIONAL,['NA'],,
13987,NCT00484939,Progression-free Survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],"AEs, Laboratory Parameters, Vital Signs",
13988,NCT02504099,Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12),2015-07,TERMINATED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Recurrent HCV Infection Post Liver Transplant,
13989,NCT02707315,percentage of subjects who successfully undergo pancreaticoduodenectomy,2013-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
13990,NCT01380600,Determine the safety of JX-594 administered by biweekly IV infusion,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Determine the anti-tumoral response of JX-594,
13991,NCT02068131,Overall response rate(ORR),2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse Events(AEs),
13992,NCT01672892,"Acute Gastrointestinal Toxicity, as Measured by Change in Expanded Prostate Cancer Index Composite (EPIC) Bowel Domain Score at 5 Weeks From the Start of Pelvic Radiation",2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Mean Change From Baseline in EPIC Bowel and Urinary Domain (Validation - Sensitivity to Treatment),
13993,NCT03852576,SFE ability to detect dimer with contrast,2019-05-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
13994,NCT04636099,Intraoperative blood loss,2020-11-01,UNKNOWN,INTERVENTIONAL,['NA'],3 years DFS,
13995,NCT06236386,Clinician Feedback,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Medication Use,
13996,NCT01841736,Progression-free Survival (PFS),2013-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Time to Second Progression for Patients Who Crossover From Placebo to Active Therapy,Biochemical Response
13997,NCT01279681,Progression-Free Survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of Participants With Grade 3 Adverse Events At Least Possibly Related to Treatment,Prognostic Single-nucleotide Polymorphisms (SNPs) for Grade 3+ Hypertension
13998,NCT00519688,To evaluate the overall response rate of UFUR and thalidomide in the treatment of advanced HCC by RECIST criteria,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],To establish the safety profile.,
13999,NCT02042378,Overall Response Rate (ORR) per RECIST v1.1 as assessed by the investigator,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Trough (Cmin) level rucaparib concentrations,
14000,NCT03682133,Truncated logistic regression analysis,2018-06-27,TERMINATED,OBSERVATIONAL,['NA'],,
14001,NCT01798160,Overall-Survival,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,
14002,NCT02724345,Overall survival,2013-01,COMPLETED,OBSERVATIONAL,['NA'],Time to recurrence,
14003,NCT00923481,Response Rate,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events,
14004,NCT05130684,rate of completion of protocol treatment,2021-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14005,NCT05209750,True malignant node (yes/no),2022-07-13,RECRUITING,INTERVENTIONAL,['NA'],To describe the value of FAPI PET/CT on tumour response evaluation following neoadjuvant treatment.,
14006,NCT05971628,Tolerance of the RAPID procedure,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Comparison of the graft survival at 2 years after LT between RAPID group and control group,
14007,NCT03601611,Rate of at least one grade improvement using the NCI CTCAE v5.0,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],Rate of sustained glucocorticoid-free remission,Biomarkers
14008,NCT02232620,Disease Control Rate (DCR),2017-03-13,TERMINATED,INTERVENTIONAL,['PHASE2'],Pharmacodynamics (biomarkers) of BBI503 when tumor biopsy is possible,
14009,NCT02337946,Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization,2014-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Participants With Grade 3 or Higher Skin Toxicity,
14010,NCT04258813,Diversity supplement primary outcome: 90-day postoperative cardiovascular complications,2021-06-14,RECRUITING,INTERVENTIONAL,['NA'],Provider-reported care coordination,PCP-reported care coordination
14011,NCT05091775,"Acute anal fissure after diarrhea. Standard management of acute fissure (Diltiazem Jelly, supportive care, placebo suppository, sitz bath)",2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Acute anal fissure after diarrhea. Intervention group (Asacol suppository, supportive care, placebo suppository, sitz bath)",
14012,NCT02858141,Collection of oncogeriatric data for future research studies,2015-05,UNKNOWN,OBSERVATIONAL,['NA'],,
14013,NCT00373022,Effect of moderate physical activity on quality of life as measured by the Functional Assessment of Cancer Therapy-Colon questionnaire,2004-01,COMPLETED,INTERVENTIONAL,['NA'],"Correlation of serum levels and patterns of immune function (cytokine, neutrophil, T cell, B cell, NK cell, and immunoglobulin levels) with physical activity levels",
14014,NCT06013228,Fatigue,2023-08-30,RECRUITING,OBSERVATIONAL,['NA'],,
14015,NCT00910741,Incidence of DLT and Response rate,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
14016,NCT03076372,Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors.,2017-02-22,UNKNOWN,INTERVENTIONAL,['PHASE1'],Progression Free Survival,
14017,NCT02228889,Overall complication rate at 1 year,2015-01,RECRUITING,INTERVENTIONAL,['NA'],Quality of life postoperatively,
14018,NCT00217737,Disease-free survival,2005-09-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Impact of tumor biologic characteristics and their relationship to overall survival,
14019,NCT01410760,Recruitment rate to this voluntary study and acquisition of sufficient data for perfusion analysis,2011-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Correlation between the tumour perfusion pattern on perfusion CT studies at baseline and shortly after the start of therapy and morphological response by RECIST criteria on CT scan 3 months post therapy in both arms of the FOXFIRE trial.,
14020,NCT03268499,Time to progression (TTP),2016-09-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14021,NCT03310008,The objective response rate (ORR) before resection as measured by RECIST (version 1.1),2017-08-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],The overall survival (OS),
14022,NCT05209295,Cmax: Observed maximum concentration,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE1'],Number of participants with a recording of concomitant procedures,
14023,NCT00779272,Postoperative Complications and liver regeneration,2008-09,COMPLETED,OBSERVATIONAL,['NA'],,
14024,NCT00944463,Time to progression,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Correlative analyses,
14025,NCT04257955,Patient's Compliance,2020-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
14026,NCT05715775,The LN dissection rate,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],LN noncompliance,
14027,NCT02277392,Number of Adverse Events,2014-09,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
14028,NCT05513742,Overall Response Rate,2022-12-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Exposure Response by Pharmacokinetic (PK) Sampling,
14029,NCT05812287,Early gastric cancer detection rate,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14030,NCT05235607,Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Number of participants with Overall survival as assessed by RECIST1.1,
14031,NCT05143099,Objective response rate (ORR),2021-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS）,biomarker analysis
14032,NCT04575935,Disease free survival (DFS),2020-08-05,RECRUITING,INTERVENTIONAL,['PHASE3'],Cost of the procedure,
14033,NCT03290209,3-year disease specific survival rate,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],operation time,
14034,NCT04288284,early postoperative morbidity after curative resection of colorectal cancer,2015-01,COMPLETED,OBSERVATIONAL,['NA'],Overall survival,
14035,NCT02554448,The number of Circulating Tumor Cells (CTCs),2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,
14036,NCT05500248,Positive Predictive Value (PPV),2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],Adenoma Detection Rate (ADR) in the rectosigmoid tract.,
14037,NCT01384864,to determine whether tissue is neoplastic or non-neoplastic,2011-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
14038,NCT00287222,Number of Participants Who Remained Free of Progression at the 27th Week.,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14039,NCT04911959,Recurrence-free survival (RFS) evaluation,2022-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival ( OS) evaluation,
14040,NCT06334965,Clinical response,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
14041,NCT02721056,Determination of the early Dose Limiting Toxicities,2016-01-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Local Progression Free Survival,
14042,NCT04183712,3-year DFS,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],3-year OS,sensitivity and specificity of ctDNA
14043,NCT05014399,The Proteome Profiler Human XL Cytokine Array Kit (https://www.rndsystems.com/products/proteome-profiler-human-xl-cytokine-array-kit_ary022b),2021-09-20,RECRUITING,OBSERVATIONAL,['NA'],,
14044,NCT03554356,Incidence of CryoBalloon-related serious adverse events,2018-09-04,RECRUITING,INTERVENTIONAL,['NA'],Proportion of Barrett's Esophagus surface area reverted to neosquamous epithelium,
14045,NCT03492827,infection rate 8 hours after ESD,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],infection rate 72 hours after ESD,complications of ESD
14046,NCT01315990,Progression-free survival,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Development of acneiforme follicular exanthema >= grade2,
14047,NCT01319084,,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],,
14048,NCT01434264,Changes in personal concerns identified by the patient in the MYCaW questionnaire.,2011-09,COMPLETED,INTERVENTIONAL,['NA'],Changes in Daily physical performance,
14049,NCT04777851,Progression-free Survival (PFS) Assessed by the Investigator as per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC,2023-10-11,RECRUITING,INTERVENTIONAL,['PHASE3'],Change from Baseline in Health-Related Quality of Life as Assessed by the EuroQol's 5-level EQ-5D Health Questionnaire (EQ-5D-5L),
14050,NCT01259414,overall survival,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Time to progression,
14051,NCT03045107,Length of hospital stay,2017-02-01,UNKNOWN,INTERVENTIONAL,['NA'],Quality of life,
14052,NCT05636150,Progression free survival (PFS),2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Disease control rate (DCR),
14053,NCT04826107,ORR(Objective Response Rate),2021-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],AEs and SAEs,
14054,NCT06042816,analgesic efficacy of free-opioid anesthesia,2019-12-30,COMPLETED,INTERVENTIONAL,['NA'],Adverse effects of free-opioid anesthesia,
14055,NCT06269744,Proportion of Participants who Complete FIT Test by Month 6,2024-03-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Proportion of Participants with Positive FIT who Complete Colonoscopy by Month 6,
14056,NCT03957590,Progression-free survival (PFS),2019-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],The incidence and severity of treatment-emergent adverse events (TEAEs) graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events'.,
14057,NCT05571839,Number of participants with dose limiting toxicities,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival (OS),
14058,NCT02854072,Overall Survival,2015-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],Toxicity according to the NCI CTCAE v4.03,
14059,NCT01088815,Safety of Combination Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas as Assessed by Number of Grade 3 or 4 Adverse Events,2010-09-17,COMPLETED,INTERVENTIONAL,['PHASE2'],Efficacy of Combination of GDC-0449 With Gemcitabine and Nab-Paclitaxel as Assessed by Hedgehog Signaling Pathway Downregulation,
14060,NCT01135498,Progression-Free Survival,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
14061,NCT01480817,Time to Progression (Efficacy),2012-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Alpha feto protein (AFP) responsiveness,
14062,NCT02519582,Progression free survival,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of Serious Adverse Events,
14063,NCT02217865,Effectiveness of Colorectal Cancer (CRC) Surveillance,2014-07-16,COMPLETED,OBSERVATIONAL,['NA'],,
14064,NCT05406206,Progression-Free Survival (PFS),2022-02-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
14065,NCT05196087,Change from Baseline in ctDNA collected from biospecimens,2022-07-20,RECRUITING,OBSERVATIONAL,['NA'],Number of participants that are identified as high risk of clinical relapse with artificial intelligence (AI) and machine learning algorithms,
14066,NCT03705897,Proportion of patients achieving appropriate screening regimen.,2013-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
14067,NCT00569673,Number of Participants With Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Progression-free Survival and Overall Survival,
14068,NCT01702558,Phase 1 (LA/mGC): MTD of Capecitabine When Combined With Trastuzumab Emtansine (2.4 mg/kg QW),2012-12-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Phase 1 (LA/mGC): t1/2 of 5-Fluorouracil (Metabolite of Capecitabine),
14069,NCT04732442,Change in expression of inflammatory cytokines in tumor tissue samples obtained prior and after intervention.,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],Changes in tissue neutrophil infiltration after preoperative nutritional intervention in tumor tissue samples obtained prior and after intervention.,
14070,NCT05036109,To estimate the ctDNA clearance rate of colorectal cancer patients with minimal residual disease,2021-10-12,RECRUITING,INTERVENTIONAL,['NA'],,
14071,NCT02527057,Pathologic response,2014-10,UNKNOWN,OBSERVATIONAL,['NA'],Progression free survival,
14072,NCT00003760,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14073,NCT02500797,Number of Participants Who Achieved a Confirmed Response,2015-08-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),OS in Patients Who Crossover From Single Agent Nivolumab to Dual Agent Treatment Following Progression
14074,NCT00138177,"Grade 3, 4, or 5 adverse events graded using the NCI CTCAE version 4.0",2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],DPD activity,
14075,NCT00259844,"To evaluate the safety, toxicity and tolerability of the TroVax vaccine in this setting.",2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],To monitor and collect data on clinical outcomes (time to progression/relapse/death).,
14076,NCT03732547,Objective response rate (ORR),2018-10-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],Level of alpha-fetoprotein (AFP),
14077,NCT01033682,"The percentage of patients who are able to achieve a bladder volume within +/- 30% of planning volume, on all treatment CBCT (cone beam computed tomography) scans",2009-05,UNKNOWN,OBSERVATIONAL,['NA'],The correlation between bladder volume and small bowel volume planning target volume,
14078,NCT05155878,Overall survival,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],Radical resection,
14079,NCT06239194,Phase 1: Recommended Phase 2 dose (RP2D),2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",All Phases: Correlation between tumor antigen expression and anti-tumor activity of MDX2001,
14080,NCT02506946,Difference in percentage liver fat between PCOS and controls in adolescents and young adults,2013-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],The association of percentage liver fat by magnetic resonance spectroscopy with total body adipose tissue,
14081,NCT03817658,OS,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],The incidence and severity of adverse events (AEs),
14082,NCT00645710,Recommended Phase II Dose,2005-02-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free Survival,
14083,NCT01747551,6-month Progression-free Survival (PFS),2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Objective Response,
14084,NCT05307367,Muscle mass,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],Patient-reported Quality-of-Life (QoL),
14085,NCT01930942,gene expression in different response groups,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"overall survival, disease free survival and local-regional free survival",toxicity
14086,NCT06049901,Evaluating the change in the serum level of Protein disulfide isomerase (PDI),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],"Evaluating the safety and tolerability of nitazoxanide through investigating Hematological parameters (hemoglobin (mg/dL), erythrocytes (cells/μL), leukocytes (cells/μL), platelets (cells/μL) and ANC (cells/μL)).",
14087,NCT05229588,Evaluate the antitumor activity,2022-06-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment safety,
14088,NCT02231086,Peritoneal Recurrence Free Survival at 18 Months,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Quality of Life Questionnaire Survey 5- Year Follow-up,
14089,NCT04221165,Average Pain Rating measured on the 11 Numeric Rating Scale,2020-08-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Death,
14090,NCT03173001,Prevalence of intestinal protozoa (commensals) in patients with colorectal cancer and association with cancerogenesis,2015-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14091,NCT05739045,pathological complete response rate (pCR),2022-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],3-year DFS,
14092,NCT05899985,Surgical quality,2024-03-21,RECRUITING,INTERVENTIONAL,['NA'],SLN Ultra-staging Overall Survival,FerroTrace enhanced MRI Response
14093,NCT01051765,overall survival,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],polymorphism of UGT1A,
14094,NCT03737591,Specificity,2010-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
14095,NCT02759718,"Diagnostic accuracy of th CgA in the patient with PNET, change from preoperative levels of CgA at 3 months",2012-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],"Disease progression of PNET using CT imaging, change from preoperative imaging of CT at 3, 6,12, and 24 months",
14096,NCT01490749,Phase I portion to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of RAD001 in combination with radiation,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Rate of surgical pathologic complete remission (pCR) (absence of evidence of cancer after surgery),
14097,NCT05600803,detection rate,2022-10-30,RECRUITING,OBSERVATIONAL,['NA'],Number needed to screen,
14098,NCT02399410,surgical morbidity and mortality,2015-11-04,COMPLETED,INTERVENTIONAL,['PHASE2'],pathological gross response of peritoneal tumour deposits to neoadjuvant combination chemotherapy with bevacizumab,
14099,NCT04279080,functional bowel outcome after low anterior resection,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14100,NCT05806333,Diagnostic performance of FAPI PET,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
14101,NCT05809661,stoma compliance,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],life quality,
14102,NCT00550108,"Patients not progressing to operation due to the development of symptoms, growth to a maximum diameter of >3cm, or development of a mural nodule.",2007-10,TERMINATED,INTERVENTIONAL,['PHASE3'],A decrease in size by >1 cm on MRCP Relative decrease in size of cyst after 1 or 2 injections with ethanol Is reduction in size durable (over what length of time)?,
14103,NCT00055705,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14104,NCT00019604,Response,1998-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Evaluate the Ability of Fludeoxyglucose (18F) Positron-Emission Tomography (FDG-PET) to Monitor Response Following Radiofrequency Ablation (RFA),
14105,NCT00375310,To evaluate the safety and tolerability of the combined treatment with Gemcitabine with Sorafenib and radiotherapy in patients with localized unresectable pancreatic cancer.,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1'],To evaluate the maximum tolerated dose (MTD) for Sorafenib during Chemo-radiation.,
14106,NCT01576666,Dose Limiting Toxicities,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Plasma pharmacokinetics (PK) parameters,
14107,NCT00247728,Tumour Non-recurrence Rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival Rate,
14108,NCT04423965,MFS,2020-05-12,RECRUITING,INTERVENTIONAL,['PHASE2'],Reported Adverse events,
14109,NCT04638751,Determine whether the microbiome composition can predict risk for colorectal cancer,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],Build a library of samples and data for future research,
14110,NCT05173077,Specific chemistry identification in the exhaled breath,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Gut microbiota analysis in relation to breath VOCs,Confounding factor analysis
14111,NCT04274790,5-FU in ribosome,2021-06-01,WITHDRAWN,OBSERVATIONAL,['NA'],Specific molecular signature,
14112,NCT05349110,"The Area Under ROC Curve (AUC) of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).",2021-08-20,UNKNOWN,OBSERVATIONAL,['NA'],The agreement in surveillance interval based on optical diagnosis and histopathology.,
14113,NCT03211715,Quality of life in association to the severity of bowel dysfunction,2017-07-19,UNKNOWN,OBSERVATIONAL,['NA'],,
14114,NCT04468607,Maximum Tolerated Dose(s) MTD(s) of BLYG8824A,2020-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Presence of Anti-drug Antibodies (ADAs),
14115,NCT02603302,Pathologic complete response,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,
14116,NCT02095236,Three-dimensional intra- and interfractional measurement of fiducial marker or transponder motion,na,WITHDRAWN,INTERVENTIONAL,['NA'],,
14117,NCT04336397,Colorectal cancer screening,2021-04-29,RECRUITING,INTERVENTIONAL,['NA'],Diagnostic follow-up,
14118,NCT05184751,"incidence of early onset colorectal neoplasias, risk factors",2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14119,NCT06256055,Incidence of Dose-limiting Toxicities (DLTs),2024-03-05,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall Survival (OS),
14120,NCT02372747,Length of the incision,2012-10,COMPLETED,INTERVENTIONAL,['NA'],Postoperative complication,
14121,NCT03304860,Change in CRC screening rate of eligible parents of internal medicine residents at NYU from before to after the intervention,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
14122,NCT00874263,Endoscopic Confocal microscopy may help distinguish small adenomatous polyps with malignant potential from non-neoplastic (hyperplastic) polyps in real- time enabling immediate diagnosis and removal of only polyps with truly malignant potential.,2008-03,COMPLETED,OBSERVATIONAL,['NA'],"Endoscopic Confocal microscopy has the potential to fundamentally change the way endoscopy and pathology interact by allowing near histological-quality imaging in vivo, without the need, risk, and cost of tissue removal.",
14123,NCT05494853,HCC screening positive,2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14124,NCT02403271,Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1.,2015-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 2: Pharmacodynamics,
14125,NCT02900950,Evaluate R1 rate differences between multicolour and monocolour inking of the specimen,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Relation between Disease Free Survival and Overall Survival of the participants and R status,
14126,NCT01101672,Post-operative pain on coughing,2009-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Recurrence and survival for cancer patient,
14127,NCT05490719,PFS assessed by investigators,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"The rates and severity of Adverse Events, Serious Adverse Events",
14128,NCT01757366,Progression-free survival (PFS),2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
14129,NCT00607594,Prolonged Stable Disease Rate (Defined as Stable Disease for ≥ 16 Weeks),2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Association Between Correlative Markers and Clinical Outcomes,
14130,NCT02713763,6 months progression free survival,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Adverse Events,
14131,NCT02970513,Hamilton anxiety and depression score comparison,2017-03-27,COMPLETED,INTERVENTIONAL,['NA'],personality traits comparison,
14132,NCT05827055,Safety of oral proglumide therapy at 1200mg daily dose with chemotherapy,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Effects of proglumide on Pain,
14133,NCT01260415,"To determine the 2 year disease-free survival rate in patients with resectable colorectal liver metastases treated with FOLFOX/FOLFIRI + panitumumab for 2 months pre-operatively and 4 months post-operatively, followed by panitumumab alone for 6 months.",2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],"To determine the incidence of hepatocellular damage (fibrosis, steatosis) in normal liver tissue induced by preoperative chemotherapy.",
14134,NCT06195514,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
14135,NCT04525768,History of variceal bleeding,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],Complications of portal hypertension,
14136,NCT05596890,Pathologic complete response rate,2022-11-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Dysphagia relief score,
14137,NCT00857246,"Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab",2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival (Adjuvant Therpary),
14138,NCT04160832,Prevalence of germline pathogenic/likely pathogenic variants in cancer predisposition genes in patients with advanced colorectal polyps,2019-10-24,RECRUITING,OBSERVATIONAL,['NA'],Risk factors for germline pathogenic/likely pathogenic variants in patients with advanced colorectal polyps,
14139,NCT04989153,Risk factors for GC,2016-03-05,UNKNOWN,OBSERVATIONAL,['NA'],,
14140,NCT01577511,Ability to maintain the cells isolated from colorectal tumors in culture or 3D collagen matrices and then infect these cells to make them express reporter genes: yes/no.,2012-06-12,COMPLETED,OBSERVATIONAL,['NA'],Number of circulating cancer cells per ml blood,
14141,NCT00112463,Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3,2005-01-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival,
14142,NCT01807546,Overall response rate,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Adverse Events,
14143,NCT01197820,Temperature standard deviation,2010-09,TERMINATED,INTERVENTIONAL,['NA'],HIFU platform improvements,
14144,NCT02320448,Number of Patients with Adverse Events.,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Feasibility: Completion of procedure in 28:35,
14145,NCT02626195,postoperative complication,2013-10,COMPLETED,INTERVENTIONAL,['NA'],postoperative cost( + nutritional support cost),immunologic change(CD4/CD8) after nutritional support
14146,NCT01910948,blood immune factors,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
14147,NCT00051441,The primary endpoint is the cumulative proportion of patients with severe mucositis (WHO mucositis score of at least 3) at a cumulative radiation dose of 5500 cGy,na,COMPLETED,INTERVENTIONAL,['PHASE3'],Secondary endpoints include cumulative RT to first use of an opioid for oral mucositis; cumulative RT to first ulceration; cumulative RT to first RT suspension due to oral mucositis,
14148,NCT04970212,Effectiveness - DICE,2021-09-24,COMPLETED,OBSERVATIONAL,['NA'],Difference between T=0 and T=24hrs CECT tissue damage,
14149,NCT00862342,Progression free survival,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity profiles,
14150,NCT00004236,,1998-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14151,NCT02638584,The Ulcer healing rate after endoscopic submucosal dissection,2015-12,COMPLETED,INTERVENTIONAL,['PHASE4'],The evaluation of symptom score as assessed by the Korean Gastrointestinal Symptom Rating Scale questionnaire.,
14152,NCT05229809,2-year disease-free survival rate,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE4'],Percentage of Participants With Adverse Events,
14153,NCT03778710,The correlation of lymph node ratio and prognosis of recurrence of gastric cancer patients,2018-12-18,COMPLETED,OBSERVATIONAL,['NA'],The correlation of total of lymph node retrieved less than 15 and more than 15 nodes and survival of gastric cancer patients,
14154,NCT02121405,Disease-free survival,2015-10,SUSPENDED,INTERVENTIONAL,['PHASE3'],Overall survival,
14155,NCT04842006,Postoperative ctDNA,2021-12-20,RECRUITING,INTERVENTIONAL,['NA'],Treatment response by patient-derived organoid (PDO) therapy response,
14156,NCT03178929,Time to tumor recurrence,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,
14157,NCT04761536,Anastomotic leak,2006-01,COMPLETED,OBSERVATIONAL,['NA'],need of postoperative blood transfusion,
14158,NCT01444755,Survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14159,NCT05638984,PFS,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
14160,NCT03541486,Overall survival (OS),2025-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Pathologic characteristics,Exploration of patient reported outcomes during combined therapy [qualitative string]
14161,NCT06080854,R0 resection rate,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
14162,NCT04796948,RP2D,2021-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],CL,
14163,NCT03654729,Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN),2018-11-07,TERMINATED,INTERVENTIONAL,['PHASE3'],Overall Survival (OS),
14164,NCT00361244,To determine the response rate of SU011248 when given in combination with irinotecan and cetuximab in this patient population.,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","to assess overall survival, progression-free survival, time to progression and duration of response.",
14165,NCT00060021,,2003-03,COMPLETED,INTERVENTIONAL,['NA'],,
14166,NCT00969124,Detection Rates for All Polyps,2009-01,COMPLETED,INTERVENTIONAL,['NA'],Time Spent During Withdrawal Phase and Total Procedure,
14167,NCT04723030,Objective remission rate(ORR),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Subject safety,
14168,NCT00229554,colorectal cancer screening compliance,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,
14169,NCT00809796,"Any severe events, tumor marker CEA, and tumor size (CT scan)",2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14170,NCT01670721,Percentage of Participants With Adverse Events (AEs),2012-08,COMPLETED,INTERVENTIONAL,['PHASE3'],Change From Baseline in HRQL EQ-5D-3L VAS Score,
14171,NCT05795010,Positive rate of preoperative MRD test,2023-03-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Positive rate of MRD test 1 month and 3 months after operation,
14172,NCT02758587,Adverse events (AEs) using CTCAE v4.03 (to determine dose limiting toxicities (DLTs) and maximum tolerated dose (MTD)),2017-07-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in immune cell infiltrate,
14173,NCT03061058,Progression-free Survival (PFS),2013-04-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Adverse Events,
14174,NCT02128243,Overall Survival (OS),2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life,Adverse Events
14175,NCT02179489,Disease-free survival,2014-11-01,COMPLETED,INTERVENTIONAL,['NA'],QOL,
14176,NCT05160896,ORR,2021-11-12,RECRUITING,INTERVENTIONAL,['PHASE2'],AEs,
14177,NCT00819650,Overall survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to recurrence,
14178,NCT02366039,distinguishing between normal esophageal squamous mucosa and Barrett's dysplasia,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,
14179,NCT02430948,Effect of educational intervention on providers' recommendations,2014-01,COMPLETED,INTERVENTIONAL,['NA'],Patient compliance,
14180,NCT00587964,Local Control,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14181,NCT06175845,"Time to first event, ie stent dysfunction",2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Total days of overnight-hospital-stays,
14182,NCT01060007,Preoperative Gastrointestinal Morbidity,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine Quality of Anorectal Function,
14183,NCT05502835,Intraoperative fluid volume,2022-08-20,COMPLETED,INTERVENTIONAL,['NA'],intestinal oedema,
14184,NCT01760616,Time to significant progression after surgery and postoperative survival period.,2011-11-07,TERMINATED,INTERVENTIONAL,['PHASE4'],Alpha-fetoprotein quantitation and related biochemical indicators,
14185,NCT03592706,Progression-Free Survival (PFS),2009-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Improvement of immune responses,
14186,NCT05218889,ORR,2021-08-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Safety and tolerability by incidence, severity and outcome of adverse events",
14187,NCT00004860,,2000-10-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14188,NCT02650635,Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide,2016-02-05,TERMINATED,INTERVENTIONAL,['PHASE1'],PFS as measured by serial imaging studies and assessed by irRECIST,Changes in immunomodulation
14189,NCT04996446,recurrence free survival,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,
14190,NCT05528614,Postoperative morbidity and mortality of simultaneous pancreatic and hepatic resectio,2022-01-13,COMPLETED,OBSERVATIONAL,['NA'],,
14191,NCT01210495,"Overall Survival (OS) - Stratified Analysis, Randomized Portion",2010-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment-Related Adverse Events (AEs) in Randomized Portion,
14192,NCT02445014,Feasibility for Imaging of Esophagus Using an SECM Tethered Endoscopic Capsule.,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
14193,NCT01183494,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2009-12-12,COMPLETED,INTERVENTIONAL,['PHASE1'],To evaluate the pharmacokinetic profile of irinotecan in combination with bevacizumab.,
14194,NCT00832299,Pathologic Complete Response,2009-01,TERMINATED,INTERVENTIONAL,['PHASE2'],"Observation of Overall Pathologic Response Rate, Correlation of Pathologic Staging With Pre-op Ultrasound and Pelvic MRI Staging Observed Toxicities Patterns of Disease Relapse Disease-free Survival Overall Survival",
14195,NCT00276744,6-month Overall Survival,2005-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14196,NCT04774198,Number of patients with persistent postoperative hypotension (<65 mmHg) after surgery,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],Number of patients with development of delirium after surgery,
14197,NCT05738447,Overall Survival,2023-02-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,
14198,NCT00361842,Progression-free Survival (PFS) Per RECIST Version 1.0,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response (DoR) Per RECIST Version 1.0,
14199,NCT03082586,Number of Dose Limiting Toxicities (DLTs) Occurring in Participants,2016-11-20,COMPLETED,INTERVENTIONAL,['NA'],Local Failure,
14200,NCT05914597,Feasibility of home delivery of CCE service,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],assessing the patient's acceptability of home delivery of CCE service,
14201,NCT05403177,Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data,2022-06-23,RECRUITING,OBSERVATIONAL,['NA'],Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine,
14202,NCT02920554,Survival rates,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],,
14203,NCT05129605,Diagnosis of prostate cancer,2020-02-12,RECRUITING,OBSERVATIONAL,['NA'],Positive predictive value of multiparametric MRI for detection of prostate cancer,
14204,NCT00399035,Overall Survival,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Time to Wound Healing Complications,
14205,NCT01793207,"Methylation markers present in peripheral blood of patients with colorectal cancer(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects",2012-12,COMPLETED,OBSERVATIONAL,['NA'],"Methylation markers present in peripheral blood of patients with hyperplastic polyps(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects",
14206,NCT04505553,Severity of chemotherapy-induced peripheral neuropathy (CIPN),2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Incidence of pain, fatigue, nausea, and anxiety",
14207,NCT00570635,"Clinical benefit, defined as either confirmed complete response, confirmed partial response, or evidence of stable disease lasting ≥16 weeks, in subjects with advanced GIST resistant to/intolerant of imatinib and/or sunitinib",2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Further characterize the pharmacokinetic and pharmacodynamic parameters of XL820 in subjects with advanced GIST,
14208,NCT00547144,To determine the time to tumor progression for this regimen.,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14209,NCT00576992,"Determine the prevalence of gastric and esophageal disease in patients presenting with the complaints of dyspepsia, GERD, or extraesophageal symptoms",2003-01,TERMINATED,OBSERVATIONAL,['NA'],"Determine whether the presence of any factors (hiatal hernia, NSAID use, age, race, gender, etc.) contribute to the above endoscopic diagnoses",
14210,NCT02574663,"Adverse events as a measure of safety and tolerability of TGR-1202 as a single agent and in combination in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.",2015-09-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Pharmacokinetic (PK) profile of TGR-1202. Area under the plasma concentration versus time curve (AUC),
14211,NCT04529135,postoperative recovery time,2020-08-26,COMPLETED,INTERVENTIONAL,['NA'],opioid related side effect.,
14212,NCT04778566,Evaluate the feasibility of the Cologuard test for Lynch Syndrome,2021-11,WITHDRAWN,OBSERVATIONAL,['NA'],Evaluate bowel preparation tolerability,
14213,NCT05356520,Disease-free survival time,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],Tumor recurrence,
14214,NCT05327400,High expression of IGHD is independent risk factors for poor prognosis in patients with pancreatic cancer.,2022-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14215,NCT03086096,"Number of indications that the device is being used for, as assessed by stage and previous treatment(s)",2018-02-02,COMPLETED,OBSERVATIONAL,['NA'],"The quality of participants' lives, as assessed by the QLQ-C30 questionnaire (developed by EORTC)",
14216,NCT01582178,Cecal Intubation Time,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Patient Comfort During Insertion Phase of the Colonoscopy,
14217,NCT05681390,MedianProgression free survival(mPFS),2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],disease control rate(DCR),
14218,NCT05327751,The change in HFS-specific QOL questionnaire (HFS-14).,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],The change in serum levels of malondialdehyde (MDA).,
14219,NCT00034619,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14220,NCT05580835,Degree of PSMA uptake by HCC,2022-09-05,RECRUITING,INTERVENTIONAL,['NA'],Presence of PSMA uptake on treated liver lesions,
14221,NCT04864067,Quality of Life and Funcional Outcomes,2021-06-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,
14222,NCT05913141,Objective response rate (ORR),2023-06,RECRUITING,OBSERVATIONAL,['NA'],12-month survival rate,
14223,NCT02635503,Early morbidity rate,2015-11,RECRUITING,INTERVENTIONAL,['PHASE3'],Plasma levels of several cytokines after colorectal cancer surgery,
14224,NCT01754987,Number of Participants That Experience Serious Adverse Events.,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants That Are Alive After 15 Weeks of Treatment.,
14225,NCT02173119,Imaging response,2014-08,COMPLETED,OBSERVATIONAL,['NA'],Survival,
14226,NCT00926757,The primary endpoint is the incidence of HBV reactivation during and within 12 months after chemotherapy,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4'],The incidence of HBsAg reverse seroconversion during and within 12 months after completing chemotherapy.,
14227,NCT05721651,Progression free survival (PFS),2023-04,RECRUITING,INTERVENTIONAL,['PHASE2'],"Safety and tolerance evaluated by incidence, severity and outcomes of AEs",
14228,NCT01365130,Number of Patients Without Progression at 3 Months,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Patients Experienced a Toxicity Associated With Cabazitaxel for Patients With Metastatic Gastroesophageal Adenocarcinomas That Have Progressed After at Least One Line of Therapy for Metastatic Disease.,
14229,NCT06134700,To compare the efficacy of low pressure versus standard pressure pneumoperitoneum in laparoscopic nephrectomy,2023-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
14230,NCT05513183,Association between the concentration of intraoperative mitomycin-C absoprtion and severe neutropenia after CRS/HIPEC,2021-05-20,COMPLETED,OBSERVATIONAL,['NA'],Quality of Life: QoR-40 questionnaire,
14231,NCT04196803,Plasma methionine cycle metabolites,2016-02-01,COMPLETED,INTERVENTIONAL,['NA'],,
14232,NCT04969887,Determine the proportion of participants with progression free survival at 6 months,2021-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Quantification of treatment related toxicities to ipi/nivo according to CTCAE V5.0,
14233,NCT01791140,Median progression-free survival,2011-03,COMPLETED,OBSERVATIONAL,['NA'],Median progression-free survival according to age group (65-74 years; >/= 75 years),
14234,NCT02096666,Phase 2- Overall Response Rate (per RECIST v1.1) in subjects with MET amplified measurable gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1),2014-04-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1- Overall Survival,
14235,NCT02809716,"HD-SCA solid tumor biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles",2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],"HD-SCA biosignatures in pre-resection liquid biopsy samples assessed by cell morphology, protein expression, and whole genome CNV profiles",
14236,NCT02148159,Percentage weight change over 8 weeks between two arms,2014-10,COMPLETED,INTERVENTIONAL,['NA'],body composition,symptom experience
14237,NCT02329821,changes of lactate level,2014-11,COMPLETED,OBSERVATIONAL,['NA'],changes of acid-base status,
14238,NCT04185272,"evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry",2020-06-30,RECRUITING,INTERVENTIONAL,['NA'],,
14239,NCT05198934,Progression-free Survival (PFS),2022-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],AUC of Panitumumab,
14240,NCT01717391,Percent Difference From Baseline IMRT Plan (%),2012-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Standardized Toxicity Severity Grades for Decreased Lymphocyte Counts.,
14241,NCT01877187,Baseline Enhancing Tumor and Response by RECIST Criteria,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],6-month Survival Rate of Patients With HCC and Liver Metastases Treated With Conventional TACE,
14242,NCT03713749,Rate of unsuccessful LND along the left RLN,2018-10-22,UNKNOWN,INTERVENTIONAL,['NA'],"European Organisation for Research and Treatment of Cancer(EORTC) QLQ-C30 , QLQ-OES18",
14243,NCT01579357,Influence of Cetuximab on metabolic activation of Capecitabine,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14244,NCT04394572,"Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on metallo proteases",2021-01-07,COMPLETED,OBSERVATIONAL,['NA'],,
14245,NCT05355298,Part B: efficacy of AMP945,2022-05-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",AMP945 levels in plasma,Effects on biomarkers
14246,NCT02549911,R0 resection,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival time,
14247,NCT02194959,Colonoscopy completion,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,
14248,NCT03216395,Bleeding free probability in 30 days after randomization,2018-01-02,COMPLETED,INTERVENTIONAL,['NA'],cost analysis (Based on the cost data from the Hospital,
14249,NCT03679039,The sensitivity and specificity of the model to predict the drug resistance,2018-09-20,UNKNOWN,OBSERVATIONAL,['NA'],,
14250,NCT05759728,To determine the overall best response to CNA3103.,2023-10-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To determine progression-free survival,
14251,NCT02548403,the quality of the bowel preparation using Preparation Scale,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],the endoscopist's tolerability[Visual Analog Score for fatigue],
14252,NCT02495337,"Effectively culture, proliferate, and store primary gastro-esophageal cell lines in order to create a bank of primary esophageal / gastric cancers for research purposes",2015-05,RECRUITING,OBSERVATIONAL,['NA'],,
14253,NCT02215577,"Surgical success rate, the rate of liver resection in each study arm",2014-06,UNKNOWN,INTERVENTIONAL,['NA'],Liver growth rate,Health economy
14254,NCT01755013,Efficacy Profile,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Safety Profile,
14255,NCT04527666,Changes of portal vein thrombosis,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,
14256,NCT03018418,Rates of Acute Toxicity,2017-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of Life Changes,
14257,NCT05039983,Recommended phase 2 dose (RP2D),2021-08-20,UNKNOWN,INTERVENTIONAL,['NA'],change in blood biochemical indicators,
14258,NCT02156739,Specificity of combining gadoxetate disodium and gadobutrol in diagnosing tumor lesions radiologically using magnetic resonance imaging (MRI),2014-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
14259,NCT00399750,To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2),2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Patients enrolled prior to the initiation of Amendment 3 (TREE1) will not be eligible to receive Avastin as a component of their treatment regimen.,
14260,NCT01996059,Body Mass Index,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Onodera Prognosis Nutritional Index,Visick rates
14261,NCT04659018,The ability to predict the presence of adenomas and colorectal cancers.,2020-08-24,COMPLETED,OBSERVATIONAL,['NA'],,
14262,NCT03546127,Delay time to send a validated exome sequencing report from sample receipt,2017-05-23,COMPLETED,OBSERVATIONAL,['NA'],The rate of patients with bioinformatic analysis available for interpretation for whom results has been discussed by MTB,
14263,NCT04248582,Dose limiting toxicity (DLT),2020-02-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
14264,NCT01834170,Number of participants with adverse events as a measure of safety and tolerability,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Proportion of participants who remain alive one year after enrollment compared to the historical matched control group,
14265,NCT01711242,disease free survival,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],5 year Overall Survival,Number of participants with adverse events as a measure of safety and tolerability
14266,NCT05757336,Safety：the incidence of adverse events and serious adverse events,2022-12-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of acceptable radical resection of primary lesions,
14267,NCT05339919,Long-term results after operation,2020-05-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Hospitalization expenses,
14268,NCT01764438,"incidence of change of BCLC stage after add-on Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.",2012-08,UNKNOWN,OBSERVATIONAL,['NA'],"Sensitivity, specificity, false positive predictive value, false negative predictive value, and accuracy of Primovist-enhanced MRI",
14269,NCT04186234,Best objective response,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,Changes in Child-Pugh status
14270,NCT04835896,Phase 2: Progression-free survival in subjects with M7824 and paclitaxel combination treatment,2021-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Safety and Tolerability, in terms of the number, severity, and duration of treatment-emergent adverse events as assessed by CTCAE v5.0",
14271,NCT02567045,Proportion of patients who participate in each screening arm,2016-02-25,COMPLETED,INTERVENTIONAL,['NA'],Costs measure: cost (euros) of the procedures associated with each screening strategy and treatment of advanced neoplastic lesions,
14272,NCT00619242,Ki-67,2006-06,TERMINATED,INTERVENTIONAL,['NA'],,
14273,NCT00976170,Dose limiting toxicity and maximum tolerated dose,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Repeat-dose pharmacokinetic behavior of GC33 and Sorafenib,
14274,NCT04063293,Wexner fecal incontinence score change,2019-05-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Number of participants with PRP injection-related adverse events as assessed by CTCAE v4.0,
14275,NCT00030667,Toxicity reported using the CTC version 2.0,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to disease progression,
14276,NCT03884751,Maximum tolerated dose (MTD),2019-08-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Antitumor efficacy-Disease control rate (DCR),
14277,NCT01137123,survival rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14278,NCT05667181,Incidence of anastomotic complications,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
14279,NCT02216955,Disease-specific survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,Disease-free survival
14280,NCT01741363,Detection rate of upper gastrointestinal tract diseases,2012-07,UNKNOWN,INTERVENTIONAL,['NA'],Helicobacter pylori eradication rate,
14281,NCT03890926,Local control time,2015-12,COMPLETED,OBSERVATIONAL,['NA'],Incidence of adverse events,
14282,NCT02935478,Weight,2017-10-18,SUSPENDED,INTERVENTIONAL,['NA'],Eligibility for liver transplant,
14283,NCT00909987,"Efficacy of XELOX/BVZ neoadjuvant therapy with selective radiotherapy use in patients with locally advanced tumors of the rectum, measured in terms of the proportion of responders (PCR + CCR), according to RECIST criteria",2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Complete Phatologic Response (pCR),
14284,NCT03739801,Progression-free survival (PFS) (Phase II),2020-04-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of adverse events graded according to CTCAE version 4.0,
14285,NCT01545687,The AUC of the MTS score,2012-04,WITHDRAWN,INTERVENTIONAL,['PHASE3'],DFS at 12 months after treatment,
14286,NCT04915326,Nodal metastasis in early rectalò cancer,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
14287,NCT01713387,Maximum tolerated dose,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants with dose limiting toxicity,
14288,NCT03484299,Incidence of Adverse and Serious Adverse events will be captured (safety and tolerability),2018-05-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Progression free survival,
14289,NCT02527785,overall response rate,2015-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity profiles - The number of participants and grade of intensity of treatment related adverse events,
14290,NCT04404101,Safety of EUS-FNA plus MFB with that of EUS-FNA by recording adverse events per published ASGE (American Society for Gastrointestinal Endoscopy) criteria.,2021-05-11,RECRUITING,INTERVENTIONAL,['NA'],Time taken for FNA and time for MFB,
14291,NCT04514341,Time to completion of diagnostic colonoscopy,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],Navigation Services Provided,
14292,NCT00113230,Pathologic Local Tumor Response,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14293,NCT02967887,Objective tumor response,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Progression-free-survival,Exploratory endpoint: Diagnostic performance of biomarkers
14294,NCT05690490,R0 resection rate,2020-11-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],intra- and postoperative complications rate,
14295,NCT06102902,Recommended phase 2 dose (dose escalation cohort),2024-11-12,RECRUITING,INTERVENTIONAL,['PHASE1'],MAPK inhibition,Presence or absence of a given gene mutation
14296,NCT01937208,Progression-free survival,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Overall survival,radiation-related advent events
14297,NCT00389870,Overall survival of patients treated with Ir vs Ir and panitumumab (IrP) and no prior cetuximab,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Patient-assessed symptom/quality of life/acceptability scores at 12 and 24 weeks in patients treated with Ir vs IrP and prior cetuximab,
14298,NCT04231526,To measure the feasibility of neoadjuvant pembrolizumab in early stage colon cancer,2020-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Measure the immune response in early stage colon cancer after neoadjuvant pembrolizumab,
14299,NCT00250796,"Determine the response rate and time to progression of the combination of thalidomide, interferon, and octreotide in patients with unresectable hepatocellular carcinoma.",2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14300,NCT01952730,Number of Patients Who Fail to Receive the First Six Scheduled Vaccinations Because of Toxicity,2013-11-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Two Year Survival,
14301,NCT00549835,Frequency of any adverse effects,2007-08,WITHDRAWN,INTERVENTIONAL,['NA'],Total amount of conventional analgesics used and Total days on Analgesic,
14302,NCT00217087,Change in Quality of Life,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14303,NCT00555334,Overall survivals,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],Recurrence rates,
14304,NCT05411718,To establish the effect of naproxen or aspirin on the abundance of T cells and other immune,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,
14305,NCT04989985,pCR,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
14306,NCT05508126,Diagnostic performance of DECT and mpMRI in tumor restaging assessment,2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],Contrast-to-noise Ratio (CNR),
14307,NCT00785421,DVT/TVE event rate,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","TTP, OS, side effects",
14308,NCT04400903,Compliance statistics for wristband use (Stage II),2020-09-21,TERMINATED,OBSERVATIONAL,['NA'],Time of PDAC diagnosis among high-risk participants who developed PDAC (Stage II),
14309,NCT01453153,Recommended Phase 2 Dose (RP2D),2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change From Baseline in CA19-9 in Participants Classified as Responders and Non-responders,
14310,NCT06135896,Primary endpoint,2023-12-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],biomarkers,
14311,NCT01097239,"Quality of life scores (EORTC QLQ-C30 and/or EORTC QLQ-CR38, EORTC QLQ-CX24, EORTC QLQ-EN24 or EORTC QLQ-OV24)",2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumour marker changes (CEA and CA19.9),
14312,NCT03002831,Overall Survival,2016-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Quality of life assessed by Questionnaire,
14313,NCT04895722,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR),2021-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants Discontinuing Study Treatment Due to an AE,
14314,NCT01257711,The aim of this study is to compare Billroth II and Roux En Y reconstruction after radical distal subtotal gastrectomy for gastric cancer in terms of postoperative outcomes.,2008-10-09,COMPLETED,INTERVENTIONAL,['NA'],Grading of gastritis and/or esophagitis on endoscopy,
14315,NCT01339832,Progression-free Survival,2010-08,COMPLETED,OBSERVATIONAL,['NA'],Incidence of Adverse Event (AE) and Serious Adverse Event (SAE),
14316,NCT04530890,To assess the prognostic impact of ctDNA (mortality) in digestive and gynecological / breast cancers.,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],Evaluate the possibility of detecting certain molecular alterations using ctDNA and exosomes,
14317,NCT05132738,No Evidence of Disease Rate (NED Rate),2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Objective response rate (ORR),Overall survival (OS)
14318,NCT01294085,One year survival rate,2010-11,COMPLETED,OBSERVATIONAL,['NA'],Progression free survival,
14319,NCT00313859,overall response rate,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],duration of response,
14320,NCT01698190,Number of needle passes needed to obtain a pathologic diagnosis.,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],Frequency of adverse side effects.,
14321,NCT00446290,Number of Participants With DLTs,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14322,NCT00300950,Recurrence free time and survival,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14323,NCT06077981,Volume of solution,2023-06-19,RECRUITING,INTERVENTIONAL,['NA'],Number of additional injections,
14324,NCT06064331,Cost of Desflurane used to maintain BIS 40-60,2021-01-21,COMPLETED,INTERVENTIONAL,['NA'],Opioid usage (mcg/kg),
14325,NCT01643811,Proportion of patients who quit previous medication for hypertension because of improved disease,2012-04,COMPLETED,OBSERVATIONAL,['NA'],"difference of serum levels of c-peptide, Ghrelin, GIP, GLP-1, glucagon, insulin between before and after operation",
14326,NCT04924686,NOD2 ligands in fecal and plasma,2020-05-10,UNKNOWN,OBSERVATIONAL,['NA'],,
14327,NCT03784677,Change of the treatment regimen such as dose delay and dose reduction over time by dose level due to treatment-related adverse events,2019-07-29,COMPLETED,INTERVENTIONAL,['PHASE1'],Predictive biomarkers,
14328,NCT05230329,we will assess the Number of harvested lymph nodes after colonic resectio,2022-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Health related quality of life,
14329,NCT06294873,Detection of colon cancer or precancer,2023-07-20,RECRUITING,OBSERVATIONAL,['NA'],,
14330,NCT05089266,Dose-limiting toxicity （DLT）,2021-11-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Objective response rate (ORR),
14331,NCT01440127,Expression of CD133 in tumors from patients treated or not treated with metformin,2011-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,
14332,NCT04634539,"Recommended phase II dose (RP2D) of combination gemcitabine, nab-paclitaxel, and L-glutamine in treatment-naive metastatic pancreatic cancer.",2021-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Describe any preliminary evidence of antitumor activity of the combination by assessment of overall survival as determined by RECIST 1.1 criteria in patients with measurable disease.,
14333,NCT03211806,Adherence,2019-06-06,COMPLETED,INTERVENTIONAL,['NA'],Readmission,
14334,NCT00986440,Percentage Rate of Progression-free Survival at 18 Weeks Following Use of CS-7017 in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy,2009-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Treatment-Emergent Adverse Events Related to Study Drug With an Incidence of ≥5% Following Use of CS-7017 Or Placebo in Colorectal Cancer Participants Who Have Achieved Disease Control Following First-Line Chemotherapy,
14335,NCT02607982,response rate,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity,
14336,NCT00291486,Number of Patients With Dose-Limiting Toxicities (DLT),2003-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Patients With Human Anti-human Antibodies (HAHA) to 131I-huA33,
14337,NCT01074385,Impact of Dignity Therapy,2010-04,COMPLETED,INTERVENTIONAL,['NA'],Establish a correlation between terminal illness acknowledgement and presence of peaceful awareness with preferences for life sustaining therapy and end-of-life goals of care.,
14338,NCT01960023,Number of patients with Overall response rate (ORR)(complete response/partial response) and progression free survival (PFS) during the Phase II portion of the study,2013-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The frequency and severity of adverse events to evaluate the overall toxicity in the Phase II portion of the study.,
14339,NCT04851119,Area under the drug concentration curve of tegavivint,2021-11-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Antitumor effects of tegavivint in patients with solid tumors,
14340,NCT03193424,Progression-free survival (PFS),2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Total Survival (OS),
14341,NCT06015971,Functionality,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],C-RP,
14342,NCT04677413,To determine the maximal tolerated dose (MTD) of dose-escalated hypofractionated RT.,2021-06-03,RECRUITING,INTERVENTIONAL,['PHASE1'],"To evaluate the rate of distant failure, defined as development of disease outside of the pelvis.",
14343,NCT02001623,Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events,2013-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Dose Expansion Part: Duration of Response (DOR),
14344,NCT02886247,pancreatic cancer,1994-06,RECRUITING,OBSERVATIONAL,['NA'],,
14345,NCT01580241,,2010-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14346,NCT04368507,"2a cohort: Safety, Tolerability of YYB101 by ORR",2019-08-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",2a cohort,
14347,NCT02944006,T-staging,2016-11-28,UNKNOWN,OBSERVATIONAL,['NA'],mean diffusivity,transient dyspnea
14348,NCT04393584,median overall survival,2019-01-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",R0-Resection rate,
14349,NCT00007943,,2000-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14350,NCT01151761,Progression-free Survival at 12 Months,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Median Time to Overall Survival,
14351,NCT01608711,Incidence of anti-AGS-1C4D4 antibody formation,2012-08-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14352,NCT05100329,Objective response rate (ORR),2021-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-emergent adverse events (TEAEs),
14353,NCT00834860,"Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.",2007-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Safety: adverse event rate and profile.,
14354,NCT02022995,evaluate the overall survival of patients with PRMT (arginine methyltransferase),2014-01,COMPLETED,OBSERVATIONAL,['NA'],evaluate the disease-free survival of patients with PRMT (arginine methyltransferase),
14355,NCT00862680,Impact of the difference in SUVmax on the lesion detectability and staging of the evaluated patients,2009-03-12,COMPLETED,OBSERVATIONAL,['NA'],,
14356,NCT04731441,Feasibility of doing exercises,2021-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Quality of Life after CRS-HIPEC,
14357,NCT04000425,Description of ctDNA changing to adjuvant chemotherapy response,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA'],The ctDNA level/mutations in gastric cancer preoperatively,
14358,NCT00016380,,2001-02-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14359,NCT06293612,Heterochronous distant metastasis,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],Distant metastasis-free survival,
14360,NCT01906216,Overall survival,2013-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse events,AFP response
14361,NCT01593098,Prevalence of adenoma and CRC,2010-06-08,RECRUITING,OBSERVATIONAL,['NA'],Differences in genetic profile between siblings of patients with advanced neoplasm and controls,
14362,NCT02426879,Safety measured by the percentage of overall postoperative complications grade 3b and higher as stated by the modified Clavien-Dindo classification (MCDC),2015-02-11,COMPLETED,INTERVENTIONAL,['NA'],postoperative recovery,pathology results 10
14363,NCT05935189,Creation of a registry,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
14364,NCT01653301,Pathological major downstaging,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],survival,
14365,NCT05534906,Biomarkers associated with small HCC (Early detection [EDx] biomarkers),2022-05-23,RECRUITING,OBSERVATIONAL,['NA'],Proportion of patients with HCC events according to time since treatment with curative intent.,
14366,NCT00048529,,2002-09,SUSPENDED,INTERVENTIONAL,['PHASE2'],,
14367,NCT05728710,Surgery,2019-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],30-days mortality rate,
14368,NCT04232176,Precision in polyps sizing the pathologist,2019-12-22,COMPLETED,OBSERVATIONAL,['NA'],Rate of polyps' recurrence at the end of the follow-up.,
14369,NCT03784040,Response Rate,2019-02-21,UNKNOWN,INTERVENTIONAL,['PHASE1'],Overall Survival,
14370,NCT03785938,Cost-benefit evaluation of the study,2019-01-20,UNKNOWN,INTERVENTIONAL,['NA'],Evaluate responsible guardian/participants experience of the MaCROS study,
14371,NCT01349075,Response to Treatment,2007-10,COMPLETED,OBSERVATIONAL,['NA'],Survival Time,
14372,NCT01618253,Maximum Tolerated Dose,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Health Related Quality of Life,
14373,NCT05552755,Percent change from baseline in polyp burden,2023-07-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Assess the pharmacodynamic (PD) effect of REC-4881, and correlation between PD and clinical outcome",
14374,NCT00965172,"Incidence/Severity of Oral Mucositis WHO Grades 1, 2, 3, and 4",2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14375,NCT02528643,Overall Survival (OS),2015-11-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression Free Survival (PFS),
14376,NCT03751761,response rate,2018-06-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14377,NCT00003951,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14378,NCT03849469,"Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.",2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14379,NCT04962958,2-year cumulative recurrence-free survival rate,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
14380,NCT00154544,,2004-08,UNKNOWN,OBSERVATIONAL,['NA'],,
14381,NCT02694081,the amount of blood loss during operations of Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],the number of patients with the complication of Reflux esophagitis,the number of patients with the complication of gastroesophageal reflux disease(GERD)
14382,NCT05404503,Choledochal cyst and cholangiocarcinoma,2022-10,RECRUITING,OBSERVATIONAL,['NA'],,
14383,NCT03175016,Tumor Response of six months,2017-06-20,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life,
14384,NCT00047307,Maximum tolerated dose of flavopiridol when administered biweekly in conjunction with radiation for patients with locally advanced pancreatic or extrahepatic bile duct cancer,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],"Molecular correlates of apoptosis including PARP cleavage and caspase-3 activation, as well as changes in expression of p21, phosphorylation status of pRb and cyclin D1",
14385,NCT01450319,Overall Survival (OS) Time,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Beta 2-microglobulin,
14386,NCT02146352,Safety/Adverse Event Outcome Measure 6,2014-06,COMPLETED,INTERVENTIONAL,['NA'],Technical Success Outcome Measure 2,
14387,NCT02715804,Overall Survival,2016-03-14,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of Participants With Clinically Significant Abnormalities in Vital Signs,
14388,NCT03910634,Overall objective response rate,2019-04-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of toxic and side effects above 3 degrees,
14389,NCT01959672,"Number of Participants With Progressive Disease,",2013-09-06,COMPLETED,INTERVENTIONAL,['PHASE2'],"Tumor Response Rate, Evaluated on the Pathology Specimen",Number of Participants With CA-125-Specific T-cell Signal.
14390,NCT04524650,the severity of portal hypertension,2020-08-31,UNKNOWN,OBSERVATIONAL,['NA'],,
14391,NCT05566093,The Chang The change of tumor size,2018-09-28,RECRUITING,INTERVENTIONAL,['NA'],Incidence of Treatment-Emergent Adverse Events,
14392,NCT02978313,PFS,2016-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",QoL,
14393,NCT01419860,Evaluation of microcirculation in colon wall and bowel anastomosis by laser induced fluorescence video angiography of indocyanine green,2010-01,COMPLETED,INTERVENTIONAL,['NA'],Predicting perfusion deficit with laser-induced ICG fluorescence video angiography,
14394,NCT00370513,Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD).,2006-12-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Various pharmacokinetic parametersAlpha-fetoprotein (AFP) measurements and scans,
14395,NCT03038256,Pathological complete response rate,2018-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],quality of surgery,
14396,NCT05743036,Dose Expansion Phase - Objective response rate (ORR),2023-02-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumor tissue BRAF V600E mutational status,
14397,NCT05199259,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],Ascertain Sample Stability,
14398,NCT06304974,Overall survival (OS),2024-03-19,RECRUITING,INTERVENTIONAL,['PHASE3'],Anti-drug antibody (ADA),
14399,NCT03957460,difference between SpHb value in g/dL and SaHb value in g/dL (SpHb - SaHb),2017-11-20,COMPLETED,OBSERVATIONAL,['NA'],,
14400,NCT05416073,Pain intensity at 3 hours after HAIC treatment,2022-06-22,RECRUITING,INTERVENTIONAL,['PHASE4'],Pain intensity on the 21st after HAIC treatment,Degree of satisfaction
14401,NCT00108745,Overall Survival,2005-03-21,UNKNOWN,INTERVENTIONAL,['PHASE3'],Patient-Reported Peripheral Neuropathy Symptoms,
14402,NCT05310643,Objective response rate (ORR) by RECIST 1.1,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],MSI/MMR status,
14403,NCT02130726,Extent of lymph node dissection,2014-12,COMPLETED,INTERVENTIONAL,['NA'],Disease-free survival,
14404,NCT04031963,Early cancer changes in the colon,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,
14405,NCT01902849,measurement of interleukins IL6 and IL 10 plasmatic level,2012-02,COMPLETED,OBSERVATIONAL,['NA'],total opioid analgesic dose (mg),total opioid dose of remifentanil (mg ) used during surgery
14406,NCT03765450,Inter-compartmental Difference in Infliximab Concentration,2018-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Change in Mayo Clinic Endoscopic Score,
14407,NCT02529761,Overall survival,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],Prognostic factor,
14408,NCT06197178,Area Under the Curve (AUC) last,2024-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of anti-LCAR-G08 antibody and positive sample titer,
14409,NCT04862949,Organ-specific response rate,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
14410,NCT05150548,Sepsis or septic shock,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14411,NCT04518774,Safety evaluation: Maximum-tolerated dose (MTD),2020-08-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Efficacy evaluation: γδT cells in peripheral blood,
14412,NCT05438927,Participant Rating on Ease of Use for the Mobile Application - Usability,2022-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Participant Compliance with Dietary Log - Intervention Adherence,
14413,NCT03823846,pain at rest (Numerical rating scale),2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],adverse events during rehabilitation,
14414,NCT05090215,Anaerobic threshold change,2022-05-13,RECRUITING,INTERVENTIONAL,['NA'],Change to the values inflammatory markers using venous blood samples after the application of a 12 week postoperative exercise programme,
14415,NCT00005818,Time to disease progression (TTP),2000-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Toxicity graded using the NCI CTC version 2.0,
14416,NCT04579380,Confirmed objective response rate (cORR) per investigator assessment,2021-01-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Trough concentration (Ctrough),
14417,NCT02578602,"Precision in tumor measurement for each type of image (CT vs. MRI), for each phase ( 4 for CT and 5 for MRI), and for each method of measuring ""size"" (1-,2-, and 3-dimensional), assessed by low inter- and intra-reader variability",2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Changes in apparent diffusion coefficient (ADC) values within lesions and within normal liver before and after administration of Gadoxetate,
14418,NCT03377270,Change in MBSImP physiologic function metrics of the oropharyngeal swallow,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],Functional Oral Intake Scale (FOIS),
14419,NCT00095966,Response rate as measured by RECIST criteria,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
14420,NCT05896956,overall survival,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],progression-free survival,
14421,NCT00293397,Efficacy - Overall Survival,2005-11,COMPLETED,INTERVENTIONAL,['NA'],,
14422,NCT03661047,The change in the marine omega-3 polyunsaturated fatty acid (MO3PUFA) composition in colorectal tissues as a result of the AMR101 treatment for up to 30 days.,2019-11-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],The change in the gut microbiome composition and function between pre- and post- AMR101 treatment period,
14423,NCT00090025,To compare survival duration for XL119 and 5-FU/LV treated subjects,2004-09,TERMINATED,INTERVENTIONAL,['PHASE3'],"To determine time to progressive disease for XL119 and 5-FU/LV treated subjects, to evaluate clinical benefit for XL119 and 5-FU/LV treated subjects, and to assess the safety profile of XL119",
14424,NCT02553031,The recurrence rate at 1 year after surgery,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],The overall survival at 1 year after surgery,
14425,NCT05969860,Mean patient-reported rating of Cancer Connected Access and Remote Expertise,2023-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,
14426,NCT05788484,Tumor-specific expansion cohorts: To further evaluate the safety of CDX-585 by tumor type.,2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Immunogenicity Evaluation,
14427,NCT02887365,3-year disease-free survival Safety profile of tegafur-uracil,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],5-year overall survival,
14428,NCT03558945,Incidence and grades of adverse events as assessed by CTCAE v5.0,2018-07-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Serum CA19-9 or CA72-4 levels,Percentages of immune cell populations in peripheral blood during the vaccination
14429,NCT01801059,Completion rate of CRC screening,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
14430,NCT04726800,Frequency of positive ctDNA preoperative converted to negative postoperatively.,2020-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14431,NCT06302179,Venous Thromboembolism,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
14432,NCT00259363,Phase II : Response and resectability rate.,2002-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14433,NCT06194461,Incidence of specific AEs,2024-06-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],"Kinetics parameters that indicate persistence (eg, Clast and Tlast)",
14434,NCT02393755,"Progression Free Survival (PFS) Rate, Defined as the Proportion of Patients Who Survive Without Disease Progression Via the RECIST Version 1.1 (Phase II)",2015-05-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II),
14435,NCT04767295,pathologic complete response (pCR),2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14436,NCT04035096,"Change from baseline by computerized tomography of Chest, abdomen and pelvis",2020-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of participants with changes of tumor markers,
14437,NCT00544908,Progression-free Survival (PFS) Rate at 4 Months,2007-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Response Rate,
14438,NCT04681248,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
14439,NCT06019312,gut microbiota composition,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],Clostridioides difficile infection,
14440,NCT04281667,Comprehensive Complication Index,2020-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Adjuvant therapy,Bowel microbiota
14441,NCT02751177,"KRAS, NRAS et BRAF mutational status",2016-03-25,COMPLETED,INTERVENTIONAL,['NA'],,
14442,NCT05414383,Diagnostic accuracy,2024-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Diagnostic time,
14443,NCT00814359,The severity of patient-reported symptoms of mucositis as determined by the change in Oral Mucositis Weekly Questionnaire - Head and Neck Cancer (OMWQ-HN) score from baseline to 6 weeks.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],Incidence of WHO Grade 3 or 4 oral mucositis after 4 weeks of radiotherapy.,
14444,NCT04101747,Number of intestinal flora,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14445,NCT03546257,the accuracy in predicting the invasion depth of EGC.,2019-03,UNKNOWN,OBSERVATIONAL,['NA'],The NBI findings that affect the accuracy for predicting of depth.,
14446,NCT01978184,Age-Adjusted Charlson Comorbidity Index,2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Rate of R0 Resection,
14447,NCT05160753,Disease-free survival (DFS) at three years,2022-01-10,RECRUITING,INTERVENTIONAL,['NA'],,
14448,NCT00222079,,2004-11,TERMINATED,INTERVENTIONAL,['NA'],,
14449,NCT05954897,Objective Response Rate,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
14450,NCT03981848,tumor recurrent status,2019-07,UNKNOWN,OBSERVATIONAL,['NA'],,
14451,NCT02479984,Probability of diagnosis of metastasis (frequency),2011-08,UNKNOWN,INTERVENTIONAL,['NA'],,
14452,NCT01707641,incidence of grade III/IV mucositis,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],percentage of patients able to complete the chemo-radiotherapy treatment,percentage of patients who need enteral nutrition
14453,NCT00323830,disease free survival,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14454,NCT01588990,Association Between Neutrophil to Lymphocyte Ratio (NLR) [NLR ≤5 Versus NLR >5] and Progression-Free Survival (PFS) as Assessed by Hazard Ratio,2012-06-26,COMPLETED,INTERVENTIONAL,['PHASE4'],FACT-C Score: Phase B,
14455,NCT04234568,Dose limiting toxicity (DLT),2020-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival,Change in deoxyribonucleoside concentrations
14456,NCT00212615,Toxicity: before treatment (each 3 weeks) and by SAE (Serious Adverse Event),2004-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Tumor assesment: after every 3rd treatment (each 9th weeks),
14457,NCT01351714,Number of additional lymph nodes removed through radical D3 resection,2011-05,UNKNOWN,INTERVENTIONAL,['NA'],Disease free survival 2 and 5 years after initial surgery,
14458,NCT02202096,Number of post-operative ER visits and readmissions,2015-02,WITHDRAWN,INTERVENTIONAL,['NA'],,
14459,NCT05945901,Progression-Free Survival (PFS) Assessed by IRC（Phase III）,2023-08-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Serious Adverse Events (SAE)（Phase III）,
14460,NCT04259944,Number of post-surgery and post-adjuvant false negative cases after a double ctDNA-negative detection,2020-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of patients experiencing ctDNA seroconversion (i.e. ctDNA+ that become ctDNA-) after any chemotherapy regimen remaining disease free,
14461,NCT00586872,Number and types of adverse events in participants who have undergone endoscopic mucosal resection with documented adverse events will be evaluated for predictors of complications,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
14462,NCT06044961,Use of radiomics,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14463,NCT00524498,Antitumor effect (tumor size reduction),2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease control rate Overall survival Progression-free survival,
14464,NCT03202758,Evaluation of the safety of Durvalumab plus Tremelimumab in combination with FOLFOX chemotherapy,2017-08-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14465,NCT03609424,Disease control rate,2019-02-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Mutational analysis,
14466,NCT05776940,Occurrence of diarrhea,2023-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Involved organ response（kidney）at 3 and 6 months after enrollment,
14467,NCT02384850,Numbers of Patients With Dose Limiting Toxicities,2015-03,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Patients Experiencing Adverse Events,
14468,NCT01907230,HBV reactivation,2013-09-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],Hepatitis flare (ALT > 100 U/L) related to biological treatments,
14469,NCT06204497,Incidence of severe complications within 90-day,2024-01-31,RECRUITING,INTERVENTIONAL,['NA'],Quality of life evaluation,
14470,NCT03594448,Correlation between presence of MSI present in circulating tumor DNA versus in primary tumor specimens,2018-09-05,RECRUITING,OBSERVATIONAL,['NA'],,
14471,NCT02705300,Time to first serious adverse event,2016-05-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Resection rate,
14472,NCT04817826,Primary outcome of Cohort 2: 2-year complete response rate,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Post gastrectomy complications,
14473,NCT04895137,PCR rate,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],3 years OS Rate,
14474,NCT01949545,Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m²,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants With Adverse Events (AEs),
14475,NCT01403064,Number of Participants With All Grades of OM at a Radiation Dose of 55 Gy,2011-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Mean Change From Baseline in C-reactive Protein (CRP) Values at Varying Weeks,
14476,NCT02012829,participation rate of patients for CRC screening,2011-12,COMPLETED,INTERVENTIONAL,['NA'],GPs participation rate over 45%,
14477,NCT03518632,Change of Oxgen consumption at anaerobic threshold :,2018-03-27,COMPLETED,INTERVENTIONAL,['NA'],Changes in Fatigue :,
14478,NCT00003993,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14479,NCT02004769,PFS(Progression-free survival ),2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety,
14480,NCT04032704,Prostate-specific antigen (PSA) response rate as determined by investigator according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria (Cohort 7 only),2019-10-09,TERMINATED,INTERVENTIONAL,['PHASE2'],Incidence of antitherapeutic antibodies (ATAs) to LV,
14481,NCT00001569,,1997-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14482,NCT03302403,Number of participants with CRA T-related adverse events as assessed by CTCAE v4.03,2017-12-29,UNKNOWN,INTERVENTIONAL,['NA'],Engraftment,Changes of cell subsets for CAR T cells against T cells
14483,NCT04933435,change in quality of life in patient cohorts receiving either Interventional Radiology Liver Directed Therapies or Hypofractionated Image-Guided Radiation Therapy,2020-11-12,RECRUITING,INTERVENTIONAL,['NA'],total healthcare system cost associated with Hypofractionated Liver Directed Therapy,
14484,NCT02642913,Progression-free survival,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14485,NCT03773367,To determine the rate of histopathological response according to Becker criteria.,2018-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
14486,NCT00425152,,1989-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14487,NCT00222378,Prevalence of Cytomegalovirus and Epstein Barr Virus in inflamed colonic tissue from patient with mild to moderate IBD as compared to inflamed mucosa from patients with other inflammatory diseases of the colon,2005-04,COMPLETED,OBSERVATIONAL,['NA'],,
14488,NCT04078828,The rate of general complications,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],"White blood cells(WBC) ,C-reactive protein (CRP) and procalcitonin (PCT) count in the blood sample",
14489,NCT02163291,Pathological complete response rate,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],"R0 rate, surgical morbidity and mortality",
14490,NCT04020276,Number of Participants with Acute Dose Limiting Toxicity (DLT),2019-11-04,SUSPENDED,INTERVENTIONAL,['PHASE1'],Local Control Rates,
14491,NCT04134559,Immune-related best overall response (irBOR),2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],DNA sequencing of specimens,
14492,NCT00975247,"Bowel preparation quality, as measured by the Ottawa scale.",2008-04,COMPLETED,INTERVENTIONAL,['NA'],Withdrawal Time,
14493,NCT02682082,Difference in pain scores at 1 month and end of the trial,2016-05-27,TERMINATED,INTERVENTIONAL,['NA'],Difference in survival,
14494,NCT00892242,Evaluate whether treatment with perioperative zoledronic acid prolongs overall survival or disease free survival.,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],Determine the pharmacodynamics of neoadjuvant zoledronic acid therapy on selected immune cell subgroups in the hepatic metastatic niche by flow cytometric analysis of pancreatic tumor samples,
14495,NCT02830737,Recurrence Rate,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall Survival Rate,Number of Participants with Adverse Events
14496,NCT02356406,Numerical Rating Scale (NRS) pain score difference from baseline,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Safety profile of the procedure - measuring the frequency and severity of treatment side effects, mainly GI toxicities",
14497,NCT02745600,Comparison of the spatial coordiantes of the real ablation zone one month after RFA treatment of liver tumors with the simulation results of the ClinicIMPPACT software.,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],"Does the follow - up (3, 6 ,12months) imaging support the assumptions regarding local tumor control",
14498,NCT02856126,Overall survival,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Number of of Patients developed Adverse Events,
14499,NCT04379232,Symptoms of Covid after surgery,2020-03-19,COMPLETED,OBSERVATIONAL,['NA'],,
14500,NCT05052723,Progression-free survival,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall participant survival rate,
14501,NCT03641976,6-month PFS rate (%),2019-01-03,RECRUITING,INTERVENTIONAL,['PHASE2'],surrogate markers predictive of survival: ctDNA,
14502,NCT02481219,Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE),2015-05,COMPLETED,INTERVENTIONAL,['NA'],Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE,
14503,NCT00546468,5 year disease free survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall survival,
14504,NCT05580887,Intestinal bacterial structure in BC and PnC (separately) patients with disease progression,2022-05-12,RECRUITING,OBSERVATIONAL,['NA'],Change from baseline in intestinal bacterial structure in PnC patients with disease relapse on or after combined treatment completion (follow up 12 months),
14505,NCT01465659,Overall Response Rate (ORR) in Patients With Advanced Neuroendocrine Tumors (PNET) Treated With Temozolomide and Pazopanib Combination Treatment at the RP2D in Phase II,2011-12-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Months That Patients Maintain a Response to Treatment Until Disease Progression or Death (Duration of Response),Amount of a Particular Tumor Biomarker in Blood as Correlated With Progression Free Survival
14506,NCT01238939,Number of patients with dose-limiting toxicity as determinant of the maximum tolerated dose/recommended dose,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Peak Plasma Concentration (Cmax) of NK012 and fluorouracil,
14507,NCT05698082,Original survival,2020-12-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14508,NCT06203821,Determining if NP137 can shift the primary tumor MAK's Signature Epithelial-to-Mesenchymal Transition (EMT) Mean Score towards a more epithelial phenotype,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]),
14509,NCT05596188,Independent risk factors of preoperative anxiety and establishment of prediction model,2022-11-10,RECRUITING,OBSERVATIONAL,['NA'],Incidence of preoperative anxiety,
14510,NCT04079946,Lymph nodes harvest,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
14511,NCT01086059,Major malformations,2003-11,COMPLETED,OBSERVATIONAL,['NA'],Infant follow-up,
14512,NCT04729738,"correlation between the development of a postoperative complication within 30 days from surgery and patient-related characteristics (comorbidity, frailty, malnutrition and sarcopenia)",2012-06-01,COMPLETED,OBSERVATIONAL,['NA'],"relatedness between the average density sarcopenia indices, HUAC, PI, TPA and the distance between the anterior-superior iliac spines and the size of the psoas muscles (RPSI)",
14513,NCT00142350,overall survival,2000-11,COMPLETED,INTERVENTIONAL,['PHASE3'],non-hospitalized survival,
14514,NCT05344664,Percentage of adverse events,2022-04-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
14515,NCT01075555,Overall survival,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Time to progression,
14516,NCT05548114,Composite end point of inability to tolerate a solid diet (defined as gastric outlet obstruction scoring system score <2) or requiring endoscopic or surgical intervention or supplemental nutrition or procedure-related adverse events.,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],Overall treatment costs from index procedure until 6 months post-index procedure.,
14517,NCT00179348,Program satisfaction measured by Yoga - Daily Practice Calendar and Yoga Class Attendance Record and Yoga Evaluation Form,2001-02-08,COMPLETED,INTERVENTIONAL,['NA'],spiritual well-being,
14518,NCT03426722,Proportion of patients who have occurrence of muscle cramps ( numeric rating scale score > 4),2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],recurrence rate,
14519,NCT05072041,Incidence of liver function impairment,2021-10-31,RECRUITING,INTERVENTIONAL,['NA'],Hepatic artery damage,
14520,NCT00002796,"Efficacy of FU in combination with PB, indomethacin and rhIFNg in patients with advanced colorectal cancer (Phase II)",1997-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14521,NCT05044065,Skeletal muscle cross sectional area,2021-05-01,RECRUITING,INTERVENTIONAL,['NA'],Prognostic markers,
14522,NCT00937079,"Detection of insulinomas, cure rate",2007-11,COMPLETED,OBSERVATIONAL,['NA'],,
14523,NCT00140894,Safety and tolerability,2002-08-06,TERMINATED,INTERVENTIONAL,['PHASE4'],Proportions of patients with improved overall colon rating,
14524,NCT01280058,Progression-free Survival Using RECIST v. 1.1,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,Percentage of Patients With Ras Pathway Activation
14525,NCT04006275,CEUS LI-RADS Grades of SonoVue and Sonazoid agents in enrolled patients.,2019-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],The sensitivity and specificity of CEUS-LI-RADS by different contrast agencies.,
14526,NCT02776527,disease free survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],overall survival,
14527,NCT03403452,PFS（progress free survival）,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],DCR（disease control rate),
14528,NCT01556490,Overall Survival (OS) Per Protocol (PP) Population,2012-03,COMPLETED,INTERVENTIONAL,['NA'],Tumor Response,
14529,NCT00858000,Proportion of hepatocellular carcinoma cancer patients whose tumor tissue -expresses any one or more of specific target antigens -overexpresses c-MET -expresses a pre-defied gene-expression signature,2009-07,COMPLETED,OBSERVATIONAL,['NA'],,
14530,NCT04707118,Ascites control,2021-02-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
14531,NCT02282839,Oral mucositis,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life,
14532,NCT01288339,Progression-free survival time according to the MMP7 status (PFS),2010-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Molecular predictive markers for response.,
14533,NCT02834780,Number of Participants With Clinically Significant Change From Baseline in Vital Sign Parameters,2016-12-28,COMPLETED,INTERVENTIONAL,['PHASE1'],"Part 2, Dose Expansion Phase: Time to Response (TTR) Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) v1.1",
14534,NCT05432492,Objective Response Rate (ORR) Per mRECIST,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),Percentage of participants who obtain a pathologic complete response (pCR)
14535,NCT02321813,proportion of patients in both groups with diseased quality of life (<50 points in at least one dimension),2014-01,COMPLETED,INTERVENTIONAL,['NA'],rates of patients with diseased quality of life in each dimension of the profile,
14536,NCT02287727,Disease free survival (DFS),2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival,
14537,NCT06137248,Change in the hydrogen sulfide-metabolizing species of bacteria,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Microbiome changes and tolerance,
14538,NCT03636620,overall survival,2013-06,COMPLETED,INTERVENTIONAL,['PHASE3'],objective response rate,
14539,NCT02599116,"Determine whether the intestinal microbiome of patients with appendiceal tumors with peritoneal carcinomatosis differs from that of a healthy, age-matched cohort",2015-12,RECRUITING,INTERVENTIONAL,['NA'],Compare the gut microbiome of appendiceal tumors by histopathology,Identify alterations in the gut microbiome post-CRS/HIPEC
14540,NCT02682992,Percentage of Participants With Severe (CTCAE v. 4.0 Grade 3-5) Oral Mucositis,2016-06,COMPLETED,INTERVENTIONAL,['NA'],Breaks in Chemoradiotherapy,
14541,NCT00493025,Pathologic Complete Response Rate to the Neoadjuvant Regimen,2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Correlation Between EGFR Pathway Component Expression and Activation With Pathologic Complete Response and Survival,
14542,NCT03228407,Correlation between the time from intravenous injection of fluorescein to visualization of fluorescein on probe based confocal endomicroscopy (pCLE) with esophageal permeability (i.e. - epithelial barrier function).,2017-04-28,UNKNOWN,INTERVENTIONAL,['NA'],Correlation between the Ussing's chamber findings (esophageal permeability) and Mucosal impedance findings of patients with symptoms of refractory GERD and controls,
14543,NCT02257541,Phase Ib Portion: Response Rate (RR),2014-10-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase Ib Study: Response Rate (RR),
14544,NCT03700411,Change in number of circulating tumor cells prior to surgery to 2 - 4 weeks after surgery,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],Pain assessment,
14545,NCT04491565,Adequacy of bowel prep,2019-11-13,COMPLETED,INTERVENTIONAL,['NA'],,
14546,NCT01170299,"Change in IBDQ-B (Inflammatory Bowel Disease Questionnaire - Bowel Subset) score between baseline (i.e., Day 1 of radiotherapy treatment) and the nadir score during treatment",2009-10,COMPLETED,INTERVENTIONAL,['NA'],Costs for symptom management,
14547,NCT02894801,death due to recurrence,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
14548,NCT04225026,Number of Subjects With of Acute Radiation Esophagitis (Defined as Grade >/= 2; NCI CTCAE Version 5) Through the End of Chemoradiotherapy for Non-Small Cell Lung (NSCLC) or Small Cell Lung Cancer (SCLC) When Avasopasem Was Added.,2019-12-19,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Subjects With Acute Severe Radiation Esophagitis (Defined as Grade 3-4; NCI CTCAE Version 5) Through Completion of Chemoradiotherapy.,
14549,NCT03214991,Overall survival rate,2017-05-12,UNKNOWN,OBSERVATIONAL,['NA'],"Overall survival rate (K-ras mutation type, EUS-FNA)",
14550,NCT04973475,False negative rate,2021-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The variation of C-reactive protein,
14551,NCT01575717,Change in serum levels of 25-hydroxyvitamin D,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],Change in Model for End stage Liver Disease score (MELD),
14552,NCT04788368,Complications after surgery,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
14553,NCT02055560,Overall survival,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
14554,NCT04909671,Mean number of adenomas per colonoscopy,2021-09-13,UNKNOWN,INTERVENTIONAL,['NA'],Subjective endoscopist measures,
14555,NCT01974661,Registration of adverse events as a measure of safety and tolerability,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],To study overall survival (OS),"Local tissue changes in injected/non-injected tumor and surrounding tissue, assessed by MRI"
14556,NCT03663712,Non-dose limiting toxicities for talimogene laherparepvec,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14557,NCT03435588,Final diagnosis of benign pancreatic mass,2018-02-14,COMPLETED,INTERVENTIONAL,['NA'],Rate of procedure-related adverse events,
14558,NCT02146508,Complete resolution of advanced esophageal squamous dysplasia,2013-06,SUSPENDED,INTERVENTIONAL,['NA'],Safety of endoscopic interventions,
14559,NCT00258323,Distant metastatic control at 1 year,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Toxicity of maintenance gefitinib as measured by CTC version 2.0 every 8 weeks after the completion of radiotherapy,
14560,NCT00687570,Bowel purity degree,2008-07,COMPLETED,INTERVENTIONAL,['NA'],physiological function,
14561,NCT01402908,Disease-Free Survival (DFS),2011-08,TERMINATED,INTERVENTIONAL,['PHASE3'],Tumor Recurrence Rate (TR Rate),
14562,NCT03737539,ctDNA methylation markers versus CT/MRI,2018-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
14563,NCT03947762,Progression-free survival (PFS) rate at 24 months,2019-07-03,TERMINATED,OBSERVATIONAL,['NA'],Patient satisfaction,
14564,NCT03220984,the disease control rate (DCR),2017-03-16,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14565,NCT00093548,,na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14566,NCT03951792,Microbial 16S rDNA Biomarkers,2021-06-30,RECRUITING,OBSERVATIONAL,['NA'],Protein Measurements,
14567,NCT04920149,Change in the occurrence of any colorectal neoplasia in LS patients,2022-03-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Significant findings & illnesses - adverse events,
14568,NCT05792254,1-year progression-free survival rate,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],the Rates of AE and SAE,
14569,NCT02909478,Complete response,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Complete response in the delay phase (25 hours-120 hours),
14570,NCT02971696,Event free survival,2016-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Sorafenib induced side effects,
14571,NCT05273489,Survival,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],Neoadjuvant Chemotherapy,
14572,NCT02107105,Health state utilities,2014-05-16,RECRUITING,OBSERVATIONAL,['NA'],,
14573,NCT04759235,change of metabolites,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,
14574,NCT03659448,Surgical resection histopathology.,2019-06-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14575,NCT00582660,Subjects With Positive Response 72 Hours After Administration of Study Treatment as Measured by Immunoblot,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14576,NCT02726360,study-specific coding structure,2015-12-14,COMPLETED,OBSERVATIONAL,['NA'],,
14577,NCT04471272,Ideal technical success rate,2020-01-06,UNKNOWN,INTERVENTIONAL,['NA'],Technical time,
14578,NCT02786342,PFS,2016-02-15,UNKNOWN,OBSERVATIONAL,['NA'],OS,
14579,NCT04444544,Health-related Quality of Life,2020-09-05,RECRUITING,OBSERVATIONAL,['NA'],Health-related Quality of Life,
14580,NCT01854749,Progression Free Survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14581,NCT05891730,Number of colorectal cancer patients who remain in clinical trial until completion.,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14582,NCT01591135,3-yr overall survival,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Number and grade of Participants with Adverse Events,
14583,NCT05300789,Metachronous peritoneal carcinomatosis,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],Time to metachronous peritoneal carcinomatosis diagnosis,
14584,NCT01787539,cancer free and overall survival,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",the rate of chemotherapy cessation,quality of life
14585,NCT06214572,Median overall survival,2024-01-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life assessment (Liver specific),
14586,NCT01474694,"TRE, measuring the error in the prediction of a surgical target location when using the navigation system.",2011-10,COMPLETED,OBSERVATIONAL,['NA'],1.Identification of suitable landmarks for registration,
14587,NCT02478476,"Occurrence of chemotherapy related toxicities including Anemia, Nephrotoxicity, Neutropenia, Neuropathy, and Thrombocytopenia associated with genotype.",2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,
14588,NCT05557955,overall survival.,2022-09-27,COMPLETED,OBSERVATIONAL,['NA'],recurrence.,
14589,NCT03049124,Number of Participants with Adverse Events,2017-11-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Socio-Demographic and Medical Information Questionnaire
14590,NCT04733794,Sexual function,2016-02-19,COMPLETED,INTERVENTIONAL,['NA'],,
14591,NCT02906059,"Number of participants dose limiting toxicities with treatment-related adverse events as assessed by common terminology criteria for adverse events (CTCAE), version 4.",2016-09,COMPLETED,INTERVENTIONAL,['PHASE1'],"Tumor assessment by imaging techniques using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1",
14592,NCT05323201,Objective response of fhB7H3.CAR-T cells,2022-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",In vivo persistence of fhB7H3.CAR-T cells,Overall survival (OS)
14593,NCT00005997,Determine the response rate in patients with advanced hepatobiliary carcinoma treated with rebeccamycin analogue.,1999-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Assess the toxicity associated with this drug in this patient population.,
14594,NCT05932719,Measure of patient loss of chance when comparing a set of activity indicators between 2020 and the average activities of previous periods (2017-2019),2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
14595,NCT01110785,Percentage of patients free from progression and alive at 11 weeks after the first dose of panitumumab measured by RECIST v 1.1,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Correlation between proteomics and objective response rate,
14596,NCT05837767,Overall Response Rate (ORR),2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],,
14597,NCT01961791,Prognostic performance,2000-01,COMPLETED,OBSERVATIONAL,['NA'],,
14598,NCT04843176,Diagnostic accuracy for HCC,2021-03-19,RECRUITING,INTERVENTIONAL,['NA'],Occurrence of technical failures,
14599,NCT06059001,"Number of AEs, SAEs to evaluate the safety and tolerability of OMO-103 plus gemcitabine/nab-paclitaxel",2023-08-31,RECRUITING,INTERVENTIONAL,['PHASE1'],To evaluate quality of life (QoL) in patients with metastatic pancreatic cancer,
14600,NCT06004687,Postoperative delirium,2023-07-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Recovery time,Neurotransmitters in the blood
14601,NCT05411094,Dose-limiting toxicities (DLTs) for olaparib in combination with durvalumab and radiation,2023-05-22,SUSPENDED,INTERVENTIONAL,['PHASE1'],Number and diversity of T cells,Correlation of efficacy endpoints with clinicopathologic variables
14602,NCT01447238,"Assess the yield of combination modalities in the diagnosis of pancreatic cysts using EUS/FNA, Fiber optics (direct visualization probe), and prototype needle based confocal laser-induced endomicroscopy miniprobe (nCLE)",2010-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
14603,NCT02508077,4-month Progression-free Survival (PFS) Rate,2016-02-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14604,NCT01847599,evaluation of the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib,2011-09-06,TERMINATED,INTERVENTIONAL,['NA'],safety and tolerability as determined by adverse events frequency,
14605,NCT04264754,To develop a molecular blood test that will be able to detect HCC based on change in methylation patterns between HCC and normal hepatic tissue,2018-02-13,TERMINATED,OBSERVATIONAL,['NA'],Liver EpiCheck Performance,
14606,NCT05278039,Change in Penetration-Aspiration Scale scores,2021-08-12,RECRUITING,INTERVENTIONAL,['NA'],Change in Modified Barium Swallow Impairment Profile (MBSImP) scores,Change in M.D. Anderson Dysphagia Inventory (MDADI) scores
14607,NCT05602974,marginal recurrence rate,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Quality of life by EORTC QLQ-C30,
14608,NCT03385148,diagnosis effecacy,2017-01-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
14609,NCT00209664,objective tumor response,2004-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],"Response duration, time to progression, median survival time, and safety will also be assessed.",
14610,NCT05023863,Incidence and severity of radiation induced oral mucositis,2021-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Time to develop grade III or IV radiation induced oral mucositis:,
14611,NCT02757846,quantitative image features extracted from CT images can be used as imaging marker for prognosis,2017-04,UNKNOWN,OBSERVATIONAL,['NA'],,
14612,NCT01900691,Number of Patients With Successful Removal of Study Stent,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Number of Patients With Benign Indications That Achieved Clinical Success,
14613,NCT06147414,% of inconclusive results,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Estimated delay for result in standard care diagnosis condition,
14614,NCT02458664,Recurrence free survival and Recurrence free survival after resection of the colon cancer,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],Overall survival,
14615,NCT04230642,Evaluation of the feasibility of the Quantum Surgical device: Number of targets reached,2020-05-25,COMPLETED,INTERVENTIONAL,['NA'],Evaluation of the safety not related to the procedure,
14616,NCT00436137,Performance of colonoscopy,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,
14617,NCT03451370,Progression Free Survival (PFS),2017-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14618,NCT01507168,Progression-free survival (tumor assessments according to RECIST criteria),2012-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],GPC-3 expression in tumor tissue (biopsy) by immunohistochemistry (IHC) assay,
14619,NCT04217096,Progression free survival,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Adverse events,
14620,NCT01399190,Progression-free Survival,2011-07,COMPLETED,OBSERVATIONAL,['NA'],Percentage of Participants With Adverse Events,
14621,NCT02077296,Plasma and tissue cytokine levels,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
14622,NCT00773097,Number of Participants With Anti Muc-1 Antibody,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events Associated With the Study Agent,
14623,NCT01533324,DCR,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],safety,
14624,NCT01604564,Evaluation of postoperatieve recovery,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
14625,NCT00965718,Progressive Disease(PD),2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life (QoL) Assessed Using Quality of Life Questionnaire Core 30(QLQ-C30) in Patients With Pancreatic Cancer(QLQ-PAN26 Questionnaire),
14626,NCT06102278,overall survival,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14627,NCT03856437,Intention to Vaccinate Free of Cost,2021-01-22,COMPLETED,INTERVENTIONAL,['NA'],Intention to Vaccinate With Cost,
14628,NCT00006198,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14629,NCT00707889,Progression-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective response rate,
14630,NCT02586610,Pathological Complete Response (pCR) Rate,2016-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall Survival (OS),
14631,NCT00019630,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14632,NCT03337347,CEA mRNA positive circulating tumor cells in colorectal cancer patients,2004-01-01,COMPLETED,INTERVENTIONAL,['NA'],Cancer specific survival in CTC positive CRC patients,
14633,NCT04754672,Progression free survival,2021-03-02,RECRUITING,INTERVENTIONAL,['NA'],Physical activity,
14634,NCT03053284,Hypoglycemia,2017-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Serum glucose regulators,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
14635,NCT01937780,Disease-free survival,2013-10-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Pain relief of palliative radiotherapy,Overall survival
14636,NCT00016133,,2001-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14637,NCT03418298,Recruitment rate,2018-02-27,COMPLETED,INTERVENTIONAL,['NA'],Change in anxiety and depression,
14638,NCT04327700,Progression-Free Survival,2021-01-26,SUSPENDED,INTERVENTIONAL,['PHASE2'],Change in Alpha-fetoprotein Levels,
14639,NCT01239381,Local Control Rate,2010-06,COMPLETED,INTERVENTIONAL,['NA'],Median Survival Among Participants With Colorectal Cancer,
14640,NCT05563441,perioperative complications,2015-01-20,COMPLETED,OBSERVATIONAL,['NA'],disease free survival,
14641,NCT02859324,Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),2016-09-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Apparent Volume of Distribution (Vz/F),
14642,NCT03814824,Time for Image Interpretation (Median - Scaled),2019-01-23,COMPLETED,INTERVENTIONAL,['NA'],Subjects With Dysplasia on Biopsies,
14643,NCT05994482,colorectal cancer incidence,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],perspectives on surveillance in older adults,
14644,NCT04131803,objective response rate,2021-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
14645,NCT02016326,Adenoma Detection Rate (ADR) in the right colon using High Definition White Light Colonoscopy Versus I-Scan enhanced Colonoscopy.,2012-11,UNKNOWN,INTERVENTIONAL,['NA'],Adenoma Detection Rate (ADR) of High Definition White Light Colonoscopy Versus I-Scan colonoscopy through out the entire colon.,Presence or absence of learning effect while using this technology
14646,NCT02220088,Progression free survival,2014-12,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",overall survival,
14647,NCT05808790,Local recurrence-free survival,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Multiparameter flow cytometric analyses (FACS),
14648,NCT00409864,Quality of life,2003-10,COMPLETED,INTERVENTIONAL,['NA'],Stent patency time will be defined by time to stent occlusion,
14649,NCT05501353,the correlation between ctDNA mutations with methylation status and recurrence,2022-07-22,RECRUITING,OBSERVATIONAL,['NA'],Compare the difference of DNA with ctDNA in predicting postoperative recurrence through statistical method,
14650,NCT02222844,Randomised Phase: To measure the difference in treatment stratification policy caused by the difference in staging on CT and MRI.,2014-08,RECRUITING,INTERVENTIONAL,['NA'],To compare permanent defunctioning stoma rates in patients staged by CT and MRI according to predicted prognostic risk.,
14651,NCT03149523,Sequencing of the exome and tumor RNA,2017-05,UNKNOWN,OBSERVATIONAL,['NA'],Transcriptomic profile of urinary RNAs,
14652,NCT05684211,Progression-free survival (PFS),2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],incidence of adverse events,
14653,NCT02582541,Stent patency rate,2014-02,UNKNOWN,INTERVENTIONAL,['NA'],Change from Baseline in Bile Duct Stricture Diameter,
14654,NCT00755118,Objective Response Rate,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,
14655,NCT05760404,Evaluate the motor effects of drugs that act on the various components of this system,2022-12-19,RECRUITING,OBSERVATIONAL,['NA'],,
14656,NCT00847119,Pathologic complete response rate. % patients with pathologic complete response (absence of tumoral cells in the resected piece),2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],To determine the angiogenic profile changes in tumour.,
14657,NCT00180960,To study overall survival,2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],To study mortality-morbidity,
14658,NCT05928312,Objective response rate (ORR),2023-08-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Assess the anti-tumor activity:DCR,
14659,NCT04294498,The rate of HBV reactivation during durvalumab treatment,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE2'],To assess the adverse events during durvalumab treatment.,
14660,NCT01848015,CTCs,2013-06,UNKNOWN,OBSERVATIONAL,['NA'],Recurrence of gastric cancer after radical resection,
14661,NCT02848079,Overall Response Rate,2016-10-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival,
14662,NCT02908048,Diagnosis of liver cancer based on tumor markers and imaging studies.,2014-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14663,NCT05160727,Objective response rate,2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
14664,NCT03878550,AUROC,2019-05-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Sensitivity,
14665,NCT02748811,Number of patients completing planned treatment without dose reductions,2015-05,COMPLETED,INTERVENTIONAL,['NA'],Quality of Life prior,
14666,NCT00006340,,1994-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14667,NCT02738294,Specificity in distinguishing HGN from non-HGN,2013-06,COMPLETED,INTERVENTIONAL,['NA'],Negative predictive value (NPV) in distinguishing HGN from non-HGN,
14668,NCT06122896,"Number of Imaging-Negative, Assay-Positive Pancreatic Cancers or High-Grade Neoplasms",2023-11-21,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Clinical Predictors of Neoplastic Development,
14669,NCT03130790,Overall Survival (OS) - Phase 3 part,2017-08-31,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Gastric Cancer 22 items (EORTC QLQ STO22) measuring patients general cancer symptoms and functioning - Phase 3 part,
14670,NCT02713373,"Number of Participants With a Response, Evaluated According to RECIST 1.1",2016-08-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression Free Survival (PFS),
14671,NCT01494324,Tumor response,2009-10-27,RECRUITING,INTERVENTIONAL,['NA'],Duration of treatment response,
14672,NCT03797209,Removal success,2019-01-15,COMPLETED,OBSERVATIONAL,['NA'],,
14673,NCT02991677,Sensory pain,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Nerve fiber density,
14674,NCT04785287,Incidence of adverse events,2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tumor response,
14675,NCT02670122,Safety and Tolerability,2015-03,COMPLETED,OBSERVATIONAL,['NA'],OS,
14676,NCT03377972,Comparison WHO diagnosis standard with JAPAN in Early Esophageal Cancer patients by accessing pathological section.,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14677,NCT01937286,Recurrence of Hepatocellular carcinoma after LDLT,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,
14678,NCT05357508,Self-reported appropriate screening uptake,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Linkage to Vaud tumor registry,
14679,NCT03950154,Progression-free survival,2019-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14680,NCT04449679,Post-intervention evaluation,2020-04-15,COMPLETED,INTERVENTIONAL,['NA'],,
14681,NCT00540332,"Pharmacokinetic profile to include Systemic clearance, volume of distribution at steady state, estimated initial concentration, area under the conc-time curve, terminal half-life and mean residual time",2007-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence (%) and duration (days) of severe Oral Mucositis WHO grade 3 or 4,
14682,NCT01656265,"Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerability",2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Antitumor effects according to RECIST 1.1.,
14683,NCT06158516,2-year disease-free survival (2y-DFS),2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],2-year Overall survival,
14684,NCT06113718,Length of hospital,2023-01-01,COMPLETED,INTERVENTIONAL,['NA'],Postoperative gastrointestinal symptoms,
14685,NCT02949596,Evaluate quality of sexual life validated questionnaire (IIEF) among patients treated for anal cancer with concurrent chemoradiotherapy who are men who have sex with other men,2015-10,COMPLETED,OBSERVATIONAL,['NA'],Evaluate quality of life among patients who are HIV positive in this cohort with the use of questionnaire HAT-QoL,
14686,NCT03498326,disease free survival,2018-04-02,RECRUITING,INTERVENTIONAL,['PHASE2'],Common Toxicity Criteria for Adverse Effects,
14687,NCT05809999,Proportion of persons with ≥ 1 neoplastic lesion detected,2022-09-23,RECRUITING,INTERVENTIONAL,['NA'],CRC incidence over five years following study colonoscopy (obtained through patient linkage to provincial cancer registries five years following trial completion),
14688,NCT02060188,Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator,2014-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],ORR by RECIST v1.1 by Independent Radiology Review Committee (IRRC),
14689,NCT03701373,maintenance progression-free survival (PFS),2016-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],toxicity relevant to S-1 maintenance/observation,
14690,NCT00004065,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14691,NCT02820389,3-month cost analysis per patient undergoing either Optical Colonoscopy or CTC as the initial imaging modality (measured in £ per patient),2016-06-14,UNKNOWN,OBSERVATIONAL,['NA'],Cost per correctly diagnosed medium to large polyps (≥6mm) and colorectal cancer using CTC as the initial investigation (measured in £ per patient),
14692,NCT06256289,liver steatosis index CAP (Controlled Attenuation Parameter) measured by FibroScan,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Gut Microbiota diversity sequencing by 16s rRNA Amplicon Sequencing Analysis,
14693,NCT00811590,The Size of Intestinal Polyps,2008-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14694,NCT05674422,ctDNA from liquid biopsy,2023-05-26,RECRUITING,OBSERVATIONAL,['NA'],TNT compliance,
14695,NCT02870153,Response Rate,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival,
14696,NCT00174564,To evaluate response rate according to RECIST criteria,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],To investigate safety using NCI-CTC criteria version 2,
14697,NCT03338166,serum LDH level as a predictor of response in hepatocellular carcinoma,2018-01-02,UNKNOWN,OBSERVATIONAL,['NA'],,
14698,NCT02416466,Safety of CAR-T cell hepatic artery infusions in combination with Sir-Spheres as Measured by Number of Participants with Adverse Events,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1'],"CAR-T detection in liver tumors, normal liver, and extrahepatic sites",
14699,NCT01216202,Sexual Function,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,
14700,NCT01380392,,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,
14701,NCT00068432,Overall Survival at 6 months,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall response rate,
14702,NCT00509444,"The primary outcome variable will be difference between the two intervention groups in the time to initiation of therapy, beginning on the date of randomization.",2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],"The proportion receiving recommended screenings for breast, cervix, colon/rectum and prostate cancer.",
14703,NCT00632268,To evaluate the confirmed objective response rates (complete and partial responses),2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],"To assess the overall survival(OS), progression-free survival(PFS), treatment-related toxicities, and pharmacokinetic profile of RAD001 used in combination with 5-FU and cisplatin",
14704,NCT01974869,changes in inflammatory cytokines,2014-03,COMPLETED,OBSERVATIONAL,['NA'],30 postoperative day complications.,
14705,NCT00025350,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14706,NCT04898842,"Symptoms of sub-acute bowel obstruction: abdominal pain, feeling bloated, feeling full-up quickly, nausea and / or vomiting",2021-03-02,UNKNOWN,INTERVENTIONAL,['NA'],Weight,
14707,NCT00027729,,2001-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14708,NCT01468623,Overall response rate (ORR),2011-09,TERMINATED,INTERVENTIONAL,['PHASE4'],Progression-free survival (PFS),
14709,NCT00034281,Optimal Dosing for Phase II Studies.,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Response Evaluation Criteria in Solid Tumors Documentation of Objective Tumor Response.,
14710,NCT03182894,Phase ll: Objective Response Rate (ORR),2018-09-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),
14711,NCT03307811,Diagnostic adequacy of the liver biopsy specimen,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],Complications/Infection,
14712,NCT06319924,Assess the quality of the bowel preparation assessed by Boston Bowel Preparation Scale (BBPS),2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],Caecal intubation rate,
14713,NCT05773105,Desease control rate (DCR),2023-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse Events (AEs),
14714,NCT00687349,"Patient and family ratings on the ""End-of-Life domain"" of the Quality of Communication Questionaire (QOC)",2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],"Patient-, family-, and nurse-assessed ratings of the quality of end-of-life care provided by study clinicians using Quality of End-of-Life Care questionaire",
14715,NCT05417932,Tumor response of SCG101 (Phase 2),2022-10-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Persistence of viral vector copy number (VCN) after SCG101 infusion,
14716,NCT05652920,Maximum tolerated dose of Ori-C101,2022-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Objective Response Rate,
14717,NCT01944540,En Bloc resection rate,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],complication rate,
14718,NCT04338542,Change of RAS mutant clones in the metastatic lesion,2020-04-08,COMPLETED,OBSERVATIONAL,['NA'],Molecular patterns other than RAS,
14719,NCT03843398,"3-year overall survival, 3y OS",2019-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Postoperative mortality at 30 days,
14720,NCT01073358,rate of disease recurrence,2010-03-09,UNKNOWN,INTERVENTIONAL,['NA'],,
14721,NCT00559598,Gather information about clinical factors surrounding the date of blood extraction that may influence the proteomic patterns of the blood samples by reviewing clinical records of participants,2004-08,COMPLETED,OBSERVATIONAL,['NA'],,
14722,NCT01549522,,2012-03,UNKNOWN,OBSERVATIONAL,['NA'],,
14723,NCT04870034,Incidence of adverse events,2024-01-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Immune subsets within the pre and posttreatment tumor tissue,
14724,NCT02853422,"Survey on the clinical utility of the QLQ-GINET21, which the investigator is to complete for each patient enrolled",2016-04,COMPLETED,OBSERVATIONAL,['NA'],Clinical assessment of patient's health status by the investigator,
14725,NCT06168825,Acceptability of the MOM intervention,2024-01-17,RECRUITING,OBSERVATIONAL,['NA'],Number of participants who reported MOM intervention as linguistically appropriate,
14726,NCT01296763,Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD),2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],"Number of Years From Cycle 1, Day 1 On-Study to Date of Death",
14727,NCT03081637,Rate of expression of Filamin A (FLNA) in HCC specimens from patients resected for HCC.,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14728,NCT05214495,Oral Mucositis Severity,2022-02-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14729,NCT00031681,Side effect profile of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in triple negative recurrent breast cancer (Part II),2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],In vivo mechanistic basis for 7-hydroxystaurosporine activity,
14730,NCT05130060,Incidence of adverse events (AE),2022-01-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Progression free survival (PFS),
14731,NCT02727062,The number of subjects who comply with the compulsory four-time daily pain entries.,2018-02-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14732,NCT03133273,Occurrence of the progression or death of the patient.,2017-07-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Grade 3 and higher adverse events related to chemotherapy,
14733,NCT06314516,Longitudinal variation in body composition,2017-12-27,COMPLETED,OBSERVATIONAL,['NA'],Patient and disease-specific factors,
14734,NCT03002727,Differential expression of CD133 based on microsatellite status and correlation with clinicopathological features.,2016-12,UNKNOWN,OBSERVATIONAL,['NA'],"If radiotherapy increases the count of CD +ve 133 cells , does that increase significantly affects the progression free survival",
14735,NCT04349384,Morbidity,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],Readmission,
14736,NCT01088789,Disease free overall survival.,2010-04-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
14737,NCT02379520,Number of patients with dose limiting toxicity (DLT),2015-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Overall response rate,
14738,NCT04483349,"Importance patients place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)",2020-06-11,COMPLETED,OBSERVATIONAL,['NA'],"Importance care providers (i.e., physicians, nurses, administrators) place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)",
14739,NCT02833753,Define the maximum tolerated dose (MTD) of intraperitoneal (IP) oxaliplatin given with systemic FOLFIRI in patients with peritoneal carcinomatosis (PC) of colorectal or appendiceal origin,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14740,NCT05083338,Chronic postsurgical pain,2021-08-10,COMPLETED,OBSERVATIONAL,['NA'],,
14741,NCT00769535,Clinical relevance,2006-01,COMPLETED,INTERVENTIONAL,['NA'],Clinical relevance,
14742,NCT00134095,Safety,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14743,NCT02322736,To describe the pattern of use of Vectibix® in combination with chemotherapy in 1st line or in 2nd line mCRC treatments as per approved Vectibix® indication.,2014-11-21,COMPLETED,OBSERVATIONAL,['NA'],"To investigate the rate of objective response (ORR, defined as either a Complete Response or a Partial Response) and the rate of stable disease as best response in 1st line or in 2nd line chemotherapy regimens of mCRC including Vectibix®.","Frequency of primary tumor resection, of metastatic lesion resection, of BRAF testing in the entire number of the study participants and frequency of BRAF mutation in the unselected Greek patient population with WT RAS mCRC included in the study."
14744,NCT05013944,Measuring and/or Improving Quality of Care,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
14745,NCT04359199,"Swallowing function 12-24 months after concurrent radiation and systemic therapy for HNC, as measured by the PCR",2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],Correlation between radiation dose and location of swallowing function and quantitative swallowing function,
14746,NCT05462613,overall survival (OS) (phase III),2023-05-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14747,NCT01770431,Incidence of Recurrence and Metastasis After Hepatectomy,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4'],Postoperative Survival Period,
14748,NCT02729506,Time to Progression (TTP) is the primary outcome.,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],"Treatment-related costs, in terms of cost of therapy and number of hospitalization days.",
14749,NCT03007446,reaction rate,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,
14750,NCT02365896,postoperative early anastomotic morbidity,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],Nutrition,
14751,NCT00342641,,2005-06-08,COMPLETED,OBSERVATIONAL,['NA'],,
14752,NCT06167967,Recurrence-free survival at 3 years,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The proportion of patients in the low-risk cohort who did not receive adjuvant chemotherapy,
14753,NCT04211168,Rate of adverse events (AE),2020-08-11,RECRUITING,INTERVENTIONAL,['PHASE2'],6-months and 1-year mortality rate,Biomarkers
14754,NCT04839471,ORR (RECIST 1.1),2021-08-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],To explore the treatment-related adverse events as assessed by CTCAE v5.0,
14755,NCT03825289,Rate of dose-limiting toxicities during the DLT assessment window.,2019-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],Response Rate,
14756,NCT05894369,Tumor diameter,2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,
14757,NCT00756782,radiologically proven progression-free survival (PFS),2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],The relationship between tumor gene expression (mRNA expression) of co-activators and co-repressors and efficacy parameters,
14758,NCT05571293,Number of complications leading to delays of 12 weeks or more in surgery after initiation of treatment,2023-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in Minimal Residual Disease assessed using ctDNA pre- and post-surgical resection,
14759,NCT01969110,"plasma resolvin E1, cell-mediated immunity",2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],infectious complication rate,
14760,NCT02850536,Safety of CAR-T cell hepatic artery infusions delivered using the Surefire Infusion System (SIS) as Measured by Number of Participants with Adverse Events,2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety of Direct Intrapancreatic CAR-T Retrograde Venous Infusions (RVI) Delivered Using the Surefire Infusion System (SIS),
14761,NCT05433701,"Local progression-free survival rate, per-protocol (PP)",2022-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"Local progression-free survival rate according to the tumor location, ITT",
14762,NCT05970133,The surgical efficiency of both NOSE procedures,2023-04-07,RECRUITING,INTERVENTIONAL,['NA'],CD4+ to CD8+ ratio,
14763,NCT03899870,Recurrence,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14764,NCT04066816,Urolithin Phenotype and Colonic Health,2019-05-20,COMPLETED,INTERVENTIONAL,['NA'],Identify Changes in Microbiota and Microbes Responsible for Urolithin Formation Followed by Walnuts Consumption using Metagenomics Sequencing,
14765,NCT01392274,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l,2012-04,COMPLETED,OBSERVATIONAL,['NA'],Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l,
14766,NCT03245554,Tumor size will be measured.,2018-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
14767,NCT04629677,Bleeding risk (Cohort A and B),2019-04-02,RECRUITING,OBSERVATIONAL,['NA'],,
14768,NCT00002608,,1994-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14769,NCT05931068,Change in energy expenditure using indirect calorimetry,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],Hospital anxiety and depression scale,
14770,NCT00537901,Effectiveness,2007-10,COMPLETED,INTERVENTIONAL,['NA'],Quality of life,
14771,NCT02821754,6 Month Progression Free Survival (PFS),2016-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Grades 1-5 Adverse Events Related to Tremelimumab and Durvalumab,Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
14772,NCT05526443,Proportion of patients with locally advanced inoperable and/or metastatic PDAC undergoing palliative second line therapy after progression on first line chemotherapy,2023-01-13,RECRUITING,OBSERVATIONAL,['NA'],To analyze the mutational landscape of advanced pancreatic cancer and its impact on treatment decision making and clinical outcome,
14773,NCT03084380,Safety: Measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0,2017-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Persistence: Duration of CAR-positive T cells in circulation,
14774,NCT03179657,Nonalcoholic fatty liver disease (NAFLD),2008-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Cognitive function,
14775,NCT02591407,Post-operative pain control day 3 using the numeric pain scale,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall benefits of analgesia treatment post-operative day 3,Patient use of supplemental narcotic analgesia post-operative day 3
14776,NCT01270984,To evaluate the pharmacokinetics of Luckyvec 400mg tablet and Glivec 100mg tablet in healthy subjects,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],"To evaluate the safety of Luckyvec 400mg tablet and Glivec 100mg tablet from vital signs, physical exam, ECG, laboratory test, adverse event and so on.",
14777,NCT04392167,Percentage of Correctly Identified Negative (Non-Dysplastic) Biopsies,2020-11-24,COMPLETED,INTERVENTIONAL,['NA'],Percentage of Participants With Adequate Tissue Contact to Acquire a High Quality Image,
14778,NCT05657080,Sensitivity of Cytosponge for GIM,2023-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Number of participants with device-related adverse events as assessed by CTCAE v4.0,
14779,NCT00892736,"MTD, DLT, recommended phase II dose of chronically dosed single-agent veliparib in patients with either a refractory BRCA 1/2- mutated solid cancer; platinum- refractory ovarian, fallopian tube, or primary peritoneal cancer; or basal-like breast cancer",2009-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Changes in BRCA 1/2 expression in tumor blocks,
14780,NCT04764084,Dose limiting toxicity (DLT) and maximum tolerated dose (MTD),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Progression-free survival (PFS),
14781,NCT05130021,progress free survival(PFS)[Part 2],2022-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],Safety and tolerability assessed by incidence and severity of adverse events,
14782,NCT00465725,Comparison of platinum levels excreted in urine from 0-8 and 8-24 hours after start of IV or oral drug,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14783,NCT02510066,"Pain scores, assessed with numeric rating scale (NRS)",2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Blood levels of nerve growth factor,
14784,NCT03787251,PFS,2019-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],ORR,
14785,NCT04526470,Progression-free survival rate at 4 months,2020-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time to response,Exploratory biomarker analysis for efficacy and resistance of alpelisib plus paclitaxel combination (using collected clinical samples) including mutations and RNA/protein expression levels of PI3K pathway genes
14786,NCT01198821,Establish the safety and tolerability of oral sodium bicarbonate in patients with advanced pancreatic carcinoma treated with gemcitabine,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],"Determine if oral bicarbonate improves overall survival, progression free-survival and response rate in patients with advanced pancreatic cancer",
14787,NCT01791309,objective response rate (ORR),2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],efficacy,
14788,NCT03222089,Progression-free survival (PFS) rate at 10 months,2017-07-20,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Quality of life (QLQ C30),
14789,NCT04494022,Compared diagnostic performance of Gd-EOB-MRI alone and Gd-EOB-MRI with CEUS.,2020-06-08,UNKNOWN,INTERVENTIONAL,['NA'],Comparing image characters between two types of ultrasound contrast media,
14790,NCT06145230,Pathological characteristics,2023-12-12,RECRUITING,OBSERVATIONAL,['NA'],Risk factors,
14791,NCT01463501,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall Survival,
14792,NCT01010126,Tumor Response Rate,2009-09-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Treatment Failure,
14793,NCT02562924,Change in Lund-Kennedy Endoscopic Scores,2015-11,COMPLETED,INTERVENTIONAL,['NA'],Change in SNOT-22 Nasal Symptom Scores,
14794,NCT05684432,Frequency and classification of radiation-induced diarrhrea in patients with prostate and rectal cancer during curative external radiotherapy,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
14795,NCT04401813,Evaluation of the objective response rate of IBI310 combined with 308 in the second-line treatment of advanced hepatocellular carcinoma,2020-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluate the ORR of IBI310 combined with 308 in the second-line treatment of advanced hepatocellular carcinoma (researched by the investigator according to RECIST V1.1).,
14796,NCT01011478,"Occurrence of ≥ 1 Adenomatous Polyp of the Colon or Rectum, Metachronous Colorectal Carcinoma, or Colon Cancer Recurrence (APMC+R)",2010-03,TERMINATED,INTERVENTIONAL,['PHASE3'],Measurements of Relevant Tumor and Blood Markers,
14797,NCT03480256,Maximum Tolerated Dose (MTD),2018-07-27,UNKNOWN,INTERVENTIONAL,['PHASE1'],Area Under the Curve,
14798,NCT00569335,Safety,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],"Progression-free survival, Response rate, Overall survival, Time to treatment failure, Treatment situation",
14799,NCT00191984,Best Overall Tumor Response,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,
14800,NCT03224221,One-year survival rate,2017-03-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life using EORTC QLQ C30 - scale,
14801,NCT03200366,Participants Completing CRC Screening Per Electronic Medical Record Documentation,2017-07-26,COMPLETED,INTERVENTIONAL,['NA'],Change in Perceived Self-Efficacy for CRC Screening by FIT,
14802,NCT04985084,Acceptability outcome: participants' satisfaction and perspectives of the intervention,2021-07-12,UNKNOWN,INTERVENTIONAL,['NA'],Dietary behavior self-efficacy,
14803,NCT02754115,Changes in arterial blood gas in perioperative period,2016-04,RECRUITING,OBSERVATIONAL,['NA'],Mortality,
14804,NCT05496777,Therapist appreciation,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Quality of life measurement,
14805,NCT05653180,Objective response rate (ORR),2023-03-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Overall Survival,OS",
14806,NCT04652986,Disease-free survival at five years,2004-01,UNKNOWN,OBSERVATIONAL,['NA'],Five years overall survival,Operative morbidity
14807,NCT04526080,Overall Survival,2021-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Response Rates,
14808,NCT06106568,Descriptive summary of healthcare costs in EOB-MRI and non-EOB-MRI group,2023-11-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Descriptive summary of the likelihood of open-close laparotomy in patients with confirmed diagnosis of pancreatic cancer who is intended the surgical intervention between those in the EOB-MRI group and non-EOB-MRI group,
14809,NCT04954794,Objective Response Rate (ORR),2021-07-14,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
14810,NCT05215964,Total psoas muscle change,2020-09-29,UNKNOWN,OBSERVATIONAL,['NA'],Total kidney volume change,
14811,NCT05740137,Adenoma detection rate (ADR),2022-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Polyps per positive patient (PPP),
14812,NCT05040646,Consensus in / No important outcome,2021-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
14813,NCT01694589,Changes in mean Gli-1 levels before and after drug,2012-11,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Complications from surgery by time of hospital discharge up to 30 days post-operatively,
14814,NCT02228668,Overall Survival (OS) up to 8 and 10 years median follow-up of the stage III population randomized in the AVANT study.,2015-03,COMPLETED,OBSERVATIONAL,['NA'],Cancer Specific Survival (CSS) in patients with stage II and stage III colon cancer.,
14815,NCT05116891,To assess the preliminary efficacy of CAN04 in combination with chemotherapy regimens measured as tumour response.,2021-09-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",To assess PK of CAN04 after a single dose and at steady state,To assess ADA formation against CAN04.
14816,NCT01920113,A comparison of safety during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil,2012-10,COMPLETED,INTERVENTIONAL,['NA'],A comparison of efficacy during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil,"A comparison of gastric motility, easiness for procedure, operator's satisfaction during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil"
14817,NCT00574327,"The goal of this study is to follow GERD and BE pts prospectively for development of dysplasia and adenocarcinoma, to identify factors responsible for progression of GERD to BE to dysplasia and adenocarcinoma.",2006-01,RECRUITING,OBSERVATIONAL,['NA'],The secondary goal is to create a tissue and serum repository for future biomarker studies.,
14818,NCT06027775,relapse-free survival,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],overall survival,
14819,NCT02774161,Spectral slope,2016-05,COMPLETED,INTERVENTIONAL,['NA'],,
14820,NCT05787197,Disease-free survival (DFS) in patients who undergo curative-intent resection of colorectal liver metastasis (CRLM),2024-01-09,RECRUITING,OBSERVATIONAL,['NA'],Association between ctDNA and clinical features.,
14821,NCT01573468,Overall survival,2012-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of adverse events,
14822,NCT00671645,"feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma",2008-07,TERMINATED,INTERVENTIONAL,['PHASE2'],"collection of response rate (T- and M-downstaging, pathological complete remission)",
14823,NCT00414232,Quality of Life (QoL),2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
14824,NCT04712032,90-days Anastomotic Leakage (AL) rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],days in hospital stay,
14825,NCT02399631,Actual hospital stay,2012-01,TERMINATED,INTERVENTIONAL,['NA'],Nutritional status,
14826,NCT02406547,Number of polyps detected with both techniques (NBI versus WLE),2015-03,COMPLETED,INTERVENTIONAL,['NA'],Number of accurate detection of adenomas with morphologic features with both groups (NBI and WLE) compared to histopathology,
14827,NCT04859595,Maintenance of functional capacities,2021-07-29,COMPLETED,INTERVENTIONAL,['NA'],,
14828,NCT04572711,Number of adverse events,2020-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Healthcare Utilization,
14829,NCT00739167,Quality of life differences between treatment groups,2008-04,COMPLETED,OBSERVATIONAL,['NA'],,
14830,NCT05717738,Number of Patients Amendable to Curative Surgical Interventions,2022-01-20,RECRUITING,OBSERVATIONAL,['NA'],Quality of Life (QoL) after treatment,
14831,NCT03357276,Relief degree of tumors,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival（OS）,
14832,NCT03415802,Objective response rate（ORR）,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety profile: Adverse events of nab-Paclitaxel plus S-1 for advanced pancreatic cancer,
14833,NCT01215539,Objective Response,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Economic evaluation,
14834,NCT00919659,nutritional status presented by phase angle,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],"quantity of port infections, quantity of oedema, quantity of diarrhea",
14835,NCT02463877,Rate of postoperative complications,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14836,NCT04993261,Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors,2015-09-23,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
14837,NCT03996031,Patient activation,2019-08-19,COMPLETED,OBSERVATIONAL,['NA'],Patient satisfaction,
14838,NCT00618319,Changes in FDG-PET imaging,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Characterize the safety profile of BIIB021,
14839,NCT06176885,PFS（Disease-free Survival）,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE2'],DCR（Disease control rate）,
14840,NCT03452553,Efficacy: Time to progression (TTP),2018-07-01,WITHDRAWN,INTERVENTIONAL,['NA'],Physician rating of the handling and visibility of LC Bead LUMI™.,
14841,NCT00805896,Time to tumor progression(TTP),2008-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
14842,NCT01646112,,2012-04-25,COMPLETED,OBSERVATIONAL,['NA'],,
14843,NCT06115733,PFS,2023-12-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],DCR,
14844,NCT02289300,Change from baseline in liver stiffness measurement (kPa) assessed by Fibroscan® at Final visit,2020-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"Changes from baseline to post-treatment visits in vital signs, laboratory examination, and physical examinations results",
14845,NCT01333332,To determine the safety of neoadjuvant accelerated fraction standard dose radiotherapy to 50 Gy with concomitant capecitabine in patients with resectable and borderline resectable pancreas cancer.,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14846,NCT03788655,Technical feasibility of intrahepatic stenting,2018-12-31,UNKNOWN,OBSERVATIONAL,['NA'],Survival rate,
14847,NCT04763408,Number of Participants with one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations of Lenvatinib,2021-04-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Number of Participants with one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations of Sorafenib,
14848,NCT03454035,Overall Survival,2018-01-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Cancer Antigen 19-9 (CA19-9) response,
14849,NCT03434379,PFS-IRF Per RECIST v1.1 in the China Population,2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population,
14850,NCT00487695,Diagnostic Yield for Neoplasia in High Risk Patients(Suspected Neoplasia),2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Mean Number of Biopsies Taken in Barrett's Surveillance Patients,
14851,NCT03803891,Technical Success,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],Histologically confirmed full-thickness resection,
14852,NCT00902343,To determine if nomogram-based allocation of ANH is superior to allocation using extent of resection alone (planned resection of 3 or more liver segments) in patients undergoing partial hepatectomy.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],To assess the impact of nomogram-based allocation of ANH compared to standard allocation on the need for fresh frozen plasma (FFP) transfusions.,
14853,NCT03300843,Percentage of Patients Who Had a Clinical Response (Complete Response (CR) + Partial Response (PR)) to Treatment,2018-04-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events,
14854,NCT03667612,correlation between the expression levels of the genes involved in the regulation of endothelial activation and the degree of tumor-infiltrating lymphocytes,2018-01-31,UNKNOWN,OBSERVATIONAL,['NA'],The RER phenotype (the replication error phenotype),
14855,NCT01099826,completing CRC screening test,2004-10,COMPLETED,INTERVENTIONAL,['NA'],,
14856,NCT01784081,Feasibility of the patients with metastatic pancreas cancer to meet with the palliative care team and to complete symptom assessments.,2014-04,WITHDRAWN,OBSERVATIONAL,['NA'],"Changes in hospice referral, use, acceptance, and length of stay, compared to similar patients in the prior 12 months (from retrospective review)",
14857,NCT01639703,Permeability Surface (PS) According to Degree of Lesions Differentiation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Permeability Surface According to Immunohistochemistry Parameter (CD31),
14858,NCT01294072,Concentration of curcumin in normal and cancerous tissue,2011-01,RECRUITING,INTERVENTIONAL,['NA'],measurement of curcumin mixed with plant exosomes on metabolic characteristics of normal colon mucosa and colon tumors,
14859,NCT04430452,Objective response rate (ORR),2022-02-04,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
14860,NCT04197856,Uptake of genetic counselling among the patient's at-risk relatives,2020-02-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Intervention - Collection of letters (only intervention group)
14861,NCT04635423,Percentage of participants with ≥1 serious adverse events (SAEs),2020-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Geometric mean titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58,
14862,NCT06129422,Safety and tolerability of a single infusion of NMK89: Frequency and severity of abnormal ECOG PS (Eastern Cooperative Oncology Group Performance Status),2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Public Safety: Radiation measurement,
14863,NCT02138370,Time to disease recurrence,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],overall survival,
14864,NCT04531930,3yCR,2020-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],3yOSR,
14865,NCT06130280,Local control rate CRC liver metastasis,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,
14866,NCT05543057,"1-, 2-, 3-year overall survival",2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],Quality of life of patients with oesophageal cancer,Biomarkers to predict radiotherapy efficacy
14867,NCT01281618,activated myofibroblasts,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,
14868,NCT05626985,GAMAD,2022-10-19,RECRUITING,OBSERVATIONAL,['NA'],circulating tumor DNA methylation,
14869,NCT05515705,Evaluation of the EUS navigation system's procedure duration compared to standard procedure times,2023-01-10,RECRUITING,INTERVENTIONAL,['NA'],Assessment of technological maturity and ergonomics,
14870,NCT05239338,Disease-free survival,2021-12-06,RECRUITING,OBSERVATIONAL,['NA'],Physical activity (Accelerometer),
14871,NCT04727541,Major Pathologic Response (MPR) measured in the surgically resected tumor,2021-07-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Adverse Events of Special Interest,
14872,NCT06139926,Changes in perioperative HADS scale scores.,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14873,NCT00535652,Tissue (Total) Concentrations of Ertapenem in the Colorectal Tissue,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4'],Safety Assessment,
14874,NCT01339000,Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on Specific Immune Responses to Vaccines (in Particular to Neo Antigens) in Older Subjects Following Chemotherapy,2011-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events,
14875,NCT05957289,Fear of Progression Questionaire-Short Form (FoP-Q-SF),2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Semi-structured interviews,
14876,NCT04168788,Correlate pharmacogenetic analysis with veno-occlusive disease.,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Participant characteristics.,
14877,NCT06283238,Number of participants with Progressive Disease,2024-04-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14878,NCT03712566,"Characterization of Genomic, epigenetic and Immune Profiling Features",2018-11-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Enable Data-Sharing,
14879,NCT00846313,Body weight,2003-12,WITHDRAWN,INTERVENTIONAL,['NA'],Dietary intake,
14880,NCT03578874,Resectability,2016-06-20,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,
14881,NCT00614393,Percentage of Participants Who Experience an AE of Infusion Site Reaction,2007-12-24,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Response Rate (ORR) of Dalotuzumab in Combination With Cetuximab + Irinotecan Versus ORR of Cetuximab + Irinotecan Alone in Participants With Wild Type of Colorectal Cancer,
14882,NCT06168552,Accuracy and sensitivity of the imaging agent,2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14883,NCT03234842,Compare the rate of a clinically significant reduction of DLCO (defined as a decrease of ≥ 10% from baseline) between protons and photons after preoperative or definitive chemoradiation,2017-10-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Compare overall survival rates,
14884,NCT02008929,"Disease free survival, DFS",2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],"Overall survival, OS",
14885,NCT00994721,The primary end-point is recurrence-free survival.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],"The secondary end-points are overall survival; local and distant control rate, and the quality of life.",
14886,NCT02843412,compare the positive rate,2016-08,UNKNOWN,OBSERVATIONAL,['NA'],,
14887,NCT00568971,"Response rate, overall survival",2007-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Side effects,
14888,NCT03799380,ED visits,2019-11-05,COMPLETED,INTERVENTIONAL,['NA'],Missed days of radiation +/- chemotherapy/immunotherapy treatment,
14889,NCT00805688,Patient Reported Symptom Severity and Interference,2008-11-12,COMPLETED,OBSERVATIONAL,['NA'],,
14890,NCT01693276,Increase overall survival,2012-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Rate of local control,
14891,NCT02836847,Progression Free Survival,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],percentage of patients with Clinical Benefit Response,
14892,NCT04805788,3-month rate of patients experiencing an increase in Child-Pugh score by 2 or more points of 5-fraction stereotactic body proton radiotherapy in the treatment of hepatocellular carcinoma (HCC),2021-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Value of volumetric imaging analysis,Blood bank patient specimens for future analysis
14893,NCT02264496,Length of stay,2014-03,COMPLETED,INTERVENTIONAL,['NA'],Quality of Life Questionnaires,
14894,NCT00493441,Pharmacokinetics,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14895,NCT02753881,Pharmacokinetics Profile-- Time of Maximum Concentration,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Assessment and Frequency of Toxicities (Laboratory and Clinical Adverse Events) According to NCI Common Toxicity Criteria for AE (CTCAE) 5.0.,
14896,NCT03702985,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0,2018-05-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],the morbidity of late radiation proctitis,
14897,NCT05723705,Textbook Outcome in Liver Surgery (TOLS),2023-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Intra-operative ICG-margin assessment,
14898,NCT01086332,Dose limiting toxicities,2009-05,TERMINATED,INTERVENTIONAL,['PHASE1'],Surgical resection rate,
14899,NCT00019825,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14900,NCT02963831,Progression-free Survival (PFS) at Week 24 as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),2017-09-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method,
14901,NCT03949933,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2015-05-01,COMPLETED,INTERVENTIONAL,['NA'],progression-free survivals,
14902,NCT06071845,Accuracy of the Oncoguard Esophagus (OGE) test,2023-10-16,RECRUITING,INTERVENTIONAL,['NA'],Trauma to the esophagus from the passage of the Cytosponge device,
14903,NCT01707511,,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14904,NCT02615210,"Number of malignant diagnoses across hree-sample techniques (Spy bite, forceps biopsy, brushings)",2015-11,TERMINATED,INTERVENTIONAL,['NA'],Time from procedure to the initiation of treatment (in cases of malignancy),
14905,NCT01853241,Comparison of the depth of insertion into the small bowel of SBE compared with SE from the pylorus.,2010-05,TERMINATED,OBSERVATIONAL,['NA'],A comparison of the mean adjusted diagnostic procedure time,
14906,NCT01634685,dose-limiting toxicities (DLT),2012-08-08,COMPLETED,INTERVENTIONAL,['PHASE1'],maximally tolerated dose (MTD),
14907,NCT03409848,Overall Survival,2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Central Imaging Review - PFS,
14908,NCT03200171,Behavior of hepatocellular carcinoma,2018-02-10,COMPLETED,OBSERVATIONAL,['NA'],Progression-free survival (PFS),
14909,NCT04641455,"Visibility score"" evaluated by blinded performing endoscopist",2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],"Visibility score"" evaluated by two blinded endoscopists using 10 endoscopic images captured during endoscopy",Duration of endoscopy
14910,NCT04814485,ORR (Objective Response Rate),2021-04-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events (per CTCAE v5.0 criteria),
14911,NCT00250328,Functioning anastomosis without leaks or obstructions,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Functioning anastomosis without stenosis,
14912,NCT06292975,withdrawal rate,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Physical activity levels,
14913,NCT05659914,Overall Response Rate (ORR),2022-11-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence and severity of AEs CTCAE v5 criteria,"To characterize the immune microenvironment of this tumours and biomarkers of HRD status, and RAD51 status in tumour tissue samples and blood samples"
14914,NCT02820194,Control of local disease,2016-06,TERMINATED,INTERVENTIONAL,['NA'],Incidence of acute and late complications,
14915,NCT00079027,Overall survival,2004-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],Proteomic and immunological analysis,
14916,NCT00003192,Objective response rate Objective response rate Objective response rate Objective response rate,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14917,NCT01172548,Recurrence Free Survival Rate,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Treatment Compliance - tracking if the patient is coming to visits as per visit schedule in protocol,
14918,NCT02724475,Overall survival,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
14919,NCT01313442,Collected samples,2011-03-02,RECRUITING,OBSERVATIONAL,['NA'],,
14920,NCT04106453,time to complete ablation,2019-09-14,COMPLETED,INTERVENTIONAL,['NA'],ablation completeness,
14921,NCT05354882,Change of physical activity (connected device),2022-03-29,RECRUITING,INTERVENTIONAL,['NA'],Motivation to physical activity pratice,Socio-demographic variables
14922,NCT02903771,Pharmacokinetic (PK) profile of Cantrixil after intra-peritoneal (IP) administration,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1'],CA-125 level,Expression of Stem Cell Markers
14923,NCT01485679,"Specificity of TEP-CT to point out malignant lesions in pancreas, the gold standard being the anatomopathological analysis of the piece of pancreas removed during the surgery.",2011-01,COMPLETED,INTERVENTIONAL,['NA'],Number of patients for which metastasis will be detected through TEP-CT and confirmed by biopsy and/or conventional specific device,
14924,NCT05911425,ORR,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],OS,
14925,NCT02923921,Overall Survival,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Percentage of Participants Alive at 1 Year (12-Month Survival Rate),
14926,NCT06106308,Objective Response Rate (ORR),2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety: Exposure Response Evaluation of Onvansertib,
14927,NCT05743959,Relapse-free survival,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
14928,NCT02709070,recurrence free survival,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],overall survival,
14929,NCT02288377,Proportion of Patients Alive and Progression-free at 6 Months,2015-01,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Overall Survival,
14930,NCT00640978,Number of Participants Surviving at 6 Months,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14931,NCT01647828,Phase 2: Median OS by Notch 3 Percentile (ITT Population),2012-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14932,NCT04953962,Three-month progression free survival rate (3M PFSR),2021-12-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival (OS),
14933,NCT05490147,Intraoperative blood loss,2022-08-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Satisfaction scale of the operator and participants,
14934,NCT02031939,overall survival,2014-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Respond rate,
14935,NCT03253185,Number of participants with dose-limiting toxicities (DLTs),2017-09-13,TERMINATED,INTERVENTIONAL,['PHASE1'],Maximum observed serum concentration (Cmax) of SC-007,
14936,NCT03520946,Overall survival,2019-01-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of life II (QoL),Explorative: Progression-free survival (PFS)
14937,NCT02101593,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with sorafenib in advanced HCC,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14938,NCT01766219,Overall Survival,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Adverse Events Using the National Cancer Institute Common Terminology Criteria,
14939,NCT00084383,Disease-free Survival,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Estimate the Association of Specific in Vivo Parameters of Immune Response With Clinical Responses in Patients Treated With Combination Chemoradiotherapy Together With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines.,
14940,NCT00541593,Mortality,2007-09,TERMINATED,INTERVENTIONAL,['NA'],,
14941,NCT03730545,Change from baseline serum concentration of immune markers to postoperative day 5,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],"Change among baseline, postoperative day 3 and 5 serum nutritional markers",
14942,NCT04242901,Number of participants who yield sequential FIT results in divergent strata used for clinical decision making,2020-10-20,COMPLETED,OBSERVATIONAL,['NA'],"Calculation of Odds Ratios for age, gender, family history of CRC, hypertension, obesity, smoking status, excessive alcohol intake, right sided tumour, stage 1 cancer",
14943,NCT05611658,"Change of interobserver variability in target volume delineation on CT, PET CT and MR.",2020-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14944,NCT01326364,"Tumor response to treatment in SBRT patients, based on WHO criteria (No Change/Progressive Disease vs. Partial/Complete Response)",2010-03,TERMINATED,OBSERVATIONAL,['NA'],,
14945,NCT03247296,HCC,2017-02-28,UNKNOWN,OBSERVATIONAL,['NA'],,
14946,NCT03332498,Phase II - Disease Control Rate at 4 Months,2018-01-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14947,NCT04191928,Serum Apixaban Level,2020-03-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14948,NCT01613430,"Completing at least one recommended cancer screenings (colorectal, breast, cervical)",2012-06,COMPLETED,INTERVENTIONAL,['NA'],"Time to completion of cancer screenings, and the effect of comorbid conditions, health literacy, patient satisfaction,and health care costs on cancer screening",
14949,NCT02448953,Long term survival,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative complications,
14950,NCT02939807,To assess objective response rate (per modified RECIST) of single agent ABC294640 in treatment of HCC,2019-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],To assess the relationship between changes in immune cell subsets in peripheral blood from subjects being given ABC294640,
14951,NCT04866862,Objective response rate(ORR),2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor Mutation Burden (TMB),immunocytes and cell factor
14952,NCT00938210,Fatigue,2009-05,COMPLETED,INTERVENTIONAL,['NA'],Social support,
14953,NCT02878109,Hepatic and tumor blood flow before HCC treatment,2016-06,COMPLETED,OBSERVATIONAL,['NA'],,
14954,NCT01950403,Dose of linaclotide acetate that produces a 60% response rate for cGMP levels in rectal tissue by radioimmunoassay (RIA),2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],PD effect on cGMP levels (Stage II),"PD effect of linaclotide acetate on GCC signaling (i.e., VASP phosphorylation) and general proliferation (Ki67 expression)"
14955,NCT00701168,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
14956,NCT03923036,Difference in rates of cardiovascular adverse events leading to hospitalization between chemotherapy treated patients and chemotherapy-free patients.,2019-04,UNKNOWN,OBSERVATIONAL,['NA'],Dose-effect relation ship between individual anticancer drugs combination/protocol and cardiovascular adverse events,
14957,NCT05648682,Thyme honey group patients' quality-of-life scores as assessed by The University of Washington Quality of Life Questionnaire,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
14958,NCT03941457,Occurrence of treatment related adverse events as assessed by CTCAE v4.03,2019-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14959,NCT00016172,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14960,NCT01290926,Overall survival at 6 months fixed endpoint,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],"To determine the correlation of growth modulation index (GMI), defined as the time to progression under the study regimen over the time to progression un-der the latest prior regimen administered to the patient, with overall survival and progression-free",
14961,NCT04471480,overall survival (OS),2020-09-01,UNKNOWN,INTERVENTIONAL,['NA'],progression-free survival(PFS),
14962,NCT00881751,Overall Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Response Rate,
14963,NCT05526079,Local recurrence free survival,2018-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life using LARS score,
14964,NCT00096330,•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14965,NCT01229111,The Response Rate of Patients Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],Identification of Factors That Predict Survival,
14966,NCT05717400,Overall Response Rate,2023-02-07,RECRUITING,INTERVENTIONAL,['PHASE4'],,
14967,NCT00032175,Survival at 1 year,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],Objective response rate,
14968,NCT00311116,"Objective mucositis score at 7, 10, 14, and 17 days post initiation of chemotherapy",2002-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Chemotherapy decrements or delays due to mucositis,
14969,NCT01279837,Clinical swallowing Ability,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Swallowing Quality of Life,
14970,NCT05475054,Major complications,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],Red blood cell transfusion,
14971,NCT02297217,Proportion of patients who achieve relief of dysphagia,2019-11-21,RECRUITING,INTERVENTIONAL,['PHASE2'],Dysphagia progression free survival,
14972,NCT01327794,Association between 25(OH)D level and OS,2011-06,COMPLETED,OBSERVATIONAL,['NA'],Association between 25(OH)D level and PFS,
14973,NCT06037902,absolute mean heart radiation dose,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],movement of tumor in cm,
14974,NCT00043433,,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14975,NCT02379377,Immunohistochemistry,2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE1'],Milan classification,
14976,NCT03329664,Time to progression (TTP),2020-02-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Patient quality of life,
14977,NCT01877018,Patient's status participation to colorectal cancer screening program,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,
14978,NCT05959213,Quantitative data - Preoperatory levels of CA 19.9 (U/ml),2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14979,NCT04791982,The effects of education provided to family members caring for colorectal cancer patients receiving chemotherapy on Caregiver Reaction Assessment Scala.,2018-08-18,COMPLETED,INTERVENTIONAL,['NA'],,
14980,NCT05609448,Feasibility of performing intraprocedural treatment planning,2023-05-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Dosimetry optimization,
14981,NCT06118125,time from date of first symptoms of cancer to the date of first MDT,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],overall survival.,
14982,NCT04149691,Safety profile,2019-07-19,RECRUITING,INTERVENTIONAL,['PHASE1'],Kel: Terminal elimination rate constant,
14983,NCT01127815,,2010-03,UNKNOWN,OBSERVATIONAL,['NA'],,
14984,NCT00888888,Short-term survival,2009-04,COMPLETED,OBSERVATIONAL,['NA'],Long-term survival,
14985,NCT03445260,The number of patients randomized to the study,2018-10-17,COMPLETED,INTERVENTIONAL,['NA'],Length of Hospital Stay,
14986,NCT00378482,Efficacy Endpoints: Survival,2007-03-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Free Survival,
14987,NCT05152498,Time to Progression,2021-01-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],complete response,
14988,NCT06118047,Remission rate of EGFR inhibitor-related acneiform eruption,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life（EORTC QLQ-C30),
14989,NCT02371655,"overall quality of bowel preparation using a 0-3 scale for each parameter (Homogeneity of solid-fluid fecal tagging, volume of residual fluid, colon distension).",2015-10-01,COMPLETED,INTERVENTIONAL,['NA'],compliance of patients,
14990,NCT06023004,ctDNA analysis,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],Cost-effectiveness of treatment,
14991,NCT00040391,,2002-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14992,NCT03005314,progression- free survival,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],overall survival,
14993,NCT05109052,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2022-09-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14994,NCT04889859,diabetes remission rate (%),2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],changes in gut microbiota,
14995,NCT02923934,To determine the clinical efficacy of the combination treatment of ipilimumab with nivolumab in rare cancers.,2017-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],To identify whether a common predictive biomarker or immune signature can be identified in responding patients that can occur irrespective of tumour type.,
14996,NCT04241731,The time from the beginning of maintenance treatment until the disease progresses.,2019-11-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life score,
14997,NCT01366118,ypTN,2009-10,COMPLETED,INTERVENTIONAL,['NA'],Feasibility,
14998,NCT00860249,Completion of CRC Screening,2009-03,TERMINATED,INTERVENTIONAL,['NA'],The Secondary Outcome for the Study is the Time to Screening Completion.,
14999,NCT01486472,The incidence of LDO,2010-11,UNKNOWN,OBSERVATIONAL,['NA'],Correlation between the concentration of S-1-related chemical compounds and the developement of LDO,
15000,NCT02464930,Sensitivity and specificity of tissue and serum microRNA expression by digital polymerase chain reaction for diagnosis of BE neoplasia,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],"Differences in the microRNA expression of biliary exosomes between GERD, Barrett's esophagus and Cancer",
15001,NCT05671315,Change of HBsAg level compared to baseline,2019-07-03,RECRUITING,INTERVENTIONAL,['NA'],Incidence of liver cirrhosis and hepatocellular carcinoma,
15002,NCT00023751,disease-free survival,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],colostomy-free survival,
15003,NCT01337492,Adverse events associated with technical aspects of the operation,2010-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Waiting Time,
15004,NCT02843425,Changes in Blood Markers and Metabolites,2016-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
15005,NCT05344339,Reflux esophagistis,2022-10-08,RECRUITING,INTERVENTIONAL,['NA'],6th month reflux esophagistis,
15006,NCT06327568,Sensitivity and specificity of BD Onclarity HPV assay for HPV detection and genotyping in case/control patients.,2022-06-17,RECRUITING,OBSERVATIONAL,['NA'],,
15007,NCT00642239,tumour local control rate,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],survival rate,
15008,NCT00499265,"Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events",2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15009,NCT06271837,Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR),2024-02-18,RECRUITING,INTERVENTIONAL,['PHASE2'],Immunogenicity of T-DXd,
15010,NCT01299688,To survey the frequency of HER2(+) CTC in gastric cancer,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,
15011,NCT00004074,Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 2.0 (CTCAE v2.0),1999-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
15012,NCT03880747,Dumping syndrome,2017-08-09,COMPLETED,OBSERVATIONAL,['NA'],Incidence of gallstones,Hospital stay
15013,NCT05495672,Progression-free survival (PFS) in advanced colorectal cancer patients with metastatic small pulmonary nodules under ctDNA guided therapeutic strategies,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],The ctDNA clearance rate after chemotherapy in patients achieving NED (Cohort 2),
15014,NCT06039202,Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To evaluate the efficacy of CA102N in combination with trifluridine/tipiracil (TAS-102) by overall survival (OS).,Quality of life measured by European Organization for the research and treatment of cancer quality of life questionnaire (EORTC QLQ-C30).
15015,NCT02514434,Resectability rate of HCC,2015-03-30,UNKNOWN,INTERVENTIONAL,['NA'],Post-treatment recurrence rate,
15016,NCT02082210,Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)],2014-03-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies,
15017,NCT06141564,HCC recurrence diagnosed by dynamic contrast enhanced CT,2023-10-16,RECRUITING,OBSERVATIONAL,['NA'],,
15018,NCT02690350,Number of Patients with Dose-Limiting Toxicities (DLTs),2016-02-29,TERMINATED,INTERVENTIONAL,['PHASE1'],Area Under the Curve to the Last Quantifiable Measure (AUClast)[,
15019,NCT05001204,Standardized uptake value of 68Ga-NOTA-RM26 in gastrointestinal stromal tumor,2021-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Adverse events collection,
15020,NCT05588297,Tumor regression grade (TRG）,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life score (QoL score）,
15021,NCT00165867,The objective response rate as defined by RECIST criteria.,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],safety and tolerability of the combination,
15022,NCT04351867,disease free survival,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Assessment of life quality,
15023,NCT04762888,Correlate biomarkers derived from PET/MRI with PSMA immuno-histochemical (IHC) grading,2021-02-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15024,NCT01614522,The percentage of patients demonstrating clear evidence of inhibition of receptor auto-phosphorylation in HER-1 and HER-2 co-expressing patients on Day 29.,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate,
15025,NCT01815879,Adverse events at day 0-90 post 90Y therapy using CTCae 3.0 criteria.,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],"Radiographic response rate at 90 days (+/- 45 days) from treatment day, compared to pretreatment scans.",
15026,NCT04398446,Change in sleep quality,2020-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Rate of side effects using medical-grade CBD concentrates,
15027,NCT02016287,progression free survival,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],overall survival,quality of life
15028,NCT03115372,Proportion of participants who report ever having had a CRC screening test,2012-02,COMPLETED,INTERVENTIONAL,['NA'],Proportion of participants who intend to obtain CRC screening in the next 6 months,
15029,NCT05457075,Soluble immune checkpoints,2022-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
15030,NCT04020614,The awareness of patients about colorectal cancer,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
15031,NCT02579616,Objective Response Rate (ORR),2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma Concentrations of Lenvatinib,
15032,NCT03859869,Change in Stool Fat From Baseline (Day 1) to Week 1 (Day 8) Among Participants With Resected Pancreatic Cancer,2020-02-25,TERMINATED,INTERVENTIONAL,['PHASE4'],Change in the Total EPI Symptoms Score From Baseline to Week 1 Among Participants With Resected Pancreatic Cancer,
15033,NCT04536220,Status of survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
15034,NCT02509806,Progression free survival,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
15035,NCT04874207,Time from inclusion to death,2021-10-22,RECRUITING,INTERVENTIONAL,['PHASE4'],Body composition,
15036,NCT04012645,Anastomotic leakage,2023-11-16,RECRUITING,INTERVENTIONAL,['NA'],the change of surgical precedure,
15037,NCT05405673,Sensitivity of FIT/FOBT,2022-06-29,RECRUITING,OBSERVATIONAL,['NA'],Microbiota changes in subjects with adenomas or normal findings after polypectomy,
15038,NCT00250029,To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen,2004-04,COMPLETED,INTERVENTIONAL,['NA'],,
15039,NCT03418909,Altered salivatory function,2017-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Treatment related pain,
15040,NCT04589468,Identify the recommended phase 2 dose (RP2D) of exercise for testing in the phase 1b.,2020-10-02,RECRUITING,INTERVENTIONAL,['NA'],,
15041,NCT04947956,The incidence of treatment-emergent adverse events (TEAE),2021-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Time to progression,
15042,NCT01374100,Change in Quality of Life (QoL),2009-02,TERMINATED,INTERVENTIONAL,['NA'],Program Satisfaction,
15043,NCT03138239,Measure the absorption of PET-CT F-18-FDG and of PET -CT Ga-68-PSMA,2017-07-02,UNKNOWN,INTERVENTIONAL,['NA'],,
15044,NCT02435602,Positive predictive value,2013-12,COMPLETED,INTERVENTIONAL,['NA'],Evaluation of endoscopy ( NBI versus Lugol staining) tolerance using Visual Analogue Scale (VAS),
15045,NCT00621725,"To assess the single dose pharmacokinetics (PK) of Cediranib, in patients with cancer with various degrees of hepatic dysfunction (defined by bilirubin levels).",2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety/tolerability of Cediranib (single and multiple dose PK),
15046,NCT01926197,Progression-free Survival (PFS),2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE3'],Grade 2 or Greater Gastrointestinal (GI) Toxicity,
15047,NCT00316888,Local Failure Rate at 3 Years,2007-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],3-year Colostomy-free Survival Rate,
15048,NCT03289988,Diagnostic Power for prediction of advanced colorectal neoplasms,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
15049,NCT00833859,Number of Participants With Resectability,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Overall Survival,
15050,NCT01986738,Distance traveled by the pancreatic tumor between radiation treatments using Computed Tomography (CT) Scans and an Active Breathing Control (ABC) Device,2012-01,COMPLETED,OBSERVATIONAL,['NA'],Assess the impact of the determined treatment margins on the radiation dose to normal tissues and the ability to escalate dose to the tumor using Intensity-Modulated Radiation Therapy (IMRT),
15051,NCT03859557,Yield of WATS biopsies compared to Forceps biopsies,2017-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
15052,NCT05511688,"Time to recurrence for stage I , II or III colorectal cancers",2017-03-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
15053,NCT05003895,"To determine the safety and feasibility of T-cells, expressing a novel humanized anti-GPC3 chimeric antigen receptor, in patients with advanced HCC, expressing GPC3",2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE1'],"To determine the best overall response (BOR) rate according to Response Evaluation Criteria (by RECIST v 1.1) of treatment with T-cells, expressing a novel humanized anti-GPC3 chimeric antigen receptor in participants with advanced HCC, expressi...",
15054,NCT02273713,Progression Free survival,2014-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,
15055,NCT04974281,Resection rate,2021-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Progression free survival (PFS),
15056,NCT04494282,The impact of the pancreatography in the endoscopic treatment of pancreatic pseudocysts,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,
15057,NCT04027790,Test Positivity,2019-05-03,COMPLETED,OBSERVATIONAL,['NA'],,
15058,NCT00004003,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15059,NCT06005740,Recommended Phase 2 Dose (RP2D),2023-12-04,RECRUITING,INTERVENTIONAL,['PHASE1'],Accumulation ratio (Rac) of TORL-4-500,
15060,NCT03808766,arterial flow through the tumor,2018-08-13,TERMINATED,INTERVENTIONAL,['NA'],The degree of tumor necrosis,
15061,NCT01016002,Rate of local response and depth of tumoricidal tissue penetration of Foscan-PDT,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Toxicity using WHO criteria and criteria for local toxicity in the biliary system,
15062,NCT05166772,ORR（Objective Response Rate）,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],AE（Adverse events）,
15063,NCT04090463,Disease-specific survival,2019-10-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],Resection rate,
15064,NCT02311712,Death from all causes,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],Change in Quality of life,
15065,NCT05487248,Optimal timepoint and cut-off value for early on-treatment ctDNA changes,2023-10-12,RECRUITING,INTERVENTIONAL,['NA'],CGP changes during treatment,prognostic value of ctDNA.
15066,NCT05729737,Evaluate if the time to peak (TP) is predictive of response to chemotherapy therapy measured by comparison of TP at CEUS imaging prior to the start of first-line chemotherapy and TP at imaging performed after 2 cycles chemotherapy,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],Assessment of overall survival,
15067,NCT04687280,arterial enhancement,2009-04-22,COMPLETED,OBSERVATIONAL,['NA'],,
15068,NCT03326791,Disease Free Survival (DFS) after three years treatment,2017-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",ASA in CRC and Cost-Effectiveness Analyses III,
15069,NCT02482701,"Successful endoscopic resection defined as complete resection of the delineated area, including all delineation markings, in a single procedure.",2015-08,COMPLETED,OBSERVATIONAL,['NA'],Histopathology,
15070,NCT03566355,3-year local control ratio of the treated lung area,2018-05-23,RECRUITING,INTERVENTIONAL,['NA'],3-year disease-free survival rate of treated patients,
15071,NCT05795725,The diagnostic accuracy of the AI-assisted fecal microbiome testing in detecting colon cancer compared to colonoscopy,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
15072,NCT02928510,The Mechanism of Action (MOA) of idelalisib will be assessed with a number of tests in order to provide variability in comparisons for the units of measure.,2016-02-01,TERMINATED,OBSERVATIONAL,['NA'],,
15073,NCT05061199,length of the resection margin,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
15074,NCT05466019,Pathological complete response (pCR),2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],type and number of intestinal flora,
15075,NCT02461836,disease-free survival (DFS),2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],safety as assessed according to NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) Ver. 4,
15076,NCT03063840,tumor evaluation,2016-07,WITHDRAWN,INTERVENTIONAL,['NA'],Assess for presence of adverse events,
15077,NCT03989115,Number of Participants With Dose Limiting Toxicities (DLTs),2019-07-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Response Rate (ORR),
15078,NCT00183794,"Tumor Response Type: CR, PR, SD or PD",2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Time to Progression (Months),
15079,NCT00178867,,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,
15080,NCT00582257,"Create registry of families w/ early onset & familial gastric cancer for analysis of risk factors, family history and unidentified susceptibility genes. Create cohorts of pts w/ low genetic risk for the development of gastric cancer",2005-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],To determine the gastric pathology evident from a single baseline endoscopic screen of unaffected first-degree relatives of a patient with EOGC or FGC.,
15081,NCT00352703,The primary efficacy endpoints are the incidence (%) and duration of severe oral mucositis (WHO grades 3 or 4).,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
15082,NCT02467582,Disease-free survival (DFS),2016-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse events (AEs),
15083,NCT02650375,incidence of adverse events,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],CL for Metatinib,
15084,NCT00596401,the annual incidence of gastric cancer in Iijima town,2007-09,COMPLETED,OBSERVATIONAL,['NA'],The annual medical care cost in Iijima town,
15085,NCT06169163,To develop a breath test for detection of OSCC,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],To evaluate the effects of known confounding variables on the target VOCs in OSCC,
15086,NCT03213444,cardiac function evaluation,2015-07,COMPLETED,INTERVENTIONAL,['NA'],Proinflammatory cytokines,
15087,NCT05823272,incidence of sarcopenia 6-month after discharge,2024-03-22,RECRUITING,INTERVENTIONAL,['NA'],Changes in BMI (weight and height will be combined to report BMI in kg/m^2),
15088,NCT02654639,Length of Progression-Free Survival,2016-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
15089,NCT05265962,OS,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events (Safety),PD-L1 CPS
15090,NCT02501980,5-year HCC specific mortality rate,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Identification of early diagnosis markers of HCC,
15091,NCT02942862,survival,2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
15092,NCT02335619,Total symptom distress score,2015-02,COMPLETED,INTERVENTIONAL,['NA'],"Details of death (survival time from first oncology appointment at BC Cancer location of death (home, hospice, Cancer Centre)",
15093,NCT05384496,best objective response,2022-05-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15094,NCT04034251,Progression Free Survival (PFS) in Participants With Peritoneal Metastases From Gastric Cancer After Repeated Intraperitoneal Chemotherapeutic Infusion (IPC) and Systemic Paclitaxel Administration With Concomitant Capecitabine Therapy,2020-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants With Intra-peritoneal Progression Free Survival (iPFS),Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
15095,NCT00543842,Maximal tolerated dose (MTD),2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
15096,NCT03879109,Proportion of curative surgery,2019-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Tolerance to treatment,
15097,NCT03206073,Number of Participants With Grade 1-5 Adverse Events,2017-12-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Response,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.3)
15098,NCT00506168,Maximal response rate and toxicities,2001-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Progression-free survival and overall survival,
15099,NCT01844817,Overall Survival,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate,
15100,NCT01836237,Surgical Site Infection (SSI) Rate,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,
15101,NCT02372500,Bowel function (as assessed by questionnaire),2015-03,UNKNOWN,INTERVENTIONAL,['NA'],Morbidity,
15102,NCT04901585,Postoperative complications,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
15103,NCT02343601,Incidence of patients presenting at least one complication after colorectal surgery,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Perioperative mortality,Medico economic evaluation of cost of treatment
15104,NCT05960955,Pathological complete response (pCR) rates,2023-11-13,RECRUITING,INTERVENTIONAL,['PHASE2'],ADA,
15105,NCT01900327,3-Year Survival Rate,2014-02,TERMINATED,INTERVENTIONAL,['PHASE3'],First site of tumor recurrence,
15106,NCT05634564,Objective Response Rate (ORR),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Events,
15107,NCT05346874,Pathological complete response (pCR) rate,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Progressive free survival,
15108,NCT04070677,Symptomatic relief of radiation-induced esophagitis grade ≥2 in cancer patients undergoing radiotherapy and radiochemotherapy after administration of ZIVEREL®.,2019-06-15,UNKNOWN,INTERVENTIONAL,['NA'],Analyze the health-related quality of life during the treatment,
15109,NCT06242197,The effectiveness of written advice VS. standard verbal advice in transferring knowledge to first degree relatives of colorectal cancer patients,2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Determining the knowledge level about colorectal cancer in first degree relatives of CRC patients,
15110,NCT02123511,Groningen Radiotherapy-Induced Xerostomia (GRIX) Sticky Saliva Total Score Area Under the Curve (AUC),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"Adverse Event, as Measured by the Number of Patients With a Maximum Grade of Any Adverse Event",
15111,NCT05067413,Rate of anastomotic leakage,2020-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],3-year disease-free survival,
15112,NCT06285591,The duration of Severe Oral mucositis (WHO grade ≥3),2023-11-10,RECRUITING,INTERVENTIONAL,['NA'],Mouth and throat soreness (MTS) scores,
15113,NCT05062837,Overall survival,2021-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Objective response rate of extrahepatic target lesions,
15114,NCT04086901,Loco-regional control,2020-01-01,TERMINATED,INTERVENTIONAL,['NA'],Treatment completion rate,
15115,NCT05062317,To establish the 1-year recurrence-free survival rate following liver resection of CLM with curative intent among ctDNA-negative patients who receive risk-stratified postoperative chemotherapy,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15116,NCT00532987,,2003-12,TERMINATED,OBSERVATIONAL,['NA'],,
15117,NCT00251485,"To assess the response rate, progression-free survival, and overall safety profile of a modified FOLFOX 6 plus cetuximab regimen in the first-line treatment of patients with metastatic colorectal cancer.",2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],To assess overall survival of patients with metastatic colorectal cancer who receive first-line therapy with a modified FOLFOX 6 + cetuximab regimen,
15118,NCT03880617,"Change in Background, Disease and Treatment Information Form (BDTIF)",2015-03-25,COMPLETED,OBSERVATIONAL,['NA'],,
15119,NCT05842174,Local Progression Free Survival,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
15120,NCT02056015,Human organ and whole body absorbed dose values from organ kinetic quantification of [68Ga]MLN6907 uptake and clearance,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],"Correlate tumor uptake of [68Ga]MLN6907 measured by PET and the level of guanylyl cyclase C (GCC) expression in tumor lesions from surgical specimens , for tumors in individual patients and for aggregated liver tumors across patients",
15121,NCT04745754,Preventive care services,2021-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Cancer recurrence,Self-reported patient demographics
15122,NCT01391572,Survival,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],Failure pattern,
15123,NCT04943484,Surgical conduct,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],Clinical variables associated with change of the surgical conduct,
15124,NCT04407611,Participant uncertainty from cancer risk assessment at 12 months,2023-03-06,RECRUITING,INTERVENTIONAL,['NA'],,
15125,NCT00579748,The OCT images will be correlated to the specific biopsy site and biopsy number.,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,
15126,NCT02130648,Analysis circulating free fetal DNA,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
15127,NCT00668863,Progression-Free Survival (PFS),2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Grade 3 or Higher Adverse Events According to Common Terminology Criteria (CTCAE).",
15128,NCT02512328,Feasibility,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],patient´s satification,
15129,NCT04758195,Number of participants with major low anterior resection syndrome score (LARS score),2021-03-01,RECRUITING,INTERVENTIONAL,['NA'],Fecal continence impairment,Anorectal function impairment
15130,NCT00866944,Disease free survival rate (DFS),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life,
15131,NCT00441376,To determine the Pharmacokinetics (PK) of ThermoDox,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],To determine the cardiotoxicity of ThermoDox through enhanced ECG monitoring.,
15132,NCT01679327,Overall response rate,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events,
15133,NCT05260385,Objective Response Rate (ORR),2022-01-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse events (AEs),
15134,NCT03532347,The sensitivity of standard Beacon FNA needle compared with the SharkCore (FNB) core biopsy needle in the sampling of solid pancreatic mass lesions.,2017-05-22,COMPLETED,INTERVENTIONAL,['NA'],Duration of sampling procedures,
15135,NCT05706779,To assess the rate of significant tumour regression (TRG 0 to 2 according to Ryan's modified score of the AJCC 2010),2023-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15136,NCT05662527,Pathological complete response (pCR),2023-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Gene expression by mRNA,Endoscopic tumour assessment
15137,NCT02686567,Incidence of AL,2016-02,COMPLETED,INTERVENTIONAL,['NA'],Incidence of TDT-related Adverse Events: bleeding,Incidence of DT-related adverse events : iatrogenic colonic perforations
15138,NCT00142480,"To determine the progression free survival rate at one year for locally advanced, or resected with positive margins, biliary tract and gallbladder cancer patients",2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],"To evaluate the safety of the combination capecitabine, oxaliplatin, bevacizumab in patients with biliary tract and gallbladder cancer",
15139,NCT01124214,compare diagnostic yield,2010-07,COMPLETED,INTERVENTIONAL,['NA'],compare the specificity and sensitivity of HRE with EM,
15140,NCT03552458,Quality of Life post Radiation,2018-06-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],Oral Bacteria Analysis and Gene Expression Analysis,
15141,NCT04763174,Change in psychological distress,2021-09-15,RECRUITING,INTERVENTIONAL,['NA'],Change in Self-Efficacy for Symptom Management,Change in Parenting Concerns
15142,NCT03604926,immunological features of metastasis,2017-10-05,COMPLETED,OBSERVATIONAL,['NA'],,
15143,NCT01093222,Progression-free Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug,
15144,NCT03923400,Location,2016-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
15145,NCT04813783,oral mucositis area measurement,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
15146,NCT02171429,"Percentage of Participants in Remission at Week 10 With Etrolizumab Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28949 Population",2014-11-14,COMPLETED,INTERVENTIONAL,['PHASE3'],"Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Anytime Post-Baseline, GA28949 Population",
15147,NCT00872755,Laparoscopic Nissen fundoplication combined with posterior gastropexy may prevent postoperative paraesophageal or sliding herniation in surgical treatment of GERD,2002-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
15148,NCT02788565,Proportion of subjects with injection problems according to the subject,2016-03,COMPLETED,OBSERVATIONAL,['NA'],"Proportion of nurses who reported ""moderately"" or ""very"" or ""very much"" confidence in giving injections",
15149,NCT02611453,Technical success of CO2 cholangiography vs. iodinated contrast,2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Radiation usage/exposure of CO2 cholangiography using conventional fluoroscopy or digital subtraction fluoroscopy vs. iodinated contrast,
15150,NCT00425906,"Determination of whether ≥ 50% of patients utilize nicotine for treating ""hunger pain"" ≥ 2 times over a 48-hour period",2003-12,WITHDRAWN,INTERVENTIONAL,['NA'],Change in circulating hormonal concentrations (for patients enrolled at the Mayo Rochester Clinic only),
15151,NCT03428425,Conversion to negative rate,2018-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Adverse events,
15152,NCT02324868,Self-reported autonomy score regarding bathing activities,2016-01,TERMINATED,INTERVENTIONAL,['NA'],Laboratory-Confirmed Bloodstream Infection,Catheter/Huber needle status
15153,NCT00515190,Overall survial in the two treatment arms,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Response rate, toxicity, duration of response, time to progression, Quality of life in the two treatment arms,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics, treatment efficacy and toxicity",
15154,NCT05740267,C-reactive protein (CRP) level,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Postoperative Recovery course:,
15155,NCT04053998,Morbidity assessed according to the Comprehensive Complications Index® (CCI®),2019-08-09,COMPLETED,OBSERVATIONAL,['NA'],Disease free survival rate,
15156,NCT02682446,To estimate the incidence (number of participants) of metachronous gastric neoplasm after ESD between H. pylori eradicated group and H. pylori persistent group,2007-01,COMPLETED,OBSERVATIONAL,['NA'],To evaluate the incidence of metachronous gastric neoplasm after ESD based on diffferent cut off point of serum pepsinogen.,
15157,NCT04331535,Time-to-new diagnosis of common complex disease,2020-07-17,RECRUITING,INTERVENTIONAL,['NA'],Medication adherence,Health status and quality of life
15158,NCT03397199,Progression-free Survival (PFS),2018-01-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival(OS),
15159,NCT00763516,"Cumulative incidence of grade 3+ bowel perforation, grade 3+ bleeding and grade 4+ nonhematologic acute adverse events (occuring within 90 days of treatment start)",2009-02,COMPLETED,INTERVENTIONAL,['NA'],Collect and analyze tumor control outcomes,
15160,NCT04234113,Part B: Number of Participants With Eastern Cooperative Oncology Group [ECOG],2019-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Immunogenicity analysis to assess antibodies to SO-C101,
15161,NCT02162563,Progression-free survival (PFS),2014-07,RECRUITING,INTERVENTIONAL,['PHASE3'],Correlation of evaluation by the panel with outcome,
15162,NCT03157128,Phase 2: Objective Response Rate,2017-05-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1 and 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib),
15163,NCT01024387,Objective Response Rate,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],1-Year Overall Survival,
15164,NCT00900094,Potential markers for early detection of cancer,2000-06,COMPLETED,OBSERVATIONAL,['NA'],,
15165,NCT00914355,"Determine one year local progression free rate, defined as lack of progression within the irradiated volume, using RECIST criteria",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Cytokine response to radiation and association with complications,
15166,NCT04994548,technical success of early esophageal cancer resection,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],preemptive methods to the risk of bleeding,
15167,NCT02594943,Highest proportion (number) of representative biopsies from tumors of diffuse gastric cancer,2018-08,WITHDRAWN,INTERVENTIONAL,['NA'],Amount of (mm2 and %) submucosal tissue within the biopsies.,
15168,NCT03762564,Overall survival (OS) at 6 months,2019-03-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence and severity of adverse events,
15169,NCT02241720,Number of Participants With Stable Disease at Eight Weeks Post-Treatment,2014-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
15170,NCT00354367,"Investigation of Clinical efficacy of certolizumab pegol for fistula closure, as measured by the proportion of patients with fistula improvement after 16 weeks of treatment.",2007-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Investigation of Clinical efficacy of certolizumab pegol for maintenance of fistula closure.,
15171,NCT05985707,Overall response rate,2023-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Frequency of adverse events,
15172,NCT02086968,Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders).,2014-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
15173,NCT03515824,Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE),2018-08-13,TERMINATED,INTERVENTIONAL,['PHASE1'],Minimum Serum Concentration (Cmin) of MK-1697,
15174,NCT01040000,Efficacy OS,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacokinetics and select immune responses to the antibody will be assessed.,
15175,NCT01968629,Calculate the percent absolute enhancement of HCCs following Eovist administration at multiple phases,2013-12,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,
15176,NCT01331928,objective tumor response rate,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"the progression-free survival, overall survival, toxicity profiles",
15177,NCT00520091,Rate of pathologic complete remission in patients with resectable disease,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Response Rate,
15178,NCT05667415,Disease progression (PD),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
15179,NCT03170180,response rate,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15180,NCT04576858,Time to recurrence,2020-02-03,RECRUITING,OBSERVATIONAL,['NA'],Response duration RECIST 1.1,
15181,NCT00735345,Percentage of complete remissions and resection rate,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Evaluation of Quality of Life,
15182,NCT05071755,Overall survival,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
15183,NCT02202564,Recurrence-free survival rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15184,NCT02823678,Percent resected volume of pancreas and diabetes development,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],Blood glucose control,
15185,NCT00201838,Anti-tumor Effect as Measured by the Proportion of Patients Free of Disease-progression at Six Months After Treatment Initiation,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Serial Levels of TNF (Tumor Necrosis Factor) and Other Inflammatory Cytokines,
15186,NCT05125393,Operation time,2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Incidence of at least one serious complication within 30 days after resection,
15187,NCT02013778,Number of Participants With Adverse Events,2013-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
15188,NCT04247984,Progression-free survival (PFS),2018-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life (QoL) Questionnaire,
15189,NCT03828396,Assay sensitivity and specificity for colorectal cancer and advanced adenoma,2018-10-26,UNKNOWN,OBSERVATIONAL,['NA'],,
15190,NCT00085371,Survival in patients receiving triapine as second-line therapy,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],"Confirmed tumor response, defined to be a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart",
15191,NCT01406574,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs),2011-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Best Overall Response,
15192,NCT05140746,Target-to-background ratio(TBR),2020-09-10,RECRUITING,INTERVENTIONAL,['NA'],Overall survival,
15193,NCT05107674,Objective Response Rate (ORR) per disease-specific response criteria as assessed by the Investigator,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE1'],PD Biomarkers: Changes from baseline in tumor tissue biopsies of immune cell infiltration or other histological features,
15194,NCT03780634,Progression Free Survival (PFS),2019-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse Events,
15195,NCT05249569,Response Rate of Combination Therapy,2022-11-04,TERMINATED,INTERVENTIONAL,['PHASE2'],Safety Profile as Measured by the Number of Participants With Lab Abnormalities as Graded by NCI CTCAE v5.0,
15196,NCT06169410,pCR,2023-12-30,RECRUITING,INTERVENTIONAL,['PHASE4'],total response time,
15197,NCT02666976,Changes of symptoms,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4'],changes of inflammatory biomarkers,
15198,NCT06204094,Complete response,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Validation of the Wexner score,
15199,NCT00835055,,2005-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
15200,NCT04619082,The rate of HBV reactivation during TAF prophylaxis,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE4'],The dynamic change of eGFR during TAF prophylaxis,
15201,NCT03963193,Progression-free Survival (PFS),2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Assessment of Health-related quality of life,
15202,NCT04252560,Microbiome,2020-01-31,RECRUITING,OBSERVATIONAL,['NA'],,
15203,NCT06205849,Safety and tolerability,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Systemic immune effects,
15204,NCT02423954,The recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer.,2015-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quantify changes in amount of blood proteins and circulating tumor DNA in patients enrolled on this study,
15205,NCT05155189,AESIs,2021-12-09,RECRUITING,INTERVENTIONAL,['PHASE1'],progression-free survival by mRECIST 1.1,
15206,NCT04180371,Part B: Overall survival (OS) at 1 year in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatment,2019-11-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Part B: The association between EphA2 expression level and overall survival (OS) at 1 year by RECIST v1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment,
15207,NCT00693173,The Genital Drop Technique (IMRT-GD) decreased the radiation dose to the testicles scrotal skin and penile shaft compared to standard prone technique.,2007-07,COMPLETED,OBSERVATIONAL,['NA'],Dosimetry comparison details.,
15208,NCT01287286,Gastrointestinal symptoms in case group reduces 10% than control group during chemotherapy.,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Life quality estimates of 10% improvement than control group.,
15209,NCT01065870,To determine the effect of neoadjuvant regimen of GTX on the 2-year disease free survival rate,2009-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']","To describe the effect of neoadjuvant GTX regimen on resectability for those with arterial involvement and those with venous involvement, separately",
15210,NCT03746392,Documentation of goals of care,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],,
15211,NCT01547923,Number and nature of grade IV toxicity.,2008-06-16,TERMINATED,INTERVENTIONAL,['NA'],Medical-financial study of pre-therapeutic screening.,
15212,NCT05924789,Describe the treatment patterns,2023-08-11,RECRUITING,OBSERVATIONAL,['NA'],,
15213,NCT05457244,Success rate (%),2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],Postoperative Parameters:Readmission and reoperation rate,
15214,NCT00640471,Overall survival,2008-05-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Molecular markers,
15215,NCT04696848,Maximum tolerated dose,2021-02-24,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival,Translational biomarker assessments obtained from blood
